PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Inoki, K; Li, Y; Zhu, TQ; Wu, J; Guan, KL				Inoki, K; Li, Y; Zhu, TQ; Wu, J; Guan, KL			TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling	NATURE CELL BIOLOGY			English	Article							PROTEIN-KINASE-B; TUBEROUS SCLEROSIS COMPLEX; CELL-GROWTH; MAMMALIAN TARGET; S6 KINASE; MUTATIONAL ANALYSIS; GENETIC-CONTROL; ORGAN GROWTH; INSULIN; RAPAMYCIN	Tuberous sclerosis (TSC) is an autosomal dominant disorder characterized by the formation of hamartomas in a wide range of human tissues. Mutation in either the TSC1 or TSC2 tumour suppressor gene is responsible for both the familial and sporadic forms of this disease. TSC1 and TSC2 proteins form a physical and functional complex in vivo. Here, we show that TSC1-TSC2 inhibits the p70 ribosomal protein S6 kinase 1 (an activator of translation) and activates the eukaryotic initiation factor 4E binding protein 1 (4E-BP1, an inhibitor of translational initiation). These functions of TSC1-TSC2 are mediated by inhibition of the mammalian target of rapamycin (mTOR). Furthermore, TSC2 is directly phosphorylated by Akt, which is involved in stimulating cell growth and is activated by growth stimulating signals, such as insulin. TSC2 is inactivated by Akt-dependent phosphorylation, which destabilizes TSC2 and disrupts its interaction with TSC1. Our data indicate a molecular mechanism for TSC2 in insulin signalling, tumour suppressor functions and in the inhibition of cell growth.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Inst Gerontol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Guan, KL (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, 1301 Catherine Rd, Ann Arbor, MI 48109 USA.	kunliang@umich.edu	Guan, Kun-Liang/ADK-7088-2022; INOKI, KEN/A-1202-2007		NIDDK NIH HHS [R01 DK124709] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Au KS, 1998, AM J HUM GENET, V62, P286, DOI 10.1086/301705; Benvenuto G, 2000, ONCOGENE, V19, P6306, DOI 10.1038/sj.onc.1204009; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Dabora SL, 2001, AM J HUM GENET, V68, P64, DOI 10.1086/316951; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; GOMEZ MR, 1991, ANN NY ACAD SCI, V615, P1; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Ito N, 1999, CELL, V96, P529, DOI 10.1016/S0092-8674(00)80657-1; Jones AC, 1999, AM J HUM GENET, V64, P1305, DOI 10.1086/302381; Kobayashi T, 2001, P NATL ACAD SCI USA, V98, P8762, DOI 10.1073/pnas.151033798; Kozma SC, 2002, BIOESSAYS, V24, P65, DOI 10.1002/bies.10031; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Miron M, 2001, NAT CELL BIOL, V3, P596, DOI 10.1038/35078571; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; NELLIST M, 1993, CELL, V75, P1305; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Onda H, 1999, J CLIN INVEST, V104, P687, DOI 10.1172/JCI7319; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Radimerski T, 2002, NAT CELL BIOL, V4, P251, DOI 10.1038/ncb763; Reynolds TH, 2002, J BIOL CHEM, V277, P17657, DOI 10.1074/jbc.M201142200; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Sekulic A, 2000, CANCER RES, V60, P3504; Shah OJ, 2000, AM J PHYSIOL-ENDOC M, V279, pE715, DOI 10.1152/ajpendo.2000.279.4.E715; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Stocker H, 2000, CURR OPIN GENET DEV, V10, P529, DOI 10.1016/S0959-437X(00)00123-4; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Tuttle RL, 2001, NAT MED, V7, P1133, DOI 10.1038/nm1001-1133; Vogt PK, 2001, TRENDS MOL MED, V7, P482, DOI 10.1016/S1471-4914(01)02161-X; Weinkove D, 2000, CURR OPIN GENET DEV, V10, P75, DOI 10.1016/S0959-437X(99)00042-8; WENG QP, 1995, MOL CELL BIOL, V15, P2333; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; Young J, 1998, MOL MED TODAY, V4, P313, DOI 10.1016/S1357-4310(98)01245-3	50	2259	2335	9	173	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2002	4	9					648	657		10.1038/ncb839	http://dx.doi.org/10.1038/ncb839			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	589WE	12172553				2022-12-25	WOS:000177783900008
J	Suzuki, T; Shen, HF; Akagi, K; Morse, HC; Malley, JD; Naiman, DQ; Jenkins, NA; Copeland, NG				Suzuki, T; Shen, HF; Akagi, K; Morse, HC; Malley, JD; Naiman, DQ; Jenkins, NA; Copeland, NG			New genes involved in cancer identified by retroviral tagging	NATURE GENETICS			English	Article							TRANSPOSITION; LYMPHOMA; MAP; PROTOONCOGENE; ACTIVATION; EXPRESSION; INSERTION; DISTANCE; CLONING; REGION	Retroviral insertional mutagenesis in BXH2 and AKXD mice induces a high incidence of myeloid leukemia and B- and T-cell lymphoma, respectively. The retroviral integration sites (RISs) in these tumors thus provide powerful genetic tags for the discovery of genes involved in cancer(1,2). Here we report the first large-scale use of retroviral tagging for cancer gene discovery in the post-genome era. Using high throughput inverse PCR1, we cloned and analyzed the sequences of 884 RISs from a tumor panel composed primarily of B- cell lymphomas. We then compared these sequences, and another 415 RIS sequences previously cloned from BXH2 myeloid leukemias and from a few AKXD lymphomas, against the recently assembled mouse genome sequence. These studies identified 152 loci that are targets of retroviral integration in more than one tumor (common retroviral integration sites, CISs) and therefore likely to encode a cancer gene. Thirty-six CISs encode genes that are known or predicted to be genes involved in human cancer or their homologs, whereas others encode candidate genes that have not yet been examined for a role in human cancer. Our studies demonstrate the power of retroviral tagging for cancer gene discovery in the post-genome era and indicate a largely unrecognized complexity in mouse and presumably human cancer.	NCI, Mouse Canc Genet Program, Frederick, MD 21702 USA; NIAID, Immunopathol Lab, Bethesda, MD 20892 USA; NIH, Ctr Informat Technol, Bethesda, MD 20892 USA; Johns Hopkins Univ, Dept Math Sci, Baltimore, MD 21218 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH Center for Information Technology (CIT); Johns Hopkins University	Copeland, NG (corresponding author), NCI, Mouse Canc Genet Program, Frederick, MD 21702 USA.	copeland@ncifcrf.gov	Naiman, Daniel Q/A-3304-2010	Naiman, Daniel Q/0000-0001-6504-9081; Morse, Herbert/0000-0002-9331-3705	CENTER FOR INFORMATION TECHNOLOGY [Z01CT000268, ZIACT000268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000858, ZIAAI000858] Funding Source: NIH RePORTER	CENTER FOR INFORMATION TECHNOLOGY(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Center for Information Technology (CIT)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEN-DAVID Y, 1990, New Biologist, V2, P1015; Cao JN, 1997, J CANCER RES CLIN, V123, P447, DOI 10.1007/s004320050085; Collins C, 1998, P NATL ACAD SCI USA, V95, P8703, DOI 10.1073/pnas.95.15.8703; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; Dupuy AJ, 2001, GENESIS, V30, P82, DOI 10.1002/gene.1037; Fischer SEJ, 2001, P NATL ACAD SCI USA, V98, P6759, DOI 10.1073/pnas.121569298; GILBERT DJ, 1993, J VIROL, V67, P2083, DOI 10.1128/JVI.67.4.2083-2090.1993; Hansen GM, 2000, GENOME RES, V10, P237, DOI 10.1101/gr.10.2.237; Hartley JW, 2000, LAB INVEST, V80, P159, DOI 10.1038/labinvest.3780020; Horie K, 2001, P NATL ACAD SCI USA, V98, P9191, DOI 10.1073/pnas.161071798; JENKINS NA, 1982, J VIROL, V42, P379, DOI 10.1128/JVI.42.2.379-388.1982; LARGAESPADA DA, 1995, J VIROL, V69, P5095, DOI 10.1128/JVI.69.8.5095-5102.1995; LAZO PA, 1990, P NATL ACAD SCI USA, V87, P170, DOI 10.1073/pnas.87.1.170; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; LUND AH, 2002, NAT GENET, V32, P80, DOI DOI 10.1038/NG956; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; Mikkers H, 2002, NAT GENET, V32, P459, DOI 10.1038/ng1102-459b; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; Mock BA, 1996, GENOMICS, V37, P24, DOI 10.1006/geno.1996.0516; Morse HC, 2001, LEUKEMIA RES, V25, P719, DOI 10.1016/S0145-2126(01)00022-4; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; Neri A, 1996, LEUKEMIA LYMPHOMA, V23, P43, DOI 10.3109/10428199609054800; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; ZEIDLER R, 1994, GENE CHROMOSOME CANC, V9, P282, DOI 10.1002/gcc.2870090408; Zeng WR, 1997, ONCOGENE, V14, P2355, DOI 10.1038/sj.onc.1201076	27	341	354	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2002	32	1					166	174		10.1038/ng949	http://dx.doi.org/10.1038/ng949			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	588RR	12185365				2022-12-25	WOS:000177714900017
J	Cha, BJ; Serbus, LR; Koppetsch, BS; Theurkauf, WE				Cha, BJ; Serbus, LR; Koppetsch, BS; Theurkauf, WE			Kinesin I-dependent cortical exclusion restricts pole plasm to the oocyte posterior	NATURE CELL BIOLOGY			English	Article							MESSENGER-RNA LOCALIZATION; TUBULIN RING COMPLEX; DROSOPHILA OOGENESIS; ANTEROPOSTERIOR POLARITY; TRANSLATIONAL CONTROL; AXIS SPECIFICATION; ANTERIOR-POSTERIOR; EARLY STEP; OSKAR RNA; PROTEIN	Microtubules and the plus-end-directed microtubule motor Kinesin I are required for the selective accumulation of oskar mRNA at the posterior cortex of the Drosophila melanogaster oocyte, which is essential to posterior patterning and pole plasm assembly. We present evidence that microtubule minus ends associate with the entire cortex, and that Kinesin and microtubules are not required for oskar mRNA association with the posterior pole, but prevent ectopic localization of this transcript and the pole plasm proteins Oskar and Vasa to other cortical regions. Cortical binding of oskar mRNA seems to be dependent on the actin cytoskeleton. We conclude that most of the actin-rich oocyte cortex can support pole plasm assembly, and propose that Kinesin restricts pole plasm formation to the posterior by moving oskar mRNA away from microtubule-rich lateral and anterior cortical regions.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Indiana Univ, Dept Biol, Bloomington, IN 47405 USA	University of Massachusetts System; University of Massachusetts Worcester; Indiana University System; Indiana University Bloomington	Theurkauf, WE (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA.			Theurkauf, William/0000-0001-7342-1912				Brendza RP, 2000, SCIENCE, V289, P2120, DOI 10.1126/science.289.5487.2120; Cha BJ, 2001, CELL, V106, P35, DOI 10.1016/S0092-8674(01)00419-6; CHOU TB, 1993, DEVELOPMENT, V119, P1359; CLARK I, 1994, CURR BIOL, V4, P289, DOI 10.1016/S0960-9822(00)00068-3; Clegg NJ, 1997, DEVELOPMENT, V124, P4661; Dollar G, 2002, DEVELOPMENT, V129, P517; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; DRIEVER W, 1990, DEVELOPMENT, V109, P811; EMMONS S, 1995, GENE DEV, V9, P2482, DOI 10.1101/gad.9.20.2482; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; ERDELYI M, 1995, NATURE, V377, P524, DOI 10.1038/377524a0; Glotzer JB, 1997, CURR BIOL, V7, P326, DOI 10.1016/S0960-9822(06)00156-4; GONZALEZREYES A, 1995, NATURE, V375, P654, DOI 10.1038/375654a0; Grunert S, 1996, CURR OPIN GENET DEV, V6, P395, DOI 10.1016/S0959-437X(96)80059-1; Gunawardane RN, 2000, J CELL BIOL, V151, P1513, DOI 10.1083/jcb.151.7.1513; HAY B, 1990, DEVELOPMENT, V109, P425; Hays T, 2000, NAT CELL BIOL, V2, pE60, DOI 10.1038/35008687; KarlinMcginness M, 1996, DEV GENET, V19, P238, DOI 10.1002/(SICI)1520-6408(1996)19:3<238::AID-DVG7>3.0.CO;2-A; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; LANE ME, 1994, GENE DEV, V8, P2986, DOI 10.1101/gad.8.24.2986; LI MG, 1994, J CELL BIOL, V126, P1475, DOI 10.1083/jcb.126.6.1475; LIN H, 1993, DEV BIOL, V159, P140, DOI 10.1006/dbio.1993.1228; Manseau L, 1996, DEVELOPMENT, V122, P2109; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MARKUSSEN FH, 1995, DEVELOPMENT, V121, P3723; Megraw TL, 1999, DEVELOPMENT, V126, P2829; Micklem DR, 1997, CURR BIOL, V7, P468, DOI 10.1016/S0960-9822(06)00218-1; Moritz M, 2000, NAT CELL BIOL, V2, P365, DOI 10.1038/35014058; NEUMANSILBERBERG FS, 1993, CELL, V75, P165, DOI 10.1016/S0092-8674(05)80093-5; POKRYWKA NJ, 1995, DEV BIOL, V167, P363, DOI 10.1006/dbio.1995.1030; POKRYWKA NJ, 1991, DEVELOPMENT, V113, P55; Riechmann V, 2001, CURR OPIN GENET DEV, V11, P374, DOI 10.1016/S0959-437X(00)00207-0; RONGO C, 1995, DEVELOPMENT, V121, P2737; ROTH S, 1995, CELL, V81, P967, DOI 10.1016/0092-8674(95)90016-0; Shulman JM, 2000, CELL, V101, P377, DOI 10.1016/S0092-8674(00)80848-X; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THEURKAUF WE, 1994, DEV BIOL, V165, P352, DOI 10.1006/dbio.1994.1258; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; THEURKAUF WE, 1994, METHOD CELL BIOL, V44, P489, DOI 10.1016/S0091-679X(08)60928-0; Tomancak P, 2000, NAT CELL BIOL, V2, P458, DOI 10.1038/35017101; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; van Eeden F, 1999, CURR OPIN GENET DEV, V9, P396, DOI 10.1016/S0959-437X(99)80060-4; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0	45	117	122	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2002	4	8					592	598		10.1038/ncb832	http://dx.doi.org/10.1038/ncb832			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	579WK	12134163				2022-12-25	WOS:000177201100014
J	Hoshijima, M; Ikeda, Y; Iwanaga, Y; Minamisawa, S; Date, MO; Gu, YS; Iwatate, M; Li, MX; Wang, LL; Wilson, JM; Wang, YB; Ross, J; Chien, KR				Hoshijima, M; Ikeda, Y; Iwanaga, Y; Minamisawa, S; Date, MO; Gu, YS; Iwatate, M; Li, MX; Wang, LL; Wilson, JM; Wang, YB; Ross, J; Chien, KR			Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery	NATURE MEDICINE			English	Article							ADENOASSOCIATED VIRUS VECTORS; LEFT-VENTRICULAR FUNCTION; DILATED CARDIOMYOPATHY; FACTOR-IX; MEMBRANE-PROTEINS; EXPRESSION; ADENOVIRUS; MUSCLE; DYSFUNCTION; EFFICIENT	The feasibility of gene therapy for cardiomyopathy, heart failure and other chronic cardiac muscle diseases is so far unproven. Here, we developed an in vivo recombinant adeno-associated virus (rAAV) transcoronary delivery system that allows stable, high efficiency and relatively cardiac-selective gene expression. We used rAAV to express a pseudophosphorylated mutant of human phospholamban (PLN), a key regulator of cardiac sarcoplasmic reticulum (SR) Ca2+ cycling in BIO14.6 cardiomyopathic hamsters. The rAAV/S16EPLN treatment enhanced myocardial SR Ca2+ uptake and suppressed progressive impairment of left ventricular (LV) systolic function and contractility for 28 - 30 weeks, thereby protecting cardiac myocytes from cytopathic plasma-membrane disruption. Low LV systolic pressure and deterioration in LV relaxation were also largely prevented by rAAV/S16EPLN treatment. Thus, transcoronary gene transfer of S16EPLN via rAAV vector is a potential therapy for progressive dilated cardiomyopathy and associated heart failure.	Univ Calif San Diego, Inst Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Maryland, Dept Physiol, Baltimore, MD 21201 USA; Univ Penn, Inst Human Gene Therapy, Philadelphia, PA 19104 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University System of Maryland; University of Maryland Baltimore; University of Pennsylvania	Chien, KR (corresponding author), Univ Calif San Diego, Inst Mol Med, La Jolla, CA 92093 USA.		gu, yu/GSD-4507-2022; Wilson, James M/F-9220-2011	Wilson, James M/0000-0002-9630-3131; Ikeda, Yasuhiro/0000-0002-2970-7304; Wang, Lili/0000-0001-9347-3939; Minamisawa, Susumu/0000-0003-4728-2116; Wang, Yibin/0000-0003-0852-0767				Antos CL, 2001, CIRC RES, V89, P997, DOI 10.1161/hh2301.100003; Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Asundi VK, 1997, EXP CELL RES, V230, P145, DOI 10.1006/excr.1996.3400; Auricchio A, 2001, HUM GENE THER, V12, P71, DOI 10.1089/104303401450988; Brauner R, 1997, J THORAC CARDIOV SUR, V114, P923, DOI 10.1016/S0022-5223(97)70006-0; Chien KR, 1999, CELL, V98, P555, DOI 10.1016/S0092-8674(00)80043-4; Christensen G, 2000, CIRCULATION, V101, P178, DOI 10.1161/01.CIR.101.2.178; Coral-Vazquez R, 1999, CELL, V98, P465, DOI 10.1016/S0092-8674(00)81975-3; del Monte F, 2001, CIRCULATION, V104, P1424, DOI 10.1161/hc3601.095574; Frank K, 2000, BIOCHEMISTRY-US, V39, P14176, DOI 10.1021/bi001049k; Freeman K, 2001, J CLIN INVEST, V107, P967, DOI 10.1172/JCI12083; Hoshijima M, 2002, J CLIN INVEST, V109, P849, DOI 10.1172/JCI15380; Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706; Ikeda Y, 2000, AM J PHYSIOL-HEART C, V278, pH1362, DOI 10.1152/ajpheart.2000.278.4.H1362; Ikeda Y, 2002, CIRCULATION, V105, P502, DOI 10.1161/hc0402.102953; Jackson WA, 1996, BIOCHEM J, V316, P201, DOI 10.1042/bj3160201; Kawada T, 2002, P NATL ACAD SCI USA, V99, P901, DOI 10.1073/pnas.022641799; Kay MA, 2000, NAT GENET, V24, P257, DOI 10.1038/73464; Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082; Lai NC, 2000, CIRCULATION, V102, P2396, DOI 10.1161/01.CIR.102.19.2396; Logeart D, 2000, HUM GENE THER, V11, P1015, DOI 10.1089/10430340050015329; Melo LG, 2002, CIRCULATION, V105, P602, DOI 10.1161/hc0502.103363; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; Miyamoto MI, 2000, P NATL ACAD SCI USA, V97, P793, DOI 10.1073/pnas.97.2.793; Nakai H, 1998, BLOOD, V91, P4600, DOI 10.1182/blood.V91.12.4600.412k22_4600_4607; Pruchnic R, 2000, HUM GENE THER, V11, P521, DOI 10.1089/10430340050015716; Ryoke T, 1999, CIRCULATION, V100, P1734, DOI 10.1161/01.CIR.100.16.1734; Sato Y, 2001, J BIOL CHEM, V276, P9392, DOI 10.1074/jbc.M006889200; Shah AS, 2001, CIRCULATION, V103, P1311; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; Snyder RO, 1997, NAT GENET, V16, P270, DOI 10.1038/ng0797-270; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; Summerford C, 1998, J VIROL, V72, P1438, DOI 10.1128/JVI.72.2.1438-1445.1998; Svensson EC, 1999, CIRCULATION, V99, P201, DOI 10.1161/01.CIR.99.2.201; TADA M, 2001, HDB PHYSL 2, V1, P301; White DC, 2000, P NATL ACAD SCI USA, V97, P5428, DOI 10.1073/pnas.090091197; Xiao X, 1998, J VIROL, V72, P2224, DOI 10.1128/JVI.72.3.2224-2232.1998; Xiao XA, 1996, J VIROL, V70, P8098, DOI 10.1128/JVI.70.11.8098-8108.1996	38	265	305	0	8	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2002	8	8					864	871		10.1038/nm739	http://dx.doi.org/10.1038/nm739			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	579WJ	12134142				2022-12-25	WOS:000177200900033
J	Bilodeau, PS; Urbanowski, JL; Winistorfer, SC; Piper, RC				Bilodeau, PS; Urbanowski, JL; Winistorfer, SC; Piper, RC			The Vps27p-Hse1p complex binds ubiquitin and mediates endosomal protein sorting	NATURE CELL BIOLOGY			English	Article							SACCHAROMYCES-CEREVISIAE; PREVACUOLAR COMPARTMENT; MULTIVESICULAR BODIES; PLASMA-MEMBRANE; VACUOLAR; GROWTH; HRS; PHOSPHATIDYLETHANOLAMINE; DEGRADATION; REGULATORS	Membrane proteins that are degraded in the vacuole of Saccharomyces cerevisiae are sorted into discrete intralumenal vesicles, analogous to the internal membranes of multi-vesiculated bodies (MVBs). Recently, it has shown that the attachment of ubiquitin (Ub) mediates sorting into lumenal membranes(1). We describe a complex of Vps27p and Hse1p that localizes to endosomal compartments and is required for the recycling of Golgi proteins, formation of lumenal membranes and sorting of ubiquitinated proteins into those membranes. The Vps27p-Hse1p complex binds to Ub and requires multiple Ub Interaction Motifs (UIMs). Mutation of these motifs results in specific defects in the sorting of ubiquitinated proteins into the vacuolar lumen. However, the recycling of Golgi proteins and the generation of lumenal membranes proceeds normally in DeltaUIM mutants. These data support a model in which the Vps27p-Hse1p complex has multiple functions at the endosome, one of which is as a sorting receptor for ubiquitinated membrane proteins destined for degradation.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa	Piper, RC (corresponding author), Univ Iowa, Dept Physiol & Biophys, 5-660 Bowen Sci Bldg, Iowa City, IA 52242 USA.			Piper, Robert/0000-0001-9995-5699	NIGMS NIH HHS [R01 GM58202, R01 GM058202] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058202] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asao H, 1997, J BIOL CHEM, V272, P32785, DOI 10.1074/jbc.272.52.32785; Chen LY, 2002, TRAFFIC, V3, P110, DOI 10.1034/j.1600-0854.2002.030204.x; Cooper AA, 1996, J CELL BIOL, V133, P529, DOI 10.1083/jcb.133.3.529; Dell'Angelica EC, 2001, CELL, V106, P395, DOI 10.1016/S0092-8674(01)00470-6; Grant AM, 2001, TRAFFIC, V2, P37, DOI 10.1034/j.1600-0854.2001.020106.x; Hicke L, 2001, CELL, V106, P527, DOI 10.1016/S0092-8674(01)00485-8; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Kean LS, 1997, J CELL BIOL, V138, P255, DOI 10.1083/jcb.138.2.255; Komada M, 2001, BIOCHEM BIOPH RES CO, V281, P1065, DOI 10.1006/bbrc.2001.4441; Lloyd TE, 2002, CELL, V108, P261, DOI 10.1016/S0092-8674(02)00611-6; Lohi O, 1998, J BIOL CHEM, V273, P21408, DOI 10.1074/jbc.273.33.21408; Mullock BM, 2000, MOL BIOL CELL, V11, P3137, DOI 10.1091/mbc.11.9.3137; PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603; Piper RC, 1997, J CELL BIOL, V138, P531, DOI 10.1083/jcb.138.3.531; Piper RC, 2001, TRAFFIC, V2, P612, DOI 10.1034/j.1600-0854.2001.20904.x; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Reggiori F, 2001, EMBO J, V20, P5176, DOI 10.1093/emboj/20.18.5176; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMEON A, 1992, FEBS LETT, V301, P231, DOI 10.1016/0014-5793(92)81254-J; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEVENS TH, 1986, J CELL BIOL, V102, P1551, DOI 10.1083/jcb.102.5.1551; Takata H, 2000, GENES CELLS, V5, P57, DOI 10.1046/j.1365-2443.2000.00303.x; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Urbanowski JL, 1999, J BIOL CHEM, V274, P38061, DOI 10.1074/jbc.274.53.38061; Urbanowski JL, 2001, TRAFFIC, V2, P622, DOI 10.1034/j.1600-0854.2001.20905.x; Wang J, 2000, BIOTECHNIQUES, V29, P976, DOI 10.2144/00295bm09	30	268	273	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	2002	4	7					534	539		10.1038/ncb815	http://dx.doi.org/10.1038/ncb815			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	568UL	12055639				2022-12-25	WOS:000176562900020
J	Oft, M; Akhurst, RJ; Balmain, A				Oft, M; Akhurst, RJ; Balmain, A			Metastasis is driven by sequential elevation of H-ras and Smad2 levels	NATURE CELL BIOLOGY			English	Article							GROWTH-FACTOR-BETA; EPITHELIAL-CELLS; TRANSFORMING GROWTH-FACTOR-BETA-1; MESENCHYMAL TRANSDIFFERENTIATION; SPINDLE CARCINOMAS; ONCOGENIC RAS; SKIN TUMORS; MOUSE SKIN; IN-VIVO; PROGRESSION	Metastasis is a multistep process that involves local tumour invasion followed by dissemination to, and re-establishment at, distant sites. Here we show that during multistage tumorigenesis, discrete expression thresholds of activated Smad2 and H-ras are sequentially surpassed, driving tumour progression through distinct phases from a differentiated squamous carcinoma to a motile invasive stage, followed by an overt change from epithelial to mesenchymal cell type, finally culminating in metastatic tumour spread. Smad2 activation alone induces migration of tumour cells. Elevated H-ras levels, however, are required for nuclear accumulation of Smad2, both of which are essential for the epithelial-mesenchymal transition (EMT). Having undergone EMT, fibroblastoid carcinoma cells with elevated levels of activated Smad2, gain the capability to spread to a wide variety of tissues by a further increase in Smad2 expression. These findings have far-reaching implications for the prevention of tumour growth, invasion and metastasis.	Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA; Onyx Pharmaceut, Richmond, CA USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Balmain, A (corresponding author), Univ Calif San Francisco, Ctr Comprehens Canc, Box 0875, San Francisco, CA 94143 USA.			AKHURST, ROSEMARY/0000-0002-4474-9668	NCI NIH HHS [K01 CA84244] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA084244] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Arsura M, 2000, MOL CELL BIOL, V20, P5381, DOI 10.1128/MCB.20.15.5381-5391.2000; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; BOS JL, 1989, CANCER RES, V49, P4682; BUCHMANN A, 1991, CANCER RES, V51, P4097; BURNS PA, 1991, ONCOGENE, V6, P2363; CAULIN C, 1995, CELL GROWTH DIFFER, V6, P1027; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; Frame S, 2000, CURR OPIN GENET DEV, V10, P106, DOI 10.1016/S0959-437X(99)00052-0; FRIEDMAN E, 1995, CANCER EPIDEM BIOMAR, V4, P549; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, GENE DEV, V14, P627; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Piek E, 1999, J CELL SCI, V112, P4557; Portella G, 1998, CELL GROWTH DIFFER, V9, P393; Seftor REB, 1998, AM J PATHOL, V153, P1347, DOI 10.1016/S0002-9440(10)65719-7; Shim KS, 1999, CANCER-AM CANCER SOC, V85, P554, DOI 10.1002/(SICI)1097-0142(19990201)85:3<554::AID-CNCR6>3.0.CO;2-X; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; WHITEHEAD JC, 1992, J ENVIRON SYST, V21, P357, DOI 10.2190/71KJ-DMFM-DB65-QH1B; Xie W, 2002, CANCER RES, V62, P497	35	296	314	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	2002	4	7					487	494		10.1038/ncb807	http://dx.doi.org/10.1038/ncb807			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	568UL	12105419				2022-12-25	WOS:000176562900012
J	Cleary, JD; Nichol, K; Wang, YH; Pearson, CE				Cleary, JD; Nichol, K; Wang, YH; Pearson, CE			Evidence of cis-acting factors in replication-mediated trinucleotide repeat instability in primate cells	NATURE GENETICS			English	Article							MYOTONIC-DYSTROPHY; DNA-REPLICATION; SIMIAN VIRUS-40; TRANSGENIC MICE; HUMAN-DISEASE; CTG REPEATS; SOMATIC INSTABILITY; SECONDARY STRUCTURE; MUSCULAR-ATROPHY; CAG REPEAT	The mechanism of disease-associated trinucleotide repeat instability involves cis-acting factors (cis-elements) in the vicinity of the repeat, but the nature of these elements is unknown. One cis-element may be the location of the replication origin relative to the repeat. We have used an SV40 DNA replication system to investigate the effect of the location of replication initiation on (CTG)(n).(CAG)(n) stability in primate cells. Depending on the distance between the SV40 replication origin and the repeat tract, templates with 79 repeats yield predominantly expansions or predominantly deletions or remain intact. All templates with 17 repeats are stable. Thus, cis-elements that affect the sites of Okazaki fragment initiation relative to the repeat are crucial determinants of instability. This model system recapitulates the bias for expansions observed in many of the diseases associated with trinucleotide repeats. Our results might explain the variable amounts of CTG/CAG instability that are observed in different chromosomal contexts.	Hosp Sick Children, Program Genet & Genom Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Rutgers State University New Brunswick; Rutgers State University Medical Center	Pearson, CE (corresponding author), Hosp Sick Children, Program Genet & Genom Biol, 555 Univ Ave,Elm Wing 11-135, Toronto, ON M5G 1X8, Canada.			Pearson, Christopher/0000-0001-9545-4205				ANDERSON S, 1979, J BIOL CHEM, V254, P1495; Ashizawa T, 1996, GENOMICS, V36, P47, DOI 10.1006/geno.1996.0424; ASHIZAWA T, 1994, AM J HUM GENET, V54, P414; Biancalana V., 1992, Human Molecular Genetics, V1, P255, DOI 10.1093/hmg/1.4.255; Brock GJR, 1999, HUM MOL GENET, V8, P1061, DOI 10.1093/hmg/8.6.1061; BURHANS WC, 1990, CELL, V62, P955, DOI 10.1016/0092-8674(90)90270-O; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Cummings CJ, 2000, HUM MOL GENET, V9, P909, DOI 10.1093/hmg/9.6.909; DEPAMPHILIS ML, 1980, ANNU REV BIOCHEM, V49, P627, DOI 10.1146/annurev.bi.49.070180.003211; Freudenreich CH, 1997, MOL CELL BIOL, V17, P2090, DOI 10.1128/MCB.17.4.2090; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; GACY AM, 1995, CELL, V81, P533; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Gordenin DA, 1997, NAT GENET, V16, P116, DOI 10.1038/ng0697-116; Gourdon G, 1997, NAT GENET, V15, P190, DOI 10.1038/ng0297-190; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; HAY RT, 1982, CELL, V28, P767, DOI 10.1016/0092-8674(82)90056-3; HAY RT, 1984, J MOL BIOL, V175, P131, DOI 10.1016/0022-2836(84)90471-6; Henricksen LA, 2000, J BIOL CHEM, V275, P16420, DOI 10.1074/jbc.M909635199; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; IMBERT G, 1993, NAT GENET, V4, P72, DOI 10.1038/ng0593-72; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; LaSpada AR, 1997, BRAIN PATHOL, V7, P943; Manley K, 1999, NAT GENET, V23, P471, DOI 10.1038/70598; Martorell L, 1998, HUM MOL GENET, V7, P307, DOI 10.1093/hmg/7.2.307; Martorell L, 2001, NEUROLOGY, V56, P328, DOI 10.1212/WNL.56.3.328; Miret JJ, 1998, P NATL ACAD SCI USA, V95, P12438, DOI 10.1073/pnas.95.21.12438; Monckton DG, 1997, NAT GENET, V15, P193, DOI 10.1038/ng0297-193; Moore H, 1999, P NATL ACAD SCI USA, V96, P1504, DOI 10.1073/pnas.96.4.1504; NETHANEL T, 1988, J VIROL, V62, P2867, DOI 10.1128/JVI.62.8.2867-2873.1988; NEVILLE CE, 1994, HUM MOL GENET, V3, P45; Pearson CE, 1998, NUCLEIC ACIDS RES, V26, P816, DOI 10.1093/nar/26.3.816; Pearson CE, 1997, HUM MOL GENET, V6, P1117, DOI 10.1093/hmg/6.7.1117; Pearson CE, 1996, BIOCHEMISTRY-US, V35, P5041, DOI 10.1021/bi9601013; Postow L, 2001, P NATL ACAD SCI USA, V98, P8219, DOI 10.1073/pnas.111006998; Richard GF, 2000, EMBO J, V19, P2381, DOI 10.1093/emboj/19.10.2381; RICHARDS RI, 1992, NAT GENET, V1, P7, DOI 10.1038/ng0492-7; RICHARDS RI, 1992, CELL, V70, P709, DOI 10.1016/0092-8674(92)90302-S; Richards RI, 1996, ANN HUM GENET, V60, P391, DOI 10.1111/j.1469-1809.1996.tb00437.x; ROBERTS JD, 1988, P NATL ACAD SCI USA, V85, P7064, DOI 10.1073/pnas.85.19.7064; Samadashwily GM, 1997, NAT GENET, V17, P298, DOI 10.1038/ng1197-298; Schweitzer JK, 1998, HUM MOL GENET, V7, P69, DOI 10.1093/hmg/7.1.69; Seigneur M, 1998, CELL, V95, P419, DOI 10.1016/S0092-8674(00)81772-9; Spiegel R, 1996, HUM MUTAT, V8, P32, DOI 10.1002/(SICI)1098-1004(1996)8:1<32::AID-HUMU4>3.0.CO;2-R; Spiro C, 1999, MOL CELL, V4, P1079, DOI 10.1016/S1097-2765(00)80236-1; TSENG BY, 1979, J MOL BIOL, V129, P531, DOI 10.1016/0022-2836(79)90467-4; VASSILEV L, 1988, NUCLEIC ACIDS RES, V16, P7742, DOI 10.1093/nar/16.15.7742; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WOHRLE D, 1995, HUM MOL GENET, V4, P1147, DOI 10.1093/hmg/4.7.1147; WONG LJC, 1995, AM J HUM GENET, V56, P114	50	153	158	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2002	31	1					37	46		10.1038/ng870	http://dx.doi.org/10.1038/ng870			10	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	547ZF	11967533	Bronze			2022-12-25	WOS:000175362500012
J	Murakami, H; Yanow, SK; Griffiths, D; Nakanishi, M; Nurse, P				Murakami, H; Yanow, SK; Griffiths, D; Nakanishi, M; Nurse, P			Maintenance of replication forks and the S-phase checkpoint by Cdc18p and Orp1p	NATURE CELL BIOLOGY			English	Article							DNA-DAMAGE CHECKPOINT; FISSION YEAST; CELL-CYCLE; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; KINASE; MITOSIS; ONSET; CHK1; PHOSPHORYLATION	S-phase and DNA damage checkpoint controls block the onset of mitosis when DNA is damaged or DNA replication is incomplete(1-3). It has been proposed that damaged or incompletely replicated DNA generates structures that are sensed by the checkpoint control pathway 4,5, although little is known about the structures and mechanisms involved. Here, we show that the DNA replication initiation proteins Orp1p(6,7) and Cdc18p(8,9) are required to induce and maintain the S-phase checkpoint in Schizosaccharomyces pombe. The presence of DNA replication structures correlates with activation of the Cds1p checkpoint protein kinase(10) and the S-phase checkpoint pathway. By contrast, induction of the DNA damage pathway is not dependent on Orp1p or Cdc18p. We propose that the presence of unresolved replication forks, together with Orp1p and Cdc18p, are necessary to activate the Cds1p-dependent S-phase checkpoint.	Canc Res UK London Res Inst, Lincolns Inn Fields Labs, Cell Cycle Lab, London WC2A 3PX, England; Nagoya City Univ, Sch Med, Dept Biochem, Mizuho Ku, Nagoya, Aichi 4678601, Japan; CALTECH, Howard Hughes Med Inst, Div Biol, Pasadena, CA 91125 USA	Cancer Research UK; Nagoya City University; California Institute of Technology; Howard Hughes Medical Institute	Murakami, H (corresponding author), Canc Res UK London Res Inst, Lincolns Inn Fields Labs, Cell Cycle Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	hmura@med.nagoya-cu.ac.jp						ARAKI H, 1995, P NATL ACAD SCI USA, V92, P11791, DOI 10.1073/pnas.92.25.11791; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; Drury LS, 2000, CURR BIOL, V10, P231, DOI 10.1016/S0960-9822(00)00355-9; Friedman KL, 1995, METHOD ENZYMOL, V262, P613; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Grallert B, 1996, GENE DEV, V10, P2644, DOI 10.1101/gad.10.20.2644; Griffiths DJF, 2001, MOL BIOL CELL, V12, P115, DOI 10.1091/mbc.12.1.115; Jallepalli PV, 1997, GENE DEV, V11, P2767, DOI 10.1101/gad.11.21.2767; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; Kim SM, 2001, EMBO J, V20, P6115, DOI 10.1093/emboj/20.21.6115; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Michael WM, 2000, SCIENCE, V289, P2133, DOI 10.1126/science.289.5487.2133; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Murakami H, 1999, GENE DEV, V13, P2581, DOI 10.1101/gad.13.19.2581; Murakami H, 2000, BIOCHEM J, V349, P1, DOI 10.1042/0264-6021:3490001; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; Murakami H, 2001, NAT GENET, V28, P290, DOI 10.1038/90142; MuziFalconi M, 1995, P NATL ACAD SCI USA, V92, P12475, DOI 10.1073/pnas.92.26.12475; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; Okayama H, 1996, ADV CANCER RES, V69, P17, DOI 10.1016/S0065-230X(08)60859-3; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; Russell P, 1998, TRENDS BIOCHEM SCI, V23, P399, DOI 10.1016/S0968-0004(98)01291-2; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; SAKA Y, 1994, EMBO J, V13, P5319, DOI 10.1002/j.1460-2075.1994.tb06866.x; Weinert T, 1998, CURR OPIN GENET DEV, V8, P185, DOI 10.1016/S0959-437X(98)80140-8; Yanow SK, 2001, EMBO J, V20, P4648, DOI 10.1093/emboj/20.17.4648	29	24	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2002	4	5					384	388		10.1038/ncb789	http://dx.doi.org/10.1038/ncb789			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	547GR	11988741				2022-12-25	WOS:000175325100021
J	Niederreither, K; Abu-Abed, S; Schuhbaur, B; Petkovich, M; Chambon, P; Dolle, P				Niederreither, K; Abu-Abed, S; Schuhbaur, B; Petkovich, M; Chambon, P; Dolle, P			Genetic evidence that oxidative derivatives of retinoic acid are not involved in retinoid signaling during mouse development	NATURE GENETICS			English	Article							ENZYME; EXPRESSION; IDENTIFICATION; DEHYDROGENASE; 4-OXORETINOL; CYP26A1; DOMAINS; LIGAND; EMBRYO; CELLS	Retinoic acid, the active derivative of vitamin A (retinol), is a hormonal signaling molecule that acts in developing and adult tissues(1). The Cyp26a1 (cytochrome p450, 26) protein metabolizes retinoic acid into more polar hydroxylated and oxidized derivatives(2,3). Whether some of these derivatives are biologically active metabolites has been debated(4,5). Cyp26a1(-/-) mouse fetuses have lethal morphogenetic phenotypes mimicking those generated by excess retinoic acid administration, indicating that human CYP26A1 may be essential in controlling retinoic acid levels during development(6,7). This hypothesis suggests that the Cyp26a1(-/-) phenotype could be rescued under conditions in which embryonic retinoic acid levels are decreased. We show that Cyp26a1(-/-) mice are phenotypically rescued by heterozygous disruption of Aldh1a2 (also known as Raldh2), which encodes a retinaldehyde dehydrogenase responsible for the synthesis of retinoic acid during early embryonic development(8,9). Aldh1a2 haploinsufficiency prevents the appearance of spina bifida and rescues the development of posterior structures (sacral/caudal vertebrae, hindgut, urogenital tract), while partly preventing cervical vertebral transformations and hindbrain pattern alterations in Cyp26a1(-/-) mice. Thus, some of these double-mutant mice can reach adulthood. This study is the first report of a mutation acting as a dominant suppressor of a lethal morphogenetic mutation in mammals. We provide genetic evidence that ALDH1A2 and CYP26A1 activities concurrently establish local embryonic retinoic acid levels that must be finely tuned to allow posterior organ development and to prevent spina bifida.	Coll France, ULP, INSERM, CNRS,Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, CU Strasbourg, France; Queens Univ, Dept Pathol, Canc Res Labs, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Biochem, Canc Res Labs, Kingston, ON K7L 3N6, Canada	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Queens University - Canada; Queens University - Canada	Dolle, P (corresponding author), Coll France, ULP, INSERM, CNRS,Inst Genet & Biol Mol & Cellulaire, BP 163, F-67404 Illkirch Graffenstaden, CU Strasbourg, France.	dolle@igbmc.u-strasbg.fr	Dolle, Pascal/A-8037-2010	Dolle, Pascal/0000-0002-9294-9090				Abu-Abed S, 2001, GENE DEV, V15, P226, DOI 10.1101/gad.855001; Achkar CC, 1996, P NATL ACAD SCI USA, V93, P4879, DOI 10.1073/pnas.93.10.4879; DECIMO D, 1995, GENE PROBES, V2, P182; DOLLE P, 1993, CELL, V75, P431, DOI 10.1016/0092-8674(93)90378-4; Fujii H, 1997, EMBO J, V16, P4163, DOI 10.1093/emboj/16.14.4163; Haines N, 2000, GENETICS, V156, P1777; Hollemann T, 1998, EMBO J, V17, P7361, DOI 10.1093/emboj/17.24.7361; Lane MA, 1999, P NATL ACAD SCI USA, V96, P13524, DOI 10.1073/pnas.96.23.13524; Livrea M. A., 2000, VITAMIN A RETINOIDS; MacLean G, 2001, MECH DEVELOP, V107, P195, DOI 10.1016/S0925-4773(01)00463-4; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; Niederreither K, 1997, MECH DEVELOP, V62, P67, DOI 10.1016/S0925-4773(96)00653-3; Northrup H, 2000, Curr Probl Pediatr, V30, P313; PIJNAPPEL WWM, 1993, NATURE, V366, P340, DOI 10.1038/366340a0; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; Sakai Y, 2001, GENE DEV, V15, P213, DOI 10.1101/gad.851501; Sonneveld E, 1999, DEV BIOL, V213, P390, DOI 10.1006/dbio.1999.9381; Swindell EC, 1999, DEV BIOL, V216, P282, DOI 10.1006/dbio.1999.9487; Valenzano M, 1999, HUM REPROD UPDATE, V5, P82, DOI 10.1093/humupd/5.1.82; White JA, 1996, J BIOL CHEM, V271, P29922, DOI 10.1074/jbc.271.47.29922; Ying LT, 2000, NAT NEUROSCI, V3, P979, DOI 10.1038/79916; Zhao D, 1996, EUR J BIOCHEM, V240, P15, DOI 10.1111/j.1432-1033.1996.0015h.x	22	181	186	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2002	31	1					84	88		10.1038/ng876	http://dx.doi.org/10.1038/ng876			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	547ZF	11953746				2022-12-25	WOS:000175362500020
J	Ozbudak, EM; Thattai, M; Kurtser, I; Grossman, AD; van Oudenaarden, A				Ozbudak, EM; Thattai, M; Kurtser, I; Grossman, AD; van Oudenaarden, A			Regulation of noise in the expression of a single gene	NATURE GENETICS			English	Article							ESCHERICHIA-COLI-CELLS; TRANSCRIPTIONAL REGULATION; NETWORKS; TRANSLATION; AUTOREGULATION; EFFICIENCY; ELEMENTS; LAMBDA	Stochastic mechanisms are ubiquitous in biological systems. Biochemical reactions that involve small numbers of molecules are intrinsically noisy, being dominated by large concentration fluctuations(1-3). This intrinsic noise has been implicated in the random lysis/lysogeny decision of bacteriophage-lambda4, in the loss of synchrony of circadian clocks(5,6) and in the decrease of precision of cell signals(7). We sought to quantitatively investigate the extent to which the occurrence of molecular fluctuations within single cells (biochemical noise) could explain the variation of gene expression levels between cells in a genetically identical population (phenotypic noise). We have isolated the biochemical contribution to phenotypic noise from that of other noise sources by carrying out a series of differential measurements. We varied independently the rates of transcription and translation of a single fluorescent reporter gene in the chromosome of Bacillus subtilis, and we quantitatively measured the resulting changes in the phenotypic noise characteristics. We report that of these two parameters, increased translational efficiency is the predominant source of increased phenotypic noise. This effect is consistent with a stochastic model of gene expression in which proteins are produced in random and sharp bursts. Our results thus provide the first direct experimental evidence of the biochemical origin of phenotypic noise, demonstrating that the level of phenotypic variation in an isogenic population can be regulated by genetic parameters.	MIT, Dept Phys, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	van Oudenaarden, A (corresponding author), MIT, Dept Phys, Cambridge, MA 02139 USA.		van Oudenaarden, Alexander/AAA-1705-2019	Ozbudak, Ertugrul/0000-0003-2858-4696				Arkin A, 1998, GENETICS, V149, P1633; Barkai N, 2000, NATURE, V403, P267, DOI 10.1038/35002258; BAUMEISTER R, 1991, NUCLEIC ACIDS RES, V19, P4595, DOI 10.1093/nar/19.17.4595; Becskei A, 2000, NATURE, V405, P590, DOI 10.1038/35014651; Berg OG, 2000, BIOPHYS J, V79, P1228, DOI 10.1016/S0006-3495(00)76377-6; BOTSFORD JL, 1992, MICROBIOL REV, V56, P100, DOI 10.1128/MMBR.56.1.100-122.1992; CHAPON C, 1982, EMBO J, V1, P369, DOI 10.1002/j.1460-2075.1982.tb01176.x; Elowitz MB, 2000, NATURE, V403, P335, DOI 10.1038/35002125; Gardner TS, 2000, NATURE, V403, P339, DOI 10.1038/35002131; GILLESPIE DT, 1977, J PHYS CHEM-US, V81, P2340, DOI 10.1021/j100540a008; Hasty J, 2001, NAT REV GENET, V2, P268, DOI 10.1038/35066056; KELLEY RL, 1982, P NATL ACAD SCI-BIOL, V79, P3120, DOI 10.1073/pnas.79.10.3120; Kepler TB, 2001, BIOPHYS J, V81, P3116, DOI 10.1016/S0006-3495(01)75949-8; Levin MD, 1998, BIOPHYS J, V74, P175, DOI 10.1016/S0006-3495(98)77777-X; Lobner-Olesen A, 1999, EMBO J, V18, P1712, DOI 10.1093/emboj/18.6.1712; Lutz R, 1997, NUCLEIC ACIDS RES, V25, P1203, DOI 10.1093/nar/25.6.1203; McAdams HH, 1999, TRENDS GENET, V15, P65, DOI 10.1016/S0168-9525(98)01659-X; McAdams HH, 1997, P NATL ACAD SCI USA, V94, P814, DOI 10.1073/pnas.94.3.814; Paulsson J, 2000, P NATL ACAD SCI USA, V97, P7148, DOI 10.1073/pnas.110057697; Plumbridge J, 1996, J BACTERIOL, V178, P2629, DOI 10.1128/jb.178.9.2629-2636.1996; PTASHNE M, 1976, SCIENCE, V194, P156, DOI 10.1126/science.959843; SPUDICH JL, 1976, NATURE, V262, P467, DOI 10.1038/262467a0; Thattai M, 2001, P NATL ACAD SCI USA, V98, P8614, DOI 10.1073/pnas.151588598; Thieffry D, 1998, BIOESSAYS, V20, P433, DOI 10.1002/(SICI)1521-1878(199805)20:5<433::AID-BIES10>3.0.CO;2-2; Trotot P, 1996, BIOCHIMIE, V78, P277, DOI 10.1016/0300-9084(96)82192-4; VELLANOWETH RL, 1992, MOL MICROBIOL, V6, P1105, DOI 10.1111/j.1365-2958.1992.tb01548.x; von Dassow G, 2000, NATURE, V406, P188, DOI 10.1038/35018085; WEISS R, 1999, P DIMACS WORKSH EV C	28	1154	1170	2	118	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2002	31	1					69	73		10.1038/ng869	http://dx.doi.org/10.1038/ng869			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	547ZF	11967532	Bronze			2022-12-25	WOS:000175362500017
J	Raiborg, C; Bache, KG; Gillooly, DJ; Madshush, IH; Stang, E; Stenmark, H				Raiborg, C; Bache, KG; Gillooly, DJ; Madshush, IH; Stang, E; Stenmark, H			Hrs sorts ubiquitinated proteins into clathrin-coated microdomains of early endosomes	NATURE CELL BIOLOGY			English	Article							TYROSINE PHOSPHORYLATION; RECEPTOR; GROWTH; ENDOCYTOSIS; DEGRADATION; TRANSFERRIN; VESICLES; FINGERS; PATHWAY; DOMAIN	After endocytosis, some membrane proteins recycle from early endosomes to the plasma membrane whereas others are transported to late endosomes and lysosomes for degradation(1). Conjugation with the small polypeptide ubiquitin is a signal for lysosomal sorting(2,3). Here we show that the hepatocyte growth factor-regulated tyrosine kinase substrate, Hrs(4), is involved in the endosomal sorting of ubiquitinated membrane proteins. Hrs contains a clathrin-binding domain(5), and by electron microscopy we show that Hrs localizes to flat clathrin lattices on early endosomes. We demonstrate that Hrs binds directly to ubiquitin by way of a ubiquitin-interacting motif (UIM), and that ubiquitinated proteins localize specifically to Hrs- and clathrin-containing microdomains. Whereas endocytosed transferrin receptors fail to colocalize with Hrs and rapidly recycle to the cell surface, transferrin receptors that are fused to ubiquitin interact with Hrs, localize to Hrs- and clathrin-containing microdomains and are sorted to the degradative pathway. Overexpression of Hrs strongly and specifically inhibits recycling of ubiquitinated transferrin receptors by a mechanism that requires a functional UIM. We conclude that Hrs sorts ubiquitinated membrane proteins into clathrin-coated microdomains of early endosomes, thereby preventing their recycling to the cell surface.	Norwegian Radium Hosp, Inst Canc Res, Dept Biochem, N-0310 Oslo, Norway; Natl Hosp Norway, Inst Pathol, N-0027 Oslo, Norway	University of Oslo; University of Oslo; National Hospital Norway	Raiborg, C (corresponding author), Norwegian Radium Hosp, Inst Canc Res, Dept Biochem, N-0310 Oslo, Norway.		Bache, Kristi G./AAD-9335-2020; Stenmark, Harald/B-8868-2008					Asao H, 1997, J BIOL CHEM, V272, P32785, DOI 10.1074/jbc.272.52.32785; Bean AJ, 2000, J BIOL CHEM, V275, P15271, DOI 10.1074/jbc.275.20.15271; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Dupre S, 2001, CURR BIOL, V11, pR932, DOI 10.1016/S0960-9822(01)00558-9; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; KOMADA M, 1995, MOL CELL BIOL, V15, P6213; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lloyd TE, 2002, CELL, V108, P261, DOI 10.1016/S0092-8674(02)00611-6; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Raiborg C, 2001, EMBO J, V20, P5008, DOI 10.1093/emboj/20.17.5008; Reggiori F, 2001, EMBO J, V20, P5176, DOI 10.1093/emboj/20.18.5176; Rocca A, 2001, MOL BIOL CELL, V12, P1293, DOI 10.1091/mbc.12.5.1293; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Simonsen A, 1998, EUR J CELL BIOL, V75, P223, DOI 10.1016/S0171-9335(98)80116-7; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Stoorvogel W, 1996, J CELL BIOL, V132, P21, DOI 10.1083/jcb.132.1.21; SUTTER G, 1995, FEBS LETT, V371, P9, DOI 10.1016/0014-5793(95)00843-X; Takata H, 2000, GENES CELLS, V5, P57, DOI 10.1046/j.1365-2443.2000.00303.x; Urbanowski JL, 2001, TRAFFIC, V2, P622, DOI 10.1034/j.1600-0854.2001.20905.x; van Kerkhof P, 2000, J BIOL CHEM, V275, P1575, DOI 10.1074/jbc.275.3.1575; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; ZERIAL M, 1986, EMBO J, V5, P1543, DOI 10.1002/j.1460-2075.1986.tb04395.x	30	542	553	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAY	2002	4	5					394	398		10.1038/ncb791	http://dx.doi.org/10.1038/ncb791			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	547GR	11988743				2022-12-25	WOS:000175325100023
J	Dove, A				Dove, A			Cell-based therapies go live	NATURE BIOTECHNOLOGY			English	Article																		Bergers G, 2001, NAT BIOTECHNOL, V19, P20, DOI 10.1038/83457; Ciancio G, 2001, TRANSPLANTATION, V71, P827, DOI 10.1097/00007890-200104150-00002; Fletcher L, 2001, NAT BIOTECHNOL, V19, P893, DOI 10.1038/nbt1001-893; Fox JL, 2001, NAT BIOTECHNOL, V19, P791, DOI 10.1038/nbt0901-791; Kaufman DS, 2001, P NATL ACAD SCI USA, V98, P10716, DOI 10.1073/pnas.191362598; Ludewig B, 2000, J EXP MED, V191, P795, DOI 10.1084/jem.191.5.795; Maus MV, 2002, NAT BIOTECHNOL, V20, P143, DOI 10.1038/nbt0202-143; Petit-Zeman S, 2001, NAT BIOTECHNOL, V19, P201, DOI 10.1038/85619; Poznansky MC, 2000, NAT BIOTECHNOL, V18, P729, DOI 10.1038/77288; Rodenhuis S, 2000, Oncologist, V5, P369, DOI 10.1634/theoncologist.5-5-369; Ryan EA, 2001, DIABETES, V50, P710, DOI 10.2337/diabetes.50.4.710	11	77	84	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2002	20	4					339	343		10.1038/nbt0402-339	http://dx.doi.org/10.1038/nbt0402-339			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	536BY	11923834				2022-12-25	WOS:000174681900016
J	Inoue, A; Saito, J; Ikebe, R; Ikebe, M				Inoue, A; Saito, J; Ikebe, R; Ikebe, M			Myosin IXb is a single-headed minus-end-directed processive motor	NATURE CELL BIOLOGY			English	Article							KINESIN; ACTIN; MECHANISM; MOVEMENT; BINDING; DOMAIN; MODEL	Myosin is an actin-based molecular motor that constitutes a diverse superfamily(1,2). In contrast to conventional myosin, which binds to actin for only a short time during cross-bridge cycling, recent studies have demonstrated that class V myosin moves along actin filaments for a long distance without dissociating(3,4). This would make it suitable for supporting cargo movement in cells. Because myosin V has a two-headed structure with an expanded neck domain, it has been postulated to 'walk' along the 36-nm helical repeat of the actin filament, with one head attached to the actin and leading the other head to the neighbouring helical pitch(5). Here, we report that myosin IXb, a single-headed myosin, moves processively on actin filaments. Furthermore, we found that myosin IXb is a minus-end-directed motor. In addition to class VI myosin, this is the first myosin superfamily member identified that moves in the reverse directions. The processive movement of the single-headed myosin IXb cannot be explained by a 'hand-over-hand' mechanism. This suggests that an alternative mechanism must be operating for the processive movement of single-headed myosin IXb.	Univ Massachusetts, Sch Med, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Ikebe, M (corresponding author), Univ Massachusetts, Sch Med, 55 Lake Ave N, Worcester, MA 01655 USA.	mitsuo.ikebe@umassmed.edu						Bahler M, 2000, BBA-MOL CELL RES, V1496, P52, DOI 10.1016/S0167-4889(00)00008-2; Chieregatti E, 1998, J CELL SCI, V111, P3597; Cross RA, 1999, CURR BIOL, V9, pR854, DOI 10.1016/S0960-9822(00)80045-7; Hodge T, 2000, J CELL SCI, V113, P3353; HOH JFY, 1976, BIOCHEM J, V157, P87, DOI 10.1042/bj1570087; Homma K, 2000, J BIOL CHEM, V275, P34766, DOI 10.1074/jbc.M003132200; Homma K, 2001, NATURE, V412, P831, DOI 10.1038/35090597; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; IKEBE M, 1985, J BIOL CHEM, V260, P3146; IKEBE M, 1987, J BIOL CHEM, V262, P13828; Kalhammer G, 1997, FEBS LETT, V414, P599, DOI 10.1016/S0014-5793(97)01076-4; Kikkawa M, 2001, NATURE, V411, P439, DOI 10.1038/35078000; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; Okada Y, 2000, P NATL ACAD SCI USA, V97, P640, DOI 10.1073/pnas.97.2.640; Okada Y, 1999, SCIENCE, V283, P1152, DOI 10.1126/science.283.5405.1152; Post PL, 1998, J CELL SCI, V111, P941; REINHARD J, 1995, EMBO J, V14, P697, DOI 10.1002/j.1460-2075.1995.tb07048.x; Rief M, 2000, P NATL ACAD SCI USA, V97, P9482, DOI 10.1073/pnas.97.17.9482; Rock RS, 2000, METHODS, V22, P373, DOI 10.1006/meth.2000.1089; Sakamoto T, 2000, BIOCHEM BIOPH RES CO, V272, P586, DOI 10.1006/bbrc.2000.2819; Sata M, 1996, BIOCHEMISTRY-US, V35, P11113, DOI 10.1021/bi960435s; SCHRODER RR, 1993, NATURE, V364, P171, DOI 10.1038/364171a0; Sellers J. R., 1999, MYOSINS; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; UYEDA TQP, 1991, NATURE, V352, P307, DOI 10.1038/352307a0; Walker ML, 2000, NATURE, V405, P804, DOI 10.1038/35015592; Wells AL, 1999, NATURE, V401, P505, DOI 10.1038/46835; Wirth JA, 1996, J CELL SCI, V109, P653; Zhu T, 1996, BIOCHEMISTRY-US, V35, P513, DOI 10.1021/bi952053c	30	73	77	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2002	4	4					302	306		10.1038/ncb774	http://dx.doi.org/10.1038/ncb774			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	541PY	11901422				2022-12-25	WOS:000174994000018
J	Mao, JR; Taylor, G; Dean, WB; Wagner, DR; Afzal, V; Lotz, JC; Rubin, EM; Bristow, J				Mao, JR; Taylor, G; Dean, WB; Wagner, DR; Afzal, V; Lotz, JC; Rubin, EM; Bristow, J			Tenascin-X deficiency mimics Ehlers-Danlos syndrome in mice through alteration of collagen deposition	NATURE GENETICS			English	Article							OSTEOGENESIS IMPERFECTA; I PROCOLLAGEN; COL5A1 GENE; GRAVIS FORM; PROPEPTIDE; MUTATIONS; FIBRILS; CHAINS	Tenascin-X is a large extracellular matrix protein of unknown function(1-3). Tenascin-X deficiency in humans is associated with Ehlers-Danlos syndrome(4,5), a generalized connective tissue disorder resulting from altered metabolism of the fibrillar collagens(6). Because TNXB is the first Ehlers-Danlos syndrome gene that does not encode a fibrillar collagen or collagen-modifying enzyme(7-14), we suggested that tenascin-X might regulate collagen synthesis or deposition(15). To test this hypothesis, we inactivated Tnxb in mice. Tnxb(-/-) mice showed progressive skin hyperextensibility, similar to individuals with Ehlers-Danlos syndrome. Biomechanical testing confirmed increased deformability and reduced tensile strength of their skin. The skin of Tnxb(-/-) mice was histologically normal, but its collagen content was significantly reduced. At the ultrastructural level, collagen fibrils of Tnxb(-/-) mice were of normal size and shape, but the density of fibrils in their skin was reduced, commensurate with the reduction in collagen content. Studies of cultured dermal fibroblasts showed that although synthesis of collagen I by Tnxb(-/-) and wildtype cells was similar, Tnxb(-/-) fibroblasts failed to deposit collagen I into cell-associated matrix. This study confirms a causative role for TNXB in human Ehlers-Danlos syndrome and suggests that tenascin-X is an essential regulator of collagen deposition by dermal fibroblasts.	Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94118 USA; Univ Calif San Francisco, Dept Orthoped Surg, San Francisco, CA 94118 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Bristow, J (corresponding author), Univ Calif San Francisco, Dept Pediat, Laurel Hts Campus,3333 Calif St,Box 1245, San Francisco, CA 94118 USA.							BARSH GS, 1982, P NATL ACAD SCI-BIOL, V79, P3838, DOI 10.1073/pnas.79.12.3838; BATEMAN JF, 1986, BIOCHEM J, V240, P699, DOI 10.1042/bj2400699; Beighton P, 1998, AM J MED GENET, V77, P31, DOI 10.1002/(SICI)1096-8628(19980428)77:1<31::AID-AJMG8>3.3.CO;2-P; BONADIO J, 1990, P NATL ACAD SCI USA, V87, P7145, DOI 10.1073/pnas.87.18.7145; Botas C, 1998, P NATL ACAD SCI USA, V95, P11869, DOI 10.1073/pnas.95.20.11869; BRISTOW J, 1993, J CELL BIOL, V122, P265, DOI 10.1083/jcb.122.1.265; Burch GH, 1997, NAT GENET, V17, P104, DOI 10.1038/ng0997-104; BURCH GH, 1995, DEV DYNAM, V203, P491, DOI 10.1002/aja.1002030411; Burrows NP, 1998, AM J HUM GENET, V63, P390, DOI 10.1086/301948; Byers PH., 1995, METABOLIC MOL BASES, V7th ed, P4029; CHENG PTH, 1969, J INVEST DERMATOL, V53, P112, DOI 10.1038/jid.1969.116; Coats WD, 1996, J MOL CELL CARDIOL, V28, P441; DALY CH, 1982, J INVEST DERMATOL, V79, P17; DePaepe A, 1997, AM J HUM GENET, V60, P547; EYRE DR, 1985, J BIOL CHEM, V260, P1322; FUNG Y, 1990, BIOMECHANICS MECH PR, P259; HYLAND J, 1992, NAT GENET, V2, P228, DOI 10.1038/ng1192-228; Lethias C, 1996, MATRIX BIOL, V15, P11, DOI 10.1016/S0945-053X(96)90122-5; Mao JR, 2001, J CLIN INVEST, V107, P1063, DOI 10.1172/JCI12881; MATSUMOTO K, 1994, J CELL BIOL, V125, P483, DOI 10.1083/jcb.125.2.483; Matsumoto K, 2001, GENES CELLS, V6, P1101, DOI 10.1046/j.1365-2443.2001.00482.x; MOREL Y, 1989, P NATL ACAD SCI USA, V86, P6582, DOI 10.1073/pnas.86.17.6582; SAGA Y, 1992, GENE DEV, V6, P1821, DOI 10.1101/gad.6.10.1821; Schalkwijk J, 2001, NEW ENGL J MED, V345, P1167, DOI 10.1056/NEJMoa002939; SMITH LT, 1992, AM J HUM GENET, V51, P235; Smith LT, 1997, J INVEST DERMATOL, V108, P241, DOI 10.1111/1523-1747.ep12286441; Toriello HV, 1996, NAT GENET, V13, P361, DOI 10.1038/ng0796-361; VOGEL A, 1979, LAB INVEST, V40, P201; Wenstrup RJ, 1996, HUM MOL GENET, V5, P1733, DOI 10.1093/hmg/5.11.1733	29	186	190	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2002	30	4					421	425		10.1038/ng850	http://dx.doi.org/10.1038/ng850			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	536BZ	11925569				2022-12-25	WOS:000174682000021
J	Broeckel, U; Hengstenberg, C; Mayer, B; Holmer, S; Martin, LJ; Comuzzie, AG; Blangero, J; Nurnberg, P; Reis, A; Riegger, GAJ; Jacob, HJ; Schunkert, H				Broeckel, U; Hengstenberg, C; Mayer, B; Holmer, S; Martin, LJ; Comuzzie, AG; Blangero, J; Nurnberg, P; Reis, A; Riegger, GAJ; Jacob, HJ; Schunkert, H			A comprehensive linkage analysis for myocardial infarction and its related risk factors	NATURE GENETICS			English	Article							CORONARY-HEART-DISEASE; SUSCEPTIBILITY LOCUS; GENETIC-LINKAGE; PAIR ANALYSIS; CHROMOSOME; HYPERTENSION; ASSOCIATION; MAPS	Coronary artery disease and myocardial infarction (MI) are leading causes of death in the western world. Numerous studies have shown that risk factors such as diabetes mellitus, arterial hypertension and hypercholesterolemia contribute to the development of the disease. Although each risk factor by itself is partly under genetic control, a positive family history is an independent predictor, which suggests that there are additional susceptibility genes(1). We have scanned the whole genome in 513 families to identify chromosomal regions linked to myocardial infarction and related risk factors that are known to be under genetic control. Here we show, by using variance component analysis and incorporating risk factors, that risk of myocardial infarction maps to a single region on chromosome 14 with a significant lod score of 3.9 (pointwise P=0.00015, genome-wide P<0.05), providing evidence of a principal MI locus. To characterize this locus we analyzed each risk factor by itself. Serum concentrations of lipoprotein (a) show linkage to both the apolipoprotein (a) locus (lod score 26.99) and a new locus on chromosome 1 (lod score 3.8). There is suggestive linkage for diabetes mellitus on chromosome 6 (lod score 2.96), for hypertension on chromosomes 1 and 6, for high-density and low-density lipoprotein cholesterol on chromosomes 1 and 17, and for triglyceride concentrations on chromosome 9. Although some of these risk factors overlap with previously identified loci, none overlaps with the newly identified susceptibility locus for myocardial infarction and coronary artery disease.	Univ Regensburg, Klin & Poliklin Innere Med 2, D-8400 Regensburg, Germany; Med Coll Wisconsin, Dept Cardiovasc Med, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Human & Mol Genet Ctr, Milwaukee, WI 53226 USA; SW Fdn Biomed Res, Dept Genet, San Antonio, TX USA; Max Delbruck Ctr Mol Med, Zentrum Genkartierung, Berlin, Germany; Univ Erlangen Nurnberg, Inst Humangenet, D-8520 Erlangen, Germany; Med Coll Wisconsin, Dept Physiol, Milwaukee, WI 53226 USA	University of Regensburg; Medical College of Wisconsin; Medical College of Wisconsin; Texas Biomedical Research Institute; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Erlangen Nuremberg; Medical College of Wisconsin	Schunkert, H (corresponding author), Univ Regensburg, Klin & Poliklin Innere Med 2, D-8400 Regensburg, Germany.	jacob@mcw.edu; heribert.schunkert@klinik.uni-regensburg.de	Blangero, John/ABA-7175-2021; Martin, Lisa/E-2425-2016; Hengstenberg, Christian/U-5485-2019; Reis, André/D-2309-2009	Martin, Lisa/0000-0001-8702-9946; Reis, André/0000-0002-6301-6363				Allison DB, 1999, AM J HUM GENET, V65, P531, DOI 10.1086/302487; Almasy L, 1998, AM J HUM GENET, V62, P1198, DOI 10.1086/301844; AMOS CI, 1994, AM J HUM GENET, V54, P535; Blangero J, 2001, ADV GENET, V42, P151, DOI 10.1016/S0065-2660(01)42021-9; BOERWINKLE E, 1992, J CLIN INVEST, V90, P52, DOI 10.1172/JCI115855; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Comuzzie AG, 1999, GENET EPIDEMIOL, V17, pS109; Dahlen GH, 1998, J INTERN MED, V244, P417; FEINGOLD E, 1993, AM J HUM GENET, V53, P234; Fulker DW, 1999, AM J HUM GENET, V64, P259, DOI 10.1086/302193; Ghosh S, 2000, AM J HUM GENET, V67, P1174, DOI 10.1016/S0002-9297(07)62948-6; Goring HHH, 1997, EUR J HUM GENET, V5, P69, DOI 10.1159/000484736; Horikawa Y, 2000, NAT GENET, V26, P163, DOI 10.1038/79876; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Lee YA, 2000, NAT GENET, V26, P470, DOI 10.1038/82625; LOBEL H, 1993, CIRCULATION, V88, P2524; Mansfield TA, 1997, NAT GENET, V16, P202, DOI 10.1038/ng0697-202; MARENBERG ME, 1994, NEW ENGL J MED, V330, P1041, DOI 10.1056/NEJM199404143301503; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Pajukanta P, 2000, AM J HUM GENET, V67, P1481, DOI 10.1086/316902; Pajukanta P, 1998, NAT GENET, V18, P369, DOI 10.1038/ng0498-369; SCHORK NJ, 1993, AM J HUM GENET, V53, P1306; Sobel E, 1996, AM J HUM GENET, V58, P1323; Stoll M, 2000, GENOME RES, V10, P473, DOI 10.1101/gr.10.4.473; THOMPSON EA, 1993, 243 U WASH DEP STAT; Vionnet N, 2000, AM J HUM GENET, V67, P1470, DOI 10.1086/316887; Weber JL, 2001, ADV GENET, V42, P77, DOI 10.1016/S0065-2660(01)42016-5	27	259	274	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2002	30	2					210	214		10.1038/ng827	http://dx.doi.org/10.1038/ng827			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	519CY	11818963				2022-12-25	WOS:000173708700024
J	Okumura, E; Fukuhara, T; Yoshida, H; Hanada, S; Kozutsumi, R; Mori, M; Tachibana, K; Kishimoto, T				Okumura, E; Fukuhara, T; Yoshida, H; Hanada, S; Kozutsumi, R; Mori, M; Tachibana, K; Kishimoto, T			Akt inhibits Myt1 the signalling pathway that leads to meiotic G2/M-phase transitions	NATURE CELL BIOLOGY			English	Article							POLO-LIKE KINASES; STARFISH OOCYTES; XENOPUS OOCYTES; MAP KINASE; CELL-CYCLE; M-PHASE; MPF ACTIVATION; MATURATION; MEIOSIS; CDC2	In eukaryotes, entry into M-phase of the cell cycle is induced by activation of cyclin B-Cdc2 kinase. At G2-phase, the activity of its inactivator, a member of the Wee1 family, of protein kinases, exceeds that of its activator, Cdc25C phosphatase. However, at M-phase entry the situation is; reversed, such that the activity of Cdc25C exceeds that of the Wee1 family. The mechanism of this reversal is unclear. Here we show that in oocytes from the starfish Asterina pectinifera, the kinase Akt (or protein kinase B (PKB)) phosphorylates and downregulates Myt1, a member of the Wee1 family. This switches the balance of regulator activities and causes the initial activation of cyclin B-Cdc2 at the meiotic G2/M-phase transition. These findings identify Myt1 as a new target of Akt, and demonstrate that Akt functions as an M-phase initiator.	Tokyo Inst Technol, Grad Sch Biosci, Lab Cell & Dev Biol, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology	Kishimoto, T (corresponding author), Tokyo Inst Technol, Grad Sch Biosci, Lab Cell & Dev Biol, Midori Ku, Yokohama, Kanagawa 2268501, Japan.	tkishimo@bio.titech.ac.jp		Mori, Masashi/0000-0001-6549-3860				Andersen CB, 1998, J BIOL CHEM, V273, P18705, DOI 10.1074/jbc.273.30.18705; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Fisher DL, 1999, DEVELOPMENT, V126, P4537; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Gross SD, 2000, CURR BIOL, V10, P430, DOI 10.1016/S0960-9822(00)00425-5; JAFFE LA, 1993, J CELL BIOL, V121, P775, DOI 10.1083/jcb.121.4.775; KANATANI H, 1969, NATURE, V221, P273, DOI 10.1038/221273a0; Kishimoto T, 1999, DEV BIOL, V214, P1, DOI 10.1006/dbio.1999.9393; KISHIMOTO T, 1986, METHOD CELL BIOL, V27, P379, DOI 10.1016/S0091-679X(08)60359-3; Kishimoto T, 1998, SEMIN CELL DEV BIOL, V9, P549, DOI 10.1006/scdb.1998.0249; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Nakajo N, 2000, GENE DEV, V14, P328; Nebreda AR, 1999, SCIENCE, V286, P1309, DOI 10.1126/science.286.5443.1309; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Okano-Uchida T, 1998, DEV BIOL, V197, P39, DOI 10.1006/dbio.1998.8881; Okumura E, 1996, J CELL BIOL, V132, P125, DOI 10.1083/jcb.132.1.125; Palmer A, 1998, EMBO J, V17, P5037, DOI 10.1093/emboj/17.17.5037; PICARD A, 1991, J CELL BIOL, V115, P337, DOI 10.1083/jcb.115.2.337; POSNER BI, 1994, J BIOL CHEM, V269, P4596; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Qian YW, 2001, MOL BIOL CELL, V12, P1791, DOI 10.1091/mbc.12.6.1791; Sadler KC, 1998, DEV BIOL, V197, P25, DOI 10.1006/dbio.1998.8869; Sagata N, 1996, TRENDS CELL BIOL, V6, P22, DOI 10.1016/0962-8924(96)81034-8; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Tachibana K, 1997, EMBO J, V16, P4333, DOI 10.1093/emboj/16.14.4333; Tachibana K, 2000, P NATL ACAD SCI USA, V97, P14301, DOI 10.1073/pnas.97.26.14301; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	36	168	177	3	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2002	4	2					111	116		10.1038/ncb741	http://dx.doi.org/10.1038/ncb741			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	520RJ	11802161				2022-12-25	WOS:000173794600014
J	Maher, J; Brentjens, RJ; Gunset, G; Riviere, I; Sadelain, M				Maher, J; Brentjens, RJ; Gunset, G; Riviere, I; Sadelain, M			Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR zeta/CD28 receptor	NATURE BIOTECHNOLOGY			English	Article							MEMBRANE ANTIGEN; MONOCLONAL-ANTIBODIES; GENE-TRANSFER; CELL CLONES; CD28; COSTIMULATION; IMMUNOTHERAPY; PROSTATE; TUMORS; MURINE	Artificial receptors provide a promising approach to target T lymphocytes to tumor antigens. However, the receptors described thus far produce either an activation or a co-stimulatory signal alone, thus limiting the spectrum of functions accomplished by the genetically modified cells. Here we show that human primary T lymphocytes expressing fusion receptors directed to prostate-specific membrane antigen (PSMA) and containing combined T-cell receptor-xi (TCR xi), and CD28 signaling elements, effectively lyse tumor cells expressing PSMA. When stimulated by cell-surface PSMA, retrovirally transduced lymphocytes undergo robust proliferation, expanding by more than 2 logs in three weeks, and produce large amounts of interleukin-2 (IL-2). Importantly, the amplified cell populations retain their antigen-specific cytolytic activity. These data demonstrate that fusion receptors containing both TCR and CD28 signaling moieties are potent molecules able to redirect and amplify human T-cell responses, These findings have important implications for adoptive immunotherapy of cancer, especially in the context of tumor cells that fail to express major histocompatibility complex antigens and co-stimulatory molecules.	Mem Sloan Kettering Canc Ctr, Dept Human Genet Med, Gene Transfer & Somat Cell Engn Lab, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet Med, Program Immunol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Sadelain, M (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Human Genet Med, Gene Transfer & Somat Cell Engn Lab, 1275 York Ave, New York, NY 10021 USA.			Maher, John/0000-0001-8275-8488	NCI NIH HHS [CA-59350, P30 CA008748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748, P01CA059350] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Almand B, 2001, J IMMUNOL, V166, P678, DOI 10.4049/jimmunol.166.1.678; Altenschmidt U, 1997, J MOL MED, V75, P259, DOI 10.1007/s001090050111; AlvarezVallina L, 1996, EUR J IMMUNOL, V26, P2304, DOI 10.1002/eji.1830261006; Boon T, 1997, IMMUNOL TODAY, V18, P267, DOI 10.1016/S0167-5699(97)80020-5; Cordaro TA, 2000, EUR J IMMUNOL, V30, P1297, DOI 10.1002/(SICI)1521-4141(200005)30:5<1297::AID-IMMU1297>3.0.CO;2-C; ESHHAR Z, 1993, P NATL ACAD SCI USA, V90, P720, DOI 10.1073/pnas.90.2.720; Eshhar Z, 2001, J IMMUNOL METHODS, V248, P67, DOI 10.1016/S0022-1759(00)00343-4; Ferrone S, 2000, IMMUNOL TODAY, V21, P70, DOI 10.1016/S0167-5699(99)01569-8; Finney HM, 1998, J IMMUNOL, V161, P2791; Gallardo HF, 1997, BLOOD, V90, P952, DOI 10.1182/blood.V90.3.952.952_952_957; Gallardo HF, 1997, GENE THER, V4, P1115, DOI 10.1038/sj.gt.3300506; Geiger TL, 1999, J IMMUNOL, V162, P5931; Gilboa E, 1999, CANCER IMMUNOL IMMUN, V48, P382, DOI 10.1007/s002620050590; Gong MC, 1999, CANCER METAST REV, V18, P483, DOI 10.1023/A:1006308826967; Gong Michael C., 1999, Neoplasia (New York), V1, P123, DOI 10.1038/sj.neo.7900018; Greenfield EA, 1998, CRIT REV IMMUNOL, V18, P389, DOI 10.1615/CritRevImmunol.v18.i5.10; Hanson HL, 2000, IMMUNITY, V13, P265, DOI 10.1016/S1074-7613(00)00026-1; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; Haynes NM, 2001, J IMMUNOL, V166, P182, DOI 10.4049/jimmunol.166.1.182; HOUGHTON AN, 1994, J EXP MED, V180, P1, DOI 10.1084/jem.180.1.1; ISRAELI RS, 1994, CANCER RES, V54, P1807; Jensen MC, 2000, MOL THER, V1, P49, DOI 10.1006/mthe.1999.0012; Kiertscher SM, 2000, J IMMUNOL, V164, P1269, DOI 10.4049/jimmunol.164.3.1269; King PD, 1997, J IMMUNOL, V158, P580; Krause A, 1998, J EXP MED, V188, P619, DOI 10.1084/jem.188.4.619; KRAUSE A, 2000, MOL THER, V1, P713; Lee PP, 1999, NAT MED, V5, P677, DOI 10.1038/9525; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; Liebowitz David N., 1998, Current Opinion in Oncology, V10, P533, DOI 10.1097/00001622-199811000-00010; Liu H, 1997, CANCER RES, V57, P3629; Marincola F M, 2000, Adv Immunol, V74, P181, DOI 10.1016/S0065-2776(08)60911-6; Marti F, 2001, J IMMUNOL, V166, P197, DOI 10.4049/jimmunol.166.1.197; Melief CJM, 2000, ADV IMMUNOL, V75, P235, DOI 10.1016/S0065-2776(00)75006-1; NANDA NK, 1995, CELL, V82, P13, DOI 10.1016/0092-8674(95)90047-0; Paillard F, 1999, HUM GENE THER, V10, P151, DOI 10.1089/10430349950018940; RIVIERE I, 1995, P NATL ACAD SCI USA, V92, P6733, DOI 10.1073/pnas.92.15.6733; Riviere I, 2000, MOL BIOTECHNOL, V15, P133, DOI 10.1385/MB:15:2:133; Sotomayor EM, 1996, CRIT REV ONCOGENESIS, V7, P433, DOI 10.1615/CritRevOncog.v7.i5-6.30; STEIN PH, 1994, MOL CELL BIOL, V14, P3392, DOI 10.1128/MCB.14.5.3392; Vukmanovic-Stejic M, 2000, BLOOD, V95, P231; Ward SG, 1996, BIOCHEM J, V318, P361, DOI 10.1042/bj3180361; Whiteside TL, 1999, CANCER IMMUNOL IMMUN, V48, P346, DOI 10.1007/s002620050585	42	643	769	3	65	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2002	20	1					70	75		10.1038/nbt0102-70	http://dx.doi.org/10.1038/nbt0102-70			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	507ME	11753365				2022-12-25	WOS:000173031600039
J	Nonaka, N; Kitajima, T; Yokobayashi, S; Xiao, GP; Yamamoto, M; Grewal, SIS; Watanabe, Y				Nonaka, N; Kitajima, T; Yokobayashi, S; Xiao, GP; Yamamoto, M; Grewal, SIS; Watanabe, Y			Recruitment of cohesin to heterochromatic regions by Swi6/HP1 in fission yeast	NATURE CELL BIOLOGY			English	Article							SISTER-CHROMATID COHESION; SCHIZOSACCHAROMYCES-POMBE; CHROMOSOME SEGREGATION; CHROMODOMAIN PROTEIN; CENTROMERE; MEIOSIS; MINICHROMOSOME; PROTEOLYSIS; SEPARATION; DOMAINS	Fission yeast centromeres, like those of higher eukaryotes, are composed of repeated DNA structures and associated heterochromatin protein complexes, that have a critical function in the faithful segregation of chromosomes during cell division(1-3). Cohesin protein complexes, which are essential for sister-chromatid cohesion and proper chromosome segregation, are enriched at centromeric repeats(4,5). We have identified a functional and physical link between heterochromatin and cohesin. We find that the preferential localization of cohesins at the centromeric repeats is dependent on Swi6, a conserved heterochromatin protein that is required for proper kinetochore function. Cohesin is also enriched at the mating-type heterochromatic region in a manner that depends on Swi6 and is required to preserve the genomic integrity of this locus. We provide evidence that a cohesin subunit Psc3 interacts with Swi6 and its mouse homologue HP1. These data define a conserved function of Swi6/HP1 in recruitment of cohesin to heterochromatic regions, promoting the proper segregation of chromosomes.	Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Tokyo 1130033, Japan; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Japan Sci & Technol Corp, PRESTO, Kawaguchi, Saitama 3320012, Japan	University of Tokyo; Cold Spring Harbor Laboratory; Japan Science & Technology Agency (JST)	Nonaka, N (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Tokyo 1130033, Japan.		Kitajima, Tomoya/A-7049-2016	Kitajima, Tomoya/0000-0002-6486-7143; Watanabe, Yoshinori/0000-0002-5488-4812	PHS HHS [59772] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; BEACH DH, 1984, EMBO J, V3, P603, DOI 10.1002/j.1460-2075.1984.tb01855.x; Blat Y, 1999, CELL, V98, P249, DOI 10.1016/S0092-8674(00)81019-3; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EKWALL K, 1995, SCIENCE, V269, P1429, DOI 10.1126/science.7660126; GONZALEZ C, 1991, EXP CELL RES, V192, P10, DOI 10.1016/0014-4827(91)90150-S; Hauf S, 2001, SCIENCE, V293, P1320, DOI 10.1126/science.1061376; Hoque MT, 2001, J BIOL CHEM, V276, P5059, DOI 10.1074/jbc.M007809200; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Megee PC, 1999, MOL CELL, V4, P445, DOI 10.1016/S1097-2765(00)80347-0; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; MURPHY TD, 1995, CELL, V82, P599, DOI 10.1016/0092-8674(95)90032-2; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nakayama J, 2000, CELL, V101, P307, DOI 10.1016/S0092-8674(00)80840-5; NIWA O, 1989, EMBO J, V8, P3045, DOI 10.1002/j.1460-2075.1989.tb08455.x; Partridge JF, 2000, GENE DEV, V14, P783; Saitoh S, 1997, CELL, V90, P131, DOI 10.1016/S0092-8674(00)80320-7; Shinozaki-Yabana S, 2000, MOL CELL BIOL, V20, P1234, DOI 10.1128/MCB.20.4.1234-1242.2000; TAKAHASHI K, 1992, MOL BIOL CELL, V3, P819, DOI 10.1091/mbc.3.7.819; Tanaka TU, 2000, NAT CELL BIOL, V2, P492, DOI 10.1038/35019529; Tanaka TU, 1999, CELL, V98, P847, DOI 10.1016/S0092-8674(00)81518-4; Tatebayashi K, 1998, GENETICS, V148, P49; Tomonaga T, 2000, GENE DEV, V14, P2757, DOI 10.1101/gad.832000; Wang GZ, 2000, MOL CELL BIOL, V20, P6970, DOI 10.1128/MCB.20.18.6970-6983.2000; Watanabe Y, 1999, NATURE, V400, P461, DOI 10.1038/22774; Watanabe Y, 2001, NATURE, V409, P359, DOI 10.1038/35053103	28	375	390	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JAN	2002	4	1					89	93		10.1038/ncb739	http://dx.doi.org/10.1038/ncb739			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	513MC	11780129				2022-12-25	WOS:000173381500022
J	Weber, W; Fux, C; Daoud-El Baba, M; Keller, B; Weber, CC; Kramer, BP; Heinzen, C; Aubel, D; Bailey, JE; Fussenegger, M				Weber, W; Fux, C; Daoud-El Baba, M; Keller, B; Weber, CC; Kramer, BP; Heinzen, C; Aubel, D; Bailey, JE; Fussenegger, M			Macrolide-based transgene control in mammalian cells and mice	NATURE BIOTECHNOLOGY			English	Article							MULTICISTRONIC EXPRESSION VECTORS; HAMSTER OVARY CELLS; GENE-EXPRESSION; RESPONSIVE PROMOTERS; ESCHERICHIA-COLI; ANTIBIOTICS; SYSTEM; 2'-PHOSPHOTRANSFERASE-I; PHARMACOKINETICS; PRODUCTIVITY	Heterologous mammalian gene regulation systems for adjustable expression of multiple transgenes are necessary for advanced human gene therapy and tissue engineering, and for sophisticated in vivo gene-function analyses, drug discovery, and biopharmaceutical manufacturing. The antibiotic-dependent interaction between the repressor (E) and operator (ETR) derived from an Escherichia coli erythromycin-resistance regulon was used to design repressible (E-OFF) and inducible (E-ON) mammalian gene regulation systems (E.REX) responsive to clinically licensed macrolide antibiotics (erythromycin, clarithromycin, and roxithromycin). The E-OFF system consists of a chimeric erythromycin-dependent transactivator (ET), constructed by fusing the prokaryotic repressor E to a eukaryotic transactivation domain that binds and activates transcription from ETR-containing synthetic eukaryotic promoters (P-ETR). Addition of macrolide antibiotic results in repression of transgene expression. The E-ON system is based on E binding to artificial ETR-derived operators cloned adjacent to constitutive promoters, resulting in repression of transgene expression. In the presence of macrolides, gene expression is induced. Control of transgene expression in primary cells, cell lines, and microencapsulated human cells transplanted into mice was demonstrated using the E.REX (E-OFF and E-ON) systems. The macrolide-responsive E.REX technology was functionally compatible with the streptogramin (PIP)-regulated and tetracycline (TET)-regulated expression systems, and therefore may be combined for multiregulated multigene therapeutic interventions in mammalian cells and tissues.	Swiss Fed Inst Technol, ETH Zurich, Inst Biotechnol, CH-8093 Zurich, Switzerland; IUTA, Dept Genie Biol, F-69200 Villeurbanne, France; Swiss Fed Inst Technol, ETH Zurich, Inst Biomed Engn, CH-8044 Zurich, Switzerland; Inotech Encapsulat AG, CH-5605 Dottingen, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich	Fussenegger, M (corresponding author), Swiss Fed Inst Technol, ETH Zurich, Inst Biotechnol, CH-8093 Zurich, Switzerland.		Weber, Wilfried/B-4732-2012	Weber, Wilfried/0000-0003-4340-4446				AIELLO L, 1979, VIROLOGY, V94, P460, DOI 10.1016/0042-6822(79)90476-8; Aubel D, 2001, J ANTIBIOT, V54, P44, DOI 10.7164/antibiotics.54.44; Bohl D, 1997, NAT MED, V3, P299, DOI 10.1038/nm0397-299; Boorsma M, 2000, NAT BIOTECHNOL, V18, P429, DOI 10.1038/74493; BRISTOW A, 1997, PHARMEUROPA, V2, P31; Cheung W, 2001, EUR J CLIN PHARMACOL, V57, P411, DOI 10.1007/s002280100324; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Ewald D, 1996, SCIENCE, V273, P1384, DOI 10.1126/science.273.5280.1384; Fussenegger M, 2000, NAT BIOTECHNOL, V18, P1203, DOI 10.1038/81208; Fussenegger M, 2000, NAT BIOTECHNOL, V18, P768, DOI 10.1038/77589; Fussenegger M, 1997, BIOTECHNOL BIOENG, V55, P927, DOI 10.1002/(SICI)1097-0290(19970920)55:6<927::AID-BIT10>3.0.CO;2-4; Fussenegger M, 2001, BIOTECHNOL PROGR, V17, P1, DOI 10.1021/bp000129c; Fussenegger M, 1997, BIOTECHNOL PROGR, V13, P733, DOI 10.1021/bp970108r; Fussenegger M, 1998, NAT BIOTECHNOL, V16, P468, DOI 10.1038/nbt0598-468; Fux C, 2001, Nucleic Acids Res, V29, pE19, DOI 10.1093/nar/29.4.e19; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Guay DRP, 1996, DRUGS, V51, P515, DOI 10.2165/00003495-199651040-00002; Malleret G, 2001, CELL, V104, P675, DOI 10.1016/S0092-8674(01)00264-1; Moosmann P, 1997, BIOL CHEM, V378, P669, DOI 10.1515/bchm.1997.378.7.669; Moser S, 2000, BIOTECHNOL PROGR, V16, P724, DOI 10.1021/bp000077r; Moser S, 2001, J GENE MED, V3, P529, DOI 10.1002/jgm.219; Moutsatsos IK, 2001, MOL THER, V3, P449, DOI 10.1006/mthe.2001.0291; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Noguchi N, 2000, J BACTERIOL, V182, P5052, DOI 10.1128/JB.182.18.5052-5058.2000; NOGUCHI N, 1995, ANTIMICROB AGENTS CH, V39, P2359, DOI 10.1128/AAC.39.10.2359; Rivera VM, 1996, NAT MED, V2, P1028, DOI 10.1038/nm0996-1028; Rodvold KA, 1999, CLIN PHARMACOKINET, V37, P385, DOI 10.2165/00003088-199937050-00003; Rossi FMV, 1998, NAT GENET, V20, P389, DOI 10.1038/3871; Schlatter S, 2002, GENE, V282, P19, DOI 10.1016/S0378-1119(01)00824-1; Serguera C, 1999, HUM GENE THER, V10, P375, DOI 10.1089/10430349950018823; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; Umana P, 1999, NAT BIOTECHNOL, V17, P176, DOI 10.1038/6179; WANG YL, 1994, P NATL ACAD SCI USA, V91, P8180, DOI 10.1073/pnas.91.17.8180; WILLIAMS JD, 1993, J ANTIMICROB CHEMOTH, V31, P11, DOI 10.1093/jac/31.suppl_C.11; Ye XH, 1999, SCIENCE, V283, P88, DOI 10.1126/science.283.5398.88	36	169	199	0	32	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2002	20	9					901	907		10.1038/nbt731	http://dx.doi.org/10.1038/nbt731			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	589KN	12205509				2022-12-25	WOS:000177757700022
J	Lee, KY; Huang, HG; Ju, BS; Yang, ZG; Lin, S				Lee, KY; Huang, HG; Ju, BS; Yang, ZG; Lin, S			Cloned zebrafish by nuclear transfer from long-term-cultured cells	NATURE BIOTECHNOLOGY			English	Article							TRANSPLANTATION; EMBRYOS; FIBROBLASTS; EXPRESSION; CALVES; FETAL; SHEEP; GENE	Although mammals have been cloned from genetically manipulated cultured cells, a comparable achievement has not been realized in lower vertebrates. Here we report that fertile transgenic zebrafish can be obtained by nuclear transfer using embryonic fibroblast cells from long-term cultures. The donor nuclei, modified by retroviral insertions expressing green fluorescent protein (GFP), were transplanted into manually enucleated eggs. Overall, a 2% success rate was achieved, resulting in 11 adult transgenic zebrafish expressing GFP. These nuclear transplants produced fertile, diploid offspring, and their F1/F2 progeny continued to express GFP in a pattern identical to that of the founder fish. This finding demonstrates that slowly dividing nuclei from cultured cells can be reprogrammed to support rapid embryonic development and sets up a foundation for targeted genetic manipulation in zebrafish.	Univ Calif Los Angeles, Dept Mol Cellular & Dev Biol, Los Angeles, CA 90095 USA; Seoul Natl Univ, Sch Agr Biotechnol, Seoul 151742, South Korea	University of California System; University of California Los Angeles; Seoul National University (SNU)	Lin, S (corresponding author), Univ Calif Los Angeles, Dept Mol Cellular & Dev Biol, Los Angeles, CA 90095 USA.				NCRR NIH HHS [R01 RR13227] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR013227] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Amsterdam A, 1999, GENE DEV, V13, P2713, DOI 10.1101/gad.13.20.2713; BRIGGS R, 1952, P NATL ACAD SCI USA, V38, P455, DOI 10.1073/pnas.38.5.455; Cibelli JB, 1998, SCIENCE, V280, P1256, DOI 10.1126/science.280.5367.1256; DIBERARDINO MA, 1992, DIFFERENTIATION, V50, P1, DOI 10.1111/j.1432-0436.1992.tb00480.x; DIBERARDINO MA, 1997, GENOMIC POTENTIAL DI; GASARYAN K G, 1979, Nature (London), V280, P585, DOI 10.1038/280585a0; Gurdon J B, 1975, Adv Exp Med Biol, V62, P35; Haffter P, 1996, DEVELOPMENT, V123, P1; Kasinathan P, 2001, NAT BIOTECHNOL, V19, P1176, DOI 10.1038/nbt1201-1176; Lai LX, 2002, SCIENCE, V295, P1089, DOI 10.1126/science.1068228; Linney E, 1999, DEV BIOL, V213, P207, DOI 10.1006/dbio.1999.9376; Long QM, 1997, DEVELOPMENT, V124, P4105; Ma CG, 2001, P NATL ACAD SCI USA, V98, P2461, DOI 10.1073/pnas.041449398; McCreath KJ, 2000, NATURE, V405, P1066, DOI 10.1038/35016604; ORR NH, 1986, P NATL ACAD SCI USA, V83, P1369, DOI 10.1073/pnas.83.5.1369; PRATHER RS, 1987, BIOL REPROD, V37, P859, DOI 10.1095/biolreprod37.4.859; PRATHER RS, 1989, BIOL REPROD, V41, P414, DOI 10.1095/biolreprod41.3.414; Sakai N, 1997, MOL MAR BIOL BIOTECH, V6, P84; SolnicaKrezel L, 1996, DEVELOPMENT, V123, P67; STICE SL, 1988, BIOL REPROD, V39, P657, DOI 10.1095/biolreprod39.3.657; WABL MR, 1975, SCIENCE, V190, P1310, DOI 10.1126/science.1198115; Wakamatsu Y, 2001, P NATL ACAD SCI USA, V98, P1071, DOI 10.1073/pnas.98.3.1071; Wang GH, 2001, GENESIS, V30, P195, DOI 10.1002/gene.1064; WILLADSEN SM, 1986, NATURE, V320, P63, DOI 10.1038/320063a0; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Zhu ZY, 2000, CELL RES, V10, P17, DOI 10.1038/sj.cr.7290032	26	118	133	0	19	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2002	20	8					795	799		10.1038/nbt721	http://dx.doi.org/10.1038/nbt721			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	579MU	12134167				2022-12-25	WOS:000177182500029
J	Grimm, OH; Gurdon, JB				Grimm, OH; Gurdon, JB			Nuclear exclusion of Smad2 is a mechanism leading to loss of competence	NATURE CELL BIOLOGY			English	Article							MESODERMAL COMPETENCE; XENOPUS-EMBRYOS; CELL FATE; EXPRESSION; ORGANIZER; GENE; INDUCTION; PROTEINS; HOMOLOG; NOGGIN	Controlling the duration of a signalling process in development by loss of competence is important because too strong an induction can change cell fate. To understand some of the mechanisms that underlie loss of competence, we have analysed the transduction of transforming growth factor-beta (TGF-beta) signalling during mesoderm formation, which is thought to be induced by TGF-beta-like signalling (1,2), in embryos of the frog Xenopus laevis. Here we show that gastrula ectoderm has the ability to express mesodermal marker genes in response to the TGF-beta signalling molecule activin for many hours, but then loses this ability within 1 h for all mesodermal genes tested. This loss of mesodermal competence correlates with the inability of Smad2, the principal intracellular signal transducer of activin, to accumulate in the nucleus. Mutating three phosphorylation sites within Smad2 abrogates the temporal restriction of Smad2 to accumulate in the nucleus. Overexpression of this mutant form of Smad2 can prolong the competence of endogenous mesodermal genes to respond to activin signalling. Thus, restricting the subcellular localization of an intracellular signal transducer constitutes a mechanism that leads to loss of mesodermal competence. This mechanism operates within less than an hour, and is therefore well suited to control an orderly sequence of inductions.	Univ Cambridge, Wellcome Trust Canc Res UK Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England	University of Cambridge; University of Cambridge	Gurdon, JB (corresponding author), Univ Cambridge, Wellcome Trust Canc Res UK Inst, Tennis Court Rd, Cambridge CB2 1QR, England.			GURDON, JOHN/0000-0002-5621-3799				Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; DANILCHICK M, 1991, METHOD CELL BIOL, V36, P679; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GURDON JB, 1985, CELL, V41, P913, DOI 10.1016/S0092-8674(85)80072-6; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Henig C, 1998, MECH DEVELOP, V71, P131, DOI 10.1016/S0925-4773(98)00006-9; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Lustig KD, 1996, DEVELOPMENT, V122, P3275; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Ryan AK, 1998, NATURE, V394, P545, DOI 10.1038/29004; Ryan K, 1996, CELL, V87, P989, DOI 10.1016/S0092-8674(00)81794-8; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; Schier AF, 2000, NATURE, V403, P385, DOI 10.1038/35000126; Schohl A, 2002, DEVELOPMENT, V129, P37; Shimizu K, 1999, P NATL ACAD SCI USA, V96, P6791, DOI 10.1073/pnas.96.12.6791; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; Steinbach OC, 1997, NATURE, V389, P395, DOI 10.1038/38755; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4; WOODLAND HR, 1987, DEVELOPMENT, V101, P925	24	87	92	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	2002	4	7					519	522		10.1038/ncb812	http://dx.doi.org/10.1038/ncb812			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	568UL	12068307				2022-12-25	WOS:000176562900017
J	Cossette, P; Liu, LD; Brisebois, K; Dong, HH; Lortie, A; Vanasse, M; Saint-Hilaire, JM; Carmant, L; Verner, A; Lu, WY; Wang, YT; Rouleau, GA				Cossette, P; Liu, LD; Brisebois, K; Dong, HH; Lortie, A; Vanasse, M; Saint-Hilaire, JM; Carmant, L; Verner, A; Lu, WY; Wang, YT; Rouleau, GA			Mutation of GABRA1 in an autosomal dominant form of juvenile myoclonic epilepsy	NATURE GENETICS			English	Article							NEURONAL SODIUM-CHANNEL; FEBRILE SEIZURES PLUS; GENERALIZED EPILEPSY; GABA(A) RECEPTORS; SUSCEPTIBILITY LOCUS; LINKAGE ANALYSIS; CHROMOSOME-6; CHILDHOOD; GENE; GAMMA-2-SUBUNIT	Although many genes that predispose for epilepsy in humans have been determined, those that underlie the classical syndromes of idiopathic generalized epilepsy (IGE) have yet to be identified. We report that an Ala322Asp mutation in GABRA1, encoding the alpha1 subunit of the gamma-aminobutyric acid receptor subtype A (GABA(A)), is found in affected individuals of a large French Canadian family with juvenile myoclonic epilepsy. Compared with wildtype receptors, GABA(A) receptors that contain the mutant subunit show a lesser amplitude of GABA-activated currents in vitro, indicating that seizures may result from loss of function of this inhibitory ligand-gated channel. Our results confirm that mutation of GABRA1 predisposes towards a common idiopathic generalized epilepsy syndrome in humans.	McGill Univ, Ctr Hlth, Inst Res, Neurosci Res Ctr, Montreal, PQ H3G 1A4, Canada; Hosp Sick Children, Program Brain & Behav, Toronto, ON M5G 1X8, Canada; Univ British Columbia, Vancouver Hosp, Res Ctr, Dept Med & Brain, Vancouver, BC, Canada; Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto, ON, Canada; Univ Toronto, Dept Anesthesia, Toronto, ON, Canada; Univ Toronto, Dept Physiol, Toronto, ON, Canada; Hop St Justine, Neurol Serv, Montreal, PQ, Canada; Univ Montreal, Ctr Hosp, Hop Notre Dame, Serv Neurol, Montreal, PQ, Canada; McGill Univ, Montreal Gen Hosp, Montreal Genome Ctr, Montreal, PQ, Canada	McGill University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of British Columbia; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; Universite de Montreal; Universite de Montreal; McGill University	Rouleau, GA (corresponding author), McGill Univ, Ctr Hlth, Inst Res, Neurosci Res Ctr, 1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.		Wang, Yu Tian/J-8255-2015; Wang, Yu Tian/A-4729-2008; Lu, Wei-Yang/K-4404-2013	Liu, Lidong/0000-0002-7026-690X				ANNEGERS JF, 1982, NEUROLOGY, V32, P174, DOI 10.1212/WNL.32.2.174; Baulac S, 2001, NAT GENET, V28, P46, DOI 10.1038/88254; Berkovic SF, 1998, ANN NEUROL, V43, P435, DOI 10.1002/ana.410430405; BERKOVIC SF, 1987, NEUROLOGY, V37, P993, DOI 10.1212/WNL.37.6.993; DOOSE H, 1973, NEUROPADIATRIE, V4, P162, DOI 10.1055/s-0028-1091737; EEGOLOFSSON O, 1971, NEUROPADIATRIE, V2, P375, DOI 10.1055/s-0028-1091791; Elmslie FV, 1996, AM J HUM GENET, V59, P653; Elmslie FV, 1997, HUM MOL GENET, V6, P1329, DOI 10.1093/hmg/6.8.1329; Escayg A, 2000, NAT GENET, V24, P343, DOI 10.1038/74159; GENTON P, 1994, IDIOPATHIC GEN EPILE, pCH22; Greenberg DA, 2000, AM J HUM GENET, V66, P508, DOI 10.1086/302763; GREENBERG DA, 1988, AM J MED GENET, V31, P185, DOI 10.1002/ajmg.1320310125; JANZ D, 1997, EPILEPSY COMPREHENSI, V3, pCH228; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LATHROP GM, 1984, AM J HUM GENET, V36, P460; Lu WY, 1998, J PHYSIOL-LONDON, V512, P29, DOI 10.1111/j.1469-7793.1998.029bf.x; Moss SJ, 2001, NAT REV NEUROSCI, V2, P240, DOI 10.1038/35067500; PANAYIOTOPOULOS CP, 1989, ANN NEUROL, V25, P440, DOI 10.1002/ana.410250504; Picard F, 2000, BRAIN, V123, P1247, DOI 10.1093/brain/123.6.1247; Pirker S, 2000, NEUROSCIENCE, V101, P815, DOI 10.1016/S0306-4522(00)00442-5; Scheffer IE, 1997, BRAIN, V120, P479, DOI 10.1093/brain/120.3.479; Sieghart W, 1999, NEUROCHEM INT, V34, P379, DOI 10.1016/S0197-0186(99)00045-5; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wallace RH, 2001, AM J HUM GENET, V68, P859, DOI 10.1086/319516; Wallace RH, 2001, NAT GENET, V28, P49, DOI 10.1038/ng0501-49; Wallace RH, 1998, NAT GENET, V19, P366, DOI 10.1038/1252; Wan Q, 1997, NATURE, V388, P686, DOI 10.1038/41792; WEISSBECKER KA, 1991, AM J MED GENET, V38, P32, DOI 10.1002/ajmg.1320380109; Wolfe B. E., 1992, J PSYCHOTHERAPY INTE, V2, P29; Xiao WZ, 2001, HUM MUTAT, V17, P439, DOI 10.1002/humu.1130.abs	30	443	466	1	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2002	31	2					184	189		10.1038/ng885	http://dx.doi.org/10.1038/ng885			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	557HR	11992121				2022-12-25	WOS:000175903500016
J	Sahai, E; Marshall, CJ				Sahai, E; Marshall, CJ			ROCK and Dia have opposing effects on adherens junctions downstream of Rho	NATURE CELL BIOLOGY			English	Article							ACTIN CYTOSKELETON; TYROSINE KINASE; PROTEIN-KINASE; FAMILY GTPASES; CADHERIN; RAC; ESTABLISHMENT; ACTIVATION; EXPRESSION; PATHWAYS	Adherens junctions (AJs) are crucial for maintaining the integrity of epithelial tissues and are often disrupted during tumour progression. Rho family proteins have been shown to regulate adherens junctions. We find that activation of the effector kinase ROCK and acto-myosin contraction disrupts AJs downstream of Rho. In contrast, signalling through the Rho effector Dia1 is required to ensure a dynamically stable interface between cells and the maintenance of adherens junction complexes. The ability of Dia1 to regulate the actin network is crucial for the localization of adherens junction components to the cell periphery.	Inst Canc Res, Canc Res UK Ctr Cell & Mol Biol, London SW3 6JB, England	Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Marshall, CJ (corresponding author), Inst Canc Res, Canc Res UK Ctr Cell & Mol Biol, 237 Fulham Rd, London SW3 6JB, England.	chrism@icr.ac.uk						Alberts AS, 2001, J BIOL CHEM, V276, P2824, DOI 10.1074/jbc.M006205200; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Calautti E, 2002, J CELL BIOL, V156, P137, DOI 10.1083/jcb.200105140; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Fukata M, 2001, NAT REV MOL CELL BIO, V2, P887, DOI 10.1038/35103068; Fukata M, 2001, MOL CELL BIOL, V21, P2165, DOI 10.1128/MCB.21.6.2165-2183.2001; Gayet J, 2001, ONCOGENE, V20, P5025, DOI 10.1038/sj.onc.1204611; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hiscox S, 1997, ANTICANCER RES, V17, P1349; Ishizaki T, 2001, NAT CELL BIOL, V3, P8; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Palazzo AF, 2001, NAT CELL BIOL, V3, P723, DOI 10.1038/35087035; Quinlan MP, 1999, ONCOGENE, V18, P6434, DOI 10.1038/sj.onc.1203026; Quinlan MP, 1999, CELL GROWTH DIFFER, V10, P839; Ridley AJ, 2001, J CELL SCI, V114, P2713; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Tokman MG, 1997, CANCER RES, V57, P1785; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; VAN AL, 1997, GENE DEV, V11, P2295; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Wojciak-Stothard B, 2001, J CELL SCI, V114, P1343; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119	33	368	380	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2002	4	6					408	415		10.1038/ncb796	http://dx.doi.org/10.1038/ncb796			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	558NN	11992112				2022-12-25	WOS:000175973600010
J	Hsu, JY; Reimann, JDR; Sorensen, CS; Lukas, J; Jackson, PK				Hsu, JY; Reimann, JDR; Sorensen, CS; Lukas, J; Jackson, PK			E2F-dependent accumulation of hEmi1 regulates S phase entry by inhibiting APC(Cdh1)	NATURE CELL BIOLOGY			English	Article							ANAPHASE-PROMOTING COMPLEX; SPINDLE ASSEMBLY CHECKPOINT; CYCLIN-A; CELL-CYCLE; DEPENDENT PROTEOLYSIS; DROSOPHILA CYCLIN; UBIQUITIN LIGASE; DNA-REPLICATION; MITOSIS; ACTIVATION	Emi1 promotes mitotic entry in Xenopus laevis embryos by inhibiting the APC(Cdc20) ubiquitination complex to allow accumulation of cyclin B. We show here that human Emi1 (hEmi1) functions to promote cyclin A accumulation and S phase entry in somatic cells by inhibiting the APC(Cdh1) complex. At the G1-S transition, hEmi1 is transcriptionally induced by the E2F transcription factor, much like cyclin A. hEmi1 overexpression accelerates S phase entry and can override a G1 block caused by overexpression of Cdh1 or the E2F-inhibitor p105 retinoblastoma protein (pRb). Depleting cells of hEmi1 through RNA interference prevents accumulation of cyclin A and inhibits S phase entry. These data suggest that E2F can activate both transcription of cyclin A and the hEmi1-dependent stabilization of APC(Cdh1) targets, such as cyclin A, to promote S phase entry.	Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Program Biophys, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Program Canc Biol, Stanford, CA 94305 USA; Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark	Stanford University; Stanford University; Stanford University; Stanford University; Danish Cancer Society	Jackson, PK (corresponding author), Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA.			Jackson, Peter/0000-0002-1742-2539; Sorensen, Claus/0000-0001-6022-9710; Lukas, Jiri/0000-0001-9087-506X	NCI NIH HHS [CA09302] Funding Source: Medline; NIGMS NIH HHS [GM54811, GM60439, GM07365] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060439, R01GM054811, T32GM007365] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; Chen J, 2001, GENE DEV, V15, P1765, DOI 10.1101/gad.898701; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; Dong XZ, 1997, GENE DEV, V11, P94, DOI 10.1101/gad.11.1.94; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Furstenthal L, 2001, NAT CELL BIOL, V3, P715, DOI 10.1038/35087026; Geley S, 2001, J CELL BIOL, V153, P137, DOI 10.1083/jcb.153.1.137; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Grosskortenhaus R, 2002, DEV CELL, V2, P29, DOI 10.1016/S1534-5807(01)00104-6; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Kramer ER, 2000, MOL BIOL CELL, V11, P1555, DOI 10.1091/mbc.11.5.1555; Kramer ER, 1998, CURR BIOL, V8, P1207, DOI 10.1016/S0960-9822(07)00510-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Lorca T, 1998, EMBO J, V17, P3565, DOI 10.1093/emboj/17.13.3565; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Petersen BO, 2000, GENE DEV, V14, P2330, DOI 10.1101/gad.832500; Pfleger CM, 2001, GENE DEV, V15, P1759, DOI 10.1101/gad.897901; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; Reimann JDR, 2001, GENE DEV, V15, P3278, DOI 10.1101/gad.945701; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Shirayama M, 1999, NATURE, V402, P203, DOI 10.1038/46080; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; Sorensen CS, 2000, MOL CELL BIOL, V20, P7613, DOI 10.1128/MCB.20.20.7613-7623.2000; Sorensen CS, 2001, MOL CELL BIOL, V21, P3692, DOI 10.1128/MCB.21.11.3692-3703.2001; Sprenger F, 1997, CURR BIOL, V7, P488, DOI 10.1016/S0960-9822(06)00220-X; Sudo T, 2001, EMBO J, V20, P6499, DOI 10.1093/emboj/20.22.6499; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vidwans SJ, 2001, NAT CELL BIOL, V3, pE35, DOI 10.1038/35050681; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721	48	267	274	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAY	2002	4	5					358	366		10.1038/ncb785	http://dx.doi.org/10.1038/ncb785			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	547GR	11988738				2022-12-25	WOS:000175325100017
J	Lemischka, I				Lemischka, I			Rethinking somatic stem cell plasticity	NATURE BIOTECHNOLOGY			English	Editorial Material							MARROW		Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Lemischka, I (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.							Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; McKinney-Freeman SL, 2002, P NATL ACAD SCI USA, V99, P1341, DOI 10.1073/pnas.032438799; Morshead CM, 2002, NAT MED, V8, P268, DOI 10.1038/nm0302-268; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; WU AM, 1967, J CELL PHYSIOL, V69, P177, DOI 10.1002/jcp.1040690208; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729	8	18	20	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2002	20	5					425	425		10.1038/nbt0502-425	http://dx.doi.org/10.1038/nbt0502-425			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	548AE	11981543	Bronze			2022-12-25	WOS:000175364800008
J	Miyagishi, M; Taira, K				Miyagishi, M; Taira, K			U6 promoter-driven siRNAs with four uridine 3 ' overhangs efficiently suppress targeted gene expression in mammalian cells	NATURE BIOTECHNOLOGY			English	Article							DOUBLE-STRANDED-RNA; INTERFERENCE; TRANSCRIPTION	The first evidence for gene disruption by double-stranded RNA (dsRNA) came from careful analysis in Caenorhabditis elegans(1). This phenomenon, called RNA interference (RNAi), was observed subsequently in various organisms, including plants, nematodes, Drosophila, and protozoans(2-5). Very recently, it has been reported that in mammalian cells, 21- or 22-nucleotide (nt) RNAs with 2-nt 3 overhangs (small inhibitory RNAs, siRNAs) exhibit an RNAi effect(6,7). This is because siRNAs are not recognized by the well-characterized host defense system against viral infections, involving dsRNA-dependent inhibition of protein synthesis. However, the current method for introducing synthetic siRNA into cells by lipofection restricts the range of applications of RNAi as a result of the low transfection efficiencies in some cell types and/or short-term persistence of silencing effects(8). Here, we report a vector-based siRNA expression system that can induce RNAi in mammalian cells. This technical advance for silencing gene expression not only facilitates a wide range of functional analysis of mammalian genes but might also allow therapeutic applications by means of vector-mediated RNAi.	Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Tokyo 1138656, Japan; Natl Inst Adv Ind Sci & Technol, Gene Discovery Res Ctr, Tsukuba 3058562, Japan	University of Tokyo; National Institute of Advanced Industrial Science & Technology (AIST)	Taira, K (corresponding author), Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Tokyo 1138656, Japan.		Miyagishi, Makoto/L-8174-2016	Miyagishi, Makoto/0000-0001-7654-3616				Akashi H, 2001, ANTISENSE NUCLEIC A, V11, P359, DOI 10.1089/108729001753411326; BOGENHAGEN DF, 1981, CELL, V24, P261, DOI 10.1016/0092-8674(81)90522-5; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; CHITTENDEN T, 1989, J VIROL, V63, P3016, DOI 10.1128/JVI.63.7.3016-3025.1989; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Fire A, 1999, TRENDS GENET, V15, P358, DOI 10.1016/S0168-9525(99)01818-1; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Hammond SM, 2001, NAT REV GENET, V2, P110, DOI 10.1038/35052556; Kawasaki H, 2002, NAT BIOTECHNOL, V20, P376, DOI 10.1038/nbt0402-376; KAWASAKI H, IN PRESS EMBO REP; Miyagishi M, 2000, J BIOL CHEM, V275, P35170, DOI 10.1074/jbc.C000258200; Ohkawa J, 2000, HUM GENE THER, V11, P577, DOI 10.1089/10430340050015761; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Sharp PA, 2001, GENE DEV, V15, P485, DOI 10.1101/gad.880001; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; Warashina M, 2001, P NATL ACAD SCI USA, V98, P5572, DOI 10.1073/pnas.091411398; Yang SC, 2001, MOL CELL BIOL, V21, P7807, DOI 10.1128/MCB.21.22.7807-7816.2001; Zamore PD, 2001, NAT STRUCT BIOL, V8, P746, DOI 10.1038/nsb0901-746	20	589	1008	0	31	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2002	20	5					497	500		10.1038/nbt0502-497	http://dx.doi.org/10.1038/nbt0502-497			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	548AE	11981564				2022-12-25	WOS:000175364800033
J	Swank, DM; Knowles, AF; Suggs, JA; Sarsoza, F; Lee, A; Maughan, DW; Bernstein, SI				Swank, DM; Knowles, AF; Suggs, JA; Sarsoza, F; Lee, A; Maughan, DW; Bernstein, SI			The myosin converter domain modulates muscle performance	NATURE CELL BIOLOGY			English	Article							HEAVY-CHAIN GENE; DROSOPHILA-MELANOGASTER; FLIGHT-MUSCLE; POWER OUTPUT; MUTATIONS; KINETICS; REGIONS; MOTORS; FORCE	Myosin is the molecular motor that powers muscle contraction as a result of conformational changes during its mechanochemical cycle. We demonstrate that the converter, a compact structural domain that differs in sequence between Drosophila melanogaster myosin isoforms, dramatically influences the kinetic properties of myosin and muscle fibres. Transgenic replacement of the converter in the fast indirect flight muscle with the converter from an embryonic muscle slowed muscle kinetics, forcing a compensatory reduction in wing beat frequency to sustain flight. Conversely, replacing the embryonic converter with the flight muscle converter sped up muscle kinetics and increased maximum power twofold, compared to flight muscles expressing the embryonic myosin isoform. The substitutions also dramatically influenced in vitro actin sliding velocity, suggesting that the converter modulates a rate-limiting step preceding cross-bridge detachment. Our integrative analysis demonstrates that isoform-specific differences in the myosin converter allow different muscle types to meet their specific locomotion demands.	San Diego State Univ, Dept Biol, Inst Mol Biol, San Diego, CA 92182 USA; San Diego State Univ, Inst Heart, San Diego, CA 92182 USA; San Diego State Univ, Dept Chem, San Diego, CA 92182 USA; Univ Vermont, Dept Physiol & Mol Biophys, Burlington, VT 05405 USA	California State University System; San Diego State University; California State University System; San Diego State University; California State University System; San Diego State University; University of Vermont	Swank, DM (corresponding author), San Diego State Univ, Dept Biol, Inst Mol Biol, San Diego, CA 92182 USA.	dswank@sciences.sdsu.edu		Bernstein, Sanford/0000-0001-7094-5390	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032443, R25GM058906] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 32443, GM 58906] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bagshaw CR., 1993, MUSCLE CONTRACTION, DOI 10.1007/978-94-015-6839-5; Bernstein SI, 1997, J MOL BIOL, V271, P1, DOI 10.1006/jmbi.1997.1160; BRENNER B, 1988, P NATL ACAD SCI USA, V85, P3265, DOI 10.1073/pnas.85.9.3265; COLLIER VL, 1990, GENE DEV, V4, P885, DOI 10.1101/gad.4.6.885; CRIPPS RM, 1994, J CELL BIOL, V126, P689, DOI 10.1083/jcb.126.3.689; CURTSINGER JW, 1981, GENETICS, V98, P549; Dickinson MH, 1997, BIOPHYS J, V73, P3122, DOI 10.1016/S0006-3495(97)78338-3; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; DRUMMOND DR, 1991, MOL GEN GENET, V226, P70, DOI 10.1007/BF00273589; Geeves MA, 2000, J BIOL CHEM, V275, P21624, DOI 10.1074/jbc.M000342200; GEORGE EL, 1989, MOL CELL BIOL, V9, P2957, DOI 10.1128/MCB.9.7.2957; Holmes KC, 1997, CURR BIOL, V7, pR112, DOI 10.1016/S0960-9822(06)00051-0; Houdusse A, 2001, CURR OPIN STRUC BIOL, V11, P182, DOI 10.1016/S0959-440X(00)00188-3; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; HUXLEY AF, 1973, COLD SPRING HARB SYM, V37, P669, DOI 10.1101/SQB.1973.037.01.081; HYATT CJ, 1994, BIOPHYS J, V67, P1149, DOI 10.1016/S0006-3495(94)80582-X; Josephson RK, 2000, J EXP BIOL, V203, P2713; Lehmann FO, 1997, J EXP BIOL, V200, P1133; Lu BD, 1999, DEV BIOL, V216, P312, DOI 10.1006/dbio.1999.9488; MOLLOY JE, 1987, NATURE, V328, P449, DOI 10.1038/328449a0; Murphy CT, 2000, J MUSCLE RES CELL M, V21, P139, DOI 10.1023/A:1005610007209; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RAYMENT I, 1995, P NATL ACAD SCI USA, V92, P3864, DOI 10.1073/pnas.92.9.3864; REEDY MC, 1993, DEV BIOL, V160, P443, DOI 10.1006/dbio.1993.1320; Regnier M, 1996, BIOPHYS J, V71, P2786, DOI 10.1016/S0006-3495(96)79471-7; Rome LC, 1999, P NATL ACAD SCI USA, V96, P5826, DOI 10.1073/pnas.96.10.5826; Rosenfeld SS, 2000, J BIOL CHEM, V275, P25418, DOI 10.1074/jbc.M002685200; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; Swank DM, 2000, MICROSC RES TECHNIQ, V50, P430, DOI 10.1002/1097-0029(20000915)50:6<430::AID-JEMT2>3.0.CO;2-E; Swank DM, 2001, J BIOL CHEM, V276, P15117, DOI 10.1074/jbc.M008379200; Wells L, 1996, EMBO J, V15, P4454, DOI 10.1002/j.1460-2075.1996.tb00822.x	31	61	61	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2002	4	4					312	316		10.1038/ncb776	http://dx.doi.org/10.1038/ncb776			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	541PY	11901423				2022-12-25	WOS:000174994000020
J	Feuerbach, F; Galy, V; Trelles-Sticken, E; Fromont-Racine, M; Jacquier, A; Gilson, E; Olivo-Marin, JC; Scherthan, H; Nehrbass, U				Feuerbach, F; Galy, V; Trelles-Sticken, E; Fromont-Racine, M; Jacquier, A; Gilson, E; Olivo-Marin, JC; Scherthan, H; Nehrbass, U			Nuclear architecture and spatial positioning help establish transcriptional states of telomeres in yeast	NATURE CELL BIOLOGY			English	Article							SACCHAROMYCES-CEREVISIAE; PORE COMPLEX; CENTROMERIC HETEROCHROMATIN; GENE DELETION; PROTEINS; CHROMOSOME; LOCALIZATION; ORGANIZATION; REPRESSION; CHROMATIN	Recent experiments have shown that gene repression can be correlated with relocation of genes to heterochromatin-rich silent domains. Here, we investigate whether nuclear architecture and spatial positioning can contribute directly to the transcriptional activity of a genetic locus in Saccharomyces cerevisiae. By disassembling telomeric silent domains without altering the chromatin-mediated silencing machinery, we show that the transcriptional activity of silencer-reporter constructs depends on intranuclear position. This demonstrates that telomeric silent domains are actively involved in transcriptional silencing. Employing fluorescent in situ hybridization (FISH) in combination with genetic assays, we demonstrate that telomeres control the establishment of transcriptional states by reversible partitioning with the perinuclear silencing domains. Anchoring telomeres interferes with their ability to assume an active state, whereas disassembly of silencing domains prevents telomeres from assuming a repressed state. Our data support a model in which domains of enriched transcriptional regulators allow genes to determine transcriptional states by spatial positioning.	Inst Pasteur, Lab Biol Cellulaire Noyau, CNRS, URA1773, F-75724 Paris 15, France; Inst Pasteur, Unite Genet Interact Macromol, F-75724 Paris, France; Inst Pasteur, Lab Anal Images Quantitat, F-75724 Paris 15, France; Univ Kaiserslautern, Abt Humanbiol, D-67663 Kaiserslautern, Germany; Ecole Normale Super Lyon, Mol & Cellular Biol Lab, CNRS, UMR5665, F-69364 Lyon, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Kaiserslautern; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON)	Nehrbass, U (corresponding author), Inst Pasteur, Lab Biol Cellulaire Noyau, CNRS, URA1773, 25 Rue Dr Roux, F-75724 Paris 15, France.		Olivo-Marin, Jean-Christophe/K-4428-2015	Olivo-Marin, Jean-Christophe/0000-0001-6796-0696; Fromont-Racine, Micheline/0000-0001-9906-0334; Nehrbass, Ulf/0000-0002-7028-8076; feuerbach, frank/0000-0002-8631-5120; JACQUIER, ALAIN/0000-0001-5707-9184				Andrulis ED, 1998, NATURE, V395, P525, DOI 10.1038/26795; APARICIO OM, 1994, GENE DEV, V8, P1133, DOI 10.1101/gad.8.10.1133; ARIS JP, 1989, J CELL BIOL, V108, P2059, DOI 10.1083/jcb.108.6.2059; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; Brown KE, 1999, MOL CELL, V3, P207, DOI 10.1016/S1097-2765(00)80311-1; Brown KE, 2001, NAT CELL BIOL, V3, P602, DOI 10.1038/35078577; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; Cockell M, 1999, CURR OPIN GENET DEV, V9, P199, DOI 10.1016/S0959-437X(99)80030-6; Cooper JP, 2000, CURR OPIN GENET DEV, V10, P169; Dernburg AF, 1996, CELL, V85, P745, DOI 10.1016/S0092-8674(00)81240-4; Fourel G, 1999, EMBO J, V18, P2522, DOI 10.1093/emboj/18.9.2522; Francastel C, 2000, NAT REV MOL CELL BIO, V1, P137, DOI 10.1038/35040083; Francastel C, 1999, CELL, V99, P259, DOI 10.1016/S0092-8674(00)81657-8; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Galy V, 2000, NATURE, V403, P108, DOI 10.1038/47528; Gerasimova TI, 2000, MOL CELL, V6, P1025, DOI 10.1016/S1097-2765(00)00101-5; Gotta M, 1996, J CELL BIOL, V134, P1349, DOI 10.1083/jcb.134.6.1349; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KINSELLA BT, 1992, J BIOL CHEM, V267, P3940; Kosova B, 2000, J BIOL CHEM, V275, P343, DOI 10.1074/jbc.275.1.343; Laroche T, 1998, CURR BIOL, V8, P653, DOI 10.1016/S0960-9822(98)70252-0; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; LOUIS EJ, 1994, GENETICS, V136, P789; Maillet L, 2001, EMBO REP, V2, P203, DOI 10.1093/embo-reports/kve044; Maillet L, 1996, GENE DEV, V10, P1796, DOI 10.1101/gad.10.14.1796; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; OLIVOMARIN J, 2001, IN PRESS PATTERN REC; Rose MD., 1990, METHODS YEAST GENETI; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; SCHERTHAN H, 1992, CHROMOSOMA, V101, P590, DOI 10.1007/BF00360535; SIKORSKI RS, 1989, GENETICS, V122, P19; Skok JA, 2001, NAT IMMUNOL, V2, P848, DOI 10.1038/ni0901-848; Strambio-de-Castillia C, 1999, J CELL BIOL, V144, P839, DOI 10.1083/jcb.144.5.839; Teixeira MT, 1997, EMBO J, V16, P5086, DOI 10.1093/emboj/16.16.5086; Tham WH, 2001, MOL CELL, V8, P189, DOI 10.1016/S1097-2765(01)00287-8; Trelles-Sticken E, 1999, J CELL SCI, V112, P651	38	146	153	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAR	2002	4	3					214	221		10.1038/ncb756	http://dx.doi.org/10.1038/ncb756			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	527VR	11862215				2022-12-25	WOS:000174209100014
J	Simmen, T; Honing, S; Icking, A; Tikkanen, R; Hunziker, W				Simmen, T; Honing, S; Icking, A; Tikkanen, R; Hunziker, W			AP-4 binds basolateral signals and participates in basolateral sorting in epithelial MDCK cells	NATURE CELL BIOLOGY			English	Article							HUMAN TRANSFERRIN RECEPTOR; CYTOPLASMIC DOMAIN; NEURONAL POLARITY; LDL RECEPTOR; COMPLEX; PROTEIN; ENDOCYTOSIS; REQUIREMENTS; SPECIFICITY; TRANSPORT	Adaptors are heterotetrameric complexes that mediate the incorporation of cargo into transport vesicles by interacting with sorting signals present in the cytosolic domain of transmembrane proteins. Four adaptors, AP-1 (beta1, gamma, mu1A or mu1B, sigma1), AP-2 (beta2, alpha, mu2, sigma2), AP-3 (beta3, delta, mu3, sigma3) or AP-4 (beta4, epsilonc, mu4, sigma4), have been characterized(1,2). AP1 and AP-3 mediate sorting events at the level of the TGN and/or endosomes, whereas AP-2 functions in endocytic clathrin coated vesicle formation; no function is known so far for AP-4. Here, we show that AP-4 can bind different types of cytosolic signals known to mediate basolateral transport in epithelial cells. Furthermore, in MDCK cells with depleted mu4 protein levels, several basolateral proteins are mis-sorted to the apical surface, showing that AP-4 participates in basolateral sorting in epithelial cells.	Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland; Univ Gottingen, D-37073 Gottingen, Germany; Univ Bonn, Inst Cell Biol, D-53122 Bonn, Germany; Inst Mol & Cell Biol, Singapore 117609, Singapore	University of Lausanne; University of Gottingen; University of Bonn; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Hunziker, W (corresponding author), Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland.	hunziker@imcb.nus.edu.sg	Hunziker, Walter/GSM-8190-2022; Hunziker, Walter/B-3140-2010	Hunziker, Walter/0000-0002-5265-4933; Tikkanen, Ritva/0000-0002-8393-1825	Fondazione Telethon Funding Source: Custom	Fondazione Telethon(Fondazione Telethon)		Aguilar RC, 2001, J BIOL CHEM, V276, P13145, DOI 10.1074/jbc.M010591200; AROETI B, 1994, EMBO J, V13, P2297, DOI 10.1002/j.1460-2075.1994.tb06513.x; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Bradke F, 2000, CURR OPIN NEUROBIOL, V10, P574, DOI 10.1016/S0959-4388(00)00124-0; Bresciani R, 1997, BIOCHEM J, V327, P811, DOI 10.1042/bj3270811; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; Dell'Angelica EC, 1999, J BIOL CHEM, V274, P7278, DOI 10.1074/jbc.274.11.7278; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; FUTTER CE, 1995, J BIOL CHEM, V270, P10999, DOI 10.1074/jbc.270.18.10999; Hirst J, 1999, MOL BIOL CELL, V10, P2787, DOI 10.1091/mbc.10.8.2787; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; Hunziker W, 1991, Semin Cell Biol, V2, P397; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; Keller P, 1997, J CELL SCI, V110, P3001; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Musch A, 1996, J CELL BIOL, V133, P543, DOI 10.1083/jcb.133.3.543; Odorizzi G, 1997, J CELL BIOL, V137, P1255, DOI 10.1083/jcb.137.6.1255; Ohno H, 1999, FEBS LETT, V449, P215, DOI 10.1016/S0014-5793(99)00432-9; PODBILEWICZ B, 1990, EMBO J, V9, P3477, DOI 10.1002/j.1460-2075.1990.tb07556.x; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; Simmen T, 1999, MOL CELL BIOL, V19, P3136; Stephens DJ, 1998, BIOCHEM J, V335, P567, DOI 10.1042/bj3350567; TOKUYASU KT, 1986, J MICROSC-OXFORD, V143, P139, DOI 10.1111/j.1365-2818.1986.tb02772.x; Winckler B, 1999, NEURON, V23, P637, DOI 10.1016/S0896-6273(01)80021-0; Yeaman C, 1999, PHYSIOL REV, V79, P73, DOI 10.1152/physrev.1999.79.1.73; YOKODE M, 1992, J CELL BIOL, V117, P39, DOI 10.1083/jcb.117.1.39; Yoshimori T, 1996, J CELL BIOL, V133, P247, DOI 10.1083/jcb.133.2.247	31	161	169	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2002	4	2					154	159		10.1038/ncb745	http://dx.doi.org/10.1038/ncb745			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	520RJ	11802162				2022-12-25	WOS:000173794600020
J	Burger, KNJ; Staffhorst, RWHM; de Vijlder, HC; Velinova, MJ; Bomans, PH; Frederik, PM; de Kruijff, B				Burger, KNJ; Staffhorst, RWHM; de Vijlder, HC; Velinova, MJ; Bomans, PH; Frederik, PM; de Kruijff, B			Nanocapsules: lipid-coated aggregates of cisplatin with high cytotoxicity	NATURE MEDICINE			English	Article							PHOSPHOLIPID-VESICLES; LIPOSOMES; PHOSPHATIDYLSERINE; COMPLEXES; CHEMISTRY	Cisplatin is one of the most widely used agents in the treatment of solid tumors, but its clinical utility is limited by toxicity. The development of less toxic, liposomal formulations of cisplatin has been hampered by the low water solubility and low lipophilicity of cisplatin, resulting in very low encapsulation efficiencies. We describe a novel method allowing the efficient encapsulation of cisplatin in a lipid formulation; it is based on repeated freezing and thawing of a concentrated solution of cisplatin in the presence of negatively charged phospholipids. The method is unique in that it generates nanocapsules, which area small aggregates of cisplatin covered by a single lipid bilayer. The nanocapsules have an unprecedented drug-to-lipid ratio and an in vitro cytotoxicity up to 1000-fold higher than the free drug. Analysis of the mechanism of nanocapsule formation suggests that the method may be generalized to other drugs showing low water solubility and lipophilicity.	Univ Utrecht, Dept Biochem Membranes, Ctr Biomembranes & Lipid Enzymol, Inst Biomembranes, Utrecht, Netherlands; Univ Limburg, Dept Pathol, EM Unit, NL-6200 MD Maastricht, Netherlands	Utrecht University; Hasselt University; Maastricht University	Burger, KNJ (corresponding author), Univ Utrecht, Dept Biochem Membranes, Ctr Biomembranes & Lipid Enzymol, Inst Biomembranes, Utrecht, Netherlands.							APPLETON TG, 1984, INORG CHEM, V23, P3514, DOI 10.1021/ic00190a016; Bandak S, 1999, ANTI-CANCER DRUG, V10, P911, DOI 10.1097/00001813-199911000-00007; Burger KNJ, 1999, BBA-BIOMEMBRANES, V1419, P43, DOI 10.1016/S0005-2736(99)00052-8; BURNELL EE, 1980, BIOCHIM BIOPHYS ACTA, V603, P63, DOI 10.1016/0005-2736(80)90391-0; CHAPMAN CJ, 1991, CHEM PHYS LIPIDS, V60, P201, DOI 10.1016/0009-3084(91)90042-A; FREDERIK PM, 1989, J MICROSC-OXFORD, V153, P81, DOI 10.1111/j.1365-2818.1989.tb01469.x; HOPE MJ, 1986, CHEM PHYS LIPIDS, V40, P89, DOI 10.1016/0009-3084(86)90065-4; HOWEGRANT ME, 1980, MET IONS BIOL SYST, V11, P63; LEWIS BA, 1983, J MOL BIOL, V166, P211, DOI 10.1016/S0022-2836(83)80007-2; Lippert B., 1999, CISPLATIN CHEM BIOCH; LONG DF, 1981, BIOPHARM DRUG DISPOS, V2, P1, DOI 10.1002/bdd.2510020102; Newman MS, 1999, CANCER CHEMOTH PHARM, V43, P1, DOI 10.1007/s002800050855; PerezSoler R, 1997, CLIN CANCER RES, V3, P373; Reedijk J, 1999, CHEM REV, V99, P2499, DOI 10.1021/cr980422f; RILEY CM, 1985, ANAL PROFILES DRUG S, V14, P78; Sharma A, 1997, INT J PHARM, V154, P123, DOI 10.1016/S0378-5173(97)00135-X; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Speelmans G, 1997, BIOCHEMISTRY-US, V36, P10545, DOI 10.1021/bi9703047; STEERENBERG PA, 1988, CANCER CHEMOTH PHARM, V21, P299, DOI 10.1007/BF00264195; SUR B, 1983, ONCOLOGY, V40, P372, DOI 10.1159/000225765	20	157	169	1	54	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2002	8	1					81	84		10.1038/nm0102-81	http://dx.doi.org/10.1038/nm0102-81			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	507XQ	11786911	Green Published			2022-12-25	WOS:000173056900035
J	Schwarz, A; Stander, S; Berneburg, M; Bohm, M; Kulms, D; van Steeg, H; Grosse-Heitmeyer, K; Krutmann, J; Schwarz, T				Schwarz, A; Stander, S; Berneburg, M; Bohm, M; Kulms, D; van Steeg, H; Grosse-Heitmeyer, K; Krutmann, J; Schwarz, T			Interleukin-12 suppresses ultraviolet radiation-induced apoptosis by inducing DNA repair	NATURE CELL BIOLOGY			English	Article							NUCLEOTIDE EXCISION-REPAIR; PROTECTS TRANSFORMED KERATINOCYTES; SKIN-CANCER; CYTOKINE PRODUCTION; HUMAN-LYMPHOCYTES; CELL-LINES; LIGAND; ACTIVATION; DAMAGE; UVB	Induction of apoptosis of keratinocytes by ultraviolet (UV) radiation is a protective phenomenon relevant in limiting the survival of cells with irreparable DNA damage. Changes in UV-induced apoptosis may therefore have significant impact on photocarcinogenesis. We have found that the immunomodulatory cytokine IL-12 suppresses UV-mediated apoptosis of keratinocytes both in vitro and in vivo. IL-12 caused a remarkable reduction in UV-specific DNA lesions which was due to induction of DNA repair. In accordance with this, IL-12 induced the expression of particular components of the nucleotide-excision repair complex. Our results show that cytokines can protect cells from apoptosis induced by DNA-damaging UV radiation by inducing DNA repair, and that nucleotide-excision repair can be manipulated by cytokines.	Univ Munster, Dept Dermatol, Ludwig Boltzmann Inst Cell Biol & Immunobiol Skin, D-48149 Munster, Germany; Univ Dusseldorf, Dept Dermatol, D-40225 Dusseldorf, Germany; Natl Inst Publ Hlth & Environm, Hlth Effects Res Lab, NL-3720 BA Bilthoven, Netherlands	University of Munster; Heinrich Heine University Dusseldorf; Netherlands National Institute for Public Health & the Environment	Schwarz, A (corresponding author), Univ Munster, Dept Dermatol, Ludwig Boltzmann Inst Cell Biol & Immunobiol Skin, Esmarchstr 58, D-48149 Munster, Germany.		Schwarz, Thomas/A-9148-2010; Kulms, Dagmar/H-1653-2014	Stander, Sonja/0000-0003-3612-7786				ARAGANE Y, 1994, J IMMUNOL, V153, P5366; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; ARLETT CF, 1993, CANCER RES, V53, P609; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; Duckett CS, 1998, MOL CELL BIOL, V18, P608, DOI 10.1128/MCB.18.1.608; Eller MS, 1997, P NATL ACAD SCI USA, V94, P12627, DOI 10.1073/pnas.94.23.12627; FAIRBAIRN DW, 1995, MUTAT RES-REV GENET, V339, P37, DOI 10.1016/0165-1110(94)00013-3; Gloster HM, 1996, DERMATOL SURG, V22, P217, DOI 10.1111/j.1524-4725.1996.tb00312.x; GREEN MHL, 1992, MUTAT RES, V273, P137, DOI 10.1016/0921-8777(92)90075-E; Hill LL, 1999, SCIENCE, V285, P898, DOI 10.1126/science.285.5429.898; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; HWANG BJ, 1993, BIOCHEMISTRY-US, V32, P1657, DOI 10.1021/bi00057a033; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; Koch F, 1996, J EXP MED, V184, P741, DOI 10.1084/jem.184.2.741; Kothny-Wilkes G, 1999, J BIOL CHEM, V274, P28916, DOI 10.1074/jbc.274.41.28916; Kothny-Wilkes G, 1998, J BIOL CHEM, V273, P29247, DOI 10.1074/jbc.273.44.29247; KRAEMER KH, 1994, ARCH DERMATOL, V130, P1018, DOI 10.1001/archderm.130.8.1018; Kulms D, 1999, P NATL ACAD SCI USA, V96, P7974, DOI 10.1073/pnas.96.14.7974; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Leverkus M, 1997, EXP CELL RES, V232, P255, DOI 10.1006/excr.1997.3514; Luger TA, 1995, PHOTOIMMUNOLOGY, P55; Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; Murphy G, 2001, EXP DERMATOL, V10, P155, DOI 10.1034/j.1600-0625.2001.010003155.x; Nishigori C, 1996, P NATL ACAD SCI USA, V93, P10354, DOI 10.1073/pnas.93.19.10354; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; PATRICK MH, 1977, PHOTOCHEM PHOTOBIOL, V25, P357, DOI 10.1111/j.1751-1097.1977.tb07355.x; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; RIVAS JM, 1992, J IMMUNOL, V148, P3133; Runger TM, 2000, INT J RADIAT BIOL, V76, P789, DOI 10.1080/09553000050028940; Schmitt DA, 2000, IMMUNOLOGY, V101, P90, DOI 10.1046/j.1365-2567.2000.00084.x; Schwarz A, 1996, J INVEST DERMATOL, V106, P1187, DOI 10.1111/1523-1747.ep12347944; SCHWARZ A, 1995, J INVEST DERMATOL, V104, P922, DOI 10.1111/1523-1747.ep12606202; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; SIMON MM, 1995, J CLIN INVEST, V95, P926, DOI 10.1172/JCI117800; Stege H, 2000, P NATL ACAD SCI USA, V97, P1790, DOI 10.1073/pnas.030528897; TRINCHIERI G, 1993, IMMUNOL TODAY, V14, P335, DOI 10.1016/0167-5699(93)90230-I; van Oosten M, 2000, P NATL ACAD SCI USA, V97, P11268, DOI 10.1073/pnas.200226697; WOLF P, 1995, J INVEST DERMATOL, V104, P287, DOI 10.1111/1523-1747.ep12612828; Wright SC, 1998, CANCER RES, V58, P5570; YAROSH D, 1994, J INVEST DERMATOL, V103, P461, DOI 10.1111/1523-1747.ep12395551; YAROSH D, 1992, CANCER RES, V52, P4227; ZernikKobak M, 1997, J BIOL CHEM, V272, P23896, DOI 10.1074/jbc.272.38.23896; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	46	200	205	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JAN	2002	4	1					26	31		10.1038/ncb717	http://dx.doi.org/10.1038/ncb717			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	513MC	11780128				2022-12-25	WOS:000173381500012
J	Eyckerman, S; Verhee, A; Van der Heyden, J; Lemmens, I; Van Ostade, X; Vandekerckhove, J; Tavernier, J				Eyckerman, S; Verhee, A; Van der Heyden, J; Lemmens, I; Van Ostade, X; Vandekerckhove, J; Tavernier, J			Design and application of a cytokine-receptor-based interaction trap	NATURE CELL BIOLOGY			English	Article							PROTEIN-PROTEIN INTERACTIONS; SIGNAL-TRANSDUCTION; LEPTIN RECEPTOR; OB RECEPTOR; IDENTIFICATION; ACTIVATION; GENES; MUTATIONS; MOTIFS; SYSTEM	Ligand-induced clustering of type I cytokine receptor subunits leads to trans-phosphorylation and activation of associated cytosolic janus kinases (JAKs). In turn, JAKs phosphorylate tyrosine residues in the receptor tails, leading to recruitment and activation of signalling molecules'. Among these, signal transducers and activators of transcription (STATs) are important in the direct transmission of signals to the nucleus(2). Here, we show that incorporation of an interaction trap in a signalling-deficient receptor allows the identification of protein-protein interactions, using a STAT-dependent complementation assay. Mammalian protein-protein interaction trap (MAPPIT) adds to existing yeast two-hybrid procedures, as originally explored by Fields and Song(3), and permits the detection of both modification-independent and of phosphorylation-dependent interactions in intact human cells. We also demonstrate that MAPPIT can be used to screen complex complementary DNA libraries, and using this approach, we identify cytokine-inducible SH2-containing protein (CIS) and suppressor of cytokine signalling-2 (SOCS-2) as interaction partners of the phosphotyrosine 402 (Tyr 402)-binding motif in the erythropoietin receptor (EpoR). Importantly, this approach places protein-protein interactions in their normal physiological context, and is especially applicable to the in situ analysis of signal transduction pathways.	State Univ Ghent VIB, Fac Med & Hlth Sci, Dept Med Prot Res, B-9000 Ghent, Belgium	Flanders Institute for Biotechnology (VIB); Ghent University	Eyckerman, S (corresponding author), State Univ Ghent VIB, Fac Med & Hlth Sci, Dept Med Prot Res, V1B09,KL Ledeganckstr 35, B-9000 Ghent, Belgium.	jan.tavernier@rug.ac.be	Tavernier, Jan/AAG-3636-2019; Van Ostade, Xaveer/AAG-9587-2020; Van Ostade, Xaveer WMP/D-1702-2015	Van Ostade, Xaveer WMP/0000-0003-4078-3014				Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Brent R, 1997, ANNU REV GENET, V31, P663, DOI 10.1146/annurev.genet.31.1.663; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Carpenter LR, 1998, P NATL ACAD SCI USA, V95, P6061, DOI 10.1073/pnas.95.11.6061; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Eyckerman S, 2000, FEBS LETT, V486, P33, DOI 10.1016/S0014-5793(00)02205-5; Eyckerman S, 1999, EUR CYTOKINE NETW, V10, P549; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; JOHNSSON N, 1994, P NATL ACAD SCI USA, V91, P10340, DOI 10.1073/pnas.91.22.10340; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; Kojima T, 1999, NAT BIOTECHNOL, V17, P487, DOI 10.1038/8666; LI B, 1993, FASEB J, V7, P957, DOI 10.1096/fasebj.7.10.8344494; Li C, 1999, P NATL ACAD SCI USA, V96, P9677, DOI 10.1073/pnas.96.17.9677; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Nicholson SE, 2000, P NATL ACAD SCI USA, V97, P6493, DOI 10.1073/pnas.100135197; Pandey A, 2000, NATURE, V405, P837, DOI 10.1038/35015709; Pattyn E, 1999, J BIOL CHEM, V274, P34838, DOI 10.1074/jbc.274.49.34838; Rossi F, 1997, P NATL ACAD SCI USA, V94, P8405, DOI 10.1073/pnas.94.16.8405; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; Schmitz J, 2000, J IMMUNOL, V164, P848, DOI 10.4049/jimmunol.164.2.848; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; TARGAGLIA LA, 1995, CELL, V83, P1263; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; Waelput W, 2000, BIOCHEM J, V348, P55, DOI 10.1042/0264-6021:3480055; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; ZORULYA S, 1999, NAT BIOTECHNOL, V17, P1193	26	163	180	0	32	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2001	3	12					1114	1119		10.1038/ncb1201-1114	http://dx.doi.org/10.1038/ncb1201-1114			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	500AM	11781573				2022-12-25	WOS:000172603700017
J	Kuroiwa, Y; Kasinathan, P; Choi, YJ; Naeem, R; Tomizuka, K; Sullivan, EJ; Knott, JG; Duteau, A; Goldsby, RA; Osborne, BA; Ishida, I; Robl, JM				Kuroiwa, Y; Kasinathan, P; Choi, YJ; Naeem, R; Tomizuka, K; Sullivan, EJ; Knott, JG; Duteau, A; Goldsby, RA; Osborne, BA; Ishida, I; Robl, JM			Cloned transchromosomic calves producing human immunoglobulin	NATURE BIOTECHNOLOGY			English	Article							NUCLEAR TRANSFER; HEAVY-CHAIN; MICE; CELL; EXPRESSION; GENE; DIVERSIFICATION; CONSTRUCTION; ANTIBODIES; DIVERSITY	Human polyclonal antibodies (hPABs) are useful therapeutics, but because they are available only from human donors, their supply and application is limited. To address this need, we prepared a human artificial chromosome (HAC) vector containing the entire unrearranged sequences of the human immunoglobulin (hIg) heavy-chain (H) and lambda (lambda) light-chain loci. The HAC vector was introduced into bovine primary fetal fibroblasts using a microcell-mediated chromosome transfer (MMCT) approach. Primary selection was carried out, and the cells were used to produce cloned bovine fetuses. Secondary selection was done on the regenerated fetal cell lines, which were then used to produce four healthy transchromosomic (Tc) calves. The HAC was retained at a high rate (78-100% of cells) in calves and the hIg loci underwent rearrangement and expressed diversified transcripts. Human immunoglobulin proteins were detected in the blood of newborn calves. The production of Tc calves is an important step in the development of a system for producing therapeutic hPABs.	Kirin Brewery Co Ltd, Pharmaceut Res Lab, Gunma 3701295, Japan; Hematech LLC, Westport, CT 06880 USA; Amherst Coll, Dept Biol, Amherst, MA 01002 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA	Kirin Brewery Company Limited; Amherst College; Baylor College of Medicine; University of Massachusetts System; University of Massachusetts Amherst	Ishida, I (corresponding author), Kirin Brewery Co Ltd, Pharmaceut Res Lab, 3 Miyahara Cho, Gunma 3701295, Japan.	i-ishida@kirin.co.jp; jrobl@hematech.com		Sullivan, Eddie/0000-0001-7468-2006				Aitken R, 1999, VET IMMUNOL IMMUNOP, V72, P21, DOI 10.1016/S0165-2427(99)00113-0; Barch MJ, 1997, AGT CYTOGENETICS LAB; BRUGGEMANN M, 1991, EUR J IMMUNOL, V21, P1323, DOI 10.1002/eji.1830210535; Butler JE, 1998, REV SCI TECH OIE, V17, P43, DOI 10.20506/rst.17.1.1096; Cibelli JB, 1998, NAT BIOTECHNOL, V16, P642, DOI 10.1038/nbt0798-642; Cibelli JB, 1998, SCIENCE, V280, P1256, DOI 10.1126/science.280.5367.1256; Dai YF, 2002, NAT BIOTECHNOL, V20, P251, DOI 10.1038/nbt0302-251; Denning C, 2001, NAT BIOTECHNOL, V19, P559, DOI 10.1038/89313; Harrington JJ, 1997, NAT GENET, V15, P345, DOI 10.1038/ng0497-345; Ikeno M, 1998, NAT BIOTECHNOL, V16, P431, DOI 10.1038/nbt0598-431; Ishida Isao, 2002, Cloning and Stem Cells, V4, P91, DOI 10.1089/153623002753632084; Kasinathan P, 2001, BIOL REPROD, V64, P1487, DOI 10.1095/biolreprod64.5.1487; Klingbeil C, 1999, TOXICOL PATHOL, V27, P1, DOI 10.1177/019262339902700101; KUROIWA Y, IN PRESS GENE THER; Lai LX, 2002, SCIENCE, V295, P1089, DOI 10.1126/science.1068228; LONBERG N, 1994, NATURE, V368, P856, DOI 10.1038/368856a0; Loupart ML, 1998, CHROMOSOMA, V107, P255, DOI 10.1007/s004120050305; Lucier MR, 1998, J IMMUNOL, V161, P5438; McCreath KJ, 2000, NATURE, V405, P1066, DOI 10.1038/35016604; Mendez MJ, 1997, NAT GENET, V15, P146, DOI 10.1038/ng0297-146; Meyer A, 1997, Int Rev Immunol, V15, P165, DOI 10.3109/08830189709068175; Nicholson IC, 1999, J IMMUNOL, V163, P6898; Popov AV, 1999, J EXP MED, V189, P1611, DOI 10.1084/jem.189.10.1611; Shen MH, 1997, HUM MOL GENET, V6, P1375, DOI 10.1093/hmg/6.8.1375; TIZARD IR, 1996, VET IMMUNOLOGY; Tomizuka K, 1997, NAT GENET, V16, P133, DOI 10.1038/ng0697-133; Tomizuka K, 2000, P NATL ACAD SCI USA, V97, P722, DOI 10.1073/pnas.97.2.722; Wall RJ, 2002, THERIOGENOLOGY, V57, P189, DOI 10.1016/S0093-691X(01)00666-5; YAMADA M, 1991, J EXP MED, V173, P395, DOI 10.1084/jem.173.2.395; Yoshimi K, 2000, NAT BIOTECHNOL, V18, P1086, DOI 10.1038/80287; Zakhartchenko V, 2001, MOL REPROD DEV, V60, P362, DOI 10.1002/mrd.1098	31	177	275	1	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2002	20	9					889	894		10.1038/nbt727	http://dx.doi.org/10.1038/nbt727			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	589KN	12172556				2022-12-25	WOS:000177757700020
J	Luttun, A; Tjwa, M; Moons, L; Wu, Y; Angelillo-Scherrer, A; Liao, F; Nagy, JA; Hooper, A; Priller, J; De Klerck, B; Compernolle, V; Daci, E; Bohlen, P; Dewerchin, M; Herbert, JM; Fava, R; Matthys, P; Carmeliet, G; Collen, D; Dvorak, HF; Hicklin, DJ; Carmeliet, P				Luttun, A; Tjwa, M; Moons, L; Wu, Y; Angelillo-Scherrer, A; Liao, F; Nagy, JA; Hooper, A; Priller, J; De Klerck, B; Compernolle, V; Daci, E; Bohlen, P; Dewerchin, M; Herbert, JM; Fava, R; Matthys, P; Carmeliet, G; Collen, D; Dvorak, HF; Hicklin, DJ; Carmeliet, P			Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; COLLAGEN-INDUCED ARTHRITIS; TYROSINE KINASE; FACTOR RECEPTOR-1; FLT-1; VEGF; DISEASE; CELLS; ARTERIOGENESIS; MECHANISMS	The therapeutic potential of placental growth factor (PlGF) and its receptor Flt1 in angiogenesis is poorly understood. Here, we report that PlGF stimulated angiogenesis and collateral growth in ischemic heart and limb with at least a comparable efficiency to vascular endothelial growth factor ( VEGF). An antibody against Flt1 suppressed neovascularization in tumors and ischemic retina, and angiogenesis and inflammatory joint destruction in autoimmune arthritis. Anti-Flt1 also reduced atherosclerotic plaque growth and vulnerability, but the atheroprotective effect was not attributable to reduced plaque neovascularization. Inhibition of VEGF receptor Flk1 did not affect arthritis or atherosclerosis, indicating that inhibition of Flk1-driven angiogenesis alone was not sufficient to halt disease progression. The anti-inflammatory effects of anti-Flt1 were attributable to reduced mobilization of bone marrow - derived myeloid progenitors into the peripheral blood; impaired infiltration of Flt1-expressing leukocytes in inflamed tissues; and defective activation of myeloid cells. Thus, PlGF and Flt1 constitute potential candidates for therapeutic modulation of angiogenesis and inflammation.	Univ Louvain VIB, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium; Univ Louvain, Rega Inst Med Res, Immunobiol Lab, Louvain, Belgium; Univ Louvain, Lab Expt Med & Endocrinol, Louvain, Belgium; ImClone Syst Inc, New York, NY USA; Ctr Med Univ Geneva, Div Angiol & Hemostasis, Geneva, Switzerland; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA USA; Humboldt Univ, Charite, Dept Neurol, Berlin, Germany; Sanofi Synthelabo, Cardiovasc Thrombosis Res Dept, Toulouse, France; Dept Vet Affairs Med Ctr, White River Jct, VT USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Med, Hanover, NH 03756 USA	Flanders Institute for Biotechnology (VIB); KU Leuven; KU Leuven; Eli Lilly; University of Geneva; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Sanofi-Aventis; Sanofi France; Dartmouth College	Carmeliet, P (corresponding author), Univ Louvain VIB, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium.	peter.carmeliet@med.kuleuven.ac.be	Luttun, Aernout/AAZ-6540-2020; Matthys, Patrick/B-4813-2018; Carmeliet, Peter/AAQ-5140-2020; Priller, Josef/ABW-3835-2022	Luttun, Aernout/0000-0001-7902-9524; Matthys, Patrick/0000-0002-9685-6836; Carmeliet, Peter/0000-0001-7961-1821; Angelillo-Scherrer, Anne/0000-0003-2872-4863; Priller, Josef/0000-0001-7596-0979; Moons, Lieve (Godelieve)/0000-0003-0186-1411				Arras M, 1998, J CLIN INVEST, V101, P40, DOI 10.1172/JCI119877; Bottomley MJ, 2000, CLIN EXP IMMUNOL, V119, P182, DOI 10.1046/j.1365-2249.2000.01097.x; Brenchley PEC, 2000, CLIN EXP IMMUNOL, V121, P426, DOI 10.1046/j.1365-2249.2000.01299.x; Carmeliet P, 2000, NAT MED, V6, P1102, DOI 10.1038/80430; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Celletti FL, 2001, NAT MED, V7, P425, DOI 10.1038/86490; Clauss M, 1998, TRENDS CARDIOVAS MED, V8, P241, DOI 10.1016/S1050-1738(98)00015-2; Couffinhal T, 1998, AM J PATHOL, V152, P1667; COURTENAY JS, 1980, NATURE, V283, P666, DOI 10.1038/283666a0; DVORAK HF, 1979, JNCI-J NATL CANCER I, V62, P1459; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; Folkman J, 2001, SEMIN ONCOL, V28, P536, DOI 10.1053/sonc.2001.29543; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Hiratsuka S, 2001, CANCER RES, V61, P1207; Hoefer IE, 2001, CARDIOVASC RES, V49, P609, DOI 10.1016/S0008-6363(00)00243-1; Ishida A, 2001, J CELL PHYSIOL, V188, P359, DOI 10.1002/jcp.1121; Isner JM, 2002, NATURE, V415, P234, DOI 10.1038/415234a; Lazarous DF, 2000, J AM COLL CARDIOL, V36, P1239, DOI 10.1016/S0735-1097(00)00882-2; Lee DM, 2001, LANCET, V358, P903, DOI 10.1016/S0140-6736(01)06075-5; Libby P, 2001, AM J CARDIOL, V88, p3J; Lutgens E, 2000, P NATL ACAD SCI USA, V97, P7464, DOI 10.1073/pnas.97.13.7464; Luttun A, 2002, ARTERIOSCL THROM VAS, V22, P499, DOI 10.1161/hq0302.104529; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Matsumoto K, 1996, J APPL PHYSIOL, V81, P1843, DOI 10.1152/jappl.1996.81.4.1843; Matthys P, 1999, J IMMUNOL, V163, P3503; Matthys P, 1998, EUR J IMMUNOL, V28, P2143, DOI 10.1002/(SICI)1521-4141(199807)28:07<2143::AID-IMMU2143>3.0.CO;2-C; McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P474; Miotla J, 2000, LAB INVEST, V80, P1195, DOI 10.1038/labinvest.3780127; Moulton K S, 2001, Curr Atheroscler Rep, V3, P225, DOI 10.1007/s11883-001-0065-0; PARK JE, 1994, J BIOL CHEM, V269, P25646; Persico MG, 1999, CURR TOP MICROBIOL, V237, P31; Pettersson A, 2000, LAB INVEST, V80, P99, DOI 10.1038/labinvest.3780013; Post MJ, 2001, CARDIOVASC RES, V49, P522, DOI 10.1016/S0008-6363(00)00216-9; Priller J, 2001, NAT MED, V7, P1356, DOI 10.1038/nm1201-1356; Riessen R, 1998, AM HEART J, V135, P357, DOI 10.1016/S0002-8703(98)70105-X; Sawano A, 2001, BLOOD, V97, P785, DOI 10.1182/blood.V97.3.785; Shibuya M, 2001, CELL STRUCT FUNCT, V26, P25, DOI 10.1247/csf.26.25; Simons M, 2000, CIRCULATION, V102, pE73, DOI 10.1161/01.CIR.102.11.e73; Sone H, 2001, BIOCHEM BIOPH RES CO, V281, P562, DOI 10.1006/bbrc.2001.4395; van Royen N, 2001, CARDIOVASC RES, V49, P543, DOI 10.1016/S0008-6363(00)00206-6; Veikkola T, 2000, CANCER RES, V60, P203; Weber AJ, 2000, JOINT BONE SPINE, V67, P366; Weng D E, 2001, Curr Oncol Rep, V3, P141, DOI 10.1007/s11912-001-0014-7; Witte L, 1998, CANCER METAST REV, V17, P155, DOI 10.1023/A:1006094117427	49	838	904	1	43	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2002	8	8					831	840		10.1038/nm731	http://dx.doi.org/10.1038/nm731			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	579WJ	12091877	Green Published			2022-12-25	WOS:000177200900029
J	Xiong, DD; Lee, GH; Badorff, C; Dorner, A; Lee, S; Wolf, P; Knowlton, KU				Xiong, DD; Lee, GH; Badorff, C; Dorner, A; Lee, S; Wolf, P; Knowlton, KU			Dystrophin deficiency markedly increases enterovirus-induced cardiomyopathy: A genetic predisposition to viral heart disease	NATURE MEDICINE			English	Article							LINKED DILATED CARDIOMYOPATHY; DUCHENNE MUSCULAR-DYSTROPHY; COXSACKIE-B VIRUSES; CLEAVES DYSTROPHIN; EXPRESSION; MUTATION; REGION; MYOCARDITIS; SARCOLEMMA; DISRUPTION	Both enteroviral infection of the heart and mutations in the dystrophin gene can cause cardiomyopathy. Little is known, however, about the interaction between genetic and acquired forms of cardiomyopathy. We previously demonstrated that the enteroviral protease 2A cleaves dystrophin; therefore, we hypothesized that dystrophin deficiency would predispose to enterovirus-induced cardiomyopathy. We observed more severe cardiomyopathy, worsening over time, and greater viral replication in dystrophin-deficient mice infected with enterovirus than in infected wild-type mice. This difference appears to be a result of more efficient release of the virus from dystrophin-deficient myocytes. In addition, we found that expression of wild-type dystrophin in cultured cells decreased the cytopathic effect of enteroviral infection and the release of virus from the cell. We also found that expression of a cleavage- resistant mutant dystrophin further inhibited the virally mediated cytopathic effect and viral release. These results indicate that viral infection can influence the severity and penetrance of the cardiomyopathy that occurs in the hearts of dystrophin-deficient individuals.	Univ Calif San Diego, Inst Mol Med, Dept Med, San Diego, CA 92103 USA; Univ Calif San Diego, Ctr Cardiovasc, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Knowlton, KU (corresponding author), Univ Calif San Diego, Inst Mol Med, Dept Med, San Diego, CA 92103 USA.				NHLBI NIH HHS [5 R01 HL57365-03] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057365] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baboonian C, 1997, CURR TOP MICROBIOL, V223, P31; Badorff C, 2000, J BIOL CHEM, V275, P11191, DOI 10.1074/jbc.275.15.11191; Badorff C, 1999, NAT MED, V5, P320, DOI 10.1038/6543; Bergelson JM, 1998, J VIROL, V72, P415, DOI 10.1128/JVI.72.1.415-419.1998; Clark W.H., 1993, CRC HDB MARICULTURE, VI, P133; CLEMENS PR, 1995, HUM GENE THER, V6, P1477, DOI 10.1089/hum.1995.6.11-1477; Cohn RD, 2001, J CLIN INVEST, V107, pR1, DOI 10.1172/JCI11642; DANILOWICZ D, 1980, MUSCLE NERVE, V3, P298, DOI 10.1002/mus.880030405; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Feldman AM, 2000, NEW ENGL J MED, V343, P1388, DOI 10.1056/NEJM200011093431908; GOLDBERG SJ, 1983, J AM COLL CARDIOL, V2, P136, DOI 10.1016/S0735-1097(83)80386-6; HENKE A, 1995, J VIROL, V69, P6720, DOI 10.1128/JVI.69.11.6720-6728.1995; JACKSON P, 1985, J VIROL, V55, P644, DOI 10.1128/JVI.55.3.644-650.1985; Knowlton KU, 1996, J VIROL, V70, P7811, DOI 10.1128/JVI.70.11.7811-7818.1996; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LEE CC, 1991, NATURE, V349, P334, DOI 10.1038/349334a0; Lee GH, 2000, CIRC RES, V87, P489; Luftig Ronald B., 1994, Trends in Microbiology, V2, P178, DOI 10.1016/0966-842X(94)90669-6; MARTINO TA, 1994, CIRC RES, V74, P182, DOI 10.1161/01.RES.74.2.182; MUNTONI F, 1993, NEW ENGL J MED, V329, P921, DOI 10.1056/NEJM199309233291304; NIGRO G, 1990, INT J CARDIOL, V26, P271, DOI 10.1016/0167-5273(90)90082-G; OrtizLopez R, 1997, CIRCULATION, V95, P2434, DOI 10.1161/01.CIR.95.10.2434; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Rafael JA, 1996, J CELL BIOL, V134, P93, DOI 10.1083/jcb.134.1.93; Rueckert Roland R., 1996, P477; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; SELPELT J, 2000, J BIOL CHEM, V275, P20084; SHOEMAN RL, 1990, P NATL ACAD SCI USA, V87, P6336, DOI 10.1073/pnas.87.16.6336; Straub V, 1997, J CELL BIOL, V139, P375, DOI 10.1083/jcb.139.2.375; Towbin JA, 1999, NAT MED, V5, P266, DOI 10.1038/6474; TOWBIN JA, 1993, CIRCULATION, V87, P1854, DOI 10.1161/01.CIR.87.6.1854; Vatta M, 2002, LANCET, V359, P936, DOI 10.1016/S0140-6736(02)08026-1; ZHANG Y, 1994, J VIROL, V68, P2544, DOI 10.1128/JVI.68.4.2544-2555.1994	33	83	83	0	5	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2002	8	8					872	877		10.1038/nm737	http://dx.doi.org/10.1038/nm737			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	579WJ	12118246				2022-12-25	WOS:000177200900034
J	Maeda, N; Shimomura, I; Kishida, K; Nishizawa, H; Matsuda, M; Nagaretani, H; Furuyama, N; Kondo, H; Takahashi, M; Arita, Y; Komuro, R; Ouchi, N; Kihara, S; Tochino, Y; Okutomi, K; Horie, M; Takeda, S; Aoyama, T; Funahashi, T; Matsuzawa, Y				Maeda, N; Shimomura, I; Kishida, K; Nishizawa, H; Matsuda, M; Nagaretani, H; Furuyama, N; Kondo, H; Takahashi, M; Arita, Y; Komuro, R; Ouchi, N; Kihara, S; Tochino, Y; Okutomi, K; Horie, M; Takeda, S; Aoyama, T; Funahashi, T; Matsuzawa, Y			Diet-induced insulin resistance in mice lacking adiponectin/ACRP30	NATURE MEDICINE			English	Article							TUMOR-NECROSIS-FACTOR; ADIPOSE-SPECIFIC PROTEIN; FACTOR-ALPHA; PLASMA-PROTEIN; GENE-EXPRESSION; OBESITY; RECEPTOR; TISSUE; SENSITIVITY; METABOLISM	Here we investigated the biological functions of adiponectin/ACRP30, a fat-derived hormone, by disrupting the gene that encodes it in mice. Adiponectin/ACRP30-knockout (KO) mice showed delayed clearance of free fatty acid in plasma, low levels of fatty-acid transport protein 1 (FATP-1) mRNA in muscle, high levels of tumor necrosis factor-alpha (TNF-alpha) mRNA in adipose tissue and high plasma TNF-alpha concentrations. The KO mice exhibited severe diet-induced insulin resistance with reduced insulin-receptor substrate 1 (IRS-1)-associated phosphatidylinositol 3 kinase (PI3-kinase) activity in muscle. Viral mediated adiponectin/ACRP30 expression in KO mice reversed the reduction of FATP-1 mRNA, the increase of adipose TNF-alpha mRNA and the diet-induced insulin resistance. In cultured myocytes, TNF-alpha decreased FATP-1 mRNA, IRS-1-associated PI3-kinase activity and glucose uptake, whereas adiponectin increased these parameters. Our results indicate that adiponectin/ACRP30 deficiency and high TNF-alpha levels in KO mice reduced muscle FATP-1 mRNA and IRS-1-mediated insulin signaling, resulting in severe diet-induced insulin resistance.	Osaka Univ, Grad Sch Med, Dept Internal Med & Mol Sci, Osaka, Japan; Otsuka Pharmaceut Co Ltd, Otsuga GEN Res Inst, Tokushima 77101, Japan; Shinshu Univ, Sch Med, Dept Aging Biochem, Nagano, Japan	Osaka University; Otsuka Pharmaceutical; Shinshu University	Shimomura, I (corresponding author), Osaka Univ, Grad Sch Frontier Biosci, Dept Organismal Biosyst, Osaka, Japan.		Horie, Minoru/ABG-7128-2020; OUCHI, Noriyuki/I-7306-2014					Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Berg AH, 2002, TRENDS ENDOCRIN MET, V13, P84, DOI 10.1016/S1043-2760(01)00524-0; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Binnert C, 2000, AM J PHYSIOL-ENDOC M, V279, pE1072, DOI 10.1152/ajpendo.2000.279.5.E1072; Combs TP, 2001, J CLIN INVEST, V108, P1875, DOI 10.1172/JCI200114120; DELQAUILA LF, 1999, AM J PHYSIOL, V276, pE849; Friedman JM, 2000, NATURE, V404, P632, DOI 10.1038/35007504; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Halleux CM, 2001, BIOCHEM BIOPH RES CO, V288, P1102, DOI 10.1006/bbrc.2001.5904; Hara K, 2002, DIABETES, V51, P536, DOI 10.2337/diabetes.51.2.536; Hirsch D, 1998, P NATL ACAD SCI USA, V95, P8625, DOI 10.1073/pnas.95.15.8625; HOFMANN C, 1994, ENDOCRINOLOGY, V134, P264, DOI 10.1210/en.134.1.264; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495; Hotta K, 2001, DIABETES, V50, P1126, DOI 10.2337/diabetes.50.5.1126; Hotta K, 2000, ARTERIOSCL THROM VAS, V20, P1595, DOI 10.1161/01.ATV.20.6.1595; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Kissebah AH, 2000, P NATL ACAD SCI USA, V97, P14478, DOI 10.1073/pnas.97.26.14478; KONDO H, IN PRESS DIABETES; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Maeda N, 2001, DIABETES, V50, P2094, DOI 10.2337/diabetes.50.9.2094; Ouchi N, 2000, CIRCULATION, V102, P1296, DOI 10.1161/01.CIR.102.11.1296; Ouchi N, 2001, CIRCULATION, V103, P1057, DOI 10.1161/01.CIR.103.8.1057; Ouchi N, 1999, CIRCULATION, V100, P2473, DOI 10.1161/01.CIR.100.25.2473; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Shapiro L, 1998, CURR BIOL, V8, P335, DOI 10.1016/S0960-9822(98)70133-2; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; Shimomura I, 1996, NAT MED, V2, P800, DOI 10.1038/nm0796-800; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Vionnet N, 2000, AM J HUM GENET, V67, P1470, DOI 10.1086/316887; Watanabe K, 2000, J BIOL CHEM, V275, P22293, DOI 10.1074/jbc.M000248200; Weyer C, 2001, J CLIN ENDOCR METAB, V86, P1930, DOI 10.1210/jc.86.5.1930; Yamauchi T, 2002, NAT GENET, V30, P221, DOI 10.1038/ng829; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984	43	1661	1790	3	117	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2002	8	7					731	737		10.1038/nm724	http://dx.doi.org/10.1038/nm724			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	567QG	12068289				2022-12-25	WOS:000176495200035
J	Hays, R; Wickline, L; Cagan, R				Hays, R; Wickline, L; Cagan, R			Morgue mediates apoptosis in the Drosophila melanogaster retina by promoting degradation of DIAP1	NATURE CELL BIOLOGY			English	Article							UBIQUITIN-PROTEIN LIGASE; PROGRAMMED CELL-DEATH; CASPASE DRONC; IAP FUNCTION; INHIBITOR; REAPER; HID; PATHWAY; ACTIVATION; TISSUE	Inhibitor of apoptosis proteins (IAPs) provide a critical barrier to inappropriate apoptotic cell death through direct binding and inhibition of caspases. We demonstrate that degradation of IAPs is an important mechanism for the initiation of apoptosis in vivo. Drosophila Morgue, a ubiquitin conjugase-related protein, promotes DIAP1 down-regulation in the developing retina to permit selective programmed cell death. Morgue complexes with DIAP1 in vitro and mediates DIAP1 degradation in a manner dependent on the Morgue UBC domain. Reaper (Rpr) and Grim, but not Hid, also promote the degradation of DIAP1 in vivo, suggesting that these proteins promote cell death through different mechanisms.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL)	Cagan, R (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, 660 S Euclid Ave,Campus Box 8103, St Louis, MO 63110 USA.		Cagan, Ross Leigh/AAV-9528-2021	Cagan, Ross/0000-0001-5297-450X	NATIONAL EYE INSTITUTE [F32EY013507, R01EY011495] Funding Source: NIH RePORTER; NEI NIH HHS [R01EY11495, EY13507] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		CAGAN RL, 1989, DEV BIOL, V136, P346, DOI 10.1016/0012-1606(89)90261-3; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Hawkins CJ, 2000, J BIOL CHEM, V275, P27084; Hawkins CJ, 1999, P NATL ACAD SCI USA, V96, P2885, DOI 10.1073/pnas.96.6.2885; Hay BA, 2000, CELL DEATH DIFFER, V7, P1045, DOI 10.1038/sj.cdd.4400765; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; HOLLEY CL, NATURE CELL BIOL; Hsu T, 2001, NAT CELL BIOL, V3, P538, DOI 10.1038/35078508; Huang HK, 2000, J BIOL CHEM, V275, P26661; JONES D, 2001, GENOME BIOL, P3; Kaiser WJ, 1998, FEBS LETT, V440, P243, DOI 10.1016/S0014-5793(98)01465-3; Lisi S, 2000, GENETICS, V154, P669; Meier P, 2000, EMBO J, V19, P598, DOI 10.1093/emboj/19.4.598; MORI C, 1995, ANAT REC, V242, P103, DOI 10.1002/ar.1092420114; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; Rodriguez A, 1999, NAT CELL BIOL, V1, P272, DOI 10.1038/12984; Rorth P, 1996, P NATL ACAD SCI USA, V93, P12418, DOI 10.1073/pnas.93.22.12418; Rusconi JC, 2000, CELL DEATH DIFFER, V7, P1063, DOI 10.1038/sj.cdd.4400767; RYOO HD, NATURE CELL BIOL; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; SO KF, 1990, J EXP BIOL, V153, P85; Song ZW, 1997, SCIENCE, V275, P536, DOI 10.1126/science.275.5299.536; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Tanenbaum SB, 2000, GENETICS, V156, P205; Thomson TM, 2000, GENOME RES, V10, P1743, DOI 10.1101/gr.GR-1405R; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Vucic D, 1997, P NATL ACAD SCI USA, V94, P10183, DOI 10.1073/pnas.94.19.10183; Vucic D, 1997, MOL CELL BIOL, V17, P667, DOI 10.1128/MCB.17.2.667; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; WILSON, NATURE CELL BIOL; WING, NATURE CELL BIOL; WOLFF T, 1991, DEVELOPMENT, V113, P825; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; YOO, NATURE CELL BIOL	38	102	103	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUN	2002	4	6					425	431		10.1038/ncb794	http://dx.doi.org/10.1038/ncb794			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	558NN	12021768				2022-12-25	WOS:000175973600012
J	Egan, ME; Glockner-Pagel, J; Ambrose, CA; Cahill, PA; Pappoe, L; Balamuth, N; Cho, E; Canny, S; Wagner, CA; Geibel, J; Caplan, MJ				Egan, ME; Glockner-Pagel, J; Ambrose, CA; Cahill, PA; Pappoe, L; Balamuth, N; Cho, E; Canny, S; Wagner, CA; Geibel, J; Caplan, MJ			Calcium-pump inhibitors induce functional surface expression of Delta F508-CFTR protein in cystic fibrosis epithelial cells	NATURE MEDICINE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; ENDOPLASMIC-RETICULUM; FLUORESCENT INDICATOR; CHLORIDE SECRETION; HELA-CELLS; CFTR; MUTATION; THAPSIGARGIN; 2,5-DI-(TERT-BUTYL)-1,4-HYDROQUINONE; PERTURBATION	The most common mutation in cystic fibrosis, DeltaF508, results in a cystic fibrosis transmembrane conductance regulator (CFTR) protein that is retained in the endoplasmic reticulum (ER). Retention is dependent upon chaperone proteins, many of which require Ca++ for optimal activity. Interfering with chaperone activity by depleting ER Ca++ stores might allow functional DeltaF508-CFTR to reach the cell surface. We exposed several cystic fibrosis cell lines to the ER Ca++ pump inhibitor thapsigargin and evaluated surface expression of DeltaF508-CFTR. Treatment released ER-retained DeltaF508-CFTR to the plasma membrane, where it functioned effectively as a Cl- channel. Treatment with aerosolized calcium-pump inhibitors reversed the nasal epithelial potential defect observed in a mouse model of DeltaF508-CFTR expression. Thus, ER calcium-pump inhibitors represent a potential target for correcting the cystic fibrosis defect.	Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Surg, New Haven, CT 06510 USA	Yale University; Yale University; Yale University	Caplan, MJ (corresponding author), Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA.			Canny, Susan/0000-0002-1762-6718; Caplan, Michael/0000-0001-5768-4405	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD032573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK050203, P01DK017433, R01DK053428, R01DK050203] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042136] Funding Source: NIH RePORTER; NICHD NIH HHS [HD32573] Funding Source: Medline; NIDDK NIH HHS [R01 DK053428, DK50203, DK53428, DK17433] Funding Source: Medline; NIGMS NIH HHS [GM42136] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIEMESDERFER D, 1992, AM J PHYSIOL, V262, pF55, DOI 10.1152/ajprenal.1992.262.1.F55; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; Brown CR, 1997, J CLIN INVEST, V99, P1432, DOI 10.1172/JCI119302; CHAO AC, 1995, J CLIN INVEST, V96, P1794, DOI 10.1172/JCI118225; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Choudhury P, 1997, J BIOL CHEM, V272, P13446, DOI 10.1074/jbc.272.20.13446; CHRISTENSEN SB, 1993, FEBS LETT, V335, P345, DOI 10.1016/0014-5793(93)80416-R; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; Davis PB, 1996, AM J RESP CRIT CARE, V154, P1229, DOI 10.1164/ajrccm.154.5.8912731; EGAN ME, 1995, AM J PHYSIOL-CELL PH, V268, pC243, DOI 10.1152/ajpcell.1995.268.1.C243; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; GOTTARDI CJ, 1993, J CELL BIOL, V121, P283, DOI 10.1083/jcb.121.2.283; GRUBB B, 1993, AM J RESP CELL MOL, V8, P454, DOI 10.1165/ajrcmb/8.4.454; GRUBB BR, 1994, AM J PHYSIOL, V266, pC1478, DOI 10.1152/ajpcell.1994.266.5.C1478; Haws CM, 1996, AM J PHYSIOL-CELL PH, V270, pC1544, DOI 10.1152/ajpcell.1996.270.5.C1544; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; Hwang TC, 1997, AM J PHYSIOL-CELL PH, V273, pC988, DOI 10.1152/ajpcell.1997.273.3.C988; KUNZELMANN K, 1993, AM J RESP CELL MOL, V8, P522, DOI 10.1165/ajrcmb/8.5.522; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Llewellyn DH, 1996, BIOCHEM J, V318, P555, DOI 10.1042/bj3180555; LODISH HF, 1990, J BIOL CHEM, V265, P10893; Maitra R, 2001, AM J PHYSIOL-CELL PH, V280, pC1031, DOI 10.1152/ajpcell.2001.280.5.C1031; MASON MJ, 1991, J BIOL CHEM, V266, P20856; Meacham GC, 1999, EMBO J, V18, P1492, DOI 10.1093/emboj/18.6.1492; Montero M, 1997, J CELL BIOL, V139, P601, DOI 10.1083/jcb.139.3.601; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; PIND S, 1994, J BIOL CHEM, V269, P12784; Rosenfeld MA, 1996, CHEST, V109, P241, DOI 10.1378/chest.109.1.241; Rubenstein RC, 1997, J CLIN INVEST, V100, P2457, DOI 10.1172/JCI119788; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; Schultz BD, 1996, AM J PHYSIOL-LUNG C, V271, pL192, DOI 10.1152/ajplung.1996.271.2.L192; SHACHAR I, 1994, J BIOL CHEM, V269, P27344; Sheppard DN, 1999, PHYSIOL REV, V79, P23; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; TSIEN RY, 1982, J CELL BIOL, V94, P325, DOI 10.1083/jcb.94.2.325; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; VERKMAN AS, 1990, AM J PHYSIOL, V259, pC375, DOI 10.1152/ajpcell.1990.259.3.C375; WARD CL, 1995, CELL, V83, P122; WONG WL, 1993, BIOCHEM J, V289, P71, DOI 10.1042/bj2890071; ZEIHER BG, 1995, J CLIN INVEST, V96, P2051, DOI 10.1172/JCI118253; ZEITLIN PL, 1991, AM J RESP CELL MOL, V4, P313, DOI 10.1165/ajrcmb/4.4.313; Zeitlin PL, 1999, J CLIN INVEST, V103, P447, DOI 10.1172/JCI6346; Zhang ZR, 2000, J MEMBRANE BIOL, V175, P35, DOI 10.1007/s002320001053	45	176	188	1	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2002	8	5					485	492		10.1038/nm0502-485	http://dx.doi.org/10.1038/nm0502-485			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	547ZW	11984593				2022-12-25	WOS:000175336800034
J	Thompson, B; Townsley, F; Rosin-Arbesfeld, R; Musisi, H; Bienz, M				Thompson, B; Townsley, F; Rosin-Arbesfeld, R; Musisi, H; Bienz, M			A new nuclear component of the Wnt signalling pathway	NATURE CELL BIOLOGY			English	Article							WINGLESS SIGNALING PATHWAY; SEGMENT-POLARITY GENE; LONG-RANGE ACTION; BETA-CATENIN; DROSOPHILA EYE; TRANSCRIPTIONAL REGULATION; PATTERN-FORMATION; TARGET GENE; ARMADILLO; LEF-1	The Wnt signalling pathway is pivotal in normal and malignant development. A key effector is Armadillo (Arm)/beta-catenin, which functions with TCF to transcribe Wnt target-genes. Here, we report the discovery of pygopus (pygo), whose mutant phenotypes specifically mimic loss-of-Wingless (Wg) signalling. pygo is required for dTCF-mediated transcription, but not for Wg-induced stabilization of Arm. Pygo is a nuclear protein that is found in a complex with Arm in vivo. Humans possess two Pygo proteins, both of which are required for TCF-mediated transcription in colorectal cancer cells. The presence of a PHD domain implicates Pygo proteins in a chromatin-related function, and we propose that they mediate chromatin access to TCF or Arm/beta-catenin.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Thompson, B (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.			Thompson, Barry/0000-0002-0103-040X				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Blair SS, 1997, DEVELOPMENT, V124, P4053; Brannon M, 1999, DEVELOPMENT, V126, P3159; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Capili AD, 2001, EMBO J, V20, P165, DOI 10.1093/emboj/20.1.165; COUSO JP, 1994, DEVELOPMENT, V120, P621; Daniels DL, 2001, TRENDS BIOCHEM SCI, V26, P672, DOI 10.1016/S0968-0004(01)01952-1; Dominguez M, 1997, GENE DEV, V11, P3254, DOI 10.1101/gad.11.23.3254; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; Freeman M, 2001, EMBO REP, V2, P157, DOI 10.1093/embo-reports/kve019; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Jacobson S, 1999, CURR OPIN GENET DEV, V9, P175, DOI 10.1016/S0959-437X(99)80027-6; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; McCartney BM, 2001, NAT CELL BIOL, V3, P933, DOI 10.1038/ncb1001-933; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Neumann C, 1997, BIOESSAYS, V19, P721, DOI 10.1002/bies.950190813; Neumann CJ, 1997, DEVELOPMENT, V124, P871; Pai LM, 1997, DEVELOPMENT, V124, P2255; Pascual J, 2000, J MOL BIOL, V304, P723, DOI 10.1006/jmbi.2000.4308; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1991, DEVELOPMENT, V111, P1029; PERRIMON N, 1994, CELL, V76, P781, DOI 10.1016/0092-8674(94)90351-4; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; Polakis P, 2000, GENE DEV, V14, P1837; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Rodriguez I, 1997, NATURE, V389, P614, DOI 10.1038/39343; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Rulifson EJ, 1996, NATURE, V384, P72, DOI 10.1038/384072a0; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; Spink KE, 2001, EMBO J, V20, P6203, DOI 10.1093/emboj/20.22.6203; STURTEVANT MA, 1995, DEVELOPMENT, V121, P785; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; THURINGER F, 1993, EMBO J, V12, P2419, DOI 10.1002/j.1460-2075.1993.tb05896.x; Tolwinski NS, 2001, DEVELOPMENT, V128, P2107; Tutter AV, 2001, GENE DEV, V15, P3342, DOI 10.1101/gad.946501; vandeWetering M, 1996, MOL CELL BIOL, V16, P745; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; von Kries JP, 2000, NAT STRUCT BIOL, V7, P800; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Wiechens N, 2001, CURR BIOL, V11, P18, DOI 10.1016/S0960-9822(00)00045-2; YOFFE KB, 1995, DEV BIOL, V170, P636, DOI 10.1006/dbio.1995.1243; Yokoya F, 1999, MOL BIOL CELL, V10, P1119, DOI 10.1091/mbc.10.4.1119; Yu X, 1996, DEVELOPMENT, V122, P849; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1	55	233	249	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAY	2002	4	5					367	373		10.1038/ncb786	http://dx.doi.org/10.1038/ncb786			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	547GR	11988739				2022-12-25	WOS:000175325100018
J	Cartegni, L; Krainer, AR				Cartegni, L; Krainer, AR			Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1	NATURE GENETICS			English	Article							MOTOR-NEURON GENE; MESSENGER-RNA; SINGLE NUCLEOTIDE; SR PROTEINS; SURVIVAL; IDENTIFICATION; MOUSE; MUTATIONS; NONSENSE; DEFINITION	Alteration of correct splicing patterns by disruption of an exonic splicing enhancer may be a frequent mechanism by which point mutations cause genetic diseases. Spinal muscular atrophy results from the lack of functional survival of motor neuron 1 gene (SMN1), even though all affected individuals carry a nearly identical, normal SMN2 gene. SMN2 is only partially active because a translationally silent, single-nucleotide difference in exon 7 causes exon skipping. Using ESE motif-prediction tools, mutational analysis and in vivo and in vitro splicing assays, we show that this single-nucleotide change occurs within a heptamer motif of an exonic splicing enhancer, which in SMN1 is recognized directly by SF2/ASF. The abrogation of the SF2/ASF-dependent ESE is the basis for inefficient inclusion of exon 7 in SMN2, resulting in the spinal muscular atrophy phenotype.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Krainer, AR (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.	krainer@cshl.org		Krainer, Adrian/0000-0001-9024-9501				Andreassi C, 2001, HUM MOL GENET, V10, P2841, DOI 10.1093/hmg/10.24.2841; Ars E, 2000, HUM MOL GENET, V9, P237, DOI 10.1093/hmg/9.2.237; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; Burge CB, 1999, RNA WORLD, P525; CACERES JF, 1997, EUKARYOTIC MRNA PROC, P174; Chang JG, 2001, P NATL ACAD SCI USA, V98, P9808, DOI 10.1073/pnas.171105098; Coulter LR, 1997, MOL CELL BIOL, V17, P2143, DOI 10.1128/MCB.17.4.2143; Emery A E, 1991, Neuromuscul Disord, V1, P19, DOI 10.1016/0960-8966(91)90039-U; Graveley BR, 1998, EMBO J, V17, P6747, DOI 10.1093/emboj/17.22.6747; Graveley BR, 1999, CURR BIOL, V9, pR6, DOI 10.1016/S0960-9822(99)80032-3; Hastings ML, 2001, RNA, V7, P471, DOI 10.1017/S1355838201002552; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; Hofmann Y, 2000, P NATL ACAD SCI USA, V97, P9618, DOI 10.1073/pnas.160181697; Hsieh-Li HM, 2000, NAT GENET, V24, P66, DOI 10.1038/71709; Jablonka S, 2000, J NEUROL, V247, P37, DOI 10.1007/s004150050555; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRAWCZAK M, 1992, HUM GENET, V90, P41; Lefebvre S, 1998, HUM MOL GENET, V7, P1531, DOI 10.1093/hmg/7.10.1531; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Lim SR, 2001, J BIOL CHEM, V276, P45476, DOI 10.1074/jbc.M107632200; Liu HX, 2001, NAT GENET, V27, P55, DOI 10.1038/83762; Liu HX, 2000, MOL CELL BIOL, V20, P1063, DOI 10.1128/MCB.20.3.1063-1071.2000; Liu HX, 1998, GENE DEV, V12, P1998, DOI 10.1101/gad.12.13.1998; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; Lorson CL, 1999, P NATL ACAD SCI USA, V96, P6307, DOI 10.1073/pnas.96.11.6307; Lorson CL, 2000, HUM MOL GENET, V9, P259, DOI 10.1093/hmg/9.2.259; Mayeda A, 1999, METH MOL B, V118, P315; Mayeda A, 1999, METH MOL B, V118, P309; Mazoyer S, 1998, AM J HUM GENET, V62, P713, DOI 10.1086/301768; Meister G, 2001, NAT CELL BIOL, V3, P945, DOI 10.1038/ncb1101-945; Monani UR, 2000, HUM MOL GENET, V9, P2451, DOI 10.1093/hmg/9.16.2451; Monani UR, 1999, HUM MOL GENET, V8, P1177, DOI 10.1093/hmg/8.7.1177; Monani UR, 2000, HUM MOL GENET, V9, P333, DOI 10.1093/hmg/9.3.333; Muro AF, 1999, MOL CELL BIOL, V19, P2657; Newman AJ, 1997, EMBO J, V16, P5797, DOI 10.1093/emboj/16.19.5797; Pellizzoni L, 1998, CELL, V95, P615, DOI 10.1016/S0092-8674(00)81632-3; Pellizzoni L, 2001, J CELL BIOL, V152, P75, DOI 10.1083/jcb.152.1.75; Penalva LOF, 2001, MOL CELL BIOL, V21, P1986, DOI 10.1128/MCB.21.6.1986-1996.2001; Reed R, 1999, METHODS, V18, P3, DOI 10.1006/meth.1999.0751; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; Rochette CF, 2001, HUM GENET, V108, P255, DOI 10.1007/s004390100473; SAITO I, 1990, PHOTOCHEMISTRY NUCL, V2, P317; Schaal TD, 1999, MOL CELL BIOL, V19, P1705; Schrank B, 1997, P NATL ACAD SCI USA, V94, P9920, DOI 10.1073/pnas.94.18.9920; TACKE R, 1992, NUCLEIC ACIDS RES, V20, P5482, DOI 10.1093/nar/20.20.5482; TANAKA K, 1994, MOL CELL BIOL, V14, P1347, DOI 10.1128/MCB.14.2.1347; Teraoka SN, 1999, AM J HUM GENET, V64, P1617, DOI 10.1086/302418; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; Zhang ML, 2001, GENE THER, V8, P1532, DOI 10.1038/sj.gt.3301550; Zhu J, 2000, GENE DEV, V14, P3166, DOI 10.1101/gad.189500	50	553	587	2	42	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2002	30	4					377	384		10.1038/ng854	http://dx.doi.org/10.1038/ng854			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	536BZ	11925564				2022-12-25	WOS:000174682000014
J	Grossman, Z; Meier-Schellersheim, M; Sousa, AE; Victorino, RMM; Paul, WE				Grossman, Z; Meier-Schellersheim, M; Sousa, AE; Victorino, RMM; Paul, WE			CD4(+) T-cell depletion in HIV infection: Are we closer to understanding the cause?	NATURE MEDICINE			English	Editorial Material							ACTIVE ANTIRETROVIRAL THERAPY; RAPID TURNOVER; ACTIVATION; LYMPHOCYTES; DYNAMICS; AIDS; HOMEOSTASIS; DYSFUNCTION; POPULATION; KINETICS	Is CD4(+) cell depletion due to rapid elimination by HIV and failure of the immune system to replace these cells at the required rate? Increasing evidence suggests that this is not the case, and that infection-induced immune activation drives both viral replication and CD4(+) cell depletion.	Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel; NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA; Fac Med Lisbon, Inst Mol Med, Lisbon, Portugal	Tel Aviv University; Sackler Faculty of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Universidade de Lisboa	Grossman, Z (corresponding author), Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel.		Grossman, Zvi/A-9643-2008; Sousa, Ana E./L-2642-2014; Victorino, Rui/N-7948-2013	Sousa, Ana E./0000-0002-4618-9799; Victorino, Rui/0000-0001-7567-1704	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000493, ZIAAI000493, Z01AI000926, ZIAAI000926] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anderson RW, 1998, J ACQ IMMUN DEF SYND, V17, P245, DOI 10.1097/00042560-199803010-00010; ARRON ST, 2002, 9 C RETR OPP INF SEA; Broussard SR, 2001, J VIROL, V75, P2262, DOI 10.1128/JVI.75.5.2262-2275.2001; CLERICI M, 1989, J CLIN INVEST, V84, P1892, DOI 10.1172/JCI114376; Deeks SG, 2002, J INFECT DIS, V185, P315, DOI 10.1086/338467; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; Douek DC, 2001, J IMMUNOL, V167, P6663, DOI 10.4049/jimmunol.167.11.6663; FEINBERG M, 2002, 9 C RETR OPP INF SEA; Grossman Z, 1997, NAT MED, V3, P486, DOI 10.1038/nm0597-486; GROSSMAN Z, 1993, CLIN IMMUNOL IMMUNOP, V69, P123, DOI 10.1006/clin.1993.1160; Grossman Z, 2001, CURR OPIN IMMUNOL, V13, P687, DOI 10.1016/S0952-7915(01)00280-1; Grossman Z, 1998, P NATL ACAD SCI USA, V95, P6314, DOI 10.1073/pnas.95.11.6314; Grossman Z, 2000, NAT MED, V6, P976, DOI 10.1038/79667; Grossman Z, 1999, SCIENCE, V284, p555a, DOI [DOI 10.1126/SCIENCE.284.5414.555A, 10.1126/science.284.5414.555a]; Grossman Zvi, 2001, Journal of Human Virology, V4, P132; Haase AT, 1999, ANNU REV IMMUNOL, V17, P625, DOI 10.1146/annurev.immunol.17.1.625; HAYASHI NLD, IN PRESS P NATL ACAD; Hazenberg MD, 2000, BLOOD, V95, P249, DOI 10.1182/blood.V95.1.249.001k40_249_255; Hazenberg MD, 2000, NAT MED, V6, P1036, DOI 10.1038/79549; Hazenberg MD, 2000, NAT IMMUNOL, V1, P285, DOI 10.1038/79724; HELLERSTEIN MK, 2002, 9 C RETR OPP INF SEA; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Kalinkovich A, 1998, CLIN EXP IMMUNOL, V114, P414; Kaur A, 1998, J VIROL, V72, P9597, DOI 10.1128/JVI.72.12.9597-9611.1998; Kovacs JA, 2001, J EXP MED, V194, P1731, DOI 10.1084/jem.194.12.1731; Lempicki RA, 2000, P NATL ACAD SCI USA, V97, P13778, DOI 10.1073/pnas.250472097; Lyles RH, 2000, J INFECT DIS, V181, P872, DOI 10.1086/315339; McCune JM, 2001, NATURE, V410, P974, DOI 10.1038/35073648; Mohri H, 2001, J EXP MED, V194, P1277, DOI 10.1084/jem.194.9.1277; Mohri H, 1998, SCIENCE, V279, P1223, DOI 10.1126/science.279.5354.1223; Pantaleo G, 1999, NAT MED, V5, P27, DOI 10.1038/4706; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Roederer M, 1997, Semin Immunol, V9, P389, DOI 10.1006/smim.1997.0097; Stuart JWTC, 2000, J ACQ IMMUN DEF SYND, V25, P203, DOI 10.1097/00126334-200011010-00001; Veazey RS, 2000, J VIROL, V74, P57, DOI 10.1128/JVI.74.1.57-64.2000; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	36	360	375	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2002	8	4					319	323		10.1038/nm0402-319	http://dx.doi.org/10.1038/nm0402-319			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	536ML	11927927				2022-12-25	WOS:000174704800016
J	Kim, SK; Selleri, L; Lee, JS; Zhang, AY; Gu, XY; Jacobs, Y; Cleary, ML				Kim, SK; Selleri, L; Lee, JS; Zhang, AY; Gu, XY; Jacobs, Y; Cleary, ML			Pbx1 inactivation disrupts pancreas development and in Ipf1-deficient mice promotes diabetes mellitus	NATURE GENETICS			English	Article							HOMEODOMAIN PROTEINS; GENE; HOX; MUTATIONS; NOTOCHORD; EXOCRINE; IPF1	Pbx1 is a member of the TALE (three-amino acid loop extension) class of homeodomain transcription factors(1,2), which are components of hetero-oligomeric protein complexes thought to regulate developmental gene expression and to maintain differentiated cell states(3). In vitro studies(4,5) have shown that Pbx1 regulates the activity of Ipf1 (also known as Pdx1), a Para-Hox homeodomain transcription factor(6,7) required for the development and function of the pancreas in mice and humans(8-10). To investigate in vivo roles of Pbx1 in pancreatic development and function, we examined pancreatic Pbx1 expression, and morphogenesis, cell differentiation and function in mice deficient(11,12) for Pbx1. Pbx1(-/-) embryos had pancreatic hypoplasia and marked defects in exocrine and endocrine cell differentiation prior to death at embryonic day (E) 15 or E16. In these embryos, expression of IsI1 and Atoh5, essential regulators of pancreatic morphogenesis and differentiation, was severely reduced. Pbx1(+/-) adults had pancreatic islet malformations, impaired glucose tolerance and hypoinsulinemia. Thus, Pbx1 is essential for normal pancreatic development and function. Analysis of trans-heterozygous Pbx1(+/-) Ipf1(+/-) mice revealed in vivo genetic interactions between Pbx1 and Ipf1 that are essential for postnatal pancreatic function; these mice developed age-dependent overt diabetes mellitus, unlike Pbx1(+/-) or Ipf1(+/-) mice. Mutations affecting the Ipf1 protein may promote diabetes mellitus in mice and humans(13-16). This study suggests that perturbation of Pbx1 activity may also promote susceptibility to diabetes mellitus.	Stanford Univ, Sch Med, Beckman Ctr B300, Dept Dev Biol,Div Oncol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Beckman Ctr B300, Dept Med,Div Oncol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University	Kim, SK (corresponding author), Stanford Univ, Sch Med, Beckman Ctr B300, Dept Dev Biol,Div Oncol, Stanford, CA 94305 USA.			Zhang, Andrew/0000-0002-6309-9947; Kim, Seung/0000-0001-6135-7810				Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; Brooke NM, 1998, NATURE, V392, P920, DOI 10.1038/31933; Coulier F, 2000, INT J ONCOL, V17, P439; DiMartino JF, 2001, BLOOD, V98, P618, DOI 10.1182/blood.V98.3.618; Dutta S, 2001, P NATL ACAD SCI USA, V98, P1065, DOI 10.1073/pnas.031561298; GOLOSOW N, 1962, DEV BIOL, V4, P242, DOI 10.1016/0012-1606(62)90042-8; Gradwohl G, 2000, P NATL ACAD SCI USA, V97, P1607, DOI 10.1073/pnas.97.4.1607; Hani EH, 1999, J CLIN INVEST, V104, pR41, DOI 10.1172/JCI7469; Hebrok M, 2000, DEVELOPMENT, V127, P4905; Hebrok M, 1998, GENE DEV, V12, P1705, DOI 10.1101/gad.12.11.1705; Jacobs Y, 1999, MOL CELL BIOL, V19, P5134, DOI 10.1128/mcb.19.7.5134; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Kim SK, 2000, GENE DEV, V14, P1866; Kim SK, 1997, DEVELOPMENT, V124, P4243; Kim SK, 1998, P NATL ACAD SCI USA, V95, P13036, DOI 10.1073/pnas.95.22.13036; Krapp A, 1998, GENE DEV, V12, P3752, DOI 10.1101/gad.12.23.3752; Macfarlane WM, 1999, J CLIN INVEST, V104, pR33, DOI 10.1172/JCI7449; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; Miralles F, 1998, J CELL BIOL, V143, P827, DOI 10.1083/jcb.143.3.827; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; NOWAKOWSKI RS, 1989, J NEUROCYTOL, V18, P311, DOI 10.1007/BF01190834; Offield MF, 1996, DEVELOPMENT, V122, P983; PEERS B, 1995, MOL CELL BIOL, V15, P7091; Schnabel CA, 2001, MECH DEVELOP, V100, P131, DOI 10.1016/S0925-4773(00)00516-5; Selleri L, 2001, DEVELOPMENT, V128, P3543; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; Swift GH, 1998, MOL CELL BIOL, V18, P5109, DOI 10.1128/MCB.18.9.5109	30	138	143	1	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2002	30	4					430	435		10.1038/ng860	http://dx.doi.org/10.1038/ng860			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	536BZ	11912494				2022-12-25	WOS:000174682000023
J	Mailand, N; Lukas, C; Kaiser, BK; Jackson, PK; Bartek, J; Lukas, J				Mailand, N; Lukas, C; Kaiser, BK; Jackson, PK; Bartek, J; Lukas, J			Deregulated human Cdc14A phosphatase disrupts centrosome separation and chromosome segregation	NATURE CELL BIOLOGY			English	Article							NUCLEAR EXPORT; CYCLE; NUCLEOLUS; MITOSIS; CELLS; EXIT	We show that human Cdc14A phosphatase(1) interacts with interphase centrosomes, and that this interaction is independent of microtubules and Cdc14A phosphatase activity, but requires active nuclear export. Disrupting the nuclear export signal (NES) led to Cdc14A being localized in nucleoli, which in unperturbed cells selectively contain Cdc14B (ref. 1). Conditional overproduction of Cdc14A, but not its phosphatase-dead or NES-deficient mutants, or Cdc14B, resulted in premature centrosome splitting and formation of supernumerary mitotic spindles. In contrast, downregulation of endogenous Cdc14A by short inhibitory RNA duplexes (siRNA) induced mitotic defects including impaired centrosome separation and failure to undergo productive cytokinesis. Consequently, both overexpression and downregulation of Cdc14A caused aberrant chromosome partitioning into daughter cells. These results indicate that Cdc14A is a physiological regulator of the centrosome duplication cycle, which, when disrupted, can lead to genomic instability in mammalian cells.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark; Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA	Danish Cancer Society; Stanford University; Stanford University	Lukas, J (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandblvd 49, DK-2100 Copenhagen, Denmark.		Bartek, Jiri/G-5870-2014	Jackson, Peter/0000-0002-1742-2539; Lukas, Jiri/0000-0001-9087-506X; Lukas, Claudia/0000-0001-7169-6883	NIGMS NIH HHS [GM60439, GM54811] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054811, R01GM060439] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; Cueille N, 2001, J CELL SCI, V114, P2649; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Hinchcliffe EH, 2001, GENE DEV, V15, P1167, DOI 10.1101/gad.894001; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li LW, 1997, J BIOL CHEM, V272, P29403, DOI 10.1074/jbc.272.47.29403; Lukas J, 1999, ONCOGENE, V18, P3930, DOI 10.1038/sj.onc.1202777; Mayor T, 2000, J CELL BIOL, V151, P837, DOI 10.1083/jcb.151.4.837; Mayor T, 1999, FEBS LETT, V452, P92, DOI 10.1016/S0014-5793(99)00534-7; Piel M, 2001, SCIENCE, V291, P1550, DOI 10.1126/science.1057330; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; Tassin AM, 1999, BIOL CELL, V91, P343, DOI 10.1016/S0248-4900(99)80095-1; Trautmann S, 2001, CURR BIOL, V11, P931, DOI 10.1016/S0960-9822(01)00268-8; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; Visintin R, 2000, CURR OPIN CELL BIOL, V12, P372, DOI 10.1016/S0955-0674(00)00102-2; White J, 1999, TRENDS CELL BIOL, V9, P61, DOI 10.1016/S0962-8924(98)01433-0	19	164	176	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	APR	2002	4	4					317	322		10.1038/ncb777	http://dx.doi.org/10.1038/ncb777			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	541PY	11901424				2022-12-25	WOS:000174994000021
J	Sata, M; Saiura, A; Kunisato, A; Tojo, A; Okada, S; Tokuhisa, T; Hirai, H; Makuuchi, M; Hirata, Y; Nagai, R				Sata, M; Saiura, A; Kunisato, A; Tojo, A; Okada, S; Tokuhisa, T; Hirai, H; Makuuchi, M; Hirata, Y; Nagai, R			Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis	NATURE MEDICINE			English	Article							TRANSPLANT ATHEROSCLEROSIS; NEOINTIMAL HYPERPLASIA; MOUSE MODEL; MICE; APOPTOSIS; RESTENOSIS; EXPRESSION; DISEASE; INJURY	Excessive accumulation of smooth-muscle cells ( SMCs) has a key role in the pathogenesis of vascular diseases. It has been assumed that SMCs derived from the outer medial layer migrate, proliferate and synthesize extracellular matrix components on the luminal side of the vessel. Although much effort has been devoted to targeting migration and proliferation of medial SMCs, there is no effective therapy that prevents occlusive vascular remodeling. We show here that in models of post-angioplasty restenosis, graft vasculopathy and hyperlipidemia-induced atherosclerosis, bone-marrow cells give rise to most of the SMCs that contribute to arterial remodeling. Notably, purified hematopoietic stem cells differentiate into SMCs in vitro and in vivo. Our findings indicate that somatic stem cells contribute to pathological remodeling of remote organs, and may provide the basis for the development of new therapeutic strategies for vascular diseases through targeting mobilization, homing, differentiation and proliferation of bone marrow-derived vascular progenitor cells.	Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Tokyo, Japan; Univ Tokyo, Grad Sch Med, Dept Surg, Tokyo, Japan; Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Tokyo, Japan; Univ Tokyo, Grad Sch Med, Dept Nephrol & Endocrinol, Tokyo, Japan; Chiba Univ, Grad Sch Med, Dept Dev Genet, Chiba, Japan; Japan Sci & Technol Corp, Precursory Res Embryon Sci & Technol, Kawaguchi, Saitama, Japan	University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo; Chiba University; Japan Science & Technology Agency (JST)	Sata, M (corresponding author), Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Tokyo, Japan.		幕内, 雅敏 m/A-2140-2012					Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; BILLINGHAM ME, 1987, TRANSPLANT P, V19, P19; CORRY RJ, 1973, TRANSPLANTATION, V16, P343, DOI 10.1097/00007890-197310000-00010; Farb A, 1999, CIRCULATION, V99, P44, DOI 10.1161/01.CIR.99.1.44; Feldman LJ, 2001, CIRCULATION, V103, P3117, DOI 10.1161/01.CIR.103.25.3117; Furukawa Y, 1999, CIRC RES, V84, P306, DOI 10.1161/01.RES.84.3.306; Kaushal S, 2001, NAT MED, V7, P1035, DOI 10.1038/nm0901-1035; Kearney M, 1997, CIRCULATION, V95, P1998, DOI 10.1161/01.CIR.95.8.1998; Manka D, 2001, CIRCULATION, V103, P1000; McKay R, 2000, NATURE, V406, P361, DOI 10.1038/35019186; Miller AM, 2001, CARDIOVASC RES, V49, P838, DOI 10.1016/S0008-6363(00)00304-7; Miyamoto T, 1997, ATHEROSCLEROSIS, V129, P207, DOI 10.1016/S0021-9150(96)06043-1; *NIH, 1985, NIH PUBL, V8623; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Okada S, 2000, INT IMMUNOL, V12, P861, DOI 10.1093/intimm/12.6.861; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; Perlman H, 1998, EMBO J, V17, P3576, DOI 10.1093/emboj/17.13.3576; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Roque M, 2000, ARTERIOSCL THROM VAS, V20, P335, DOI 10.1161/01.ATV.20.2.335; ROSS R, 1973, SCIENCE, V180, P1332, DOI 10.1126/science.180.4093.1332; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Ross R, 1996, NAT MED, V2, P527, DOI 10.1038/nm0596-527; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Saiura A, 2001, NAT MED, V7, P382, DOI 10.1038/86394; Sata M, 2000, J MOL CELL CARDIOL, V32, P2097, DOI 10.1006/jmcc.2000.1238; Sata M, 1998, J BIOL CHEM, V273, P33103, DOI 10.1074/jbc.273.50.33103; Schwartz RS, 1998, AM J CARDIOL, V81, p14E, DOI 10.1016/S0002-9149(98)00191-X; Shimizu K, 2001, NAT MED, V7, P738, DOI 10.1038/89121; Tojo A, 1999, J AM SOC NEPHROL, V10, P464; Tricot O, 2000, CIRCULATION, V101, P2450, DOI 10.1161/01.CIR.101.21.2450; Walsh K, 1996, Semin Interv Cardiol, V1, P173; Wright DE, 2001, SCIENCE, V294, P1933, DOI 10.1126/science.1064081; Zambrowicz BP, 1997, P NATL ACAD SCI USA, V94, P3789, DOI 10.1073/pnas.94.8.3789; Zohlnhofer D, 2001, MOL CELL, V7, P1059, DOI 10.1016/S1097-2765(01)00239-8; Zohlnhofer D, 2001, CIRCULATION, V103, P1396, DOI 10.1161/01.CIR.103.10.1396	36	956	1041	0	46	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2002	8	4					403	409		10.1038/nm0402-403	http://dx.doi.org/10.1038/nm0402-403			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	536ML	11927948				2022-12-25	WOS:000174704800034
J	Harper, SQ; Hauser, MA; DelloRusso, C; Duan, DS; Crawford, RW; Phelps, SF; Harper, HA; Robinson, AS; Engelhardt, JF; Brooks, SV; Chamberlain, JS				Harper, SQ; Hauser, MA; DelloRusso, C; Duan, DS; Crawford, RW; Phelps, SF; Harper, HA; Robinson, AS; Engelhardt, JF; Brooks, SV; Chamberlain, JS			Modular flexibility of dystrophin: Implications for gene therapy of Duchenne muscular dystrophy	NATURE MEDICINE			English	Article							RECOMBINANT ADENOASSOCIATED VIRUS; TRANSGENIC MDX MICE; GLYCOPROTEIN COMPLEX; IMMUNOCOMPETENT MICE; TERMINAL DOMAIN; MUSCLE; VECTOR; EXPRESSION; SEQUENCE; SPECTRIN	Attempts to develop gene therapy for Duchenne muscular dystrophy (DMD) have been complicated by the enormous size of the dystrophin gene. We have performed a detailed functional analysis of dystrophin structural domains and show that multiple regions of the protein can be deleted in various combinations to generate highly functional mini- and micro-dystrophins. Studies in transgenic mdx mice, a model for DMD, reveal that a wide variety of functional characteristics of dystrophy are prevented by some of these truncated dystrophins. Muscles expressing the smallest dystrophins are fully protected against damage caused by muscle activity and are not morphologically different from normal muscle. Moreover, injection of adeno-associated viruses carrying micro-dystrophins into dystrophic muscles of immunocompetent mdx mice results in a striking reversal of histopathological features of this disease. These results demonstrate that the dystrophic pathology can be both prevented and reversed by gene therapy using micro-dystrophins.	Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA; Univ Michigan, Sch Med, Mol & Cellular Biol Program, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA; Univ Iowa, Sch Med, Dept Anat & Cell Biol, Iowa City, IA 52242 USA	University of Washington; University of Washington Seattle; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Duke University; Duke University; University of Iowa	Chamberlain, JS (corresponding author), Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA.			Engelhardt, John/0000-0003-2389-9277; Brooks, Susan/0000-0003-1954-967X; Duan, Dongsheng/0000-0003-4109-1132; Chamberlain, Jeffrey/0000-0001-5299-0059				BYERS TJ, 1989, J CELL BIOL, V109, P1633, DOI 10.1083/jcb.109.4.1633; Corrado K, 1996, J CELL BIOL, V134, P873, DOI 10.1083/jcb.134.4.873; COX GA, 1993, NATURE, V364, P725, DOI 10.1038/364725a0; Crawford GE, 2000, J CELL BIOL, V150, P1399, DOI 10.1083/jcb.150.6.1399; CROSS RA, 1990, FEBS LETT, V262, P87, DOI 10.1016/0014-5793(90)80160-K; DELLORUSSO C, IN PRESS J MUS RES C; Duan DS, 2000, NAT MED, V6, P595, DOI 10.1038/75080; Emery A.E.H., 1993, DUCHENNE MUSCULAR DY; ENGLAND SB, 1990, NATURE, V343, P180, DOI 10.1038/343180a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Fisher KJ, 1997, NAT MED, V3, P306, DOI 10.1038/nm0397-306; Greelish JP, 1999, NAT MED, V5, P439, DOI 10.1038/7439; Hartigan-O'Connor D, 2000, MICROSC RES TECHNIQ, V48, P223, DOI 10.1002/(SICI)1097-0029(20000201/15)48:3/4<223::AID-JEMT10>3.0.CO;2-L; Hartigan-O'Connor D, 2001, MOL THER, V4, P525, DOI 10.1006/mthe.2001.0496; Hauser MA, 2000, MOL THER, V2, P16, DOI 10.1006/mthe.2000.0089; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; KAHANA E, 1994, J MOL BIOL, V235, P1271, DOI 10.1006/jmbi.1994.1080; KAHANA E, 1995, BIOCHEMISTRY-US, V34, P8110, DOI 10.1021/bi00025a017; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Lynch GS, 1997, AM J PHYSIOL-CELL PH, V272, pC2063, DOI 10.1152/ajpcell.1997.272.6.C2063; Lynch GS, 2000, AM J PHYSIOL-CELL PH, V279, pC1290, DOI 10.1152/ajpcell.2000.279.4.C1290; Pascual J, 1997, BIOESSAYS, V19, P811, DOI 10.1002/bies.950190911; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; PHELPS SF, 1995, HUM MOL GENET, V4, P1251, DOI 10.1093/hmg/4.8.1251; Rafael JA, 1996, J CELL BIOL, V134, P93, DOI 10.1083/jcb.134.1.93; Snyder RO, 1997, HUM GENE THER, V8, P1891, DOI 10.1089/hum.1997.8.16-1891; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; Straub V, 1997, J CELL BIOL, V139, P375, DOI 10.1083/jcb.139.2.375; Thomas GH, 1997, MOL BIOL EVOL, V14, P1285, DOI 10.1093/oxfordjournals.molbev.a025738; Wang B, 2000, P NATL ACAD SCI USA, V97, P13714, DOI 10.1073/pnas.240335297; Xiao X, 1998, J VIROL, V72, P2224, DOI 10.1128/JVI.72.3.2224-2232.1998; Xiao XA, 1996, J VIROL, V70, P8098, DOI 10.1128/JVI.70.11.8098-8108.1996; Yazaki M, 1999, EUR NEUROL, V42, P145, DOI 10.1159/000008089; Yuasa K, 1998, FEBS LETT, V425, P329, DOI 10.1016/S0014-5793(98)00251-8	37	419	444	0	37	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2002	8	3					253	261		10.1038/nm0302-253	http://dx.doi.org/10.1038/nm0302-253			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	526PU	11875496				2022-12-25	WOS:000174139500030
J	Kreisel, D; Krupnick, AS; Gelman, AE; Engels, FH; Popma, SH; Krasinskas, AM; Balsara, KR; Szeto, WY; Turka, LA; Rosengard, BR				Kreisel, D; Krupnick, AS; Gelman, AE; Engels, FH; Popma, SH; Krasinskas, AM; Balsara, KR; Szeto, WY; Turka, LA; Rosengard, BR			Non-hematopoietic allograft cells directly activate CD8(+) T cells and trigger acute rejection: An alternative mechanism of allorecognition	NATURE MEDICINE			English	Article							ANTIGEN-PRESENTING CELLS; VASCULAR ENDOTHELIAL-CELLS; CARDIAC ALLOGRAFTS; CLASS-I; IMMUNOGENICITY; COSTIMULATION; PREVENTION; RESPONSES; INVIVO; RAT	Despite evidence that human non-hematopoietic cells, such as vascular endothelium, can activate allogeneic T lymphocytes in vitro, the prevailing view has been that hematopoietic antigen-presenting cells are required to trigger alloimmune responses in vivo. Here we report that mouse non-hematopoietic cells activate alloreactive CD8(+) T lymphocytes in vitro and in vivo. We also show that vascularized cardiac allografts are acutely rejected via CD8(+) direct allorecognition even if the alloantigen is not presented by hematopoietic professional antigen-presenting cells. Because activation of alloreactive CD8(+) T cells by donor-type non-hematopoietic cells can continue for the life of the allograft, these findings present a new clinically relevant mechanism of allorecognition and should be taken into consideration when developing strategies to prevent allograft vasculopathy or to induce tolerance.	Univ Penn, Med Ctr, Dept Surg, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Rosengard, BR (corresponding author), Univ Penn, Med Ctr, Dept Surg, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043626, P01AI041521, R01AI047257, R21AI043626, R01AI037691] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-43626, AI-37691, AI-41521, AI47257-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUCHINCLOSS H, 1988, TRANSPLANTATION, V45, P1118, DOI 10.1097/00007890-198806000-00024; Benichou G, 1999, J IMMUNOL, V162, P352; BENNUN A, 1983, J EXP MED, V157, P2147, DOI 10.1084/jem.157.6.2147; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; Chin R, 2001, NAT MED, V7, P1165, DOI 10.1038/nm1101-1165a; COLLINS T, 1984, P NATL ACAD SCI-BIOL, V81, P4917, DOI 10.1073/pnas.81.15.4917; Dengler TJ, 2000, J IMMUNOL, V164, P5146, DOI 10.4049/jimmunol.164.10.5146; ENGERS HD, 1975, J IMMUNOL, V115, P356; EPPERSON DE, 1994, J IMMUNOL, V153, P5402; FERRY B, 1987, TRANSPLANTATION, V44, P499, DOI 10.1097/00007890-198710000-00008; GAO EK, 1991, J EXP MED, V174, P435, DOI 10.1084/jem.174.2.435; HADLEY GA, 1992, TRANSPLANTATION, V54, P537, DOI 10.1097/00007890-199209000-00028; Hornick PI, 1998, CIRCULATION, V97, P1257, DOI 10.1161/01.CIR.97.13.1257; Hornick PI, 2000, CIRCULATION, V101, P2405, DOI 10.1161/01.CIR.101.20.2405; Jones ND, 2001, J IMMUNOL, V166, P2824, DOI 10.4049/jimmunol.166.4.2824; Jones ND, 2000, J IMMUNOL, V165, P1111, DOI 10.4049/jimmunol.165.2.1111; Kaech SM, 2001, NAT IMMUNOL, V2, P415, DOI 10.1038/87720; KOSAKA H, 1992, J EXP MED, V176, P1291, DOI 10.1084/jem.176.5.1291; Krasinskas AM, 2000, TRANSPLANTATION, V70, P514, DOI 10.1097/00007890-200008150-00020; Kreisel D, 2001, J IMMUNOL METHODS, V254, P31, DOI 10.1016/S0022-1759(01)00371-4; LACY PE, 1979, TRANSPLANTATION, V27, P171, DOI 10.1097/00007890-197903000-00006; LAFFERTY KJ, 1975, SCIENCE, V188, P259, DOI 10.1126/science.1118726; Lakkis FG, 2000, NAT MED, V6, P686, DOI 10.1038/76267; LARSEN CP, 1990, J EXP MED, V171, P307, DOI 10.1084/jem.171.1.307; Latouche JB, 2000, NAT BIOTECHNOL, V18, P405, DOI 10.1038/74455; LODGE PA, 1993, TRANSPLANTATION, V56, P656, DOI 10.1097/00007890-199309000-00030; LOMBARDI G, 1990, INT IMMUNOL, V2, P9, DOI 10.1093/intimm/2.1.9; Marelli-Berg FM, 2000, J IMMUNOL, V165, P4182, DOI 10.4049/jimmunol.165.8.4182; MEDAWAR PB, 1957, P ROY SOC LOND B BIO, V149, P145; MILTON AD, 1985, J EXP MED, V161, P98, DOI 10.1084/jem.161.1.98; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; Perez VL, 1998, CELL IMMUNOL, V189, P31, DOI 10.1006/cimm.1998.1362; ROSENBERG AS, 1987, J EXP MED, V165, P1296, DOI 10.1084/jem.165.5.1296; ROUABHIA M, 1993, TRANSPLANTATION, V56, P259, DOI 10.1097/00007890-199308000-00001; Sayegh MH, 1997, TRANSPLANTATION, V64, P1646, DOI 10.1097/00007890-199712270-00003; SAYEGH MH, 1991, TRANSPLANTATION, V51, P296, DOI 10.1097/00007890-199102000-00003; Sigal LJ, 1999, NATURE, V398, P77, DOI 10.1038/18038; SINGER A, 1984, J IMMUNOL, V132, P2199; STROBER S, 1965, J EXP MED, V122, P347, DOI 10.1084/jem.122.2.347; Suchin EJ, 2001, J IMMUNOL, V166, P973, DOI 10.4049/jimmunol.166.2.973; Tellides G, 2000, NATURE, V403, P207, DOI 10.1038/35003221; Trambley J, 1999, J CLIN INVEST, V104, P1715, DOI 10.1172/JCI8082; van Stipdonk MJB, 2001, NAT IMMUNOL, V2, P423, DOI 10.1038/87730; Wang B, 2000, J IMMUNOL, V164, P1216, DOI 10.4049/jimmunol.164.3.1216; Whitmire JK, 1999, J IMMUNOL, V163, P3194	45	174	181	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2002	8	3					233	239		10.1038/nm0302-233	http://dx.doi.org/10.1038/nm0302-233			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	526PU	11875493				2022-12-25	WOS:000174139500027
J	Gervais, FG; Singaraja, R; Xanthoudakis, S; Gutekunst, CA; Leavitt, BR; Metzler, M; Hackam, AS; Tam, J; Vaillancourt, JP; Houtzager, V; Rasper, DM; Roy, S; Hayden, MR; Nicholson, DW				Gervais, FG; Singaraja, R; Xanthoudakis, S; Gutekunst, CA; Leavitt, BR; Metzler, M; Hackam, AS; Tam, J; Vaillancourt, JP; Houtzager, V; Rasper, DM; Roy, S; Hayden, MR; Nicholson, DW			Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partners Hippi	NATURE CELL BIOLOGY			English	Article							FLUORESCENT CERAMIDE ANALOG; CELL-DEATH; GOLGI-APPARATUS; GENE FAMILY; DISEASE; LOCALIZATION; CYTOSKELETON; ENDOCYTOSIS; APOPTOSIS; DOMAIN	In Huntington disease, polyglutamine expansion of the protein huntingtin (Htt) leads to selective neurodegenerative loss of medium spiny neurons throughout the striatum by an unknown apoptotic mechanism. Binding of Hip-1, a protein normally associated with Htt, is reduced by polyglutamine expansion. Free Hip-1 binds to a hitherto unknown polypeptide, Hippi (Hip-1 protein interactor), which has partial: sequence homology to Hip-1 and similar tissue and subcellular distribution. The availability of free Hip-1 is modulated by polyglutamine length within Htt, with disease-associated polyglutamine expansion favouring the formation of pro-apoptotic Hippi-Hip-1 heterodimers. This heterodimer can recruit procaspase-8 into a complex of Hippi, Hip-1 and procaspase-8, and launch apoptosis through components of the 'extrinsic' cell-death pathway. We propose that Htt polyglutamine expansion liberates Hip-1 so that it can form a caspase-8 recruitment complex with Hippi. This novel non-receptor-mediated pathway for activating caspase-8 might contribute to neuronal death in Huntington disease.	Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Pointe Claire, PQ H9R 4P8, Canada; Univ British Columbia, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada; Univ British Columbia, Dept Med Genet, Vancouver, BC V5Z 4H4, Canada; Emory Univ, Dept Neurol, Atlanta, GA 30322 USA	Merck & Company; University of British Columbia; University of British Columbia; Emory University	Nicholson, DW (corresponding author), Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, POB 1005, Pointe Claire, PQ H9R 4P8, Canada.	donald_nicholson@merck.com	Leavitt, Blair R/G-1934-2012; Hayden, Michael R/D-8581-2011	Hayden, Michael R/0000-0001-5159-1419; Singaraja, Roshni/0000-0002-3418-3867				Aravind L, 1999, TRENDS BIOCHEM SCI, V24, P47, DOI 10.1016/S0968-0004(98)01341-3; Chopra VS, 2000, MAMM GENOME, V11, P1006, DOI 10.1007/s003350010195; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; DIFIGLIA M, 1990, TRENDS NEUROSCI, V13, P286, DOI 10.1016/0166-2236(90)90111-M; Dragatsis I, 2000, NAT GENET, V26, P300, DOI 10.1038/81593; DRAGUNOW M, 1995, NEUROREPORT, V6, P1053, DOI 10.1097/00001756-199505090-00026; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; Garcia-Calvo M, 1999, CELL DEATH DIFFER, V6, P362, DOI 10.1038/sj.cdd.4400497; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Gutekunst CA, 1998, J NEUROSCI, V18, P7674, DOI 10.1523/jneurosci.18-19-07674.1998; Hackam AS, 2000, J BIOL CHEM, V275, P41299, DOI 10.1074/jbc.M008408200; Hemmings L, 1996, J CELL SCI, V109, P2715; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; HOLTZMAN DA, 1993, J CELL BIOL, V122, P635, DOI 10.1083/jcb.122.3.635; ITOH N, 1993, J BIOL CHEM, V268, P10932; Kalchman MA, 1997, NAT GENET, V16, P44, DOI 10.1038/ng0597-44; KREMER B, 1994, NEW ENGL J MED, V330, P1401, DOI 10.1056/NEJM199405193302001; Leavitt BR, 2001, AM J HUM GENET, V68, P313, DOI 10.1086/318207; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Metzler M, 2001, J BIOL CHEM, V276, P39271, DOI 10.1074/jbc.C100401200; MUGURUMA M, 1995, J BIOCHEM-TOKYO, V117, P1036, DOI 10.1093/oxfordjournals.jbchem.a124803; Mulholland J, 1997, MOL BIOL CELL, V8, P1481, DOI 10.1091/mbc.8.8.1481; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; NIHEI K, 1992, ANN NEUROL, V31, P59, DOI 10.1002/ana.410310111; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; Roy S, 2000, J EXP MED, V192, pF21, DOI 10.1084/jem.192.8.F21; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; Sapp E, 1999, J NEUROPATH EXP NEUR, V58, P165, DOI 10.1097/00005072-199902000-00006; SATO N, 1992, J CELL SCI, V103, P131; Seki N, 1998, J HUM GENET, V43, P268, DOI 10.1007/s100380050087; THOMAS LB, 1995, EXP NEUROL, V133, P265, DOI 10.1006/exnr.1995.1029; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; Wellington CL, 1998, J BIOL CHEM, V273, P9158, DOI 10.1074/jbc.273.15.9158; Wesp A, 1997, MOL BIOL CELL, V8, P2291, DOI 10.1091/mbc.8.11.2291	42	232	243	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2002	4	2					95	105		10.1038/ncb735	http://dx.doi.org/10.1038/ncb735			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	520RJ	11788820				2022-12-25	WOS:000173794600012
J	Guba, M; von Breitenbuch, P; Steinbauer, M; Koehl, G; Flegel, S; Hornung, M; Bruns, CJ; Zuelke, C; Farkas, S; Anthuber, M; Jauch, KW; Geissler, EK				Guba, M; von Breitenbuch, P; Steinbauer, M; Koehl, G; Flegel, S; Hornung, M; Bruns, CJ; Zuelke, C; Farkas, S; Anthuber, M; Jauch, KW; Geissler, EK			Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor	NATURE MEDICINE			English	Article							IN-VIVO; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; ANGIOGENESIS; TRANSPLANTATION; MECHANISM; CARCINOMA; CANCER; CELLS; VEGF	Conventional immunosuppressive drugs have been used effectively to prevent immunologic rejection in organ transplantation. Individuals taking these drugs are at risk, however, for the development and recurrence of cancer. In the present study we show that the new immunosuppressive drug rapamycin (RAPA) may reduce the risk of cancer development while simultaneously providing effective immunosuppression. Experimentally, RAPA inhibited metastatic tumor growth and angiogenesis in in vivo mouse models. In addition, normal immunosuppressive doses of RAPA effectively controlled the growth of established tumors. In contrast, the most widely recognized immunosuppressive drug, cyclosporine, promoted tumor growth. From a mechanistic perspective, RAPA showed antiangiogenic activities linked to a decrease in production of vascular endothelial growth factor (VEGF) and to a markedly inhibited response of vascular endothelial cells to stimulation by VEGF. Thus, the use of RAPA, instead of cyclosporine, may reduce the chance of recurrent or de novo cancer in high-risk transplant patients.	Univ Regensburg, Dept Surg, D-8400 Regensburg, Germany	University of Regensburg	Guba, M (corresponding author), Univ Regensburg, Dept Surg, D-8400 Regensburg, Germany.	markus.guba@klinik.uni-regensburg.de; edward.geissler@klinik.uni-regensburg.de	Guba, Markus/M-4309-2019; Geissler, Edward/R-4131-2016; Farkas, Stefan/AAG-5843-2020	Hornung, Matthias/0000-0001-9759-8958				ASAISHI K, 1981, CANCER RES, V41, P1898; Benelli U, 1997, INVEST OPHTH VIS SCI, V38, P274; BRATTAIN MG, 1980, CANCER RES, V40, P2142; Browder T, 2000, CANCER RES, V60, P1878; Bruns CJ, 2000, CANCER, V89, P488, DOI 10.1002/1097-0142(20000801)89:3<488::AID-CNCR3>3.3.CO;2-O; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Dayanir V, 2001, J BIOL CHEM, V276, P17686, DOI 10.1074/jbc.M009128200; Drixler TA, 2000, CANCER RES, V60, P1761; DUMONT FJ, 1990, J IMMUNOL, V144, P251; ENG CP, 1984, J ANTIBIOT, V37, P1231, DOI 10.7164/antibiotics.37.1231; FERRARA N, 1995, BREAST CANCER RES TR, V36, P127, DOI 10.1007/BF00666035; Folkman J, 2001, THROMB HAEMOSTASIS, V86, P23; Fukumura D, 1997, AM J PATHOL, V151, P679; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Garver RI, 1999, NEW ENGL J MED, V340, P1071, DOI 10.1056/NEJM199904083401403; Gohongi T, 1999, NAT MED, V5, P1203, DOI 10.1038/13524; Guba M, 2000, SHOCK, V13, P190, DOI 10.1097/00024382-200003000-00004; Guba M, 2001, CANCER RES, V61, P5575; Hajitou A, 2001, CANCER RES, V61, P3450; Hojo M, 1999, NATURE, V397, P530, DOI 10.1038/17401; Ilan N, 1998, J CELL SCI, V111, P3621; Iurlaro M, 1998, EXP HEMATOL, V26, P1215; Kahan BD, 2000, LANCET, V356, P194, DOI 10.1016/S0140-6736(00)02480-6; Klement G, 2000, J CLIN INVEST, V105, pR15, DOI 10.1172/JCI8829; Meyer CG, 2000, TRANSPLANTATION, V69, P1633; Ondrus D., 1999, International Urology and Nephrology, V31, P417, DOI 10.1023/A:1007194607496; Overbergh L, 1999, CYTOKINE, V11, P305, DOI 10.1006/cyto.1998.0426; Penn I, 1998, Clin Transpl, P147; Salomon-Nguyen F, 2000, P NATL ACAD SCI USA, V97, P6757, DOI 10.1073/pnas.120162297; Sanchez-Elsner T, 2001, J BIOL CHEM, V276, P38527, DOI 10.1074/jbc.M104536200; Saunders RN, 2001, KIDNEY INT, V59, P3, DOI 10.1046/j.1523-1755.2001.00460.x; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Schwarte-Waldhoff I, 2000, P NATL ACAD SCI USA, V97, P9624, DOI 10.1073/pnas.97.17.9624; Sehgal SN, 1998, CLIN BIOCHEM, V31, P335, DOI 10.1016/S0009-9120(98)00045-9; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; Vinals F, 1999, J BIOL CHEM, V274, P26776, DOI 10.1074/jbc.274.38.26776; Wiederrecht G J, 1995, Prog Cell Cycle Res, V1, P53; Yu Y, 1999, J CELL PHYSIOL, V178, P235, DOI 10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.3.CO;2-J; Zheng W, 2001, AM J PHYSIOL-HEART C, V280, pH909, DOI 10.1152/ajpheart.2001.280.2.H909; Zhong H, 2000, CANCER RES, V60, P1541	41	1395	1508	2	117	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2002	8	2					128	135		10.1038/nm0202-128	http://dx.doi.org/10.1038/nm0202-128			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	517FN	11821896				2022-12-25	WOS:000173600600021
J	Peeper, DS; Shvarts, A; Brummelkamp, T; Douma, S; Koh, EY; Daley, GQ; Bernards, R				Peeper, DS; Shvarts, A; Brummelkamp, T; Douma, S; Koh, EY; Daley, GQ; Bernards, R			A functional screen identifies hDRIL1 as an oncogene that rescues RAS-induced senescence	NATURE CELL BIOLOGY			English	Article							CYCLIN-E; TRANSCRIPTION FACTOR; TUMOR-SUPPRESSOR; DEREGULATED EXPRESSION; CELL-PROLIFERATION; BINDING-PROTEIN; G(1) CONTROL; MYC; FAMILY; GENE	Primary fibroblasts respond to activated H-RAS(V12) by undergoing premature arrest, which resembles replicative senescence(1). This irreversible 'fail-safe mechanism' requires p19(ARF), p53 and the Retinoblastoma (Rb) family: upon their disruption, RAS(V12)-expressing cells fail to undergo senescence and continue to proliferate(1-7). Similarly, co-expression of oncogenes such as c-MYC or E1A rescues RAS(V12)-induced senescence. To identify novel genes that allow escape from RAS(V12)-induced senescence, we designed an unbiased, retroviral complementary DNA library screen. We report on the identification of DRIL1, the human orthologue of the mouse Bright and Drosophila dead ringer transcriptional regulators. DRIL1 renders primary murine fibroblasts unresponsive to RAS(V12)-induced anti-proliferative signalling by p19(ARF)/p53/p21(CIP1), as well as by p16(INK4a). In this way, DRIL1 not only rescues RAS(V12)-induced senescence but also causes these fibroblasts to become highly oncogenic. Furthermore, DRIL1 immortalizes mouse fibroblasts, in the presence of high levels of p16(INK4a). Immortalization by DRIL1, whose product binds the pRB-controlled transcription factor E2F1 (ref. 8), is correlated with induction of E2F1 activity. Correspondingly, DRIL1 induces the E2F1 target Cyclin E1, overexpression of which is sufficient to trigger escape from senescence. Thus, DRIL1 disrupts cellular protection against RASV12-induced proliferation downstream of the p19(ARF)/p53 pathway.	Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	Netherlands Cancer Institute; Netherlands Cancer Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute	Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.		Peeper, Daniel/AAA-2430-2020	Bernards, Rene/0000-0001-8677-3423				Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Gregory SL, 1996, MOL CELL BIOL, V16, P792; Groth A, 2000, J BIOL CHEM, V275, P27473; Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434; Herrscher RF, 1995, GENE DEV, V9, P3067, DOI 10.1101/gad.9.24.3067; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Karsunky H, 1999, ONCOGENE, V18, P7816, DOI 10.1038/sj.onc.1203205; Keyomarsi K, 1997, Prog Cell Cycle Res, V3, P171; Kortschak RD, 1998, GENOMICS, V51, P288, DOI 10.1006/geno.1998.5259; Kortschak RD, 2000, TRENDS BIOCHEM SCI, V25, P294, DOI 10.1016/S0968-0004(00)01597-8; LEE GH, 1995, AM J PATHOL, V147, P1811; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; O'Hagan RC, 2000, GENE DEV, V14, P2185, DOI 10.1101/gad.827200; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; Peeper DS, 2001, NAT CELL BIOL, V3, P198, DOI 10.1038/35055110; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Randle DH, 2001, P NATL ACAD SCI USA, V98, P9654, DOI 10.1073/pnas.171217498; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Suzuki M, 1998, ONCOGENE, V17, P853, DOI 10.1038/sj.onc.1202163; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	30	88	93	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	FEB	2002	4	2					148	153		10.1038/ncb742	http://dx.doi.org/10.1038/ncb742			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	520RJ	11812999	Green Published			2022-12-25	WOS:000173794600019
J	Virolle, T; Adamson, ED; Baron, V; Birle, D; Mercola, D; Mustelin, T; de Belle, I				Virolle, T; Adamson, ED; Baron, V; Birle, D; Mercola, D; Mustelin, T; de Belle, I			The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling	NATURE CELL BIOLOGY			English	Article							TUMOR-SUPPRESSOR GENE; CELL-SURVIVAL; PHOSPHATASE-ACTIVITY; GERMLINE MUTATIONS; COWDEN-DISEASE; HT1080 CELLS; IN-VIVO; GROWTH; CANCER; BREAST	The PTEN tumour suppressor(1) and pro-apoptotic(2) gene is frequently mutated in human cancers. We show that PTEN transcription is upregulated by Egr-1 after irradiation in wild-type, but not egr-1(-/-), mice in vivo. We found that Egr-1 specifically binds to the PTEN 5' untranslated region, which contains a functional GCGGCGGCG Egr-1-binding site. Inducing Egr-1 by exposing cells to ultraviolet light upregulates expression of PTEN messenger RNA and protein, and leads to apoptosis. egr-1(-/-) cells, which cannot upregulate PTEN expression after irradiation, are resistant to ultraviolet-light-induced apoptosis. Therefore, Egr-1 can directly regulate PTEN, triggering the initial step in this apoptotic pathway. Loss of Egr-1 expression, which often occurs in human cancers, could deregulate the PTEN gene and contribute to the radiation resistance of some cancer cells.	Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA; Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA	Sanford Burnham Prebys Medical Discovery Institute	de Belle, I (corresponding author), Burnham Inst, Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		mercola, dan/L-4182-2013; Virolle, Thierry/E-5838-2016	mercola, dan/0000-0002-0281-9840; Mustelin, Tomas/0000-0001-5912-8840				Ahmed MM, 1997, J BIOL CHEM, V272, P33056, DOI 10.1074/jbc.272.52.33056; Ahmed MM, 1996, J BIOL CHEM, V271, P29231, DOI 10.1074/jbc.271.46.29231; Arch EM, 1997, AM J MED GENET, V71, P489, DOI 10.1002/(SICI)1096-8628(19970905)71:4<489::AID-AJMG24>3.0.CO;2-B; de Belle I, 2000, BIOTECHNIQUES, V29, P162; de Belle I, 1999, ONCOGENE, V18, P3633, DOI 10.1038/sj.onc.1202696; Ge NL, 2000, ONCOGENE, V19, P4091, DOI 10.1038/sj.onc.1203801; HUANG RP, 1994, ONCOGENE, V9, P1367; Huang RP, 1996, J CELL BIOL, V133, P211, DOI 10.1083/jcb.133.1.211; HUANG RP, 1995, ONCOGENE, V10, P467; Huang RP, 1997, INT J CANCER, V72, P102, DOI 10.1002/(SICI)1097-0215(19970703)72:1<102::AID-IJC15>3.0.CO;2-L; HUANG RP, 1995, CANCER RES, V55, P5054; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Liu CT, 1999, J BIOL CHEM, V274, P4400, DOI 10.1074/jbc.274.7.4400; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Wang XD, 2000, J IMMUNOL, V164, P1934, DOI 10.4049/jimmunol.164.4.1934; Weng LP, 1999, CANCER RES, V59, P5808; Weng LP, 2001, HUM MOL GENET, V10, P237, DOI 10.1093/hmg/10.3.237	27	334	352	0	18	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2001	3	12					1124	1128		10.1038/ncb1201-1124	http://dx.doi.org/10.1038/ncb1201-1124			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	500AM	11781575				2022-12-25	WOS:000172603700019
J	Park, JH; Cosgrove, MS; Youngman, E; Wolberger, C; Boeke, JD				Park, JH; Cosgrove, MS; Youngman, E; Wolberger, C; Boeke, JD			A core nucleosome surface crucial for transcriptional silencing	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; RIBOSOMAL DNA; YEAST; ACETYLATION; DOMAINS; SIR2; DEACETYLASE; REPRESSION; HISTONE-H4; PARTICLE	Transcriptional silencing in yeast provides a genetically tractable system for analyzing the formation and maintenance of heterochromatin, a transcriptionally repressive chromatin structure found in all organisms. The nucleosome constitutes the central structure of chromatin and comprises two chains each of histones H2A, H2B, H3 and H4. The structure of the nucleosome consists of a central globular core surrounded by outwardly protruding amino-terminal histone tails. We show that a specific surface of the assembled nucleosome core is required for silencing in yeast. This surface is located at a H3/H4 histone-fold motif and contains amino-acid side chains located on the nucleosome disk surface and on an adjacent surface that interacts with DNA. The side chains, identified from mutants in which all three forms of silencing (rDNA, telomere and silent mating locus silencing) are eliminated, are centered around Lys79 of histone H3, a residue methylated by the yeast Dot1 protein(1,2). Moreover, mutations in the genes encoding H3 (HHT1 and HHT2) and H4 (HHF1 and HHF2) mapping to spatially adjacent amino-acid residues affected the three forms of silencing distinctly, suggesting that specific interactions mediate each form of silencing. Several of the mutations that we identified resemble those in a cluster of previously identified mutations affecting a distinct histone-fold motif elsewhere in the nucleosome core. These two clusters relieve distinct forms of transcriptional repression (silencing versus repression resulting from lack of Swi/Snf chromatin remodeling activity).	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University	Boeke, JD (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, 725 N Wolfe St, Baltimore, MD 21205 USA.		Youngman, Elaine/O-7449-2019	Wolberger, Cynthia/0000-0001-8578-2969; Boeke, Jef/0000-0001-5322-4946				BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Cockell MM, 2000, GENETICS, V154, P1069; DELANO WL, 2002, PYMOL MOL GRAPHICS; Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B; GOTTSCHLING DE, 1992, P NATL ACAD SCI USA, V89, P4062, DOI 10.1073/pnas.89.9.4062; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Guarente L, 2000, GENE DEV, V14, P1021; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; KRUGER W, 1995, GENE DEV, V9, P2770, DOI 10.1101/gad.9.22.2770; LOO S, 1994, SCIENCE, V264, P1768, DOI 10.1126/science.8209257; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luger K, 1998, CURR OPIN GENET DEV, V8, P140, DOI 10.1016/S0959-437X(98)80134-2; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; Moazed D, 1997, P NATL ACAD SCI USA, V94, P2186, DOI 10.1073/pnas.94.6.2186; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; Ng HH, 2002, GENE DEV, V16, P1518, DOI 10.1101/gad.1001502; PARK EC, 1990, MOL CELL BIOL, V10, P4932, DOI 10.1128/MCB.10.9.4932; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; Reynolds A., 1997, CURRENT PROTOCOLS MO; SIKORSKI RS, 1989, GENETICS, V122, P19; Singer MS, 1998, GENETICS, V150, P613; SINGH D, 1994, INDIAN J CHEM TECHN, V1, P266; SINGH J, 1992, GENE DEV, V6, P186, DOI 10.1101/gad.6.2.186; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; Smith JS, 1999, MOL CELL BIOL, V19, P3184; Straight AF, 1999, CELL, V97, P245, DOI 10.1016/S0092-8674(00)80734-5; Suka N, 2001, MOL CELL, V8, P473, DOI 10.1016/S1097-2765(01)00301-X; Tanner KG, 2000, P NATL ACAD SCI USA, V97, P14178, DOI 10.1073/pnas.250422697; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; White CL, 2001, EMBO J, V20, P5207, DOI 10.1093/emboj/20.18.5207	32	102	103	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2002	32	2					273	279		10.1038/ng982	http://dx.doi.org/10.1038/ng982			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	599AP	12244315				2022-12-25	WOS:000178311100016
J	Tebbutt, NC; Giraud, AS; Inglese, M; Jenkins, B; Waring, P; Clay, FJ; Malki, S; Alderman, BM; Grail, D; Hollande, F; Heath, JK; Ernst, M				Tebbutt, NC; Giraud, AS; Inglese, M; Jenkins, B; Waring, P; Clay, FJ; Malki, S; Alderman, BM; Grail, D; Hollande, F; Heath, JK; Ernst, M			Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice	NATURE MEDICINE			English	Article							CYTOKINE RECEPTORS; TRANSGENIC MICE; IN-VIVO; INTESTINAL INFLAMMATION; INTERLEUKIN-6 FAMILY; SIGNAL TRANSDUCER; HEPATIC CELLS; RESPONSES; DISEASE; COLITIS	The intracellular signaling mechanisms that specify tissue-specific responses to the interleukin-6 (IL-6) family of cytokines are not well understood. Here, we evaluated the functions of the two major signaling pathways, the signal transducers and activators of transcription 1 and 3 (STAT1/3) and the Src-homology tyrosine phosphatase 2 (SHP2)-Ras-ERK, emanating from the common signal transducer, gp130, in the gastrointestinal tract. Gp130(757F) mice, with a `knock-in' mutation abrogating SHP2-Ras-ERK signaling, developed gastric adenomas by three months of age. In contrast, mice harboring the reciprocal mutation ablating STAT1/3 signaling (gp130Delta(STAT)), or deficient in IL-6-mediated gp130 signaling (IL- 6(-/-) mice), showed impaired colonic mucosal wound healing. These gastrointestinal phenotypes are highly similar to the phenotypes exhibited by mice deficient in trefoil factor 1 (pS2/TFF1) and intestinal trefoil factor (ITF)/TFF3, respectively, and corresponded closely with the capacity of the two pathways to stimulate transcription of the genes encoding pS2/TFF1 and ITF/TFF3. We propose a model whereby mucosal wound healing depends solely on activation of STAT1/3, whereas gastric hyperplasia ensues when the coordinated activation of the STAT1/3 and SHP2-Ras-ERK pathways is disrupted.	Royal Melbourne Hosp, Ludwig Inst Canc Res, Parkville, Vic, Australia; Univ Melbourne, Western Hosp, Dept Med, Footscray, Vic, Australia; Peter MacCallum Canc Inst, Dept Pathol, Melbourne, Vic, Australia; Fac Pharm Montpellier, Lab Signalisat Cellulaire Normale & Tumorale, Montpellier, France	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; University of Melbourne; Western Hospital; Peter Maccallum Cancer Center; Universite de Montpellier	Ernst, M (corresponding author), Royal Melbourne Hosp, Ludwig Inst Canc Res, Parkville, Vic, Australia.	matthias.ernst@ludwig.edu.au	Hollande, Frederic/E-3133-2013; Hollande, Frederic/GLS-4120-2022; Ernst, Matthias/D-5111-2012; jenkins, brendan/J-7854-2012; jenkins, brendan/A-2401-2009; Heath, Joan/D-3054-2012	Hollande, Frederic/0000-0002-7046-8392; Ernst, Matthias/0000-0002-6399-1177; Heath, Joan/0000-0001-6955-232X; Jenkins, Brendan/0000-0002-7552-4656				Atreya R, 2000, NAT MED, V6, P583, DOI 10.1038/75068; BAUMANN H, 1994, J BIOL CHEM, V269, P16297; Betz UAK, 1998, J EXP MED, V188, P1955, DOI 10.1084/jem.188.10.1955; Boivin GP, 1996, LAB INVEST, V74, P513; Bossenmeyer-Pourie C, 2002, J CELL BIOL, V157, P761, DOI 10.1083/jcb200108056; COOPER HS, 1993, LAB INVEST, V69, P238; Du XX, 1997, BLOOD, V89, P3897, DOI 10.1182/blood.V89.11.3897; Egger B, 1999, DIGEST DIS SCI, V44, P836, DOI 10.1023/A:1026642715764; Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200; Ernst M, 1999, J BIOL CHEM, V274, P9729, DOI 10.1074/jbc.274.14.9729; Ernst M, 2001, J EXP MED, V194, P189, DOI 10.1084/jem.194.2.189; Giraud AS, 2000, AM J PHYSIOL-GASTR L, V278, pG501, DOI 10.1152/ajpgi.2000.278.4.G501; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HIROTA H, 1995, P NATL ACAD SCI USA, V92, P4862, DOI 10.1073/pnas.92.11.4862; Hollande F, 2001, AM J PHYSIOL-GASTR L, V280, pG910, DOI 10.1152/ajpgi.2001.280.5.G910; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kim H, 1999, MOL CELL BIOL, V19, P5326; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Lefebvre O, 1996, SCIENCE, V274, P259, DOI 10.1126/science.274.5285.259; Mashimo H, 1996, SCIENCE, V274, P262, DOI 10.1126/science.274.5285.262; Nicholson SE, 2000, P NATL ACAD SCI USA, V97, P6493, DOI 10.1073/pnas.100135197; NICOLA NA, 1994, STEM CELLS, V12, P3; Ohtani T, 2000, IMMUNITY, V12, P95, DOI 10.1016/S1074-7613(00)80162-4; Park WS, 2000, GASTROENTEROLOGY, V119, P691, DOI 10.1053/gast.2000.16483; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Peters M, 1997, J EXP MED, V185, P755, DOI 10.1084/jem.185.4.755; Podolsky Daniel K., 2000, Journal of Gastroenterology, V35, P69; RAMSAY AJ, 1994, SCIENCE, V264, P561, DOI 10.1126/science.8160012; Robb L, 1998, NAT MED, V4, P303, DOI 10.1038/nm0398-303; SANDS BE, 1995, J BIOL CHEM, V270, P9353, DOI 10.1074/jbc.270.16.9353; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; Srivatsa G, 2002, HISTOPATHOLOGY, V40, P261, DOI 10.1046/j.1365-2559.2002.01347.x; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Suzuki A, 2001, J EXP MED, V193, P471, DOI 10.1084/jem.193.4.471; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; TAKAGI H, 1992, J CLIN INVEST, V90, P1161, DOI 10.1172/JCI115936; Taupin D, 1999, J CLIN INVEST, V103, pR31, DOI 10.1172/JCI3304; Taupin DR, 2000, P NATL ACAD SCI USA, V97, P799, DOI 10.1073/pnas.97.2.799; TAUPIN DR, 1995, PEPTIDES, V16, P1001, DOI 10.1016/0196-9781(95)00070-Z; Terada T, 2001, BIOL PHARM BULL, V24, P135, DOI 10.1248/bpb.24.135; Ulaganathan M, 2001, J GASTROEN HEPATOL, V16, P506, DOI 10.1046/j.1440-1746.2001.02469.x; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407	43	383	405	1	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2002	8	10					1089	1097		10.1038/nm763	http://dx.doi.org/10.1038/nm763			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	599AN	12219085				2022-12-25	WOS:000178311000035
J	Hoogenraad, CC; Koekkoek, B; Akhmanova, A; Krugers, H; Dortland, B; Miedema, M; van Alphen, A; Kistler, WM; Jaegle, M; Koutsourakis, M; Van Camp, N; Verhoye, M; van der Linden, A; Kaverina, I; Grosveld, F; De Zeeuw, CI; Galjart, N				Hoogenraad, CC; Koekkoek, B; Akhmanova, A; Krugers, H; Dortland, B; Miedema, M; van Alphen, A; Kistler, WM; Jaegle, M; Koutsourakis, M; Van Camp, N; Verhoye, M; van der Linden, A; Kaverina, I; Grosveld, F; De Zeeuw, CI; Galjart, N			Targeted mutation of Cyln2 in the Williams syndrome critical region links CLIP-115 haploinsufficiency to neurodevelopmental abnormalities in mice	NATURE GENETICS			English	Article							SUPRAVALVULAR AORTIC-STENOSIS; BEUREN-SYNDROME; IN-VIVO; MUTANT MICE; PROTEIN; 7Q11.23; GENE; DELETION; BRAIN; FEAR	Williams syndrome is a neurodevelopmental disorder caused by the hemizygous deletion of 1.6 Mb on human chromosome 7q11.23. This region comprises the gene CYLN2, encoding CLIP-115, a microtubule-binding protein of 115 kD. Using a gene-targeting approach, we provide evidence that mice with haploinsufficiency for Cyln2 have features reminiscent of Williams syndrome, including mild growth deficiency, brain abnormalities, hippocampal dysfunction and particular deficits in motor coordination. Absence of CLIP-115 also leads to increased levels of CLIP-170 (a closely related cytoplasmic linker protein) and dynactin at the tips of growing microtubules. This protein redistribution may affect dynein motor regulation and, together with the loss of CLIP-115-specific functions, underlie neurological alterations in Williams syndrome.	Erasmus Univ, MGC Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, MGC Dept Neurosci, NL-3000 DR Rotterdam, Netherlands; Univ Amsterdam, Swammerdam Inst Life Sci, NL-1012 WX Amsterdam, Netherlands; Univ Antwerp, RUCA, Bioimaging Lab, B-2020 Antwerp, Belgium; Austrian Acad Sci, Inst Mol Biol, A-5020 Salzburg, Austria	Erasmus University Rotterdam; Erasmus University Rotterdam; University of Amsterdam; University of Antwerp; Austrian Academy of Sciences	Galjart, N (corresponding author), Erasmus Univ, MGC Dept Cell Biol & Genet, POB 1738, NL-3000 DR Rotterdam, Netherlands.	dezeeuw@anat.fgg.eur.nl; galjart@ch1.fgg.eur.nl	Galjart, Niels/D-1146-2010; Van Camp, Nadja/AAC-4357-2019; Akhmanova, Anna S/B-8896-2011; Hoogenraad, Casper/B-8866-2011; Van der Linden, Annemie/L-7855-2017; Van Camp, Nadja/H-5141-2017	Galjart, Niels/0000-0003-1964-3607; Van Camp, Nadja/0000-0002-2261-7314; Akhmanova, Anna S/0000-0002-9048-8614; Hoogenraad, Casper/0000-0002-2666-0758; Van der Linden, Annemie/0000-0003-2941-6520; Van Camp, Nadja/0000-0002-2261-7314; Verhoye, Marleen/0000-0002-6267-0611				Akhmanova A, 2001, CELL, V104, P923, DOI 10.1016/S0092-8674(01)00288-4; Anagnostaras SG, 2000, LEARN MEMORY, V7, P58, DOI 10.1101/lm.7.1.58; ARMSTRONG DM, 1986, PROG NEUROBIOL, V26, P273, DOI 10.1016/0301-0082(86)90021-3; Bellugi U, 2000, J COGNITIVE NEUROSCI, V12, P7, DOI 10.1162/089892900561959; Bellugi U, 1999, TRENDS NEUROSCI, V22, P197, DOI 10.1016/S0166-2236(99)01397-1; Bloedel JR, 1981, HDB PHYSL, VII, P735; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Brunner D, 2000, CELL, V102, P695, DOI 10.1016/S0092-8674(00)00091-X; Coquelle FM, 2002, MOL CELL BIOL, V22, P3089, DOI 10.1128/MCB.22.9.3089-3102.2002; De Zeeuw CI, 1998, TRENDS NEUROSCI, V21, P391, DOI 10.1016/S0166-2236(98)01310-1; De Zeeuw CI, 1997, NEURON, V19, P1187, DOI 10.1016/S0896-6273(00)80411-0; De Zeeuw CI, 1998, NEURON, V20, P495, DOI 10.1016/S0896-6273(00)80990-3; Franceschi S., 1996, Journal of Epidemiology and Biostatistics, V1, P59; Francke U, 1999, HUM MOL GENET, V8, P1947, DOI 10.1093/hmg/8.10.1947; Fransen E, 1998, HUM MOL GENET, V7, P999, DOI 10.1093/hmg/7.6.999; Heisler LK, 1998, P NATL ACAD SCI USA, V95, P15049, DOI 10.1073/pnas.95.25.15049; Hoogenraad CC, 2000, J CELL SCI, V113, P2285; Hoogenraad CC, 1998, GENOMICS, V53, P348, DOI 10.1006/geno.1998.5529; Jaegle M, 1996, SCIENCE, V273, P507, DOI 10.1126/science.273.5274.507; Kaverina I, 1999, J CELL BIOL, V146, P1033, DOI 10.1083/jcb.146.5.1033; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; Kooy RF, 1999, EUR J HUM GENET, V7, P526, DOI 10.1038/sj.ejhg.5200348; Krugers HJ, 1997, NEUROREPORT, V8, P2505, DOI 10.1097/00001756-199707280-00018; MORRIS CA, 1988, J PEDIATR-US, V113, P318, DOI 10.1016/S0022-3476(88)80272-5; OLSON TM, 1995, HUM MOL GENET, V4, P1677, DOI 10.1093/hmg/4.9.1677; Osborne LR, 1999, MOL GENET METAB, V67, P1, DOI 10.1006/mgme.1999.2844; Osborne LR, 1996, GENOMICS, V36, P328, DOI 10.1006/geno.1996.0469; PANKAU R, 1992, EUR J PEDIATR, V151, P751, DOI 10.1007/BF01959084; Peoples R, 2000, AM J HUM GENET, V66, P47, DOI 10.1086/302722; Perez F, 1999, CELL, V96, P517, DOI 10.1016/S0092-8674(00)80656-X; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; Reiss AL, 2000, J COGNITIVE NEUROSCI, V12, P65, DOI 10.1162/089892900561986; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schmitt JE, 2001, DEV MED CHILD NEUROL, V43, P155, DOI 10.1017/S0012162201000305; Schuyler SC, 2001, CELL, V105, P421, DOI 10.1016/S0092-8674(01)00364-6; Sijbers J, 1997, MAGN RESON IMAGING, V15, P679, DOI 10.1016/S0730-725X(97)00033-7; Silva AJ, 1997, NEURON, V19, P755, DOI 10.1016/S0896-6273(00)80958-7; Storm DR, 1998, NEURON, V20, P1199, DOI 10.1016/S0896-6273(00)80500-0; Tarantino LM, 2000, MAMM GENOME, V11, P555, DOI 10.1007/s003350010107; Tassabehji M, 1997, HUM MOL GENET, V6, P1029, DOI 10.1093/hmg/6.7.1029; Tassabehji M, 1999, AM J HUM GENET, V64, P118, DOI 10.1086/302214; Valero MC, 2000, GENOMICS, V69, P1, DOI 10.1006/geno.2000.6312; Valetti C, 1999, MOL BIOL CELL, V10, P4107, DOI 10.1091/mbc.10.12.4107; Vallee RB, 2001, TRENDS CELL BIOL, V11, P155, DOI 10.1016/S0962-8924(01)01956-0; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; Vaughan KT, 1999, J CELL SCI, V112, P1437; Voogd J, 1998, TRENDS NEUROSCI, V21, P370, DOI 10.1016/S0166-2236(98)01318-6; YUAN C, 1993, JMRI-J MAGN RESON IM, V3, P894, DOI 10.1002/jmri.1880030617	49	126	129	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2002	32	1					116	127		10.1038/ng954	http://dx.doi.org/10.1038/ng954			12	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	588RR	12195424				2022-12-25	WOS:000177714900010
J	Adams, JY; Johnson, M; Sato, M; Berger, F; Gambhir, SS; Carey, M; Iruela-Arispe, ML; Wu, L				Adams, JY; Johnson, M; Sato, M; Berger, F; Gambhir, SS; Carey, M; Iruela-Arispe, ML; Wu, L			Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging	NATURE MEDICINE			English	Article							ANDROGEN RECEPTOR; THERAPY; CELLS; AMPLIFICATION; MECHANISM	Non-invasive imaging and transcriptional targeting can improve the safety of therapeutic approaches in cancer. Here we demonstrate the ability to identify metastases in a human-prostate cancer model, employing a prostate-specific adenovirus vector (AdPSE-BC-luc) and a charge-coupled device-imaging system. AdPSE-BC-luc, which expresses firefly luciferase from an enhanced prostate-specific antigen promoter, restricted expression in the liver but produced robust signals in prostate tumors. In fact, expression was higher in advanced, androgen-independent tumors than in androgen-dependent lesions. Repetitive imaging over a three-week period after AdPSE-BC-luc injection into tumor-bearing mice revealed that the virus could locate and illuminate metastases in the lung and spine. Systemic injection of low doses of AdPSE-BC-luc illuminated lung metastasis. These results demonstrate the potential use of a non-invasive imaging modality in therapeutic and diagnostic strategies to manage prostate cancer.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Crump Inst Mol Imaging, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Coll Letters & Sci, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Wu, L (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA.		Iruela-Arispe, M. Luisa/AAJ-1297-2020	Iruela-Arispe, M. Luisa/0000-0002-3050-4168; Carey, Michael/0000-0003-3899-6280	NATIONAL CANCER INSTITUTE [R24CA092865, R01CA082214, P50CA086306] Funding Source: NIH RePORTER; NCI NIH HHS [R24 CA92865, R0-1 CA82214, P50 CA86306] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bloomfield DJ, 1998, J CLIN ONCOL, V16, P2272, DOI 10.1200/JCO.1998.16.6.2272; Craft N, 1999, CANCER RES, V59, P5030; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; FREIDMANN T, 1999, DEV HUMAN GENE THERA; Gregory CW, 2001, CANCER RES, V61, P4315; Harrington KJ, 2001, J UROLOGY, V166, P1220, DOI 10.1016/S0022-5347(05)65742-4; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Leav I, 2001, AM J PATHOL, V159, P79, DOI 10.1016/S0002-9440(10)61676-8; Linja MJ, 2001, CANCER RES, V61, P3550; Nash AF, 2000, ENDOCR-RELAT CANCER, V7, P37, DOI 10.1677/erc.0.0070037; Rehemtulla A, 2000, NEOPLASIA, V2, P491, DOI 10.1038/sj.neo.7900121; Rini BI, 2001, CURR OPIN ONCOL, V13, P204, DOI 10.1097/00001622-200105000-00013; Tao NJ, 2001, MOL THER, V3, P28, DOI 10.1006/mthe.2000.0227; Waller AS, 2000, J MOL ENDOCRINOL, V24, P339, DOI 10.1677/jme.0.0240339; Wu JC, 2001, MOL THER, V4, P297, DOI 10.1006/mthe.2001.0460; Wu L, 2001, GENE THER, V8, P1416, DOI 10.1038/sj.gt.3301549; Yaghoubi SS, 2001, GENE THER, V8, P1072, DOI 10.1038/sj.gt.3301490; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; Zhang LQ, 2002, MOL THER, V5, P223, DOI 10.1006/mthe.2002.0551; Zhao XY, 2000, NAT MED, V6, P703, DOI 10.1038/76287	20	130	136	0	6	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2002	8	8					891	896		10.1038/nm743	http://dx.doi.org/10.1038/nm743			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	579WJ	12134144				2022-12-25	WOS:000177200900037
J	Cheung, I; Schertzer, M; Rose, A; Lansdorp, PM				Cheung, I; Schertzer, M; Rose, A; Lansdorp, PM			Disruption of dog-1 in Caenorhabditis elegans triggers deletions upstream of guanine-rich DNA	NATURE GENETICS			English	Article							ORIENTATION-DEPENDENT INSTABILITY; C-ELEGANS; SECONDARY STRUCTURE; SYNDROME HELICASE; ESCHERICHIA-COLI; REPEATS EXHIBIT; LAGGING-STRAND; G4 DNA; REPLICATION; GERMLINE	Genetic integrity is crucial to normal cell function, and mutations in genes required for DNA replication and repair underlie various forms of genetic instability and disease, including cancer(1). One structural feature of intact genomes is runs of homopolymeric dC/dG. Here we describe an unusual mutator phenotype in Caenorhabditis elegans characterized by deletions that start around the 3' end of polyguanine tracts and terminate at variable positions 5' from such tracts. We observed deletions throughout genomic DNA in about half of polyguanine tracts examined, especially those containing 22 or more consecutive guanine nucleotides. The mutator phenotype results from disruption of the predicted gene F33H2.1, which encodes a protein with characteristics of a DEAH helicase and which we have named dog-1 (for deletions of guanine-rich DNA). Nematodes mutated in dog-1 showed germline as well as somatic deletions in genes containing polyguanine tracts, such as vab-1. We propose that DOG-1 is required to resolve the secondary structures of guanine-rich DNA that occasionally form during lagging-strand DNA synthesis.	British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada; Univ British Columbia, Dept Med, Vancouver, BC, Canada; Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada	British Columbia Cancer Agency; University of British Columbia; University of British Columbia	Lansdorp, PM (corresponding author), British Columbia Canc Agcy, Terry Fox Lab, 601 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.	plansdor@bccancer.bc.ca		Lansdorp, Peter/0000-0001-7435-1071				Ahmed S, 2000, NATURE, V403, P159, DOI 10.1038/35003120; Balakumaran BS, 2000, HUM MOL GENET, V9, P93, DOI 10.1093/hmg/9.1.93; BORK P, 1993, NUCLEIC ACIDS RES, V21, P751, DOI 10.1093/nar/21.3.751; BRENNER S, 1974, GENETICS, V77, P71; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; Dalgaard JZ, 2001, GENE DEV, V15, P2060, DOI 10.1101/gad.200801; Degtyareva NP, 2002, P NATL ACAD SCI USA, V99, P2158, DOI 10.1073/pnas.032671599; Dempsey LA, 1999, J BIOL CHEM, V274, P1066, DOI 10.1074/jbc.274.2.1066; FOLFSMEIER ML, 2001, GENETICS, V157, P1569; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Gartner A, 2000, MOL CELL, V5, P435, DOI 10.1016/S1097-2765(00)80438-4; George SE, 1998, CELL, V92, P633, DOI 10.1016/S0092-8674(00)81131-9; Hirst MC, 1998, NUCLEIC ACIDS RES, V26, P2353, DOI 10.1093/nar/26.10.2353; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Kamath RS, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2000-2-1-research0002; Kamath-Loeb AS, 2001, J BIOL CHEM, V276, P16439, DOI 10.1074/jbc.M100253200; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Reinke V, 2000, MOL CELL, V6, P605, DOI 10.1016/S1097-2765(00)00059-9; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; Seydoux G, 2001, INT REV CYTOL, V203, P139; Simonsson T, 2001, BIOL CHEM, V382, P621, DOI 10.1515/BC.2001.073; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; Sun H, 1998, J BIOL CHEM, V273, P27587, DOI 10.1074/jbc.273.42.27587; TRINH TQ, 1991, NATURE, V352, P544, DOI 10.1038/352544a0; Wicky C, 1996, P NATL ACAD SCI USA, V93, P8983, DOI 10.1073/pnas.93.17.8983; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; ZETKA MC, 1995, GENETICS, V141, P1339	28	215	220	2	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2002	31	4					405	409		10.1038/ng928	http://dx.doi.org/10.1038/ng928			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	578XV	12101400				2022-12-25	WOS:000177147100017
J	Halbert, CL; Allen, JM; Miller, AD				Halbert, CL; Allen, JM; Miller, AD			Efficient mouse airway transduction following recombination between AAV vectors carrying parts of a larger gene	NATURE BIOTECHNOLOGY			English	Article							ADENOASSOCIATED VIRUS VECTORS; CYSTIC-FIBROSIS; FACTOR-IX; IN-VIVO; EXPRESSION; THERAPY; TYPE-5; CELLS; MICE	The small packaging capacity of adeno-associated virus (AAV) vectors limits the utility of this promising vector system for transfer of large genes. We explored the possibility that larger genes could be reconstituted following homologous recombination between AAV vectors carrying overlapping gene fragments. An alkaline phosphatase (AP) gene was split between two such AAV vectors (rec vectors) and packaged using AAV2 or AAV6 capsid proteins. Rec vectors having either capsid protein recombined to express AP in cultured cells at about 1-2% of the rate observed for an intact vector. Surprisingly, the AAV6 rec vectors transduced lung cells in mice almost as efficiently as did an intact vector, with 10% of airway epithelial cells, the target for treatment of cystic fibrosis (CF), being positive. Thus AAV rec vectors may be useful for diseases such as CF that require transfer of large genes.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Miller, AD (corresponding author), Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA.			Miller, Dusty/0000-0002-3736-3660	NHLBI NIH HHS [HL66947] Funding Source: Medline; NIDDK NIH HHS [DK47754] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL066947] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK047754] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allen JM, 2000, MOL THER, V1, P88, DOI 10.1006/mthe.1999.0010; Chao HJ, 2000, MOL THER, V2, P619, DOI 10.1006/mthe.2000.0219; Davidson BL, 2000, P NATL ACAD SCI USA, V97, P3428, DOI 10.1073/pnas.050581197; Duan DS, 2001, MOL THER, V4, P383, DOI 10.1006/mthe.2001.0456; Fisher KJ, 1997, NAT MED, V3, P306, DOI 10.1038/nm0397-306; FLOTTE TR, 1993, P NATL ACAD SCI USA, V90, P10613, DOI 10.1073/pnas.90.22.10613; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Halbert CL, 1997, J VIROL, V71, P5932, DOI 10.1128/JVI.71.8.5932-5941.1997; Halbert CL, 2001, J VIROL, V75, P6615, DOI 10.1128/JVI.75.14.6615-6624.2001; Halbert CL, 2000, J VIROL, V74, P1524, DOI 10.1128/JVI.74.3.1524-1532.2000; Hildinger M, 2001, J VIROL, V75, P6199, DOI 10.1128/JVI.75.13.6199-6203.2001; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; JOHNSON LG, 1992, NAT GENET, V2, P21, DOI 10.1038/ng0992-21; Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082; MUZYCZKA N, 1992, CURR TOP MICROBIOL, V158, P97; Nakai H, 2000, NAT BIOTECHNOL, V18, P527, DOI 10.1038/75390; Snyder RO, 1997, NAT GENET, V16, P270, DOI 10.1038/ng0797-270; Sun LW, 2000, NAT MED, V6, P599, DOI 10.1038/75087; Xiao WD, 1999, J VIROL, V73, P3994, DOI 10.1128/JVI.73.5.3994-4003.1999; Xiao XA, 1996, J VIROL, V70, P8098, DOI 10.1128/JVI.70.11.8098-8108.1996; Yan ZY, 2000, P NATL ACAD SCI USA, V97, P6716, DOI 10.1073/pnas.97.12.6716; Zabner J, 2000, J VIROL, V74, P3852, DOI 10.1128/JVI.74.8.3852-3858.2000; Zhang L, 1998, P NATL ACAD SCI USA, V95, P10158, DOI 10.1073/pnas.95.17.10158	24	89	101	1	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2002	20	7					697	701		10.1038/nbt0702-697	http://dx.doi.org/10.1038/nbt0702-697			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	567QC	12089554				2022-12-25	WOS:000176494800023
J	Teshima, T; Ordemann, R; Reddy, P; Gagin, S; Liu, C; Cooke, KR; Ferrara, JLM				Teshima, T; Ordemann, R; Reddy, P; Gagin, S; Liu, C; Cooke, KR; Ferrara, JLM			Acute graft-versus-host disease does not require alloantigen expression on host epithelium	NATURE MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; ANTIGEN-PRESENTING CELLS; NECROSIS-FACTOR-ALPHA; RAT EPIDERMAL-CELLS; DONOR T-CELLS; IA-ANTIGEN; FAS LIGAND; GUT EPITHELIUM; LYMPHOCYTES; PATHOGENESIS	Alloantigen expression on host antigen-presenting cells (APCs) is essential to initiate graft-versus-host disease (GvHD); therefore, alloantigen expression on host target epithelium is also thought to be essential for tissue damage. We tested this hypothesis in mouse models of GvHD using bone-marrow chimeras in which either major histocompatibility complex class I or class II alloantigen was expressed only on APCs. We found that acute GvHD does not require alloantigen expression on host target epithelium and that neutralization of tumor necrosis factor-alpha and interleukin-1 prevents acute GvHD. These results pertain particularly to CD4-mediated GvHD but also apply, at least in part, to CD8-mediated GvHD. These results challenge current paradigms about the antigen specificity of GvHD effector mechanisms and confirm the central roles of both host APCs and inflammatory cytokines in acute GvHD.	Univ Michigan, Ctr Canc, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Canc, Dept Pediat, Ann Arbor, MI 48109 USA; Univ Florida, Coll Med, Dept Pathol, Gainesville, FL USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; State University System of Florida; University of Florida	Ferrara, JLM (corresponding author), Univ Michigan, Ctr Canc, Dept Internal Med, Ann Arbor, MI 48109 USA.		teshima, takanori/G-1671-2012	Reddy, Pavan/0000-0001-7264-8429	NATIONAL CANCER INSTITUTE [P01CA039542] Funding Source: NIH RePORTER; NCI NIH HHS [CA39542] Funding Source: Medline; NHLBI NIH HHS [HL03565-05] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amrani A, 2000, J CLIN INVEST, V105, P459, DOI 10.1172/JCI8185; Baker MB, 1996, J EXP MED, V183, P2645, DOI 10.1084/jem.183.6.2645; BARCLAY AN, 1982, J EXP MED, V156, P1665, DOI 10.1084/jem.156.6.1665; Blazar BR, 1997, TRANSPLANTATION, V64, P571, DOI 10.1097/00007890-199708270-00004; Braun MY, 1996, J EXP MED, V183, P657, DOI 10.1084/jem.183.2.657; Cooke KR, 1996, BLOOD, V88, P3230, DOI 10.1182/blood.V88.8.3230.bloodjournal8883230; Cooke KR, 1998, BLOOD, V92, P2571, DOI 10.1182/blood.V92.7.2571.2571_2571_2580; Crawford JM., 1997, GRAFT VERSUS HOST DI, P315; FERRARA JLM, 1991, NEW ENGL J MED, V324, P667; Graubert TA, 1997, J CLIN INVEST, V100, P904, DOI 10.1172/JCI119606; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; Hattori K, 1998, BLOOD, V91, P4051, DOI 10.1182/blood.V91.11.4051.411k16_4051_4055; Hill GR, 1999, J CLIN INVEST, V104, P459, DOI 10.1172/JCI6896; Hill GR, 1998, J CLIN INVEST, V102, P115, DOI 10.1172/JCI3132; Hill GR, 1997, BLOOD, V90, P3204, DOI 10.1182/blood.V90.8.3204; Jiang Z, 2001, BLOOD, V98, P390, DOI 10.1182/blood.V98.2.390; KORNGOLD R, 1990, GRAFT VERSUS HOST DI, P31; Krasinskas AM, 2000, TRANSPLANTATION, V70, P514, DOI 10.1097/00007890-200008150-00020; LAMPERT IA, 1981, NATURE, V293, P149, DOI 10.1038/293149a0; Martin PJ, 1998, BLOOD, V92, P2177, DOI 10.1182/blood.V92.6.2177.418k02_2177_2181; MASON DW, 1981, NATURE, V293, P150, DOI 10.1038/293150a0; Mori T, 1998, BLOOD, V92, P101, DOI 10.1182/blood.V92.1.101.413k14_101_107; Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219; Murai M, 1999, J CLIN INVEST, V104, P49, DOI 10.1172/JCI6642; NESTEL FP, 1992, J EXP MED, V175, P405, DOI 10.1084/jem.175.2.405; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; PIGUET PF, 1987, J EXP MED, V166, P1280, DOI 10.1084/jem.166.5.1280; Reddy P, 2001, J EXP MED, V194, P1433, DOI 10.1084/jem.194.10.1433; Sallusto F, 1999, EUR J IMMUNOL, V29, P1617, DOI 10.1002/(SICI)1521-4141(199905)29:05<1617::AID-IMMU1617>3.0.CO;2-3; Santamaria P, 2001, CURR OPIN IMMUNOL, V13, P663, DOI 10.1016/S0952-7915(01)00276-X; Shlomchik WD, 1999, SCIENCE, V285, P412, DOI 10.1126/science.285.5426.412; SITKOVSKY MV, 1997, GRAFT VERSUS HOST DI, P219; SPRENT J, 1988, J EXP MED, V167, P556, DOI 10.1084/jem.167.2.556; Surh CD, 2000, J EXP MED, V192, pF9, DOI 10.1084/jem.192.4.F9; Teshima T, 2001, CANCER RES, V61, P162; TRUITT RL, 1997, GRAFT VERSUS HOST DI, P385; Via CS, 1996, J IMMUNOL, V157, P5387; WALL DA, 1988, J IMMUNOL, V140, P2970	38	412	420	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2002	8	6					575	581		10.1038/nm0602-575	http://dx.doi.org/10.1038/nm0602-575			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	557KG	12042807				2022-12-25	WOS:000175907300027
J	Walder, RY; Landau, D; Meyer, P; Shalev, H; Tsolia, M; Borochowitz, Z; Boettger, MB; Beck, GE; Englehardt, RK; Carmi, R; Sheffield, VC				Walder, RY; Landau, D; Meyer, P; Shalev, H; Tsolia, M; Borochowitz, Z; Boettger, MB; Beck, GE; Englehardt, RK; Carmi, R; Sheffield, VC			Mutation of TRPM6 causes familial hypomagnesemia with secondary hypocalcemia	NATURE GENETICS			English	Article							PROTEIN-KINASES; MAGNESIUM; PARACELLIN-1; TRANSPORT	Familial hypomagnesemia with secondary hypocalcemia (OMIM 602014) is an autosomal recessive disease that results in electrolyte abnormalities shortly after birth(1-6). Affected individuals show severe hypomagnesemia and hypocalcemia. which lead to seizures and tetany. The disorder has been thought to be caused by a defect in the intestinal absorption of magnesium, rather than by abnormal renal loss of magnesium. Restoring the concentrations of serum magnesium to normal values by high-dose magnesium supplementation can overcome the apparent defect in magnesium absorption and in serum concentrations of calcium. Life-long magnesium supplementation is required to overcome the defect in magnesium handling by these individuals(1,3,4). We previously mapped the gene locus to chromosome 9q in three large inbred kindreds from israel(2). Here we report that mutation of TRPM6 causes hypomagnesemia with secondary hypocalcemia and show that individuals carrying mutations in this gene have abnormal renal magnesium excretion.	Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; Univ Iowa, Howard Hughes Med Inst, Iowa City, IA 52242 USA; Ben Gurion Univ Negev, Dept Pediat, Beer Sheva, Israel; Univ Heidelberg, INF 328, Inst Human Genet, D-69120 Heidelberg, Germany; Univ Athens, Dept Pediat, P A Kyriakou Childrens Hosp, Athens, Greece; Bnai Zion Med Ctr, Simon Winter Inst Human Genet, Haifa, Israel	University of Iowa; Howard Hughes Medical Institute; University of Iowa; Ben Gurion University; Ruprecht Karls University Heidelberg; National & Kapodistrian University of Athens; Bnai Zion Medical Center	Sheffield, VC (corresponding author), Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA.			Sheffield, Val/0000-0002-6282-0835				ABDULRAZZAQ YM, 1989, EUR J PEDIATR, V148, P459, DOI 10.1007/BF00595914; ALGHAMDI SMG, 1994, AM J KIDNEY DIS, V24, P737, DOI 10.1016/S0272-6386(12)80667-6; Blanchard A, 2001, KIDNEY INT, V59, P2206, DOI 10.1046/j.1523-1755.2001.00736.x; CHALLA A, 1995, ACTA PAEDIATR, V84, P1075, DOI 10.1111/j.1651-2227.1995.tb13830.x; Dai LJ, 2001, PHYSIOL REV, V81, P51, DOI 10.1152/physrev.2001.81.1.51; Meyer P, 2001, J INHERIT METAB DIS, V24, P875, DOI 10.1023/A:1013952510698; MILLA PJ, 1979, GUT, V20, P1028, DOI 10.1136/gut.20.11.1028; Nadler MJS, 2001, NATURE, V411, P590, DOI 10.1038/35079092; PRAGA M, 1995, KIDNEY INT, V47, P1419, DOI 10.1038/ki.1995.199; PRONICKA E, 1991, J INHERIT METAB DIS, V14, P397, DOI 10.1007/BF01811713; RODRIGUEZSORIANO J, 1987, PEDIATR NEPHROL, V1, P465, DOI 10.1007/BF00849255; Runnels LW, 2001, SCIENCE, V291, P1043, DOI 10.1126/science.1058519; Ryazanov AG, 1997, P NATL ACAD SCI USA, V94, P4884, DOI 10.1073/pnas.94.10.4884; Ryazanov AG, 1999, CURR BIOL, V9, pR43, DOI 10.1016/S0960-9822(99)80006-2; RYZEN E, 1985, Magnesium, V4, P137; Schlingmann KP, 2002, NAT GENET, V31, P166, DOI 10.1038/ng889; Shalev H, 1998, ARCH DIS CHILD, V78, P127, DOI 10.1136/adc.78.2.127; Simon DB, 1999, SCIENCE, V285, P103, DOI 10.1126/science.285.5424.103; Simon DB, 1996, NAT GENET, V12, P24, DOI 10.1038/ng0196-24; STAPLETON FB, 1983, J PEDIATR-US, V102, P88, DOI 10.1016/S0022-3476(83)80297-2; Walder RY, 1997, HUM MOL GENET, V6, P1491, DOI 10.1093/hmg/6.9.1491; YAMAMOTO T, 1985, Magnesium, V4, P153	22	386	412	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2002	31	2					171	174		10.1038/ng901	http://dx.doi.org/10.1038/ng901			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	557HR	12032570				2022-12-25	WOS:000175903500013
J	Demain, AL				Demain, AL			Prescription for an ailing pharmaceutical industry	NATURE BIOTECHNOLOGY			English	Editorial Material									Drew Univ, Madison, NJ 07940 USA	Drew University	Demain, AL (corresponding author), Drew Univ, 330 Hall Sci, Madison, NJ 07940 USA.								0	48	48	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	2002	20	4					331	331		10.1038/nbt0402-331	http://dx.doi.org/10.1038/nbt0402-331			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	536BY	11923826	Bronze			2022-12-25	WOS:000174681900009
J	Keenan, RJ; Stemmer, WPC				Keenan, RJ; Stemmer, WPC			Nontransgenic crops from transgenic plants	NATURE BIOTECHNOLOGY			English	Editorial Material									Maxygen Inc, Res & Dev, Redwood City, CA 94063 USA		Keenan, RJ (corresponding author), Maxygen Inc, Res & Dev, Redwood City, CA 94063 USA.			Keenan, Robert/0000-0003-1466-0889				Buchholz F, 2001, NAT BIOTECHNOL, V19, P1047, DOI 10.1038/nbt1101-1047; Sclimenti CR, 2001, NUCLEIC ACIDS RES, V29, P5044, DOI 10.1093/nar/29.24.5044; Sugita K, 2000, PLANT J, V22, P461, DOI 10.1046/j.1365-313X.2000.00745.x; Thyagarajan B, 2000, GENE, V244, P47, DOI 10.1016/S0378-1119(00)00008-1; Zuo JR, 2001, NAT BIOTECHNOL, V19, P157, DOI 10.1038/84428	5	30	38	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2002	20	3					215	216		10.1038/nbt0302-215	http://dx.doi.org/10.1038/nbt0302-215			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	526RE	11875408	Green Submitted			2022-12-25	WOS:000174142800022
J	Kazman, S; Miller, HI				Kazman, S; Miller, HI			The perils of federalizing vaccine production	NATURE BIOTECHNOLOGY			English	Editorial Material									Hoover Inst War Revolut & Peace, Stanford, CA 94305 USA										0	1	1	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2002	20	2					113	113		10.1038/nbt0202-113	http://dx.doi.org/10.1038/nbt0202-113			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	517FT	11821845	Bronze			2022-12-25	WOS:000173601000009
J	Perrelet, D; Ferri, A; Liston, P; Muzzin, P; Korneluk, RG; Kato, AC				Perrelet, D; Ferri, A; Liston, P; Muzzin, P; Korneluk, RG; Kato, AC			IAPs are essential for GDNF-mediated neuroprotective effects in injured motor neurons in vivo	NATURE CELL BIOLOGY			English	Article							NEUROTROPHIC FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; FAMILY PROTEINS; RAT HIPPOCAMPUS; IN-VIVO; APOPTOSIS; SURVIVAL; MOTONEURONS; ACTIVATION	During embryonic development, and in certain neurodegenerative diseases, neurons die by apoptosis(1). A new family of anti-apoptotic proteins, termed inhibitors of apoptosis (IAP), suppresses apoptosis through the direct inhibition of caspases(2-5). The anti-apoptotic activity of IAPs is inhibited by second mitochondria-derived activator of caspase (Smac)/DIABLO(6,7) and XAF1 (ref. 8). IAPs, as well as neurotrophic factors, can protect degenerating neurons both in vivo and in vitro(9-12). However, the downstream targets of neurotrophic factors have not yet been identified. Here, we demonstrate that XIAP and NAIP, but not HIAP2, are directly involved in the intracellular response to glial cell-derived neurotrophic factor (GDNF). In newborn rats, GDNF regulates endogenous levels of XIAP and NAIP in motor neurons after sciatic nerve, axotomy. The inhibition of XIAP or NAIP activity prevents GDNF-mediated neuroprotective effects. These results suggest that XIAP and NAIP are essential for intracellular signalling of GDNF in motor neuron survival.	Fac Med, Div Clin Res, CH-1211 Geneva 4, Switzerland; Fac Med, Dept APSIC, CH-1211 Geneva, Switzerland; Fac Med, Dept Biochem Med, CH-1211 Geneva 4, Switzerland; Childrens Hosp Eastern Ontario, Mol Genet Res Lab, Ottawa, ON K1H 8L1, Canada; AEgera Therapeut Inc, Ottawa, ON K1H 8L1, Canada	University of Geneva; University of Geneva; University of Geneva; University of Ottawa; Children's Hospital of Eastern Ontario	Kato, AC (corresponding author), Fac Med, Div Clin Res, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.							Creedon DJ, 1997, P NATL ACAD SCI USA, V94, P7018, DOI 10.1073/pnas.94.13.7018; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Dolcet X, 1999, J NEUROCHEM, V73, P521, DOI 10.1046/j.1471-4159.1999.0730521.x; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Goyal L, 2001, CELL, V104, P805, DOI 10.1016/S0092-8674(01)00276-8; Hefti F, 1997, ANNU REV PHARMACOL, V37, P239, DOI 10.1146/annurev.pharmtox.37.1.239; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Nishimune H, 2000, NAT CELL BIOL, V2, P906, DOI 10.1038/35046558; PANAYOTATOS N, 1993, J BIOL CHEM, V268, P19000; Perrelet D, 2000, EUR J NEUROSCI, V12, P2059, DOI 10.1046/j.1460-9568.2000.00098.x; Simons M, 1999, J NEUROCHEM, V72, P292, DOI 10.1046/j.1471-4159.1999.0720292.x; Soler RM, 1999, J NEUROSCI, V19, P9160; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vejsada R, 1998, NEUROSCIENCE, V84, P129, DOI 10.1016/S0306-4522(97)00497-1; VEJSADA R, 1995, EUR J NEUROSCI, V7, P108, DOI 10.1111/j.1460-9568.1995.tb01025.x; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wiese S, 1999, NAT NEUROSCI, V2, P978, DOI 10.1038/14777; Wiese S, 2001, NAT NEUROSCI, V4, P137, DOI 10.1038/83960; Xu DG, 1999, J NEUROSCI, V19, P5026; Xu DG, 1997, NAT MED, V3, P997, DOI 10.1038/nm0997-997; Yang YL, 2000, CELL RES, V10, P169, DOI 10.1038/sj.cr.7290046	23	74	78	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	FEB	2002	4	2					175	179		10.1038/ncb751	http://dx.doi.org/10.1038/ncb751			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	520RJ	11813002				2022-12-25	WOS:000173794600024
J	Niiler, E				Niiler, E			Bioterrorism - biotechnology to the rescue?	NATURE BIOTECHNOLOGY			English	Article																		Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Dennis C, 2001, NATURE, V411, P232, DOI 10.1038/35077161; Dorey E, 2001, NAT BIOTECHNOL, V19, P793, DOI 10.1038/nbt0901-793; Pannifer AD, 2001, NATURE, V414, P229, DOI 10.1038/n35101998; Sellman BR, 2001, SCIENCE, V292, P695, DOI 10.1126/science.109563; 2001, MMWR, V50	6	16	15	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2002	20	1					21	25		10.1038/nbt0102-21	http://dx.doi.org/10.1038/nbt0102-21			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	507ME	11753354	Bronze			2022-12-25	WOS:000173031600024
J	Yoon, BJ; Herman, H; Sikora, A; Smith, LT; Plass, C; Soloway, PD				Yoon, BJ; Herman, H; Sikora, A; Smith, LT; Plass, C; Soloway, PD			Regulation of DNA methylation of Rasgrf1	NATURE GENETICS			English	Article							HMLH1 PROMOTER HYPERMETHYLATION; TUMOR-SUPPRESSOR GENE; IMPRINTED EXPRESSION; CPG METHYLATION; H19 GENE; LOCUS; IGF2; REPEAT; CTCF; INACTIVATION	In mammals, DNA is methylated at cytosines within CpG dinucleoticles. Properly regulated methylation is crucial for normal development(1,2). Inappropriate methylation may contribute to tumorigenesis by silencing tumor-suppressor genes(3-10) or by activating growth-stimulating genes(11-13). Although many genes have been identified that acquire methylation and whose expression is methylation-sensitive(14,15), little is known about how DNA methylation is controlled(16). We have identified a DNA sequence that regulates establishment of DNA methylation in the male germ line at Rasgrf1. In mice, the imprinted Rasgrf1 locus is methylated on the paternal allele within a differentially methylated domain (DMD) 30 kbp 5' of the promoter. Expression is exclusively from the paternal allele in neonatal brain(17). Methylation is regulated by a repeated sequence, consisting of a 41-mer repeated 40 times, found immediately 3' of the DMD. This sequence is present in organisms in which Rasgrf1 is imprinted(18). In addition, DMD methylation is required for imprinted Rasgrf1 expression. Together the DMD and repeat element constitute a binary switch that regulates imprinting at the locus.	Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA; Ohio State Univ, Div Human Canc Genet, Columbus, OH 43210 USA	Roswell Park Cancer Institute; University System of Ohio; Ohio State University	Soloway, PD (corresponding author), Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Elm & Carlton St, Buffalo, NY 14263 USA.		Reever, Larson/H-9685-2019; Soloway, Paul/T-8243-2019; Yoon, Bong June/L-7126-2017; Plass, Christoph/H-7192-2014	Reever, Larson/0000-0002-5692-4793; Soloway, Paul/0000-0003-1967-0437	NCI NIH HHS [R01 CA098597, R01 CA098597-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098597] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baylin SB, 1998, ADV CANCER RES, V72, P141; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Birger Y, 1999, NATURE, V397, P84, DOI 10.1038/16291; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Esteller M, 1999, AM J PATHOL, V155, P1767, DOI 10.1016/S0002-9440(10)65492-2; Garrick D, 1998, NAT GENET, V18, P56, DOI 10.1038/ng0198-56; Goyon C, 1996, MOL CELL BIOL, V16, P3054; GRAFF JR, 1995, CANCER RES, V55, P5195; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Herman JG, 1996, CANCER RES, V56, P722; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Issa JPJ, 1996, P NATL ACAD SCI USA, V93, P11757, DOI 10.1073/pnas.93.21.11757; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; Jones BK, 1998, GENE DEV, V12, P2200, DOI 10.1101/gad.12.14.2200; Kanduri C, 2000, CURR BIOL, V10, P853, DOI 10.1016/S0960-9822(00)00597-2; Lewandoski M, 1997, CURR BIOL, V7, P148, DOI 10.1016/S0960-9822(06)00059-5; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LINN F, 1990, MOL GEN GENET, V222, P329, DOI 10.1007/BF00633837; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pearsall RS, 1999, GENOMICS, V55, P194, DOI 10.1006/geno.1998.5660; Plass C, 1996, NAT GENET, V14, P106, DOI 10.1038/ng0996-106; Shibata H, 1998, GENOMICS, V49, P30, DOI 10.1006/geno.1998.5218; Stadnick MP, 1999, DEV GENES EVOL, V209, P239, DOI 10.1007/s004270050248; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693; TREMBLAY KD, 1995, NAT GENET, V9, P407, DOI 10.1038/ng0495-407; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416	30	133	137	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2002	30	1					92	96		10.1038/ng795	http://dx.doi.org/10.1038/ng795			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	508TL	11753386	Green Accepted			2022-12-25	WOS:000173105600020
J	Hao, WS; Wenzel, A; Obin, MS; Chen, CK; Brill, E; Krasnoperova, NV; Eversole-Cire, P; Kleyner, Y; Taylor, A; Simon, MI; Grimm, C; Reme, C; Reme, CE; Lem, J				Hao, WS; Wenzel, A; Obin, MS; Chen, CK; Brill, E; Krasnoperova, NV; Eversole-Cire, P; Kleyner, Y; Taylor, A; Simon, MI; Grimm, C; Reme, C; Reme, CE; Lem, J			Evidence for two apoptotic pathways in light-induced retinal degeneration	NATURE GENETICS			English	Article							STATIONARY NIGHT BLINDNESS; RETINITIS-PIGMENTOSA; RHODOPSIN KINASE; PHOTORECEPTOR APOPTOSIS; MACULAR DEGENERATION; OCULAR PIGMENTATION; VISUAL CYCLE; OGUCHI FORM; CELL-DEATH; VITAMIN-A	Excessive phototransduction signaling is thought to be involved in light-induced and inherited retinal degeneration. Using knockout mice with defects in rhodopsin shut-off and transducin signaling, we show that two different pathways of photoreceptor-cell apoptosis are induced by light. Bright light induces apoptosis that is independent of transducin and accompanied by induction of the transcription factor AP-1. By contrast, low light induces an apoptotic pathway that requires transducin. We also provide evidence that additional genetic factors regulate sensitivity to light-induced damage. Our use of defined mouse mutants resolves some of the complexity underlying the mechanisms that regulate susceptibility to retinal degeneration.	Tufts Univ, New England Med Ctr, Dept Ophthalmol, Boston, MA 02111 USA; Tufts Univ, New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA; Univ Zurich Hosp, Lab Retinal Cell Biol, CH-8091 Zurich, Switzerland; Tufts Univ, Human Nutr Res Ctr Aging, JMUSDA, Nutr & Vis Res Lab, Boston, MA 02111 USA; Tufts Univ, Sch Med, Genet Program, Boston, MA 02111 USA; Univ Utah, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84112 USA	Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University; California Institute of Technology; University of Zurich; University Zurich Hospital; Tufts University; United States Department of Agriculture (USDA); Tufts University; Utah System of Higher Education; University of Utah	Lem, J (corresponding author), Tufts Univ, New England Med Ctr, Dept Ophthalmol, Boston, MA 02111 USA.			Grimm, Christian/0000-0001-9318-4352				Alloway PG, 2000, NEURON, V28, P129, DOI 10.1016/S0896-6273(00)00091-X; Bentrop J, 1998, ACTA ANAT, V162, P85; Calvert PD, 2000, P NATL ACAD SCI USA, V97, P13913, DOI 10.1073/pnas.250478897; CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y; Chen CK, 1999, P NATL ACAD SCI USA, V96, P3718, DOI 10.1073/pnas.96.7.3718; Chen J, 1999, INVEST OPHTH VIS SCI, V40, P2978; CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042; Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246; Danciger M, 2000, MAMM GENOME, V11, P422, DOI 10.1007/s003350010081; Dillon J, 1996, PHOTOCHEM PHOTOBIOL, V63, P680, DOI 10.1111/j.1751-1097.1996.tb05673.x; FAIN GL, 1993, EXP EYE RES, V57, P335, DOI 10.1006/exer.1993.1132; Fain GL, 1999, INVEST OPHTH VIS SCI, V40, P2770; Gal A, 1997, PROG RETIN EYE RES, V16, P51, DOI 10.1016/S1350-9462(96)00021-3; Grimm C, 2000, NAT GENET, V25, P63, DOI 10.1038/75614; Hafezi F, 1999, VISION RES, V39, P2511, DOI 10.1016/S0042-6989(98)00313-7; Keller C, 2001, INVEST OPHTH VIS SCI, V42, P476; Khani SC, 1998, P NATL ACAD SCI USA, V95, P2824, DOI 10.1073/pnas.95.6.2824; Kiselev A, 2000, NEURON, V28, P139, DOI 10.1016/S0896-6273(00)00092-1; LAVAIL MM, 1987, INVEST OPHTH VIS SCI, V28, P1043; LAVAIL MM, 1987, EXP EYE RES, V44, P877, DOI 10.1016/S0014-4835(87)80050-7; LaVail MM, 1999, INVEST OPHTH VIS SCI, V40, P1020; LEIST M, 1994, J IMMUNOL, V153, P1778; LISMAN J, 1995, NAT MED, V1, P1254, DOI 10.1038/nm1295-1254; Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497; Nakazawa M, 1998, ARCH OPHTHALMOL-CHIC, V116, P498, DOI 10.1001/archopht.116.4.498; NOELL WK, 1971, SCIENCE, V172, P76, DOI 10.1126/science.172.3978.76; Obin M, 2000, MECH AGEING DEV, V114, P133, DOI 10.1016/S0047-6374(00)00096-8; Organisciak DT, 1999, CURR EYE RES, V19, P188, DOI 10.1076/ceyr.19.2.188.5333; PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974; RAPP LM, 1980, VISION RES, V20, P1127, DOI 10.1016/0042-6989(80)90050-4; RAPP LM, 1980, EFFECTS CONSTANT LIG, P135; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Reme CE, 1998, PROG RETIN EYE RES, V17, P443, DOI 10.1016/S1350-9462(98)00009-3; Sieving PA, 2001, P NATL ACAD SCI USA, V98, P1835, DOI 10.1073/pnas.041606498; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; Wang M, 1997, VISUAL NEUROSCI, V14, P55, DOI 10.1017/S0952523800008750; Wenzel A, 2000, J NEUROSCI, V20, P81, DOI 10.1523/JNEUROSCI.20-01-00081.2000; Wenzel A, 2001, INVEST OPHTH VIS SCI, V42, P1653; Wenzel A, 2001, J NEUROSCI, V21, P53, DOI 10.1523/JNEUROSCI.21-01-00053.2001; Yamada T, 1999, Ophthalmic Genet, V20, P117, DOI 10.1076/opge.20.2.117.2293; Yamamoto S, 1997, NAT GENET, V15, P175, DOI 10.1038/ng0297-175	41	200	206	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2002	32	2					254	260		10.1038/ng984	http://dx.doi.org/10.1038/ng984			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	599AP	12219089				2022-12-25	WOS:000178311100013
J	Gao, XS; Zhang, Y; Arrazola, P; Hino, O; Kobayashi, T; Yeung, RS; Ru, BG; Pan, DJ				Gao, XS; Zhang, Y; Arrazola, P; Hino, O; Kobayashi, T; Yeung, RS; Ru, BG; Pan, DJ			Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling	NATURE CELL BIOLOGY			English	Article							P70 S6 KINASE; CELL-GROWTH; TUBEROUS SCLEROSIS; DROSOPHILA HOMOLOG; GENE-PRODUCT; HAMARTIN; SIZE; PROLIFERATION; RAPAMYCIN; PATHWAYS	Target of Rapamycin (TOR) mediates a signalling pathway that couples amino acid availability to S6 kinase (S6K) activation, translational initiation and cell growth(1,2). Here, we show that tuberous sclerosis 1 (Tsc1) and Tsc2, tumour suppressors that are responsible for the tuberous sclerosis syndrome(3,4), antagonize this amino acid-TOR signalling pathway. We show that Tsc1 and Tsc2 can physically associate with TOR and function upstream of TOR genetically. In Drosophila melanogaster and mammalian cells, loss of Tsc1 and Tsc2 results in a TOR-dependent increase of S6K activity. Furthermore, although S6K is normally inactivated in animal cells in response to amino acid starvation, loss of Tsc1-Tsc2 renders cells resistant to amino acid starvation. We propose that the Tsc1-Tsc2 complex antagonizes the TOR-mediated response to amino acid availability. Our studies identify Tsc1 and Tsc2 as regulators of the amino acid-TOR pathway and provide a new paradigm for how proteins involved in nutrient sensing function as tumour suppressors.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Inst Canc Res, Dept Expt Pathol, Toshima Ku, Tokyo 1708455, Japan; Univ Washington, Dept Surg, Div Med Genet, Seattle, WA 98195 USA; Peking Univ, Dept Biochem, Beijing 100871, Peoples R China	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Washington; University of Washington Seattle; Peking University	Pan, DJ (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Zhang, Yong/D-4884-2011	Zhang, Yong/0000-0001-8765-7037	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062323] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62323] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benvenuto G, 2000, ONCOGENE, V19, P6306, DOI 10.1038/sj.onc.1204009; Chen EH, 2001, DEV CELL, V1, P705, DOI 10.1016/S1534-5807(01)00084-3; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Echalier G., 1997, DROSOPHILA CELLS CUL; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Ito N, 1999, CELL, V96, P529, DOI 10.1016/S0092-8674(00)80657-1; Kobayashi T, 2001, P NATL ACAD SCI USA, V98, P8762, DOI 10.1073/pnas.151033798; Kuruvilla FG, 1999, CHEM BIOL, V6, pR129, DOI 10.1016/S1074-5521(99)80070-2; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Miron M, 2001, NAT CELL BIOL, V3, P596, DOI 10.1038/35078571; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Nellist M, 1999, J BIOL CHEM, V274, P35647, DOI 10.1074/jbc.274.50.35647; NELLIST M, 1993, CELL, V75, P1305; Oldham S, 2000, GENE DEV, V14, P2689, DOI 10.1101/gad.845700; Plank TL, 1998, CANCER RES, V58, P4766; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Radimerski T, 2002, NAT CELL BIOL, V4, P251, DOI 10.1038/ncb763; Seegmiller AC, 2002, DEV CELL, V2, P229, DOI 10.1016/S1534-5807(01)00119-8; Stocker H, 2000, CURR OPIN GENET DEV, V10, P529, DOI 10.1016/S0959-437X(00)00123-4; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413; Young J, 1998, MOL MED TODAY, V4, P313, DOI 10.1016/S1357-4310(98)01245-3; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000	32	528	556	4	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	2002	4	9					699	704		10.1038/ncb847	http://dx.doi.org/10.1038/ncb847			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	589WE	12172555				2022-12-25	WOS:000177783900014
J	Mata, J; Lyne, R; Burns, G; Bahler, J				Mata, J; Lyne, R; Burns, G; Bahler, J			The transcriptional program of meiosis and sporulation in fission yeast	NATURE GENETICS			English	Article							SCHIZOSACCHAROMYCES-POMBE; MEIOTIC RECOMBINATION; SPORE FORMATION; DNA-SYNTHESIS; GENES; EXPRESSION; PROTEIN; ENCODES; CONJUGATION; REGULATOR	Sexual reproduction requires meiosis to produce haploid gametes, which in turn can fuse to regenerate a diploid organism. We have studied the transcriptional program that drives this developmental process in Schizosaccharomyces pombe using DNA microarrays. Here we show that hundreds of genes are regulated in successive waves of transcription that correlate with major biological events of meiosis and sporulation. Each wave is associated with specific promoter motifs. Clusters of neighboring genes (mostly close to telomeres) are co-expressed early in the process, which reflects a more global control of these genes. We find that two Atf-like transcription factors are essential for the expression of late genes and formation of spores, and identify dozens of potential Atf target genes. Comparison with the meiotic program of the distantly related Saccharomyces cerevisiae reveals an unexpectedly small shared meiotic transcriptome, suggesting that the transcriptional regulation of meiosis evolved independently in both species.	Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England	Wellcome Trust Sanger Institute	Bahler, J (corresponding author), Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England.	jurg@sanger.ac.uk	Bahler, Jurg/B-4572-2009; Lyne, Rachel/AAE-2189-2020	Bahler, Jurg/0000-0003-4036-1532; Lyne, Rachel/0000-0001-8050-402X; Mata, Juan/0000-0002-5514-3653	Cancer Research UK [A6517] Funding Source: Medline; Wellcome Trust [077118] Funding Source: Medline	Cancer Research UK(Cancer Research UK); Wellcome Trust(Wellcome TrustEuropean Commission)		Abe H, 2000, GENETICS, V154, P1497; Asakawa H, 2001, MOL GENET GENOMICS, V265, P424, DOI 10.1007/s004380000429; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Blanco MA, 2001, J CELL SCI, V114, P2135; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Cooper KF, 2000, P NATL ACAD SCI USA, V97, P14548, DOI 10.1073/pnas.250351297; Davis L, 2001, P NATL ACAD SCI USA, V98, P8395, DOI 10.1073/pnas.121005598; Ding R, 1998, MOL GEN GENET, V258, P663, DOI 10.1007/s004380050780; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fares H, 1996, J CELL BIOL, V132, P399, DOI 10.1083/jcb.132.3.399; Horie S, 1998, MOL CELL BIOL, V18, P2118, DOI 10.1128/MCB.18.4.2118; IINO Y, 1985, MOL GEN GENET, V198, P416, DOI 10.1007/BF00332932; LOWNDES NF, 1992, NATURE, V355, P449, DOI 10.1038/355449a0; MIYAMOTO M, 1994, EMBO J, V13, P1873, DOI 10.1002/j.1460-2075.1994.tb06456.x; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Nakamura T, 2001, MOL BIOL CELL, V12, P3955, DOI 10.1091/mbc.12.12.3955; NIMMO ER, 1994, EMBO J, V13, P3801, DOI 10.1002/j.1460-2075.1994.tb06691.x; NURSE P, 1985, MOL GEN GENET, V198, P497, DOI 10.1007/BF00332946; Ohmiya R, 1999, MOL GEN GENET, V261, P297, DOI 10.1007/s004380050970; PETERSEN J, 1995, MOL CELL BIOL, V15, P3697; Primig M, 2000, NAT GENET, V26, P415, DOI 10.1038/82539; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; SUGIMOTO A, 1991, GENE DEV, V5, P1990, DOI 10.1101/gad.5.11.1990; SUGIYAMA A, 1994, EMBO J, V13, P1881, DOI 10.1002/j.1460-2075.1994.tb06457.x; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724; Yamamoto A, 2001, BIOESSAYS, V23, P526, DOI 10.1002/bies.1072; YAMAMOTO M, 1997, MOL CELLULAR BIOL YE, P1035; ZHU Y, 1994, GENE DEV, V8, P885, DOI 10.1101/gad.8.8.885	30	380	395	1	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2002	32	1					143	147		10.1038/ng951	http://dx.doi.org/10.1038/ng951			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	588RR	12161753				2022-12-25	WOS:000177714900013
J	Brugnera, E; Haney, L; Grimsley, C; Lu, MJ; Walk, SF; Tosello-Trampont, AC; Macara, IG; Madhani, H; Fink, GR; Ravichandran, KS				Brugnera, E; Haney, L; Grimsley, C; Lu, MJ; Walk, SF; Tosello-Trampont, AC; Macara, IG; Madhani, H; Fink, GR; Ravichandran, KS			Unconventional Rac-GEF activity is mediated through the Dock180-ELMO complex	NATURE CELL BIOLOGY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; DBL HOMOLOGY DOMAIN; CELL-MIGRATION; FAMILY PROTEINS; CRYSTAL-STRUCTURE; APOPTOTIC CELLS; MYOBLAST CITY; PHAGOCYTOSIS; MEMBRANE; BINDING	Mammalian Dock180 and ELMO proteins, and their homologues in Caenorhabditis elegans and Drosophila melanogaster, function as critical upstream regulators of Rac during development and cell migration. The mechanism by which Dock180 or ELMO mediates Rac activation is not understood. Here, we identify a domain within Dock180 (denoted Docker) that specifically recognizes nucleotide-free Rac and can mediate GTP loading of Rac in vitro. The Docker domain is conserved among known Dock180 family members in metazoans and in a yeast protein. In cells, binding of Dock180 to Rac alone is insufficient for GTP loading, and a Dock180-ELMO1 interaction is required. We can also detect a trimeric ELMO1-Dock180-Rac1 complex and ELMO augments the interaction between Dock180 and Rac. We propose that the Dock180-ELMO complex functions as an unconventional two-part exchange factor for Rac.	Univ Virginia, Beirne Carter Ctr Immunol Res, Charlottesville, VA 22908 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA; Univ Virginia, Markey Ctr Cell Signaling, Charlottesville, VA 22908 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Nine Cambridge Ctr, Whitehead Inst, Cambridge, MA 02142 USA	University of Virginia; University of Virginia; University of Virginia; University of Virginia; University of California System; University of California San Francisco; Massachusetts Institute of Technology (MIT); Whitehead Institute	Ravichandran, KS (corresponding author), Univ Virginia, Beirne Carter Ctr Immunol Res, Charlottesville, VA 22908 USA.		Lu, Mingjian/AGK-0751-2022; Lu, Mingjian/AAO-6179-2021	Lu, Mingjian/0000-0001-9328-4935; Madhani, Hiten/0000-0001-7400-6657				Aghazadeh B, 1998, NAT STRUCT BIOL, V5, P1098, DOI 10.1038/4209; Albert ML, 2000, NAT CELL BIOL, V2, P899, DOI 10.1038/35046549; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Duchek P, 2001, CELL, V107, P17, DOI 10.1016/S0092-8674(01)00502-5; Erickson MRS, 1997, J CELL BIOL, V138, P589, DOI 10.1083/jcb.138.3.589; Fukui Y, 2001, NATURE, V412, P826, DOI 10.1038/35090591; Gumienny TL, 2001, CELL, V107, P27, DOI 10.1016/S0092-8674(01)00520-7; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kobayashi S, 2001, BIOCHEM J, V354, P73, DOI 10.1042/0264-6021:3540073; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Lundquist EA, 2001, DEVELOPMENT, V128, P4475; Nemergut ME, 2001, SCIENCE, V292, P1540, DOI 10.1126/science.292.5521.1540; Nishihara H, 1999, BBA-MOL CELL RES, V1452, P179, DOI 10.1016/S0167-4889(99)00133-0; Nolan KM, 1998, GENE DEV, V12, P3337, DOI 10.1101/gad.12.21.3337; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Shinohara M, 2002, NATURE, V416, P759, DOI 10.1038/416759a; Snyder JT, 2001, J BIOL CHEM, V276, P45868, DOI 10.1074/jbc.M106731200; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Tosello-Trampont AC, 2001, J BIOL CHEM, V276, P13797, DOI 10.1074/jbc.M011238200; VAN AL, 1997, GENE DEV, V11, P2295; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Walk SF, 1998, EUR J IMMUNOL, V28, P2265, DOI 10.1002/(SICI)1521-4141(199808)28:08<2265::AID-IMMU2265>3.0.CO;2-P; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Wu YC, 2001, DEV CELL, V1, P491, DOI 10.1016/S1534-5807(01)00056-9; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163; Zhou Z, 2001, DEV CELL, V1, P477, DOI 10.1016/S1534-5807(01)00058-2	33	440	458	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2002	4	8					574	582		10.1038/ncb824	http://dx.doi.org/10.1038/ncb824			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	579WK	12134158				2022-12-25	WOS:000177201100012
J	Fulda, S; Wick, W; Weller, M; Debatin, KM				Fulda, S; Wick, W; Weller, M; Debatin, KM			Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo	NATURE MEDICINE			English	Article							TRAIL-INDUCED APOPTOSIS; DEATH RECEPTOR; TUMORICIDAL ACTIVITY; CD95 APO-1/FAS; SMAC/DIABLO; INHIBITION; PROTEIN; INACTIVATION; ACTIVATION; CASPASES	A major concern in cancer therapy is resistance of tumors such as glioblastoma to current treatment protocols. Here, we report that transfer of the gene encoding second mitochondria-derived activator of caspase ( Smac) or Smac peptides sensitized various tumor cells in vitro and malignant glioma cells in vivo for apoptosis induced by death-receptor ligation or cytotoxic drugs. Expression of a cytosolic active form of Smac or cell-permeable Smac peptides bypassed the Bcl-2 block, which prevented the release of Smac from mitochondria, and also sensitized resistant neuroblastoma or melanoma cells and patient-derived primary neuroblastoma cells ex vivo. Most importantly, Smac peptides strongly enhanced the antitumor activity of Apo2L/tumor necrosis factor - related apoptosis-inducing ligand ( TRAIL) in an intracranial malignant glioma xenograft model in vivo. Complete eradication of established tumors and survival of mice was only achieved upon combined treatment with Smac peptides and Apo2L/TRAIL without detectable toxicity to normal brain tissue. Thus, Smac agonists are promising candidates for cancer therapy by potentiating cytotoxic therapies.	Univ Childrens Hosp, Ulm, Germany; Univ Tubingen, Dept Neurol, D-7400 Tubingen, Germany; German Canc Res Ctr, Div Mol Oncol Pediat, D-6900 Heidelberg, Germany	Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Eberhard Karls University of Tubingen; Helmholtz Association; German Cancer Research Center (DKFZ)	Debatin, KM (corresponding author), Univ Childrens Hosp, Ulm, Germany.	klaus-michael.debatin@medizin.uni-ulm.de	Debatin, Klaus-Michael/J-9704-2014; Fulda, Simone/D-5864-2011; Wick, Wolfgang/AAA-2545-2020	Debatin, Klaus-Michael/0000-0002-8397-1886; Wick, Wolfgang/0000-0002-6171-634X; Fulda, Simone/0000-0002-0459-6417; Weller, Michael/0000-0002-1748-174X				Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chuntharapai A, 2001, J IMMUNOL, V166, P4891, DOI 10.4049/jimmunol.166.8.4891; DeAngelis LM, 2001, NEW ENGL J MED, V344, P114, DOI 10.1056/NEJM200101113440207; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Fulda S, 1998, CANCER RES, V58, P4453; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Fulda S, 2001, ONCOGENE, V20, P1063, DOI 10.1038/sj.onc.1204141; Goyal L, 2001, CELL, V104, P805, DOI 10.1016/S0092-8674(01)00276-8; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Hanemann CO, 1998, GLIA, V23, P89, DOI 10.1002/(SICI)1098-1136(199806)23:2<89::AID-GLIA1>3.0.CO;2-Z; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Jeremias I, 1998, EUR J IMMUNOL, V28, P143, DOI 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Mow BMF, 2001, CURR OPIN ONCOL, V13, P453, DOI 10.1097/00001622-200111000-00007; Nagane M, 2001, APOPTOSIS, V6, P191, DOI 10.1023/A:1011336726649; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Peto J, 2001, NATURE, V411, P390, DOI 10.1038/35077256; Ponder BAJ, 2001, NATURE, V411, P336, DOI 10.1038/35077207; Roth W, 1999, BIOCHEM BIOPH RES CO, V265, P479, DOI 10.1006/bbrc.1999.1693; Roy S, 2000, J EXP MED, V192, pF21, DOI 10.1084/jem.192.8.F21; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wagenknecht B, 1999, CELL DEATH DIFFER, V6, P370, DOI 10.1038/sj.cdd.4400503; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Weissert R, 1998, J CLIN INVEST, V102, P1265, DOI 10.1172/JCI3022; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhang XD, 2001, CANCER RES, V61, P7339	45	644	740	0	58	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2002	8	8					808	815		10.1038/nm735	http://dx.doi.org/10.1038/nm735			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	579WJ	12118245				2022-12-25	WOS:000177200900026
J	Perez, JM; Josephson, L; O'Loughlin, T; Hogemann, D; Weissleder, R				Perez, JM; Josephson, L; O'Loughlin, T; Hogemann, D; Weissleder, R			Magnetic relaxation switches capable of sensing molecular interactions	NATURE BIOTECHNOLOGY			English	Article							NANOPARTICLE PROBES; MULTIPLE SAMPLES; DNA; NMR; BIOSENSOR; POLYNUCLEOTIDES; NANOCRYSTALS	Highly sensitive, efficient, and high-throughput biosensors are required for genomic and proteomic data acquisition in complex biological samples and potentially for in vivo applications. To facilitate these studies, we have developed biocompatible magnetic nanosensors that act as magnetic relaxation switches (MRS) to detect molecular interactions in the reversible self-assembly of disperse magnetic particles into stable nanoassemblies. Using four different types of molecular interactions (DNA-DNA, protein-protein, protein-small molecule, and enzyme reactions) as model systems, we show that the MRS technology can be used to detect these interactions with high efficiency and sensitivity using magnetic relaxation measurements including magnetic resonance imaging (MRI). Furthermore, the magnetic changes are detectable in turbid media and in whole-cell lysates without protein purification. The developed magnetic nanosensors can be used in a variety of biological applications such as in homogenous assays, as reagents in miniaturized microfluidic systems, as affinity ligands for rapid and high-throughput magnetic readouts of arrays, as probes for magnetic force microscopy, and potentially for in vivo imaging.	Massachusetts Gen Hosp, Ctr Mol Imaging Res, Boston, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Weissleder, R (corresponding author), Massachusetts Gen Hosp, Ctr Mol Imaging Res, Boston, MA 02129 USA.			/0000-0003-0828-4143	NATIONAL CANCER INSTITUTE [P50CA086355] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA86355] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alivisatos AP, 1996, SCIENCE, V271, P933, DOI 10.1126/science.271.5251.933; Alivisatos AP, 1996, NATURE, V382, P609, DOI 10.1038/382609a0; Baselt DR, 1998, BIOSENS BIOELECTRON, V13, P731, DOI 10.1016/S0956-5663(98)00037-2; Bremer C, 2001, NAT MED, V7, P743, DOI 10.1038/89126; Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013; Chan WCW, 1998, SCIENCE, V281, P2016, DOI 10.1126/science.281.5385.2016; Chemla YR, 2000, P NATL ACAD SCI USA, V97, P14268, DOI 10.1073/pnas.97.26.14268; Diebel CE, 2000, NATURE, V406, P299, DOI 10.1038/35018561; Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434; Edelstein RL, 2000, BIOSENS BIOELECTRON, V14, P805, DOI 10.1016/S0956-5663(99)00054-8; Eis PS, 2001, NAT BIOTECHNOL, V19, P673, DOI 10.1038/90290; Elghanian R, 1997, SCIENCE, V277, P1078, DOI 10.1126/science.277.5329.1078; Han MY, 2001, NAT BIOTECHNOL, V19, P631, DOI 10.1038/90228; Hogemann D, 2002, BIOCONJUGATE CHEM, V13, P116, DOI 10.1021/bc015549h; Hou T, 2001, ANAL CHEM, V73, P2541, DOI 10.1021/ac0100751; Jamet M, 2001, PHYS REV LETT, V86, P4676, DOI 10.1103/PhysRevLett.86.4676; Josephson L, 2001, ANGEW CHEM INT EDIT, V40, P3204, DOI 10.1002/1521-3773(20010903)40:17<3204::AID-ANIE3204>3.0.CO;2-H; Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h; Keifer PA, 2000, J COMB CHEM, V2, P151, DOI 10.1021/cc990066u; Keifer PA, 1999, CURR OPIN BIOTECH, V10, P34, DOI 10.1016/S0958-1669(99)80007-X; Kriz K, 1998, BIOSENS BIOELECTRON, V13, P817, DOI 10.1016/S0956-5663(98)00047-5; Lewin M, 2000, NAT BIOTECHNOL, V18, P410, DOI 10.1038/74464; Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0; Ross A, 2001, ANGEW CHEM INT EDIT, V40, P3243, DOI 10.1002/1521-3773(20010903)40:17<3243::AID-ANIE3243>3.0.CO;2-F; Saeki Y, 2001, MOL THER, V3, P591, DOI 10.1006/mthe.2001.0294; Storhoff JJ, 1998, J AM CHEM SOC, V120, P1959, DOI 10.1021/ja972332i; Taton TA, 2000, SCIENCE, V289, P1757, DOI 10.1126/science.289.5485.1757; Weissleder R, 1999, NAT BIOTECHNOL, V17, P375, DOI 10.1038/7933; WEISSLEDER R, 1995, ADV DRUG DELIVER REV, V16, P321, DOI 10.1016/0169-409X(95)00033-4; Weissleder Ralph, 2000, Nature Medicine, V6, P351, DOI 10.1038/73219; Wunderbaldinger P, 2002, BIOCONJUGATE CHEM, V13, P264, DOI 10.1021/bc015563u	31	686	743	11	306	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2002	20	8					816	820		10.1038/nbt720	http://dx.doi.org/10.1038/nbt720			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	579MU	12134166				2022-12-25	WOS:000177182500033
J	Bu, L; Jin, YP; Shi, YF; Chu, RY; Ban, AR; Eiberg, H; Andres, L; Jiang, HS; Zheng, GY; Qian, MQ; Cui, B; Xia, Y; Liu, J; Hu, LD; Zhao, GP; Hayden, MR; Kong, XY				Bu, L; Jin, YP; Shi, YF; Chu, RY; Ban, AR; Eiberg, H; Andres, L; Jiang, HS; Zheng, GY; Qian, MQ; Cui, B; Xia, Y; Liu, J; Hu, LD; Zhao, GP; Hayden, MR; Kong, XY			Mutant DNA-binding domain of HSF4 is associated with autosomal dominant lamellar and Marner cataract	NATURE GENETICS			English	Article							LINKAGE ANALYSIS; SHOCK; ACTIVATOR; HUMANS	Congenital cataracts cause 10-30% of all blindness in children, with one-third of cases estimated to have a genetic cause(1). Lamellar cataract is the most common type of infantile cataract(2). We carried out whole-genome linkage analysis of Chinese individuals with lamellar cataract, and found that the disorder is associated with inheritance of a 5.11-cM locus on chromosome 16. This locus coincides with one previously described for Marner cataract(3). We screened individuals of three Chinese families for mutations in HSF4 (a gene at this locus that encodes heat-shock transcription factor 4) and discovered that in each family, a distinct missense mutation, predicted to affect the DNA-binding domain of the protein, segregates with the disorder. We also discovered an association between a missense mutation and Marner cataract in an extensive Danish family. We suggest that HSF4 is critical to lens development.	Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Res Ctr Biotechnol, Shanghai 200233, Peoples R China; Univ Sci & Technol China, Hefei 230026, Peoples R China; Fudan Univ, Coll Med, EENT Hosp, Dept Ophthalmol, Shanghai, Peoples R China; Peoples Hosp Yichuan, Dept Ophthalmol, Luoyang, Peoples R China; Univ Copenhagen, Panum Inst, DK-2200 Copenhagen, Denmark; Xenon Genet, Burnaby, BC, Canada; Univ British Columbia, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 1M9, Canada; Chinese Acad Sci, Shanghai Inst Biol Sci, Hlth Sci Ctr, Shanghai 200025, Peoples R China; Shanghai Med Univ 2, Shanghai 200025, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Fudan University; University of Copenhagen; University of British Columbia; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University	Kong, XY (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Res Ctr Biotechnol, Shanghai 200233, Peoples R China.		Hayden, Michael R/D-8581-2011	Hayden, Michael R/0000-0001-5159-1419; BU, LEI/0000-0003-4476-2157				Bagchi M, 2002, J CELL BIOCHEM, V84, P278, DOI 10.1002/jcb.10023; Bagchi M, 2001, J CELL BIOCHEM, V82, P409, DOI 10.1002/jcb.1168; Berry V, 2001, AM J HUM GENET, V69, P1141, DOI 10.1086/324158; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; EIBERG H, 1988, CLIN GENET, V34, P272; Falls HF, 1943, ARCH OPHTHALMOL-CHIC, V29, P210, DOI 10.1001/archopht.1943.00880140056002; FAWCETT TW, 1994, J BIOL CHEM, V269, P32272; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LUND AM, 1992, CLIN GENET, V41, P65; MARNER E, 1949, ACTA OPHTHALMOL, V27, P537; Monaghan KG, 1997, AM J MED GENET, V73, P180, DOI 10.1002/(SICI)1096-8628(1997)73:2<180::AID-AJMG13>3.0.CO;2-Q; Nakai A, 1997, MOL CELL BIOL, V17, P469, DOI 10.1128/MCB.17.1.469; SCHAFFER AA, 1994, HUM HERED, V44, P225, DOI 10.1159/000154222; STRAATSMA BR, 1985, ANN INTERN MED, V102, P82, DOI 10.7326/0003-4819-102-1-82; Tanabe M, 1999, J BIOL CHEM, V274, P27845, DOI 10.1074/jbc.274.39.27845; TORRES FAG, 1995, MOL CELL BIOL, V15, P5063; Xiao SX, 2000, GENOMICS, V68, P247, DOI 10.1006/geno.2000.6285	19	208	252	1	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2002	31	3					276	278		10.1038/ng921	http://dx.doi.org/10.1038/ng921			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	567PW	12089525				2022-12-25	WOS:000176494100015
J	Linggi, B; Muller-Tidow, C; van de Locht, L; Hu, M; Nip, J; Serve, H; Berdel, WE; van der Reijden, B; Quelle, DE; Rowley, JD; Cleveland, J; Jansen, JH; Pandolfi, PP; Hiebert, SW				Linggi, B; Muller-Tidow, C; van de Locht, L; Hu, M; Nip, J; Serve, H; Berdel, WE; van der Reijden, B; Quelle, DE; Rowley, JD; Cleveland, J; Jansen, JH; Pandolfi, PP; Hiebert, SW			The t(8;21) fusion protein, AML1-ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia	NATURE MEDICINE			English	Article							WILD-TYPE P53; HEMATOLOGICAL MALIGNANCIES; INK4A LOCUS; GENE; P19(ARF); P16(INK4A); CELLS; MDM2; SENESCENCE; EXPRESSION	The t( 8; 21) is one of the most frequent chromosomal translocations associated with acute leukemia. This translocation creates a fusion protein consisting of the acute myeloid leukemia-1 transcription factor and the eight-twenty-one corepressor (AML1-ETO), which represses transcription through AML1 (RUNX1) DNA binding sites and immortalizes hematopoietic progenitor cells. We have identified the p14(ARF) tumor suppressor, a mediator of the p53 oncogene checkpoint, as a direct transcriptional target of AML1-ETO. AML1-ETO repressed the p14(ARF) promoter and reduced endogenous levels of p14(ARF) expression in multiple cell types. In contrast, AML1 stimulated p14(ARF) expression and induced phenotypes consistent with cellular senescence. Chromatin immunoprecipitation assays demonstrated that AML1-ETO was specifically bound to the p14(ARF) promoter. In acute myeloid leukemia samples containing the t( 8; 21), levels of p14(ARF) mRNA were markedly lower when compared with other acute myeloid leukemias lacking this translocation. Repression of p14(ARF) may explain why p53 is not mutated in t( 8; 21)-containing leukemias and suggests that p14(ARF) is an important tumor suppressor in a large number of human leukemias.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37212 USA; Univ Munster, Dept Med Hematol & Oncol, D-4400 Munster, Germany; Radboud Univ Nijmegen Med Ctr, Dept Hematol, Nijmegen, Netherlands; Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA; Cornell Univ, New York, NY USA; Univ Iowa, Dept Pharmacol, Iowa City, IA 52242 USA; Univ Chicago, Dept Hematol & Oncol, Chicago, IL 60637 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; Univ Tennessee, Dept Mol Sci, Memphis, TN USA	Vanderbilt University; University of Munster; Radboud University Nijmegen; Memorial Sloan Kettering Cancer Center; Cornell University; University of Iowa; University of Chicago; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Hiebert, SW (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37212 USA.	scott.hiebert@mcmail.vanderbilt.edu	Müller-Tidow, Carsten CMT/B-5257-2014; Hiebert, Scott W/C-9979-2010; Jansen, J.H./H-8054-2014; van der Reijden, Bert A/A-3543-2014; Müller-Tidow, Carsten/O-7207-2018	Jansen, J.H./0000-0001-9459-568X; Müller-Tidow, Carsten/0000-0002-7166-5232; Quelle, Dawn/0000-0001-8776-0122	NATIONAL CANCER INSTITUTE [R01CA064140, P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013726] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485, R01-CA64140] Funding Source: Medline; NIA NIH HHS [R01-AG13726] Funding Source: Medline; PHS HHS [R01-87549] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Banker DE, 1998, CLIN CANCER RES, V4, P3051; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Cong F, 1999, ONCOGENE, V18, P7731, DOI 10.1038/sj.onc.1203290; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; IMAMURA J, 1994, BLOOD, V84, P2412, DOI 10.1182/blood.V84.8.2412.bloodjournal8482412; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; LENNY N, 1995, ONCOGENE, V11, P1761; Licht JD, 2001, ONCOGENE, V20, P5660, DOI 10.1038/sj.onc.1204593; MELNIKOVA IN, 1993, J VIROL, V67, P2408, DOI 10.1128/JVI.67.4.2408-2411.1993; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Mulloy JC, 2002, BLOOD, V99, P15, DOI 10.1182/blood.V99.1.15; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Quesnel B, 1996, LEUKEMIA LYMPHOMA, V22, P11, DOI 10.3109/10428199609051724; Rhoades KL, 2000, BLOOD, V96, P2108; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Rowley JD, 1999, SEMIN HEMATOL, V36, P59; Ruas M, 1998, BIOCHIM BIOPHYS ACTA, V1378, P115, DOI 10.1016/s0304-419x(98)00017-1; Rubnitz JE, 1999, LEUKEMIA, V13, P6, DOI 10.1038/sj.leu.2401258; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SIMMONS D, 1988, J IMMUNOL, V141, P2797; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Taniguchi T, 1999, LEUKEMIA, V13, P1760, DOI 10.1038/sj.leu.2401557; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; ZHOU MX, 1995, BLOOD, V85, P1608, DOI 10.1182/blood.V85.6.1608.bloodjournal8561608; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	44	202	209	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2002	8	7					743	750		10.1038/nm726	http://dx.doi.org/10.1038/nm726			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	567QG	12091906				2022-12-25	WOS:000176495200037
J	Taylor, MD; Liu, L; Raffel, C; Hui, CC; Mainprize, TG; Zhang, XY; Agatep, R; Chiappa, S; Gao, LZ; Lowrance, A; Hao, AH; Goldstein, AM; Stavrou, T; Scherer, SW; Dura, WT; Wainwright, B; Squire, JA; Rutka, JT; Hogg, D				Taylor, MD; Liu, L; Raffel, C; Hui, CC; Mainprize, TG; Zhang, XY; Agatep, R; Chiappa, S; Gao, LZ; Lowrance, A; Hao, AH; Goldstein, AM; Stavrou, T; Scherer, SW; Dura, WT; Wainwright, B; Squire, JA; Rutka, JT; Hogg, D			Mutations in SUFU predispose to medulloblastoma	NATURE GENETICS			English	Article							BASAL-CELL CARCINOMAS; PRIMITIVE NEUROECTODERMAL TUMORS; CENTRAL-NERVOUS-SYSTEM; HUMAN HOMOLOG; SONIC HEDGEHOG; GORLIN SYNDROME; PATCHED PTCH; GENE; SUPPRESSOR; SKIN	The sonic hedgehog (SHH) signaling pathway directs the embryonic development of diverse organisms and is disrupted in a variety of malignancies. Pathway activation is triggered by binding of hedgehog proteins to the multipass Patched-1 (PTCH) receptor, which in the absence of hedgehog suppresses the activity of the seven-pass membrane protein Smoothened (SMOH). De-repression of SMOH culminates in the activation of one or more of the GLI transcription factors that regulate the transcription of downstream targets. Individuals with germline mutations of the SHH receptor gene PTCH are at high risk of developmental anomalies and of basal-cell carcinomas, medulloblastomas and other cancers (a pattern consistent with nevoid basal-cell carcinoma syndrome, NBCCS). In keeping with the role of PTCH as a tumor-suppressor gene, somatic mutations of this gene occur in sporadic basal-cell carcinomas and medulloblastomas. We report here that a subset of children with medulloblastoma carry germline and somatic mutations in SUFU (encoding the human suppressor of fused) of the SHH pathway, accompanied by loss of heterozygosity of the wildtype allele. Several of these mutations encode truncated proteins that are unable to export the GLI transcription factor from nucleus to cytoplasm, resulting in the activation of SHH signaling. SUFU is a newly identified tumor-suppressor gene that predisposes individuals to medulloblastoma by modulating the SHH signaling pathway through a newly identified mechanism.	Univ Toronto, Div Clin Sci, Toronto, ON, Canada; Hosp Sick Children, Arthur & Sonia Labatt Brain Tumour Res Ctr, Div Neurosurg, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada; Mayo Clin, Dept Neurosurg, Rochester, MN USA; NCI, Genet Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA; Childrens Natl Med Ctr, Dept Hematol Oncol, Washington, DC 20010 USA; Univ Warsaw, Dept Pathol, Warsaw, Poland; Univ Queensland, Ritchie Res Labs, St Lucia, Qld, Australia; Univ Toronto, Ontario Canc Inst, Princess Margaret Hosp, Dept Lab Med & Pathobiol, Toronto, ON, Canada; Univ Toronto, Ontario Canc Inst, Princess Margaret Hosp, Dept Med Biophys, Toronto, ON, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto; Mayo Clinic; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Children's National Health System; University of Warsaw; University of Queensland; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Rutka, JT (corresponding author), Univ Toronto, Div Clin Sci, Toronto, ON, Canada.		Squire, Jeremy A/F-4437-2012; Squire, Jeremy A/A-9352-2012; Scherer, Stephen W./B-3785-2013	Squire, Jeremy A/0000-0002-9863-468X; Scherer, Stephen W./0000-0002-8326-1999; Taylor, Michael/0000-0001-7009-3466; Wainwright, Brandon/0000-0003-0406-2092				Bayani J, 2000, J NEUROSURG, V93, P437, DOI 10.3171/jns.2000.93.3.0437; Chidambaram A, 1996, CANCER RES, V56, P4599; Dahmane N, 1999, DEVELOPMENT, V126, P3089; Ding Q, 1999, CURR BIOL, V9, P1119, DOI 10.1016/S0960-9822(99)80482-5; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; Grachtchouk M, 2000, NAT GENET, V24, P216, DOI 10.1038/73417; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kimonis VE, 1997, AM J MED GENET, V69, P299, DOI 10.1002/(SICI)1096-8628(19970331)69:3<299::AID-AJMG16>3.0.CO;2-M; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; Liu L, 1999, NAT GENET, V21, P128, DOI 10.1038/5082; LOBO S, 1992, AM J MED GENET, V43, P701, DOI 10.1002/ajmg.1320430410; Meng XW, 2001, J BIOL CHEM, V276, P40113, DOI 10.1074/jbc.M105317200; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; Ohlmeyer JT, 1998, NATURE, V396, P749, DOI 10.1038/25533; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Raffel C, 1997, CANCER RES, V57, P842; Raffel C, 1999, CLIN CANCER RES, V5, P4085; Reifenberger J, 1998, CANCER RES, V58, P1798; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Taylor MD, 2000, NEUROSURGERY, V47, P888, DOI 10.1097/00006123-200010000-00020; Unden AB, 1996, CANCER RES, V56, P4562; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Wicking C, 1997, AM J HUM GENET, V60, P21; Wolter M, 1997, CANCER RES, V57, P2581; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Zurawel RH, 1998, CANCER RES, V58, P896; Zurawel RH, 2000, GENE CHROMOSOME CANC, V27, P44, DOI 10.1002/(SICI)1098-2264(200001)27:1<44::AID-GCC6>3.0.CO;2-V	31	595	622	1	42	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2002	31	3					306	310		10.1038/ng916	http://dx.doi.org/10.1038/ng916			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	567PW	12068298				2022-12-25	WOS:000176494100021
J	Bulavin, DV; Demidov, ON; Saito, S; Kauraniemi, P; Phillips, C; Amundson, SA; Ambrosino, C; Sauter, G; Nebreda, AR; Anderson, CW; Kallioniemi, A; Fornace, AJ; Appella, E				Bulavin, DV; Demidov, ON; Saito, S; Kauraniemi, P; Phillips, C; Amundson, SA; Ambrosino, C; Sauter, G; Nebreda, AR; Anderson, CW; Kallioniemi, A; Fornace, AJ; Appella, E			Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity	NATURE GENETICS			English	Article							POSTTRANSLATIONAL MODIFICATIONS; PREMATURE SENESCENCE; GENETIC ALTERATIONS; HUMAN FIBROBLASTS; BREAST-CANCER; UV-RADIATION; P38 KINASE; PATHWAY; PROTEIN; PHOSPHATASE	Expression of oncogenic Ras in primary human cells activates p53, thereby protecting cells from transformation. We show that in Ras-expressing IMR-90 cells, p53 is phosphorylated at Ser33 and Ser46 by the p38 mitogen-activated protein kinase (MAPK). Activity of p38 MAPK is regulated by the p53-inducible phosphatase PPM1D, creating a potential feedback loop. Expression of oncogenic Ras suppresses PPM1D mRNA induction, leaving p53 phosphorylated at Ser33 and Ser46 and in an active state. Retrovirus-mediated overexpression of PPM1D reduced p53 phosphorylation at these sites, abrogated Ras-induced apoptosis and partially rescued cells from cell-cycle arrest. Inactivation of p38 MAPK (the product of Mapk14) in vivo by gene targeting or by PPM1D overexpression expedited tumor formation after injection of mouse embryo fibroblasts (MEFs) expressing E1A+Ras into nude mice. The gene encoding PPM1D (PPM1D, at 17q22/q23) is amplified in human breast-tumor cell lines and in approximately 11% of primary breast tumors, most of which harbor wildtype p53. These findings suggest that inactivation of the p38 MAPK through PPM1D overexpression resulting from PPM1D amplification contributes to the development of human cancers by suppressing p53 activation.	NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; NIH, Gene Response Sect, Bethesda, MD 20892 USA; NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; Tampere Univ, Inst Med Technol, Canc Genet Lab, Tampere, Finland; Tampere Univ Hosp, Tampere, Finland; European Mol Biol Lab, Heidelberg, Germany; Univ Basel, Inst Pathol, Basel, Switzerland; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Tampere University; Tampere University; Tampere University Hospital; European Molecular Biology Laboratory (EMBL); University of Basel; United States Department of Energy (DOE); Brookhaven National Laboratory	Appella, E (corresponding author), NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA.		Nebreda, Angel Rodriguez/R-9594-2019; Demidov, Oleg/U-2050-2017; Fornace, Albert J/A-7407-2008; Demidov, Oleg/AAC-4462-2021; ambrosino, concetta/AAB-3452-2019	Demidov, Oleg/0000-0003-4323-7174; Fornace, Albert J/0000-0001-9695-085X; Demidov, Oleg/0000-0003-4323-7174; Kallioniemi, Anne/0000-0003-3552-8158; Dudgeon, Crissy/0000-0001-9010-2569				Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; Bulavin DV, 1999, ONCOGENE, V18, P5611, DOI 10.1038/sj.onc.1202945; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Choi J, 2002, MOL CELL BIOL, V22, P1094, DOI 10.1128/MCB.22.4.1094-1105.2002; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Esteller M, 2000, CANCER RES, V60, P129; Ferbeyre G, 2000, GENE DEV, V14, P2015; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Ho GH, 2001, BREAST CANCER RES TR, V65, P225, DOI 10.1023/A:1010686518990; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; LI J, 2002, NATURE GENET, V31; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; OConnor PM, 1997, CANCER RES, V57, P4285; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Oster SK, 2000, MOL CELL BIOL, V20, P6768, DOI 10.1128/MCB.20.18.6768-6778.2000; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; Saito S, 2002, J BIOL CHEM, V277, P12491, DOI 10.1074/jbc.C200093200; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Tirkkonen M, 1998, GENE CHROMOSOME CANC, V21, P177, DOI 10.1002/(SICI)1098-2264(199803)21:3<177::AID-GCC1>3.3.CO;2-C; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Webley K, 2000, MOL CELL BIOL, V20, P2803, DOI 10.1128/MCB.20.8.2803-2808.2000; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	31	342	364	1	26	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2002	31	2					210	215		10.1038/ng894	http://dx.doi.org/10.1038/ng894			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	557HR	12021785				2022-12-25	WOS:000175903500021
J	Holley, CL; Olson, MR; Colon-Ramos, DA; Kornbluth, S				Holley, CL; Olson, MR; Colon-Ramos, DA; Kornbluth, S			Reaper eliminates IAP proteins through stimulated IAP degradation and generalized translational inhibition	NATURE CELL BIOLOGY			English	Article							PROGRAMMED CELL-DEATH; STRUCTURAL BASIS; APOPTOSIS; DROSOPHILA; GRIM; XIAP; MITOCHONDRIA; CASPASE-3; FRAGMENT; LIGASE	Inhibitors of apoptosis (IAPs) inhibit caspases, thereby preventing proteolysis of apoptotic substrates. IAPs occlude the active sites of caspases to which they are bound(1-3) and can function as ubiquitin ligases. IAPs are also reported to ubiquitinate themselves and caspases(4,5). Several proteins induce apoptosis, at least in part, by binding and inhibiting IAPs. Among these are the Drosophila melanogaster proteins Reaper (Rpr), Grim, and HID, and the mammalian proteins Smac/Diablo and Omi/HtrA2, all of which share a conserved amino-terminal IAP-binding motif(6-14). We report here that Rpr not only inhibits IAP function, but also greatly decreases IAP abundance. This decrease in IAP levels results from a combination of increased IAP degradation and a previously unrecognized ability of Rpr to repress total protein translation. Rpr-stimulated IAP degradation required both IAP ubiquitin ligase activity and an unblocked Rpr N terminus. In contrast, Rpr lacking a free N terminus still inhibited protein translation. As the abundance of short-lived proteins are severely affected after translational inhibition, the coordinated dampening of protein synthesis and the ubiquitin-mediated destruction of IAPs can effectively reduce IAP levels to lower the threshold for apoptosis.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Kornbluth, S (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, C370 LSRC,Res Dr,Box 3813, Durham, NC 27710 USA.		Holley, Christopher/ABB-6677-2020; Holley, Christopher/T-1312-2019	Holley, Christopher/0000-0002-2870-3352	NIGMS NIH HHS [GM61919, R01 GM061919, R01 GM061919-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061919] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Avdonin V, 1998, P NATL ACAD SCI USA, V95, P11703, DOI 10.1073/pnas.95.20.11703; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; Clem RJ, 2001, J BIOL CHEM, V276, P7602, DOI 10.1074/jbc.M010259200; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Evans EK, 1997, EMBO J, V16, P7372, DOI 10.1093/emboj/16.24.7372; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; HAYS R, NATURE CELL BIOL; Huang HK, 2000, J BIOL CHEM, V275, P26661; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; RICHTER BW, 2000, SCIENCE STKE ONLINE; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; RYOO HD, NATURE CELL BIOL; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; SWENSON KI, 1989, CELL, V57, P145, DOI 10.1016/0092-8674(89)90180-3; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; WING JP, NATURE CELL BIOL; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Wu JW, 2001, MOL CELL, V8, P95, DOI 10.1016/S1097-2765(01)00282-9; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; YOO SJ, NATURE CELL BIOL	26	166	177	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUN	2002	4	6					439	444		10.1038/ncb798	http://dx.doi.org/10.1038/ncb798			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	558NN	12021770	Green Accepted			2022-12-25	WOS:000175973600014
J	Legg, JW; Lewis, CA; Parsons, M; Ng, T; Isacke, CM				Legg, JW; Lewis, CA; Parsons, M; Ng, T; Isacke, CM			A novel PKC-regulated mechanism controls CD44-ezrin association and directional cell motility	NATURE CELL BIOLOGY			English	Article							PROTEIN-KINASE-C; EZRIN/RADIXIN/MOESIN ERM PROTEINS; CYTOSKELETAL INTERACTION; HYALURONAN RECEPTOR; CYTOPLASMIC DOMAIN; EPITHELIAL-CELLS; MELANOMA-CELLS; ACTIN-BINDING; MDCK CELLS; CD44	The dynamic assembly and disassembly of membrane-cytoskeleton junctional complexes is critical in cell migration. Here we describe a novel phosphorylation mechanism that regulates the hyaluronan receptor CD44. In resting cells, CD44 is constitutively phosphorylated at a single serine residue, Ser325. After protein kinase C is activated, a switch in phosphorylation results in CD44 being phosphorylated solely at an alternative residue, Ser291. Using fluorescence resonance energy transfer (FRET) monitored by fluorescence lifetime imaging microscopy (FLIM) and chemotaxis assays we show that phosphorylation of Ser291 modulates the interaction between CD44 and the cytoskeletal linker protein ezrin in vivo, and that this phosphorylation is critical for CD44-dependent directional cell motility.	Inst Canc Res, Chester Beatty Labs, Breakthrough Toby Robins Breast Canc Res Ctr, London SW3 6JB, England; Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AZ, England; St Thomas Hosp, Richard Dimbleby ICRF Dept Canc Res, London SE1 7EH, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Imperial College London; Guy's & St Thomas' NHS Foundation Trust	Isacke, CM (corresponding author), Inst Canc Res, Chester Beatty Labs, Breakthrough Toby Robins Breast Canc Res Ctr, Mary Jean Mitchell Bldg,237 Fulham Rd, London SW3 6JB, England.	c.isacke@icr.ac.uk	Parsons, Maddy/B-2203-2013	Parsons, Maddy/0000-0002-2021-8379; Ng, Tony/0000-0003-3894-5619; Isacke, Clare/0000-0002-9222-3345				Bajorath J, 2000, PROTEINS, V39, P103, DOI 10.1002/(SICI)1097-0134(20000501)39:2<103::AID-PROT1>3.3.CO;2-7; Ballestrem C, 2000, MOL BIOL CELL, V11, P2999, DOI 10.1091/mbc.11.9.2999; Barret C, 2000, J CELL BIOL, V151, P1067, DOI 10.1083/jcb.151.5.1067; Bastiaens PIH, 1999, TRENDS CELL BIOL, V9, P48, DOI 10.1016/S0962-8924(98)01410-X; Bastiaens PIH, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 3, P136; Bourguignon LYW, 2000, J BIOL CHEM, V275, P1829, DOI 10.1074/jbc.275.3.1829; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; CAMP RL, 1991, J CELL BIOL, V115, P1283, DOI 10.1083/jcb.115.5.1283; Castelo L, 1999, MOL BIOL CELL, V10, P1511, DOI 10.1091/mbc.10.5.1511; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; Gautreau A, 2000, J CELL BIOL, V150, P193, DOI 10.1083/jcb.150.1.193; Goebeler M, 1996, J CELL SCI, V109, P1957; Herrera-Gayol A, 1999, EXP MOL PATHOL, V66, P99, DOI 10.1006/exmp.1999.2236; Herreros J, 2001, MOL BIOL CELL, V12, P2947, DOI 10.1091/mbc.12.10.2947; Huang LQ, 1999, J BIOL CHEM, V274, P12803, DOI 10.1074/jbc.274.18.12803; Imamura H, 1998, MOL BIOL CELL, V9, P2561, DOI 10.1091/mbc.9.9.2561; KALOMIRIS EL, 1989, J BIOL CHEM, V264, P8113; Lamb RF, 1997, CURR BIOL, V7, P682, DOI 10.1016/S0960-9822(06)00295-8; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; Legg JW, 1998, CURR BIOL, V8, P705, DOI 10.1016/S0960-9822(98)70277-5; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; Levy M, 1998, J BIOL CHEM, V273, P6495, DOI 10.1074/jbc.273.11.6495; Lewis CA, 2001, BIOCHEM J, V357, P843, DOI 10.1042/0264-6021:3570843; Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927; Mangeat P, 1999, TRENDS CELL BIOL, V9, P187, DOI 10.1016/S0962-8924(99)01544-5; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Naor D, 1997, ADV CANCER RES, V71, P241, DOI 10.1016/S0065-230X(08)60101-3; NEAME SJ, 1993, J CELL BIOL, V121, P1299, DOI 10.1083/jcb.121.6.1299; NEAME SJ, 1992, EMBO J, V11, P4733, DOI 10.1002/j.1460-2075.1992.tb05578.x; Ng T, 2001, EMBO J, V20, P2723, DOI 10.1093/emboj/20.11.2723; Ng T, 1999, SCIENCE, V283, P2085, DOI 10.1126/science.283.5410.2085; Ng T, 1999, EMBO J, V18, P3909, DOI 10.1093/emboj/18.14.3909; Parekh DB, 2000, BIOCHEM J, V352, P425, DOI 10.1042/0264-6021:3520425; PARSONS M, IN PRESS METHODS CEL; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Peck D, 1998, J CELL SCI, V111, P1595; Peck D, 1996, CURR BIOL, V6, P884, DOI 10.1016/S0960-9822(02)00612-7; Potter LR, 2000, J BIOL CHEM, V275, P31099, DOI 10.1074/jbc.M005506200; Rigot V, 1998, J CELL SCI, V111, P3119; Selvin PR, 2000, NAT STRUCT BIOL, V7, P730, DOI 10.1038/78948; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Squire A, 1999, J MICROSC-OXFORD, V193, P36, DOI 10.1046/j.1365-2818.1999.00427.x; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; Taunton J, 2000, J CELL BIOL, V148, P519, DOI 10.1083/jcb.148.3.519; THOMAS L, 1993, J INVEST DERMATOL, V100, P115, DOI 10.1111/1523-1747.ep12462776; Tsukita S, 1999, J BIOL CHEM, V274, P34507, DOI 10.1074/jbc.274.49.34507; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Zarkowska T, 1997, ONCOGENE, V14, P249, DOI 10.1038/sj.onc.1200824; Zicha D, 1997, Methods Mol Biol, V75, P449	50	199	203	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2002	4	6					399	407		10.1038/ncb797	http://dx.doi.org/10.1038/ncb797			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	558NN	12032545				2022-12-25	WOS:000175973600009
J	Schlingmann, KP; Weber, S; Peters, M; Nejsum, LN; Vitzthum, H; Klingel, K; Kratz, M; Haddad, E; Ristoff, E; Dinour, D; Syrrou, M; Nielsen, S; Sassen, M; Waldegger, S; Seyberth, HW; Konrad, M				Schlingmann, KP; Weber, S; Peters, M; Nejsum, LN; Vitzthum, H; Klingel, K; Kratz, M; Haddad, E; Ristoff, E; Dinour, D; Syrrou, M; Nielsen, S; Sassen, M; Waldegger, S; Seyberth, HW; Konrad, M			Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family	NATURE GENETICS			English	Article							MAGNESIUM; EXPRESSION; PROTEIN; CHANNELS; KINASE; PARACELLIN-1; ABSORPTION; RESORPTION; TRANSPORT; CDNA	Magnesium is an essential ion involved in many biochemical and physiological processes. Homeostasis of magnesium levels is tightly regulated and depends on the balance between intestinal absorption and renal excretion. However, little is known about specific proteins mediating transepithelial magnesium transport. Using a positional candidate gene approach, we identified mutations in TRPM6 (also known as CHAK2), encoding TRPM6, in autosomal-recessive hypomagnesemia with secondary hypocalcemia (HSH, OMIM 602014)(1,2), previously mapped to chromosome 9q22 (ref. 3). The TRPM6 protein is a new member of the long transient receptor potential channel (TRPM) family 4 and is highly similar to TRPM7 (also known as TRP-PLIK), a bifunctional protein that combines calcium- and magnesium-permeable cation channel properties with protein kinase activity(5-7). TRPM6 is expressed in intestinal epithelia and kidney tubules. These findings indicate that TRPM6 is crucial for magnesium homeostasis and implicate a TRPM family member in human disease.	Univ Marburg, Dept Pediat, D-35037 Marburg, Germany; Aarhus Univ, Inst Anat, Water & Salt Res Ctr, DK-8000 Aarhus C, Denmark; Univ Regensburg, Dept Physiol 1, D-8400 Regensburg, Germany; Univ Hosp, Dept Mol Pathol, Tubingen, Germany; Univ Childrens Hosp, Mannheim, Germany; Robert Debre Hosp, Paris, France; Huddinge Univ, Karolinska Inst, Dept Pediat, Stockholm, Sweden; Chaim Sheba Med Ctr, Dept Nephrol, Ramat Gan, Israel; Univ Ioannina, Lab Gen Biol Genet, GR-45110 Ioannina, Greece	Philipps University Marburg; Aarhus University; University of Regensburg; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Ruprecht Karls University Heidelberg; University of Hamburg; University Medical Center Hamburg-Eppendorf; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Karolinska Institutet; Chaim Sheba Medical Center; University of Ioannina	Konrad, M (corresponding author), Univ Marburg, Dept Pediat, Deutschhausstr 12, D-35037 Marburg, Germany.	konradm@mailer.uni-marburg.de	Haddad, Elie/AAQ-4971-2020	Haddad, Elie/0000-0003-2446-6879; Nejsum, Lene Niemann/0000-0003-4368-8821; SYRROU, MARIA/0000-0002-5748-5008				ANAST CS, 1972, SCIENCE, V177, P606, DOI 10.1126/science.177.4049.606; Andre E, 1998, EMBO J, V17, P3867, DOI 10.1093/emboj/17.14.3867; Cahalan MD, 2001, NATURE, V411, P542, DOI 10.1038/35079231; CHALLA A, 1995, ACTA PAEDIATR, V84, P1075, DOI 10.1111/j.1651-2227.1995.tb13830.x; Cole DEC, 2000, J AM SOC NEPHROL, V11, P1937, DOI 10.1681/ASN.V11101937; Duncan LM, 2001, J CLIN ONCOL, V19, P568, DOI 10.1200/JCO.2001.19.2.568; FINE KD, 1991, J CLIN INVEST, V88, P396, DOI 10.1172/JCI115317; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; KAYNE LH, 1993, MINER ELECTROL METAB, V19, P210; KLINGEL K, 1992, P NATL ACAD SCI USA, V89, P314, DOI 10.1073/pnas.89.1.314; Koizumi K, 2001, INT J MOL MED, V8, P273; Konrad M, 2000, J AM SOC NEPHROL, V11, P1449, DOI 10.1681/ASN.V1181449; MATZKIN H, 1989, NEPHRON, V52, P83, DOI 10.1159/000185588; Meij IC, 2000, NAT GENET, V26, P265, DOI 10.1038/81543; MILLA PJ, 1979, GUT, V20, P1028, DOI 10.1136/gut.20.11.1028; Nadler MJS, 2001, NATURE, V411, P590, DOI 10.1038/35079092; PAUNIER L, 1968, PEDIATRICS, V41, P385; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Quamme GA, 1997, KIDNEY INT, V52, P1180, DOI 10.1038/ki.1997.443; Reddy S, 1998, J CELL PHYSIOL, V177, P636, DOI 10.1002/(SICI)1097-4652(199812)177:4<636::AID-JCP14>3.3.CO;2-8; Runnels LW, 2001, SCIENCE, V291, P1043, DOI 10.1126/science.1058519; Ryazanov AG, 1997, P NATL ACAD SCI USA, V94, P4884, DOI 10.1073/pnas.94.10.4884; Ryazanova LV, 2001, MOL BIOL+, V35, P271, DOI 10.1023/A:1010499720185; Shalev H, 1998, ARCH DIS CHILD, V78, P127, DOI 10.1136/adc.78.2.127; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Simon DB, 1999, SCIENCE, V285, P103, DOI 10.1126/science.285.5424.103; Walder RY, 2002, NAT GENET, V31, P171, DOI 10.1038/ng901; Walder RY, 1999, AM J HUM GENET, V65, pA451; Walder RY, 1997, HUM MOL GENET, V6, P1491, DOI 10.1093/hmg/6.9.1491; Weber S, 2001, J AM SOC NEPHROL, V12, P2664, DOI 10.1681/ASN.V12122664	30	540	576	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2002	31	2					166	170		10.1038/ng889	http://dx.doi.org/10.1038/ng889			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	557HR	12032568				2022-12-25	WOS:000175903500012
J	Wing, JP; Schreader, BA; Yokokura, T; Wang, UQ; Andrews, PS; Huseinovic, N; Dong, CK; Ogdahl, JL; Schwartz, LM; White, K; Nambu, JR				Wing, JP; Schreader, BA; Yokokura, T; Wang, UQ; Andrews, PS; Huseinovic, N; Dong, CK; Ogdahl, JL; Schwartz, LM; White, K; Nambu, JR			Drosophila Morgue is an F box/ubiquitin conjugase domain protein important for grim-reaper mediated apoptosis	NATURE CELL BIOLOGY			English	Article							PROGRAMMED CELL-DEATH; LIGASE ACTIVITY; UBIQUITIN; PROTEASOMES; DEGRADATION; INHIBITOR; CASPASE-3; PATHWAY; CYCLE		Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA; Univ Massachusetts, Mol & Cellular Biol Program, Amherst, MA 01003 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst; Harvard University; Massachusetts General Hospital	Nambu, JR (corresponding author), Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA.		White, Kristin/D-7936-2013		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055568] Funding Source: NIH RePORTER; NIA NIH HHS [AG55118] Funding Source: Medline; NIGMS NIH HHS [R01 GM055568, GM55568] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrams JM, 1999, TRENDS CELL BIOL, V9, P435, DOI 10.1016/S0962-8924(99)01646-3; Bangs P, 2000, DEV DYNAM, V218, P68, DOI 10.1002/(SICI)1097-0177(200005)218:1<68::AID-DVDY6>3.0.CO;2-9; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; COOLEY L, 1990, P NATL ACAD SCI USA, V87, P3170, DOI 10.1073/pnas.87.8.3170; Grimm LM, 1996, EMBO J, V15, P3835, DOI 10.1002/j.1460-2075.1996.tb00757.x; HAAS AL, 1995, J BIOL CHEM, V270, P9407, DOI 10.1074/jbc.270.16.9407; Hay BA, 2000, CELL DEATH DIFFER, V7, P1045, DOI 10.1038/sj.cdd.4400765; HAYS R, NATURE CELL BIOL; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; HOLLEY CL, NATURE CELL BIOL; Huang HK, 2000, J BIOL CHEM, V275, P26661; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Kipreos ET, 2000, GENOME BIOL, V1; Lisi S, 2000, GENETICS, V154, P669; Ma Y, 2000, J NEUROSCI, V20, P4596, DOI 10.1523/JNEUROSCI.20-12-04596.2000; Orlowski RZ, 1999, CELL DEATH DIFFER, V6, P303, DOI 10.1038/sj.cdd.4400505; Rorth P, 1998, DEVELOPMENT, V125, P1049; RYOO HD, NATURE CELL BIOL; Sadoul R, 1996, EMBO J, V15, P3845, DOI 10.1002/j.1460-2075.1996.tb00758.x; Sancho E, 1998, MOL CELL BIOL, V18, P576, DOI 10.1128/MCB.18.1.576; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; TITTEL JN, 2000, GENOME BIOL, V1; Tyers M, 2000, CURR OPIN GENET DEV, V10, P54, DOI 10.1016/S0959-437X(99)00049-0; Vernooy SY, 2000, J CELL BIOL, V150, pF69, DOI 10.1083/jcb.150.2.F69; WILSON, NATURE CELL BIOL; Wing JP, 2002, CURR BIOL, V12, P131, DOI 10.1016/S0960-9822(01)00664-9; Wing JP, 2001, MECH DEVELOP, V102, P193, DOI 10.1016/S0925-4773(01)00316-1; Wojcik C, 1999, CELL MOL LIFE SCI, V56, P908, DOI 10.1007/s000180050483; Xiao W, 1998, NUCLEIC ACIDS RES, V26, P3908, DOI 10.1093/nar/26.17.3908; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; YOO, NATURE CELL BIOL; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X; Zhou L, 1997, P NATL ACAD SCI USA, V94, P5131, DOI 10.1073/pnas.94.10.5131	33	102	103	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUN	2002	4	6					451	456		10.1038/ncb800	http://dx.doi.org/10.1038/ncb800			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	558NN	12021772				2022-12-25	WOS:000175973600016
J	DeVito, JA; Mills, JA; Liu, VG; Agarwal, A; Sizemore, CF; Yao, ZJ; Stoughton, DM; Cappiello, MG; Barbosa, MDFS; Foster, LA; Pompliano, DL				DeVito, JA; Mills, JA; Liu, VG; Agarwal, A; Sizemore, CF; Yao, ZJ; Stoughton, DM; Cappiello, MG; Barbosa, MDFS; Foster, LA; Pompliano, DL			An array of target-specific screening strains for antibacterial discovery	NATURE BIOTECHNOLOGY			English	Article							SITE-SPECIFIC RECOMBINATION; ESCHERICHIA-COLI; ENOLPYRUVYL TRANSFERASE; ANTIBIOTIC-RESISTANCE; GENE; DEFORMYLASE; INHIBITOR; ENZYME	As the global threat of drug- and antibiotic-resistant bacteria continues to rise, new strategies are required to advance the drug discovery process. This work describes the construction of an array of Escherichia coli strains for use in whole-cell screens to identify new antimicrobial compounds. We used the recombination systems from bacteriophages lambda and P1 to engineer each strain in the array for low-level expression of a single, essential gene product, thus making each strain hypersusceptible to specific inhibitors of that gene target. Screening of nine strains from the array in parallel against a large chemical library permitted identification of new inhibitors of bacterial growth. As an example of the target specificity of the approach, compounds identified in the whole-cell screen for MurA inhibitors were also found to block the biochemical function of the target when tested in vitro.	Bristol Myers Squibb Co, Dept Antimicrobial Res, Wilmington, DE 19880 USA; GlaxoSmithKline, Collegeville, PA 19426 USA	Bristol-Myers Squibb; GlaxoSmithKline	Pompliano, DL (corresponding author), Bristol Myers Squibb Co, Dept Antimicrobial Res, Wilmington, DE 19880 USA.			Sizemore, Christine/0000-0002-2807-471X				ABREMSKI K, 1983, CELL, V32, P1301, DOI 10.1016/0092-8674(83)90311-2; Apfel CM, 2001, ANTIMICROB AGENTS CH, V45, P1058, DOI 10.1128/AAC.45.4.1058-1064.2001; Arigoni F, 1998, NAT BIOTECHNOL, V16, P851, DOI 10.1038/nbt0998-851; Bostian KA, 1997, ANTIBACTERIAL THERAP, P61; Chen DZ, 2000, BIOCHEMISTRY-US, V39, P1256, DOI 10.1021/bi992245y; Court D, 1983, LAMBDA, P251; Davies JE, 1997, CIBA F SYMP, V207, P15; ELIOPOULOS GM, 1996, ANTIBIOTICS LAB MED, P330; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Heath RJ, 1998, J BIOL CHEM, V273, P30316, DOI 10.1074/jbc.273.46.30316; HOESS RH, 1982, P NATL ACAD SCI-BIOL, V79, P3398, DOI 10.1073/pnas.79.11.3398; Kim DH, 1996, BIOCHEMISTRY-US, V35, P4923, DOI 10.1021/bi952937w; LOPILATO J, 1986, MOL GEN GENET, V205, P285, DOI 10.1007/BF00430440; MARQUARDT JL, 1992, J BACTERIOL, V174, P5748, DOI 10.1128/JB.174.17.5748-5752.1992; Miller J.H., 1972, EXPT MOL GENETICS; Monroe S, 2000, CURR OPIN MICROBIOL, V3, P496, DOI 10.1016/S1369-5274(00)00129-6; MURPHY KC, 1991, J BACTERIOL, V173, P5808, DOI 10.1128/jb.173.18.5808-5821.1991; Murphy KC, 1998, J BACTERIOL, V180, P2063, DOI 10.1128/JB.180.8.2063-2071.1998; Ochman H, 2000, NATURE, V405, P299, DOI 10.1038/35012500; Pucci M J, 1998, Expert Opin Investig Drugs, V7, P1233, DOI 10.1517/13543784.7.8.1233; PUCCI MJ, 2000, CURR OPIN ANTIINFECT, V2, P123; Read TD, 2001, DRUG DISCOV TODAY, V6, P887, DOI 10.1016/S1359-6446(01)01914-6; ROBERTS JW, 1983, LAMBDA, V2, P123; SAMBROOK J, 2001, MOL CLON LAB MANUAL; Schleif R, 2000, TRENDS GENET, V16, P559, DOI 10.1016/S0168-9525(00)02153-3; Schmid MB, 1998, CURR OPIN CHEM BIOL, V2, P529, DOI 10.1016/S1367-5931(98)80130-0; SILVER LL, 1993, ANTIMICROB AGENTS CH, V37, P377, DOI 10.1128/AAC.37.3.377; STERNBERG N, 1986, J MOL BIOL, V187, P197, DOI 10.1016/0022-2836(86)90228-7; Trias Joaquim, 2001, P499; Tsiodras S, 2001, LANCET, V358, P207, DOI 10.1016/S0140-6736(01)05410-1; Witte W, 2000, INT J ANTIMICROB AG, V16, pS19, DOI 10.1016/S0924-8579(00)00301-0; WOLF H, 1974, P NATL ACAD SCI USA, V71, P4910, DOI 10.1073/pnas.71.12.4910; WONG KK, 1999, RESOLVING ANTIBIOTIC, P1; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597; Zhang YM, 1998, NAT GENET, V20, P123, DOI 10.1038/2417	35	91	99	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2002	20	5					478	483		10.1038/nbt0502-478	http://dx.doi.org/10.1038/nbt0502-478			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	548AE	11981561				2022-12-25	WOS:000175364800030
J	Eggan, K; Rode, A; Jentsch, I; Samuel, C; Hennek, T; Tintrup, H; Zevnik, B; Erwin, J; Loring, J; Jackson-Grusby, L; Speicher, MR; Kuehn, R; Jaenisch, R				Eggan, K; Rode, A; Jentsch, I; Samuel, C; Hennek, T; Tintrup, H; Zevnik, B; Erwin, J; Loring, J; Jackson-Grusby, L; Speicher, MR; Kuehn, R; Jaenisch, R			Male and female mice derived from the same embryonic stem cell clone by tetraploid embryo complementation	NATURE BIOTECHNOLOGY			English	Article							DNA	We have devised a general strategy for producing female mice from 39, X0 embryonic stem (ES) cells derived from male cell lines carrying a targeted mutation of interest. We show that the Y chromosome is lost in 2% of subclones from 40, XY ES cell lines, making the identification of targeted 39, X0 subclones a routine procedure. After gene targeting, male and female mice carrying the mutation can be generated by tetraploid embryo complementation from the 40, XY ES cell line and its 39, X0 derivatives. A single intercross then produces homozygous mutant offspring. Because this strategy avoids outcrossing and therefore segregation of mutant alleles introduced into the ES cells, the time and expense required for production of experimental mutant animals from a targeted ES cell clone are substantially reduced. Our data also indicate that ES cells have inherently unstable karyotypes, but this instability does not interfere with production of adult ES cell-tetraploid mice.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA; Artemis Pharmaceut GmbH, D-51063 Cologne, Germany; Tech Univ Munich, Inst Human Genet, Munich, Germany; GSF Munich, Natl Res Ctr, Inst Human Genet, Munich, Germany	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Jaenisch, R (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	Jaenisch@wi.mit.edu	Speicher, Michael R/B-5362-2013; Loring, Jeanne F/A-1620-2011; Zevnik, Branko/AAB-7853-2020; Eggan, Kevin/P-7119-2018; Kühn, Ralf/U-1278-2017	Speicher, Michael R/0000-0003-0105-955X; Loring, Jeanne F/0000-0001-6226-9767; Zevnik, Branko/0000-0001-7845-9522; Kühn, Ralf/0000-0003-1694-9803; Erwin, Jennifer/0000-0002-6784-9290	NCI NIH HHS [R01-CA84198, 5-R35-CA44339] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044339, R01CA084198] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALSHAWI R, 1991, MOL CELL BIOL, V11, P4207, DOI 10.1128/MCB.11.8.4207; BISHOP CE, 1987, NUCLEIC ACIDS RES, V15, P2959, DOI 10.1093/nar/15.7.2959; BROOK JD, 1983, GENET RES, V41, P85, DOI 10.1017/S001667230002108X; CATTANACH BM, 1962, GENET RES, V3, P487, DOI 10.1017/S0016672300003335; Eggan K, 2001, P NATL ACAD SCI USA, V98, P6209, DOI 10.1073/pnas.101118898; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; Hogan BLM, 1994, MANIPULATING MOUSE E, P253, DOI [10. 1007/ 978- 1- 60327- 019- 9_ 13 PMID: 19504073, DOI 10.1007/978-1-60327-019-9_]; Jentsch I, 2001, CHROMOSOME RES, V9, P211, DOI 10.1023/A:1016696303479; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LAKSO M, 1992, P NATL ACAD SCI USA, V89, P6232, DOI 10.1073/pnas.89.14.6232; LAMAR EE, 1984, CELL, V37, P171, DOI 10.1016/0092-8674(84)90312-X; Liu X, 1997, DEV DYNAM, V209, P85; Marahrens Y, 1997, GENE DEV, V11, P156, DOI 10.1101/gad.11.2.156; Minichiello L, 1999, NEURON, V24, P401, DOI 10.1016/S0896-6273(00)80853-3; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Possemato R, 2002, GENESIS, V32, P184, DOI 10.1002/gene.10039; Rodriguez CI, 2000, NAT GENET, V25, P139, DOI 10.1038/75973; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Wang PJ, 2001, NAT GENET, V27, P422, DOI 10.1038/86927	20	97	117	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2002	20	5					455	459		10.1038/nbt0502-455	http://dx.doi.org/10.1038/nbt0502-455			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	548AE	11981557				2022-12-25	WOS:000175364800026
J	Appay, V; Dunbar, PR; Callan, M; Klenerman, P; Gillespie, GMA; Papagno, L; Ogg, GS; King, A; Lechner, F; Spina, CA; Little, S; Havlir, DV; Richman, DD; Gruener, N; Pape, G; Waters, A; Easterbrook, P; Salio, M; Cerundolo, V; McMichael, AJ; Rowland-Jones, SL				Appay, V; Dunbar, PR; Callan, M; Klenerman, P; Gillespie, GMA; Papagno, L; Ogg, GS; King, A; Lechner, F; Spina, CA; Little, S; Havlir, DV; Richman, DD; Gruener, N; Pape, G; Waters, A; Easterbrook, P; Salio, M; Cerundolo, V; McMichael, AJ; Rowland-Jones, SL			Memory CD8(+) T cells vary in differentiation phenotype in different persistent virus infections	NATURE MEDICINE			English	Article							HEPATITIS-C VIRUS; LYMPHOCYTE RESPONSES; IMMUNE-RESPONSES; HIV-INFECTION; IN-VIVO; EXPRESSION; CYTOMEGALOVIRUS; CYTOKINES; APOPTOSIS; ANTIGEN	The viruses HIV-1, Epstein Barr virus (EBV), cytomegalovirus ( CMV) and hepatitis C virus ( HCV) are characterized by the establishment of lifelong infection in the human host, where their replication is thought to be tightly controlled by virus-specific CD8(+) T cells. Here we present detailed studies of the differentiation phenotype of these cells, which can be separated into three distinct subsets based on expression of the costimulatory receptors CD28 and CD27. Whereas CD8(+) T cells specific for HIV, EBV and HCV exhibit similar characteristics during primary infection, there are significant enrichments at different stages of cellular differentiation in the chronic phase of persistent infection according to the viral specificity, which suggests that distinct memory T-cell populations are established in different virus infections. These findings challenge the current definitions of memory and effector subsets in humans, and suggest that ascribing effector and memory functions to subsets with different differentiation phenotypes is no longer appropriate.	John Radcliffe Hosp, Inst Mol Med, MRC, Human Immunol Unit, Oxford OX3 9DU, England; Peter Medawar Bldg Pathogen Res, Nuffield Dept Med, Oxford, England; Univ Calif San Diego, La Jolla, CA 92093 USA; San Diego VA Res Ctr AIDS & HIV Infect, San Diego, CA USA; Inst Immunol, D-8000 Munich, Germany; Guys Kings & St Thomas Sch Med, Dept HIV GUM, London, England; Weston Educ Ctr, London, England	University of Oxford; University of Oxford; University of California System; University of California San Diego; University of London; King's College London	Appay, V (corresponding author), John Radcliffe Hosp, Inst Mol Med, MRC, Human Immunol Unit, Oxford OX3 9DU, England.		Little, Susan/AAA-6116-2019; Easterbrook, Philippa J/A-3937-2009; Appay, Victor/M-4830-2017; Dunbar, Rod/C-2570-2012; Appay, Victor/AAM-7701-2021	Dunbar, Rod/0000-0001-9626-2600; Cerundolo, Vincenzo/0000-0003-0040-3793; Ogg, Graham/0000-0002-3097-045X; Easterbrook, Philippa/0000-0002-2603-5418; Appay, Victor/0000-0001-5434-3963; klenerman, paul/0000-0003-4307-9161; Salio, Mariolina/0000-0002-4821-3801	Medical Research Council [G116/121] Funding Source: Medline; MRC [G116/121] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; Altman JD, 1998, SCIENCE, V280, P1821; ANDREWS DM, 2001, NATURE IMMUNOL, V22, P22; Appay V, 2000, J EXP MED, V192, P63, DOI 10.1084/jem.192.1.63; Baars PA, 2000, J IMMUNOL, V165, P1910, DOI 10.4049/jimmunol.165.4.1910; Bevan MJ, 2001, NAT IMMUNOL, V2, P381, DOI 10.1038/87676; Borthwick NJ, 2000, INT IMMUNOL, V12, P1005, DOI 10.1093/intimm/12.7.1005; Bunce M, 1995, TISSUE ANTIGENS, V46, P355, DOI 10.1111/j.1399-0039.1995.tb03127.x; Callan MFC, 2000, J CLIN INVEST, V106, P1251, DOI 10.1172/JCI10590; Callan MFC, 1996, NAT MED, V2, P906, DOI 10.1038/nm0896-906; Campbell JJ, 1998, J CELL BIOL, V141, P1053, DOI 10.1083/jcb.141.4.1053; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; Champagne P, 2001, NATURE, V410, P106, DOI 10.1038/35065118; Chen G, 2001, BLOOD, V98, P156, DOI 10.1182/blood.V98.1.156; De Rosa SC, 2001, NAT MED, V7, P245, DOI 10.1038/84701; Doherty PC, 2000, ANNU REV IMMUNOL, V18, P561, DOI 10.1146/annurev.immunol.18.1.561; Easterbrook PJ, 1999, J INFECTION, V38, P71, DOI 10.1016/S0163-4453(99)90071-3; EFFROS RB, 1996, AIDS, V10, P17; FERBAS J, 1995, J INFECT DIS, V172, P329, DOI 10.1093/infdis/172.2.329; Gillespie GMA, 2000, J VIROL, V74, P8140, DOI 10.1128/JVI.74.17.8140-8150.2000; Globerson A, 2000, IMMUNOL TODAY, V21, P515, DOI 10.1016/S0167-5699(00)01714-X; Grayson JM, 2000, J IMMUNOL, V164, P3950, DOI 10.4049/jimmunol.164.8.3950; Hamann D, 1997, J EXP MED, V186, P1407, DOI 10.1084/jem.186.9.1407; Hamann D, 1999, INT IMMUNOL, V11, P1027, DOI 10.1093/intimm/11.7.1027; Hendriks J, 2000, NAT IMMUNOL, V1, P433, DOI 10.1038/80877; Hislop AD, 2001, J IMMUNOL, V167, P2019, DOI 10.4049/jimmunol.167.4.2019; Homann D, 2001, NAT MED, V7, P913, DOI 10.1038/90950; Hu H, 2001, NAT IMMUNOL, V2, P705, DOI 10.1038/90643; Kalams SA, 1998, J EXP MED, V188, P2199, DOI 10.1084/jem.188.12.2199; Kostense S, 2001, EUR J IMMUNOL, V31, P677, DOI 10.1002/1521-4141(200103)31:3<677::AID-IMMU677>3.0.CO;2-M; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Lechner F, 2000, EUR J IMMUNOL, V30, P2479, DOI 10.1002/1521-4141(200009)30:9<2479::AID-IMMU2479>3.0.CO;2-B; Lechner F, 2000, J EXP MED, V191, P1499, DOI 10.1084/jem.191.9.1499; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; Medley QG, 1996, P NATL ACAD SCI USA, V93, P685, DOI 10.1073/pnas.93.2.685; Mueller YM, 2001, IMMUNITY, V15, P871, DOI 10.1016/S1074-7613(01)00246-1; Posnett DN, 1999, INT IMMUNOL, V11, P229, DOI 10.1093/intimm/11.2.229; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Roos MTL, 2000, J INFECT DIS, V182, P451, DOI 10.1086/315737; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Wills MR, 1996, J VIROL, V70, P7569, DOI 10.1128/JVI.70.11.7569-7579.1996	42	1246	1297	1	61	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2002	8	4					379	385		10.1038/nm0402-379	http://dx.doi.org/10.1038/nm0402-379			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	536ML	11927944				2022-12-25	WOS:000174704800030
J	Di, A; Krupa, B; Bindokas, VP; Chen, YM; Brown, ME; Palfrey, HC; Naren, AP; Kirk, KL; Nelson, DJ				Di, A; Krupa, B; Bindokas, VP; Chen, YM; Brown, ME; Palfrey, HC; Naren, AP; Kirk, KL; Nelson, DJ			Quantal release of free radicals during exocytosis of phagosomes	NATURE CELL BIOLOGY			English	Article							NADPH OXIDASE; SECRETION; CELLS; PHAGOCYTOSIS; MACROPHAGES; FIBROBLASTS; LYSOSOMES; IDENTIFICATION; LOCALIZATION; NEUTROPHILS	Secretion of lysosomes and related organelles is important for immune system function. High-resolution membrane capacitance techniques were used to track changes in membrane area in single phagocytes during opsonized polystyrene bead uptake and release. Secretagogue stimulation of cells preloaded with beads resulted in immediate vesicle discharge, visualized as step increases in capacitance. The size of the increases were consistent with phagosome size. This hypothesis was confirmed by direct observation of dye release from bead-containing phagosomes after secretagogue stimulation. Capacitance recordings of exocytosis were correlated with quantal free radical release, as determined by amperometry. Thus, phagosomes undergo regulated secretion in macrophages, one function of which may be to deliver sequestered free radicals to the extracellular space.	Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Univ Alabama, Gregory Fleming James Cyst Fibrosis Res Ctr, Dept Physiol & Biophys, Birmingham, AL 35294 USA	University of Chicago; University of Chicago; University of Alabama System; University of Alabama Birmingham	Nelson, DJ (corresponding author), Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK042086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036823] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42086] Funding Source: Medline; NIGMS NIH HHS [R01 GM36823] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrews NW, 2000, TRENDS CELL BIOL, V10, P316, DOI 10.1016/S0962-8924(00)01794-3; Bajjalieh S, 2001, TRENDS NEUROSCI, V24, P678, DOI 10.1016/S0166-2236(00)01965-2; Bajno L, 2000, J CELL BIOL, V149, P697, DOI 10.1083/jcb.149.3.697; BRECKENRIDGE LJ, 1987, P NATL ACAD SCI USA, V84, P1945, DOI 10.1073/pnas.84.7.1945; Campos-Toimil M, 2000, J PHYSIOL-LONDON, V528, P317, DOI 10.1111/j.1469-7793.2000.00317.x; Chen D, 2000, BLOOD, V95, P921, DOI 10.1182/blood.V95.3.921.003k17_921_929; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; DeLeo FR, 1999, J IMMUNOL, V163, P6732; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; Delon J, 2000, CURR BIOL, V10, pR214, DOI 10.1016/S0960-9822(00)00392-4; Delon J, 2000, CURR BIOL, V10, pR923, DOI 10.1016/S0960-9822(00)00870-8; Desjardins M, 1997, J CELL SCI, V110, P2303; DETOLEDO GA, 1990, J GEN PHYSIOL, V95, P397, DOI 10.1085/jgp.95.3.397; Di AK, 2001, J BIOL CHEM, V276, P37124, DOI 10.1074/jbc.M105038200; Diakonova M, 1997, J CELL SCI, V110, P1199; Fujiwara T, 2001, BBA-MOL CELL RES, V1539, P225, DOI 10.1016/S0167-4889(01)00109-4; Gillis KD, 2000, PFLUG ARCH EUR J PHY, V439, P655, DOI 10.1007/s004240050990; Hackam DJ, 1998, P NATL ACAD SCI USA, V95, P11691, DOI 10.1073/pnas.95.20.11691; Hackam DJ, 1996, J IMMUNOL, V156, P4377; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; Hansen NJ, 1999, J BIOL CHEM, V274, P22871, DOI 10.1074/jbc.274.32.22871; HIRANO T, 1991, J CLIN INVEST, V87, P865, DOI 10.1172/JCI115091; Holevinsky KO, 1998, BIOPHYS J, V75, P2577, DOI 10.1016/S0006-3495(98)77703-3; HUBER LA, 1994, FEBS LETT, V347, P273, DOI 10.1016/0014-5793(94)00562-1; MARKLUND S, 1976, J BIOL CHEM, V251, P7504; Martin F, 1996, BIOCHEM J, V320, P201, DOI 10.1042/bj3200201; Martinez I, 2000, J CELL BIOL, V148, P1141, DOI 10.1083/jcb.148.6.1141; Naren AP, 1998, P NATL ACAD SCI USA, V95, P10972, DOI 10.1073/pnas.95.18.10972; NEHER E, 1988, J PHYSIOL-LONDON, V395, P195; NELSON DJ, 1985, J CLIN INVEST, V76, P500, DOI 10.1172/JCI111999; Ninomiya Y, 1996, J BIOL CHEM, V271, P17751, DOI 10.1074/jbc.271.30.17751; Privat C, 1999, FREE RADICAL BIO MED, V27, P554, DOI 10.1016/S0891-5849(99)00097-0; Reddy A, 2001, CELL, V106, P157, DOI 10.1016/S0092-8674(01)00421-4; Rodriguez A, 1997, J CELL BIOL, V137, P93, DOI 10.1083/jcb.137.1.93; Segura F, 2000, J NEUROSCI METH, V103, P151, DOI 10.1016/S0165-0270(00)00309-5; SILVERSTEIN RL, 1992, BLOOD, V80, P1470; Stinchcombe JC, 2001, IMMUNITY, V15, P751, DOI 10.1016/S1074-7613(01)00234-5; Suzaki E, 1997, CELL MOTIL CYTOSKEL, V38, P215; Tapper H, 1996, J LEUKOCYTE BIOL, V59, P613, DOI 10.1002/jlb.59.5.613; Tjelle TE, 1998, J CELL SCI, V111, P141; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7	43	31	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	APR	2002	4	4					279	285		10.1038/ncb771	http://dx.doi.org/10.1038/ncb771			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	541PY	11901421				2022-12-25	WOS:000174994000015
J	Schweitzer, B; Roberts, S; Grimwade, B; Shao, WP; Wang, MJ; Fu, Q; Shu, QP; Laroche, I; Zhou, ZM; Tchernev, VT; Christiansen, J; Velleca, M; Kingsmore, SF				Schweitzer, B; Roberts, S; Grimwade, B; Shao, WP; Wang, MJ; Fu, Q; Shu, QP; Laroche, I; Zhou, ZM; Tchernev, VT; Christiansen, J; Velleca, M; Kingsmore, SF			Multiplexed protein profiling on microarrays by rolling-circle amplification	NATURE BIOTECHNOLOGY			English	Article							DENDRITIC CELL; CHEMOKINE; RECEPTOR; EXPRESSION; T(H)2; LYMPHOCYTES; ACTIVATION; ANTIBODIES; MONOCYTES; CYTOKINES	Fluorescent-sandwich immunoassays on microarrays hold appeal for proteomics studies, because equipment and antibodies are readily available, and assays are simple, scalable, and reproducible. The achievement of adequate sensitivity and specificity, however, requires a general method of immunoassay amplification. We describe coupling of isothermal rolling-circle amplification (RCA) to universal antibodies for this purpose. A total of 75 cytokines were measured simultaneously on glass arrays with signal amplification by RCA with high specificity, femtomolar sensitivity, 3 log quantitative range, and economy of sample consumption. A 51-feature RCA cytokine glass array was used to measure secretion from human dendritic cells (DCs) induced by lipopolysaccharide (LPS) or tumor necrosis factor-alpha (TNF-alpha). As expected, LPS induced rapid secretion of inflammatory cytokines such as macrophage inflammatory protein (MIP)-1beta, interleukin (IL)-8, and interferon-inducible protein (IP)-10. We found that eotaxin-2 and I-309 were induced by LPS; in addition, macrophage-derived chemokine (MDC), thymus and activation-regulated chemokine (TARC), soluble interleukin 6 receptor (sIL-6R), and soluble tumor necrosis factor receptor I (sTNF-RI) were induced by TNF-alpha treatment. Because microarrays can accommodate 1,000 sandwich immunoassays of this type, a relatively small number of RCA microarrays seem to offer a tractable approach for proteomic surveys.	Cellular Genom Inc, Branford, CT 06405 USA; Mol Staging Inc, New Haven, CT 06511 USA		Kingsmore, SF (corresponding author), Protometrix Inc, 66 High St, Guilford, CT 06437 USA.	stephenk@molecularstaging.com		kingsmore, stephen/0000-0002-3758-4631; Kingsmore, Stephen/0000-0001-7180-2527	NIAID NIH HHS [P01 AI039824-050002, P01 AI039824] Funding Source: Medline; NIAMS NIH HHS [R43 AR049106-01] Funding Source: Medline; NICHD NIH HHS [U19 HD077693] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U19HD077693] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI039824] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R43AR049106] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Andrew DP, 1998, J IMMUNOL, V161, P5027; Baba M, 1997, J BIOL CHEM, V272, P14893, DOI 10.1074/jbc.272.23.14893; Bussow K, 1998, NUCLEIC ACIDS RES, V26, P5007, DOI 10.1093/nar/26.21.5007; Cavani A, 1998, J INVEST DERMATOL, V111, P621, DOI 10.1046/j.1523-1747.1998.00334.x; Chomarat P, 2000, NAT IMMUNOL, V1, P510, DOI 10.1038/82763; de Wildt RMT, 2000, NAT BIOTECHNOL, V18, P989, DOI 10.1038/79494; Dean FB, 2001, GENOME RES, V11, P1095, DOI 10.1101/gr.180501; Emili AQ, 2000, NAT BIOTECHNOL, V18, P393, DOI 10.1038/74442; Figeys D, 1999, CURR OPIN MOL THER, V1, P685; Foster JR, 2001, INT J EXP PATHOL, V82, P171, DOI 10.1046/j.1365-2613.2001.00192.x; Gatti E, 2000, J IMMUNOL, V164, P3600, DOI 10.4049/jimmunol.164.7.3600; Ge H, 2000, Nucleic Acids Res, V28, pe3, DOI 10.1093/nar/28.2.e3; Gesser B, 1996, J LEUKOCYTE BIOL, V59, P407, DOI 10.1002/jlb.59.3.407; Gu L, 2000, NATURE, V404, P407, DOI 10.1038/35006097; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Haab BB, 2001, GENOME BIOL, V2; Hanes J, 2000, NAT BIOTECHNOL, V18, P1287, DOI 10.1038/82407; Harford J. B., 1997, POSTTRANSCRIPTIONAL; Holt LJ, 2000, CURR OPIN BIOTECH, V11, P445, DOI 10.1016/S0958-1669(00)00133-6; Imai T, 1999, INT IMMUNOL, V11, P81, DOI 10.1093/intimm/11.1.81; Imai T, 1998, J BIOL CHEM, V273, P1764, DOI 10.1074/jbc.273.3.1764; Karpus WJ, 1997, J LEUKOCYTE BIOL, V62, P681, DOI 10.1002/jlb.62.5.681; Kawai T, 1999, J IMMUNOL, V163, P3269; Langenkamp A, 2000, NAT IMMUNOL, V1, P311, DOI 10.1038/79758; Lillard JW, 2001, J IMMUNOL, V166, P162, DOI 10.4049/jimmunol.166.1.162; Liu YJ, 2001, CELL, V106, P259, DOI 10.1016/S0092-8674(01)00456-1; Lizardi PM, 1998, NAT GENET, V19, P225, DOI 10.1038/898; Loetscher P, 2001, J BIOL CHEM, V276, P2986, DOI 10.1074/jbc.M005652200; Lohse P A, 2001, Curr Opin Drug Discov Devel, V4, P198; Lueking A, 1999, ANAL BIOCHEM, V270, P103, DOI 10.1006/abio.1999.4063; MacBeath G, 2000, SCIENCE, V289, P1760; MATSUSHIMA K, 1989, J EXP MED, V169, P1485, DOI 10.1084/jem.169.4.1485; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Mendoza LG, 1999, BIOTECHNIQUES, V27, P778, DOI 10.2144/99274rr01; Moody MD, 2001, BIOTECHNIQUES, V31, P186, DOI 10.2144/01311dd03; Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219; Moser M, 2000, NAT IMMUNOL, V1, P199, DOI 10.1038/79734; Mullenix MC, 2001, CLIN CHEM, V47, P1926; Naaby-Hansen S, 2001, TRENDS PHARMACOL SCI, V22, P376, DOI 10.1016/S0165-6147(00)01663-1; Nallur G, 2001, NUCLEIC ACIDS RES, V29, part. no., DOI 10.1093/nar/29.23.e118; Nord K, 2000, J BIOTECHNOL, V80, P45, DOI 10.1016/S0168-1656(00)00232-7; Pulendran B, 2001, SCIENCE, V293, P253, DOI 10.1126/science.1062060; Sallusto F, 1999, EUR J IMMUNOL, V29, P1617, DOI 10.1002/(SICI)1521-4141(199905)29:05<1617::AID-IMMU1617>3.0.CO;2-3; Sallusto F, 2000, IMMUNOL REV, V177, P134, DOI 10.1034/j.1600-065X.2000.17717.x; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Schweitzer B, 2000, P NATL ACAD SCI USA, V97, P10113, DOI 10.1073/pnas.170237197; Sebastiani S, 2001, J IMMUNOL, V166, P996, DOI 10.4049/jimmunol.166.2.996; THIJS LG, 1995, INTENS CARE MED, V21, pS258, DOI 10.1007/BF01740764; Wiese R, 2001, CLIN CHEM, V47, P1451; Wiltshire S, 2000, CLIN CHEM, V46, P1990; Zhu H, 2001, SCIENCE, V293, P2101, DOI 10.1126/science.1062191; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	52	459	534	2	192	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2002	20	4					359	365		10.1038/nbt0402-359	http://dx.doi.org/10.1038/nbt0402-359			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	536BY	11923841	Green Accepted			2022-12-25	WOS:000174681900022
J	Wang, DN; Liu, SY; Trummer, BJ; Deng, C; Wang, AL				Wang, DN; Liu, SY; Trummer, BJ; Deng, C; Wang, AL			Carbohydrate microarrays for the recognition of cross-reactive molecular markers of microbes and host cells	NATURE BIOTECHNOLOGY			English	Article							SPERM-EGG INTERACTION; MONOCLONAL-ANTIBODIES; ISOMALTOSYL OLIGOSACCHARIDES; CAPSULAR POLYSACCHARIDE; VARIABLE REGION; SPECIFICITY; BINDING; MOUSE; ALPHA(1->6)DEXTRAN; DETERMINANTS	We describe here the development of a carbohydrate-based microarray to extend the scope of biomedical research on carbohydrate-mediated molecular recognition and anti-infection responses. We have demonstrated that microbial polysaccharides can be immobilized on a surface-modified glass slide without chemical conjugation. With this procedure, a large repertoire of microbial antigens (similar to20,000 spots) can be patterned on a single micro-glass slide, reaching the capacity to include most common pathogens. Glycoconjugates of different structural characteristics are shown here to be applicable for microarray fabrication, extending the repertoires of diversity and complexity of carbohydrate microarrays. The printed microarrays can be air-dried and stably stored at room temperature for long periods of time. In addition, the system is highly sensitive, allowing simultaneous detection of a broad spectrum of antibody specificities with as little as a few microliters of serum specimen. Finally, the potential of carbohydrate microarrays is demonstrated by the discovery of previously undescribed cellular markers, Dex-Ids.	Columbia Univ Coll Phys & Surg, Columbia Genome Ctr, Funct Genom Div, New York, NY 10032 USA	Columbia University	Wang, DN (corresponding author), Columbia Univ Coll Phys & Surg, Columbia Genome Ctr, Funct Genom Div, 1150 St Nicholas Ave, New York, NY 10032 USA.	dw8@columbia.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI045326] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 45326] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI M, 1988, J EXP MED, V167, P323, DOI 10.1084/jem.167.2.323; Avrameas S, 1988, Int Rev Immunol, V3, P1, DOI 10.3109/08830188809051179; CHEN HT, 1987, MOL IMMUNOL, V24, P333; CISAR J, 1975, J EXP MED, V142, P435, DOI 10.1084/jem.142.2.435; Crocker PR, 1996, CURR OPIN STRUC BIOL, V6, P679, DOI 10.1016/S0959-440X(96)80036-4; FEIZI T, 1982, ADV EXP MED BIOL, V152, P167; Feizi T, 2000, IMMUNOL REV, V173, P79, DOI 10.1034/j.1600-065X.2000.917310.x; Feizi T, 1996, AM J RESP CRIT CARE, V154, pS133, DOI 10.1164/ajrccm/154.4_Pt_2.S133; Feizi T, 2000, GLYCOCONJUGATE J, V17, P553, DOI 10.1023/A:1011022509500; FINNE J, 1983, LANCET, V2, P355; Focarelli R, 2001, CELLS TISSUES ORGANS, V168, P76, DOI 10.1159/000016808; HAKOMORI S, 1985, CANCER RES, V45, P2405; HERZENBERG LA, 1989, CELL, V59, P953, DOI 10.1016/0092-8674(89)90748-4; HOWARD JG, 1987, BETTER CARBOHYDRATE, P221; JEANES A, 1986, MOL IMMUNOL, V23, P999, DOI 10.1016/0161-5890(86)90131-8; KABAT EA, 1980, J EXP MED, V152, P979, DOI 10.1084/jem.152.4.979; KABAT EA, 1984, CARBOHYD RES, V130, P289, DOI 10.1016/0008-6215(84)85286-6; KABAT EA, 1988, J EXP MED, V168, P699, DOI 10.1084/jem.168.2.699; KARLSSON KA, 1992, APMIS, V100, P71; LAI E, 1985, MOL IMMUNOL, V22, P1021, DOI 10.1016/0161-5890(85)90105-1; Leteux C, 2000, J EXP MED, V191, P1117, DOI 10.1084/jem.191.7.1117; LIAO J, 1995, INFECT IMMUN, V63, P4429, DOI 10.1128/IAI.63.11.4429-4432.1995; MANDRELL RE, 1992, INFECT IMMUN, V60, P1322, DOI 10.1128/IAI.60.4.1322-1328.1992; MATSUDA T, 1989, J IMMUNOL, V142, P863; NAKAISHI H, 1988, CANCER RES, V48, P1753; OSHANNESSY DJ, 1984, IMMUNOL LETT, V8, P273, DOI 10.1016/0165-2478(84)90008-7; Rosati F, 2000, INT J DEV BIOL, V44, P609; Schachter H, 1999, BBA-MOL BASIS DIS, V1455, P179, DOI 10.1016/S0925-4439(99)00054-X; SELL S, 1990, HUM PATHOL, V21, P1003, DOI 10.1016/0046-8177(90)90250-9; SHARON J, 1982, MOL IMMUNOL, V19, P389, DOI 10.1016/0161-5890(82)90204-8; Spiro RG, 2000, J BIOL CHEM, V275, P35657, DOI 10.1074/jbc.R000022200; THOMPSON KM, 1992, IMMUNOLOGY, V76, P146; Thorpe SJ, 1998, IMMUNOLOGY, V93, P129; WANG D, 1991, MOL IMMUNOL, V28, P1387, DOI 10.1016/0161-5890(91)90041-H; Wang D, 1996, STRUCTURE ANTIGENS, P247; WANG DN, 1990, J IMMUNOL, V145, P3002; WANG DN, 1994, P NATL ACAD SCI USA, V91, P2502, DOI 10.1073/pnas.91.7.2502; Zuber C, 2000, MOL BIOL CELL, V11, P4227, DOI 10.1091/mbc.11.12.4227	38	452	506	2	81	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2002	20	3					275	281		10.1038/nbt0302-275	http://dx.doi.org/10.1038/nbt0302-275			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	526RE	11875429				2022-12-25	WOS:000174142800046
J	Ward, CJ; Hogan, MC; Rossetti, S; Walker, D; Sneddon, T; Wang, XF; Kubly, V; Cunningham, JM; Bacallao, R; Ishibashi, M; Milliner, DS; Torres, VE; Harris, PC				Ward, CJ; Hogan, MC; Rossetti, S; Walker, D; Sneddon, T; Wang, XF; Kubly, V; Cunningham, JM; Bacallao, R; Ishibashi, M; Milliner, DS; Torres, VE; Harris, PC			The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein	NATURE GENETICS			English	Article							PRENATAL-DIAGNOSIS; PHYSICAL MAP; FAMILY; ARPKD; PKHD1; IDENTIFICATION; TRANSMEMBRANE; 6P21.1-P12; PREDICTION; EXCLUSION	Autosomal recessive polycystic kidney disease (ARPKD) is characterized by dilation of collecting ducts and by biliary dysgenesis and is an important cause of renal- and liver-related morbidity and mortality. Genetic analysis of a rat with recessive polycystic kidney disease revealed an orthologous relationship between the rat locus and the ARPKD region in humans; a candidate gene was identified. A mutation was characterized in the rat and screening the 66 coding exons of the human ortholog (PKHD1) in 14 probands with ARPKD revealed 6 truncating and 12 missense mutations; 8 of the affected individuals were compound heterozygotes. The PKHD1 transcript, approximately 16 kb long, is expressed in adult and fetal kidney, liver and pancreas and is predicted to encode a large novel protein, fibrocystin, with multiple copies of a domain shared with plexins and transcription factors. Fibrocystin may be a receptor protein that acts in collecting-duct and biliary differentiation.	Mayo Clin, Div Nephrol, Rochester, MN 55905 USA; Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA; Indiana Univ, Med Ctr, Dept Med, Indianapolis, IN 46202 USA; Azabu Univ, Sagamihara, Kanagawa, Japan	Mayo Clinic; Mayo Clinic; Indiana University System; Indiana University-Purdue University Indianapolis; Azabu University		harris.peter@mayo.edu		Sneddon, Tam Paterson/0000-0003-1137-8992; Torres, Vicente/0000-0003-2008-1576				Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; BERNSTEIN J, 1992, PEDIATRIC KIDNEY DIS, V2, P1139; BLICKMAN JG, 1995, AM J ROENTGENOL, V164, P1247, DOI 10.2214/ajr.164.5.7717240; BLYTH H, 1971, J MED GENET, V8, P257, DOI 10.1136/jmg.8.3.257; Bork P, 1999, TRENDS BIOCHEM SCI, V24, P261, DOI 10.1016/S0968-0004(99)01416-4; CALVET JP, 1993, KIDNEY INT, V43, P101, DOI 10.1038/ki.1993.17; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; COLE BR, 1987, J PEDIATR-US, V111, P693, DOI 10.1016/S0022-3476(87)80244-5; DEGET F, 1995, CLIN GENET, V47, P248, DOI 10.1111/j.1399-0004.1995.tb04305.x; DELL KMM, 2001, GENEREVIEWS GENETIC; DESMET VJ, 1992, HEPATOLOGY, V16, P1069, DOI 10.1002/hep.1840160434; GUAYWOODFORD LM, 1995, AM J HUM GENET, V56, P1101; GUAYWOODFORD LM, 1996, POLYCYSTIC KIDNEY DI, P237; HARRIS PC, 1991, LANCET, V338, P1484, DOI 10.1016/0140-6736(91)92300-Q; Hofmann Y, 2000, EUR J HUM GENET, V8, P163, DOI 10.1038/sj.ejhg.5200426; Jorgensen M J, 1977, Acta Pathol Microbiol Scand Suppl, P1; KAARIAINEN H, 1988, PEDIATR NEPHROL, V2, P296; KAPLAN BS, 1989, PEDIATR NEPHROL, V3, P43, DOI 10.1007/BF00859625; KAPLAN BS, 1988, AM J MED GENET, V29, P639, DOI 10.1002/ajmg.1320290323; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Lager DJ, 2001, KIDNEY INT, V59, P126, DOI 10.1046/j.1523-1755.2001.00473.x; Lens XM, 1997, GENOMICS, V41, P463, DOI 10.1006/geno.1997.4671; MACKAY K, 1988, KIDNEY INT, V33, P677, DOI 10.1038/ki.1988.53; McDonald R, 1999, PEDIAT NEPHROLOGY, P459; MCDONALD RA, 1996, POLYCYSTIC KIDNEY DI, P63; MOYER JH, 1994, SCIENCE, V264, P1329, DOI 10.1126/science.8191288; Mucher G, 1998, GENOMICS, V48, P40, DOI 10.1006/geno.1997.5145; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Onuchic LF, 1999, MAMM GENOME, V10, P1175, DOI 10.1007/s003359901186; OSATHANONDH V, 1964, ARCH PATHOL, V77, P466; Park JH, 1999, GENOMICS, V57, P249, DOI 10.1006/geno.1999.5777; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; ROSSETTI S, 2002, IN PRESS KIDNEY INT; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; Roy S, 1997, PEDIATR NEPHROL, V11, P302, DOI 10.1007/s004670050281; Sanzen T, 2001, AM J PATHOL, V158, P1605, DOI 10.1016/S0002-9440(10)64116-8; Scott DA, 2000, GENE, V246, P265, DOI 10.1016/S0378-1119(00)00090-1; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; UHARI M, 1979, ACTA PAEDIATR SCAND, V68, P443, DOI 10.1111/j.1651-2227.1979.tb05035.x; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; Xiao WZ, 2001, HUM MUTAT, V17, P439, DOI 10.1002/humu.1130.abs; Yeh RF, 2001, GENOME RES, V11, P803, DOI 10.1101/gr.175701; Zerres K, 1996, ACTA PAEDIATR, V85, P437, DOI 10.1111/j.1651-2227.1996.tb14056.x; Zerres K, 1998, J MOL MED, V76, P303, DOI 10.1007/s001090050221; ZERRES K, 1994, NAT GENET, V7, P429, DOI 10.1038/ng0794-429; ZERRES K, 1984, HUM GENET, V68, P104, DOI 10.1007/BF00279301; Zerres K, 1998, AM J MED GENET, V76, P137, DOI 10.1002/(SICI)1096-8628(19980305)76:2<137::AID-AJMG6>3.0.CO;2-Q	50	516	552	2	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAR	2002	30	3					259	269		10.1038/ng833	http://dx.doi.org/10.1038/ng833			11	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	526YP	11919560				2022-12-25	WOS:000174157600009
J	Sun, XY; Hung, K; Wu, L; Sidransky, D; Guo, BB				Sun, XY; Hung, K; Wu, L; Sidransky, D; Guo, BB			Detection of tumor mutations in the presence of excess amounts of normal DNA	NATURE BIOTECHNOLOGY			English	Article							ONCOGENE MUTATIONS; COLORECTAL-CANCER; GENE-MUTATIONS; LUNG-CANCER; P53 GENE; ASSAY	Mutations are important markers in the early detection of cancer(1-3). Clinical specimens such as bodily fluid samples often contain a small percentage of mutated cells in a large background of normal cells. Thus, assays to detect mutations leading to cancer need to be highly sensitive and specific(4-8). In addition, they should be possible to carry out in an automated and high-throughput manner to allow large-scale screening(4-8). Here we describe a screening method, termed PPEM (PNA-directed PCR, primer extension, MALDI-TOF), that addresses these needs more effectively than do existing methods. DNA samples are first amplified using peptide nucleic acid (PNA)-directed PCR clamping reactions in which mutated DNA is preferentially enriched. The PCR-amplified DNA fragments are then sequenced through primer extension to generate diagnostic products. Finally, mutations are identified using matrix-assisted laser-desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry. This method can detect as few as 3 copies of mutant alleles in the presence of a 10,000-fold excess of normal alleles in a robust and specific manner. In addition, the method can be adapted for simultaneous detection of multiple mutations and is amenable to high-throughput automation.	Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA; Johns Hopkins Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21287 USA	University System of Ohio; Cleveland State University; Johns Hopkins University; Johns Hopkins Medicine	Guo, BB (corresponding author), Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA.				NCI NIH HHS [CA81653] Funding Source: Medline; NHGRI NIH HHS [HG01815] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R33CA081653, R21CA081653] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R29HG001815] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Ahlquist DA, 2000, GASTROENTEROLOGY, V119, P1219, DOI 10.1053/gast.2000.19580; Ahrendt SA, 1999, JNCI-J NATL CANCER I, V91, P332, DOI 10.1093/jnci/91.4.332; Ahrendt SA, 1999, P NATL ACAD SCI USA, V96, P7382, DOI 10.1073/pnas.96.13.7382; Behn M, 1998, NUCLEIC ACIDS RES, V26, P1356, DOI 10.1093/nar/26.5.1356; Behn M, 2000, J PATHOL, V190, P69; Braun A, 1997, CLIN CHEM, V43, P1151; BRENNAN JA, 1995, NEW ENGL J MED, V332, P712, DOI 10.1056/NEJM199503163321104; Dong SM, 2001, J NATL CANCER I, V93, P858, DOI 10.1093/jnci/93.11.858; Hirsch FR, 2001, CLIN CANCER RES, V7, P5; JACOBSON DR, 1994, ONCOGENE, V9, P553; Khanna M, 1999, ONCOGENE, V18, P27, DOI 10.1038/sj.onc.1202291; Lehman TA, 1996, ANAL BIOCHEM, V239, P153, DOI 10.1006/abio.1996.0310; Nollau P, 1997, CLIN CHEM, V43, P1114; Nordhoff E, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.20.e86; ORUM H, 1993, NUCLEIC ACIDS RES, V21, P5332, DOI 10.1093/nar/21.23.5332; Potter JD, 1999, JNCI-J NATL CANCER I, V91, P916, DOI 10.1093/jnci/91.11.916; Shuber AP, 1995, GENOME RES, V5, P488, DOI 10.1101/gr.5.5.488; Sidransky D, 1997, SCIENCE, V278, P1054, DOI 10.1126/science.278.5340.1054; Srivastava S, 2001, CLIN CANCER RES, V7, P1118; Sun XY, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.12.e68	20	48	67	0	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2002	20	2					186	189		10.1038/nbt0202-186	http://dx.doi.org/10.1038/nbt0202-186			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	517FT	11821866				2022-12-25	WOS:000173601000029
J	Kumamoto, T; Huang, EK; Paek, HJ; Morita, A; Matsue, H; Valentini, RF; Takashima, A				Kumamoto, T; Huang, EK; Paek, HJ; Morita, A; Matsue, H; Valentini, RF; Takashima, A			Induction of tumor-specific protective immunity by in situ Langerhans cell vaccine	NATURE BIOTECHNOLOGY			English	Article							INFLAMMATORY PROTEIN 3-ALPHA; PULSED DENDRITIC CELLS; THERAPEUTIC ANTITUMOR IMMUNITY; CYTOTOXIC T-LYMPHOCYTES; IN-VITRO; CHEMOKINE RECEPTORS; APOPTOTIC CELLS; CANCER VACCINES; MELANOMA-CELLS; GROWTH-FACTOR	Although anti-tumor immunity is inducible by dendritic cell (DC)-based vaccines, time- and cost-consuming "customizing" processes required for ex vivo DC manipulation have hindered broader clinical applications of this concept. Epidermal Langerhans cells (LCs) migrate to draining lymph nodes and undergo maturational changes on exposure to reactive haptens. We entrapped these migratory LCs by subcutaneous implantation of ethylene-vinyl-acetate (EVA) polymer rods releasing macrophage inflammatory protein (MIP)-3 beta (to create an artificial gradient of an LC-attracting chemokine) and topical application of hapten (to trigger LC emigration from epidermis). The entrapped LCs were antigen-loaded in situ by co-Implantation of the second EVA rods releasing tumor-associated antigens (TAAs). Potent cytotoxic T-lymphocyte (CTL) activities and protective immunity against tumors were induced efficiently with each of three tested TAA preparations. Thus, tumor-specific immunity is inducible by the combination of LC entrapment and in situ LC loading technologies. Our new vaccine strategy requires no ex vivo DC manipulation and thus may provide time and cost savings.	Univ Texas, SW Med Ctr, Dept Dermatol, Dallas, TX 75390 USA; Brown Univ, Dept Mol Pharmacol Physiol & Biotechnol, Artificial Organs Biomat & Cellular Technol Progr, Providence, RI 02912 USA; Nagoya City Univ, Sch Med, Dept Dermatol, Nagoya, Aichi 467, Japan	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Brown University; Nagoya City University	Takashima, A (corresponding author), Univ Texas, SW Med Ctr, Dept Dermatol, Dallas, TX 75390 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043777, R01AR035068] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI43262] Funding Source: Medline; NIAMS NIH HHS [R01-AR43777, R01-AR35068] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Albert ML, 1998, J EXP MED, V188, P1359, DOI 10.1084/jem.188.7.1359; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Berard F, 2000, J EXP MED, V192, P1535, DOI 10.1084/jem.192.11.1535; Biragyn A, 1999, NAT BIOTECHNOL, V17, P253, DOI 10.1038/6995; Boczkowski D, 1996, J EXP MED, V184, P465, DOI 10.1084/jem.184.2.465; CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0; Celluzzi CM, 1996, J EXP MED, V183, P283, DOI 10.1084/jem.183.1.283; Charbonnier AS, 1999, J EXP MED, V190, P1755, DOI 10.1084/jem.190.12.1755; Cyster JG, 1999, J EXP MED, V189, P447, DOI 10.1084/jem.189.3.447; Dallal RM, 2000, CURR OPIN IMMUNOL, V12, P583, DOI 10.1016/S0952-7915(00)00146-1; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; Dieu-Nosjean MC, 2000, J EXP MED, V192, P705, DOI 10.1084/jem.192.5.705; EDELMAN ER, 1991, BIOMATERIALS, V12, P619, DOI 10.1016/0142-9612(91)90107-L; Fong L, 2000, ANNU REV IMMUNOL, V18, P245, DOI 10.1146/annurev.immunol.18.1.245; Fushimi T, 2000, J CLIN INVEST, V105, P1383, DOI 10.1172/JCI7548; Gong JL, 1997, NAT MED, V3, P558, DOI 10.1038/nm0597-558; GRABBE S, 1991, J IMMUNOL, V146, P3656; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Jenne L, 2000, CANCER RES, V60, P4446; KAMINSKI MJ, 1993, CANCER RES, V53, P4014; Kim HD, 1997, BIOMATERIALS, V18, P1175; Klein C, 2000, J EXP MED, V191, P1699, DOI 10.1084/jem.191.10.1699; Kugler A, 2000, NAT MED, V6, P332, DOI 10.1038/73193; Lodge PA, 2000, CANCER RES, V60, P829; LOTZE MT, 1999, DENDRITIC CELLS BIOL, P459; LOVESCHIMENTI CD, 1994, J IMMUNOL, V153, P3450; MANDELBOIM O, 1994, NATURE, V369, P67, DOI 10.1038/369067a0; Matsue H, 1999, J IMMUNOL, V162, P5287; Matsue H, 1999, NAT MED, V5, P930, DOI 10.1038/11375; MAYORDOMO JI, 1995, NAT MED, V1, P1297, DOI 10.1038/nm1295-1297; Mohamadzadeh M, 1996, J IMMUNOL, V156, P3102; Mummert ME, 2000, J EXP MED, V192, P769, DOI 10.1084/jem.192.6.769; Nair SK, 2000, NAT MED, V6, P1011, DOI 10.1038/79519; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; Paglia P, 1996, J EXP MED, V183, P317, DOI 10.1084/jem.183.1.317; Porgador A, 1996, J IMMUNOL, V156, P2918; Russo V, 2000, P NATL ACAD SCI USA, V97, P2185, DOI 10.1073/pnas.040540197; Saeki H, 1999, J IMMUNOL, V162, P2472; Sallusto F, 2000, ANNU REV IMMUNOL, V18, P593, DOI 10.1146/annurev.immunol.18.1.593; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Sasaki S, 1997, EUR J IMMUNOL, V27, P3121, DOI 10.1002/eji.1830271207; Song W, 1997, J EXP MED, V186, P1247, DOI 10.1084/jem.186.8.1247; Sozzani S, 1998, J IMMUNOL, V161, P1083; Specht JM, 1997, J EXP MED, V186, P1213, DOI 10.1084/jem.186.8.1213; Syrengelas AD, 1996, NAT MED, V2, P1038, DOI 10.1038/nm0996-1038; Takayama T, 2000, GENE THER, V7, P1265, DOI 10.1038/sj.gt.3301244; THOMAS WR, 1980, IMMUNOLOGY, V39, P21; Thurner B, 1999, J EXP MED, V190, P1669, DOI 10.1084/jem.190.11.1669; Yanagihara S, 1998, J IMMUNOL, V161, P3096; Zitvogel L, 1996, ANN NY ACAD SCI, V795, P284, DOI 10.1111/j.1749-6632.1996.tb52678.x	52	68	100	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2002	20	1					64	69		10.1038/nbt0102-64	http://dx.doi.org/10.1038/nbt0102-64			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	507ME	11753364				2022-12-25	WOS:000173031600038
J	Murakami, H; Hohsaka, T; Sisido, M				Murakami, H; Hohsaka, T; Sisido, M			Random insertion and deletion of arbitrary number of bases for codon-based random mutation of DNAs	NATURE BIOTECHNOLOGY			English	Article							NONNATURAL AMINO-ACIDS; SITE-DIRECTED INCORPORATION; GREEN FLUORESCENT PROTEIN; IN-VITRO; CASSETTE MUTAGENESIS; GENERAL-METHOD; STREPTAVIDIN; MUTANTS; EVOLUTION; EXTENSION	A general method was developed for the construction of a library of mutant genes. The method, termed random insertion/deletion (RID) mutagenesis, enables deletion of an arbitrary number of consecutive bases at random positions and, at the same time, insertion of a specific sequence or random sequences of an arbitrary number into the same position. The applicability of the RID mutagenesis was demonstrated by replacing three randomly selected consecutive bases by the Bg/ll recognition sequence (AGATCT) in the GFP(uv) gene. In addition, the randomly selected three bases were replaced by a mixture of 20 codons. These mutants were expressed in Escherichia coli, and those that showed fluorescence properties different from the wild-type GFP were selected. A yellow fluorescent protein and an enhanced green fluorescent protein, neither of which could be obtained by error-prone PCR mutagenesis, were found among the six mutants selected. Several mutants of the DsRed protein that show different fluorescence properties were also obtained.	Okayama Univ, Fac Engn, Dept Biosci & Biotechnol, Okayama 7008530, Japan	Okayama University	Sisido, M (corresponding author), Okayama Univ, Fac Engn, Dept Biosci & Biotechnol, 3-1-1 Tsushimanaka, Okayama 7008530, Japan.	sisido@cc.okayama-u.ac.jp						Baird GS, 2000, P NATL ACAD SCI USA, V97, P11984, DOI 10.1073/pnas.97.22.11984; Baptiste J, 1991, NUCLEIC ACIDS RES, V19, P5227; BERGER SL, 1994, ANAL BIOCHEM, V222, P1, DOI 10.1006/abio.1994.1445; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; CUBITT AB, 1996, NAT BIOTECHNOL, V14, P315; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DALBADIEMCFARLAND G, 1982, P NATL ACAD SCI-BIOL, V79, P6409, DOI 10.1073/pnas.79.21.6409; Fabret C, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.21.e95; Fradkov AF, 2000, FEBS LETT, V479, P127, DOI 10.1016/S0014-5793(00)01895-0; Gaytan P, 1998, CHEM BIOL, V5, P519, DOI 10.1016/S1074-5521(98)90007-2; GLASER SM, 1992, J IMMUNOL, V149, P3903; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hohsaka T, 2001, BIOCHEMISTRY-US, V40, P11060, DOI 10.1021/bi0108204; Hohsaka T, 1996, J AM CHEM SOC, V118, P9778, DOI 10.1021/ja9614225; Hohsaka T, 1999, J AM CHEM SOC, V121, P12194, DOI 10.1021/ja992204p; Hohsaka T, 1999, J AM CHEM SOC, V121, P34, DOI 10.1021/ja9813109; Ito Y, 1999, BIOCHEM BIOPH RES CO, V264, P556, DOI 10.1006/bbrc.1999.1541; KEGLEREBO DM, 1994, NUCLEIC ACIDS RES, V22, P1593, DOI 10.1093/nar/22.9.1593; LEHTOVAARA PM, 1988, PROTEIN ENG, V2, P63, DOI 10.1093/protein/2.1.63; Lund AH, 1996, NUCLEIC ACIDS RES, V24, P800, DOI 10.1093/nar/24.4.800; Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657; Miyazaki K, 1999, J MOL EVOL, V49, P716, DOI 10.1007/PL00006593; Murakami H, 1998, J AM CHEM SOC, V120, P7520, DOI 10.1021/ja971890u; Murakami H, 2000, BIOMACROMOLECULES, V1, P118, DOI 10.1021/bm990012g; Neuner P, 1998, NUCLEIC ACIDS RES, V26, P1223, DOI 10.1093/nar/26.5.1223; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Petrounia IP, 2000, CURR OPIN BIOTECH, V11, P325, DOI 10.1016/S0958-1669(00)00107-5; PHEIFFER BH, 1983, NUCLEIC ACIDS RES, V11, P7853, DOI 10.1093/nar/11.22.7853; Roberts RW, 1997, P NATL ACAD SCI USA, V94, P12297, DOI 10.1073/pnas.94.23.12297; Shibata Y, 2001, BIOTECHNIQUES, V30, P1250, DOI 10.2144/01306st01; SONDEK J, 1992, P NATL ACAD SCI USA, V89, P3581, DOI 10.1073/pnas.89.8.3581; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; Sumaoka J, 2000, CHEM LETT, P56; WELLS JA, 1985, GENE, V34, P315, DOI 10.1016/0378-1119(85)90140-4; Wiehler J, 2001, FEBS LETT, V487, P384, DOI 10.1016/S0014-5793(00)02365-6	38	70	101	0	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2002	20	1					76	81		10.1038/nbt0102-76	http://dx.doi.org/10.1038/nbt0102-76			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	507ME	11753366				2022-12-25	WOS:000173031600040
J	Vasioukhin, V; Bowers, E; Bauer, C; Degenstein, L; Fuchs, E				Vasioukhin, V; Bowers, E; Bauer, C; Degenstein, L; Fuchs, E			Desmoplakin is essential in epidermal sheet formation	NATURE CELL BIOLOGY			English	Article							DESMOSOMAL PLAQUE PROTEIN; INTERMEDIATE FILAMENTS; ADHERENS JUNCTIONS; EMBRYONIC HEART; CULTURED-CELLS; PLAKOGLOBIN; HEMIDESMOSOMES; ADHESION; CADHERIN; CALCIUM	We have generated an epidermis-specific desmoplakin (DP) mouse knockout, and show that epidermal integrity requires DP; mechanical stresses to DP-null skin cause intercellular separations. The number of epidermal desmosomes in DP-null skin is similar to wild type (WT), but they lack keratin filaments, which compromise their function. DP-null keratinocytes have few desmosomes in vitro, and are unable to undergo actin reorganization and membrane sealing during epithelial sheet formation. Adherens junctions are also reduced. In vitro, DP transgene expression rescues these defects. DP is therefore required for assembly of functional desmosomes, maintaining cytoskeletal architecture and reinforcing membrane attachments essential for stable intercellular adhesion.	Univ Chicago, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago	Vasioukhin, V (corresponding author), Univ Chicago, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, 5841 S Maryland Ave, Chicago, IL 60637 USA.		Fuchs, Elaine/G-1565-2016	Vasioukhin, Valeri/0000-0002-6730-0281	NIAMS NIH HHS [R01-AR27883] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR027883] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Andra K, 1998, GENE DEV, V12, P3442, DOI 10.1101/gad.12.21.3442; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Bierkamp C, 1996, DEV BIOL, V180, P780, DOI 10.1006/dbio.1996.0346; Bornslaeger EA, 1996, J CELL BIOL, V134, P985, DOI 10.1083/jcb.134.4.985; COWIN P, 1986, CELL, V46, P1063, DOI 10.1016/0092-8674(86)90706-3; Fuchs E, 2001, GENE DEV, V15, P1, DOI 10.1101/gad.861501; Gallicano GI, 1998, J CELL BIOL, V143, P2009, DOI 10.1083/jcb.143.7.2009; Garrod DR, 1993, CURR OPIN CELL BIOL, V5, P30, DOI 10.1016/S0955-0674(05)80005-5; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Hatzfeld M, 2000, J CELL BIOL, V149, P209, DOI 10.1083/jcb.149.1.209; HAUGWITZ M, 1994, CELL, V79, P303, DOI 10.1016/0092-8674(94)90199-6; Jones JCR, 1998, BIOESSAYS, V20, P488, DOI 10.1002/(SICI)1521-1878(199806)20:6<488::AID-BIES7>3.0.CO;2-I; Keith D, 1999, HUM MOL GENET, V8, P143, DOI 10.1093/hmg/8.1.143; KOCH PJ, 1994, CURR OPIN CELL BIOL, V6, P682, DOI 10.1016/0955-0674(94)90094-9; KOUKLIS PD, 1994, J CELL BIOL, V127, P1049, DOI 10.1083/jcb.127.4.1049; Kowalczyk AP, 1999, INT REV CYTOL, V185, P237; Kowalczyk AP, 1997, J CELL BIOL, V139, P773, DOI 10.1083/jcb.139.3.773; LEWIS JE, 1994, J INVEST DERMATOL, V102, P870, DOI 10.1111/1523-1747.ep12382690; Lewis JE, 1997, J CELL BIOL, V136, P919, DOI 10.1083/jcb.136.4.919; McGrath JE., 1997, GROUP DYN-THEOR RES, V1, P7, DOI [10.1037/1089-2699.1.1.7, DOI 10.1037/1089-2699.1.1.7]; Mertens C, 1996, J CELL BIOL, V135, P1009, DOI 10.1083/jcb.135.4.1009; Nievers MG, 1999, MATRIX BIOL, V18, P5, DOI 10.1016/S0945-053X(98)00003-1; Norgett EE, 2000, HUM MOL GENET, V9, P2761, DOI 10.1093/hmg/9.18.2761; OGorman S, 1997, SCIENCE, V277, P1025; OKEEFE EJ, 1987, J CELL BIOL, V105, P807, DOI 10.1083/jcb.105.2.807; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; RIDDELLE KS, 1992, J CELL SCI, V103, P475; Ruhrberg C, 1997, CURR OPIN GENET DEV, V7, P392, DOI 10.1016/S0959-437X(97)80154-2; Ruiz P, 1996, J CELL BIOL, V135, P215, DOI 10.1083/jcb.135.1.215; Schmidt A, 1999, DIFFERENTIATION, V64, P291, DOI 10.1046/j.1432-0436.1999.6450291.x; Schmidt A, 1997, CELL TISSUE RES, V290, P481, DOI 10.1007/s004410050956; Smith EA, 1998, J CELL BIOL, V141, P1229, DOI 10.1083/jcb.141.5.1229; STAPPENBECK TS, 1992, J CELL BIOL, V116, P1197, DOI 10.1083/jcb.116.5.1197; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Vasioukhin V, 1999, P NATL ACAD SCI USA, V96, P8551, DOI 10.1073/pnas.96.15.8551; Wang XM, 1997, P NATL ACAD SCI USA, V94, P219, DOI 10.1073/pnas.94.1.219; WHEELOCK MJ, 1992, J CELL BIOL, V117, P415, DOI 10.1083/jcb.117.2.415	37	239	245	0	7	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2001	3	12					1076	1085		10.1038/ncb1201-1076	http://dx.doi.org/10.1038/ncb1201-1076			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	500AM	11781569				2022-12-25	WOS:000172603700013
J	Shin, I; Yakes, FM; Rojo, F; Shin, NY; Bakin, AV; Baselga, J; Arteaga, CL				Shin, I; Yakes, FM; Rojo, F; Shin, NY; Bakin, AV; Baselga, J; Arteaga, CL			PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization	NATURE MEDICINE			English	Article							KINASE INHIBITOR P27; AKT PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; SUBCELLULAR-LOCALIZATION; GENE-TRANSCRIPTION; COMPLEX-FORMATION; CDK-INHIBITORS; TUMOR-CELLS; DEGRADATION; EXPRESSION	We have shown a novel mechanism of Akt-mediated regulation of the CDK inhibitor p27(kip1). Blockade of HER2/neu in tumor cells inhibits Akt kinase activity and upregulates nuclear levels of the CDK inhibitor p27(Kip1). Recombinant Akt and Akt precipitated from tumor cells phosphorylated wild-type p27 in vitro. p27 contains an Akt consensus RXRXXT157 D within its nuclear localization motif. Active (myristoylated) Akt phosphorylated wild-type p27 in vivo but was unable to phosphorylate a T157A-p27 mutant. Wild-type p27 localized in the cytosol and nucleus, whereas T157A-p27 localized exclusively in the nucleus and was resistant to nuclear exclusion by Akt. T157A-p27 was more effective than wild-type p27 in inhibiting cyclin E/CDK2 activity and cell proliferation; these effects were not rescued by active Akt. Expression of Ser(473) phospho Akt in primary human breast cancers statistically correlated with expression of p27 in tumor cytosol. These data indicate that Akt may contribute to tumor-cell proliferation by phosphorylation and cytosolic retention of p27, thus relieving CDK2 from p27-induced inhibition.	Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA; Vall Hebron Univ Hosp, Oncol Serv, Barcelona, Spain	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Hospital Universitari Vall d'Hebron	Arteaga, CL (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA.		Rojo, Federico/S-6551-2016	Bakin, Andrei/0000-0002-7728-1969	NATIONAL CANCER INSTITUTE [P30CA068485, R01CA080195] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485, R01 CA80195] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbott DW, 1999, J BIOL CHEM, V274, P2732, DOI 10.1074/jbc.274.5.2732; Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Albanell J, 2001, CANCER RES, V61, P6500; Alessandrini A, 1997, LEUKEMIA, V11, P342, DOI 10.1038/sj.leu.2400581; Baldassarre G, 1999, J CLIN INVEST, V104, P865, DOI 10.1172/JCI6443; Boehm M, 2002, EMBO J, V21, P3390, DOI 10.1093/emboj/cdf343; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Ciaparrone M, 1998, CANCER RES, V58, P114; DEL PL, 1997, SCIENCE, V278, P687; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fujita E, 1999, BIOCHEM BIOPH RES CO, V264, P550, DOI 10.1006/bbrc.1999.1387; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Ishida N, 2000, J BIOL CHEM, V275, P25146, DOI 10.1074/jbc.M001144200; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; Kotani K, 1999, J BIOL CHEM, V274, P21305, DOI 10.1074/jbc.274.30.21305; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Lenferink AEG, 2001, CANCER RES, V61, P6583; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Sanchez-Beato M, 1999, BLOOD, V94, P765, DOI 10.1182/blood.V94.2.765.414a29_765_772; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; Singh SP, 1998, CANCER RES, V58, P1730; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; UREN A, 1997, J BIOL CHEM, V272, P21699; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; Yaroslavskiy B, 1999, BLOOD, V93, P2907; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	44	652	680	4	36	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2002	8	10					1145	1152		10.1038/nm759	http://dx.doi.org/10.1038/nm759			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	599AN	12244301				2022-12-25	WOS:000178311000042
J	Hess, P; Pihan, G; Sawyers, CL; Flavell, RA; Davis, RJ				Hess, P; Pihan, G; Sawyers, CL; Flavell, RA; Davis, RJ			Survival signaling mediated by c-Jun NH2-terminal kinase in transformed B lymphoblasts	NATURE GENETICS			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; BCR-ABL ONCOGENE; HEMATOPOIETIC-CELLS; MYELOPROLIFERATIVE DISEASE; PHILADELPHIA-CHROMOSOME; BCL-2 EXPRESSION; BONE-MARROW; PATHWAY; ACTIVATION; APOPTOSIS	The c-Jun NH2-terminal kinase (JNK) is implicated in the apoptotic response of cells exposed to stress(1), but the JNK signal transduction pathway may not act exclusively in apoptosis(1). In some studies of tumor cells, JNK has been implicated in signaling cell survival(1). The possibility that JNK might mediate a survival signal in tumor cells is consistent with the observation that it is activated in response to some oncogenes, such as the leukemogenic oncogene BCR-ABL, which is created by a reciprocal translocation between human chromosomes 9 and 22 (ref. 2). The BCR-ABL protein activates the JNK signaling pathway in hematopoietic cells and increases transcriptional activity mediated by the transcription factor AP1 (ref. 3). Also, inhibition of c-Jun or JNK prevents BCR-ABL-induced cell transformation in vitro(3,4). Although this implicates the JNK signaling pathway in transformation by BCR-ABL, the possible role of JNK in this process is unclear. We find that disruption of the JNK ortholog Mapk8 (also known as Jnk1) in mice causes defective transformation of pre-B cells by BCR-ABL in vitro and in vivo. The Jnk1 protein is required for the survival of the transformed cells in the absence of stromal support. Failure to survive is associated with decreased expression of Bcl2, and the effect of Jnk1 deficiency can be rescued by transgenic expression of Bcl2. Our results show that Jnk1 signals cell survival in transformed B lymphoblasts and suggest that it may contribute to the pathogenesis of some proliferative diseases.	Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Program Mol Biol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Med, Worcester, MA USA; Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06510 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; Yale University; Yale University	Davis, RJ (corresponding author), Univ Massachusetts, Sch Med, Howard Hughes Med Inst, 373 Plantat St, Worcester, MA 01605 USA.		Sawyers, Charles/G-5327-2016					Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; COLLINS LS, 1987, J IMMUNOL, V138, P1082; Cortez D, 1997, ONCOGENE, V15, P2333, DOI 10.1038/sj.onc.1201400; DALEY GQ, 1991, P NATL ACAD SCI USA, V88, P11335, DOI 10.1073/pnas.88.24.11335; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; Gesbert F, 2000, BLOOD, V96, P2269, DOI 10.1182/blood.V96.6.2269.h8002269_2269_2276; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Neshat MS, 2000, MOL CELL BIOL, V20, P1179, DOI 10.1128/MCB.20.4.1179-1186.2000; Packham G, 1998, GENE DEV, V12, P2475, DOI 10.1101/gad.12.16.2475; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Shuai K, 1996, ONCOGENE, V13, P247; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; WHITLOCK CA, 1984, J IMMUNOL METHODS, V67, P353, DOI 10.1016/0022-1759(84)90475-7; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	29	140	145	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2002	32	1					201	205		10.1038/ng946	http://dx.doi.org/10.1038/ng946			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	588RR	12161751				2022-12-25	WOS:000177714900023
J	Monje, ML; Mizumatsu, S; Fike, JR; Palmer, TD				Monje, ML; Mizumatsu, S; Fike, JR; Palmer, TD			Irradiation induces neural precursor-cell dysfunction	NATURE MEDICINE			English	Article							DENTATE GYRUS; ADULT NEUROGENESIS; BRAIN IRRADIATION; STEM-CELLS; RADIATION; MICE; DIFFERENTIATION; PROLIFERATION; NEURONS; NICHE	In both pediatric and adult patients, cranial radiation therapy causes a debilitating cognitive decline that is poorly understood and currently untreatable. This decline is characterized by hippocampal dysfunction, and seems to involve a radiation-induced decrease in postnatal hippocampal neurogenesis. Here we show that the deficit in neurogenesis reflects alterations in the microenvironment that regulates progenitor-cell fate, as well as a defect in the proliferative capacity of the neural progenitor-cell population. Not only is hippocampal neurogenesis ablated, but the remaining neural precursors adopt glial fates and transplants of non-irradiated neural precursor cells fail to differentiate into neurons in the irradiated hippocampus. The inhibition of neurogenesis is accompanied by marked alterations in the neurogenic microenvironment, including disruption of the microvascular angiogenesis associated with adult neurogenesis and a marked increase in the number and activation status of microglia within the neurogenic zone. These findings provide clear targets for future therapeutic interventions.	Stanford Univ, Dept Neurosurg, Stanford, CA 94305 USA; Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA	Stanford University; University of California System; University of California San Francisco	Palmer, TD (corresponding author), Stanford Univ, Dept Neurosurg, Stanford, CA 94305 USA.	tpalmer@stanford.edu	Palmer, Theo/GSI-6635-2022	Palmer, Theo/0000-0002-6266-1862	NCI NIH HHS [R01CA76141] Funding Source: Medline; NIMH NIH HHS [MH20016-05] Funding Source: Medline; NINDS NIH HHS [R01NS40088] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076141] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS040088] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abayomi OK, 1996, ACTA ONCOL, V35, P659, DOI 10.3109/02841869609083995; CALVO W, 1988, BRIT J RADIOL, V61, P1043, DOI 10.1259/0007-1285-61-731-1043; CROSSEN JR, 1994, J CLIN ONCOL, V12, P627, DOI 10.1200/JCO.1994.12.3.627; Dawirs RR, 1998, J NEURAL TRANSM, V105, P317, DOI 10.1007/s007020050061; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; Gould E, 1999, NAT NEUROSCI, V2, P260, DOI 10.1038/6365; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; Heyser CJ, 1997, P NATL ACAD SCI USA, V94, P1500, DOI 10.1073/pnas.94.4.1500; Hodges H, 1998, BEHAV BRAIN RES, V91, P99, DOI 10.1016/S0166-4328(97)00108-3; HONG JH, 1995, INT J RADIAT ONCOL, V33, P619, DOI 10.1016/0360-3016(95)00279-8; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kuhn HG, 1996, J NEUROSCI, V16, P2027; LEE PWH, 1989, J NEUROL NEUROSUR PS, V52, P488, DOI 10.1136/jnnp.52.4.488; Leventhal C, 1999, MOL CELL NEUROSCI, V13, P450, DOI 10.1006/mcne.1999.0762; Lim DA, 2000, NEURON, V28, P713, DOI 10.1016/S0896-6273(00)00148-3; Louissaint A, 2002, NEURON, V34, P945, DOI 10.1016/S0896-6273(02)00722-5; MARKS JE, 1981, INT J RADIAT ONCOL, V7, P243, DOI 10.1016/0360-3016(81)90443-0; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Parent JM, 1999, J NEUROSCI, V19, P4508; Peissner W, 1999, MOL BRAIN RES, V71, P61, DOI 10.1016/S0169-328X(99)00170-9; PEZNER RD, 1981, INT J RADIAT ONCOL, V7, P397, DOI 10.1016/0360-3016(81)90115-2; ROMAN DD, 1995, INT J RADIAT ONCOL, V31, P983, DOI 10.1016/0360-3016(94)00550-8; Seaberg RM, 2002, J NEUROSCI, V22, P1784, DOI 10.1523/JNEUROSCI.22-05-01784.2002; SHELINE GE, 1980, INT J RADIAT ONCOL, V6, P1215, DOI 10.1016/0360-3016(80)90175-3; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; SIENKIEWICZ ZJ, 1994, INT J RADIAT BIOL, V65, P611, DOI 10.1080/09553009414550701; Snyder JS, 2001, J NEUROPHYSIOL, V85, P2423, DOI 10.1152/jn.2001.85.6.2423; STROTHER DR, 2002, PRINCIPLES PRACTICE, P751; Suhonen JO, 1996, NATURE, V383, P624, DOI 10.1038/383624a0; Surma-aho O, 2001, NEUROLOGY, V56, P1285, DOI 10.1212/WNL.56.10.1285; Tada E, 2000, NEUROSCIENCE, V99, P33, DOI 10.1016/S0306-4522(00)00151-2; Vallieres L, 2002, J NEUROSCI, V22, P486, DOI 10.1523/JNEUROSCI.22-02-00486.2002	32	900	983	1	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2002	8	9					955	962		10.1038/nm749	http://dx.doi.org/10.1038/nm749			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	589KQ	12161748				2022-12-25	WOS:000177757900030
J	Gan, YB; McGraw, TE; Rodriguez-Boulan, E				Gan, YB; McGraw, TE; Rodriguez-Boulan, E			The epithelial-specific adaptor AP1B mediates post-endocytic recycling to the basolateral membrane	NATURE CELL BIOLOGY			English	Article							DARBY CANINE KIDNEY; MDCK CELLS; STRUCTURAL REQUIREMENTS; POLARITY; RECEPTOR; PATHWAYS; SIGNALS; RECOGNITION; TRANSPORT; COMPLEX	To perform vectorial secretory and transport functions that are critical for the survival of the organism, epithelial cells sort plasma membrane proteins into polarized apical and basolateral domains(1,2). Sorting occurs post-synthetically, in the trans Golgi network (TGN) or after internalization from the cell surface in recycling endosomes, and is mediated by apical and basolateral sorting signals embedded in the protein structure(3,4). Basolateral sorting signals include tyrosine motifs in the cytoplasmic domain that are structurally similar to signals involved in receptor internalization by clathrin-coated pits(5,6). Recently, an epithelial-specific adaptor protein complex, AP1B, was identified(7,8). AP-1B recognizes a subset of basolateral tyrosine motifs through its mu1B subunit(7,8). Here, we characterized the post-synthetic and post-endocytic sorting of the fast recycling low density lipoprotein receptor (LDLR) and transferrin receptor (TfR) in LLC-PK1 cells, which lack mu1B and mis-sort both receptors to the apical surface(8). Targeting and recycling assays in LLC-PK1 cells, before and after transfection with mu1B, and in MDCK cells, which express mu1B constitutively, suggest that AP1B sorts basolateral proteins post-endocytically.	Cornell Univ, Weill Med Coll, Dyson Vis Res Inst, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Cell Biol, New York, NY 10021 USA	Cornell University; Dyson; Cornell University; Cornell University	Rodriguez-Boulan, E (corresponding author), Cornell Univ, Weill Med Coll, Dyson Vis Res Inst, 1300 York Ave, New York, NY 10021 USA.	boulan@med.cornell.edu			NATIONAL EYE INSTITUTE [R01EY008538] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052852, R01DK057689] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034107] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY008538, EY08538] Funding Source: Medline; NIDDK NIH HHS [DK-52852, DK-57689] Funding Source: Medline; NIGMS NIH HHS [R01 GM034107, GM34107] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AROETI B, 1994, EMBO J, V13, P2297, DOI 10.1002/j.1460-2075.1994.tb06513.x; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Brown PS, 2000, TRAFFIC, V1, P124, DOI 10.1034/j.1600-0854.2000.010205.x; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; Folsch H, 2001, J CELL BIOL, V152, P595, DOI 10.1083/jcb.152.3.595; Futter CE, 1998, J CELL BIOL, V141, P611, DOI 10.1083/jcb.141.3.611; Girotti M, 1996, J CELL SCI, V109, P2915; GOTTARDI CJ, 1995, AM J PHYSIOL-RENAL, V268, pF285, DOI 10.1152/ajprenal.1995.268.2.F285; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; Keller P, 1997, J CELL SCI, V110, P3001; Koivisto UM, 2001, CELL, V105, P575, DOI 10.1016/S0092-8674(01)00371-3; LEGALL AH, 1995, SEMIN NEPHROL, V15, P272; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MAXFIELD DR, 1991, INTRACELLUALR TRAFFI, P157; MAXFIELD FR, 1978, CELL, V14, P805, DOI 10.1016/0092-8674(78)90336-7; MCGRAW T, 1999, ENDOCYTOSIS BIOCH AN; Mostov KE, 2000, CURR OPIN CELL BIOL, V12, P483, DOI 10.1016/S0955-0674(00)00120-4; Nishimura N, 2002, P NATL ACAD SCI USA, V99, P6755, DOI 10.1073/pnas.092150699; Odorizzi G, 1997, J CELL BIOL, V137, P1255, DOI 10.1083/jcb.137.6.1255; Ohno H, 1999, FEBS LETT, V449, P215, DOI 10.1016/S0014-5793(99)00432-9; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; Roush DL, 1998, J BIOL CHEM, V273, P26862, DOI 10.1074/jbc.273.41.26862; Simmen T, 2002, NAT CELL BIOL, V4, P154, DOI 10.1038/ncb745; Wang XY, 2000, J BIOL CHEM, V275, P29138, DOI 10.1074/jbc.M004410200; Yeaman C, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P239	30	154	157	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2002	4	8					605	609		10.1038/ncb827	http://dx.doi.org/10.1038/ncb827			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	579WK	12105417				2022-12-25	WOS:000177201100016
J	Lambert, JM; Lambert, QT; Reuther, GW; Malliri, A; Siderovski, DP; Sondek, J; Collard, JG; Der, CJ				Lambert, JM; Lambert, QT; Reuther, GW; Malliri, A; Siderovski, DP; Sondek, J; Collard, JG; Der, CJ			Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism	NATURE CELL BIOLOGY			English	Article							GUANOSINE TRIPHOSPHATASES; PROTEIN; BINDING; TRANSFORMATION; EFFECTOR; DOMAIN; GTPASE	Rac is a member of the Ras superfamily of GTPases and functions as a GDP/GTP-regulated switch(1). Formation of active Rac-GTP is stimulated by Dbl family guanine nucleotide exchange factors (GEFs), such as Tiam1 (ref. 2). Once activated, Rac stimulates signalling pathways that regulate actin organization, gene expression and cellular proliferation. Rac also functions downstream of the Ras oncoprotein in pathways that stimulate membrane ruffling(3), growth transformation(4,5), activation of the c-Jun amino-terminal kinase (JNK) mitogen-activated protein kinase(6), activation of the NF-kappaB transcription factor and promotion of cell survival(7,8). Although recent studies support phosphatidylinositol 3-OH kinase (PI( 3) K)-dependent mechanisms through which Ras might activate Rac (refs 9,10), the precise mechanism remains to be determined. Here we demonstrate that Tiam1, a Rac-specific GEF, preferentially associates with activated GTP-bound Ras through a Ras-binding domain. Furthermore, activated Ras and Tiam1 cooperate to cause synergistic formation of Rac-GTP in a PI( 3) K-independent manner. Thus, Tiam1 can function as an effector that directly mediates Ras activation of Rac.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Neurosci, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Netherlands	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Netherlands Cancer Institute	Der, CJ (corresponding author), Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA.	cjder@med.unc.edu	Reuther, Gary/AFR-2892-2022; Siderovski, David Peter/AAA-9603-2019	Siderovski, David Peter/0000-0002-0688-8210; Malliri, Angeliki/0000-0001-6848-090X; Sondek, John/0000-0002-1127-8310; Der, Channing/0000-0002-7751-2747	NCI NIH HHS [CA69577] Funding Source: Medline; NIGMS NIH HHS [GM62299, GM62338] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062299, R01GM062338] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; Crompton AM, 2000, J BIOL CHEM, V275, P25751, DOI 10.1074/jbc.M002050200; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; Fischer D, 1999, PROTEINS, P209; Fleming IN, 2000, BIOCHEM J, V351, P173, DOI 10.1042/0264-6021:3510173; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Joneson T, 1999, MOL CELL BIOL, V19, P5892; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Murphy GA, 2002, J BIOL CHEM, V277, P9966, DOI 10.1074/jbc.M109059200; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Peterson SN, 1996, J BIOL CHEM, V271, P29903, DOI 10.1074/jbc.271.47.29903; Ponting CP, 1999, J MOL MED, V77, P695, DOI 10.1007/s001099900054; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; REUTHER GW, IN PRESS J BIOL CHEM; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Snyder JT, 2001, J BIOL CHEM, V276, P45868, DOI 10.1074/jbc.M106731200; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	30	240	252	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2002	4	8					621	625		10.1038/ncb833	http://dx.doi.org/10.1038/ncb833			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	579WK	12134164				2022-12-25	WOS:000177201100019
J	Ueki, S; Citovsky, V				Ueki, S; Citovsky, V			The systemic movement of a tobamovirus is inhibited by a cadmium-ion-induced glycine-rich protein	NATURE CELL BIOLOGY			English	Article							TOBACCO-MOSAIC-VIRUS; TO-CELL MOVEMENT; NONTOXIC CONCENTRATIONS; CAPSID PROTEIN; TRANSPORT; PLANTS; ACCUMULATION; RNA; PHOSPHORYLATION; LOCALIZATION	Systemic movement is central to plant viral infection. Exposure of tobacco plants to low levels of cadmium ions blocks the systemic spread of turnip vein-clearing tobamovirus (TVCV). We identified a tobacco glycine-rich protein, cdiGRP, specifically induced by low concentrations of cadmium and expressed in the cell walls of plant vascular tissues. Constitutive cdiGRP expression inhibited systemic transport of TVCV, whereas suppression of cdiGRP production allowed TVCV movement in the presence of cadmium. cdiGRP exerted its inhibitory effect on TVCV transport by enhancing callose deposits in the vasculature. So cdiGRP may function to control plant viral systemic movement.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Citovsky, V (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.	vitaly.citovsky@stonybrook.edu	Ueki, Shoko/F-5338-2011	Ueki, Shoko/0000-0002-6558-652X; Citovsky, Vitaly/0000-0003-2024-6844				ABEL PP, 1986, SCIENCE, V232, P738, DOI 10.1126/science.3457472; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Beffa RS, 1996, PLANT CELL, V8, P1001, DOI 10.1105/tpc.8.6.1001; Boyko V, 2000, NAT CELL BIOL, V2, P826, DOI 10.1038/35041072; Bucher GL, 2001, PLANT J, V28, P361, DOI 10.1046/j.1365-313X.2001.01181.x; Chen MH, 2000, EMBO J, V19, P913, DOI 10.1093/emboj/19.5.913; Cheng NH, 2000, PLANT J, V23, P349, DOI 10.1046/j.1365-313x.2000.00788.x; Citovsky V, 1998, PLANT J, V16, P13, DOI 10.1046/j.1365-313x.1998.00263.x; Creager Angela N. H., 1999, Plant Cell, V11, P301; DELMER DP, 1993, PROTOPLASMA, V176, P33, DOI 10.1007/BF01378937; DEOM CM, 1987, SCIENCE, V237, P389, DOI 10.1126/science.237.4813.389; Derrick PM, 1997, MOL PLANT MICROBE IN, V10, P589, DOI 10.1094/MPMI.1997.10.5.589; Domingo C, 1999, PLANT J, V20, P563, DOI 10.1046/j.1365-313X.1999.00631.x; Dorokhov YL, 1999, FEBS LETT, V461, P223, DOI 10.1016/S0014-5793(99)01447-7; Esau K., 1977, ANATOMY SEED PLANTS, P157; Fagard M, 2000, ANNU REV PLANT PHYS, V51, P167, DOI 10.1146/annurev.arplant.51.1.167; GALLIE DR, 1989, PLANT CELL, V1, P301, DOI 10.1105/tpc.1.3.301; Ghoshroy S, 1998, PLANT J, V13, P591, DOI 10.1046/j.1365-313X.1998.00061.x; Ghoshroy S, 1998, J VIROL METHODS, V74, P223, DOI 10.1016/S0166-0934(98)00084-6; GOLEMBOSKI DB, 1990, P NATL ACAD SCI USA, V87, P6311, DOI 10.1073/pnas.87.16.6311; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; HEINLEIN M, 1995, SCIENCE, V270, P1983, DOI 10.1126/science.270.5244.1983; HILF ME, 1993, VIROLOGY, V193, P106, DOI 10.1006/viro.1993.1107; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; Iglesias VA, 2000, PLANT J, V21, P157, DOI 10.1046/j.1365-313x.2000.00658.x; Jackson D, 2000, CURR OPIN PLANT BIOL, V3, P394, DOI 10.1016/S1369-5266(00)00102-3; Kang DC, 1998, P NATL ACAD SCI USA, V95, P13788, DOI 10.1073/pnas.95.23.13788; Kawakami S, 1999, J VIROL, V73, P6831, DOI 10.1128/JVI.73.8.6831-6840.1999; KUNIK T, 1994, BIO-TECHNOL, V12, P500, DOI 10.1038/nbt0594-500; Lartey R, 1997, PLANT J, V12, P537, DOI 10.1046/j.1365-313X.1997.00537.x; Lartey RT, 1995, GENE, V166, P331, DOI 10.1016/0378-1119(95)00674-5; LARTEY RT, 1993, PLANT DIS, V77, P21, DOI 10.1094/PD-77-0021; Leisner S M, 1993, Trends Microbiol, V1, P314, DOI 10.1016/0966-842X(93)90009-G; LINTHORST HJM, 1989, PLANT CELL, V1, P285, DOI 10.1105/tpc.1.3.285; Mourrain P, 2000, CELL, V101, P533, DOI 10.1016/S0092-8674(00)80863-6; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Oparka KJ, 2000, ANNU REV PLANT PHYS, V51, P323, DOI 10.1146/annurev.arplant.51.1.323; Rhee Y, 2000, MOL PLANT PATHOL, V1, P33, DOI 10.1046/j.1364-3703.2000.00005.x; Roberts AG, 1997, PLANT CELL, V9, P1381, DOI 10.1105/tpc.9.8.1381; Sachetto-Martins G, 2000, BBA-GENE STRUCT EXPR, V1492, P1, DOI 10.1016/S0167-4781(00)00064-6; SALT DE, 1995, PLANT PHYSIOL, V109, P1427, DOI 10.1104/pp.109.4.1427; Shilperoort, 1994, PLANT MOL BIOL MAN D, P1, DOI 10.1007/978-94-011-0511-8_16; Stone BA, 1992, CHEM BIOL 1 3 BETA G; Tzfira T, 2000, ANNU REV MICROBIOL, V54, P187, DOI 10.1146/annurev.micro.54.1.187; Ueki S, 2001, PLANT J, V28, P283, DOI 10.1046/j.1365-313X.2001.01145.x; van Kan J A, 1988, Mol Plant Microbe Interact, V1, P107, DOI 10.1094/MPMI-1-107; Vaucheret H, 1998, PLANT J, V16, P651, DOI 10.1046/j.1365-313x.1998.00337.x; Waigmann E, 2000, EMBO J, V19, P4875, DOI 10.1093/emboj/19.18.4875; Xoconostle-Cazares B, 1999, SCIENCE, V283, P94, DOI 10.1126/science.283.5398.94	50	88	91	3	14	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2002	4	7					478	485		10.1038/ncb806	http://dx.doi.org/10.1038/ncb806			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	568UL	12055637				2022-12-25	WOS:000176562900011
J	Jacobs, T				Jacobs, T			Sense and antisense for investors	NATURE BIOTECHNOLOGY			English	Editorial Material																		Dove A, 2002, NAT BIOTECHNOL, V20, P121, DOI 10.1038/nbt0202-121; 2002, NAT BIOTECHNOL, V20, P533	2	2	2	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2002	20	6					543	543		10.1038/nbt0602-543	http://dx.doi.org/10.1038/nbt0602-543			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	558NM	12042846	Bronze			2022-12-25	WOS:000175973500010
J	Levin, MC; Lee, SM; Kalume, F; Morcos, Y; Dohan, FC; Hasty, KA; Callaway, JC; Zunt, J; Desiderio, DM; Stuart, JM				Levin, MC; Lee, SM; Kalume, F; Morcos, Y; Dohan, FC; Hasty, KA; Callaway, JC; Zunt, J; Desiderio, DM; Stuart, JM			Autoimmunity due to molecular mimicry as a cause of neurological disease	NATURE MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; I-ASSOCIATED MYELOPATHY; MYELIN BASIC-PROTEIN; MULTIPLE-SCLEROSIS; VIRUS; LYMPHOCYTES; MECHANISMS; EXPRESSION; HAM/TSP; CELLS	One hypothesis that couples infection with autoimmune disease is molecular mimicry. Molecular mimicry is characterized by an immune response to an environmental agent that cross-reacts with a host antigen, resulting in disease(1,2). This hypothesis has been implicated in the pathogenesis of diabetes, lupus and multiple sclerosis (MS)(1-4). There is limited direct evidence linking causative agents with pathogenic immune reactions in these diseases. Our study establishes a clear link between viral infection, autoimmunity and neurological disease in humans. As a model for molecular mimicry, we studied patients with human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP), a disease that can be indistinguishable from MS (refs. 5-7). HAM/TSP patients develop antibodies to neurons(8). We hypothesized these antibodies would identify a central nervous system (CNS) autoantigen. Immunoglobulin G isolated from HAM/TSP patients identified heterogeneous nuclear ribonuclear protein-A1 (hnRNP-A1) as the autoantigen. Antibodies to hnRNP-A1 cross-reacted with HTLV-1-tax, the immune response to which is associated with HAM/TSP (refs. 5,9). Immunoglobulin G specifically stained human Betz cells, whose axons are preferentially damaged(7). Infusion of autoantibodies in brain sections inhibited neuronal firing, indicative of their pathogenic nature. These data demonstrate the importance of molecular mimicry between an infecting agent and hnRNP-A1 in autoimmune disease of the CNS.	Vet Affairs Med Ctr, Res Serv, Memphis, TN 38104 USA; Univ Tennessee, Hlth Sci Ctr, Ctr Neurobiol Brain Dis, Memphis, TN USA; Univ Tennessee, Hlth Sci Ctr, Dept Neurol, Memphis, TN USA; Univ Tennessee, Hlth Sci Ctr, Dept Anat, Memphis, TN USA; Univ Tennessee, Hlth Sci Ctr, Dept Pathol, Memphis, TN USA; Univ Tennessee, Hlth Sci Ctr, Orthoped Campbell Clin, Memphis, TN USA; Univ Tennessee, Hlth Sci Ctr, Dept Mol Sci, Memphis, TN USA; Univ Tennessee, Hlth Sci Ctr, Dept Med, Charles B Stout Neurosci Mass Spect Lab, Memphis, TN USA; Univ Tennessee, Hlth Sci Ctr, Ctr Excellence Connect Tissue Dis, Memphis, TN USA; Univ Washington, Dept Neurol, Seattle, WA 98195 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Washington; University of Washington Seattle	Levin, MC (corresponding author), Vet Affairs Med Ctr, Res Serv, Memphis, TN 38104 USA.		Zunt, Joseph/ABD-2886-2021	Levin, Michael/0000-0002-3880-9193	NCRR NIH HHS [RR 10522] Funding Source: Medline; NIAID NIH HHS [K23 AI001600, K23 AI001600-04] Funding Source: Medline; NINDS NIH HHS [R01-NS-38876] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR010522] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI001600] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038876] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Albert LJ, 1999, NEW ENGL J MED, V341, P2068, DOI 10.1056/NEJM199912303412707; Beranova-Giorgianni S, 2000, RAPID COMMUN MASS SP, V14, P161, DOI 10.1002/(SICI)1097-0231(20000215)14:3<161::AID-RCM859>3.0.CO;2-7; Biamonti G, 1998, CLIN EXP RHEUMATOL, V16, P317; CALLAWAY JC, 1993, J NEUROSCI, V13, P1157; Chen WH, 1999, J NEUROSCI RES, V57, P706, DOI 10.1002/(SICI)1097-4547(19990901)57:5<706::AID-JNR12>3.3.CO;2-7; FUJINAMI RS, 1985, SCIENCE, V230, P1043, DOI 10.1126/science.2414848; Giraudon P, 2000, J IMMUNOL, V164, P2718, DOI 10.4049/jimmunol.164.5.2718; Gran B, 1999, ANN NEUROL, V45, P559, DOI 10.1002/1531-8249(199905)45:5<559::AID-ANA3>3.0.CO;2-Q; JACOBSON S, 1990, NATURE, V348, P245, DOI 10.1038/348245a0; KAHN R, 2001, NEUROLOGIST, V7, P271; KAMMA H, 1995, EXP CELL RES, V221, P187, DOI 10.1006/excr.1995.1366; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; LAL RB, 1994, J INFECT DIS, V169, P496, DOI 10.1093/infdis/169.3.496; Lassek AM, 1942, J COMP NEUROL, V76, P217, DOI 10.1002/cne.900760203; Levin MC, 1998, ANN NEUROL, V44, P87, DOI 10.1002/ana.410440115; Levin MC, 1997, J NEUROVIROL, V3, P126, DOI 10.3109/13550289709015802; Levin MC, 1997, NEW ENGL J MED, V336, P839, DOI 10.1056/NEJM199703203361205; MULLER S, 1995, CLIN IMMUNOL IMMUNOP, V77, P282, DOI 10.1006/clin.1995.1154; Munro TP, 1999, J BIOL CHEM, V274, P34389, DOI 10.1074/jbc.274.48.34389; Nagai M, 1998, J NEUROVIROL, V4, P586, DOI 10.3109/13550289809114225; Nakielny S, 1997, CURR OPIN CELL BIOL, V9, P420, DOI 10.1016/S0955-0674(97)80016-6; Oldstone MBA, 1998, FASEB J, V12, P1255, DOI 10.1096/fasebj.12.13.1255; Romero IA, 2000, J VIROL, V74, P6021, DOI 10.1128/JVI.74.13.6021-6030.2000; Shyu AB, 2000, CELL, V102, P135, DOI 10.1016/S0092-8674(00)00018-0; WARREN KG, 1995, P NATL ACAD SCI USA, V92, P11061, DOI 10.1073/pnas.92.24.11061	25	184	192	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2002	8	5					509	513		10.1038/nm0502-509	http://dx.doi.org/10.1038/nm0502-509			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	547ZW	11984596	Green Accepted			2022-12-25	WOS:000175336800037
J	Greeley, SAW; Katsumata, M; Yu, LP; Eisenbarth, GS; Moore, DJ; Goodarzi, H; Barker, CF; Naji, A; Noorchashm, H				Greeley, SAW; Katsumata, M; Yu, LP; Eisenbarth, GS; Moore, DJ; Goodarzi, H; Barker, CF; Naji, A; Noorchashm, H			Elimination of maternally transmitted autoantibodies prevents diabetes in nonobese diabetic mice	NATURE MEDICINE			English	Article							ANTIGEN-PRESENTING CELLS; B-LYMPHOCYTES; NOD MICE; TRANSGENIC MICE; VIRUS-INFECTION; EXPRESSION; INITIATION; APPEARANCE; BABYDIAB	The influence of maternally transmitted immunoglobulins on the development of autoimmune diabetes mellitus in genetically susceptible human progeny remains unknown. Given the presence of islet beta cell reactive autoantibodies in prediabetic nonobese diabetic (NOD) mice(1,2), we abrogated the maternal transmission of such antibodies in order to assess their influence on the susceptibility of progeny to diabetes. First, we used B cell deficient NOD mothers to eliminate the transmission of maternal immunoglobulins. In a complementary approach, we used immunoglobulin transgenic NOD mothers to exclude autoreactive specificities from the maternal B- cell repertoire. Finally, we implanted NOD embryos in pseudopregnant mothers of a non-autoimmune strain. The NOD progeny in all three groups were protected from spontaneous diabetes. These findings demonstrate that the maternal transmission of antibodies is a critical environmental parameter influencing the ontogeny of T cell-mediated destruction of islet beta cells in NOD mice(3). It will be important to definitively determine whether the transmission of maternal autoantibodies in humans(4-8) affects diabetes progression in susceptible offspring.	Univ Penn, Sch Med, Harrison Dept Surg Res, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Colorado, Hlth Sci Ctr, Barbara Davis Ctr Childhood Diabet, Denver, CO 80262 USA	University of Pennsylvania; University of Pennsylvania; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Naji, A (corresponding author), Univ Penn, Sch Med, Harrison Dept Surg Res, Philadelphia, PA 19104 USA.		Moore, Daniel/V-6145-2019; Greeley, Siri Atma W./N-1294-2014; Moore, Daniel J/A-4924-2008	Moore, Daniel/0000-0002-6889-9345; Greeley, Siri Atma W./0000-0002-0741-3567; Moore, Daniel J/0000-0002-6889-9345	NICHD NIH HHS [HD37754] Funding Source: Medline; NIDDK NIH HHS [DK54215] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037754] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054215] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abiru N, 2001, J AUTOIMMUN, V17, P1, DOI 10.1006/jaut.2001.0530; Bach JF, 2001, ANNU REV IMMUNOL, V19, P131, DOI 10.1146/annurev.immunol.19.1.131; Bras A, 1996, IMMUNOLOGY, V89, P20, DOI 10.1046/j.1365-2567.1996.d01-717.x; Cooke A, 1999, PARASITE IMMUNOL, V21, P169, DOI 10.1046/j.1365-3024.1999.00213.x; Falcone M, 1998, J IMMUNOL, V161, P1163; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; Greeley SAW, 2001, J IMMUNOL, V167, P4351, DOI 10.4049/jimmunol.167.8.4351; Hamalainen AM, 2000, J CLIN ENDOCR METAB, V85, P4249, DOI 10.1210/jc.85.11.4249; HERMITTE L, 1990, EUR J IMMUNOL, V20, P1297, DOI 10.1002/eji.1830200615; Hulbert C, 2001, J IMMUNOL, V167, P5535, DOI 10.4049/jimmunol.167.10.5535; Naserke HE, 1999, J CLIN ENDOCR METAB, V84, P1239, DOI 10.1210/jc.84.4.1239; Naserke HE, 2001, J CLIN ENDOCR METAB, V86, P4826; Noorchashm H, 2000, J IMMUNOL, V165, P4685, DOI 10.4049/jimmunol.165.8.4685; Noorchashm H, 1999, J IMMUNOL, V163, P743; OLDSTONE MBA, 1988, SCIENCE, V239, P500, DOI 10.1126/science.3277269; REILLY MP, 1994, METHOD ENZYMOL, V231, P403; Serreze DV, 1998, J IMMUNOL, V161, P3912; Serreze DV, 1996, J EXP MED, V184, P2049, DOI 10.1084/jem.184.5.2049; TAKEI I, 1992, J AUTOIMMUN, V5, P665, DOI 10.1016/0896-8411(92)90184-R; Yu LP, 2000, P NATL ACAD SCI USA, V97, P1701, DOI 10.1073/pnas.040556697; ZIEGLER AG, 1993, DIABETOLOGIA, V36, P402, DOI 10.1007/BF00402275; Ziegler AG, 1999, DIABETES, V48, P460, DOI 10.2337/diabetes.48.3.460	22	157	163	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2002	8	4					399	402		10.1038/nm0402-399	http://dx.doi.org/10.1038/nm0402-399			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	536ML	11927947				2022-12-25	WOS:000174704800033
J	Lincoln, AJ; Wickramasinghe, D; Stein, P; Schultz, RM; Palko, ME; De Miguel, MP; Tessarollo, L; Donovan, PJ				Lincoln, AJ; Wickramasinghe, D; Stein, P; Schultz, RM; Palko, ME; De Miguel, MP; Tessarollo, L; Donovan, PJ			Cdc25b phosphatase is required for resumption of meiosis during oocyte maturation	NATURE GENETICS			English	Article							MEIOTIC COMPETENCE; MOUSE OOCYTES; CELL-CYCLE; PROTEIN; YEAST; HOMOLOG; DEPHOSPHORYLATION; ACTIVATION; MITOSIS; ACQUISITION	In a wide variety of animal species, oocyte maturation is arrested temporarily at prophase of meiosis I (ref. 1). Resumption of meiosis requires activation of cyclin-dependent kinase-1 (CDK1, p34cdc2), one component of maturation-promoting factor (MPF)(2,3). The dual specificity phosphatases Cdc25a, Cdc25b and Cdc25c are activators of cyclin-dependent kinases(4-8); consequently, they are postulated to regulate cell-cycle progression in meiosis and mitosis as well as the DNA-damage response(9-12). We generated Cdc25b-deficient (Cdc25b(-/-)) mice and found that they are viable. As compared with wildtype cells, fibroblasts from Cdc25b(-/-) mice grew vigorously in culture and arrested normally in response to DNA damage. Female Cdc25b(-/-) mice were sterile, and Cdc25b(-/-) oocytes remained arrested at prophase with low MPF activity. Microinjection of wildtype Cdc25b mRNA into Cdc25b(-/-) oocytes caused activation of MPF and resumption of meiosis. Thus, Cdc25b(-/-) female mice are sterile because of permanent meiotic arrest resulting from the inability to activate MPF. Cdc25b is therefore essential for meiotic resumption in female mice. Mice lacking Cdc25b provide the first genetic model for studying the mechanisms regulating prophase arrest in vertebrates.	NCI, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; Univ Penn, Dept Biol, Philadelphia, PA 19104 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Pennsylvania	Donovan, PJ (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA.		Stein, Paula/ABE-9388-2020; Holt, Janet E/B-2415-2013	Stein, Paula/0000-0002-2040-4593; 				Chen MS, 2001, MOL CELL BIOL, V21, P3853, DOI 10.1128/MCB.21.12.3853-3861.2001; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; Eckstein J., 1997, BIOCHIM BIOPHYS ACTA, V1332, P53; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; Gopalan G, 1997, J CELL BIOL, V138, P643, DOI 10.1083/jcb.138.3.643; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; Jessus C, 1995, Prog Cell Cycle Res, V1, P215; KAKIZUKA A, 1992, GENE DEV, V6, P578, DOI 10.1101/gad.6.4.578; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; Masui Y, 1979, Int Rev Cytol, V57, P185, DOI 10.1016/S0074-7696(08)61464-3; Mitra J, 1996, J CELL SCI, V109, P2407; NAGATA A, 1991, NEW BIOL, V3, P959; NARGI JL, 1994, IMMUNOGENETICS, V39, P99, DOI 10.1007/BF00188612; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; Svoboda P, 2000, DEVELOPMENT, V127, P4147; TESSAROLLO L, 1994, P NATL ACAD SCI USA, V91, P11844, DOI 10.1073/pnas.91.25.11844; Weinert T, 1997, SCIENCE, V277, P1450, DOI 10.1126/science.277.5331.1450; WICKRAMASINGHE D, 1991, DEV BIOL, V143, P162, DOI 10.1016/0012-1606(91)90063-9; WICKRAMASINGHE D, 1995, DEVELOPMENT, V121, P2047; WU S, 1995, DEV BIOL, V170, P195, DOI 10.1006/dbio.1995.1207	26	203	219	0	20	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2002	30	4					446	449		10.1038/ng856	http://dx.doi.org/10.1038/ng856			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	536BZ	11912493				2022-12-25	WOS:000174682000026
J	Coghill, EL; Hugill, A; Parkinson, N; Davison, C; Glenister, P; Clements, S; Hunter, J; Cox, RD; Brown, SDM				Coghill, EL; Hugill, A; Parkinson, N; Davison, C; Glenister, P; Clements, S; Hunter, J; Cox, RD; Brown, SDM			A gene-driven approach to the identification of ENU mutants in the mouse	NATURE GENETICS			English	Article							EMBRYONIC STEM-CELLS; SENSORINEURAL DEAFNESS; CONNEXIN-26 MUTATIONS; GENOME-WIDE; MICE; MUTAGENESIS	The construction of parallel archives of DNA and sperm from mice mutagenized with ethylnitrosurea (ENU) represents a potentially powerful and rapid approach for identifying point mutations in any gene in the mouse genome. We provide support for this approach and report the identification of mutations in the gene (Gjb2) encoding connexin 26, using archives established from the UK ENU mutagenesis program.	MRC, Mammalian Genet Unit, Harwell OX11 0RD, Berks, England; UK Mouse Genome Ctr, Harwell OX11 0RD, Berks, England; GlaxoSmithKline, Harlow CM19 5AW, Essex, England	GlaxoSmithKline	Brown, SDM (corresponding author), MRC, Mammalian Genet Unit, Harwell OX11 0RD, Berks, England.			Cox, Roger/0000-0001-7170-5014				Beier DR, 2000, MAMM GENOME, V11, P594, DOI 10.1007/s003350010113; Chen YJ, 2000, NAT GENET, V24, P314, DOI 10.1038/73557; de Angelis MH, 2000, NAT GENET, V25, P444, DOI 10.1038/78146; Denoyelle F, 1997, HUM MOL GENET, V6, P2173, DOI 10.1093/hmg/6.12.2173; Denoyelle F, 1998, NATURE, V393, P319, DOI 10.1038/30639; Dobson-Stone C, 2000, EUR J HUM GENET, V8, P24, DOI 10.1038/sj.ejhg.5200409; Estivill X, 1998, LANCET, V351, P394, DOI 10.1016/S0140-6736(97)11124-2; Gabriel HD, 1998, J CELL BIOL, V140, P1453, DOI 10.1083/jcb.140.6.1453; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; Munroe RJ, 2000, NAT GENET, V24, P318, DOI 10.1038/73563; Nadeau JH, 2001, SCIENCE, V291, P1251, DOI 10.1126/science.1058244; Nolan PM, 2000, NAT GENET, V25, P440, DOI 10.1038/78140; Scott DA, 1998, HUM MUTAT, V11, P387, DOI 10.1002/(SICI)1098-1004(1998)11:5<387::AID-HUMU6>3.3.CO;2-#; STEEL KP, 1996, WHATS WRONG MY MOUSE, P26; Thornton CE, 1999, MAMM GENOME, V10, P987, DOI 10.1007/s003359901145	15	141	145	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2002	30	3					255	256		10.1038/ng847	http://dx.doi.org/10.1038/ng847			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	526YP	11850622				2022-12-25	WOS:000174157600007
J	Feinberg, MB; Moore, JP				Feinberg, MB; Moore, JP			AIDS vaccine models: Challenging challenge viruses	NATURE MEDICINE			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; RHESUS-MONKEYS; VIRAL LOAD; INFECTION; MACAQUES; TYPE-1; DISEASE; SIV; PROGRESSION; VIREMIA		Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA USA; Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY USA	Emory University; Emory University; Emory University; Cornell University	Feinberg, MB (corresponding author), Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA.							Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915; Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486; Barouch DH, 2002, NATURE, V415, P335, DOI 10.1038/415335a; Barouch DH, 2001, J VIROL, V75, P5151, DOI 10.1128/JVI.75.11.5151-5158.2001; Blancou P, 2001, P NATL ACAD SCI USA, V98, P13237, DOI 10.1073/pnas.231348598; Chen XN, 2001, NAT MED, V7, P1225, DOI 10.1038/nm1101-1225; Etemad-Moghadam B, 2001, J VIROL, V75, P5646, DOI 10.1128/JVI.75.12.5646-5655.2001; Harouse JM, 1999, SCIENCE, V284, P816, DOI 10.1126/science.284.5415.816; Hirsch V M, 2000, Adv Pharmacol, V49, P437; Joag SV, 1996, J VIROL, V70, P3189, DOI 10.1128/JVI.70.5.3189-3197.1996; KUWATA T, 1995, J GEN VIROL, V76, P2181, DOI 10.1099/0022-1317-76-9-2181; LI JT, 1995, J VIROL, V69, P7061, DOI 10.1128/JVI.69.11.7061-7067.1995; Lifson JD, 2000, J VIROL, V74, P2584, DOI 10.1128/JVI.74.6.2584-2593.2000; Lori F, 2000, SCIENCE, V290, P1591, DOI 10.1126/science.290.5496.1591; Mascola JR, 2001, CURR OPIN IMMUNOL, V13, P489, DOI 10.1016/S0952-7915(00)00246-6; Matano T, 2001, J VIROL, V75, P11891, DOI 10.1128/JVI.75.23.11891-11896.2001; McCune JM, 2001, NATURE, V410, P974, DOI 10.1038/35073648; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Michael NL, 1997, J INFECT DIS, V175, P1352, DOI 10.1086/516467; Montagnier L, 1997, J INFECT DIS, V175, P955, DOI 10.1086/513999; Montefiori DC, 1998, J VIROL, V72, P3427, DOI 10.1128/JVI.72.4.3427-3431.1998; Nathanson N, 1999, AIDS, V13, pS113; Ourmanov I, 2000, J VIROL, V74, P2740, DOI 10.1128/JVI.74.6.2740-2751.2000; Oxenius A, 2001, EUR J IMMUNOL, V31, P3782, DOI 10.1002/1521-4141(200112)31:12<3782::AID-IMMU3782>3.0.CO;2-#; Parker RA, 2001, J VIROL, V75, P11234, DOI 10.1128/JVI.75.22.11234-11238.2001; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Reimann KA, 1996, J VIROL, V70, P6922, DOI 10.1128/JVI.70.10.6922-6928.1996; Rose NF, 2001, CELL, V106, P539, DOI 10.1016/S0092-8674(01)00482-2; Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SCHULTZ AM, 2001, AIDS S, V15, pS127; Seth A, 2000, J VIROL, V74, P2502, DOI 10.1128/JVI.74.6.2502-2509.2000; Shiver JW, 2002, NATURE, V415, P331, DOI 10.1038/415331a; Veazey RS, 2001, TRENDS IMMUNOL, V22, P626, DOI 10.1016/S1471-4906(01)02039-7; Zhang YJ, 2000, J VIROL, V74, P6893, DOI 10.1128/JVI.74.15.6893-6910.2000	35	155	181	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2002	8	3					207	210		10.1038/nm0302-207	http://dx.doi.org/10.1038/nm0302-207			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	526PU	11875482	Bronze			2022-12-25	WOS:000174139500018
J	Koulen, P; Cai, YQ; Geng, L; Maeda, Y; Nishimura, S; Witzgall, R; Ehrlich, BE; Somlo, S				Koulen, P; Cai, YQ; Geng, L; Maeda, Y; Nishimura, S; Witzgall, R; Ehrlich, BE; Somlo, S			Polycystin-2 is an intracellular calcium release channel	NATURE CELL BIOLOGY			English	Article							KIDNEY-DISEASE PROTEIN; SARCOPLASMIC-RETICULUM; CATION CONDUCTION; GENE; RECEPTOR; PKD2; MUTATIONS; CA2+; INACTIVATION; CEREBELLUM	Polycystin-2, the product of the gene mutated in type 2 autosomal dominant polycystic kidney disease (ADPKD), is the prototypical member of a subfamily of the transient receptor potential (TRP) channel superfamily, which is expressed abundantly in the endoplasmic reticulum (ER) membrane. Here, we show by single channel studies that polycystin-2 behaves as a calcium-activated, high conductance ER channel that is permeable to divalent cations. Epithelial cells overexpressing polycystin-2 show markedly augmented intracellular calcium release signals that are lost after carboxy-terminal truncation or by the introduction of a disease-causing missense mutation. These data suggest that polycystin-2 functions as a calcium-activated intracellular calcium release channel in vivo and that polycystic kidney disease results from the loss of a regulated intracellular calcium release signalling mechanism.	Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA; Heidelberg Univ, Inst Anat & Cell Biol, D-69120 Heidelberg, Germany	Yale University; Yale University; Yale University; Yale University; Ruprecht Karls University Heidelberg	Koulen, P (corresponding author), Yale Univ, Sch Med, Dept Internal Med, 333 Cedar St, New Haven, CT 06520 USA.	stefan.somlo@yale.edu	/AAX-8408-2021; Nishimura, Sayoko/F-4648-2015	/0000-0001-9657-9704; Witzgall, Ralph/0000-0002-5283-4846	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051041, P50DK057328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051480] Funding Source: NIH RePORTER; NIDDK NIH HHS [P50 DK057328, DK57328, R01 DK051041, P50 DK57328] Funding Source: Medline; NIGMS NIH HHS [GM51480] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barr MM, 1999, NATURE, V401, P386, DOI 10.1038/43916; Barr MM, 2001, CURR BIOL, V11, P1341, DOI 10.1016/S0960-9822(01)00423-7; Bassi MT, 2000, AM J HUM GENET, V67, P1110, DOI 10.1016/S0002-9297(07)62941-3; Beam KG, 1997, METHOD CELL BIOL, V52, P283, DOI 10.1016/S0091-679X(08)60384-2; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BEZPROZVANNY I, 1994, J GEN PHYSIOL, V104, P821, DOI 10.1085/jgp.104.5.821; BEZPROZVANNY I, 1995, J MEMBRANE BIOL, V145, P205; Cadiou H, 2000, EUR J NEUROSCI, V12, P2805, DOI 10.1046/j.1460-9568.2000.00166.x; Cai ZQ, 1999, J BIOL CHEM, V274, P28557, DOI 10.1074/jbc.274.40.28557; Chen XZ, 1999, NATURE, V401, P383, DOI 10.1038/43907; Dibas AI, 1997, AM J PHYSIOL-CELL PH, V272, pC810, DOI 10.1152/ajpcell.1997.272.3.C810; EHRLICH BE, 1988, NATURE, V336, P583, DOI 10.1038/336583a0; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; GABOW PA, 1997, DIS KIDNEY, P521; Gonzalez-Perrett S, 2001, P NATL ACAD SCI USA, V98, P1182, DOI 10.1073/pnas.021456598; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; KIM DH, 1983, J BIOL CHEM, V258, P9662; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Lehtonen S, 2000, J BIOL CHEM, V275, P32888, DOI 10.1074/jbc.M006624200; Littleton JT, 2000, NEURON, V26, P35, DOI 10.1016/S0896-6273(00)81135-6; Lu WN, 1997, NAT GENET, V17, P179, DOI 10.1038/ng1097-179; Markovska RP, 1999, ADSORPT SCI TECHNOL, V17, P25, DOI 10.1177/026361749901700103; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Moy GW, 1996, J CELL BIOL, V133, P809, DOI 10.1083/jcb.133.4.809; Munger SD, 2000, J BIOL CHEM, V275, P20450, DOI 10.1074/jbc.M001989200; Neill AT, 2000, MOL BIOL CELL, V11, p405A; Obermuller N, 1999, AM J PHYSIOL-RENAL, V277, pF914, DOI 10.1152/ajprenal.1999.277.6.F914; Ong ACM, 1999, AM J PATHOL, V154, P1721, DOI 10.1016/S0002-9440(10)65428-4; Qian F, 1996, CELL, V87, P979, DOI 10.1016/S0092-8674(00)81793-6; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; Reynolds DM, 1999, J AM SOC NEPHROL, V10, P2342; Somlo S, 2001, CURR BIOL, V11, pR356, DOI 10.1016/S0960-9822(01)00193-2; Sun M, 2000, HUM MOL GENET, V9, P2471, DOI 10.1093/hmg/9.17.2471; TINKER A, 1993, CARDIOVASC RES, V27, P1820, DOI 10.1093/cvr/27.10.1820; TINKER A, 1992, J GEN PHYSIOL, V100, P479, DOI 10.1085/jgp.100.3.479; Torres VE, 2001, J AM SOC NEPHROL, V12, P1, DOI 10.1681/ASN.V1211; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; Vassilev PM, 2001, BIOCHEM BIOPH RES CO, V282, P341, DOI 10.1006/bbrc.2001.4554; WARD CJ, 1994, CELL, V77, P881; WATRAS J, 1991, J NEUROSCI, V11, P3239; Wu GQ, 2000, NAT GENET, V24, P75, DOI 10.1038/71724; Wu GQ, 1998, CELL, V93, P177, DOI 10.1016/S0092-8674(00)81570-6; Zuhlke RD, 1998, P NATL ACAD SCI USA, V95, P3287, DOI 10.1073/pnas.95.6.3287	45	518	536	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2002	4	3					191	197		10.1038/ncb754	http://dx.doi.org/10.1038/ncb754			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	527VR	11854751				2022-12-25	WOS:000174209100011
J	Hirao, I; Ohtsuki, T; Fujiwara, T; Mitsui, T; Yokogawa, T; Okuni, T; Nakayama, H; Takio, K; Yabuki, T; Kigawa, T; Kodama, K; Yokogawa, T; Nishikawa, K; Yokoyama, S				Hirao, I; Ohtsuki, T; Fujiwara, T; Mitsui, T; Yokogawa, T; Okuni, T; Nakayama, H; Takio, K; Yabuki, T; Kigawa, T; Kodama, K; Yokogawa, T; Nishikawa, K; Yokoyama, S			An unnatural base pair for incorporating amino acid analogs into proteins	NATURE BIOTECHNOLOGY			English	Article							SITE-SPECIFIC INCORPORATION; TRANSFER-RNA-SYNTHETASE; IN-VIVO INCORPORATION; ESCHERICHIA-COLI; GENETIC ALPHABET; TRANSLATION; EFFICIENT; EXPANSION; REPLICATION; CODE	An unnatural base pair of 2-amino-6-(2-thienyl) purine (denoted by s) and pyridin-2-one (denoted by y) was developed to expand the genetic code. The ribonucleoside triphosphate of y was site-specifically incorporated into RNA, opposite s in a template, by T7 RNA polymerase. This transcription was coupled with translation in an Escherichia coli cell-free system. The yAG codon in the transcribed ras mRNA was recognized by the CUs anticodon of a yeast tyrosine transfer RNA (tRNA) variant, which had been enzymatically aminoacylated with an unnatural amino acid, 3-chlorotyrosine. Site-specific incorporation of 3-chlorotyrosine into the Ras protein was demonstrated by liquid chromatography-mass spectrometry (LC-MS) analysis of the products. This coupled transcription-translation system will permit the efficient synthesis of proteins with a tyrosine analog at the desired position.	RIKEN, JST, ERATO, Yokoyama CytoLog Project, Wako, Saitama 3510198, Japan; RIKEN, Genom Sci Ctr, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; RIKEN, Biomol Characterizat Div, Wako, Saitama 3510198, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan; Gifu Univ, Fac Engn, Dept Biomol Sci, Gifu 5011193, Japan	Japan Science & Technology Agency (JST); RIKEN; RIKEN; RIKEN; University of Tokyo; Gifu University	Hirao, I (corresponding author), RIKEN, Genom Sci Ctr, Prot Preparat NMR Facil, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	ihirao@postman.riken.go.jp; yokoyama@biochem.s.u-tokyo.ac.jp	Yokoyama, Shigeyuki/N-6911-2015; Hirao, Ichiro/G-3041-2012; OHTSUKI, Takashi/B-1471-2011; Kigawa, Takanori/A-7679-2010	Yokoyama, Shigeyuki/0000-0003-3133-7338; OHTSUKI, Takashi/0000-0002-3183-5305; Kigawa, Takanori/0000-0003-0146-9719				BAIN JD, 1992, NATURE, V356, P537, DOI 10.1038/356537a0; BAIN JD, 1989, J AM CHEM SOC, V111, P8013, DOI 10.1021/ja00202a052; Benner S. A., 1999, RNA WORLD, P163; Bock A, 2001, SCIENCE, V292, P453, DOI 10.1126/science.1060637; CHOW CM, 1993, J BIOL CHEM, V268, P12855; Cload ST, 1996, CHEM BIOL, V3, P1033, DOI 10.1016/S1074-5521(96)90169-6; CORNISH VW, 1994, P NATL ACAD SCI USA, V91, P2910, DOI 10.1073/pnas.91.8.2910; Doring V, 2001, SCIENCE, V292, P501, DOI 10.1126/science.1057718; Fujiwara T, 2001, BIOORG MED CHEM LETT, V11, P2221, DOI 10.1016/S0960-894X(01)00415-2; HECHT SM, 1992, ACCOUNTS CHEM RES, V25, P545, DOI 10.1021/ar00024a001; Hocek M, 2001, COLLECT CZECH CHEM C, V66, P483, DOI 10.1135/cccc20010483; Hohsaka T, 1999, J AM CHEM SOC, V121, P34, DOI 10.1021/ja9813109; Ishikawa M, 2000, TETRAHEDRON LETT, V41, P3931, DOI 10.1016/S0040-4039(00)00520-7; JUDICE JK, 1993, SCIENCE, V261, P1578, DOI 10.1126/science.8103944; KAWASAKI H, 1990, ANAL BIOCHEM, V191, P332, DOI 10.1016/0003-2697(90)90227-Z; KERN D, 1972, EUR J BIOCHEM, V31, P148, DOI 10.1111/j.1432-1033.1972.tb02513.x; Kigawa T, 1999, FEBS LETT, V442, P15, DOI 10.1016/S0014-5793(98)01620-2; KIGAWA T, 1995, J BIOMOL NMR, V6, P129, DOI 10.1007/BF00211776; Kowal AK, 2001, P NATL ACAD SCI USA, V98, P2268, DOI 10.1073/pnas.031488298; LEINFELDER W, 1988, NATURE, V331, P723, DOI 10.1038/331723a0; Lutz MJ, 1998, BIOORG MED CHEM LETT, V8, P499, DOI 10.1016/S0960-894X(98)00057-2; Madin K, 2000, P NATL ACAD SCI USA, V97, P559, DOI 10.1073/pnas.97.2.559; Magliery TJ, 2001, J MOL BIOL, V307, P755, DOI 10.1006/jmbi.2001.4518; Mamaev SV, 1996, J AM CHEM SOC, V118, P7243, DOI 10.1021/ja961053c; MASAKI T, 1981, BIOCHIM BIOPHYS ACTA, V660, P44, DOI 10.1016/0005-2744(81)90106-6; Matray TJ, 1999, NATURE, V399, P704, DOI 10.1038/21453; Moore B, 2000, J MOL BIOL, V298, P195, DOI 10.1006/jmbi.2000.3658; Morales JC, 1998, NAT STRUCT BIOL, V5, P950, DOI 10.1038/2925; Murakami H, 1998, J AM CHEM SOC, V120, P7520, DOI 10.1021/ja971890u; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; NOWAK MW, 1995, SCIENCE, V268, P439, DOI 10.1126/science.7716551; Nowak MW, 1998, METHOD ENZYMOL, V293, P504; Ogawa AK, 2000, J AM CHEM SOC, V122, P3274, DOI 10.1021/ja9940064; Ohno S, 2001, J BIOCHEM-TOKYO, V130, P417, DOI 10.1093/oxfordjournals.jbchem.a003001; Ohno S, 1998, J BIOCHEM, V124, P1065, DOI 10.1093/oxfordjournals.jbchem.a022221; Ohtsuki T, 2001, P NATL ACAD SCI USA, V98, P4922, DOI 10.1073/pnas.091532698; Ohtsuki T, 1996, NUCLEIC ACIDS RES, V24, P662, DOI 10.1093/nar/24.4.662; OHYAMA T, 1985, J BIOCHEM, V97, P29, DOI 10.1093/oxfordjournals.jbchem.a135053; PICCIRILLI JA, 1990, NATURE, V343, P33, DOI 10.1038/343033a0; RAPPAPORT HP, 1993, BIOCHEMISTRY-US, V32, P3047, DOI 10.1021/bi00063a016; Saks ME, 1996, J BIOL CHEM, V271, P23169, DOI 10.1074/jbc.271.38.23169; Service RF, 2000, SCIENCE, V289, P232, DOI 10.1126/science.289.5477.232; Shimizu Y, 2001, NAT BIOTECHNOL, V19, P751, DOI 10.1038/90802; Short GF, 1999, BIOCHEMISTRY-US, V38, P8808, DOI 10.1021/bi990281r; Short GF, 2000, BIOCHEMISTRY-US, V39, P8768, DOI 10.1021/bi000214t; SPIRIN AS, 1988, SCIENCE, V242, P1162, DOI 10.1126/science.3055301; SWITZER CY, 1993, BIOCHEMISTRY-US, V32, P10489, DOI 10.1021/bi00090a027; Turcatti G, 1996, J BIOL CHEM, V271, P19991, DOI 10.1074/jbc.271.33.19991; van Hest JCM, 2000, J AM CHEM SOC, V122, P1282, DOI 10.1021/ja992749j; Wang L, 2001, SCIENCE, V292, P498, DOI 10.1126/science.1060077; Wu YQ, 2000, J AM CHEM SOC, V122, P7621, DOI 10.1021/ja0009931; Yabuki T, 1998, J BIOMOL NMR, V11, P295, DOI 10.1023/A:1008276001545	52	187	254	3	43	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2002	20	2					177	182		10.1038/nbt0202-177	http://dx.doi.org/10.1038/nbt0202-177			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	517FT	11821864				2022-12-25	WOS:000173601000027
J	Chang, J; Braciale, TJ				Chang, J; Braciale, TJ			Respiratory syncytial virus infection suppresses lung CD8(+) T-cell effector activity and peripheral CD8(+) T-cell memory in the respiratory tract	NATURE MEDICINE			English	Article							EPITHELIAL-CELLS; VACCINIA VIRUS; LYMPHOCYTES-T; CLEAR VIRUS; M2 PROTEIN; MICE; DISEASE; ANERGY; DNA; IMMUNIZATION	Respiratory syncytial virus (RSV) is a major cause of morbidity from respiratory infection in infants, young children and the elderly. No effective vaccine against RSV is currently available and studies of the natural history of RSV infection suggest repeated infections with antigenically related virus strains are common throughout an individual's lifetime. We have studied the CD8(+) T-cell response during experimental murine RSV infection and found that RSV inhibits the expression of effector activity by activated RSV-specific CD8(+) T cells infiltrating the lung parenchyma and the development of pulmonary CD8(+) T-cell memory by interfering with TCR-mediated signaling. These data suggest a possible mechanism to explain the limited duration of protective immunity in RSV infection.	Univ Virginia, Hlth Sci Ctr, Beirne B Carter Ctr Immunol Res, Charlottesville, VA 22903 USA; Univ Virginia, Hlth Sci Ctr, Dept Pathol & Microbiol, Charlottesville, VA USA	University of Virginia; University of Virginia	Braciale, TJ (corresponding author), Univ Virginia, Hlth Sci Ctr, Beirne B Carter Ctr Immunol Res, Charlottesville, VA 22903 USA.			CHANG, JUN/0000-0002-8423-5987				Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; ALWAN WH, 1994, J EXP MED, V179, P81, DOI 10.1084/jem.179.1.81; ALWAN WH, 1992, CLIN EXP IMMUNOL, V88, P527; BECKER S, 1991, J IMMUNOL, V147, P4307; BEEM M, 1967, J IMMUNOL, V98, P1115; BOUSSIOTIS VA, 1994, SCIENCE, V266, P1039, DOI 10.1126/science.7973657; CANNON MJ, 1988, J EXP MED, V168, P1163, DOI 10.1084/jem.168.3.1163; Chang J, 2001, J IMMUNOL, V167, P4254, DOI 10.4049/jimmunol.167.8.4254; CHANOCK RM, 1992, PEDIATRICS, V90, P137; Falsey AR, 1998, J INFECT DIS, V177, P463, DOI 10.1086/517376; Flynn KJ, 1998, IMMUNITY, V8, P683, DOI 10.1016/S1074-7613(00)80573-7; GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026; GLEZEN WP, 1973, NEW ENGL J MED, V288, P498, DOI 10.1056/NEJM197303082881005; HALL CB, 1981, INFECT IMMUN, V33, P779, DOI 10.1128/IAI.33.3.779-783.1981; HALL CB, 1991, J INFECT DIS, V163, P693, DOI 10.1093/infdis/163.4.693; HENDERSON FW, 1979, NEW ENGL J MED, V300, P530, DOI 10.1056/NEJM197903083001004; KULKARNI AB, 1995, J VIROL, V69, P1261, DOI 10.1128/JVI.69.2.1261-1264.1995; KULKARNI AB, 1993, J VIROL, V67, P1044, DOI 10.1128/JVI.67.2.1044-1049.1993; Madrenas J, 1996, P NATL ACAD SCI USA, V93, P9736, DOI 10.1073/pnas.93.18.9736; McCluskie MJ, 1999, MOL MED, V5, P287, DOI 10.1007/BF03402065; McCluskie MJ, 1998, ANTISENSE NUCLEIC A, V8, P401, DOI 10.1089/oli.1.1998.8.401; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; Olszewska-Pazdrak B, 1998, J VIROL, V72, P4756, DOI 10.1128/JVI.72.6.4756-4764.1998; OPENSHAW PJM, 1990, J VIROL, V64, P1683, DOI 10.1128/JVI.64.4.1683-1689.1990; PRESTON FM, 1995, J INFECT DIS, V172, P919, DOI 10.1093/infdis/172.4.919; SAD S, 1995, IMMUNITY, V2, P271, DOI 10.1016/1074-7613(95)90051-9; Schwartz DA, 1997, J CLIN INVEST, V100, P68, DOI 10.1172/JCI119523; Slifka MK, 1999, NATURE, V401, P76, DOI 10.1038/43454; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; Srikiatkhachorn A, 1997, J EXP MED, V186, P421, DOI 10.1084/jem.186.3.421; SWEETSER MT, 1989, J EXP MED, V170, P1357, DOI 10.1084/jem.170.4.1357; Thomas LH, 2000, J VIROL, V74, P8425, DOI 10.1128/JVI.74.18.8425-8433.2000; Tripp RA, 1999, J VIROL, V73, P7099, DOI 10.1128/JVI.73.9.7099-7107.1999; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205	35	176	178	1	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2002	8	1					54	60		10.1038/nm0102-54	http://dx.doi.org/10.1038/nm0102-54			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	507XQ	11786907				2022-12-25	WOS:000173056900031
J	Blanc-Brude, OP; Yu, J; Simosa, H; Conte, MS; Sessa, WC; Altieri, DC				Blanc-Brude, OP; Yu, J; Simosa, H; Conte, MS; Sessa, WC; Altieri, DC			Inhibitor of apoptosis protein survivin regulates vascular injury	NATURE MEDICINE			English	Article							SMOOTH-MUSCLE-CELLS; EXPRESSION INDUCES APOPTOSIS; INTIMAL HYPERPLASIA; NEOINTIMAL HYPERPLASIA; GROWTH; ANGIOPLASTY; ACTIVATION; RIBOZYME; SPINDLE	Survivin (also termed Birc5) belongs to the family of genes known as inhibitors of apoptosis, and it has been implicated in both prevention of cell death and control of mitosis. The survivin pathway is exploited in cancer, but its potential role in vascular injury is unknown. Here, we show that balloon-mediated arterial injury in rabbits resulted in expression of survivin in vascular cells. Serum or PDGF-AB stimulated survivin expression in cultured smooth-muscle cells (SMCs), which suppressed apoptosis and prevented caspase activation. Adenoviral delivery of a phosphorylation-defective survivin mutant reversed the cytoprotective effect of PDGF in SMCs without affecting mitotic progression, suppressed neointimal formation in wire-injured mouse femoral arteries, and induced vascular cell apoptosis in vivo. These data identify survivin as a critical regulator of SMC apoptosis after acute vascular injury. Disrupting the survivin pathway may provide a novel therapy to limit pathological vessel-wall remodeling.	Yale Univ, Sch Med, Boyer Ctr Mol Med, New Haven, CT 06510 USA; Harvard Univ, Sch Med, Harvard Inst Med, Brigham & Womens Hosp,Div Vasc Surg, Boston, MA USA	Yale University; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Altieri, DC (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, 333 Cedar St, New Haven, CT 06510 USA.	dario.altieri@umassmed.edu	Sessa, William C/B-6844-2011; BLANC-BRUDE, Olivier/O-8629-2017	Sessa, William C/0000-0001-5759-1938; BLANC-BRUDE, Olivier/0000-0002-4015-0615	NCI NIH HHS [CA90917, CA78810] Funding Source: Medline; NHLBI NIH HHS [HL54131, HL57665, HL64793] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078810, R01CA090917] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054131, R37HL054131, R01HL057665, R01HL064793] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altieri DC, 2001, TRENDS MOL MED, V7, P542, DOI 10.1016/S1471-4914(01)02243-2; Bennett MR, 1999, CARDIOVASC RES, V41, P361, DOI 10.1016/S0008-6363(98)00212-0; Carter BZ, 2001, BLOOD, V97, P2784, DOI 10.1182/blood.V97.9.2784; Charles R, 2000, CIRC RES, V87, P282, DOI 10.1161/01.RES.87.4.282; Choy JC, 2001, J MOL CELL CARDIOL, V33, P1673, DOI 10.1006/jmcc.2001.1419; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Ekhterae D, 2001, AM J PHYSIOL-CELL PH, V281, pC157, DOI 10.1152/ajpcell.2001.281.1.C157; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; FORTUGNO P, IN PRESS J CELL SCI; Grossman D, 2001, P NATL ACAD SCI USA, V98, P635, DOI 10.1073/pnas.230450097; Grossman D, 2001, J CLIN INVEST, V108, P991, DOI 10.1172/JCI200113345; Hart CE, 1999, CIRCULATION, V99, P564, DOI 10.1161/01.CIR.99.4.564; Hayakawa Y, 1999, ARTERIOSCL THROM VAS, V19, P2066, DOI 10.1161/01.ATV.19.9.2066; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Kanwar JR, 2001, J NATL CANCER I, V93, P1541, DOI 10.1093/jnci/93.20.1541; Leppanen O, 2000, ARTERIOSCL THROM VAS, V20, pE89, DOI 10.1161/01.ATV.20.11.e89; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Mahboubi K, 2001, LAB INVEST, V81, P327, DOI 10.1038/labinvest.3780241; Mesri M, 2001, J CLIN INVEST, V108, P981, DOI 10.1172/JCI12983; Mesri M, 2001, AM J PATHOL, V158, P1757, DOI 10.1016/S0002-9440(10)64131-4; Miyamoto T, 1998, J CELL PHYSIOL, V177, P58, DOI 10.1002/(SICI)1097-4652(199810)177:1<58::AID-JCP6>3.0.CO;2-D; Niemann-Jonsson A, 2001, ARTERIOSCL THROM VAS, V21, P1909, DOI 10.1161/hq1201.100222; O'Connor DS, 2000, AM J PATHOL, V156, P393, DOI 10.1016/S0002-9440(10)64742-6; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Obata H, 1996, BIOCHEM BIOPH RES CO, V224, P27, DOI 10.1006/bbrc.1996.0979; Okura Y, 2000, CIRCULATION, V102, P2680, DOI 10.1161/01.CIR.102.22.2680; Olie RA, 2000, CANCER RES, V60, P2805; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Pennati M, 2002, J CLIN INVEST, V109, P285; Perlman H, 2000, CARDIOVASC RES, V45, P570, DOI 10.1016/S0008-6363(99)00346-6; Perlman H, 1997, CIRCULATION, V95, P981; Plescia J, 1998, J BIOL CHEM, V273, P20372, DOI 10.1074/jbc.273.32.20372; Pollman MJ, 1998, NAT MED, V4, P222, DOI 10.1038/nm0298-222; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Schaub FJ, 2000, NAT MED, V6, P790, DOI 10.1038/77521; Signore PE, 2001, J VASC INTERV RADIOL, V12, P79, DOI 10.1016/S1051-0443(07)61408-0; SOLLOTT SJ, 1995, J CLIN INVEST, V95, P1869, DOI 10.1172/JCI117867; Tran J, 1999, BIOCHEM BIOPH RES CO, V264, P781, DOI 10.1006/bbrc.1999.1589; Walsh K, 2000, CIRC RES, V87, P184, DOI 10.1161/01.RES.87.3.184; Wheatley SP, 2001, CURR BIOL, V11, P886, DOI 10.1016/S0960-9822(01)00238-X	42	114	130	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2002	8	9					987	994		10.1038/nm750	http://dx.doi.org/10.1038/nm750			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	589KQ	12172543				2022-12-25	WOS:000177757900034
J	Pickering, MC; Cook, HT; Warren, J; Bygrave, AE; Moss, J; Walport, MJ; Botto, M				Pickering, MC; Cook, HT; Warren, J; Bygrave, AE; Moss, J; Walport, MJ; Botto, M			Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H	NATURE GENETICS			English	Article							HEMOLYTIC-UREMIC SYNDROME; HOMOZYGOUS FACTOR-H; ALTERNATIVE PATHWAY; GLOMERULAR DEPOSITS; PROTEIN BETA-1H; CONVERTASE; DISEASE; HYPOCOMPLEMENTEMIA; HEREDITARY; FAMILY	The alternative pathway of complement is activated continuously in vivo through the C3 'tick-over' pathway(1). This pathway is triggered by the hydrolysis of C3, resulting in the formation of C3 convertase. This, in turn, generates C3b, which mediates many of the biological functions of complement. Factor H, the main regulator of this activation, prevents formation and promotes dissociation of the C3 convertase enzyme(2,3), and, together with factor I, mediates the proteolytic inactivation of C3b(4). Factor H deficiency, described in 29 individuals from 12 families(5-14) and in pigs(15), allows unhindered activation of fluid-phase C3 and severe depletion of plasma C3 (ref. 11). Membranoproliferative glomerulonephritis (MPGN) occurs in factor H-deficient humans(6,12,13) and pigs(15). Although MPGN has been reported in other conditions in which uncontrolled activation of C3 occurs, the role of C3 dysregulation in the pathogenesis of MPGN is not understood. Here we show that mice deficient in factor H (Cfh(-/-) mice) develop MPGN spontaneously and are hypersensitive to developing renal injury caused by immune complexes. Introducing a second mutation in the gene encoding complement factor B, which prevents C3 turnover in vivo, obviates the phenotype of Cfh(-/-) mice. Thus, uncontrolled C3 activation in vivo is essential for the development of MPGN associated with deficiency of factor H.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Rheumatol Sect, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Histopathol, London W12 0NN, England; Charing Cross Hosp, Dept Histopathol, Electron Microscopy Unit, London W6 8RF, England	Imperial College London; Imperial College London; Imperial College London	Botto, M (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Rheumatol Sect, Hammersmith Campus,Du Cane Rd, London W12 0NN, England.		Mohammed, Imran/J-8271-2012	Mohammed, Imran/0000-0002-8412-0768; Walport, Mark/0000-0001-7220-5273; Pickering, Matthew/0000-0002-1153-0192				Alexander JJ, 2001, J BIOL CHEM, V276, P32129, DOI 10.1074/jbc.M101299200; BERGER J, 1962, J Urol Nephrol (Paris), V68, P116; BRAI M, 1988, J CLIN IMMUNOL, V8, P50, DOI 10.1007/BF00915156; DAHA MR, 1976, J IMMUNOL, V116, P1; DROZ D, 1979, KIDNEY INT, V15, P386, DOI 10.1038/ki.1979.50; Fijen CAP, 1996, CLIN EXP IMMUNOL, V105, P511, DOI 10.1046/j.1365-2249.1996.d01-777.x; GALLE P, 1975, AM J MED, V58, P749, DOI 10.1016/0002-9343(75)90631-2; HOGASEN K, 1995, J CLIN INVEST, V95, P1054, DOI 10.1172/JCI117751; LEVY M, 1986, KIDNEY INT, V30, P949, DOI 10.1038/ki.1986.278; LOPEZLARREA C, 1987, BIOCHEM SOC T, V15, P648, DOI 10.1042/bst0150648; Matsumoto M, 1997, P NATL ACAD SCI USA, V94, P8720, DOI 10.1073/pnas.94.16.8720; NIELSEN HE, 1989, SCAND J IMMUNOL, V30, P711, DOI 10.1111/j.1365-3083.1989.tb02480.x; Ohali M, 1998, PEDIATR NEPHROL, V12, P619, DOI 10.1007/s004670050515; PANGBURN MK, 1980, J EXP MED, V152, P1102, DOI 10.1084/jem.152.4.1102; PANGBURN MK, 1977, J EXP MED, V146, P257, DOI 10.1084/jem.146.1.257; PANGBURN MK, 1978, P NATL ACAD SCI USA, V75, P2416, DOI 10.1073/pnas.75.5.2416; PEPYS MB, 1977, IMMUNOLOGY, V33, P491; PICHETTE V, 1994, AM J KIDNEY DIS, V24, P936, DOI 10.1016/S0272-6386(12)81065-1; Robson MG, 2001, J IMMUNOL, V166, P6820, DOI 10.4049/jimmunol.166.11.6820; Rougier N, 1998, J AM SOC NEPHROL, V9, P2318; SIMPSON IJ, 1978, KIDNEY INT, V13, P467, DOI 10.1038/ki.1978.69; SPITZER RE, 1969, SCIENCE, V164, P436, DOI 10.1126/science.164.3878.436; THOMPSON RA, 1981, CLIN EXP IMMUNOL, V46, P110; VERROUST PJ, 1974, KIDNEY INT, V6, P157, DOI 10.1038/ki.1974.94; VIK DP, 1988, J BIOL CHEM, V263, P16720; VOGT BA, 1995, PEDIATR NEPHROL, V9, P11, DOI 10.1007/BF00858956; WEILER JM, 1976, P NATL ACAD SCI USA, V73, P3268, DOI 10.1073/pnas.73.9.3268; West CD, 2001, AM J KIDNEY DIS, V37, P1120, DOI 10.1053/ajkd.2001.24511; WEST CD, 1995, AM J KIDNEY DIS, V25, P853, DOI 10.1016/0272-6386(95)90567-7; WOODROW DF, 1989, J PATHOL, V157, P47, DOI 10.1002/path.1711570107	30	376	400	0	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2002	31	4					424	428		10.1038/ng912	http://dx.doi.org/10.1038/ng912			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	578XV	12091909				2022-12-25	WOS:000177147100021
J	Novina, CD; Murray, MF; Dykxhoorn, DM; Beresford, PJ; Riess, J; Lee, SK; Collman, RG; Lieberman, J; Shankar, P; Sharp, PA				Novina, CD; Murray, MF; Dykxhoorn, DM; Beresford, PJ; Riess, J; Lee, SK; Collman, RG; Lieberman, J; Shankar, P; Sharp, PA			siRNA-directed inhibition of HIV-1 infection	NATURE MEDICINE			English	Article							SHORT-INTERFERING RNAS; SMALL TEMPORAL RNAS; CAENORHABDITIS-ELEGANS; GENE-EXPRESSION; HAIRPIN RNAS; C-ELEGANS; DROSOPHILA; RECEPTOR; PROTEIN; INDIVIDUALS	RNA interference silences gene expression through short interfering 21-23-mer double-strand RNA segments that guide mRNA degradation in a sequence-specific fashion. Here we report that siRNAs inhibit virus production by targeting the mRNAs for either the HIV-1 cellular receptor CD4, the viral structural Gag protein or green fluorescence protein substituted for the Nef regulatory protein. siRNAs effectively inhibit pre- and/or post-integration infection events in the HIV-1 life cycle. Thus, siRNAs may have potential for therapeutic intervention in HIV-1 and other viral infections.	Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; MIT, Ctr Canc Res, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA USA; MIT, McGovern Inst Brain Res, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; University of Pennsylvania	Novina, CD (corresponding author), Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA.	shankar@cbr.harvard.med.edu; sharppa@mit.edu	Lieberman, Judy/A-2717-2015; Dykxhoorn, Derek M/D-1357-2015	Collman, Ronald/0000-0002-0508-3701	NATIONAL CANCER INSTITUTE [P01CA042063, P30CA014051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI010523, R21AI045306, R01AI035502, R29AI035502] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034277, T32GM007748] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA42063, P30-CA14051] Funding Source: Medline; NIAID NIH HHS [F32AI10523, AI 35502, AI45306] Funding Source: Medline; NIGMS NIH HHS [T32-GM07748, R37-GM34277] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Banerjee D, 2002, BIOESSAYS, V24, P119, DOI 10.1002/bies.10046; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; BITKO V, 2001, BMC MICROBIOL, V34, P1; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chackerian B, 1997, J VIROL, V71, P3932, DOI 10.1128/JVI.71.5.3932-3939.1997; COCHRANE AW, 1990, P NATL ACAD SCI USA, V87, P1198, DOI 10.1073/pnas.87.3.1198; Dorman N, 2001, HIV Med, V2, P114, DOI 10.1046/j.1468-1293.2001.00052.x; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Gaudet J, 1996, MOL BIOL CELL, V7, P1107, DOI 10.1091/mbc.7.7.1107; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; James HA, 1998, BLOOD, V91, P371, DOI 10.1182/blood.V91.2.371.371_371_382; JONES AR, 1995, GENE DEV, V9, P1491, DOI 10.1101/gad.9.12.1491; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; Kumar M, 1998, MICROBIOL MOL BIOL R, V62, P1415, DOI 10.1128/MMBR.62.4.1415-1434.1998; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; McManus MT, 2002, RNA, V8, P842, DOI 10.1017/S1355838202024032; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Page KA, 1997, AIDS RES HUM RETROV, V13, P1077, DOI 10.1089/aid.1997.13.1077; Pal-Bhadra M, 1999, CELL, V99, P35, DOI 10.1016/S0092-8674(00)80060-4; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; PAVLAKIS GN, 1991, ANN REV AIDS RES, P41; Ratcliff F, 1997, SCIENCE, V276, P1558, DOI 10.1126/science.276.5318.1558; RATNER L, 1987, AIDS RES HUM RETROV, V3, P57, DOI 10.1089/aid.1987.3.57; Rougvie AE, 2001, NAT REV GENET, V2, P690, DOI 10.1038/35088566; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Shankar P, 1999, BLOOD, V94, P3084, DOI 10.1182/blood.V94.9.3084.421k02_3084_3093; Sharp PA, 2001, GENE DEV, V15, P485, DOI 10.1101/gad.880001; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Waterhouse PM, 2001, NATURE, V411, P834, DOI 10.1038/35081168; Wu YT, 2001, SCIENCE, V293, P1503, DOI 10.1126/science.1061548; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499; Zamore PD, 2001, NAT STRUCT BIOL, V8, P746, DOI 10.1038/nsb0901-746; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0	45	648	811	1	55	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2002	8	7					681	686		10.1038/nm725	http://dx.doi.org/10.1038/nm725			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	567QG	12042777				2022-12-25	WOS:000176495200028
J	Wang, F; Herzmark, P; Weiner, OD; Srinivasan, S; Servant, G; Bourne, HR				Wang, F; Herzmark, P; Weiner, OD; Srinivasan, S; Servant, G; Bourne, HR			Lipid products of PI(3)Ks maintain persistent cell polarity and directed motility in neutrophils	NATURE CELL BIOLOGY			English	Article							ACTIN POLYMERIZATION; CHEMOATTRACTANT RECEPTOR; F-ACTIN; CHEMOTAXIS; ACTIVATION; PROTEIN; CYTOSKELETON; PI3K-GAMMA; MIGRATION; KINASE	In gradients of external chemo-attractant, mammalian neutrophilic leukocytes (neutrophils)(1) and Dictyostelium discoideum amoebae 2 adopt a polarized morphology and selectively accumulate lipid products of phosphatidylinositol-3-OH kinases (PI(3) Ks), including PtdIns(3,4,5) P-3, at their up-gradient edges; the internal PtdIns(3,4,5) P-3 gradient substantially exceeds that of the external attractant. An accompanying report 3 presents evidence for a positive feedback loop that amplifies the gradient of internal signal: PtdIns(3,4,5) P-3 at the leading edge stimulates its own accumulation by inducing activation of one or more Rho GTPases (Rac, Cdc42, and/or Rho), which in turn increase PtdIns(3,4,5) P-3 accumulation. Here we show that interruption of this feedback by treatment with PI(3) K inhibitors reduces the size and stability of pseudopods and causes cells to migrate in jerky trajectories that deviate more from the up-gradient direction than do those of controls. Moreover, amplification of the internal PtdIns(3,4,5) P-3 gradient is markedly impaired by latrunculin or jasplakinolide, toxins that inhibit polymerization (4,5) or depolymerization(6) of actin, respectively. Thus reciprocal interplay between PtdIns(3,4,5) P-3 and polymerized actin initiates and maintains the asymmetry of intracellular signals responsible for cell polarity and directed motility.	Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bourne, HR (corresponding author), Univ Calif San Francisco, Sch Med, S-1212,Box 0450,513 Parnassus Ave, San Francisco, CA 94143 USA.		Weiner, Orion D/F-2576-2011; Wang, Fei/A-7968-2013	Weiner, Orion D/0000-0002-1778-6543; 	NATIONAL CANCER INSTITUTE [R01CA054427] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027800, R37GM027800] Funding Source: NIH RePORTER; NCI NIH HHS [CA-54427] Funding Source: Medline; NHLBI NIH HHS [HL07713] Funding Source: Medline; NIGMS NIH HHS [GM-27800] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ayscough KR, 1998, CURR BIOL, V8, P927, DOI 10.1016/S0960-9822(07)00374-0; Ayscough KR, 2000, CURR BIOL, V10, P1587, DOI 10.1016/S0960-9822(00)00859-9; BUBB MR, 1994, J BIOL CHEM, V269, P14869; Chung CY, 2001, TRENDS BIOCHEM SCI, V26, P557, DOI 10.1016/S0968-0004(01)01934-X; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; Foxman EF, 1997, J CELL BIOL, V139, P1349, DOI 10.1083/jcb.139.5.1349; Funamoto S, 2001, J CELL BIOL, V153, P795, DOI 10.1083/jcb.153.4.795; Hannigan M, 2002, P NATL ACAD SCI USA, V99, P3603, DOI 10.1073/pnas.052010699; Haugh JM, 2000, J CELL BIOL, V151, P1269, DOI 10.1083/jcb.151.6.1269; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Knall C, 1997, P NATL ACAD SCI USA, V94, P3052, DOI 10.1073/pnas.94.7.3052; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; Naccache PH, 2000, J BIOL CHEM, V275, P23636, DOI 10.1074/jbc.M001780200; Niggli V, 2000, FEBS LETT, V473, P217, DOI 10.1016/S0014-5793(00)01534-9; Niggli V, 1997, EUR J PHARMACOL, V335, P43, DOI 10.1016/S0014-2999(97)01169-2; Peyrollier K, 2000, BIOCHEM J, V352, P617, DOI 10.1042/0264-6021:3520617; Rickert P, 2000, TRENDS CELL BIOL, V10, P466, DOI 10.1016/S0962-8924(00)01841-9; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Servant G, 1999, MOL BIOL CELL, V10, P1163, DOI 10.1091/mbc.10.4.1163; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Sheikh S, 1997, BIOCHEM BIOPH RES CO, V238, P910, DOI 10.1006/bbrc.1997.7407; SPECTOR I, 1983, SCIENCE, V219, P493, DOI 10.1126/science.6681676; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; Weiner OD, 1999, NAT CELL BIOL, V1, P75, DOI 10.1038/10042; WEINER OD, NATURE CELL BIOL	26	308	314	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	2002	4	7					513	518		10.1038/ncb810	http://dx.doi.org/10.1038/ncb810			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	568UL	12080345				2022-12-25	WOS:000176562900016
J	Butzkueven, H; Zhang, JG; Hanninen, MS; Hochrein, H; Chionh, F; Shipham, KA; Emery, B; Turnley, AM; Petratos, S; Ernst, M; Bartlett, PF; Kilpatrick, TJ				Butzkueven, H; Zhang, JG; Hanninen, MS; Hochrein, H; Chionh, F; Shipham, KA; Emery, B; Turnley, AM; Petratos, S; Ernst, M; Bartlett, PF; Kilpatrick, TJ			LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival	NATURE MEDICINE			English	Article							LEUKEMIA INHIBITORY FACTOR; CILIARY NEUROTROPHIC FACTOR; MULTIPLE-SCLEROSIS LESIONS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CELL-DEATH; KAPPA-B; ACTIVATION; GAMMA; MICE; GENE	Multiple sclerosis (MS) is a disabling inflammatory demyelinating disease of the central nervous system (CNS) that primarily affects young adults. Available therapies can inhibit the inflammatory component of MS but do not suppress progressive clinical disability. An alternative approach would be to inhibit mechanisms that drive the neuropathology of MS, which often includes the death of oligodendrocytes, the cells responsible for myelinating the CNS. Identification of molecular mechanisms that mediate the stress response of oligodendrocytes to optimize their survival would serve this need. This study shows that the neurotrophic cytokine leukemia inhibitory factor (LIF) directly prevents oligodendrocyte death in animal models of MS. We also demonstrate that this therapeutic effect complements endogenous LIF receptor signaling, which already serves to limit oligodendrocyte loss during immune attack. Our results provide a novel approach for the treatment of MS.	Univ Melbourne, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3052, Australia; Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne, Vic, Australia	University of Melbourne; Walter & Eliza Hall Institute; Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Kilpatrick, TJ (corresponding author), Univ Melbourne, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3052, Australia.	kilpatrick@wehi.edu.au	Emery, Ben/I-6223-2013; Bartlett, Perry/F-3813-2012; Ernst, Matthias/D-5111-2012; Turnley, Ann/A-8125-2010; Hochrein, Hubertus/L-3697-2013	Ernst, Matthias/0000-0002-6399-1177; Hochrein, Hubertus/0000-0001-9904-1934; Butzkueven, Helmut/0000-0003-3940-8727; Turnley, Ann/0000-0002-8442-127X; Emery, Ben/0000-0002-9132-3045; Kilpatrick, Trevor/0000-0003-3999-085X				ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; *AIHW, 2000, 7 AIHW; ALOISI F, 1994, J IMMUNOL, V152, P5022; Banner LR, 1997, EXP NEUROL, V147, P1, DOI 10.1006/exnr.1997.6536; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BARRES BA, 1993, CURR BIOL, V3, P489, DOI 10.1016/0960-9822(93)90039-Q; BARRES BA, 1993, DEVELOPMENT, V118, P283; Bonetti B, 1999, AM J PATHOL, V155, P1433, DOI 10.1016/S0002-9440(10)65456-9; Bonetti B, 1997, J IMMUNOL, V159, P5733; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Brysha M, 2001, J BIOL CHEM, V276, P22086, DOI 10.1074/jbc.M102737200; Bugga L, 1998, J NEUROBIOL, V36, P509, DOI 10.1002/(SICI)1097-4695(19980915)36:4<509::AID-NEU5>3.0.CO;2-#; COMPSTON DAS, 1998, MCALPINES MULTIPLE S, P437; DSouza SD, 1996, J NEUROSCI RES, V43, P289, DOI 10.1002/(SICI)1097-4547(19960201)43:3<289::AID-JNR4>3.0.CO;2-F; Ernst M, 2001, J EXP MED, V194, P189, DOI 10.1084/jem.194.2.189; Fukunaga K, 1998, MOL NEUROBIOL, V16, P79, DOI 10.1007/BF02740604; GARD AL, 1995, DEV BIOL, V167, P596, DOI 10.1006/dbio.1995.1051; Giess R, 2002, ARCH NEUROL-CHICAGO, V59, P407, DOI 10.1001/archneur.59.3.407; GOW A, 1992, J CELL BIOL, V119, P605, DOI 10.1083/jcb.119.3.605; Hisahara S, 2000, EMBO J, V19, P341, DOI 10.1093/emboj/19.3.341; Hochrein H, 2001, J IMMUNOL, V166, P5448, DOI 10.4049/jimmunol.166.9.5448; Kappos L, 1998, LANCET, V352, P1491, DOI 10.1016/S0140-6736(98)10039-9; Kuchroo VK, 1998, RES IMMUNOL, V149, P759, DOI 10.1016/S0923-2494(99)80003-0; Lucchinetti C, 1999, BRAIN, V122, P2279, DOI 10.1093/brain/122.12.2279; Lucchinetti C, 2000, ANN NEUROL, V47, P707, DOI 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q; Marmur R, 1998, J NEUROSCI, V18, P9800; Massaro AR, 1997, EUR NEUROL, V37, P243, DOI 10.1159/000117451; Mathisen PM, 1997, J EXP MED, V186, P159, DOI 10.1084/jem.186.1.159; MATTOLI S, 1990, AM J RESP CELL MOL, V3, P145, DOI 10.1165/ajrcmb/3.2.145; MAYER M, 1994, DEVELOPMENT, V120, P143; Middleton G, 2000, J CELL BIOL, V148, P325, DOI 10.1083/jcb.148.2.325; Miller SD, 1998, RES IMMUNOL, V149, P753, DOI 10.1016/S0923-2494(99)80002-9; Morita Y, 2000, P NATL ACAD SCI USA, V97, P5405, DOI 10.1073/pnas.090084797; POZZILLI C, 1988, J NEUROL NEUROSUR PS, V51, P1058, DOI 10.1136/jnnp.51.8.1058; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; Skaper SD, 1998, MOL CELL NEUROSCI, V12, P179, DOI 10.1006/mcne.1998.0714; Slavin A, 1998, AUTOIMMUNITY, V28, P109, DOI 10.3109/08916939809003872; Soilu-Hanninen M, 2000, J NEUROSCI RES, V59, P712, DOI 10.1002/(SICI)1097-4547(20000315)59:6<712::AID-JNR3>3.3.CO;2-C; STAHL N, 1994, J NEUROBIOL, V25, P1454, DOI 10.1002/neu.480251111; TUOHY VK, 1992, J NEUROIMMUNOL, V39, P67, DOI 10.1016/0165-5728(92)90175-K; Turnley AM, 2000, J NEUROCHEM, V74, P889, DOI 10.1046/j.1471-4159.2000.0740889.x; VANDERVEEN RC, 1989, J NEUROIMMUNOL, V21, P183, DOI 10.1016/0165-5728(89)90174-4; VARTANIAN T, 1995, MOL MED, V1, P732, DOI 10.1007/BF03401888; WARE CB, 1995, DEVELOPMENT, V121, P1283	45	220	224	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2002	8	6					613	619		10.1038/nm0602-613	http://dx.doi.org/10.1038/nm0602-613			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	557KG	12042813				2022-12-25	WOS:000175907300033
J	Gloy, J; Hikasa, H; Sokol, SY				Gloy, J; Hikasa, H; Sokol, SY			Frodo interacts with Dishevelled to transduce Wnt signals	NATURE CELL BIOLOGY			English	Article							BETA-CATENIN; CELL POLARITY; XENOPUS GASTRULATION; TISSUE POLARITY; EYE DEVELOPMENT; AXIS FORMATION; PROTEIN; PATHWAYS; KINASE; DOMAINS	Dishevelled (Dsh) is required for the specification of cell fate and polarity by secreted Wnt proteins. Frodo, a novel conserved Dsh-binding protein, synergized with Xenopus Dsh (XDsh) in secondary axis induction in Xenopus laevis embryos. A dominant inhibitory construct and antisense oligonucleotide-mediated depletion of Frodo inhibited axial development in response to XDsh and XWnt8, and suppressed transcriptional activation of a reporter construct. At later embryonic stages, both dominant negative Frodo and antisense oligonucleotides interfered with the expression of regional neural markers and caused eye deficiencies, indicating that Frodo is required for normal eye and neural tissue development. Full-length Frodo RNA suppressed these loss-of-function phenotypes, attesting to their specificity. These findings establish a function for Frodo as an essential positive regulator of Wnt signalling.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Mol Med Unit, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Gloy, J (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, 330 Brookline Ave, Boston, MA 02215 USA.			Sokol, Sergei/0000-0002-3963-9202				Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; BLAKE DJ, 1995, TRENDS BIOCHEM SCI, V20, P133, DOI 10.1016/S0968-0004(00)88986-0; Boutros M, 1999, MECH DEVELOP, V83, P27, DOI 10.1016/S0925-4773(99)00046-5; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; GUGER KA, 1995, DEV BIOL, V172, P115, DOI 10.1006/dbio.1995.0009; Gumbiner BM, 1998, CURR OPIN GENET DEV, V8, P430, DOI 10.1016/S0959-437X(98)80114-7; Habas R, 2001, CELL, V107, P843, DOI 10.1016/S0092-8674(01)00614-6; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; Holowacz T, 1999, DEV BIOL, V205, P296, DOI 10.1006/dbio.1998.9108; Itoh K, 1998, MECH DEVELOP, V74, P145, DOI 10.1016/S0925-4773(98)00076-8; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; Itoh K, 2000, MOL CELL BIOL, V20, P2228, DOI 10.1128/MCB.20.6.2228-2238.2000; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Liu PT, 1999, NAT GENET, V22, P361, DOI 10.1038/11932; Mathers PH, 1997, NATURE, V387, P603, DOI 10.1038/42475; Miller JR, 1999, J CELL BIOL, V146, P427, DOI 10.1083/jcb.146.2.427; Moriguchi T, 1999, J BIOL CHEM, V274, P30957, DOI 10.1074/jbc.274.43.30957; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Park M, 2002, NAT CELL BIOL, V4, P20, DOI 10.1038/ncb716; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P245, DOI 10.1016/S0968-0004(96)30027-3; Rasmussen JT, 2001, P NATL ACAD SCI USA, V98, P3861, DOI 10.1073/pnas.071586298; Rothbacher U, 2000, EMBO J, V19, P1010, DOI 10.1093/emboj/19.5.1010; Rousset R, 2001, GENE DEV, V15, P658, DOI 10.1101/gad.869201; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Sambrook J., 2002, MOL CLONING LAB MANU; Shulman JM, 1998, TRENDS GENET, V14, P452, DOI 10.1016/S0168-9525(98)01584-4; SIVE HL, 1995, EARLY DEV XENOPUS LA; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Sokol S, 2000, NAT CELL BIOL, V2, pE124, DOI 10.1038/35017136; Sokol SY, 1999, CURR OPIN GENET DEV, V9, P405, DOI 10.1016/S0959-437X(99)80061-6; Sokol SY, 1996, CURR BIOL, V6, P1456, DOI 10.1016/S0960-9822(96)00750-6; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; Sumanas S, 2000, DEVELOPMENT, V127, P1981; Summerton J, 1997, ANTISENSE NUCLEIC A, V7, P187, DOI 10.1089/oli.1.1997.7.187; Sun TQ, 2001, NAT CELL BIOL, V3, P628, DOI 10.1038/35083016; Tada M, 2000, DEVELOPMENT, V127, P2227; Wallingford JB, 2000, NATURE, V405, P81, DOI 10.1038/35011077; Willert K, 1997, EMBO J, V16, P3089, DOI 10.1093/emboj/16.11.3089; Winklbauer R, 2001, NATURE, V413, P856, DOI 10.1038/35101621; Yan D, 2001, P NATL ACAD SCI USA, V98, P3802, DOI 10.1073/pnas.071041898; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	50	88	91	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAY	2002	4	5					351	357		10.1038/ncb784	http://dx.doi.org/10.1038/ncb784			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	547GR	11941372				2022-12-25	WOS:000175325100016
J	Hafezi-Moghadam, A; Simoncini, T; Yang, ZQ; Limbourg, FP; Plumier, JC; Rebsamen, MC; Hsieh, CM; Chui, DS; Thomas, KL; Prorock, AJ; Laubach, VE; Moskowitz, MA; French, BA; Ley, K; Liao, JK				Hafezi-Moghadam, A; Simoncini, T; Yang, ZQ; Limbourg, FP; Plumier, JC; Rebsamen, MC; Hsieh, CM; Chui, DS; Thomas, KL; Prorock, AJ; Laubach, VE; Moskowitz, MA; French, BA; Ley, K; Liao, JK			Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase	NATURE MEDICINE			English	Article							PROTEIN-KINASE-B; GLUCOCORTICOID RECEPTOR; LEUKOCYTE ADHESION; DNA-BINDING; CELLS; AKT; DEFICIENCY; INHIBITION; INDUCTION; HORMONE	Corticosteroids have been shown to exert beneficial effects in the treatment of acute myocardial infarction, but the precise mechanisms underlying their protective effects are unknown. Here we show that high-dose corticosteroids exert cardiovascular protection through a novel mechanism involving the rapid, non-transcriptional activation of endothelial nitric oxide synthase (eNOS). Binding of corticosteroids to the glucocorticoid receptor (GR) stimulated phosphatidylinositol 3-kinase and protein kinase Akt, leading to eNOS activation and nitric oxide-dependent vasorelaxation. Acute administration of pharmacological concentrations of corticosteroids in mice led to decreased vascular inflammation and reduced myocardial infarct size following ischemia and reperfusion injury. These beneficial effects of corticosteroids were abolished by GR antagonists or eNOS inhibitors in wild-type mice and were completely absent in eNOS-deficient (Nos3(-/-)) mice. The rapid activation of eNOS by the non-nuclear actions of GR, therefore, represents an important cardiovascular protective effect of acute high-dose corticosteroid therapy.	Brigham & Womens Hosp, Dept Med, Vasc Med Res Unit, Boston, MA 02115 USA; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Stroke & Neurovasc Regulat Lab, Charlestown, MA USA; Harvard Univ, Sch Med, Charlestown, MA USA; Univ Virginia, Dept Biomed Engn, Charlottesville, VA USA; Univ Virginia, Dept Surg, Charlottesville, VA USA; Univ Pisa, Dept Reprod Med & Child Dev, Pisa, Italy	Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; University of Virginia; University of Virginia; University of Pisa	Liao, JK (corresponding author), Brigham & Womens Hosp, Dept Med, Vasc Med Res Unit, 75 Francis St, Boston, MA 02115 USA.		Simoncini, Tommaso/AAC-1879-2019; Limbourg, Florian/AAF-5010-2019; Moskowitz, Michael A/D-9916-2011; Laubach, Victor E./E-8818-2015	Simoncini, Tommaso/0000-0002-2971-0079; Limbourg, Florian/0000-0002-8313-7226; Laubach, Victor E./0000-0001-9673-5383; Hafezi-Moghadam, Ali/0000-0002-5336-0697	NHLBI NIH HHS [HL48743, HL58582, R01 HL052233, P01 HL048743-080008, R01 HL052233-07, P01 HL048743-100008, F32 HL067574, R01 HL070274, R01 HL052233-06, R01 HL058582, R01 HL052233-05, HL65754, HL54136, HL62602, P01 HL048743-090008, P01 HL048743, HL70274] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065754, R01HL058582, R01HL054136, P01HL048743, R01HL062602, F32HL067574, R01HL070274, R01HL052233] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; BARZILAI D, 1972, CHEST, V61, P488, DOI 10.1378/chest.61.5.488; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BECKER PB, 1986, NATURE, V324, P686, DOI 10.1038/324686a0; Brostjan C, 1996, J BIOL CHEM, V271, P19612, DOI 10.1074/jbc.271.32.19612; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Charmandari E, 2001, J ENDOCRINOL, V169, P65, DOI 10.1677/joe.0.1690065; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; CRONSTEIN BN, 1992, P NATL ACAD SCI USA, V89, P9991, DOI 10.1073/pnas.89.21.9991; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Damiano ER, 1996, CIRC RES, V79, P1122, DOI 10.1161/01.RES.79.6.1122; DE CR, 1995, J CLIN INVEST, V96, P60; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; FLOWER RJ, 1979, NATURE, V278, P456, DOI 10.1038/278456a0; Frangogiannis NG, 1998, J MOL CELL CARDIOL, V30, P2567, DOI 10.1006/jmcc.1998.0829; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; HAMMERMAN H, 1984, CIRCULATION, V69, P611, DOI 10.1161/01.CIR.69.3.611; Huang ZH, 1996, J CEREBR BLOOD F MET, V16, P981, DOI 10.1097/00004647-199609000-00023; Ishida A, 1997, J BIOL CHEM, V272, P10050; Karin M, 1998, CELL, V93, P487, DOI 10.1016/S0092-8674(00)81177-0; Kawashima S, 2001, ARTERIOSCL THROM VAS, V21, P201, DOI 10.1161/01.ATV.21.2.201; KIRWAN JR, 1995, NEW ENGL J MED, V333, P142, DOI 10.1056/NEJM199507203330302; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; Laufs U, 2000, J CLIN INVEST, V106, P15, DOI 10.1172/JCI9639; Laufs U, 1998, CIRCULATION, V97, P1129, DOI 10.1161/01.CIR.97.12.1129; LEWIS GP, 1975, NATURE, V254, P308, DOI 10.1038/254308a0; LIBBY P, 1973, J CLIN INVEST, V52, P599, DOI 10.1172/JCI107221; LOSCALZO J, 1995, NEW ENGL J MED, V333, P251, DOI 10.1056/NEJM199507273330410; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MCGREGOR AM, 1990, NEW ENGL J MED, V322, P1739, DOI 10.1056/NEJM199006143222409; Moroi M, 1998, J CLIN INVEST, V101, P1225, DOI 10.1172/JCI1293; MULVANY MJ, 1977, CIRC RES, V41, P19, DOI 10.1161/01.RES.41.1.19; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P5193, DOI 10.1073/pnas.87.13.5193; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; Sholter DE, 2000, CAN J CARDIOL, V16, P505; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; SPATH JA, 1974, CIRC RES, V35, P44, DOI 10.1161/01.RES.35.1.44; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; VYDEN JK, 1974, AM J CARDIOL, V34, P677, DOI 10.1016/0002-9149(74)90157-X; WALSH JP, 1991, P NATL ACAD SCI USA, V88, P9184, DOI 10.1073/pnas.88.20.9184; Wenting-Van Wijk MJG, 1999, CLIN EXP RHEUMATOL, V17, P305; Yang ZQ, 2000, CIRCULATION, V101, P1019, DOI 10.1161/01.CIR.101.9.1019	44	423	441	1	36	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2002	8	5					473	479		10.1038/nm0502-473	http://dx.doi.org/10.1038/nm0502-473			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	547ZW	11984591	Green Accepted			2022-12-25	WOS:000175336800032
J	O'Connor, DH; Allen, TM; Vogel, TU; Jing, PC; DeSouza, IP; Dodds, E; Dunphy, EJ; Melsaether, C; Mothe, B; Yamamoto, H; Horton, H; Wilson, N; Hughes, AL; Watkins, DI				O'Connor, DH; Allen, TM; Vogel, TU; Jing, PC; DeSouza, IP; Dodds, E; Dunphy, EJ; Melsaether, C; Mothe, B; Yamamoto, H; Horton, H; Wilson, N; Hughes, AL; Watkins, DI			Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection	NATURE MEDICINE			English	Article							I MOLECULE MAMU-A-ASTERISK-01; CELLULAR IMMUNE-RESPONSES; MHC CLASS-I; RHESUS MACAQUES; CD8(+) LYMPHOCYTES; HIGH-AVIDITY; NUCLEOTIDE SUBSTITUTIONS; PERIPHERAL-BLOOD; RAPID SELECTION; HIV-1 INFECTION	Cytotoxic T-lymphocyte (CTL) responses peak coincident with the decline in acute HIV viremia. Despite two reports of CTL-resistant HIV variants emerging during acute infection, the contribution of acute CTL escape to HIV pathogenesis remains unclear. Difficulties inherent in studying acute HIV infection can be overcome by modeling virus-host interactions in SIV-infected rhesus macaques. We sequenced 21 complete simian immunodeficiency virus (SIV) mac239 genomes at four weeks post-infection to determine the extent of acute CTL escape. Here we show that viruses from 19 of 21 macaques escaped from CTLs during acute infection and that these escape-selecting CTLs were responsive to lower concentrations of peptide than other SIV-specific CTLs. Interestingly, CTLs that require low peptide concentrations for stimulation (high 'functional avidity') are particularly effective at controlling other viral infections. Our results suggest that acute viral escape from CTLs is a hallmark of SIV infection and that CTLs with high functional avidity can rapidly select for escape variants.	Univ Wisconsin, Wisconsin Reg Primate Res Ctr, Madison, WI 53706 USA; Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI USA; Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Watkins, DI (corresponding author), Univ Wisconsin, Wisconsin Reg Primate Res Ctr, 1223 Capitol Court, Madison, WI 53706 USA.		Allen, Todd/F-5473-2011	Allen, Todd/0000-0002-6609-1318; o'connor, david/0000-0003-2139-470X	NATIONAL CENTER FOR RESEARCH RESOURCES [R24RR015371, P51RR000167] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI049120, R01AI049120, R01AI046366] Funding Source: NIH RePORTER; NCRR NIH HHS [RR0167, RR15371] Funding Source: Medline; NIAID NIH HHS [AI49120, AI 46366] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alexander L, 2001, J VIROL, V75, P4019, DOI 10.1128/JVI.75.8.4019-4022.2001; AlexanderMiller MA, 1996, P NATL ACAD SCI USA, V93, P4102, DOI 10.1073/pnas.93.9.4102; Allen TM, 2002, J VIROL, V76, P4108, DOI 10.1128/JVI.76.8.4108-4112.2002; Allen TM, 2000, NATURE, V407, P386, DOI 10.1038/35030124; Allen TM, 2000, J IMMUNOL, V164, P4968, DOI 10.4049/jimmunol.164.9.4968; Allen TM, 1998, J IMMUNOL, V160, P6062; Allen TM, 2001, J VIROL, V75, P738, DOI 10.1128/JVI.75.2.738-749.2001; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; Chen ZW, 2000, J IMMUNOL, V164, P6474, DOI 10.4049/jimmunol.164.12.6474; Cooper S, 1999, IMMUNITY, V10, P439, DOI 10.1016/S1074-7613(00)80044-8; Day CL, 2001, J VIROL, V75, P6279, DOI 10.1128/JVI.75.14.6279-6291.2001; Derby MA, 2001, J IMMUNOL, V166, P1690, DOI 10.4049/jimmunol.166.3.1690; Evans DT, 1999, NAT MED, V5, P1270, DOI 10.1038/15224; Gallimore A, 1998, J EXP MED, V187, P1647; Goulder PJR, 2001, J EXP MED, V193, P181, DOI 10.1084/jem.193.2.181; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; Goulder PJR, 2001, NATURE, V412, P334, DOI 10.1038/35085576; Gray PM, 2001, J VIROL, V75, P10065, DOI 10.1128/JVI.75.21.10065-10072.2001; Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991; Kaul R, 2001, IMMUNOL LETT, V79, P3, DOI 10.1016/S0165-2478(01)00260-7; Kaul R, 2001, J CLIN INVEST, V107, P1303, DOI 10.1172/JCI12433; Kaul R, 2001, J CLIN INVEST, V107, P341, DOI 10.1172/JCI10714; Knapp LA, 1997, TISSUE ANTIGENS, V50, P657, DOI 10.1111/j.1399-0039.1997.tb02927.x; KOUP RA, 1994, NATURE, V370, P416, DOI 10.1038/370416a0; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Kuroda MJ, 1999, J VIROL, V73, P1573, DOI 10.1128/JVI.73.2.1573-1579.1999; Matano T, 1998, J VIROL, V72, P164, DOI 10.1128/JVI.72.1.164-169.1998; McMichael AJ, 2001, NATURE, V410, P980, DOI 10.1038/35073658; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; Mortara L, 1998, J VIROL, V72, P1403, DOI 10.1128/JVI.72.2.1403-1410.1998; NEI M, 1986, MOL BIOL EVOL, V3, P418; NEI M, 1989, MOL BIOL EVOL, V6, P290; Price DA, 1997, P NATL ACAD SCI USA, V94, P1890, DOI 10.1073/pnas.94.5.1890; REGIER DA, 1990, AIDS RES HUM RETROV, V6, P1221, DOI 10.1089/aid.1990.6.1221; REIMANN KA, 1994, J VIROL, V68, P2362, DOI 10.1128/JVI.68.4.2362-2370.1994; Robinson S, 2001, J VIROL, V75, P10179, DOI 10.1128/JVI.75.21.10179-10186.2001; Rowland-Jones SL, 2001, IMMUNOL LETT, V79, P15, DOI 10.1016/S0165-2478(01)00261-9; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; Slifka MK, 2001, NAT IMMUNOL, V2, P711, DOI 10.1038/90650; Soudeyns H, 1999, EUR J IMMUNOL, V29, P3629, DOI 10.1002/(SICI)1521-4141(199911)29:11<3629::AID-IMMU3629>3.0.CO;2-O; Trivedi P, 1996, J VIROL, V70, P6876, DOI 10.1128/JVI.70.10.6876-6883.1996; Van Baalen CA, 1998, J VIROL, V72, P6851, DOI 10.1128/JVI.72.8.6851-6857.1998; Vidal C, 1998, AIDS, V12, P1285, DOI 10.1097/00002030-199811000-00009; Wilson CC, 1999, J VIROL, V73, P3975, DOI 10.1128/JVI.73.5.3975-3985.1999; Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537; YASUTOMI Y, 1993, J VIROL, V67, P1707, DOI 10.1128/JVI.67.3.1707-1711.1993	47	318	324	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2002	8	5					493	499		10.1038/nm0502-493	http://dx.doi.org/10.1038/nm0502-493			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	547ZW	11984594				2022-12-25	WOS:000175336800035
J	Peng, KW; Facteau, S; Wegman, T; O'Kane, D; Russell, SJ				Peng, KW; Facteau, S; Wegman, T; O'Kane, D; Russell, SJ			Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides	NATURE MEDICINE			English	Article							ATTENUATED MEASLES-VIRUS; CARCINOEMBRYONIC ANTIGEN; LIVING ANIMALS; MICE; XENOGRAFTS; THERAPY; REGRESSION; KINETICS; DISEASE; SPREAD	Noninvasive methods are needed to study the kinetic properties of viruses in living organisms. Oncolytic viruses are used increasingly for cancer therapy but there is currently no satisfactory way to measure efficiency of tumor transduction, changing levels of viral gene expression or the timing of virus elimination. We therefore generated trackable oncolytic measles viruses expressing inert (nonimmunogenic, nonfunctional and accurately measurable) soluble marker peptides. The marker peptides did not compromise virus replication. Ex vivo and in vivo kinetics of the trackable viruses could be easily followed by measuring the concentrations of virally encoded marker peptides in culture supernatant or in serum. When mice bearing human tumor xenografts were challenged with the trackable viruses, distinct kinetic profiles of marker-gene expression could be correlated with distinct therapeutic outcomes. Oncolytic viruses expressing inert soluble marker polypeptides should greatly facilitate the rational development of effective, individually tailored cancer virotherapy.	Mayo Fdn, Program Mol Med, Rochester, MN 55905 USA; Mayo Fdn, Dept Lab Med & Pathol, Rochester, MN USA	Mayo Clinic; Mayo Clinic	Russell, SJ (corresponding author), Mayo Fdn, Program Mol Med, Rochester, MN 55905 USA.				NHLBI NIH HHS [HL 66958-1 A1] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bennett JJ, 2001, NAT MED, V7, P859, DOI 10.1038/89991; Bidart JM, 1999, CLIN CHEM, V45, P1695; Duprex WP, 1999, J VIROL, V73, P9568, DOI 10.1128/JVI.73.11.9568-9575.1999; GO VLW, 1976, CANCER, V37, P562, DOI 10.1002/1097-0142(197601)37:1+<562::AID-CNCR2820370721>3.0.CO;2-0; Grote D, 2001, BLOOD, V97, P3746, DOI 10.1182/blood.V97.12.3746; Heise C, 2000, J CLIN INVEST, V105, P847, DOI 10.1172/JCI9762; KIM D, 2001, NAT MED, V7, P781; LORENCE RM, 1994, JNCI-J NATL CANCER I, V86, P1228, DOI 10.1093/jnci/86.16.1228; Markert JM, 2000, GENE THER, V7, P867, DOI 10.1038/sj.gt.3301205; MARTIN KW, 1984, CANCER RES, V44, P5475; Martuza RL, 2000, J CLIN INVEST, V105, P841, DOI 10.1172/JCI9744; Mrkic B, 1998, J VIROL, V72, P7420, DOI 10.1128/JVI.72.9.7420-7427.1998; Nemunaitis J, 2001, J CLIN ONCOL, V19, P289, DOI 10.1200/JCO.2001.19.2.289; Norman KL, 2000, J CLIN INVEST, V105, P1035, DOI 10.1172/JCI9871; Oldstone MBA, 1999, CELL, V98, P629, DOI 10.1016/S0092-8674(00)80050-1; Peng KW, 2001, BLOOD, V98, P2002, DOI 10.1182/blood.V98.7.2002; RADECKE F, 1995, EMBO J, V14, P5773, DOI 10.1002/j.1460-2075.1995.tb00266.x; Shih IM, 2000, NAT MED, V6, P711, DOI 10.1038/76299; Sun X, 2001, GENE THER, V8, P1572, DOI 10.1038/sj.gt.3301554; Yoshimasu T, 1999, INT J BIOL MARKER, V14, P99, DOI 10.1177/172460089901400207	20	146	155	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2002	8	5					527	531		10.1038/nm0502-527	http://dx.doi.org/10.1038/nm0502-527			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	547ZW	11984600				2022-12-25	WOS:000175336800041
J	Lai, EC				Lai, EC			Micro RNAs are complementary to 3 ' UTR sequence motifs that mediate negative post-transcriptional regulation	NATURE GENETICS			English	Article							CAENORHABDITIS-ELEGANS; C-ELEGANS; ENHANCER; PROTEIN; LIN-14; ENCODES; BOX	Micro RNAs are a large family of noncoding RNAs of 21-22 nucleotides whose functions are generally unknown. Here a large subset of Drosophila micro RNAs is shown to be perfectly complementary to several classes of sequence motif previously demonstrated to mediate negative post-transcriptional regulation. These findings suggest a more general role for micro RNAs in gene regulation through the formation of RNA duplexes.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Lai, EC (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 545 Life Sci Addit 3200, Berkeley, CA 94720 USA.	lai@fruitfly.bdgp.berkeley.edu	Lai, Eric C/A-3412-2008; Lai, Eric/AAO-1143-2021	Lai, Eric/0000-0002-8432-5851				Ambros V, 2001, CELL, V107, P823, DOI 10.1016/S0092-8674(01)00616-X; Ha I, 1996, GENE DEV, V10, P3041, DOI 10.1101/gad.10.23.3041; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lai EC, 1998, CELL, V93, P1103, DOI 10.1016/S0092-8674(00)81454-3; Lai EC, 1997, DEVELOPMENT, V124, P4847; Lai EC, 2000, DEVELOPMENT, V127, P291; Lai EC, 1998, DEVELOPMENT, V125, P4077; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Leviten MW, 1997, DEVELOPMENT, V124, P4039; Moss EG, 1997, CELL, V88, P637, DOI 10.1016/S0092-8674(00)81906-6; Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4	15	1143	1249	2	69	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2002	30	4					363	364		10.1038/ng865	http://dx.doi.org/10.1038/ng865			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	536BZ	11896390				2022-12-25	WOS:000174682000011
J	Tomlinson, IPM; Alam, NA; Rowan, AJ; Barclay, E; Jaeger, EEM; Kelsell, D; Leigh, I; Gorman, P; Lamlum, H; Rahman, S; Roylance, RR; Olpin, S; Bevan, S; Barker, K; Hearle, N; Houlston, RS; Kiuru, M; Lehtonen, R; Karhu, A; Vilkki, S; Laiho, P; Eklund, C; Vierimaa, O; Aittomaki, K; Hietala, M; Sistonen, P; Paetau, A; Salovaara, R; Herva, R; Launonen, V; Aaltonen, LA				Tomlinson, IPM; Alam, NA; Rowan, AJ; Barclay, E; Jaeger, EEM; Kelsell, D; Leigh, I; Gorman, P; Lamlum, H; Rahman, S; Roylance, RR; Olpin, S; Bevan, S; Barker, K; Hearle, N; Houlston, RS; Kiuru, M; Lehtonen, R; Karhu, A; Vilkki, S; Laiho, P; Eklund, C; Vierimaa, O; Aittomaki, K; Hietala, M; Sistonen, P; Paetau, A; Salovaara, R; Herva, R; Launonen, V; Aaltonen, LA		Multiple Leiomyoma Consortium	Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer	NATURE GENETICS			English	Article							FUMARASE DEFICIENCY; MITOCHONDRIAL; GENE; ENCEPHALOPATHY; PARAGANGLIOMA; RISK	Uterine leiomyomata (fibroids) are common and clinically important tumors, but little is known about their etiology and pathogenesis(1-3). We previously mapped a gene that predisposes to multiple fibroids, cutaneous leiomyomata and renal cell carcinoma to chromosome 1q42.3-q43 (refs 4-6). Here we show, through a combination of mapping critical recombinants, identifying individuals with germline mutations and screening known and predicted transcripts, that this gene encodes fumarate hydratase, an enzyme of the tricarboxylic acid cycle. Leiomyomatosis-associated mutations are predicted to result in absent or truncated protein, or substitutions or deletions of highly conserved amino acids. Activity of fumarate hydratase is reduced in lymphoblastoid cells from individuals with leiomyomatosis. This enzyme acts as a tumor suppressor in familial leiomyomata, and its measured activity is very low or absent in tumors from individuals with leiomyomatosis. Mutations in FH also occur in the recessive condition fumarate hydratase deficiency(7-11), and some parents of people with this condition are susceptible to leiomyomata. Thus, heterozygous and homozygous or compound heterozygous mutants have very different clinical phenotypes. Our results provide clues to the pathogenesis of fibroids and emphasize the importance of mutations of housekeeping and mitochondrial proteins in the pathogenesis of common types of tumor(12-14).	Imperial Canc Res Fund, Mol & Populat Genet Lab, London WC2A 3PX, England; Univ London Queen Mary Coll, St Bartholomews & London Sch Med & Dent, Ctr Cutaneous Res, London E1 4NS, England; Inst Child Hlth, Biochem Endocrinol & Metab Unit, London, England; Sheffield Childrens Hosp, Sheffield S10 2TH, S Yorkshire, England; Inst Canc Res, Haddow Labs, Sect Canc Genet, Sutton SM2 5NG, Surrey, England; Univ Helsinki, Biomedicum Helsinki, Dept Med Genet, FIN-00014 Helsinki, Finland; Oulu Univ Hosp, Dept Clin Genet, FIN-90220 Oulu, Finland; Turku Univ Hosp, Dept Clin Genet, FIN-20520 Turku, Finland; Turku Univ Hosp, Dept Med Genet, FIN-20520 Turku, Finland; Finnish Red Cross Blood Transfus Serv, FIN-00310 Helsinki, Finland; Univ Helsinki, Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland; Oulu Univ Hosp, Dept Pathol, FIN-90220 Oulu, Finland	Cancer Research UK; University of London; Queen Mary University London; University of London; University College London; Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital; University of London; Institute of Cancer Research - UK; University of Helsinki; University of Oulu; University of Turku; University of Turku; University of Helsinki; University of Oulu	Tomlinson, IPM (corresponding author), Imperial Canc Res Fund, Mol & Populat Genet Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Rahman, Shamima/M-7904-2019; Kelsell, David P/F-8767-2011; Toon, Christopher W/G-3610-2012; Aaltonen, Lauri/A-5375-2010; Rahman, Shamima/C-5232-2008	Aaltonen, Lauri/0000-0001-6839-4286; Rahman, Shamima/0000-0003-2088-730X; Kiuru, Maija/0000-0002-7010-5516; Lehtonen, Rainer Juhani/0000-0002-8343-0318; Karhu, Auli/0000-0002-7927-0796; Houlston, Richard/0000-0002-5268-0242; Bevan, Steve/0000-0003-0490-6830; Kelsell, David/0000-0002-9910-7144; olpin, simon/0000-0001-9018-5173; Kuismin, Outi/0000-0002-0157-8985	PHS HHS [U59309] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alam NA, 2001, AM J HUM GENET, V68, P1264, DOI 10.1086/320124; Astuti D, 2001, AM J HUM GENET, V69, P49, DOI 10.1086/321282; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; BOURGERON T, 1994, J CLIN INVEST, V93, P2514, DOI 10.1172/JCI117261; Coughlin EM, 1998, MOL GENET METAB, V63, P254, DOI 10.1006/mgme.1998.2684; GELLERA C, 1990, NEUROLOGY, V40, P495, DOI 10.1212/WNL.40.3_Part_1.495; HATCH MD, 1978, ANAL BIOCHEM, V85, P271, DOI 10.1016/0003-2697(78)90299-3; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; Kiuru M, 2001, AM J PATHOL, V159, P825, DOI 10.1016/S0002-9440(10)61757-9; Launonen V, 2001, P NATL ACAD SCI USA, V98, P3387, DOI 10.1073/pnas.051633798; LIOCHEV SI, 1992, P NATL ACAD SCI USA, V89, P5892, DOI 10.1073/pnas.89.13.5892; Luoto R, 2000, MATURITAS, V37, P15, DOI 10.1016/S0378-5122(00)00160-2; Niemann S, 2000, NAT GENET, V26, P268, DOI 10.1038/81551; Rustin P, 1997, BBA-MOL BASIS DIS, V1361, P185, DOI 10.1016/S0925-4439(97)00035-5; Takamizawa S, 1999, GYNECOL OBSTET INVES, V48, P193, DOI 10.1159/000010172; VIKHLYAEVA EM, 1995, INT J GYNECOL OBSTET, V51, P127, DOI 10.1016/0020-7292(95)02533-I; Weaver T, 1997, PROTEIN SCI, V6, P834	17	1070	1099	0	46	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2002	30	4					406	410		10.1038/ng849	http://dx.doi.org/10.1038/ng849			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	536BZ	11865300				2022-12-25	WOS:000174682000018
J	Wu, XFS; Rao, K; Zhang, H; Wang, F; Sellers, JR; Matesic, LE; Copeland, NG; Jenkins, NA; Hammer, JA				Wu, XFS; Rao, K; Zhang, H; Wang, F; Sellers, JR; Matesic, LE; Copeland, NG; Jenkins, NA; Hammer, JA			Identification of an organelle receptor for myosin-Va	NATURE CELL BIOLOGY			English	Article							KINESIN-LIKE PROTEIN; MELANOSOME TRANSPORT; DILUTE MELANOCYTES; RAB27A; MUTATIONS; FAMILY	Little is known about how molecular motors bind to their vesicular cargo. Here we show that myosin-Va, an actin-based vesicle motor, binds to one of its cargoes, the melanosome, by interacting with a receptor-protein complex containing Rab27a and melanophilin, a postulated Rab27a effector. Rab27a binds to the melanosome first and then recruits melanophilin, which in turn recruits myosin-Va. Melanophilin creates this link by binding to Rab27a in a GTP-dependent fashion through its amino terminus, and to myosin-Va through its carboxy terminus. Moreover, this latter interaction, similar to the ability of myosin-Va to colocalize with melanosomes and influence their distribution in vivo, is absolutely dependent on the presence of exon-F, an alternatively spliced exon in the myosin-Va tall. These results provide the first molecular description of an organelle receptor for an actin-based motor, illustrate how alternate exon usage can be used to specify cargo, and further expand the functional repertoire of Rab GTPases and their effectors.	NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA; NCI, Mouse Canc Genet Program, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wu, XFS (corresponding author), NHLBI, Cell Biol Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.	hammerj@nhlbi.nih.gov			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000514, Z01HL000514] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bahadoran P, 2001, J CELL BIOL, V152, P843, DOI 10.1083/jcb.152.4.843; DekkerOhno K, 1996, BRAIN RES, V714, P226, DOI 10.1016/0006-8993(95)01560-4; Echard A, 1998, SCIENCE, V279, P580, DOI 10.1126/science.279.5350.580; Fontijn RD, 2001, MOL CELL BIOL, V21, P2944, DOI 10.1128/MCB.21.8.2944-2955.2001; Haddad EK, 2001, J CELL BIOL, V152, P835, DOI 10.1083/jcb.152.4.835; Hales CM, 2001, J BIOL CHEM, V276, P39067, DOI 10.1074/jbc.M104831200; Hammer JA, 2002, CURR OPIN CELL BIOL, V14, P69, DOI 10.1016/S0955-0674(01)00296-4; Hearing V. J., 1993, PIGMENTATION PIGMENT, P4; Hill E, 2000, EMBO J, V19, P5711, DOI 10.1093/emboj/19.21.5711; Huang JD, 1998, GENETICS, V148, P1963; Hume AN, 2001, J CELL BIOL, V152, P795, DOI 10.1083/jcb.152.4.795; Jung G, 2001, J CELL BIOL, V153, P1479, DOI 10.1083/jcb.153.7.1479; Karcher RL, 2001, SCIENCE, V293, P1317, DOI 10.1126/science.1061086; Klopfenstein DR, 2000, CELL, V103, P537, DOI 10.1016/S0092-8674(00)00144-6; KOYAMA YI, 1981, ANAT REC, V201, P599, DOI 10.1002/ar.1092010404; Lapierre LA, 2001, MOL BIOL CELL, V12, P1843, DOI 10.1091/mbc.12.6.1843; Matesic LE, 2001, P NATL ACAD SCI USA, V98, P10238, DOI 10.1073/pnas.181336698; Menasche G, 2000, NAT GENET, V25, P173, DOI 10.1038/76024; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; MOORE KJ, 1988, GENETICS, V119, P933; Nielsen E, 1999, NAT CELL BIOL, V1, P376, DOI 10.1038/14075; Pastural E, 1997, NAT GENET, V16, P289, DOI 10.1038/ng0797-289; Provance DW, 1996, P NATL ACAD SCI USA, V93, P14554, DOI 10.1073/pnas.93.25.14554; Pruyne D, 2000, J CELL SCI, V113, P571; Schott D, 1999, J CELL BIOL, V147, P791, DOI 10.1083/jcb.147.4.791; SEABRA MC, 1995, J BIOL CHEM, V270, P24420, DOI 10.1074/jbc.270.41.24420; SEPERACK PK, 1995, EMBO J, V14, P2326, DOI 10.1002/j.1460-2075.1995.tb07227.x; Stinchcombe JC, 2001, J CELL BIOL, V152, P825, DOI 10.1083/jcb.152.4.825; STROBEL MC, 1990, MOL CELL BIOL, V10, P501, DOI 10.1128/MCB.10.2.501; WalchSolimena C, 1997, J CELL BIOL, V137, P1495, DOI 10.1083/jcb.137.7.1495; Wei Q, 1997, J MUSCLE RES CELL M, V18, P517, DOI 10.1023/A:1018659117569; Wilson SM, 2000, P NATL ACAD SCI USA, V97, P7933, DOI 10.1073/pnas.140212797; WU X, 2000, TRENDS CELL BIOL, V12, P42; Wu XF, 1997, J CELL SCI, V110, P847; Wu XF, 1998, J CELL BIOL, V143, P1899, DOI 10.1083/jcb.143.7.1899; Wu XF, 2001, J CELL SCI, V114, P1091; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	37	358	366	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2002	4	4					271	278		10.1038/ncb760	http://dx.doi.org/10.1038/ncb760			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	541PY	11887186				2022-12-25	WOS:000174994000014
J	Yeakley, JM; Fan, JB; Doucet, D; Luo, L; Wickham, E; Ye, Z; Chee, MS; Fu, XD				Yeakley, JM; Fan, JB; Doucet, D; Luo, L; Wickham, E; Ye, Z; Chee, MS; Fu, XD			Profiling alternative splicing on fiber-optic arrays	NATURE BIOTECHNOLOGY			English	Article							KERATINOCYTE GROWTH-FACTOR; PRE-MESSENGER-RNA; HUMAN GENOME; RECEPTOR; DIVERSITY; CANCER; CELLS; GENE; OVEREXPRESSION; ACTIVATION	The human transcriptome is marked by extensive alternative mRNA splicing and the expression of many closely related genes, which may be difficult to distinguish using standard microarray techniques. Here we describe a sensitive and specific assay for parallel analysis of mRNA isoforms on a fiber-optic microarray platform. The method permits analysis of mRNA transcripts without prior RNA purification or cDNA synthesis. Using an endogenously expressed viral transcript as a model, we demonstrated that the assay readily detects mRNA isoforms from as little as 10-100 pg of total cellular RNA or directly from a few cells. Multiplexed analysis of human cancer cell lines revealed differences in mRNA splicing and suggested a potential autocrine mechanism in the development of choriocarcinomas. Our approach may be useful in the large-scale analysis of the role of alternative splicing in development and disease.	Illumina INc, San Diego, CA 92121 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA	Illumina; University of California System; University of California San Diego	Fan, JB (corresponding author), Illumina INc, 9885 TowneCtr Dr, San Diego, CA 92121 USA.	jfan@illumina.com; xdfu@ucsd.edu						Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Carstens RP, 1997, ONCOGENE, V15, P3059, DOI 10.1038/sj.onc.1201498; De Moerlooze L, 2000, DEVELOPMENT, V127, P483; Fan JB, 2000, GENOME RES, V10, P853, DOI 10.1101/gr.10.6.853; Ferguson JA, 2000, ANAL CHEM, V72, P5618, DOI 10.1021/ac0008284; Gerry NP, 1999, J MOL BIOL, V292, P251, DOI 10.1006/jmbi.1999.3063; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; Hajihosseini MK, 2001, P NATL ACAD SCI USA, V98, P3855, DOI 10.1073/pnas.071586898; Harper Joan E., 1992, Gene Expression, V2, P19; Hu GK, 2001, GENOME RES, V11, P1237, DOI 10.1101/gr.165501; James M C, 2000, Prog Cell Cycle Res, V4, P71; Jiang ZH, 1999, P SOC EXP BIOL MED, V220, P64, DOI 10.1046/j.1525-1373.1999.d01-11.x; KLEPPE K, 1970, P NATL ACAD SCI USA, V67, P68, DOI 10.1073/pnas.67.1.68; LANDEGREN U, 1988, SCIENCE, V241, P1077, DOI 10.1126/science.3413476; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Liggett WH, 1998, J CLIN ONCOL, V16, P1197, DOI 10.1200/JCO.1998.16.3.1197; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Michael KL, 1998, ANAL CHEM, V70, P1242, DOI 10.1021/ac971343r; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; Nilsson M, 2001, NUCLEIC ACIDS RES, V29, P578, DOI 10.1093/nar/29.2.578; Schmucker D, 2000, CELL, V101, P671, DOI 10.1016/S0092-8674(00)80878-8; Shoemaker DD, 2001, NATURE, V409, P922, DOI 10.1038/35057141; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Taniguchi F, 1998, MOL REPROD DEV, V50, P54, DOI 10.1002/(SICI)1098-2795(199805)50:1&lt;54::AID-MRD7&gt;3.0.CO;2-W; Taniguchi F, 2000, AM J OBSTET GYNECOL, V182, P692, DOI 10.1067/mob.2000.104225; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Walt DR, 2000, SCIENCE, V287, P451, DOI 10.1126/science.287.5452.451; Watanabe M, 2000, PATHOL INT, V50, P363, DOI 10.1046/j.1440-1827.2000.01054.x; Xu XL, 1999, CELL TISSUE RES, V296, P33, DOI 10.1007/s004410051264; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513	33	164	203	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2002	20	4					353	358		10.1038/nbt0402-353	http://dx.doi.org/10.1038/nbt0402-353			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	536BY	11923840				2022-12-25	WOS:000174681900021
J	Hamada, F; Bienz, M				Hamada, F; Bienz, M			A Drosophila APC tumour suppressor homologue functions in cellular adhesion	NATURE CELL BIOLOGY			English	Article							CADHERIN-BASED ADHESION; REGULATES BETA-CATENIN; POLYPOSIS-COLI; UBIQUITOUS EXPRESSION; SMALL-INTESTINE; ARMADILLO; PROTEIN; GENE; LOCALIZATION; CANCER	Adenomatous polyposis coli (APC) is an important tumour suppressor in the intestinal epithelium. Its function in reducing nuclear beta-catenin and T-cell factor (TCF)-mediated transcription is conserved from Drosophila to mammals. But APC proteins are also associated with the plasma membrane. Here, we show that mutational inactivation of Drosophila E-APC causes delocalization of Armadillo (the Drosophila beta-catenin) but not DE-cadherin from adhesive plasma membranes. Extensive gaps between these membranes are visible at the ultrastructural level. The oocyte is also mislocalized in E-APC mutant egg chambers, a phenotype that results from a failure of cadherin-based adhesion. These results indicate that Drosophila APC functions in cellular adhesion; these results could have implications for colorectal adenoma formation and tumour progression in humans.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Bienz, M (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.							Ahmed Y, 1998, CELL, V93, P1171, DOI 10.1016/S0092-8674(00)81461-0; Ayscough K, 1998, METHOD ENZYMOL, V298, P18, DOI 10.1016/S0076-6879(98)98004-1; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Bienz M, 1999, CURR OPIN GENET DEV, V9, P595, DOI 10.1016/S0959-437X(99)00016-7; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; Chou TB, 1996, GENETICS, V144, P1673; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Cox RT, 1996, J CELL BIOL, V134, P133, DOI 10.1083/jcb.134.1.133; DAWSON PA, 1976, CANCER, V37, P2388, DOI 10.1002/1097-0142(197605)37:5<2388::AID-CNCR2820370531>3.0.CO;2-9; Godt D, 1998, NATURE, V395, P387, DOI 10.1038/26493; Gonzalez-Reyes A, 1998, DEVELOPMENT, V125, P3635; Hamada F, 1999, GENES CELLS, V4, P465, DOI 10.1046/j.1365-2443.1999.00272.x; Hayashi S, 1997, P NATL ACAD SCI USA, V94, P242, DOI 10.1073/pnas.94.1.242; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Lu BW, 2001, NATURE, V409, P522, DOI 10.1038/35054077; MAHOWALD AP, 1980, OOGENESIS; McCartney BM, 1999, J CELL BIOL, V146, P1303, DOI 10.1083/jcb.146.6.1303; MUGHAL S, 1978, JNCI-J NATL CANCER I, V60, P753, DOI 10.1093/jnci/60.4.753; NAGASE H, 1993, HUM MUTAT, V2, P425, DOI 10.1002/humu.1380020602; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Neufeld KL, 2000, P NATL ACAD SCI USA, V97, P12085, DOI 10.1073/pnas.220401797; NOORDERMEER J, 1992, DEVELOPMENT, V116, P711; ODA H, 1994, DEV BIOL, V165, P716, DOI 10.1006/dbio.1994.1287; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1993, DEVELOPMENT, V118, P1191; Polakis P, 2000, GENE DEV, V14, P1837; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Rosin-Arbesfeld R, 2001, EMBO J, V20, P5929, DOI 10.1093/emboj/20.21.5929; Samowitz WS, 1999, CANCER RES, V59, P1442; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; Senda T, 1996, BIOCHEM BIOPH RES CO, V223, P329, DOI 10.1006/bbrc.1996.0894; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; TEPASS U, 1994, DEV BIOL, V161, P563, DOI 10.1006/dbio.1994.1054; Tepass U, 1997, BIOESSAYS, V19, P673, DOI 10.1002/bies.950190807; Tilney LG, 1996, J CELL BIOL, V133, P61, DOI 10.1083/jcb.133.1.61; Townsley FM, 2000, CURR BIOL, V10, P1339, DOI 10.1016/S0960-9822(00)00770-3; Wieschaus E., 1986, P199; YOFFE KB, 1995, DEV BIOL, V170, P636, DOI 10.1006/dbio.1995.1243; Yu X, 1999, MECH DEVELOP, V84, P69, DOI 10.1016/S0925-4773(99)00072-6; Yu X, 1999, NAT CELL BIOL, V1, P144, DOI 10.1038/11064; Yu X, 1996, DEVELOPMENT, V122, P849	49	60	62	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAR	2002	4	3					208	213		10.1038/ncb755	http://dx.doi.org/10.1038/ncb755			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	527VR	11862214				2022-12-25	WOS:000174209100013
J	Stemmer, WPC				Stemmer, WPC			How to publish DNA sequences with copyright protection	NATURE BIOTECHNOLOGY			English	Editorial Material									Maxygen Inc, Res & Dev, Redwood City, CA 94063 USA		Stemmer, WPC (corresponding author), Maxygen Inc, Res & Dev, 515 Galveston Dr, Redwood City, CA 94063 USA.							BOORSTYN N, 1994, BOORSTYN COPYRIGHT, V1; COOPER IP, 1982, BIOTECHNOLOGY LAW, V1	2	6	6	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2002	20	3					217	217		10.1038/nbt0302-217	http://dx.doi.org/10.1038/nbt0302-217			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	526RE	11875409	Bronze			2022-12-25	WOS:000174142800023
J	Boerkoel, CF; Takashima, H; John, J; Yan, J; Stankiewicz, P; Rosenbarker, L; Andre, JL; Bogdanovic, R; Burguet, A; Cockfield, S; Cordeiro, I; Frund, S; Illies, F; Joseph, M; Kaitila, I; Lama, G; Loirat, C; McLeod, DR; Milford, DV; Petty, EM; Rodrigo, F; Saraiva, JM; Schmidt, B; Smith, GC; Spranger, J; Stein, A; Thiele, H; Tizard, J; Weksberg, R; Lupski, JR; Stockton, DW				Boerkoel, CF; Takashima, H; John, J; Yan, J; Stankiewicz, P; Rosenbarker, L; Andre, JL; Bogdanovic, R; Burguet, A; Cockfield, S; Cordeiro, I; Frund, S; Illies, F; Joseph, M; Kaitila, I; Lama, G; Loirat, C; McLeod, DR; Milford, DV; Petty, EM; Rodrigo, F; Saraiva, JM; Schmidt, B; Smith, GC; Spranger, J; Stein, A; Thiele, H; Tizard, J; Weksberg, R; Lupski, JR; Stockton, DW			Mutant chromatin remodeling protein SMARCAL1 causes Schimke immuno-osseous dysplasia	NATURE GENETICS			English	Article							CRYSTAL-STRUCTURE; DNA; MUTATIONS; COMPLEX; MOTIFS; DOMAIN	Schimke immuno-osseous dysplasia (SIOD, MIM 242900) is an autosomal-recessive pleiotropic disorder with the diagnostic features of spondyloepiphyseal dysplasia, renal dysfunction and T-cell immunodeficiency(1-3). using genome-wide linkage mapping and a positional candidate approach, we determined that mutations in SMARCAL1 (SWI/SNF2-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a-like 1), are responsible for SIOD. Through analysis of data from persons with SIOD in 26 unrelated families, we observed that affected individuals from 13 of 23 families with severe disease had two alleles with nonsense, frameshift or splicing mutations, whereas affected individuals from 3 of 3 families with milder disease had a missense mutation on each allele. These observations indicate that some missense mutations allow retention of partial SMARCAL1 function and thus cause milder disease.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Ophthalmol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Kleberg Genotyping Ctr, Houston, TX 77030 USA; CHU Nancy, Hop Enfants, Vandoeuvre Les Nancy, France; Inst Mother & Child Hlth Care Serbia, Belgrade, Yugoslavia; CHU Besancon, Unite Nephrol Pediat, F-25030 Besancon, France; Univ Alberta, Edmonton, AB, Canada; Hosp Santa Maria, Unidade Genet, Serv Pediat, Lisbon, Portugal; KfH Kinderdialyse, Munster, Germany; Univ Essen Gesamthsch Klinikum, Kinderklin, D-4300 Essen, Germany; Phoenix Childrens Hosp, Sect Pediat Nephrol, Phoenix, AZ USA; Univ Helsinki, Cent Hosp, Clin Genet Unit, Helsinki, Finland; Univ Naples Federico II, Dept Pediat, Naples, Italy; Hop Robert Debre, Serv Nephrol, F-75019 Paris, France; Alberta Childrens Prov Gen Hosp, Calgary, AB T2T 5C7, Canada; Birmingham Childrens Hosp, Dept Nephrol, Birmingham, W Midlands, England; Univ Michigan, Sch Med, Div Med Genet, Ann Arbor, MI USA; Univ Madrid, Hosp Virgen Arrixaca, Madrid, Spain; Hosp Pediat Coimbra, Consulta Genet, Coimbra, Portugal; Univ Cologne, Kinderklin, Cologne, Germany; Univ Wales Hosp, KRUF Childrens Kidney Ctr, Cardiff CF4 4XW, S Glam, Wales; Johannes Gutenberg Univ Mainz, Kinderklin, D-6500 Mainz, Germany; Univ Halle Wittenberg, Inst Humangenet & Med Biol, Halle An Der Saale, Germany; Bristol Royal Hosp Children, Renal Unit, Bristol, Avon, England; Univ Toronto, Hosp Sick Children, Dept Pediat, Div Clin & Metab Genet, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Dept Med Genet & Microbiol, Div Clin & Metab Genet, Toronto, ON M5G 1X8, Canada	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; CHU de Nancy; Universite de Franche-Comte; CHU Besancon; University of Alberta; Universidade de Lisboa; Hospital Santa Maria; University of Duisburg Essen; Phoenix Children's Hospital; University of Helsinki; Helsinki University Central Hospital; University of Naples Federico II; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Alberta Childrens Hospital; University of Calgary; University of Birmingham; University of Michigan System; University of Michigan; Hospital Clinico Universitario Virgen de la Arrixaca; Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra (CHUC); University of Cologne; Cardiff University; Johannes Gutenberg University of Mainz; Martin Luther University Halle Wittenberg; Bristol Royal Hospital For Children; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Boerkoel, CF (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.	boerkoel@bcm.tmc.edu	Bogdanovic, Radovan/R-8847-2019; Thiele, Holger/ABE-6792-2020; Stankiewicz, Paweł/AAP-7906-2021; Boerkoel, Cornelius Franciscus/AFW-4948-2022	Thiele, Holger/0000-0002-0169-998X; Stankiewicz, Paweł/0000-0002-6456-7490; Boerkoel, Cornelius Franciscus/0000-0003-3097-241X; Yan, Jiong/0000-0003-0536-8130; Saraiva, Jorge Manuel/0000-0002-7232-3509; Stein, Anja/0000-0002-0497-4609				Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Boerkoel CF, 2000, EUR J PEDIATR, V159, P1, DOI 10.1007/s004310050001; Coleman MA, 2000, GENOMICS, V65, P274, DOI 10.1006/geno.2000.6174; den Dunnen JT, 2000, HUM MUTAT, V15, P7; GIBBONS RJ, 1995, CELL, V80, P837, DOI 10.1016/0092-8674(95)90287-2; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; Gudbjartsson DF, 2000, NAT GENET, V25, P12, DOI 10.1038/75514; Hall MC, 1997, J BIOL CHEM, V272, P18614, DOI 10.1074/jbc.272.30.18614; Hall MC, 1998, J MOL BIOL, V277, P257, DOI 10.1006/jmbi.1997.1614; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; Havas K, 2001, CELL MOL LIFE SCI, V58, P673, DOI 10.1007/PL00000891; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; Saraiva JM, 1999, J MED GENET, V36, P786, DOI 10.1136/jmg.36.10.786; SCHAFFER AA, 1994, HUM HERED, V44, P225, DOI 10.1159/000154222; SCHIMKE RN, 1971, LANCET, V2, P1088; Sevenet N, 1999, HUM MOL GENET, V8, P2359, DOI 10.1093/hmg/8.13.2359; Shaffer LG, 1997, AM J MED GENET, V69, P325, DOI 10.1002/(SICI)1096-8628(19970331)69:3<325::AID-AJMG20>3.0.CO;2-S; SPRANGER J, 1991, J PEDIATR-US, V119, P64, DOI 10.1016/S0022-3476(05)81040-6; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463	25	229	245	0	10	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2002	30	2					215	220		10.1038/ng821	http://dx.doi.org/10.1038/ng821			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	519CY	11799392				2022-12-25	WOS:000173708700025
J	Enattah, NS; Sahi, T; Savilahti, E; Terwilliger, JD; Peltonen, L; Jarvela, I				Enattah, NS; Sahi, T; Savilahti, E; Terwilliger, JD; Peltonen, L; Jarvela, I			Identification of a variant associated with adult-type hypolactasia	NATURE GENETICS			English	Article							PERSISTENCE/NON-PERSISTENCE POLYMORPHISM; LACTASE-PHLORIZIN HYDROLASE; LINKAGE ANALYSIS; POINT MUTATIONS; GENE; DISEQUILIBRIUM; DEFICIENCY; EVOLUTION; CHILDREN; HUMANS	Adult-type hypolactasia, also known as lactase non-persistence (lactose intolerance), is a common autosomal recessive condition resulting from the physiological decline in activity of the lactase-phlorizin hydrolase (LPH) in intestinal cells after weaning. LPH hydrolyzes lactose into glucose and galactose. Sequence analyses of the coding and promoter regions of LCT, the gene encoding LPH, has revealed no DNA variations correlating with lactase nonpersistence(1,2). An associated haplotype spanning LCT, as well as a distinct difference in the transcript levels of 'non-persistence' and 'persistence' alleles in heterozygotes, suggest that a cis-acting element contributes to the lactase non-persistence phenotype(3,4). Using linkage disequilibrium (LD) and haplotype analysis of nine extended Finnish families, we restricted the locus to a 47-kb interval on 2q21. Sequence analysis of the complete region and subsequent association analyses revealed that a DNA variant, C/T-13910, roughly 14 kb upstream from the LCT locus, completely associates with biochemically verified lactase non-persistence in Finnish families and a sample set of 236 individuals from four different populations. A second variant, G/A(-22018), 8 kb telomeric to C/T-13910, is also associated with the trait in 229 of 236 cases. Prevalence of the C/T-13910 variant in 1,047 DNA samples is consistent with the reported prevalence of adult-type hypolactasla in four different populations. That the variant (C/T-13910) occurs in distantly related populations indicates that it is very old.	Natl Publ Hlth Inst, Dept Mol Med, FIN-00251 Helsinki, Finland; Univ Helsinki, Dept Med Genet, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Publ Hlth, FIN-00014 Helsinki, Finland; Univ Helsinki, Hosp Children & Adolescents, FIN-00014 Helsinki, Finland; Columbia Univ, Dept Psychiat, New York, NY USA; Columbia Univ, Columbia Genome Ctr, New York, NY USA; New York State Psychiat Inst & Hosp, Div Med Genet, New York, NY 10032 USA; Univ Calif Los Angeles, Sch Med, Dept Human Genet, Los Angeles, CA USA; HUCH, Diagnost Lab, Mol Genet Lab, FIN-00290 Helsinki, Finland	Finland National Institute for Health & Welfare; University of Helsinki; University of Helsinki; University of Helsinki; Columbia University; Columbia University; New York State Psychiatry Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Peltonen, L (corresponding author), Natl Publ Hlth Inst, Dept Mol Med, Haartmaninkatu 8,POB 104, FIN-00251 Helsinki, Finland.	lpeltonen@mednet.ucla.edu	Jarvela, Irma E/L-5836-2013	Jarvela, Irma E/0000-0002-1770-6187				AROLA H, 1994, SCAND J GASTROENTERO, V29, P26, DOI 10.3109/00365529409091742; BOLL W, 1991, AM J HUM GENET, V48, P889; CLARE H, 1997, HUM BIOL, V69, P605; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; CUDDENEC Y, 1982, GASTROEN CLIN BIOL, V6, P776; Goring HHH, 2000, AM J HUM GENET, V66, P1310, DOI 10.1086/302845; Goring HHH, 2000, AM J HUM GENET, V66, P1298, DOI 10.1086/302846; Harvey CB, 1996, FEBS LETT, V398, P135, DOI 10.1016/S0014-5793(96)01189-1; Harvey CB, 1998, ANN HUM GENET, V62, P215, DOI 10.1046/j.1469-1809.1998.6230215.x; HARVEY CB, 1995, EUR J HUM GENET, V3, P27; IHALAINEN J, 1994, BIOTECHNIQUES, V16, P938; Jarvela I, 1998, AM J HUM GENET, V63, P1078, DOI 10.1086/302064; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; MANTEI N, 1988, EMBO J, V7, P2705, DOI 10.1002/j.1460-2075.1988.tb03124.x; MCCRACKEN RD, 1971, CURR ANTHROPOL, V12, P479, DOI 10.1086/201234; MCLELLAN T, 1984, AM J HUM GENET, V36, P836; MESSER M, 1966, ANAL BIOCHEM, V14, P376, DOI 10.1016/0003-2697(66)90280-6; SAHI T, 1994, SCAND J GASTROENTERO, V29, P7, DOI 10.3109/00365529409091740; SAHI T, 1974, SCAND J GASTROENTERO, V9, P7; SAHI T, 1972, ACTA PAEDIATR SCAND, V61, P11, DOI 10.1111/j.1651-2227.1972.tb15897.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sulkanen S, 1998, GASTROENTEROLOGY, V115, P1322, DOI 10.1016/S0016-5085(98)70008-3; SYVANEN AC, 1994, HUM MUTAT, V3, P172, DOI 10.1002/humu.1380030303; Wang YX, 1998, GASTROENTEROLOGY, V114, P1230, DOI 10.1016/S0016-5085(98)70429-9; WANG YX, 1995, HUM MOL GENET, V4, P657, DOI 10.1093/hmg/4.4.657	26	717	749	1	134	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2002	30	2					233	237		10.1038/ng826	http://dx.doi.org/10.1038/ng826			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	519CY	11788828				2022-12-25	WOS:000173708700028
J	Homey, B; Alenius, H; Muller, A; Soto, H; Bowman, EP; Yuan, W; McEvoy, L; Lauerma, AI; Assmann, T; Bunemann, E; Lehto, M; Wolff, H; Yen, D; Marxhausen, H; To, W; Sedgwick, J; Ruzicka, T; Lehmann, P; Zlotnik, A				Homey, B; Alenius, H; Muller, A; Soto, H; Bowman, EP; Yuan, W; McEvoy, L; Lauerma, AI; Assmann, T; Bunemann, E; Lehto, M; Wolff, H; Yen, D; Marxhausen, H; To, W; Sedgwick, J; Ruzicka, T; Lehmann, P; Zlotnik, A			CCL27-CCR10 interactions regulate T cell-mediated skin inflammation	NATURE MEDICINE			English	Article							PROTEIN-COUPLED RECEPTOR-2; ALLERGIC DERMATITIS; ENDOTHELIAL-CELLS; ATOPIC-DERMATITIS; CUTTING EDGE; CHEMOKINE; PSORIASIS; EXPRESSION; ANTIGEN; BINDING	The skin-associated chemokine CCL27 (also called CTACK, ALP and ESkine) and its receptor CCR10 (GPR-2) mediate chemotactic responses of skin-homing T cells in vitro. Here we report that most skin-infiltrating lymphocytes in patients suffering from psoriasis, atopic or allergic-contact dermatitis express CCR10. Epidermal basal keratinocytes produced CCL27 protein that bound to extracellular matrix, mediated adhesion and was displayed on the surface of dermal endothelial cells. Tumor necrosis factor-alpha and interleukin-1beta induced CCL27 production whereas the glucocorticosteroid clobetasol propionate suppressed it. Circulating skin-homing CLA(+) T cells, dermal microvascular endothelial cells and fibroblasts expressed CCR10 on their cell surface. In vivo, intracutaneous CCL27 injection attracted lymphocytes and, conversely, neutralization of CCL27-CCR10 interactions impaired lymphocyte recruitment to the skin leading to the suppression of allergen-induced skin inflammation. Together, these findings indicate that CCL27-CCR10 interactions have a pivotal role in T cell-mediated skin inflammation.	DNAX Res Inst Molec & Cellular Biol Inc, Palo Alto, CA USA; Finnish Inst Occupat Hlth, Dept Ind Hyg & Toxicol, Helsinki, Finland; Univ Dusseldorf, Dept Dermatol, D-4000 Dusseldorf, Germany; Univ Dusseldorf, Dept Radiat Oncol, D-4000 Dusseldorf, Germany; Univ Helsinki, Cent Hosp, Dept Dermatol, FIN-00170 Helsinki, Finland; Finnish Inst Occupat Hlth, Dept Pathol, Helsinki, Finland; Kymenlaakso Cent Hosp, Kotka, Finland; R&D Syst, Minneapolis, MN USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Finnish Institute of Occupational Health; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; University of Helsinki; Helsinki University Central Hospital; Finnish Institute of Occupational Health	Homey, B (corresponding author), DNAX Res Inst Molec & Cellular Biol Inc, Palo Alto, CA USA.		Lauerma, Antti/J-8180-2016; Zlotnik, Albert/C-3791-2011	Alenius, Harri/0000-0003-0106-8923				ANCDREW DP, 2001, J IMMUNOL, V166, P103; Baekkevold ES, 2001, J EXP MED, V193, P1105, DOI 10.1084/jem.193.9.1105; Bondeson J, 2001, INT J CLIN PRACT, V55, P211; BOS JD, 1993, ARCH DERMATOL RES, V285, P179, DOI 10.1007/BF00372006; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Campbell JJ, 1999, NATURE, V400, P776, DOI 10.1038/23495; Cinamon G, 2001, NAT IMMUNOL, V2, P515, DOI 10.1038/88710; Goebeler M, 1998, J PATHOL, V184, P89, DOI 10.1002/(SICI)1096-9896(199801)184:1<89::AID-PATH975>3.0.CO;2-Z; GOTTLIEB AB, 1988, J EXP MED, V168, P941, DOI 10.1084/jem.168.3.941; Grabbe S, 1998, IMMUNOL TODAY, V19, P37, DOI 10.1016/S0167-5699(97)01186-9; Grabovsky V, 2000, J EXP MED, V192, P495, DOI 10.1084/jem.192.4.495; Homey B, 1999, CURR OPIN IMMUNOL, V11, P626, DOI 10.1016/S0952-7915(99)00028-X; Homey B, 2000, J IMMUNOL, V164, P3465, DOI 10.4049/jimmunol.164.7.3465; Homey B, 2000, J IMMUNOL, V164, P6621, DOI 10.4049/jimmunol.164.12.6621; Hong K, 1999, J IMMUNOL, V162, P7480; Jarmin DI, 2000, J IMMUNOL, V164, P3460, DOI 10.4049/jimmunol.164.7.3460; Kirby B, 2001, CLIN EXP DERMATOL, V26, P27, DOI 10.1046/j.1365-2230.2001.00753.x; Leung DYM, 2001, J AM ACAD DERMATOL, V44, pS1, DOI 10.1067/mjd.2001.109815; Middleton J, 1997, CELL, V91, P385, DOI 10.1016/S0092-8674(00)80422-5; Morales J, 1999, P NATL ACAD SCI USA, V96, P14470, DOI 10.1073/pnas.96.25.14470; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nickoloff BJ, 2000, EXP DERMATOL, V9, P359, DOI 10.1034/j.1600-0625.2000.009005359.x; PICKER LJ, 1990, J IMMUNOL, V145, P3247; PICKER LJ, 1990, AM J PATHOL, V136, P1053; PIGUET PF, 1993, RES IMMUNOL, V144, P320, DOI 10.1016/S0923-2494(93)80074-9; Proudfoot AEI, 2001, J BIOL CHEM, V276, P10620, DOI 10.1074/jbc.M010867200; Reiss Y, 2001, J EXP MED, V194, P1541, DOI 10.1084/jem.194.10.1541; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; Rot A, 1996, J LEUKOCYTE BIOL, V59, P39, DOI 10.1002/jlb.59.1.39; Ruzicka T, 1997, NEW ENGL J MED, V337, P816, DOI 10.1056/NEJM199709183371203; Ruzicka T, 1999, ARCH DERMATOL, V135, P574, DOI 10.1001/archderm.135.5.574; SANTAMARIA LF, 1995, INT ARCH ALLERGY IMM, V107, P359, DOI 10.1159/000237032; Schon MP, 1999, J INVEST DERMATOL, V112, P405, DOI 10.1046/j.1523-1747.1999.00538.x; Schon MP, 1997, NAT MED, V3, P183, DOI 10.1038/nm0297-183; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Spergel JM, 1999, J CLIN INVEST, V103, P1103, DOI 10.1172/JCI5669; SPRECHER E, 1992, ARCH VIROL, V126, P253, DOI 10.1007/BF01309699; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TSAI JC, 1994, ARCH DERMATOL RES, V286, P242, DOI 10.1007/BF00387595; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9; WOOD LC, 1992, J CLIN INVEST, V90, P482, DOI 10.1172/JCI115884; Woodward AL, 2001, J ALLERGY CLIN IMMUN, V107, P359, DOI 10.1067/mai.2001.112695; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	45	578	607	1	31	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2002	8	2					157	165		10.1038/nm0202-157	http://dx.doi.org/10.1038/nm0202-157			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	517FN	11821900				2022-12-25	WOS:000173600600025
J	Miller, DG; Rutledge, EA; Russell, DW				Miller, DG; Rutledge, EA; Russell, DW			Chromosomal effects of adeno-associated virus vector integration	NATURE GENETICS			English	Article							SITE-SPECIFIC INTEGRATION; ADENOASSOCIATED VIRUS; DNA; RECOMBINATION; JUNCTIONS; TRANSDUCTION; INCREASE	Adeno-associated virus (AAV) vectors are currently being used in several clinical gene-therapy trials (see the NIH OBA Human Gene Transfer Clinical Trials Database); however, little is known about the chromosomal effects of vector integration. Here we report that integrated vector proviruses are associated with chromosomal deletions and other rearrangements and are frequently located on chromosome 19 (although not at the wildtype AAV integration site).	Univ Washington, Dept Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Russell, DW (corresponding author), Univ Washington, Dept Med, Seattle, WA 98195 USA.			Miller, Daniel/0000-0002-5700-3048	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK062100] Funding Source: NIH RePORTER; NIDDK NIH HHS [K08 DK062100] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDER IE, 1994, J VIROL, V68, P8282, DOI 10.1128/JVI.68.12.8282-8287.1994; GIRAUD C, 1995, J VIROL, V69, P6917, DOI 10.1128/JVI.69.11.6917-6924.1995; Hirata RK, 2000, J VIROL, V74, P4612, DOI 10.1128/JVI.74.10.4612-4620.2000; KOTIN RM, 1992, EMBO J, V11, P5071, DOI 10.1002/j.1460-2075.1992.tb05614.x; Linden RM, 1996, P NATL ACAD SCI USA, V93, P11288, DOI 10.1073/pnas.93.21.11288; Nakai H, 1999, J VIROL, V73, P5438, DOI 10.1128/JVI.73.7.5438-5447.1999; RUSSELL DW, 1995, P NATL ACAD SCI USA, V92, P5719, DOI 10.1073/pnas.92.12.5719; Rutledge EA, 1997, J VIROL, V71, P8429, DOI 10.1128/JVI.71.11.8429-8436.1997; Yang CC, 1997, J VIROL, V71, P9231, DOI 10.1128/JVI.71.12.9231-9247.1997; Young SM, 2000, J VIROL, V74, P3953, DOI 10.1128/JVI.74.9.3953-3966.2000	10	123	127	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2002	30	2					147	148		10.1038/ng824	http://dx.doi.org/10.1038/ng824			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	519CY	11799395				2022-12-25	WOS:000173708700012
J	Kumar, A; Harrison, PM; Cheung, KH; Lan, N; Echols, N; Bertone, P; Miller, P; Gerstein, MB; Snyder, M				Kumar, A; Harrison, PM; Cheung, KH; Lan, N; Echols, N; Bertone, P; Miller, P; Gerstein, MB; Snyder, M			An integrated approach for finding overlooked genes in yeast	NATURE BIOTECHNOLOGY			English	Article							LARGE-SCALE ANALYSIS; HEMIASCOMYCETOUS YEASTS; GENOMIC EXPLORATION; SEQUENCE; ANNOTATION; DATABASE; EXPRESSION	We report here the discovery of 137 previously unappreciated genes in yeast through a widely applicable and highly scalable approach integrating methods of gene-trapping, microarray-based expression analysis, and genome-wide homology searching. Our approach is a multistep process in which expressed sequences are first trapped using a modified transposon that produces protein fusions to beta -galactosidase (beta -gal); nonannotated open reading frames (ORFs) translated as P-gal chimeras are selected as a candidate pool of potential genes. To verify expression of these sequences, labeled RNA is hybridized against a microarray of oligonuclectides designed to detect gene transcripts in a strand-specific manner. In complement to this experimental method, novel genes are also identified in silico by homology to previously annotated proteins. As these methods are capable of identifying both short ORFs and antisense ORFs, our approach provides an effective supplement to current gene-finding schemes. In total, the genes discovered using this approach constitute 2% of the yeast genome and represent a wealth of overlooked biology.	Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Yale Univ, Dept Biochem & Mol Biophys, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Anesthesiol, Ctr Med Informat, New Haven, CT 06510 USA	Yale University; Yale University; Yale University	Snyder, M (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, POB 208103, New Haven, CT 06520 USA.	michael.snyder@yale.edu	Bertone, Paul/Z-3734-2019; Bertone, Paul/A-6600-2013	Bertone, Paul/0000-0001-5059-4829; Bertone, Paul/0000-0001-5059-4829; Kumar, Anuj/0000-0002-8923-297X; Snyder, Michael/0000-0003-0784-7987	NCI NIH HHS [R01-CA77808] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077808] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P45, DOI 10.1093/nar/28.1.45; Ball CA, 2001, NUCLEIC ACIDS RES, V29, P80, DOI 10.1093/nar/29.1.80; Basrai MA, 1999, MOL CELL BIOL, V19, P7041; Basrai MA, 1997, GENOME RES, V7, P768, DOI 10.1101/gr.7.8.768; Blandin G, 2000, FEBS LETT, V487, P31, DOI 10.1016/S0014-5793(00)02275-4; Cliften PF, 2001, GENOME RES, V11, P1175, DOI 10.1101/gr.182901; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Gopal S, 2001, NAT GENET, V27, P337, DOI 10.1038/85922; HENIKOFF S, 1986, CELL, V44, P33, DOI 10.1016/0092-8674(86)90482-4; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kane MD, 2000, NUCLEIC ACIDS RES, V28, P4552, DOI 10.1093/nar/28.22.4552; Kumar A, 2000, METHOD ENZYMOL, V328, P550, DOI 10.1016/S0076-6879(00)28418-8; Mackiewicz P, 1999, NUCLEIC ACIDS RES, V27, P3503, DOI 10.1093/nar/27.17.3503; Malpertuy A, 2000, FEBS LETT, V487, P113, DOI 10.1016/S0014-5793(00)02290-0; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; Pearson WR, 1997, GENOMICS, V46, P24, DOI 10.1006/geno.1997.4995; Philippsen P, 1997, NATURE, V387, P93, DOI 10.1038/387s093; Reboul J, 2001, NAT GENET, V27, P332, DOI 10.1038/85913; Ross-Macdonald P, 1999, NATURE, V402, P413, DOI 10.1038/46558; RossMacdonald P, 1997, P NATL ACAD SCI USA, V94, P190, DOI 10.1073/pnas.94.1.190; SEIFERT HS, 1986, P NATL ACAD SCI USA, V83, P735, DOI 10.1073/pnas.83.3.735; Selinger DW, 2000, NAT BIOTECHNOL, V18, P1262, DOI 10.1038/82367; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; Shoemaker DD, 2001, NATURE, V409, P922, DOI 10.1038/35057141; SPENCER CA, 1986, NATURE, V322, P279, DOI 10.1038/322279a0; Stein L, 2001, NAT REV GENET, V2, P493, DOI 10.1038/35080529; Vanhee-Brossollet C, 1998, GENE, V211, P1, DOI 10.1016/S0378-1119(98)00093-6; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; WAGNER EGH, 1994, ANNU REV MICROBIOL, V48, P713, DOI 10.1146/annurev.mi.48.100194.003433; Wood V, 2001, COMP FUNCT GENOM, V2, P143, DOI 10.1002/cfg.86; WOOTTON JC, 1994, COMPUT CHEM, V18, P269, DOI 10.1016/0097-8485(94)85023-2; Zhang CT, 2000, NUCLEIC ACIDS RES, V28, P2804, DOI 10.1093/nar/28.14.2804; Zhu J, 1999, BIOINFORMATICS, V15, P607, DOI 10.1093/bioinformatics/15.7.607	37	80	221	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2002	20	1					58	63		10.1038/nbt0102-58	http://dx.doi.org/10.1038/nbt0102-58			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	507ME	11753363				2022-12-25	WOS:000173031600037
J	Liang, J; Zubovitz, J; Petrocelli, T; Kotchetkov, R; Connor, MK; Han, K; Lee, JH; Ciarallo, S; Catzavelos, C; Beniston, R; Franssen, E; Slingerland, JM				Liang, J; Zubovitz, J; Petrocelli, T; Kotchetkov, R; Connor, MK; Han, K; Lee, JH; Ciarallo, S; Catzavelos, C; Beniston, R; Franssen, E; Slingerland, JM			PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest	NATURE MEDICINE			English	Article							GROWTH-FACTOR-BETA; PROTEIN-KINASE B; CELL-CYCLE ARREST; DEPENDENT KINASE; CDK INHIBITORS; BREAST-CANCER; SUBCELLULAR-LOCALIZATION; P27(KIP1); AKT; P15(INK4B)	Mechanisms linking mitogenic and growth inhibitory cytokine signaling and the cell cycle have not been fully elucidated in either cancer or in normal cells. Here we show that activation of protein kinase B (PKB)/Akt contributes to resistance to antiproliferative signals and breast cancer progression in part by impairing the nuclear import and action of p27. Akt transfection caused cytoplasmic p27 accumulation and resistance to cytokine-mediated G1 arrest. The nuclear localization signal of p27 contains an Akt consensus site at threonine 157, and p27 phosphorylation by Akt impaired its nuclear import in vitro. Akt phosphorylated wild-type p27 but not p27T157A. In cells transfected with constitutively active Akt(T308DS473D) (PKBDD), p27WT mislocalized to the cytoplasm, but p27T157A was nuclear. In cells with activated Akt, p27WT failed to cause G1 arrest, while the antiproliferative effect of p27T157A was not impaired. Cytoplasmic p27 was seen in 41% (52 of 128) of primary human breast cancers in conjunction with Akt activation and was correlated with a poor patient prognosis. Thus, we show a novel mechanism whereby Akt impairs p27 function that is associated with an aggressive phenotype in human breast cancer.	McGill Univ, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Pathol, Montreal, PQ, Canada; McGill Univ, St Marys Hosp, Dept Pathol, Montreal, PQ, Canada; Toronto Sunnybrook Reg Canc Ctr, Div Clin Epidemiol & Biostat, Toronto, ON, Canada	McGill University; University of Toronto; University Toronto Affiliates; Sunnybrook Health Science Center; McGill University; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Slingerland, JM (corresponding author), McGill Univ, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Pathol, Montreal, PQ, Canada.	jslingerland@med.miami.edu		Han, Kathy/0000-0001-8439-3929				ADAM SA, 1992, METHOD ENZYMOL, V219, P97; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BOS JL, 1989, CANCER RES, V49, P4682; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Coffer PJ, 1998, BIOCHEM J, V335, P1; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Donovan J, 2000, BREAST CANCER RES, V2, P116, DOI 10.1186/bcr43; Donovan JCH, 2001, J BIOL CHEM, V276, P40888, DOI 10.1074/jbc.M106448200; Florenes VA, 1999, ONCOGENE, V18, P1023, DOI 10.1038/sj.onc.1202382; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HERLYN M, 1990, CANCER METAST REV, V9, P101, DOI 10.1007/BF00046337; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; Kretzschmar M, 2000, BREAST CANCER RES, V2, P107, DOI 10.1186/bcr42; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Li Y, 2002, J BIOL CHEM, V277, P11352, DOI 10.1074/jbc.M109062200; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Singh SP, 1998, CANCER RES, V58, P1730; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; Stampfer M, 1985, J TISSUE CULTURE MET, V9, P107; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Tsihlias J, 1999, ANNU REV MED, V50, P401; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; Zeng Y, 2000, BIOCHEM BIOPH RES CO, V274, P37, DOI 10.1006/bbrc.2000.3098; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	45	765	791	0	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2002	8	10					1153	1160		10.1038/nm761	http://dx.doi.org/10.1038/nm761			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	599AN	12244302				2022-12-25	WOS:000178311000043
J	Mikkers, H; Allen, J; Knipscheer, P; Romeyn, L; Hart, A; Vink, E; Berns, A				Mikkers, H; Allen, J; Knipscheer, P; Romeyn, L; Hart, A; Vink, E; Berns, A			High-throughput retroviral tagging to identify components of specific signaling pathways in cancer (vol 32, pg 153, 2002)	NATURE GENETICS			English	Correction																		Mikkers H, 2002, NAT GENET, V32, P459, DOI 10.1038/ng1102-459b	1	7	7	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2002	32	2					331	331		10.1038/ng1002-331d	http://dx.doi.org/10.1038/ng1002-331d			1	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	599AP	12185366	Bronze			2022-12-25	WOS:000178311100030
J	Grifantini, R; Bartolini, E; Muzzi, A; Draghi, M; Frigimelica, E; Berger, J; Ratti, G; Petracca, R; Galli, G; Agnusdei, M; Giuliani, MM; Santini, L; Brunelli, B; Tettelin, H; Rappuoli, R; Randazzo, F; Grandi, G				Grifantini, R; Bartolini, E; Muzzi, A; Draghi, M; Frigimelica, E; Berger, J; Ratti, G; Petracca, R; Galli, G; Agnusdei, M; Giuliani, MM; Santini, L; Brunelli, B; Tettelin, H; Rappuoli, R; Randazzo, F; Grandi, G			Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays	NATURE BIOTECHNOLOGY			English	Article							BACTERIAL VIRULENCE GENES; COMPLETE GENOME SEQUENCE; NEISSERIA-MENINGITIDIS; EPITHELIAL-CELLS; ESCHERICHIA-COLI; INTRACELLULAR SURVIVAL; LEGIONELLA-PNEUMOPHILA; STRAIN MC58; EXPRESSION; PROTEIN	We have used DNA microarrays to follow Neisseria meningitidis serogroup B (MenB) gene regulation during interaction with human epithelial cells. Host-cell contact induced changes in the expression of 347 genes, more than 30% of which encode proteins with unknown function. The upregulated genes included transporters of iron, chloride, amino acids, and sulfate, many virulence factors, and the entire pathway of sulfur-containing amino acids. Approximately 40% of the 189 upregulated genes coded for peripherally located proteins, suggesting that cell contact promoted a substantial reorganization of the cell membrane. This was confirmed by fluorescence activated cell sorting (FACS) analysis on adhering bacteria using mouse sera against twelve adhesion-induced proteins. Of the 12 adhesion-induced surface antigens, 5 were able to induce bactericidal antibodies in mice, demonstrating that microarray technology is a valid approach for identifying new vaccine candidates and nicely complements other genome mining strategies used for vaccine discovery.	Chiron SpA, I-53100 Siena, Italy; Chiron Corp, Emeryville, CA 94608 USA; Inst Genom Res, Rockville, MD 20850 USA	Novartis; Novartis; J. Craig Venter Institute	Grandi, G (corresponding author), Chiron SpA, Via Fiorentina 1, I-53100 Siena, Italy.	guido_grandi@chiron.it	Gorson, Kenneth/K-7778-2019; Renata, Grifantini/AAB-9969-2022; Muzzi, Alessandro/J-6200-2012	Renata, Grifantini/0000-0003-0024-3355; Grandi, Guido/0000-0001-9724-2185				Adegbola RA, 1998, J INFECT DIS, V177, P1758, DOI 10.1086/517440; Belcher CE, 2000, P NATL ACAD SCI USA, V97, P13847, DOI 10.1073/pnas.230262797; BRAATEN BA, 1994, CELL, V76, P577, DOI 10.1016/0092-8674(94)90120-1; Cummings CA, 2000, EMERG INFECT DIS, V6, P513, DOI 10.3201/eid0605.000511; Dagan R, 2002, J INFECT DIS, V185, P927, DOI 10.1086/339525; Deghmane AE, 2000, EMBO J, V19, P1068, DOI 10.1093/emboj/19.5.1068; DEMATTEIS MA, 1994, P NATL ACAD SCI USA, V91, P1114, DOI 10.1073/pnas.91.3.1114; Etz H, 2002, P NATL ACAD SCI USA, V99, P6573, DOI 10.1073/pnas.092569199; Garcia-Del Portillo F, 1999, P NATL ACAD SCI USA, V96, P11578, DOI 10.1073/pnas.96.20.11578; GOTSCHLICH EC, 1969, J EXP MED, V129, P1349, DOI 10.1084/jem.129.6.1349; Grandi G, 2001, TRENDS BIOTECHNOL, V19, P181, DOI 10.1016/S0167-7799(01)01600-6; Heithoff DM, 1999, SCIENCE, V284, P967, DOI 10.1126/science.284.5416.967; HENSEL M, 1995, SCIENCE, V269, P400, DOI 10.1126/science.7618105; Horne SM, 1997, INFECT IMMUN, V65, P806, DOI 10.1128/IAI.65.2.806-810.1997; KLEBANOFF SJ, 1983, CIBA F SYMP, V99, P92; Long AD, 2001, J BIOL CHEM, V276, P19937, DOI 10.1074/jbc.M010192200; LOTTENBERG R, 1992, J BACTERIOL, V174, P5204, DOI 10.1128/JB.174.16.5204-5210.1992; MAHAN MJ, 1993, SCIENCE, V259, P686, DOI 10.1126/science.8430319; Martin D, 1997, J EXP MED, V185, P1173, DOI 10.1084/jem.185.7.1173; Mathiassen S, 2001, EUR J IMMUNOL, V31, P1239, DOI 10.1002/1521-4141(200104)31:4<1239::AID-IMMU1239>3.0.CO;2-C; Merz AJ, 2000, ANNU REV CELL DEV BI, V16, P423, DOI 10.1146/annurev.cellbio.16.1.423; NAESS A, 1994, ACTA NEUROL SCAND, V89, P139; Nassif X, 1999, MOL MICROBIOL, V32, P1124, DOI 10.1046/j.1365-2958.1999.01416.x; Pancholi V, 1997, J EXP MED, V186, P1633, DOI 10.1084/jem.186.10.1633; Pandey A, 2000, NATURE, V405, P837, DOI 10.1038/35015709; Peeters CCAM, 1999, VACCINE, V17, P2702, DOI 10.1016/S0264-410X(99)00011-0; Pizza M, 2000, SCIENCE, V287, P1816, DOI 10.1126/science.287.5459.1816; Pujol C, 1999, P NATL ACAD SCI USA, V96, P4017, DOI 10.1073/pnas.96.7.4017; Pujol C, 1997, INFECT IMMUN, V65, P4836, DOI 10.1128/IAI.65.11.4836-4842.1997; Ramarao N, 2000, MOL MICROBIOL, V38, P103, DOI 10.1046/j.1365-2958.2000.02114.x; Rappuoli R, 2000, CURR OPIN MICROBIOL, V3, P445, DOI 10.1016/S1369-5274(00)00119-3; Rappuoli R, 2000, P NATL ACAD SCI USA, V97, P13467, DOI 10.1073/pnas.010505497; Saunders NJ, 2000, MOL MICROBIOL, V37, P207, DOI 10.1046/j.1365-2958.2000.02000.x; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Seller A, 1996, MOL MICROBIOL, V19, P841, DOI 10.1046/j.1365-2958.1996.437970.x; Shea JE, 2000, CURR OPIN MICROBIOL, V3, P451, DOI 10.1016/S1369-5274(00)00120-X; Sun YH, 2000, NAT MED, V6, P1269, DOI 10.1038/81380; Susa M, 1996, INFECT IMMUN, V64, P1679, DOI 10.1128/IAI.64.5.1679-1684.1996; Tettelin H, 2000, SCIENCE, V287, P1809, DOI 10.1126/science.287.5459.1809; TRIEUCUOT P, 1990, NUCLEIC ACIDS RES, V18, P3660, DOI 10.1093/nar/18.12.3660; TRIEUCUOT P, 1985, EMBO J, V4, P3583, DOI 10.1002/j.1460-2075.1985.tb04120.x; Winram SB, 1996, MICROBIOL-SGM, V142, P2311, DOI 10.1099/13500872-142-8-2311; WINTERMEYER E, 1995, INFECT IMMUN, V63, P4576, DOI 10.1128/IAI.63.12.4576-4583.1995; Yu J, 2000, INFECT IMMUN, V68, P6449, DOI 10.1128/IAI.68.11.6449-6456.2000; Zhang HZ, 1996, MOL MICROBIOL, V21, P787, DOI 10.1046/j.1365-2958.1996.431403.x; Zhang YL, 2000, MICROBIOL-SGM, V146, P999, DOI 10.1099/00221287-146-4-999; Zollinger W.D., 1997, NEW GENERATION VACCI, V2nd ed., P469	47	165	189	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2002	20	9					914	921		10.1038/nbt728	http://dx.doi.org/10.1038/nbt728			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	589KN	12172557				2022-12-25	WOS:000177757700024
J	Avizienyte, E; Wyke, AW; Jones, RJ; McLean, GW; Westhoff, MA; Brunton, VG; Frame, MC				Avizienyte, E; Wyke, AW; Jones, RJ; McLean, GW; Westhoff, MA; Brunton, VG; Frame, MC			Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling	NATURE CELL BIOLOGY			English	Article							FOCAL ADHESION KINASE; RECEPTOR TYROSINE KINASES; C-SRC; FAMILY KINASES; V-SRC; CATALYTIC ACTIVITY; PHOSPHORYLATION; SELECTION; COMPLEX; GENE	Although Src expression and activity are often elevated in colon cancer(1-3), the precise consequences of overexpression of the non-catalytic Src homology (SH) domains, or enhanced catalytic activity, are unknown. We show that, in KM12C colon cancer cells, elevated Src activity causes the components of adherens junctions, including vinculin, to be redistributed to Src-induced integrin-adhesion complexes. Specifically, elevated Src activity blocks proper assembly of cell-cell contacts after cells are switched from media containing a low level of calcium to media containing a high level of calcium, and E-cadherin remains internalized. In contrast, although elevated expression of the non-catalytic domains of Src is sufficient to induce assembly of integrin-adhesion complexes, it does not induce disorganization of E-cadherin-associated intercellular contacts. Surprisingly, Src-induced disruption of E-cadherin localization requires specific integrin signalling, because E-cadherin redistribution is blocked by loss of cell-matrix interaction, or by inhibitory antibodies to alpha(v) or beta(1) integrin subunits. Furthermore, phosphorylation of the integrin-regulated focal adhesion kinase (FAK) on Src-specific sites is required for Src-induced de-regulation of E-cadherin, demonstrating interdependence between integrin-induced signals and cadherin-associated adhesion changes induced by Src.	Univ Glasgow, Inst Biol & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; Beatson Inst Canc Res, Canc Res UK Beatson Labs, Glasgow G61 1BD, Lanark, Scotland	University of Glasgow; Beatson Institute	Frame, MC (corresponding author), Western Infirm & Associated Hosp, Beatson Oncol Ctr, Glasgow G11 6NT, Lanark, Scotland.		Westhoff, Mike-Andrew/ABA-9272-2021	Westhoff, Mike-Andrew/0000-0003-3256-7100; Jones, Robert/0000-0002-2904-6980				Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Boyer B, 1997, EMBO J, V16, P5904, DOI 10.1093/emboj/16.19.5904; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Calautti E, 2002, J CELL BIOL, V156, P137, DOI 10.1083/jcb.200105140; CARTWRIGHT CA, 1994, J CLIN INVEST, V93, P509, DOI 10.1172/JCI117000; Felsenfeld DP, 1999, NAT CELL BIOL, V1, P200, DOI 10.1038/12021; Fincham VJ, 2000, MOL CELL BIOL, V20, P6518, DOI 10.1128/MCB.20.17.6518-6536.2000; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; LEWIS JM, 1995, MOL BIOL CELL, V6, P151, DOI 10.1091/mbc.6.2.151; Mao WG, 1997, ONCOGENE, V15, P3083, DOI 10.1038/sj.onc.1201496; McLean GW, 2000, J BIOL CHEM, V275, P23333, DOI 10.1074/jbc.M909322199; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MORIKAWA K, 1988, CANCER RES, V48, P1943; Owens DW, 2000, MOL BIOL CELL, V11, P51, DOI 10.1091/mbc.11.1.51; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; WARREN SL, 1987, MOL CELL BIOL, V7, P1326, DOI 10.1128/MCB.7.4.1326	24	292	299	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2002	4	8					632	638		10.1038/ncb829	http://dx.doi.org/10.1038/ncb829			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	579WK	12134161				2022-12-25	WOS:000177201100021
J	Bennett, D; Alphey, L				Bennett, D; Alphey, L			PP1 binds Sara and negatively regulates Dpp signaling in Drosophila melanogaster	NATURE GENETICS			English	Article							TGF-BETA RECEPTOR; PROTEIN PHOSPHATASE-1; STRUCTURAL BASIS; KINASE; RECOGNITION; EXPRESSION; ACTIVATION; POSITION; GRADIENT; MITOSIS	In signaling involving the transforming growth factor-beta (TGF-beta) superfamily of proteins, ligand binding brings the constitutively active type II receptor kinase into close proximity to its substrate, the type I receptor kinase, which it then activates by phosphorylation(1). The type I receptor kinase in turn phosphorylates one of the Smad family of transcription factors, which translocates to the nucleus and regulates gene expression(2-5). Smads are recruited to the receptor complex by an anchor protein, SARA (Smad anchor for receptor activation)(6). Although several protein kinases in this pathway were known, including the receptors themselves, the relevant phosphatases had not previously been identified. Here we report the isolation of a Drosophila melanogaster homolog of SARA (Sara) in a screen for proteins that bind the catalytic subunit of type I serine/threonine protein phosphatase (PP1c). We identified a PP1c-binding motif in Sara, disruption of which reduced the ability of Sara to bind PP1c. Expression of this non-PP1c- binding mutant resulted in hyperphosphorylation of the type I receptor and stimulated expression of a target of TGF-beta signaling. Reducing PP1c activity enhanced the increase in the basal level of expression of genes responsive to Dpp (Decapentaplegic) caused by ectopic expression of the type II receptor Punt. Together these data suggest that PP1c is targeted to Dpp receptor complexes by Sara, where it acts as a negative regulator of Dpp signaling by affecting the phosphorylation state of the type I receptor.	Univ Oxford, Dept Zool, Oxford OX1 3PS, England	University of Oxford	Alphey, L (corresponding author), Univ Oxford, Dept Zool, S Parks Rd, Oxford OX1 3PS, England.		Bennett, Daimark/E-2701-2014	Bennett, Daimark/0000-0002-0014-2290; Alphey, Luke/0000-0002-2916-3802				Adachi-Yamada T, 1999, NATURE, V400, P166, DOI 10.1038/22112; Alphey L, 1997, J CELL BIOL, V138, P395, DOI 10.1083/jcb.138.2.395; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; AXTON JM, 1990, CELL, V63, P33, DOI 10.1016/0092-8674(90)90286-N; BAKSA K, 1993, GENETICS, V135, P117; Bennett D, 1999, BIOCHEMISTRY-US, V38, P16276, DOI 10.1021/bi9917028; Bollen M, 2001, TRENDS BIOCHEM SCI, V26, P426, DOI 10.1016/S0968-0004(01)01836-9; CHEN RH, 1995, J BIOL CHEM, V270, P12235, DOI 10.1074/jbc.270.20.12235; Cohen PTW, 2002, J CELL SCI, V115, P241; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Grimm S, 1996, SCIENCE, V271, P1601, DOI 10.1126/science.271.5255.1601; Gurdon JB, 1998, CELL, V95, P159, DOI 10.1016/S0092-8674(00)81747-X; Haerry TE, 1998, DEVELOPMENT, V125, P3977; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; Moustakas A, 2001, J CELL SCI, V114, P4359; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Parker L, 2001, BIOTECHNIQUES, V31, P1280, DOI 10.2144/01316st01; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; Raftery LA, 1999, DEV BIOL, V210, P251, DOI 10.1006/dbio.1999.9282; Raghavan S, 2000, CURR BIOL, V10, P269, DOI 10.1016/S0960-9822(00)00364-X; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; VENTURA F, 1994, EMBO J, V13, P5581, DOI 10.1002/j.1460-2075.1994.tb06895.x; Westphal RS, 1999, SCIENCE, V285, P93, DOI 10.1126/science.285.5424.93; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Wu G, 2000, SCIENCE, V287, P92, DOI 10.1126/science.287.5450.92	29	76	87	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2002	31	4					419	423		10.1038/ng938	http://dx.doi.org/10.1038/ng938			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	578XV	12134149				2022-12-25	WOS:000177147100020
J	Jeon, NL; Baskaran, H; Dertinger, SKW; Whitesides, GM; Van de Water, L; Toner, M				Jeon, NL; Baskaran, H; Dertinger, SKW; Whitesides, GM; Van de Water, L; Toner, M			Neutrophil chemotaxis in linear and complex gradients of interleukin-8 formed in a microfabricated device	NATURE BIOTECHNOLOGY			English	Article							POLYMORPHONUCLEAR LEUKOCYTES; CELLS; CHEMOKINES; SEPARATION; RECEPTORS; MIGRATION; AGAROSE; TISSUE	Although a wealth of knowledge about chemotaxis has accumulated in the past 40 years, these studies have been hampered by the inability of researchers to generate simple linear gradients instantaneously and to maintain them at steady state. Here we describe a device microfabricated by soft lithography and consisting of a network of microfluidic channels that can generate spatially and temporally controlled gradients of chemotactic factors. When human neutrophils are positioned within a microchannel, their migration in simple and complex interleukin-8 (IL-8) gradients can be tested. The cells exhibit strong directional migration toward increasing concentrations of IL-8 in linear gradients. Neutrophil migration halts abruptly when cells encounter a sudden drop in the chemoattractant concentration to zero ("cliff" gradient). When neutrophils are challenged with a gradual increase and decrease in chemoattractant ("hill" gradient), however, the cells traverse the crest of maximum concentration and migrate further before reversing direction. The technique described in this paper provides a robust method to investigate migratory cells under a variety of conditions not accessible to study by earlier techniques.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med & Surg Serv, Boston, MA 02114 USA; Shriners Hosp Children, Boston, MA 02114 USA; Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Albany Medical College	Toner, M (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med & Surg Serv, Boston, MA 02114 USA.	mtoner@sbi.org			NCRR NIH HHS [RR13322] Funding Source: Medline; NIGMS NIH HHS [GM 56442] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R21RR013322] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056442] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER J, 1969, SCIENCE, V166, P1588, DOI 10.1126/science.166.3913.1588; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; BARNETT ML, 1993, BIOCHIM BIOPHYS ACTA, V1177, P275, DOI 10.1016/0167-4889(93)90123-7; BEHAR TN, 1994, J NEUROSCI, V14, P29; BIGNOLD LP, 1988, J IMMUNOL METHODS, V108, P1, DOI 10.1016/0022-1759(88)90396-1; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; BROWN AF, 1982, J CELL SCI, V58, P455; Campbell JJ, 2000, CURR OPIN IMMUNOL, V12, P336, DOI 10.1016/S0952-7915(00)00096-0; Chiu DT, 2000, P NATL ACAD SCI USA, V97, P2408, DOI 10.1073/pnas.040562297; Clemons MJ, 1998, BLOOD, V92, P1532, DOI 10.1182/blood.V92.5.1532.417k18_1532_1540; Dertinger SKW, 2001, ANAL CHEM, V73, P1240, DOI 10.1021/ac001132d; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; Firtel RA, 2000, BIOESSAYS, V22, P603, DOI 10.1002/1521-1878(200007)22:7<603::AID-BIES3>3.0.CO;2-#; Foxman EF, 1997, J CELL BIOL, V139, P1349, DOI 10.1083/jcb.139.5.1349; Grunstein J, 2000, MOL CELL BIOL, V20, P7282, DOI 10.1128/MCB.20.19.7282-7291.2000; HASTON WS, 1988, CURR OPIN IMMUNOL, V1, P5, DOI 10.1016/0952-7915(88)90044-1; Ismagilov RF, 2000, APPL PHYS LETT, V76, P2376, DOI 10.1063/1.126351; KOLBER DL, 1995, J NATL CANCER I, V87, P304, DOI 10.1093/jnci/87.4.304; Lauffenburger D. A., 1993, RECEPTORS MODELS BIN; LAUFFENBURGER DA, 1981, J IMMUNOL METHODS, V40, P45, DOI 10.1016/0022-1759(81)90079-X; McDowell N, 2001, INT J DEV BIOL, V45, P199; MOGHE PV, 1995, J IMMUNOL METHODS, V180, P193, DOI 10.1016/0022-1759(94)00314-M; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NELSON RD, 1975, J IMMUNOL, V115, P1650; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; Strigini M, 2000, CURR BIOL, V10, P293, DOI 10.1016/S0960-9822(00)00378-X; TRANQUILLO RT, 1988, CELL MOTIL CYTOSKEL, V11, P1, DOI 10.1002/cm.970110102; Whitesides GM, 2001, ANNU REV BIOMED ENG, V3, P335, DOI 10.1146/annurev.bioeng.3.1.335; WILKINSON PC, 1982, CHEMOTAXIS INFLAMMAT; Yang XD, 1999, J LEUKOCYTE BIOL, V66, P401, DOI 10.1002/jlb.66.3.401; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233; YOSHIMURA T, 1987, J IMMUNOL, V139, P788; ZICHA D, 1991, J CELL SCI, V99, P769; ZIGMOND SH, 1977, J CELL BIOL, V75, P606, DOI 10.1083/jcb.75.2.606; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	38	737	765	1	146	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2002	20	8					826	830		10.1038/nbt712	http://dx.doi.org/10.1038/nbt712			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	579MU	12091913				2022-12-25	WOS:000177182500035
J	Savage, DB; Agostini, M; Barroso, I; Gurnell, M; Luan, J; Meirhaeghe, A; Harding, AH; Ihrke, G; Rajanayagam, O; Soos, MA; George, S; Berger, D; Thomas, EL; Bell, JD; Meeran, K; Ross, RJ; Vidal-Puig, A; Wareham, NJ; O'Rahilly, S; Chatterjee, VKK; Schafer, AJ				Savage, DB; Agostini, M; Barroso, I; Gurnell, M; Luan, J; Meirhaeghe, A; Harding, AH; Ihrke, G; Rajanayagam, O; Soos, MA; George, S; Berger, D; Thomas, EL; Bell, JD; Meeran, K; Ross, RJ; Vidal-Puig, A; Wareham, NJ; O'Rahilly, S; Chatterjee, VKK; Schafer, AJ			Digenic inheritance of severe insulin resistance in a human pedigree	NATURE GENETICS			English	Article							PPAR-GAMMA; PROTEIN PHOSPHATASE-1; SKELETAL-MUSCLE; MICE; CELL; FAT; EXPRESSION; METABOLISM; RECEPTORS; AGONISTS	Impaired insulin action is a key feature of type 2 diabetes and is also found, to a more extreme degree, in familial syndromes of insulin resistance. Although inherited susceptibility to insulin resistance may involve the interplay of several genetic loci, no clear examples of interactions among genes have yet been reported. Here we describe a family in which five individuals with severe insulin resistance, but no unaffected family members, were compound heterozygous with respect to frameshift/premature stop mutations in two unlinked genes, PPARG and PPP1R3A these encode peroxisome proliferator activated receptor, which is highly expressed in adipocytes, and protein phosphatase 1, regulatory subunit 3, the muscle-specific regulatory subunit of protein phosphatase 1, which are centrally involved in the regulation of carbohydrate and lipid metabolism, respectively. That mutant molecules primarily involved in either carbohydrate or lipid metabolism can combine to produce a phenotype of extreme insulin resistance provides a model of interactions among genes that may underlie common human metabolic disorders such as type 2 diabetes.	Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England; Incyte Genom, Palo Alto, CA USA; Univ Cambridge, Addenbrookes Hosp, Dept Publ Hlth, Cambridge CB2 2QQ, England; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med,Robert Steiner MRI Unit, MRC,Clin Sci Ctr, London, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Charing Cross Hosp, Dept Endocrinol, London, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Hammersmith Hosp, Dept Endocrinol, London, England; Univ Sheffield, Div Clin Sci, Sheffield, S Yorkshire, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Incyte; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Imperial College London; Imperial College London; Imperial College London; University of Sheffield	O'Rahilly, S (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Hills Rd, Cambridge CB2 2QQ, England.		Thomas, Elizabeth Louise/AIF-0055-2022; Ross, Richard/B-2672-2012; Meirhaeghe, Aline/E-4663-2015; O'Rahilly, Stephen/ABF-6509-2020	Ross, Richard/0000-0001-9222-9678; Meirhaeghe, Aline/0000-0001-6983-2364; O'Rahilly, Stephen/0000-0003-2199-4449; Vidal-Puig, Antonio/0000-0003-4220-9577; Ihrke, Gudrun/0000-0003-4604-735X; Thomas, Elizabeth/0000-0003-4235-4694; Barroso, Ines/0000-0001-5800-4520; Chatterjee, Vengalil Krishna/0000-0002-2654-8854; Savage, David Bousfield/0000-0002-7857-7032	MRC [MC_U120061305] Funding Source: UKRI; Medical Research Council [MC_U120061305] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575; Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; Birnbaum MJ, 2001, NATURE, V409, P672, DOI 10.1038/35055643; BJORNTORP P, 1978, METABOLISM, V27, P1853, DOI 10.1016/S0026-0495(78)80004-3; BLACK D, 1983, J R COLL PHYSICIANS, V17, P5; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; Burghes AHM, 2001, SCIENCE, V293, P2213, DOI 10.1126/science.1065930; COLLINGWOOD TN, 1994, MOL ENDOCRINOL, V8, P1262, DOI 10.1210/me.8.9.1262; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Kelley DE, 2001, DIABETES CARE, V24, P933, DOI 10.2337/diacare.24.5.933; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; Miles PDG, 2000, J CLIN INVEST, V105, P287, DOI 10.1172/JCI8538; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; Newgard CB, 2000, DIABETES, V49, P1967, DOI 10.2337/diabetes.49.12.1967; Nielsen JN, 2001, J PHYSIOL-LONDON, V531, P757, DOI 10.1111/j.1469-7793.2001.0757h.x; Olefsky JM, 2000, J CLIN INVEST, V106, P467, DOI 10.1172/JCI10843; Rasmussen SK, 2000, DIABETOLOGIA, V43, P718, DOI 10.1007/s001250051369; Rico-Sanz J, 1999, J APPL PHYSIOL, V87, P2068, DOI 10.1152/jappl.1999.87.6.2068; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Steppan CM, 2002, TRENDS ENDOCRIN MET, V13, P18, DOI 10.1016/S1043-2760(01)00522-7; Suzuki Y, 2001, MOL CELL BIOL, V21, P2683, DOI 10.1128/MCB.21.8.2683-2694.2001; TANG PM, 1991, J BIOL CHEM, V266, P15782; Thomas EL, 1998, J APPL PHYSIOL, V85, P1778, DOI 10.1152/jappl.1998.85.5.1778; Thorpe KL, 1999, IMMUNOGENETICS, V49, P256, DOI 10.1007/s002510050491; Yamauchi T, 2001, J CLIN INVEST, V108, P1001, DOI 10.1172/JCI12864; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847	29	113	117	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2002	31	4					379	384		10.1038/ng926	http://dx.doi.org/10.1038/ng926			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	578XV	12118251				2022-12-25	WOS:000177147100012
J	Compernolle, V; Brusselmans, K; Acker, T; Hoet, P; Tjwa, M; Beck, H; Plaisance, S; Dor, Y; Keshet, E; Lupu, F; Nemery, B; Dewerchin, M; Van Veldhoven, P; Plate, K; Moons, L; Collen, D; Carmeliet, P				Compernolle, V; Brusselmans, K; Acker, T; Hoet, P; Tjwa, M; Beck, H; Plaisance, S; Dor, Y; Keshet, E; Lupu, F; Nemery, B; Dewerchin, M; Van Veldhoven, P; Plate, K; Moons, L; Collen, D; Carmeliet, P			Loss of HIF-2 and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; TRANSCRIPTION FACTOR; HYPOXIA; EXPRESSION; GLYCOGEN; ANGIOGENESIS; DECREASES; HOMEOSTASIS; MECHANISMS; ISOFORMS	Respiratory distress syndrome (RDS) due to insufficient production of surfactant is a common and severe complication of preterm delivery. Here, we report that loss of the hypoxia-inducible transcription factor-2alpha (HIF-2alpha) caused fatal RDS in neonatal mice due to insufficient surfactant production by alveolar type 2 cells. VEGF, a target of HIF-2alpha, regulates fetal lung maturation: because VEGF levels in alveolar cells were reduced in HIF-2alpha-deficient fetuses; mice with a deficiency of the VEGF(164) and VEGF(188) isoforms or of the HIF-binding site in the VEGF promotor died of RDS; intrauterine delivery of anti-VEGF-receptor-2 antibodies caused RDS and VEGF stimulated production of surfactant proteins by cultured type 2 pneumocytes. Intrauterine delivery or postnatal intratracheal instillation of VEGF stimulated conversion of glycogen to surfactant and protected preterm mice against RDS. The pneumotrophic effect of VEGF may have therapeutic potential for lung maturation in preterm infants.	Flanders Interuniv, Inst Biotechnol, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium; Goethe Univ Frankfurt, Inst Neurol, D-6000 Frankfurt, Germany; Katholieke Univ Leuven, Unit Lung Toxicol, Lab Pneumol, Louvain, Belgium; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, IL-91010 Jerusalem, Israel; Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; Katholieke Univ Leuven, Dept Pharmacol, Louvain, Belgium	Goethe University Frankfurt; KU Leuven; Hebrew University of Jerusalem; Oklahoma Medical Research Foundation; KU Leuven	Carmeliet, P (corresponding author), Flanders Interuniv, Inst Biotechnol, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium.	peter.carmeliet@med.kuleuven.ac.be	Lupu, Florea/C-3162-2009; Carmeliet, Peter/AAQ-5140-2020; Plaisance, Stephane/ABI-6307-2020; Lupu, Florea/AAV-3257-2021; , Van Veldhoven Paul/U-6359-2019; Hoet, Peter/H-9987-2013; Nemery, Benoit/N-3155-2019; Plaisance, Stephane/B-3488-2009; Keshet, Eli/GQR-0445-2022; Dor, Yuval/C-2405-2011; Nemery, Benoit/D-1224-2013	Lupu, Florea/0000-0003-1249-9278; Carmeliet, Peter/0000-0001-7961-1821; Plaisance, Stephane/0000-0002-1651-241X; Lupu, Florea/0000-0003-1249-9278; , Van Veldhoven Paul/0000-0002-4478-2564; Hoet, Peter/0000-0002-0292-6603; Nemery, Benoit/0000-0003-0571-4689; Plaisance, Stephane/0000-0002-1651-241X; Acker, Till/0000-0001-6357-7227; Moons, Lieve (Godelieve)/0000-0003-0186-1411				Bernatchez PN, 2001, BRIT J PHARMACOL, V134, P197, DOI 10.1038/sj.bjp.0704215; Bhakoo O. N., 2000, Indian Journal of Pediatrics, V67, P803, DOI 10.1007/BF02726222; Bhatt AJ, 2001, AM J RESP CRIT CARE, V164, P1971, DOI 10.1164/ajrccm.164.10.2101140; Bhatt AJ, 2000, PEDIATR RES, V47, P606, DOI 10.1203/00006450-200005000-00009; Botas C, 1998, P NATL ACAD SCI USA, V95, P11869, DOI 10.1073/pnas.95.20.11869; BOURBON JR, 1991, EXP LUNG RES, V17, P789, DOI 10.3109/01902149109062878; BOURBON JR, 1982, BIOCHIM BIOPHYS ACTA, V712, P382, DOI 10.1016/0005-2760(82)90356-3; Brown KRS, 2001, AM J PHYSIOL-LUNG C, V281, pL1001, DOI 10.1152/ajplung.2001.281.4.L1001; Brusselmans K, 2001, J BIOL CHEM, V276, P39192, DOI 10.1074/jbc.C100428200; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Corne J, 2000, J CLIN INVEST, V106, P783, DOI 10.1172/JCI9674; D'Angio CT, 1999, BIOL NEONATE, V76, P266, DOI 10.1159/000014168; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; GILDEN C, 1977, PEDIATR RES, V11, P845, DOI 10.1203/00006450-197707000-00014; Goldenberg RL, 2000, NEW ENGL J MED, V342, P1500, DOI 10.1056/NEJM200005183422007; Healy AM, 2000, DEV DYNAM, V219, P341, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1061>3.0.CO;2-M; Hoet PHM, 2001, TOXICOL APPL PHARM, V175, P184, DOI 10.1006/taap.2001.9247; Jain S, 1998, MECH DEVELOP, V73, P117, DOI 10.1016/S0925-4773(98)00038-0; Jakkula M, 2000, AM J PHYSIOL-LUNG C, V279, pL600, DOI 10.1152/ajplung.2000.279.3.L600; Kaner RJ, 2001, MOL MED, V7, P240, DOI 10.1007/BF03401843; Kennedy JD, 1999, J PAEDIATR CHILD H, V35, P516, DOI 10.1046/j.1440-1754.1999.00422.x; Klekamp JG, 1999, AM J PATHOL, V154, P823, DOI 10.1016/S0002-9440(10)65329-1; Lassus P, 1999, AM J RESP CRIT CARE, V159, P1429, DOI 10.1164/ajrccm.159.5.9806073; Lassus P, 2001, AM J RESP CRIT CARE, V164, P1981, DOI 10.1164/ajrccm.164.10.2012036; LIANG Y, 2002, J BIOL CHEM     0323; Ng YS, 2001, DEV DYNAM, V220, P112, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1093>3.0.CO;2-D; Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842; Peng J, 2000, P NATL ACAD SCI USA, V97, P8386, DOI 10.1073/pnas.140087397; PUGAZHENTHI S, 1995, MOL CELL BIOCHEM, V149, P95, DOI 10.1007/BF01076568; Rannels SR, 1996, EXP LUNG RES, V22, P213, DOI 10.3109/01902149609050848; Rayani HH, 1999, EXP LUNG RES, V25, P69, DOI 10.1080/019021499270439; REN JM, 1992, AM J PHYSIOL, V263, pE1086; Rooney SA, 2001, COMP BIOCHEM PHYS A, V129, P233, DOI 10.1016/S1095-6433(01)00320-8; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Stalmans I, 2002, J CLIN INVEST, V109, P327, DOI 10.1172/jci0214362; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; Walfisch A, 2001, OBSTET GYNECOL, V98, P491, DOI 10.1016/S0029-7844(01)01368-0; Yu AY, 1998, AM J PHYSIOL-LUNG C, V275, pL818, DOI 10.1152/ajplung.1998.275.4.L818	43	566	586	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2002	8	7					702	710		10.1038/nm721	http://dx.doi.org/10.1038/nm721			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	567QG	12053176				2022-12-25	WOS:000176495200031
J	Nikaido, M; Kawakami, A; Sawada, A; Furutani-Seiki, M; Takeda, H; Araki, K				Nikaido, M; Kawakami, A; Sawada, A; Furutani-Seiki, M; Takeda, H; Araki, K			Tbx24, encoding a T-box protein, is mutated in the zebrafish somite-segmentation mutant fused somites	NATURE GENETICS			English	Article							GENE; EXPRESSION; MUTATIONS; EMBRYOS; SOMITOGENESIS; SPADETAIL; MESODERM; FAMILY; GENOME; MOTIF	Somites are fundamental structures within the paraxial mesoderm of the vertebrate embryo that give rise to the vertebrae and muscle of the trunk and tail. Studies of knockout mice and gene expression analyses have shown that the Notch pathway is crucial in establishing the reiterative pattern of somites(1). A large-scale screen in zebrafish previously identified five mutants that show abnormalities in somite boundary formation(2). Four have essentially the same phenotype, with posterior somite defects(2-4) and neuronal hyperplasia(5,6); recent work has suggested that genes affected in these mutants encode components of the Notch signaling cascade(5). The fifth mutant, fused somites (fss), shows a different phenotype characterized by complete lack of somite formation along the entire antero-posterior axis(2,3). Gene expression and phenotypic analyses in mutant embryos have implicated Fss in somite formation independent of Notch signaling(4,5), suggesting the presence of a new pathway regulating somite boundary formation. We show here that the fss gene encodes a T-box transcription factor that is expressed in intermediate to anterior presomitic mesoderm (PSM) and is involved in PSM maturation.	Natl Inst Genet, Div Early Embryogenesis, Mishima, Shizuoka, Japan; Natl Res Inst Aquaculture, Div Genet, Cell Engn Sect, Mie, Wataria 5190423, Japan; Japan Sci & Technol Corp, ERATO Kondoh Differentiat Signaling Project, Sakyo Ku, Kyoto 6068305, Japan	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Japan Fisheries Research & Education Agency (FRA); Japan Science & Technology Agency (JST)	Takeda, H (corresponding author), Natl Inst Genet, Div Early Embryogenesis, Mishima, Shizuoka, Japan.		Kawakami, Atsushi/D-3785-2019; TAKEDA, HIROYUKI/G-4950-2014	Kawakami, Atsushi/0000-0001-9461-6372; 				Alexandre D, 1996, DEVELOPMENT, V122, P735; Amemiya CT, 1999, METHOD CELL BIOL, V60, P235; Bamshad M, 1997, NAT GENET, V16, P311, DOI 10.1038/ng0797-311; BOLLAG RJ, 1994, NAT GENET, V7, P383, DOI 10.1038/ng0794-383; CAMPBELL C, 1995, GENOMICS, V28, P255, DOI 10.1006/geno.1995.1139; Chapman DL, 1998, NATURE, V391, P695, DOI 10.1038/35624; Durbin L, 2000, DEVELOPMENT, V127, P1703; Furthauer M, 1997, DEVELOPMENT, V124, P4253; Gray M, 2001, DEV BIOL, V237, P306, DOI 10.1006/dbio.2001.0381; Griffin KJP, 1998, DEVELOPMENT, V125, P3379; Holley SA, 2000, GENE DEV, V14, P1678; Hug B, 1997, DEV BIOL, V183, P61, DOI 10.1006/dbio.1996.8490; Hukriede NA, 1999, P NATL ACAD SCI USA, V96, P9745, DOI 10.1073/pnas.96.17.9745; Jiang YJ, 2000, NATURE, V408, P475, DOI 10.1038/35044091; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; KRAUSS S, 1991, EMBO J, V10, P3609, DOI 10.1002/j.1460-2075.1991.tb04927.x; Kwok C, 1998, NUCLEIC ACIDS RES, V26, P3562, DOI 10.1093/nar/26.15.3562; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; Pourquie O, 2001, DEV CELL, V1, P619, DOI 10.1016/S1534-5807(01)00082-X; Reifers F, 1998, DEVELOPMENT, V125, P2381; Saga Y, 2001, NAT REV GENET, V2, P835, DOI 10.1038/35098552; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sawada A, 2000, DEVELOPMENT, V127, P1691; Sawada A, 2001, DEVELOPMENT, V128, P4873; Shimoda N, 1999, GENOMICS, V58, P219, DOI 10.1006/geno.1999.5824; STACHEL SE, 1993, DEVELOPMENT, V117, P1261; Van Eeden FJM, 1998, DEV GENET, V23, P65; vanEeden FJM, 1996, DEVELOPMENT, V123, P153; Weinberg ES, 1996, DEVELOPMENT, V122, P271; Zhang J, 1998, CELL, V94, P515, DOI 10.1016/S0092-8674(00)81592-5	30	131	135	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2002	31	2					195	199		10.1038/ng899	http://dx.doi.org/10.1038/ng899			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	557HR	12021786				2022-12-25	WOS:000175903500018
J	Agarwal, AK; Arioglu, E; de Almeida, S; Akkoc, N; Taylor, SI; Bowcock, AM; Barnes, RI; Garg, A				Agarwal, AK; Arioglu, E; de Almeida, S; Akkoc, N; Taylor, SI; Bowcock, AM; Barnes, RI; Garg, A			AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34	NATURE GENETICS			English	Article							LYSOPHOSPHATIDIC ACID ACYLTRANSFERASES; CDNA CLONING; EXPRESSION; LOCALIZATION; GENE	Congenital generalized lipodystrophy is an autosomal recessive disorder characterized by marked paucity of adipose tissue, extreme insulin resistance, hypertriglyceridemia, hepatic steatosis and early onset of diabetes. We report several different mutations of the gene (AGPAT2) encoding 1-acylglycerol-3-phosphate O-acyltransferase 2 in 20 affected individuals from 11 pedigrees of diverse ethnicities showing linkage to chromosome 9q34. The AGPAT2 enzyme catalyzes the acylation of lysophosphatidic acid to form phosphatidic acid, a key intermediate in the biosynthesis of triacylglycerol and glycerophospholipids. AGPAT2 mRNA is highly expressed in adipose tissue. We conclude that mutations in AGPAT2 may cause congenital generalized lipodystrophy by inhibiting triacylglycerol synthesis and storage in adipocytes.	Univ Texas, SW Med Ctr, Dept Internal Med, Div Nutr & Metab Dis, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, McDermott Ctr Human Growth & Dev, Ctr Human Nutr, Dallas, TX 75390 USA; NIDDKD, Diabet Branch, Bethesda, MD 20892 USA; Hosp Dona Estefania, Serv Genet Med, Lisbon, Portugal; Dokuz Eylul Univ, Sch Med, Dept Internal Med, Izmir, Turkey; Washington Univ, Sch Med, Dept Genet, Div Human Genet, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Univ Texas, SW Med Ctr, McDermott Ctr Human Growth & Dev, Dallas, TX USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Dokuz Eylul University; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Garg, A (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, Div Nutr & Metab Dis, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	abhimanyu.garg@utsouthwestern.edu	Akkoc, Nurullah/D-9870-2011	Akkoc, Nurullah/0000-0002-3718-171X; Bowcock, Anne/0000-0001-8691-9090; Oral, Elif/0000-0002-9171-1144				Eberhardt C, 1997, J BIOL CHEM, V272, P20299, DOI 10.1074/jbc.272.32.20299; Eberhardt C, 1999, ADV EXP MED BIOL, V469, P351; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; GARG A, 1992, J CLIN ENDOCR METAB, V75, P358, DOI 10.1210/jc.75.2.358; Garg A, 1999, J CLIN ENDOCR METAB, V84, P3390, DOI 10.1210/jc.84.9.3390; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; HUSEMAN C, 1978, J PEDIATR-US, V93, P221, DOI 10.1016/S0022-3476(78)80500-9; Leung DW, 2001, FRONT BIOSCI, V6, pD944, DOI 10.2741/Leung; Lewin TM, 1999, BIOCHEMISTRY-US, V38, P5764, DOI 10.1021/bi982805d; Magre J, 2001, NAT GENET, V28, P365, DOI 10.1038/ng585; Oral EA, 2002, NEW ENGL J MED, V346, P570, DOI 10.1056/NEJMoa012437; Pages C, 2001, PROSTAG OTH LIPID M, V64, P1, DOI 10.1016/S0090-6980(01)00110-1; Seip M, 1996, ACTA PAEDIATR, V85, P2, DOI 10.1111/j.1651-2227.1996.tb14262.x; Vigouroux C, 1997, J CLIN ENDOCR METAB, V82, P3438, DOI 10.1210/jc.82.10.3438; West J, 1997, DNA CELL BIOL, V16, P691, DOI 10.1089/dna.1997.16.691	15	362	376	1	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2002	31	1					21	23		10.1038/ng880	http://dx.doi.org/10.1038/ng880			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	547ZF	11967537	Bronze			2022-12-25	WOS:000175362500009
J	Zabel, U; Kleinschnitz, C; Oh, P; Nedvetsky, P; Smolenski, A; Muller, H; Kronich, P; Kugler, P; Walter, U; Schnitzer, JE; Schmidt, HHHW				Zabel, U; Kleinschnitz, C; Oh, P; Nedvetsky, P; Smolenski, A; Muller, H; Kronich, P; Kugler, P; Walter, U; Schnitzer, JE; Schmidt, HHHW			Calcium-dependent membrane association sensitizes soluble guanylyl cyclase to nitric	NATURE CELL BIOLOGY			English	Article							OXIDE SYNTHASE; RAT LUNG; IN-SITU; ENDOTHELIUM; CAVEOLAE; PURIFICATION; EXPRESSION; DIFFUSION; MESSENGER; SUBUNITS	Nitric oxide (NO) is a ubiquitous, cell-permeable intercellular messenger'. The current concept assumes that NO diffuses freely through the plasma membrane(2) into the cytoplasm of a target cell, where it activates its cytosolic receptor enzyme(3), soluble guanylyl cyclase (sGC). Recent evidence, however, suggests that cellular membranes are not only the predominant site of calcium-dependent NO synthesis(4), but also the site of its distribution and binding(5). Here we extend this concept to NO signalling to show that active sGC is partially associated with the plasma membrane in a state of enhanced NO sensitivity. After cellular activation, sGC further translocates to the membrane fraction in human platelets and associates with the NO-synthase-containing caveolar fraction in rat lung endothelial cells, in a manner that is dependent on the concentration of intracellular calcium. Our data suggest that the entire NO signalling pathway is more spatially confined than previously assumed and that sGC dynamically translocates to the plasma membrane, where it is sensitized to NO.	Univ Giessen, Rudolf Buchheim Inst Pharmacol, D-35392 Giessen, Germany; Univ Wurzburg, Dept Pharmacol & Toxicol, D-97078 Wurzburg, Germany; Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA; Univ Wurzburg, Dept Clin Biochem & Pathobiochem, Wurzburg, Germany; Univ Wurzburg, Inst Anat & Cell Biol, Wurzburg, Germany	Justus Liebig University Giessen; University of Wurzburg; University of Wurzburg; University of Wurzburg	Schmidt, HHHW (corresponding author), Univ Giessen, Rudolf Buchheim Inst Pharmacol, Frankfurter Str 107, D-35392 Giessen, Germany.		Walter, ulrich/W-2478-2017; Schmidt, Harald HHW/B-1549-2008; Nedvetsky, Pavel I/F-1260-2011	Walter, ulrich/0000-0001-6784-2307; Schmidt, Harald HHW/0000-0003-0419-5549; Smolenski, Albert/0000-0001-9210-9406; Nedvetsky, Pavel/0000-0002-0572-9074				ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203; Brouet A, 2001, J BIOL CHEM, V276, P32663, DOI 10.1074/jbc.M101371200; BUCHIER WA, 1991, BIOCHEM BIOPH RES CO, V174, P351; Feussner M, 2001, ACTA HISTOCHEM, V103, P265, DOI 10.1078/0065-1281-00602; GARBERS DL, 1979, J BIOL CHEM, V254, P240; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; Lancaster JR, 1997, NITRIC OXIDE-BIOL CH, V1, P18, DOI 10.1006/niox.1996.0112; Liu XP, 1998, J BIOL CHEM, V273, P18709, DOI 10.1074/jbc.273.30.18709; MALINSKI T, 1993, BIOCHEM BIOPH RES CO, V193, P1076, DOI 10.1006/bbrc.1993.1735; MARKERT T, 1995, J CLIN INVEST, V96, P822, DOI 10.1172/JCI118128; McNicol A., 1996, PRACT APPROACH SER, P1; MUNDEL P, 1995, HISTOCHEM CELL BIOL, V103, P75, DOI 10.1007/BF01464478; Pawloski JR, 2001, NATURE, V409, P622, DOI 10.1038/35054560; PITTS BJR, 1979, J BIOL CHEM, V254, P6232; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; Rizzo V, 1998, J BIOL CHEM, V273, P26323, DOI 10.1074/jbc.273.41.26323; Russwurm M, 2001, J BIOL CHEM, V276, P44647, DOI 10.1074/jbc.M105587200; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; SESSA WC, 1993, CIRC RES, V72, P921, DOI 10.1161/01.RES.72.4.921; SHAW AW, 1977, J CHEM SOC FARADAY T, V8, P1239; Stasch JP, 2001, NATURE, V410, P212, DOI 10.1038/35065611; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Zabel U, 1998, BIOCHEM J, V335, P51, DOI 10.1042/bj3350051; Zabel U, 1999, J BIOL CHEM, V274, P18149, DOI 10.1074/jbc.274.26.18149	26	119	126	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	APR	2002	4	4					307	311		10.1038/ncb775	http://dx.doi.org/10.1038/ncb775			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	541PY	11887187				2022-12-25	WOS:000174994000019
J	Zhang, JZ; Zhang, YP; Rosenberg, HF				Zhang, JZ; Zhang, YP; Rosenberg, HF			Adaptive evolution of a duplicated pancreatic ribonuclease gene in a leaf-eating monkey	NATURE GENETICS			English	Article							POSITIVE DARWINIAN SELECTION; RAPID EVOLUTION; SUBSTITUTIONS; FEATURES; PROTEIN; RATES	Although the complete genome sequences of over 50 representative species have revealed the many duplicated genes in all three domains of life(1-4), the roles of gene duplication in organismal adaptation and biodiversity are poorly understood. In addition, the evolutionary forces behind the functional divergence of duplicated genes are often unknown, leading to disagreement on the relative importance of positive Darwinian selection versus relaxation of functional constraints in this process(5-10). The methodology of earlier studies relied largely on DNA sequence analysis but lacked functional assays of duplicated genes, frequently generating contentious results(11,12). Here we use both computational and experimental approaches to address these questions in a study of the pancreatic ribonuclease gene (RNASE1) and its duplicate gene (RNASE1B) in a leaf-eating colobine monkey, douc langur. We show that RNASE1B has evolved rapidly under positive selection for enhanced ribonucleolytic activity in an altered microenvironment, a response to increased demands for the enzyme for digesting bacterial RNA. At the same time, the ability to degrade double-stranded RNA, a non-digestive activity characteristic of primate RNASE1, has been lost in RNASE1B, indicating functional specialization and relaxation of purifying selection. Our findings demonstrate the contribution of gene duplication to organismal adaptation and show the power of combining sequence analysis and functional assays in delineating the molecular basis of adaptive evolution.	NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA; Univ Michigan, Dept Ecol & Evolutionary Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Chinese Acad Sci, Kunming Inst Zool, Kunming, Yunnan, Peoples R China	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Chinese Academy of Sciences; Kunming Institute of Zoology	Zhang, JZ (corresponding author), NIAID, Host Def Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.							BARNARD EA, 1969, NATURE, V221, P340, DOI 10.1038/221340a0; BEINTEMA JJ, 1990, MOL BIOL EVOL, V7, P470; BROOKFIELD JFY, 1994, TRENDS GENET, V10, P109, DOI 10.1016/0168-9525(94)90201-1; Charlesworth B, 1999, NATURE, V400, P519, DOI 10.1038/22922; CODE CF, 1968, HDB PHYSL, V3; Delson Eric, 1994, P11; FITCH WM, 1971, SYST ZOOL, V20, P406, DOI 10.2307/2412116; Futami J, 1997, DNA CELL BIOL, V16, P413, DOI 10.1089/dna.1997.16.413; Gaudieri S, 1999, GENOME RES, V9, P541; Goodman M, 1998, MOL PHYLOGENET EVOL, V9, P585, DOI 10.1006/mpev.1998.0495; GOODMAN M, 1975, NATURE, V253, P603, DOI 10.1038/253603a0; Guyton A.C., 2011, HALL TXB MED PHYSL; Hughes A.L., 1999, ADAPTIVE EVOLUTION G; HUGHES AL, 1994, P ROY SOC B-BIOL SCI, V256, P119, DOI 10.1098/rspb.1994.0058; Kay Robin N. B., 1994, P229; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; Kimura M., 1983, NEUTRAL THEORY MOL; LI WH, 1983, MOL BIOL EVOL, V1, P94; LI WH, 1997, MOL EVOLUTION, P221; LIBONATI M, 1969, EUR J BIOCHEM, V8, P81, DOI 10.1111/j.1432-1033.1969.tb00498.x; Lynch M, 2000, GENETICS, V154, P459; Makarova KS, 1999, GENOME RES, V9, P608; OHNO S, 1973, NATURE, V244, P259, DOI 10.1038/244259a0; Rooney AP, 1999, MOL BIOL EVOL, V16, P706, DOI 10.1093/oxfordjournals.molbev.a026153; ROSENBERG HF, 1995, J BIOL CHEM, V270, P21539, DOI 10.1074/jbc.270.37.21539; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Sorrentino S, 1997, FEBS LETT, V404, P1, DOI 10.1016/S0014-5793(97)00086-0; TAJIMA F, 1993, GENETICS, V135, P599; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Zhang JZ, 1997, J MOL EVOL, V44, pS139, DOI 10.1007/PL00000067; Zhang JZ, 1998, P NATL ACAD SCI USA, V95, P3708, DOI 10.1073/pnas.95.7.3708; Zhang JZ, 1997, MOL BIOL EVOL, V14, P1335, DOI 10.1093/oxfordjournals.molbev.a025743; Zhang JZ, 2000, J MOL EVOL, V50, P56, DOI 10.1007/s002399910007	33	257	289	1	60	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2002	30	4					411	415		10.1038/ng852	http://dx.doi.org/10.1038/ng852			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	536BZ	11925567				2022-12-25	WOS:000174682000019
J	Chester, J; Ruchatz, A; Gough, M; Crittenden, M; Chong, H; Loic-Cosset, L; Diaz, RM; Harrington, K; Alvarez-Vallina, L; Vile, R				Chester, J; Ruchatz, A; Gough, M; Crittenden, M; Chong, H; Loic-Cosset, L; Diaz, RM; Harrington, K; Alvarez-Vallina, L; Vile, R			Tumor antigen-specific induction of transcriptionally targeted retroviral vectors from chimeric immune receptor-modified T cells	NATURE BIOTECHNOLOGY			English	Article							NF-KAPPA-B; GENE-THERAPY; CARCINOEMBRYONIC ANTIGEN; REGULATORY SEQUENCES; LENTIVIRAL VECTOR; ADOPTIVE TRANSFER; IN-VIVO; LYMPHOCYTES; CANCER; IMMUNOTHERAPY	High-level systemic delivery of viral vectors to tumors has proved problematic as a result of immune neutralization, nonspecific adhesion, and clearance of circulating viral particles. Some cell types localize to tumors in response to particular biological properties associated with tumor growth. Their use to deliver viral vectors to tumors would allow precious viral stocks to be protected until they can be released at high local concentrations. Here, we describe a mechanism by which retroviral vector production by T cells can be regulated by a tumor-specific trigger through engagement of a chimeric immune receptor (CIR) with its target antigen. The virus that is released from the T cells can also be transcriptionally targeted. Finally, we show that it is possible to use vector-loaded, antigen-triggered human T cells as therapeutic, tumor-specific vector delivery cells in models of both local intratumoral and systemic delivery to both lung and liver metastases. This strategy incorporates multiple levels of targeting into the delivery system at the stages of surface targeting, viral production, and gene expression.	Mayo Clin, Program Mol Med, Rochester, MN 55905 USA; INSERM, U412, Lyon 07, France; Inst Canc Res, Chester Beatty Labs, London SW3 6JB, England; Hosp Univ Clin Puerta Hierro, Dept Immunol, Madrid, Spain	Mayo Clinic; Institut National de la Sante et de la Recherche Medicale (Inserm); Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Hospital Puerta de Hierro-Majadahonda	Vile, R (corresponding author), Mayo Clin, Program Mol Med, Guggenheim 18,200 1st St SW, Rochester, MN 55905 USA.		Alvarez-Vallina, Luis/A-2033-2010; Cosset, François-Loïc/M-5862-2019; Alvarez-Vallina, Luis/ABD-2431-2020; Álvarez-Vallina, Luis/A-2032-2010; Gough, Michael/AAY-3419-2020	Cosset, François-Loïc/0000-0001-8842-3726; Alvarez-Vallina, Luis/0000-0003-3053-6757; Gough, Michael/0000-0002-5575-0074; Harrington, Kevin/0000-0002-6014-348X				Alemany R, 2000, J GEN VIROL, V81, P2605, DOI 10.1099/0022-1317-81-11-2605; Alemany R, 2000, NAT BIOTECHNOL, V18, P723, DOI 10.1038/77283; Altenschmidt U, 1997, J IMMUNOL, V159, P5509; Alvarez-Vallina L, 2000, CANCER GENE THER, V7, P526, DOI 10.1038/sj.cgt.7700128; Alvarez-Vallina L, 1997, J IMMUNOL, V159, P5889; Alvarez-Vallina L, 1999, HUM GENE THER, V10, P559, DOI 10.1089/10430349950018634; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; Bolhuis RLH, 1998, GENE THER, V5, P1153, DOI 10.1038/sj.gt.3300697; Boon T, 1996, J EXP MED, V183, P725, DOI 10.1084/jem.183.3.725; Brocker T, 1996, EUR J IMMUNOL, V26, P1770, DOI 10.1002/eji.1830260816; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Carta L, 2001, J IMMUNOL, V166, P5374, DOI 10.4049/jimmunol.166.9.5374; Chirmule N, 2000, J VIROL, V74, P3345, DOI 10.1128/JVI.74.7.3345-3352.2000; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; Di Carlo E, 2001, BLOOD, V97, P339, DOI 10.1182/blood.V97.2.339; Diaz RM, 1998, J VIROL, V72, P789, DOI 10.1128/JVI.72.1.789-795.1998; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Duisit G, 1999, HUM GENE THER, V10, P189, DOI 10.1089/10430349950018986; Emiliusen L, 2001, GENE THER, V8, P987, DOI 10.1038/sj.gt.3301470; ESHHAR Z, 1993, P NATL ACAD SCI USA, V90, P720, DOI 10.1073/pnas.90.2.720; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; FREEMAN SM, 1993, CANCER RES, V53, P5274; Gomez-Navarro J, 2000, GENE THER, V7, P43, DOI 10.1038/sj.gt.3301054; Griffiths L, 2000, GENE THER, V7, P255, DOI 10.1038/sj.gt.3301058; Grill J, 2001, CLIN CANCER RES, V7, P641; Hollander GA, 1999, SEMIN IMMUNOL, V11, P357; Hombach A, 1999, GENE THER, V6, P300, DOI 10.1038/sj.gt.3300813; IOANNIDES CG, 1993, CLIN IMMUNOL IMMUNOP, V66, P91, DOI 10.1006/clin.1993.1012; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; Kirn D, 2001, NAT MED, V7, P781, DOI 10.1038/89901; Krasnykh V, 2001, J VIROL, V75, P4176, DOI 10.1128/JVI.75.9.4176-4183.2001; MCELHINNY JA, 1995, J VIROL, V69, P1500, DOI 10.1128/JVI.69.3.1500-1509.1995; MELIEF CJM, 1992, ADV CANCER RES, V58, P143, DOI 10.1016/S0065-230X(08)60294-8; MILLER DG, 1990, MOL CELL BIOL, V10, P4239, DOI 10.1128/MCB.10.8.4239; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Paillard F, 1998, HUM GENE THER, V9, P454; Pastorino S, 2001, GENE THER, V8, P431, DOI 10.1038/sj.gt.3301405; Patel SD, 1999, GENE THER, V6, P412, DOI 10.1038/sj.gt.3300831; Pizzato M, 1999, J VIROL, V73, P8599, DOI 10.1128/JVI.73.10.8599-8611.1999; RICHARDS CA, 1995, HUM GENE THER, V6, P881, DOI 10.1089/hum.1995.6.7-881; ROSENBERG SA, 1992, J CLIN ONCOL, V10, P180, DOI 10.1200/JCO.1992.10.2.180; ROSENBERG SA, 1984, CANCER TREAT REP, V68, P233; Russell SJ, 1999, J GENE MED, V1, P300, DOI 10.1002/(SICI)1521-2254(199909/10)1:5<300::AID-JGM59>3.0.CO;2-T; SEN J, 1995, J IMMUNOL, V154, P3213; Takeuchi Y, 1996, NATURE, V379, P85, DOI 10.1038/379085a0; Trushin SA, 1999, J BIOL CHEM, V274, P22923, DOI 10.1074/jbc.274.33.22923; Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410; Vile RG, 2000, GENE THER, V7, P2, DOI 10.1038/sj.gt.3301084; VILE RG, 1994, CANCER RES, V54, P6228; WAGNER MJ, 1981, P NATL ACAD SCI-BIOL, V78, P1441, DOI 10.1073/pnas.78.3.1441; Weijtens MEM, 1996, J IMMUNOL, V157, P836; Whiteside TL, 2000, CLIN DIAGN LAB IMMUN, V7, P327, DOI 10.1128/CDLI.7.3.327-332.2000; Wu P, 2000, J VIROL, V74, P8635, DOI 10.1128/JVI.74.18.8635-8647.2000; Yee C, 2000, J EXP MED, V192, P1637, DOI 10.1084/jem.192.11.1637; Yee C, 2001, CURR OPIN IMMUNOL, V13, P141, DOI 10.1016/S0952-7915(00)00196-5; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	58	33	37	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2002	20	3					256	263		10.1038/nbt0302-256	http://dx.doi.org/10.1038/nbt0302-256			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	526RE	11875426				2022-12-25	WOS:000174142800043
J	Lee, TS; Chau, LY				Lee, TS; Chau, LY			Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice	NATURE MEDICINE			English	Article							SIGNAL-TRANSDUCTION PATHWAY; NECROSIS-FACTOR-ALPHA; CARBON-MONOXIDE; MONONUCLEAR PHAGOCYTES; PROVIDES PROTECTION; NITRIC-OXIDE; KINASE; CELLS; P38; TRANSCRIPTION	The mechanisms underlying the action of the potent anti-inflammatory interleukin-10 (IL-10) are poorly understood. Here we show that, in murine macrophages, IL-10 induces expression of heme oxygenase-1 (HO-1), a stress-inducible protein with potential anti-inflammatory effect, via a p38 mitogen-activated protein kinase-dependent pathway. Inhibition of HO-1 protein synthesis or activity significantly reversed the inhibitory effect of IL-10 on production of tumor necrosis factor-alpha induced by lipopolysaccharide (LPS). Additional experiments revealed the involvement of carbon monoxide, one of the products of HO-1-mediated heme degradation, in the anti-inflammatory effect of IL-10 in vitro. Induction of HO-1 by IL-10 was also evident in vivo. IL-10-mediated protection against LPS-induced septic shock in mice was significantly attenuated by cotreatment with the HO inhibitor, zinc protoporphyrin. The identification of HO-1 as a downstream effector of IL-10 provides new possibilities for improved therapeutic approaches for treating inflammatory diseases.	Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan; Acad Sinica, Inst Biomed Sci, Taipei, Taiwan	National Defense Medical Center; Academia Sinica - Taiwan	Chau, LY (corresponding author), Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan.	lyc@mail.ibms.sinica.edu.tw	Chau, Lee-Young/N-7659-2018; Lee, Tzong-Shyuan/AAE-5803-2020	Chau, Lee-Young/0000-0002-6316-2328; Lee, Tzong-Shyuan/0000-0002-9593-4062				Alam J, 2000, J BIOL CHEM, V275, P27694; Aste-Amezaga M, 1998, J IMMUNOL, V160, P5936; BONKOVSKY HL, 1990, EUR J BIOCHEM, V189, P155, DOI 10.1111/j.1432-1033.1990.tb15472.x; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen K, 2000, CELL MOL BIOL, V46, P609; Crawley JB, 1996, J BIOL CHEM, V271, P16357, DOI 10.1074/jbc.271.27.16357; Deramaudt TB, 1999, P SOC EXP BIOL MED, V222, P185, DOI 10.1046/j.1525-1373.1999.d01-130.x; DING AH, 1988, J IMMUNOL, V141, P2407; Donnelly RP, 1999, J INTERF CYTOK RES, V19, P563, DOI 10.1089/107999099313695; Geiss G, 2001, J BIOL CHEM, V276, P30178, DOI 10.1074/jbc.C100137200; Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2; HOWARD M, 1992, IMMUNOL TODAY, V13, P198, DOI 10.1016/0167-5699(92)90153-X; Kacimi R, 2000, CARDIOVASC RES, V46, P139, DOI 10.1016/S0008-6363(00)00007-9; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KLEINER DE, 1994, ANAL BIOCHEM, V218, P325, DOI 10.1006/abio.1994.1186; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Kontoyiannis D, 2001, EMBO J, V20, P3760, DOI 10.1093/emboj/20.14.3760; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; LACRAZ S, 1995, J CLIN INVEST, V96, P2304, DOI 10.1172/JCI118286; Lai CF, 1996, J BIOL CHEM, V271, P13968, DOI 10.1074/jbc.271.24.13968; Lee PJ, 2000, AM J PHYSIOL-LUNG C, V279, pL175, DOI 10.1152/ajplung.2000.279.1.L175; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165; Mtairag E, 2001, CARDIOVASC RES, V49, P882; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; OTTERBEIN L, 1995, AM J RESP CELL MOL, V13, P595, DOI 10.1165/ajrcmb.13.5.7576696; Otterbein LE, 2000, AM J PHYSIOL-LUNG C, V279, pL1029, DOI 10.1152/ajplung.2000.279.6.L1029; Otterbein LE, 1999, AM J PHYSIOL-LUNG C, V276, pL688; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Ponka P, 1999, AM J MED SCI, V318, P241, DOI 10.1097/00000441-199910000-00004; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; PRABHAKAR NR, 1995, P NATL ACAD SCI USA, V92, P1994, DOI 10.1073/pnas.92.6.1994; PRICHETT W, 1995, J INFLAMM, V45, P97; Riley JK, 1999, J BIOL CHEM, V274, P16513, DOI 10.1074/jbc.274.23.16513; Sato K, 2001, J IMMUNOL, V166, P4185, DOI 10.4049/jimmunol.166.6.4185; Terry CM, 1998, AM J PHYSIOL-HEART C, V274, pH883, DOI 10.1152/ajpheart.1998.274.3.H883; van den Blink B, 2001, J IMMUNOL, V166, P582, DOI 10.4049/jimmunol.166.1.582; Wang LJ, 1998, AM J PATHOL, V152, P711; WANG P, 1994, J IMMUNOL, V153, P811; WELGUS HG, 1985, J CLIN INVEST, V76, P219, DOI 10.1172/JCI111949; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87; Xu K, 2001, J IMMUNOL, V166, P6358, DOI 10.4049/jimmunol.166.10.6358; Zhang C, 1997, J BIOL CHEM, V272, P13397, DOI 10.1074/jbc.272.20.13397	45	872	920	0	47	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2002	8	3					240	246		10.1038/nm0302-240	http://dx.doi.org/10.1038/nm0302-240			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	526PU	11875494				2022-12-25	WOS:000174139500028
J	Muratani, M; Gerlich, D; Janicki, SM; Gebhard, M; Eils, R; Spector, DL				Muratani, M; Gerlich, D; Janicki, SM; Gebhard, M; Eils, R; Spector, DL			Metabolic-energy-dependent movement of PML bodies within the mammalian cell nucleus	NATURE CELL BIOLOGY			English	Article							LIVING CELLS; PROTEINS; RECEPTOR; SP100; GENE; TRANSLOCATION; VISUALIZATION; INTERFERONS; INDUCTION; DOMAIN-10	Promyelocytic leukaemia (PML) nuclear bodies are present in most mammalian cell nuclei. PML bodies are disrupted by PML retinoic acid receptor alpha (RARalpha) oncoproteins in acute promyelocytic leukaemia. These bodies contain numerous proteins, including Sp100, SUMO-1, HAUSP(USP7), CBP and BLM, and they have been implicated in aspects of transcriptional regulation or as nuclear storage depots. Here, we show that three classes of PML nuclear bodies can be distinguished, on the basis of their dynamic properties in living cells. One class of PML bodies is particularly noteworthy in that it moves by a metabolic-energy-dependent mechanism. This represents the first example of metabolic-energy-dependent transport of a nuclear body within the mammalian cell nucleus.	Cold Spring Harbor Lab, Watson Sch Biol Sci, Cold Spring Harbor, NY 11724 USA; German Canc Res Ctr, D-69120 Heidelberg, Germany	Cold Spring Harbor Laboratory; Helmholtz Association; German Cancer Research Center (DKFZ)	Spector, DL (corresponding author), Cold Spring Harbor Lab, Watson Sch Biol Sci, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.		Eils, Roland/B-6121-2009; Muratani, Masafumi/A-6379-2011; Gerlich, Daniel Wolfram W/A-6991-2016	Eils, Roland/0000-0002-0034-4036; Gerlich, Daniel Wolfram W/0000-0003-1637-3365	NIGMS NIH HHS [GM498100] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; Cao TY, 1998, J CELL SCI, V111, P1319; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; CRAMER LP, 1995, J CELL BIOL, V131, P179, DOI 10.1083/jcb.131.1.179; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Eils R, 2000, MOL BIOL CELL, V11, P413, DOI 10.1091/mbc.11.2.413; Everett RD, 1999, J CELL SCI, V112, P3443; Everett RD, 1997, EMBO J, V16, P1519, DOI 10.1093/emboj/16.7.1519; Grande MA, 1996, J CELL BIOCHEM, V63, P280, DOI 10.1002/(SICI)1097-4644(19961201)63:3<280::AID-JCB3>3.0.CO;2-T; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; GULDNER HH, 1992, J IMMUNOL, V149, P4067; Heun P, 2001, SCIENCE, V294, P2181, DOI 10.1126/science.1065366; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LAVAU C, 1995, ONCOGENE, V11, P871; Marshall WF, 1997, CURR BIOL, V7, P930, DOI 10.1016/S0960-9822(06)00412-X; MAUL GG, 1993, J GEN VIROL, V74, P2679, DOI 10.1099/0022-1317-74-12-2679; Maul GG, 1998, BIOESSAYS, V20, P660, DOI 10.1002/(SICI)1521-1878(199808)20:8<660::AID-BIES9>3.0.CO;2-M; Maul GG, 1995, J CELL BIOCHEM, V59, P498, DOI 10.1002/jcb.240590410; Misteli T, 2001, SCIENCE, V291, P843, DOI 10.1126/science.291.5505.843; Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0; Negorev D, 2001, J CELL SCI, V114, P59; Pederson T, 2000, MOL BIOL CELL, V11, P799, DOI 10.1091/mbc.11.3.799; Pederson T, 2001, CELL, V104, P635, DOI 10.1016/S0092-8674(02)01455-1; Pestic-Dragovich L, 2000, SCIENCE, V290, P337, DOI 10.1126/science.290.5490.337; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Platani M, 2000, J CELL BIOL, V151, P1561, DOI 10.1083/jcb.151.7.1561; Plehn-Dujowich D, 2000, CHROMOSOMA, V109, P266, DOI 10.1007/s004120000073; Rando OJ, 2000, TRENDS CELL BIOL, V10, P92, DOI 10.1016/S0962-8924(99)01713-4; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; Seeler JS, 1998, P NATL ACAD SCI USA, V95, P7316, DOI 10.1073/pnas.95.13.7316; Spector DL, 2001, J CELL SCI, V114, P2891; Stadler M, 1995, ONCOGENE, V11, P2565; Steinhorst A, 1998, ACCREDIT QUAL ASSUR, V3, P294, DOI 10.1007/s007690050249; Stenoien DL, 2001, NAT CELL BIOL, V3, P15, DOI 10.1038/35050515; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; STUURMAN N, 1992, J CELL SCI, V101, P773; Tsukamoto T, 2000, NAT CELL BIOL, V2, P871, DOI 10.1038/35046510; Tvarusko W, 1999, P NATL ACAD SCI USA, V96, P7950, DOI 10.1073/pnas.96.14.7950; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583	41	145	147	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	FEB	2002	4	2					106	110		10.1038/ncb740	http://dx.doi.org/10.1038/ncb740			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	520RJ	11753375				2022-12-25	WOS:000173794600013
J	Tsang, M; Friesel, R; Kudoh, T; Dawid, IB				Tsang, M; Friesel, R; Kudoh, T; Dawid, IB			Identification of Sef, a novel modulator of FGF signalling	NATURE CELL BIOLOGY			English	Article							MIDBRAIN-HINDBRAIN BOUNDARY; GROWTH-FACTOR RECEPTORS; ZEBRAFISH; XENOPUS; EXPRESSION; MESODERM; SPROUTY; TRANSMEMBRANE; INHIBITOR; ORGANIZER	Fibroblast growth factors (FGFs) are members of a family of some 30 secreted proteins important in the regulation of cellular proliferation, migration, differentiation and survival(1-4). Here we report the identification of a novel modulator of FGF signal transduction, sef, isolated from a zebrafish embryo library through an in situ hybridization screen. The sef gene encodes a transmembrane protein, and belongs to the synexpression group that includes some of the fgf genes. Sef expression is positively regulated by FGF, and ectopic expression of sef in zebrafish or Xenopus laevis embryos specifically inhibits FGF signalling. In co-immunoprecipitation assays, the intracellular domain of Sef interacts with FGF receptors, FGFR1 and FGFR2. Injection of antisense sef morpholino oligos mimicked the phenotypes observed by ectopic fgf8 expression, suggesting that Sef is required to limit FGF signalling during development.	NICHHD, Genet Mol Lab, NIH, Bethesda, MD 20892 USA; Maine Med Ctr, Res Inst, Ctr Mol Med, Scarborough, ME 04074 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Maine Medical Center	Dawid, IB (corresponding author), NICHHD, Genet Mol Lab, NIH, Bethesda, MD 20892 USA.		TSANG, Michael/E-2758-2013; Tsang, Michael/ABV-0504-2022; Tsang, Michael W/I-9305-2014; Tsang, Michael/AAG-9338-2020	TSANG, Michael/0000-0001-6384-2422; Tsang, Michael/0000-0001-7123-0063; Tsang, Michael W/0000-0001-7123-0063; 	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001002] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001002] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015555] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013248] Funding Source: NIH RePORTER; NCRR NIH HHS [RR15555] Funding Source: Medline; NHLBI NIH HHS [HL65301] Funding Source: Medline; NIDCR NIH HHS [DE13248] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AMAYA E, 1993, DEVELOPMENT, V118, P477; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Friesel R, 1999, THROMB HAEMOSTASIS, V82, P748; FRIESEL R, 1991, MOL CELL BIOL, V11, P2481, DOI 10.1128/MCB.11.5.2481; FRIESEL R, 1992, DEVELOPMENT, V116, P1051; Furthauer M, 1997, DEVELOPMENT, V124, P4253; FURTHAUER M, 2002, NATURE CELL BIOL; Gawantka V, 1998, MECH DEVELOP, V77, P95, DOI 10.1016/S0925-4773(98)00115-4; Ghiglione C, 1999, CELL, V96, P847, DOI 10.1016/S0092-8674(00)80594-2; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GRIFFIN K, 1995, DEVELOPMENT, V121, P2983; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; ISAACS HV, 1994, EMBO J, V13, P4469, DOI 10.1002/j.1460-2075.1994.tb06769.x; Joyner AL, 2000, CURR OPIN CELL BIOL, V12, P736, DOI 10.1016/S0955-0674(00)00161-7; Kudoh T, 2001, GENOME RES, V11, P1979, DOI 10.1101/gr.209601; Lun K, 1998, DEVELOPMENT, V125, P3049; Macdonald R, 1997, DEVELOPMENT, V124, P2397; Martinez S, 1999, DEVELOPMENT, V126, P1189; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; Neilson KM, 1996, J BIOL CHEM, V271, P25049, DOI 10.1074/jbc.271.40.25049; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; Onichtchouk D, 1999, NATURE, V401, P480, DOI 10.1038/46794; Reich A, 1999, DEVELOPMENT, V126, P4139; Reifers F, 1998, DEVELOPMENT, V125, P2381; Reifers F, 2000, MECH DEVELOP, V99, P39, DOI 10.1016/S0925-4773(00)00475-5; Sun X, 1999, GENE DEV, V13, P1834, DOI 10.1101/gad.13.14.1834; Trumpp A, 1999, GENE DEV, V13, P3136, DOI 10.1101/gad.13.23.3136; Tsang M, 2000, GENESIS, V28, P47, DOI 10.1002/1526-968X(200010)28:2<47::AID-GENE20>3.0.CO;2-S; Weinstein DC, 1998, NATURE, V394, P904, DOI 10.1038/29808	29	248	261	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	FEB	2002	4	2					165	169		10.1038/ncb749	http://dx.doi.org/10.1038/ncb749			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	520RJ	11802164				2022-12-25	WOS:000173794600022
J	Hetzer, M; Meyer, HH; Walther, TC; Bilbao-Cortes, D; Warren, G; Mattaj, IW				Hetzer, M; Meyer, HH; Walther, TC; Bilbao-Cortes, D; Warren, G; Mattaj, IW			Distinct AAA-ATPase p97 complexes function in discrete steps of nuclear assembly	NATURE CELL BIOLOGY			English	Article							MEMBRANE-PROTEIN; IN-VITRO; PORE COMPLEXES; GTP HYDROLYSIS; SYNTAXIN 5; ENVELOPE; FUSION; UBIQUITIN	Although nuclear envelope (NE) assembly is known to require the GTPase Ran, the membrane fusion machinery involved is uncharacterized. NE assembly involves formation of a reticular network on chromatin, fusion of this network into a closed NE and subsequent expansion. Here we show that p97, an AAA-ATPase previously implicated in fusion of Golgi and transitional endoplasmic reticulum (ER) membranes together with the adaptor p47, has two discrete functions in NE assembly. Formation of a closed NE requires the p97-Ufd1-Npl4 complex, not previously implicated in membrane fusion. Subsequent NE growth involves a p97-p47 complex. This study provides the first insights into the molecular mechanisms and specificity of fusion events involved in NE formation.	European Mol Biol Lab, D-69117 Heidelberg, Germany; Yale Univ, Sch Med, Dept Cell Biol, SHM, New Haven, CT 06520 USA	European Molecular Biology Laboratory (EMBL); Yale University	Mattaj, IW (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.	Mattaj@EMBL-Heidelberg.de	Meyer, Hemmo/GNH-5784-2022	Meyer, Hemmo/0000-0003-1883-1796; Walther, Tobias/0000-0003-1442-1327; Mattaj, Iain/0000-0002-5537-8284; Bilbao Cortes, Daniel/0000-0003-1630-8811				BENAVENTE R, 1989, CHROMOSOMA, V98, P233, DOI 10.1007/BF00327308; BOMAN AL, 1992, J CELL BIOL, V116, P281, DOI 10.1083/jcb.116.2.281; BURKE B, 1986, CELL, V44, P639, DOI 10.1016/0092-8674(86)90273-4; DAVIS LI, 1987, P NATL ACAD SCI USA, V84, P7552, DOI 10.1073/pnas.84.21.7552; DeHoratius C, 1996, MOL BIOL CELL, V7, P1835, DOI 10.1091/mbc.7.11.1835; Dreier L, 2000, J CELL BIOL, V148, P883, DOI 10.1083/jcb.148.5.883; Drummond S, 1999, J CELL BIOL, V144, P225, DOI 10.1083/jcb.144.2.225; Ellenberg J, 1997, J CELL BIOL, V138, P1193, DOI 10.1083/jcb.138.6.1193; FRANKE WW, 1981, J CELL BIOL, V91, pS39, DOI 10.1083/jcb.91.3.39s; Gant TM, 1997, ANNU REV CELL DEV BI, V13, P669, DOI 10.1146/annurev.cellbio.13.1.669; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; Ghislain M, 1996, EMBO J, V15, P4884, DOI 10.1002/j.1460-2075.1996.tb00869.x; Hetzer M, 2000, MOL CELL, V5, P1013, DOI 10.1016/S1097-2765(00)80266-X; Hoppe T, 2000, CELL, V102, P577, DOI 10.1016/S0092-8674(00)00080-5; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; Lavoie C, 1996, J CELL SCI, V109, P1415; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; Macaulay C, 1996, J CELL BIOL, V132, P5, DOI 10.1083/jcb.132.1.5; Marshall ICB, 1997, TRENDS CELL BIOL, V7, P69, DOI 10.1016/S0962-8924(96)10047-7; Meyer HH, 2000, EMBO J, V19, P2181, DOI 10.1093/emboj/19.10.2181; NEWPORT J, 1992, J CELL BIOL, V116, P295, DOI 10.1083/jcb.116.2.295; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; POWELL L, 1990, J CELL BIOL, V111, P2225, DOI 10.1083/jcb.111.6.2225; Rabouille C, 1998, CELL, V92, P603, DOI 10.1016/S0092-8674(00)81128-9; Rossanese OW, 1999, J CELL BIOL, V145, P69, DOI 10.1083/jcb.145.1.69; Roy L, 2000, MOL BIOL CELL, V11, P2529, DOI 10.1091/mbc.11.8.2529; Sasagawa S, 1999, EUR J CELL BIOL, V78, P593, DOI 10.1016/S0171-9335(99)80025-9; SOULLAM B, 1995, J CELL BIOL, V130, P15, DOI 10.1083/jcb.130.1.15; VIGERS GPA, 1991, J CELL BIOL, V112, P545, DOI 10.1083/jcb.112.4.545; WILSON KL, 1988, J CELL BIOL, V107, P57, DOI 10.1083/jcb.107.1.57; Zhang CM, 2000, SCIENCE, V288, P1429, DOI 10.1126/science.288.5470.1429; Zhang CM, 2001, CURR BIOL, V11, P208, DOI 10.1016/S0960-9822(01)00053-7; [No title captured]	35	265	270	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2001	3	12					1086	1091		10.1038/ncb1201-1086	http://dx.doi.org/10.1038/ncb1201-1086			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	500AM	11781570				2022-12-25	WOS:000172603700014
J	Viglietto, G; Motti, ML; Bruni, P; Melillo, RM; D'Alessio, A; Califano, D; Vinci, F; Chiappetta, G; Tsichlis, P; Bellacosa, A; Fusco, A; Santoro, M				Viglietto, G; Motti, ML; Bruni, P; Melillo, RM; D'Alessio, A; Califano, D; Vinci, F; Chiappetta, G; Tsichlis, P; Bellacosa, A; Fusco, A; Santoro, M			Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer	NATURE MEDICINE			English	Article							PROTEIN-KINASE; CDK-INHIBITORS; AKT ACTIVATION; CELL-SURVIVAL; EXPRESSION; GROWTH; P27; LOCALIZATION; D1; DEGRADATION	The cyclin-dependent kinase inhibitor p27(kip1) is a putative tumor suppressor for human cancer. The mechanism underlying p27(kip1) deregulation in human cancer is, however, poorly understood. We demonstrate that the serine/threonine kinase Akt regulates cell proliferation in breast cancer cells by preventing p27(kip1)-mediated growth arrest. Threonine 157 (T157), which maps within the nuclear localization signal of p27(kip1), is a predicted Akt-phosphorylation site. Akt-induced T157 phosphorylation causes retention of p27(kip1) in the cytoplasm, precluding p27(kip1)-induced G1 arrest. Conversely, the p27(kip1)-T157A mutant accumulates in cell nuclei and Akt does not affect p27(kip1)-T157A-mediated cell cycle arrest. Lastly, T157-phosphorylated p27(kip1) accumulates in the cytoplasm of primary human breast cancer cells coincident with Akt activation. Thus, cytoplasmic relocalization of p27(kip1), secondary to Akt-mediated phosphorylation, is a novel mechanism whereby the growth inhibitory properties of p27(kip1) are functionally inactivated and the proliferation of breast cancer cells is sustained.	Dipartimento Biol & Patol Cellulare & Mol, CNR, Ist Endocrinol & Oncol Sperimentale, Naples, Italy; Univ Naples Federico II, Fac Med & Chirurg 2, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy; Ist Nazl Tumori, Fdn Pascale, Naples, Italy; Complesso Univ Monte S Angelo, Dipartimento Chim Organ & Biochim, Naples, Italy; Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Univ Cattolica Sacro Cuore, Sch Med, Dept Med Genet, I-00168 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; IRCCS Fondazione Pascale; Jefferson University; Fox Chase Cancer Center; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Viglietto, G (corresponding author), Dipartimento Biol & Patol Cellulare & Mol, CNR, Ist Endocrinol & Oncol Sperimentale, Naples, Italy.	viglietto@sun.ceos.na.cnr.it	Viglietto, Giuseppe/AAC-2852-2019; melillo, rosa marina/O-5255-2015; Califano, Daniela/Y-6313-2018	Viglietto, Giuseppe/0000-0003-2327-7515; Califano, Daniela/0000-0001-6945-3209; Fusco, Alfredo/0000-0003-3332-5197; MELILLO, Rosa Marina/0000-0002-9233-5275				Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Baldassarre G, 1999, J CLIN INVEST, V104, P865, DOI 10.1172/JCI6443; Baldassarre G, 1999, ONCOGENE, V18, P6241, DOI 10.1038/sj.onc.1203031; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Bruni P, 2000, ONCOGENE, V19, P3146, DOI 10.1038/sj.onc.1203633; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Ciaparrone M, 1998, CANCER RES, V58, P114; Coffer PJ, 1998, BIOCHEM J, V335, P1; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jiang YH, 2000, P NATL ACAD SCI USA, V97, P10538, DOI 10.1073/pnas.190104497; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Lenferink AEG, 2001, CANCER RES, V61, P6583; Liu XD, 2000, ONCOGENE, V19, P5926, DOI 10.1038/sj.onc.1203991; Lloyd RV, 1997, AM J PATHOL, V150, P401; Lobenhofer EK, 2000, CELL GROWTH DIFFER, V11, P99; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; OTSUKI T, 1995, CANCER RES, V55, P1436; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Rocco JW, 2001, EXP CELL RES, V264, P42, DOI 10.1006/excr.2000.5149; Sgambato A, 2000, J CELL PHYSIOL, V183, P18, DOI 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Singh SP, 1998, CANCER RES, V58, P1730; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tsai EM, 2001, CANCER RES, V61, P8390; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; Yang HY, 2001, ONCOGENE, V20, P3695, DOI 10.1038/sj.onc.1204472; Yaroslavskiy B, 1999, BLOOD, V93, P2907; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	44	572	601	0	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2002	8	10					1136	1144		10.1038/nm762	http://dx.doi.org/10.1038/nm762			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	599AN	12244303				2022-12-25	WOS:000178311000041
J	Arvidsson, A; Collin, T; Kirik, D; Kokaia, Z; Lindvall, O				Arvidsson, A; Collin, T; Kirik, D; Kokaia, Z; Lindvall, O			Neuronal replacement from endogenous precursors in the adult brain after stroke	NATURE MEDICINE			English	Article							CEREBRAL-ARTERY OCCLUSION; CENTRAL-NERVOUS-SYSTEM; NEURAL STEM-CELLS; DENTATE GYRUS; NEUROTROPHIC FACTOR; SUBVENTRICULAR ZONE; PROGENITOR CELLS; RAT; NEUROGENESIS; DIFFERENTIATION	In the adult brain, new neurons are continuously generated in the subventricular zone and dentate gyrus, but it is unknown whether these neurons can replace those lost following damage or disease. Here we show that stroke, caused by transient middle cerebral artery occlusion in adult rats, leads to a marked increase of cell proliferation in the subventricular zone. Stroke-generated new neurons, as well as neuroblasts probably already formed before the insult, migrate into the severely damaged area of the striatum, where they express markers of developing and mature, striatal medium-sized spiny neurons. Thus, stroke induces differentiation of new neurons into the phenotype of most of the neurons destroyed by the ischemic lesion. Here we show that the adult brain has the capacity for self-repair after insults causing extensive neuronal death. If the new neurons are functional and their formation can be stimulated, a novel therapeutic strategy might be developed for stroke in humans.	Univ Lund Hosp, Sect Restorat Neurol, Wallenberg Neurosci Ctr, S-22185 Lund, Sweden; Univ Lund Hosp, Neurobiol Sect, Wallenberg Neurosci Ctr, S-22185 Lund, Sweden	Lund University; Skane University Hospital; Lund University; Skane University Hospital	Arvidsson, A (corresponding author), Univ Lund Hosp, Sect Restorat Neurol, Wallenberg Neurosci Ctr, S-22185 Lund, Sweden.		Kirik, Deniz/E-5156-2011; Kokaia, Zaal/AAL-6009-2020	Kokaia, Zaal/0000-0003-2296-2449				Aboody KS, 2000, P NATL ACAD SCI USA, V97, P12846, DOI 10.1073/pnas.97.23.12846; Arvidsson A, 2001, EUR J NEUROSCI, V14, P10, DOI 10.1046/j.0953-816x.2001.01611.x; BARAMI K, 1995, J NEUROBIOL, V28, P82, DOI 10.1002/neu.480280108; Bengzon J, 1997, P NATL ACAD SCI USA, V94, P10432, DOI 10.1073/pnas.94.19.10432; Benraiss A, 2001, J NEUROSCI, V21, P6718, DOI 10.1523/JNEUROSCI.21-17-06718.2001; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Davies CA, 1998, EXP NEUROL, V154, P199, DOI 10.1006/exnr.1998.6891; Doetsch F, 1999, P NATL ACAD SCI USA, V96, P11619, DOI 10.1073/pnas.96.20.11619; Ekdahl CT, 2001, EUR J NEUROSCI, V14, P937, DOI 10.1046/j.0953-816x.2001.01713.x; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gu WG, 2000, J CEREBR BLOOD F MET, V20, P1166, DOI 10.1097/00004647-200008000-00002; Heimer L., 1995, P579; Herrera DG, 1999, ANN NEUROL, V46, P867, DOI 10.1002/1531-8249(199912)46:6<867::AID-ANA9>3.0.CO;2-Z; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Koizumi J., 1986, JPN J STROKE, V8, P1, DOI DOI 10.3995/JSTROKE.8.1; KOKAIA Z, 1995, EXP NEUROL, V136, P73, DOI 10.1006/exnr.1995.1085; Liu JL, 1998, J NEUROSCI, V18, P7768; Lois C, 1996, SCIENCE, V271, P978, DOI 10.1126/science.271.5251.978; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; MARUSICH MF, 1994, J NEUROBIOL, V25, P143, DOI 10.1002/neu.480250206; Mason HA, 2001, J NEUROSCI, V21, P7654, DOI 10.1523/JNEUROSCI.21-19-07654.2001; Nacher J, 2001, EUR J NEUROSCI, V14, P629, DOI 10.1046/j.0953-816x.2001.01683.x; Ouimet CC, 1998, BRAIN RES, V808, P8, DOI 10.1016/S0006-8993(98)00724-0; OUIMET CC, 1984, J NEUROSCI, V4, P111; Parent JM, 1997, J NEUROSCI, V17, P3727; Pencea V, 2001, J NEUROSCI, V21, P6706, DOI 10.1523/JNEUROSCI.21-17-06706.2001; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Toresson H, 2000, MECH DEVELOP, V94, P183, DOI 10.1016/S0925-4773(00)00324-5; Toresson H, 1999, DEVELOPMENT, V126, P1317; Veizovic T, 2001, STROKE, V32, P1012, DOI 10.1161/01.STR.32.4.1012; Wichterle H, 1997, NEURON, V18, P779, DOI 10.1016/S0896-6273(00)80317-7; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8; ZHAO Q, 1994, BRAIN RES, V649, P253, DOI 10.1016/0006-8993(94)91071-5	34	2204	2360	2	181	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2002	8	9					963	970		10.1038/nm747	http://dx.doi.org/10.1038/nm747			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	589KQ	12161747	Green Published			2022-12-25	WOS:000177757900031
J	Otani, A; Kinder, K; Ewalt, K; Otero, FJ; Schimmel, P; Friedlander, M				Otani, A; Kinder, K; Ewalt, K; Otero, FJ; Schimmel, P; Friedlander, M			Bone marrow-derived stem cells target retinal astrocytes and can promote or inhibit retinal angiogenesis	NATURE MEDICINE			English	Article							PROLIFERATIVE DIABETIC-RETINOPATHY; ADULT MAMMALIAN EYE; GROWTH; NEOVASCULARIZATION; INVOLVEMENT; VESSELS; INJURY; MICE; VIVO	Adult bone marrow (BM) contains cells capable of differentiating along hematopoietic (Lin(+)) or non-hematopoietic (Lin(-)) lineages. Lin(-) hematopoietic stem cells (HSCs) have recently been shown to contain a population of endothelial precursor cells (EPCs) capable of forming blood vessels. Here we show that intravitreally injected Lin(-) BM cells selectively target retinal astrocytes, cells that serve as a template for both developmental and injury-associated retinal angiogenesis. When Lin(-) BM cells were injected into neonatal mouse eyes, they extensively and stably incorporated into forming retinal vasculature. When EPC-enriched HSCs were injected into the eyes of neonatal rd/rd mice, whose vasculature ordinarily degenerates with age, they rescued and maintained a normal vasculature. In contrast, normal retinal angiogenesis was inhibited when EPCs expressing a potent angiostatic protein were injected. We have demonstrated that Lin(-) BM cells and astrocytes specifically interact with one another during normal angiogenesis and pathological vascular degeneration in the retina. Selective targeting with Lin(-) HSC may be a useful therapeutic approach for the treatment of many ocular diseases.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Biol Mol, La Jolla, CA USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Friedlander, M (corresponding author), Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA.				NCI NIH HHS [CA92577] Funding Source: Medline; NEI NIH HHS [EY12598, EY11254, EY12599] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092577] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY012598, R01EY012599, R01EY011254] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ahmad I, 2000, BIOCHEM BIOPH RES CO, V270, P517, DOI 10.1006/bbrc.2000.2473; Amin RH, 1997, INVEST OPHTH VIS SCI, V38, P36; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Carmeliet P, 2000, NAT MED, V6, P1102, DOI 10.1038/80430; Davidoff AM, 2001, CLIN CANCER RES, V7, P2870; Dyer MA, 2000, NAT NEUROSCI, V3, P873, DOI 10.1038/78774; Grant MB, 2002, NAT MED, V8, P607, DOI 10.1038/nm0602-607; Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; MacLaren RE, 1996, BRIT J OPHTHALMOL, V80, P458, DOI 10.1136/bjo.80.5.458; MADIGAN MC, 1994, RETINA-J RET VIT DIS, V14, P65, DOI 10.1097/00006982-199401000-00014; MATTHES MT, 1984, INVEST OPHTH VIS SCI, V25, P364; McLeod DS, 1998, INVEST OPHTH VIS SCI, V39, P1918; Mizutani M, 1998, DIABETES, V47, P445, DOI 10.2337/diabetes.47.3.445; NORK TM, 1987, ARCH OPHTHALMOL-CHIC, V105, P1424; OHIRA A, 1990, OPHTHALMOLOGICA, V201, P187, DOI 10.1159/000310150; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Otani A, 2002, P NATL ACAD SCI USA, V99, P178, DOI 10.1073/pnas.012601899; Priller J, 2001, NAT MED, V7, P1356, DOI 10.1038/nm1201-1356; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Rungger-Brandle E, 2000, INVEST OPHTH VIS SCI, V41, P1971; SCHNITZER J, 1988, GLIA, V1, P74, DOI 10.1002/glia.440010109; Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032; Wakasugi K, 2002, P NATL ACAD SCI USA, V99, P173, DOI 10.1073/pnas.012602099; Wang SM, 2000, INVEST OPHTH VIS SCI, V41, P537; Zhang YF, 1997, INVEST OPHTH VIS SCI, V38, P1653	28	263	303	0	15	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2002	8	9					1004	1010		10.1038/nm744	http://dx.doi.org/10.1038/nm744			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	589KQ	12145646	Green Submitted			2022-12-25	WOS:000177757900036
J	Takeshita, S; Namba, N; Zhao, JJ; Jiang, YB; Genant, HK; Silva, MJ; Brodt, MD; Helgason, CD; Kalesnikoff, J; Rauh, MJ; Humphries, RK; Krystal, G; Teitelbaum, SL; Ross, FP				Takeshita, S; Namba, N; Zhao, JJ; Jiang, YB; Genant, HK; Silva, MJ; Brodt, MD; Helgason, CD; Kalesnikoff, J; Rauh, MJ; Humphries, RK; Krystal, G; Teitelbaum, SL; Ross, FP			SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts	NATURE MEDICINE			English	Article							BONE MECHANICAL-PROPERTIES; INOSITOL PHOSPHATASE SHIP; COLONY-STIMULATING FACTOR; PAGETS-DISEASE; MULTIPLE CYTOKINES; SHC; DIFFERENTIATION; RECEPTOR; PROTEIN; LIGAND	The hematopoietic-restricted protein Src homology 2-containing inositol-5-phosphatase (SHIP) blunts phosphatidylinositol-3-kinase-initiated signaling by dephosphorylating its major substrate, phosphatidylinositol-3,4,5-trisphosphate. As SHIP-/- mice contain increased numbers of osteoclast precursors, that is, macrophages, we examined bones from these animals and found that osteoclast number is increased two-fold. This increased number is due to the prolonged life span of these cells and to hypersensitivity of precursors to macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor-B ligand (RANKL). Similar to pagetic osteoclasts, SHIP-/- osteoclasts are enlarged, containing upwards of 100 nuclei, and exhibit enhanced resorptive activity. Moreover, as in Paget disease, serum levels of interleukin-6 are markedly increased in SHIP-/- mice. Consistent with accelerated resorptive activity, 3D trabecular volume fraction, trabecular thickness, number and connectivity density of SHIP-/- long bones are reduced, resulting in a 22% loss of bone-mineral density and a 49% decrease in fracture energy. Thus, SHIP negatively regulates osteoclast formation and function and the absence of this enzyme results in severe osteoporosis.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63108 USA; Okayama Univ, Grad Sch Med & Dent, Dept Pediat, Okayama, Japan; Univ Calif San Francisco, Dept Radiol, Osteoporosis & Arthritis Res Grp, San Francisco, CA 94143 USA; Washington Univ, Sch Med, Dept Orthoped Surg, St Louis, MO 63108 USA; British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada	Washington University (WUSTL); Okayama University; University of California System; University of California San Francisco; Washington University (WUSTL); British Columbia Cancer Agency	Ross, FP (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63108 USA.	rossf@medicine.wustl.edu		Humphries, Richard/0000-0003-0540-7005; Silva, Matthew/0000-0001-7375-4522; Teitelbaum, Steven/0000-0002-4054-6679; Rauh, Michael/0000-0002-8346-5537; Krystal, Gerald/0000-0002-1961-6281				Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Brodt MD, 1999, J BONE MINER RES, V14, P2159, DOI 10.1359/jbmr.1999.14.12.2159; Cantley LC, 2001, SCIENCE, V292, P2019, DOI 10.1126/science.1062796; Clement S, 2001, NATURE, V409, P92, DOI 10.1038/35051094; Crowley MT, 1996, J BIOL CHEM, V271, P1145, DOI 10.1074/jbc.271.2.1145; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Hocking LJ, 2001, AM J HUM GENET, V69, P1055, DOI 10.1086/323798; HOSKING DJ, 1981, BRIT MED J, V283, P686, DOI 10.1136/bmj.283.6293.686; Huber M, 1998, P NATL ACAD SCI USA, V95, P11330, DOI 10.1073/pnas.95.19.11330; Hughes AE, 2000, NAT GENET, V24, P45, DOI 10.1038/71667; Hurley JH, 2001, CURR OPIN CELL BIOL, V13, P146, DOI 10.1016/S0955-0674(00)00191-5; IBBOTSON KJ, 1984, J CELL BIOL, V99, P471, DOI 10.1083/jcb.99.2.471; JIANG Y, 2002, PRINCIPLES BONE BIOL, P1599; Jiang YB, 1998, J BONE MINER RES, V13, P1783, DOI 10.1359/jbmr.1998.13.11.1783; Jiang YB, 1999, J CLIN DENSITOM, V2, P423, DOI 10.1016/S1094-6950(06)60408-3; Kalesnikoff J, 2002, J IMMUNOL, V168, P4737, DOI 10.4049/jimmunol.168.9.4737; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KODAMA H, 1991, J EXP MED, V173, P1291, DOI 10.1084/jem.173.5.1291; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Krystal G, 2000, SEMIN IMMUNOL, V12, P397, DOI 10.1006/smim.2000.0222; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; Liu L, 1997, J BIOL CHEM, V272, P8983; Liu QR, 1999, GENE DEV, V13, P786, DOI 10.1101/gad.13.7.786; Lorenzo J.A., 2002, PRINCIPLES BONE BIOL, VSecond, P961; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; NAKAMURA I, 1995, FEBS LETT, V361, P79, DOI 10.1016/0014-5793(95)00153-Z; Nandurkar HH, 2001, P NATL ACAD SCI USA, V98, P9499, DOI 10.1073/pnas.171306098; Neale SD, 2000, BONE, V27, P409, DOI 10.1016/S8756-3282(00)00345-8; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Rohrschneider LR, 2000, GENE DEV, V14, P505; Roodman GD, 1996, BONE, V19, P209, DOI 10.1016/8756-3282(96)00211-6; SAXTON TM, 1994, J IMMUNOL, V153, P623; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; TEITELBAUM SL, 1977, PATHOLOGY, P1905; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; VIGNERY A, 1980, ANAT REC, V196, P191, DOI 10.1002/ar.1091960210; Ware MD, 1996, BLOOD, V88, P2833, DOI 10.1182/blood.V88.8.2833.bloodjournal8882833; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Xu Y, 2001, BIOCHEM J, V360, P513, DOI 10.1042/0264-6021:3600513; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	45	198	210	1	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2002	8	9					943	949		10.1038/nm752	http://dx.doi.org/10.1038/nm752			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	589KQ	12161749				2022-12-25	WOS:000177757900028
J	Weijzen, S; Rizzo, P; Braid, M; Vaishnav, R; Jonkheer, SM; Zlobin, A; Osborne, BA; Gottipati, S; Aster, JC; Hahn, WC; Rudolf, M; Siziopikou, K; Kast, WM; Miele, L				Weijzen, S; Rizzo, P; Braid, M; Vaishnav, R; Jonkheer, SM; Zlobin, A; Osborne, BA; Gottipati, S; Aster, JC; Hahn, WC; Rudolf, M; Siziopikou, K; Kast, WM; Miele, L			Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells	NATURE MEDICINE			English	Article							INTRACELLULAR DOMAIN; NUCLEAR ACCESS; EXPRESSION; DROSOPHILA; PATHWAY; DIFFERENTIATION; TRANSCRIPTION; INDUCTION; ALLELES; GENE	Truncated Notch receptors have transforming activity in vitro and in vivo. However, the role of wild-type Notch signaling in neoplastic transformation remains unclear. Ras signaling is deregulated in a large fraction of human malignancies and is a major target for the development of novel cancer treatments. We show that oncogenic Ras activates Notch signaling and that wildtype Notch-1 is necessary to maintain the neoplastic phenotype in Ras-transformed human cells in vitro and in vivo. Oncogenic Ras increases levels and activity of the intracellular form of wildtype Notch-1, and upregulates Notch ligand Delta-1 and also presenilin-1, a protein involved in Notch processing, through a p38-mediated pathway. These observations place Notch signaling among key downstream effectors of oncogenic Ras and suggest that it might be a novel therapeutic target.	Univ Illinois, Dept Biopharmaceut Sci & Canc Ctr, Chicago, IL 60607 USA; Loyola Univ, Canc Immunol Program, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA; Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA USA; Loyola Univ, Dept Pathol, Maywood, IL 60153 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Loyola University Chicago; University of Massachusetts System; University of Massachusetts Amherst; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Loyola University Chicago	Miele, L (corresponding author), Univ Illinois, Dept Biopharmaceut Sci & Canc Ctr, Chicago, IL 60607 USA.			Miele, Lucio/0000-0002-5853-7287; Kast, W Martin/0000-0003-2321-3159; rizzo, paola/0000-0001-7174-9674	NATIONAL CANCER INSTITUTE [R01CA078399, R01CA084065] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA/AI 78399, R01 CA 84065/01] Funding Source: Medline; PHS HHS [R01 A47922] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Berset T, 2001, SCIENCE, V291, P1055, DOI 10.1126/science.1055642; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; BOS JL, 1989, CANCER RES, V49, P4682; Callahan R, 2001, J MAMMARY GLAND BIOL, V6, P23, DOI 10.1023/A:1009512414430; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Carlesso N, 1999, BLOOD, V93, P838, DOI 10.1182/blood.V93.3.838.403k29_838_848; Carmena A, 2002, DEV BIOL, V244, P226, DOI 10.1006/dbio.2002.0606; Daniel B, 1997, J GEN VIROL, V78, P1095, DOI 10.1099/0022-1317-78-5-1095; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Deftos ML, 1998, IMMUNITY, V9, P777, DOI 10.1016/S1074-7613(00)80643-3; Dievart A, 1999, ONCOGENE, V18, P5973, DOI 10.1038/sj.onc.1202991; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Fitzgerald K, 2000, ONCOGENE, V19, P4191, DOI 10.1038/sj.onc.1203766; Garces C, 1997, J BIOL CHEM, V272, P29729, DOI 10.1074/jbc.272.47.29729; Gohring UJ, 1999, TUMOR BIOL, V20, P173, DOI 10.1159/000030061; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hoemann CD, 2000, MOL CELL BIOL, V20, P3831, DOI 10.1128/MCB.20.11.3831-3842.2000; Jeffries S, 2000, MOL CELL BIOL, V20, P3928, DOI 10.1128/MCB.20.11.3928-3941.2000; Jehn BM, 1999, J IMMUNOL, V162, P635; Jundt F, 2002, BLOOD, V99, P3398, DOI 10.1182/blood.V99.9.3398; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703; Li LH, 1998, GENOMICS, V51, P45, DOI 10.1006/geno.1998.5330; Malaney S, 2001, J MAMMARY GLAND BIOL, V6, P101, DOI 10.1023/A:1009572700317; McLendon C, 2000, FASEB J, V14, P2383; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Nickoloff BJ, 2002, CELL DEATH DIFFER, V9, P842, DOI 10.1038/sj.cdd.4401036; Osborne B, 1999, IMMUNITY, V11, P653, DOI 10.1016/S1074-7613(00)80140-5; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Price JV, 1997, GENETICS, V147, P1139; Rae FK, 2000, INT J CANCER, V88, P726, DOI 10.1002/1097-0215(20001201)88:5<726::AID-IJC7>3.0.CO;2-H; Ronchini C, 2001, MOL CELL BIOL, V21, P5925, DOI 10.1128/MCB.21.17.5925-5934.2001; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Shelly LL, 1999, J CELL BIOCHEM, V73, P164, DOI 10.1002/(SICI)1097-4644(19990501)73:2<164::AID-JCB3>3.0.CO;2-0; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Tohda S, 2001, LEUKEMIA LYMPHOMA, V42, P467, DOI 10.3109/10428190109064603; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Yasutomo K, 2000, NATURE, V404, P506, DOI 10.1038/35006664; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414; Zecchini V, 1999, CURR BIOL, V9, P460, DOI 10.1016/S0960-9822(99)80211-5; Zentrich E, 2002, J BIOL CHEM, V277, P4110, DOI 10.1074/jbc.M107824200	45	445	499	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2002	8	9					979	986		10.1038/nm754	http://dx.doi.org/10.1038/nm754			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	589KQ	12185362				2022-12-25	WOS:000177757900033
J	Kuperman, DA; Huang, XZ; Koth, LL; Chang, GH; Dolganov, GM; Zhu, Z; Elias, JA; Sheppard, D; Erle, DJ				Kuperman, DA; Huang, XZ; Koth, LL; Chang, GH; Dolganov, GM; Zhu, Z; Elias, JA; Sheppard, D; Erle, DJ			Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma	NATURE MEDICINE			English	Article							SIGNAL TRANSDUCER; MURINE MODEL; INFLAMMATION; EXPRESSION; MICE; LUNG; HYPERRESPONSIVENESS; RESPONSIVENESS; IL-13; GENE	Asthma is an increasingly common disease that remains poorly understood and difficult to manage. This disease is characterized by airway hyperreactivity (AHR, defined by exaggerated airflow obstruction in response to bronchoconstrictors), mucus overproduction and chronic eosinophilic inflammation(1). AHR and mucus overproduction are consistently linked to asthma symptoms and morbidity(2,3). Asthma is mediated by Th2 lymphocytes(4-7), which produce a limited repertoire of cytokines, including interleukin-4 (IL-4), IL-5, IL-9 and IL-13. Although each of these cytokines has been implicated in asthma(4,5,7-11), IL-13 is now thought to be especially critical. In animal models of allergic asthma, blockade of IL-13 markedly inhibits allergen-induced AHR, mucus production and eosinophilia(10,11). Furthermore, IL-13 delivery to the airway causes all of these effects(10,11). IL-13 is thus both necessary and sufficient for experimental models of asthma. However, the IL-13-responsive cells causing these effects have not been identified. Here we show that mice lacking signal transducer and activator of transcription 6 (STAT6) were protected from all pulmonary effects of IL-13. Reconstitution of STAT6 only in epithelial cells was sufficient for IL-13-induced AHR and mucus production in the absence of inflammation, fibrosis or other lung pathology. These results demonstrate the importance of direct effects of IL-13 on epithelial cells in causing two central features of asthma.	Univ Calif San Francisco, Sch Med, Dept Med, Lung Biol Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Program Immunol, San Francisco, CA USA; Yale Univ, Sch Med, Dept Internal Med, Pulm & Crit Care Med Sect, New Haven, CT 06510 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Yale University	Erle, DJ (corresponding author), Univ Calif San Francisco, Sch Med, Dept Med, Lung Biol Ctr, San Francisco, CA 94143 USA.	erle@itsa.ucsf.edu		Erle, David/0000-0002-2171-0648				Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; BRUSSELLE G, 1995, AM J RESP CELL MOL, V12, P254, DOI 10.1165/ajrcmb.12.3.7873190; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; Dolganov GM, 2001, GENOME RES, V11, P1473, DOI 10.1101/gr.191301; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587, DOI 10.1165/ajrcmb.10.6.8003337; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Haley KJ, 1998, AM J RESP CRIT CARE, V157, P1; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; JUNIPER EF, 1981, THORAX, V36, P575, DOI 10.1136/thx.36.8.575; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; LUKACS NW, 1994, AM J RESP CELL MOL, V10, P526, DOI 10.1165/ajrcmb.10.5.8179915; McLane MP, 1998, AM J RESP CELL MOL, V19, P713, DOI 10.1165/ajrcmb.19.5.3457; MORENO RH, 1986, AM REV RESPIR DIS, V133, P1171; Mullings RE, 2001, J ALLERGY CLIN IMMUN, V108, P832, DOI 10.1067/mai.2001.119554; Nakanishi A, 2001, P NATL ACAD SCI USA, V98, P5175, DOI 10.1073/pnas.081510898; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Ordonez CL, 2001, AM J RESP CRIT CARE, V163, P517, DOI 10.1164/ajrccm.163.2.2004039; Richter A, 2001, AM J RESP CELL MOL, V25, P385, DOI 10.1165/ajrcmb.25.3.4437; STRIPP BR, 1992, J BIOL CHEM, V267, P14703; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Zheng T, 2000, J CLIN INVEST, V106, P1081, DOI 10.1172/JCI10458; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; Zhu Z, 2002, J IMMUNOL, V168, P2953, DOI 10.4049/jimmunol.168.6.2953	26	706	758	0	57	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2002	8	8					885	889		10.1038/nm734	http://dx.doi.org/10.1038/nm734			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	579WJ	12091879				2022-12-25	WOS:000177200900036
J	Michieli, P; Cavassa, S; Basilico, C; De Luca, A; Mazzone, M; Asti, C; Chiusaroli, R; Guglielmi, M; Bossu, P; Colotta, F; Caselli, G; Comoglio, PM				Michieli, P; Cavassa, S; Basilico, C; De Luca, A; Mazzone, M; Asti, C; Chiusaroli, R; Guglielmi, M; Bossu, P; Colotta, F; Caselli, G; Comoglio, PM			An HGF-MSP chimera disassociates the trophic properties of scatter factors from their pro-invasive activity	NATURE BIOTECHNOLOGY			English	Article							HEPATOCYTE GROWTH-FACTOR; MACROPHAGE-STIMULATING PROTEIN; C-MET PROTOONCOGENE; PROTEOLYTIC CLEAVAGE; FACTOR RECEPTOR; RON GENE; OVEREXPRESSION; MORPHOGENESIS; LIGAND; METASTASIS	Hepatocyte growth factor (HGF) and macrophage-stimulating protein (MSP) have an intrinsic dual nature: they are trophic cytokines preventing apoptosis on one side and scatter factors promoting invasion on the other. For therapeutic use, their anti-apoptotic activity must be separated from their pro-invasive activity. To this end, we engineered chimeric factors containing selected functional domains of HGF and/or MSP in different combinations, and tested their biological activity. Here we present a chimeric cytokine derived from the chains of HGF and MSP, named Metron factor 1 for its ability to concomitantly activate the HGF receptor (Met) and the MSP receptor (Ron). We provide evidence that Metron factor 1 prevents apoptosis and stimulates cell proliferation at nanomolar concentrations, but is devoid of any pro-invasive activity. In an in vivo murine model of drug-induced nephrotoxicity, intravenous injection of recombinant Metron factor 1 prevented renal damage and preserved tubular integrity.	Univ Turin, Sch Med, IRCC, Div Mol Oncol, I-10060 Turin, Italy; Dompe SpA Res Ctr, Sect Preclin Pharmacol, I-67100 Laquila, Italy	University of Turin; Dompe	Michieli, P (corresponding author), Univ Turin, Sch Med, IRCC, Div Mol Oncol, I-10060 Turin, Italy.	pmichieli@ircc.unito.it	Bossù, Paola/E-4832-2014; Nacmias, Benedetta/J-5084-2018; Basilico, Cristina/A-3253-2011; Michieli, Paolo/A-2588-2011; Caselli, Gianfranco/AAS-2507-2021	Bossù, Paola/0000-0002-1432-0078; Nacmias, Benedetta/0000-0001-9338-9040; Michieli, Paolo/0000-0002-3093-8871; Caselli, Gianfranco/0000-0002-1075-7408; Colotta, Francesco/0000-0001-8601-2309; Comoglio, Paolo/0000-0002-7056-5328; Mazzone, Massimiliano/0000-0001-8824-4015				Banu N, 1996, J IMMUNOL, V156, P2933; BERDICHEVSKY F, 1994, J CELL SCI, V107, P3557; Birchmeier W, 1997, CIBA F SYMP, V212, P230; BOIX L, 1994, HEPATOLOGY, V19, P88, DOI 10.1016/0270-9139(94)90057-4; Bradbury J, 1998, LANCET, V351, P272, DOI 10.1016/S0140-6736(05)78259-3; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Chirgadze DY, 1998, FEBS LETT, V430, P126, DOI 10.1016/S0014-5793(98)00558-4; Comoglio PM, 2001, NAT CELL BIOL, V3, pE161, DOI 10.1038/35083116; Danilkovitch A, 2000, MOL CELL BIOL, V20, P2218, DOI 10.1128/MCB.20.6.2218-2227.2000; Danilkovitch A, 1999, J BIOL CHEM, V274, P29937, DOI 10.1074/jbc.274.42.29937; Date K, 1998, ONCOGENE, V17, P3045, DOI 10.1038/sj.onc.1202231; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DIRENZO MF, 1992, ONCOGENE, V7, P2549; Ebens A, 1996, NEURON, V17, P1157, DOI 10.1016/S0896-6273(00)80247-0; Follenzi A, 2000, ONCOGENE, V19, P3041, DOI 10.1038/sj.onc.1203620; GAK E, 1992, FEBS LETT, V311, P17, DOI 10.1016/0014-5793(92)81356-Q; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Gaudino G, 1995, ONCOGENE, V11, P2627; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; KAWAIDA K, 1994, P NATL ACAD SCI USA, V91, P4357, DOI 10.1073/pnas.91.10.4357; KOBAYASHI T, 1994, J BIOL CHEM, V269, P9817; Koochekpour S, 1997, CANCER RES, V57, P5391; Leonard EJ, 1997, CIBA F SYMP, V212, P183; LIU C, 1992, ONCOGENE, V7, P181; LYON M, 1994, J BIOL CHEM, V269, P11216; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; MARK MR, 1992, J BIOL CHEM, V267, P26166; Matsumoto K, 1997, CIBA F SYMP, V212, P198; Matsumoto K, 1998, J BIOL CHEM, V273, P22913, DOI 10.1074/jbc.273.36.22913; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; MEDICO E, 1999, Patent No. 9900478; MEDICO E, 1999, Patent No. 9938968; MEDICO E, 1999, Patent No. 9900502; MEDICO E, 1999, Patent No. 9938967; Meiners S, 1998, ONCOGENE, V16, P9, DOI 10.1038/sj.onc.1201486; Michieli P, 1999, ONCOGENE, V18, P5221, DOI 10.1038/sj.onc.1202899; Miyazawa K, 1996, J BIOL CHEM, V271, P3615; MIYAZAWA K, 1994, J BIOL CHEM, V269, P8966; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schwall RH, 1996, J CELL BIOL, V133, P709, DOI 10.1083/jcb.133.3.709; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; Takayama H, 1996, P NATL ACAD SCI USA, V93, P5866, DOI 10.1073/pnas.93.12.5866; Tamagnone Luca, 1997, Cytokine and Growth Factor Reviews, V8, P129, DOI 10.1016/S1359-6101(97)00007-5; Trusolino L, 1998, FASEB J, V12, P1267, DOI 10.1096/fasebj.12.13.1267; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; Wang MH, 1996, EXP CELL RES, V226, P39, DOI 10.1006/excr.1996.0200; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; WOOLF AS, 1995, J CELL BIOL, V128, P171, DOI 10.1083/jcb.128.1.171; YANAGITA K, 1993, J BIOL CHEM, V268, P21212; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	61	22	26	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2002	20	5					488	495		10.1038/nbt0502-488	http://dx.doi.org/10.1038/nbt0502-488			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	548AE	11981563				2022-12-25	WOS:000175364800032
J	Zhou, HL; Ranish, JA; Watts, JD; Aebersold, R				Zhou, HL; Ranish, JA; Watts, JD; Aebersold, R			Quantitative proteome analysis by solid-phase isotope tagging and mass spectrometry	NATURE BIOTECHNOLOGY			English	Article							CODED AFFINITY TAGS; PROTEINS	The adaptation of sequences of chemical reactions to a solid-phase format has been essential to the automation, reproducibility, and efficiency of a number of biotechnological processes including peptide and oligonucleotide synthesis and sequencing(1-4). Here we describe a method for the site-specific, stable isotopic labeling of cysteinyl peptides in complex peptide mixtures through a solid-phase capture and release process, and the concomitant isolation of the labeled peptides. The recovered peptides were analyzed by microcapillary liquid chromatography and tandem mass spectrometry (muLC-MS/MS) to determine their sequences and relative quantities. The method was used to detect galactose-induced changes in protein abundance in the yeast Saccharomyces cerevisiae. A side-by-side comparison with the isotope-coded affinity tag (ICAT) method(5) demonstrated that the solid-phase method for stable isotope tagging of peptides is comparatively simpler, more efficient, and more sensitive.	Inst Syst Biol, Seattle, WA 98103 USA	Institute for Systems Biology (ISB)	Aebersold, R (corresponding author), Inst Syst Biol, 1441 N 34th St, Seattle, WA 98103 USA.		Abrams, William R/A-5782-2008	Zhou, Huilin/0000-0002-1350-4430	NATIONAL CANCER INSTITUTE [R33CA084698] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NCI NIH HHS [CA84698] Funding Source: Medline; NCRR NIH HHS [RR11823] Funding Source: Medline; NIGMS NIH HHS [GM19884, GM 41109] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1992, CURRENT PROTOCOLS MO; CARUTHERS MH, 1987, METHOD ENZYMOL, V154, P287; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Han DK, 2001, NAT BIOTECHNOL, V19, P946, DOI 10.1038/nbt1001-946; HOLMES CP, 1995, J ORG CHEM, V60, P2318, DOI 10.1021/jo00113a004; HUNKAPILLER M, 1984, NATURE, V310, P105, DOI 10.1038/310105a0; Ideker T, 2001, SCIENCE, V292, P929, DOI 10.1126/science.292.5518.929; JOHNSTON M, 1992, MOL CELLULAR BIOL YE, P193; LAPATSANIS L, 1983, SYNTHESIS-STUTTGART, P671, DOI 10.1055/s-1983-30468; Merrifield RB, 1976, SCIENCE, V232, P341, DOI DOI 10.1126/SCIENCE.3961484; Oda Y, 1999, P NATL ACAD SCI USA, V96, P6591, DOI 10.1073/pnas.96.12.6591; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Zhou HL, 2001, NAT BIOTECHNOL, V19, P375, DOI 10.1038/86777	15	317	347	1	27	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2002	20	5					512	515		10.1038/nbt0502-512	http://dx.doi.org/10.1038/nbt0502-512			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	548AE	11981568				2022-12-25	WOS:000175364800037
J	Ficarro, SB; McCleland, ML; Stukenberg, PT; Burke, DJ; Ross, MM; Shabanowitz, J; Hunt, DF; White, FM				Ficarro, SB; McCleland, ML; Stukenberg, PT; Burke, DJ; Ross, MM; Shabanowitz, J; Hunt, DF; White, FM			Phosphoproteome analysis by mass spectrometry and its application to Saccharomyces cerevisiae	NATURE BIOTECHNOLOGY			English	Article								Protein kinases are coded by more than 2,000 genes and thus constitute the largest single enzyme family in the human genome. Most cellular processes are in fact regulated by the reversible phosphorylation of proteins on serine, threonine, and tyrosine residues(1). At least 30% of all proteins are thought to contain covalently bound phosphate. Despite the importance and widespread occurrence of this modification, identification of sites of protein phosphorylation is still a challenge, even when performed on highly purified protein(2). Reported here is methodology that should make it possible to characterize most, if not all, phosphoproteins from a whole-cell lysate in a single experiment. Proteins are digested with trypsin and the resulting peptides are then converted to methyl esters, enriched for phosphopeptides by immobilized metal-affinity chromatography (IMAC)(3,4), and analyzed by nanoflow HPLC/electrospray ionization mass spectrometry. More than 1,000 phosphopeptides were detected when the methodology was applied to the analysis of a whole-cell lysate from Saccharomyces cerevisiae. A total of 216 peptide sequences defining 383 sites of phosphorylation were determined. Of these, 60 were singly phosphorylated, 145 doubly phosphorylated, and 11 triply phosphorylated. Comparison with the literature revealed that 18 of these sites were previously identified, including the doubly phosphorylated motif pTXpY derived from the activation loop of two mitogen-activated protein (MAP) kinases. We note that the methodology can easily be extended to display and quantify differential expression of phosphoproteins in two different cell systems, and therefore demonstrates an approach for "phosphoprofiling" as a measure of cellular states.	MDS Proteom, Charlottesville, VA 22901 USA; Univ Virginia, Dept Chem, Charlottesville, VA 22901 USA; Univ Virginia, Hlth Sci Ctr, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Pathol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	White, FM (corresponding author), MDS Proteom, Charlottesville, VA 22901 USA.		Hunt, Donald F/I-6936-2012	Hunt, Donald F/0000-0003-2815-6368; Stukenberg, Todd/0000-0002-6788-2111; White, Forest/0000-0002-1545-1651	NIGMS NIH HHS [GM 37537] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037537] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON L, 1986, ANAL BIOCHEM, V154, P250, DOI 10.1016/0003-2697(86)90523-3; Annan RS, 2001, ANAL CHEM, V73, P393, DOI 10.1021/ac001130t; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Martin SE, 2000, ANAL CHEM, V72, P4266, DOI 10.1021/ac000497v; MICHEL H, 1988, J BIOL CHEM, V263, P1123; Oda Y, 2001, NAT BIOTECHNOL, V19, P379, DOI 10.1038/86783; Zarling AL, 2000, J EXP MED, V192, P1755, DOI 10.1084/jem.192.12.1755; Zhou HL, 2001, NAT BIOTECHNOL, V19, P375, DOI 10.1038/86777	10	1378	1466	6	263	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2002	20	3					301	305		10.1038/nbt0302-301	http://dx.doi.org/10.1038/nbt0302-301			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	526RE	11875433				2022-12-25	WOS:000174142800050
J	Jacob, S; McClintock, MK; Zelano, B; Ober, C				Jacob, S; McClintock, MK; Zelano, B; Ober, C			Paternally inherited HLA alleles are associated with women's choice of male odor	NATURE GENETICS			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; MATING PREFERENCES; MICE; RECOGNITION; HUMANS; MOUSE; GENES; INFORMATION; MOLECULES; PATTERNS	The major histocompatibility complex (MHC) is a source of unique individual odors that influence individual recognition, mating preferences, nesting behavior and selective block of pregnancy in animals(1-10). Such phenomena have been difficult to study in humans, because the human leukocyte antigen (HLA, human MHC loci are the most polymorphic loci in the human genome(11), with the potential to generate millions of unique combinations of genotypes. In addition, high variability in background odors, encoded by the rest of the genome and influenced by cultural practices, contribute to a low signal-to-noise ratio that could mask HLA-based olfactory cues. Here we show that women can detect differences of one HLA allele among male odor donors with different MHC genotypes. Notably, the mechanism for a woman's ability to discriminate and choose odors is based on HLA alleles inherited from her father but not her mother. The parents' HLA alleles that she does not inherit show no relationship with odor choice, despite exposure to these HLA-encoded odors throughout her life. Our data indicate that paternally inherited HLA-associated odors influence odor preference and may serve as social cues.	Univ Chicago, Inst Mind & Biol, Chicago, IL 60637 USA; Univ Chicago, Dept Psychol, Chicago, IL 60637 USA; Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago	McClintock, MK (corresponding author), Univ Chicago, Inst Mind & Biol, 5730 S Woodlawn Ave, Chicago, IL 60637 USA.	mkm1@midway.uchicago.edu	Jacob, Suma/J-7941-2013	Jacob, Suma/0000-0001-7434-7398	NATIONAL INSTITUTE OF MENTAL HEALTH [K23MH082121] Funding Source: NIH RePORTER; NIMH NIH HHS [K23 MH082121] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Amadou C, 1999, IMMUNOL REV, V167, P211, DOI 10.1111/j.1600-065X.1999.tb01394.x; Bateson P., 1983, P257; BEAUCHAMP GK, 1985, P NATL ACAD SCI USA, V82, P4186, DOI 10.1073/pnas.82.12.4186; Berridge KC, 1998, BRAIN RES REV, V28, P309, DOI 10.1016/S0165-0173(98)00019-8; BROWN RE, 1987, PHYSIOL BEHAV, V40, P65, DOI 10.1016/0031-9384(87)90186-7; Devos M., 1990, STANDARDIZED HUMAN O; EGID K, 1989, ANIM BEHAV, V38, P548, DOI 10.1016/S0003-3472(89)80051-X; EKLUND A, 1991, ANIM BEHAV, V42, P693, DOI 10.1016/S0003-3472(05)80254-4; Fan WF, 1996, IMMUNOGENETICS, V44, P97, DOI 10.1007/s002510050095; GILBERT AN, 1986, J COMP PSYCHOL, V100, P262, DOI 10.1037/0735-7036.100.3.262; GILDER PM, 1978, NATURE, V274, P364, DOI 10.1038/274364a0; HERRICK CJ, 1924, NEUROLOGICAL FDN BEH; Isles AR, 2001, NATURE, V409, P783, DOI 10.1038/35057323; MANNING CJ, 1992, NATURE, V360, P581, DOI 10.1038/360581a0; MCCARTY R, 1977, BEHAV BIOL, V19, P255, DOI 10.1016/S0091-6773(77)91542-5; Mori K, 1999, SCIENCE, V286, P711, DOI 10.1126/science.286.5440.711; Ober C, 1997, AM J HUM GENET, V61, P497, DOI 10.1086/515511; OBER C, 1999, CHEM SIGNALS VERTEBR, V8, P189; Ochoa G, 1999, J THEOR BIOL, V199, P1, DOI 10.1006/jtbi.1999.0931; Parham P, 1996, SCIENCE, V272, P67, DOI 10.1126/science.272.5258.67; Pause BM, 1996, BIOL PSYCHOL, V44, P31, DOI 10.1016/S0301-0511(96)05207-6; Pearse-Pratt R, 1998, GENETICA, V104, P223, DOI 10.1023/A:1026489524199; Penn DJ, 1999, AM NAT, V153, P145, DOI 10.1086/303166; POTTS WK, 1991, NATURE, V352, P619, DOI 10.1038/352619a0; QUADAGNO DM, 1970, ANIM BEHAV, V18, P379, DOI 10.1016/S0003-3472(70)80051-3; SCHAAL B, 1991, ADV STUD BEHAV, V20, P135, DOI 10.1016/S0065-3454(08)60321-6; Schaefer ML, 2001, J NEUROSCI, V21, P2481, DOI 10.1523/JNEUROSCI.21-07-02481.2001; SMITH K, 2000, DEP PSYCHOL, P167; VINCENT C, 1979, TRANSPLANT P, V11, P1301; Wedekind C, 1997, P ROY SOC B-BIOL SCI, V264, P1471, DOI 10.1098/rspb.1997.0204; WEDEKIND C, 1995, P ROY SOC B-BIOL SCI, V260, P245, DOI 10.1098/rspb.1995.0087; Weitkamp LR, 1999, IMMUNOGENETICS, V49, P491, DOI 10.1007/s002510050525; YAMAGUCHI M, 1981, P NATL ACAD SCI-BIOL, V78, P5817, DOI 10.1073/pnas.78.9.5817; YAMAZAKI K, 1976, J EXP MED, V144, P1324, DOI 10.1084/jem.144.5.1324; YAMAZAKI K, 1979, J EXP MED, V150, P755, DOI 10.1084/jem.150.4.755; YAMAZAKI K, 1988, SCIENCE, V240, P1331, DOI 10.1126/science.3375818; YAMAZAKI K, 1983, SCIENCE, V221, P186, DOI 10.1126/science.6857281; YAMAZAKI K, 1999, CHEM SIGNALS VERTEBR, V8, P173	38	293	306	1	76	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2002	30	2					175	179		10.1038/ng830	http://dx.doi.org/10.1038/ng830			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	519CY	11799397				2022-12-25	WOS:000173708700017
J	Nordborg, M; Borevitz, JO; Bergelson, J; Berry, CC; Chory, J; Hagenblad, J; Kreitman, M; Maloof, JN; Noyes, T; Oefner, PJ; Stahl, EA; Weigel, D				Nordborg, M; Borevitz, JO; Bergelson, J; Berry, CC; Chory, J; Hagenblad, J; Kreitman, M; Maloof, JN; Noyes, T; Oefner, PJ; Stahl, EA; Weigel, D			The extent of linkage disequilibrium in Arabidopsis thaliana	NATURE GENETICS			English	Article							FLOWERING TIME; POPULATIONS; LOCUS; POLYMORPHISMS; ECOTYPES; RECOMBINATION; DIVERGENCE; DIVERSITY; GENES	Linkage disequilibrium (LD), the nonrandom occurrence of alleles in haplotypes, has long been of interest to population geneticists. Recently, the rapidly increasing availability of genomic polymorphism data has fueled interest in LD as a tool for fine-scale mapping, in particular for human disease loci(1). The chromosomal extent of LD is crucial in this context, because it determines how dense a map must be for associations to be detected and, conversely, limits how finely loci may be mapped(2). Arabidopsis thaliana is expected to harbor unusually extensive LD because of its high degree of selfing(3). Several polymorphism studies have found very strong LD within individual loci, but also evidence of some recombination(4-6). Here we investigate the pattern of LD on a genomic scale and show that in global samples, LD decays within approximately 1 cM, or 250 kb. We also show that LD in local populations may be much stronger than that of global populations, presumably as a result of founder events. The combination of a relatively high level of polymorphism and extensive haplotype structure bodes well for developing a genome-wide LD map in A. thaliana.	Univ So Calif, Dept Biol Sci, Los Angeles, CA 90089 USA; Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA; Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA; Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA; Howard Hughes Med Inst, La Jolla, CA USA; Lund Univ, Dept Genet, S-22362 Lund, Sweden; Stanford Univ, Dept Biochem, Sch Med, Stanford, CA 94305 USA; Max Planck Inst Dev Biol, Dept Mol Biol, Tubingen, Germany	University of Southern California; Salk Institute; University of Chicago; University of California System; University of California San Diego; Howard Hughes Medical Institute; Lund University; Stanford University; Max Planck Society	Nordborg, M (corresponding author), Univ So Calif, Dept Biol Sci, Los Angeles, CA 90089 USA.		Weigel, Detlef/C-1418-2008; Weigel, Detlef/GSJ-0799-2022; Borevitz, Justin/B-5423-2012; Weigel, Detlef/AAR-3312-2021	Weigel, Detlef/0000-0002-2114-7963; Weigel, Detlef/0000-0002-2114-7963; Borevitz, Justin/0000-0001-8408-3699; Hagenblad, Jenny/0000-0002-9850-5546; Bergelson, Joy/0000-0001-7893-7387; Nordborg, Magnus/0000-0001-7178-9748; Maloof, Julin/0000-0002-9623-2599				ABBOTT RJ, 1989, HEREDITY, V62, P411, DOI 10.1038/hdy.1989.56; Aguade M, 2001, MOL BIOL EVOL, V18, P1, DOI 10.1093/oxfordjournals.molbev.a003714; Altshuler D, 2000, NAT GENET, V26, P135, DOI 10.1038/79839; Bergelson J, 1998, GENETICS, V148, P1311; Breyne P, 1999, MOL GEN GENET, V261, P627, DOI 10.1007/s004380050005; Cardon LR, 2001, NAT REV GENET, V2, P91, DOI 10.1038/35052543; Cho RJ, 1999, NAT GENET, V23, P203, DOI 10.1038/13833; Dunning AM, 2000, AM J HUM GENET, V67, P1544, DOI 10.1086/316906; Goddard KAB, 2000, AM J HUM GENET, V66, P216, DOI 10.1086/302727; HANFSTINGL U, 1994, GENETICS, V138, P811; Innan H, 1996, GENETICS, V143, P1761; Johanson U, 2000, SCIENCE, V290, P344, DOI 10.1126/science.290.5490.344; KING G, 1993, THEOR APPL GENET, V86, P1028, DOI 10.1007/BF00211057; Kruglyak L, 1999, NAT GENET, V22, P139, DOI 10.1038/9642; Long AD, 1998, GENETICS, V149, P999; Miyashita NT, 1999, GENETICS, V152, P1723; Noel L, 1999, PLANT CELL, V11, P2099, DOI 10.1105/tpc.11.11.2099; Nordborg M, 1997, GENETICS, V146, P1501; Nordborg M, 1999, AM J BOT, V86, P470, DOI 10.2307/2656807; Nordborg M, 2000, GENETICS, V154, P923; Pritchard JK, 2001, AM J HUM GENET, V69, P1, DOI 10.1086/321275; Reich DE, 2001, NATURE, V411, P199, DOI 10.1038/35075590; Sharbel TF, 2000, MOL ECOL, V9, P2109, DOI 10.1046/j.1365-294X.2000.01122.x; Stahl EA, 1999, NATURE, V400, P667, DOI 10.1038/23260; Stephens JC, 2001, SCIENCE, V293, P489, DOI 10.1126/science.1059431; Tenaillon MI, 2001, P NATL ACAD SCI USA, V98, P9161, DOI 10.1073/pnas.151244298; Thornsberry JM, 2001, NAT GENET, V28, P286, DOI 10.1038/90135; TODOKORO S, 1995, JPN J GENET, V70, P543, DOI 10.1266/jjg.70.543; Wright AF, 1999, NAT GENET, V23, P397, DOI 10.1038/70501	29	362	390	3	40	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2002	30	2					190	193		10.1038/ng813	http://dx.doi.org/10.1038/ng813			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	519CY	11780140				2022-12-25	WOS:000173708700020
J	Reggiori, F; Pelham, HRB				Reggiori, F; Pelham, HRB			A transmembrane ubiquitin ligase required to sort membrane proteins into multivesicular bodies	NATURE CELL BIOLOGY			English	Article							ENDOPLASMIC-RETICULUM; YEAST-CELLS; DOMAINS; GOLGI; DEGRADATION; INTERNALIZATION; LOCALIZATION; ENDOCYTOSIS; ENDOSOMES; RETENTION	Membrane proteins with transmembrane domains (TMDs) that contain polar residues exposed to the lipid bilayer are selectively sorted into multivesicular bodies (MVBs) and delivered to the yeast vacuole. Sorting of some, although not all, proteins into these structures is mediated by ubiquitination. We have, identified a transmembrane ubiquitin ligase, Tul1, that is resident in the Golgi apparatus and is required for the ubiquitination of proteins with polar TMDs, including vacuolar proteins such as carboxypeptidase S. We suggest that Tul1 provides quality control, identifying misfolded membrane proteins and marking them for transport to endosomes and degradation in the vacuole.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Pelham, HRB (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.		Reggiori, Fulvio/U-8327-2019	Reggiori, Fulvio/0000-0003-2652-2686				Babst M, 1997, EMBO J, V16, P1820, DOI 10.1093/emboj/16.8.1820; Bays NW, 2001, NAT CELL BIOL, V3, P24, DOI 10.1038/35050524; Becherer KA, 1996, MOL BIOL CELL, V7, P579, DOI 10.1091/mbc.7.4.579; Beck T, 1999, J CELL BIOL, V146, P1227, DOI 10.1083/jcb.146.6.1227; Black MW, 2000, J CELL BIOL, V151, P587, DOI 10.1083/jcb.151.3.587; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; Dunn R, 2001, MOL BIOL CELL, V12, P421, DOI 10.1091/mbc.12.2.421; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; Gardner RG, 2001, MOL CELL BIOL, V21, P4276, DOI 10.1128/MCB.21.13.4276-4291.2001; Helliwell SB, 2001, J CELL BIOL, V153, P649, DOI 10.1083/jcb.153.4.649; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; James P, 1996, GENETICS, V144, P1425; Jelinsky SA, 1999, P NATL ACAD SCI USA, V96, P1486, DOI 10.1073/pnas.96.4.1486; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Letourneur F, 1998, J BIOL CHEM, V273, P33273, DOI 10.1074/jbc.273.50.33273; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Lewis MJ, 1997, EMBO J, V16, P3017, DOI 10.1093/emboj/16.11.3017; Lewis MJ, 2000, MOL BIOL CELL, V11, P23, DOI 10.1091/mbc.11.1.23; Munro S, 1998, TRENDS CELL BIOL, V8, P11, DOI 10.1016/S0962-8924(97)01197-5; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; Odorizzi G, 1998, CELL, V95, P847, DOI 10.1016/S0092-8674(00)81707-9; Reggiori F, 2000, MOL BIOL CELL, V11, P3737, DOI 10.1091/mbc.11.11.3737; Reggiori F, 2001, EMBO J, V20, P5176, DOI 10.1093/emboj/20.18.5176; Rocca A, 2001, MOL BIOL CELL, V12, P1293, DOI 10.1091/mbc.12.5.1293; Roth FP, 1998, NAT BIOTECHNOL, V16, P939, DOI 10.1038/nbt1098-939; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; Sato K, 1997, P NATL ACAD SCI USA, V94, P9693, DOI 10.1073/pnas.94.18.9693; Sato K, 2001, J CELL BIOL, V152, P935, DOI 10.1083/jcb.152.5.935; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; Swaminathan S, 1999, MOL BIOL CELL, V10, P2583, DOI 10.1091/mbc.10.8.2583; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Urbanowski JL, 2001, TRAFFIC, V2, P622, DOI 10.1034/j.1600-0854.2001.20905.x; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; Wang GL, 2001, MOL CELL BIOL, V21, P3564, DOI 10.1128/MCB.21.10.3564-3575.2001; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wooding S, 1998, MOL BIOL CELL, V9, P2667, DOI 10.1091/mbc.9.9.2667; Zaliauskiene L, 2000, MOL BIOL CELL, V11, P2643, DOI 10.1091/mbc.11.8.2643	42	151	158	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	FEB	2002	4	2					117	123		10.1038/ncb743	http://dx.doi.org/10.1038/ncb743			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	520RJ	11788821				2022-12-25	WOS:000173794600015
J	Fukui, S; Feizi, T; Galustian, C; Lawson, AM; Chai, WG				Fukui, S; Feizi, T; Galustian, C; Lawson, AM; Chai, WG			Oligosaccharide microarrays for high-throughput detection and specificity assignments of carbohydrate-protein interactions	NATURE BIOTECHNOLOGY			English	Article							O-LINKED OLIGOSACCHARIDES; HUMAN L-SELECTIN; MILD PERIODATE-OXIDATION; CORE-BRANCHING PATTERN; BLOOD-GROUP CHAINS; CHONDROITIN-SULFATE; MONOCLONAL-ANTIBODY; NEOGLYCOLIPID TECHNOLOGY; 3'-SULFATED LEWIS(A); LECTIN-BINDING	We describe microarrays of oligosaccharides as neoglycolipids and their robust display on nitrocellulose. The arrays are sourced from glycoproteins, glycolipids, proteoglycans, polysaccharides, whole organs, or from chemically synthesized oligosaccharides. We show that carbohydrate- recognizing proteins single out their ligands not only in arrays of homogeneous oligosaccharides but also in arrays of heterogeneous oligosaccharides. Initial applications have revealed new findings, including: (i) among O-glycans in brain, a relative abundance of the Lewis x sequence based on N-acetyllactosamine recognized by anti-L5, and a paucity of the Lewis x sequence based on poly-N-acetyllactosamine recognized by anti-SSEA-1; (ii) insights into chondroitin sulfate oligosaccharides recognized by an antiserum and an antibody (CS-56) to chondroitin sulfates; and (iii) binding of the cytokine interferon-gamma (IFN-gamma) and the chemokine RANTES to sulfated sequences such as HNK-1, sulfo-Lewis(x), and sulfo-Lewis(a), in addition to glycosaminoglycans. The approach opens the way for discovering new carbohydrate- recognizing proteins in the proteome and for mapping the repertoire of carbohydrate recognition structures in the glycome.	Northwick Pk Hosp & Clin Res Ctr, Imperial Coll Fac Med, Glycosci Lab, Harrow HA1 3UJ, Middx, England; Kyoto Sangyo Univ, Fac Engn, Dept Biotechnol, Kyoto 603, Japan	Imperial College London; Kyoto Sangyo University	Feizi, T (corresponding author), Northwick Pk Hosp & Clin Res Ctr, Imperial Coll Fac Med, Glycosci Lab, Watford Rd, Harrow HA1 3UJ, Middx, England.	t.feizi@ic.ac.uk		Feizi, Ten/0000-0001-6495-0329				AVNUR Z, 1984, CELL, V38, P811, DOI 10.1016/0092-8674(84)90276-9; BERTOLOTTO A, 1986, J NEUROL SCI, V73, P233, DOI 10.1016/0022-510X(86)90148-6; BROWN A, 1983, BIOSCIENCE REP, V3, P163, DOI 10.1007/BF01121947; CHAI W, 1991, BIOL MASS SPECTROM, V20, P169, DOI 10.1002/bms.1200200403; Chai WG, 1996, ANAL BIOCHEM, V237, P88, DOI 10.1006/abio.1996.0205; Chai WG, 1997, GLYCOBIOLOGY, V7, P861, DOI 10.1093/glycob/7.6.861; CHAI WG, 1993, CARBOHYD RES, V239, P107, DOI 10.1016/0008-6215(93)84207-M; Chai WG, 1999, EUR J BIOCHEM, V263, P879, DOI 10.1046/j.1432-1327.1999.00572.x; Chai WG, 1999, ANAL BIOCHEM, V270, P314, DOI 10.1006/abio.1999.4105; CHARYCH DH, 1993, SCIENCE, V261, P585, DOI 10.1126/science.8342021; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; Crocker PR, 1996, CURR OPIN STRUC BIOL, V6, P679, DOI 10.1016/S0959-440X(96)80036-4; Crocker PR, 2001, IMMUNOLOGY, V103, P137, DOI 10.1046/j.0019-2805.2001.01241.x; Feizi T, 2002, ROY SOC CH, P186, DOI 10.1039/9781847550323-00186; Feizi T, 2001, Results Probl Cell Differ, V33, P201; FEIZI T, 1994, METHOD ENZYMOL, V230, P484; Feizi T, 2000, GLYCOCONJUGATE J, V17, P553, DOI 10.1023/A:1011022509500; Galustian C, 1997, BIOCHEMISTRY-US, V36, P5260, DOI 10.1021/bi962887a; Galustian C, 2002, IMMUNOLOGY, V105, P350, DOI 10.1046/j.1365-2567.2002.01369.x; Galustian C, 1997, BIOCHEM BIOPH RES CO, V240, P748, DOI 10.1006/bbrc.1997.7737; Galustian C, 1999, J BIOL CHEM, V274, P18213, DOI 10.1074/jbc.274.26.18213; GHOSH P, 1981, ARCH BIOCHEM BIOPHYS, V206, P454, DOI 10.1016/0003-9861(81)90113-2; GOOI HC, 1981, NATURE, V292, P156, DOI 10.1038/292156a0; HASEGAWA A, 1992, CARBOHYD RES, V230, pC1, DOI 10.1016/S0008-6215(00)90524-X; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Hirose J, 2001, J BIOL CHEM, V276, P5228, DOI 10.1074/jbc.M007542200; HOUNSELL EF, 1981, FEBS LETT, V131, P279, DOI 10.1016/0014-5793(81)80384-5; Houseman BT, 2002, CHEM BIOL, V9, P443, DOI 10.1016/S1074-5521(02)00124-2; Hurt-Camejo E, 1999, J BIOL CHEM, V274, P18957, DOI 10.1074/jbc.274.27.18957; Isogai Y, 1996, J CARBOHYD CHEM, V15, P1001, DOI 10.1080/07328309608005705; Karlsson KA, 1998, MOL MICROBIOL, V29, P1, DOI 10.1046/j.1365-2958.1998.00854.x; Kiessling LL, 2002, NAT BIOTECHNOL, V20, P234, DOI 10.1038/nbt0302-234; Komba S, 1996, BIOORGAN MED CHEM, V4, P1833, DOI 10.1016/S0968-0896(96)00165-4; Leteux C, 2001, J BIOL CHEM, V276, P12539, DOI 10.1074/jbc.M010291200; Liang R, 1996, SCIENCE, V274, P1520, DOI 10.1126/science.274.5292.1520; LOVELESS RW, 1992, EMBO J, V11, P813, DOI 10.1002/j.1460-2075.1992.tb05118.x; Lubineau A, 1997, CARBOHYD RES, V305, P501, DOI 10.1016/S0008-6215(97)10043-X; Lubineau A, 1994, Bioorg Med Chem, V2, P1143, DOI 10.1016/S0968-0896(00)82066-0; Lubineau A, 2000, J CARBOHYD CHEM, V19, P151, DOI 10.1080/07328300008544072; Smith PL, 1996, J BIOL CHEM, V271, P8250, DOI 10.1074/jbc.271.14.8250; Srinivas O, 2002, J AM CHEM SOC, V124, P2124, DOI 10.1021/ja0173066; Stoll MS, 2000, EUR J BIOCHEM, V267, P1795, DOI 10.1046/j.1432-1327.2000.01178.x; STOLL MS, 1990, EUR J BIOCHEM, V189, P499, DOI 10.1111/j.1432-1033.1990.tb15515.x; STOLL MS, 1988, BIOCHEM J, V256, P661, DOI 10.1042/bj2560661; Streit A, 1996, J NEUROCHEM, V66, P834; SUROLIA A, 1975, NATURE, V257, P802, DOI 10.1038/257802a0; TANG PW, 1985, BIOCHEM BIOPH RES CO, V132, P474, DOI 10.1016/0006-291X(85)91158-1; Wang DN, 2002, NAT BIOTECHNOL, V20, P275, DOI 10.1038/nbt0302-275; Yuen CT, 1997, J BIOL CHEM, V272, P8924; YUEN CT, 1992, BIOCHEMISTRY-US, V31, P9126, DOI 10.1021/bi00153a003	50	483	535	0	105	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2002	20	10					1011	1017		10.1038/nbt735	http://dx.doi.org/10.1038/nbt735			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	599AZ	12219077				2022-12-25	WOS:000178313100018
J	Vadlamudi, RK; Li, F; Adam, L; Nguyen, D; Ohta, Y; Stossel, TP; Kumar, R				Vadlamudi, RK; Li, F; Adam, L; Nguyen, D; Ohta, Y; Stossel, TP; Kumar, R			Filamin is essential in actin cytoskeletal assembly mediated by p21-activated kinase 1	NATURE CELL BIOLOGY			English	Article							BREAST-CANCER CELLS; PROTEIN-KINASE; RHO-GTPASES; ALPHA-PAK; BINDING; GROWTH; ORGANIZATION; RAC1; REORGANIZATION; ACTIVATION	The serine/threonine kinase p21-activated kinase 1 (Pak1) controls the actin cytoskeletal and ruffle formation through mechanisms that are independent of GTPase activity. Here we identify filamin FLNa as a Pak1-interacting protein through a yeast two-hybrid screen using the amino terminus of Pak1 as a bait. FLNa is stimulated by physiological signalling molecules to undergo phosphorylation by Pak1 and to interact and colocalize with endogenous Pak1 in membrane ruffles. The ruffle-forming activity of Pak1 is functional in FLNa-expressing cells but not in FLNa-deficient cells. In FLNa, the Pak1-binding site involves tandem repeat 23 in the carboxyl terminus and phosphorylation takes place on serine 2152. The FLNa-binding site in Pak1 is localized between amino acids 52 and 132 in the conserved Cdc42/Rac-interacting (CRIB) domain; accordingly, FLNa binding to the CRIB domain stimulates Pak1 kinase activity. Our results indicate that FLNa may be essential for Pak1-induced cytoskeletal reorganization and that the two-way regulatory interaction between Pak1 and FLNa may contribute to the local stimulation of Pak1 activity and its targets in cytoskeletal structures.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA	University of Texas System; UTMD Anderson Cancer Center; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.							Adam L, 2000, J BIOL CHEM, V275, P12041, DOI 10.1074/jbc.275.16.12041; Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Bagheri-Yarmand R, 2001, J BIOL CHEM, V276, P29403, DOI 10.1074/jbc.M103129200; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; Chan WH, 1999, J CELL PHYSIOL, V178, P397, DOI 10.1002/(SICI)1097-4652(199903)178:3<397::AID-JCP14>3.3.CO;2-U; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Fox JW, 1998, NEURON, V21, P1315, DOI 10.1016/S0896-6273(00)80651-0; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Kozma R, 1996, MOL CELL BIOL, V16, P5069; Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Marti A, 1997, J BIOL CHEM, V272, P2620, DOI 10.1074/jbc.272.5.2620; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; Ohta Y, 1996, J BIOL CHEM, V271, P11858, DOI 10.1074/jbc.271.20.11858; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rivero F, 1996, J CELL SCI, V109, P2679; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 2000, J CELL BIOL, V151, P1449, DOI 10.1083/jcb.151.7.1449; Stahlhut M, 2000, MOL BIOL CELL, V11, P325, DOI 10.1091/mbc.11.1.325; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; Tao WK, 2001, GENE DEV, V15, P1796, DOI 10.1101/gad.894301; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200; WEIHING RR, 1988, BIOCHEMISTRY-US, V27, P1865, DOI 10.1021/bi00406a011; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	35	250	261	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	2002	4	9					681	690		10.1038/ncb838	http://dx.doi.org/10.1038/ncb838			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	589WE	12198493				2022-12-25	WOS:000177783900012
J	Wong, JMY; Kusdra, L; Collins, K				Wong, JMY; Kusdra, L; Collins, K			Subnuclear shuttling of human telomerase induced by transformation and DNA damage	NATURE CELL BIOLOGY			English	Article							HUMAN-CELLS; IMMORTALIZATION; REPLICATION; FIBROBLASTS; ELONGATION; END	The telomerase ribonucleoprotein complex caps chromosome ends by adding telomeric repeats. Here we show that catalytically active human telomerase has a regulated intranuclear localization that is dependent on the cell-cycle stage, transformation and DNA damage. In primary cell lines, low expression of a fusion protein of green fluorescent protein and telomerase reverse transcriptase (GFP-hTERT) increases telomerase activity and stabilizes the maintenance of telomere length. Confocal microscopy shows that the release of telomerase to the nucleoplasm from sequestration at nucleolar sites is enhanced at the expected time of telomere replication. By contrast, in tumour and transformed cells, there is an almost complete dissociation of telomerase from nucleoli at all stages of the cell cycle. Transfection of the simian virus 40 genome into a primary cell line is sufficient to mobilize telomerase from nucleoli to the nucleoplasm. Conversely, ionizing radiation induces the reassociation of telomerase with nucleoli in both primary and transformed cells. These findings show that transformation and DNA damage have opposite effects on the cellular regulation of active telomerase, affecting the enzyme's access to both telomeric and nontelomeric substrates.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Collins, K (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.		Wong, Judy/AAG-1868-2021	Wong, Judy/0000-0001-5572-4143				Blackburn EH, 2000, NAT STRUCT BIOL, V7, P847, DOI 10.1038/79594; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Collins K, 2002, ONCOGENE, V21, P564, DOI 10.1038/sj.onc.1205083; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Holt SE, 1997, P NATL ACAD SCI USA, V94, P10687, DOI 10.1073/pnas.94.20.10687; LUSKY M, 1981, NATURE, V293, P79, DOI 10.1038/293079a0; Marcand S, 2000, CURR BIOL, V10, P487, DOI 10.1016/S0960-9822(00)00450-4; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Newport J, 1996, CURR OPIN CELL BIOL, V8, P365, DOI 10.1016/S0955-0674(96)80011-1; O'Hare MJ, 2001, P NATL ACAD SCI USA, V98, P646, DOI 10.1073/pnas.98.2.646; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Sprung CN, 1999, P NATL ACAD SCI USA, V96, P6781, DOI 10.1073/pnas.96.12.6781; Stewart SA, 2000, SEMIN CANCER BIOL, V10, P399, DOI 10.1006/scbi.2000.0339; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	16	205	215	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	2002	4	9					731	U5		10.1038/ncb846	http://dx.doi.org/10.1038/ncb846			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	589WE	12198499				2022-12-25	WOS:000177783900020
J	Camenisch, TD; Schroeder, JA; Bradley, J; Klewer, SE; McDonald, JA				Camenisch, TD; Schroeder, JA; Bradley, J; Klewer, SE; McDonald, JA			Heart-valve mesenchyme formation is dependent on hyaluronan-augmented activation of ErbB2-ErbB3 receptors	NATURE MEDICINE			English	Article							NEU DIFFERENTIATION FACTOR; ERBB SIGNALING NETWORK; CARDIAC DEVELOPMENT; NEUREGULIN RECEPTOR; PROTEIN-KINASE; MICE; CD44; MORPHOGENESIS; GROWTH; RAS	Heart septation and valve malformations constitute the most common anatomical birth defects. These structures arise from the endocardial cushions within the atrioventricular canal (AVC) through dynamic interactions between cushion cells and the extracellular matrix ( termed cardiac jelly). Transformation of endothelial cells to mesenchymal cells is essential for the proper development of the AVC and subsequent septation and valve formation. Atrioventricular septal defects can result from incomplete endocardial cushion morphogenesis. We show that hyaluronan-deficient AVC explants from Has2(-/-) embryos, which normally lack mesenchyme formation, are rescued by heregulin treatment, which restores phosphorylation of ErbB2 and ErbB3. These events were blocked using a soluble ErbB3 molecule, as well as with an inhibitor of ErbB2, herstatin. We show further that ErbB3 is activated during hyaluronan treatment of Has2(-/-) explants. These data provide a link between extracellular matrix-hyaluronan and ErbB receptor activation during development of early heart-valve and septal mesenchyme.	Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA; Univ Arizona, Sch Med, Steele Mem Childrens Res Ctr, Tucson, AZ USA; Mayo Clin, Dept Biochem & Mol Biol, Scottsdale, AZ USA; Univ Arizona, Sch Med, Dept Pediat, Tucson, AZ USA; Salt Lake City Vet Adm Hlth Care Syst, Salt Lake City, UT USA; Univ Utah, Salt Lake City, UT USA	University of Arizona; University of Arizona; Mayo Clinic; Mayo Clinic Phoenix; University of Arizona; Utah System of Higher Education; University of Utah	Camenisch, TD (corresponding author), Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA.			Camenisch, Todd/0000-0002-7797-9822; schroeder, joyce/0000-0003-1277-5172				Anderson RH, 1998, CARDIOVASC RES, V39, P155, DOI 10.1016/S0008-6363(98)00037-6; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BALDWIN HS, 1996, CARDIOVASC RES, V31, P34; Bourguignon LYW, 1997, J BIOL CHEM, V272, P27913, DOI 10.1074/jbc.272.44.27913; Camenisch T D, 2001, Exp Clin Cardiol, V6, P4; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; Chen BB, 2000, NAT GENET, V24, P296, DOI 10.1038/73528; Doherty JK, 1999, P NATL ACAD SCI USA, V96, P10869, DOI 10.1073/pnas.96.19.10869; EISENBERG LM, 1995, CIRC RES, V77, P1, DOI 10.1161/01.RES.77.1.1; Erickson SL, 1997, DEVELOPMENT, V124, P4999; Ferencz Charlotte, 1993, Cardiology Clinics, V11, P557; Fitzgerald KA, 2000, J IMMUNOL, V164, P2053, DOI 10.4049/jimmunol.164.4.2053; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Hertig CM, 1999, J BIOL CHEM, V274, P37362, DOI 10.1074/jbc.274.52.37362; Lakkis MM, 1998, DEVELOPMENT, V125, P4359; Lee H, 2001, CANCER RES, V61, P4467; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Markwald R, 1996, ACTA ANAT, V156, P173; MEYER D, 1995, NATURE, V378, P753, DOI 10.1038/378753a0; O'Shea S, 2001, AM J PATHOL, V158, P1871, DOI 10.1016/S0002-9440(10)64144-2; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; Riethmacher D, 1997, NATURE, V389, P725, DOI 10.1038/39593; RUBIN JD, 1985, MARYLAND MED J, V34, P1079; RUNYAN RB, 1983, DEV BIOL, V95, P108, DOI 10.1016/0012-1606(83)90010-6; Schmits R, 1997, BLOOD, V90, P2217, DOI 10.1182/blood.V90.6.2217.2217_2217_2233; Serbulea M, 1999, INT J ONCOL, V14, P733; SHERMAN L, 1994, CURR OPIN CELL BIOL, V6, P726, DOI 10.1016/0955-0674(94)90100-7; Srivastava D, 2001, ANNU REV PHYSIOL, V63, P451, DOI 10.1146/annurev.physiol.63.1.451; Walsh EC, 2001, SCIENCE, V293, P1670, DOI 10.1126/science.293.5535.1670; Webb S, 1998, CIRC RES, V82, P645, DOI 10.1161/01.RES.82.6.645; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	34	248	255	0	10	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2002	8	8					850	855		10.1038/nm742	http://dx.doi.org/10.1038/nm742			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	579WJ	12134143				2022-12-25	WOS:000177200900031
J	Fernandez-Valle, C; Tang, Y; Ricard, J; Rodenas-Ruano, A; Taylor, A; Hackler, E; Biggerstaff, J; Iacovelli, J				Fernandez-Valle, C; Tang, Y; Ricard, J; Rodenas-Ruano, A; Taylor, A; Hackler, E; Biggerstaff, J; Iacovelli, J			Paxillin binds schwannomin and regulates its density-dependent localization and effect on cell morphology	NATURE GENETICS			English	Article							NEUROFIBROMATOSIS TYPE-2 GENE; NF2 TUMOR-SUPPRESSOR; LIM DOMAINS; FERM DOMAIN; LD4 MOTIF; PROTEIN; MERLIN; KINASE; EXPRESSION; MUTATIONS	Neurofibromatosis type 2 is an autosomal dominant disorder characterized by tumors, predominantly schwannomas, in the nervous system. It is caused by mutations in the gene NF2, encoding the growth regulator schwannomin (also known as merlin). Mutations occur throughout the 17-exon gene, with most resulting in protein truncation and undetectable amounts of schwannomin protein. Pathogenic mutations that result in production of defective schwannomin include in-frame deletions of exon 2 and three independent missense mutations within this same exon. Mice with conditional deletion of exon 2 in Schwann cells develop schwannomas, which confirms the crucial nature of exon 2 for growth control. Here we report that the molecular adaptor paxillin binds directly to schwannomin at residues 50-70, which are encoded by exon 2. This interaction mediates the membrane localization of schwannomin to the plasma membrane, where it associates with beta1 integrin and erbB2. It defines a pathogenic mechanism for the development of NF2 in humans with mutations in exon 2 of NF2.	Univ Cent Florida, Dept Mol Biol & Microbiol, Orlando, FL 32826 USA	State University System of Florida; University of Central Florida	Fernandez-Valle, C (corresponding author), Univ Cent Florida, Dept Mol Biol & Microbiol, Orlando, FL 32826 USA.	cfernand@mail.ucf.edu	Iacovelli, Jared/G-3668-2011	Ricard, Jerome/0000-0002-9019-4165; Taylor, Anna/0000-0002-6501-3393				BIANCHI AB, 1994, NAT GENET, V6, P185, DOI 10.1038/ng0294-185; BOURN D, 1994, HUM MOL GENET, V3, P813, DOI 10.1093/hmg/3.5.813; Brown MC, 1998, MOL BIOL CELL, V9, P1803, DOI 10.1091/mbc.9.7.1803; Bunge Richard P., 1995, P44; Chen LM, 2000, J NEUROSCI, V20, P3776, DOI 10.1523/JNEUROSCI.20-10-03776.2000; Deguen B, 1998, HUM MOL GENET, V7, P217, DOI 10.1093/hmg/7.2.217; Edwards SD, 2001, BIOCHEMISTRY-US, V40, P7061, DOI 10.1021/bi010419h; ELDRIDGE CF, 1987, J CELL BIOL, V105, P1023, DOI 10.1083/jcb.105.2.1023; FernandezValle C, 1997, J NEUROSCI, V17, P241, DOI 10.1523/JNEUROSCI.17-01-00241.1997; FERNANDEZVALLE C, 1994, J NEUROBIOL, V25, P1207, DOI 10.1002/neu.480251004; FERNANDEZVALLE C, 1993, DEVELOPMENT, V119, P867; Fields RD, 1998, J NEUROBIOL, V37, P158, DOI 10.1002/(SICI)1097-4695(199810)37:1<158::AID-NEU12>3.0.CO;2-A; Giovannini M, 2000, GENE DEV, V14, P1617; Gonzalez-Agosti C, 1999, J BIOL CHEM, V274, P34438, DOI 10.1074/jbc.274.48.34438; Goutebroze L, 2000, MOL CELL BIOL, V20, P1699, DOI 10.1128/MCB.20.5.1699-1712.2000; Gronholm M, 1999, J CELL SCI, V112, P895; Heiska L, 1998, J BIOL CHEM, V273, P21893, DOI 10.1074/jbc.273.34.21893; Jacoby LB, 1996, GENE CHROMOSOME CANC, V17, P45, DOI 10.1002/(SICI)1098-2264(199609)17:1<45::AID-GCC7>3.0.CO;2-2; Jannatipour M, 2001, J BIOL CHEM, V276, P33093, DOI 10.1074/jbc.M105792200; Kang BS, 2002, ACTA CRYSTALLOGR D, V58, P381, DOI 10.1107/S0907444901021175; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; MORRISSEY TK, 1995, P NATL ACAD SCI USA, V92, P1431, DOI 10.1073/pnas.92.5.1431; Nikolopoulos SN, 2002, J BIOL CHEM, V277, P1568, DOI 10.1074/jbc.M108612200; Norman JC, 1998, J CELL BIOL, V143, P1981, DOI 10.1083/jcb.143.7.1981; Obremski VJ, 1998, J NEUROBIOL, V37, P487, DOI 10.1002/(SICI)1097-4695(199812)37:4<487::AID-NEU1>3.3.CO;2-2; PLOPPER G, 1993, BIOCHEM BIOPH RES CO, V193, P571, DOI 10.1006/bbrc.1993.1662; PYKETT MJ, 1994, HUM MOL GENET, V3, P559, DOI 10.1093/hmg/3.4.559; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Sainio M, 1997, J CELL SCI, V110, P2249; Scherer SS, 1996, J NEUROSCI RES, V46, P595, DOI 10.1002/(SICI)1097-4547(19961201)46:5<595::AID-JNR8>3.3.CO;2-2; Schmucker B, 1997, EUR J CELL BIOL, V72, P46; Scoles DR, 2000, HUM MOL GENET, V9, P1567, DOI 10.1093/hmg/9.11.1567; Scoles DR, 1998, NAT GENET, V18, P354, DOI 10.1038/ng0498-354; Scoles DR, 1996, NEUROLOGY, V47, P544, DOI 10.1212/WNL.47.2.544; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Stokowski RP, 2000, AM J HUM GENET, V66, P873, DOI 10.1086/302812; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Turner CE, 2001, CURR OPIN CELL BIOL, V13, P593, DOI 10.1016/S0955-0674(00)00256-8; Turner CE, 2000, J CELL SCI, V113, P4139; TURNER CE, 1994, J CELL SCI, V107, P1583; Turunen O, 1998, BBA-PROTEIN STRUCT M, V1387, P1, DOI 10.1016/S0167-4838(98)00103-4; Vadlamudi R, 1999, ONCOGENE, V18, P7253, DOI 10.1038/sj.onc.1203163; Vartanian T, 1997, J CELL BIOL, V137, P211, DOI 10.1083/jcb.137.1.211; Welling DB, 1996, HUM GENET, V98, P189, DOI 10.1007/s004390050188; West KA, 2001, J CELL BIOL, V154, P161, DOI 10.1083/jcb.200101039; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200; Xing BD, 2001, J BIOL CHEM, V276, P44373, DOI 10.1074/jbc.M108587200	50	100	102	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2002	31	4					354	362		10.1038/ng930	http://dx.doi.org/10.1038/ng930			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	578XV	12118253				2022-12-25	WOS:000177147100009
J	Kury, S; Dreno, B; Bezieau, S; Giraudet, S; Kharfi, M; Kamoun, R; Moisan, JP				Kury, S; Dreno, B; Bezieau, S; Giraudet, S; Kharfi, M; Kamoun, R; Moisan, JP			Identification of SLC39A4, a gene involved in acrodermatitis enteropathica	NATURE GENETICS			English	Article							ZINC TRANSPORTER; METAL TRANSPORTER; ARABIDOPSIS; PROTEIN; FAMILY; YEAST		Fac Med, Lab Etud Polymorphisme ADN, F-44035 Nantes, France; Hop Hotel Dieu, Ctr Hosp Univ, Serv Dermatol, F-44093 Nantes, France; Hop Charles Nicolle, Serv Dermatol, Tunis, Tunisia	Nantes Universite; CHU de Nantes; Universite de Tunis-El-Manar; Hopital Charles Nicolle	Kury, S (corresponding author), Fac Med, Lab Etud Polymorphisme ADN, 1 Rue Gaston Veil, F-44035 Nantes, France.		KÜRY, Sébastien/G-5971-2015; Bézieau, stéphane/G-5621-2015	KÜRY, Sébastien/0000-0001-5497-0465; Bézieau, stéphane/0000-0003-0095-1319				ATHERTON DJ, 1979, CLIN SCI, V56, P505, DOI 10.1042/cs0560505; Gaither LA, 2000, J BIOL CHEM, V275, P5560, DOI 10.1074/jbc.275.8.5560; Gaither LA, 2001, J BIOL CHEM, V276, P22258, DOI 10.1074/jbc.M101772200; Grotz N, 1998, P NATL ACAD SCI USA, V95, P7220, DOI 10.1073/pnas.95.12.7220; Guerinot ML, 2000, BBA-BIOMEMBRANES, V1465, P190, DOI 10.1016/S0005-2736(00)00138-3; Guerinot ML, 1999, CURR OPIN PLANT BIOL, V2, P244, DOI 10.1016/S1369-5266(99)80042-9; Korshunova YO, 1999, PLANT MOL BIOL, V40, P37, DOI 10.1023/A:1026438615520; LOMBECK I, 1975, LANCET, V1, P855; Rogers EE, 2000, P NATL ACAD SCI USA, V97, P12356, DOI 10.1073/pnas.210214197; Wang K, 2001, AM J HUM GENET, V68, P1055, DOI 10.1086/319514; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454	11	369	390	0	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2002	31	3					239	240		10.1038/ng913	http://dx.doi.org/10.1038/ng913			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	567PW	12068297				2022-12-25	WOS:000176494100009
J	McKay, R				McKay, R			A more astonishing hypothesis	NATURE BIOTECHNOLOGY			English	Editorial Material							HEMATOPOIETIC STEM-CELLS; MARROW		NINCDS, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	McKay, R (corresponding author), NINCDS, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.	mckayr@ninds.nih.gov						Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; McKinney-Freeman SL, 2002, P NATL ACAD SCI USA, V99, P1341, DOI 10.1073/pnas.032438799; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Rolink AG, 1999, NATURE, V401, P603, DOI 10.1038/44164; Seale P, 2000, CELL, V102, P777, DOI 10.1016/S0092-8674(00)00066-0; Tada M, 2001, CURR BIOL, V11, P1553, DOI 10.1016/S0960-9822(01)00459-6; Tanaka M, 2001, Methods Mol Biol, V158, P135; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729	11	18	19	0	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2002	20	5					426	427		10.1038/nbt0502-426	http://dx.doi.org/10.1038/nbt0502-426			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	548AE	11981544				2022-12-25	WOS:000175364800009
J	Runnels, LW; Yue, LX; Clapham, DE				Runnels, LW; Yue, LX; Clapham, DE			The TRPM7 channel is inactivated by PIP2 hydrolysis	NATURE CELL BIOLOGY			English	Article							PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; INOSITOL 1,4,5-TRISPHOSPHATE; DIFFERENTIAL REGULATION; DIRECT ACTIVATION; CATION CHANNEL; RECEPTOR; DROSOPHILA; CALCIUM; DIACYLGLYCEROL	TRPM7 (ChaK1, TRP-PLIK, LTRPC7) is a ubiquitous, calcium-permeant ion channel that is unique in being both an ion channel and a serine/threonine kinase. The kinase domain of TRPM7 directly associates with the C2 domain of phospholipase C ( PLC). Here, we show that in native cardiac cells and heterologous expression systems, Galphaq-linked receptors or tyrosine kinase receptors that activate PLC potently inhibit channel activity. Numerous experimental approaches demonstrated that phosphatidylinositol 4,5-bisphosphate (PIP2), the substrate of PLC, is a key regulator of TRPM7. We conclude that receptor-mediated activation of PLC results in the hydrolysis of localized PIP2, leading to inactivation of the TRPM7 channel.	Harvard Univ, Sch Med, Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute	Runnels, LW (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Howard Hughes Med Inst, Enders 1309,320 Longwood Ave, Boston, MA 02115 USA.	dclapham@enders.tch.harvard.edu	Clapham, David/R-5974-2019; Clapham, David/S-1123-2019	Clapham, David/0000-0002-4459-9428; Runnels, Loren/0000-0002-2537-7360				ASHKENAZI A, 1989, TRENDS PHARMACOL SCI, P16; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; Broad LM, 2001, J BIOL CHEM, V276, P15945, DOI 10.1074/jbc.M011571200; Cho H, 2001, J BIOL CHEM, V276, P159, DOI 10.1074/jbc.M004826200; Chuang HH, 2001, NATURE, V411, P957, DOI 10.1038/35082088; Chyb S, 1999, NATURE, V397, P255, DOI 10.1038/16703; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COCHET C, 1991, J BIOL CHEM, V266, P637; Contos JJA, 2000, MOL PHARMACOL, V58, P1188, DOI 10.1124/mol.58.6.1188; Downing GJ, 1996, BIOCHEMISTRY-US, V35, P3587, DOI 10.1021/bi9517493; Duncan LM, 2001, J CLIN ONCOL, V19, P568, DOI 10.1200/JCO.2001.19.2.568; FUKAMI K, 1988, P NATL ACAD SCI USA, V85, P9057, DOI 10.1073/pnas.85.23.9057; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; Hardie RC, 2001, NATURE, V413, P186, DOI 10.1038/35093002; Hardie RC, 2001, NEURON, V30, P149, DOI 10.1016/S0896-6273(01)00269-0; HARMAN AW, 1990, BIOCHEM BIOPH RES CO, V170, P477, DOI 10.1016/0006-291X(90)92116-H; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; HILGEMANND W, 2001, SCI STKE        1204; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Ishii I, 2000, MOL PHARMACOL, V58, P895, DOI 10.1124/mol.58.5.895; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MCLAUGHLIN S, IN PRESS ANN REV BIO; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; MONTELL C, 2001, SCI STKE        0710; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; Morris Andrew J., 1999, Trends in Pharmacological Sciences, V20, P393, DOI 10.1016/S0165-6147(99)01390-5; Nadler MJS, 2001, NATURE, V411, P590, DOI 10.1038/35079092; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; Niemeyer BA, 1996, CELL, V85, P651, DOI 10.1016/S0092-8674(00)81232-5; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; ROMANI AMP, 2000, FRONT BIOSCI, V5, P7210; Runnels LW, 2001, SCIENCE, V291, P1043, DOI 10.1126/science.1058519; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; Thomas CL, 1999, BIOCHEM SOC T, V27, P648, DOI 10.1042/bst0270648; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Wakelam MJO, 1998, BBA-MOL CELL BIOL L, V1436, P117, DOI 10.1016/S0005-2760(98)00123-4; Willars GB, 1998, J BIOL CHEM, V273, P5037, DOI 10.1074/jbc.273.9.5037; WU DQ, 1993, J BIOL CHEM, V268, P3704; Xie LH, 1999, P NATL ACAD SCI USA, V96, P15292, DOI 10.1073/pnas.96.26.15292; Xu XZS, 2000, NEURON, V26, P647, DOI 10.1016/S0896-6273(00)81201-5	50	414	445	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2002	4	5					329	336		10.1038/ncb781	http://dx.doi.org/10.1038/ncb781			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	547GR	11941371				2022-12-25	WOS:000175325100013
J	Boon, EM; Salas, JE; Barton, JK				Boon, EM; Salas, JE; Barton, JK			An electrical probe of protein-DNA interactions on DNA-modified surfaces	NATURE BIOTECHNOLOGY			English	Article							CRYSTAL-STRUCTURE; HHAL METHYLTRANSFERASE; BASE; ELECTROCATALYSIS; RECOGNITION; GLYCOSYLASE; ELECTRODES; DEPENDENCE; TRANSPORT; MECHANISM	DNA charge transport chemistry is found to provide a sensitive method for probing protein-dependent changes in DNA structure and enzymatic reactions. Here we describe the development of an electrochemical assay of protein binding to DNA-modified electrodes based upon the detection of associated perturbations in DNA base stacking. Gold electrode surfaces that were modified with loosely packed DNA duplexes, covalently crosslinked to a redox-active intercalator and containing the binding site of the test protein, were constructed. Charge transport through DNA as a function of protein binding was then assayed. Substantial attenuation in current is seen in the presence of the base-flipping enzymes HhaI methylase and uracil DNA glycosylase, as well as with TATA-binding protein. When restriction endonuclease PvuII (R. PvuII) binds to its methylated target, little base-stacking perturbation occurs and little diminution in current flow is observed. Importantly, the kinetics of restriction by R. PvuII of its nonmethylated target is also easily monitored electrochemically. This approach should be generally applicable to assaying protein-DNA interactions and reactions on surfaces.	CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA	California Institute of Technology	Barton, JK (corresponding author), CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA.		Boon, Elizabeth/AAR-8229-2020	Boon, Elizabeth/0000-0003-1891-839X	NIGMS NIH HHS [GM 61077] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061077] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSON FC, 1983, J CHEM EDUC, V60, P293, DOI 10.1021/ed060p293; Arcamone F., 1981, DOXORUBICIN ANTICANC; Armistead PM, 2000, ANAL CHEM, V72, P3764, DOI 10.1021/ac000051e; Bard A. J., 1980, ELECTROCHEMICAL METH; Boon EM, 2000, NAT BIOTECHNOL, V18, P1096, DOI 10.1038/80301; CHENG XD, 1994, EMBO J, V13, P3927, DOI 10.1002/j.1460-2075.1994.tb06708.x; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; Garcia RA, 1996, P NATL ACAD SCI USA, V93, P7618, DOI 10.1073/pnas.93.15.7618; Hall DB, 1997, J AM CHEM SOC, V119, P5045, DOI 10.1021/ja970366k; Hartwich G, 1999, J AM CHEM SOC, V121, P10803, DOI 10.1021/ja9920664; HASHIMOTO K, 1994, ANAL CHEM, V66, P3830, DOI 10.1021/ac00093a045; Herne TM, 1997, J AM CHEM SOC, V119, P8916, DOI 10.1021/ja9719586; JOHNSTON PJ, 1991, NUCLEIC ACIDS RES, V19, P2735, DOI 10.1093/nar/19.10.2735; Kelley SO, 1999, SCIENCE, V283, P375, DOI 10.1126/science.283.5400.375; Kelley SO, 1998, LANGMUIR, V14, P6781, DOI 10.1021/la980874n; Kelley SO, 1999, NUCLEIC ACIDS RES, V27, P4830, DOI 10.1093/nar/27.24.4830; Kelley SO, 1997, BIOCONJUGATE CHEM, V8, P31, DOI 10.1021/bc960070o; Kelley SO, 1997, J AM CHEM SOC, V119, P9861, DOI 10.1021/ja9714651; Kelley SO, 1999, ANGEW CHEM INT EDIT, V38, P941, DOI 10.1002/(SICI)1521-3773(19990401)38:7<941::AID-ANIE941>3.0.CO;2-7; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; MI S, 1995, NUCLEIC ACIDS RES, V23, P620, DOI 10.1093/nar/23.4.620; Mui S., 2001, LANGMUIR, V17, P5727; Nunez ME, 2000, CURR OPIN CHEM BIOL, V4, P199, DOI 10.1016/S1367-5931(99)00075-7; O'Gara M, 1998, NAT STRUCT BIOL, V5, P872, DOI 10.1038/2312; OGara M, 1996, J MOL BIOL, V261, P634, DOI 10.1006/jmbi.1996.0489; Patolsky F, 2001, NAT BIOTECHNOL, V19, P253, DOI 10.1038/85704; Rajski SR, 2001, BIOCHEMISTRY-US, V40, P5556, DOI 10.1021/bi002684t; Rajski SR, 1999, J AM CHEM SOC, V121, P5615, DOI 10.1021/ja9900813; Schuster GB, 2000, ACCOUNTS CHEM RES, V33, P253, DOI 10.1021/ar980059z; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; Stivers JT, 1999, BIOCHEMISTRY-US, V38, P952, DOI 10.1021/bi9818669; Wagenknecht HA, 2001, J AM CHEM SOC, V123, P4400, DOI 10.1021/ja003986l	33	220	225	0	62	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2002	20	3					282	286		10.1038/nbt0302-282	http://dx.doi.org/10.1038/nbt0302-282			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	526RE	11875430				2022-12-25	WOS:000174142800047
J	Halin, C; Rondini, S; Nilsson, F; Berndt, A; Kosmehl, H; Zardi, L; Neri, D				Halin, C; Rondini, S; Nilsson, F; Berndt, A; Kosmehl, H; Zardi, L; Neri, D			Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature	NATURE BIOTECHNOLOGY			English	Article							RECOMBINANT ANTIBODY FRAGMENTS; FIBRONECTIN ISOFORM; MONOCLONAL-ANTIBODIES; IN-VIVO; ANGIOGENESIS; GAMMA; IL-12; MECHANISMS; CYTOKINE; AFFINITY	Interleukin-12 (IL-12) is a heterodimeric cytokine with potent immunostimulatory activity and anti-angiogenic properties. Its clinical applications are limited, however, by severe side-effects. Here we report that an IL-12 fusion protein, consisting of IL-12 fused to a human antibody fragment specific to the oncofetal ED-B domain of fibronectin, markedly enhances the antitumor activity of this cytokine, as demonstrated in a mouse lung-metastasis model and in two models of mice bearing different aggressive murine tumors. The residual small tumor masses seen in the treated mice were infiltrated with lymphocytes, macrophages, and natural killer cells and had elevated interferon gamma (IFN-gamma). These results are of therapeutic relevance as the ED-B domain of fibronectin, a naturally occurring marker of angiogenesis identical in mouse and man, is expressed in the majority of aggressive solid tumors but is not detectable in normal vessels and tissues.	Swiss Fed Inst Technol, Inst Pharmaceut Sci, CH-8057 Zurich, Switzerland; Univ Jena, Inst Pathol, D-07740 Jena, Germany; Ist Nazl Ric Canc, Cell Biol Lab, I-16132 Genoa, Italy	Swiss Federal Institutes of Technology Domain; ETH Zurich; Friedrich Schiller University of Jena; University of Genoa; IRCCS AOU San Martino IST	Neri, D (corresponding author), Swiss Fed Inst Technol, Inst Pharmaceut Sci, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	neri@pharma.ethz.ch	Rondini, Simona/N-1780-2013; Neri, Dario/P-4368-2016	Rondini, Simona/0000-0002-7993-9656; Neri, Dario/0000-0001-5234-7370; Halin, Cornelia/0000-0002-7899-2850				Atkins MB, 1997, CLIN CANCER RES, V3, P409; BERNSTINE EG, 1973, P NATL ACAD SCI USA, V70, P3899, DOI 10.1073/pnas.70.12.3899; Birchler M, 1999, NAT BIOTECHNOL, V17, P984, DOI 10.1038/13679; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Bosslet K, 1998, CANCER RES, V58, P1195; BRUNDA MJ, 1993, J EXP MED, V178, P1223, DOI 10.1084/jem.178.4.1223; Car BD, 1999, TOXICOL PATHOL, V27, P58, DOI 10.1177/019262339902700112; CARNEMOLLA B, 1989, J CELL BIOL, V108, P1139, DOI 10.1083/jcb.108.3.1139; CASTELLANI P, 1994, INT J CANCER, V59, P612, DOI 10.1002/ijc.2910590507; CORBETT TH, 1975, CANCER RES, V35, P2434; Demartis S, 2001, EUR J NUCL MED, V28, P534, DOI 10.1007/s002590100480; Duda DG, 2000, CANCER RES, V60, P1111; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; GATELY MK, 1995, CURRENT PROTOCOLS IM; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Halin C, 2001, CRIT REV THER DRUG, V18, P299; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; JAIN RK, 1988, CANCER RES, V48, P7022; KACZMAREK J, 1994, INT J CANCER, V59, P11, DOI 10.1002/ijc.2910590104; KING DJ, 1994, CANCER RES, V54, P6176; Lieschke GJ, 1997, NAT BIOTECHNOL, V15, P35, DOI 10.1038/nbt0197-35; Lode HN, 1998, BLOOD, V91, P1706, DOI 10.1182/blood.V91.5.1706.1706_1706_1715; NASTALA CL, 1994, J IMMUNOL, V153, P1697; Neri D, 1996, NAT BIOTECHNOL, V14, P485, DOI 10.1038/nbt0496-485; Nilsson F, 2001, CANCER RES, V61, P711; Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4; Peng LS, 1999, J IMMUNOL, V163, P250; Rodolfo M, 1999, METHODS, V19, P114, DOI 10.1006/meth.1999.0836; SMITHGILL SJ, 1984, J IMMUNOL, V132, P963; Tannenbaum CS, 2000, SEMIN CANCER BIOL, V10, P113, DOI 10.1006/scbi.2000.0314; Tarli L, 1999, BLOOD, V94, P192, DOI 10.1182/blood.V94.1.192.413k22_192_198; TARLI L, 2000, THESIS SWISS FEDERAL; TRINCHIERI G, 1994, BLOOD, V84, P4008, DOI 10.1182/blood.V84.12.4008.bloodjournal84124008; Tsung K, 1997, J IMMUNOL, V158, P3359; Viti F, 1999, CANCER RES, V59, P347; VOEST EE, 1995, J NATL CANCER I, V87, P581, DOI 10.1093/jnci/87.8.581; ZARDI L, 1987, EMBO J, V6, P2337, DOI 10.1002/j.1460-2075.1987.tb02509.x	37	225	262	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2002	20	3					264	269		10.1038/nbt0302-264	http://dx.doi.org/10.1038/nbt0302-264			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	526RE	11875427				2022-12-25	WOS:000174142800044
J	Morshead, CM; Benveniste, P; Iscove, NN; van der Kooy, D				Morshead, CM; Benveniste, P; Iscove, NN; van der Kooy, D			Hematopoietic competence is a rare property of neural stem cells that may depend on genetic and epigenetic alterations	NATURE MEDICINE			English	Article							IN-VIVO; BONE-MARROW; BRAIN; EXPRESSION; FOREBRAIN; MUSCLE; BLOOD; EGF; CNS	The concept of stem-cell plasticity received strong support from a recent observation that extensively passaged, clonally derived neural stem cells could contribute to hematopoiesis. We investigated whether hematopoietic potential was a consistent or unusual feature of neural stem cells, and whether it depended on the extent of in vitro passaging before transplantation. Here we transplanted over 128 x 10(6) neurosphere cells into 128 host animals; however, we never observed contribution to hematopoiesis, irrespective of the number of passages and despite the use of an assay that could detect the contribution of a single blood stem cell to hematopoietic repopulation. Although extensively cultured neurosphere cells continued to generate neural progeny, marked changes in their growth properties occurred, including changes in growth-factor dependence, cell-cycle kinetics, cell adhesion and gene expression. Our results exclude hematopoietic competence as a consistent property of intravenously infused neural stem cells. However, the consistent changes that occurred during extended passaging are compatible with genetic or epigenetic alterations and suggest that rare transformation events may account for the neural-to-blood fate switch originally reported.	Univ Toronto, Dept Surg, Toronto, ON, Canada; Univ Toronto, Dept Anat & Cell Biol, Toronto, ON, Canada; Univ Toronto, Ontario Canc Inst, Toronto, ON, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Morshead, CM (corresponding author), Univ Toronto, Dept Surg, Toronto, ON, Canada.			Benveniste, Patricia/0000-0002-5673-0542				Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; CABOT B, 1988, NATURE, V335, P88; Clarke DL, 2000, SCIENCE, V288, P1660, DOI 10.1126/science.288.5471.1660; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Gage FH, 1998, NATURE, V392, P18; Galli R, 2000, NAT NEUROSCI, V3, P986, DOI 10.1038/79924; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Jackson KA, 1999, P NATL ACAD SCI USA, V96, P14482, DOI 10.1073/pnas.96.25.14482; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; LANGFORD LA, 1988, J NEUROCYTOL, V17, P521, DOI 10.1007/BF01189807; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Morshead CM, 1998, DEVELOPMENT, V125, P2251; Namba M, 1996, CRIT REV ONCOGENESIS, V7, P19, DOI 10.1615/CritRevOncog.v7.i1-2.20; PORTER S, 1987, P NATL ACAD SCI USA, V84, P7768, DOI 10.1073/pnas.84.21.7768; Reynolds BA, 1996, DEV BIOL, V175, P1, DOI 10.1006/dbio.1996.0090; Shih CC, 2001, BLOOD, V98, P2412, DOI 10.1182/blood.V98.8.2412; Trevisan M, 1996, BLOOD, V88, P4149, DOI 10.1182/blood.V88.11.4149.bloodjournal88114149; Tropepe V, 2001, NEURON, V30, P65, DOI 10.1016/S0896-6273(01)00263-X; Tropepe V, 1999, DEV BIOL, V208, P166, DOI 10.1006/dbio.1998.9192; Vescovi AL, 1999, EXP NEUROL, V156, P71, DOI 10.1006/exnr.1998.6998	22	307	343	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2002	8	3					268	273		10.1038/nm0302-268	http://dx.doi.org/10.1038/nm0302-268			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	526PU	11875498				2022-12-25	WOS:000174139500032
J	Gerull, B; Gramlich, M; Atherton, J; McNabb, M; Trombitas, K; Sasse-Klaassen, S; Seidman, JG; Seidman, C; Granzier, H; Labeit, S; Frenneaux, M; Thierfelder, L				Gerull, B; Gramlich, M; Atherton, J; McNabb, M; Trombitas, K; Sasse-Klaassen, S; Seidman, JG; Seidman, C; Granzier, H; Labeit, S; Frenneaux, M; Thierfelder, L			Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy	NATURE GENETICS			English	Article							IDENTIFICATION; PROTEINS; ELASTICITY; EXPRESSION; CONNECTIN; SEQUENCE; DISEASE; GENE; EXON	Congestive heart failure (CHF) can result from various disease states with inadequate cardiac output. CHF due to dilated cardiomyopathy (DCM) is a familial disease in 20-30% of cases and is associated with mutations in genes encoding cytoskeletal, contractile or inner-nuclear membrane proteins(1). We show that mutations in the gene encoding giant-muscle filament titin (TTN) cause autosomal dominant DCM linked to chromosome 2q31 (CMD1G; MIM 604145). Titin molecules extend from sarcomeric Z-discs to M-lines, provide an extensible scaffold for the contractile machinery and are crucial for myofibrillar elasticity and integrity(2). in a large DCM kindred, a segregating 2-bp insertion mutation in TTN exon 326 causes a frameshift, truncating A-band titin. The truncated protein of approximately 2 mD is expressed in skeletal muscle, but western blot studies with epitope-specific anti-titin antibodies suggest that the mutant protein is truncated to a 1.14-mD subfragment by site-specific cleavage. In another large family with DCM linked to CMD1G, a TTN missense mutation (Trp930Arg) is predicted to disrupt a highly conserved hydrophobic core sequence of an immunoglobulin fold located in the Z-disc-1-band transition zone. The identification of TTN mutations in individuals with CMD1G should provide further insights into the pathogenesis of familial forms of CHF and myofibrillar titin turnover.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Humboldt Univ, HELIOS Kliniken GmbH, Franz Volhard Klin, Charite, Berlin, Germany; Royal Brisbane Hosp, Dept Cardiol, Brisbane, Qld 4029, Australia; Washington State Univ, Dept Vet & Comparat Anat Pharmacol & Physiol, Pullman, WA 99164 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Brigham & Womens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Univ Hosp Mannheim, D-68135 Mannheim, Germany; Cardiff Univ, Dept Cardiol, Cardiff CF4 4XN, S Glam, Wales	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Franz-Volhard Clinical Research Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helios Kliniken; Royal Brisbane & Women's Hospital; Washington State University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Ruprecht Karls University Heidelberg; Cardiff University	Thierfelder, L (corresponding author), Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany.	lthier@mdc-berlin.de	Atherton, John J/B-9994-2011	Atherton, John J/0000-0003-2271-578X				Bang ML, 2001, CIRC RES, V89, P1065, DOI 10.1161/hh2301.100981; Cazorla O, 2000, CIRC RES, V86, P59, DOI 10.1161/01.RES.86.1.59; Centner T, 2001, J MOL BIOL, V306, P717, DOI 10.1006/jmbi.2001.4448; Freiburg A, 2000, CIRC RES, V86, P1114; Granzier H, 1996, BIOPHYS J, V70, P430, DOI 10.1016/S0006-3495(96)79586-3; Gregorio CC, 1999, CURR OPIN CELL BIOL, V11, P18, DOI 10.1016/S0955-0674(99)80003-9; Halaby DM, 1999, PROTEIN ENG, V12, P563, DOI 10.1093/protein/12.7.563; Hutchison CJ, 2001, J CELL SCI, V114, P9; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; Macrae CA, 2000, EUR HEART J, V21, P1817, DOI 10.1053/euhj.2000.2374; Mestroni L, 1999, EUR HEART J, V20, P93, DOI 10.1053/euhj.1998.1145; Satoh M, 1999, BIOCHEM BIOPH RES CO, V262, P411, DOI 10.1006/bbrc.1999.1221; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; Siu BL, 1999, CIRCULATION, V99, P1022, DOI 10.1161/01.CIR.99.8.1022; Sorimachi H, 1997, J MOL BIOL, V270, P688, DOI 10.1006/jmbi.1997.1145; Sorimachi H, 1995, J BIOL CHEM, V270, P31158, DOI 10.1074/jbc.270.52.31158; TAKAHASHI K, 1992, J BIOCHEM-TOKYO, V111, P778, DOI 10.1093/oxfordjournals.jbchem.a123835; Trinick J, 1999, TRENDS CELL BIOL, V9, P377, DOI 10.1016/S0962-8924(99)01641-4; Xu XL, 2002, NAT GENET, V30, P205, DOI 10.1038/ng816	19	394	414	3	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2002	30	2					201	204		10.1038/ng815	http://dx.doi.org/10.1038/ng815			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	519CY	11788824				2022-12-25	WOS:000173708700022
J	Liu, LZ; Chahroudi, A; Silvestri, G; Wernett, ME; Kaiser, WJ; Safrit, JT; Komoriya, A; Altman, JD; Packard, BZ; Feinberg, MB				Liu, LZ; Chahroudi, A; Silvestri, G; Wernett, ME; Kaiser, WJ; Safrit, JT; Komoriya, A; Altman, JD; Packard, BZ; Feinberg, MB			Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogenic caspase substrates	NATURE MEDICINE			English	Article							IMMUNE EVASION; GRANZYME-B; INFECTION; ACTIVATION	We have developed a non-radioactive flow-cytometry assay to monitor and quantify the target-cell killing activities mediated by cytotoxic T lymphocytes (CTLs). This flow-cytometry CTL (FCC) assay is predicated on measurement of CTL-induced caspase activation in target cells through detection of the specific cleavage of fluorogenic caspase substrates. Here we show that this assay reliably detects antigen-specific CTL killing of target cells, and demonstrate that it provides a more sensitive, more informative and safer alternative to the standard Cr-51-release assay most often used to quantify CTL responses. The FCC assay can be used to study CTL-mediated killing of primary host target cells of different cell lineages, and enables the study of antigen-specific cellular immune responses in real time at the single-cell level. As such, the FCC assay can provide a valuable tool for studies of infectious disease pathogenesis and development of new vaccines and immunotherapies.	Emory Vaccine Ctr, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Atlanta, GA USA; Oncolmmunin, Gaithersburg, MD USA	Emory University; Emory University	Feinberg, MB (corresponding author), Emory Vaccine Ctr, Atlanta, GA 30322 USA.		Kaiser, William/A-3079-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI049089, P01AI046007] Funding Source: NIH RePORTER; NIAID NIH HHS [R2AI49089, P01AI46007] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altman JD, 1998, SCIENCE, V280, P1821; Appay V, 2000, J EXP MED, V192, P63, DOI 10.1084/jem.192.1.63; Atkinson EA, 1998, J BIOL CHEM, V273, P21261, DOI 10.1074/jbc.273.33.21261; BRUNNER KT, 1968, IMMUNOLOGY, V14, P181; Butz EA, 1998, IMMUNITY, V8, P167, DOI 10.1016/S1074-7613(00)80469-0; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; Doherty PC, 2000, ANNU REV IMMUNOL, V18, P561, DOI 10.1146/annurev.immunol.18.1.561; Komoriya A, 2000, J EXP MED, V191, P1819, DOI 10.1084/jem.191.11.1819; Lecoeur H, 2001, J IMMUNOL METHODS, V253, P177, DOI 10.1016/S0022-1759(01)00359-3; Lee PP, 1999, NAT MED, V5, P677, DOI 10.1038/9525; Liu LZ, 1999, J VIROL, V73, P9849, DOI 10.1128/JVI.73.12.9849-9857.1999; Maino VC, 1998, CYTOMETRY, V34, P207, DOI 10.1002/(SICI)1097-0320(19981015)34:5<207::AID-CYTO1>3.0.CO;2-J; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; Nociari MM, 1998, J IMMUNOL METHODS, V213, P157, DOI 10.1016/S0022-1759(98)00028-3; Packard BZ, 1996, P NATL ACAD SCI USA, V93, P11640, DOI 10.1073/pnas.93.21.11640; Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248; RUPPERT J, 1993, CELL, V74, P929, DOI 10.1016/0092-8674(93)90472-3; Sheehy ME, 2001, J IMMUNOL METHODS, V249, P99, DOI 10.1016/S0022-1759(00)00329-X; Sheehy ME, 2001, J IMMUNOL METHODS, V252, P219, DOI 10.1016/S0022-1759(01)00383-0; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205	21	121	127	1	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2002	8	2					185	189		10.1038/nm0202-185	http://dx.doi.org/10.1038/nm0202-185			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	517FN	11821904				2022-12-25	WOS:000173600600029
J	Bevis, BJ; Glick, BS				Bevis, BJ; Glick, BS			Rapidly maturing variants of the Discosoma red fluorescent protein (DsRed)	NATURE BIOTECHNOLOGY			English	Article							SACCHAROMYCES-CEREVISIAE; GFP; CORAL	The red fluorescent protein DsRed has spectral properties that are ideal for dual-color experiments with green fluorescent protein (GFP)(l). But wild-type DsRed has several drawbacks, including slow chromophore maturation and poor solubility(2,3). To overcome the slow maturation, we used random and directed mutagenesis to create DsRed variants that mature 10-15 times faster than the wild-type protein. An asparagine-to-glutamine substitution at position 42 greatly accelerates the maturation of DsRed, but also increases the level of green emission. Additional amino acid substitutions suppress this green emission while further accelerating the maturation. To enhance the solubility of DsRed, we reduced the net charge near the N terminus of the protein. The optimized DsRed variants yield bright fluorescence even in rapidly growing organisms such as yeast.	Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	University of Chicago	Glick, BS (corresponding author), Univ Chicago, Dept Mol Genet & Cell Biol, 920 E 58Th St, Chicago, IL 60637 USA.	bsglick@midway.uchicago.edu						Baird GS, 2000, P NATL ACAD SCI USA, V97, P11984, DOI 10.1073/pnas.97.22.11984; Cadwell R. Craig, 1995, P583; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Cronin S, 1999, TRENDS CELL BIOL, V9, P36, DOI 10.1016/S0962-8924(98)01421-4; Gross LA, 2000, P NATL ACAD SCI USA, V97, P11990, DOI 10.1073/pnas.97.22.11990; Hawley TS, 2001, BIOTECHNIQUES, V30, P1028, DOI 10.2144/01305rr01; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Jakobs S, 2000, FEBS LETT, V479, P131, DOI 10.1016/S0014-5793(00)01896-2; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Lauf U, 2001, FEBS LETT, V498, P11, DOI 10.1016/S0014-5793(01)02462-0; Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Rossanese OW, 1999, J CELL BIOL, V145, P69, DOI 10.1083/jcb.145.1.69; Rossanese OW, 2001, J CELL BIOL, V153, P47, DOI 10.1083/jcb.153.1.47; SIKORSKI RS, 1989, GENETICS, V122, P19; SULLIVAN KF, 1999, METHODS CELL BIOL, V58; Terskikh A, 2000, SCIENCE, V290, P1585, DOI 10.1126/science.290.5496.1585; Verkhusha VV, 2001, J BIOL CHEM, V276, P29621, DOI 10.1074/jbc.C100200200; Wall MA, 2000, NAT STRUCT BIOL, V7, P1133; Wiehler J, 2001, FEBS LETT, V487, P384, DOI 10.1016/S0014-5793(00)02365-6; Yarbrough D, 2001, P NATL ACAD SCI USA, V98, P462, DOI 10.1073/pnas.98.2.462; 2001, CLONTECHNIQUES, V16, P2	23	460	516	5	82	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2002	20	1					83	87		10.1038/nbt0102-83	http://dx.doi.org/10.1038/nbt0102-83			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	507ME	11753367				2022-12-25	WOS:000173031600041
J	Falati, S; Gross, P; Merrill-Skoloff, G; Furie, BC; Furie, B				Falati, S; Gross, P; Merrill-Skoloff, G; Furie, BC; Furie, B			Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse	NATURE MEDICINE			English	Article							FACTOR ANTIGEN; RECEPTOR; CDNA	We have used confocal and widefield microscopy to image thrombus formation in real time in the microcirculation of a living mouse. This system provides high-speed, near-simultaneous acquisition of images of multiple fluorescent probes and of a brightfield channel. Vascular injury is induced with a laser focused through the microscope optics. We observed platelet deposition, tissue factor accumulation and fibrin generation after laser-induced endothelial injury in a single developing thrombus. The initiation of blood coagulation in vivo entailed the initial accumulation of tissue factor on the upstream and thrombus-vessel wall interface of the developing thrombus. Subsequently tissue factor was associated with the interior of the thrombus. Tissue factor was biologically active, and was associated with fibrin generation within the thrombus.	Beth Israel Deaconess Med Ctr, Ctr Hemostasis & Thrombosis Res, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Furie, B (corresponding author), Beth Israel Deaconess Med Ctr, Ctr Hemostasis & Thrombosis Res, Boston, MA 02215 USA.			Merrill-Skoloff, Glenn/0000-0003-2337-5107	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR015680] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069435, R01HL051926] Funding Source: NIH RePORTER; NCRR NIH HHS [S10RR15680] Funding Source: Medline; NHLBI NIH HHS [HL51926, HL69435] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		FAREED J, 1995, BLOOD COAGUL FIBRIN, V6, pS32, DOI 10.1097/00001721-199506001-00006; Giesen PLA, 1999, P NATL ACAD SCI USA, V96, P2311, DOI 10.1073/pnas.96.5.2311; INOUE S, 2000, DIRECT VIEW HIGH SPE; KOYAMA T, 1994, BRIT J HAEMATOL, V87, P343, DOI 10.1111/j.1365-2141.1994.tb04919.x; Ley Klaus, 1995, Microcirculation (New York), V2, P141, DOI 10.3109/10739689509146762; MORRISSEY JH, 1987, CELL, V50, P129, DOI 10.1016/0092-8674(87)90669-6; Morrissey JH, 2001, THROMB HAEMOSTASIS, V86, P66; Rosen ED, 2001, AM J PATHOL, V158, P1613, DOI 10.1016/S0002-9440(10)64117-X; SPICER EK, 1987, P NATL ACAD SCI USA, V84, P5148, DOI 10.1073/pnas.84.15.5148; Yang J, 1999, J EXP MED, V190, P1769, DOI 10.1084/jem.190.12.1769; Zumbach M, 1997, EXP CLIN ENDOCR DIAB, V105, P206, DOI 10.1055/s-0029-1211753	12	517	539	4	73	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2002	8	10					1175	1180		10.1038/nm782	http://dx.doi.org/10.1038/nm782			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	599AN	12244306	Green Published			2022-12-25	WOS:000178311000047
J	Spring, K; Ahangari, F; Scott, SP; Waring, P; Purdie, DM; Chen, PC; Hourigan, K; Ramsay, J; McKinnon, PJ; Swift, M; Lavin, MF				Spring, K; Ahangari, F; Scott, SP; Waring, P; Purdie, DM; Chen, PC; Hourigan, K; Ramsay, J; McKinnon, PJ; Swift, M; Lavin, MF			Mice heterozygous for mutation in Atm, the gene involved in ataxia-telangiectasia, have heightened susceptibility to cancer	NATURE GENETICS			English	Article							BREAST-CANCER; IONIZING-RADIATION; EARLY-ONSET; MISSENSE MUTATIONS; ALLELIC VARIANTS; DEFICIENT MICE; PHENOTYPE; FAMILIES; IDENTIFICATION; KINASE	Ataxia-telangiectasia is characterized by radiosensitivity, genome instability and predisposition to cancer(1,2). Heterozygous carriers of ATM, the gene defective in ataxia-telangiectasia, have a higher than normal risk of developing breast and other cancers(3-6). We demonstrate here that Atm 'knock-in' (Atm-DeltaSRI) heterozygous mice harboring an in-frame deletion corresponding to the human 7636del9 mutation show an increased susceptibility to developing tumors. In contrast, no tumors are observed in Atm knockout (Atm(+/-)) heterozygous mice. In parallel, we report the appearance of tumors in 6 humans from 12 families who are heterozygous for the 7636del9 mutation. Expression of ATM cDNA containing the 7636del9 mutation had a dominant-negative effect in control cells, inhibiting radiation-induced ATM kinase activity in vivo and in vitro. This reduces the survival of these cells after radiation exposure and enhances the level of radiation-induced chromosomal aberrations. These results show for the first time that mouse carriers of a mutated Atm that are capable of expressing Atm have a higher risk of cancer. This finding provides further support for cancer predisposition in human ataxia-telangiectasia carriers.	Queensland Inst Med Res, Herston, Qld 4029, Australia; Peter MacCallum Canc Inst, Melbourne, Vic, Australia; Alexandra House, Brisbane, Qld, Australia; St Jude Childrens Res Hosp, Dept Genet, Memphis, TN 38105 USA; Pace Univ, Dept Biol Sci, Pleasantville, NY USA; Royal Brisbane Hosp, Dept Surg, Herston, Qld 4029, Australia	QIMR Berghofer Medical Research Institute; Peter Maccallum Cancer Center; St Jude Children's Research Hospital; Pace University; Royal Brisbane & Women's Hospital	Lavin, MF (corresponding author), Queensland Inst Med Res, PO Royal Brisbane Hosp, Herston, Qld 4029, Australia.	martinL@qimr.edu.au	Lavin, Martin F/F-5961-2014; Ramsay, Jonathan/F-7009-2013	Lavin, Martin F/0000-0002-5940-4769; Spring, Kevin/0000-0003-0601-924X				Athma P, 1996, CANCER GENET CYTOGEN, V92, P130, DOI 10.1016/S0165-4608(96)00328-7; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Barlow C, 1999, NAT GENET, V21, P359, DOI 10.1038/7684; Becker-Catania SG, 2000, MOL GENET METAB, V70, P122, DOI 10.1006/mgme.2000.2998; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CHEN PC, 1978, NATURE, V274, P484, DOI 10.1038/274484a0; Chenevix-Trench G, 2002, JNCI-J NATL CANCER I, V94, P205, DOI 10.1093/jnci/94.3.205; Dork T, 2001, CANCER RES, V61, P7608; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; FitzGerald MG, 1997, NAT GENET, V15, P307, DOI 10.1038/ng0397-307; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; Gueven N, 2001, J BIOL CHEM, V276, P8884, DOI 10.1074/jbc.M006190200; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Inskip HM, 1999, BRIT J CANCER, V79, P1304, DOI 10.1038/sj.bjc.6690209; Izatt L, 1999, GENE CHROMOSOME CANC, V26, P286, DOI 10.1002/(SICI)1098-2264(199912)26:4<286::AID-GCC2>3.0.CO;2-X; Larson GP, 1997, GENET TEST, V1, P165, DOI 10.1089/gte.1997.1.165; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Li AR, 2000, AM J MED GENET, V92, P170, DOI 10.1002/(SICI)1096-8628(20000529)92:3<170::AID-AJMG3>3.0.CO;2-#; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Olsen JH, 2001, JNCI-J NATL CANCER I, V93, P121, DOI 10.1093/jnci/93.2.121; PATERSON MC, 1985, ATAXIA TELANGIECTASI, P73; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Scott SP, 2002, P NATL ACAD SCI USA, V99, P925, DOI 10.1073/pnas.012329699; Spring K, 2001, CANCER RES, V61, P4561; Stewart GS, 2001, J BIOL CHEM, V276, P30133, DOI 10.1074/jbc.M103160200; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; Teraoka SN, 2001, CANCER-AM CANCER SOC, V92, P479, DOI 10.1002/1097-0142(20010801)92:3<479::AID-CNCR1346>3.0.CO;2-G; Vorechovsky I, 1996, CANCER RES, V56, P4130; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021	30	117	120	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2002	32	1					185	190		10.1038/ng958	http://dx.doi.org/10.1038/ng958			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	588RR	12195425				2022-12-25	WOS:000177714900020
J	Adam, GC; Sorensen, EJ; Cravatt, BF				Adam, GC; Sorensen, EJ; Cravatt, BF			Proteomic profiling of mechanistically distinct enzyme classes using a common chemotype	NATURE BIOTECHNOLOGY			English	Article							SERINE HYDROLASE ACTIVITIES; COMPLEX PROTEOMES; GLOBAL ANALYSIS; IDENTIFICATION; PROTEINS; NUCLEOPHILE; EXPRESSION; PROBES	Proteomics research requires methods to characterize the expression and function of proteins in complex mixtures. Toward this end, chemical probes that incorporate known affinity labeling agents have facilitated the activity-based profiling of certain enzyme families. To accelerate the discovery of proteomics probes for enzyme classes lacking cognate affinity labels, we describe here a combinatorial strategy. Members of a probe library bearing a sulfonate ester chemotype were screened against complex proteomes for activity-dependent protein reactivity, resulting in the labeling of at least six mechanistically distinct enzyme classes. Surprisingly, none of these enzymes represented targets of previously described proteomics probes. The sulfonate library was used to identify an omega-class glutathione S-transferase whose activity was upregulated in invasive human breast cancer lines. These results indicate that activity-based probes compatible with whole-proteome analysis can be developed for numerous enzyme classes and applied to identify enzymes associated with discrete pathological states.	Scripps Res Inst, Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Cravatt, BF (corresponding author), Scripps Res Inst, Res Inst, Dept Chem, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R37CA087660, R01CA087660] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA087660, R01 CA087660-02, CA87660] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam GC, 2001, CHEM BIOL, V8, P81, DOI 10.1016/S1074-5521(00)90060-7; Anderson NL, 1998, ELECTROPHORESIS, V19, P1853, DOI 10.1002/elps.1150191103; Armstrong RN, 1999, DRUG METAB REV, V31, P71, DOI 10.1081/DMR-100101908; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; Corthals GL, 2000, ELECTROPHORESIS, V21, P1104, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1104::AID-ELPS1104>3.3.CO;2-3; Cravatt BF, 2000, CURR OPIN CHEM BIOL, V4, P663, DOI 10.1016/S1367-5931(00)00147-2; Dakoji S, 2001, J AM CHEM SOC, V123, P9749, DOI 10.1021/ja011226k; Dawson John F., 1999, Frontiers in Bioscience, V4, pd646, DOI 10.2741/Dawson; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; Greenbaum D, 2000, CHEM BIOL, V7, P569, DOI 10.1016/S1074-5521(00)00014-4; Gygi SP, 2000, P NATL ACAD SCI USA, V97, P9390, DOI 10.1073/pnas.160270797; HARA A, 1991, BIOCHEM J, V275, P113, DOI 10.1042/bj2750113; Hempel J, 1999, ADV EXP MED BIOL, V463, P53; Kidd D, 2001, BIOCHEMISTRY-US, V40, P4005, DOI 10.1021/bi002579j; Kodym R, 1999, J BIOL CHEM, V274, P5131, DOI 10.1074/jbc.274.8.5131; Legrain P, 2000, CURR OPIN BIOTECH, V11, P402, DOI 10.1016/S0958-1669(00)00117-8; Liu YS, 1999, P NATL ACAD SCI USA, V96, P14694, DOI 10.1073/pnas.96.26.14694; MacBeath G, 2000, SCIENCE, V289, P1760; Nelson PS, 2000, ELECTROPHORESIS, V21, P1823; Pandey A, 2000, NATURE, V405, P837, DOI 10.1038/35015709; Patricelli MP, 2001, PROTEOMICS, V1, P1067, DOI 10.1002/1615-9861(200109)1:9<1067::AID-PROT1067>3.0.CO;2-4; Penzes P, 1997, BBA-PROTEIN STRUCT M, V1342, P175, DOI 10.1016/S0167-4838(97)00102-7; Rochefort H, 1998, J STEROID BIOCHEM, V65, P163, DOI 10.1016/S0960-0760(98)00010-7; Santoni V, 2000, ELECTROPHORESIS, V21, P1054, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1054::AID-ELPS1054>3.3.CO;2-#; Terada T, 2001, BBA-PROTEIN STRUCT M, V1547, P127, DOI 10.1016/S0167-4838(01)00179-0; THOMPSON S, 1989, BIOCHEMISTRY-US, V28, P5735, DOI 10.1021/bi00440a006; Uetz P, 2002, CURR OPIN CHEM BIOL, V6, P57, DOI 10.1016/S1367-5931(01)00288-5; Zhu H, 2001, SCIENCE, V293, P2101, DOI 10.1126/science.1062191	29	188	216	2	31	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2002	20	8					805	809		10.1038/nbt714	http://dx.doi.org/10.1038/nbt714			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	579MU	12091914				2022-12-25	WOS:000177182500031
J	Lipkin, SM; Moens, PB; Wang, V; Lenzi, M; Shanmugarajah, D; Gilgeous, A; Thomas, J; Cheng, J; Touchman, JW; Green, ED; Schwartzberg, P; Collins, FS; Cohen, PE				Lipkin, SM; Moens, PB; Wang, V; Lenzi, M; Shanmugarajah, D; Gilgeous, A; Thomas, J; Cheng, J; Touchman, JW; Green, ED; Schwartzberg, P; Collins, FS; Cohen, PE			Meiotic arrest and aneuploidy in MLH3-deficient mice	NATURE GENETICS			English	Article							DNA MISMATCH REPAIR; CROSSING-OVER; MUTS HOMOLOG; SACCHAROMYCES-CEREVISIAE; CHROMOSOME SYNAPSIS; MEIOSIS; GENE; RECOMBINATION; MLH1; MSH5	MutL homolog 3 (Mlh3) is a member of a family of proteins conserved during evolution and having dual roles in DNA mismatch repair and meiosis(1,2). The pathway in eukaryotes consists of the DNA-binding components, which are the homologs of the bacterial MutS protein (MSH 2-6), and the MutL homologs, which bind to the MutS homologs and are essential for the repair process. Three of the six homologs of MutS that function in these processes, Msh2, Msh3 and Msh6, are involved in the mismatch repair of mutations, frameshifts and replication errors(2,3), and two others, Msh4 and Msh5, have specific roles in meiosis(4-10). Of the four MutL homologs, Mlh1, Mlh3, Pms1 and Pms2, three are involved in mismatch repair and at least two, Pms2 and Mlh1, are essential for meiotic progression in both yeast and mice(2,3,11-14). To assess the role of Mlh3 in mammalian meiosis, we have generated and characterized Mlh3(-/-) mice 15. Here we show that Mlh3(-/-) mice are viable but sterile. Mlh3 is required for Mlh1 binding to meiotic chromosomes and localizes to meiotic chromosomes from the mid pachynema stage of prophase I. Mlh3(-/-) spermatocytes reach metaphase before succumbing to apoptosis, but oocytes fail to complete meiosis I after fertilization. Our results show that Mlh3 has an essential and distinct role in mammalian meiosis.	Univ Calif Irvine, Dept Med, Div Hematol Oncol, Irvine, CA 92697 USA; NHGRI, Genet & Mol Biol Branch, Bethesda, MD 20892 USA; York Univ, Dept Biol, N York, ON M3J 1P3, Canada; Albert Einstein Coll Med, Coll Med, Dept Mol Genet, Bronx, NY 10467 USA; NHGRI, Genome Technol Branch, Bethesda, MD 20892 USA; NHGRI, Transgen & Knockout Core Facil, Bethesda, MD 20892 USA	University of California System; University of California Irvine; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); York University - Canada; Yeshiva University; Albert Einstein College of Medicine; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Cohen, PE (corresponding author), Univ Calif Irvine, Dept Med, Div Hematol Oncol, Irvine, CA 92697 USA.		wang, vicky/AAO-6474-2020		NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000123, ZIAHG000123] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Anderson LK, 1999, GENETICS, V151, P1569; Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; Cohen PE, 2001, BIOESSAYS, V23, P996, DOI 10.1002/bies.1145; de Vries SS, 1999, GENE DEV, V13, P523, DOI 10.1101/gad.13.5.523; Edelmann W, 1999, NAT GENET, V21, P123, DOI 10.1038/5075; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; Edelmann W, 2000, CANCER RES, V60, P803; Ellsworth RE, 2000, P NATL ACAD SCI USA, V97, P1172, DOI 10.1073/pnas.97.3.1172; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Flores-Rozas H, 1998, P NATL ACAD SCI USA, V95, P12404, DOI 10.1073/pnas.95.21.12404; Green ED, 2001, NAT REV GENET, V2, P573, DOI 10.1038/35084503; Guarne A, 2001, EMBO J, V20, P5521, DOI 10.1093/emboj/20.19.5521; Her CT, 1999, MAMM GENOME, V10, P1054, DOI 10.1007/s003359901161; HOLLINGSWORTH NM, 1995, GENE DEV, V9, P1728, DOI 10.1101/gad.9.14.1728; Hunter N, 1997, GENE DEV, V11, P1573, DOI 10.1101/gad.11.12.1573; Kneitz B, 2000, GENE DEV, V14, P1085; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Lipkin SM, 2000, NAT GENET, V24, P27, DOI 10.1038/71643; Marra G, 1998, P NATL ACAD SCI USA, V95, P8568, DOI 10.1073/pnas.95.15.8568; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Moens PB, 2002, J CELL SCI, V115, P1611; Osoegawa K, 2000, GENOME RES, V10, P116; PaquisFlucklinger V, 1997, GENOMICS, V44, P188, DOI 10.1006/geno.1997.4857; ROSSMACDONALD P, 1994, CELL, V79, P1069, DOI 10.1016/0092-8674(94)90037-X; Touchman JW, 2000, GENOME RES, V10, P165, DOI 10.1101/gr.10.2.165; Wang DH, 1996, CANCER LETT, V100, P31, DOI 10.1016/0304-3835(95)04068-4; Wang TF, 1999, P NATL ACAD SCI USA, V96, P13914, DOI 10.1073/pnas.96.24.13914; Woods LM, 1999, J CELL BIOL, V145, P1395, DOI 10.1083/jcb.145.7.1395	29	274	288	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2002	31	4					385	390		10.1038/ng931	http://dx.doi.org/10.1038/ng931			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	578XV	12091911				2022-12-25	WOS:000177147100013
J	Murphy, LO; Smith, S; Chen, RH; Fingar, DC; Blenis, J				Murphy, LO; Smith, S; Chen, RH; Fingar, DC; Blenis, J			Molecular interpretation of ERK signal duration by immediate early gene products	NATURE CELL BIOLOGY			English	Article							ACTIVATED PROTEIN-KINASE; NERVE GROWTH-FACTOR; RIBOSOMAL S6 KINASE; NIH 3T3 CELLS; C-FOS; PC12 CELLS; MAP KINASE; REGULATED KINASE; CYCLIN D1; NEURONAL DIFFERENTIATION	The duration of intracellular signalling is associated with distinct biological responses, but how cells interpret differences in signal duration are unknown. We show that the immediate early gene product c-Fos functions as a sensor for ERK1 (extracellular-signal-regulated kinase 1) and ERK2 signal duration. When ERK activation is transient, its activity declines before the c-Fos protein accumulates, and under these conditions c-Fos is unstable. However, when ERK signalling is sustained, c-Fos is phosphorylated by still-active ERK and RSK (90K-ribosomal S6 kinase). Carboxy-terminal phosphorylation stabilizes c-Fos and primes additional phosphorylation by exposing a docking site for ERK, termed the FXFP (DEF) domain. Mutating the DEF domain disrupts the c-Fos sensor and c-Fos-mediated signalling. Other immediate early gene products that control cell cycle progression, neuronal differentiation and circadium rhythms also contain putative DEF domains, indicating that multiple sensors exist for sustained ERK signalling. Together, our data identify a general mechanism by which cells can interpret differences in ERK activation kinetics.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Blenis, J (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	jblenis@hms.harvard.edu	Chen, Rey-Huei/AAA-5087-2021	Chen, Rey-Huei/0000-0002-6006-2137	NATIONAL CANCER INSTITUTE [F32CA068712, R01CA046595, F32CA069808] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA46595, F32-CA68712, F32-CA69808] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; Akashi M, 2000, GENE DEV, V14, P645; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; Chen RH, 1996, ONCOGENE, V12, P1493; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHUNG JK, 1991, MOL CELL BIOL, V11, P1868, DOI 10.1128/MCB.11.4.1868; Cook SJ, 1996, BIOCHEM J, V320, P237, DOI 10.1042/bj3200237; CURRAN T, 1984, CELL, V36, P259; Dustin ML, 2000, CELL, V103, P283, DOI 10.1016/S0092-8674(00)00120-3; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Fantz DA, 2001, J BIOL CHEM, V276, P27256, DOI 10.1074/jbc.M102512200; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Gurdon JB, 1998, CELL, V95, P159, DOI 10.1016/S0092-8674(00)81747-X; Harada T, 2001, NAT CELL BIOL, V3, P453, DOI 10.1038/35074516; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Jordan JD, 2000, CELL, V103, P193, DOI 10.1016/S0092-8674(00)00112-4; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; Lezzi G, 1998, IMMUNITY, V8, P89, DOI 10.1016/S1074-7613(00)80461-6; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MEHMET H, 1990, CELL GROWTH DIFFER, V1, P293; MILBRANDT J, 1986, P NATL ACAD SCI USA, V83, P4789, DOI 10.1073/pnas.83.13.4789; MILLER AD, 1984, CELL, V36, P51; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; Richards SA, 1999, CURR BIOL, V9, P810, DOI 10.1016/S0960-9822(99)80364-9; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; STEIN R, 1988, DEV BIOL, V127, P316, DOI 10.1016/0012-1606(88)90318-1; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; WEISS A, 1987, J IMMUNOL, V138, P2169	46	733	753	1	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2002	4	8					556	564		10.1038/ncb822	http://dx.doi.org/10.1038/ncb822			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	579WK	12134156				2022-12-25	WOS:000177201100010
J	Sagot, I; Rodal, AA; Moseley, J; Goode, BL; Pellman, D				Sagot, I; Rodal, AA; Moseley, J; Goode, BL; Pellman, D			An actin nucleation mechanism mediated by Bni1 and profilin	NATURE CELL BIOLOGY			English	Article							YEAST ARP2/3 COMPLEX; IN-VIVO; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE EXCHANGE; FISSION YEAST; PROTEIN; POLYMERIZATION; ACTIVATION; FILAMENTS; ROLES	Formins are required for cell polarization and cytokinesis, but do not have a defined biochemical activity. In Saccharomyces cerevisiae, formins and the actin-monomer-binding protein profilin are specifically required to assemble linear actin structures called 'actin cables'. These structures seem to be assembled independently of the Arp2/3 complex, the only well characterized cellular mediator of actin nucleation. Here, an activated yeast formin was purified and found to promote the nucleation of actin filaments in vitro. Formin-dependent actin nucleation was stimulated by profilin. Thus, formin and profilin mediate actin nucleation by an Arp2/3-independent mechanism. These findings suggest that distinct actin nucleation mechanisms may underlie the assembly of different actin cytoskeletal structures.	Harvard Univ, Sch Med, Dept Pediat Oncol, Dana Farber Canc Inst,Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat Hematol, Childrens Hosp, Boston, MA 02115 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Brandeis Univ, Rosenstiel Med Ctr, Dept Biol, Waltham, MA 02454 USA	Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; University of California System; University of California Berkeley; Brandeis University	Pellman, D (corresponding author), Harvard Univ, Sch Med, Dept Pediat Oncol, Dana Farber Canc Inst,Childrens Hosp, 44 Binney ST, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061345] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM61345] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberts AS, 2001, J BIOL CHEM, V276, P2824, DOI 10.1074/jbc.M006205200; Condeelis J, 2001, TRENDS CELL BIOL, V11, P288, DOI 10.1016/S0962-8924(01)02008-6; DRENCKHAHN D, 1986, J BIOL CHEM, V261, P2754; Du JY, 1998, BIOCHEMISTRY-US, V37, P13276, DOI 10.1021/bi981117r; Evangelista M, 2002, NAT CELL BIOL, V4, P32, DOI 10.1038/ncb718; Feierbach B, 2001, CURR BIOL, V11, P1656, DOI 10.1016/S0960-9822(01)00525-5; Goode BL, 1999, J CELL BIOL, V144, P83, DOI 10.1083/jcb.144.1.83; Goode BL, 2001, J CELL BIOL, V153, P627, DOI 10.1083/jcb.153.3.627; HAARER BK, 1990, J CELL BIOL, V110, P105, DOI 10.1083/jcb.110.1.105; Higgs HN, 1999, BIOCHEMISTRY-US, V38, P15212, DOI 10.1021/bi991843+; Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649; Holt MR, 2001, TRENDS CELL BIOL, V11, P38, DOI 10.1016/S0962-8924(00)01876-6; Hudson AM, 2002, J CELL BIOL, V156, P677, DOI 10.1083/jcb.200109065; LEE DJ, 2002, NATURE CELL BIOL, V4, pE29; Lu J, 2001, MOL BIOL CELL, V12, P1161, DOI 10.1091/mbc.12.4.1161; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; MACLEANFLETCHER S, 1980, CELL, V20, P329, DOI 10.1016/0092-8674(80)90619-4; Nakano K, 1999, MOL BIOL CELL, V10, P2481, DOI 10.1091/mbc.10.8.2481; Ozaki-Kuroda K, 2001, MOL CELL BIOL, V21, P827, DOI 10.1128/MCB.21.3.827-839.2001; Pantaloni D, 2000, NAT CELL BIOL, V2, P385, DOI 10.1038/35017011; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; POLLARD TD, 1984, BIOCHEMISTRY-US, V23, P6631, DOI 10.1021/bi00321a054; PRUYNE D, 2002, SCIENCE, DOI [DOI 10.1126/SCIENCE.1072309, 10.1126/science.295.5552.93, DOI 10.1126/SCIENCE.295.5552.93]; Sagot I, 2002, NAT CELL BIOL, V4, P42, DOI 10.1038/ncb719; SAMPATH P, 1991, BIOCHEMISTRY-US, V30, P1973, DOI 10.1021/bi00221a034; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Winter D, 1999, CURR BIOL, V9, P501, DOI 10.1016/S0960-9822(99)80218-8; Winter DC, 1999, P NATL ACAD SCI USA, V96, P7288, DOI 10.1073/pnas.96.13.7288; Wolven AK, 2000, J CELL BIOL, V150, P895, DOI 10.1083/jcb.150.4.895	30	379	386	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2002	4	8					626	631		10.1038/ncb834	http://dx.doi.org/10.1038/ncb834			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	579WK	12134165				2022-12-25	WOS:000177201100020
J	Palsson, B				Palsson, B			In silico biology through "omics"	NATURE BIOTECHNOLOGY			English	Editorial Material							ESCHERICHIA-COLI; IN-SILICO; METABOLIC CAPABILITIES; NETWORKS; GENOTYPE		Univ Calif San Diego, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Palsson, B (corresponding author), Univ Calif San Diego, La Jolla, CA 92093 USA.			Palsson, Bernhard/0000-0003-2357-6785				Bonarius HPJ, 1997, TRENDS BIOTECHNOL, V15, P308, DOI 10.1016/S0167-7799(97)01067-6; Covert MW, 2001, TRENDS BIOCHEM SCI, V26, P179, DOI 10.1016/S0968-0004(00)01754-0; Covert MW, 2001, J THEOR BIOL, V213, P73, DOI 10.1006/jtbi.2001.2405; COVERT MW, 2002, IN PRESS J BIOL CHEM, V277; Edwards JS, 2000, P NATL ACAD SCI USA, V97, P5528, DOI 10.1073/pnas.97.10.5528; Edwards JS, 1999, J BIOL CHEM, V274, P17410, DOI 10.1074/jbc.274.25.17410; Edwards JS, 2001, NAT BIOTECHNOL, V19, P125, DOI 10.1038/84379; Fiehn O, 2000, NAT BIOTECHNOL, V18, P1157, DOI 10.1038/81137; MAJEWSKI RA, 1990, BIOTECHNOL BIOENG, V35, P732, DOI 10.1002/bit.260350711; Palsson B, 2000, NAT BIOTECHNOL, V18, P1147, DOI 10.1038/81125; Pilpel Y, 2001, NAT GENET, V29, P153, DOI 10.1038/ng724; Pramanik J, 1997, BIOTECHNOL BIOENG, V56, P398, DOI 10.1002/(SICI)1097-0290(19971120)56:4<398::AID-BIT6>3.0.CO;2-J; Price ND, 2002, GENOME RES, V12, P760, DOI 10.1101/gr.218002; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Salgado H, 2001, NUCLEIC ACIDS RES, V29, P72, DOI 10.1093/nar/29.1.72; Sauer U, 2001, Adv Biochem Eng Biotechnol, V73, P129; SCHILLING CH, 2002, IN PRESS J BACTERIOL, V101; Selkov E, 1998, NUCLEIC ACIDS RES, V26, P43, DOI 10.1093/nar/26.1.43; VARMA A, 1993, J THEOR BIOL, V165, P477, DOI 10.1006/jtbi.1993.1202; Wyrick JJ, 2002, CURR OPIN GENET DEV, V12, P130, DOI 10.1016/S0959-437X(02)00277-0; Yeung MKS, 2002, P NATL ACAD SCI USA, V99, P6163, DOI 10.1073/pnas.092576199	21	65	69	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2002	20	7					649	650		10.1038/nbt0702-649	http://dx.doi.org/10.1038/nbt0702-649			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	567QC	12089538				2022-12-25	WOS:000176494800007
J	McLysaght, A; Hokamp, K; Wolfe, KH				McLysaght, A; Hokamp, K; Wolfe, KH			Extensive genomic duplication during early chordate evolution	NATURE GENETICS			English	Article							VERTEBRATE EVOLUTION; LARGE-SCALE; GENE FAMILIES; ANCIENT; HYPOTHESIS; SEQUENCE; CHROMOSOMES; POLYPLOIDS; RECEPTOR; HISTORY	Opinions on the hypothesis(1) that ancient genome duplications contributed to the vertebrate genome range from strong skepticism(2-4) to strong credence(5-7). Previous studies concentrated on small numbers of gene families or chromosomal regions that might not have been representative of the whole genome(4,5), or used subjective methods to identify paralogous genes and regions(5,8). Here we report a systematic and objective analysis of the draft human genome sequence to identify paralogous chromosomal regions (paralogons) formed during chordate evolution and to estimate the ages of duplicate genes. We found that the human genome contains many more paralogons than would be expected by chance. Molecular clock analysis of all protein families in humans that have orthologs in the fly and nematode indicated that a burst of gene duplication activity took place in the period 350-650 Myr ago and that many of the duplicate genes formed at this time are located within paralogons. Our results support the contention that many of the gene families in vertebrates were formed or expanded by large- scale DNA duplications in an early chordate. Considering the incompleteness of the sequence data and the antiquity of the event, the results are compatible with at least one round of polyploidy.	Univ Dublin, Trinity Coll, Smurfit Inst, Dept Genet, Dublin 2, Ireland	Trinity College Dublin	Wolfe, KH (corresponding author), Univ Dublin, Trinity Coll, Smurfit Inst, Dept Genet, Dublin 2, Ireland.	khwolfe@tcd.ie	Wolfe, Kenneth H/B-4653-2009; Hokamp, Karsten/C-5534-2009	McLysaght, Aoife/0000-0003-2552-6220; Hokamp, Karsten/0000-0001-7464-2370; Wolfe, Kenneth/0000-0003-4992-4979				Flajnik MF, 2001, IMMUNITY, V15, P351, DOI 10.1016/S1074-7613(01)00198-4; Friedman R, 2001, GENOME RES, V11, P1842, DOI 10.1101/gr.200601; Gu X, 2002, GENOME RES, V12, P1, DOI 10.1101/gr.214402; Gu X, 2002, NAT GENET, V31, P205, DOI 10.1038/ng902; Gu X, 1997, MOL BIOL EVOL, V14, P1106, DOI 10.1093/oxfordjournals.molbev.a025720; HOLLAND PWH, 1994, DEVELOPMENT, P125; Hughes AL, 1998, MOL BIOL EVOL, V15, P854, DOI 10.1093/oxfordjournals.molbev.a025990; Hughes AL, 2001, GENOME RES, V11, P771, DOI 10.1101/gr.GR-1600R; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Koh YS, 1999, GENOMICS, V57, P289, DOI 10.1006/geno.1998.5683; Kojima S, 2000, FEBS LETT, V480, P142, DOI 10.1016/S0014-5793(00)01919-0; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Makalowski W, 2001, GENOME RES, V11, P667, DOI 10.1101/gr.188801; Martin A, 2001, MOL BIOL EVOL, V18, P89, DOI 10.1093/oxfordjournals.molbev.a003723; Miyata T, 2001, BIOESSAYS, V23, P1018, DOI 10.1002/bies.1147; Nei M, 2001, P NATL ACAD SCI USA, V98, P2497, DOI 10.1073/pnas.051611498; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Ohno S., 1970, EVOLUTION GENE DUPLI; Pebusque MJ, 1998, MOL BIOL EVOL, V15, P1145, DOI 10.1093/oxfordjournals.molbev.a026022; Popovici C, 2001, BIOCHEM BIOPH RES CO, V288, P362, DOI 10.1006/bbrc.2001.5794; RUDDLE FH, 1994, DEVELOPMENT, P155; Smith NGC, 1999, BIOESSAYS, V21, P697, DOI 10.1002/(SICI)1521-1878(199908)21:8<697::AID-BIES9>3.0.CO;2-X; Spring J, 1997, FEBS LETT, V400, P2, DOI 10.1016/S0014-5793(96)01351-8; TAKEZAKI N, 1995, MOL BIOL EVOL, V12, P823; Thornton JW, 2001, P NATL ACAD SCI USA, V98, P5671, DOI 10.1073/pnas.091553298; Tomsig JL, 2000, BIOCHEMISTRY-US, V39, P16163, DOI 10.1021/bi0019949; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wang DYC, 1999, P ROY SOC B-BIOL SCI, V266, P163, DOI 10.1098/rspb.1999.0617; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; Wolfe KH, 2001, NAT REV GENET, V2, P333, DOI 10.1038/35072009	31	409	420	0	40	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2002	31	2					200	204		10.1038/ng884	http://dx.doi.org/10.1038/ng884			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	557HR	12032567				2022-12-25	WOS:000175903500019
J	Ryoo, HD; Bergmann, A; Gonen, H; Ciechanover, A; Steller, H				Ryoo, HD; Bergmann, A; Gonen, H; Ciechanover, A; Steller, H			Regulation of Drosophila IAP1 degradation and apoptosis by reaper and ubcD1	NATURE CELL BIOLOGY			English	Article							PROGRAMMED CELL-DEATH; UBIQUITIN-PROTEIN LIGASE; SERINE-PROTEASE; GENE-EXPRESSION; CASPASE DRONC; INHIBITOR; HID; IDENTIFICATION; SURVIVAL; PATHWAY	Cell death in higher organisms is negatively regulated by Inhibitor of Apoptosis Proteins (IAPs), which contain a ubiquitin ligase motif, but how ubiquitin-mediated protein degradation is regulated during apoptosis is poorly understood. Here, we report that Drosophila melanogaster IAP1 (DIAP1) auto-ubiquitination and degradation is actively regulated by Reaper (Rpr) and UBCD1. We show that Rpr, but not Hid (head involution defective), promotes significant DIAP1 degradation. Rpr-mediated DIAP1 degradation requires an intact DIAP1 RING domain. Among the mutations affecting ubiquitination, we found ubcD1, which suppresses rpr-induced apoptosis. UBCD1 and Rpr specifically bind to DIAP1 and stimulate DIAP1 auto-ubiquitination in vitro. Our results identify a novel function of Rpr in stimulating DIAP1 auto-ubiquitination through UBCD1, thereby promoting its degradation.	Rockefeller Univ, Howard Hughes Med Inst, Strang Lab Canc Res, New York, NY 10021 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Technion Israel Inst Technol, Fac Med, Dept Biochem, IL-31096 Haifa, Israel	Howard Hughes Medical Institute; Rockefeller University; University of Texas System; UTMD Anderson Cancer Center; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Steller, H (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Strang Lab Canc Res, Box 252,1230 York Ave, New York, NY 10021 USA.	steller@mail.rockefeller.edu	Ciechanover, Aaron J/C-9166-2017		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060124] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM60124] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baehrecke EH, 2000, CELL DEATH DIFFER, V7, P1057, DOI 10.1038/sj.cdd.4400753; Baker NE, 2001, CELL, V104, P699, DOI 10.1016/S0092-8674(02)06076-2; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; BLAIR SS, 1993, DEVELOPMENT, V119, P339; BRAND AH, 1993, DEVELOPMENT, V118, P401; Calleja M, 1996, SCIENCE, V274, P252, DOI 10.1126/science.274.5285.252; Cenci G, 1997, GENE DEV, V11, P863, DOI 10.1101/gad.11.7.863; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; COHEN B, 1993, DEVELOPMENT, V117, P597; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; FISCHERVIZE JA, 1992, DEVELOPMENT, V116, P985; Gaumer S, 2000, CELL DEATH DIFFER, V7, P804, DOI 10.1038/sj.cdd.4400714; Goyal L, 2001, CELL, V104, P805, DOI 10.1016/S0092-8674(01)00276-8; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HAYS R, NATURE CELL BIOL, DOI DOI 10.1038/NCB704; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Holley CL, 2002, NAT CELL BIOL, V4, P439, DOI 10.1038/ncb798; Huang HK, 2000, J BIOL CHEM, V275, P26661; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jiang CA, 2000, MOL CELL, V5, P445, DOI 10.1016/S1097-2765(00)80439-6; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kanuka H, 1999, MOL CELL, V4, P757, DOI 10.1016/S1097-2765(00)80386-X; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; Lee CY, 2000, MOL CELL, V6, P433, DOI 10.1016/S1097-2765(00)00042-3; Lisi S, 2000, GENETICS, V154, P669; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Matuschewski K, 1996, J BIOL CHEM, V271, P2789, DOI 10.1074/jbc.271.5.2789; Meier P, 2000, EMBO J, V19, P598, DOI 10.1093/emboj/19.4.598; Neufeld TP, 1998, GENETICS, V148, P277; Quinn LM, 2000, J BIOL CHEM, V275, P40416, DOI 10.1074/jbc.M002935200; Rodriguez A, 1999, NAT CELL BIOL, V1, P272, DOI 10.1038/12984; SAVILLE KJ, 1993, P NATL ACAD SCI USA, V90, P8842, DOI 10.1073/pnas.90.19.8842; Spradling AC, 1999, GENETICS, V153, P135; Srinivasan A, 1998, CELL DEATH DIFFER, V5, P1004, DOI 10.1038/sj.cdd.4400449; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Tamm I, 2000, CLIN CANCER RES, V6, P1796; TREIER M, 1992, EMBO J, V11, P367, DOI 10.1002/j.1460-2075.1992.tb05059.x; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; WILSON P, NATURE CELL BIOL, DOI DOI 10.1038/NCB700; WING, NATURE CELL BIOL, DOI DOI 10.1038/NCB800; Wu JW, 2001, MOL CELL, V8, P95, DOI 10.1016/S1097-2765(01)00282-9; XU T, 1993, DEVELOPMENT, V117, P1223; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; YOO, NATURE CELL BIOL, DOI DOI 10.1038/NCB793; Zhou L, 1997, P NATL ACAD SCI USA, V94, P5131, DOI 10.1073/pnas.94.10.5131	53	229	232	3	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2002	4	6					432	438		10.1038/ncb795	http://dx.doi.org/10.1038/ncb795			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	558NN	12021769				2022-12-25	WOS:000175973600013
J	Nagase, T; Uozumi, N; Ishii, S; Kita, Y; Yamamoto, H; Ohga, E; Ouchi, Y; Shimizu, T				Nagase, T; Uozumi, N; Ishii, S; Kita, Y; Yamamoto, H; Ohga, E; Ouchi, Y; Shimizu, T			A pivotal role of cytosolic phospholipase A(2) in bleomycin-induced pulmonary fibrosis	NATURE MEDICINE			English	Article							PLATELET-ACTIVATING-FACTOR; FACTOR-RECEPTOR; TRANSGENIC MICE; MOLECULAR-CLONING; AIRWAY HYPERRESPONSIVENESS; ARACHIDONIC-ACID; LEUKOTRIENE B-4; LUNG INJURY; EXPRESSION; ENDOTOXIN	Pulmonary fibrosis is an interstitial disorder of the lung parenchyma whose mechanism is poorly understood. Potential mechanisms include the infiltration of inflammatory cells to the lungs and the generation of pro-inflammatory mediators. In particular, idiopathic pulmonary fibrosis is a progressive and fatal form of the disorder characterized by alveolar inflammation, fibroblast proliferation and collagen deposition. Here, we investigated the role of cytosolic phospholipase A(2) (cPLA(2)) in pulmonary fibrosis using cPLA(2)-null mutant mice, as cPLA(2) is a key enzyme in the generation of pro-inflammatory eicosanoids. Disruption of the gene encoding cPLA(2) (Pla2g4a) attenuated IPF and inflammation induced by bleomycin administration. Bleomycin-induced overproduction of thromboxanes and leukotrienes in lung was significantly reduced in cPLA(2)-null mice. Our data suggest that cPLA(2) has an important role in the pathogenesis of pulmonary fibrosis. The inhibition of cPLA(2)-initiated pathways might provide a novel therapeutic approach to pulmonary fibrosis, for which no pharmaceutical agents are currently available.	Univ Tokyo, Grad Sch Med, Dept Geriatr Med, Tokyo, Japan; Univ Tokyo, Grad Sch Med, Dept Biochem & Mol Biol, Tokyo, Japan; Japan Sci & Technol Corp, CREST, Tokyo, Japan	University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST)	Nagase, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Geriatr Med, Tokyo, Japan.	takahide-tky@umin.ac.jp	Uozumi, Nobuyuki/AAG-3252-2019	Yamamoto, Hiroshi/0000-0001-8907-3166				*AM THOR SOC, 2000, AM J RESP CRIT CARE, V161, P646, DOI DOI 10.1164/AJRCCM.161.2.ATS3-00; BITO H, 1994, EUR J BIOCHEM, V221, P211, DOI 10.1111/j.1432-1033.1994.tb18731.x; CHAO W, 1993, BIOCHEM J, V292, P617, DOI 10.1042/bj2920617; Chiang N, 1999, J CLIN INVEST, V104, P309, DOI 10.1172/JCI7016; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DAHLEN SE, 1981, P NATL ACAD SCI-BIOL, V78, P3887, DOI 10.1073/pnas.78.6.3887; Eitzman DT, 1996, J CLIN INVEST, V97, P232, DOI 10.1172/JCI118396; Hattori N, 2000, J CLIN INVEST, V106, P1341, DOI 10.1172/JCI10531; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; Ishii S, 2000, PROG LIPID RES, V39, P41, DOI 10.1016/S0163-7827(99)00016-8; Ishii S, 1998, J EXP MED, V187, P1779, DOI 10.1084/jem.187.11.1779; Ishii S, 1996, BIOCHEM J, V314, P671, DOI 10.1042/bj3140671; Ishii S, 1997, EMBO J, V16, P133, DOI 10.1093/emboj/16.1.133; Izumi T, 1995, BBA-LIPID LIPID MET, V1259, P317, DOI 10.1016/0005-2760(95)00171-9; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; KUNZ D, 1992, J BIOL CHEM, V267, P9101; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LOEHRER PJ, 1995, J CLIN ONCOL, V13, P470, DOI 10.1200/JCO.1995.13.2.470; Lynch KR, 1999, NATURE, V399, P789; MOSELEY PL, 1986, J CLIN INVEST, V78, P1150, DOI 10.1172/JCI112695; Nagase T, 1999, J CLIN INVEST, V104, P1071, DOI 10.1172/JCI7727; Nagase T, 2000, NAT IMMUNOL, V1, P42, DOI 10.1038/76897; Nagase T, 1997, AM J RESP CRIT CARE, V156, P1621, DOI 10.1164/ajrccm.156.5.9703016; Nagase T, 2002, AM J RESP CRIT CARE, V165, P200, DOI 10.1164/ajrccm.165.2.2106131; Nagase T, 1997, J APPL PHYSIOL, V83, P46, DOI 10.1152/jappl.1997.83.1.46; Nagase T, 1998, AM J RESP CRIT CARE, V157, P560, DOI 10.1164/ajrccm.157.2.9706009; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; SCHEULE RK, 1992, AM J PHYSIOL, V262, pL386, DOI 10.1152/ajplung.1992.262.4.L386; SHARP JD, 1991, J BIOL CHEM, V266, P14850; Shindou H, 2000, BIOCHEM BIOPH RES CO, V271, P812, DOI 10.1006/bbrc.2000.2723; SUGIMOTO T, 1992, BIOCHEM BIOPH RES CO, V189, P617, DOI 10.1016/0006-291X(92)92245-S; Tran PL, 1997, J CLIN INVEST, V99, P608, DOI 10.1172/JCI119203; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; Wilborn J, 1996, J CLIN INVEST, V97, P1827, DOI 10.1172/JCI118612; YE RD, 1991, BIOCHEM BIOPH RES CO, V180, P105, DOI 10.1016/S0006-291X(05)81261-6; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	39	128	131	1	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2002	8	5					480	484		10.1038/nm0502-480	http://dx.doi.org/10.1038/nm0502-480			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	547ZW	11984592				2022-12-25	WOS:000175336800033
J	Pendas, AM; Zhou, ZJ; Cadinanos, J; Freije, JMP; Wang, JM; Hultenby, K; Astudillo, A; Wernerson, A; Rodriguez, F; Tryggvason, K; Lopez-Otin, C				Pendas, AM; Zhou, ZJ; Cadinanos, J; Freije, JMP; Wang, JM; Hultenby, K; Astudillo, A; Wernerson, A; Rodriguez, F; Tryggvason, K; Lopez-Otin, C			Defective prelamin A processing and muscular and adipocyte alterations in Zmpste24 metalloproteinase-deficient mice	NATURE GENETICS			English	Article							ENCODING LAMIN A/C; NUCLEAR LAMINA; DYSTROPHY; MATURATION; PROTEINS; DISEASE; PROTEOLYSIS; MUTATIONS; HEART; GENE	The mouse ortholog of human FACE-1, Zmpste24, is a multi-spanning membrane protein widely distributed in mammalian tissues(1,2) and structurally related to Afc1p/ste24p, a yeast metalloproteinase involved in the maturation of fungal pheromones(3). Disruption of the gene Zmpste24 caused severe growth retardation and premature death in homozygous-null mice. Histopathological analysis of the mutant mice revealed several abnormalities, including dilated cardiomyopathy, muscular dystrophy and lipodystrophy. These alterations are similar to those developed by mice deficient in A-type lamin(4), a major component of the nuclear lamina(5), and phenocopy most defects observed in humans with diverse congenital laminopathies(6-8). In agreement with this finding, Zmpste24-null mice are defective in the proteolytic processing of prelamin A. This deficiency in prelamin A maturation leads to the generation of abnormalities in nuclear architecture that probably underlie the many phenotypes observed in both mice and humans with mutations in the lamin A gene. These results indicate that prelamin A is a specific substrate for Zmpste24 and demonstrate the usefulness of genetic approaches for identifying the in vivo substrates of proteolytic enzymes.	Univ Oviedo, Inst Univ Oncol, Fac Med, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain; Karolinska Inst, Dept Med Biochem & Biophys, Div Matrix Biol, Stockholm, Sweden; Huddinge Univ Hosp, Karolinska Inst, Dept Pathol, S-14186 Huddinge, Sweden; Univ Oviedo, Hosp Cent Asturias, Serv Anat Patol, E-33080 Oviedo, Spain	University of Oviedo; Instituto Universitario de Oncologia de Asturias; Karolinska Institutet; Karolinska Institutet; Central University Hospital Asturias; University of Oviedo	Lopez-Otin, C (corresponding author), Univ Oviedo, Inst Univ Oncol, Fac Med, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain.		Freije, José M.P./A-6535-2008; López-Otín, Carlos/AAB-2106-2020; Pendas, Alberto M/L-1017-2014; zhou, zhongjun/D-4818-2012; Zhou, Zhongjun/C-4476-2009	Freije, José M.P./0000-0002-4688-8266; López-Otín, Carlos/0000-0001-6964-1904; Zhou, Zhongjun/0000-0001-7092-8128; Astudillo Gonzalez, Maria Aurora/0000-0001-8947-8809; Wernerson, Annika/0000-0003-2792-0010; Cadinanos, Juan/0000-0001-7561-7759; Pendas, Alberto M/0000-0001-9264-3721				Bonne G, 1999, NAT GENET, V21, P285, DOI 10.1038/6799; Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; Cohen M, 2001, TRENDS BIOCHEM SCI, V26, P41, DOI 10.1016/S0968-0004(00)01727-8; Fatkin D, 1999, NEW ENGL J MED, V341, P1715, DOI 10.1056/NEJM199912023412302; FISHER DZ, 1986, P NATL ACAD SCI USA, V83, P6450, DOI 10.1073/pnas.83.17.6450; Freije JMP, 1999, GENOMICS, V58, P270, DOI 10.1006/geno.1999.5834; Hogan B, 1994, MANIPULATING MOUSE E; Leung GK, 2001, J BIOL CHEM, V276, P29051, DOI 10.1074/jbc.M102908200; Manilal S, 1999, HUM MOL GENET, V8, P353, DOI 10.1093/hmg/8.2.353; Morris GE, 1999, HUM MOL GENET, V8, P1847, DOI 10.1093/hmg/8.10.1847; Palmero I, 2001, METHOD ENZYMOL, V333, P247; Shackleton S, 2000, NAT GENET, V24, P153, DOI 10.1038/72807; SINENSKY M, 1994, J CELL SCI, V107, P61; Sullivan T, 1999, J CELL BIOL, V147, P913, DOI 10.1083/jcb.147.5.913; Tam A, 1998, J CELL BIOL, V142, P635, DOI 10.1083/jcb.142.3.635; WEBER K, 1989, FEBS LETT, V257, P411, DOI 10.1016/0014-5793(89)81584-4; Wilson KL, 2001, CELL, V104, P647, DOI 10.1016/S0092-8674(02)01452-6; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	18	411	435	0	22	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2002	31	1					94	99		10.1038/ng871	http://dx.doi.org/10.1038/ng871			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	547ZF	11923874	Bronze			2022-12-25	WOS:000175362500022
J	Stromme, P; Mangelsdorf, ME; Shaw, MA; Lower, KM; Lewis, SME; Bruyere, H; Lutcherath, V; Gedeon, AK; Wallace, RH; Scheffer, IE; Turner, G; Partington, M; Frints, SGM; Fryns, JP; Sutherland, GR; Mulley, JC; Gecz, J				Stromme, P; Mangelsdorf, ME; Shaw, MA; Lower, KM; Lewis, SME; Bruyere, H; Lutcherath, V; Gedeon, AK; Wallace, RH; Scheffer, IE; Turner, G; Partington, M; Frints, SGM; Fryns, JP; Sutherland, GR; Mulley, JC; Gecz, J			Mutations in the human ortholog of Aristaless cause X-linked mental retardation and epilepsy	NATURE GENETICS			English	Article							OCULOPHARYNGEAL MUSCULAR-DYSTROPHY; INFANTILE SPASMS; WEST-SYNDROME; SPECTRUM; LINKAGE; DISEASE	Mental retardation and epilepsy often occur together. They are both heterogeneous conditions with acquired and genetic causes. Where causes are primarily genetic, major advances have been made in unraveling their molecular basis. The human X chromosome alone is estimated to harbor more than 100 genes that, when mutated, cause mental retardation(1). At least eight autosomal genes involved in idiopathic epilepsy have been identified(2), and many more have been implicated in conditions where epilepsy is a feature. We have identified mutations in an X chromosome-linked, Aristaless-related, homeobox gene (ARX), in nine families with mental retardation (syndromic and nonspecific), various forms of epilepsy, including infantile spasms and myoclonic seizures, and dystonia. Two recurrent mutations, present in seven families, result in expansion of polyalanine tracts of the ARX protein. These probably cause protein aggregation, similar to other polyalanine(3) and polyglutamine(4) disorders. In addition, we have identified a missense mutation within the ARX homeodomain and a truncation mutation. Thus, it would seem that mutation of ARX is a major contributor to X-linked mental retardation and epilepsy.	Womens & Childrens Hosp, Dept Cytogenet & Mol Genet, Adelaide, SA 5006, Australia; Univ Adelaide, Dept Paediat, Adelaide, SA, Australia; Childrens & Womens Hlth Ctr British Columbia, Dept Med Genet, Vancouver, BC, Canada; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; Cent Hosp Rogaland, Dept Paediat, Stavanger, Norway; Univ Melbourne, Austin & Repatriat Med Ctr, Monash Med Ctr, Dept Med Neurol, Melbourne, Vic, Australia; Royal Childrens Hosp, Melbourne, Vic, Australia; Hunter Genet, Waratah, NSW, Australia; Univ Newcastle, Waratah, NSW, Australia; Univ Louvain Hosp VIB, Human Genome Lab, Louvain, Belgium; Univ Hosp, Dept Human Genet, B-3000 Louvain, Belgium; Univ Hosp, Dept Clin Genet, B-3000 Louvain, Belgium; Univ Adelaide, Dept Mol Biosci, Adelaide, SA, Australia	Womens & Childrens Hospital Australia; University of Adelaide; BC Women's Hospital & Health Centre; University of British Columbia; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Monash University; University of Melbourne; Royal Children's Hospital Melbourne; University of Newcastle; Flanders Institute for Biotechnology (VIB); Universite Catholique Louvain; Universite Catholique Louvain Hospital; University of Adelaide	Gecz, J (corresponding author), Womens & Childrens Hosp, Dept Cytogenet & Mol Genet, Adelaide, SA 5006, Australia.	jozef.gecz@adelaide.edu.au	Gecz, Jozef/X-3469-2019; Scheffer, Ingrid E/G-1668-2013; Sutherland, Grant Robert/D-2606-2012; Mangelsdorf, Marie E/A-2318-2013; Gedeon, Agi/G-7890-2011	Gecz, Jozef/0000-0002-7884-6861; Scheffer, Ingrid E/0000-0002-2311-2174; Mangelsdorf, Marie E/0000-0002-7855-7701; Lower, Karen/0000-0003-2196-5234; Wallace, Robyn/0000-0001-6141-3317; Lewis, Suzanne/0000-0002-6300-5381; Frints, Suzanna G.M./0000-0002-5027-8364				Banerjee-Basu S, 2001, NUCLEIC ACIDS RES, V29, P3258, DOI 10.1093/nar/29.15.3258; Berkovic SF, 2001, EPILEPSIA, V42, P16, DOI 10.1046/j.1528-1157.2001.0420s5016.x; Brais B, 1998, NAT GENET, V18, P164, DOI 10.1038/ng0298-164; Brown LY, 2001, HUM MOL GENET, V10, P791, DOI 10.1093/hmg/10.8.791; Brown SA, 1998, NAT GENET, V20, P180, DOI 10.1038/2484; Bruyere H, 1999, CLIN GENET, V55, P173, DOI 10.1034/j.1399-0004.1999.550305.x; Calado A, 2000, HUM MOL GENET, V9, P2321, DOI 10.1093/oxfordjournals.hmg.a018924; Chelly J, 2001, NAT REV GENET, V2, P669, DOI 10.1038/35088558; Claes S, 1997, ANN NEUROL, V42, P360, DOI 10.1002/ana.410420313; Crisponi L, 2001, NAT GENET, V27, P159, DOI 10.1038/84781; FEINBERG AP, 1977, DEV MED CHILD NEUROL, V19, P524; FRINTS SGM, IN PRESS AM J MED GE; Gall H, 1999, HAUTARZT, V50, P186, DOI 10.1007/s001050050887; Galliot B, 2000, TRENDS GENET, V16, P1, DOI 10.1016/S0168-9525(99)01888-0; Goodman FR, 2000, AM J HUM GENET, V67, P197, DOI 10.1086/302961; Gusella JF, 2000, NAT REV NEUROSCI, V1, P109, DOI 10.1038/35039051; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; Hill ME, 2001, BRAIN, V124, P522, DOI 10.1093/brain/124.3.522; Meijlink F, 1999, INT J DEV BIOL, V43, P651; Miura H, 1997, MECH DEVELOP, V65, P99, DOI 10.1016/S0925-4773(97)00062-2; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Muragaki Y, 1996, SCIENCE, V272, P548, DOI 10.1126/science.272.5261.548; Ohira R, 2000, AM J HUM GENET, V67, P169; PARTINGTON MW, 1988, AM J MED GENET, V30, P251, DOI 10.1002/ajmg.1320300127; SCHEFFER IE, IN PRESS NEUROLOGY; Stromme P, 1999, J MED GENET, V36, P374; VIGEVANO F, 1993, EPILEPSIA, V34, P743, DOI 10.1111/j.1528-1157.1993.tb00456.x; Wilson DS, 1996, P NATL ACAD SCI USA, V93, P6886, DOI 10.1073/pnas.93.14.6886; Wong M, 2001, PEDIATR NEUROL, V24, P89, DOI 10.1016/S0887-8994(00)00238-1	29	352	361	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	APR	2002	30	4					441	445		10.1038/ng862	http://dx.doi.org/10.1038/ng862			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	536BZ	11889467				2022-12-25	WOS:000174682000025
J	Berg, JS; Cheney, RE				Berg, JS; Cheney, RE			Myosin-X is an unconventional myosin that undergoes intrafilopodial motility	NATURE CELL BIOLOGY			English	Article							NEURONAL GROWTH CONES; NERVE GROWTH; ACTIN; FILOPODIA; TRANSPORT; CELLS; RETRACTION; EXTENSION; DYNAMICS; DOMAIN	Filopodia are thin cellular protrusions that are important in cell motility and neuronal growth cone guidance. The actin filaments that make up the core of a filopodium undergo continuous retrograde flow towards the cell body(1,2). Surface receptors or particles can couple to this retrograde flow(3,4) and can also move forward to the tips of filopodia(4,5), although the molecular basis of forward transport is unknown. We report here that myosin-X (Myo10 or M10), the founding member of a novel class of myosins(6), localizes to the tips of filopodia and undergoes striking forward and rearward movements within filopodia, which we term intrafilopodial motility. The movements of the GFP-M10 puncta correspond to forward and rearward movements of phase-dense granules along the filopodia. Finally, overexpressing full-length M10 (but not truncated forms of M10) causes an increase in the number and length of filopodia, indicating that M10 or its cargo may function in filopodial dynamics. The localization and movements of M10 strongly suggest that it functions as a motor for intrafilopodial motility.	Univ N Carolina, Curriculum Neurobiol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Berg, JS (corresponding author), Univ N Carolina, Curriculum Neurobiol, Chapel Hill, NC 27599 USA.			Berg, Jonathan/0000-0003-2360-2664; Cheney, Richard/0000-0001-6565-7888	NIDCD NIH HHS [R29 DC003299, DC03299] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R29DC003299, R01DC003299] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Berg JS, 2000, J CELL SCI, V113, P3439; Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; Borisy GG, 2000, CURR OPIN CELL BIOL, V12, P104, DOI 10.1016/S0955-0674(99)00063-0; Bryant PJ, 1999, CURR BIOL, V9, pR655, DOI 10.1016/S0960-9822(99)80416-3; CHEN LC, 1999, MOL BIOL CELL S, V10, pA152; Cox D, 2000, MOL BIOL CELL, V11, p375A; Felsenfeld DP, 1996, NATURE, V383, P438, DOI 10.1038/383438a0; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; Grabham PW, 2000, J CELL SCI, V113, P3003; Homma K, 2001, J BIOL CHEM, V276, P34348, DOI 10.1074/jbc.M104785200; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; Lanier LM, 1999, NEURON, V22, P313, DOI 10.1016/S0896-6273(00)81092-2; Lee WL, 2000, J CELL BIOL, V151, P789, DOI 10.1083/jcb.151.4.789; Lin CH, 1996, NEURON, V16, P769, DOI 10.1016/S0896-6273(00)80097-5; Mallavarapu A, 1999, J CELL BIOL, V146, P1097, DOI 10.1083/jcb.146.5.1097; MITCHISON T, 1988, NEURON, V1, P761, DOI 10.1016/0896-6273(88)90124-9; MITCHISON TJ, 1992, CELL MOTIL CYTOSKEL, V22, P135, DOI 10.1002/cm.970220207; Moores SL, 1996, P NATL ACAD SCI USA, V93, P443, DOI 10.1073/pnas.93.1.443; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Ramirez-Weber FA, 1999, CELL, V97, P599, DOI 10.1016/S0092-8674(00)80771-0; Rosenbaum JL, 1999, J CELL BIOL, V144, P385, DOI 10.1083/jcb.144.3.385; SHEETZ MP, 1990, CELL, V61, P231, DOI 10.1016/0092-8674(90)90804-N; SHEETZ MP, 1992, CELL MOTIL CYTOSKEL, V22, P160, DOI 10.1002/cm.970220303; Tang NY, 2001, CURR BIOL, V11, P1131, DOI 10.1016/S0960-9822(01)00320-7; Titus MA, 1999, CURR BIOL, V9, P1297, DOI 10.1016/S0960-9822(00)80051-2; Tsakraklides V, 1999, J CELL SCI, V112, P2853; Tuxworth RI, 2001, CURR BIOL, V11, P318, DOI 10.1016/S0960-9822(01)00097-5; Wei QZ, 2000, MOL BIOL CELL, V11, P3617, DOI 10.1091/mbc.11.10.3617; WU DY, 1993, J CELL BIOL, V123, P653, DOI 10.1083/jcb.123.3.653; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885	30	250	256	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAR	2002	4	3					246	250		10.1038/ncb762	http://dx.doi.org/10.1038/ncb762			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	527VR	11854753				2022-12-25	WOS:000174209100018
J	Falck, J; Petrini, JHJ; Williams, BR; Lukas, J; Bartek, J				Falck, J; Petrini, JHJ; Williams, BR; Lukas, J; Bartek, J			The DNA damage-dependent intra-S phase checkpoint is regulated by parallel pathways	NATURE GENETICS			English	Article							ATAXIA-TELANGIECTASIA; CHROMATIN ASSOCIATION; POLYMERASE-ALPHA; CELL-CYCLE; ATM; REPLICATION; COMPLEX; PHOSPHORYLATION; INITIATION; PROTEIN	To preserve genetic integrity, mammalian cells exposed to ionizing radiation activate the ATM kinase, which initiates a complex response including the S-phase checkpoint pathways to delay DNA replication(1,2). Defects in ATM or its substrates Nbs1 or Chk2 (ref. 3), the Nbs1-interacting Mre11 protein(4), or the Chk2-regulated Cdc25A-Cdk2 cascade all cause radio-resistant DNA synthesis (RDS)(5,6). It is unknown, however, whether these proteins operate in a common signaling cascade. Here we show that experimental blockade of either the Nbs1-Mre11 function or the Chk2-triggered events leads to a partial RDS phenotype in human cells. In contrast, concomitant interference with Nbs1-Mre11 and the Chk2-Cdc25A-Cdk2 pathways entirely abolishes inhibition of DNA synthesis induced by ionizing radiation, resulting in complete RDS analogous to that caused by defective ATM. In addition, Cdk2-dependent loading of Cdc45 onto replication origins, a prerequisite for recruitment of DNA polymerase(7,8), was prevented upon irradiation of normal or Nbs1/Mre11-defective cells but not cells with defective ATM. We conclude that in response to ionizing radiation, phosphorylations of Nbs1 and Chk2 by ATM trigger two parallel branches of the DNA damage-dependent S-phase checkpoint that cooperate by inhibiting distinct steps of DNA replication.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark; Univ Wisconsin, Sch Med, Madison, WI 53706 USA	Danish Cancer Society; University of Wisconsin System; University of Wisconsin Madison	Bartek, J (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandblvd 49, DK-2100 Copenhagen, Denmark.		Bartek, Jiri/G-5870-2014	Lukas, Jiri/0000-0001-9087-506X				Aparicio OM, 1999, P NATL ACAD SCI USA, V96, P9130, DOI 10.1073/pnas.96.16.9130; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Carr AM, 2000, SCIENCE, V287, P1765, DOI 10.1126/science.287.5459.1765; Costanzo V, 2000, MOL CELL, V6, P649, DOI 10.1016/S1097-2765(00)00063-0; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kukimoto I, 1999, EUR J BIOCHEM, V265, P936, DOI 10.1046/j.1432-1327.1999.00791.x; Larner JM, 1999, NUCLEIC ACIDS RES, V27, P803, DOI 10.1093/nar/27.3.803; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Maser RS, 2001, MOL CELL BIOL, V21, P6006, DOI 10.1128/MCB.21.17.6006-6016.2001; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sorensen CS, 2000, MOL CELL BIOL, V20, P7613, DOI 10.1128/MCB.20.20.7613-7623.2000; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Takisawa H, 2000, CURR OPIN CELL BIOL, V12, P690, DOI 10.1016/S0955-0674(00)00153-8; Tao L, 2000, J CELL BIOCHEM, V78, P442, DOI 10.1002/1097-4644(20000901)78:3<442::AID-JCB9>3.0.CO;2-1; Trivedi A, 1998, DNA CELL BIOL, V17, P885, DOI 10.1089/dna.1998.17.885; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000	30	301	308	1	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2002	30	3					290	294		10.1038/ng845	http://dx.doi.org/10.1038/ng845			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	526YP	11850621				2022-12-25	WOS:000174157600013
J	Maison, C; Bailly, D; Peters, AHFM; Quivy, JP; Roche, D; Taddei, A; Lachner, M; Jenuwein, T; Almouzni, G				Maison, C; Bailly, D; Peters, AHFM; Quivy, JP; Roche, D; Taddei, A; Lachner, M; Jenuwein, T; Almouzni, G			Higher-order structure in pericentric heterochromatin involves a distinct pattern of histone modification and an RNA component	NATURE GENETICS			English	Article							CHROMATIN; PROTEINS	Post-translational modification of histone tails is thought to modulate higher-order chromatin structure(1-3). Combinations of modifications including acetylation, phosphorylation and methylation have been proposed to provide marks recognized by specific proteins(4). This is exemplified, in both mammalian cells and fission yeast, by transcriptionally silent constitutive pericentric heterochromatin. Such heterochromatin contains histones that are generally hypoacetylated(5) and methylated by Suv39h methyltransferases at lysine 9 of histone H3 (H3- K9)(6,7). Each of these modification states has been implicated in the maintenance of HP1 protein-binding at pericentric heterochromatin, in transcriptional silencing and in centromere function(7-12). In particular, H3-K9 methylation is thought to provide a marking system for the establishment and maintenance of stably repressed regions and heterochromatin subdomains(3,13). To address the question of how these two types of modifications, as well as other unidentified parameters, function to maintain pericentric heterochromatin, we used a combination of histone deacetylase inhibitors, RNAse treatments and an antibody raised against methylated branched H3- K9 peptides. Our results show that both H3- K9 acetylation and methylation can occur on independent sets of H3 molecules in pericentric heterochromatin. In addition, we identify an RNA-and histone modification-dependent structure that brings methylated H3- K9 tails together in a specific configuration required for the accumulation of HP1 proteins in these domains.	Inst Curie, Res Sect, CNRS, UMR 218, F-75248 Paris 05, France; Vienna Bioctr, Res Inst Mol Pathol, A-1030 Vienna, Austria	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Almouzni, G (corresponding author), Inst Curie, Res Sect, CNRS, UMR 218, 26 Rue Ulm, F-75248 Paris 05, France.		Almouzni, Genevieve/ABG-1029-2021; taddei, angela/AAL-2413-2021	Almouzni, Genevieve/0000-0001-5570-0723; taddei, angela/0000-0002-3217-0739; quivy, jean-pierre/0000-0001-6557-7204; Peters, Antoine/0000-0002-0311-1887				Aagaard L, 1999, EMBO J, V18, P1923, DOI 10.1093/emboj/18.7.1923; Akhtar A, 2000, NATURE, V407, P405, DOI 10.1038/35030169; Avner P, 2001, NAT REV GENET, V2, P59, DOI 10.1038/35047580; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Ekwall K, 1997, CELL, V91, P1021, DOI 10.1016/S0092-8674(00)80492-4; Gasser SM, 2001, CELL, V104, P639, DOI 10.1016/S0092-8674(01)00259-8; Jacobs SA, 2001, EMBO J, V20, P5232, DOI 10.1093/emboj/20.18.5232; Jaeger L, 1997, CURR OPIN STRUC BIOL, V7, P324, DOI 10.1016/S0959-440X(97)80047-4; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; JEPPESEN P, 1992, CHROMOSOMA, V101, P322, DOI 10.1007/BF00346011; Jones DO, 2000, BIOESSAYS, V22, P124, DOI 10.1002/(SICI)1521-1878(200002)22:2&lt;124::AID-BIES4&gt;3.0.CO;2-E; KIPLING D, 1994, CHROMOSOMA, V103, P46, DOI 10.1007/BF00364725; KORNBERG RD, 1989, METHOD ENZYMOL, V170, P3; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lyon MF, 1999, CURR BIOL, V9, pR235, DOI 10.1016/S0960-9822(99)80151-1; Martini E, 1998, J CELL BIOL, V143, P563, DOI 10.1083/jcb.143.3.563; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nielsen AL, 2001, MOL CELL, V7, P729, DOI 10.1016/S1097-2765(01)00218-0; ONeill LP, 1996, METHOD ENZYMOL, V274, P189; Peters AHFM, 2002, NAT GENET, V30, P77, DOI 10.1038/ng789; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Taddei A, 2001, NAT CELL BIOL, V3, P114, DOI 10.1038/35055010; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	30	542	555	0	20	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2002	30	3					329	334		10.1038/ng843	http://dx.doi.org/10.1038/ng843			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	526YP	11850619				2022-12-25	WOS:000174157600021
J	Koishi, R; Ando, Y; Ono, M; Shimamura, M; Yasumo, H; Fujiwara, T; Horikoshi, H; Furukawa, H				Koishi, R; Ando, Y; Ono, M; Shimamura, M; Yasumo, H; Fujiwara, T; Horikoshi, H; Furukawa, H			Angptl3 regulates lipid metabolism in mice	NATURE GENETICS			English	Article							TRIGLYCERIDE-TRANSFER-PROTEIN; DEPENDENT DIABETES-MELLITUS; LIPOPROTEIN METABOLISM; APOLIPOPROTEIN-B; TANGIER-DISEASE; IN-VIVO; GENE; MUTATIONS; IDENTIFICATION; ABETALIPOPROTEINEMIA	The KK obese mouse is moderately obese and has abnormally high levels of plasma insulin (hyperinsulinemia), glucose (hyperglycemia) and lipids (hyperlipidemia). In one strain (KK/San), we observed abnormally low plasma lipid levels (hypolipidemia). This mutant phenotype is inherited recessively as a mendelian trait. Here we report the mapping of the hypolipidemia (hypo locus to the middle of chromosome 4 and positional cloning of the autosomal recessive mutation responsible for the hypolipidemia. The hypl locus encodes a unique angiopoietin-like lipoprotein modulator, which we named Allm1. it is identical to angiopoietin-like protein 3, encoded by Angptl3, and has a highly conserved counterpart in humans. Overexpression of Angpl3 or intravenous injection of the purified protein in KK/San mice elicited an increase in circulating plasma lipid levels. This increase was also observed in C57BL/6J normal mice. Taken together, these data suggest that Angptl3 regulates lipid metabolism in animals.	Sankyo Co Ltd, Biomed Res Labs, Shinagawa Ku, Tokyo 1408710, Japan; Sankyo Co Ltd, Med Safety Res Labs, Shizuoka 4370065, Japan; Sankyo Co Ltd, Pharmacol & Mol Biol Res Labs, Shinagawa Ku, Tokyo 1408710, Japan; Sankyo Pharma Res Inst, La Jolla, CA 92037 USA	Daiichi Sankyo Company Limited; Daiichi Sankyo Company Limited; Daiichi Sankyo Company Limited	Koishi, R (corresponding author), Sankyo Co Ltd, Biomed Res Labs, Shinagawa Ku, 1-2-58 Hiromachi, Tokyo 1408710, Japan.	koishi@shina.sankyo.co.jp		Ando, Yukio/0000-0001-7115-9105				Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; BRUNZELL JD, 1976, METABOLISM, V25, P313, DOI 10.1016/0026-0495(76)90089-5; Conklin D, 1999, GENOMICS, V62, P477, DOI 10.1006/geno.1999.6041; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; FARESE RV, 1992, J INTERN MED, V231, P643, DOI 10.1111/j.1365-2796.1992.tb01253.x; Fujiwara T, 1998, GENOMICS, V54, P155, DOI 10.1006/geno.1998.5554; GENEST JJ, 1992, CIRCULATION, V85, P2025, DOI 10.1161/01.CIR.85.6.2025; GOLDSTEIN JL, 1973, J CLIN INVEST, V52, P1544, DOI 10.1172/JCI107332; GREENFIELD M, 1980, DIABETOLOGIA, V18, P441; GREENFIELD MS, 1982, ARCH INTERN MED, V142, P1498, DOI 10.1001/archinte.142.8.1498; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; Kondo K., 1957, B EXP ANIM, V6, P107; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; NAKAMURA M, 1962, P JPN ACAD, V38, P348, DOI 10.2183/pjab1945.38.348; Nakamura M, 1967, Diabetologia, V3, P212, DOI 10.1007/BF01222198; NARCISI TME, 1995, AM J HUM GENET, V57, P1298; Parhofer KG, 1996, J LIPID RES, V37, P844; Procopio WN, 1999, J BIOL CHEM, V274, P30196, DOI 10.1074/jbc.274.42.30196; PURCELLHUYNH DA, 1995, J CLIN INVEST, V96, P1845, DOI 10.1172/JCI118230; REAVEN GM, 1987, METABOLISM, V36, P1, DOI 10.1016/0026-0495(87)90193-4; Rehberg EF, 1996, J BIOL CHEM, V271, P29945, DOI 10.1074/jbc.271.47.29945; Reue K, 1996, J LIPID RES, V37, P1387; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SCHAEFER EJ, 1994, ATHEROSCLEROSIS, V108, pS41, DOI 10.1016/0021-9150(94)90152-X; SCHONFELD G, 1995, ANNU REV NUTR, V15, P23, DOI 10.1146/annurev.nu.15.070195.000323; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SHIRAKI T, 1993, DIABETES FRONTIER, V4, P641; SHOULDERS CC, 1993, HUM MOL GENET, V2, P2109, DOI 10.1093/hmg/2.12.2109; STANBURY JB, 1983, METABOLIC BASIS INHE, P589; TALMUD PJ, 1994, J LIPID RES, V35, P468; Valenzuela DM, 1999, P NATL ACAD SCI USA, V96, P1904, DOI 10.1073/pnas.96.5.1904; Welch CL, 1996, J LIPID RES, V37, P1406; WELTY FK, 1995, CIRCULATION, V92, P2036, DOI 10.1161/01.CIR.92.8.2036; WETTERAU JR, 1992, SCIENCE, V258, P999	38	306	351	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2002	30	2					151	157		10.1038/ng814	http://dx.doi.org/10.1038/ng814			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	519CY	11788823				2022-12-25	WOS:000173708700014
J	Paulson, M; Press, C; Smith, E; Tanese, N; Levy, DE				Paulson, M; Press, C; Smith, E; Tanese, N; Levy, DE			IFN-Stimulated transcription through a TBP-free acetyltransferase complex escapes viral shutoff	NATURE CELL BIOLOGY			English	Article							ALPHA-INTERFERON; ACETYLASE COMPLEX; BINDING PROTEIN; RETINOIC ACID; IN-VIVO; GENE; POLIOVIRUS; TRANSLATION; INHIBITION; INITIATION	Type I interferon (IFN) stimulates transcription through a heteromeric transcription factor that contains tyrosine-phosphorylated STAT2. We show that STAT2 recruits histone acetyltransferases (HAT) through its transactivation domain, resulting in localized transient acetylation of histones. GCN5, but not p300/CBP or PCAF, is required for STAT2 function. However, GCN5 function is impaired by the transcriptional antagonist, adenovirus E1A oncoprotein. The TFIID component TAF(II)30 potentiates STAT2 function, but TAF(II)28 or the HAT activity of TAF(II)250 do not, and transcriptional induction can proceed independently of the TATA-binding protein, TBP. Moreover, IFN-stimulated transcription was resistant to poliovirus-targeted degradation by TBP, and continued despite host-cell transcriptional shutoff during poliovirus infection. We conclude that a non-classical transcriptional mechanism combats an anticellular action of poliovirus, through a TBP-free TAF-containing complex and GCN5.	NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; NYU, Sch Med, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA	New York University; New York University; New York University	Levy, DE (corresponding author), NYU, Sch Med, Dept Pathol, 550 1st Ave, New York, NY 10016 USA.		Levy, David/GPS-4945-2022; Levy, David/AAG-6202-2019	Levy, David/0000-0002-7320-7788; Tanese, Naoko/0000-0002-1946-3211	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028900, P01AI048204, R01AI046503] Funding Source: NIH RePORTER; NIAID NIH HHS [AI48204, AI28900, AI46503] Funding Source: Medline; NIGMS NIH HHS [5T32GM03708] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Baker E, 1997, Chromosome Res, V5, P572; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Beresford GW, 2001, NAT IMMUNOL, V2, P652, DOI 10.1038/89810; Bluyssen Hans A. R., 1996, Cytokine and Growth Factor Reviews, V7, P11, DOI 10.1016/1359-6101(96)00005-6; BLUYSSEN HAR, 1994, GENOMICS, V24, P137, DOI 10.1006/geno.1994.1591; Brand M, 1999, SCIENCE, V286, P2151, DOI 10.1126/science.286.5447.2151; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; CLARK ME, 1993, MOL CELL BIOL, V13, P1232, DOI 10.1128/MCB.13.2.1232; CRAWFORD N, 1981, CELL, V27, P555, DOI 10.1016/0092-8674(81)90397-4; DANI C, 1984, EUR J BIOCHEM, V145, P299, DOI 10.1111/j.1432-1033.1984.tb08552.x; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Dunphy EL, 2000, MOL CELL BIOL, V20, P1134, DOI 10.1128/MCB.20.4.1134-1139.2000; FLOROS J, 1978, CELL BIOL INT REP, P259; Guo JJ, 2000, EMBO J, V19, P6891, DOI 10.1093/emboj/19.24.6891; Gustin KE, 2001, EMBO J, V20, P240, DOI 10.1093/emboj/20.1.240; Holcik M, 2000, TRENDS GENET, V16, P469, DOI 10.1016/S0168-9525(00)02106-5; Iizuka N, 1995, CURR TOP MICROBIOL, V203, P155; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; LARNER AC, 1986, J BIOL CHEM, V261, P453; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; LEVY D, 1986, P NATL ACAD SCI USA, V83, P8929, DOI 10.1073/pnas.83.23.8929; Levy DE, 1999, CELL MOL LIFE SCI, V55, P1559, DOI 10.1007/s000180050395; Levy DE, 2001, CYTOKINE GROWTH F R, V12, P143, DOI 10.1016/S1359-6101(00)00027-7; Liu CJ, 2000, MOL CELL BIOL, V20, P7024, DOI 10.1128/MCB.20.18.7024-7036.2000; Look DC, 1998, IMMUNITY, V9, P871, DOI 10.1016/S1074-7613(00)80652-4; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Martinez E, 1998, J BIOL CHEM, V273, P23781, DOI 10.1074/jbc.273.37.23781; Mengus G, 1997, GENE DEV, V11, P1381, DOI 10.1101/gad.11.11.1381; MIRKOVITCH J, 1992, MOL CELL BIOL, V12, P1; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Park C, 1999, NUCLEIC ACIDS RES, V27, P4191, DOI 10.1093/nar/27.21.4191; Park C, 2000, IMMUNITY, V13, P795, DOI 10.1016/S1074-7613(00)00077-7; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; Qureshi SA, 1996, MOL CELL BIOL, V16, P288; Raval A, 2001, MOL CELL, V7, P105, DOI 10.1016/S1097-2765(01)00159-9; REICH N, 1988, J VIROL, V62, P114, DOI 10.1128/JVI.62.1.114-119.1988; RHATTACHARYA S, 1996, NATURE, V383, P344; SADOVSKY Y, 1995, MOL CELL BIOL, V15, P1554; SONENBERG N, 1989, BIOESSAYS, V11, P128, DOI 10.1002/bies.950110504; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; Xu WT, 1998, MOL CELL BIOL, V18, P5659, DOI 10.1128/MCB.18.10.5659; Xu WT, 2000, NAT GENET, V26, P229, DOI 10.1038/79973; Yalamanchili P, 1996, J VIROL, V70, P2922, DOI 10.1128/JVI.70.5.2922-2929.1996; Yu M, 1997, P NATL ACAD SCI USA, V94, P7406, DOI 10.1073/pnas.94.14.7406; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	50	89	91	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	FEB	2002	4	2					140	147		10.1038/ncb747	http://dx.doi.org/10.1038/ncb747			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	520RJ	11802163				2022-12-25	WOS:000173794600018
J	Reynolds, LE; Wyder, L; Lively, JC; Taverna, D; Robinson, SD; Huang, XZ; Sheppard, D; Hynes, O; Hodivala-Dilke, KM				Reynolds, LE; Wyder, L; Lively, JC; Taverna, D; Robinson, SD; Huang, XZ; Sheppard, D; Hynes, O; Hodivala-Dilke, KM			Enhanced pathological angiogenesis in mice lacking beta(3) integrin or beta(3) and beta(5) integrins	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; RECONSTITUTED BASEMENT-MEMBRANE; ALPHA-V INTEGRINS; TUMOR-GROWTH; PROGENITOR CELLS; POSTNATAL NEOVASCULARIZATION; BLOOD-VESSELS; ALPHA(V)BETA(3); INHIBITION; CANCER	Inhibition of a alpha (v)beta (3) or alpha (v)beta (5) integrin function has been reported to suppress neovascularization and tumor growth, suggesting that these integrins are critical modulators of angiogenesis. Here we report that mice lacking beta (3) integrins or both beta (3) and beta (5) integrins not only support tumorigenesis, but have enhanced tumor growth as well: Moreover, the tumors in these integrin-deficient mice display enhanced angiogenesis, strongly suggesting that neither beta (3) nor beta (5) integrins are essential for neovascularization. We, also observed that angiogenic responses to hypoxia and vascular endothelial growth factor (VEGF) are augmented significantly in the absence of beta (3) integrins. We found no evidence that the expression or functions of other integrins were altered as a consequence of the beta (3) deficiency, but we did observe elevated levels of VEGF receptor-2 (also called Flk-1) in beta (3)-null endothelial cells. These data indicate that a alpha (v)beta (3) and alpha (v)beta (5) integrins are not essential for vascular development or pathological angiogenesis and highlight the need for further evaluation of the mechanisms of action of alpha (v)-integrin antagonists in anti-angiogenic therapeutics.	St Thomas Hosp, Cell Adhes & Dis Lab, Richard Dimbleby Dept, Imperial Canc Res Fund, London, England; MIT, Ctr Canc Res, Howard Hughes Med Inst, Cambridge, MA 02139 USA; Univ Calif San Francisco, Lung Biol Ctr, San Francisco, CA 94143 USA	Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); University of California System; University of California San Francisco	Hodivala-Dilke, KM (corresponding author), St Thomas Hosp, Cell Adhes & Dis Lab, Richard Dimbleby Dept, Imperial Canc Res Fund, London, England.	k.hodivala-dilke@icrf.icnet.uk	taverna, daniela/J-8358-2016	taverna, daniela/0000-0002-6365-527X; Robinson, Stephen/0000-0002-6606-7588; Hodivala-Dilke, Kairbaan/0000-0002-2859-749X	NCI NIH HHS [R01CA17007] Funding Source: Medline; NHLBI NIH HHS [P01HL66105, R01 HL53949, R01 HL64353, P01HL41484] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA017007] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053949, P01HL041484, R01HL064353, P01HL066105] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5; Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; Bader BL, 1998, CELL, V95, P507, DOI 10.1016/S0092-8674(00)81618-9; BLYSTONE SD, 1994, J CELL BIOL, V127, P1129, DOI 10.1083/jcb.127.4.1129; Brekken RA, 2000, CANCER RES, V60, P5117; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CHEN YP, 1994, J BIOL CHEM, V269, P18307; DiazGonzalez F, 1996, MOL BIOL CELL, V7, P1939, DOI 10.1091/mbc.7.12.1939; DRAKE CJ, 1995, J CELL SCI, V108, P2655; Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764; Gutheil JC, 2000, CLIN CANCER RES, V6, P3056; Hammes HP, 1996, NAT MED, V2, P820; Hodivala-Dilke KM, 1999, J CLIN INVEST, V103, P229, DOI 10.1172/JCI5487; Huang XZ, 2000, MOL CELL BIOL, V20, P755, DOI 10.1128/MCB.20.3.755-759.2000; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; Hynes RO, 1999, BRAZ J MED BIOL RES, V32, P501, DOI 10.1590/S0100-879X1999000500002; Isner JM, 1999, J CLIN INVEST, V103, P1231, DOI 10.1172/JCI6889; Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397; Kim S, 2000, J BIOL CHEM, V275, P33920, DOI 10.1074/jbc.M003668200; Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5; Kroon ME, 2000, BLOOD, V96, P2775; Kumar CC, 2001, CANCER RES, V61, P2232; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; MARCANTONIO EE, 1988, J CELL BIOL, V106, P1765, DOI 10.1083/jcb.106.5.1765; NICOSIA RF, 1990, IN VITRO CELL DEV B, V26, P119; PASSANITI A, 1992, LAB INVEST, V67, P519; Pierce EA, 1997, ARCH OPHTHALMOL-CHIC, V115, P427; Saaristo A, 2000, ONCOGENE, V19, P6122, DOI 10.1038/sj.onc.1203969; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Stone EM, 1996, INVEST OPHTH VIS SCI, V37, P3100; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Taverna D, 2001, CANCER RES, V61, P5255; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3	45	511	538	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2002	8	1					27	34		10.1038/nm0102-27	http://dx.doi.org/10.1038/nm0102-27			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	507XQ	11786903				2022-12-25	WOS:000173056900027
J	Ayte, J; Schweitzer, C; Zarzov, P; Nurse, P; DeCaprio, JA				Ayte, J; Schweitzer, C; Zarzov, P; Nurse, P; DeCaprio, JA			Feedback regulation of the MBF transcription factor by cyclin Cig2	NATURE CELL BIOLOGY			English	Article							YEAST SCHIZOSACCHAROMYCES-POMBE; DNA-SYNTHESIS GENES; B-TYPE CYCLINS; FISSION YEAST; CELL-CYCLE; S-PHASE; SACCHAROMYCES-CEREVISIAE; NEGATIVE REGULATION; PROTEIN; START	The Mlu1-binding factor (MBF) from the fission yeast Schizosaccharomyces pombe contains the proteins Res1p and Res2p and binds to the Mlu1 cell-cycle box (MCB) element in DNA, activating the transcription of genes required for S phase. We report here that the cell-cycle-regulated expression of the cyclin cig2 gene is dependent on MBF Deletion of MCB elements in the cig2 promoter perturbed the expression not only of cig2 but also of other MBF-dependent genes, indicating that Cig2p could regulate MBF activity. Cig2p can bind to Res2p, promote the phosphorylation of Res1p and inhibit MBF-dependent gene transcription. Cig2p thus forms an autoregulating feedback-inhibition loop with MBF which is important for normal regulation of the cell cycle.	Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Imperial Canc Res Fund, London WC2A 3PX, England; Univ Pompeu Fabra, Dept Ciencias Expt & Salut, Cell Signalling Unit, Barcelona 08003, Spain	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Cancer Research UK; Pompeu Fabra University	DeCaprio, JA (corresponding author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	james_decaprio@dfci.harvard.edu	Ayte, Jose/L-5217-2014	Ayte, Jose/0000-0002-6354-0536				Adams PD, 1996, MOL CELL BIOL, V16, P6623; Alfa C, 1993, EXPT FISSION YEAST L; AYTE J, 1995, MOL CELL BIOL, V15, P2589; Ayte J, 1997, MOL CELL BIOL, V17, P6246, DOI 10.1128/MCB.17.11.6246; Baum B, 1997, EMBO J, V16, P4676, DOI 10.1093/emboj/16.15.4676; Baum B, 1998, EMBO J, V17, P5689, DOI 10.1093/emboj/17.19.5689; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BUENO A, 1991, CELL, V66, P149, DOI 10.1016/0092-8674(91)90147-Q; BUENO A, 1993, MOL CELL BIOL, V13, P2286, DOI 10.1128/MCB.13.4.2286; CALIGIURI M, 1993, CELL, V72, P607, DOI 10.1016/0092-8674(93)90079-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONNOLLY T, 1994, MOL CELL BIOL, V14, P768, DOI 10.1128/MCB.14.1.768; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; FISHER D, 1995, SEMIN CELL BIOL, V6, P73, DOI 10.1016/1043-4682(95)90003-9; HOFMANN JFX, 1994, EMBO J, V13, P425, DOI 10.1002/j.1460-2075.1994.tb06277.x; Jallepalli PV, 1997, GENE DEV, V11, P2767, DOI 10.1101/gad.11.21.2767; Jallepalli PV, 1998, P NATL ACAD SCI USA, V95, P8159, DOI 10.1073/pnas.95.14.8159; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; Kominami K, 1997, GENE DEV, V11, P1548, DOI 10.1101/gad.11.12.1548; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; Lopez-Girona A, 1998, MOL BIOL CELL, V9, P63, DOI 10.1091/mbc.9.1.63; LOWNDES NF, 1992, NATURE, V357, P505, DOI 10.1038/357505a0; LOWNDES NF, 1992, NATURE, V355, P449, DOI 10.1038/355449a0; Martin-Castellanos C, 1996, EMBO J, V15, P839, DOI 10.1002/j.1460-2075.1996.tb00419.x; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MCINERNY C, 1993, NUCLEIC ACIDS RES, V23, P4761; MIYAMOTO M, 1994, EMBO J, V13, P1873, DOI 10.1002/j.1460-2075.1994.tb06456.x; Mondesert O, 1996, MOL CELL BIOL, V16, P1527; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; NAKASHIMA N, 1995, EMBO J, V14, P4794, DOI 10.1002/j.1460-2075.1995.tb00161.x; NISHIDA T, 1997, CORNEA FUNDAMENTALS, V1, P3; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; OBARAISHIHARA T, 1994, EMBO J, V13, P1863, DOI 10.1002/j.1460-2075.1994.tb06455.x; REYMOND A, 1993, EMBO J, V12, P4325, DOI 10.1002/j.1460-2075.1993.tb06117.x; RICHARDSON H, 1992, GENE DEV, V6, P2021, DOI 10.1101/gad.6.11.2021; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SARABIA MJF, 1993, MOL GEN GENET, V238, P241, DOI 10.1007/BF00279553; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SIDOROVA J, 1993, MOL CELL BIOL, V13, P1069, DOI 10.1128/MCB.13.2.1069; SIMANIS V, 1989, J CELL SCI, V92, P51; Sturm S, 1996, MOL BIOL CELL, V7, P1967, DOI 10.1091/mbc.7.12.1967; TANAKA K, 1992, EMBO J, V11, P4923, DOI 10.1002/j.1460-2075.1992.tb05599.x; ZHU Y, 1994, GENE DEV, V8, P885, DOI 10.1101/gad.8.8.885; Zhu Y, 1997, EMBO J, V16, P1023, DOI 10.1093/emboj/16.5.1023	48	40	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2001	3	12					1043	1050		10.1038/ncb1201-1043	http://dx.doi.org/10.1038/ncb1201-1043			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	500AM	11781565				2022-12-25	WOS:000172603700009
J	Merrifield, CJ; Feldman, ME; Wan, L; Almers, W				Merrifield, CJ; Feldman, ME; Wan, L; Almers, W			Imaging actin and dynamin recruitment during invagination of single clathrin-coated pits	NATURE CELL BIOLOGY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; GREEN FLUORESCENT PROTEIN; BINDING-PROTEIN; FUSION PROTEIN; CYTOSKELETON; VESICLES; RINGS	As a final step in endocytosis, clathrin-coated pits must separate from the plasma membrane and move into the cytosol as a coated vesicle. Because these events involve minute movements that conventional light microscopy cannot resolve, they have not been observed directly and their dynamics remain unexplored. Here, we used evanescent field (EF) microscopy to observe single clathrin-coated pits or vesicles as they draw inwards from the plasma membrane and finally lose their coats. This inward movement occurred immediately after a brief burst of dynamin recruitment and was accompanied by transient actin assembly. Therefore, dynamin may provide the trigger and actin may provide the force for movement into the cytosol.	Oregon Hlth & Sci Univ, Vollum Inst L474, Portland, OR 97201 USA	Oregon Health & Science University	Almers, W (corresponding author), Oregon Hlth & Sci Univ, Vollum Inst L474, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	almersw@ohsu.edu			NIDDK NIH HHS [DK44239] Funding Source: Medline; NIMH NIH HHS [MH60600] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044239] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH060600] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Aizawa H, 1997, CELL STRUCT FUNCT, V22, P335, DOI 10.1247/csf.22.335; Axelrod D, 2001, TRAFFIC, V2, P764, DOI 10.1034/j.1600-0854.2001.21104.x; Ballestrem C, 1998, J CELL SCI, V111, P1649; Burack MA, 2000, NEURON, V26, P465, DOI 10.1016/S0896-6273(00)81178-2; Buss F, 2001, EMBO J, V20, P3676, DOI 10.1093/emboj/20.14.3676; Choidas A, 1998, EUR J CELL BIOL, V77, P81, DOI 10.1016/S0171-9335(98)80075-7; Damke H, 2001, MOL BIOL CELL, V12, P2578, DOI 10.1091/mbc.12.9.2578; Engqvist-Goldstein AEY, 2001, J CELL BIOL, V154, P1209, DOI 10.1083/jcb.200106089; Frischknecht F, 1999, CURR BIOL, V9, P89, DOI 10.1016/S0960-9822(99)80020-7; Fujimoto LM, 2000, TRAFFIC, V1, P161, DOI 10.1034/j.1600-0854.2000.010208.x; Gaidarov I, 1999, NAT CELL BIOL, V1, P1, DOI 10.1038/8971; GOTTLIEB TA, 1993, J CELL BIOL, V120, P695, DOI 10.1083/jcb.120.3.695; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Kessels MM, 2001, J CELL BIOL, V153, P351, DOI 10.1083/jcb.153.2.351; Lang T, 1997, NEURON, V18, P857, DOI 10.1016/S0896-6273(00)80325-6; Lee E, 2002, P NATL ACAD SCI USA, V99, P161, DOI 10.1073/pnas.012607799; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; Merrifield CJ, 1999, NAT CELL BIOL, V1, P72, DOI 10.1038/9048; Nesterov A, 1999, EMBO J, V18, P2489, DOI 10.1093/emboj/18.9.2489; Ochoa GC, 2000, J CELL BIOL, V150, P377, DOI 10.1083/jcb.150.2.377; Orth JD, 2002, P NATL ACAD SCI USA, V99, P167, DOI 10.1073/pnas.012607899; OSHIRO S, 1993, J BIOL CHEM, V268, P21586; Qualmann B, 1999, MOL BIOL CELL, V10, P501, DOI 10.1091/mbc.10.2.501; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Sever S, 2000, TRAFFIC, V1, P385, DOI 10.1034/j.1600-0854.2000.010503.x; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; SMYTHE E, 1992, J CELL BIOL, V119, P1163, DOI 10.1083/jcb.119.5.1163; Steyer JA, 2001, NAT REV MOL CELL BIO, V2, P268, DOI 10.1038/35067069; Stowell MHB, 1999, NAT CELL BIOL, V1, P27, DOI 10.1038/8997; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Taunton J, 2000, J CELL BIOL, V148, P519, DOI 10.1083/jcb.148.3.519; WILLINGHAM MC, 1983, P NATL ACAD SCI-BIOL, V80, P5617, DOI 10.1073/pnas.80.18.5617; Witke W, 1998, EMBO J, V17, P967, DOI 10.1093/emboj/17.4.967	39	541	552	2	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2002	4	9					691	698		10.1038/ncb837	http://dx.doi.org/10.1038/ncb837			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	589WE	12198492				2022-12-25	WOS:000177783900013
J	Fukata, Y; Itoh, TJ; Kimura, T; Menager, C; Nishimura, T; Shiromizu, T; Watanabe, H; Inagaki, N; Iwamatsu, A; Hotani, H; Kaibuchi, K				Fukata, Y; Itoh, TJ; Kimura, T; Menager, C; Nishimura, T; Shiromizu, T; Watanabe, H; Inagaki, N; Iwamatsu, A; Hotani, H; Kaibuchi, K			CRMP-2 binds to tubulin heterodimers to promote microtubule assembly	NATURE CELL BIOLOGY			English	Article							RESPONSE MEDIATOR PROTEIN-2; CULTURED HIPPOCAMPAL-NEURONS; GROWTH CONE COLLAPSE; DYNAMIC INSTABILITY; GROWING AXONS; TAU-PROTEIN; POLARITY; IDENTIFICATION; UNC-33; BRAIN	Regulated increase in the formation of microtubule arrays is thought to be important for axonal growth. Collapsin response mediator protein-2 (CRMP-2) is a mammalian homologue of UNC-33, mutations in which result in abnormal axon termination. We recently demonstrated that CRMP-2 is critical for axonal differentiation. Here, we identify two activities of CRMP-2: tubulin-heterodimer binding and the promotion of microtubule assembly. CRMP-2 bound tubulin dimers with higher affinity than it bound microtubules. Association of CRMP-2 with microtubules was enhanced by tubulin polymerization in the presence of CRMP-2. The binding property of CRMP-2 with tubulin was apparently distinct from that of Tau, which preferentially bound microtubules. In neurons, overexpression of CRMP-2 promoted axonal growth and branching. A mutant of CRMP-2, lacking the region responsible for microtubule assembly, inhibited axonal growth and branching in a dominant-negative manner. Taken together, our results suggest that CRMP-2 regulates axonal growth and branching as a partner of the tubulin heterodimer, in a different fashion from traditional MAPs.	Nagoya Univ, Grad Sch Med, Dept Cell Pharmacol, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Sci, Div Biol Sci, Nagoya, Aichi 4648602, Japan; Nara Inst Sci & Technol, Div Signal Transduct, Ikoma 6300101, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Yokohama, Kanagawa 2360004, Japan	Nagoya University; Nagoya University; Nara Institute of Science & Technology; Kirin Brewery Company Limited	Kaibuchi, K (corresponding author), Nagoya Univ, Grad Sch Med, Dept Cell Pharmacol, 65 Tsurumai, Nagoya, Aichi 4668550, Japan.		Nishimura, Takashi/D-7672-2017; Nishimura, Takashi/AAQ-9299-2020	Nishimura, Takashi/0000-0002-6773-0302; Nishimura, Takashi/0000-0002-6773-0302; Fukata, Yuko/0000-0001-7724-8643; Inagaki, Naoyuki/0000-0002-2664-9196				AHMAD FJ, 1995, J CELL SCI, V108, P2761; Arimura N, 2000, J BIOL CHEM, V275, P23973, DOI 10.1074/jbc.M001032200; Baas PW, 1997, CURR OPIN CELL BIOL, V9, P29, DOI 10.1016/S0955-0674(97)80148-2; Baas PW, 1999, NEURON, V22, P23, DOI 10.1016/S0896-6273(00)80675-3; Black MM, 1996, J NEUROSCI, V16, P3601; BROWN A, 1992, J CELL BIOL, V119, P867, DOI 10.1083/jcb.119.4.867; BROWN A, 1993, J CELL SCI, V104, P339; Byk T, 1998, EUR J BIOCHEM, V254, P14, DOI 10.1046/j.1432-1327.1998.2540014.x; CRAIG AM, 1994, ANNU REV NEUROSCI, V17, P267, DOI 10.1146/annurev.ne.17.030194.001411; DETRICH HW, 1978, BIOCHEMISTRY-US, V17, P3900, DOI 10.1021/bi00612a002; DOTTI CG, 1988, J NEUROSCI, V8, P1454; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; Esch T, 1999, J NEUROSCI, V19, P6417; Gaetano C, 1997, J BIOL CHEM, V272, P12195, DOI 10.1074/jbc.272.18.12195; Gallo G, 1999, J NEUROSCI, V19, P3860; Garcia ML, 2001, CURR OPIN CELL BIOL, V13, P41, DOI 10.1016/S0955-0674(00)00172-1; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; GOSLIN K, 1989, J CELL BIOL, V108, P1507, DOI 10.1083/jcb.108.4.1507; Gu YJ, 2000, J BIOL CHEM, V275, P17917, DOI 10.1074/jbc.C000179200; Gu YJ, 2000, BIOCHEMISTRY-US, V39, P4267, DOI 10.1021/bi992323h; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; HORIO T, 1986, NATURE, V321, P605, DOI 10.1038/321605a0; Inagaki N, 2001, NAT NEUROSCI, V4, P781, DOI 10.1038/90476; Inatome R, 2000, J BIOL CHEM, V275, P27291; Itoh TJ, 1997, BIOCHEMISTRY-US, V36, P12574, DOI 10.1021/bi962606z; ITOH TJ, 1994, CELL STRUCT FUNCT, V19, P279, DOI 10.1247/csf.19.279; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; KANAI Y, 1995, NEURON, V14, P421, DOI 10.1016/0896-6273(95)90298-8; LEGER JG, 1994, J CELL SCI, V107, P3403; LUDUENA RF, 1977, J BIOL CHEM, V252, P7006; MINTURN JE, 1995, J NEUROSCI, V15, P6757; Nixon RA, 1998, CURR OPIN CELL BIOL, V10, P87, DOI 10.1016/S0955-0674(98)80090-2; Okabe S, 1989, CURR OPIN CELL BIOL, V1, P91, DOI 10.1016/S0955-0674(89)80043-2; PEDROTTI B, 1994, BIOCHEMISTRY-US, V33, P12463, DOI 10.1021/bi00207a013; Rochlin MW, 1996, J NEUROSCI, V16, P3236; Shah JV, 2002, CURR OPIN CELL BIOL, V14, P58, DOI 10.1016/S0955-0674(01)00294-0; Wang LH, 1997, J NEUROCHEM, V69, P2261; YU WQ, 1995, J NEUROSCI, V15, P6827; YU WQ, 1994, J NEUROSCI, V14, P2818; Yu WQ, 1996, J CELL BIOL, V133, P151, DOI 10.1083/jcb.133.1.151; YU WQ, 1994, J NEUROSCI, V14, P5872	43	602	625	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2002	4	8					583	591		10.1038/ncb825	http://dx.doi.org/10.1038/ncb825			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	579WK	12134159				2022-12-25	WOS:000177201100013
J	Hoffmann, K; Dreger, CK; Olins, AL; Olins, DE; Shultz, LD; Lucke, B; Karl, H; Kaps, R; Muller, D; Vaya, A; Aznar, J; Ware, RE; Cruz, NS; Lindner, TH; Herrmann, H; Reis, A; Sperling, K				Hoffmann, K; Dreger, CK; Olins, AL; Olins, DE; Shultz, LD; Lucke, B; Karl, H; Kaps, R; Muller, D; Vaya, A; Aznar, J; Ware, RE; Cruz, NS; Lindner, TH; Herrmann, H; Reis, A; Sperling, K			Mutations in the gene encoding the lamin B receptor produce an altered nuclear morphology in granulocytes (Pelger-Huet anomaly)	NATURE GENETICS			English	Article							DREIFUSS MUSCULAR-DYSTROPHY; ENVELOPE INNER MEMBRANE; INTEGRAL PROTEIN; PORE COMPLEXES; ROD DOMAIN; A/C; LBR; ORGANIZATION; SYSTEM; CELLS	Pelger-Huet anomaly (PHA; OMIM *169400) is an autosomal dominant disorder characterized by abnormal nuclear shape and chromatin organization in blood granulocytes. Affected individuals show hypolobulated neutrophil nuclei with coarse chromatin. Presumed homozygous individuals have ovoid neutrophil nuclei, as well as varying degrees of developmental delay, epilepsy and skeletal abnormalities(1-3). Homozygous off-spring in an extinct rabbit lineage showed severe chondrodystrophy, developmental anomalies and increased pre- and postnatal mortality(4,5). Here we show, by carrying out a genome-wide linkage scan, that PHA is linked to chromosome 1q41-43. We identified four splice-site, two frameshift and two nonsense mutations in LBR, encoding the lamin B receptor. The lamin B receptor (LBR), a member of the sterol reductase family(6), is evolutionarily conserved and integral to the inner nuclear membrane; it targets heterochromatin and lamins to the nuclear membrane(7,8). Lymphoblastoid cells from heterozygous individuals affected with PHA show reduced expression of the lamin B receptor, and cells homozygous with respect to PHA contain only trace amounts of it. We found that expression of the lamin B receptor affects neutrophil nuclear shape and chromatin distribution in a dose-dependent manner. Our findings have implications for understanding nuclear envelope-heterochromatin interactions, the pathogenesis of Pelger-like conditions in leukemia(9), infection(10) and toxic drug reactions(11), and the evolution of neutrophil nuclear shape(12).	Max Delbruck Ctr Mol Med, Gene Mapping Ctr, D-13125 Berlin, Germany; Humboldt Univ, Charite, HELIOS Klinikum, Franz Volhard Clin, Berlin, Germany; German Canc Res Ctr, D-6900 Heidelberg, Germany; Fdn Blood Res, Scarborough, ME 04074 USA; Bowdoin Coll, Brunswick, ME 04011 USA; Jackson Lab, Bar Harbor, ME 04609 USA; DRK, Inst Transfus Med, Chemnitz, Germany; Klinikum Chemnitz, Inst Med Genet, Chemnitz, Germany; La Fe Univ Hosp, Dept Clin Pathol, Valencia, Spain; Duke Univ, Dept Pediat, Med Ctr, Durham, NC 27706 USA; Hosp Infantil Estado Sonora, Hermosillo, Sonora, Mexico; Univ Wurzburg, Med Clin, Dept Nephrol, Wurzburg, Germany; Univ Erlangen Nurnberg, Inst Human Genet, D-8520 Erlangen, Germany; Humboldt Univ, Charite, Inst Human Genet, D-13353 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Franz-Volhard Clinical Research Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helios Kliniken; Helmholtz Association; German Cancer Research Center (DKFZ); Foundation for Blood Research (FBR); Bowdoin College; Jackson Laboratory; Chemnitz Clinic; Duke University; University of Wurzburg; University of Erlangen Nuremberg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Sperling, K (corresponding author), Max Delbruck Ctr Mol Med, Gene Mapping Ctr, Robert Rossle Str 10, D-13125 Berlin, Germany.		Reis, André/D-2309-2009	Reis, André/0000-0002-6301-6363				AZNAR J, 1981, ACTA HAEMATOL-BASEL, V66, P59, DOI 10.1159/000207095; BEGEMANN NH, 1952, ACTA HAEMATOL-BASEL, V7, P295, DOI 10.1159/000204063; Bonne G, 1999, NAT GENET, V21, P285, DOI 10.1038/6799; Fatkin D, 1999, NEW ENGL J MED, V341, P1715, DOI 10.1056/NEJM199912023412302; Fitzky BU, 1998, P NATL ACAD SCI USA, V95, P8181, DOI 10.1073/pnas.95.14.8181; GREEN MC, 1975, TRANSPLANTATION, V20, P172, DOI 10.1097/00007890-197508000-00014; HOGER TH, 1990, CHROMOSOMA, V99, P379, DOI 10.1007/BF01726689; Holmer L, 1998, GENOMICS, V54, P469, DOI 10.1006/geno.1998.5615; JOHANSSON EO, 1963, THESIS UPPSALA U; Juneja SK, 1996, BRIT J HAEMATOL, V93, P139, DOI 10.1046/j.1365-2141.1996.4701020.x; KARL H, 1967, THESIS HUMBOLDT U BE; LATIMER KS, 1988, VET PATHOL, V25, P325, DOI 10.1177/030098588802500416; LenzBohme B, 1997, J CELL BIOL, V137, P1001, DOI 10.1083/jcb.137.5.1001; Liu J, 2000, MOL BIOL CELL, V11, P3937, DOI 10.1091/mbc.11.11.3937; NACHTSHEIM H, 1950, J HERED, V41, P131, DOI 10.1093/oxfordjournals.jhered.a106108; Ognibene A, 1999, MUSCLE NERVE, V22, P864, DOI 10.1002/(SICI)1097-4598(199907)22:7<864::AID-MUS8>3.3.CO;2-7; Olins AL, 2001, EXP CELL RES, V268, P115, DOI 10.1006/excr.2001.5269; Sainty D, 2000, BLOOD, V96, P1287; Schirmer EC, 2001, J CELL BIOL, V153, P479, DOI 10.1083/jcb.153.3.479; SCHULER E, 1994, J BIOL CHEM, V269, P11312; Shackleton S, 2000, NAT GENET, V24, P153, DOI 10.1038/72807; SHENKENBERG TD, 1982, ARCH INTERN MED, V142, P153, DOI 10.1001/archinte.142.1.153; Siegert E, 1983, Kinderarztl Prax, V51, P164; Silve S, 1998, BBA-LIPID LIPID MET, V1392, P233, DOI 10.1016/S0005-2760(98)00041-1; SKENDZEL LP, 1962, AM J CLIN PATHOL, V37, P294; UNDRITZ E, 1939, SCHWEIZ MED WSCHR, V69, P1177; UNDRITZ E, 1943, FOLIA HAEMATOL, V67, P249; Vigouroux C, 2001, J CELL SCI, V114, P4459; YE Q, 1994, J BIOL CHEM, V269, P11306; Ye QA, 1997, J BIOL CHEM, V272, P14983, DOI 10.1074/jbc.272.23.14983	30	249	262	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2002	31	4					410	414		10.1038/ng925	http://dx.doi.org/10.1038/ng925			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	578XV	12118250				2022-12-25	WOS:000177147100018
J	Toma, DP; White, KP; Hirsch, J; Greenspan, RJ				Toma, DP; White, KP; Hirsch, J; Greenspan, RJ			Identification of genes involved in Drosophila melanogaster geotaxis, a complex behavioral trait	NATURE GENETICS			English	Article							MICROARRAY ANALYSIS; PROTEIN; EVOLUTION; PHOTORECEPTOR; CRYPTOCHROME; POPULATIONS; SELECTION; MUTATION; SYSTEMS; MUTANTS	Identifying the genes involved in polygenic traits has been difficult. In the 1950s and 1960s, laboratory selection experiments for extreme geotaxic behavior in fruit flies established for the first time that a complex behavioral trait has a genetic basis. But the specific genes responsible for the behavior have never been identified using this classical model. To identify the individual genes involved in geotaxic response, we used cDNA microarrays to identify candidate genes and assessed fly lines mutant in these genes for behavioral confirmation. We have thus determined the identities of several genes that contribute to the complex, polygenic behavior of geotaxis.	Inst Neurosci, San Diego, CA 92121 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; Univ Illinois, Dept Psychol, Urbana, IL 61801 USA; Univ Illinois, Dept Biol Anim, Urbana, IL 61801 USA	Yale University; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	White, KP (corresponding author), Inst Neurosci, 10640 John Jay Hopkins Dr, San Diego, CA 92121 USA.							CHOI KW, 1994, CELL, V78, P125, DOI 10.1016/0092-8674(94)90579-7; Claridge-Chang A, 2001, NEURON, V32, P657, DOI 10.1016/S0896-6273(01)00515-3; DOBZHANSKY T, 1972, PROC R SOC SER B-BIO, V180, P21, DOI 10.1098/rspb.1972.0003; DOBZHANSKY T, 1968, P ROY SOC LOND B BIO, V173, P191; DOBZHANSKY T, 1966, GENETICS, V55, P723; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; ERLENMEYER L, 1961, SCIENCE, V134, P1068, DOI 10.1126/science.134.3485.1068; ERLENMEYERKIMLI.L, 1962, J COMP PHYSIOL PSYCH, V55, P722, DOI 10.1037/h0042089; Greenspan RJ, 1997, CURR OPIN NEUROBIOL, V7, P805, DOI 10.1016/S0959-4388(97)80139-0; HIRSCH J, 1962, J COMP PHYSIOL PSYCH, V55, P732, DOI 10.1037/h0039714; HIRSCH J, 1961, SCIENCE, V134, P835, DOI 10.1126/science.134.3482.835; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; KUSSEL P, 1995, J CELL BIOL, V129, P1491, DOI 10.1083/jcb.129.6.1491; Lin YJ, 1998, SCIENCE, V282, P943, DOI 10.1126/science.282.5390.943; McDonald MJ, 2001, CELL, V107, P567, DOI 10.1016/S0092-8674(01)00545-1; MCMILLAN PA, 1992, BEHAV GENET, V22, P557, DOI 10.1007/BF01074308; Melzig J, 1998, J NEUROSCI, V18, P7160; Osborne KA, 1997, SCIENCE, V277, P834, DOI 10.1126/science.277.5327.834; Renn SCP, 1999, CELL, V99, P791, DOI 10.1016/S0092-8674(00)81676-1; RICKER JP, 1988, J COMP PSYCHOL, V102, P203, DOI 10.1037/0735-7036.102.3.203; RICKER JP, 1985, J COMP PSYCHOL, V99, P380, DOI 10.1037/0735-7036.99.4.380; Roch F, 1998, MOL GEN GENET, V257, P103, DOI 10.1007/PL00008620; Shaw PJ, 2000, SCIENCE, V287, P1834, DOI 10.1126/science.287.5459.1834; SONG W, 2001, DROS RES C, V42, P51; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Stoltenberg SF, 1996, J COMP PSYCHOL, V110, P252, DOI 10.1037/0735-7036.110.3.252; TOROK I, 1995, J CELL BIOL, V129, P1473, DOI 10.1083/jcb.129.6.1473; Tully T, 1996, P NATL ACAD SCI USA, V93, P13460, DOI 10.1073/pnas.93.24.13460; White KP, 2001, NAT REV GENET, V2, P528, DOI 10.1038/35080565; White KP, 1999, SCIENCE, V286, P2179, DOI 10.1126/science.286.5447.2179; ZINSMAIER KE, 1994, SCIENCE, V263, P977, DOI 10.1126/science.8310297	32	154	159	0	33	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2002	31	4					349	353		10.1038/ng893	http://dx.doi.org/10.1038/ng893			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	578XV	12042820				2022-12-25	WOS:000177147100008
J	Chavakis, T; Hussain, M; Kanse, SM; Peters, G; Bretzel, RG; Flock, JI; Herrmann, M; Preissner, KT				Chavakis, T; Hussain, M; Kanse, SM; Peters, G; Bretzel, RG; Flock, JI; Herrmann, M; Preissner, KT			Staphylococcus aureus extracellular adherence protein serves as anti-inflammatory factor by inhibiting the recruitment of host leukocytes	NATURE MEDICINE			English	Article							FIBRINOGEN-BINDING PROTEIN; UROKINASE RECEPTOR; CLUMPING FACTOR; MOLECULAR CHARACTERIZATION; VITRONECTIN-BINDING; P-SELECTIN; INTEGRIN; ADHESION; EXPRESSION; COAGULASE	Staphylococcus aureus is a human pathogen that secretes proteins that contribute to bacterial colonization. Here we describe the extracellular adherence protein (Eap) as a novel anti-inflammatory factor that inhibits host leukocyte recruitment. Due to its direct interactions with the host adhesive proteins intercellular adhesion molecule 1 (ICAM-1), fibrinogen or vitronectin, Eap disrupted beta(2)-integrin and urokinase receptor-mediated leukocyte adhesion in vitro. Whereas Eap-expressing S. aureus induced a 2-3-fold lower neutrophil recruitment in bacterial peritonitis in mice as compared with an Eap-negative strain, isolated Eap prevented beta(2)-integrin-dependent neutrophil recruitment in a mouse model of acute thioglycollate-induced peritonitis. Thus, the specific interactions with ICAM-1 and extracellular matrix proteins render Eap a potent anti-inflammatory factor, which may serve as a new therapeutic substance to block leukocyte extravasation in patients with hyperinflammatory pathologies.	Univ Giessen, Inst Biochem, Giessen, Germany; Univ Giessen, Dept Internal Med 3, Giessen, Germany; Univ Hosp, Inst Med Microbiol, Munster, Germany; Huddinge Univ Hosp, Karolinska Inst, Dept Microbiol Pathol & Immunol, S-14186 Huddinge, Sweden; Saarland Univ Hosp, Inst Med Microbiol & Hyg, Dept Bacteriol & Hyg, Homburg, Germany	Justus Liebig University Giessen; Justus Liebig University Giessen; University of Munster; Karolinska Institutet; Universitatsklinikum des Saarlandes	Chavakis, T (corresponding author), Univ Giessen, Inst Biochem, Giessen, Germany.	triantafyllos.chavakis@innere.med.uni-giessen.de	Herrmann, Mathias/B-6475-2013; Bruckner, Peter/F-4817-2019; Chavakis, Triantafyllos/ABE-8845-2020	Herrmann, Mathias/0000-0003-2638-2257; Bruckner, Peter/0000-0002-5566-5611; Kanse, Sandip/0000-0003-0782-9957				BODEN MK, 1989, INFECT IMMUN, V57, P2358; Borges E, 1997, BLOOD, V90, P1934, DOI 10.1182/blood.V90.5.1934; BOSSE R, 1994, EUR J IMMUNOL, V24, P3019, DOI 10.1002/eji.1830241215; BRUMFITT W, 1989, NEW ENGL J MED, V320, P1188, DOI 10.1056/NEJM198905043201806; CARLOS TM, 1994, BLOOD, V84, P2068; Chapman HA, 1999, THROMB HAEMOSTASIS, V82, P291; Chavakis T, 2000, BLOOD, V96, P514; Chavakis T, 1999, BLOOD, V93, P2976; Chavakis T, 2001, FASEB J, V15, P2365, DOI 10.1096/fj.01-0201com; Flock JI, 1999, MOL MED TODAY, V5, P532, DOI 10.1016/S1357-4310(99)01597-X; FLOCK JI, 1987, EMBO J, V6, P2351, DOI 10.1002/j.1460-2075.1987.tb02511.x; Hartleib J, 2000, BLOOD, V96, P2149; HENDRIX H, 1983, J BIOL CHEM, V258, P3637; Hoyer-Hansen G, 1997, FEBS LETT, V420, P79, DOI 10.1016/S0014-5793(97)01491-9; HUSSAIN M, 1991, J MED MICROBIOL, V34, P143, DOI 10.1099/00222615-34-3-143; Hussain M, 2001, CLIN DIAGN LAB IMMUN, V8, P1271, DOI 10.1128/CDLI.8.6.1271-1276.2001; HUSSAIN M, 2002, IN PRESS INFECT IMMU; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; JONSSON K, 1995, J BIOL CHEM, V270, P21457, DOI 10.1074/jbc.270.37.21457; KIM JS, 1994, SCIENCE, V266, P1870, DOI 10.1126/science.7997880; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; May AE, 1998, J EXP MED, V188, P1029, DOI 10.1084/jem.188.6.1029; MCDEVITT D, 1994, MOL MICROBIOL, V11, P237, DOI 10.1111/j.1365-2958.1994.tb00304.x; MCGAVIN MH, 1993, INFECT IMMUN, V61, P2479, DOI 10.1128/IAI.61.6.2479-2485.1993; Mizgerd JP, 1998, J LEUKOCYTE BIOL, V64, P291, DOI 10.1002/jlb.64.3.291; MOREILLON P, 1995, INFECT IMMUN, V63, P4738, DOI 10.1128/IAI.63.12.4738-4743.1995; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; Palma M, 1996, INFECT IMMUN, V64, P5284, DOI 10.1128/IAI.64.12.5284-5289.1996; Palma M, 1999, J BACTERIOL, V181, P2840, DOI 10.1128/JB.181.9.2840-2845.1999; Palma M, 1998, J BIOL CHEM, V273, P13177, DOI 10.1074/jbc.273.21.13177; Park PW, 1996, J BIOL CHEM, V271, P15803, DOI 10.1074/jbc.271.26.15803; PATTI JM, 1992, J BIOL CHEM, V267, P4766; PAULSSON M, 1992, ZBL BAKT-INT J MED M, V277, P54; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Preissner KT, 2000, CURR OPIN CELL BIOL, V12, P621, DOI 10.1016/S0955-0674(00)00141-1; Sawai T, 1997, INFECT IMMUN, V65, P466, DOI 10.1128/IAI.65.2.466-471.1997; SCHLIEVERT PM, 1993, J INFECT DIS, V167, P997, DOI 10.1093/infdis/167.5.997; Sinha B, 1999, CELL MICROBIOL, V1, P101, DOI 10.1046/j.1462-5822.1999.00011.x; Sinha B, 2000, INFECT IMMUN, V68, P6871, DOI 10.1128/IAI.68.12.6871-6878.2000; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STOCKMANN A, 1993, J BIOL CHEM, V268, P22874; Waldvogel FA, 1999, NEW ENGL J MED, V340, P556, DOI 10.1056/NEJM199902183400709	42	180	184	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2002	8	7					687	693		10.1038/nm728	http://dx.doi.org/10.1038/nm728			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	567QG	12091905				2022-12-25	WOS:000176495200029
J	Cox, D; Berg, JS; Cammer, M; Chinegwundoh, JO; Dale, BM; Cheney, RE; Greenberg, S				Cox, D; Berg, JS; Cammer, M; Chinegwundoh, JO; Dale, BM; Cheney, RE; Greenberg, S			Myosin X is a downstream effector of PI(3)K during phagocytosis	NATURE CELL BIOLOGY			English	Article							RECEPTOR-MEDIATED PHAGOCYTOSIS; PLECKSTRIN HOMOLOGY DOMAINS; PHOSPHATIDYLINOSITOL 3-KINASE; UNCONVENTIONAL MYOSIN; PHOSPHOINOSITIDE 3-KINASE; CHAIN KINASE; IN-VIVO; PROTEIN; MACROPHAGES; ACTIVATION	Phagocytosis is a phosphatidylinositol-3-OH-kinase (PI(3)K)-dependent process in macrophages. We identified Myo10 (Myosin-X), an unconventional myosin with pleckstrin homology (PH) domains, as a potential downstream target of PI(3) K. Myo10 was recruited to phagocytic cups in a wortmannin-sensitive manner. Expression of a truncation construct of Myo10 (Myo10 tail) in a macrophage cell line or cytosolic loading of anti-Myo10 antibodies in bovine alveolar macrophages inhibited phagocytosis. In contrast, expression of a Myo10 tail construct containing a point mutation in one of its PH domains failed to inhibit phagocytosis. Expression of Myo10 tail inhibited spreading, but not adhesion, on IgG-coated substrates, consistent with a function for Myo10 in pseudopod extension. We propose that Myo10 provides a molecular link between PI(3) K and pseudopod extension during phagocytosis.	Columbia Univ, Dept Med, New York, NY 10032 USA; Columbia Univ, Dept Pharmacol, New York, NY 10032 USA; Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA	Columbia University; Columbia University; University of North Carolina; University of North Carolina Chapel Hill; Yeshiva University; Albert Einstein College of Medicine	Greenberg, S (corresponding author), Columbia Univ, Dept Med, 630 W 168th St, New York, NY 10032 USA.	greenber@cuccfa.ccc.columbia.edu		Cammer, Michael/0000-0003-4930-1739; Berg, Jonathan/0000-0003-2360-2664; Cox, Dianne/0000-0002-0591-9767; Cheney, Richard/0000-0001-6565-7888	NHLBI NIH HHS [HL54164] Funding Source: Medline; NIAMS NIH HHS [K01 AR02158, K01 AR002158] Funding Source: Medline; NIDCD NIH HHS [R29 DC003299, DC03299] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054164] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K01AR002158] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R29DC003299, R01DC003299] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ALLEN LAH, 1995, J EXP MED, V182, P829, DOI 10.1084/jem.182.3.829; Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; Bajno L, 2000, J CELL BIOL, V149, P697, DOI 10.1083/jcb.149.3.697; Berg JS, 2000, J CELL SCI, V113, P3439; Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; Berg JS, 2002, NAT CELL BIOL, V4, P246, DOI 10.1038/ncb762; Buczynski G, 1997, J CELL BIOL, V136, P1271, DOI 10.1083/jcb.136.6.1271; Chen ZY, 2001, GENOMICS, V72, P285, DOI 10.1006/geno.2000.6456; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; Cox D, 1997, J EXP MED, V186, P1487, DOI 10.1084/jem.186.9.1487; Cox D, 1999, J BIOL CHEM, V274, P1240, DOI 10.1074/jbc.274.3.1240; Cox D, 2001, J EXP MED, V193, P61, DOI 10.1084/jem.193.1.61; Cox D, 2000, P NATL ACAD SCI USA, V97, P680, DOI 10.1073/pnas.97.2.680; DELANEROLLE P, 1993, J BIOL CHEM, V268, P16883; DIVIRGILIO F, 1988, J CELL BIOL, V106, P657, DOI 10.1083/jcb.106.3.657; ELKHOURY J, 1994, J BIOL CHEM, V269, P10197; Fukuda M, 1996, J BIOL CHEM, V271, P18838, DOI 10.1074/jbc.271.31.18838; Greenberg S, 1999, J LEUKOCYTE BIOL, V66, P712, DOI 10.1002/jlb.66.5.712; GREENBERG S, 1994, J BIOL CHEM, V269, P3897; Greenberg S, 1999, ADV CELL MOL BIOL ME, V5, P149, DOI 10.1016/S1874-5172(99)80031-5; Hamada K, 2000, EMBO J, V19, P4449, DOI 10.1093/emboj/19.17.4449; Hasson T, 1997, CELL MOTIL CYTOSKEL, V37, P127, DOI 10.1002/(SICI)1097-0169(1997)37:2<127::AID-CM5>3.0.CO;2-5; Hodge T, 2000, J CELL SCI, V113, P3353; Homma K, 2001, J BIOL CHEM, V276, P34348, DOI 10.1074/jbc.M104785200; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; Ishikawa G, 2000, COMP BIOCHEM PHYS A, V125, P351, DOI 10.1016/S1095-6433(00)00165-3; IZZARD CS, 1976, J CELL SCI, V21, P129; Jung G, 1996, J CELL BIOL, V133, P305, DOI 10.1083/jcb.133.2.305; Lapierre LA, 2001, MOL BIOL CELL, V12, P1843, DOI 10.1091/mbc.12.6.1843; Liu XR, 1999, J NEUROSCI, V19, P6267; Mansfield PJ, 2000, BLOOD, V95, P2407, DOI 10.1182/blood.V95.7.2407.007k02_2407_2412; Marshall JG, 2001, J CELL BIOL, V153, P1369, DOI 10.1083/jcb.153.7.1369; MCNEIL PL, 1987, J CELL SCI, V88, P669; Neuhaus EM, 2000, J CELL BIOL, V150, P1013, DOI 10.1083/jcb.150.5.1013; NINOMIYA N, 1994, J BIOL CHEM, V269, P22732; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Schwarz EC, 2000, J CELL SCI, V113, P621; Seastone DJ, 1998, MOL BIOL CELL, V9, P2891, DOI 10.1091/mbc.9.10.2891; SHEPHERD PR, 1995, BIOCHEM BIOPH RES CO, V211, P535, DOI 10.1006/bbrc.1995.1846; SMITH CL, 1994, J NEUROSCI, V14, P384; Spiro DJ, 1996, MOL BIOL CELL, V7, P355, DOI 10.1091/mbc.7.3.355; Swanson JA, 1999, J CELL SCI, V112, P307; Szczepanowska J, 1997, P NATL ACAD SCI USA, V94, P8503, DOI 10.1073/pnas.94.16.8503; Titus MA, 1999, CURR BIOL, V9, P1297, DOI 10.1016/S0960-9822(00)80051-2; Tuxworth RI, 2000, TRAFFIC, V1, P11, DOI 10.1034/j.1600-0854.2000.010103.x; Tuxworth RI, 2001, CURR BIOL, V11, P318, DOI 10.1016/S0960-9822(01)00097-5; Wu CL, 1996, J BIOL CHEM, V271, P31787, DOI 10.1074/jbc.271.50.31787; Zhou KM, 1998, J CELL SCI, V111, P283	48	173	176	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2002	4	7					469	477		10.1038/ncb805	http://dx.doi.org/10.1038/ncb805			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	568UL	12055636				2022-12-25	WOS:000176562900010
J	Ntziachristos, V; Tung, CH; Bremer, C; Weissleder, R				Ntziachristos, Vasilis; Tung, Ching-Hsuan; Bremer, Christoph; Weissleder, Ralph			Fluorescence molecular tomography resolves protease activity in vivo	NATURE MEDICINE			English	Article							TUMORS	Systematic efforts are under way to develop novel technologies that would allow molecular sensing in intact organisms in vivo. Using near-infrared fluorescent molecular beacons and inversion techniques that take into account the diffuse nature of photon propagation in tissue, we were able to obtain three-dimensional in vivo images of a protease in orthopic gliomas. We demonstrate that enzyme-activatable fluorochromes can be detected with high positional accuracy in deep tissues, that molecular specificities of different beacons towards enzymes can be resolved and that tomography of beacon activation is linearly related to enzyme concentration. The tomographic imaging method offers a range of new capabilities for studying biological function; for example, identifying molecular-expression patterns by multispectral imaging or continuously monitoring the efficacy of therapeutic drugs.	[Ntziachristos, Vasilis] Massachusetts Gen Hosp, Ctr Mol Imaging Res, Charlestown, MA 02129 USA; Harvard Med Sch, Charlestown, MA USA	Harvard University; Massachusetts General Hospital	Ntziachristos, V (corresponding author), Massachusetts Gen Hosp, Ctr Mol Imaging Res, Charlestown, MA 02129 USA.	vasilis@helix.mgh.harvard.edu	Tung, Ching-Hsuan/AHC-5070-2022; Tung, Ching-Hsuan/AIE-6009-2022	Tung, Ching-Hsuan/0000-0001-6648-6195; Tung, Ching-Hsuan/0000-0001-6648-6195; /0000-0003-0828-4143				Arridge SR, 1999, INVERSE PROBL, V15, pR41, DOI 10.1088/0266-5611/15/2/022; Bremer C, 2001, NAT MED, V7, P743, DOI 10.1038/89126; Brown EB, 2001, NAT MED, V7, P864, DOI 10.1038/89997; Demchik LL, 1999, INT J DEV NEUROSCI, V17, P483, DOI 10.1016/S0736-5748(99)00011-8; Gross LA, 2000, P NATL ACAD SCI USA, V97, P11990, DOI 10.1073/pnas.97.22.11990; Han MY, 2001, NAT BIOTECHNOL, V19, P631, DOI 10.1038/90228; MacBeath G, 2000, SCIENCE, V289, P1760; Ntziachristos V, 2000, P NATL ACAD SCI USA, V97, P2767, DOI 10.1073/pnas.040570597; Ntziachristos V, 2002, OPT LETT, V27, P333, DOI 10.1364/OL.27.000333; Ntziachristos V, 2001, OPT LETT, V26, P893, DOI 10.1364/OL.26.000893; Ntziachristos V, 2002, MED PHYS, V29, P803, DOI 10.1118/1.1470209; Paithankar DY, 1997, APPL OPTICS, V36, P2260, DOI 10.1364/AO.36.002260; Pepperkok R, 1999, CURR BIOL, V9, P269, DOI 10.1016/S0960-9822(99)80117-1; Pollok BA, 1999, TRENDS CELL BIOL, V9, P57, DOI 10.1016/S0962-8924(98)01434-2; Tung CH, 2000, CANCER RES, V60, P4953; Turk BE, 2001, NAT BIOTECHNOL, V19, P661, DOI 10.1038/90273; Weissleder R, 1999, NAT BIOTECHNOL, V17, P375, DOI 10.1038/7933; Weissleder R, 2002, NAT REV CANCER, V2, P11, DOI 10.1038/nrc701; Wouters FS, 2001, TRENDS CELL BIOL, V11, P203, DOI 10.1016/S0962-8924(01)01982-1	19	651	676	2	57	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2002	8	7					757	760		10.1038/nm729	http://dx.doi.org/10.1038/nm729			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	VL1EJ	12091907				2022-12-25	WOS:000792138400001
J	Reichert, JM; Paquette, C				Reichert, JM; Paquette, C			Therapeutic cancer vaccines on trial - Therapeutic cancer vaccines offer hope for patients for whom traditional treatments have failed, but various obstacles may impede the launch of these new agents.	NATURE BIOTECHNOLOGY			English	Article							IMMUNOTHERAPY		Tufts Univ, Ctr Study Drug Dev, Boston, MA 02111 USA	Tufts University	Reichert, JM (corresponding author), Tufts Univ, Ctr Study Drug Dev, Boston, MA 02111 USA.			Reichert, Janice/0000-0003-0400-1951				Armstrong AC, 2001, BMJ-BRIT MED J, V323, P1289, DOI 10.1136/bmj.323.7324.1289; Armstrong AC, 2001, BRIT J RADIOL, V74, P991, DOI 10.1259/bjr.74.887.740991; Chung KT, 2001, PERSPECT BIOL MED, V44, P379, DOI 10.1353/pbm.2001.0044; Dalgleish AG, 2000, BRIT J CANCER, V82, P1619; Durrant LG, 1997, ANTI-CANCER DRUG, V8, P727, DOI 10.1097/00001813-199709000-00001; Edwards BK, 2002, CANCER-AM CANCER SOC, V94, P2766, DOI 10.1002/cncr.10593; Kaitin KI, 2000, DRUG INF J, V34, P1; Pardoll DM, 1998, NAT MED, V4, P525, DOI 10.1038/nm0598supp-525; Reichert JM, 2002, CURR OPIN MOL THER, V4, P110; Reichert JM, 2001, DRUG INF J, V35, P85, DOI 10.1177/009286150103500109; Timmerman JM, 1999, ANNU REV MED, V50, P507	11	7	8	2	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2002	20	7					659	663		10.1038/nbt0702-659	http://dx.doi.org/10.1038/nbt0702-659			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	567QC	12089545				2022-12-25	WOS:000176494800015
J	Knabel, M; Franz, TJ; Schiemann, M; Wulf, A; Villmow, B; Schmidt, B; Bernhard, H; Wagner, H; Busch, DH				Knabel, M; Franz, TJ; Schiemann, M; Wulf, A; Villmow, B; Schmidt, B; Bernhard, H; Wagner, H; Busch, DH			Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer	NATURE MEDICINE			English	Article								Recently developed major histocompatibility complex (MHC) multimer technologies allow visualization and isolation of antigen-specific T cells. However, functional analysis and in vivo transfer of MHC multimer-stained cells is hampered by the persistence of T-cell receptor (TCR)-MHC interactions and subsequently induced signaling events. As MHC monomers do not stably bind to TCRs, we postulated that targeted disassembly of multimers into MHC monomers would result in dissociation of surface-bound TCR ligands. We generated a new type of MHC multimers, which can be monomerized in the presence of a competitor, resulting in rapid loss of the staining reagent. Following dissociation, the T cells are phenotypically and functionally indistinguishable from untreated cells. This 'reversible' T-cell staining procedure, which maintains the specificity and sensitivity of MHC multimer staining while preserving the functional status of T lymphocytes, may be of broad benefit for ex vivo investigation of T-cell functions and clinical applications.	Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, D-8000 Munich, Germany; Tech Univ Munich, Dept Hematol Oncol, D-8000 Munich, Germany	Technical University of Munich; Technical University of Munich	Busch, DH (corresponding author), Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, D-8000 Munich, Germany.								0	172	200	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2002	8	6					631	636		10.1038/nm0602-631	http://dx.doi.org/10.1038/nm0602-631			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	557KG	12042816				2022-12-25	WOS:000175907300036
J	Cai, WW; Mao, JH; Chow, CW; Damani, S; Balmain, A; Bradley, A				Cai, WW; Mao, JH; Chow, CW; Damani, S; Balmain, A; Bradley, A			Genome-wide detection of chromosomal imbalances in tumors using BAC microarrays	NATURE BIOTECHNOLOGY			English	Article							MOUSE THYMIC LYMPHOMAS; HYBRIDIZATION; MAP; GENE; TUMORIGENESIS; SEQUENCE; LOCI	Chromosomal imbalances such as deletions and amplifications are common rearrangements in most tumors(1). Specific rearrangements are consistently associated with specific tumor types or stages, implicating the role of the genes in a region of chromosomal imbalance in tumor initiation and progression(2). The development of comparative genomic hybridization (CGH)(3) has obviated the need to obtain metaphase spreads from tumors, so that the chromosomal imbalances in many solid tumors may be revealed using an extracted genomic DNA sample. However, the resolution of the cytogenetic method remains and the extreme technical difficulty of CGH has restricted its use. Conceptually, DNA microarray(4)-based CGH is an obvious solution to all of the limitations of conventional CGH. Although arrays have been used for CGH studies(5-8), their success has been limited by poor specific signal-to-noise ratios. Here we demonstrate a microarray-based CGH method that allows reliable detection of chromosomal deletions and amplifications with high resolution. Our microarray system is fundamentally different from most current microarray technologies in that activated DNA is printed on natural glass surfaces while other systems almost exclusively focus on activating the surfaces, a strategy that invariably introduces hybridization backgrounds. The concept of using pre-modification may be generally applied for making arrays of other biological materials, as modifying the substrates will be more controllable in solution than on surfaces.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Univ Calif San Francisco, Ctr Canc, San Francisco, CA 94143 USA; Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England	Baylor College of Medicine; University of California System; University of California San Francisco; Wellcome Trust Sanger Institute	Bradley, A (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.	abradley@sanger.ac.uk	Mao, Jian-Hua/EIZ-8595-2022	Mao, Jian-Hua/0000-0001-9320-6021; Bradley, Allan/0000-0002-2349-8839				Cai WW, 2001, NAT GENET, V29, P133, DOI 10.1038/ng716; Cai WW, 1998, GENOMICS, V54, P387, DOI 10.1006/geno.1998.5620; Cheung VG, 2001, NATURE, V409, P953, DOI 10.1038/35057192; DIETRICH WF, 1994, P NATL ACAD SCI USA, V91, P9451, DOI 10.1073/pnas.91.20.9451; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Hodgson G, 2001, NAT GENET, V29, P459, DOI 10.1038/ng771; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Liu PT, 1998, GENETICS, V150, P1155; Matsumoto Y, 1998, ONCOGENE, V16, P2747, DOI 10.1038/sj.onc.1201810; McPherson JD, 2001, NATURE, V409, P934, DOI 10.1038/35057157; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; Okano H, 1999, ONCOGENE, V18, P6677, DOI 10.1038/sj.onc.1203100; PARANGI S, 1995, CANCER RES, V55, P6071; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SolinasToldo S, 1997, GENE CHROMOSOME CANC, V20, P399, DOI 10.1002/(SICI)1098-2264(199712)20:4<399::AID-GCC12>3.0.CO;2-I; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040	20	135	148	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	2002	20	4					393	396		10.1038/nbt0402-393	http://dx.doi.org/10.1038/nbt0402-393			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	536BY	11923847				2022-12-25	WOS:000174681900028
J	Krendel, M; Zenke, FT; Bokoch, GM				Krendel, M; Zenke, FT; Bokoch, GM			Nucleotide exchange factor GEF-H1 mediates cross-talk between microtubules and the actin cytoskeleton	NATURE CELL BIOLOGY			English	Article							GTP-BINDING PROTEIN; CULTURED-CELLS; FOCAL ADHESIONS; STRESS FIBERS; RHO; ACTIVATION; FIBROBLAST; GTPASES; RAC; DEPOLYMERIZATION	Regulation of the actin cytoskeleton by microtubules is mediated by the Rho family GTPases. However, the molecular mechanisms that link microtubule dynamics to Rho GTPases have not, as yet, been identified. Here we show that the Rho guanine nucleotide exchange factor (GEF)-H1 is regulated by an interaction with microtubules. GEF-H1 mutants that are deficient in microtubule binding have higher activity levels than microtubule-bound forms. These mutants also induce Rho-dependent changes in cell morphology and actin organization. Furthermore, drug-induced microtubule depolymerization induces changes in cell morphology and gene expression that are similar to the changes induced by the expression of active forms of GEF-H1. Furthermore, these effects are inhibited by dominant-negative versions of GEF-H1. Thus, GEF-H1 links changes in microtubule integrity to Rho-dependent regulation of the actin cytoskeleton.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Bokoch, GM (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	bokoch@scripps.edu		Krendel, Mira/0000-0002-7008-9069; Zenke, Frank/0000-0002-2226-3755	NIGMS NIH HHS [GM34934] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; BERSHADSKY AD, 1991, CELL MOTIL CYTOSKEL, V19, P152, DOI 10.1002/cm.970190303; BULINSKI JC, 1988, J CELL BIOL, V106, P1213, DOI 10.1083/jcb.106.4.1213; Cook TA, 1998, J CELL BIOL, V141, P175, DOI 10.1083/jcb.141.1.175; DANOWSKI BA, 1989, J CELL SCI, V93, P255; DOWNWARD J, 1995, METHOD ENZYMOL, V255, P110; Drechsel DN, 1997, CURR BIOL, V7, P12, DOI 10.1016/S0960-9822(06)00023-6; Enomoto T, 1996, CELL STRUCT FUNCT, V21, P317, DOI 10.1247/csf.21.317; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; Glaven JA, 1999, J BIOL CHEM, V274, P2279, DOI 10.1074/jbc.274.4.2279; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; King CC, 2000, J BIOL CHEM, V275, P41201, DOI 10.1074/jbc.M006553200; LIAO GJ, 1995, J CELL SCI, V108, P3473; Liu BP, 1998, CELL ADHES COMMUN, V5, P249, DOI 10.3109/15419069809040295; Mandato CA, 2000, CELL MOTIL CYTOSKEL, V45, P87, DOI 10.1002/(SICI)1097-0169(200002)45:2<87::AID-CM1>3.0.CO;2-0; Mira JP, 2000, P NATL ACAD SCI USA, V97, P185, DOI 10.1073/pnas.97.1.185; O'Connell CB, 1999, J CELL BIOL, V144, P305, DOI 10.1083/jcb.144.2.305; OLSON KR, 1995, J CELL BIOL, V130, P639, DOI 10.1083/jcb.130.3.639; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ren Y, 1998, J BIOL CHEM, V273, P34954, DOI 10.1074/jbc.273.52.34954; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; Sterpetti P, 1999, MOL CELL BIOL, V19, P1334; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; van Horck FPG, 2001, J BIOL CHEM, V276, P4948, DOI 10.1074/jbc.M003839200; VASILIEV JM, 1970, J EMBRYOL EXP MORPH, V24, P625; Waterman-Storer CM, 1999, NAT CELL BIOL, V1, P45, DOI 10.1038/9018; Welsh CF, 2001, NAT CELL BIOL, V3, P950, DOI 10.1038/ncb1101-950; Wittmann T, 2001, J CELL SCI, V114, P3795	31	458	472	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	APR	2002	4	4					294	301		10.1038/ncb773	http://dx.doi.org/10.1038/ncb773			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	541PY	11912491				2022-12-25	WOS:000174994000017
J	Zhang, JH; Zhang, DS; McQuade, JS; Behbehani, M; Tsien, JZ; Xu, M				Zhang, JH; Zhang, DS; McQuade, JS; Behbehani, M; Tsien, JZ; Xu, M			c-fos regulates neuronal excitability and survival	NATURE GENETICS			English	Article							KAINIC ACID; INDUCED SEIZURES; NERVOUS-SYSTEM; BRAIN; EXPRESSION; MICE; GLUTAMATE; EPILEPSY; RECEPTOR; GENE	Excitotoxicity is a process in which glutamate or other excitatory amino acids induce neuronal cell death. Accumulating evidence suggests that excitotoxicity may contribute to human neuronal cell loss caused by acute insults and chronic degeneration in the central nervous system(1-4). The immediate early gene (IEG) c-fos encodes a transcription factor(5-6). The c-Fos proteins form heterodimers with Jun family proteins, and the resulting AP-1 complexes regulate transcription by binding to the AP-1 sequence found in many cellular genes(7-9). Emerging evidence suggests that c-fos is essential in regulating neuronal cell survival versus death(10). Although c-fos is induced by neuronal activity, including kainic acid induced seizures(11-14), whether and how c-fos is involved in excitotoxicity is still unknown. To address this issue, we generated a mouse in which c-fos expression is largely eliminated in the hippocampus. We found that these mutant mice have more severe kainic acid-induced seizures, increased neuronal excitability and neuronal cell death, compared with control mice. Moreover, c-Fos regulates the expression of the kainic acid receptor GluR6 and brain-derived neurotrophic factor (BDNF), both in vivo and in vitro. Our results suggest that c-fos is a genetic regulator for cellular mechanisms mediating neuronal excitability and survival.	Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Cellular & Mol Physiol, Cincinnati, OH 45267 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Princeton University	Xu, M (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA.		zhang, jianhua/D-3404-2009	Zhang, Jianhua/0000-0002-2128-9574				BENARI Y, 1985, NEUROSCIENCE, V14, P375, DOI 10.1016/0306-4522(85)90299-4; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; FERKANY JW, 1984, NATURE, V308, P561, DOI 10.1038/308561a0; GALL CM, 1993, EXP NEUROL, V124, P150, DOI 10.1006/exnr.1993.1186; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; KOH JY, 1995, SCIENCE, V268, P573, DOI 10.1126/science.7725105; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Mandelzys A, 1997, J NEUROSCI, V17, P5407; McNamara JO, 1999, NATURE, V399, pA15, DOI 10.1038/399a015; Medvedev A, 2000, BRAIN RES BULL, V52, P89, DOI 10.1016/S0361-9230(00)00239-2; MERLIO JP, 1993, NEURON, V10, P151, DOI 10.1016/0896-6273(93)90307-D; Mulle C, 1998, NATURE, V392, P601, DOI 10.1038/33408; MULLER R, 1983, NATURE, V304, P454, DOI 10.1038/304454a0; NADLER JV, 1978, NATURE, V271, P676, DOI 10.1038/271676a0; POPOVICI T, 1990, BRAIN RES, V536, P183, DOI 10.1016/0006-8993(90)90024-6; Roux PP, 1999, J NEUROSCI, V19, P6887, DOI 10.1523/JNEUROSCI.19-16-06887.1999; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; Tandon P, 1999, NEUROSCIENCE, V91, P293, DOI 10.1016/S0306-4522(98)00609-5; Tsien JZ, 1996, CELL, V87, P1317, DOI 10.1016/S0092-8674(00)81826-7; XU M, 1994, CELL, V79, P729, DOI 10.1016/0092-8674(94)90557-6; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899	27	226	230	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2002	30	4					416	420		10.1038/ng859	http://dx.doi.org/10.1038/ng859			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	536BZ	11925568				2022-12-25	WOS:000174682000020
J	Lucht, JM; Mauch-Mani, B; Steiner, HY; Metraux, JP; Ryals, J; Hohn, B				Lucht, JM; Mauch-Mani, B; Steiner, HY; Metraux, JP; Ryals, J; Hohn, B			Pathogen stress increases somatic recombination frequency in Arabidopsis	NATURE GENETICS			English	Article							INTRACHROMOSOMAL HOMOLOGOUS RECOMBINATION; SYSTEMIC ACQUIRED-RESISTANCE; DISEASE RESISTANCE; SIGNAL-TRANSDUCTION; WHOLE PLANTS; EVOLUTION; GENES; RESPONSES; GENOME; EVENTS	Evolution is based on genetic variability and subsequent phenotypic selection. Mechanisms that modulate the rate of mutation according to environmental cues, and thus control the balance between genetic stability and flexibility, might provide a distinct evolutionary advantage(1-4). Stress-induced mutations stimulated by unfavorable environments, and possible mechanisms for their induction, have been described for several organisms(2-4), but research in this area has mainly focused on microorganisms. We have analyzed the influence of adverse environmental conditions on the genetic stability of the higher plant Arabidopsis thaliana. Here we show that a biotic stress factor-attack by the oomycete pathogen Peronospora parasitica can stimulate somatic recombination in Arabidopsis. The same effect was observed when plant pathogen-defense mechanisms were activated by the chemicals 2,6-dichloroisonicotinic acid (INA) or benzothiadiazole (BTH), or by a mutation (cim3). Together with previous studies of recombination induced by abiotic factors, these findings suggest that increased somatic recombination is a general stress response in plants. The increased genetic flexibility might facilitate evolutionary adaptation of plant populations to stressful environments.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland; Univ Fribourg, Dept Biol, CH-1700 Fribourg, Switzerland; Syngenta, Res Triangle Pk, NC 27709 USA; Paradigm Genet, Res Triangle Pk, NC 27709 USA	Friedrich Miescher Institute for Biomedical Research; University of Fribourg; Syngenta	Lucht, JM (corresponding author), Univ Freiburg, Sonnenstr 5, D-79104 Freiburg, Germany.		Mauch-Mani, Brigitte/O-2387-2014; Metraux, Jean-Pierre JP/C-1111-2012	Lucht, Jan/0000-0002-4722-1244; Mauch-Mani, Brigitte/0000-0002-6743-8520				Alvarez ME, 1998, CELL, V92, P773, DOI 10.1016/S0092-8674(00)81405-1; Caporale LH, 2000, BIOESSAYS, V22, P388, DOI 10.1002/(SICI)1521-1878(200004)22:4<388::AID-BIES9>3.0.CO;2-4; Ellis J, 2000, CURR OPIN PLANT BIOL, V3, P278, DOI 10.1016/S1369-5266(00)00080-7; Gallego ME, 2001, PLANT J, V25, P31, DOI 10.1046/j.1365-313x.2001.00928.x; Heath MC, 2000, PLANT MOL BIOL, V44, P321, DOI 10.1023/A:1026592509060; Kovalchuk I, 1998, NAT BIOTECHNOL, V16, P1054, DOI 10.1038/3505; Lawton KA, 1996, PLANT J, V10, P71, DOI 10.1046/j.1365-313X.1996.10010071.x; LEBEL EG, 1993, P NATL ACAD SCI USA, V90, P422, DOI 10.1073/pnas.90.2.422; Maleck K, 2000, NAT GENET, V26, P403, DOI 10.1038/82521; MauchMani B, 1996, PLANT CELL, V8, P203, DOI 10.1105/tpc.8.2.203; MCCLINTOCK B, 1984, SCIENCE, V226, P792, DOI 10.1126/science.15739260; McDowell JM, 2000, TRENDS BIOCHEM SCI, V25, P79, DOI 10.1016/S0968-0004(99)01532-7; Mittler R, 1997, PLANT MOL BIOL, V34, P209, DOI 10.1023/A:1005868402827; Parniske M, 1997, CELL, V91, P821, DOI 10.1016/S0092-8674(00)80470-5; PUCHTA H, 1995, PLANT J, V7, P203, DOI 10.1046/j.1365-313X.1995.7020203.x; Puchta H, 1996, TRENDS PLANT SCI, V1, P340; PUCHTA H, 1995, PLANT MOL BIOL, V28, P281, DOI 10.1007/BF00020247; Radman M, 1999, ANN NY ACAD SCI, V870, P146, DOI 10.1111/j.1749-6632.1999.tb08874.x; Richter TE, 2000, PLANT MOL BIOL, V42, P195, DOI 10.1023/A:1006388223475; Ries G, 2000, NATURE, V406, P98, DOI 10.1038/35017595; Rosenberg SM, 2001, NAT REV GENET, V2, P504, DOI 10.1038/35080556; Ryals JA, 1996, PLANT CELL, V8, P1809, DOI 10.1105/tpc.8.10.1809; Saxe D, 2000, MOL CELL BIOL, V20, P5404, DOI 10.1128/MCB.20.15.5404-5414.2000; SWOBODA P, 1994, EMBO J, V13, P484, DOI 10.1002/j.1460-2075.1994.tb06283.x; TINLAND B, 1994, P NATL ACAD SCI USA, V91, P8000, DOI 10.1073/pnas.91.17.8000; UKNES S, 1992, PLANT CELL, V4, P645, DOI 10.1105/tpc.4.6.645; Walbot V, 1996, TRENDS PLANT SCI, V1, P27, DOI 10.1016/S1360-1385(96)80020-3; Weymann K, 1995, PLANT CELL, V7, P2013, DOI 10.1105/tpc.7.12.2013; Yang YO, 1997, GENE DEV, V11, P1621, DOI 10.1101/gad.11.13.1621; Young ND, 2000, CURR OPIN PLANT BIOL, V3, P285, DOI 10.1016/S1369-5266(00)00081-9	30	166	173	0	39	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2002	30	3					311	314		10.1038/ng846	http://dx.doi.org/10.1038/ng846			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	526YP	11836502	Green Submitted			2022-12-25	WOS:000174157600017
J	Calderwood, DA; Huttenlocher, A; Kiosses, WB; Rose, DM; Woodside, DG; Schwartz, MA; Ginsberg, MH				Calderwood, DA; Huttenlocher, A; Kiosses, WB; Rose, DM; Woodside, DG; Schwartz, MA; Ginsberg, MH			Increased filamin binding to beta-integrin cytoplasmic domains inhibits cell migration	NATURE CELL BIOLOGY			English	Article							TARGETS FILAMIN; ALPHA-ACTININ; PROTEIN; FIBRONECTIN; ACTIVATION; ADHESION; TALIN; KINASE; IDENTIFICATION; MODULATION	Multicellular animal development depends on integrins. These adhesion receptors link to the actin cytoskeleton, transmitting biochemical signals and force during cell migration and interactions with the extracellular matrix. Many integrin-cytoskeleton connections are formed by filamins and talin. The beta (7) integrin tail binds strongly to filamin and supports less migration, fibronectin matrix assembly and focal adhesion formation than either the beta (1D) tail, which binds strongly to talin, or the beta (1A) tail, which binds modestly to both filamin and talin. To probe the role of filamin binding, we mapped the filamin-binding site of integrin tails and identified amino acid substitutions that led to selective loss of filamin binding to the beta (7) tail and gain of filamin binding to the beta (1A) tail. These changes affected cell migration and membrane protrusions but not fibronectin matrix assembly or focal adhesion formation. Thus, tight filamin binding restricts integrin-dependent cell migration by inhibiting transient membrane protrusion and cell polarization.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Univ Wisconsin, Dept Pediat, Madison, WI 53706 USA; Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA; Scripps Res Inst, La Jolla, CA 92037 USA	Scripps Research Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Scripps Research Institute	Ginsberg, MH (corresponding author), Scripps Res Inst, Dept Vasc Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	ginsberg@scripps.edu	Calderwood, David A/AAC-6954-2019	Calderwood, David A/0000-0002-0791-4142; schwartz, martin/0000-0002-2071-1243				ALI IU, 1977, BIOCHIM BIOPHYS ACTA, V471, P16, DOI 10.1016/0005-2736(77)90388-1; Bashaw GJ, 2000, CELL, V101, P703, DOI 10.1016/S0092-8674(00)80883-1; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; Belkin AM, 1997, J CELL BIOL, V139, P1583, DOI 10.1083/jcb.139.6.1583; Bellanger JM, 2000, NAT CELL BIOL, V2, P888, DOI 10.1038/35046533; BROWN PJ, 1985, SCIENCE, V228, P1448, DOI 10.1126/science.4012302; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; Cox EA, 2001, MOL BIOL CELL, V12, P265, DOI 10.1091/mbc.12.2.265; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; DERVEN PF, 2000, J CELL BIOL, V151, P235; Djinovic-Carugo K, 1999, CELL, V98, P537, DOI 10.1016/S0092-8674(00)81981-9; Fox JW, 1998, NEURON, V21, P1315, DOI 10.1016/S0896-6273(00)80651-0; Glogauer M, 1998, J BIOL CHEM, V273, P1689, DOI 10.1074/jbc.273.3.1689; GOLDMANN WH, 1994, J STRUCT BIOL, V112, P3, DOI 10.1006/jsbi.1994.1002; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; Greenwood JA, 2000, J CELL BIOL, V150, P627, DOI 10.1083/jcb.150.3.627; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Huttenlocher A, 1996, J CELL BIOL, V134, P1551, DOI 10.1083/jcb.134.6.1551; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; Kiosses WB, 2001, NAT CELL BIOL, V3, P316, DOI 10.1038/35060120; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Liu S, 1999, NATURE, V402, P676, DOI 10.1038/45264; Liu SC, 2000, J CELL SCI, V113, P3563; Loo DT, 1998, J BIOL CHEM, V273, P23304, DOI 10.1074/jbc.273.36.23304; Marti A, 1997, J BIOL CHEM, V272, P2620, DOI 10.1074/jbc.272.5.2620; Meyer SC, 1998, J BIOL CHEM, V273, P3013, DOI 10.1074/jbc.273.5.3013; MITTAL B, 1987, CELL MOTIL CYTOSKEL, V8, P345, DOI 10.1002/cm.970080407; Mulrooney J, 2000, EXP CELL RES, V258, P332, DOI 10.1006/excr.2000.4964; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; Romzek NC, 1998, MOL BIOL CELL, V9, P2715, DOI 10.1091/mbc.9.10.2715; Rose DM, 2000, BLOOD, V95, P602, DOI 10.1182/blood.V95.2.602; Rost B, 1996, METHOD ENZYMOL, V266, P525; Sampath R, 1998, J BIOL CHEM, V273, P33588, DOI 10.1074/jbc.273.50.33588; Sechler JL, 1996, J CELL BIOL, V134, P573, DOI 10.1083/jcb.134.2.573; SHARMA CP, 1995, J IMMUNOL, V154, P3461; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; van der Flier A, 2001, BBA-MOL CELL RES, V1538, P99, DOI 10.1016/S0167-4889(01)00072-6; WANG K, 1975, P NATL ACAD SCI USA, V72, P4483, DOI 10.1073/pnas.72.11.4483; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223	50	184	187	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2001	3	12					1060	1068		10.1038/ncb1201-1060	http://dx.doi.org/10.1038/ncb1201-1060			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	500AM	11781567				2022-12-25	WOS:000172603700011
J	Trotman, LC; Mosberger, N; Fornerod, M; Stidwill, RP; Greber, UF				Trotman, LC; Mosberger, N; Fornerod, M; Stidwill, RP; Greber, UF			Import of adenovirus DNA involves the nuclear pore complex receptor CAN/Nup214 and histone H1	NATURE CELL BIOLOGY			English	Article							PROTEIN IMPORT; IN-VITRO; BINDING; TRANSPORT; ENTRY; CELLS; CYTOPLASM; ARCHITECTURE; CHROMATIN; EPITOPE	Adenovirus type 2 (Ad2) imports its DNA genome through the nuclear pore complex (NPC) of cells in interphase for viral production. Here we identify the NPC-filament protein CAN/Nup214 as a docking site for incoming Ad2 capsids. Binding to CAN is independent of cytosolic factors. Capsids disassemble at NPCs to free their DNA for import. This process requires binding of nuclear histone HI to the stably docked capsids and involves Hl-import factors, restricting this irreversible process to the proximity of the nucleus. Our results provide a molecular mechanism for disassembly of Ad2 and reveal an unexpected function of histone H1 in virus-mediated DNA import.	Univ Zurich, Inst Zool, CH-8057 Zurich, Switzerland; Netherlands Canc Inst, NL-1066 CX Amsterdam, Netherlands	University of Zurich; Netherlands Cancer Institute	Trotman, LC (corresponding author), Univ Zurich, Inst Zool, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	ufgreber@zool.unizh.ch	Greber, Urs F/G-9458-2015; Fornerod, Maarten/A-7503-2010	Greber, Urs F/0000-0003-2278-120X; Fornerod, Maarten/0000-0002-6166-3030				BUSTIN M, 1972, J BIOL CHEM, V247, P5716; BUSTIN M, 1989, METHOD ENZYMOL, V170, P214; CERT C, 1994, BIOCHEMISTRY-US, V33, P11079; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; Doenecke D, 1997, HISTOCHEM CELL BIOL, V107, P1, DOI 10.1007/s004180050083; DRABENT B, 1993, BIOCHIM BIOPHYS ACTA, V1172, P193, DOI 10.1016/0167-4781(93)90293-M; FOMEROD M, 1996, ONCOGENE, V13, P1801; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; GREBER UF, 1992, J CELL BIOL, V116, P15, DOI 10.1083/jcb.116.1.15; Greber UF, 1997, EMBO J, V16, P5998, DOI 10.1093/emboj/16.19.5998; Greber UF, 1996, EMBO J, V15, P1766, DOI 10.1002/j.1460-2075.1996.tb00525.x; GREBER UF, 1993, CELL, V75, P477, DOI 10.1016/0092-8674(93)90382-Z; Huber J, 1998, EMBO J, V17, P4114, DOI 10.1093/emboj/17.14.4114; Jakel S, 1999, EMBO J, V18, P2411, DOI 10.1093/emboj/18.9.2411; Kann M, 1999, J CELL BIOL, V145, P45, DOI 10.1083/jcb.145.1.45; Leclerc D, 1999, J VIROL, V73, P553, DOI 10.1128/JVI.73.1.553-560.1999; Lever MA, 2000, NATURE, V408, P873, DOI 10.1038/35048603; Mabit H, 2001, J VIROL, V75, P1968, DOI 10.1128/JVI.75.4.1968-1977.2001; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; Misteli T, 2000, NATURE, V408, P877, DOI 10.1038/35048610; Nakano MY, 2000, J STRUCT BIOL, V129, P57, DOI 10.1006/jsbi.1999.4201; Nakano MY, 2000, J VIROL, V74, P7085, DOI 10.1128/JVI.74.15.7085-7095.2000; Nakielny S, 1999, EMBO J, V18, P1982, DOI 10.1093/emboj/18.7.1982; Ojala PM, 2000, MOL CELL BIOL, V20, P4922, DOI 10.1128/MCB.20.13.4922-4931.2000; PANTE N, 1994, J CELL BIOL, V126, P603, DOI 10.1083/jcb.126.3.603; PARSEGHIAN MH, 1994, PROTEIN SCI, V3, P575; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Russell WC, 2000, J GEN VIROL, V81, P2573, DOI 10.1099/0022-1317-81-11-2573; Rux JJ, 2000, MOL THER, V1, P18, DOI 10.1006/mthe.1999.0001; Ryan KJ, 2000, CURR OPIN CELL BIOL, V12, P361, DOI 10.1016/S0955-0674(00)00101-0; Saphire ACS, 2000, J BIOL CHEM, V275, P4298, DOI 10.1074/jbc.275.6.4298; SHENK T, 1996, FUNDAMENTAL VIROLOGY; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; Sodeik B, 2000, TRENDS MICROBIOL, V8, P465, DOI 10.1016/S0966-842X(00)01824-2; Stoffler D, 1999, CURR OPIN CELL BIOL, V11, P391, DOI 10.1016/S0955-0674(99)80055-6; Suomalainen M, 1999, J CELL BIOL, V144, P657, DOI 10.1083/jcb.144.4.657; Suomalainen M, 2001, EMBO J, V20, P1310, DOI 10.1093/emboj/20.6.1310; Thomas JO, 1999, CURR OPIN CELL BIOL, V11, P312, DOI 10.1016/S0955-0674(99)80042-8; Whittaker GR, 2000, ANNU REV CELL DEV BI, V16, P627, DOI 10.1146/annurev.cellbio.16.1.627; Wisnivesky JP, 1999, HUM GENE THER, V10, P2187, DOI 10.1089/10430349950017176; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	44	239	242	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2001	3	12					1092	1100		10.1038/ncb1201-1092	http://dx.doi.org/10.1038/ncb1201-1092			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	500AM	11781571				2022-12-25	WOS:000172603700015
J	Hartman, AR; Ford, JM				Hartman, AR; Ford, JM			BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair	NATURE GENETICS			English	Article							GLOBAL GENOMIC REPAIR; CYCLOBUTANE PYRIMIDINE DIMERS; TRANSCRIPTION-COUPLED REPAIR; HUMAN FIBROBLASTS; P53 MUTATIONS; HUMAN-CELLS; GENE; EXPRESSION; CANCER; BREAST	Inheritance of a mutation in the gene BRCA1 confers on women a 50-85% lifetime risk of developing breast cancer(1,2). Mutations in the TP53 tumor-suppressor gene are found in 70-80% of BRCA1-mutated breast cancer but only 30% of those with wildtype BRCA1 (ref. 3). The p53 protein regulates nucleotide excision repair (NER) through transcriptional regulation of genes involved in the recognition of adducts in genomic DNA. Loss of p53 function results in deficient global genomic repair (GGR), a subset of NER that targets and removes lesions from the whole genome(4-6). Here we show that BRCA1 specifically enhances the GGR pathway, independent of p53, and can induce p53-independent expression of the NER genes XPC, DDB2, and GADD45. Defects in the NER pathway in BRCA1-associated breast cancers may be causal in tumor development, suggesting a multistep model of carcinogenesis.	Stanford Univ, Med Ctr, Dept Internal Med Oncol, Stanford, CA 94305 USA; Stanford Univ, Med Ctr, Dept Genet, Stanford, CA 94305 USA	Stanford University; Stanford University	Ford, JM (corresponding author), Stanford Univ, Med Ctr, Dept Internal Med Oncol, Stanford, CA 94305 USA.			Ford, James/0000-0002-2513-7025				Adimoolam S, 2001, J BIOL CHEM, V276, P25813, DOI 10.1074/jbc.M102240200; Bowman KK, 2000, MOL CARCINOGEN, V29, P17, DOI 10.1002/1098-2744(200009)29:1<17::AID-MC3>3.3.CO;2-5; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Cressman VL, 1999, MOL CELL BIOL, V19, P7061; EASTON DF, 1995, AM J HUM GENET, V56, P65; Emmert S, 2000, P NATL ACAD SCI USA, V97, P2151, DOI 10.1073/pnas.040559697; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; Ford JM, 1998, CANCER RES, V58, P599; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Gorlewska-Roberts K, 2002, ENVIRON MOL MUTAGEN, V39, P184, DOI 10.1002/em.10060; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Greenblatt MS, 2001, CANCER RES, V61, P4092; Hanawalt PC, 2001, ENVIRON MOL MUTAGEN, V38, P89, DOI 10.1002/em.1057; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Husain A, 1998, CANCER RES, V58, P1120; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; Lloyd DR, 2000, CANCER RES, V60, P517; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MORI T, 1991, PHOTOCHEM PHOTOBIOL, V54, P225, DOI 10.1111/j.1751-1097.1991.tb02010.x; Motykiewicz G, 2001, CANCER DETECT PREV, V25, P328; Reed E, 1998, CANCER TREAT REV, V24, P331, DOI 10.1016/S0305-7372(98)90056-1; Schuyer M, 1999, MOL CELL ENDOCRINOL, V155, P143, DOI 10.1016/S0303-7207(99)00117-3; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Tang JY, 2000, MOL CELL, V5, P737, DOI 10.1016/S1097-2765(00)80252-X; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7	30	180	191	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2002	32	1					180	184		10.1038/ng953	http://dx.doi.org/10.1038/ng953			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	588RR	12195423				2022-12-25	WOS:000177714900019
J	Lund, AH; Turner, G; Trubetskoy, A; Verhoeven, E; Wientjens, E; Hulsman, D; Russell, R; DePinho, RA; Lenz, J; van Lohuizen, M				Lund, AH; Turner, G; Trubetskoy, A; Verhoeven, E; Wientjens, E; Hulsman, D; Russell, R; DePinho, RA; Lenz, J; van Lohuizen, M			Genome-wide retroviral insertional tagging of genes involved in cancer in Cdkn2a-deficient mice	NATURE GENETICS			English	Article							P53-DEPENDENT APOPTOSIS; CELL-PROLIFERATION; SENESCENCE; EXPRESSION; RAS; ACTIVATION; P19(ARF); ARREST; MYC; P53	We have used large-scale insertional mutagenesis to identify functional landmarks relevant to cancer in the recently completed mouse genome sequence. We infected Cdkn2a(-/-) mice with Moloney murine leukemia virus (MoMuLV) to screen for loci that can participate in tumorigenesis in collaboration with loss of the Cdkn2a-encoded tumor suppressors p16INK4a and p19ARF. Insertional mutagenesis by the latent retrovirus was synergistic with loss of Cdkn2a expression, as indicated by a marked acceleration in the development of both myeloid and lymphoid tumors. We isolated 747 unique sequences flanking retroviral integration sites and mapped them against the mouse genome sequence databases from Celera and Ensembl. In addition to 17 insertions targeting gene loci known to be cancer-related, we identified a total of 37 new common insertion sites (CISs), of which 8 encode components of signaling pathways that are involved in cancer. The effectiveness of large-scale insertional mutagenesis in a sensitized genetic background is demonstrated by the preference for activation of MAP kinase signaling, collaborating with Cdkn2a loss in generating the lymphoid and myeloid tumors. Collectively, our results show that large-scale retroviral insertional mutagenesis in genetically predisposed mice is useful both as a system for identifying genes underlying cancer and as a genetic framework for the assignment of such genes to specific oncogenic pathways.	Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10467 USA; Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10467 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol Genet & Med, Boston, MA 02115 USA	Yeshiva University; Albert Einstein College of Medicine; Netherlands Cancer Institute; Yeshiva University; Albert Einstein College of Medicine; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Lenz, J (corresponding author), Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10467 USA.	lenz@aecom.yu.edu; m.v.lohuizen@nki.nl	Lund, Anders H./F-4786-2014	Lund, Anders H./0000-0002-7407-3398; DePinho, Ronald/0000-0002-5625-577X				Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; Joyce D, 2001, CYTOKINE GROWTH F R, V12, P73, DOI 10.1016/S1359-6101(00)00018-6; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Mikkers H, 2002, NAT GENET, V32, P459, DOI 10.1038/ng1102-459b; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Radhika V, 2001, ONCOGENE, V20, P1607, DOI 10.1038/sj.onc.1204274; Roth P, 1998, BLOOD, V91, P3773, DOI 10.1182/blood.V91.10.3773.3773_3773_3783; Ruas M, 1998, BIOCHIM BIOPHYS ACTA, V1378, P115, DOI 10.1016/s0304-419x(98)00017-1; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; SUZUKI T, 2002, NAT GENET, V32, P86; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	29	188	197	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2002	32	1					160	165		10.1038/ng956	http://dx.doi.org/10.1038/ng956			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	588RR	12185367				2022-12-25	WOS:000177714900016
J	Okamoto, R; Yajima, T; Yamazaki, M; Kanai, T; Mukai, M; Okamoto, S; Ikeda, Y; Hibi, T; Inazawa, J; Watanabe, M				Okamoto, R; Yajima, T; Yamazaki, M; Kanai, T; Mukai, M; Okamoto, S; Ikeda, Y; Hibi, T; Inazawa, J; Watanabe, M			Damaged epithelia regenerated by bone marrow-derived cells in the human gastrointestinal tract	NATURE MEDICINE			English	Article							STEM-CELLS; HEPATOCYTES; DIFFERENTIATION; ORIGIN	Studies have shown that bone marrow cells have the potential to differentiate into a variety of cell types. Here we show that bone marrow cells can repopulate the epithelia of the human gastrointestinal tract. Epithelial cells of male donor origin were distributed in every part of the gastrointestinal tract of female bone marrow transplant recipients. Donor-derived epithelial cells substantially repopulated the gastrointestinal tract during epithelial regeneration after graft-versus-host disease or ulcer formation. Regeneration of gastrointestinal epithelia with donor-derived cells in humans shows a potential clinical application of bone marrow-derived cells for repairing severely damaged epithelia, not only in the gastrointestinal tract but also in other tissues.	Tokyo Med & Dent Univ, Grad Sch, Dept Gastroenterol & Hepatol, Bunkyo Ku, Tokyo, Japan; Keio Univ, Sch Med, Dept Internal Med, Tokyo, Japan; Keio Univ, Sch Med, Div Diagnost Pathol, Tokyo, Japan; Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Tokyo, Japan	Tokyo Medical & Dental University (TMDU); Keio University; Keio University; Tokyo Medical & Dental University (TMDU)	Watanabe, M (corresponding author), Tokyo Med & Dent Univ, Grad Sch, Dept Gastroenterol & Hepatol, Bunkyo Ku, Tokyo, Japan.	mamoru.gast@tmd.ac.jp	Okamoto, Ryuichi/I-1130-2019; Watanabe, Mamoru/AHE-0489-2022	Okamoto, Ryuichi/0000-0002-7047-571X; 				Alison MR, 2000, NATURE, V406, P257, DOI 10.1038/35018642; Bach SP, 2000, CARCINOGENESIS, V21, P469, DOI 10.1093/carcin/21.3.469; Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; Booth C, 2000, J CLIN INVEST, V105, P1493, DOI 10.1172/JCI10229; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Ishino S, 1998, CANCER, V83, P360, DOI 10.1002/(SICI)1097-0142(19980715)83:2<360::AID-CNCR21>3.0.CO;2-Q; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Korbling M, 2002, NEW ENGL J MED, V346, P738, DOI 10.1056/NEJMoa3461002; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; McKay R, 2002, NAT BIOTECHNOL, V20, P426, DOI 10.1038/nbt0502-426; NAKAHORI Y, 1986, NUCLEIC ACIDS RES, V14, P7569, DOI 10.1093/nar/14.19.7569; NEGRIN RS, 2001, WILLIAMS HEMATOLOGY, P209; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Theise ND, 2000, HEPATOLOGY, V32, P11, DOI 10.1053/jhep.2000.9124; Wright Nicholas A., 1997, P315, DOI 10.1016/B978-012563455-7/50011-8; WUMSER AE, 2002, NATURE, V416, P485; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729	22	311	345	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2002	8	9					1011	1017		10.1038/nm755	http://dx.doi.org/10.1038/nm755			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	589KQ	12195435				2022-12-25	WOS:000177757900037
J	Bhattacharya, M; Anborgh, PH; Babwah, AV; Dale, LB; Dobransky, T; Benovic, JL; Feldman, RD; Verdi, JM; Rylett, RJ; Ferguson, SSG				Bhattacharya, M; Anborgh, PH; Babwah, AV; Dale, LB; Dobransky, T; Benovic, JL; Feldman, RD; Verdi, JM; Rylett, RJ; Ferguson, SSG			beta-arrestins regulate a Ral-GDS-Ral effector pathway that mediates cytoskeletal reorganization	NATURE CELL BIOLOGY			English	Article							GTP-BINDING PROTEIN; COUPLED RECEPTOR; PHOSPHOLIPASE-D; C-SRC; ACTIVATION; ENDOCYTOSIS; ASSOCIATION; CHEMOTAXIS; INVOLVEMENT; RECRUITMENT	beta-Arrestins are important in chemoattractant receptor-induced granule release, a process that may involve Ral-dependent regulation of the actin cytoskeleton. We have identified the Ral GDP dissociation stimulator (Ral-GDS) as a beta-arrestin-binding protein by yeast two-hybrid screening and co-immunoprecipitation from human polymorphonuclear neutrophilic leukocytes (PMNs). Under basal conditions, Ral-GDS is localized to the cytosol and remains inactive in a complex formed with beta-arrestins. In response to formyl-Met-Leu-Phe (fMLP) receptor stimulation, arrestin-Ral-GDS protein complexes dissociate and Ral-GDS translocates with beta-arrestin from the cytosol to the plasma membrane, resulting in the Ras-independent activation of the Ral effector pathway required for cytoskeletal rearrangement. The subsequent re-association of beta-arrestin-Ral-GDS complexes is associated with the inactivation of Ral signalling. Thus, beta-arrestins regulate multiple steps in the Ral-dependent processes that result in chemoattractant-induced cytoskeletal reorganization.	Univ Western Ontario, Cell Biol Res Grp, John P Robarts Res Inst, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Physiol, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Pharmacol & Toxicol, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Med, London, ON N6A 5K8, Canada; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Jefferson University	Ferguson, SSG (corresponding author), Univ Western Ontario, Cell Biol Res Grp, John P Robarts Res Inst, 100 Perth Dr, London, ON N6A 5K8, Canada.	ferguson@rri.on.ca	Feldman, Ross/G-3293-2011; Rylett, Rebecca Jane/K-3597-2013	Rylett, Rebecca Jane/0000-0002-9158-9599				ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; Bai C, 1997, METHOD ENZYMOL, V283, P141; Barlic J, 2000, NAT IMMUNOL, V1, P227, DOI 10.1038/79767; Brymora A, 2001, J BIOL CHEM, V276, P29792, DOI 10.1074/jbc.C100320200; Chung CY, 2000, P NATL ACAD SCI USA, V97, P5225, DOI 10.1073/pnas.97.10.5225; Claing A, 2001, J BIOL CHEM, V276, P42509, DOI 10.1074/jbc.M108399200; de Leeuw HPJC, 2001, ARTERIOSCL THROM VAS, V21, P899, DOI 10.1161/01.ATV.21.6.899; de Leeuw HPJC, 1999, THROMB HAEMOSTASIS, V82, P1177, DOI 10.1055/s-0037-1614349; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Fong AM, 2002, P NATL ACAD SCI USA, V99, P7478, DOI 10.1073/pnas.112198299; Frankel P, 1999, BIOCHEM BIOPH RES CO, V255, P502, DOI 10.1006/bbrc.1999.0234; Glogauer M, 2000, J CELL BIOL, V150, P785, DOI 10.1083/jcb.150.4.785; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; Hartt JK, 1999, J EXP MED, V190, P741, DOI 10.1084/jem.190.5.741; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Hofer F, 1998, CURR BIOL, V8, P839, DOI 10.1016/S0960-9822(98)70327-6; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lee T, 1996, DEVELOPMENT, V122, P409; Liu Q, 1999, LUMINESCENCE, V14, P327, DOI 10.1002/(SICI)1522-7243(199911/12)14:6<327::AID-BIO571>3.0.CO;2-A; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; M'Rabet L, 1999, J BIOL CHEM, V274, P21847, DOI 10.1074/jbc.274.31.21847; Mark BL, 1996, BIOCHEM BIOPH RES CO, V225, P40, DOI 10.1006/bbrc.1996.1128; Matsubara K, 1999, ONCOGENE, V18, P1303, DOI 10.1038/sj.onc.1202425; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Miki H, 2000, NATURE, V408, P732, DOI 10.1038/35047107; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; QUINN MT, 1995, J LEUKOCYTE BIOL, V58, P263, DOI 10.1002/jlb.58.3.263; Rosario M, 2001, MOL CELL BIOL, V21, P3750, DOI 10.1128/MCB.21.11.3750-3762.2001; ROTHWELL SW, 1989, J CELL BIOL, V108, P2313, DOI 10.1083/jcb.108.6.2313; SANDBORG RR, 1988, LAB INVEST, V59, P300; Santini F, 2000, J CELL SCI, V113, P2463; Sawamoto K, 1999, ONCOGENE, V18, P1967, DOI 10.1038/sj.onc.1202522; SCHIFFMANN E, 1975, J IMMUNOL, V114, P1831; Seachrist JL, 2002, J BIOL CHEM, V277, P679, DOI 10.1074/jbc.M109022200; Su SB, 1999, J EXP MED, V189, P395, DOI 10.1084/jem.189.2.395; Suzuki J, 2000, MOL CELL BIOL, V20, P4658, DOI 10.1128/MCB.20.13.4658-4665.2000; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; VOLKNANDT W, 1993, FEBS LETT, V317, P53, DOI 10.1016/0014-5793(93)81490-Q; Weiner OD, 1999, NAT CELL BIOL, V1, P75, DOI 10.1038/10042; WenzelSeifert K, 1997, J LEUKOCYTE BIOL, V61, P703, DOI 10.1002/jlb.61.6.703; Witko-Sarsat V, 2000, LAB INVEST, V80, P617, DOI 10.1038/labinvest.3780067; Wolthuis RMF, 1998, CURR BIOL, V8, P471, DOI 10.1016/S0960-9822(98)70183-6	48	112	114	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2002	4	8					547	555		10.1038/ncb821	http://dx.doi.org/10.1038/ncb821			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	579WK	12105416				2022-12-25	WOS:000177201100009
J	Dong, HD; Strome, SE; Salomao, DR; Tamura, H; Hirano, F; Flies, DB; Roche, PC; Lu, J; Zhu, GF; Tamada, K; Lennon, VA; Celis, E; Chen, LP				Dong, HD; Strome, SE; Salomao, DR; Tamura, H; Hirano, F; Flies, DB; Roche, PC; Lu, J; Zhu, GF; Tamada, K; Lennon, VA; Celis, E; Chen, LP			Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion	NATURE MEDICINE			English	Article; Proceedings Paper	Symposium on Tumor Escape from Immune Recognition: Molecular Mechanism and Functional Significance	AUG 22-23, 1999	BALTIMORE, MARYLAND				FAS LIGAND; COSTIMULATORY MOLECULES; MELANOMA-CELLS; B7 FAMILY; EXPRESSION; ACTIVATION; DEATH; PD-1; ANTIGEN; CD28	B7-H1, a recently described member of the B7 family of costimulatory molecules, is thought to be involved in the regulation of cellular and humoral immune responses through the PD-1 receptor on activated T and B cells. We report here that, except for cells of the macrophage lineage, normal human tissues do not express B7-H1. In contrast, B7-H1 is abundant in human carcinomas of lung, ovary and colon and in melanomas. The pro-inflammatory cytokine interferon. upregulates B7-H1 on the surface of tumor cell lines. Cancer cell - associated B7-H1 increases apoptosis of antigen-specific human T-cell clones in vitro, and the apoptotic effect of B7-H1 is mediated largely by one or more receptors other than PD-1. In addition, expression of B7-H1 on mouse P815 tumor increases apoptosis of activated tumor-reactive T cells and promotes the growth of highly immunogenic B7-1(+) tumors in vivo. These findings have implications for the design of T cell - based cancer immunotherapy.	Mayo Clin, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin, Dept Otorhinolaryngol, Rochester, MN USA; Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA; Mayo Clin, Dept Neurol, Rochester, MN USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Chen, LP (corresponding author), Mayo Clin, Dept Immunol, Rochester, MN 55905 USA.		Tamura, Hideto/AAV-3532-2020	Chen, Lieping/0000-0002-6825-3069; Dong, Haidong/0000-0002-5782-2983	NCI NIH HHS [CA37343, CA85721, CA79915, CA80782, CA15083, CA82677] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037343, R01CA080782, R01CA082677, R01CA079915, R01CA085721, P30CA015083] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agata Y, 1996, INT IMMUNOL, V8, P765, DOI 10.1093/intimm/8.5.765; Arai H, 1997, P NATL ACAD SCI USA, V94, P13862, DOI 10.1073/pnas.94.25.13862; BOISE LH, 1995, CURR OPIN IMMUNOL, V7, P620, DOI 10.1016/0952-7915(95)80067-0; Chambers CA, 1997, CURR OPIN IMMUNOL, V9, P396, DOI 10.1016/S0952-7915(97)80087-8; Chapoval AI, 2000, METH MOLEC MED, V45, P247, DOI 10.1385/1-59259-079-9:247; Chappell DB, 1999, CANCER RES, V59, P59; CHEN LP, 1994, J EXP MED, V179, P523, DOI 10.1084/jem.179.2.523; CHEN LP, 1993, IMMUNOL TODAY, V14, P483, DOI 10.1016/0167-5699(93)90262-J; Dong HD, 1999, NAT MED, V5, P1365; Finger LR, 1997, GENE, V197, P177, DOI 10.1016/S0378-1119(97)00260-6; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Georgescu L, 1997, J CLIN INVEST, V100, P2622, DOI 10.1172/JCI119806; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hurtado JC, 1997, J IMMUNOL, V158, P2600; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; Jeremias I, 1998, EUR J IMMUNOL, V28, P143, DOI 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3; Kobayashi H, 2000, CANCER RES, V60, P5228; Krummel MF, 1996, J EXP MED, V183, P2533, DOI 10.1084/jem.183.6.2533; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; LINSLEY PS, 1994, IMMUNITY, V1, P793, DOI 10.1016/S1074-7613(94)80021-9; Lu J, 2000, CANCER RES, V60, P5223; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nakashima M, 1999, NAT MED, V5, P938, DOI 10.1038/11383; Nishimura H, 2001, SCIENCE, V291, P319, DOI 10.1126/science.291.5502.319; Nishimura H, 1999, IMMUNITY, V11, P141, DOI 10.1016/S1074-7613(00)80089-8; Noel PJ, 1996, J IMMUNOL, V157, P636; O'Connell J, 1999, NAT MED, V5, P267, DOI 10.1038/6477; RIVOLTINI L, 1995, CANCER RES, V55, P3149; Rogers PR, 2001, IMMUNITY, V15, P445, DOI 10.1016/S1074-7613(01)00191-1; Smyth MJ, 2001, NAT IMMUNOL, V2, P293, DOI 10.1038/86297; Strand S, 1998, MOL MED TODAY, V4, P63, DOI 10.1016/S1357-4310(97)01191-X; SYKULEV Y, 1994, P NATL ACAD SCI USA, V91, P11487, DOI 10.1073/pnas.91.24.11487; Takahashi C, 1999, J IMMUNOL, V162, P5037; Tamada K, 2002, J CLIN INVEST, V109, P549, DOI 10.1172/JCI200213604; Tamura H, 2001, BLOOD, V97, P1809, DOI 10.1182/blood.V97.6.1809; Walunas TL, 1996, J EXP MED, V183, P2541, DOI 10.1084/jem.183.6.2541; Watts TH, 1999, CURR OPIN IMMUNOL, V11, P286, DOI 10.1016/S0952-7915(99)80046-6; Yu ZY, 2001, ANN NEUROL, V49, P146; Zhao SR, 1999, BRIT J HAEMATOL, V106, P827, DOI 10.1046/j.1365-2141.1999.01630.x	39	3327	3803	18	426	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2002	8	8					793	800		10.1038/nm730	http://dx.doi.org/10.1038/nm730			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	579WJ	12091876				2022-12-25	WOS:000177200900024
J	Liu, XS; Brutlag, DL; Liu, JS				Liu, XS; Brutlag, DL; Liu, JS			An algorithm for finding protein-DNA binding sites with applications to chromatin-immunoprecipitation microarray experiments	NATURE BIOTECHNOLOGY			English	Article							YEAST-CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; REGULATORY SITES; SEQUENCE; IDENTIFICATION; ALIGNMENT; GENES	Chromatin immunoprecipitation followed by cDNA microarray hybridization (ChIP-array) has become a popular procedure for studying genome-wide protein-DNA interactions and transcription regulation. However, it can only map the probable protein-DNA interaction loci within 1-2 kilobases resolution. To pinpoint interaction sites down to the base-pair level, we introduce a computational method, Motif Discovery scan (MDscan), that examines the ChIP-array-selected sequences and searches for DNA sequence motifs representing the protein-DNA interaction sites. MDscan combines the advantages of two widely adopted motif search strategies, word enumeration(1-4) and position-specific weight matrix updating(5-9), and incorporates the ChIP-array ranking information to accelerate searches and enhance their success rates. MDscan correctly identified all the experimentally verified motifs from published ChIP-array experiments in yeast(10-13) (STE12, GAL4, RAP1, SCB, MCB, MCM1, SFF, and SWI5), and predicted two motif patterns for the differential binding of Rap1 protein in telomere regions. In our studies, the method was faster and more accurate than several established motif-finding algorithms(5,8,9). MDscan can be used to find DNA motifs not only in ChIP-array experiments but also in other experiments in which a subgroup of the sequences can be inferred to contain relatively abundant motif sites. The MDscan web server can be accessed at http:// BioProspector.stanford.edu/MDscan/.	Harvard Univ, Dept Stat, Cambridge, MA 02138 USA; Stanford Univ, Dept Biochem, Stanford, CA 94305 USA	Harvard University; Stanford University	Liu, JS (corresponding author), Harvard Univ, Dept Stat, 1 Oxford St, Cambridge, MA 02138 USA.	jliu@stat.harvard.edu		Liu, Xiaole/0000-0003-4736-7339	NHGRI NIH HHS [R01 HGF02235, R01 HG02518-01] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG002235, R01HG002518] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BAILEY TL, 1994, ISMB, V2, P28; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; Bussemaker HJ, 2000, P NATL ACAD SCI USA, V97, P10096, DOI 10.1073/pnas.180265397; DOLAN JW, 1989, P NATL ACAD SCI USA, V86, P5703, DOI 10.1073/pnas.86.15.5703; GRAHAM IR, 1994, NUCLEIC ACIDS RES, V22, P124, DOI 10.1093/nar/22.2.124; HERTZ GZ, 1990, COMPUT APPL BIOSCI, V6, P81; Idrissi FZ, 1999, BIOCHEM J, V341, P477, DOI 10.1042/0264-6021:3410477; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; LAWRENCE CE, 1993, SCIENCE, V262, P208, DOI 10.1126/science.8211139; Lieb JD, 2001, NAT GENET, V28, P327, DOI 10.1038/ng569; Liu JS, 1995, J AM STAT ASSOC, V90, P1156, DOI 10.2307/2291508; LIU JS, 2001, MONTE CARLO STRATEGI; Liu X, 2001, Pac Symp Biocomput, P127; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Roth FP, 1998, NAT BIOTECHNOL, V16, P939, DOI 10.1038/nbt1098-939; Simon I, 2001, CELL, V106, P697, DOI 10.1016/S0092-8674(01)00494-9; Sinha S, 2000, Proc Int Conf Intell Syst Mol Biol, V8, P344; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; van Helden J, 1998, J MOL BIOL, V281, P827, DOI 10.1006/jmbi.1998.1947; Vilo J, 2000, Proc Int Conf Intell Syst Mol Biol, V8, P384	20	477	509	0	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2002	20	8					835	839		10.1038/nbt717	http://dx.doi.org/10.1038/nbt717			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	579MU	12101404				2022-12-25	WOS:000177182500037
J	Wolff, JA				Wolff, JA			The "grand" problem of synthetic delivery	NATURE BIOTECHNOLOGY			English	Editorial Material							GENE		Univ Wisconsin, Waisman Ctr, Dept Pediat, Madison, WI 53705 USA; Univ Wisconsin, Waisman Ctr, Dept Med Genet, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Wolff, JA (corresponding author), Univ Wisconsin, Waisman Ctr, Dept Pediat, 1500 Highland Ave, Madison, WI 53705 USA.							BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; LEHN JM, 1988, ANGEW CHEM INT EDIT, V27, P89, DOI 10.1002/anie.198800891; REINER D, 1995, BIOCHEMISTRY-US, V34, P12877; SEBESTYEN MG, 1999, NONVIRAL VECTORS GEN, P140; Trubetskoy VS, 1998, NUCLEIC ACIDS RES, V26, P4178, DOI 10.1093/nar/26.18.4178; WOLFF JA, 1994, HUM GENE THER, V5, P469, DOI 10.1089/hum.1994.5.4-469; WOLFF JA, 1999, DEV HUMAN GENE THERA, P279	7	36	46	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2002	20	8					768	769		10.1038/nbt0802-768	http://dx.doi.org/10.1038/nbt0802-768			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	579MU	12147992				2022-12-25	WOS:000177182500010
J	Crone, SA; Zhao, YY; Fan, L; Gu, YS; Minamisawa, S; Liu, Y; Peterson, KL; Chen, J; Kahn, R; Condorelli, G; Ross, J; Chien, KR; Lee, KF				Crone, SA; Zhao, YY; Fan, L; Gu, YS; Minamisawa, S; Liu, Y; Peterson, KL; Chen, J; Kahn, R; Condorelli, G; Ross, J; Chien, KR; Lee, KF			ErbB2 is essential in the prevention of dilated cardiomyopathy	NATURE MEDICINE			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; DEFICIENT MICE; HEART-FAILURE; TRASTUZUMAB HERCEPTIN; CARDIAC DEVELOPMENT; SIGNALING NETWORK; REQUIREMENT; EXPRESSION; RECEPTORS; CANCER	Amplification of the gene encoding the ErbB2 (Her2/neu) receptor tyrosine kinase is critical for the progression of several forms of breast cancer. In a large-scale clinical trial, treatment with Herceptin (trastuzumab), a humanized blocking antibody against ErbB2, led to marked improvement in survival. However, cardiomyopathy was uncovered as a mitigating side effect, thereby suggesting an important role for ErbB2 signaling as a modifier of human heart failure. To investigate the physiological role of ErbB2 signaling in the adult heart, we generated mice with a ventricular-restricted deletion of Erbb2. These ErbB2-deficient conditional mutant mice were viable and displayed no overt phenotype. However, physiological analysis revealed the onset of multiple independent parameters of dilated cardiomyopathy, including chamber dilation, wall thinning and decreased contractility. Additionally, cardiomyocytes isolated from these conditional mutants were more susceptible to anthracycline toxicity. ErbB2 signaling in cardiomyocytes is therefore essential for the prevention of dilated cardiomyopathy.	Salk Inst Biol Studies, La Jolla, CA 92037 USA; Univ Calif San Diego, UCSD Salk Program Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Div Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Inst Mol Med, La Jolla, CA 92093 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Salk Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Scripps Research Institute; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Lee, KF (corresponding author), Salk Inst Biol Studies, La Jolla, CA 92037 USA.	klee@salk.edu	Chen, Ju/E-5579-2011; gu, yu/GSD-4507-2022; Condorelli, Gianluigi/Q-6736-2017	Condorelli, Gianluigi/0000-0003-0481-6843; Crone, Steven/0000-0001-9644-2767; ZHAO, YOU-YANG/0000-0002-0041-0339; Minamisawa, Susumu/0000-0003-4728-2116				Agus DB, 2000, SEMIN ONCOL, V27, P53; Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Baselga J, 2000, SEMIN ONCOL, V27, P27; BENJAMIN RS, 1978, CANCER TREAT REP, V62, P935; BILLINGHAM ME, 1978, CANCER TREAT REP, V62, P865; Britsch S, 1998, GENE DEV, V12, P1825, DOI 10.1101/gad.12.12.1825; Chen J, 1998, J BIOL CHEM, V273, P1252, DOI 10.1074/jbc.273.2.1252; Chen J, 1998, DEVELOPMENT, V125, P1943; Cho MC, 1999, J BIOL CHEM, V274, P22251, DOI 10.1074/jbc.274.32.22251; Christensen G, 2000, CIRCULATION, V101, P178, DOI 10.1161/01.CIR.101.2.178; Coral-Vazquez R, 1999, CELL, V98, P465, DOI 10.1016/S0092-8674(00)81975-3; Deconinck AE, 1997, CELL, V90, P717, DOI 10.1016/S0092-8674(00)80532-2; Erickson SL, 1997, DEVELOPMENT, V124, P4999; FERRANS VJ, 1978, CANCER TREAT REP, V62, P955; Grady RM, 1997, CELL, V90, P729, DOI 10.1016/S0092-8674(00)80533-4; GROVE D, 1969, CIRC RES, V25, P473, DOI 10.1161/01.RES.25.4.473; Haunstetter A, 1998, CIRC RES, V82, P1111, DOI 10.1161/01.RES.82.11.1111; Heiden MGV, 2001, J BIOL CHEM, V276, P19414, DOI 10.1074/jbc.M101590200; Hirota H, 1999, CELL, V97, P189, DOI 10.1016/S0092-8674(00)80729-1; HUNTER JJ, 1999, MOL BASIS CARDIOVASC, P211; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Ikeda S, 1999, CLIN SCI, V97, P239, DOI 10.1042/CS19980374; Klapper LN, 2000, ADV CANCER RES, V77, P25; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; Rohrbach S, 1999, CIRCULATION, V100, P407, DOI 10.1161/01.CIR.100.4.407; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Sparano JA, 2001, SEMIN ONCOL, V28, P20, DOI 10.1053/sonc.2001.22813; Sun XH, 2001, EUR J ORAL SCI, V109, P103, DOI 10.1034/j.1600-0722.2001.00982.x; Suzuki T, 2001, AM J PHYSIOL-REG I, V280, pR1399, DOI 10.1152/ajpregu.2001.280.5.R1399; Tanaka N, 1996, CIRCULATION, V94, P1109, DOI 10.1161/01.CIR.94.5.1109; Wang X, 1999, CLIN HEMORHEOL MICRO, V21, P137; YOUNG RC, 1981, NEW ENGL J MED, V305, P139, DOI 10.1056/NEJM198107163050305; Zhao YY, 1998, J BIOL CHEM, V273, P10261, DOI 10.1074/jbc.273.17.10261	37	623	652	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2002	8	5					459	465		10.1038/nm0502-459	http://dx.doi.org/10.1038/nm0502-459			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	547ZW	11984589				2022-12-25	WOS:000175336800030
J	Nichols, BJ				Nichols, BJ			A distinct class of endosome mediates clathrin-independent endocytosis to the Golgi complex	NATURE CELL BIOLOGY			English	Article							CHOLERA-TOXIN; CELL-SURFACE; PLASMA-MEMBRANE; LIPID RAFTS; CAVEOLAE; INTERNALIZATION; PROTEINS; DOMAINS; INTERFERENCE; MICRODOMAINS	Mammalian cells endocytose a variety of proteins and lipids without utilising clathrin-coated pits(1-5). Detailed molecular mechanisms for clathrin-independent endocytosis are unclear. Several markers for this process, including glycosphingolipid-binding bacterial toxin subunits such as cholera toxin B subunit ( CTxB), and glycosyl-phosphatidyl-inositol (GPI)-anchored proteins, are found in detergent-resistant membrane fractions (DRMs), or lipid rafts'(2,3,5-7). The Golgi complex constitutes one principal intracellular destination for these markers(2). Uptake of both CTxB and GPI-anchored proteins may involve caveolae, small invaginations in the plasma membrane (PM)(8-13). However, the identity of intermediate organelles involved in PM to Golgi trafficking, as well as the function of caveolins, defining protein components of caveolae(12,13), are unclear. This paper shows that molecules which partition into DRMs and are endocytosed in a clathrin-independent fashion, accumulate in a discrete population of endosomes en route to the Golgi complex. These endosomes are devoid of markers for classical early and recycling endosomes, but do contain caveolin-1. Caveolin-1-positive endosomes are sites for the sorting of caveolin-1 away from Golgi-bound cargoes, although caveolin-1 itself is unlikely to have a direct function in PM to Golgi transport.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Nichols, BJ (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.							Abrami L, 2001, J BIOL CHEM, V276, P30729, DOI 10.1074/jbc.M102039200; Benting JH, 1999, J CELL BIOL, V146, P313, DOI 10.1083/jcb.146.2.313; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Chatterjee S, 2001, EMBO J, V20, P1583, DOI 10.1093/emboj/20.7.1583; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Iversen TG, 2001, MOL BIOL CELL, V12, P2099, DOI 10.1091/mbc.12.7.2099; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Lamaze C, 2001, MOL CELL, V7, P661, DOI 10.1016/S1097-2765(01)00212-X; Lipardi C, 2000, MOL BIOL CELL, V11, P531, DOI 10.1091/mbc.11.2.531; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; Oh P, 2001, MOL BIOL CELL, V12, P685, DOI 10.1091/mbc.12.3.685; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Puri V, 2001, J CELL BIOL, V154, P535, DOI 10.1083/jcb.200102084; Razani B, 2001, J BIOL CHEM, V276, P38121; Razani B, 2001, EXP CELL RES, V271, P36, DOI 10.1006/excr.2001.5372; Scheiffele P, 1998, J CELL BIOL, V140, P795, DOI 10.1083/jcb.140.4.795; Schnitzer JE, 1996, SCIENCE, V274, P239, DOI 10.1126/science.274.5285.239; Schubert W, 2001, J BIOL CHEM, V276, P48619, DOI 10.1074/jbc.C100613200; Shogomori H, 2001, J BIOL CHEM, V276, P9182, DOI 10.1074/jbc.M009414200; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Torgersen ML, 2001, J CELL SCI, V114, P3737	28	209	213	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAY	2002	4	5					374	378		10.1038/ncb787	http://dx.doi.org/10.1038/ncb787			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	547GR	11951093				2022-12-25	WOS:000175325100019
J	Schon, MP; Krahn, T; Schon, M; Rodriguez, ML; Antonicek, H; Schultz, JE; Ludwig, RJ; Zollner, TM; Bischoff, E; Bremm, KD; Schramm, M; Henninger, K; Kaufmann, R; Gollnick, HPM; Parker, CM; Boehncke, WH				Schon, MP; Krahn, T; Schon, M; Rodriguez, ML; Antonicek, H; Schultz, JE; Ludwig, RJ; Zollner, TM; Bischoff, E; Bremm, KD; Schramm, M; Henninger, K; Kaufmann, R; Gollnick, HPM; Parker, CM; Boehncke, WH			Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation	NATURE MEDICINE			English	Article							HOMING T-CELLS; CYCLOSPORINE-A; SCID MICE; LYMPHOCYTE RECIRCULATION; ENDOTHELIAL-CELLS; HUMAN SKIN; PSORIASIS; NEUTROPHILS; EXPRESSION; RAPAMYCIN	Specific interference with molecular mechanisms guiding tissue localization of leukocytes may be of great utility for selective immunosuppressive therapies. We have discovered and characterized efomycines, a new family of selective small-molecule inhibitors of selectin functions. Members of this family significantly inhibited leukocyte adhesion in vitro. Efomycine M, which was nontoxic and showed the most selective inhibitory effects on selectin-mediated leukocyte-endothelial adhesion in vitro, significantly diminished rolling in mouse ear venules in vivo as seen by intravital microscopy. In addition, efomycine M alleviated cutaneous inflammation in two complementary mouse models of psoriasis, one of the most common chronic inflammatory skin disorders. Molecular modeling demonstrated a spatial conformation of efomycines mimicking naturally occurring selectin ligands. Efomycine M might be efficacious in the treatment of human inflammatory disorders through a similar mechanism.	Otto Von Guericke Univ, Dept Dermatol, Magdeburg, Germany; Bayer AG, Pharmaceut Res, D-5600 Wuppertal, Germany; Bayer AG, Cent Res, D-5090 Leverkusen, Germany; Univ Frankfurt, Dept Dermatol, D-6000 Frankfurt, Germany; Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA	Otto von Guericke University; Bayer AG; Bayer AG; Goethe University Frankfurt; Harvard University; Brigham & Women's Hospital	Schon, MP (corresponding author), Otto Von Guericke Univ, Dept Dermatol, Magdeburg, Germany.		Ludwig, Ralf/F-3996-2018; Ludwig, Ralf J/A-2629-2008	Ludwig, Ralf/0000-0002-1394-1737; Ludwig, Ralf J/0000-0002-1394-1737; Schon, Michael/0000-0002-0698-4130				Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Barros LFM, 2000, SHOCK, V13, P67, DOI 10.1097/00024382-200013010-00012; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; Boehncke WH, 1996, NATURE, V379, P777, DOI 10.1038/379777a0; BOEHNCKE WH, 1994, ARCH DERMATOL RES, V286, P325, DOI 10.1007/BF00402223; Boehncke WH, 1999, ARCH DERMATOL RES, V291, P104, DOI 10.1007/s004030050391; BONFANTI R, 1989, BLOOD, V73, P1109; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Christophers E, 1996, INT ARCH ALLERGY IMM, V110, P199, DOI 10.1159/000237288; Dam TN, 1999, J INVEST DERMATOL, V113, P1082, DOI 10.1046/j.1523-1747.1999.00811.x; DETMAR M, 1992, J INVEST DERMATOL, V98, P147, DOI 10.1111/1523-1747.ep12555746; Falke P, 2000, CEREBROVASC DIS, V10, P97, DOI 10.1159/000016037; Goodarzi MT, 1998, GLYCOCONJUGATE J, V15, P1149, DOI 10.1023/A:1006920007227; GOTTLIEB SL, 1995, NAT MED, V1, P442, DOI 10.1038/nm0595-442; HAMANN P, 1990, J ANTIBIOT, V43, P1431; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MILLER KE, 1992, BIOCHEMISTRY-US, V31, P6703, DOI 10.1021/bi00144a009; MORRISSEY PJ, 1993, J EXP MED, V178, P237, DOI 10.1084/jem.178.1.237; NICKOLOFF BJ, 1991, ARCH DERMATOL, V127, P871, DOI 10.1001/archderm.127.6.871; Nickoloff BJ, 1999, ARCH DERMATOL, V135, P1104, DOI 10.1001/archderm.135.9.1104; NICKOLOFF BJ, 1995, AM J PATHOL, V146, P580; PETERS DH, 1993, DRUGS, V46, P746, DOI 10.2165/00003495-199346040-00009; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; PICKER LJ, 1993, J IMMUNOL, V150, P1122; POWRIE F, 1993, INT IMMUNOL, V5, P1461, DOI 10.1093/intimm/5.11.1461; Robert C, 1999, J EXP MED, V189, P627, DOI 10.1084/jem.189.4.627; Salmi M, 1998, INFLAMM BOWEL DIS, V4, P149; Schon M, 2000, J INVEST DERMATOL, V114, P976, DOI 10.1046/j.1523-1747.2000.00953.x; Schon MP, 1999, J INVEST DERMATOL, V112, P405, DOI 10.1046/j.1523-1747.1999.00538.x; Schon MP, 1997, NAT MED, V3, P183, DOI 10.1038/nm0297-183; Schon MP, 2001, NAT IMMUNOL, V2, P91, DOI 10.1038/84293; SCHON MP, 2000, DERMATOPHARMACOLOGY, P179; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SCHRODER JM, 1992, J INVEST DERMATOL, V98, P241, DOI 10.1111/1523-1747.ep12556058; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; SMITH CH, 1993, J IMMUNOL, V151, P3274; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SRIVASTAVA D, 1990, ENDOCRINOLOGY, V127, P1770, DOI 10.1210/endo-127-4-1770; Todderud G, 1997, J PHARMACOL EXP THER, V282, P1298; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; Weninger W, 2000, IMMUNITY, V12, P665, DOI 10.1016/S1074-7613(00)80217-4; WroneSmith T, 1996, J CLIN INVEST, V98, P1878, DOI 10.1172/JCI118989	45	113	118	1	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2002	8	4					366	372		10.1038/nm0402-366	http://dx.doi.org/10.1038/nm0402-366			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	536ML	11927942				2022-12-25	WOS:000174704800028
J	Arap, W; Kolonin, MG; Trepel, M; Lahdenranta, J; Cardo-Vila, M; Giordano, RJ; Mintz, PJ; Ardelt, PU; Yao, VJ; Vidal, CI; Chen, L; Flamm, A; Valtanen, H; Weavind, LM; Hicks, ME; Pollock, RE; Botz, GH; Bucana, CD; Koivunen, E; Cahill, D; Troncoso, P; Baggerly, KA; Pentz, RD; Do, KA; Logothetis, CJ; Pasqualini, R				Arap, W; Kolonin, MG; Trepel, M; Lahdenranta, J; Cardo-Vila, M; Giordano, RJ; Mintz, PJ; Ardelt, PU; Yao, VJ; Vidal, CI; Chen, L; Flamm, A; Valtanen, H; Weavind, LM; Hicks, ME; Pollock, RE; Botz, GH; Bucana, CD; Koivunen, E; Cahill, D; Troncoso, P; Baggerly, KA; Pentz, RD; Do, KA; Logothetis, CJ; Pasqualini, R			Steps toward mapping the human vasculature by phage display	NATURE MEDICINE			English	Article							TARGETED DRUG-DELIVERY; AMINOPEPTIDASE N; PEPTIDES; EXPRESSION; RECEPTOR; NEOVASCULATURE; ENDOTHELIUM; INHIBITION; INTEGRINS; SEQUENCE	The molecular diversity of receptors in human blood vessels remains largely unexplored. We developed a selection method in which peptides that home to specific vascular beds are identified after administration of a peptide library. Here we report the first in vivo screening of a peptide library in a patient. We surveyed 47,160 motifs that localized to different organs. This large-scale screening indicates that the tissue distribution of circulating peptides is nonrandom. High-throughput analysis of the motifs revealed similarities to ligands for differentially expressed cell-surface proteins, and a candidate ligand-receptor pair was validated. These data represent a step toward the construction of a molecular map of human vasculature and may have broad implications for the development of targeted therapies.	Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Clin Eth, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Crit Care, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Diagnost Radiol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Helsinki, Dept Biochem, Div Biosci, Helsinki, Finland; Max Planck Inst Mol Genet, Berlin, Germany	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Finland National Institute for Health & Welfare; University of Helsinki; Max Planck Society	Arap, W (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	warap@notes.mdacc.tmc.edu; rpasqual@notes/mdacc.tmc.edu	Giordano, Ricardo/A-2074-2010	Giordano, Ricardo/0000-0001-8116-6771; Kolonin, Mikhail/0000-0002-3743-7869; Koivunen, Erkki/0000-0002-6443-9595	NATIONAL CANCER INSTITUTE [U54CA090810, P50CA090270, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA9081001, CA90270, CA8297601, P30 CA016672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Bacich DJ, 2001, MAMM GENOME, V12, P117, DOI 10.1007/s003350010240; Barrow PA, 1997, TRENDS MICROBIOL, V5, P268, DOI 10.1016/S0966-842X(97)01054-8; Bhagwat SV, 2001, BLOOD, V97, P652, DOI 10.1182/blood.V97.3.652; Burg MA, 1999, CANCER RES, V59, P2869; Campbell CL, 2001, AM J PATHOL, V158, P25, DOI 10.1016/S0002-9440(10)63940-5; Carson-Walter EB, 2001, CANCER RES, V61, P6649; Chang SS, 1999, CANCER RES, V59, P3192; Curnis F, 2000, NAT BIOTECHNOL, V18, P1185, DOI 10.1038/81183; Daluiski A, 2001, NAT GENET, V27, P84, DOI 10.1038/83810; Ellerby HM, 1999, NAT MED, V5, P1032, DOI 10.1038/12469; Hong FD, 2000, CANCER RES, V60, P6551; Koivunen E, 1999, NAT BIOTECHNOL, V17, P768, DOI 10.1038/11703; Koivunen E, 2001, J CELL BIOL, V153, P905, DOI 10.1083/jcb.153.5.905; Kolonin M, 2001, CURR OPIN CHEM BIOL, V5, P308, DOI 10.1016/S1367-5931(00)00207-6; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Latham PW, 1999, NAT BIOTECHNOL, V17, P755, DOI 10.1038/11686; Lin BZ, 1997, J BIOL CHEM, V272, P24145, DOI 10.1074/jbc.272.39.24145; Mahboubi K, 2000, J IMMUNOL, V164, P3837, DOI 10.4049/jimmunol.164.7.3837; Nugent MA, 2000, P NATL ACAD SCI USA, V97, P6722, DOI 10.1073/pnas.97.12.6722; Pasqualini R, 2000, CANCER RES, V60, P722; Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; PASQUALINI R, 2000, PHAGE DISPLAY LAB MA, P1; *PC, 1983, PRES COMM STUD ETH P; Rajotte D, 1998, J CLIN INVEST, V102, P430, DOI 10.1172/JCI3008; Rajotte D, 1999, J BIOL CHEM, V274, P11593, DOI 10.1074/jbc.274.17.11593; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; St Croix B, 2000, SCIENCE, V289, P1197; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Trepel M, 2000, HUM GENE THER, V11, P1971, DOI 10.1089/10430340050143408; Vendruscolo M, 2001, NATURE, V409, P641, DOI 10.1038/35054591; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wijdicks EFM, 2001, NEW ENGL J MED, V344, P1215, DOI 10.1056/NEJM200104193441606; Wu KK, 2001, CIRCULATION, V103, P1386, DOI 10.1161/01.CIR.103.10.1386	35	472	525	0	60	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2002	8	2					121	127		10.1038/nm0202-121	http://dx.doi.org/10.1038/nm0202-121			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	517FN	11821895				2022-12-25	WOS:000173600600020
J	Bodnar, JS; Chatterjee, A; Castellani, LW; Ross, DA; Ohmen, J; Cavalcoli, J; Wu, CY; Dains, KM; Catanese, J; Chu, M; Sheth, SS; Charugundla, K; Demant, P; West, DB; de Jong, P; Lusis, AJ				Bodnar, JS; Chatterjee, A; Castellani, LW; Ross, DA; Ohmen, J; Cavalcoli, J; Wu, CY; Dains, KM; Catanese, J; Chu, M; Sheth, SS; Charugundla, K; Demant, P; West, DB; de Jong, P; Lusis, AJ			Positional cloning of the combined hyperlipidemia gene Hyplip1	NATURE GENETICS			English	Article							FAMILIAL COMBINED HYPERLIPIDEMIA; RECOMBINANT CONGENIC STRAINS; CORONARY HEART-DISEASE; UP-REGULATED PROTEIN-1; REDOX REGULATION; THIOREDOXIN FUNCTION; CHROMOSOME 1Q21-Q23; ACID; LINKAGE; EXPRESSION	Familial combined hyperlipidemia (FCHL, MIM-144250) is a common, multifactorial and heterogeneous dyslipidemia predisposing to premature coronary artery disease(1-2) and characterized by elevated plasma triglycerides, cholesterol, or both(3-4). We identified a mutant mouse strain, HcB-19/Dem (HcB-19), that shares features with FCHL, including hyper-triglyceridemia hypercholesterolemia, elevated plasma apolipoprotein B and increased secretion of triglyceride-rich lipoproteins(5). The hyperlipidemia results from spontaneous mutation at a locus, Hyplip1, on distal mouse chromosome 3 in a region syntenic with a 1q21-q23 FCHL locus identified in Finnish, German, Chinese and US families(6-8). We fine-mapped Hyplip1 to roughly 160 kb, constructed a BAC contig and sequenced overlapping BACs to identify 13 candidate genes. We found substantially decreased mRNA expression for thioredoxin interacting protein (Txnip). Sequencing of the critical region revealed a Txnip nonsense mutation in HcB-19 that is absent in its normolipidemic parental strains. Txnip encodes a cytoplasmic protein that binds and inhibits thioredoxin, a major regulator of cellular redox state, The mutant mice have decreased CO2 production but increased ketone body synthesis, suggesting that altered redox status down-regulates the citric-acid cycle, sparing fatty acids for triglyceride and ketone body production. These results reveal a new pathway of potential clinical significance that contributes to plasma lipid metabolism.	Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; Pfizer Inc, Ann Arbor Labs, Dept Mol Sci, Pfizer Global Res & Dev, Ann Arbor, MI 48105 USA; Netherlands Canc Inst, Div Mol Genet, Amsterdam, Netherlands	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Pfizer; Netherlands Cancer Institute	Lusis, AJ (corresponding author), Univ Calif Los Angeles, Sch Med, Inst Mol Biol, 47-123 CHS, Los Angeles, CA 90095 USA.				NHLBI NIH HHS [P01 HL030568-190011, P01 HL028481, P01 HL030568-190009, P01 HL028481-170010, P01 HL030568, P01 HL028481-17] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568, P01HL028481] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Castellani LW, 1998, NAT GENET, V18, P374, DOI 10.1038/ng0498-374; CASTELLANI LW, 1991, BIOCHIM BIOPHYS ACTA, V1086, P197, DOI 10.1016/0005-2760(91)90008-6; CHEN KS, 1994, BBA-GENE STRUCT EXPR, V1219, P26, DOI 10.1016/0167-4781(94)90242-9; Coon H, 2000, ARTERIOSCL THROM VAS, V20, P2275, DOI 10.1161/01.ATV.20.10.2275; Culbertson MR, 1999, TRENDS GENET, V15, P74, DOI 10.1016/S0168-9525(98)01658-8; DEMANT P, 1986, IMMUNOGENETICS, V24, P416, DOI 10.1007/BF00377961; DOOLITTLE MH, 1987, J LIPID RES, V28, P1326; GASDASKA JR, 1995, CELL GROWTH DIFFER, V6, P1643; GENEST JJ, 1992, CIRCULATION, V85, P2025, DOI 10.1161/01.CIR.85.6.2025; GOLDSTEIN JL, 1973, J CLIN INVEST, V52, P1544, DOI 10.1172/JCI107332; GROOT PC, 1992, FASEB J, V6, P2826, DOI 10.1096/fasebj.6.10.1634045; GRUNDY SM, 1987, ARTERIOSCLEROSIS, V7, P203; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Junn E, 2000, J IMMUNOL, V164, P6287, DOI 10.4049/jimmunol.164.12.6287; KIMURA RE, 1988, PEDIATR RES, V23, P262, DOI 10.1203/00006450-198803000-00006; Lanford Robert E., 1998, V19, P501; LANOUE KF, 1972, J BIOL CHEM, V247, P667; LEEDS P, 1991, GENE DEV, V5, P2303, DOI 10.1101/gad.5.12a.2303; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; NIKKILA EA, 1973, LANCET, V1, P954; Nishiyama A, 1999, J BIOL CHEM, V274, P21645, DOI 10.1074/jbc.274.31.21645; OLUBADEWO JO, 1993, BIOCHEM PHARMACOL, V45, P2441, DOI 10.1016/0006-2952(93)90225-L; Pajukanta P, 1998, NAT GENET, V18, P369, DOI 10.1038/ng0498-369; Pajukanta P, 2001, MAMM GENOME, V12, P238, DOI 10.1007/s003350010265; Pei WD, 2000, CLIN GENET, V57, P29, DOI 10.1034/j.1399-0004.2000.570105.x; Sambrook J., 2002, MOL CLONING LAB MANU; Ueda S, 1998, J IMMUNOL, V161, P6689; WILLIAMSON DH, 1967, BIOCHEM J, V103, P514, DOI 10.1042/bj1030514; YODOI J, 1992, IMMUNOL TODAY, V13, P405, DOI 10.1016/0167-5699(92)90091-K	30	174	183	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2002	30	1					110	116		10.1038/ng811	http://dx.doi.org/10.1038/ng811			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	508TL	11753387	Green Accepted			2022-12-25	WOS:000173105600024
J	Nagai, T; Ibata, K; Park, ES; Kubota, M; Mikoshiba, K; Miyawaki, A				Nagai, T; Ibata, K; Park, ES; Kubota, M; Mikoshiba, K; Miyawaki, A			A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applications	NATURE BIOTECHNOLOGY			English	Article							SECRETION		RIKEN, Lab Cell Funct & Dynam, Ctr Adv Technol, Wako, Saitama 3510198, Japan; RIKEN, Dev Neurobiol Lab, Wako, Saitama 3510198, Japan; RIKEN, Lab Mol Dynam Mental Disorder, Brain Sci Inst, Wako, Saitama 3510198, Japan	RIKEN; RIKEN; RIKEN	Miyawaki, A (corresponding author), RIKEN, Lab Cell Funct & Dynam, Ctr Adv Technol, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.		Miyawaki, Atsushi/K-3569-2014; Mikoshiba, Katsuhiko/N-7943-2015; Ibata, Keiji/L-5802-2013	Miyawaki, Atsushi/0000-0002-2329-3235; Nagai, Takeharu/0000-0003-2650-9895				Angleson JK, 1997, TRENDS NEUROSCI, V20, P281, DOI 10.1016/S0166-2236(97)01083-7; CADWELL RC, 1994, PCR METH APPL, V3, pS136; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; Griesbeck O, 2001, J BIOL CHEM, V276, P29188, DOI 10.1074/jbc.M102815200; Heikal AA, 2000, P NATL ACAD SCI USA, V97, P11996, DOI 10.1073/pnas.97.22.11996; Jayaraman S, 2000, J BIOL CHEM, V275, P6047, DOI 10.1074/jbc.275.9.6047; Lang T, 1997, NEURON, V18, P857, DOI 10.1016/S0896-6273(00)80325-6; Miyawaki A, 1999, P NATL ACAD SCI USA, V96, P2135, DOI 10.1073/pnas.96.5.2135; Miyawaki A, 2000, METHOD ENZYMOL, V327, P472, DOI 10.1016/S0076-6879(00)27297-2; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Nagai T, 2001, P NATL ACAD SCI USA, V98, P3197, DOI 10.1073/pnas.051636098; Pouli AE, 1998, BIOCHEM J, V331, P669, DOI 10.1042/bj3310669; Reid BG, 1997, BIOCHEMISTRY-US, V36, P6786, DOI 10.1021/bi970281w; Sawano A, 2000, Nucleic Acids Res, V28, pE78, DOI 10.1093/nar/28.16.e78; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Tsuboi T, 2000, CURR BIOL, V10, P1307, DOI 10.1016/S0960-9822(00)00756-9	16	2106	2244	8	346	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2002	20	1					87	90		10.1038/nbt0102-87	http://dx.doi.org/10.1038/nbt0102-87			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	507ME	11753368				2022-12-25	WOS:000173031600042
J	Sambandamurthy, VK; Wang, XJ; Chen, B; Russell, RG; Derrick, S; Collins, FM; Morris, SL; Jacobs, WR				Sambandamurthy, VK; Wang, XJ; Chen, B; Russell, RG; Derrick, S; Collins, FM; Morris, SL; Jacobs, WR			A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis	NATURE MEDICINE			English	Article							BCG VACCINES; VIRULENCE; PERSISTENCE; GENE	With the advent of HIV and the widespread emergence of drug-resistant strains of Mycobacterium tuberculosis, newer control strategies in the form of a better vaccine could decrease the global incidence of tuberculosis. A desirable trait in an effective live attenuated vaccine strain is an ability to persist within the host in a limited fashion in order to produce important protective antigens in vivo(1,2). Attenuated M. tuberculosis vaccine candidates have been constructed by deleting genes required for growth in mice(3-5). These candidate vaccines did not elicit adequate protective immunity in animal models, due to their inability to persist sufficiently long within the host tissues. Here we report that an auxotrophic mutant of M. tuberculosis defective in the de novo biosynthesis of pantothenic acid (vitamin B5) is highly attenuated in immunocompromised SCID mice and in immunocompetent BALB/c mice. SCID mice infected with the pantothenate auxotroph survived significantly longer (250 days) than mice infected with either bacille Calmette-Guerin (BCG) vaccine or virulent M. tuberculosis (77 and 35 days, respectively). Subcutaneous immunization with this auxotroph conferred protection in C57BL/6J mice against an aerosol challenge with virulent M. tuberculosis, which was comparable with that afforded by BCG vaccination. Our findings highlight the importance of de novo pantothenate biosynthesis in limiting the intracellular survival and pathogenesis of M. tuberculosis without reducing its immunogenicity in vaccinated mice.	Albert Einstein Coll Med, Howard Hughes Med Inst, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10467 USA; US FDA, Ctr Biol Evaluat & Res, Bethesda, MD USA	Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; US Food & Drug Administration (FDA)	Jacobs, WR (corresponding author), Albert Einstein Coll Med, Howard Hughes Med Inst, Bronx, NY 10467 USA.	jacobsw@hhmi.org		Jacobs, William/0000-0003-3321-3080				Afshar K, 2001, GENETICS, V157, P1267; BARDAROV S, 1999, ONE STEP ALLELIC EXC, V6034; Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520; Camacho LR, 1999, MOL MICROBIOL, V34, P257, DOI 10.1046/j.1365-2958.1999.01593.x; COLLINS FM, 1985, TUBERCLE, V66, P267, DOI 10.1016/0041-3879(85)90064-9; Cox JS, 1999, NATURE, V402, P79, DOI 10.1038/47042; De Voss JJ, 2000, P NATL ACAD SCI USA, V97, P1252, DOI 10.1073/pnas.97.3.1252; Glickman MS, 2000, MOL CELL, V5, P717, DOI 10.1016/S1097-2765(00)80250-6; Hondalus MK, 2000, INFECT IMMUN, V68, P2888, DOI 10.1128/IAI.68.5.2888-2898.2000; JACKOWSKI S, 1990, J BACTERIOL, V172, P3842, DOI 10.1128/jb.172.7.3842-3848.1990; Jackowski S., 1996, ESCHERICHIA COLI SAL, P687; Jackson M, 1999, INFECT IMMUN, V67, P2867, DOI 10.1128/IAI.67.6.2867-2873.1999; KANAI K, 1955, Jpn J Med Sci Biol, V8, P115; Kaushal D, 2002, P NATL ACAD SCI USA, V99, P8330, DOI 10.1073/pnas.102055799; Manca C, 2001, P NATL ACAD SCI USA, V98, P5752, DOI 10.1073/pnas.091096998; McKenney D, 1999, SCIENCE, V284, P1523, DOI 10.1126/science.284.5419.1523; McKinney JD, 2000, NATURE, V406, P735, DOI 10.1038/35021074; Raman S, 2001, J BACTERIOL, V183, P6119, DOI 10.1128/JB.183.20.6119-6125.2001; Saliba KJ, 2001, J BIOL CHEM, V276, P18115, DOI 10.1074/jbc.M010942200; Slyshenkov VS, 1996, FREE RADICAL BIO MED, V20, P793, DOI 10.1016/0891-5849(95)02210-4; Smith DA, 2001, INFECT IMMUN, V69, P1142, DOI 10.1128/IAI.69.2.1442-1150.2001; Steyn AJC, 2002, P NATL ACAD SCI USA, V99, P3147, DOI 10.1073/pnas.052705399; Weber I, 2000, MOL MICROBIOL, V35, P1017, DOI 10.1046/j.1365-2958.2000.01794.x	23	268	289	0	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2002	8	10					1171	1174		10.1038/nm765	http://dx.doi.org/10.1038/nm765			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	599AN	12219086				2022-12-25	WOS:000178311000046
J	Mikkers, H; Allen, J; Knipscheer, P; Romeyn, L; Hart, A; Vink, E; Berns, A				Mikkers, H; Allen, J; Knipscheer, P; Romeyn, L; Hart, A; Vink, E; Berns, A			High-throughput retroviral tagging to identify components of specific signaling pathways in cancer	NATURE GENETICS			English	Article							E-MU-MYC; C-MYC; TRANSGENIC MICE; PIM-1 KINASE; COOPERATING ONCOGENES; STEEL FACTOR; ACTIVATION; PHOSPHORYLATION; LYMPHOMAGENESIS; IDENTIFICATION	Genetic screens carried out in lower organisms such as yeast(1), Drosophila melanogaster(2) and Caenorhabditis elegans 3 have revealed many signaling pathways. For example, components of the RAS signaling cascade were identified using a mutant eye phenotype in D. melanogaster as a readout(2). Screening is usually based on enhancing or suppressing a phenotype by way of a known mutation in a particular signaling pathway. Such in vivo screens have been difficult to carry out in mammals, however, owing to their relatively long generation times and the limited number of animals that can be screened. Here we describe an in vivo mammalian genetic screen used to identify components of pathways contributing to oncogenic transformation. We applied retroviral insertional mutagenesis in Myc transgenic (EmuMyc) mice lacking expression of Pim1 and Pim2 to search for genes that can substitute for Pim1 and Pim2 in lymphomagenesis. We determined the chromosomal positions of 477 retroviral insertion sites (RISs) derived from 38 tumors from EmuMyc Pim1(-/-) Pim2(-/-) mice and 27 tumors from EmuMyc control mice using the Ensembl and Celera annotated mouse genome databases. There were 52 sites occupied by proviruses in more than one tumor. These common insertion sites (CISs) are likely to contain genes contributing to tumorigenesis. Comparison of the RISs in tumors of Pim-null mice with the RISs in tumors of EmuMyc control mice indicated that 10 of the 52 CISs belong to the Pim complementation group. In addition, we found that Pim3 is selectively activated in Pim-null tumor cells, which supports the validity of our approach.	Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Radiotherapy, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute	Berns, A (corresponding author), Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	a.berns@nki.nl						Allen JD, 1996, SEMIN CANCER BIOL, V7, P299, DOI 10.1006/scbi.1996.0038; Allen JD, 1997, ONCOGENE, V15, P1133, DOI 10.1038/sj.onc.1201288; Craig NL, 1997, ANNU REV BIOCHEM, V66, P437, DOI 10.1146/annurev.biochem.66.1.437; CUYPERS HT, 1984, CELL, V37, P141; DEVON RS, 1995, NUCLEIC ACIDS RES, V23, P1644, DOI 10.1093/nar/23.9.1644; Ishibashi Y, 2001, FEBS LETT, V506, P33, DOI 10.1016/S0014-5793(01)02881-2; Jacobs H, 1999, J EXP MED, V190, P1059, DOI 10.1084/jem.190.8.1059; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; Koike N, 2000, FEBS LETT, V467, P17, DOI 10.1016/S0014-5793(00)01105-4; LAIRD PW, 1993, NUCLEIC ACIDS RES, V21, P4750, DOI 10.1093/nar/21.20.4750; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Losman J, 1999, COLD SPRING HARB SYM, V64, P405, DOI 10.1101/sqb.1999.64.405; LUND AH, 2002, NAT GENET, V32, P80, DOI DOI 10.1038/NG956; MIYAZAWA K, 1992, BLOOD, V80, P1685; Mochizuki T, 1999, J BIOL CHEM, V274, P18659, DOI 10.1074/jbc.274.26.18659; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; Rainio EM, 2002, J IMMUNOL, V168, P1524, DOI 10.4049/jimmunol.168.4.1524; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; Scheijen B, 1997, J VIROL, V71, P9, DOI 10.1128/JVI.71.1.9-16.1997; SELTEN G, 1984, EMBO J, V3, P3215, DOI 10.1002/j.1460-2075.1984.tb02281.x; Sternberg PW, 1998, TRENDS GENET, V14, P466, DOI 10.1016/S0168-9525(98)01592-3; SUZUKI T, 2002, NAT GENET, V32, P86; TSUJI K, 1992, BLOOD, V79, P2855; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; WASSARMAN DA, 1995, CURR OPIN GENET DEV, V5, P44, DOI 10.1016/S0959-437X(95)90052-7	30	7	7	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2002	32	1					153	159		10.1038/ng950	http://dx.doi.org/10.1038/ng950			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	588RR	12185366				2022-12-25	WOS:000177714900015
J	Pedelacq, JD; Piltch, E; Liong, EC; Berendzen, J; Kim, CY; Rho, BS; Park, MS; Terwilliger, TC; Waldo, GS				Pedelacq, JD; Piltch, E; Liong, EC; Berendzen, J; Kim, CY; Rho, BS; Park, MS; Terwilliger, TC; Waldo, GS			Engineering soluble proteins for structural genomics	NATURE BIOTECHNOLOGY			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; X-RAY-STRUCTURE; IN-VITRO; LYSOZYME; ASSAY	Structural genomics has the ambitious goal of delivering three-dimensional structural information on a genome-wide scale. Yet only a small fraction of natural proteins are suitable for structure determination because of bottlenecks such as poor expression, aggregation, and misfolding of proteins, and difficulties in solubilization and crystallization. We propose to overcome these bottlenecks by producing soluble, highly expressed proteins that are derived from and closely related to their natural homologs. Here we demonstrate the utility of this approach by using a green fluorescent protein (GFP) folding reporter assay to evolve an enzymatically active, soluble variant of a hyperthermophilic protein that is normally insoluble when expressed in Escherichia coli, and determining its structure by X-ray crystallography. Analysis of the structure provides insight into the substrate specificity of the enzyme and the improved solubility of the variant.	Los Alamos Natl Lab, Biosci Div, Los Alamos, NM 87545 USA; Los Alamos Natl Lab, Biophys Grp, Los Alamos, NM 87545 USA; Univ Rochester, Rochester, NY 14627 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Los Alamos National Laboratory; University of Rochester	Waldo, GS (corresponding author), Los Alamos Natl Lab, Biosci Div, MS-M888, Los Alamos, NM 87545 USA.	waldo@telomere.lanl.gov	Pedelacq, Jean-Denis/C-6053-2011; Terwilliger, Thomas/AAM-4079-2020; Terwilliger, Thomas C/K-4109-2012; Terwilliger, Thomas/AEF-4827-2022; Park, Min Sung/HCH-2207-2022	Terwilliger, Thomas/0000-0001-6384-0320; Terwilliger, Thomas C/0000-0001-6384-0320; Kim, Chang-Yub/0000-0001-9353-5909; Berendzen, Joel/0000-0002-9454-9074; PEDELACQ, Jean-Denis/0000-0002-3202-2517				Armstrong N, 1999, PROTEIN SCI, V8, P1475, DOI 10.1110/ps.8.7.1475; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHERFILS J, 1994, BIOCHEMISTRY-US, V33, P9062, DOI 10.1021/bi00197a006; Christendat D, 2000, PROG BIOPHYS MOL BIO, V73, P339, DOI 10.1016/S0079-6107(00)00010-9; DALE GE, 1994, PROTEIN ENG, V7, P933, DOI 10.1093/protein/7.7.933; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; Gaasterland T, 1999, CURR OPIN MICROBIOL, V2, P542, DOI 10.1016/S1369-5274(99)00014-4; HAGEL L, 1989, J CHROMATOGR, V476, P329, DOI 10.1016/S0021-9673(01)93880-4; HEINZ DW, 1992, P NATL ACAD SCI USA, V89, P3751, DOI 10.1073/pnas.89.9.3751; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Janin J, 2000, J BIOENERG BIOMEMBR, V32, P215, DOI 10.1023/A:1005528811303; Karamohamed S, 1999, BIOTECHNIQUES, V26, P728, DOI 10.2144/99264rr02; Kim CA, 2001, EMBO J, V20, P4173, DOI 10.1093/emboj/20.15.4173; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lacombe ML, 2000, J BIOENERG BIOMEMBR, V32, P247, DOI 10.1023/A:1005584929050; Lascu I, 2000, J BIOENERG BIOMEMBR, V32, P237, DOI 10.1023/A:1005532912212; Lascu I, 2000, J BIOENERG BIOMEMBR, V32, P227, DOI 10.1023/A:1005580828141; Makrides SC, 1996, MICROBIOL REV, V60, P512, DOI 10.1128/MMBR.60.3.512-538.1996; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Morera S, 1995, STRUCTURE, V3, P1307, DOI 10.1016/S0969-2126(01)00268-4; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PORATH J, 1992, PROTEIN EXPRES PURIF, V3, P263, DOI 10.1016/1046-5928(92)90001-D; Rudolph R, 1996, FASEB J, V10, P49, DOI 10.1096/fasebj.10.1.8566547; Skinner MM, 1996, P NATL ACAD SCI USA, V93, P10753, DOI 10.1073/pnas.93.20.10753; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P1863, DOI 10.1107/S0907444999010033; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Trivedi VD, 1999, J BIOCHEM BIOPH METH, V40, P49, DOI 10.1016/S0165-022X(99)00021-4; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Waldo GS, 1999, NAT BIOTECHNOL, V17, P691, DOI 10.1038/10904; WILLIAMS RL, 1993, J MOL BIOL, V234, P1230, DOI 10.1006/jmbi.1993.1673; Yang JK, 2002, ACTA CRYSTALLOGR D, V58, P303, DOI 10.1107/S0907444901018789	33	130	144	1	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2002	20	9					927	932		10.1038/nbt732	http://dx.doi.org/10.1038/nbt732			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	589KN	12205510				2022-12-25	WOS:000177757700026
J	Dove, A				Dove, A			Uncorking the biomanufacturing bottleneck	NATURE BIOTECHNOLOGY			English	Article																			0	60	82	0	21	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2002	20	8					777	779		10.1038/nbt0802-777	http://dx.doi.org/10.1038/nbt0802-777			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	579MU	12148000				2022-12-25	WOS:000177182500017
J	Coverley, D; Laman, H; Laskey, RA				Coverley, D; Laman, H; Laskey, RA			Distinct roles for cyclins E and A during DNA replication complex assembly and activation	NATURE CELL BIOLOGY			English	Article							MINICHROMOSOME MAINTENANCE PROTEINS; S-PHASE; CDC6; CHROMATIN; ACCUMULATION; ASSOCIATION; INITIATION; ORIGINS; CELLS	Initiation of DNA replication is regulated by cyclin-dependent protein kinase 2 (Cdk2) in association with two different regulatory subunits, cyclin A and cyclin E (reviewed in ref. 1). But why two different cyclins are required and why their order of activation is tightly regulated are unknown. Using a cell-free system for initiation of DNA replication that is based on G1 nuclei, G1 cytosol and recombinant proteins, we find that cyclins E and A have specialized roles during the transition from G0 to S phase. Cyclin E stimulates replication complex assembly by cooperating with Cdc6, to make G1 nuclei competent to replicate in vitro. Cyclin A has two separable functions: it activates DNA synthesis by replication complexes that are already assembled, and it inhibits the assembly of new complexes. Thus, cyclin E opens a 'window of opportunity' for replication complex assembly that is closed by cyclin A. The dual functions of cyclin A ensure that the assembly phase (G1) ends before DNA synthesis (S) begins, thereby preventing re-initiation until the next cell cycle.	Hutchison MRC Res Ctr, Canc Cell Unit, Cambridge CB2 2XZ, England; Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England; Canc Res UK, London WC2A 3PX, England	University of York - UK; Cancer Research UK	Coverley, D (corresponding author), Hutchison MRC Res Ctr, Canc Cell Unit, Hills Rd, Cambridge CB2 2XZ, England.	dc17@york.ac.uk		Coverley, Dawn/0000-0001-8262-7023; Laman, Heike/0000-0002-6089-171X				Blow JJ, 2001, EMBO J, V20, P3293, DOI 10.1093/emboj/20.13.3293; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; Cook JG, 2002, P NATL ACAD SCI USA, V99, P1347, DOI 10.1073/pnas.032677499; Coverley D, 2000, J CELL SCI, V113, P1929; Diffley JFX, 2002, J CELL SCI, V115, P869; Dimitrova DS, 1999, MOL CELL, V4, P983, DOI 10.1016/S1097-2765(00)80227-0; Ekholm SV, 2001, MOL CELL BIOL, V21, P3256, DOI 10.1128/MCB.21.9.3256-3265.2001; Erlandsson F, 2000, EXP CELL RES, V259, P86, DOI 10.1006/excr.2000.4889; Furstenthal L, 2001, NAT CELL BIOL, V3, P715, DOI 10.1038/35087026; Furstenthal L, 2001, J CELL BIOL, V152, P1267, DOI 10.1083/jcb.152.6.1267; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; Laman H, 2001, MOL CELL BIOL, V21, P624, DOI 10.1128/MCB.21.2.624-635.2001; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Madine MA, 2000, J STRUCT BIOL, V129, P198, DOI 10.1006/jsbi.2000.4218; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Nguyen VQ, 2001, NATURE, V411, P1068, DOI 10.1038/35082600; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Pelizon C, 2000, GENE DEV, V14, P2526, DOI 10.1101/gad.176300; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; Seki T, 2000, P NATL ACAD SCI USA, V97, P14115, DOI 10.1073/pnas.97.26.14115; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Stoeber K, 1998, EMBO J, V17, P7219, DOI 10.1093/emboj/17.24.7219; Strausfeld UP, 1996, J CELL SCI, V109, P1555; Su TT, 1998, J CELL BIOL, V140, P451, DOI 10.1083/jcb.140.3.451; Swanson C, 2000, P NATL ACAD SCI USA, V97, P7796, DOI 10.1073/pnas.97.14.7796; Williams RS, 1997, P NATL ACAD SCI USA, V94, P142, DOI 10.1073/pnas.94.1.142	32	233	237	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2002	4	7					523	528		10.1038/ncb813	http://dx.doi.org/10.1038/ncb813			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	568UL	12080347				2022-12-25	WOS:000176562900018
J	Cummings, DE; Clement, K; Purnell, JQ; Vaisse, C; Foster, KE; Frayo, RS; Schwartz, MW; Basdevant, A; Weigle, DS				Cummings, DE; Clement, K; Purnell, JQ; Vaisse, C; Foster, KE; Frayo, RS; Schwartz, MW; Basdevant, A; Weigle, DS			Elevated plasma ghrelin levels in Prader-Willi syndrome	NATURE MEDICINE			English	Letter							MELANOCORTIN-4 RECEPTOR; STOMACH; OBESITY; SIGNAL		VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA 98108 USA; Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA; Univ Paris 06, Hotel Dieu EA 3502, Serv Med & Nutr, F-75252 Paris, France; Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA; Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; Harborview Medical Center; University of Washington; University of Washington Seattle; UDICE-French Research Universities; Sorbonne Universite; Oregon Health & Science University; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Cummings, DE (corresponding author), VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA 98108 USA.		Purnell, Jonathan Q/GVS-8854-2022; Vaisse, Christian/F-1067-2011; Clément, karine/R-1120-2017; Schwartz, Michael W/H-9950-2012	Purnell, Jonathan Q/0000-0001-5505-6333; 	NIDDK NIH HHS [R01 DK060540] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060540] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Asakawa A, 2001, GASTROENTEROLOGY, V120, P337, DOI 10.1053/gast.2001.22158; Barsh GS, 2000, NATURE, V404, P644, DOI 10.1038/35007519; Burman P, 2001, ENDOCR REV, V22, P787, DOI 10.1210/er.22.6.787; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Cummings DE, 2001, DIABETES, V50, P1714, DOI 10.2337/diabetes.50.8.1714; Cummings DE, 2002, NEW ENGL J MED, V346, P1623, DOI 10.1056/NEJMoa012908; Dubern B, 2001, J PEDIATR-US, V139, P204, DOI 10.1067/mpd.2001.116284; Inui A, 2001, NAT REV NEUROSCI, V2, P551, DOI 10.1038/35086018; Janssen JAMJL, 2001, EUR J ENDOCRINOL, V145, P711, DOI 10.1530/eje.0.1450711; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Nakazato M, 2001, NATURE, V409, P194, DOI 10.1038/35051587; Nicholls RD, 2001, ANNU REV GENOM HUM G, V2, P153, DOI 10.1146/annurev.genom.2.1.153; RITTMASTER RS, 1987, NEUROENDOCRINOLOGY, V45, P118, DOI 10.1159/000124713; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090; Vaisse C, 2000, J CLIN INVEST, V106, P253, DOI 10.1172/JCI9238; Weigle DS, 1997, J CLIN ENDOCR METAB, V82, P566, DOI 10.1210/jc.82.2.566; Wren AM, 2001, J CLIN ENDOCR METAB, V86, P5992, DOI 10.1210/jc.86.12.5992; Wren AM, 2001, DIABETES, V50, P2540, DOI 10.2337/diabetes.50.11.2540	18	443	461	0	31	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2002	8	7					643	644		10.1038/nm0702-643	http://dx.doi.org/10.1038/nm0702-643			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	567QG	12091883	Green Published			2022-12-25	WOS:000176495200003
J	Miyawaki, K; Yamada, Y; Ban, N; Ihara, Y; Tsukiyama, K; Zhou, HY; Fujimoto, S; Oku, A; Tsuda, K; Toyokuni, S; Hiai, H; Mizunoya, W; Fushiki, T; Holst, JJ; Makino, M; Tashita, A; Kobara, Y; Tsubamoto, Y; Jinnouchi, T; Jomori, T; Seino, Y				Miyawaki, K; Yamada, Y; Ban, N; Ihara, Y; Tsukiyama, K; Zhou, HY; Fujimoto, S; Oku, A; Tsuda, K; Toyokuni, S; Hiai, H; Mizunoya, W; Fushiki, T; Holst, JJ; Makino, M; Tashita, A; Kobara, Y; Tsubamoto, Y; Jinnouchi, T; Jomori, T; Seino, Y			Inhibition of gastric inhibitory polypeptide signaling prevents obesity	NATURE MEDICINE			English	Article							RESISTANCE; MICE; FAT; METABOLISM; RECEPTOR; GENE; MEAL	Secretion of gastric inhibitory polypeptide (GIP), a duodenal hormone, is primarily induced by absorption of ingested fat. Here we describe a novel pathway of obesity promotion via GIP. Wild-type mice fed a high-fat diet exhibited both hypersecretion of GIP and extreme visceral and subcutaneous fat deposition with insulin resistance. In contrast, mice lacking the GIP receptor (Gipr(-/-)) fed a high-fat diet were clearly protected from both the obesity and the insulin resistance. Moreover, double-homozygous mice (Gipr(-/-), Lep(ob)/Lep(ob)) generated by crossbreeding Gipr(-/-) and obese ob/ob (Lep(ob)/Lep(ob)) mice gained less weight and had lower adiposity than Lep(ob)/Lep(ob) mice. The Gipr(-/-) mice had a lower respiratory quotient and used fat as the preferred energy substrate, and were thus resistant to obesity. Therefore, GIP directly links overnutrition to obesity and it is a potential target for anti-obesity drugs.	Kyoto Univ, Dept Diabet & Clin Nutr, Kyoto, Japan; Kyoto Univ, Grad Sch Med, Dept Pathol & Biol Dis, Kyoto, Japan; Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Kyoto, Japan; Univ Copenhagen, Panum Inst, Dept Med Physiol, DK-2200 Copenhagen N, Denmark; Sanwa Kagaku Kenkyusho Co Ltd, Inabe, Mie, Japan	Kyoto University; Kyoto University; Kyoto University; University of Copenhagen; Sanwa Kagaku Kenkyusho Co., Ltd.	Seino, Y (corresponding author), Kyoto Univ, Dept Diabet & Clin Nutr, Kyoto, Japan.		Yamada, Yuichiro/G-4766-2011; Toyokuni, Shinya/ABE-7714-2021; Holst, Jens/AAA-8022-2022; Mizunoya, Wataru/W-1674-2019; Toyokuni, Shinya/C-1358-2010	Toyokuni, Shinya/0000-0002-5757-1109; Mizunoya, Wataru/0000-0002-2258-1964; Toyokuni, Shinya/0000-0002-5757-1109; Holst, Jens Juul/0000-0001-6853-3805				Bray GA, 1998, AM J CLIN NUTR, V68, P1157, DOI 10.1093/ajcn/68.6.1157; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; EBERT R, 1980, CLIN GASTROENTEROL, V9, P679; FALKO JM, 1975, J CLIN ENDOCR METAB, V41, P260, DOI 10.1210/jcem-41-2-260; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; Golay A, 1997, INT J OBESITY, V21, pS2; Goldberg IJ, 1996, J LIPID RES, V37, P693; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Guggenbuhl P, 1995, METHOD FIND EXP CLIN, V17, P621; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; KRARUP T, 1983, J CLIN ENDOCR METAB, V56, P1306, DOI 10.1210/jcem-56-6-1306; Miyawaki K, 1999, P NATL ACAD SCI USA, V96, P14843, DOI 10.1073/pnas.96.26.14843; Neel JV, 1999, NUTR REV, V57, pS2, DOI 10.1111/j.1753-4887.1999.tb01782.x; NEEL JV, 1962, AM J HUM GENET, V14, P353; Ohnuki K, 2001, LIPIDS, V36, P583, DOI 10.1007/s11745-001-0760-2; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Steinberg GR, 2000, AM J PHYSIOL-ENDOC M, V279, pE1374, DOI 10.1152/ajpendo.2000.279.6.E1374; STENGER J, 1995, PHYSIOL BEHAV, V57, P319, DOI 10.1016/0031-9384(94)00216-R; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; USDIN TB, 1993, ENDOCRINOLOGY, V133, P2861, DOI 10.1210/en.133.6.2861; WOODS SC, 1981, DIABETOLOGIA, V20, P305, DOI 10.1007/BF00254497; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	24	653	729	1	23	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2002	8	7					738	742		10.1038/nm727	http://dx.doi.org/10.1038/nm727			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	567QG	12068290				2022-12-25	WOS:000176495200036
J	Redegeld, FA; van der Heijden, MW; Kool, M; Heijdra, BM; Garssen, J; Kraneveld, AD; Van Loveren, H; Roholl, P; Saito, T; Verbeek, JS; Claassens, J; Koster, AS; Nijkamp, FP				Redegeld, FA; van der Heijden, MW; Kool, M; Heijdra, BM; Garssen, J; Kraneveld, AD; Van Loveren, H; Roholl, P; Saito, T; Verbeek, JS; Claassens, J; Koster, AS; Nijkamp, FP			Immunoglobulin-free light chains elicit immediate hypersensitivity-like responses	NATURE MEDICINE			English	Article							DELAYED-TYPE HYPERSENSITIVITY; MAST-CELL ACTIVATION; FC-EPSILON-RI; CONTACT SENSITIVITY; MULTIPLE-SCLEROSIS; CEREBROSPINAL-FLUID; CYTOKINE PRODUCTION; DEFICIENT MICE; IGE ANTIBODY; GAMMA-CHAIN	Immunoglobulin (Ig)-free light chains IgLC are present in serum and their production is augmented under pathological conditions such as multiple sclerosis, rheumatoid arthritis and neurological disorders. Until now, no (patho)physiological function has been ascribed to circulating Ig light chains. Here we show that IgLCs can confer mast cell-dependent hypersensitivity in mice. Antigenic stimulation results in plasma extravasation, cutaneous swelling and mast-cell degranulation. We show that IgLCs have a crucial role in development of contact sensitivity, which could be completely prevented by a novel IgLC antagonist. Although IgE and IgG(1) are central to the induction of immediate hypersensitivity reactions, our results show that IgLCs have similar activity. IgLCs may therefore be a novel factor in the humoral immune response to antigen exposure. Our findings open new avenues in investigating the pathogenesis of autoimmune diseases and their treatments.	Univ Utrecht, Utrecht Inst Pharmaceut Sci, Dept Pharmacol & Pathophysiol, Utrecht, Netherlands; Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands; Chiba Univ, Dept Mol Genet, Chuo Ku, Chiba, Japan; Leiden Univ, Med Ctr, Dept Human Genet, Leiden, Netherlands	Utrecht University; Netherlands National Institute for Public Health & the Environment; Chiba University; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Redegeld, FA (corresponding author), Univ Utrecht, Utrecht Inst Pharmaceut Sci, Dept Pharmacol & Pathophysiol, Utrecht, Netherlands.		Koster, Andries/T-8807-2019; Saito, Takashi/C-9684-2009; Redegeld, Frank A/O-6534-2016; garssen, johan/I-7159-2016; Kraneveld, Aletta D/J-3351-2016	Koster, Andries/0000-0001-7772-4654; Saito, Takashi/0000-0001-9495-3547; Redegeld, Frank A/0000-0001-8830-7960; Kraneveld, Aletta D/0000-0001-9819-383X				Asai K, 2001, IMMUNITY, V14, P791, DOI 10.1016/S1074-7613(01)00157-1; Askenase PW, 2000, CURR TOP MICROBIOL, V252, P171; Biedermann T, 2000, J EXP MED, V192, P1441, DOI 10.1084/jem.192.10.1441; Corry DB, 1999, NATURE, V402, pB18; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; FAGNART OC, 1988, J NEUROIMMUNOL, V19, P119, DOI 10.1016/0165-5728(88)90041-0; Geba GP, 1996, J IMMUNOL, V157, P557; HANNAMHARRIS AC, 1981, IMMUNOLOGY, V43, P417; HOPPER JE, 1986, CELL IMMUNOL, V101, P122, DOI 10.1016/0008-8749(86)90191-7; Hsu C, 1996, IMMUNOL LETT, V52, P129, DOI 10.1016/0165-2478(96)02599-0; Huang ZQ, 1997, J CLIN INVEST, V99, P732, DOI 10.1172/JCI119218; Kalesnikoff J, 2001, IMMUNITY, V14, P801, DOI 10.1016/S1074-7613(01)00159-5; Karimi K, 1999, EXP HEMATOL, V27, P654, DOI 10.1016/S0301-472X(98)00083-6; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; LEDBETTER JA, 1987, MOL IMMUNOL, V24, P1255, DOI 10.1016/0161-5890(87)90119-2; Lee KH, 2000, J IMMUNOL, V165, P4970, DOI 10.4049/jimmunol.165.9.4970; Lukacs NW, 1996, BLOOD, V87, P2262, DOI 10.1182/blood.V87.6.2262.bloodjournal8762262; Maeda A, 1998, J EXP MED, V188, P991, DOI 10.1084/jem.188.5.991; Marone G, 1998, CLIN EXP RHEUMATOL, V16, P245; MASAT L, 1994, P NATL ACAD SCI USA, V91, P893, DOI 10.1073/pnas.91.3.893; MEADE R, 1988, J IMMUNOL, V141, P2704; Miyajima I, 1997, J CLIN INVEST, V99, P901, DOI 10.1172/JCI119255; MOUTSOPOULOS HM, 1983, J IMMUNOL, V130, P2663; OETTGEN HC, 1994, NATURE, V370, P367, DOI 10.1038/370367a0; PAINTER RG, 1972, BIOCHEMISTRY-US, V11, P1327, DOI 10.1021/bi00758a001; PIROZZI G, 1995, J IMMUNOL, V155, P5811; ROZNIECKI JJ, 1995, ANN NEUROL, V37, P63, DOI 10.1002/ana.410370112; SCHECHTER I, 1976, BIOCHEMISTRY-US, V15, P2785, DOI 10.1021/bi00658a013; Secor VH, 2000, J EXP MED, V191, P813, DOI 10.1084/jem.191.5.813; SHAPIRO AL, 1966, NATURE, V211, P243, DOI 10.1038/211243a0; Sheets ED, 1999, J CELL BIOL, V145, P877, DOI 10.1083/jcb.145.4.877; SKVORTSOV VT, 1968, NATURE, V218, P377, DOI 10.1038/218377a0; Smith DA, 1995, MOL IMMUNOL, V32, P1339, DOI 10.1016/0161-5890(95)00113-1; SOLLING K, 1981, ACTA MED SCAND, V209, P473; SUN M, 1994, J BIOL CHEM, V269, P734; SUN M, 1994, J IMMUNOL, V153, P5121; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; Thiagarajan P, 2000, BIOCHEMISTRY-US, V39, P6459, DOI 10.1021/bi992588w; TRIBBICK G, 1989, MOL IMMUNOL, V26, P625, DOI 10.1016/0161-5890(89)90044-8; Tsuji RF, 1997, J EXP MED, V186, P1015, DOI 10.1084/jem.186.7.1015; VANLOVEREN H, 1986, EUR J IMMUNOL, V16, P1203, DOI 10.1002/eji.1830161004; WALDMANN TA, 1972, J CLIN INVEST, V51, P2162, DOI 10.1172/JCI107023; Woolley DE, 2000, ARTHRITIS RES, V2, P65, DOI 10.1186/ar70; Yamaguchi M, 1997, J EXP MED, V185, P663, DOI 10.1084/jem.185.4.663; YOO TJ, 1967, SCIENCE, V157, P707, DOI 10.1126/science.157.3789.707	45	142	150	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2002	8	7					694	701		10.1038/nm722	http://dx.doi.org/10.1038/nm722			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	567QG	12068287				2022-12-25	WOS:000176495200030
J	Futscher, BW; Oshiro, MM; Wozniak, RJ; Holtan, N; Hanigan, CL; Duan, H; Domann, FE				Futscher, BW; Oshiro, MM; Wozniak, RJ; Holtan, N; Hanigan, CL; Duan, H; Domann, FE			Role for DNA methylation in the control of cell type-specific maspin expression	NATURE GENETICS			English	Article							SUPPRESSOR GENE MASPIN; CPG ISLANDS; CYTOSINE METHYLATION; PROMOTER; DIFFERENTIATION; INACTIVATION; SITE; ETS	The nucleotide 5-methylcytosine is involved in processes crucial in mammalian development, such as X-chromosome inactivation and gene imprinting(1-5). In addition, cytosine methylation has long been speculated to be involved in the establishment and maintenance of cell type specific expression of developmentally regulated genes 6,7; however, it has been difficult to identify clear examples of such genes, particularly in humans(8). Here we provide evidence that cytosine methylation of the maspin gene (SERPINB5) promoter controls, in part, normal cell type specific SERPINB5 expression. In normal cells expressing SERPINB5, the SERPINB5 promoter is unmethylated and the promoter region has acetylated histones and an accessible chromatin structure. By contrast, normal cells that do not express SERPINB5 have a completely methylated SERPINB5 promoter with hypoacetylated histones, an inaccessible chromatin structure and a transcriptional repression that is relieved by inhibition of DNA methylation. These findings indicate that cytosine methylation is important in the establishment and maintenance of cell type restricted gene expression.	Univ Arizona, Arizona Canc Ctr, Bone Marrow Transplant Program, Dept Pharmacol & Toxicol, Tucson, AZ 85724 USA; Univ Iowa, Holden Comprehens Canc Ctr, Free Rad & Radiat Biol, Dept Radiat Oncol, Iowa City, IA 52242 USA	Arizona Center Cancer Care; University of Arizona; University of Iowa	Futscher, BW (corresponding author), Univ Arizona, Arizona Canc Ctr, Bone Marrow Transplant Program, Dept Pharmacol & Toxicol, Tucson, AZ 85724 USA.			Domann, Frederick/0000-0002-0489-2179				ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Baylin SB, 1998, ADV CANCER RES, V72, P141; BEARD C, 1995, GENE DEV, V9, P2325, DOI 10.1101/gad.9.19.2325; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Cody DT, 1999, ORAL ONCOL, V35, P516, DOI 10.1016/S1368-8375(99)00026-3; Czerwenka KF, 2001, CANCER DETECT PREV, V25, P268; Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GARTLER SM, 1983, ANNU REV GENET, V17, P155, DOI 10.1146/annurev.ge.17.120183.001103; HOLLIDAY R, 1975, SCIENCE, V187, P226, DOI 10.1126/science.1111098; Huang YH, 1999, ARCH BIOCHEM BIOPHYS, V364, P241, DOI 10.1006/abbi.1999.1142; Ioshikhes IP, 2000, NAT GENET, V26, P61, DOI 10.1038/79189; Johnson GK, 1997, J PERIODONTAL RES, V32, P447, DOI 10.1111/j.1600-0765.1997.tb00557.x; JONES A, 1967, ECON BOT, V21, P163, DOI 10.1007/BF02897864; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; KONDO M, 1991, AM J PHYSIOL, V261, pL106, DOI 10.1152/ajplung.1991.261.2.L106; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Maass N, 2001, CLIN BIOCHEM, V34, P303, DOI 10.1016/S0009-9120(01)00220-X; Rice JC, 2000, NUCLEIC ACIDS RES, V28, P3233, DOI 10.1093/nar/28.17.3233; RIGGS AD, 1975, CYTOGENET CELL GENET, V14, P9, DOI 10.1159/000130315; VENOLIA L, 1982, P NATL ACAD SCI-BIOL, V79, P2352, DOI 10.1073/pnas.79.7.2352; Walsh CP, 1999, GENE DEV, V13, P26, DOI 10.1101/gad.13.1.26; Watts GS, 1997, MOL CELL BIOL, V17, P5612, DOI 10.1128/MCB.17.9.5612; Zabner J, 1996, J VIROL, V70, P6994, DOI 10.1128/JVI.70.10.6994-7003.1996; Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	31	348	372	0	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2002	31	2					175	179		10.1038/ng886	http://dx.doi.org/10.1038/ng886			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	557HR	12021783				2022-12-25	WOS:000175903500014
J	Suzuki, H; Gabrielson, E; Chen, W; Anbazhagan, R; van Engeland, M; Weijenberg, MP; Herman, JG; Baylin, SB				Suzuki, H; Gabrielson, E; Chen, W; Anbazhagan, R; van Engeland, M; Weijenberg, MP; Herman, JG; Baylin, SB			A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer	NATURE GENETICS			English	Article							METHYLATED CPG ISLAND; DIFFERENTIAL EXPRESSION; BETA-CATENIN; ANNEXIN-II; DNA; HYPERMETHYLATION; IDENTIFICATION; FAMILY; ASSAY; APC	Aberrant hypermethylation of gene promoters is a major mechanism associated with inactivation of tumor-suppressor genes in cancer. We previously showed this transcriptional silencing to be mediated by both methylation and histone deacetylase activity, with methylation being dominant. Here, we have used cDNA microarray analysis to screen for genes that are epigenetically silenced in human colorectal cancer. By screening over 10,000 genes, we show that our approach can identify a substantial number of genes with promoter hypermethylation in a given cancer; these are distinct from genes with unmethylated promoters, for which increased expression is produced by histone deacetylase inhibition alone. Many of the hypermethylated genes we identified have high potential for roles in tumorigenesis by virtue of their predicted function and chromosome position. We also identified a group of genes that are preferentially hypermethylated in colorectal cancer and gastric cancer. One of these genes, SFRP1, belongs to a gene family; we show that hypermethylation of four genes in this family occurs very frequently in colorectal cancer, providing for (i) a unique potential mechanism for loss of tumor-suppressor gene function and (ii) construction of a molecular marker panel that could detect virtually all colorectal cancer.	Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Predoctoral Training Program Human Genet, Baltimore, MD USA; Univ Maastricht, Dept Pathol, Maastricht, Netherlands; Univ Maastricht, Dept Epidemiol, Maastricht, Netherlands; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Maastricht University; Maastricht University; Johns Hopkins University	Baylin, SB (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, 1650 Orleans St, Baltimore, MD 21231 USA.		van Engeland, Manon/A-7479-2009	van Engeland, Manon/0000-0002-7952-6843				Abu-Jawdeh G, 1999, LAB INVEST, V79, P439; Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; Bachman KE, 1999, CANCER RES, V59, P798; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chang JHT, 1999, HUM MOL GENET, V8, P575, DOI 10.1093/hmg/8.4.575; Chetcuti A, 2001, CANCER RES, V61, P6331; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Esteller M, 2001, CANCER RES, V61, P3225; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; Frattini A, 1997, GENOMICS, V46, P167, DOI 10.1006/geno.1997.5006; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gonzalgo ML, 1997, CANCER RES, V57, P594; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Heston WDW, 1997, UROLOGY, V49, P104, DOI 10.1016/S0090-4295(97)00177-5; KUBE E, 1991, GENE, V102, P255, DOI 10.1016/0378-1119(91)90086-Q; MAKOSWALES M, 1995, NAT MED, V1, P570; Matsuo K, 2001, BLOOD, V97, P3205, DOI 10.1182/blood.V97.10.3205; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; Mimori-Kiyosue Y, 2001, J CELL BIOL, V154, P1105, DOI 10.1083/jcb.200106113; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nicholls RD, 1998, TRENDS GENET, V14, P194, DOI 10.1016/S0168-9525(98)01432-2; Nishioka M, 2000, ONCOGENE, V19, P6251, DOI 10.1038/sj.onc.1204031; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Smiraglia DJ, 2001, HUM MOL GENET, V10, P1413, DOI 10.1093/hmg/10.13.1413; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Song CY, 2001, CANCER RES, V61, P3272; Strehl S, 1998, GENOMICS, V53, P81, DOI 10.1006/geno.1998.5467; SUTCLIFFE JS, 1994, NAT GENET, V8, P52, DOI 10.1038/ng0994-52; Toyota M, 1999, CANCER RES, V59, P2307; Toyota M, 2000, CANCER RES, V60, P4044; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739; Ugolini F, 2001, ONCOGENE, V20, P5810, DOI 10.1038/sj.onc.1204706; White GRM, 1998, ONCOGENE, V17, P3513, DOI 10.1038/sj.onc.1202487; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532	41	721	788	1	30	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2002	31	2					141	149		10.1038/ng892	http://dx.doi.org/10.1038/ng892			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	557HR	11992124	Green Published			2022-12-25	WOS:000175903500009
J	Gabriel, SB; Salomon, R; Pelet, A; Angrist, M; Amiel, J; Fornage, M; Attie-Bitach, T; Olson, JM; Hofstra, R; Buys, C; Steffann, J; Munnich, A; Lyonnet, S; Chakravarti, A				Gabriel, SB; Salomon, R; Pelet, A; Angrist, M; Amiel, J; Fornage, M; Attie-Bitach, T; Olson, JM; Hofstra, R; Buys, C; Steffann, J; Munnich, A; Lyonnet, S; Chakravarti, A			Segregation at three loci explains familial and population risk in Hirschsprung disease	NATURE GENETICS			English	Article							GERM-LINE MUTATIONS; LINKAGE ANALYSIS; MULTIGENIC INHERITANCE; GENETIC DISSECTION; GENOMIC STRUCTURE; COMPLEX TRAITS; RET; EXPRESSION; DEFECTS; MODELS	Hirschsprung disease (HSCR), the most common hereditary cause of intestinal obstruction, shows considerable variation and complex inheritance. Coding sequence mutations in RET, GDNF, EDNRB, EDN3 and SOX10 lead to long-segment (L-HSCR) and syndromic HSCR but fail to explain the transmission of the much more common short-segment form (S-HSCR). We conducted a genome scan in families with S-HSCR and identified susceptibility loci at 3p21, 10q11 and 19q12 that seem to be necessary and sufficient to explain recurrence risk and population incidence. The gene at 10q11 is probably RET, supporting its crucial role in all forms of HSCR; however, coding sequence mutations are present in only 40% of linked families, suggesting the importance of noncoding variation. Here we show oligogenic inheritance of S-HSCR, the 3p21 and 19q12 loci as RET-dependent modifiers, and a parent-of-origin effect at RET. This study demonstrates by a complete genetic dissection why the inheritance pattern of S-HSCR is nonmendelian.	Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Ctr Human Genet, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Hosp Necker Enfants Malad, Dept Genet, Paris, France; Hosp Necker Enfants Malad, INSERM, U393, Paris, France; Univ Groningen, Dept Med Genet, Groningen, Netherlands	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Groningen	Chakravarti, A (corresponding author), Case Western Reserve Univ, Sch Med, Dept Genet, Metro Hlth Campus, Cleveland, OH 44106 USA.		amiel, jeanne/H-3501-2017; Steffann, Julie/I-2820-2017; Lyonnet, Stanislas/H-5483-2017; amiel, jeanne/AGX-1124-2022; ATTIE-BITACH, Tania/K-1453-2017	amiel, jeanne/0000-0001-5973-4728; Steffann, Julie/0000-0001-9493-3239; Lyonnet, Stanislas/0000-0001-5426-9417; ATTIE-BITACH, Tania/0000-0002-1155-3626; Hofstra, Robert/0000-0001-7498-3829; PELET, Anastella/0000-0002-8353-1725				Angrist M, 1998, ONCOGENE, V17, P3065, DOI 10.1038/sj.onc.1202226; Angrist M, 1998, GENOMICS, V48, P354, DOI 10.1006/geno.1997.5191; ATTIE T, 1995, HUM MOL GENET, V4, P1381, DOI 10.1093/hmg/4.8.1381; BADNER JA, 1990, AM J HUM GENET, V46, P568; Bolk S, 2000, P NATL ACAD SCI USA, V97, P268, DOI 10.1073/pnas.97.1.268; Borrego S, 2000, J MED GENET, V37, P572, DOI 10.1136/jmg.37.8.572; Chakravarti A, 1999, NAT GENET, V21, P56, DOI 10.1038/4482; CHAKRAVARTI A, 2001, METABOLIC MOL BASES, P6231; Doray B, 1998, HUM MOL GENET, V7, P1449, DOI 10.1093/hmg/7.9.1449; Fitze G, 1999, AM J HUM GENET, V65, P1469, DOI 10.1086/302618; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; Hofstra RMW, 1999, AM J HUM GENET, V64, P304, DOI 10.1086/302184; HOLSCHNEIDER AM, 1982, HIRSCHSPRUNGS DIS; Kong A, 1997, AM J HUM GENET, V61, P1179, DOI 10.1086/301592; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; KRUGLYAK L, 1995, AM J HUM GENET, V57, P439; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; Myers SM, 1999, J MED GENET, V36, P217; O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904; Olson JM, 1997, HUM HERED, V47, P110, DOI 10.1159/000154398; Otterson GA, 1997, P NATL ACAD SCI USA, V94, P12036, DOI 10.1073/pnas.94.22.12036; PUFFENBERGER EG, 1994, CELL, V79, P1257, DOI 10.1016/0092-8674(94)90016-7; QIU MS, 1995, GENE DEV, V9, P2523, DOI 10.1101/gad.9.20.2523; RARVEHAREL N, 1997, AM J HUM GENET, V60, P87; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SCHUCHARDT V, 1994, NATURE, V367, P380; Slaugenhaupt SA, 2001, AM J HUM GENET, V68, P598, DOI 10.1086/318810	30	189	193	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2002	31	1					89	93		10.1038/ng868	http://dx.doi.org/10.1038/ng868			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	547ZF	11953745				2022-12-25	WOS:000175362500021
J	Hakelien, AM; Landsverk, HB; Robl, JM; Skalhegg, BS; Collas, P				Hakelien, AM; Landsverk, HB; Robl, JM; Skalhegg, BS; Collas, P			Reprogramming fibroblasts to express T-cell functions using cell extracts	NATURE BIOTECHNOLOGY			English	Article							DNA METHYLATION; SOMATIC-CELLS; HISTONE H4; PROTEIN; CHROMATIN; TRANSCRIPTION; COMPLEX; NUCLEI; TRANSDIFFERENTIATION; DIFFERENTIATION	We demonstrate here the functional reprogramming of a somatic cell using a nuclear and cytoplasmic extract derived from another somatic cell type. Reprogramming of 293T fibroblasts in an extract from primary human T cells or from a transformed T-cell line is evidenced by nuclear uptake and assembly of transcription factors, induction of activity of a chromatin remodeling complex, histone acetylation, and activation of lymphoid cell-specific genes. Reprogrammed cells express T cell-specific receptors and assemble the interleukin-2 receptor in response to T cell receptor-CD3 (TCR-CD3) complex stimulation. Reprogrammed primary skin fibroblasts also express T cell-specific antigens. After exposure to a neuronal precursor extract, 293T fibroblasts express a neurofilament protein and extend neurite-like outgrowths. In vitro reprogramming of differentiated somatic cells creates possibilities for producing isogenic replacement cells for therapeutic applications.	Univ Oslo, Inst Med Biochem, N-0317 Oslo, Norway; Univ Oslo, Inst Nutr Res, N-0317 Oslo, Norway; Nucleotech LLC, Westport, CT 06880 USA	University of Oslo; University of Oslo	Collas, P (corresponding author), Univ Oslo, Inst Med Biochem, POB 1112, N-0317 Oslo, Norway.		Skålhegg, Bjørn Steen/AAZ-2976-2021	Skålhegg, Bjørn Steen/0000-0002-3481-8084; Landsverk, Helga/0000-0003-1373-2166				Cibelli JB, 1998, NAT BIOTECHNOL, V16, P642, DOI 10.1038/nbt0798-642; Cibelli JB, 1998, SCIENCE, V280, P1256, DOI 10.1126/science.280.5367.1256; Collas P, 1998, NUCLEIC ACIDS RES, V26, P4454, DOI 10.1093/nar/26.19.4454; Collas P, 1999, J CELL BIOL, V147, P1167, DOI 10.1083/jcb.147.6.1167; Collas P, 1999, J CELL SCI, V112, P1045; Condorelli G, 2001, P NATL ACAD SCI USA, V98, P10733, DOI 10.1073/pnas.191217898; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DEBUS E, 1983, DIFFERENTIATION, V25, P193, DOI 10.1111/j.1432-0436.1984.tb01355.x; Funderburgh JL, 2001, J BIOL CHEM, V276, P44173, DOI 10.1074/jbc.M107596200; GURDON JB, 1966, NATURE, V210, P1240, DOI 10.1038/2101240a0; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; KAEMPFER R, 1994, P SOC EXP BIOL MED, V206, P176; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; Kikyo N, 2000, SCIENCE, V289, P2360, DOI 10.1126/science.289.5488.2360; Lin J, 2001, J CELL SCI, V114, P243; Miyazaki T, 1996, CANCER SURV, V27, P25; Morrison SJ, 2001, CURR BIOL, V11, pR7, DOI 10.1016/S0960-9822(00)00033-6; Munsie MJ, 2000, CURR BIOL, V10, P989, DOI 10.1016/S0960-9822(00)00648-5; ONeill LP, 1996, METHOD ENZYMOL, V274, P189; ONEILL LP, 1995, EMBO J, V14, P3946, DOI 10.1002/j.1460-2075.1995.tb00066.x; Shen CN, 2000, NAT CELL BIOL, V2, P879, DOI 10.1038/35046522; SKALHEGG BS, 1994, SCIENCE, V263, P84, DOI 10.1126/science.8272870; Steen RL, 2000, J CELL BIOL, V149, P531, DOI 10.1083/jcb.149.3.531; Surani MA, 2001, NATURE, V414, P122, DOI 10.1038/35102186; Tada M, 1997, EMBO J, V16, P6510, DOI 10.1093/emboj/16.21.6510; Tada M, 2001, CURR BIOL, V11, P1553, DOI 10.1016/S0960-9822(01)00459-6; Wakayama T, 2001, SCIENCE, V292, P740, DOI 10.1126/science.1059399; WANGH LJ, 1995, J CELL SCI, V108, P2187; Ward SB, 1998, NUCLEIC ACIDS RES, V26, P2923, DOI 10.1093/nar/26.12.2923; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	31	189	233	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2002	20	5					460	466		10.1038/nbt0502-460	http://dx.doi.org/10.1038/nbt0502-460			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	548AE	11981558				2022-12-25	WOS:000175364800027
J	Neildez-Nguyen, TMA; Wajcman, H; Marden, MC; Bensidhoum, M; Moncollin, V; Giarratana, MC; Kobari, L; Thierry, D; Douay, L				Neildez-Nguyen, TMA; Wajcman, H; Marden, MC; Bensidhoum, M; Moncollin, V; Giarratana, MC; Kobari, L; Thierry, D; Douay, L			Human erythroid cells produced ex vivo at large scale differentiate into red blood cells in vivo	NATURE BIOTECHNOLOGY			English	Article							GROWTH-FACTOR-I; COLONY-FORMING-UNITS; PROGENITOR CELLS; FLOW-CYTOMETRY; GROUP ANTIGENS; ERYTHROPOIETIN; VITRO; CULTURE; PROLIFERATION; INSULIN	New sources of red blood cells (RBCs) would improve the transfusion capacity of blood centers. Our objective was to generate cells for transfusion by inducing a massive proliferation of hematopoietic stem and progenitor cells, followed by terminal erythroid differentiation. We describe here a procedure for amplifying hematopoietic stem cells (HSCs) from human cord blood (CB) by the sequential application of specific combinations of growth factors in a serum-free culture medium. The procedure allowed the ex vivo expansion of CD34(+) progenitor and stem cells into a pure erythroid precursor population. When injected into nonobese diabetic, severe combined immunodeficient (NOD/SCID) mice, the erythroid cells were capable of proliferation and terminal differentiation into mature enucleated RBCs. The approach may eventually be useful in clinical transfusion applications.	Hop St Antoine, INSERM, U417, F-75571 Paris, France; Hop Henri Mondor, INSERM, U468, F-94010 Creteil, France; Hop Bicetre, INSERM, U473, F-94276 Le Kremlin Bicetre, France; Inst Protect & Surete Nucl, DPHD, SARAM, IPSN, F-92265 Fontenay Aux Roses, France; Hop Armand Trousseau, Serv Hematol Biol, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite	Douay, L (corresponding author), Hop St Antoine, INSERM, U417, F-75571 Paris, France.		MONCOLLIN, Vincent/R-1941-2017; Marden, Michael/AAA-5923-2020; Neildez, Thi My Anh/J-6900-2013; Marden, Michael C/G-3139-2012	MONCOLLIN, Vincent/0000-0002-4163-0231; Marden, Michael C/0000-0002-5254-6385; Bensidhoum, Morad/0000-0002-6621-6010				Alexander WS, 1996, BLOOD, V87, P2162, DOI 10.1182/blood.V87.6.2162.bloodjournal8762162; Bony V, 1999, BRIT J HAEMATOL, V107, P263, DOI 10.1046/j.1365-2141.1999.01721.x; BOYER SH, 1992, BLOOD, V80, P2503; CHELUCCI C, 1995, BLOOD, V85, P1181, DOI 10.1182/blood.V85.5.1181.bloodjournal8551181; DEXTER TM, 1981, BLOOD, V58, P699; ELIASON JF, 1979, NATURE, V281, P382, DOI 10.1038/281382a0; Freyssinier JM, 1999, BRIT J HAEMATOL, V106, P912; Giarratana MC, 1998, BONE MARROW TRANSPL, V22, P707, DOI 10.1038/sj.bmt.1701399; Hentzen ER, 2000, BLOOD, V95, P911, DOI 10.1182/blood.V95.3.911.003k36_911_920; Kobari L, 2000, EXP HEMATOL, V28, P1470, DOI 10.1016/S0301-472X(00)00557-9; KOURY MJ, 1992, EUR J BIOCHEM, V210, P649, DOI 10.1111/j.1432-1033.1992.tb17466.x; LAROCHELLE A, 1995, HUM MOL GENET, V4, P163, DOI 10.1093/hmg/4.2.163; LEVANKIM C, 1994, BRIT J HAEMATOL, V88, P193; Lewis DE, 1996, CYTOMETRY, V23, P218; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; Majka M, 2000, STEM CELLS, V18, P128, DOI 10.1634/stemcells.18-2-128; Malik P, 1998, BLOOD, V91, P2664, DOI 10.1182/blood.V91.8.2664.2664_2664_2671; MARDEN MC, 1988, BIOCHEMISTRY-US, V27, P1659, DOI 10.1021/bi00405a041; METCALF D, 1993, BLOOD, V82, P3515; MUTA K, 1994, J CLIN INVEST, V94, P34, DOI 10.1172/JCI117327; MUTA K, 1995, BLOOD, V86, P572, DOI 10.1182/blood.V86.2.572.bloodjournal862572; OKUMURA N, 1992, BLOOD, V80, P642; Panzenbock B, 1998, BLOOD, V92, P3658, DOI 10.1182/blood.V92.10.3658.422k18_3658_3668; Papassotiriou I, 1998, HEMOGLOBIN, V22, P469, DOI 10.3109/03630269809071544; PIC P, 1994, ANN BIOL CLIN-PARIS, V52, P129; Samakoglu S, 2001, BLOOD, V97, P2213, DOI 10.1182/blood.V97.8.2213; SAWADA K, 1989, J CLIN INVEST, V83, P1701, DOI 10.1172/JCI114070; SAWADA K, 1990, J CELL PHYSIOL, V142, P219, DOI 10.1002/jcp.1041420202; Southcott MJG, 1999, BLOOD, V93, P4425, DOI 10.1182/blood.V93.12.4425.412k22_4425_4435; von Lindern M, 1999, BLOOD, V94, P550, DOI 10.1182/blood.V94.2.550.414k39_550_559; Young JC, 1996, BLOOD, V88, P1619; ZANJANI ED, 1979, NATURE, V280, P495, DOI 10.1038/280495a0	32	198	218	1	22	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2002	20	5					467	472		10.1038/nbt0502-467	http://dx.doi.org/10.1038/nbt0502-467			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	548AE	11981559				2022-12-25	WOS:000175364800028
J	Pan, Z; Yang, DM; Nararaj, RY; Nosek, TA; Nishi, M; Takeshima, H; Cheng, HP; Ma, JJ				Pan, Z; Yang, DM; Nararaj, RY; Nosek, TA; Nishi, M; Takeshima, H; Cheng, HP; Ma, JJ			Dysfunction of store-operated calcium channel in muscle cells lacking mg29	NATURE CELL BIOLOGY			English	Article							MUTANT MICE LACKING; SKELETAL-MUSCLE; RYANODINE-RECEPTOR; CA2+ ENTRY; MAST-CELLS; RELEASE; INHIBITION; DEPLETION; FIBERS; SK-AND-F-96365	The store-operated calcium channel (SOC) located in the plasma membrane (PM) mediates capacitative entry of extracellular calcium after depletion of intracellular calcium stores in the endoplasmic or sarcoplasmic reticulum (ER/SR)(1,2). An intimate interaction between the PM and the ER/SR is essential for the operation of this calcium signalling pathway(3-5). Mitsugumin 29 (MG29) is a synaptophysin-family-related protein located in the junction between the PM and SR of skeletal muscle(6,7). Here, we identify SOC in skeletal muscle and characterise its regulation by MG29 and the ryanodine receptor (RyR) located in the SR. Targeted deletion of mg29 alters the junctional membrane structure, causes severe dysfunction of SOC and SR calcium homeostasis and increases the susceptibility of muscle to fatigue stimulation(8). Severe dysfunction of SOC is also identified in muscle cells lacking both type 1 and type 3 RyRs, indicating that SOC activation requires an intact interaction between the PM and the SR, and is linked to conformational changes of RyRs. Whereas defective SOC seems to be inconsequential to short-term excitation contraction coupling, the slow cumulative calcium entry through SOC is crucial for long-term calcium homeostasis, such that reduced SOC activity exaggerates muscle fatigue under conditions of intensive exercise.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA; NIA, Cardiovasc Sci Lab, Gerontol Res Ctr, Baltimore, MD 21224 USA; Peking Univ, Coll Life Sci, Natl Lab Biomembrane & Membrane Biotechnol, Beijing 100871, Peoples R China; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Tohoku Univ, Grad Sch Med, Dept Biochem, Sendai, Miyagi 9808575, Japan; Japan Sci & Technol Corp, CREST, Sendai, Miyagi 9808575, Japan	Rutgers State University New Brunswick; Rutgers State University Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Peking University; Case Western Reserve University; Tohoku University; Japan Science & Technology Agency (JST)	Pan, Z (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, 675 Hoes Lane, Piscataway, NJ 08854 USA.		cheng, heping/A-7299-2011; Heping, Cheng/AAE-2680-2019	Heping, Cheng/0000-0002-9604-6702; Nosek, Thomas/0000-0001-6466-9035; Pan, Zui/0000-0003-4105-901X; Takeshima, Hiroshi/0000-0003-4525-3725				Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; COTA G, 1989, J GEN PHYSIOL, V94, P937, DOI 10.1085/jgp.94.5.937; Doi S, 2000, AM J PHYSIOL-LUNG C, V278, pL118, DOI 10.1152/ajplung.2000.278.1.L118; FASOLATO C, 1993, PFLUG ARCH EUR J PHY, V423, P225, DOI 10.1007/BF00374399; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Ikemoto T, 1997, J PHYSIOL-LONDON, V501, P305, DOI 10.1111/j.1469-7793.1997.305bn.x; JOHNSTON PA, 1989, J BIOL CHEM, V264, P1265; Kiselyov KI, 2000, MOL CELL, V6, P421, DOI 10.1016/S1097-2765(00)00041-1; Kurebayashi N, 2001, J PHYSIOL-LONDON, V533, P185, DOI 10.1111/j.1469-7793.2001.0185b.x; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; Leung YM, 1996, BIOCHEM PHARMACOL, V51, P605, DOI 10.1016/S0006-2952(95)02181-7; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; Nagaraj RY, 2000, PHYSIOL GENOMICS, V4, P43, DOI 10.1152/physiolgenomics.2000.4.1.43; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; Nishi M, 1999, J CELL BIOL, V147, P1473, DOI 10.1083/jcb.147.7.1473; Pan Z, 2000, J BIOL CHEM, V275, P19978, DOI 10.1074/jbc.M908329199; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; Putney JW, 1997, CELL CALCIUM, V21, P257, DOI 10.1016/S0143-4160(97)90050-6; RIOS E, 1991, J MUSCLE RES CELL M, V12, P127, DOI 10.1007/BF01774031; SCHNEIDER MF, 1994, ANNU REV PHYSIOL, V56, P463, DOI 10.1146/annurev.ph.56.030194.002335; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; Takeshima H, 1998, BIOCHEM J, V331, P317, DOI 10.1042/bj3310317; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; Takeshima H, 1996, J BIOL CHEM, V271, P19649, DOI 10.1074/jbc.271.33.19649; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Yang DM, 2001, J BIOL CHEM, V276, P40210, DOI 10.1074/jbc.M106944200	28	140	148	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAY	2002	4	5					379	383		10.1038/ncb788	http://dx.doi.org/10.1038/ncb788			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	547GR	11988740				2022-12-25	WOS:000175325100020
J	Pagani, F; Buratti, E; Stuani, C; Bendix, R; Dork, T; Baralle, FE				Pagani, F; Buratti, E; Stuani, C; Bendix, R; Dork, T; Baralle, FE			A new type of mutation causes a splicing defect in ATM	NATURE GENETICS			English	Article							SMALL NUCLEAR-RNA; MESSENGER-RNA; U1 SNRNP; ATAXIA-TELANGIECTASIA; SITE; GENE; EXON; ELEMENT; POLYADENYLATION; ASSOCIATION	Disease-causing splicing mutations described in the literature primarily produce changes in splice sites and, to a lesser extent, variations in exon-regulatory sequences such as the enhancer elements(1-6). The gene ATM is mutated in individuals with ataxia-telangiectasia; we have indentified the aberrant inclusion of a cryptic exon of 65 by in one affected individual with a deletion of four nucleotides (GTAA) in intron 20. The deletion is located 12 by downstream and 53 by upstream from the 5' and 3' ends of the cryptic exon, respectively. Through analysis of the splicing defect using a hybrid minigene system, we identified a new intron-splicing processing element (ISPE) complementary to U1 snRNA, the RNA component of the U1 small nuclear ribonucleoprotein (snRNP). This element mediates accurate intron processing and interacts specifically with U1 snRNP particles. The 4-nt deletion completely abolished this interaction, causing activation of the cryptic exon. On the basis of this analysis, we describe a new type of U1 snRNP binding site in an intron that is essential for accurate intron removal. Deletion of this sequence is directly involved in the splicing processing defect.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Hannover Med Sch, Clin Obstet & Gynecol, Dept Radiat Oncol, D-3000 Hannover, Germany; Hannover Med Sch, Clin Obstet & Gynecol, Dept Biochem & Tumour Biol, D-3000 Hannover, Germany	International Center for Genetic Engineering & Biotechnology (ICGEB); Hannover Medical School; Hannover Medical School	Baralle, FE (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.		Buratti, Emanuele/K-4691-2016; Dörk, Thilo/J-8620-2012	Buratti, Emanuele/0000-0002-1356-9074; Dörk, Thilo/0000-0002-9458-0282	Telethon [GGP02453] Funding Source: Medline	Telethon(Fondazione Telethon)		Ars E, 2000, HUM MOL GENET, V9, P237, DOI 10.1093/hmg/9.2.237; Ashe MP, 1997, EMBO J, V16, P5752, DOI 10.1093/emboj/16.18.5752; Buratti E, 2001, EMBO J, V20, P1774, DOI 10.1093/emboj/20.7.1774; CHILLON M, 1995, AM J HUM GENET, V56, P623; Fairbrother WG, 2000, MOL CELL BIOL, V20, P6816, DOI 10.1128/MCB.20.18.6816-6825.2000; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; Gunderson SI, 1998, MOL CELL, V1, P255, DOI 10.1016/S1097-2765(00)80026-X; Hatton AR, 1998, MOL CELL, V2, P787, DOI 10.1016/S1097-2765(00)80293-2; HIGHSMITH WE, 1994, NEW ENGL J MED, V331, P974, DOI 10.1056/NEJM199410133311503; Hwang DY, 1997, MOL CELL BIOL, V17, P7099, DOI 10.1128/MCB.17.12.7099; Karpova AY, 2000, GENE DEV, V14, P2813, DOI 10.1101/gad.813800; Labourier E, 2001, MOL CELL, V8, P363, DOI 10.1016/S1097-2765(01)00311-2; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Liu HX, 2001, NAT GENET, V27, P55, DOI 10.1038/83762; Lou H, 1998, MOL CELL BIOL, V18, P4977, DOI 10.1128/MCB.18.9.4977; LUND E, 1984, J BIOL CHEM, V259, P2013; McCullough AJ, 2000, MOL CELL BIOL, V20, P9225, DOI 10.1128/MCB.20.24.9225-9235.2000; McNally LM, 1999, J VIROL, V73, P2385, DOI 10.1128/JVI.73.3.2385-2393.1999; Pagani F, 2000, J BIOL CHEM, V275, P21041, DOI 10.1074/jbc.M910165199; Sandoval N, 1999, HUM MOL GENET, V8, P69, DOI 10.1093/hmg/8.1.69; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; SIEBEL CW, 1992, GENE DEV, V6, P1386, DOI 10.1101/gad.6.8.1386; Sun HZ, 2000, MOL CELL BIOL, V20, P6414, DOI 10.1128/MCB.20.17.6414-6425.2000; Vervoort R, 1998, HUM GENET, V103, P686, DOI 10.1007/PL00008709; Wang M, 1997, BREAST CANCER RES TR, V44, P145, DOI 10.1023/A:1005753117205; WASSARMAN KM, 1993, GENE DEV, V7, P647, DOI 10.1101/gad.7.4.647; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4	27	163	177	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2002	30	4					426	429		10.1038/ng858	http://dx.doi.org/10.1038/ng858			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	536BZ	11889466				2022-12-25	WOS:000174682000022
J	Contente, A; Dittmer, A; Koch, MC; Roth, J; Dobbelstein, M				Contente, A; Dittmer, A; Koch, MC; Roth, J; Dobbelstein, M			A polymorphic microsatellite that mediates induction of PIG3 by p53	NATURE GENETICS			English	Article							DNA-BINDING; TRANSCRIPTIONAL REPRESSION; ADENOVIRUS TYPE-5; APOPTOSIS; PROTEIN; DOMAIN; ONCOPROTEINS; MUTATIONS; COMPLEXES; GROWTH	The gene PIG3 is induced by the tumor suppressor p53 but not by p53 mutants unable to induce apoptosis, suggesting its involvement in p53-mediated cell death(1-3). Here we show that p53 directly binds and activates the PIG3 promoter, but not through the previously described DNA element(1). Instead, p53 interacts with a pentanucleotide microsatellite sequence within the PIG3 promoter (TGYCC)(n) where Y= C or T. Despite its limited similarity to the p53-binding consensus(4,5), this sequence is necessary and sufficient for transcriptional activation of the PIG3 promoter by p53 and binds specifically to p53 in vitro and in vivo. In a population of 117 healthy donors from Germany, the microsatellite was found to be polymorphic, the number of pentanucleotide repeats being 10, 15, 16 or 17, and the frequency of alleles 5.1%, 62.0%, 21.4% and 11.5%, respectively. The number of repeats directly correlated with the extent of transcriptional activation by p53. This is the first time that a microsatellite has been shown to mediate the induction of a promoter through direct interaction with a transcription factor. Moreover, this sequence of PIG3 is the first p53-responsive element found to be polymorphic. Inheritance of this microsatellite may affect an individual's susceptibility to cancer.	Univ Marburg Klinikum, Inst Virol, Marburg, Germany; Univ Marburg Klinikum, Inst Humangenet, Marburg, Germany; Univ Marburg Klinikum, Abt Gastroenterol & Stoffwechsel, Marburg, Germany		Dobbelstein, M (corresponding author), Univ Marburg Klinikum, Inst Virol, Marburg, Germany.			Dobbelstein, Matthias/0000-0001-5052-3967				Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; Djian P, 1998, CELL, V94, P155, DOI 10.1016/S0092-8674(00)81415-4; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Koch P, 2001, CANCER RES, V61, P5941; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Roth J, 2000, ONCOGENE, V19, P1834, DOI 10.1038/sj.onc.1203500; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Wienzek S, 2000, J VIROL, V74, P193, DOI 10.1128/JVI.74.1.193-202.2000; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533; Zhu KC, 1999, ONCOGENE, V18, P7740, DOI 10.1038/sj.onc.1203235	22	193	204	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2002	30	3					315	320		10.1038/ng836	http://dx.doi.org/10.1038/ng836			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	526YP	11919562				2022-12-25	WOS:000174157600018
J	Vreugde, S; Ereven, A; Kros, CJ; Marcotti, W; Fuchs, H; Kurima, K; Wilcox, ER; Friedman, TB; Griffith, AJ; Balling, R; de Angelis, MH; Avraham, KB; Steel, KP				Vreugde, S; Ereven, A; Kros, CJ; Marcotti, W; Fuchs, H; Kurima, K; Wilcox, ER; Friedman, TB; Griffith, AJ; Balling, R; de Angelis, MH; Avraham, KB; Steel, KP			Beethoven, a mouse model for dominant, progressive hearing loss DFNA36	NATURE GENETICS			English	Article							OUTER HAIR-CELLS; POTASSIUM CURRENT; EXPRESSION; DEAFNESS; INNER; MICE; COCHLEA; MAPS	Despite recent progress in identifying genes underlying deafness, there are still relatively few mouse models of specific forms of human deafness. Here we describe the phenotype of the Beethoven (Bth) mouse mutant and a missense mutation in Tmc1 (transmembrane cochlear-expressed gene 1). Progressive hearing loss (DFNA36) and profound congenital deafness (DFNB7/B11) are caused by dominant and recessive mutations of the human ortholog, TMC1 (ref. 1), for which Bth and deafness (dn)(1) are mouse models, respectively.	Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, IL-69978 Tel Aviv, Israel; MRC, Inst Hearing Res, Nottingham NG7 2RD, England; Univ Sussex, Sch Biol Sci, Brighton BN1 9QG, E Sussex, England; GSF, Res Ctr Environm & Hlth, Inst Expt Genet, D-85764 Neuherberg, Germany; Natl Inst Deafness & Other Commun Disorders, Mol Genet Lab, NIH, Rockville, MD 20850 USA	Tel Aviv University; Sackler Faculty of Medicine; University of Sussex; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Avraham, KB (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, IL-69978 Tel Aviv, Israel.		de Angelis, Martin Hrabe/F-5531-2012; Fuchs, Helmut/M-7347-2014; Balling, Rudi/E-9680-2010	de Angelis, Martin Hrabe/0000-0002-7898-2353; Fuchs, Helmut/0000-0002-5143-2677; Balling, Rudi/0000-0003-2902-5650; Avraham, Karen B/0000-0002-4913-251X; Vreugde, Sarah/0000-0003-4719-9785	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000035, ZIADC000048, ZIADC000060, Z01DC000060, Z01DC000048, Z01DC000039, ZIADC000039] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BOCK GR, 1983, ACTA OTO-LARYNGOL, V96, P39, DOI 10.3109/00016488309132873; de Angelis MH, 2000, NAT GENET, V25, P444, DOI 10.1038/78146; EHRET G, 1975, J COMP PHYSIOL, V103, P329, DOI 10.1007/BF00612025; KEATS BJB, 1995, MAMM GENOME, V6, P8, DOI 10.1007/BF00350886; KROS CJ, 1992, P ROY SOC B-BIOL SCI, V249, P185, DOI 10.1098/rspb.1992.0102; Kros CJ, 1998, NATURE, V394, P281, DOI 10.1038/28401; Marcotti W, 1999, J PHYSIOL-LONDON, V520, P653, DOI 10.1111/j.1469-7793.1999.00653.x; Marcotti W, 1999, PFLUG ARCH EUR J PHY, V439, P113, DOI 10.1007/s004240051134; Moller S, 2001, BIOINFORMATICS, V17, P646, DOI 10.1093/bioinformatics/17.7.646; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; STEEL KP, 1992, NAT GENET, V2, P75, DOI 10.1038/ng0992-75; STEEL KP, 1980, NATURE, V288, P159, DOI 10.1038/288159a0; Vreugde S, 2002, NAT GENET, V30, P257, DOI 10.1038/ng848	13	192	197	1	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2002	30	3					257	258		10.1038/ng848	http://dx.doi.org/10.1038/ng848			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Genetics & Heredity	526YP	11850623				2022-12-25	WOS:000174157600008
J	Casadevall, A				Casadevall, A			Antibodies for defense against biological attack	NATURE BIOTECHNOLOGY			English	Editorial Material							INFECTIOUS-DISEASES		Yeshiva Univ Albert Einstein Coll Med, Div Infect Dis, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Casadevall, A (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Div Infect Dis, 1300 Morris Pk Ave, Bronx, NY 10461 USA.							CASADEVALL A, 1995, CLIN INFECT DIS, V21, P150, DOI 10.1093/clinids/21.1.150; Flexner S, 1913, J EXP MED, V17, P553, DOI 10.1084/jem.17.5.553; Keller MA, 2000, CLIN MICROBIOL REV, V13, P602, DOI 10.1128/CMR.13.4.602-614.2000; Pirofski LA, 1998, CLIN MICROBIOL REV, V11, P1; Welkos S, 2001, MICROBIOL-SGM, V147, P1677, DOI 10.1099/00221287-147-6-1677	5	27	56	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2002	20	2					114	114		10.1038/nbt0202-114	http://dx.doi.org/10.1038/nbt0202-114			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	517FT	11821846				2022-12-25	WOS:000173601000010
J	Dove, A				Dove, A			Antisense and sensibility	NATURE BIOTECHNOLOGY			English	Article																		Dove A, 2000, NAT BIOTECHNOL, V18, P19, DOI 10.1038/71852; Elbashir Sayda M., 2001, NATURE, V411, P494; Niiler E, 2001, NAT BIOTECHNOL, V19, P898, DOI 10.1038/nbt1001-898; Tyler BM, 1999, P NATL ACAD SCI USA, V96, P7053, DOI 10.1073/pnas.96.12.7053	4	66	67	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2002	20	2					121	124		10.1038/nbt0202-121	http://dx.doi.org/10.1038/nbt0202-121			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	517FT	11821852				2022-12-25	WOS:000173601000016
J	Fandrich, F; Lin, XB; Chai, GX; Schulze, M; Ganten, D; Bader, M; Holle, J; Huang, DS; Parwaresch, R; Zavazava, N; Binas, B				Fandrich, F; Lin, XB; Chai, GX; Schulze, M; Ganten, D; Bader, M; Holle, J; Huang, DS; Parwaresch, R; Zavazava, N; Binas, B			Preimplantation-stage stem cells induce long-term allogeneic graft acceptance without supplementary host conditioning	NATURE MEDICINE			English	Article							CONFER IMMUNE PRIVILEGE; DONOR BONE-MARROW; TRANSPLANTATION TOLERANCE; FAS LIGAND; CLASS-I; MIXED CHIMERISM; ALLOGRAFTS; MECHANISMS; PREGNANCY; THYMUS	Hematopoietic stem cells have been successfully employed for tolerance induction in a variety of rodent and large animal studies. However, clinical transplantation of fully allogeneic bone marrow or blood-borne stem cells is still associated with major obstacles, such as graft-versus-host disease or cytoreductive conditioning-related toxicity. Here we show that when rat embryonic stem cell-like cells of WKY origin are injected intraportally into fully MHC-mismatched DA rats, they engraft permanently (>150 days) without supplementary host conditioning. This deviation of a potentially alloreactive immune response sets the basis for long-term graft acceptance of second-set transplanted WKY cardiac allografts. Graft survival was strictly correlated with a state of mixed chimerism, which required functional thymic host competence. Our results provide a rationale for using preimplantation-stage stem cells as vehicles in gene therapy and for the induction of long-term graft acceptance.	Univ Kiel, Dept Gen Surg & Thorac Surg, D-24105 Kiel, Germany; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Univ Kiel, Inst Hematopathol, D-24105 Kiel, Germany; Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA; VA Med Ctr, Iowa City, IA USA; Texas A&M Univ, Coll Vet Med, Dept Vet Pathobiol, College Stn, TX 77843 USA	University of Kiel; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Yale University; University of Kiel; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; Texas A&M University System; Texas A&M University College Station	Fandrich, F (corresponding author), Univ Kiel, Dept Gen Surg & Thorac Surg, D-24105 Kiel, Germany.	ffaendrich@surgery.uni-kiel.de	Faendrich, Fred/B-1705-2010; Bader, Michael/K-2124-2013; Holle, Julia/G-6138-2012	Bader, Michael/0000-0003-4780-4164; Schulze, Maren/0000-0002-4577-6473				Allison J, 1997, P NATL ACAD SCI USA, V94, P3943, DOI 10.1073/pnas.94.8.3943; Bianchi DW, 1998, J PERINAT MED, V26, P175; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; Fandrich F, 1999, J LEUKOCYTE BIOL, V65, P16, DOI 10.1002/jlb.65.1.16; FERRARA JL, 1989, BIOL BLOOD MARROW TR, V5, P347; FINK PJ, 1978, J EXP MED, V148, P766, DOI 10.1084/jem.148.3.766; French LE, 1996, J CELL BIOL, V133, P335, DOI 10.1083/jcb.133.2.335; George JF, 1999, INT J MOL MED, V4, P475; George JF, 1998, NAT MED, V4, P333, DOI 10.1038/nm0398-333; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; GRUSBY MJ, 1993, P NATL ACAD SCI USA, V90, P3913, DOI 10.1073/pnas.90.9.3913; HESS AD, 1990, J IMMUNOL, V145, P526; IANNACCONE PM, 1994, DEV BIOL, V163, P288, DOI 10.1006/dbio.1994.1146; Iannaccone PM, 1997, DEV BIOL, V185, P124, DOI 10.1006/dbio.1997.8558; ILDSTAD ST, 1984, NATURE, V307, P168, DOI 10.1038/307168a0; KAMPINGA J, 1990, TRANSPLANTATION, V50, P669, DOI 10.1097/00007890-199010000-00028; Kang SM, 1997, NAT MED, V3, P738, DOI 10.1038/nm0797-738; Li XK, 1998, TRANSPLANTATION, V66, P1416, DOI 10.1097/00007890-199812150-00003; Liechty KW, 2000, NAT MED, V6, P1282, DOI 10.1038/81395; MEDAWAR PB, 1953, SYM SOC EXP BIOL, V7, P320; O'Connell J, 2001, NAT MED, V7, P271, DOI 10.1038/85395; ONO K, 1969, J THORAC CARDIOV SUR, V57, P225, DOI 10.1016/S0022-5223(19)42744-X; Reisner Y, 2000, CURR OPIN IMMUNOL, V12, P536, DOI 10.1016/S0952-7915(00)00135-7; Reisner Y, 2000, EXP HEMATOL, V28, P119, DOI 10.1016/S0301-472X(99)00132-0; Restifo NP, 2000, NAT MED, V6, P493, DOI 10.1038/74955; SHARABI Y, 1989, J EXP MED, V169, P493, DOI 10.1084/jem.169.2.493; Shizuru JA, 2000, P NATL ACAD SCI USA, V97, P9555, DOI 10.1073/pnas.170279297; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Swenson KM, 1998, TRANSPLANTATION, V65, P155; Sykes M, 1997, NAT MED, V3, P783, DOI 10.1038/nm0797-783; TAFURI A, 1995, SCIENCE, V270, P630, DOI 10.1126/science.270.5236.630; Vacchio MS, 1999, CRIT REV IMMUNOL, V19, P461; Weissman IL, 2000, SCIENCE, V287, P1442, DOI 10.1126/science.287.5457.1442; Wekerle T, 1999, TRANSPLANTATION, V68, P459, DOI 10.1097/00007890-199908270-00001; Wekerle T, 1999, TRANSPLANTATION, V68, P1348, DOI 10.1097/00007890-199911150-00022; Werkele T, 2000, NAT MED, V6, P464, DOI 10.1038/74731; Zhou M, 1998, J REPROD IMMUNOL, V40, P47, DOI 10.1016/S0165-0378(98)00030-8; ZINKERNAGEL RM, 1978, NATURE, V271, P251, DOI 10.1038/271251a0	39	230	271	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2002	8	2					171	178		10.1038/nm0202-171	http://dx.doi.org/10.1038/nm0202-171			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	517FN	11821902				2022-12-25	WOS:000173600600027
J	Furthauer, M; Lin, W; Ang, SL; Thisse, B; Thisse, C				Furthauer, M; Lin, W; Ang, SL; Thisse, B; Thisse, C			Sef is a feed back-induced antagonist of Ras/MAPK-mediated FGF signalling	NATURE CELL BIOLOGY			English	Article							MESODERM INDUCTION; XENOPUS EMBRYO; MAP KINASE; ZEBRAFISH; SPROUTY; REQUIREMENT; ACTIVATION; RECEPTOR; PATTERN; PATHWAY	Fibroblast growth factors (FGFs) are pleiotrophic growth factors that control cell proliferation, migration, differentiation and embryonic patterning(1). During early zebrafish embryonic development, FGFs regulate dorsoventral patterning by controlling ventral bone morphogenetic protein (BMP) expression(2,3). FGFs function by binding and activating high-affinity tyrosine kinase receptors(4). FGF activity is negatively regulated by members of the Sprouty family, which antagonize Ras signalling induced by receptor tyrosine kinases(3,5-8). On the basis of similarities in their expression patterns during embryonic development, we have identified five genes that define a synexpression group - fgf8, fgf3, sprouty2, sprouty4, as well as a novel gene, sef (similar expression to fgf genes). Sef encodes a conserved putative transmembrane protein that shares sequence similarities with the intracellular domain of the interleukin 17 receptors. Here we show that in zebrafish, Sef functions as a feedback-induced antagonist of Ras/Raf/MEK/MAPK-mediated FGF signalling.	ULP, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Thisse, C (corresponding author), ULP, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, BP 163, F-67404 Illkirch Graffenstaden, France.		FÃrthauer, Maximilian/AAY-4516-2020	FÃrthauer, Maximilian/0000-0001-6344-6585; THISSE, Christine/0000-0002-8684-1681	Medical Research Council [MC_U117570533] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; CONLON RA, 1993, METHOD ENZYMOL, V225, P373; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; Furthauer M, 1997, DEVELOPMENT, V124, P4253; Furthauer M, 2001, DEVELOPMENT, V128, P2175; Gabay L, 1997, SCIENCE, V277, P1103, DOI 10.1126/science.277.5329.1103; Goldfarb Mitchell, 1996, Cytokine and Growth Factor Reviews, V7, P311, DOI 10.1016/S1359-6101(96)00039-1; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; Kim J, 1998, BIOCHEM BIOPH RES CO, V250, P516, DOI 10.1006/bbrc.1998.9280; KLINT P, 1999, FRONT BIOSCI, V4, P165; Minowada G, 1999, DEVELOPMENT, V126, P4465; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; Mullins MC, 1996, DEVELOPMENT, V123, P81; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; Raible F, 2001, MECH DEVELOP, V107, P105, DOI 10.1016/S0925-4773(01)00456-7; Reifers F, 1998, DEVELOPMENT, V125, P2381; Roehl H, 2001, CURR BIOL, V11, P503, DOI 10.1016/S0960-9822(01)00143-9; SCHULTEMERKER S, 1995, CURR BIOL, V5, P62, DOI 10.1016/S0960-9822(95)00017-0; Tefft JD, 1999, CURR BIOL, V9, P219, DOI 10.1016/S0960-9822(99)80094-3; THISSE C, 1994, DEV BIOL, V164, P420, DOI 10.1006/dbio.1994.1212; Umbhauer M, 2000, J CELL SCI, V113, P2865; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; Wilson SI, 2000, CURR BIOL, V10, P421, DOI 10.1016/S0960-9822(00)00431-0; Yao ZB, 1995, IMMUNITY, V3, P811, DOI 10.1016/1074-7613(95)90070-5	28	258	264	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	FEB	2002	4	2					170	174		10.1038/ncb750	http://dx.doi.org/10.1038/ncb750			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	520RJ	11802165				2022-12-25	WOS:000173794600023
J	Chung, HM; Struhl, G				Chung, HM; Struhl, G			Nicastrin is required for Presenilin-mediated transmembrane cleavage in Drosophila	NATURE CELL BIOLOGY			English	Article							INTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; PROTEOLYTIC RELEASE; NUCLEAR ACCESS; IN-VIVO; NOTCH; LOCALIZATION; PHENOTYPES; PROTEINS; EMBRYOS	The transmembrane glycoprotein Nicastrin was identified in a complex with the multipass membrane protein Presenilin(1). Presenilin mediates transmembrane cleavage of single-pass transmembrane proteins with short extracellular domains(2), including the ligand-activated form of the receptor Notch(3-5) and beta -amyloid precursor protein (beta -APP)(6,7). Transmembrane cleavage of Notch is essential for signal transduction(3-5), and transmembrane cleavage of beta -APP generates pathogenic amyloid peptides implicated in Alzheimer's disease(8). Here, we investigate the requirement for Nicastrin in Presenilin-mediated transmembrane cleavage. We show that, in Drosophila, loss of Nicastrin activity blocks the accumulation of Presenilin associated with the apical plasma membrane, abolishes Presenilin-dependent cleavage of the transmembrane domains of Notch and beta -APP, and abrogates Notch signal transduction.	Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, Dept Genet & Dev, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute	Struhl, G (corresponding author), Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, Dept Genet & Dev, New York, NY 10032 USA.							Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Chen FS, 2001, NAT CELL BIOL, V3, P751, DOI 10.1038/35087069; CHOU TB, 1992, GENETICS, V131, P643; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Fagan R, 2001, TRENDS BIOCHEM SCI, V26, P213, DOI 10.1016/S0968-0004(01)01789-3; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; Goutte C, 2000, DEVELOPMENT, V127, P2481; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Guo YQ, 1999, J NEUROSCI, V19, P8435; Irvine KD, 1999, CURR OPIN GENET DEV, V9, P434, DOI 10.1016/S0959-437X(99)80066-5; Kidd S, 1998, GENE DEV, V12, P3728, DOI 10.1101/gad.12.23.3728; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Lecourtois M, 1998, CURR BIOL, V8, P771, DOI 10.1016/S0960-9822(98)70300-8; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Nolo R, 2000, CELL, V102, P349, DOI 10.1016/S0092-8674(00)00040-4; Nowotny P, 2000, MOL CELL NEUROSCI, V15, P88, DOI 10.1006/mcne.1999.0805; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Struhl G, 2001, P NATL ACAD SCI USA, V98, P229, DOI 10.1073/pnas.011530298; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Ye YH, 1998, MECH DEVELOP, V79, P199, DOI 10.1016/S0925-4773(98)00169-5; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009	33	126	131	0	2	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2001	3	12					1129	1132		10.1038/ncb1201-1129	http://dx.doi.org/10.1038/ncb1201-1129			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	500AM	11781576				2022-12-25	WOS:000172603700020
J	Shimizu-Sato, S; Huq, E; Tepperman, JM; Quail, PH				Shimizu-Sato, S; Huq, E; Tepperman, JM; Quail, PH			A light-switchable gene promoter system	NATURE BIOTECHNOLOGY			English	Article							LONG HYPOCOTYL MUTANTS; PHYTOCHROME-A; EXPRESSION; ARABIDOPSIS; BIOSYNTHESIS; DEFICIENT; PIF3	Regulatable transgene systems providing easily controlled, conditional induction or repression of expression are indispensable tools in biomedical and agricultural research and biotechnology. Several such systems have been developed for eukaryotes(1-6). Most of these rely on the administration of either exogenous chemicals or heat shock. Despite the general success of many of these systems, the potential for problems, such as toxic, unintended, or pleiotropic effects of the inducing chemical or treatment, can impose limitations on their use. We have developed a promoter system that can be induced, rapidly and reversibly, by short pulses of light. This system is based on the known red light-induced binding of the plant photoreceptor phytochrome to the protein PIF3 and the reversal of this binding by far-red light(7,8). We show here that yeast cells expressing two chimeric proteins, a phytochrome-GAL4-DNA-binding- domain fusion and a PIF3-GAL4-activation- domain fusion, are induced by red light to express selectable or "scorable" marker genes containing promoters with a GAL4 DNA-binding site, and that this induction is rapidly abrogated by subsequent far-red light. We further show that the extent of induction can be controlled precisely by titration of the number of photons delivered to the cells by the light pulse. Thus, this system has the potential to provide rapid, noninvasive, switchable control of the expression of a desired gene to a preselected level in any suitable cell by simple exposure to a light signal.	Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; ARS, USDA, Ctr Plant Gene Express, Albany, CA 94710 USA	University of California System; University of California Berkeley; United States Department of Agriculture (USDA)	Quail, PH (corresponding author), Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA.			Huq, Enamul/0000-0001-7692-5139	NIGMS NIH HHS [GM47475] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047475] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blau HM, 1999, P NATL ACAD SCI USA, V96, P797, DOI 10.1073/pnas.96.3.797; BOYLAN MT, 1991, P NATL ACAD SCI USA, V88, P10806, DOI 10.1073/pnas.88.23.10806; Gambetta GA, 2001, P NATL ACAD SCI USA, V98, P10566, DOI 10.1073/pnas.191375198; Gatz C, 1997, ANNU REV PLANT PHYS, V48, P89, DOI 10.1146/annurev.arplant.48.1.89; Gatz C, 1996, CURR OPIN BIOTECH, V7, P168, DOI 10.1016/S0958-1669(96)80008-5; HARPER JW, 1993, CELL, V75, P805; James P, 1996, GENETICS, V144, P1425; Lewandoski M, 2001, NAT REV GENET, V2, P743, DOI 10.1038/35093537; Mills AA, 2001, GENE DEV, V15, P1461, DOI 10.1101/gad.909301; Ni M, 1999, NATURE, V400, P781, DOI 10.1038/23500; PARKS BM, 1991, PLANT CELL, V3, P1177, DOI 10.1105/tpc.3.11.1177; PARKS BM, 1993, PLANT CELL, V5, P39, DOI 10.1105/tpc.5.1.39; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; Quail PH, 2002, NAT REV MOL CELL BIO, V3, P85, DOI 10.1038/nrm728; Quail PH, 1997, PLANT CELL ENVIRON, V20, P657, DOI 10.1046/j.1365-3040.1997.d01-108.x; Ronicke V, 1997, METHOD ENZYMOL, V283, P313; Roslan HA, 2001, PLANT J, V28, P225, DOI 10.1046/j.1365-313X.2001.01146.x; Scheer H., 1984, TECHNIQUES PHOTOMORP, P227, DOI [10.5282/ubm/epub.2167, DOI 10.5282/UBM/EPUB.2167]; SMITH H, 1987, PLANT PHYSIOL, V84, P1059, DOI 10.1104/pp.84.4.1059; Zhu YX, 2000, P NATL ACAD SCI USA, V97, P13419, DOI 10.1073/pnas.230433797	20	445	480	4	112	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2002	20	10					1041	1044		10.1038/nbt734	http://dx.doi.org/10.1038/nbt734			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	599AZ	12219076				2022-12-25	WOS:000178313100023
J	Kitami, T; Nadeau, JH				Kitami, T; Nadeau, JH			Biochemical networking contributes more to genetic buffering in human and mouse metabolic pathways than does gene duplication	NATURE GENETICS			English	Article							SEQUENCE; ROBUSTNESS; MUTATIONS; GENOME	During evolution different genes evolve at unequal rates, reflecting the varying functional constraints on phenotype. An important contributor to this variation is genetic buffering, which reduces the potential detrimental effects of mutations. We studied whether gene duplication and redundant metabolic networks affect genetic buffering by comparing the evolutionary rate of 242 human and mouse orthologous genes involved in metabolic pathways. A gene with a redundant network is defined as one for which the structural layout of metabolic pathways provides an alternative metabolic route that can, in principle, compensate for the loss of a protein function encoded by the gene. We found that genes with redundant networks evolved more quickly than did genes without redundant networks, but no significant difference was detected between single-copy genes and gene families. This implies that redundancy in metabolic networks provides significantly more genetic buffering than do gene families. We also found that genes encoding proteins involved in glycolysis and gluconeogenesis showed as a group a distinct pattern of variation, in contrast to genes involved in other pathways. These results suggest that redundant networks provide genetic buffering and contribute to the functional diversification of metabolic pathways.	Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Computat Genom, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Ctr Human Genet, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	Nadeau, JH (corresponding author), Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA.	jhn4@po.cwru.edu	Kitami, Toshimori/N-7460-2019	Kitami, Toshimori/0000-0001-8418-5230				Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P45, DOI 10.1093/nar/28.1.45; Comeron JM, 1998, J MOL EVOL, V47, P268, DOI 10.1007/PL00006384; Force A, 1999, GENETICS, V151, P1531; Hirsh AE, 2001, NATURE, V411, P1046, DOI 10.1038/35082561; Jeong H, 2000, NATURE, V407, P651, DOI 10.1038/35036627; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lenski RE, 1999, NATURE, V400, P661, DOI 10.1038/23245; Lynch M, 2000, SCIENCE, V290, P1151, DOI 10.1126/science.290.5494.1151; Makalowski W, 1998, P NATL ACAD SCI USA, V95, P9407, DOI 10.1073/pnas.95.16.9407; MICHAEL G, 1999, BIOCH PATHWAYS ATLAS; NEI M, 1986, MOL BIOL EVOL, V3, P418; Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29; Ohno S., 1970, P1; PICKETT FB, 1995, PLANT CELL, V7, P1347, DOI 10.1105/tpc.7.9.1347; Rebhan M, 1998, BIOINFORMATICS, V14, P656, DOI 10.1093/bioinformatics/14.8.656; REDER C, 1988, J THEOR BIOL, V135, P175, DOI 10.1016/S0022-5193(88)80073-0; Remold SK, 2001, P NATL ACAD SCI USA, V98, P11388, DOI 10.1073/pnas.201140198; Rivera MC, 1998, P NATL ACAD SCI USA, V95, P6239, DOI 10.1073/pnas.95.11.6239; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Schuster S, 1999, TRENDS BIOTECHNOL, V17, P53, DOI 10.1016/S0167-7799(98)01290-6; TAJIMA F, 1993, GENETICS, V135, P599; THOMAS JH, 1993, TRENDS GENET, V9, P395, DOI 10.1016/0168-9525(93)90140-D; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wagner A, 2000, NAT GENET, V24, P355, DOI 10.1038/74174; Wagner A, 2000, P NATL ACAD SCI USA, V97, P6579, DOI 10.1073/pnas.110147097; WALSH JB, 1995, GENETICS, V139, P421; WRIGHT F, 1990, GENE, V87, P23, DOI 10.1016/0378-1119(90)90491-9	30	65	66	0	5	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2002	32	1					191	194		10.1038/ng945	http://dx.doi.org/10.1038/ng945			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	588RR	12161750				2022-12-25	WOS:000177714900021
J	Reich, DE; Schaffner, SF; Daly, MJ; McVean, G; Mullikin, JC; Higgins, JM; Richter, DJ; Lander, ES; Altshuler, D				Reich, DE; Schaffner, SF; Daly, MJ; McVean, G; Mullikin, JC; Higgins, JM; Richter, DJ; Lander, ES; Altshuler, D			Human genome sequence variation and the influence of gene history, mutation and recombination	NATURE GENETICS			English	Article							SINGLE-NUCLEOTIDE POLYMORPHISMS; NEUTRAL ALLELE MODEL; LINKAGE DISEQUILIBRIUM; INTRAGENIC RECOMBINATION; POPULATION EXPANSION; FINITE POPULATION; CANDIDATE GENES; SNP MAP; DIVERSITY; REGIONS	Variation in the human genome sequence is key to understanding susceptibility to disease in modern populations and the history of ancestral populations. Unlocking this information requires knowledge of the patterns and underlying causes of human sequence diversity. By applying a new population-genetic framework to two genome-wide polymorphism surveys, we find that the human genome contains sizeable regions (stretching over tens of thousands of base pairs) that have intrinsically high and low rates of sequence variation. We show that the primary determinant of these patterns is shared genealogical history. Only a fraction of the variation (at most 25%) is due to the local mutation rate. By measuring the average distance over which genealogical histories are typically preserved, these data provide the first genome-wide estimate of the average extent of correlation among variants (linkage disequilibrium). The results are best explained by extreme variability in the recombination rate at a fine scale, and provide the first empirical evidence that such recombination 'hot spots' are a general feature of the human genome and have a principal role in shaping genetic variation in the human population.	MIT, Ctr Genome Res, Whitehead Inst, Cambridge, MA 02139 USA; Univ Oxford, Dept Stat, Oxford OX1 3TG, England; Wellcome Trust Sanger Inst, Cambridge, England; MIT, Dept Biol, Cambridge, MA USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; University of Oxford; Wellcome Trust Sanger Institute; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Altshuler, D (corresponding author), MIT, Ctr Genome Res, Whitehead Inst, 1 Kendall Sq, Cambridge, MA 02139 USA.	altshuler@molbio.mgh.harvard.edu	Altshuler, David M/A-4476-2009; Daly, Mark J/B-2453-2017; Schaffner, Stephen F/D-1189-2011	Altshuler, David M/0000-0002-7250-4107; Daly, Mark J/0000-0002-0949-8752; Richter, Daniel/0000-0002-9238-5571; Schaffner, Stephen/0000-0001-6699-3568				Abecasis GR, 2001, AM J HUM GENET, V68, P191, DOI 10.1086/316944; Altshuler D, 2000, NATURE, V407, P513, DOI 10.1038/35035083; Broman KW, 1998, AM J HUM GENET, V63, P861, DOI 10.1086/302011; Cambien F, 1999, AM J HUM GENET, V65, P183, DOI 10.1086/302448; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; Cavalli-Sforza L. L., 1994, HIST GEOGRAPHY HUMAN; CHAKRAVARTI A, 1984, AM J HUM GENET, V36, P1239; Daly MJ, 2001, NAT GENET, V29, P229, DOI 10.1038/ng1001-229; DEVLIN B, 1995, GENOMICS, V29, P311, DOI 10.1006/geno.1995.9003; Dunning AM, 2000, AM J HUM GENET, V67, P1544, DOI 10.1086/316906; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Griffiths R., 1991, IMS LECT NOTES MONOG, V18, P100; GRIFFITHS RC, 1981, THEOR POPUL BIOL, V19, P169, DOI 10.1016/0040-5809(81)90016-2; Halushka MK, 1999, NAT GENET, V22, P239, DOI 10.1038/10297; Hudson R.R., 1990, Oxford Surveys in Evolutionary Biology, V7, P1; HUDSON RR, 1983, EVOLUTION, V37, P203, DOI 10.1111/j.1558-5646.1983.tb05528.x; HUDSON RR, 1983, THEOR POPUL BIOL, V23, P183, DOI 10.1016/0040-5809(83)90013-8; Jeffreys AJ, 2000, HUM MOL GENET, V9, P725, DOI 10.1093/hmg/9.5.725; Jeffreys AJ, 2001, NAT GENET, V29, P217, DOI 10.1038/ng1001-217; KAPLAN N, 1985, THEOR POPUL BIOL, V28, P382, DOI 10.1016/0040-5809(85)90036-X; Kimmel M, 1998, GENETICS, V148, P1921; Kimura MA, 1985, NEUTRAL THEORY MOL E; Kong A, 2002, NAT GENET, V31, P241, DOI 10.1038/ng917; Kruglyak L, 1999, NAT GENET, V22, P139, DOI 10.1038/9642; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li W. H, 1997, MOL EVOLUTION; LI WH, 1991, GENETICS, V129, P513; Lui BH, 1998, STAT GENOMICS LINKAG; Mullikin JC, 2000, NATURE, V407, P516, DOI 10.1038/35035089; Nachman MW, 2000, GENETICS, V156, P297; OHTA T, 1971, GENETICS, V68, P571; Przeworski M, 2000, TRENDS GENET, V16, P296, DOI 10.1016/S0168-9525(00)02030-8; Reich DE, 2001, NATURE, V411, P199, DOI 10.1038/35075590; Reich DE, 1998, P NATL ACAD SCI USA, V95, P8119, DOI 10.1073/pnas.95.14.8119; Risch NJ, 2000, NATURE, V405, P847, DOI 10.1038/35015718; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; STROBECK C, 1978, GENETICS, V88, P829; SVED J A, 1971, Theoretical Population Biology, V2, P125; Taillon-Miller P, 2000, NAT GENET, V25, P324, DOI 10.1038/77100; Takahata N, 1997, P NATL ACAD SCI USA, V94, P4811, DOI 10.1073/pnas.94.9.4811; Tishkoff SA, 1996, SCIENCE, V271, P1380, DOI 10.1126/science.271.5254.1380; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wakeley J, 1999, GENETICS, V153, P1863; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; Yu A, 2001, NATURE, V409, P951, DOI 10.1038/35057185	46	222	246	1	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2002	32	1					135	142		10.1038/ng947	http://dx.doi.org/10.1038/ng947			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	588RR	12161752				2022-12-25	WOS:000177714900012
J	Hattori, K; Heissig, B; Wu, Y; Dias, S; Tejada, R; Ferris, B; Hicklin, DJ; Zhu, ZP; Bohlen, P; Witte, L; Hendrikx, J; Hackett, NR; Crystal, RG; Moore, MAS; Werb, Z; Lyden, D; Rafii, S				Hattori, K; Heissig, B; Wu, Y; Dias, S; Tejada, R; Ferris, B; Hicklin, DJ; Zhu, ZP; Bohlen, P; Witte, L; Hendrikx, J; Hackett, NR; Crystal, RG; Moore, MAS; Werb, Z; Lyden, D; Rafii, S			Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment	NATURE MEDICINE			English	Article							TUMOR ANGIOGENESIS; FACTOR RECEPTOR-1; PROGENITOR CELLS; TYROSINE KINASE; FACTOR VEGF; FLT-1; INHIBITION; LINEAGE; MOBILIZATION; ENGRAFTMENT	The mechanism by which angiogenic factors recruit bone marrow ( BM)-derived quiescent endothelial and hematopoietic stem cells ( HSCs) is not known. Here, we report that functional vascular endothelial growth factor receptor-1 (VEGFR1) is expressed on human CD34(+) and mouse Lin(-)Sca-1(+)c-Kit(+) BM-repopulating stem cells, conveying signals for recruitment of HSCs and reconstitution of hematopoiesis. Inhibition of VEGFR1, but not VEGFR2, blocked HSC cell cycling, differentiation and hematopoietic recovery after BM suppression, resulting in the demise of the treated mice. Placental growth factor ( PlGF), which signals through VEGFR1, restored early and late phases of hematopoiesis following BM suppression. PlGF enhanced early phases of BM recovery directly through rapid chemotaxis of VEGFR1(+) BM-repopulating and progenitor cells. The late phase of hematopoietic recovery was driven by PlGF-induced upregulation of matrix metalloproteinase-9, mediating the release of soluble Kit ligand. Thus, PlGF promotes recruitment of VEGFR1(+) HSCs from a quiescent to a proliferative BM microenvironment, favoring differentiation, mobilization and reconstitution of hematopoiesis.	Cornell Univ, Coll Med, Dept Med, New York, NY 10021 USA; Sloan Kettering Inst, New York, NY USA; ImClone Syst Inc, New York, NY USA; New York Blood Ctr, New York, NY 10021 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA	Cornell University; Memorial Sloan Kettering Cancer Center; Eli Lilly; New York Blood Center; University of California System; University of California San Francisco	Rafii, S (corresponding author), Cornell Univ, Coll Med, Dept Med, New York, NY 10021 USA.	srafii@med.cornell.edu	Mordwinkin, Nicholas M/A-4347-2010; Dias, Sergio/L-1250-2014; Heissig, Beate/AAF-6771-2021	Dias, Sergio/0000-0002-7603-4616; Heissig, Beate/0000-0002-0348-5934	NATIONAL CANCER INSTITUTE [R01CA075072, P01CA072006] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061849, R01HL061401, R01HL058707, P01HL067839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046238] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039278] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA072006, R01 CA075072-03, CA 72006, P01 CA072006-07, CA 75072] Funding Source: Medline; NHLBI NIH HHS [P01 HL067839, R01 HL61401, R01 HL061849, R01 HL61849, R01 HL-58707, R01 HL-66592, R01 HL-67839] Funding Source: Medline; NIAMS NIH HHS [R01 AR046238-03, AR46238, R01 AR046238] Funding Source: Medline; NINDS NIH HHS [NS39278, R01 NS039278-05A1, R01 NS039278] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; BERARDI AC, 1995, SCIENCE, V267, P104, DOI 10.1126/science.7528940; BRIDDELL RA, 1993, BLOOD, V82, P1720; Broxmeyer HE, 1995, INT J HEMATOL, V62, P203; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Cho NK, 2002, CELL, V108, P865, DOI 10.1016/S0092-8674(02)00676-1; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; Dias S, 2001, P NATL ACAD SCI USA, V98, P10857, DOI 10.1073/pnas.191117498; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fong GH, 1999, DEVELOPMENT, V126, P3015; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; Goodell MA, 1997, NAT MED, V3, P1337, DOI 10.1038/nm1297-1337; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Haruta H, 2001, FEBS LETT, V507, P45, DOI 10.1016/S0014-5793(01)02921-0; Hattori K, 2001, BLOOD, V97, P3354, DOI 10.1182/blood.V97.11.3354; Hattori K, 2001, J EXP MED, V193, P1005, DOI 10.1084/jem.193.9.1005; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Hiratsuka S, 2001, CANCER RES, V61, P1207; Huang XL, 1999, BIOCHEM BIOPH RES CO, V264, P133, DOI 10.1006/bbrc.1999.1472; Kabrun N, 1997, DEVELOPMENT, V124, P2039; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; LATERVEER L, 1995, BLOOD, V85, P2269, DOI 10.1182/blood.V85.8.2269.bloodjournal8582269; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Morrison SJ, 1997, DEVELOPMENT, V124, P1929; Morrison SJ, 1997, P NATL ACAD SCI USA, V94, P1908, DOI 10.1073/pnas.94.5.1908; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Phillips RL, 2000, SCIENCE, V288, P1635, DOI 10.1126/science.288.5471.1635; Prewett M, 1999, CANCER RES, V59, P5209; Randall TD, 1997, BLOOD, V89, P3596, DOI 10.1182/blood.V89.10.3596.3596_3596_3606; Ratajczak MZ, 1998, BRIT J HAEMATOL, V103, P969, DOI 10.1046/j.1365-2141.1998.01076.x; Sawano A, 2001, BLOOD, V97, P785, DOI 10.1182/blood.V97.3.785; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; VANZANT G, 1984, J EXP MED, V159, P679, DOI 10.1084/jem.159.3.679; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Witte L, 1998, CANCER METAST REV, V17, P155, DOI 10.1023/A:1006094117427; Zhu ZP, 1999, CANCER LETT, V136, P203, DOI 10.1016/S0304-3835(98)00324-3; Zhu ZP, 1998, CANCER RES, V58, P3209; Ziegler BL, 1999, SCIENCE, V285, P1553, DOI 10.1126/science.285.5433.1553	42	489	543	2	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2002	8	8					841	849		10.1038/nm740	http://dx.doi.org/10.1038/nm740			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	579WJ	12091880	Green Accepted			2022-12-25	WOS:000177200900030
J	Lercher, MJ; Urrutia, AO; Hurst, LD				Lercher, MJ; Urrutia, AO; Hurst, LD			Clustering of housekeeping genes provides a unified model of gene order in the human genome	NATURE GENETICS			English	Article							MAP; CHROMOSOME; EXPRESSION; COMPLEX	It is often supposed that, except for tandem duplicates, genes are randomly distributed throughout the human genome. However, recent analyses suggest that when all the genes expressed in a given tissue (notably placenta(1) and skeletal muscle(2)) are examined, these genes do not map to random locations but instead resolve to clusters. We have asked three questions: (i) is this clustering true for most tissues, or are these the exceptions; (ii) is any clustering simply the result of the expression of tandem duplicates and (iii) how, if at all, does this relate to the observed clustering of genes with high expression rates(3) ? We provide a unified model of gene clustering that explains the previous observations. We examined Serial Analysis of Gene Expression (SAGE)(4) data for 14 tissues and found significant clustering, in each tissue, that persists even after the removal of tandem duplicates. We confirmed clustering by analysis of independent expressed-sequence tag (EST) data. We then tested the possibility that the human genome is organized into subregions, each specializing in genes needed in a given tissue. By comparing genes expressed in different tissues, we show that this is not the case: those genes that seem to be tissue-specific in their expression do not, as a rule, cluster. We report that genes that are expressed in most tissues (housekeeping genes) show strong clustering. In addition, we show that the apparent clustering of genes with high expression rates(3) is a consequence of the clustering of housekeeping genes.	Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England	University of Bath	Hurst, LD (corresponding author), Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England.	l.d.hurst@bath.ac.uk	Lercher, Martin/K-7939-2013; Martinez, Octavio/B-7375-2009; Hurst, Laurence/F-9215-2010	Lercher, Martin/0000-0003-3940-1621; Hurst, Laurence/0000-0002-1002-1054; Urrutia, Araxi/0000-0001-9011-8675				Beck S, 1999, NATURE, V401, P921, DOI 10.1038/44853; Blumenthal T, 1998, BIOESSAYS, V20, P480, DOI 10.1002/(SICI)1521-1878(199806)20:6&lt;480::AID-BIES6&gt;3.0.CO;2-Q; Bortoluzzi S, 1998, GENOME RES, V8, P817, DOI 10.1101/gr.8.8.817; Caron H, 2001, SCIENCE, V291, P1289, DOI 10.1126/science.1056794; Dandekar T, 1998, TRENDS BIOCHEM SCI, V23, P324, DOI 10.1016/S0968-0004(98)01274-2; DURET L, 1994, NUCLEIC ACIDS RES, V22, P2360, DOI 10.1093/nar/22.12.2360; Fisher R.A., 1930, GENETICAL THEORY NAT; Hurst LD, 1996, NAT GENET, V12, P234, DOI 10.1038/ng0396-234; Ko MSH, 1998, HUM MOL GENET, V7, P1967, DOI 10.1093/hmg/7.12.1967; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lash AE, 2000, GENOME RES, V10, P1051, DOI 10.1101/gr.10.7.1051; Paul AL, 1999, PLANT MOL BIOL, V41, P713, DOI 10.1023/A:1006323222693; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Zavattari P, 2000, HUM MOL GENET, V9, P2947, DOI 10.1093/hmg/9.20.2947	15	418	431	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2002	31	2					180	183		10.1038/ng887	http://dx.doi.org/10.1038/ng887			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	557HR	11992122				2022-12-25	WOS:000175903500015
J	Abi-Rached, L; Gilles, A; Shiina, T; Pontarotti, P; Inoko, H				Abi-Rached, L; Gilles, A; Shiina, T; Pontarotti, P; Inoko, H			Evidence of en bloc duplication in vertebrate genomes	NATURE GENETICS			English	Article							CLASS-I; EVOLUTION; LINKAGE; REGION; SYSTEM; GENES; BLAST	It has been 30 years since it was first proposed that the vertebrate genome evolved through several rounds of genome-wide duplications (polyploidizations)(1). Despite rapid advances in genetics, including sequencing of the complete genomes of several divergent species, this hypothesis has not been tested rigorously and is still a matter of debate(2). If polyploidizations occurred during chordate evolution, there should be a network of paralogous regions in the present-day jawed vertebrate (Gnathostomata) genomes(3). Here we present an investigation of the major histocompatibility complex (MHC) paralogous regions, which we accomplished by characterizing the corresponding region in amphioxus by identifying nine anchor genes and sequencing both the anchor genes and the regions that flank them (a total of 400 kb). Phylogenetic analysis of 31 genes (including the anchor genes) in these regions shows that duplications occurred after the divergence of cephalochordates and vertebrates but before the Gnathostomata radiation. The distribution of human and amphioxus orthologs in their respective genomes and the relationship between these distributions support the en bloc duplication events. Our analysis represents the first step towards demonstrating that the human ancestral genome has undergone polyploidization. Moreover, reconstruction of the pre-duplicated region indicates that one of the duplicated regions retains the ancestral organization.	INSERM, U119, F-13009 Marseille, France; Univ Aix Marseille 1, UPRES Biodivers 2202, F-13331 Marseille 3, France; Tokai Univ, Sch Med, Dept Mol Life Sci, Kanagawa 2591193, Japan	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Tokai University	Abi-Rached, L (corresponding author), INSERM, U119, 27 Bd Lei Roure, F-13009 Marseille, France.	abi-rached@marseille.inserm.fr; pontarot@marseille.inserm.fr	Abi-Rached, Laurent/H-7236-2012; , pontarotti/ABB-1753-2021	Pierre, Pontarotti/0000-0001-7202-3648; Shiina, Takashi/0000-0002-2067-6708				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Boone M, 2000, BIOINFORMATICS, V16, P1054, DOI 10.1093/bioinformatics/16.11.1054; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Clark MS, 2001, IMMUNOGENETICS, V52, P174, DOI 10.1007/s002510000285; FARRIS JS, 1994, CLADISTICS, V10, P315, DOI 10.1111/j.1096-0031.1996.tb00196.x; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FITCH WM, 1970, SYST ZOOL, V19, P99, DOI 10.2307/2412448; Gelfand MS, 1996, P NATL ACAD SCI USA, V93, P9061, DOI 10.1073/pnas.93.17.9061; Gu X, 1999, MOL BIOL EVOL, V16, P1664, DOI 10.1093/oxfordjournals.molbev.a026080; Guigo R, 2000, GENOME RES, V10, P1631, DOI 10.1101/gr.122800; Hansen JD, 1999, J IMMUNOL, V163, P774; Huang XQ, 1999, GENOME RES, V9, P868, DOI 10.1101/gr.9.9.868; Kasahara M, 1997, TRENDS GENET, V13, P90, DOI 10.1016/S0168-9525(97)01065-2; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; KUMAR S, 1994, COMPUT APPL BIOSCI, V10, P189; LUNDIN LG, 1993, GENOMICS, V16, P1, DOI 10.1006/geno.1993.1133; Maresco DL, 1998, CYTOGENET CELL GENET, V82, P71, DOI 10.1159/000015067; Ohno S., 1970, EVOLUTION GENE DUPLI; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J, 1989, MOL CLONING; Shiina T, 2001, GENOME RES, V11, P789, DOI 10.1101/gr.175801; SOLOVYEV V, 1997, ISMB, V5, P294; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; Swofford D. L., 2011, PAUP PHYLOGENETIC AN; Takami K, 1997, J IMMUNOL, V159, P6052; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wolfe KH, 2001, NAT REV GENET, V2, P333, DOI 10.1038/35072009; ZEHETNER G, 1994, NATURE, V367, P489, DOI 10.1038/367489a0	30	198	207	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2002	31	1					100	105		10.1038/ng855	http://dx.doi.org/10.1038/ng855			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	547ZF	11967531				2022-12-25	WOS:000175362500023
J	Marras, D; Bruggeman, LA; Gao, F; Tanji, N; Mansukhani, MM; Cara, A; Ross, MD; Gusella, GL; Benson, G; D'Agati, VD; Hahn, BH; Klotman, ME; Klotman, PE				Marras, D; Bruggeman, LA; Gao, F; Tanji, N; Mansukhani, MM; Cara, A; Ross, MD; Gusella, GL; Benson, G; D'Agati, VD; Hahn, BH; Klotman, ME; Klotman, PE			Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CHEMOKINE RECEPTOR CCR5; TRANSGENIC MICE; RENAL-DISEASE; INFECTION; EXPRESSION; RESERVOIR; TYPE-1; CELLS; CORECEPTORS	HIV-associated nephropathy is a clinicopathologic entity that includes proteinuria, focal segmental glomerulosclerosis often of the collapsing variant, and microcystic tubulointerstitial disease(1-4). Increasing evidence supports a role for HIV-1 infection of renal epithelium in the pathogenesis of HIV-associated nephropathy(5-8). Using in situ hybridization, we previously demonstrated HIV-1 gag and nef mRNA in renal epithelial cells of patients with HIV-associated nephropathy(9). Here, to investigate whether renal epithelial cells were productively infected by HIV-1, we examined renal tissue for the presence of HIV-1 DNA and mRNA by in situ hybridization and PCR, and we molecularly characterized the HIV-1 quasispecies in the renal compartment. Infected renal epithelial cells were removed by laser-capture microdissection from biopsies of two patients, DNA was extracted, and HIV-1 V3-loop or gp120-envelope sequences were amplified from individually dissected cells by nested PCR. Phylogenetic analysis of kidney-derived sequences as well as corresponding sequences from peripheral blood mononuclear cells of the same patients revealed evidence of tissue-specific viral evolution. In phylogenetic trees constructed from V3 and gp120 sequences, kidney-derived sequences formed tissue-specific subclusters within the radiation of blood mononuclear cell-derived viral sequences from both patients. These data, along with the detection of HIV-1-specific proviral DNA and mRNA in tubular epithelium cells, argue strongly for localized replication of HIV-1 in the kidney and the existence of a renal viral reservoir.	Mt Sinai Sch Med, Dept Med, Div Nephrol, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Med, Div Infect Dis, New York, NY USA; Mt Sinai Sch Med, Dept Biomath Sci, New York, NY USA; Columbia Presbyterian Med Ctr, Dept Pathol, New York, NY 10032 USA; Univ Alabama, Dept Med & Microbiol, Birmingham, AL USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Ist Super Sanita, I-00161 Rome, Italy	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Columbia University; NewYork-Presbyterian Hospital; University of Alabama System; University of Alabama Birmingham; Duke University; Istituto Superiore di Sanita (ISS)	Marras, D (corresponding author), Mt Sinai Sch Med, Dept Med, Div Nephrol, New York, NY 10029 USA.		Cara, Andrea/M-4865-2015; klotman, mary e/A-1921-2016; Cara, Andrea/AAA-4238-2021	Cara, Andrea/0000-0003-4967-1895; Cara, Andrea/0000-0003-4967-1895; Hahn, Beatrice/0000-0002-9400-9887	NIAID NIH HHS [P20AI27767, N01 AI85338] Funding Source: Medline; NIDDK NIH HHS [P01 DK50795, P01 DK56492] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI085338, P30AI027767] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK056492, P01DK050795] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOTTARO M, 1994, BLOOD, V83, P3271, DOI 10.1182/blood.V83.11.3271.bloodjournal83113271; BOURGOIGNIE JJ, 1989, TRANSPLANT P, V21, P3899; Bruggeman LA, 1997, J CLIN INVEST, V100, P84, DOI 10.1172/JCI119525; BRUGGEMAN LA, 2000, J AM SOC NEPHROL; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; CANTOR ES, 1991, ARCH INTERN MED, V151, P125, DOI 10.1001/archinte.151.1.125; Choe H, 1998, J VIROL, V72, P6113, DOI 10.1128/JVI.72.7.6113-6118.1998; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; COHEN AH, 1989, MODERN PATHOL, V2, P125; Conaldi PG, 1998, J CLIN INVEST, V102, P2041, DOI 10.1172/JCI3480; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DICKIE P, 1991, VIROLOGY, V185, P109, DOI 10.1016/0042-6822(91)90759-5; Eitner F, 2000, J AM SOC NEPHROL, V11, P856, DOI 10.1681/ASN.V115856; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; FAULKNER DV, 1988, TRENDS BIOCHEM SCI, V13, P321, DOI 10.1016/0968-0004(88)90129-6; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Hoffman TL, 1998, P NATL ACAD SCI USA, V95, P11360, DOI 10.1073/pnas.95.19.11360; HUMPHREYS MH, 1995, KIDNEY INT, V48, P311, DOI 10.1038/ki.1995.299; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; Lagaye S, 2001, J VIROL, V75, P4780, DOI 10.1128/JVI.75.10.4780-4791.2001; Mack M, 2000, NAT MED, V6, P769, DOI 10.1038/77498; Meng G, 2002, NAT MED, V8, P150, DOI 10.1038/nm0202-150; Moore JP, 1997, SCIENCE, V276, P51, DOI 10.1126/science.276.5309.51; *NIH NIDDK, 1997, US REN DAT SYST; Owman C, 1998, P NATL ACAD SCI USA, V95, P9530, DOI 10.1073/pnas.95.16.9530; RAO TKS, 1987, NEW ENGL J MED, V316, P1062, DOI 10.1056/NEJM198704233161705; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; STRAUSS J, 1989, NEW ENGL J MED, V321, P625, DOI 10.1056/NEJM198909073211001; TANJI N, 2000, EXP NEPHROL; Winston JA, 2000, SEMIN NEPHROL, V20, P293; Winston JA, 2001, NEW ENGL J MED, V344, P1979, DOI 10.1056/NEJM200106283442604	31	233	241	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2002	8	5					522	526		10.1038/nm0502-522	http://dx.doi.org/10.1038/nm0502-522			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	547ZW	11984599				2022-12-25	WOS:000175336800040
J	Shen-Orr, SS; Milo, R; Mangan, S; Alon, U				Shen-Orr, SS; Milo, R; Mangan, S; Alon, U			Network motifs in the transcriptional regulation network of Escherichia coli	NATURE GENETICS			English	Article							GENE-REGULATION; ORGANIZATION; SIMULATION; ELEMENTS; OPERON	Little is known about the design principles(1-10) of transcriptional regulation networks that control gene expression in cells. Recent advances in data collection and analysis(2,11,12), however, are generating unprecedented amounts of information about gene regulation networks. To understand these complex wiring diagrams(1-10,13), we sought to break down such networks into basic building blocks(2). We generalize the notion of motifs, widely used for sequence analysis, to the level of networks. We define 'network motifs' as patterns of interconnections that recur in many different parts of a network at frequencies much higher than those found in randomized networks. We applied new algorithms for systematically detecting network motifs to one of the best-characterized regulation networks, that of direct transcriptional interactions in Escherichia coli(3,6). We find that much of the network is composed of repeated appearances of three highly significant motifs. Each network motif has a specific function in determining gene expression, such as generating temporal expression programs and governing the responses to fluctuating external signals. The motif structure also allows an easily interpretable view of the entire known transcriptional network of the organism. This approach may help define the basic computational elements of other biological networks.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Phys Complex Syst, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Alon, U (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	urialon@wisemail.weizmann.ac.il	Milo, Hilla/C-8767-2016; Yang, Chen/G-1379-2010	Shen-Orr, Shai/0000-0002-6991-7736; Milo, Ron/0000-0003-1641-2299; Li, Jun/0000-0003-4440-5862				Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; BRAY D, 1995, NATURE, V376, P307, DOI 10.1038/376307a0; Duda R. O., 1973, PATTERN CLASSIFICATI; Hartemink A J, 2001, Pac Symp Biocomput, P422; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; HENGGEARONIS R, 1993, CELL, V72, P165, DOI 10.1016/0092-8674(93)90655-A; Hughes JD, 2000, J MOL BIOL, V296, P1205, DOI 10.1006/jmbi.2000.3519; Jeong H, 2000, NATURE, V407, P651, DOI 10.1038/35036627; Kalir S, 2001, SCIENCE, V292, P2080, DOI 10.1126/science.1058758; Kannan R, 1999, RANDOM STRUCT ALGOR, V14, P293, DOI 10.1002/(SICI)1098-2418(199907)14:4<293::AID-RSA1>3.0.CO;2-G; KAUFFMAN SA, 1969, J THEOR BIOL, V22, P437, DOI 10.1016/0022-5193(69)90015-0; MCADAMS HH, 1995, SCIENCE, V269, P650, DOI 10.1126/science.7624793; McAdams HH, 1998, ANNU REV BIOPH BIOM, V27, P199, DOI 10.1146/annurev.biophys.27.1.199; Newman MEJ, 2001, PHYS REV E, V64, DOI [10.1103/PhysRevE.64.016131, 10.1103/PhysRevE.64.016132]; Rao CV, 2001, ANNU REV BIOMED ENG, V3, P391, DOI 10.1146/annurev.bioeng.3.1.391; Salgado H, 2001, NUCLEIC ACIDS RES, V29, P72, DOI 10.1093/nar/29.1.72; SAVAGEAU M, 1996, ESCHERICHIA COLL SAL, P1310; Schleif R, 2000, TRENDS GENET, V16, P559, DOI 10.1016/S0168-9525(00)02153-3; Strogatz SH, 2001, NATURE, V410, P268, DOI 10.1038/35065725; Thieffry D, 1998, BIOESSAYS, V20, P433, DOI 10.1002/(SICI)1521-1878(199805)20:5<433::AID-BIES10>3.0.CO;2-2; Yuh CH, 1998, SCIENCE, V279, P1896, DOI 10.1126/science.279.5358.1896	21	1945	2021	3	136	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2002	31	1					64	68		10.1038/ng881	http://dx.doi.org/10.1038/ng881			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	547ZF	11967538	Bronze			2022-12-25	WOS:000175362500016
J	Carpten, J; Nupponen, N; Isaacs, S; Sood, R; Robbins, C; Xu, J; Faruque, M; Moses, T; Ewing, C; Gillanders, E; Hu, P; Buinovszky, P; Makalowska, I; Baffoe-Bonnie, A; Faith, D; Smith, J; Stephan, D; Wiley, K; Brownstein, M; Gildea, D; Kelly, B; Jenkins, R; Hostetter, G; Matikainen, M; Schleutker, J; Klinger, K; Connors, T; Xiang, Y; Wang, Z; De Marzo, A; Papadopoulos, N; Kallioniemi, OP; Burk, R; Meyers, D; Gronberg, H; Meltzer, P; Silverman, R; Bailey-Wilson, J; Walsh, P; Isaacs, W; Trent, J				Carpten, J; Nupponen, N; Isaacs, S; Sood, R; Robbins, C; Xu, J; Faruque, M; Moses, T; Ewing, C; Gillanders, E; Hu, P; Buinovszky, P; Makalowska, I; Baffoe-Bonnie, A; Faith, D; Smith, J; Stephan, D; Wiley, K; Brownstein, M; Gildea, D; Kelly, B; Jenkins, R; Hostetter, G; Matikainen, M; Schleutker, J; Klinger, K; Connors, T; Xiang, Y; Wang, Z; De Marzo, A; Papadopoulos, N; Kallioniemi, OP; Burk, R; Meyers, D; Gronberg, H; Meltzer, P; Silverman, R; Bailey-Wilson, J; Walsh, P; Isaacs, W; Trent, J			Germline mutations in the ribonuclease L gene in families showing linkage with HPC1	NATURE GENETICS			English	Article							PROSTATE-CANCER INCIDENCE; 2-5A-DEPENDENT RNASE; INTERFERON ACTION; PROTEIN-SYNTHESIS; EXPRESSION; MORTALITY; CLEAVAGE; TRENDS; CELLS	Although prostate cancer is the most common non-cutaneous malignancy diagnosed in men in the United States(1,2), little is known about inherited factors that influence its genetic predisposition(3-5). Here we report that germline mutations in the gene encoding 2'-5'-oligoadenylate(2-5A)-dependent RNase L (RNASEL)(6-8) segregate in prostate cancer families that show linkage to the HPC1 (hereditary prostate cancer 1) region at 1q24-25 (ref. 9). We identified RNASEL by a positional cloning/candidate gene method, and show that a nonsense mutation and a mutation in an initiation codon of RNASEL segregate independently in two HPC1-linked families. inactive RNASEL alleles are present at a low frequency in the general population. RNASEL regulates cell proliferation and apoptosis through the interferon-regulated 2-5A pathway and has been suggested to be a candidate tumor suppressor gene(10-12). We found that microdissected tumors with a germline mutation showed loss of heterozygosity and loss of RNase L protein, and that RNASEL activity was reduced in lymphoblasts from heterozyogous individuals compared with family members who were homozygous with respect to the wildtype allele. Thus, germline mutations in RNASEL may be of diagnostic value, and the 2-5A pathway might provide opportunities for developing therapies for those with prostate cancer.	NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; Johns Hopkins Med Inst, James Buchanan Brady Urol Inst, Baltimore, MD 21205 USA; Wake Forest Univ, Bowman Gray Sch Med, Ctr Human Genom, Winston Salem, NC USA; NHGRI, Genome Technol Branch, NIH, Bethesda, MD 20892 USA; NHGRI, Genet Dis Res Branch, NIH, Bethesda, MD 20892 USA; Fox Chase Canc Ctr, Div Populat Sci, Philadelphia, PA 19111 USA; Vanderbilt Univ, Div Med Genet, Nashville, TN USA; Childrens Natl Med Ctr, Med Genet Res Ctr, Washington, DC 20010 USA; NIMH, Genet Lab, NIH, Bethesda, MD 20892 USA; Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Rochester, MN 55905 USA; Univ Tampere, Canc Genet Lab, Inst Med Technol, FIN-33101 Tampere, Finland; Tampere Univ Hosp, Canc Genet Lab, Inst Med Technol, Tampere, Finland; Genzyme Mol Oncol, Framingham, MA USA; Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, Cleveland, OH 44195 USA; Columbia Univ, Dept Pathol, Inst Canc Genet, New York, NY USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Albert Einstein Sch Med, Bronx, NY 10461 USA; Umea Univ, Dept Oncol, Umea, Sweden	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Johns Hopkins University; Johns Hopkins Medicine; Wake Forest University; Wake Forest Baptist Medical Center; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Fox Chase Cancer Center; Vanderbilt University; Children's National Health System; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Mayo Clinic; Tampere University; Tampere University; Tampere University Hospital; Sanofi-Aventis; Cleveland Clinic Foundation; Columbia University; Yeshiva University; Albert Einstein College of Medicine; Umea University	Trent, J (corresponding author), NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA.		Brownstein, Michael/B-8609-2009; Makalowska, Izabela/AAF-4967-2021; Makalowska, Izabela/AAU-2682-2021; Smith, Jeff/C-3484-2012; Kallioniemi, Olli P/H-5111-2011; Papadopoulos, Nickolas/K-7272-2012	Makalowska, Izabela/0000-0002-8144-5671; Kallioniemi, Olli P/0000-0002-3231-0332; Schleutker, Johanna/0000-0002-1863-0305; Smith, Jeffrey/0000-0001-8424-910X; Bailey-Wilson, Joan/0000-0002-9153-2920	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000107] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH002771] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Carpten JD, 2000, GENOMICS, V64, P1, DOI 10.1006/geno.1999.6051; CARTER BS, 1992, P NATL ACAD SCI USA, V89, P3367, DOI 10.1073/pnas.89.8.3367; CLEMENS MJ, 1978, CELL, V13, P565, DOI 10.1016/0092-8674(78)90329-X; Dennis LK, 2000, PROSTATE, V42, P247; DONG BH, 1995, J BIOL CHEM, V270, P4133, DOI 10.1074/jbc.270.8.4133; FLOYDSMITH G, 1981, SCIENCE, V212, P1030, DOI 10.1126/science.6165080; Hankey BF, 1999, JNCI-J NATL CANCER I, V91, P1017, DOI 10.1093/jnci/91.12.1017; Hartge P, 1999, AM J HUM GENET, V64, P963, DOI 10.1086/302320; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; ISAACS JT, 1994, SEMIN CANCER BIOL, V5, P391; KAIGHN ME, 1979, INVEST UROL, V17, P16; KERR IM, 1978, P NATL ACAD SCI USA, V75, P256, DOI 10.1073/pnas.75.1.256; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ostrander EA, 2000, AM J HUM GENET, V67, P1367, DOI 10.1086/316916; SHERMAN F, 1980, BIOCHIM BIOPHYS ACTA, V609, P343, DOI 10.1016/0005-2787(80)90246-4; SILVERMAN RH, 1983, J VIROL, V46, P1051, DOI 10.1128/JVI.46.3.1051-1055.1983; Smith JR, 1996, SCIENCE, V274, P1371, DOI 10.1126/science.274.5291.1371; Sood R, 2001, GENOMICS, V73, P211, DOI 10.1006/geno.2001.6500; STEINBERG GD, 1990, PROSTATE, V17, P337, DOI 10.1002/pros.2990170409; Tnani M, 1998, BBA-MOL CELL RES, V1402, P139, DOI 10.1016/S0167-4889(97)00158-4; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355	23	381	398	0	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2002	30	2					181	184		10.1038/ng823	http://dx.doi.org/10.1038/ng823			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	519CY	11799394	Green Published			2022-12-25	WOS:000173708700018
J	Heyduk, T; Heyduk, E				Heyduk, T; Heyduk, E			Molecular beacons for detecting DNA binding proteins	NATURE BIOTECHNOLOGY			English	Article							RESONANCE ENERGY-TRANSFER; CAMP RECEPTOR PROTEIN; ESCHERICHIA-COLI; EQUILIBRIUM BINDING; TRP REPRESSOR; FLUORESCENCE; BIOMOLECULES; SPECTROSCOPY; IMMUNOASSAY; SPECIFICITY	We report here a simple, rapid, homogeneous fluorescence assay, the molecular beacon assay, for the detection and quantification of sequence-specific DNA-binding proteins. The central feature of the assay is the protein-dependent association of two DNA fragments each containing about half of a DNA sequence defining a protein-binding site. Protein-dependent association of DNA fragments can be detected by any proximity-based spectroscopic signal, such as fluorescence resonance energy transfer (FRET) between fluorochromes introduced into these DNA molecules. The assay is fully homogeneous and requires no manipulations aside from mixing of the sample and the test solution. It offers flexibility with respect to the mode of signal detection and the fluorescence probe, and is compatible with multicolor simultaneous detection of several proteins. The assay can be used in research and medical diagnosis and for high-throughput screening of drugs targeted to DNA-binding proteins.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Heyduk, T (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.				NIGMS NIH HHS [GM 50514] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050514, R21GM050514] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY M, 1995, BIOCHEMISTRY-US, V34, P15802, DOI 10.1021/bi00048a026; Bjornson KP, 1996, BIOCHEMISTRY-US, V35, P2268, DOI 10.1021/bi9522763; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; CAMPBELL AK, 1983, BIOCHEM J, V216, P185, DOI 10.1042/bj2160185; EBRIGHT RH, 1989, NUCLEIC ACIDS RES, V17, P10295, DOI 10.1093/nar/17.24.10295; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; Gourves AS, 2000, J BIOL CHEM, V275, P10864, DOI 10.1074/jbc.275.15.10864; GUNSALUS RP, 1986, J BACTERIOL, V167, P272, DOI 10.1128/jb.167.1.272-278.1986; HART HE, 1979, MOL IMMUNOL, V16, P265, DOI 10.1016/0161-5890(79)90065-8; Hey T, 2001, BIOCHEMISTRY-US, V40, P2901, DOI 10.1021/bi002166i; Heyduk E, 1997, ANAL BIOCHEM, V248, P216, DOI 10.1006/abio.1997.2148; HEYDUK T, 1990, P NATL ACAD SCI USA, V87, P1744, DOI 10.1073/pnas.87.5.1744; HEYDUK T, 1989, BIOCHEMISTRY-US, V28, P6914, DOI 10.1021/bi00443a021; Hill JJ, 1997, METHOD ENZYMOL, V278, P390; JIN LH, 1993, BIOCHEMISTRY-US, V32, P7302, DOI 10.1021/bi00079a029; KALOWICZ JR, 1999, PRINCIPLES FLUORESCE; Kimura H, 1999, MOL CELL BIOL, V19, P5383; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lewin B., 2000, GENES; Lima LMTR, 2000, P NATL ACAD SCI USA, V97, P14289, DOI 10.1073/pnas.250352197; Matthews KS, 1998, PROG NUCLEIC ACID RE, V58, P127; Nichols NM, 2001, BIOCHEMISTRY-US, V40, P3847, DOI 10.1021/bi002088z; Nolan JP, 1998, NAT BIOTECHNOL, V16, P633, DOI 10.1038/nbt0798-633; Ozers MS, 1997, J BIOL CHEM, V272, P30405, DOI 10.1074/jbc.272.48.30405; Packard BZ, 1997, BIOPHYS CHEM, V67, P167, DOI 10.1016/S0301-4622(97)00036-7; Pandolfi PP, 2001, ONCOGENE, V20, P3116, DOI 10.1038/sj.onc.1204299; Parkhurst KM, 1996, BIOCHEMISTRY-US, V35, P7459, DOI 10.1021/bi9530301; Reedstrom RJ, 1997, J MOL BIOL, V273, P572, DOI 10.1006/jmbi.1997.1333; Rippe K, 2000, BIOCHEMISTRY-US, V39, P2131, DOI 10.1021/bi9922190; SELVIN PR, 1994, J AM CHEM SOC, V116, P6029, DOI 10.1021/ja00092a088; SHA M, 1995, J BIOL CHEM, V270, P19325, DOI 10.1074/jbc.270.33.19325; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; Tan MJ, 2001, CARCINOGENESIS, V22, P295, DOI 10.1093/carcin/22.2.295; Tyagi S, 1996, NAT BIOTECHNOL, V14, P303, DOI 10.1038/nbt0396-303; Tyagi S, 1998, NAT BIOTECHNOL, V16, P49, DOI 10.1038/nbt0198-49; von Hippel P H, 1974, Proc Natl Acad Sci U S A, V71, P4808; Wang G, 2001, MOL CELL BIOL, V21, P4604, DOI 10.1128/MCB.21.14.4604-4613.2001; Wang K, 1998, BIOCHEMISTRY-US, V37, P41, DOI 10.1021/bi972004v; Weiss S, 1999, SCIENCE, V283, P1676, DOI 10.1126/science.283.5408.1676; Xu Y, 1999, P NATL ACAD SCI USA, V96, P151, DOI 10.1073/pnas.96.1.151; YOUDERIAN P, 1994, GENE, V150, P1, DOI 10.1016/0378-1119(94)90850-8	42	186	200	1	50	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2002	20	2					171	176		10.1038/nbt0202-171	http://dx.doi.org/10.1038/nbt0202-171			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	517FT	11821863				2022-12-25	WOS:000173601000026
J	Jarosch, E; Taxis, C; Volkwein, C; Bordallo, J; Finley, D; Wolf, DH; Sommer, T				Jarosch, E; Taxis, C; Volkwein, C; Bordallo, J; Finley, D; Wolf, DH; Sommer, T			Protein dislocation from the ER requires polyubiquitination and the AAA-ATPase Cdc48	NATURE CELL BIOLOGY			English	Article							ENDOPLASMIC-RETICULUM DEGRADATION; YEAST MUTANT; PROTEASOME; UBIQUITIN; PATHWAY; CHAINS; BIP; MULTIUBIQUITINATION; TRANSLOCATION; PROTEOLYSIS	Endoplasmic reticulum (ER)-associated protein degradation by the ubiquitin-proteasome system requires the dislocation of substrates from the ER into the cytosol. It has been speculated that a functional ubiquitin proteasome pathway is not only essential for proteolysis, but also for the preceding export step. Here, we show that short ubiquitin chains synthesized on proteolytic substrates are not sufficient to complete dislocation; the size of the chain seems to be a critical determinant. Moreover, our results suggest that the AAA proteins of the 26S proteasome are not directly involved in substrate export. Instead, a related AAA complex Cdc48, is required for ER-associated protein degradation upstream of the proteasome.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Univ Stuttgart, Inst Biochem, D-70569 Stuttgart, Germany; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Stuttgart; Harvard University; Harvard Medical School	Sommer, T (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.		Taxis, Christof/P-6188-2019; Taxis, Christof/AAP-7408-2021; bordallo, javier/X-5360-2019	Taxis, Christof/0000-0001-5952-7091; bordallo, javier/0000-0002-5786-3929; Jarosch, Ernst/0000-0002-5897-3492				Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Bays NW, 2001, NAT CELL BIOL, V3, P24, DOI 10.1038/35050524; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Bordallo J, 1998, MOL BIOL CELL, V9, P209, DOI 10.1091/mbc.9.1.209; Chillaron J, 2000, MOL BIOL CELL, V11, P217, DOI 10.1091/mbc.11.1.217; Dai RM, 2001, NAT CELL BIOL, V3, P740, DOI 10.1038/35087056; de Virgilio M, 1998, J BIOL CHEM, V273, P9734, DOI 10.1074/jbc.273.16.9734; Deak PM, 2001, J BIOL CHEM, V276, P10663, DOI 10.1074/jbc.M008608200; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Friedlander R, 2000, NAT CELL BIOL, V2, P379, DOI 10.1038/35017001; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hitchcock AL, 2001, MOL BIOL CELL, V12, P3226, DOI 10.1091/mbc.12.10.3226; Hoppe T, 2000, CELL, V102, P577, DOI 10.1016/S0092-8674(00)00080-5; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Knop M, 1996, EMBO J, V15, P753, DOI 10.1002/j.1460-2075.1996.tb00411.x; Kohler A, 2001, MOL CELL, V7, P1143, DOI 10.1016/S1097-2765(01)00274-X; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Madeo F, 1997, J CELL BIOL, V139, P729, DOI 10.1083/jcb.139.3.729; Mayer TU, 1998, EMBO J, V17, P3251, DOI 10.1093/emboj/17.12.3251; Meyer HH, 2000, EMBO J, V19, P2181, DOI 10.1093/emboj/19.10.2181; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; Rouiller I, 2000, MOL CELL, V6, P1485, DOI 10.1016/S1097-2765(00)00144-1; Rubin DM, 1998, EMBO J, V17, P4909, DOI 10.1093/emboj/17.17.4909; Shamu CE, 1999, J CELL BIOL, V147, P45, DOI 10.1083/jcb.147.1.45; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Walter J, 2001, EMBO J, V20, P3124, DOI 10.1093/emboj/20.12.3124; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800; Yu H, 1999, J BIOL CHEM, V274, P36852, DOI 10.1074/jbc.274.52.36852	37	422	427	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	FEB	2002	4	2					134	139		10.1038/ncb746	http://dx.doi.org/10.1038/ncb746			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	520RJ	11813000				2022-12-25	WOS:000173794600017
J	Kelly, G; Bell, A; Rickinson, A				Kelly, G; Bell, A; Rickinson, A			Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2	NATURE MEDICINE			English	Article							C-MYC; INITIAL-STAGES; GENE PROMOTER; STRAIN P3HR-1; LATENT GENES; EXPRESSION; CELLS; TRANSCRIPTION; PHENOTYPE; DELETION	Epstein-Barr virus (EBV) is etiologically linked to endemic Burkitt lymphoma (BL), but its contribution to lymphomagenesis, versus that of the chromosomal translocation leading to c-myc gene deregulation, remains unclear. The virus's growth-transforming (Latency III) program of gene expression is extinguished in tumor cells, and only a single viral protein, the EBV nuclear antigen (EBNA) 1, is expressed via the alternative Latency I program. It is not known if BL arises from a B-cell subset in which EBV naturally adopts a Latency I infection or if a clone with limited antigen expression has been selected from an EBV-transformed Latency III progenitor pool. Here we identify a subset of BL tumors in which the Latency III-associated EBNA promoter Wp is active and most EBNAs are expressed, but where a gene deletion has specifically abrogated the expression of EBNA2. This implies that BL can be selected from a Latency III progenitor and that the principal selection pressure is for downregulation of the c-Myc antagonist EBNA2.	Univ Birmingham, Canc Res UK Inst Canc Studies, Birmingham, W Midlands, England	Cancer Research UK; University of Birmingham	Rickinson, A (corresponding author), Univ Birmingham, Canc Res UK Inst Canc Studies, Birmingham, W Midlands, England.	a.b.rickinson@bham.ac.uk	Kelly, Gemma/AAG-6352-2020	Bell, Andrew/0000-0001-9520-4417				AB RICKINSON, 2001, FIELDS VIROLOGY, P2575; ABBOT SD, 1990, J VIROL, V64, P2126, DOI 10.1128/JVI.64.5.2126-2134.1990; Babcock GJ, 2000, IMMUNITY, V13, P497, DOI 10.1016/S1074-7613(00)00049-2; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; BORNKAMM GW, 1982, J VIROL, V43, P952, DOI 10.1128/JVI.43.3.952-968.1982; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; FAHRAEUS R, 1990, P NATL ACAD SCI USA, V87, P7390, DOI 10.1073/pnas.87.19.7390; FINKE J, 1987, J VIROL, V61, P3870, DOI 10.1128/JVI.61.12.3870-3878.1987; Gavioli R, 2001, NAT CELL BIOL, V3, P283, DOI 10.1038/35060076; Goossens T, 1998, P NATL ACAD SCI USA, V95, P2463, DOI 10.1073/pnas.95.5.2463; GREGORY CD, 1987, J IMMUNOL, V139, P313; Habeshaw G, 1999, J VIROL, V73, P965, DOI 10.1128/JVI.73.2.965-975.1999; Hinuma Y, 1967, J Virol, V1, P1045; JONES MD, 1984, EMBO J, V3, P813, DOI 10.1002/j.1460-2075.1984.tb01890.x; Kaiser C, 1999, J VIROL, V73, P4481, DOI 10.1128/JVI.73.5.4481-4484.1999; KEMPKES B, 1995, EMBO J, V14, P88, DOI 10.1002/j.1460-2075.1995.tb06978.x; KHANNA R, 1994, INT IMMUNOL, V6, P639, DOI 10.1093/intimm/6.4.639; Khanna R, 2000, ANNU REV MICROBIOL, V54, P19, DOI 10.1146/annurev.micro.54.1.19; KIEFF E, 2001, FIELDS VIROLOGY, P2511; Komano J, 1998, J VIROL, V72, P9150, DOI 10.1128/JVI.72.11.9150-9156.1998; Kovalchuk AL, 2000, J EXP MED, V192, P1183, DOI 10.1084/jem.192.8.1183; Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; Nonkwelo C, 1996, J VIROL, V70, P623, DOI 10.1128/JVI.70.1.623-627.1996; Pajic A, 2001, INT J CANCER, V93, P810, DOI 10.1002/ijc.1404; PARKER BD, 1990, VIROLOGY, V179, P339, DOI 10.1016/0042-6822(90)90302-8; Polack A, 1996, P NATL ACAD SCI USA, V93, P10411, DOI 10.1073/pnas.93.19.10411; RABSON M, 1982, J VIROL, V44, P834, DOI 10.1128/JVI.44.3.834-844.1982; ROONEY CM, 1986, J NATL CANCER I, V77, P681, DOI 10.1093/jnci/77.3.681; ROWE M, 1995, EUR J IMMUNOL, V25, P1374, DOI 10.1002/eji.1830250536; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; Ruf IK, 1999, MOL CELL BIOL, V19, P1651; SAMPLE J, 1991, P NATL ACAD SCI USA, V88, P6343, DOI 10.1073/pnas.88.14.6343; SCHAEFER BC, 1991, P NATL ACAD SCI USA, V88, P6550, DOI 10.1073/pnas.88.15.6550; SCHAEFER BC, 1995, P NATL ACAD SCI USA, V92, P10565, DOI 10.1073/pnas.92.23.10565; Staege MS, 2002, P NATL ACAD SCI USA, V99, P4550, DOI 10.1073/pnas.072495599; SUNG NS, 1991, J VIROL, V65, P2164, DOI 10.1128/JVI.65.5.2164-2169.1991; TIERNEY RJ, 1994, J VIROL, V68, P7374, DOI 10.1128/JVI.68.11.7374-7385.1994; WANG F, 1990, J VIROL, V64, P3407, DOI 10.1128/JVI.64.7.3407-3416.1990; WOISETSCHLAEGER M, 1990, P NATL ACAD SCI USA, V87, P1725, DOI 10.1073/pnas.87.5.1725; WOISETSCHLAEGER M, 1991, P NATL ACAD SCI USA, V88, P3942, DOI 10.1073/pnas.88.9.3942; Yoo L, 2000, J VIROL, V74, P11115, DOI 10.1128/JVI.74.23.11115-11120.2000; Yoo LI, 1997, J VIROL, V71, P9134, DOI 10.1128/JVI.71.12.9134-9142.1997; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604; ZIMBERSTROBL U, 1991, J VIROL, V65, P415, DOI 10.1128/JVI.65.1.415-423.1991	45	162	165	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2002	8	10					1098	1104		10.1038/nm758	http://dx.doi.org/10.1038/nm758			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	599AN	12219084				2022-12-25	WOS:000178311000036
J	Twell, D; Park, SK; Hawkins, TJ; Schubert, D; Schmidt, R; Smertenko, A; Hussey, PJ				Twell, D; Park, SK; Hawkins, TJ; Schubert, D; Schmidt, R; Smertenko, A; Hussey, PJ			MOR1/GEM1 has an essential role in the plant-specific cytokinetic phragmoplast	NATURE CELL BIOLOGY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN; XENOPUS EGGS; SPINDLE; COMPONENT; DYNAMICS; DIVISION; XMAP215; HEAT	MOR1 is a member of the MAP215 family of microtubule-associated proteins and is required to establish interphase arrays of cortical microtubules in plant cells(1). Here we show that MOR1 binds microtubules in vivo, localizing to both cortical microtubules and to areas of overlapping microtubules in the phragmoplast. Genetic complementation of the cytokinesis-defective gemini pollen 1-1 (gem1-1) mutation with MOR1 shows that MOR1 (which is synonymous with the protein GEM1) is essential in cytokinesis. Phenotypic analysis of gem1-1 and gem1-2, which contains a T-DNA insertion, confirm that MOR1/GEM1 is essential for regular patterns of cytokinesis. Both the gem1-1 and gem1-2 mutations cause the truncation of the MOR1/GEM1 protein. In addition, the carboxy-terminal domain of the protein, which is absent in both mutants, binds microtubules in vitro. Our data show that MOR1/GEM1 has an essential role in the cytokinetic phragmoplast.	Univ Leicester, Dept Biol, Leicester LE1 7RH, Leics, England; Univ Durham, Sch Biol & Biomed Sci, Integrat Cell Biol Lab, Durham DH1 3LE, England; Max Planck Inst Mol Plant Physiol, D-14424 Potsdam, Germany	University of Leicester; Durham University; Max Planck Society	Twell, D (corresponding author), Univ Leicester, Dept Biol, Univ Rd, Leicester LE1 7RH, Leics, England.	twe@le.ac.uk; p.j.hussey@durham.ac.uk	Twell, David/D-8043-2011; Schubert, Daniel/H-2871-2012	Twell, David/0000-0003-0483-1461; Schubert, Daniel/0000-0003-2390-0733; Smertenko, Andrei/0000-0002-5078-4881; Schmidt, Renate/0000-0002-8037-3581; Hussey, Patrick/0000-0002-7349-8722	Biotechnology and Biological Sciences Research Council [G08788] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		ASADA T, 1991, NATURE, V350, P238, DOI 10.1038/350238a0; Charrasse S, 1998, J CELL SCI, V111, P1371; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Cullen CF, 1999, J CELL BIOL, V146, P1005, DOI 10.1083/jcb.146.5.1005; Garcia MA, 2001, EMBO J, V20, P3389, DOI 10.1093/emboj/20.13.3389; GARD DL, 1987, J CELL BIOL, V105, P2203, DOI 10.1083/jcb.105.5.2203; GODDIJN OJM, 1993, PLANT J, V4, P863, DOI 10.1046/j.1365-313X.1993.04050863.x; Graf R, 2000, J CELL SCI, V113, P1747; HIRSH D, 1976, DEV BIOL, V49, P220, DOI 10.1016/0012-1606(76)90268-2; Hussey PJ, 2001, TRENDS PLANT SCI, V6, P389, DOI 10.1016/S1360-1385(01)02090-8; HUSSEY PJ, IN PRESS PLANT MOL B; Igarashi H, 2000, PLANT CELL PHYSIOL, V41, P920, DOI 10.1093/pcp/pcd015; Neuwald AF, 2000, GENOME RES, V10, P1445, DOI 10.1101/gr.147400; OHKURA H, 1988, EMBO J, V7, P1465, DOI 10.1002/j.1460-2075.1988.tb02964.x; Park SK, 1998, DEVELOPMENT, V125, P3789; Park SK, 2001, PLANT PHYSIOL, V126, P899, DOI 10.1104/pp.126.2.899; Popov AV, 2001, EMBO J, V20, P397, DOI 10.1093/emboj/20.3.397; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; Smertenko A, 2000, NAT CELL BIOL, V2, P750, DOI 10.1038/35036390; Smertenko AP, 1998, PROTOPLASMA, V203, P138, DOI 10.1007/BF01279470; Tournebize R, 2000, NAT CELL BIOL, V2, P13, DOI 10.1038/71330; Twell D, 1998, TRENDS PLANT SCI, V3, P305, DOI 10.1016/S1360-1385(98)01277-1; VASQUEZ RJ, 1994, J CELL BIOL, V127, P985, DOI 10.1083/jcb.127.4.985; Wang PJJ, 1997, J CELL BIOL, V139, P1271, DOI 10.1083/jcb.139.5.1271; Whittington AT, 2001, NATURE, V411, P610, DOI 10.1038/35079128	25	170	179	4	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2002	4	9					711	714		10.1038/ncb844	http://dx.doi.org/10.1038/ncb844			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	589WE	12198497	Green Accepted			2022-12-25	WOS:000177783900016
J	Vaish, NK; Dong, F; Andrews, L; Schweppe, RE; Ahn, NG; Blatt, L; Seiwert, SD				Vaish, NK; Dong, F; Andrews, L; Schweppe, RE; Ahn, NG; Blatt, L; Seiwert, SD			Monitoring post-translational modification of proteins with allosteric ribozymes	NATURE BIOTECHNOLOGY			English	Article							IN-VITRO SELECTION; HAMMERHEAD RIBOZYMES; STRUCTURAL BASIS; RIBOSOMAL-RNA; ACTIVATION; PHOSPHORYLATION; OPTIMIZATION; MATURATION; CLEAVAGE; KINASES	An allosteric hammerhead ribozyme activated specifically by the unphosphorylated form of the protein kinase ERK2 was created through a rational design strategy that relies on molecular recognition of ERK2 to decrease the formation of an alternate, inactive ribozyme conformer. Neither closely related mitogen-activated protein kinases (MAPKs) nor the phosphorylated form of ERK2 induced ribozyme activity. The ribozyme quantitatively detected ERK2 added to mammalian cell lysates and also functioned quantitatively in a multiplexed solution-phase assay. This same strategy was used to construct a second ribozyme selectively activated by the phosphorylated (active) form of ERK2. This approach is generally applicable to the development of ribozymes capable of monitoring post-translational modification of specific proteins.	Ribozyme Pharmaceut Inc, Boulder, CO 80301 USA; Univ Colorado, Howard Hughes Med Inst, Boulder, CO 80309 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder	Vaish, NK (corresponding author), Ribozyme Pharmaceut Inc, 2950 Wilderness Pl, Boulder, CO 80301 USA.	VaishN@rpi.com; SeiwerS@rpi.com		Schweppe, Rebecca/0000-0001-7502-0151				Ahn NG, 2001, NAT BIOTECHNOL, V19, P317, DOI 10.1038/86687; ARES M, 1995, PROG NUCLEIC ACID RE, V50, P131, DOI 10.1016/S0079-6603(08)60813-2; BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; Beaudry A, 2000, CHEM BIOL, V7, P323, DOI 10.1016/S1074-5521(00)00110-1; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Cox JC, 2001, BIOORGAN MED CHEM, V9, P2525, DOI 10.1016/S0968-0896(01)00028-1; Curtis EA, 2001, RNA, V7, P546, DOI 10.1017/S1355838201002357; DAI XC, 1995, SCIENCE, V267, P237, DOI 10.1126/science.7809628; EKLAND EH, 1995, NUCLEIC ACIDS RES, V23, P3231, DOI 10.1093/nar/23.16.3231; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; Golden MC, 2000, J BIOTECHNOL, V81, P167, DOI 10.1016/S0168-1656(00)00290-X; Haab BB, 2001, GENOME BIOL, V2; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; HERTEL KJ, 1994, BIOCHEMISTRY-US, V33, P3374, DOI 10.1021/bi00177a031; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; Koizumi M, 1999, NAT STRUCT BIOL, V6, P1062; Kultz D, 1998, J MOL EVOL, V46, P571, DOI 10.1007/PL00006338; Lewis AJ, 1999, CURR OPIN CHEM BIOL, V3, P489, DOI 10.1016/S1367-5931(99)80071-4; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Mansour SJ, 1996, CELL GROWTH DIFFER, V7, P243; Merryman C, 1999, J MOL BIOL, V285, P107, DOI 10.1006/jmbi.1998.2243; Murray JB, 1998, CELL, V92, P665, DOI 10.1016/S0092-8674(00)81134-4; Pape T, 2000, NAT STRUCT BIOL, V7, P104; Peracchi A, 1996, P NATL ACAD SCI USA, V93, P11522, DOI 10.1073/pnas.93.21.11522; PORTA H, 1995, BIO-TECHNOL, V13, P161, DOI 10.1038/nbt0295-161; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robertson MP, 2000, NUCLEIC ACIDS RES, V28, P1751, DOI 10.1093/nar/28.8.1751; Robertson MP, 2001, NAT BIOTECHNOL, V19, P650, DOI 10.1038/90256; Seetharaman S, 2001, NAT BIOTECHNOL, V19, P336, DOI 10.1038/86723; Seiwert SD, 2000, CHEM BIOL, V7, P833, DOI 10.1016/S1074-5521(00)00032-6; Service RF, 2001, SCIENCE, V294, P2074, DOI 10.1126/science.294.5549.2074; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; Soukup GA, 1999, P NATL ACAD SCI USA, V96, P3584, DOI 10.1073/pnas.96.7.3584; Soukup GA, 2001, RNA, V7, P524, DOI 10.1017/S1355838201002175; Stage-Zimmermann TK, 1998, RNA, V4, P875, DOI 10.1017/S1355838298980876; Tang J, 1997, CHEM BIOL, V4, P453, DOI 10.1016/S1074-5521(97)90197-6; THOMSON JB, 1993, NUCLEIC ACIDS RES, V21, P5600, DOI 10.1093/nar/21.24.5600; Valcarcel J, 1996, SCIENCE, V273, P1706, DOI 10.1126/science.273.5282.1706; Zinnen SP, 2002, RNA, V8, P214, DOI 10.1017/S1355838202014723	42	48	51	2	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2002	20	8					810	815		10.1038/nbt719	http://dx.doi.org/10.1038/nbt719			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	579MU	12118241				2022-12-25	WOS:000177182500032
J	Chiu, VK; Bivona, T; Hach, A; Sajous, JB; Silletti, J; Wiener, H; Johnson, RL; Cox, AD; Philips, MR				Chiu, VK; Bivona, T; Hach, A; Sajous, JB; Silletti, J; Wiener, H; Johnson, RL; Cox, AD; Philips, MR			Ras signalling on the endoplasmic reticulum and the Golgi	NATURE CELL BIOLOGY			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; PLASMA-MEMBRANE; H-RAS; CELLULAR-TRANSFORMATION; POLYBASIC DOMAIN; TYROSINE KINASES; EXCHANGE FACTOR; ACTIVATE RAF-1; EGF RECEPTOR; CAAX MOTIF	Current models evoke the plasma membrane ( PM) as the exclusive platform from which Ras regulates signalling. We developed a fluorescent probe that reports where and when Ras is activated in living cells. We show that oncogenic H-Ras and N-Ras engage Raf-1 on the Golgi and that endogenous Ras and unpalmitoylated H-Ras are activated in response to mitogens on the Golgi and endoplasmic reticulum ( ER), respectively. We also demonstrate that H-Ras that is restricted to the ER can activate the Erk pathway and transform fibroblasts, and that Ras localized on different membrane compartments differentially engages various signalling pathways. Thus, Ras signalling is not limited to the PM, but also proceeds on the endomembrane.	NYU, Sch Med, Dept Med, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; Univ N Carolina, Sch Med, Dept Radiat Oncol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA	New York University; New York University; New York University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Chiu, VK (corresponding author), NYU, Sch Med, Dept Med, 550 1st Ave, New York, NY 10016 USA.			Mark, Philips/0000-0002-1179-8156; Cox, Adrienne D./0000-0002-4901-2454	NCI NIH HHS [CA76092, CA67771] Funding Source: Medline; NCRR NIH HHS [M01RR00096] Funding Source: Medline; NIAID NIH HHS [AI36224] Funding Source: Medline; NIGMS NIH HHS [GM55279] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U19CA067771, R01CA076092] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000096] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036224, R29AI036224] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Bastiaens PIH, 1996, EMBO J, V15, P4246, DOI 10.1002/j.1460-2075.1996.tb00799.x; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; COX AD, 1994, METHOD ENZYMOL, V238, P277; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; Di Fiore PP, 1999, CURR OPIN CELL BIOL, V11, P483, DOI 10.1016/S0955-0674(99)80069-6; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Foos G, 1998, J BIOL CHEM, V273, P18871, DOI 10.1074/jbc.273.30.18871; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; Hart KC, 2000, EXP CELL RES, V257, P89, DOI 10.1006/excr.2000.4874; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIAO F, 1993, BIOCHEM BIOPH RES CO, V191, P1028, DOI 10.1006/bbrc.1993.1320; Lorenzo PS, 2001, CANCER RES, V61, P943; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Punnonen EL, 1998, EUR J CELL BIOL, V75, P344, DOI 10.1016/S0171-9335(98)80067-8; Schmidt WK, 1998, P NATL ACAD SCI USA, V95, P11175, DOI 10.1073/pnas.95.19.11175; Sorkin A, 2000, CURR BIOL, V10, P1395, DOI 10.1016/S0960-9822(00)00785-5; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Voice JK, 1999, J BIOL CHEM, V274, P17164, DOI 10.1074/jbc.274.24.17164; Walsh AB, 2001, J BIOL CHEM, V276, P15609, DOI 10.1074/jbc.M010573200; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052	35	490	503	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAY	2002	4	5					343	350		10.1038/ncb783	http://dx.doi.org/10.1038/ncb783			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	547GR	11988737				2022-12-25	WOS:000175325100015
J	Collin, GB; Marshall, JD; Ikeda, A; So, WV; Russell-Eggitt, I; Maffei, P; Beck, S; Boerkoel, CF; Sicolo, N; Martin, M; Nishina, PM; Naggert, JK				Collin, GB; Marshall, JD; Ikeda, A; So, WV; Russell-Eggitt, I; Maffei, P; Beck, S; Boerkoel, CF; Sicolo, N; Martin, M; Nishina, PM; Naggert, JK			Mutations in ALMS1 cause obesity, type 2 diabetes and neurosensory degeneration in Alstrom syndrome	NATURE GENETICS			English	Article							BARDET-BIEDL-SYNDROME; NATURAL-HISTORY; GENE; INHERITANCE; DYSFUNCTION; DISORDER; LINKAGE; FAMILY	Alstrom syndrome is a homogeneous autosomal recessive disorder that is characterized by childhood obesity associated with hyperinsulinemia, chronic hyperglycemia and neurosensory deficits(1,2). The gene involved in Alstrom syndrome probably interacts with genetic modifiers, as subsets of affected individuals present with additional features such as dilated cardiomyopathy(3), hepatic dysfunction(4), hypothyroidism(5), male hypogonadism, short stature and mild to moderate developmental delay, and with secondary complications normally associated with type 2 diabetes, such as hyperlipidemia and atherosclerosis. Our detection of an uncharacterized transcript, KIAA0328, led us to identify the gene ALMS1, which contains sequence variations, including four frameshift mutations and two nonsense mutations, that segregate with Alstrom syndrome in six unrelated families. ALMS1 is ubiquitously expressed at low levels and does not share significant sequence homology with other genes reported so far. The identification of ALMS1 provides an entry point into a new pathway leading toward the understanding of both Alstrom syndrome and the common diseases that characterize it.	Jackson Lab, Bar Harbor, ME 04609 USA; Hoffmann La Roche Inc, Computat Genom & Genet, Nutley, NJ 07110 USA; Great Ormond St Hosp Sick Children, London WC1N 3JH, England; Univ Padua, Ist Semeiot Med, I-35100 Padua, Italy; Inst Nacl Saude, Lisbon, Portugal; Baylor Coll Med, Houston, TX 77030 USA	Jackson Laboratory; Roche Holding; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of Padua; Instituto Nacional de Saude Dr. Ricardo Jorge; Baylor College of Medicine	Naggert, JK (corresponding author), Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.	jkn@jax.org	Boerkoel, Cornelius Franciscus/AFW-4948-2022; Maffei, Pietro/O-1878-2013	Boerkoel, Cornelius Franciscus/0000-0003-3097-241X; Maffei, Pietro/0000-0002-1717-263X; Ikeda, Akihiro/0000-0001-8440-3891				Alstrom CH, 1959, ACTA PSYCHIAT S S129, V34, P1; CHARLES SJ, 1990, J MED GENET, V27, P590, DOI 10.1136/jmg.27.9.590; Collin GB, 1999, HUM GENET, V105, P474, DOI 10.1007/s004390051133; Collin GB, 1996, GENOMICS, V37, P125, DOI 10.1006/geno.1996.0529; Collin GB, 1997, HUM MOL GENET, V6, P213, DOI 10.1093/hmg/6.2.213; CONNOLLY MB, 1991, AM J MED GENET, V40, P421, DOI 10.1002/ajmg.1320400408; Froguel P, 2001, RECENT PROG HORM RES, V56, P91, DOI 10.1210/rp.56.1.91; GOLDSTEIN JL, 1973, MEDICINE, V52, P53, DOI 10.1097/00005792-197301000-00003; Hearn T, 2002, NAT GENET, V31, P79, DOI 10.1038/ng874; Inui A, 1999, TRENDS NEUROSCI, V22, P62, DOI 10.1016/S0166-2236(98)01292-2; Katsanis N, 2001, SCIENCE, V293, P2256, DOI 10.1126/science.1063525; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245; Macari F, 1998, HUM GENET, V103, P658, DOI 10.1007/s004390050887; Marshall JD, 1997, AM J MED GENET, V73, P150, DOI 10.1002/(SICI)1096-8628(19971212)73:2<150::AID-AJMG9>3.0.CO;2-Y; Michaud JL, 1996, J PEDIATR-US, V128, P225, DOI 10.1016/S0022-3476(96)70394-3; Mykytyn K, 2001, NAT GENET, V28, P188, DOI 10.1038/88925; Naggert J, 1997, CURR OPIN GENET DEV, V7, P398, DOI 10.1016/S0959-437X(97)80155-4; Nishimura DY, 2001, HUM MOL GENET, V10, P865, DOI 10.1093/hmg/10.8.865; Nishina PM, 1998, GENOMICS, V54, P215, DOI 10.1006/geno.1998.5567; Rastogi P A, 2000, Methods Mol Biol, V132, P47; Slavotinek AM, 2000, NAT GENET, V26, P15, DOI 10.1038/79116	22	257	271	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2002	31	1					74	78		10.1038/ng867	http://dx.doi.org/10.1038/ng867			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	547ZF	11941369	Bronze			2022-12-25	WOS:000175362500018
J	Dai, YF; Vaught, TD; Boone, J; Chen, SH; Phelps, CJ; Ball, S; Monahan, JA; Jobst, PM; McCreath, KJ; Lamborn, AE; Cowell-Lucero, JL; Wells, KD; Colman, A; Polejaeva, IA; Ayares, DL				Dai, YF; Vaught, TD; Boone, J; Chen, SH; Phelps, CJ; Ball, S; Monahan, JA; Jobst, PM; McCreath, KJ; Lamborn, AE; Cowell-Lucero, JL; Wells, KD; Colman, A; Polejaeva, IA; Ayares, DL			Targeted disruption of the alpha 1,3-galactosyltransferase gene in cloned pigs	NATURE BIOTECHNOLOGY			English	Article							NUCLEAR TRANSFER; SOMATIC-CELLS; EPITOPES; MOUSE; XENOTRANSPLANTATION; EXPRESSION; FETAL	Galactose-alpha1,3-galactose (alpha1,3Gal) is the major xenoantigen causing hyperacute rejection in pig-to-human xenotransplantation. Disruption of the gene encoding pig alpha1,3-galactosyltransferase (alpha1,3GT) by homologous recombination is a means to completely remove the alpha1,3Gal epitopes from xenografts. Here we report the disruption of one allele of the pig alpha1,3GT gene in both male and female porcine primary fetal fibroblasts. Targeting was confirmed in 17 colonies by Southern blot analysis, and 7 of them were used for nuclear transfer. Using cells from one colony, we produced six cloned female piglets, of which five were of normal weight and apparently healthy. Southern blot analysis confirmed that these five piglets contain one disrupted pig alpha1,3GT allele.	PPL Therapeut Inc, Blacksburg, VA 24060 USA; PPL Therapeut Ltd, Roslin EH25 9PP, Midlothian, Scotland		Dai, YF (corresponding author), PPL Therapeut Inc, 1700 Kraft Dr, Blacksburg, VA 24060 USA.		Polejaeva, Irina/G-4881-2012	Yang, Haiyuan/0000-0001-5253-0079; Polejaeva, Irina/0000-0002-0858-5889; Dai, Yifan/0000-0003-2872-8442				Baguisi A, 1999, NAT BIOTECHNOL, V17, P456, DOI 10.1038/8632; Cibelli JB, 1998, SCIENCE, V280, P1256, DOI 10.1126/science.280.5367.1256; Denning C, 2001, NAT BIOTECHNOL, V19, P559, DOI 10.1038/89313; GALILI U, 1988, J BIOL CHEM, V263, P17755; GALILI U, 1985, J EXP MED, V162, P573, DOI 10.1084/jem.162.2.573; Galili U, 2001, BIOCHIMIE, V83, P557, DOI 10.1016/S0300-9084(01)01294-9; Joziasse DH, 1999, BBA-MOL BASIS DIS, V1455, P403, DOI 10.1016/S0925-4439(99)00056-3; KIM HS, 1991, GENE, V103, P227; Lai LX, 2002, SCIENCE, V295, P1089, DOI 10.1126/science.1068228; McCreath KJ, 2000, NATURE, V405, P1066, DOI 10.1038/35016604; Polejaeva IA, 2000, NATURE, V407, P86, DOI 10.1038/35024082; SANDRIN MS, 1994, IMMUNOL REV, V141, P169, DOI 10.1111/j.1600-065X.1994.tb00877.x; SHULDINER AR, 1991, BIOTECHNIQUES, V11, P760; Tanemura M, 2000, TRANSPLANTATION, V69, P187, DOI 10.1097/00007890-200001150-00034; Tearle RG, 1996, TRANSPLANTATION, V61, P13, DOI 10.1097/00007890-199601150-00004; THALL AD, 1995, J BIOL CHEM, V270, P21437, DOI 10.1074/jbc.270.37.21437; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Zakhartchenko V, 2001, MOL REPROD DEV, V60, P362, DOI 10.1002/mrd.1098	18	553	670	1	41	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2002	20	3					251	255		10.1038/nbt0302-251	http://dx.doi.org/10.1038/nbt0302-251			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	526RE	11875425				2022-12-25	WOS:000174142800042
J	Peters, PJ; Ning, K; Palacios, F; Boshans, RL; Kazantsev, A; Thompson, LM; Woodman, B; Bates, GP; D'Souza-Schorey, C				Peters, PJ; Ning, K; Palacios, F; Boshans, RL; Kazantsev, A; Thompson, LM; Woodman, B; Bates, GP; D'Souza-Schorey, C			Arfaptin 2 regulates the aggregation of mutant huntingtin protein	NATURE CELL BIOLOGY			English	Article							ADP-RIBOSYLATION FACTOR; RAC1-INTERACTING PROTEIN; POLYGLUTAMINE; DISEASE; TRANSGLUTAMINASE; CHAPERONES; MEMBRANE; EXON-1	Huntington's disease (HD) is an inherited neurodegenerative disorder. Here we demonstrate that expression of arfaptin 2/POR1 (partner of Rac1) in cultured cells induces the formation of pericentriolar and nuclear aggregates, which morphologically resemble mutant huntingtin aggregates characteristic of HD. Endogenous arfaptin 2 localizes to aggregates induced by expression of an abnormal amino-terminal fragment of huntingtin that contains polyglutamine (polyQ) expansions. A dominant inhibitory mutant of arfaptin 2 inhibits aggregation of mutant huntingtin, but not in the presence of proteasome inhibitors. Using cell-free biochemical assays, we show that arfaptin 2 inhibits proteasome activity. Finally, we show that expression of arfaptin 2 is increased at sites of neurodegeneration and the protein localizes to huntingtin aggregates in HD transgenic mouse brains. Our data suggest that arfaptin 2 is involved in regulating huntingtin protein aggregation, possibly by impairing proteasome function.	Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA; Univ Notre Dame, Walther Canc Inst, Notre Dame, IN 46556 USA; Univ Utrecht, Sch Med, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands; Netherlands Canc Inst, Div Tumor Biol, Amsterdam, Netherlands; MIT, Ctr Canc Res, Cambridge, MA 02139 USA; Univ Calif Irvine, Dept Biol Chem Psychiat & Behav Sci, Irvine, CA 92697 USA; Guys & St Thomass Sch Med, Div Med & Mol Genet, London SE1 9RT, England	University of Notre Dame; University of Notre Dame; Walther Cancer Institute; Utrecht University; Netherlands Cancer Institute; Massachusetts Institute of Technology (MIT); University of California System; University of California Irvine; University of London; King's College London	Peters, PJ (corresponding author), Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA.	D'Souza-Schorey.1@nd.edu	Ning, Ke/B-4561-2009; Bates, Gillian P/E-1146-2012	Bates, Gillian P/0000-0002-4041-6305; Ning, Ke/0000-0002-0771-1134				Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Boshans RL, 2000, MOL CELL BIOL, V20, P3685, DOI 10.1128/MCB.20.10.3685-3694.2000; Carmichael J, 2000, P NATL ACAD SCI USA, V97, P9701, DOI 10.1073/pnas.170280697; Chun WJ, 2001, J CELL BIOL, V153, P25, DOI 10.1083/jcb.153.1.25; D'Souza-Schorey C, 1997, EMBO J, V16, P5445, DOI 10.1093/emboj/16.17.5445; D'Souza-Schorey C, 1998, J CELL BIOL, V140, P603, DOI 10.1083/jcb.140.3.603; Davies SW, 1999, METHOD ENZYMOL, V309, P687; Dorsman JC, 1999, PHILOS T R SOC B, V354, P1061, DOI 10.1098/rstb.1999.0459; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kahlem P, 1998, MOL CELL, V1, P595, DOI 10.1016/S1097-2765(00)80059-3; Kanoh H, 1997, J BIOL CHEM, V272, P5421, DOI 10.1074/jbc.272.9.5421; Karpuj MV, 1999, P NATL ACAD SCI USA, V96, P7388, DOI 10.1073/pnas.96.13.7388; Kazantsev A, 1999, P NATL ACAD SCI USA, V96, P11404, DOI 10.1073/pnas.96.20.11404; Krobitsch S, 2000, P NATL ACAD SCI USA, V97, P1589, DOI 10.1073/pnas.97.4.1589; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Meriin AB, 2001, J CELL BIOL, V153, P851, DOI 10.1083/jcb.153.4.851; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Muchowski PJ, 2000, P NATL ACAD SCI USA, V97, P7841, DOI 10.1073/pnas.140202897; Sathasivam K, 1999, HUM MOL GENET, V8, P813, DOI 10.1093/hmg/8.5.813; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Shin OH, 2001, BIOCHEM BIOPH RES CO, V285, P1267, DOI 10.1006/bbrc.2001.5330; Sittler A, 2001, HUM MOL GENET, V10, P1307, DOI 10.1093/hmg/10.12.1307; Sittler A, 1998, MOL CELL, V2, P427, DOI 10.1016/S1097-2765(00)80142-2; Suhr ST, 2001, J CELL BIOL, V153, P283, DOI 10.1083/jcb.153.2.283; Tarricone C, 2001, NATURE, V411, P215, DOI 10.1038/35075620; VanAelst L, 1996, EMBO J, V15, P3778, DOI 10.1002/j.1460-2075.1996.tb00751.x; Waelter S, 2001, MOL BIOL CELL, V12, P1393, DOI 10.1091/mbc.12.5.1393; Wanker EE, 2000, BIOL CHEM, V381, P937, DOI 10.1515/BC.2000.114; Wigley WC, 1999, J CELL BIOL, V145, P481	30	38	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2002	4	3					240	245		10.1038/ncb761	http://dx.doi.org/10.1038/ncb761			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	527VR	11854752				2022-12-25	WOS:000174209100017
J	De Renzis, S; Sonnichsen, B; Zerial, M				De Renzis, S; Sonnichsen, B; Zerial, M			Divalent Rab effectors regulate the sub-compartmental organization and sorting of early endosomes	NATURE CELL BIOLOGY			English	Article							TRANS-GOLGI NETWORK; CIS-SNARE COMPLEX; ENDOCYTIC PATHWAY; RECYCLING ENDOSOMES; MEMBRANE-TRANSPORT; PROTEIN; FUSION; TRANSFERRIN; DOCKING; EEA1	The three GTPases Rab5, Rab4 and Rab11 regulate sequential transport steps along the endocytic/recycling pathway, and occupy distinct membrane domains on early and recycling endosomes. To address the mechanisms that regulate communication between such domains, we searched for proteins that interact with both Rab5 and Rab4. Here, we report that Rabenosyn-5, a previously identified Rab5 effector, also binds to Rab4. Rabenosyn-5 overexpression increased the association between Rab5 and Rab4 endosomal domains and decreased the fraction of Rab4- and Rab11-positive structures. This redistribution was accompanied by a faster rate of transferrin recycling from early endosomes to the cell surface and reduced transport to Rab11-containing perinuclear recycling endosomes. These effects depend on the ability of Rabenosyn-5 to interact with Rab4. We propose that divalent Rab effectors regulate protein sorting and recycling by connecting Rab domains on early endosomes.	Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; Cenix Biosci GmbH, D-01307 Dresden, Germany	Max Planck Society	Zerial, M (corresponding author), Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany.			De Renzis, Stefano/0000-0003-4764-2070				Allan BB, 2000, SCIENCE, V289, P444, DOI 10.1126/science.289.5478.444; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Burd CG, 1997, MOL BIOL CELL, V8, P1089, DOI 10.1091/mbc.8.6.1089; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; Christiansen OB, 1999, HUM REPROD UPDATE, V5, P249, DOI 10.1093/humupd/5.3.249; Christoforidis S, 2000, METHODS, V20, P403, DOI 10.1006/meth.2000.0953; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Clague MJ, 1999, CURR BIOL, V9, pR258, DOI 10.1016/S0960-9822(99)80158-4; Cormont M, 2001, P NATL ACAD SCI USA, V98, P1637, DOI 10.1073/pnas.031586998; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; GEUZE HJ, 1983, EUR J CELL BIOL, V32, P38; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; Guo W, 1999, EMBO J, V18, P1071, DOI 10.1093/emboj/18.4.1071; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Miaczynska M, 2002, EXP CELL RES, V272, P8, DOI 10.1006/excr.2001.5401; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Murphy C, 1996, NATURE, V384, P427, DOI 10.1038/384427a0; Nielsen E, 2000, J CELL BIOL, V151, P601, DOI 10.1083/jcb.151.3.601; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; Prekeris R, 1998, J CELL BIOL, V143, P957, DOI 10.1083/jcb.143.4.957; Price A, 2000, J CELL BIOL, V148, P1231, DOI 10.1083/jcb.148.6.1231; Rohn WM, 2000, J CELL SCI, V113, P2093; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Simonsen A, 1999, J BIOL CHEM, V274, P28857, DOI 10.1074/jbc.274.41.28857; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; SIPE DM, 1991, J BIOL CHEM, V266, P3469; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; VanRheenen SM, 1998, J CELL BIOL, V141, P1107, DOI 10.1083/jcb.141.5.1107; Vitale G, 1998, EMBO J, V17, P1941, DOI 10.1093/emboj/17.7.1941; Wilcke M, 2000, J CELL BIOL, V151, P1207, DOI 10.1083/jcb.151.6.1207; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; Zacchi P, 1998, J CELL BIOL, V140, P1039, DOI 10.1083/jcb.140.5.1039; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	44	251	260	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	FEB	2002	4	2					124	133		10.1038/ncb744	http://dx.doi.org/10.1038/ncb744			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	520RJ	11788822				2022-12-25	WOS:000173794600016
J	Maus, MV; Thomas, AK; Leonard, DGB; Allman, D; Addya, K; Schlienger, K; Riley, JL; June, CH				Maus, MV; Thomas, AK; Leonard, DGB; Allman, D; Addya, K; Schlienger, K; Riley, JL; June, CH			Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB	NATURE BIOTECHNOLOGY			English	Article							ADOPTIVE TRANSFER; MONOCLONAL-ANTIBODIES; PRESENTING CELLS; GENE-TRANSFER; IN-VIVO; COSTIMULATION; PROLIFERATION; ACTIVATION; DIFFERENTIATION; IMMUNOTHERAPY	The ex vivo priming and expansion of human cytotoxic T lymphocytes (CTLs) has potential for use in immunotherapy applications for cancer and infectious diseases. To overcome the difficulty in obtaining sufficient numbers of CTLs, we have developed artificial antigen-presenting cells (aAPCs) expressing ligands for the T-cell receptor (TCR) and the CD28 and 4-1BB co-stimulatory surface molecules. These aAPCs reproducibly activate and rapidly expand polyclonal or antigen-specific CD8(+) T cells. The starting repertoire of CD8(+) T cells was preserved during culture. Furthermore, apoptosis of cultured CD8(+) T cells was diminished by this approach. This approach may have important therapeutic implications for adoptive immunotherapy.	Univ Penn, Ctr Canc, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	June, CH (corresponding author), Univ Penn, Ctr Canc, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.		Riley, James L/D-1255-2009	Riley, James/0000-0002-1057-576X; Maus, Marcela/0000-0002-7578-0393; June, Carl/0000-0003-0241-3557	NATIONAL CANCER INSTITUTE [P30CA016520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK019525, T32DK007748] Funding Source: NIH RePORTER; NCI NIH HHS [CA-16520] Funding Source: Medline; NIDDK NIH HHS [DK-19525, DK07748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Almand B, 2000, CLIN CANCER RES, V6, P1755; Brodie SJ, 1999, NAT MED, V5, P34, DOI 10.1038/4716; Claret EJ, 1997, J CLIN INVEST, V100, P855, DOI 10.1172/JCI119601; Curtsinger JM, 1998, J IMMUNOL, V160, P3236; Dahl AM, 2000, J EXP MED, V191, P2031, DOI 10.1084/jem.191.12.2031; DeBenedette MA, 1997, J IMMUNOL, V158, P551; Deeths MJ, 1999, J IMMUNOL, V163, P102; Deeths MJ, 1997, EUR J IMMUNOL, V27, P598, DOI 10.1002/eji.1830270305; Dudley ME, 2001, J IMMUNOTHER, V24, P363, DOI 10.1097/00002371-200107000-00012; Dunbar PR, 1998, CURR BIOL, V8, P413, DOI 10.1016/S0960-9822(98)70161-7; GOODWIN RG, 1993, EUR J IMMUNOL, V23, P2631, DOI 10.1002/eji.1830231037; Guinn B, 1999, J IMMUNOL, V162, P5003; Heslop HE, 1996, NAT MED, V2, P551, DOI 10.1038/nm0596-551; Hurtado JC, 1997, J IMMUNOL, V158, P2600; HURTADO JC, 1995, J IMMUNOL, V155, P3360; JUNE CH, 1987, MOL CELL BIOL, V7, P4472, DOI 10.1128/MCB.7.12.4472; Latouche JB, 2000, NAT BIOTECHNOL, V18, P405, DOI 10.1038/74455; Laux I, 2000, CLIN IMMUNOL, V96, P187, DOI 10.1006/clim.2000.4902; Levine BL, 1997, J IMMUNOL, V159, P5921; Lord JD, 1998, J IMMUNOL, V161, P4627; Melero I, 1997, NAT MED, V3, P682, DOI 10.1038/nm0697-682; Melero I, 1998, EUR J IMMUNOL, V28, P1116, DOI 10.1002/(SICI)1521-4141(199803)28:03<1116::AID-IMMU1116>3.0.CO;2-A; MELIEF CJM, 1995, IMMUNOL REV, V145, P167, DOI 10.1111/j.1600-065X.1995.tb00081.x; POLLOK KE, 1993, J IMMUNOL, V150, P771; Prakken B, 2000, NAT MED, V6, P1406, DOI 10.1038/82231; RIDDELL SR, 1992, HUM GENE THER, V3, P319, DOI 10.1089/hum.1992.3.3-319; RIDDELL SR, 1990, J IMMUNOL METHODS, V128, P189, DOI 10.1016/0022-1759(90)90210-M; RIDDELL SR, 1995, ANNU REV IMMUNOL, V13, P545; RIDDELL SR, 1992, SCIENCE, V257, P238; Riley JL, 2001, J IMMUNOL, V166, P4943, DOI 10.4049/jimmunol.166.8.4943; Rooney CM, 1998, BLOOD, V92, P1549, DOI 10.1182/blood.V92.5.1549.417k32_1549_1555; ROSENBERG SA, 1990, NEW ENGL J MED, V323, P570, DOI 10.1056/NEJM199008303230904; SAGERSTROM CG, 1993, P NATL ACAD SCI USA, V90, P8987, DOI 10.1073/pnas.90.19.8987; Saoulli K, 1998, J EXP MED, V187, P1849, DOI 10.1084/jem.187.11.1849; Shuford WW, 1997, J EXP MED, V186, P47, DOI 10.1084/jem.186.1.47; Takahashi C, 1999, J IMMUNOL, V162, P5037; Tan EM, 2001, J CLIN INVEST, V108, P1411, DOI 10.1172/JCI200114451; Tan JT, 2000, J IMMUNOL, V164, P2320, DOI 10.4049/jimmunol.164.5.2320; Voltz R, 1999, NEW ENGL J MED, V340, P1788, DOI 10.1056/NEJM199906103402303; Wang B, 2000, J IMMUNOL, V164, P1216, DOI 10.4049/jimmunol.164.3.1216; Yee C, 2000, J EXP MED, V192, P1637, DOI 10.1084/jem.192.11.1637; Yee C, 1999, J IMMUNOL, V162, P2227; Yee C, 2001, CURR OPIN IMMUNOL, V13, P141, DOI 10.1016/S0952-7915(00)00196-5	43	339	400	1	33	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2002	20	2					143	148		10.1038/nbt0202-143	http://dx.doi.org/10.1038/nbt0202-143			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	517FT	11821859				2022-12-25	WOS:000173601000022
J	Cibelli, JB; Campbell, KH; Seidel, GE; West, MD; Lanza, RP				Cibelli, JB; Campbell, KH; Seidel, GE; West, MD; Lanza, RP			The health profile of cloned animals	NATURE BIOTECHNOLOGY			English	Editorial Material							CULTURED SOMATIC-CELLS; TAIL-TIP CELLS; NUCLEAR TRANSFER; FIBROBLAST CELLS; TELOMERE LENGTHS; ADULT; CLONING; CALVES; MICE; FETAL		Adv Cell Technol, Res, Worcester, MA USA; Adv Cell Technol, Med & Sci Dev, Worcester, MA USA; Univ Nottingham, Div Biol Sci, Loughborough, Leics, England; Colorado State Univ, Anim Reprod & Biotechnol Lab, Ft Collins, CO 80523 USA	University of Nottingham; Colorado State University	Cibelli, JB (corresponding author), Adv Cell Technol, Res, Worcester, MA USA.		Seidel, George/AAE-2371-2019	Lanza, Robert/0000-0002-3047-3074; Cibelli, Jose/0000-0002-2176-3854; West, Michael/0000-0002-4842-5468				Baguisi A, 1999, NAT BIOTECHNOL, V17, P456, DOI 10.1038/8632; BEHBOODI E, 1995, THERIOGENOLOGY, V44, P227, DOI 10.1016/0093-691X(95)00172-5; Betthauser J, 2000, NAT BIOTECHNOL, V18, P1055, DOI 10.1038/80242; Bondioli K, 2001, MOL REPROD DEV, V60, P189, DOI 10.1002/mrd.1076; Denning C, 2001, NAT BIOTECHNOL, V19, P559, DOI 10.1038/89313; Eggan K, 2001, P NATL ACAD SCI USA, V98, P6209, DOI 10.1073/pnas.101118898; Galli C, 1999, Cloning, V1, P161, DOI 10.1089/15204559950019924; Garry FB, 1996, THERIOGENOLOGY, V45, P141, DOI 10.1016/0093-691X(95)00363-D; HASLER JF, 1995, THERIOGENOLOGY, V43, P141, DOI 10.1016/0093-691X(94)00020-U; Hill JR, 2000, BIOL REPROD, V62, P1135, DOI 10.1095/biolreprod62.5.1135; Kang YK, 2001, FEBS LETT, V499, P55, DOI 10.1016/S0014-5793(01)02514-5; Kasinathan P, 2001, NAT BIOTECHNOL, V19, P1176, DOI 10.1038/nbt1201-1176; Kato Y, 1998, SCIENCE, V282, P2095, DOI 10.1126/science.282.5396.2095; Kato Y, 2000, J REPROD FERTIL, V120, P231, DOI 10.1530/reprod/120.2.231; Keefer CL, 2001, BIOL REPROD, V64, P849, DOI 10.1095/biolreprod64.3.849; Kishi M, 2000, THERIOGENOLOGY, V54, P675, DOI 10.1016/S0093-691X(00)00382-4; Kubota C, 2000, P NATL ACAD SCI USA, V97, P990, DOI 10.1073/pnas.97.3.990; Lacham-Kaplan O, 2000, Cloning, V2, P55, DOI 10.1089/152045500436078; Lanza R.P., 2000, PRINCIPLES TISSUE EN; Lanza RP, 1999, NAT BIOTECHNOL, V17, P1171, DOI 10.1038/70709; Lanza RP, 2001, SCIENCE, V294, P1893, DOI 10.1126/science.1063440; Loi P, 2001, NAT BIOTECHNOL, V19, P962, DOI 10.1038/nbt1001-962; McCreath KJ, 2000, NATURE, V405, P1066, DOI 10.1038/35016604; Ogura A, 2000, MOL REPROD DEV, V57, P55, DOI 10.1002/1098-2795(200009)57:1&lt;55::AID-MRD8&gt;3.0.CO;2-W; Ogura A, 2000, BIOL REPROD, V62, P1579, DOI 10.1095/biolreprod62.6.1579; Ohgane J, 2001, GENESIS, V30, P45, DOI 10.1002/gene.1031; Onishi A, 2000, SCIENCE, V289, P1188, DOI 10.1126/science.289.5482.1188; Ono Y, 2001, BIOL REPROD, V64, P44, DOI 10.1095/biolreprod64.1.44; Polejaeva IA, 2000, NATURE, V407, P86, DOI 10.1038/35024082; Ramsahoye BH, 2000, P NATL ACAD SCI USA, V97, P5237, DOI 10.1073/pnas.97.10.5237; Reggio BC, 2001, BIOL REPROD, V65, P1528, DOI 10.1095/biolreprod65.5.1528; Renard JP, 1999, LANCET, V353, P1489, DOI 10.1016/S0140-6736(98)12173-6; Schnieke AE, 1997, SCIENCE, V278, P2130, DOI 10.1126/science.278.5346.2130; Shiels PG, 1999, NATURE, V399, P316, DOI 10.1038/20580; Shiga K, 1999, THERIOGENOLOGY, V52, P527, DOI 10.1016/S0093-691X(99)00149-1; Tamashiro KLK, 2000, BIOL REPROD, V63, P328, DOI 10.1095/biolreprod63.1.328; Tian XC, 2000, NAT GENET, V26, P272, DOI 10.1038/81559; van Wagtendonk-de Leeuw AM, 2000, THERIOGENOLOGY, V53, P575, DOI 10.1016/S0093-691X(99)00259-9; Wakayama T, 2000, NATURE, V407, P318, DOI 10.1038/35030301; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wakayama T, 2001, REPRODUCTION, V122, P49, DOI 10.1530/rep.0.1220049; Wakayama T, 2001, MOL REPROD DEV, V58, P376, DOI 10.1002/1098-2795(20010401)58:4<376::AID-MRD4>3.0.CO;2-L; Wakayama T, 1999, NAT GENET, V22, P127, DOI 10.1038/9632; WALKER SK, 1992, THERIOGENOLOGY, V37, P111, DOI 10.1016/0093-691X(92)90250-U; Wells DN, 1999, BIOL REPROD, V60, P996, DOI 10.1095/biolreprod60.4.996; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Yamazaki Y, 2001, P NATL ACAD SCI USA, V98, P14022, DOI 10.1073/pnas.231489398; Zakhartchenko V, 1999, MOL REPROD DEV, V54, P264, DOI 10.1002/(SICI)1098-2795(199911)54:3&lt;264::AID-MRD7&gt;3.0.CO;2-Y; Zakhartchenko V, 2001, MOL REPROD DEV, V60, P362, DOI 10.1002/mrd.1098; Zhou Q, 2000, Cloning, V2, P35, DOI 10.1089/15204550050145111	50	169	186	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2002	20	1					13	14		10.1038/nbt0102-13	http://dx.doi.org/10.1038/nbt0102-13			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	507ME	11753346				2022-12-25	WOS:000173031600019
J	Ortiz-Urda, S; Thyagarajan, B; Keene, DR; Lin, Q; Fang, M; Calos, MP; Khavari, PA				Ortiz-Urda, S; Thyagarajan, B; Keene, DR; Lin, Q; Fang, M; Calos, MP; Khavari, PA			Stable nonviral genetic correction of inherited human skin disease	NATURE MEDICINE			English	Article							DYSTROPHIC EPIDERMOLYSIS-BULLOSA; ANCHORING FIBRILS; STEM-CELLS; KERATINOCYTES; INTEGRATION; EXPRESSION; COL7A1; MICE	Current gene-transfer technologies display limitations in achieving effective gene delivery. Among these limitations are difficulties in stably integrating large corrective sequences into the genomes of long-lived progenitor-cell populations. Current larger-capacity viral vectors suffer from biosafety concerns, whereas plasmid-based approaches have poor efficiency of stable gene transfer(1,2). These barriers hinder genetic correction of many severe inherited human diseases, such as the blistering skin disorder recessive dystrophic epidermolysis bullosa (RDEB)(3), caused by mutations in the large COL7A1 gene. To circumvent these barriers, we used the phiC31 bacteriophage integrase(4-6), which stably integrates large DNA sequences containing a specific 285-base-pair attB sequence into genomic 'pseudo-attP sites'. phiC31 integrase-based gene transfer stably integrated the COL7A1 cDNA into genomes of primary epidermal progenitor cells from four unrelated RDEB patients. Skin regenerated using these cells displayed stable correction of hallmark RDEB disease features, including Type VII collagen protein expression, anchoring fibril formation and dermal-epidermal cohesion. These findings establish a practical approach to nonviral genetic correction of severe human genetic disorders requiring stable genomic integration of large DNA sequences.	VA Palo Alto Healthcare Syst, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Program Epithelial Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Shriners Hosp Children, Portland, OR 97201 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University; Stanford University	Khavari, PA (corresponding author), VA Palo Alto Healthcare Syst, Palo Alto, CA 94304 USA.				NHLBI NIH HHS [HL68112] Funding Source: Medline; NIAMS NIH HHS [AR44012] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068112, R56HL068112] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR044012] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARRANDON Y, 1987, P NATL ACAD SCI USA, V84, P2302, DOI 10.1073/pnas.84.8.2302; Bruckner-Tuderman L, 1999, MATRIX BIOL, V18, P43, DOI 10.1016/S0945-053X(98)00007-9; Burton EA, 2002, CELL, V108, P5, DOI 10.1016/S0092-8674(01)00626-2; Choate KA, 1996, NAT MED, V2, P1263, DOI 10.1038/nm1196-1263; CHOATE KA, 1997, HUM GENE THER, V8, P1671; CHRISTIANO AM, 1994, GENOMICS, V21, P169, DOI 10.1006/geno.1994.1239; Evans JT, 2000, HUM GENE THER, V11, P2331, DOI 10.1089/104303400750038444; Freiberg RA, 1997, J CLIN INVEST, V99, P2610, DOI 10.1172/JCI119449; FREIBERG RA, 1997, HUM MOL GENET, V6, P937; Groth AC, 2000, P NATL ACAD SCI USA, V97, P5995, DOI 10.1073/pnas.090527097; Heinonen S, 1999, J CELL SCI, V112, P3641; Hengge UR, 1996, J CLIN INVEST, V97, P2911, DOI 10.1172/JCI118750; KEENE DR, 1987, J CELL BIOL, V104, P611, DOI 10.1083/jcb.104.3.611; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kochanek S, 1999, HUM GENE THER, V10, P2451, DOI 10.1089/10430349950016807; Kolodka TM, 1998, P NATL ACAD SCI USA, V95, P4356, DOI 10.1073/pnas.95.8.4356; KUHSTOSS S, 1991, J MOL BIOL, V222, P897, DOI 10.1016/0022-2836(91)90584-S; MARINKOVICH MP, 1999, DERMATOLOGY GEN MED, V1, P690; Mathor MB, 1996, P NATL ACAD SCI USA, V93, P10371, DOI 10.1073/pnas.93.19.10371; Medalie DA, 1996, J INVEST DERMATOL, V107, P121, DOI 10.1111/1523-1747.ep12298363; Pfutzner W, 1999, J INVEST DERMATOL, V112, P552; Robbins PB, 2001, P NATL ACAD SCI USA, V98, P5193, DOI 10.1073/pnas.091484998; Sclimenti CR, 2001, NUCLEIC ACIDS RES, V29, P5044, DOI 10.1093/nar/29.24.5044; Seitz CS, 1999, GENE THER, V6, P42, DOI 10.1038/sj.gt.3300809; STOCKSCHLADER MAR, 1994, GENE THER, V1, P317; Thyagarajan B, 2001, MOL CELL BIOL, V21, P3926, DOI 10.1128/MCB.21.12.3926-3934.2001	26	179	200	1	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	OCT	2002	8	10					1166	1170		10.1038/nm766	http://dx.doi.org/10.1038/nm766			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	599AN	12244305				2022-12-25	WOS:000178311000045
J	Kruger, C; Hu, YZ; Pan, Q; Marcotte, H; Hultberg, A; Delwar, D; van Dalen, PJ; Pouwels, PH; Leer, RJ; Kelly, CG; van Dollenweerd, C; Ma, JK; Hammarstrom, L				Kruger, C; Hu, YZ; Pan, Q; Marcotte, H; Hultberg, A; Delwar, D; van Dalen, PJ; Pouwels, PH; Leer, RJ; Kelly, CG; van Dollenweerd, C; Ma, JK; Hammarstrom, L			In situ delivery of passive immunity by lactobacilli producing single-chain antibodies	NATURE BIOTECHNOLOGY			English	Article							LACTIC-ACID BACTERIA; HUMAN DENTAL DECAY; TOXIN FRAGMENT-C; STREPTOCOCCUS-MUTANS; MONOCLONAL-ANTIBODIES; ORAL IMMUNIZATION; ACUTE DIARRHEA; BOVINE-MILK; SURFACE; CARIES	Lactobacilli have previously been used to deliver vaccine components for active immunization in vivo. Vectors encoding a single-chain Fv (scFv) antibody fragment, which recognizes the streptococcal antigen I/II (SAI/II) adhesion molecule of Streptococcus mutans, were constructed and expressed in Lactobacillus zeae (American Type Culture Collection (ATCC) 393). The scFv antibody fragments secreted into the supernatant or expressed on the surface of the bacteria showed binding activity against SAI/II in enzyme-linked immunosorbent assay (ELISA), and surface scFv-expressing lactobacilli agglutinated SAI/II-expressing S. mutans in vitro without affecting the corresponding SAI/II knockout strain. Lactobacilli expressing the scFv fragment fused to an E-tag were visualized by scanning electron microscopy (SEM) using beads coated with a monoclonal anti-E-tag antibody, and they bound directly to beads coated with SAI/II. After administration of scFv-expressing bacteria to a rat model of dental caries development, S. mutans bacteria counts and caries scores were markedly reduced. As lactobacilli are generally regarded as safe (GRAS) microorganisms, this approach may be of considerable commercial interest for in vivo immunotherapy.	Novum, Karolinska Inst, Ctr Oral Biol, SE-14186 Huddinge, Sweden; Huddinge Hosp, Karolinska Inst, Div Clin Immunol, SE-14186 Huddinge, Sweden; TNO Prevent & Hlth, Div Infect Dis & Immunol, NL-2301 CE Leiden, Netherlands; TNO Voeding, Dept Appl Microbiol & Gene Technol, NL-3600 AJ Zeist, Netherlands; Univ London Kings Coll, Guys Hosp, Dept Oral Med & Pathol, London WC2R 2LS, England	Karolinska Institutet; Karolinska Institutet; Netherlands Organization Applied Science Research; Netherlands Organization Applied Science Research; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Hammarstrom, L (corresponding author), Novum, Karolinska Inst, Ctr Oral Biol, SE-14186 Huddinge, Sweden.		Marcotte, Harold/P-9375-2017; hammarstrom, qiang pan/ABA-4589-2021	Marcotte, Harold/0000-0002-7168-349X; Ma, Julian/0000-0003-0767-0042; van Dolleweerd, Craig/0000-0002-1380-6930; pan-hammarstrom, qiang/0000-0003-1990-8804				Ahrne S, 1998, J APPL MICROBIOL, V85, P88; Beninati C, 2000, NAT BIOTECHNOL, V18, P1060, DOI 10.1038/80250; BLEIWEIS AS, 1990, ARCH ORAL BIOL, V35, pS15, DOI 10.1016/0003-9969(90)90126-U; BOWEN WH, 1988, J DENT RES, V67, P21, DOI 10.1177/00220345880670010301; Casswall TH, 1996, ACTA PAEDIATR, V85, P1126, DOI 10.1111/j.1651-2227.1996.tb14231.x; de Vos WM, 1999, CURR OPIN MICROBIOL, V2, P289, DOI 10.1016/S1369-5274(99)80050-2; EIBL MM, 1988, NEW ENGL J MED, V319, P1, DOI 10.1056/NEJM198807073190101; FILLER SJ, 1991, ARCH ORAL BIOL, V36, P41, DOI 10.1016/0003-9969(91)90052-V; Giddings G, 2000, NAT BIOTECHNOL, V18, P1151, DOI 10.1038/81132; Gionchetti P, 2000, J GASTROEN HEPATOL, V15, P489, DOI 10.1046/j.1440-1746.2000.02162.x; Guandalini S, 2000, J PEDIATR GASTR NUTR, V30, P54, DOI 10.1097/00005176-200001000-00018; Gunneriusson E, 1996, J BACTERIOL, V178, P1341, DOI 10.1128/jb.178.5.1341-1346.1996; HAMADA S, 1991, INFECT IMMUN, V59, P4161, DOI 10.1128/IAI.59.11.4161-4167.1991; HAMMARSTROM V, 1993, LANCET, V341, P1036, DOI 10.1016/0140-6736(93)91136-A; Hatta H, 1997, CARIES RES, V31, P268, DOI 10.1159/000262410; ISOLAURI E, 1995, VACCINE, V13, P310, DOI 10.1016/0264-410X(95)93319-5; KEYES PAUL H., 1958, JOUR DENTAL RES, V37, P1088, DOI 10.1177/00220345580370060901; KRASSE B, 1970, ARCH ORAL BIOL, V15, P25, DOI 10.1016/0003-9969(70)90142-1; KRASSE B, 1967, ARCH ORAL BIOL, V12, P231, DOI 10.1016/0003-9969(67)90042-8; Lamarre A, 1997, EUR J IMMUNOL, V27, P3447, DOI 10.1002/eji.1830271245; LEHNER T, 1976, J DENT RES, V55, pC166, DOI 10.1177/002203457605500311011; LEHNER T, 1985, INFECT IMMUN, V50, P796, DOI 10.1128/IAI.50.3.796-799.1985; LEHNER T, 1992, ADV EXP MED BIOL, V327, P151; Little M, 2000, IMMUNOL TODAY, V21, P364, DOI 10.1016/S0167-5699(00)01668-6; LOESCHE WJ, 1986, MICROBIOL REV, V50, P353, DOI 10.1128/MMBR.50.4.353-380.1986; LOESCHE WJ, 1975, INFECT IMMUN, V11, P1252, DOI 10.1128/IAI.11.6.1252-1260.1975; Lorenzen N, 2000, NAT BIOTECHNOL, V18, P1177, DOI 10.1038/81169; MA JKC, 1995, SCIENCE, V268, P716, DOI 10.1126/science.7732380; MA JKC, 1987, INFECT IMMUN, V55, P1274, DOI 10.1128/IAI.55.5.1274-1278.1987; Ma JKC, 1998, NAT MED, V4, P601, DOI 10.1038/nm0598-601; MA JKC, 1990, INFECT IMMUN, V58, P3407, DOI 10.1128/IAI.58.10.3407-3414.1990; Maassen CBM, 1999, VACCINE, V17, P2117, DOI 10.1016/S0264-410X(99)00010-9; Magliani W, 1997, NAT BIOTECHNOL, V15, P155, DOI 10.1038/nbt0297-155; MATTHEWS R, 1995, J INFECT DIS, V171, P1668, DOI 10.1093/infdis/171.6.1668; MICHALEK SM, 1987, INFECT IMMUN, V55, P2341, DOI 10.1128/IAI.55.10.2341-2347.1987; Mottershead DG, 2000, BIOCHEM BIOPH RES CO, V275, P84, DOI 10.1006/bbrc.2000.3264; PERDIGON G, 1988, IMMUNOLOGY, V63, P17; Piard JC, 1997, ADV EXP MED BIOL, V418, P545; Pouwels PH, 1996, J BIOTECHNOL, V44, P183, DOI 10.1016/0168-1656(95)00140-9; Pouwels PH, 2001, METHOD ENZYMOL, V336, P369, DOI 10.1016/S0076-6879(01)36602-8; Pouwels PH, 1998, INT J FOOD MICROBIOL, V41, P155, DOI 10.1016/S0168-1605(98)00048-8; Russell M W, 1992, Curr Opin Dent, V2, P72; Savijoki K, 1997, GENE, V186, P255, DOI 10.1016/S0378-1119(96)00717-2; Shaw DM, 2000, IMMUNOLOGY, V100, P510, DOI 10.1046/j.1365-2567.2000.00069.x; Shornikova AV, 1997, J PEDIATR GASTR NUTR, V24, P399, DOI 10.1097/00005176-199704000-00008; Steidler L, 2000, SCIENCE, V289, P1352, DOI 10.1126/science.289.5483.1352; TJELLSTROM B, 1993, LANCET, V341, P701, DOI 10.1016/0140-6736(93)90477-X; Vanderhoof JA, 1999, J PEDIATR-US, V135, P564, DOI 10.1016/S0022-3476(99)70053-3; Weiner C, 1999, CLIN EXP IMMUNOL, V116, P193	49	141	164	3	22	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2002	20	7					702	706		10.1038/nbt0702-702	http://dx.doi.org/10.1038/nbt0702-702			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	567QC	12089555	Bronze			2022-12-25	WOS:000176494800024
J	Zuany-Amorim, C; Sawicka, E; Manlius, C; Le Moine, AL; Brunet, LR; Kemeny, DM; Bowen, G; Rook, G; Walker, C				Zuany-Amorim, C; Sawicka, E; Manlius, C; Le Moine, AL; Brunet, LR; Kemeny, DM; Bowen, G; Rook, G; Walker, C			Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells	NATURE MEDICINE			English	Article							IN-VITRO; INFECTION; MICE; PROLIFERATION; LYMPHOCYTE; RESPONSES; INHIBIT; GAMMA	Allergic asthma is a chronic inflammatory disease and despite the introduction of potent and effective drugs, the prevalence has increased substantially over the past few decades(1). The explanation that has attracted the most attention is the 'hygiene hypothesis', which suggests that the increase in allergic diseases is caused by a cleaner environment and fewer childhood infections(2-4). Indeed, certain mycobacterial strains can cause a shift from T-helper cell 2 (Th2) to Th1 immune responses, which may subsequently prevent the development of allergy in mice(5-7). Although the reconstitution of the balance between Th1 and Th2 is an attractive theory, it is unlikely to explain the whole story, as autoimmune diseases characterized by Th1 responses can also benefit from treatment with mycobacteria and their prevalence has also increased in parallel to allergies(8). Here we show that treatment of mice with SRP299, a killed Mycobacterium vaccae-suspension, gives rise to allergen-specific CD4(+)CD45RB(Lo) regulatory T cells, which confer protection against airway inflammation. This specific inhibition was mediated through interleukin-10 (IL-10) and transforming growth factor-beta (TGF-beta), as antibodies against IL-10 and TGF-beta completely reversed the inhibitory effect of CD4(+)CD45RB(Lo) T cells. Thus, regulatory T cells generated by mycobacteria treatment may have an essential role in restoring the balance of the immune system to prevent and treat allergic diseases.	Novartis Pharmaceut Ltd, Novartis Horsham Res Ctr, Horsham, W Sussex, England; Kings Coll London, Rayne Inst, London WC2R 2LS, England; Free Univ Brussels, Expt Immunol Lab, B-1050 Brussels, Belgium; UCL Royal Free & Univ Coll Med Sch, Windeyer Inst Med Sci, Dept Med Microbiol, London, England; SR Pharma, Ctr Point, London, England	Novartis; University of London; King's College London; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of London; University College London; UCL Medical School	Zuany-Amorim, C (corresponding author), Novartis Pharmaceut Ltd, Novartis Horsham Res Ctr, Wimblehurst Rd, Horsham, W Sussex, England.	claudia.zuany-amorim_fromond@pharma.novartis.com		Rook, Graham/0000-0002-8041-8110				Arkwright PD, 2001, J ALLERGY CLIN IMMUN, V107, P531, DOI 10.1067/mai.2001.113081; Asseman C, 1999, J EXP MED, V190, P995, DOI 10.1084/jem.190.7.995; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; CAMPOROTA L, 2000, AM J RESP CRIT CARE, V161, pA477; Cottrez F, 2000, J IMMUNOL, V165, P4848, DOI 10.4049/jimmunol.165.9.4848; Davies JD, 1999, J IMMUNOL, V163, P5353; Erb KJ, 1998, J EXP MED, V187, P561, DOI 10.1084/jem.187.4.561; Farooqi IS, 1998, THORAX, V53, P927, DOI 10.1136/thx.53.11.927; GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Herz U, 1998, J ALLERGY CLIN IMMUN, V102, P867, DOI 10.1016/S0091-6749(98)70030-2; Hopkin JM, 2001, PROG R RES, V31, P226; Levings MK, 2001, J EXP MED, V193, P1295, DOI 10.1084/jem.193.11.1295; Maloy KJ, 2001, NAT IMMUNOL, V2, P816, DOI 10.1038/ni0901-816; Martinez FD, 1999, LANCET, V354, pS12, DOI 10.1016/S0140-6736(99)90437-3; Roncarolo MG, 2001, J EXP MED, V193, pF5, DOI 10.1084/jem.193.2.F5; Roncarolo MG, 2000, CURR OPIN IMMUNOL, V12, P676, DOI 10.1016/S0952-7915(00)00162-X; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Shirtcliffe PM, 2001, AM J RESP CRIT CARE, V163, P1410, DOI 10.1164/ajrccm.163.6.2003050; Stene LC, 2001, LANCET, V357, P607, DOI 10.1016/S0140-6736(00)04067-8; Thornton AM, 1998, J EXP MED, V188, P287, DOI 10.1084/jem.188.2.287; Wang CC, 1998, IMMUNOLOGY, V93, P307; Zuany-Amorim C, 1998, SCIENCE, V280, P1265, DOI 10.1126/science.280.5367.1265; ZuanyAmorim C, 1996, J IMMUNOL, V157, P377	24	427	462	0	22	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2002	8	6					625	629		10.1038/nm0602-625	http://dx.doi.org/10.1038/nm0602-625			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	557KG	12042815				2022-12-25	WOS:000175907300035
J	Chesne, P; Adenot, PG; Viglietta, C; Baratte, M; Boulanger, L; Renard, JP				Chesne, P; Adenot, PG; Viglietta, C; Baratte, M; Boulanger, L; Renard, JP			Cloned rabbits produced by nuclear transfer from adult somatic cells	NATURE BIOTECHNOLOGY			English	Article							OOCYTES; ACTIVATION; TIME	We have developed a method to produce live somatic clones in the rabbit, one of the mammalian species considered up to now as difficult to clone. To do so, we have modified current cloning protocols proven successful in other species by taking into account both the rapid kinetics of the cell cycle of rabbit embryos and the narrow window of time for their implantation after transfer into foster recipients. Although our method still has a low level of efficiency, it has produced several clones now proven to be fertile. Our work indicates that cloning can probably be carried out successfully in any mammalian species by taking into account physiological features of their oocytes and embryos. Our results will contribute to extending the use of rabbit models for biomedical research.	INRA, Unite Biol Dev & Biotechnol, F-78352 Jouy En Josas, France; INRA, Unite Commune Expt Anim, F-78352 Jouy En Josas, France	INRAE; UDICE-French Research Universities; Universite Paris Saclay; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Renard, JP (corresponding author), INRA, Unite Biol Dev & Biotechnol, F-78352 Jouy En Josas, France.	renard@jouy.inra.fr						Adenot PG, 1997, MOL REPROD DEV, V46, P325, DOI 10.1002/(SICI)1098-2795(199703)46:3&lt;325::AID-MRD11&gt;3.0.CO;2-Y; BROMHALL JD, 1975, NATURE, V258, P719, DOI 10.1038/258719a0; Campbell K H, 1996, Rev Reprod, V1, P40, DOI 10.1530/ror.0.0010040; CHANG MC, 1950, J EXP ZOOL, V114, P197, DOI 10.1002/jez.1401140110; Chen JM, 2001, MOL BIOL EVOL, V18, P1771, DOI 10.1093/oxfordjournals.molbev.a003965; DENKER HW, 1981, ADV ANAT EMBRYOL CEL, V53, P1; Dinnyes A, 2001, BIOL REPROD, V64, P257, DOI 10.1095/biolreprod64.1.257; GOTTSCHEWSKI GHM, 1973, EMBRYONALENTWICKLUNG, P103; Graur D, 1996, NATURE, V379, P333, DOI 10.1038/379333a0; Heape W., 1890, P R SOC LONDON, V48, P457; Hoeg JM, 1996, P NATL ACAD SCI USA, V93, P11448, DOI 10.1073/pnas.93.21.11448; Hoffman LH, 1998, ENDOCRINOLOGY, V139, P266, DOI 10.1210/en.139.1.266; MEYER L, 1997, METHOD ENZYMOL, V283, P113; Ozil JP, 2001, DEVELOPMENT, V128, P917; Soloy E, 1997, BIOL REPROD, V57, P27, DOI 10.1095/biolreprod57.1.27; STINNAKRE MG, 1997, TRANSGENIC ANIMALS G, P461; SZOLLOSI D, 1966, ANAT REC, V154, P209, DOI 10.1002/ar.1091540203; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wells DN, 1999, BIOL REPROD, V60, P996, DOI 10.1095/biolreprod60.4.996; Yin XJ, 2000, THERIOGENOLOGY, V54, P1469, DOI 10.1016/S0093-691X(00)00468-4	20	397	503	1	55	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2002	20	4					366	369		10.1038/nbt0402-366	http://dx.doi.org/10.1038/nbt0402-366			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	536BY	11923842				2022-12-25	WOS:000174681900023
J	Volpert, OV; Zaichuk, T; Zhou, W; Reiher, F; Ferguson, TA; Stuart, PM; Amin, M; Bouck, NP				Volpert, OV; Zaichuk, T; Zhou, W; Reiher, F; Ferguson, TA; Stuart, PM; Amin, M; Bouck, NP			Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium derived factor	NATURE MEDICINE			English	Article							CELL-SURFACE TRAFFICKING; GROWTH-FACTOR; DYNAMIC BALANCE; APOPTOSIS; EXPRESSION; LIGAND; INDUCTION; SURVIVAL; MECHANISMS; INHIBITOR	Natural inhibitors of angiogenesis are able to block pathological neovascularization without harming the preexisting vasculature. Here we show that two such inhibitors, thrombospondin-1 and pigment epithelium derived factor, derive specificity for remodeling vessels from their dependence on Fas/Fas ligand ( FasL)-mediated apoptosis to block angiogenesis. Both inhibitors upregulated FasL on endothelial cells. Expression of the essential partner of FasL, Fas/CD95 receptor, was low on quiescent endothelial cells and vessels but greatly enhanced by inducers of angiogenesis, thereby specifically sensitizing the stimulated cells to apoptosis by inhibitor-generated FasL. The anti-angiogenic activity of thrombospondin-1 and pigment epithelium derived factor both in vitro and in vivo was dependent on this dual induction of Fas and FasL and the resulting apoptosis. This example of cooperation between pro- and anti-angiogenic factors in the inhibition of angiogenesis provides one explanation for the ability of inhibitors to select remodeling capillaries for destruction.	Northwestern Univ, Sch Med, Dept Urol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Med, Chicago, IL USA; Northwestern Univ, Sch Med, Dept Microbiol & Immunol, Chicago, IL USA; Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA; Washington Univ, Dept Ophthalmol & Visual Sci, St Louis, MO 63130 USA	Northwestern University; Northwestern University; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Washington University (WUSTL)	Volpert, OV (corresponding author), Northwestern Univ, Sch Med, Dept Urol, Chicago, IL 60611 USA.	olgavolp@northwestern.edu		Volpert, Olga/0000-0003-1381-5543	NCI NIH HHS [CA64239, R01 CA52750] Funding Source: Medline; NEI NIH HHS [EY12707, EY12826] Funding Source: Medline; PHS HHS [R01 68003-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052750, R01CA064239] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY012707, R01EY012826] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Alberdi E, 1999, J BIOL CHEM, V274, P31605, DOI 10.1074/jbc.274.44.31605; Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; Becerra SP, 1997, ADV EXP MED BIOL, V425, P223; Benjamin LE, 2000, CANCER METAST REV, V19, P75, DOI 10.1023/A:1026552415576; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bossi G, 2000, EUR J CELL BIOL, V79, P539, DOI 10.1078/0171-9335-00077; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Carmeliet, 1999, Curr Interv Cardiol Rep, V1, P322; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; Dejana E, 1999, EXP CELL RES, V252, P13, DOI 10.1006/excr.1999.4601; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869; Filleur S, 2001, GENE DEV, V15, P1373, DOI 10.1101/gad.193501; Freyberg MA, 2001, BIOCHEM BIOPH RES CO, V286, P141, DOI 10.1006/bbrc.2001.5314; Fukuo K, 1997, HEART VESSELS, P81; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Golstein P, 2000, SCIENCE, V288, P2328, DOI 10.1126/science.288.5475.2328; Holash J, 1999, ONCOGENE, V18, P5356, DOI 10.1038/sj.onc.1203035; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Jimenez B, 2001, ONCOGENE, V20, P3443, DOI 10.1038/sj.onc.1204464; Kaplan HJ, 1999, NAT MED, V5, P292, DOI 10.1038/6509; Kenyon BM, 1996, INVEST OPHTH VIS SCI, V37, P1625; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Larsson H, 2000, CANCER RES, V60, P6723; Lucas R, 1998, BLOOD, V92, P4730; Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; O'Connor DS, 2000, AM J PATHOL, V156, P393, DOI 10.1016/S0002-9440(10)64742-6; Okada Y, 2001, CYTOKINE, V15, P66, DOI 10.1006/cyto.2001.0916; PASSANITI A, 1992, LAB INVEST, V67, P519; Roberts DD, 1996, FASEB J, V10, P1183, DOI 10.1096/fasebj.10.10.8751720; Sata M, 1998, NAT MED, V4, P415, DOI 10.1038/nm0498-415; Sata M, 2000, ARTERIOSCL THROM VAS, V20, P309, DOI 10.1161/01.ATV.20.2.309; Shichiri M, 2001, FASEB J, V15, P1044, DOI 10.1096/fj.99-1083com; Sodeman T, 2000, AM J PHYSIOL-GASTR L, V278, pG992, DOI 10.1152/ajpgi.2000.278.6.G992; Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398; Suhara T, 2001, CIRC RES, V89, P13, DOI 10.1161/hh1301.092506; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Tran J, 1999, BIOCHEM BIOPH RES CO, V264, P781, DOI 10.1006/bbrc.1999.1589; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Volpert OV, 2000, CANCER METAST REV, V19, P87, DOI 10.1023/A:1026560618302; Volpert OV, 1998, P NATL ACAD SCI USA, V95, P6343, DOI 10.1073/pnas.95.11.6343; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yue TL, 1997, MOL PHARMACOL, V51, P951, DOI 10.1124/mol.51.6.951	46	338	371	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2002	8	4					349	357		10.1038/nm0402-349	http://dx.doi.org/10.1038/nm0402-349			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	536ML	11927940				2022-12-25	WOS:000174704800026
J	Bykov, VJN; Issaeva, N; Shilov, A; Hultcrantz, M; Pugacheva, E; Chumakov, P; Bergman, J; Wiman, KG; Selivanova, G				Bykov, VJN; Issaeva, N; Shilov, A; Hultcrantz, M; Pugacheva, E; Chumakov, P; Bergman, J; Wiman, KG; Selivanova, G			Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound	NATURE MEDICINE			English	Article							DNA-BINDING FUNCTION; C-TERMINAL PEPTIDE; HUMAN CANCER-CELLS; REGULATORY REGION; CORE DOMAIN; RESCUE; ACTIVATION; MUTATIONS; THERAPY; REACTIVATION	The tumor suppressor p53 inhibits tumor growth primarily through its ability to induce apoptosis. Mutations in p53 occur in at least 50% of human tumors. We hypothesized that reactivation of mutant p53 in such tumors should trigger massive apoptosis and eliminate the tumor cells. To test this, we screened a library of low-molecular-weight compounds in order to identify compounds that can restore wild-type function to mutant p53. We found one compound capable of inducing apoptosis in human tumor cells through restoration of the transcriptional transactivation function to mutant p53. This molecule, named PRIMA-1, restored sequence-specific DNA binding and the active conformation to mutant p53 proteins in vitro and in living cells. PRIMA-1 rescued both DNA contact and structural p53 mutants. In vivo studies in mice revealed an antitumor effect with no apparent toxicity. This molecule may serve as a lead compound for the development of anticancer drugs targeting mutant p53.	Karolinska Hosp, Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, S-10401 Stockholm, Sweden; RAN, Inst Cytol & Genet, Novosibirsk, Russia; Russian Acad Sci, VA Engelhardt Mol Biol Inst, Moscow, Russia; Karolinska Inst, Novum, Dept Biosci, Huddinge, Sweden	Karolinska Institutet; Karolinska University Hospital; Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB RAS; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Karolinska Institutet	Wiman, KG (corresponding author), Karolinska Hosp, Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, S-10401 Stockholm, Sweden.		Wiman, Klas/AAB-8399-2021; Issaeva, Natalia/K-4577-2019; Chumakov, Peter M/E-7731-2014	Wiman, Klas/0000-0002-7113-524X; Chumakov, Peter/0000-0002-8078-2908; Issaeva, Natalia/0000-0001-5483-6610; Selivanova, Galina/0000-0002-8698-4332; Pugacheva, Elena/0000-0001-9814-7446; Nakade Bykov, Vladimir/0000-0002-7199-8942				ABARZUA P, 1995, CANCER RES, V55, P3490; Asker C, 1999, BIOCHEM BIOPH RES CO, V265, P1, DOI 10.1006/bbrc.1999.1446; Beroud C, 1998, NUCLEIC ACIDS RES, V26, P200, DOI 10.1093/nar/26.1.200; Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; Bullock AN, 2000, ONCOGENE, V19, P1245, DOI 10.1038/sj.onc.1203434; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Cohen PA, 1999, FEBS LETT, V463, P179, DOI 10.1016/S0014-5793(99)01603-8; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Friedlander P, 1996, J BIOL CHEM, V271, P25468, DOI 10.1074/jbc.271.41.25468; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Hansen S, 1996, J BIOL CHEM, V271, P3917; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Kim AL, 1999, J BIOL CHEM, V274, P34924, DOI 10.1074/jbc.274.49.34924; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Lindstrom MS, 2000, EXP CELL RES, V256, P400, DOI 10.1006/excr.2000.4854; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Muller-Tiemann BF, 1998, P NATL ACAD SCI USA, V95, P6079, DOI 10.1073/pnas.95.11.6079; Nikolova PV, 2000, EMBO J, V19, P370, DOI 10.1093/emboj/19.3.370; Selivanova G, 1998, SEMIN CANCER BIOL, V8, P369, DOI 10.1006/scbi.1998.0099; Selivanova G, 1996, NUCLEIC ACIDS RES, V24, P3560, DOI 10.1093/nar/24.18.3560; Selivanova G, 1999, MOL CELL BIOL, V19, P3395; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; SELIVANOVA G, 2001, TUMOR SUPPRESSING VI, P397; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Wieczorek AM, 1996, NAT MED, V2, P1143, DOI 10.1038/nm1096-1143; WIMAN KG, 1991, ONCOGENE, V6, P1633	31	805	836	0	95	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2002	8	3					282	288		10.1038/nm0302-282	http://dx.doi.org/10.1038/nm0302-282			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	526PU	11875500				2022-12-25	WOS:000174139500034
J	Ogonuki, N; Inoue, K; Yamamoto, Y; Noguchi, Y; Tanemura, K; Suzuki, O; Nakayama, H; Doi, K; Ohtomo, Y; Satoh, M; Nishida, A; Ogura, A				Ogonuki, N; Inoue, K; Yamamoto, Y; Noguchi, Y; Tanemura, K; Suzuki, O; Nakayama, H; Doi, K; Ohtomo, Y; Satoh, M; Nishida, A; Ogura, A			Early death of mice cloned from somatic cells	NATURE GENETICS			English	Article							CLONING	Here we report that the lifespan of mice cloned from somatic cells is significantly shorter than that of genotype- and sex-matched controls, most likely due to severe pneumonia and hepatic failure. This finding demonstrates the possibility of long-term deleterious effects of somatic-cell cloning, even after normal birth.	Natl Inst Infect Dis, Dept Vet Sci, Shinjuku Ku, Tokyo, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Vet Pathol, Tokyo, Japan; Tohoku Univ, Fac Agr, Grad Sch Agr Sci, Sendai, Miyagi, Japan	National Institute of Infectious Diseases (NIID); University of Tokyo; Tohoku University	Ogura, A (corresponding author), Natl Inst Infect Dis, Dept Vet Sci, Shinjuku Ku, Tokyo, Japan.		Ogura, Atsuo/J-3916-2014	Ogura, Atsuo/0000-0003-0447-1988				Antonini JM, 2001, CHEST, V120, P240, DOI 10.1378/chest.120.1.240; Fein AM, 1999, CLIN INFECT DIS, V28, P726, DOI 10.1086/515218; Keefer CL, 2001, BIOL REPROD, V64, P849, DOI 10.1095/biolreprod64.3.849; KIMURA Y, 1995, DEVELOPMENT, V121, P2397; MILLER RA, 1991, INT REV CYTOL, V124, P187; Ogura A, 2000, BIOL REPROD, V62, P1579, DOI 10.1095/biolreprod62.6.1579; Renard JP, 1999, LANCET, V353, P1489, DOI 10.1016/S0140-6736(98)12173-6; Tamashiro KLK, 2000, BIOL REPROD, V63, P328, DOI 10.1095/biolreprod63.1.328; Tian XC, 2000, NAT GENET, V26, P272, DOI 10.1038/81559; Wakayama T, 2000, NATURE, V407, P318, DOI 10.1038/35030301; WEIR DM, 1973, HDB EXPT IMMUNOLOGY	11	172	189	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2002	30	3					253	254		10.1038/ng841	http://dx.doi.org/10.1038/ng841			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	526YP	11836501				2022-12-25	WOS:000174157600006
J	Bolay, H; Reuter, U; Dunn, AK; Huang, ZH; Boas, DA; Moskowitz, MA				Bolay, H; Reuter, U; Dunn, AK; Huang, ZH; Boas, DA; Moskowitz, MA			Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model	NATURE MEDICINE			English	Article							GENE-RELATED PEPTIDE; CEREBRAL BLOOD-FLOW; VASCULAR HEAD PAIN; SPREADING DEPRESSION; SUBSTANCE-P; DURA-MATER; POSSIBLE PATHWAY; RAT; STIMULATION; NEURONS	Although the trigeminal nerve innervates the meninges and participates in the genesis of migraine headaches, triggering mechanisms remain controversial and poorly understood. Here we establish a link between migraine aura and headache by demonstrating that cortical spreading depression, implicated in migraine visual aura, activates trigeminovascular afferents and evokes a series of cortical meningeal and brainstem events consistent with the development of headache. Cortical spreading depression caused long-lasting blood-flow enhancement selectively within the middle meningeal artery dependent upon trigeminal and parasympathetic activation, and plasma protein leakage within the dura mater in part by a neurokinin-1-receptor mechanism. Our findings provide a neural mechanism by which extracerebral cephalic blood flow couples to brain events; this mechanism explains vasodilation during headache and links intense neurometabolic brain activity with the transmission of headache pain by the trigeminal nerve.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Stroke & Neurovasc Regulat Lab, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol,NMR Ctr, Boston, MA USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Moskowitz, MA (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Stroke & Neurovasc Regulat Lab, Boston, MA 02114 USA.		Moskowitz, Michael A/D-9916-2011; Bolay, Hayrunnisa/ABG-8829-2020; Dunn, Andrew/I-9527-2014	Bolay, Hayrunnisa/0000-0002-3357-7733; Reuter, Uwe/0000-0002-8527-0725	NINDS NIH HHS [K25 NS41291, 2P01 NS10828, 1R29NS38842] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K25NS041291, P01NS010828, R29NS038842] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allen GV, 1996, BRAIN RES, V715, P125, DOI 10.1016/0006-8993(95)01580-9; Burstein R, 2000, ANN NEUROL, V47, P614, DOI 10.1002/1531-8249(200005)47:5<614::AID-ANA9>3.3.CO;2-E; BUZZI MG, 1990, BRIT J PHARMACOL, V99, P202, DOI 10.1111/j.1476-5381.1990.tb14679.x; Cao Y, 1999, ARCH NEUROL-CHICAGO, V56, P548, DOI 10.1001/archneur.56.5.548; Cumberbatch MJ, 1999, BRIT J PHARMACOL, V126, P1478, DOI 10.1038/sj.bjp.0702444; DRUMMOND PD, 1983, J NEUROL NEUROSUR PS, V46, P611, DOI 10.1136/jnnp.46.7.611; DRUMMOND PD, 1993, BRAIN, V116, P233, DOI 10.1093/brain/116.1.233; Dunn AK, 2001, J CEREBR BLOOD F MET, V21, P195, DOI 10.1097/00004647-200103000-00002; Ebersberger A, 2001, ANN NEUROL, V49, P7, DOI 10.1002/1531-8249(200101)49:1<7::AID-ANA4>3.3.CO;2-B; EDVINSSON L, 1981, J PHYSIOL-LONDON, V318, P251; FEINDEL W, 1960, NEUROLOGY, V10, P555, DOI 10.1212/WNL.10.6.555; FERRARI MD, 1993, TRENDS PHARMACOL SCI, V14, P129, DOI 10.1016/0165-6147(93)90084-W; GOADSBY PJ, 1987, AM J PHYSIOL, V253, pR270, DOI 10.1152/ajpregu.1987.253.2.R270; GOBEL N, 2000, CEPHALALGIA, V20, P287; Grafstein B, 2000, ANN NEUROL, V47, P18, DOI 10.1002/1531-8249(200001)47:1<18::AID-ANA6>3.3.CO;2-E; Graham JR, 1938, ARCH NEURO PSYCHIATR, V39, P737, DOI 10.1001/archneurpsyc.1938.02270040093005; Hadjikhani N, 2001, P NATL ACAD SCI USA, V98, P4687, DOI 10.1073/pnas.071582498; HUNT SP, 1987, NATURE, V328, P632, DOI 10.1038/328632a0; KRAIG RP, 1978, NEUROSCIENCE, V3, P1045, DOI 10.1016/0306-4522(78)90122-7; KUSCHINSKY W, 1978, PHYSIOL REV, V58, P656, DOI 10.1152/physrev.1978.58.3.656; LAMBERT GA, 1984, J NEUROSURG, V61, P307, DOI 10.3171/jns.1984.61.2.0307; LAURITZEN M, 1984, BRAIN, V107, P447, DOI 10.1093/brain/107.2.447; LAURITZEN M, 1990, J CEREBR BLOOD F MET, V10, P115, DOI 10.1038/jcbfm.1990.14; Leao AA, 1944, J NEUROPHYSIOL, V7; LEE WS, 1994, BRIT J PHARMACOL, V112, P920, DOI 10.1111/j.1476-5381.1994.tb13168.x; LIUCHEN LY, 1983, NEUROSCIENCE, V9, P803, DOI 10.1016/0306-4522(83)90268-3; MARKOWITZ S, 1987, J NEUROSCI, V7, P4129, DOI 10.1523/jneurosci.07-12-04129.1987; MAYBERG M, 1981, SCIENCE, V213, P228, DOI 10.1126/science.6166046; MOSKOWITZ MA, 1988, HEADACHE, V28, P584, DOI 10.1111/j.1526-4610.1988.hed2809584.x; MOSKOWITZ MA, 1991, NEUROLOGY, V41, P182, DOI 10.1212/WNL.41.2_Part_1.182; MOSKOWITZ MA, 1984, ANN NEUROL, V16, P157, DOI 10.1002/ana.410160202; MOSKOWITZ MA, 1993, J NEUROSCI, V13, P1167, DOI 10.1523/jneurosci.13-03-01167.1993; OCONNOR TP, 1986, J NEUROSCI, V6, P2200; Penfield W, 1940, ARCH NEURO PSYCHIATR, V44, P43, DOI 10.1001/archneurpsyc.1940.02280070051003; Ray BS, 1940, ARCH SURG-CHICAGO, V41, P813, DOI 10.1001/archsurg.1940.01210040002001; Richter F, 1998, EUR J NEUROSCI, V10, P135; SPENCER SE, 1990, BRAIN RES, V534, P149, DOI 10.1016/0006-8993(90)90125-U; Strassman AM, 1996, NATURE, V384, P560, DOI 10.1038/384560a0; SUZUKI N, 1988, J CEREBR BLOOD F MET, V8, P697, DOI 10.1038/jcbfm.1988.117; SUZUKI N, 1989, NEUROSCIENCE, V31, P427, DOI 10.1016/0306-4522(89)90385-0; SUZUKI N, 1990, J CEREBR BLOOD F MET, V10, P383, DOI 10.1038/jcbfm.1990.68; SUZUKI N, 1990, ACTA PHYSIOL SCAND, V138, P307, DOI 10.1111/j.1748-1716.1990.tb08851.x; UDDMAN R, 1989, J AUTONOM NERV SYST, V26, P69, DOI 10.1016/0165-1838(89)90109-4; Williamson DJ, 1997, CEPHALALGIA, V17, P518, DOI 10.1046/j.1468-2982.1997.1704518.x; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765	45	830	884	0	80	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2002	8	2					136	142		10.1038/nm0202-136	http://dx.doi.org/10.1038/nm0202-136			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	517FN	11821897				2022-12-25	WOS:000173600600022
J	Herron, BJ; Lu, WN; Rao, C; Liu, SM; Peters, H; Bronson, RT; Justice, MJ; McDonald, JD; Beier, DR				Herron, BJ; Lu, WN; Rao, C; Liu, SM; Peters, H; Bronson, RT; Justice, MJ; McDonald, JD; Beier, DR			Efficient generation and mapping of recessive developmental mutations using ENU mutagenesis	NATURE GENETICS			English	Article							POLYCYSTIC KIDNEY-DISEASE; MOUSE MUTANT; GENOME-WIDE; GENE; MICE; ETHYLNITROSOUREA; DEFECTS	Treatment with N-ethyl-N-nitrosourea (ENU) efficiently generates single-nucleotide mutations in mice(1-3). Along with the renewed interest in this approach, much attention has been given recently to large screens with broad aims(4,5); however, more finely focused studies have proven very productive as well(6-8). Here we show how mutagenesis together with genetic mapping can facilitate the rapid characterization of recessive loci required for normal embryonic development. We screened third-generation progeny of mutagenized mice at embryonic day (E) 18.5 for abnormalities of organogenesis. We ascertained 15 monogenic mutations in the 54 families that were comprehensively analyzed. We carried out the experiment as an outcross, which facilitated the genetic mapping of the mutations by haplotype analysis. We mapped seven of the mutations and identified the affected locus in two lines. Using a hierarchical approach, it is possible to maximize the effciency of this analysis so that it can be carried out easily with modest infrastructure and resources.	Harvard Univ, Brigham & Womens Hosp, Div Genet, Sch Med, Boston, MA 02115 USA; Tufts Univ, Sch Vet Med, North Grafton, MA 01536 USA; Baylor Coll Med, Houston, TX 77030 USA; Wichita State Univ, Wichita, KS USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Tufts University; Baylor College of Medicine; Wichita State University	Beier, DR (corresponding author), Harvard Univ, Brigham & Womens Hosp, Div Genet, Sch Med, Boston, MA 02115 USA.			Lu, Weining/0000-0002-6570-3044				Beckers J, 2000, MECH DEVELOP, V95, P35, DOI 10.1016/S0925-4773(00)00323-3; BODE VC, 1988, GENETICS, V118, P299; Daniells C, 1998, HUM GENET, V102, P216, DOI 10.1007/s004390050681; de Angelis MH, 2000, NAT GENET, V25, P444, DOI 10.1038/78146; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; Eggenschwiler JT, 2001, NATURE, V412, P194, DOI 10.1038/35084089; Favor J, 2000, MAMM GENOME, V11, P520, DOI 10.1007/s003350010099; Hentges K, 1999, DEVELOPMENT, V126, P1601; Justice MJ, 1999, HUM MOL GENET, V8, P1955, DOI 10.1093/hmg/8.10.1955; Kasarskis A, 1998, P NATL ACAD SCI USA, V95, P7485, DOI 10.1073/pnas.95.13.7485; Kusumi K, 1998, NAT GENET, V19, P274, DOI 10.1038/961; Lu WN, 1997, NAT GENET, V17, P179, DOI 10.1038/ng1097-179; LUNA IJ, 1960, MANUAL HISTOLOGIC ST; MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306; Neuhaus IM, 1998, MAMM GENOME, V9, P150, DOI 10.1007/s003359900706; Nolan PM, 2000, NAT GENET, V25, P440, DOI 10.1038/78140; RUSSELL WL, 1982, P NATL ACAD SCI-BIOL, V79, P3592, DOI 10.1073/pnas.79.11.3592; RUSSELL WL, 1979, P NATL ACAD SCI USA, V76, P5818, DOI 10.1073/pnas.76.11.5818; Sporle R, 1996, DEVELOPMENT, V122, P79; Sporle R, 1998, DEV GENET, V22, P359, DOI 10.1002/(SICI)1520-6408(1998)22:4<359::AID-DVG6>3.0.CO;2-5; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; Turco AE, 1997, HUM MUTAT, V10, P164, DOI 10.1002/(SICI)1098-1004(1997)10:2<164::AID-HUMU9>3.3.CO;2-8; Wu GQ, 1998, CELL, V93, P177, DOI 10.1016/S0092-8674(00)81570-6	23	146	150	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2002	30	2					185	189		10.1038/ng812	http://dx.doi.org/10.1038/ng812			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	519CY	11818962				2022-12-25	WOS:000173708700019
J	Lemjabbar, H; Basbaum, C				Lemjabbar, H; Basbaum, C			Platelet-activating factor receptor and ADAM10 mediate responses to Staphylococcus aureus in epithelial cells	NATURE MEDICINE			English	Article							EPIDERMAL GROWTH-FACTOR; PROTEIN-COUPLED RECEPTORS; PSEUDOMONAS-AERUGINOSA; CYSTIC-FIBROSIS; STREPTOCOCCUS-PNEUMONIAE; INTESTINAL MUCIN; EGF RECEPTOR; LUNG; TRANSACTIVATION; SEQUESTRATION	In the lungs of cystic fibrosis patients, overproduction of mucus leads to morbidity and mortality by obstructing airflow and shielding bacteria from antibiotics. Here we demonstrate that overproduction of mucus is a direct result of the activation of mucin gene expression by Grampositive bacteria. Bacterial lipoteichoic acid activates the platelet-activating factor receptor, which is G protein-coupled. This results in activation of a disintegrin and metalloproteinase (ADAM10), kuzbanian, cleavage of pro heparin-binding epidermal growth factor and activation of the epidermal growth factor receptor. Unlike responses in macrophages, the epithelial-cell response to lipoteichoic acid does not require Toll-like receptor 2 or 4.	Univ Calif San Francisco, Program Biomed Sci, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Basbaum, C (corresponding author), Univ Calif San Francisco, Program Biomed Sci, Cardiovasc Res Inst, San Francisco, CA 94143 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024136] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43726, HL24136] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Albert DH, 1996, SHOCK, V6, P112, DOI 10.1097/00024382-199608000-00006; BOAT TF, 1994, TXB RESP MED, P1418; CUNDELL DR, 1995, NATURE, V377, P435, DOI 10.1038/377435a0; Cundell DR, 1996, ADV EXP MED BIOL, V416, P89; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Dohrman A, 1998, BBA-MOL BASIS DIS, V1406, P251, DOI 10.1016/S0925-4439(98)00010-6; FINKBEINER WE, 1988, AM J PATHOL, V131, P290; Gum JR, 1997, BIOCHEM J, V325, P259, DOI 10.1042/bj3250259; GUM JR, 1992, J BIOL CHEM, V267, P21375; Guzman K, 1995, BIOCHEM BIOPH RES CO, V217, P412, DOI 10.1006/bbrc.1995.2792; Hardie WD, 1999, PEDIATR DEVEL PATHOL, V2, P415, DOI 10.1007/s100249900144; Ishii I, 1998, J BIOL CHEM, V273, P9878, DOI 10.1074/jbc.273.16.9878; KUAN SF, 1987, CANCER RES, V47, P5715; Li JD, 1998, P NATL ACAD SCI USA, V95, P5718, DOI 10.1073/pnas.95.10.5718; Li JD, 1997, P NATL ACAD SCI USA, V94, P967, DOI 10.1073/pnas.94.3.967; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Michelsen KS, 2001, J BIOL CHEM, V276, P25680, DOI 10.1074/jbc.M011615200; Mograbi B, 1997, EUR CYTOKINE NETW, V8, P73; Oliver A, 2000, SCIENCE, V288, P1251, DOI 10.1126/science.288.5469.1251; Opitz B, 2001, J BIOL CHEM, V276, P22041, DOI 10.1074/jbc.M010481200; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; STAHLMAN MT, 1988, LAB INVEST, V59, P25; STGEORGE JA, 1991, AM J RESP CELL MOL, V4, P95, DOI 10.1165/ajrcmb/4.2.95; Taddei F, 1997, NATURE, V387, P700, DOI 10.1038/42696; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Takeyama K, 1999, P NATL ACAD SCI USA, V96, P3081, DOI 10.1073/pnas.96.6.3081; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279	30	269	283	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2002	8	1					41	46		10.1038/nm0102-41	http://dx.doi.org/10.1038/nm0102-41			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	507XQ	11786905				2022-12-25	WOS:000173056900029
J	Tsui, LV; Kelly, M; Zayek, N; Rojas, V; Ho, K; Ge, Y; Moskalenko, M; Mondesire, J; Davis, J; Van Roey, M; Dull, T; McArthur, JG				Tsui, LV; Kelly, M; Zayek, N; Rojas, V; Ho, K; Ge, Y; Moskalenko, M; Mondesire, J; Davis, J; Van Roey, M; Dull, T; McArthur, JG			Production of human clotting Factor IX without toxicity in mice after vascular delivery of a lentiviral vector	NATURE BIOTECHNOLOGY			English	Article							MEDIATED GENE-TRANSFER; LONG-TERM EXPRESSION; IN-VIVO; NONDIVIDING CELLS; FACTOR-VIII; EFFICIENT; TRANSDUCTION; LIVER; REQUIREMENTS; TRANSGENE	Replication-deficient lentiviral vectors (LV) have been shown to enable the stable genetic modification of multiple cell types in vivo. We demonstrate here that vascular and hepatic delivery of a third-generation HIV-derived lentiviral vector encoding human Factor IX (LV-hFIX) produced potentially therapeutic serum levels of hFIX protein with no vector-mediated local or systemic toxicity of adult mice. Portal vein administration produced the highest serum levels of hFIX and demonstrated proportionally higher levels of gene transfer to the liver with up to 4% of hepatocytes expressing hFIX Vascular delivery of a lentiviral vector encoding GFP resulted in genetic modification of up to 12% of liver cells. Cell proliferation was not required for hepatocyte transduction with either vector, Serum hFIX levels reached 4% of normal levels following vascular LV-mediated hFIX gene transfer and remained stable for months following vector administration.	Cell Genesys Inc, Foster City, CA 94404 USA	Cell Genesys Inc	McArthur, JG (corresponding author), Cell Genesys Inc, 342 Lakeside Dr, Foster City, CA 94404 USA.	jamesm@cellgenesys.com						Blomer U, 1997, J VIROL, V71, P6641; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; GANSBACHER B, 1990, J EXP MED, V172, P1217, DOI 10.1084/jem.172.4.1217; Gasmi M, 1999, J VIROL, V73, P1828, DOI 10.1128/JVI.73.3.1828-1834.1999; Ge Y, 2001, BLOOD, V97, P3733, DOI 10.1182/blood.V97.12.3733; Johnston JC, 1999, J VIROL, V73, P4991, DOI 10.1128/JVI.73.6.4991-5000.1999; Lipshutz GS, 2001, MOL THER, V3, P284, DOI 10.1006/mthe.2001.0267; McCormack JE, 2001, MOL THER, V3, P516, DOI 10.1006/mthe.2000.0259; MCGUINNESS R, 1996, HUM GENE THER, V9, P165; Naldini L, 1996, P NATL ACAD SCI USA, V93, P11382, DOI 10.1073/pnas.93.21.11382; Naldini L, 1998, CURR OPIN BIOTECH, V9, P457, DOI 10.1016/S0958-1669(98)80029-3; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Nguyen KHY, 1998, J RHEUMATOL, V25, P1118; Park F, 2000, BLOOD, V96, P1173, DOI 10.1182/blood.V96.3.1173.015k34_1173_1176; Park F, 2000, NAT GENET, V24, P49, DOI 10.1038/71673; Patijn GA, 1998, HUM GENE THER, V9, P1449, DOI 10.1089/hum.1998.9.10-1449; Patijn GA, 1998, HEPATOLOGY, V28, P707, DOI 10.1002/hep.510280317; Pfeifer A, 2001, MOL THER, V3, P319, DOI 10.1006/mthe.2001.0276; ROBERTS MR, 1994, BLOOD, V84, P2878; Snyder RO, 1997, NAT GENET, V16, P270, DOI 10.1038/ng0797-270; WION KL, 1985, NATURE, V317, P726, DOI 10.1038/317726a0; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998; Zufferey R, 1999, J VIROL, V73, P2886, DOI 10.1128/JVI.73.4.2886-2892.1999	25	52	59	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2002	20	1					53	57		10.1038/nbt0102-53	http://dx.doi.org/10.1038/nbt0102-53			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	507ME	11753362				2022-12-25	WOS:000173031600036
J	Bakre, MM; Zhu, YH; Yin, H; Burton, DW; Terkeltaub, R; Deftos, LJ; Varner, JA				Bakre, MM; Zhu, YH; Yin, H; Burton, DW; Terkeltaub, R; Deftos, LJ; Varner, JA			Parathyroid hormone-related peptide is a naturally occurring, protein kinase A-dependent angiogenesis inhibitor	NATURE MEDICINE			English	Article							VASCULAR SMOOTH-MUSCLE; ENDOCHONDRAL BONE-FORMATION; SIGNAL-TRANSDUCTION; CELL-MIGRATION; BREAST-CANCER; RECEPTOR; GROWTH; CARTILAGE; APOPTOSIS; MICE	Angiogenesis is a highly regulated process that results from the sequential actions of naturally occurring stimulators and inhibitors. Here, we show that parathyroid hormone-related peptide, a peptide hormone derived from normal and tumor cells that regulates bone metabolism and vascular tone, is a naturally occurring angiogenesis inhibitor. Parathyroid hormone-related peptide or a ten-amino-acid peptide from its N terminus inhibits endothelial cell migration in vitro and angiogenesis in vivo by activating endothelial cell protein kinase A. Activation of protein kinase A inhibits cell migration and angiogenesis by inhibiting the small GTPase Rac. In contrast, inhibition of protein kinase A reverses the anti-migratory and anti-angiogenic properties of parathyroid hormone-related peptide. These studies show that parathyroid hormone-related peptide is a naturally occurring angiogenesis inhibitor that functions by activation of protein kinase A.	Univ Calif San Diego, Ctr Comprehens Canc, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Vet Affairs Med Ctr, La Jolla, CA USA	University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Varner, JA (corresponding author), Univ Calif San Diego, Ctr Comprehens Canc, La Jolla, CA 92093 USA.			Varner, Judith/0000-0002-9251-0600	NATIONAL CANCER INSTITUTE [R01CA083133, R01CA071619] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060588] Funding Source: NIH RePORTER; NCI NIH HHS [CA71619, CA83133] Funding Source: Medline; NIAMS NIH HHS [AR47347] Funding Source: Medline; NIDDK NIH HHS [DK60588] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABDEEN O, 1995, AM J GASTROENTEROL, V90, P1864; ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; Akino K, 2000, ENDOCRINOLOGY, V141, P4313, DOI 10.1210/en.141.11.4313; AMIZUKA N, 1994, J CELL BIOL, V126, P1611, DOI 10.1083/jcb.126.6.1611; BRINGHURST FR, 1993, ENDOCRINOLOGY, V132, P2090, DOI 10.1210/en.132.5.2090; BRINGHURST FR, 1998, WILLIAMS TXB ENDOCRI, P1155; BUKOSKI RD, 1995, SEMIN NEPHROL, V15, P536; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Dong JM, 1998, J BIOL CHEM, V273, P22554, DOI 10.1074/jbc.273.35.22554; Dormond O, 2001, NAT MED, V7, P1041, DOI 10.1038/nm0901-1041; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gasparini G, 1998, CLIN CANCER RES, V4, P2625; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; Guijal A., 2001, CANCER RES, V61, P2282; Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947; HANSON AS, 1994, HYPERTENSION, V23, P468, DOI 10.1161/01.HYP.23.4.468; Hoare SRJ, 2001, J BIOL CHEM, V276, P7741, DOI 10.1074/jbc.M009395200; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Howe AK, 2000, NAT CELL BIOL, V2, P593, DOI 10.1038/35023536; Ishikawa M, 1998, ATHEROSCLEROSIS, V136, P59, DOI 10.1016/S0021-9150(97)00187-1; IWAMOTO M, 1994, J BIOL CHEM, V269, P17245; Jiang BB, 1998, J CARDIOVASC PHARM, V31, pS142, DOI 10.1097/00005344-199800001-00042; Jin L, 2000, J BIOL CHEM, V275, P27238; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; Kim S, 2000, J BIOL CHEM, V275, P33920, DOI 10.1074/jbc.M003668200; Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5; Lanske B, 1999, J CLIN INVEST, V104, P399, DOI 10.1172/JCI6629; Maeda S, 1999, ENDOCRINOLOGY, V140, P1815, DOI 10.1210/en.140.4.1815; Maeshima Y, 2001, J BIOL CHEM, V276, P15240, DOI 10.1074/jbc.M007764200; Morikawa S, 2002, AM J PATHOL, V160, P985, DOI 10.1016/S0002-9440(10)64920-6; Moseley J. M., 1996, P363; NICKOLS GA, 1989, ENDOCRINOLOGY, V125, P834, DOI 10.1210/endo-125-2-834; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Padmanabhan J, 1999, J NEUROBIOL, V39, P407, DOI 10.1002/(SICI)1097-4695(19990605)39:3<407::AID-NEU7>3.0.CO;2-S; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Shimizu M, 2000, J BIOL CHEM, V275, P21836, DOI 10.1074/jbc.M909861199; Terkeltaub R, 1998, ARTHRITIS RHEUM-US, V41, P2152, DOI 10.1002/1529-0131(199812)41:12<2152::AID-ART10>3.3.CO;2-O; Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451; Varner J A, 1997, EXS, V79, P361; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Yoneda T, 1998, EUR J CANCER, V34, P240, DOI 10.1016/S0959-8049(97)10132-0	45	81	87	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2002	8	9					995	1003		10.1038/nm753	http://dx.doi.org/10.1038/nm753			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	589KQ	12185361				2022-12-25	WOS:000177757900035
J	Geisbrecht, ER; Montell, DJ				Geisbrecht, ER; Montell, DJ			Myosin VI is required for E-cadherin-mediated border cell migration	NATURE CELL BIOLOGY			English	Article							UNCONVENTIONAL MYOSIN; DROSOPHILA OOGENESIS; ARMADILLO; COMPLEX; PROTEIN; GENETICS; ADHESION; POLARITY; HOMOLOG	Myosin VI (MyoVI) is a pointed-end-directed, actin-based motor protein(1,2), and mutations in the gene result in disorganization of hair cell stereocilia and cause deafness in mice(3). MyoVI also localizes to the leading edges of growth-factor-stimulated fibroblast cells(4) and has been suggested to be involved in cell motility(5). There has been no direct test of this hypothesis, however. Drosophila melanogaster MyoVI is expressed in a small group of migratory follicle cells, known as border cells. Here we show that depletion of MyoVI specifically from border cells severely inhibited their migration. Similar to MyoVI, E-cadherin is required for border cell migration. We found that E-cadherin and Armadillo (Arm, Drosophila beta-catenin) protein levels were specifically reduced in cells lacking MyoVI, whereas other proteins were not. In addition, MyoVI protein levels were reduced in cells lacking DE-cadherin or Arm. MyoVI and Arm co-immunoprecipitated from ovarian protein extracts. These data suggest that MyoVI is required for border cell migration where it stabilizes E-cadherin and Arm. Mutations in MyoVIIA, another unconventional myosin protein, also lead to deafness, and MyoVIIA interacts with E-cadherin through a membrane protein called vezatin(6). Multiple biochemical mechanisms may exist, therefore, for cadherins to associate with diverse unconventional myosins that are required for normal stereocilium formation or maintenance.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University	Montell, DJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe ST, Baltimore, MD 21205 USA.				NIGMS NIH HHS [GM46425] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046425, R01GM046425] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bai JW, 2000, CELL, V103, P1047, DOI 10.1016/S0092-8674(00)00208-7; Buss F, 2001, EMBO J, V20, P3676, DOI 10.1093/emboj/20.14.3676; Buss F, 1998, J CELL BIOL, V143, P1535, DOI 10.1083/jcb.143.6.1535; Deng WM, 1999, J CELL SCI, V112, P3677; Friedman TB, 1999, AM J MED GENET, V89, P147, DOI 10.1002/(SICI)1096-8628(19990924)89:3<147::AID-AJMG5>3.0.CO;2-6; Hicks JL, 1999, MOL BIOL CELL, V10, P4341, DOI 10.1091/mbc.10.12.4341; Kussel-Andermann P, 2000, EMBO J, V19, P6020, DOI 10.1093/emboj/19.22.6020; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MERMALL V, 1995, J CELL BIOL, V129, P1575, DOI 10.1083/jcb.129.6.1575; MONTELL DJ, 1992, CELL, V71, P51, DOI 10.1016/0092-8674(92)90265-E; Montell DJ, 2001, MECH DEVELOP, V105, P19, DOI 10.1016/S0925-4773(01)00393-8; Murphy AM, 1996, J CELL BIOL, V133, P617, DOI 10.1083/jcb.133.3.617; Niewiadomska P, 1999, J CELL BIOL, V144, P533, DOI 10.1083/jcb.144.3.533; ODA H, 1994, DEV BIOL, V165, P716, DOI 10.1006/dbio.1994.1287; Palmer RH, 1999, J BIOL CHEM, V274, P35621, DOI 10.1074/jbc.274.50.35621; PEIFER M, 1993, J CELL SCI, V105, P993; Rodriguez OC, 2000, TRENDS CELL BIOL, V10, P307, DOI 10.1016/S0962-8924(00)01797-9; Rorth P, 1998, DEVELOPMENT, V125, P1049; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; Silver DL, 2001, CELL, V107, P831, DOI 10.1016/S0092-8674(01)00607-9; Spradling Allan C., 1993, P1; Titus MA, 2000, CURR BIOL, V10, pR294, DOI 10.1016/S0960-9822(00)00433-4; Wells AL, 1999, NATURE, V401, P505, DOI 10.1038/46835	24	176	178	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2002	4	8					616	620		10.1038/ncb830	http://dx.doi.org/10.1038/ncb830			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	579WK	12134162				2022-12-25	WOS:000177201100018
J	Weiner, OD; Neilsen, PO; Prestwich, GD; Kirschner, MW; Cantley, LC; Bourne, HR				Weiner, OD; Neilsen, PO; Prestwich, GD; Kirschner, MW; Cantley, LC; Bourne, HR			A PtdInsP(3)- and Rho GTPase-mediated positive feedback loop regulates neutrophil polarity	NATURE CELL BIOLOGY			English	Article							PHOSPHOINOSITIDE 3-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; CHEMOATTRACTANT RECEPTOR; SIGNAL-TRANSDUCTION; CELL MOTILITY; LIVING CELLS; ACTIVATION; CHEMOTAXIS; PROTEIN; KINASE	When presented with a gradient of chemoattractant, many eukaryotic cells respond with polarized accumulation of the phospholipid PtdIns( 3,4,5) P-3. This lipid asymmetry is one of the earliest readouts of polarity in neutrophils, Dictyostelium discoideum and fibroblasts. However, the mechanisms that regulate PtdInsP(3) polarization are not well understood. Using a cationic lipid shuttling system, we have delivered exogenous PtdInsP(3) to neutrophils. Exogenous PtdInsP(3) elicits accumulation of endogenous PtdInsP(3) in a positive feedback loop that requires endogenous phosphatidylinositol-3-OH kinases (PI(3) Ks) and Rho family GTPases. This feedback loop is important for establishing PtdInsP(3) polarity in response to both chemoattractant and to exogenous PtdInsP(3); it may function through a self-organizing pattern formation system. Emergent properties of positive and negative regulatory links between PtdInsP(3) and Rho family GTPases may constitute a broadly conserved module for the establishment of cell polarity during eukaryotic chemotaxis.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Cell Biol,Div Signal Transduct, Boston, MA 02215 USA; Echelon Res Labs, Salt Lake City, UT 84108 USA; Univ Utah, Dept Med Chem, Salt Lake City, UT 84108 USA	University of California System; University of California San Francisco; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Utah System of Higher Education; University of Utah	Bourne, HR (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA.		Cantley, Lewis C/D-1800-2014; Weiner, Orion D/F-2576-2011	Cantley, Lewis C/0000-0002-1298-7653; Weiner, Orion D/0000-0002-1778-6543	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890, R44GM062734, R01GM026875, R37GM041890] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029632] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41890, GM62734-03, GM26825, R01 GM026875-25, R37 GM041890, R01 GM041890, R01 GM026875] Funding Source: Medline; NINDS NIH HHS [R01 NS029632, NS29632] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bokoch GM, 1996, BIOCHEM J, V315, P775, DOI 10.1042/bj3150775; Carpenter CL, 1997, ADV ENZYME REGUL, V37, P377, DOI 10.1016/S0065-2571(96)00005-2; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; Funamoto S, 2001, J CELL BIOL, V153, P795, DOI 10.1083/jcb.153.4.795; Genot EM, 2000, MOL CELL BIOL, V20, P5469, DOI 10.1128/MCB.20.15.5469-5478.2000; Gulli MP, 2000, MOL CELL, V6, P1155, DOI 10.1016/S1097-2765(00)00113-1; Haugh JM, 2000, J CELL BIOL, V151, P1269, DOI 10.1083/jcb.151.6.1269; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Jin T, 2000, SCIENCE, V287, P1034, DOI 10.1126/science.287.5455.1034; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Liu QR, 1999, GENE DEV, V13, P786, DOI 10.1101/gad.13.7.786; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; Meinhardt H, 2000, BIOESSAYS, V22, P753, DOI 10.1002/1521-1878(200008)22:8<753::AID-BIES9>3.0.CO;2-Z; Niggli V, 2000, FEBS LETT, V473, P217, DOI 10.1016/S0014-5793(00)01534-9; Niggli V, 1997, EUR J PHARMACOL, V335, P43, DOI 10.1016/S0014-2999(97)01169-2; Ozaki S, 2000, P NATL ACAD SCI USA, V97, P11286, DOI 10.1073/pnas.210197897; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Servant G, 1999, MOL BIOL CELL, V10, P1163, DOI 10.1091/mbc.10.4.1163; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; Weiner OD, 1999, NAT CELL BIOL, V1, P75, DOI 10.1038/10042; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; Xiao Z, 1997, J CELL BIOL, V139, P365, DOI 10.1083/jcb.139.2.365; Yang FC, 2000, IMMUNITY, V12, P557, DOI 10.1016/S1074-7613(00)80207-1; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	30	423	434	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	2002	4	7					509	512		10.1038/ncb811	http://dx.doi.org/10.1038/ncb811			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	568UL	12080346	Green Accepted			2022-12-25	WOS:000176562900015
J	Grant, MB; May, WS; Caballero, S; Brown, GAJ; Guthrie, SM; Mames, RN; Byrne, BJ; Vaught, T; Spoerri, PE; Peck, AB; Scott, EW				Grant, MB; May, WS; Caballero, S; Brown, GAJ; Guthrie, SM; Mames, RN; Byrne, BJ; Vaught, T; Spoerri, PE; Peck, AB; Scott, EW			Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization	NATURE MEDICINE			English	Article							ENDOTHELIAL PROGENITOR CELLS; BONE-MARROW CELLS; POSTNATAL NEOVASCULARIZATION; DIABETIC-RETINOPATHY; BLOOD; TRANSPLANTATION; ANGIOGENESIS; ENGRAFTMENT; MYOCARDIUM; PHENOTYPE	Adults maintain a reservoir of hematopoietic stem cells that can enter the circulation to reach organs in need of regeneration. We developed a novel model of retinal neovascularization in adult mice to examine the role of hematopoietic stem cells in revascularizing ischemic retinas. Adult mice were durably engrafted with hematopoietic stem cells isolated from transgenic mice expressing green fluorescent protein. We performed serial long-term transplants, to ensure activity arose from self-renewing stem cells, and single hematopoietic stem-cell transplants to show clonality. After durable hematopoietic engraftment was established, retinal ischemia was induced to promote neovascularization. Our results indicate that self-renewing adult hematopoietic stem cells have functional hemangioblast activity, that is, they can clonally differentiate into all hematopoietic cell lineages as well as endothelial cells that revascularize adult retina. We also show that recruitment of endothelial precursors to sites of ischemic injury has a significant role in neovascularization.	Univ Florida, Program Stem Cell Biol, Gainesville, FL 32611 USA; Univ Florida, Dept Pharmacol & Therapeut, Gainesville, FL USA; Univ Florida, Shands Canc Ctr, Gainesville, FL USA; Univ Florida, McKnight Brain Inst, Gainesville, FL USA; Univ Florida, Dept Pathol, Gainesville, FL 32611 USA; Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL USA; Retina Ctr, Gainesville, FL USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Grant, MB (corresponding author), Univ Florida, Program Stem Cell Biol, Gainesville, FL 32611 USA.				NCI NIH HHS [CA72769] Funding Source: Medline; NEI NIH HHS [EY012601, EY007739] Funding Source: Medline; NIDDK NIH HHS [DK52558] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072769] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY007739, R01EY012601, R29EY007739] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK052558] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; Beck L, 1997, FASEB J, V11, P365, DOI 10.1096/fasebj.11.5.9141503; Bhattacharya V, 2000, BLOOD, V95, P581, DOI 10.1182/blood.V95.2.581; Choi K, 1998, BIOCHEM CELL BIOL, V76, P947, DOI 10.1139/bcb-76-6-947; Cilloni D, 2000, BLOOD, V96, P3637; Crosby JR, 2000, CIRC RES, V87, P728, DOI 10.1161/01.RES.87.9.728; Devine SM, 2001, EXP HEMATOL, V29, P244, DOI 10.1016/S0301-472X(00)00635-4; Dimmeler S, 2001, J CLIN INVEST, V108, P391, DOI 10.1172/JCI200113152; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FRANK RN, 1991, OPHTHALMOLOGY, V98, P586; Gehling UM, 2000, BLOOD, V95, P3106; Goodell MA, 2001, ANN NY ACAD SCI, V938, P208; GRANT M, 1986, DIABETES, V35, P416, DOI 10.2337/diabetes.35.4.416; HARRISON DE, 1993, EXP HEMATOL, V21, P206; JORDAN CT, 1990, GENE DEV, V4, P220, DOI 10.1101/gad.4.2.220; Kalka C, 2000, CIRC RES, V86, P1198, DOI 10.1161/01.RES.86.12.1198; Kawamoto A, 2001, CIRCULATION, V103, P634; Koc ON, 2000, J CLIN ONCOL, V18, P307, DOI 10.1200/JCO.2000.18.2.307; Koc ON, 1999, EXP HEMATOL, V27, P1675, DOI 10.1016/S0301-472X(99)00101-0; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Limb GA, 1996, BRIT J OPHTHALMOL, V80, P168, DOI 10.1136/bjo.80.2.168; Lin Y, 2000, J CLIN INVEST, V105, P71, DOI 10.1172/JCI8071; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Mosca JD, 2000, CLIN ORTHOP RELAT R, pS71; MULLERSIEBURG C, 1992, HEMATOPOIETIC STEM C; Murohara T, 2000, J CLIN INVEST, V105, P1527, DOI 10.1172/JCI8296; NODEN DM, 1989, AM REV RESPIR DIS, V140, P1097, DOI 10.1164/ajrccm/140.4.1097; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Sharkis SJ, 2001, ANN NY ACAD SCI, V938, P191; SIMMONS PJ, 1987, NATURE, V328, P429, DOI 10.1038/328429a0; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Takakura N, 2000, CELL, V102, P199, DOI 10.1016/S0092-8674(00)00025-8; VONBEKKUM DW, 1967, RAD CHIMERAS	37	537	592	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2002	8	6					607	612		10.1038/nm0602-607	http://dx.doi.org/10.1038/nm0602-607			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	557KG	12042812				2022-12-25	WOS:000175907300032
J	Gu, X; Wang, YF; Gu, JY				Gu, X; Wang, YF; Gu, JY			Age distribution of human gene families shows significant roles of both large- and small-scale duplications in vertebrate evolution	NATURE GENETICS			English	Article							GENOME DUPLICATIONS; DIVERGENCE; HYPOTHESIS; SEQUENCE; SUPPORT; REGIONS; TREES; RULE	The classical (two-round) hypothesis(1) of vertebrate genome duplication proposes two successive whole-genome duplication( s) (polyploidizations) predating the origin of fishes, a view now being seriously challenged(2-7). As the debate largely concerns the relative merits of the 'big-bang mode' theory(8-13) (large-scale duplication) and the 'continuous mode' theory (constant creation by small-scale duplications)(2-7,14), we tested whether a significant proportion of paralogous genes in the contemporary human genome was indeed generated in the early stage of vertebrate evolution. After an extensive search of major databases, we dated 1,739 gene duplication events from the phylogenetic analysis of 749 vertebrate gene families. We found a pattern characterized by two waves (I, II) and an ancient component. Wave I represents a recent gene family expansion by tandem or segmental duplications(15), whereas wave II, a rapid paralogous gene increase in the early stage of vertebrate evolution, supports the idea of genome duplication( s) (the big-bang mode). Further analysis indicated that large- and small-scale gene duplications both make a significant contribution during the early stage of vertebrate evolution to build the current hierarchy of the human proteome.	Iowa State Univ, Dept Zool & Genet, Ames, IA 50011 USA; Iowa State Univ, LHB Ctr Bioinformat & Biol Stat, Ames, IA 50011 USA; ATCC, Dept Bioinformat, Manassas, VA USA	Iowa State University; Iowa State University	Gu, X (corresponding author), Iowa State Univ, Dept Zool & Genet, Ames, IA 50011 USA.	xgu@iastate.edu		Wang, Yufeng/0000-0002-9959-4149				Eichler EE, 2001, TRENDS GENET, V17, P661, DOI 10.1016/S0168-9525(01)02492-1; Fishman MC, 2001, SCIENCE, V294, P1290, DOI 10.1126/science.1066652; Hughes AL, 1999, J MOL EVOL, V48, P565, DOI 10.1007/PL00006499; Hughes AL, 2001, GENOME RES, V11, P771, DOI 10.1101/gr.GR-1600R; Iwabe N, 1996, MOL BIOL EVOL, V13, P483, DOI 10.1093/oxfordjournals.molbev.a025609; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li WH, 2001, NATURE, V409, P847, DOI 10.1038/35057039; Long MY, 2001, SCIENCE, V293, P1551; Lopreato GF, 2001, P NATL ACAD SCI USA, V98, P7588, DOI 10.1073/pnas.131171798; LUNDIN LG, 1993, GENOMICS, V16, P1, DOI 10.1006/geno.1993.1133; Lynch M, 2000, SCIENCE, V290, P1151, DOI 10.1126/science.290.5494.1151; Martin A, 2001, MOL BIOL EVOL, V18, P89, DOI 10.1093/oxfordjournals.molbev.a003723; McLysaght A, 2002, NAT GENET, V31, P200, DOI 10.1038/ng884; Meyer A, 1999, CURR OPIN CELL BIOL, V11, P699, DOI 10.1016/S0955-0674(99)00039-3; Nadeau JH, 1997, GENETICS, V147, P1259; Nei M, 1997, P NATL ACAD SCI USA, V94, P7799, DOI 10.1073/pnas.94.15.7799; Nei M, 2001, P NATL ACAD SCI USA, V98, P2497, DOI 10.1073/pnas.051611498; Nikoh N, 1997, J MOL EVOL, V45, P97, DOI 10.1007/PL00006208; Ohno S., 1970, EVOLUTION GENE DUPLI; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SCHUGHART K, 1989, P NATL ACAD SCI USA, V86, P7067, DOI 10.1073/pnas.86.18.7067; Sidow A, 1996, CURR OPIN GENET DEV, V6, P715, DOI 10.1016/S0959-437X(96)80026-8; Spring J, 1997, FEBS LETT, V400, P2, DOI 10.1016/S0014-5793(96)01351-8; TAKEZAKI N, 1995, MOL BIOL EVOL, V12, P823; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wang YF, 2000, J MOL EVOL, V51, P88, DOI 10.1007/s002390010069; Wolfe KH, 2001, NAT REV GENET, V2, P333, DOI 10.1038/35072009; Xun G, 1998, J MOL EVOL, V47, P369, DOI 10.1007/PL00013150	30	202	212	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2002	31	2					205	209		10.1038/ng902	http://dx.doi.org/10.1038/ng902			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	557HR	12032571				2022-12-25	WOS:000175903500020
J	Gottlieb, PD; Pierce, SA; Sims, RJ; Yamagishi, H; Weihe, EK; Harriss, JV; Maika, SD; Kuziel, WA; King, HL; Olson, EN; Nakagawa, O; Srivastava, D				Gottlieb, PD; Pierce, SA; Sims, RJ; Yamagishi, H; Weihe, EK; Harriss, JV; Maika, SD; Kuziel, WA; King, HL; Olson, EN; Nakagawa, O; Srivastava, D			Bop encodes a muscle-restricted protein containing MYND and SET domains and is essential for cardiac differentiation and morphogenesis	NATURE GENETICS			English	Article							LIGHT CHAIN-2 EXPRESSION; DEVELOPING HEART; CHROMATIN STRUCTURE; MOUSE CD8B; TRANSCRIPTION; DHAND; METHYLTRANSFERASES; SPECIFICATION; LEUKEMIA; SUBCLASS	Many transcription factors regulate specific temporal-spatial events during cardiac differentiation; however, the mechanisms that regulate such events are largely unknown. Using a modified subtractive hybridization method to identify specific genes that influence early cardiac development, we found that Bop is expressed specifically in cardiac and skeletal muscle precursors before differentiation of these lineages. Bop encodes a protein containing MYND and SET domains, which have been shown to regulate transcription by mediating distinct chromatin modifications. We show that m-Bop is a histone deacetylase-dependent transcriptional repressor. Targeted deletion of Bop in mice disrupted maturation of ventricular cardiomyocytes and interfered with formation of the right ventricle. Normal expression of Hand2, a transcription factor essential for right ventricular development, in cardiomyocyte precursors is dependent upon m-Bop. These results indicate that m-Bop is essential for cardiomyocyte differentiation and cardiac morphogenesis.	Univ Texas, Sect Mol Genet & Microbiol, Austin, TX 78712 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA; Univ Texas, SW Med Ctr, Dept Pediat Cardiol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gottlieb, PD (corresponding author), Univ Texas, Sect Mol Genet & Microbiol, Austin, TX 78712 USA.		Yamagishi, Hiroyuki/A-6345-2017					Bao ZZ, 1999, SCIENCE, V283, P1161, DOI 10.1126/science.283.5405.1161; BERNANKE DH, 1984, DEV BIOL, V106, P360, DOI 10.1016/0012-1606(84)90234-3; Biben C, 1997, GENE DEV, V11, P1357, DOI 10.1101/gad.11.11.1357; Bruneau BG, 1999, DEV BIOL, V211, P100, DOI 10.1006/dbio.1999.9298; Bruneau BG, 2000, DEV BIOL, V217, P266, DOI 10.1006/dbio.1999.9548; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Firulli AB, 1997, TRENDS GENET, V13, P364, DOI 10.1016/S0168-9525(97)01171-2; Fishman MC, 1997, DEVELOPMENT, V124, P2099; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; GREEN SJ, 1988, J CELL SCI, V90, P145; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HURLE JM, 1980, J EMBRYOL EXP MORPH, V56, P211; Hwang I, 1997, J IMMUNOL, V158, P1165; HWANG I, 1995, IMMUNOGENETICS, V42, P353, DOI 10.1007/BF00179396; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jenuwein T, 2001, TRENDS CELL BIOL, V11, P266, DOI 10.1016/S0962-8924(01)02001-3; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; KUBALAK SW, 1994, J BIOL CHEM, V269, P16961; LINTS TJ, 1993, DEVELOPMENT, V119, P419; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; Marmorstein R, 2001, CURR OPIN GENET DEV, V11, P155, DOI 10.1016/S0959-437X(00)00173-8; McFadden DG, 2000, DEVELOPMENT, V127, P5331; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Nakagawa O, 1999, DEV BIOL, V216, P72, DOI 10.1006/dbio.1999.9454; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; OBRIEN TX, 1993, P NATL ACAD SCI USA, V90, P5157, DOI 10.1073/pnas.90.11.5157; Pereira FA, 1999, GENE DEV, V13, P1037, DOI 10.1101/gad.13.8.1037; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; SRIVASTAVA D, 1995, SCIENCE, V270, P1995, DOI 10.1126/science.270.5244.1995; Srivastava D, 2000, NATURE, V407, P221, DOI 10.1038/35025190; Srivastava D, 1997, NAT GENET, V16, P154, DOI 10.1038/ng0697-154; Yamagishi H, 1999, SCIENCE, V283, P1158, DOI 10.1126/science.283.5405.1158; Yamagishi H, 2001, DEV BIOL, V239, P190, DOI 10.1006/dbio.2001.0417; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510	38	235	247	2	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2002	31	1					25	32		10.1038/ng866	http://dx.doi.org/10.1038/ng866			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	547ZF	11923873	Bronze			2022-12-25	WOS:000175362500010
J	Rape, M; Jentsch, M				Rape, M; Jentsch, M			Taking a bite: proteasomal protein processing	NATURE CELL BIOLOGY			English	Editorial Material							NF-KAPPA-B; NF-KAPPA-B1 PRECURSOR PROTEIN; GLYCINE-RICH REGION; CUBITUS-INTERRUPTUS; P50; P105; GENERATION; HEDGEHOG; TRANSCRIPTION; PROTEOLYSIS	The proteasome is a hollow cylindrical protease that contains active sites concealed within its central cavity. Proteasomes usually completely degrade substrates into small peptides, but in a few cases, degradation can yield biologically active protein fragments. Examples of this are the transcription factors NF-kappaB, Spt23p and Mga2p, which are generated from precursors by proteasomal processing. How distinct protein domains are spared from degradation remains a matter of debate. Here, we discuss several models and suggest a novel mechanism for proteasomal processing.	Max Planck Inst Biochem, Dept Mol Cell Biol, D-82152 Martinsried, Germany	Max Planck Society	Rape, M (corresponding author), Max Planck Inst Biochem, Dept Mol Cell Biol, Klopferspitz 18A, D-82152 Martinsried, Germany.	jentsch@biochem.mpg.de		Rape, Michael/0000-0003-4849-6343				AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Betts JC, 1996, MOL CELL BIOL, V16, P6363; Braun S, 2002, EMBO J, V21, P615, DOI 10.1093/emboj/21.4.615; Chen CH, 1999, CELL, V98, P305, DOI 10.1016/S0092-8674(00)81960-1; Ciechanover A, 2001, BIOCHIMIE, V83, P341, DOI 10.1016/S0300-9084(01)01239-1; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; Groll M, 2000, NAT STRUCT BIOL, V7, P1062, DOI 10.1038/80992; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Hoppe T, 2000, CELL, V102, P577, DOI 10.1016/S0092-8674(00)00080-5; Hoppe T, 2001, CURR OPIN CELL BIOL, V13, P344, DOI 10.1016/S0955-0674(00)00218-0; Ingham PW, 1998, NATURE, V394, P16, DOI 10.1038/27764; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; JOHNSTON JA, 1995, J BIOL CHEM, V270, P8172, DOI 10.1074/jbc.270.14.8172; Kohler A, 2001, BIOCHIMIE, V83, P325, DOI 10.1016/S0300-9084(01)01242-1; Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X; LEVITSKAYA J, 1995, NATURE, V375, P685, DOI 10.1038/375685a0; Lin L, 2000, EMBO J, V19, P4712, DOI 10.1093/emboj/19.17.4712; Lin L, 1996, MOL CELL BIOL, V16, P2248; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; Lupas A, 1997, TRENDS BIOCHEM SCI, V22, P399, DOI 10.1016/S0968-0004(97)01117-1; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Orian A, 1999, MOL CELL BIOL, V19, P3664; Orr HT, 2001, GENE DEV, V15, P925, DOI 10.1101/gad.888401; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Rape M, 2001, CELL, V107, P667, DOI 10.1016/S0092-8674(01)00595-5; Sears C, 1998, J BIOL CHEM, V273, P1409, DOI 10.1074/jbc.273.3.1409; Watanabe N, 1997, EMBO J, V16, P3609, DOI 10.1093/emboj/16.12.3609; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Zhang SR, 1999, GENETICS, V151, P473	30	91	93	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2002	4	5					E113	E116		10.1038/ncb0502-e113	http://dx.doi.org/10.1038/ncb0502-e113			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	547GR	11988749				2022-12-25	WOS:000175325100005
J	Ikeda, A; Zheng, QY; Zuberi, AR; Johnson, KR; Naggert, JK; Nishina, PM				Ikeda, A; Zheng, QY; Zuberi, AR; Johnson, KR; Naggert, JK; Nishina, PM			Microtubule-associated protein 1A is a modifier of tubby hearing (moth1)	NATURE GENETICS			English	Article							RETINAL DEGENERATION; GENE FAMILY; MOUSE; IDENTIFICATION; LOCALIZATION; ORGANIZATION; MUTATION; INSULIN; MICE	Once a mutation in the gene tub was identified as the cause of obesity, retinal degeneration and hearing loss in tubby mice(1-2), it became increasingly evident that the members of the tub gene family (tulps) influence maintenance and function of the neuronal cell lineage(3-6). Suggested molecular functions of tubby-like proteins include roles in vesicular trafficking(4,7), mediation of insulin signaling(8) and gene transcription(9,10). The mechanisms through which tub functions in neurons, however, have yet to be elucidated. Here we report the positional cloning of an auditory quantitative trait locus (QTL), the modifier of tubby hearing 1 gene (moth1)(11), whose wildtype alleles from strains AKR/J, CAST/Ei and 129P2/OlaHsd protect tubby mice from hearing loss. Through a transgenic rescue experiment, we verified that sequence polymorphisms in the neuron-specific microtubule-associated protein 1a gene (Mtap1a) observed in the susceptible strain C57BL/6J(B6) are crucial for the hearing-loss phenotype. We also show that these polymorphisms change the binding efficiency of MTAP1A to postsynaptic density molecule 95 (PSD95), a core component in the cytoarchitecture of synapses. This indicates that at least some of the observed polymorphisms are functionally important and that the hearing loss in C57BL/6J-tub/tub (B6-tub/tub) mice may be caused by impaired protein interactions involving MTAP1A. We therefore propose that tub may be associated with synaptic function in neuronal cells.	Jackson Lab, Bar Harbor, ME 04609 USA; Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA	Jackson Laboratory; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Nishina, PM (corresponding author), Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.		Zheng, Qing/C-1731-2012	Ikeda, Akihiro/0000-0001-8440-3891	NATIONAL EYE INSTITUTE [R01EY016501] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046977] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R03DC004376, R01DC004301, R01DC005827] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY016501-06, R01 EY016501] Funding Source: Medline; NIDCD NIH HHS [R01 DC005827-01, R01 DC004301, R03 DC004376-01A1, R01 DC004301-01, R01 DC005827] Funding Source: Medline; NIDDK NIH HHS [R01 DK046977-10, R01 DK046977, R01 DK046977-07] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aitman TJ, 1999, NAT GENET, V21, P76, DOI 10.1038/5013; Boggon TJ, 1999, SCIENCE, V286, P2119, DOI 10.1126/science.286.5447.2119; Brenman JE, 1998, J NEUROSCI, V18, P8805; Darvasi A, 1998, NAT GENET, V18, P19, DOI 10.1038/ng0198-19; Hagstrom SA, 1999, INVEST OPHTH VIS SCI, V40, P2795; Hagstrom SA, 2001, INVEST OPHTH VIS SCI, V42, P1955; Hata Y, 1999, CELL MOL LIFE SCI, V56, P461, DOI 10.1007/s000180050445; HECKENLIVELY JR, 1995, P NATL ACAD SCI USA, V92, P11100, DOI 10.1073/pnas.92.24.11100; Ikeda A, 1999, HUM MOL GENET, V8, P1761, DOI 10.1093/hmg/8.9.1761; Ikeda A, 2001, HUM MOL GENET, V10, P1325, DOI 10.1093/hmg/10.12.1325; Ikeda S, 1999, INVEST OPHTH VIS SCI, V40, P2706; Ikeda S, 2000, HUM MOL GENET, V9, P155, DOI 10.1093/hmg/9.2.155; Kapeller R, 1999, J BIOL CHEM, V274, P24980, DOI 10.1074/jbc.274.35.24980; Kleyn PW, 1996, CELL, V85, P281, DOI 10.1016/S0092-8674(00)81104-6; NobenTrauth K, 1996, NATURE, V380, P534, DOI 10.1038/380534a0; Ohlemiller KK, 1997, AUDIOL NEURO-OTOL, V2, P175, DOI 10.1159/000259242; Santagata S, 2001, SCIENCE, V292, P2041, DOI 10.1126/science.1061233; Stubdal H, 2000, MOL CELL BIOL, V20, P878, DOI 10.1128/MCB.20.3.878-882.2000; Thomas U, 2000, CURR BIOL, V10, P1108, DOI 10.1016/S0960-9822(00)00696-5; Wu Q, 1999, CELL, V97, P779, DOI 10.1016/S0092-8674(00)80789-8	20	70	72	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2002	30	4					401	405		10.1038/ng838	http://dx.doi.org/10.1038/ng838			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	536BZ	11925566	Green Accepted			2022-12-25	WOS:000174682000017
J	Meng, G; Wei, XP; Wu, XY; Sellers, MT; Decker, JM; Moldoveanu, Z; Orenstein, JM; Graham, MF; Kappes, JC; Mestecky, J; Shaw, GM; Smith, PD				Meng, G; Wei, XP; Wu, XY; Sellers, MT; Decker, JM; Moldoveanu, Z; Orenstein, JM; Graham, MF; Kappes, JC; Mestecky, J; Shaw, GM; Smith, PD			Primary intestinal epithelial cells selectively transfer R5 HIV-1 to CCR5(+) cells	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LAMINA PROPRIA LYMPHOCYTES; T-CELLS; TYPE-1 INFECTION; SEXUAL-BEHAVIOR; TRANSMISSION; CHEMOKINE; REPLICATION; EXPRESSION; MACROPHAGES	The upper gastrointestinal tract is a principal route of HIV-1 entry in vertical transmission and after oral-genital contact. The phenotype of the newly acquired virus is predominantly R5 (CCR5-tropic) and not X4 (CXCR4-tropic), although both R5 and X4 viruses are frequently inoculated onto the mucosa. Here we show that primary intestinal (jejunal) epithelial cells express galactosylceramide, an alternative primary receptor for HIV-1, and CCR5 but not CXCR4. Moreover, we show that intestinal epithelial cells transfer R5, but not X4, viruses to CCR5(+) indicator cells, which can efficiently replicate and amplify virus expression. Transfer was remarkably efficient and was not inhibited by the fusion blocker T-20, but was substantially reduced by colchicine and low (4 degreesC) temperature, suggesting endocytotic uptake and microtubule-dependent transcytosis of HIV-1. Our finding that CCR5(+) intestinal epithelial cells select and transfer exclusively R5 viruses indicates a mechanism for the selective transmission of R5 HIV-1 in primary infection acquired through the upper gastrointestinal tract.	Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA; Vet Adm Med Ctr, Birmingham, AL USA; Howard Hughes Med Inst, Birmingham, AL 35294 USA; George Washington Univ, Med Ctr, Dept Pathol, Washington, DC 20037 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pediat, Richmond, VA 23298 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); Howard Hughes Medical Institute; George Washington University; Virginia Commonwealth University	Smith, PD (corresponding author), Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.	pdsmith@uab.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD041361] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA073470] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027767, U01AI041530, U01AI028147, R01AI035467, U19AI028147, R37AI035467] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [N01DE072621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047322] Funding Source: NIH RePORTER; NCI NIH HHS [CA-73470] Funding Source: Medline; NIAID NIH HHS [AI-28147, P30-AI-27767, AI-35467, AI-41530] Funding Source: Medline; NICHD NIH HHS [HD-41361] Funding Source: Medline; NIDCR NIH HHS [DE-72621] Funding Source: Medline; NIDDK NIH HHS [DK-47322] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agace WW, 2000, CURR BIOL, V10, P325, DOI 10.1016/S0960-9822(00)00380-8; Alfsen A, 2001, J IMMUNOL, V166, P6257, DOI 10.4049/jimmunol.166.10.6257; Amara A, 1999, J BIOL CHEM, V274, P23916, DOI 10.1074/jbc.274.34.23916; Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; Baba TW, 1996, SCIENCE, V272, P1486, DOI 10.1126/science.272.5267.1486; Bomsel M, 1997, NAT MED, V3, P42, DOI 10.1038/nm0197-42; Bomsel M, 1998, IMMUNITY, V9, P277, DOI 10.1016/S1074-7613(00)80610-X; CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913; Cecilia D, 1998, J VIROL, V72, P6988, DOI 10.1128/JVI.72.9.6988-6996.1998; Derdeyn CA, 2000, J VIROL, V74, P8358, DOI 10.1128/JVI.74.18.8358-8367.2000; Dezzutti CS, 2001, J INFECT DIS, V183, P1204, DOI 10.1086/319676; Dwinell MB, 1999, GASTROENTEROLOGY, V117, P359, DOI 10.1053/gast.1999.0029900359; FANTINI J, 1993, P NATL ACAD SCI USA, V90, P2700, DOI 10.1073/pnas.90.7.2700; FANTINI J, 1992, J VIROL, V66, P580, DOI 10.1128/JVI.66.1.580-585.1992; Frankel SS, 1996, SCIENCE, V272, P115, DOI 10.1126/science.272.5258.115; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; GHOSH K, 1993, VIROLOGY, V194, P858, DOI 10.1006/viro.1993.1331; HAROUSE JM, 1991, SCIENCE, V253, P320, DOI 10.1126/science.1857969; Jordan NJ, 1999, J CLIN INVEST, V104, P1061, DOI 10.1172/JCI6685; Kewenig S, 1999, GASTROENTEROLOGY, V116, P1115, DOI 10.1016/S0016-5085(99)70014-4; Lapenta C, 1999, EUR J IMMUNOL, V29, P1202, DOI 10.1002/(SICI)1521-4141(199904)29:04<1202::AID-IMMU1202>3.0.CO;2-O; Lee B, 1999, J BIOL CHEM, V274, P9617, DOI 10.1074/jbc.274.14.9617; Li L, 1999, GASTROENTEROLOGY, V116, P1043, DOI 10.1016/S0016-5085(99)70007-7; LI YX, 1991, J VIROL, V65, P3973, DOI 10.1128/JVI.65.8.3973-3985.1991; MAAYAN S, 1993, ISRAEL J PSYCHIAT, V30, P150; MCNEARNEY T, 1992, P NATL ACAD SCI USA, V89, P10247, DOI 10.1073/pnas.89.21.10247; MCNEELY TB, 1995, J CLIN INVEST, V96, P456, DOI 10.1172/JCI118056; Meng G, 2000, J INFECT DIS, V182, P785, DOI 10.1086/315790; PHILLIPS DM, 1994, AIDS, V8, P719, DOI 10.1097/00002030-199406000-00001; Poles MA, 2001, J VIROL, V75, P8390, DOI 10.1128/JVI.75.18.8390-8399.2001; PRATT RD, 1995, J INFECT DIS, V172, P851, DOI 10.1093/infdis/172.3.851; Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001; SCHNEIDER T, 1995, GUT, V37, P524, DOI 10.1136/gut.37.4.524; SCHWARCZ SK, 1995, AM J EPIDEMIOL, V142, P314, DOI 10.1093/oxfordjournals.aje.a117637; Smith PD, 1997, J IMMUNOL METHODS, V202, P1, DOI 10.1016/S0022-1759(96)00204-9; SMITH PD, 1994, J EXP MED, V180, P1541, DOI 10.1084/jem.180.4.1541; Smith PD, 2001, J IMMUNOL, V167, P2651, DOI 10.4049/jimmunol.167.5.2651; SMITH PD, 1999, MUCOSAL IMMUNOLOGY, P977; Stahl-Hennig C, 1999, SCIENCE, V285, P1261, DOI 10.1126/science.285.5431.1261; VANTWOUT AB, 1994, J CLIN INVEST, V94, P2060, DOI 10.1172/JCI117560; Veazey RS, 1998, SCIENCE, V280, P427, DOI 10.1126/science.280.5362.427; WAHL LM, 1991, CURRENT PROTOCOLS IM; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316; Zhang ZQ, 1999, SCIENCE, V286, P1353, DOI 10.1126/science.286.5443.1353; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453	46	200	208	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2002	8	2					150	156		10.1038/nm0202-150	http://dx.doi.org/10.1038/nm0202-150			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	517FN	11821899				2022-12-25	WOS:000173600600024
J	Wechsler, J; Greene, M; McDevitt, MA; Anastasi, J; Karp, JE; Le Beau, MM; Crispino, JD				Wechsler, J; Greene, M; McDevitt, MA; Anastasi, J; Karp, JE; Le Beau, MM; Crispino, JD			Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome	NATURE GENETICS			English	Article							TRANSCRIPTION FACTOR GATA-1; CELL-LINE; MEGAKARYOCYTIC DIFFERENTIATION; AML1/PEBP2-ALPHA-B GENE; POINT MUTATIONS; DNA-BINDING; RUNT DOMAIN; ZINC-FINGER; IN-VIVO; THROMBOCYTOPENIA	Children with Down syndrome have a 10-20-fold elevated risk of developing leukemia, particularly acute megakaryoblastic leukemia (AMKL)(1). While a subset of pediatric AMKLs is associated with the 1;22 translocation and expression of a mutant fusion protein(2,3), the genetic alterations that promote Down syndrome-related AMKL (DS-AMKL) have remained elusive. Here we show that leukemic cells from every individual with DS-AMKL that we examined contain mutations in GATA1, encoding the essential hematopoietic transcription factor GATA1 (GATA binding protein 1 or globin transcription factor 1). Each mutation results in the introduction of a premature stop codon in the gene sequence that encodes the amino-terminal activation domain. These mutations prevent synthesis of full-length GATA1, but not synthesis of a shorter variant that is initiated downstream. We show that the shorter GATA1 protein, which lacks the N-terminal activation domain, binds DNA and interacts with its essential cofactor Friend of GATA1 (FOG1; encoded by ZFPM1)(4) to the same extent as does full-length GATA1, but has a reduced transactivation potential. Although some reports suggest that the activation domain is dispensable in cell-culture models of hematopoiesis(5,6), one study has shown that it is required for normal development in vivo(7). Together, these findings indicate that loss of wildtype GATA1 constitutes one step in the pathogenesis of AMKL in Down syndrome.	Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA; Johns Hopkins Univ, Sch Med, Div Hematol, Baltimore, MD USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA	University of Chicago; Johns Hopkins University; University of Chicago; University System of Maryland; University of Maryland Baltimore; University of Chicago	Crispino, JD (corresponding author), Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA.	crispino@huggins.bsd.uchicago.edu		Crispino, John/0000-0002-8182-8306; Wechsler, Joshua/0000-0002-1275-3275				Busson-Le Coniat M, 2001, GENE CHROMOSOME CANC, V32, P244, DOI 10.1002/gcc.1188; CALLIGARIS R, 1995, P NATL ACAD SCI USA, V92, P11598, DOI 10.1073/pnas.92.25.11598; Crispino JD, 1999, MOL CELL, V3, P219, DOI 10.1016/S1097-2765(00)80312-3; Dal Cin P, 2001, GENE CHROMOSOME CANC, V30, P407, DOI 10.1002/1098-2264(2001)9999:9999<::AID-GCC1107>3.0.CO;2-C; Dickstein JI, 2001, CANCER GENET CYTOGEN, V129, P150, DOI 10.1016/S0165-4608(01)00508-8; Freson K, 2001, BLOOD, V98, P85, DOI 10.1182/blood.V98.1.85; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; Kelly L, 2002, CURR OPIN ONCOL, V14, P10, DOI 10.1097/00001622-200201000-00003; KOMATSU N, 1989, BLOOD, V74, P42; Lange B, 2000, BRIT J HAEMATOL, V110, P512, DOI 10.1046/j.1365-2141.2000.02027.x; Ma ZG, 2001, NAT GENET, V28, P220, DOI 10.1038/90054; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; McDevitt MA, 1997, P NATL ACAD SCI USA, V94, P6781, DOI 10.1073/pnas.94.13.6781; Mehaffey MG, 2001, BLOOD, V98, P2681, DOI 10.1182/blood.V98.9.2681; Michaud J, 2002, BLOOD, V99, P1364, DOI 10.1182/blood.V99.4.1364; Nichols KE, 2000, NAT GENET, V24, P266, DOI 10.1038/73480; Orkin SH, 2000, NAT REV GENET, V1, P57, DOI 10.1038/35049577; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Preudhomme C, 2000, BLOOD, V96, P2862, DOI 10.1182/blood.V96.8.2862.h8002862_2862_2869; SATO T, 1989, BRIT J HAEMATOL, V72, P184, DOI 10.1111/j.1365-2141.1989.tb07681.x; Shimizu R, 2001, EMBO J, V20, P5250, DOI 10.1093/emboj/20.18.5250; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Takahashi S, 1998, BLOOD, V92, P434, DOI 10.1182/blood.V92.2.434.414k24_434_442; Trainor CD, 1996, MOL CELL BIOL, V16, P2238; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; VISVADER JE, 1995, MOL CELL BIOL, V15, P634; Vyas P, 1999, BLOOD, V93, P2867; Wang P, 1997, GENE CHROMOSOME CANC, V20, P282, DOI 10.1002/(SICI)1098-2264(199711)20:3<282::AID-GCC9>3.0.CO;2-Z; Weiss MJ, 1997, MOL CELL BIOL, V17, P1642, DOI 10.1128/MCB.17.3.1642	30	552	567	1	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2002	32	1					148	152		10.1038/ng955	http://dx.doi.org/10.1038/ng955			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	588RR	12172547				2022-12-25	WOS:000177714900014
J	Butler, AR; Bate, N; Kiehl, DE; Kirst, HA; Cundliffe, E				Butler, AR; Bate, N; Kiehl, DE; Kirst, HA; Cundliffe, E			Genetic engineering of aminodeoxyhexose biosynthesis in Streptomyces fradiae	NATURE BIOTECHNOLOGY			English	Article							SACCHAROPOLYSPORA-ERYTHRAEA; TYLOSIN; PRODUCER; REGION	The antibacterial properties of macrolide antibiotics (such as erythromycin, tylosin, and narbomycin) depend ultimately on the glycosylation of otherwise inactive polyketide lactones. Among the sugars commonly found in such macrolides are various 6-deoxyhexoses including the 3-dimethylamino sugars mycaminose and desosamine (4-deoxymycaminose). Some macrolides (such as tylosin) possess multiple sugar moieties, whereas others (such as narbomycin) have only single sugar substituents. As patterns of glycosylation markedly influence a macrolide's drug activity, there is considerable interest in the possibility of using combinatorial biosynthesis to generate new pairings of polyketide lactones with sugars, especially 6-deoxyhexoses. Here, we report a successful attempt to alter the aminodeoxyhexose-biosynthetic capacity of Streptomyces fradiae (a producer of tylosin) by importing genes from the narbomycin producer Streptomyces narbonensis. This engineered S. fradiae produced substantial amounts of two potentially useful macrolides that had not previously been obtained by fermentation.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Elanco Anim Hlth R&D, Greenfield, IN 46140 USA	University of Leicester	Cundliffe, E (corresponding author), Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England.							BIBB MJ, 1994, MOL MICROBIOL, V14, P533, DOI 10.1111/j.1365-2958.1994.tb02187.x; BIERMAN M, 1992, GENE, V116, P43, DOI 10.1016/0378-1119(92)90627-2; Butler AR, 1999, CHEM BIOL, V6, P287, DOI 10.1016/S1074-5521(99)80074-X; CORCORAN JW, 1977, J ANTIBIOT, V30, P1012, DOI 10.7164/antibiotics.30.1012; Fish SA, 1996, J ANTIBIOT, V49, P1044, DOI 10.7164/antibiotics.49.1044; Fish SA, 1997, MICROBIOL-UK, V143, P3871, DOI 10.1099/00221287-143-12-3871; Gaisser S, 2000, MOL MICROBIOL, V36, P391, DOI 10.1046/j.1365-2958.2000.01856.x; Gaisser S, 1997, MOL GEN GENET, V256, P239, DOI 10.1007/s004380050566; Gale E.F., 1981, MOL BASIS ANTIBIOTIC, Vsecond; Gandecha AR, 1997, GENE, V184, P197, DOI 10.1016/S0378-1119(96)00595-1; Katz L, 1997, CHEM REV, V97, P2557, DOI 10.1021/cr960025+; Khosla C, 1997, CHEM REV, V97, P2577, DOI 10.1021/cr960027u; KIRST HA, 1982, J ANTIBIOT, V35, P1675, DOI 10.7164/antibiotics.35.1675; KIRST HA, 1992, KIRK OTHMER ENCY CHE, V3, P169; Leadlay PF, 1997, CURR OPIN CHEM BIOL, V1, P162, DOI 10.1016/S1367-5931(97)80005-1; MELLAERT LV, 1998, MICROBIOL, V144, P3351; OMURA S, 1983, J ANTIBIOT, V36, P1709, DOI 10.7164/antibiotics.36.1709; Poulsen SM, 2000, J MOL BIOL, V304, P471, DOI 10.1006/jmbi.2000.4229; Salah-Bey K, 1998, MOL GEN GENET, V257, P542; Summers RG, 1997, MICROBIOL-UK, V143, P3251, DOI 10.1099/00221287-143-10-3251; TANAKA A, 1981, J ANTIBIOT, V34, P1374, DOI 10.7164/antibiotics.34.1374; TANAKA A, 1982, J ANTIBIOT, V35, P113, DOI 10.7164/antibiotics.35.113; TANAKA A, 1981, J ANTIBIOT, V34, P1381, DOI 10.7164/antibiotics.34.1381; Wilson VTW, 1998, GENE, V214, P95, DOI 10.1016/S0378-1119(98)00210-8	24	34	36	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2002	20	7					713	716		10.1038/nbt0702-713	http://dx.doi.org/10.1038/nbt0702-713			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	567QC	12089557				2022-12-25	WOS:000176494800026
J	Jimbo, T; Kawasaki, Y; Koyama, R; Sato, R; Takada, S; Haraguchi, K; Akiyama, T				Jimbo, T; Kawasaki, Y; Koyama, R; Sato, R; Takada, S; Haraguchi, K; Akiyama, T			Identification of a link between the tumour suppressor APC and the kinesin superfamily	NATURE CELL BIOLOGY			English	Article							POLYPOSIS-COLI PROTEIN; MICROTUBULES; CANCER; MOTOR	The tumour suppressor gene adenomatous polyposis coli (APC) is mutated in sporadic and familial colorectal tumours(1-3). APC is involved in the proteasome-mediated degradation of beta-catenin, through its interaction with beta-catenin, GSK-3beta and Axin(4,5). APC also interacts with the microtubule cytoskeleton(6-8) and has been localized to clusters near the distal ends of microtubules at the edges of migrating epithelial cells'. Moreover, in Xenopus laevis epithelial cells, APC has been shown to move along microtubules and accumulate at their growing plus ends(10). However, the mechanism of APC accumulation and the nature of these APC clusters remain unknown. We show here that APC interacts with the kinesin superfamily (KIF) 3A-KIF3B proteins, microtubule plus-end-directed motor proteins, through an association with the kinesin superfamily-associated protein 3 (KAP3). The interaction of APC with KAP3 was required for its accumulation in clusters, and mutant APCs derived from cancer cells were unable to accumulate efficiently in clusters. These results suggest that APC and beta-catenin are transported along microtubules by KAP3-KIF3A-KIF3B, accumulate in the tips of membrane protrusions, and may thus regulate cell migration.	Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, Tokyo 1130032, Japan; Kyoto Univ, Grad Sch Sci, Ctr Mol & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan	University of Tokyo; Kyoto University	Akiyama, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	akiyama@iam.u-tokyo.ac.jp		Takada, Shinji/0000-0003-4125-6056				Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bienz M, 1999, CURR OPIN GENET DEV, V9, P595, DOI 10.1016/S0959-437X(99)00016-7; Goldstein LSB, 2000, ANNU REV NEUROSCI, V23, P39, DOI 10.1146/annurev.neuro.23.1.39; Graham TA, 2000, CELL, V103, P885, DOI 10.1016/S0092-8674(00)00192-6; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; McCartney BM, 2000, NAT CELL BIOL, V2, pE58, DOI 10.1038/35008685; Mimori-Kiyosue Y, 2000, J CELL BIOL, V148, P505, DOI 10.1083/jcb.148.3.505; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; Shibamoto S, 1998, GENES CELLS, V3, P659; Shimizu K, 1996, J BIOL CHEM, V271, P27013, DOI 10.1074/jbc.271.43.27013; SMITH KJ, 1994, CANCER RES, V54, P3672; Takeda S, 2000, J CELL BIOL, V148, P1255, DOI 10.1083/jcb.148.6.1255; Terada S, 2000, CURR OPIN NEUROBIOL, V10, P566, DOI 10.1016/S0959-4388(00)00129-X; Tighe A, 2001, EMBO REP, V2, P609, DOI 10.1093/embo-reports/kve127; Yamazaki H, 1996, P NATL ACAD SCI USA, V93, P8443, DOI 10.1073/pnas.93.16.8443; YAMAZAKI H, 1995, J CELL BIOL, V130, P1387, DOI 10.1083/jcb.130.6.1387; Zumbrunn J, 2001, CURR BIOL, V11, P44, DOI 10.1016/S0960-9822(01)00002-1	22	236	243	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2002	4	4					323	327		10.1038/ncb779	http://dx.doi.org/10.1038/ncb779			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	541PY	11912492				2022-12-25	WOS:000174994000022
J	Meloni, I; Muscettola, M; Raynaud, M; Longo, I; Bruttini, M; Moizard, MP; Gomot, M; Chelly, J; des Portes, V; Fryns, JP; Ropers, HH; Magi, B; Bellan, C; Volpi, N; Yntema, HG; Lewis, SE; Schaffer, JE; Renieri, A				Meloni, I; Muscettola, M; Raynaud, M; Longo, I; Bruttini, M; Moizard, MP; Gomot, M; Chelly, J; des Portes, V; Fryns, JP; Ropers, HH; Magi, B; Bellan, C; Volpi, N; Yntema, HG; Lewis, SE; Schaffer, JE; Renieri, A			FACL4, encoding fatty acid-CoA ligase 4, is mutated in nonspecific X-linked mental retardation	NATURE GENETICS			English	Article							ALPORT-SYNDROME; RETT-SYNDROME; MIDFACE HYPOPLASIA; GENE; SYNTHETASE; ELLIPTOCYTOSIS; IDENTIFICATION; MECP2; INACTIVATION; EXPRESSION	X-linked mental retardation (XLMR) is an inherited condition that causes failure to develop cognitive abilities, owing to mutations in a gene on the X chromosome. The latest XLMR update lists up to 136 conditions leading to 'syndromic', or 'specific', mental retardation (MRXS) and 66 entries leading to 'nonspecific' mental retardation (MRX)(1). For 9 of the 66 MRX entries, the causative gene has been identified 1. Our recent discovery of the contiguous gene deletion syndrome ATS-MR (previously known as Alport syndrome, mental retardation, midface hypoplasia, elliptocytosis, OMIM #300194), characterized by Alport syndrome (ATS) and mental retardation (MR), indicated Xq22.3 as a region containing one mental retardation gene(2,3). Comparing the extent of deletion between individuals with ATS-MR and individuals with ATS alone allowed us to define a critical region for mental retardation of approximately 380 kb, containing four genes(4-6). Here we report the identification of two point mutations, one missense and one splice-site change, in the gene FACL4 in two families with nonspecific mental retardation. Analysis of enzymatic activity in lymphoblastoid cell lines from affected individuals of both families revealed low levels compared with normal cells, indicating that both mutations are null mutations. All carrier females with either point mutations or genomic deletions in FACL4 showed a completely skewed X-inactivation, suggesting that the gene influences survival advantage. FACL4 is the first gene shown to be involved in nonspecific mental retardation and fatty-acid metabolism.	Univ Siena, Dept Mol Biol, I-53100 Siena, Italy; INSERM, U316, Serv Genet, Tours, France; CHU Cochin, ICGM, INSERM, U129, Paris, France; Katholieke Univ Leuven, Dept Genet, Louvain, Belgium; Max Planck Inst Mol Genet, Berlin, Germany; Univ Siena, Dept Pathol, I-53100 Siena, Italy; Univ Siena, Dept Biomed Sci, I-53100 Siena, Italy; Dept Human Genet, Nijmegen, Netherlands; Washington Univ, Dept Internal Med, St Louis, MO USA; Washington Univ, Dept Mol Biol, St Louis, MO USA; Washington Univ, Dept Pharmacol, St Louis, MO USA	University of Siena; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Hopital Universitaire Hotel-Dieu - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; KU Leuven; Max Planck Society; University of Siena; University of Siena; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Renieri, A (corresponding author), Univ Siena, Dept Mol Biol, I-53100 Siena, Italy.	renieri@unisi.it	Meloni, Ilaria/R-6627-2018; Raynaud, Martine/R-9811-2019; Lewis, Sheena E M/ABI-8338-2020; BELLAN, CRISTIANA/ABG-4750-2021; BELLAN, CRISTIANA/L-3903-2013; Yntema, H.G./L-4771-2015; Renieri, Alessandra/K-5950-2016; Gomot, Marie/N-3135-2016; Chelly, Jamel/J-7528-2015	Meloni, Ilaria/0000-0002-6255-9761; Raynaud, Martine/0000-0002-6888-6480; BELLAN, CRISTIANA/0000-0001-6119-9007; BELLAN, CRISTIANA/0000-0001-6119-9007; Renieri, Alessandra/0000-0002-0846-9220; Gomot, Marie/0000-0003-1747-5806; Chelly, Jamel/0000-0002-0939-8719; Longo, Ilaria/0000-0003-2056-8763; VOLPI, NILA/0000-0002-0837-1864	Telethon [E.1145] Funding Source: Medline	Telethon(Fondazione Telethon)		American Psychiatric Association, 1994, DIAGN STAT MAN MENT, V4th ed.; Black PN, 1997, J BIOL CHEM, V272, P4896, DOI 10.1074/jbc.272.8.4896; BURGEMEISTER B, 1954, MANUAL USE COLUMBIA; Cao Y, 2000, FEBS LETT, V467, P263, DOI 10.1016/S0014-5793(00)01159-5; Cao Y, 2000, P NATL ACAD SCI USA, V97, P11280, DOI 10.1073/pnas.200367597; Cao Y, 1998, GENOMICS, V49, P327, DOI 10.1006/geno.1998.5268; Chiurazzi P, 2001, EUR J HUM GENET, V9, P71, DOI 10.1038/sj.ejhg.5200603; Couvert P, 2001, HUM MOL GENET, V10, P941, DOI 10.1093/hmg/10.9.941; des Portes V, 1999, AM J MED GENET, V85, P263, DOI 10.1002/(SICI)1096-8628(19990730)85:3<263::AID-AJMG15>3.0.CO;2-0; Faergeman NJ, 1997, BIOCHEM J, V323, P1; GAUTHIER L, 1989, INT J CLIN NEUROPSYC, V11, P49; Goodglass H., 1983, BOSTON DIAGNOSTIC AP, V2nd; Herold A, 2000, MOL CELL BIOL, V20, P8996, DOI 10.1128/MCB.20.23.8996-9008.2000; Jonsson JJ, 1998, J MED GENET, V35, P273, DOI 10.1136/jmg.35.4.273; Malhotra KT, 1999, BIOCHEM J, V344, P135, DOI 10.1042/0264-6021:3440135; McCarthy D., 1972, MANUAL MCCARTHY SCAL; Meloni I, 2000, AM J HUM GENET, V67, P982, DOI 10.1086/303078; MELONI I, IN PRESS J MED GENET, V39; Merienne K, 1999, NAT GENET, V22, P13, DOI 10.1038/8719; Nielsen JB, 2001, EUR J HUM GENET, V9, P178, DOI 10.1038/sj.ejhg.5200600; PEGORARO E, 1994, AM J HUM GENET, V54, P989; Piccini M, 1999, GENOMICS, V60, P251, DOI 10.1006/geno.1999.5904; Piccini M, 1998, GENOMICS, V47, P350, DOI 10.1006/geno.1997.5104; Raynaud M, 2000, EUR J HUM GENET, V8, P253, DOI 10.1038/sj.ejhg.5200437; Stuhlsatz-Krouper SM, 1998, J BIOL CHEM, V273, P28642, DOI 10.1074/jbc.273.44.28642; Tanaka T, 1981, Methods Enzymol, V71 Pt C, P334; Vitelli F, 1999, GENOMICS, V55, P335, DOI 10.1006/geno.1998.5666; Watkins PA, 1998, J BIOL CHEM, V273, P18210, DOI 10.1074/jbc.273.29.18210; Wechsler D, 1987, WMS R WECHSLER MEMOR; Zappella M, 2001, AM J MED GENET, V104, P14, DOI 10.1002/ajmg.10005	30	120	126	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2002	30	4					436	440		10.1038/ng857	http://dx.doi.org/10.1038/ng857			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	536BZ	11889465				2022-12-25	WOS:000174682000024
J	Radimerski, T; Montagne, J; Rintelen, F; Stocker, H; van der Kaay, J; Downes, CP; Hafen, E; Thomas, G				Radimerski, T; Montagne, J; Rintelen, F; Stocker, H; van der Kaay, J; Downes, CP; Hafen, E; Thomas, G			dS6K-regulated cell growth is dPKB/dPI(3)K-independent, but requires dPDK1	NATURE CELL BIOLOGY			English	Article							PROTEIN-KINASE; SIGNALING PATHWAY; PHOSPHOINOSITIDE 3-KINASE; DROSOPHILA HOMOLOG; S6 KINASE; SIZE; PHOSPHORYLATION; ACTIVATION; RAPAMYCIN; P70(S6K)	Genetic studies in Drosophila melanogaster underscore the importance of the insulin-signalling pathway in controlling cell, organ and animal size(1). Effectors of this pathway include Chico (the insulin receptor substrate homologue), dPI(3) K, dPKB, dPTEN, and dS6K(2). Mutations in any of these components have a striking effect on cell size and number(3-7), with the exception of dS6K(8). Mutants in dS6K affect cell size but not cell number, seemingly consistent with arguments that dS6K is a distal effector in the signalling pathway, directly controlled by dTOR, a downstream effector of dPI(3) K and dPKB(1,9,10). Unexpectedly, recent studies showed that dS6K activity is unimpaired in chico-deficient larvae, suggesting that dS6K activation may be mediated through the dPI(3) K docking sites of the Drosophila insulin receptor(11). Here, we show genetically, pharmacologically and biochemically that dS6K resides on an insulin signalling pathway distinct from that of dPKB, and surprisingly also from that of dPI(3) K. More striking, despite dPKB-dPI(3) K-independence, dS6K activity is dependent on the Drosophila homologue of the phosphoinositide-dependent protein kinase 1, dPDK1, demonstrating that both dPDK1, as well as dTOR, mediated dS6K activation is phosphatidylinositide-3,4,5-trisphosphate (PIP3)independent.	Novartis Res Fdn, Friedrich Miescher Inst, CH-4058 Basel, Switzerland; Univ Zurich, Inst Zool, CH-8057 Zurich, Switzerland; Univ Dundee, Dept Life Sci, Dundee DD1 5EH, Scotland	Friedrich Miescher Institute for Biomedical Research; Novartis; University of Zurich; University of Dundee	Radimerski, T (corresponding author), Novartis Res Fdn, Friedrich Miescher Inst, Maulbeerstr 66, CH-4058 Basel, Switzerland.		Stoecker, Horst/F-8382-2012; Thomas, George/K-9235-2014	Stoecker, Horst/0000-0002-3282-3664; Thomas, George/0000-0003-3518-8149				ALESSI D, 1996, EMBO J, V23, P6541; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; ANDJELKOVIC M, 1995, J BIOL CHEM, V270, P4066, DOI 10.1074/jbc.270.8.4066; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; Conus NM, 1998, J BIOL CHEM, V273, P4776, DOI 10.1074/jbc.273.8.4776; Dennis PB, 1998, J BIOL CHEM, V273, P14845, DOI 10.1074/jbc.273.24.14845; Dufner A, 1999, MOL CELL BIOL, V19, P4525; Edgar BA, 1999, NAT CELL BIOL, V1, pE191, DOI 10.1038/70217; Goberdhan DCI, 1999, GENE DEV, V13, P3244, DOI 10.1101/gad.13.24.3244; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Huang H, 1999, DEVELOPMENT, V126, P5365; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Majewski M, 2000, P NATL ACAD SCI USA, V97, P4285, DOI 10.1073/pnas.080068597; Miron M, 2001, NAT CELL BIOL, V3, P596, DOI 10.1038/35078571; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; MONTAGNE J, 2001, SCI STKE, pE36; Oldham S, 2000, GENE DEV, V14, P2689, DOI 10.1101/gad.845700; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Radimerski T, 2000, BIOCHEMISTRY-US, V39, P5766, DOI 10.1021/bi9927484; Rintelen F, 2001, P NATL ACAD SCI USA, V98, P15020, DOI 10.1073/pnas.011318098; Rorth P, 1996, P NATL ACAD SCI USA, V93, P12418, DOI 10.1073/pnas.93.22.12418; Scanga SE, 2000, ONCOGENE, V19, P3971, DOI 10.1038/sj.onc.1203739; Sekulic A, 2000, CANCER RES, V60, P3504; Staveley BE, 1998, CURR BIOL, V8, P599, DOI 10.1016/S0960-9822(98)70231-3; Stocker H, 2000, CURR OPIN GENET DEV, V10, P529, DOI 10.1016/S0959-437X(00)00123-4; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Thomas G, 2000, NAT CELL BIOL, V2, pE71, DOI 10.1038/35010581; van der Kaay J, 1998, Methods Mol Biol, V105, P109; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; Weinkove D, 1999, CURR BIOL, V9, P1019, DOI 10.1016/S0960-9822(99)80450-3; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000	37	148	151	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAR	2002	4	3					251	255		10.1038/ncb763	http://dx.doi.org/10.1038/ncb763			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	527VR	11862217	Green Accepted			2022-12-25	WOS:000174209100019
J	Olbrich, H; Haffner, K; Kispert, A; Volkel, A; Volz, A; Sasmaz, G; Reinhardt, R; Hennig, S; Lehrach, H; Konietzko, N; Zariwala, M; Noone, PG; Knowles, M; Mitchison, HM; Meeks, M; Chung, EMK; Hildebrandt, F; Sudbrak, R; Omran, H				Olbrich, H; Haffner, K; Kispert, A; Volkel, A; Volz, A; Sasmaz, G; Reinhardt, R; Hennig, S; Lehrach, H; Konietzko, N; Zariwala, M; Noone, PG; Knowles, M; Mitchison, HM; Meeks, M; Chung, EMK; Hildebrandt, F; Sudbrak, R; Omran, H			Mutations in DNAH5 cause primary ciliary dyskinesia and randomization of left-right and asymmetry	NATURE GENETICS			English	Article							INTERMEDIATE-CHAIN; HEAVY-CHAIN; DYNEIN; GENE; INVERSUS	Primary ciliary dyskinesia (PCD, MIM 242650) is characterized by recurrent infections of the respiratory tract due to reduced mucociliary clearance and by sperm immobility. Half of the affected offspring have situs inversus (reversed organs), which results from randomization of left-right (LR) asymmetry(1). We previously localized to chromosome 5p a PCD locus containing DNAH5, which encodes a protein highly similar to the Chlamydomonas gamma-dynein heavy chain(2). Here we characterize the full-length 14-kb transcript of DNAH5. Sequence analysis in individuals with PCD with randomization of LR asymmetry identified mutations resulting in non-functional DNAH5 proteins.	Univ Freiburg, Dept Pediat & Adolescent Med, D-79106 Freiburg, Germany; Med Hochschule Hannover, Hannover, Germany; Max Planck Inst Mol Genet, Berlin, Germany; Ruhrland Klin, Essen, Germany; Univ N Carolina, Chapel Hill, NC USA; Royal Free & UCL, Dept Paediat & Child Hlth, London, England	University of Freiburg; Hannover Medical School; Max Planck Society; University of North Carolina; University of North Carolina Chapel Hill; University of London; University College London	Omran, H (corresponding author), Univ Freiburg, Dept Pediat & Adolescent Med, Hugstetter Str 55, D-79106 Freiburg, Germany.	omran@kikli.uk.uni-freiburg.de	Volz, Andreas/AAA-6290-2019; Sudbrak, Ralf/HHZ-8821-2022; Mitchison, Hannah M./C-1891-2008	Meeks, Maggie/0000-0003-2593-235X; Reinhardt, Richard/0000-0001-9376-2132; Omran, Heymut/0000-0003-0282-6765; Mitchison, Hannah/0000-0002-3163-6293				Afzelius BA, 1995, METABOLIC MOL BASES, P3943; ASDAI J, 2001, TRENDS CELL BIOL, V11, P196; Chen JC, 1998, J CLIN INVEST, V102, P1077, DOI 10.1172/JCI4786; Gee MA, 1997, NATURE, V390, P636, DOI 10.1038/37663; Guichard C, 2001, AM J HUM GENET, V68, P1030, DOI 10.1086/319511; Mocz G, 2001, STRUCTURE, V9, P93, DOI 10.1016/S0969-2126(00)00557-8; Murcia NS, 2000, DEVELOPMENT, V127, P2347; Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; Omran H, 2000, AM J RESP CELL MOL, V23, P696, DOI 10.1165/ajrcmb.23.5.4257; Pennarun G, 1999, AM J HUM GENET, V65, P1508, DOI 10.1086/302683; Supp DM, 1997, NATURE, V389, P963, DOI 10.1038/40140; Takeda S, 1999, J CELL BIOL, V145, P825, DOI 10.1083/jcb.145.4.825; Taulman PD, 2001, MOL BIOL CELL, V12, P589, DOI 10.1091/mbc.12.3.589; WILKERSON CG, 1995, J CELL BIOL, V129, P169, DOI 10.1083/jcb.129.1.169; WILKERSON CG, 1994, J CELL SCI, V107, P497	15	375	397	1	31	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2002	30	2					143	144		10.1038/ng817	http://dx.doi.org/10.1038/ng817			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	519CY	11788826				2022-12-25	WOS:000173708700010
J	Wallenius, V; Wallenius, K; Ahren, B; Rudling, M; Carlsten, H; Dickson, SL; Ohlsson, C; Jansson, JO				Wallenius, V; Wallenius, K; Ahren, B; Rudling, M; Carlsten, H; Dickson, SL; Ohlsson, C; Jansson, JO			Interleukin-6-deficient mice develop mature-onset obesity	NATURE MEDICINE			English	Article							SUBCUTANEOUS ADIPOSE-TISSUE; CILIARY NEUROTROPHIC FACTOR; INSULIN-RESISTANCE; VISCERAL OBESITY; BODY-WEIGHT; RAT; LEPTIN; HYPOTHALAMUS; INFLAMMATION; ACTIVATION	The immune-modulating cytokine interleukin-6 (IL-6) its expressed both in adipose tissue and centrally in hypothalamic nuclei that regulate body composition. We investigated the impact of loss of IL-6 on body composition in mice lacking the gene encoding IL-6 (116(-/-) mice) and found that they developed mature-onset obesity that was partly reversed by IL-6 replacement: The obese 116(-/-) mice had disturbed carbohydrate and lipid metabolism, increased leptin levels and decreased responsiveness to leptin treatment. To investigate the possible mechanism and site of action of the anti-obesity effect of IL-6, we injected rats centrally and peripherally with IL-6 at low doses. Intracerebroventricular, but not intraperitoneal IL-6 treatment increased energy expenditure. In conclusion, centrally acting IL-6 exerts anti-obesity effects in rodents.	Univ Gothenburg, Res Ctr Endocrinol & Metab, Sahlgrenska Acad, Gothenburg, Sweden; Univ Gothenburg, Dept Rheumatol & Clin Immunol, Sahlgrenska Acad, Gothenburg, Sweden; Lund Univ, Malmo Univ Hosp, Dept Med, Lund, Sweden; Huddinge Univ Hosp, Karolinska Inst, Dept Gastroenterol, Stockholm, Sweden; Univ Cambridge, Dept Physiol, Cambridge, England	University of Gothenburg; University of Gothenburg; Lund University; Skane University Hospital; Karolinska Institutet; University of Cambridge	Jansson, JO (corresponding author), Univ Gothenburg, Res Ctr Endocrinol & Metab, Sahlgrenska Acad, Gothenburg, Sweden.	john-olov.jansson@medic.gu.se	Dickson, Suzanne L/U-4628-2019; Wallenius, Ville Raymond/C-5486-2014; Ohlsson, Claes/AGP-3544-2022	Wallenius, Ville Raymond/0000-0001-8668-3196; Ohlsson, Claes/0000-0002-9633-2805; Dickson, Suzanne/0000-0002-3822-5294; Wallenius, Kristina/0000-0002-3231-2733				Ahren B, 1997, AM J PHYSIOL-REG I, V273, pR113, DOI 10.1152/ajpregu.1997.273.1.R113; Aschner M, 1998, TOXICOL LETT, V103, P283, DOI 10.1016/S0378-4274(98)00324-5; Barsh GS, 2000, NATURE, V404, P644, DOI 10.1038/35007519; Bastard JP, 2000, J CLIN ENDOCR METAB, V85, P3338, DOI 10.1210/jc.85.9.3338; Bjorbaek C, 1999, ENDOCRINOLOGY, V140, P2035, DOI 10.1210/en.140.5.2035; Bjorntorp P, 1997, NUTRITION, V13, P795, DOI 10.1016/S0899-9007(97)00191-3; Bray GA, 2000, NATURE, V404, P672, DOI 10.1038/35007544; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; DICKSON SL, 1995, NEUROENDOCRINOLOGY, V61, P36, DOI 10.1159/000126825; Ershler WB, 2000, ANNU REV MED, V51, P245, DOI 10.1146/annurev.med.51.1.245; Espat NJ, 1996, AM J PHYSIOL-REG I, V271, pR185, DOI 10.1152/ajpregu.1996.271.1.R185; FLIER JS, 1998, WILLIAMS TXB ENDOCRI, P1061; Fried SK, 1998, J CLIN ENDOCR METAB, V83, P847, DOI 10.1210/jc.83.3.847; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Gloaguen I, 1997, P NATL ACAD SCI USA, V94, P6456, DOI 10.1073/pnas.94.12.6456; GREENBERG AS, 1992, CANCER RES, V52, P4113; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Lambert PD, 2001, P NATL ACAD SCI USA, V98, P4652, DOI 10.1073/pnas.061034298; Liao W, 1996, BIOCHEM J, V313, P873, DOI 10.1042/bj3130873; Luheshi GN, 1999, P NATL ACAD SCI USA, V96, P7047, DOI 10.1073/pnas.96.12.7047; McCarty MF, 1999, MED HYPOTHESES, V52, P465, DOI 10.1054/mehy.1997.0684; Mohamed-Ali V, 1997, J CLIN ENDOCR METAB, V82, P4196, DOI 10.1210/jc.82.12.4196; NONOGAKI K, 1995, ENDOCRINOLOGY, V136, P2143, DOI 10.1210/en.136.5.2143; Pedersen BK, 2001, J PHYSIOL-LONDON, V536, P329, DOI 10.1111/j.1469-7793.2001.0329c.xd; Robinson SW, 2000, ANNU REV GENET, V34, P687, DOI 10.1146/annurev.genet.34.1.687; ROTHWELL NJ, 1991, CAN J PHYSIOL PHARM, V69, P1465, DOI 10.1139/y91-219; SCHOBITZ B, 1993, EUR J NEUROSCI, V5, P1426, DOI 10.1111/j.1460-9568.1993.tb00210.x; Shizuya K, 1998, LIFE SCI, V62, P2315, DOI 10.1016/S0024-3205(98)00212-4; Sjogren K, 2001, DIABETES, V50, P1539, DOI 10.2337/diabetes.50.7.1539; Sleeman M W, 2000, Pharm Acta Helv, V74, P265, DOI 10.1016/S0031-6865(99)00050-3; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Tsigos C, 1997, J CLIN ENDOCR METAB, V82, P4167, DOI 10.1210/jc.82.12.4167; Verdrengh M, 2000, ARTHRITIS RHEUM, V43, P2276, DOI 10.1002/1529-0131(200010)43:10<2276::AID-ANR15>3.0.CO;2-C; Vgontzas AN, 2000, J CLIN ENDOCR METAB, V85, P1151, DOI 10.1210/jc.85.3.1151; Xing Z, 1998, J CLIN INVEST, V101, P311, DOI 10.1172/JCI1368; Yudkin JS, 2000, ATHEROSCLEROSIS, V148, P209, DOI 10.1016/S0021-9150(99)00463-3	36	917	958	1	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2002	8	1					75	79		10.1038/nm0102-75	http://dx.doi.org/10.1038/nm0102-75			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	507XQ	11786910				2022-12-25	WOS:000173056900034
J	Kapfhamer, D; Valladares, O; Sun, Y; Nolan, PM; Rux, JJ; Arnold, SE; Veasey, SC; Bucan, M				Kapfhamer, D; Valladares, O; Sun, Y; Nolan, PM; Rux, JJ; Arnold, SE; Veasey, SC; Bucan, M			Mutations in Rab3a alter circadian period and homeostatic response to sleep loss in the mouse	NATURE GENETICS			English	Article							STRUCTURAL BASIS; CLOCK; TRANSCRIPTION; MUTAGENESIS; PACEMAKER; COMPONENT; RHYTHMS	Rab3a is the most abundant Rab (ras-associated binding) protein in the brain and has a regulatory role in synaptic vesicle trafficking(1). Mice with a targeted loss-of-function mutation in Rab3a have defects in Ca2+-dependent synaptic transmission: the number of vesicles released in response to an action potential is greater than in wildtype mice, resulting in greater synaptic depression(2,3) and the abolishment of CA3 mossy-fiber long term potentiation(4). The effect of these changes on behavior is unknown. In a screen for mouse mutants with abnormal rest-activity and sleep patterns, we identified a semidominant mutation, called earlybird, that shortens the circadian period of locomotor activity. Sequence analysis of Rab3a identified a point mutation in the conserved amino acid (Asp77Gly) within the GTP-binding domain of this protein in earlybird mutants, resulting in significantly reduced levels of Rab3a protein. Phenotypic assessment of earlybird mice and a null allele of Rab3a revealed anomalies in circadian period and sleep homeostasis, providing evidence that Rab3a-mediated synaptic transmission is involved in these behaviors.	Univ Penn, Ctr Neurobiol Behav, Dept Psychiat, Philadelphia, PA 19104 USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Sleep & Resp Neurobiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; The Wistar Institute; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania	Bucan, M (corresponding author), Univ Penn, Ctr Neurobiol Behav, Dept Psychiat, Philadelphia, PA 19104 USA.	bucan@pobox.upenn.edu	Nolan, Patrick/W-3918-2019	Nolan, Patrick/0000-0001-5550-0334; Valladares, Otto/0000-0001-8055-2187				BENINGTON JH, 1994, SLEEP, V17, P28, DOI 10.1093/sleep/17.1.28; Borbely A A, 1982, Hum Neurobiol, V1, P195; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Bunger MK, 2000, CELL, V103, P1009, DOI 10.1016/S0092-8674(00)00205-1; Castillo PE, 1997, NATURE, V388, P590, DOI 10.1038/41574; D'Adamo P, 1998, NAT GENET, V19, P134, DOI 10.1038/487; Dumas JJ, 1999, STRUCTURE, V7, P413, DOI 10.1016/S0969-2126(99)80054-9; Franken P, 2000, J NEUROSCI, V20, P617, DOI 10.1523/JNEUROSCI.20-02-00617.2000; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; Geppert M, 1997, NATURE, V387, P810, DOI 10.1038/42954; JOHN J, 1993, J BIOL CHEM, V268, P923; JUNG V, 1994, MOL CELL BIOL, V14, P3707, DOI 10.1128/MCB.14.6.3707; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; King DP, 2000, ANNU REV NEUROSCI, V23, P713, DOI 10.1146/annurev.neuro.23.1.713; Klein D.C., 1991, SUPRACHIASMATIC NUCL; Naylor E, 2000, J NEUROSCI, V20, P8138; Nolan Patrick M., 1998, P143; Nolan PM, 1997, METHODS, V13, P379, DOI 10.1006/meth.1997.0545; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; Pennartz CMA, 2002, NATURE, V416, P286, DOI 10.1038/nature728; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tobler I, 1996, NATURE, V380, P639, DOI 10.1038/380639a0; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; Veasey SC, 2000, SLEEP, V23, P1025; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Zheng BH, 1999, NATURE, V400, P169, DOI 10.1038/22118	28	66	70	1	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2002	32	2					290	295		10.1038/ng991	http://dx.doi.org/10.1038/ng991			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	599AP	12244319				2022-12-25	WOS:000178311100019
J	Nakai, J; Biggs, WH; Kitamura, T; Cavenee, WK; Wright, CVE; Arden, KC; Accili, D				Nakai, J; Biggs, WH; Kitamura, T; Cavenee, WK; Wright, CVE; Arden, KC; Accili, D			Regulation of insulin action and pancreatic beta-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1	NATURE GENETICS			English	Article							FACTOR FKHR; CHOROID-PLEXUS; RESISTANCE; RECEPTOR; DAF-16; LIVER; MICE; PHOSPHORYLATION; LIFE; TRANSTHYRETIN	Type 2 diabetes results from impaired action and secretion of insulin. It is not known whether the two defects share a common pathogenesis. We show that haploinsufficiency of the Foxo1 gene, encoding a forkhead transcription factor (forkhead box transcription factor O1), restores insulin sensitivity and rescues the diabetic phenotype in insulin-resistant mice by reducing hepatic expression of glucogenetic genes and increasing adipocyte expression of insulin-sensitizing genes. Conversely, a gain-of-function Foxo1 mutation targeted to liver and pancreatic beta-cells results in diabetes arising from a combination of increased hepatic glucose production and impaired beta-cell compensation due to decreased Pdx1 expression. These data indicate that Foxo1 is a negative regulator of insulin sensitivity in liver, adipocytes and pancreatic beta-cells. Impaired insulin signaling to Foxo1 provides a unifying mechanism for the common metabolic abnormalities of type 2 diabetes.	Columbia Univ, Coll Phys & Surg, Dept Med, Naomi Berrie Diabet Ctr, New York, NY 10032 USA; Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37212 USA	Columbia University; Ludwig Institute for Cancer Research; University of California System; University of California San Diego; Vanderbilt University	Accili, D (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Med, Naomi Berrie Diabet Ctr, Berrie Res Pavil,1150 St Nicholas Ave, New York, NY 10032 USA.	da230@columbia.edu	Nakae, Jun/Q-6141-2019					Accili D, 1996, NAT GENET, V12, P106, DOI 10.1038/ng0196-106; Allen-Jennings AE, 2001, J BIOL CHEM, V276, P29507, DOI 10.1074/jbc.M100986200; Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Apfeld J, 1998, CELL, V95, P199, DOI 10.1016/S0092-8674(00)81751-1; Bergman RN, 2000, TRENDS ENDOCRIN MET, V11, P351, DOI 10.1016/S1043-2760(00)00323-4; Bonner-Weir S, 2000, TRENDS ENDOCRIN MET, V11, P375, DOI 10.1016/S1043-2760(00)00305-2; Bonner-Weir S, 2000, P NATL ACAD SCI USA, V97, P7999, DOI 10.1073/pnas.97.14.7999; Bouwens L, 1998, DIABETOLOGIA, V41, P629, DOI 10.1007/s001250050960; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; Cherrington AD, 1999, DIABETES, V48, P1198, DOI 10.2337/diabetes.48.5.1198; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Hotamisligil GS, 2000, INT J OBESITY, V24, pS23, DOI 10.1038/sj.ijo.0801497; JACOBSSON B, 1989, J HISTOCHEM CYTOCHEM, V37, P31, DOI 10.1177/37.1.2642294; Kadowaki T, 2000, J CLIN INVEST, V106, P459, DOI 10.1172/JCI10830; Kaestner KH, 2000, GENE DEV, V14, P142; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; Kido Y, 2000, DIABETES, V49, P589, DOI 10.2337/diabetes.49.4.589; Kitamura T, 2001, MOL CELL BIOL, V21, P5624, DOI 10.1128/MCB.21.16.5624-5630.2001; Kitamura T, 2001, DIABETES, V50, pA345; Kubota N, 2000, DIABETES, V49, P1880, DOI 10.2337/diabetes.49.11.1880; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Kulkarni RN, 1999, J CLIN INVEST, V104, pR69, DOI 10.1172/JCI8339; Lin K, 2001, NAT GENET, V28, P139, DOI 10.1038/88850; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; Nakae J, 2001, DIABETES, V50, pA22; Nakae J, 2001, ANN MED, V33, P22, DOI 10.3109/07853890109002056; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; Nakae J, 2000, EMBO J, V19, P989, DOI 10.1093/emboj/19.5.989; Nasrin N, 2000, P NATL ACAD SCI USA, V97, P10412, DOI 10.1073/pnas.190326997; *NAT DIAB DAT GROU, 1995, DIAB AM; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Rother KI, 1998, J BIOL CHEM, V273, P17491, DOI 10.1074/jbc.273.28.17491; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Sharma A, 1999, DIABETES, V48, P507, DOI 10.2337/diabetes.48.3.507; Shen W, 2001, J BIOL CHEM, V276, P42812, DOI 10.1074/jbc.M106344200; TAYLOR SI, 1994, DIABETES, V43, P735, DOI 10.2337/diab.43.6.735; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; YAN C, 1990, EMBO J, V9, P869, DOI 10.1002/j.1460-2075.1990.tb08184.x	40	494	529	2	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2002	32	2					245	253		10.1038/ng890	http://dx.doi.org/10.1038/ng890			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	599AP	12219087				2022-12-25	WOS:000178311100012
J	Batourina, E; Choi, C; Paragas, N; Bello, N; Hensle, T; Costantini, FD; Schuchardt, A; Bacallao, RL; Mendelsohn, CL				Batourina, E; Choi, C; Paragas, N; Bello, N; Hensle, T; Costantini, FD; Schuchardt, A; Bacallao, RL; Mendelsohn, CL			Distal ureter morphogenesis depends on epithelial cell remodeling mediated by vitamin A and Ret	NATURE GENETICS			English	Article							RETINOIC ACID RECEPTORS; NEUROTROPHIC FACTOR; URINARY-TRACT; TYROSINE KINASE; CONGENITAL-ANOMALIES; BUD DEVELOPMENT; RENAL AGENESIS; MICE LACKING; GDNF; KIDNEY	Almost 1% of human infants are born with urogenital abnormalities, many of which are linked to irregular connections between the distal ureters and the bladder. During development, ureters migrate by an unknown mechanism from their initial integration site in the Wolffian ducts up to the base of the bladder in a process that we call ureter maturation. Rara(-/-) Rarb2(-/-) mice display impaired vitamin A signaling and develop syndromic urogenital malformations similar to those that occur in humans, including renal hypoplasia, hydronephrosis and mega-ureter, abnormalities also seen in mice with mutations in the proto-oncogene Ret. Here we show that ureter maturation depends on formation of the 'trigonal wedge', a newly identified epithelial outgrowth from the base of the Wolffian ducts, and that the distal ureter abnormalities seen in Rara(-/-) Rarb2(-/-) and Ret(-/-) mutant mice are probably caused by a failure of this process. Our studies indicate that formation of the trigonal wedge may be essential for correct insertion of the distal ureters into the bladder, and that these events are mediated by the vitamin A and Ret signaling pathways.	Columbia Univ, Dept Urol, New York, NY 10032 USA	Columbia University	Mendelsohn, CL (corresponding author), Columbia Univ, Dept Urol, 630 W 168th St, New York, NY 10032 USA.		Mendelsohn, Cathy/H-4280-2016; Bello, Natalie/J-1001-2019	Mendelsohn, Cathy/0000-0002-4026-4073; Bello, Natalie/0000-0003-3257-3623; Paragas, Neal/0000-0001-6084-8220; Bacallao, Robert/0000-0002-5703-5701	NIDDK NIH HHS [R01 DK061459-09, R56 DK082963-01, R01 DK061459-06, R56 DK082963, R01 DK061459, R01 DK061459-07S1, R01 DK061459-07, R01 DK061459-08] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061459, R56DK082963] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Batourina E, 2001, NAT GENET, V27, P74, DOI 10.1038/83792; Clendenon JL, 2002, AM J PHYSIOL-CELL PH, V282, pC213, DOI 10.1152/ajpcell.2002.282.1.C213; DOLLE P, 1990, DEVELOPMENT, V110, P1133; Frazer JE, 1935, J ANAT, V69, P455; Giguere V, 1996, ANN NY ACAD SCI, V785, P12, DOI 10.1111/j.1749-6632.1996.tb56238.x; HUTCH JA, 1972, ANATOMY PHYSL BLADDE; Ichikawa I, 2002, KIDNEY INT, V61, P889, DOI 10.1046/j.1523-1755.2002.00188.x; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Kume T, 2000, DEVELOPMENT, V127, P1387; MACKIE GG, 1975, J UROLOGY, V114, P274, DOI 10.1016/S0022-5347(17)67007-1; MAIZELS M, 1997, CAMPBELLS UROLOGY, V2, P1545; Mendelsohn C, 1999, DEVELOPMENT, V126, P1139; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2749; MEYER R, 1946, ANAT REC, V68, P355; Miyazaki Y, 2000, J CLIN INVEST, V105, P863, DOI 10.1172/JCI8256; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; Nishimura H, 1999, MOL CELL, V3, P1, DOI 10.1016/S1097-2765(00)80169-0; Pepicelli CV, 1997, DEV BIOL, V192, P193, DOI 10.1006/dbio.1997.8745; Pope JC, 1999, J AM SOC NEPHROL, V10, P2018; Sainio K, 1997, DEVELOPMENT, V124, P4077; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; SCHLUSSEL RN, 1997, CAMPBELLS UROLOGY, V2, P1814; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Schuchardt A, 1996, DEVELOPMENT, V122, P1919; SCHUCHARDT A, 1994, THESIS COLUMBIA U; SCOTT JES, 1987, BRIT J UROL, V59, P291, DOI 10.1111/j.1464-410X.1987.tb04634.x; SCOTT JES, 1988, BRIT J UROL, V62, P295, DOI 10.1111/j.1464-410X.1988.tb04351.x; Srinivas S, 1999, DEV GENET, V24, P241; Srinivas S, 1999, DEVELOPMENT, V126, P1375; TANAGHO EA, 1981, DEV URETER; Tang MJ, 1998, J CELL BIOL, V142, P1337, DOI 10.1083/jcb.142.5.1337; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Vega QC, 1996, P NATL ACAD SCI USA, V93, P10657, DOI 10.1073/pnas.93.20.10657; Vilar J, 1996, KIDNEY INT, V49, P1478, DOI 10.1038/ki.1996.208; WILSON JG, 1948, AM J ANAT, V83, P357, DOI 10.1002/aja.1000830303; WILSON JG, 1953, AM J ANAT, V92, P189, DOI 10.1002/aja.1000920202; Zile MH, 2001, J NUTR, V131, P705, DOI 10.1093/jn/131.3.705	40	111	113	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2002	32	1					109	115		10.1038/ng952	http://dx.doi.org/10.1038/ng952			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	588RR	12195422				2022-12-25	WOS:000177714900009
J	Jacobs, T				Jacobs, T			Just mad about mAbs	NATURE BIOTECHNOLOGY			English	Editorial Material																		Fletcher L, 2001, NAT BIOTECHNOL, V19, P395, DOI 10.1038/88010; Reichert JM, 2001, NAT BIOTECHNOL, V19, P819, DOI 10.1038/nbt0901-819; 2002, CURR OPIN MOL THER, V4, P110	3	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2002	20	9					869	869		10.1038/nbt0902-869	http://dx.doi.org/10.1038/nbt0902-869			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	589KN	12205498	Bronze			2022-12-25	WOS:000177757700011
J	Rosenberg, MJ; Agarwala, R; Bouffard, G; Davis, J; Fiermonte, G; Hilliard, MS; Koch, T; Kalikin, LM; Makalowska, I; Morton, DH; Petty, EM; Weber, JL; Palmieri, F; Kelley, RI; Schaffer, AA; Biesecker, LG				Rosenberg, MJ; Agarwala, R; Bouffard, G; Davis, J; Fiermonte, G; Hilliard, MS; Koch, T; Kalikin, LM; Makalowska, I; Morton, DH; Petty, EM; Weber, JL; Palmieri, F; Kelley, RI; Schaffer, AA; Biesecker, LG			Mutant deoxynucleotide carrier is associated with congenital microcephaly	NATURE GENETICS			English	Article							LINKAGE ANALYSIS; GENE; RECONSTITUTION; TRANSPORT; PROTEINS; MARKERS; AMISH; MAP	The disorder Amish microcephaly (MCPHA) is characterized by severe congenital microcephaly, elevated levels of alpha-ketoglutarate in the urine and premature death(1). The disorder is inherited in an autosomal recessive pattern and has been observed only in Old Order Amish families whose ancestors lived in Lancaster County, Pennsylvania. Here we show, by using a genealogy database and automated pedigree software, that 23 nuclear families affected with MCPHA are connected to a single ancestral couple. Through a whole-genome scan, fine mapping and haplotype analysis, we localized the gene affected in MCPHA to a region of 3 cM, or 2 Mb, on chromosome 17q25. We constructed a map of contiguous genomic clones spanning this region. One of the genes in this region, SLC25A19, which encodes a nuclear mitochondrial deoxynucleotide carrier (DNC)(2), contains a substitution that segregates with the disease in affected individuals and alters an amino acid that is highly conserved in similar proteins. Functional analysis shows that the mutant DNC protein lacks the normal transport activity, implying that failed deoxynucleotide transport across the inner mitochondrial membrane causes MCPHA. Our data indicate that mitochondrial deoxynucleotide transport may be essential for prenatal brain growth.	NHGRI, NIH, Bethesda, MD 20892 USA; NIH, Natl Ctr Biotechnol Informat, Bethesda, MD 20892 USA; NIH, Intramural Sequencing Ctr, Gaithersburg, MD USA; Univ Bari, Dept Pharmacobiol, Biochem & Mol Biol Lab, Bari, Italy; Logicon ROW Sci Corp, Rockville, MD USA; Konrad Zuse Zentrum Informat Tech, Berlin, Germany; Univ Michigan, Med Ctr, Dept Internal Med, Ann Arbor, MI 48109 USA; Clin Special Children, Strasburg, PA USA; Marshfield Med Res Fdn, Marshfield, WI 54449 USA; Johns Hopkins Univ, Kennedy Krieger Inst, Baltimore, MD USA; Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21218 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Universita degli Studi di Bari Aldo Moro; Zuse Institute Berlin; University of Michigan System; University of Michigan; Johns Hopkins University; Kennedy Krieger Institute; Johns Hopkins University	Rosenberg, MJ (corresponding author), NHGRI, NIH, 49 Convent Dr, Bethesda, MD 20892 USA.	marjr@nhgri.nih.gov	Makalowska, Izabela/AAU-2682-2021; Fiermonte, Giuseppe/D-3680-2018; Lindhurst, Marjorie/AHD-3412-2022; Schaffer, Alejandro A/F-2902-2012; Schaffer, Alejandro/N-1222-2019; Biesecker, Leslie/AAG-2526-2021; Makalowska, Izabela/AAF-4967-2021	Fiermonte, Giuseppe/0000-0002-6764-9395; Makalowska, Izabela/0000-0002-8144-5671; Koch, Thorsten/0000-0002-1967-0077	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000182] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [ZIALM000097, Z01LM000097] Funding Source: NIH RePORTER; Telethon [E.0958] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); Telethon(Fondazione Telethon)		Agarwala R, 1998, GENOME RES, V8, P211, DOI 10.1101/gr.8.3.211; Agarwala R, 2001, HUM BIOL, V73, P533, DOI 10.1353/hub.2001.0045; Becker A, 1998, HUM HERED, V48, P49, DOI 10.1159/000022781; BIESECKER LG, 1995, AM J MED GENET, V58, P389, DOI 10.1002/ajmg.1320580426; Broman KW, 1998, AM J HUM GENET, V63, P861, DOI 10.1086/302011; CAREY JC, 1996, RUDOLPHS PEDIAT, P427; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; Dolce V, 2001, P NATL ACAD SCI USA, V98, P2284, DOI 10.1073/pnas.031430998; FIERMONTE G, 1993, BIOCHEM J, V294, P293, DOI 10.1042/bj2940293; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Johnston JJ, 2000, AM J HUM GENET, V67, P814, DOI 10.1086/303089; Kalikin LM, 1999, GENOMICS, V57, P36, DOI 10.1006/geno.1998.5740; KELLEY RI, 2002, AM J MED GENET, DOI DOI 10.1002/AJMG10529; Koch T, 1998, NETWORKS, V32, P207, DOI 10.1002/(SICI)1097-0037(199810)32:3<207::AID-NET5>3.0.CO;2-O; Kuhlenbaumer G, 1999, GENOMICS, V62, P242, DOI 10.1006/geno.1999.5991; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; Makalowska I, 2001, BIOINFORMATICS, V17, P843, DOI 10.1093/bioinformatics/17.9.843; MARCHANT CD, 1983, PEDIATR CLIN N AM, V30, P281; Palmieri F, 1995, METHOD ENZYMOL, V260, P349, DOI 10.1016/0076-6879(95)60150-3; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; Risk JM, 1999, DIS ESOPHAGUS, V12, P173, DOI 10.1046/j.1442-2050.1999.00042.x; Rosenberg MJ, 2001, HUM GENET, V109, P311, DOI 10.1007/s004390100559; SCHAFFER AA, 1994, HUM HERED, V44, P225, DOI 10.1159/000154222; Vollrath D, 1999, GENOME ANAL, V4, P187; Weber JL, 2001, ADV GENET, V42, P77, DOI 10.1016/S0065-2660(01)42016-5	26	110	113	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2002	32	1					175	179		10.1038/ng948	http://dx.doi.org/10.1038/ng948			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	588RR	12185364				2022-12-25	WOS:000177714900018
J	Roulet, E; Busso, S; Camargo, AA; Simpson, AJG; Mermod, N; Bucher, P				Roulet, E; Busso, S; Camargo, AA; Simpson, AJG; Mermod, N; Bucher, P			High-throughput SELEX-SAGE method for quantitative modeling of transcription-factor binding sites	NATURE BIOTECHNOLOGY			English	Article							MNT REPRESSOR; DNA; SPECIFICITY; PREDICTION; SELECTION; PROTEINS	The ability to determine the location and relative strength of all transcription-factor binding sites in a genome is important both for a comprehensive understanding of gene regulation and for effective promoter engineering in biotechnological applications. Here we present a bioinformatically driven experimental method to accurately define the DNA-binding sequence specificity of transcription factors. A generalized profile(1) was used as a predictive quantitative model for binding sites, and its parameters were estimated from in vitro-selected ligands using standard hidden Markov model training algorithms(2,3). Computer simulations showed that several thousand low- to medium-affinity sequences are required to generate a profile of desired accuracy. To produce data on this scale, we applied high-throughput genomics methods to the biochemical problem addressed here. A method combining systematic evolution of ligands by exponential enrichment (SELEX)(4) and serial analysis of gene expression (SAGE)(5) protocols was coupled to an automated quality-controlled sequence extraction procedure based on Phred quality scores(6). This allowed the sequencing of a database of more than 10,000 potential DNA ligands for the CTF/NFI transcription factor. The resulting binding-site model defines the sequence specificity of this protein with a high degree of accuracy not achieved earlier and thereby makes it possible to identify previously unknown regulatory sequences in genomic DNA. A covariance analysis of the selected sites revealed non-independent base preferences at different nucleotide positions, providing insight into the binding mechanism.	Swiss Inst Expt Canc Res, Swiss Inst Bioinformat, CH-1066 Epalinges, Switzerland; EPFL, UNIL, Lab Mol Biotechnol, Ctr Biotechnol, CH-1015 Lausanne, Switzerland; Univ Lausanne, Inst Biol Anim, CH-1015 Lausanne, Switzerland; Ludwig Inst Canc Res, Canc Genet Lab, BR-01509010 Sao Paulo, Brazil	Swiss Institute Experimental Cancer Research; Swiss Institute of Bioinformatics; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of Lausanne; Ludwig Institute for Cancer Research	Bucher, P (corresponding author), Swiss Inst Expt Canc Res, Swiss Inst Bioinformat, CH-1066 Epalinges, Switzerland.		Camargo, Anamaria A/E-9388-2012; Simpson, Amelia/HGB-1823-2022	Camargo, Anamaria A/0000-0002-6076-9597; 				BERG OG, 1987, J MOL BIOL, V193, P723, DOI 10.1016/0022-2836(87)90354-8; Bucher P, 1996, COMPUT CHEM, V20, P3, DOI 10.1016/S0097-8485(96)80003-9; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Durbin R., 1998, BIOL SEQUENCE ANAL P; Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Fields DS, 1997, J MOL BIOL, V271, P178, DOI 10.1006/jmbi.1997.1171; Goodman SD, 1999, J BACTERIOL, V181, P3246, DOI 10.1128/JB.181.10.3246-3255.1999; Hughey R, 1996, COMPUT APPL BIOSCI, V12, P95; KLUG SJ, 1994, MOL BIOL REP, V20, P97, DOI 10.1007/BF00996358; Man TK, 2001, NUCLEIC ACIDS RES, V29, P2471, DOI 10.1093/nar/29.12.2471; MEISTERERNST M, 1988, NUCLEIC ACIDS RES, V16, P4419, DOI 10.1093/nar/16.10.4419; Perier RC, 2000, NUCLEIC ACIDS RES, V28, P302, DOI 10.1093/nar/28.1.302; Roulet E, 2000, J MOL BIOL, V297, P833, DOI 10.1006/jmbi.2000.3614; Roulet E, 1998, In Silico Biol, V1, P21; Vant-Hull B, 1998, J MOL BIOL, V278, P579, DOI 10.1006/jmbi.1998.1727; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; ZHANG MQ, 1993, COMPUT APPL BIOSCI, V9, P499	18	164	177	0	25	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2002	20	8					831	835		10.1038/nbt718	http://dx.doi.org/10.1038/nbt718			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	579MU	12101405				2022-12-25	WOS:000177182500036
J	Tender, LM; Reimers, CE; Stecher, HA; Holmes, DE; Bond, DR; Lowy, DA; Pilobello, K; Fertig, SJ; Lovley, DR				Tender, LM; Reimers, CE; Stecher, HA; Holmes, DE; Bond, DR; Lowy, DA; Pilobello, K; Fertig, SJ; Lovley, DR			Harnessing microbially generated power on the seafloor	NATURE BIOTECHNOLOGY			English	Article							16S RIBOSOMAL-RNA; ELEMENTAL SULFUR; SEDIMENT; SEAWATER	In many marine environments, a voltage gradient exists across the water-sediment interface resulting from sedimentary microbial activity. Here we show that a fuel cell consisting of an anode embedded in marine sediment and a cathode in overlying seawater can use this voltage gradient to generate electrical power in situ. Fuel cells of this design generated sustained power in a boat basin carved into a salt marsh near Tuckerton, New Jersey, and in the Yaquina Bay Estuary near Newport, Oregon. Retrieval and analysis of the Tuckerton fuel cell indicates that power generation results from at least two anode reactions: oxidation of sediment sulfide (a by-product of microbial oxidation of sedimentary organic carbon) and oxidation of sedimentary organic carbon catalyzed by microorganisms colonizing the anode. These results demonstrate in real marine environments a new form of power generation that uses an immense, renewable energy reservoir (sedimentary organic carbon) and has near-immediate application.	USN, Res Lab, Ctr Biomol Sci & Engn, Washington, DC 20375 USA; Oregon State Univ, Hatfield Marine Sci Ctr, Newport, OR 97365 USA; Univ Massachusetts, Dept Microbiol, Amherst, MA 01003 USA; Nova Res Inc, Alexandria, VA 22308 USA	United States Department of Defense; United States Navy; Naval Research Laboratory; Oregon State University; University of Massachusetts System; University of Massachusetts Amherst; Nova Research, Inc.	Tender, LM (corresponding author), USN, Res Lab, Ctr Biomol Sci & Engn, Code 6900,4555 Overlook Ave SW, Washington, DC 20375 USA.		Lowy, Daniel A/C-3265-2016	Bond, Daniel/0000-0001-8083-7107; Lowy, Daniel/0000-0003-2210-6757				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AUSUBEL FA, 1997, PROTOCOLS MOL BIOL; BARD AJ, 1980, ELECTROCHEMICAL METH, P130; Berner R.A., 1980, EARLY DIAGENESIS THE, P241; Bond DR, 2002, SCIENCE, V295, P483, DOI 10.1126/science.1066771; Boudreau BP, 1997, DIAGENETIC MODELS TH, V1st; Cai WJ, 1995, DEEP-SEA RES PT I, V42, P1681, DOI 10.1016/0967-0637(95)00073-F; CLINE JD, 1969, LIMNOL OCEANOGR, V14, P454, DOI 10.4319/lo.1969.14.3.0454; Finster K, 1998, APPL ENVIRON MICROB, V64, P119; FROELICH PN, 1979, GEOCHIM COSMOCHIM AC, V43, P1075, DOI 10.1016/0016-7037(79)90095-4; HART AB, 1967, FUEL CELLS THEORY AP, P54; Kennett JP, 2000, SCIENCE, V288, P128, DOI 10.1126/science.288.5463.128; Lane D.J., 1991, NUCL ACID TECHNIQUES, P115, DOI DOI 10.4135/9781446279281.N7; LANE DJ, 1985, P NATL ACAD SCI USA, V82, P6955, DOI 10.1073/pnas.82.20.6955; LOVLEY DR, 1994, APPL ENVIRON MICROB, V60, P2394, DOI 10.1128/AEM.60.7.2394-2399.1994; Lovley DR, 1996, NATURE, V382, P445, DOI 10.1038/382445a0; Maidak BL, 1999, NUCLEIC ACIDS RES, V27, P171, DOI 10.1093/nar/27.1.171; Marchesi JR, 1998, APPL ENVIRON MICROB, V64, P795; MEASURES CI, 1995, MAR CHEM, V50, P3, DOI 10.1016/0304-4203(95)00022-J; Morel F., 1993, PRINCIPLES APPL AQUA, P588; Palmore G.T.R., 1994, ACS SYM SER, P271; Reimers CE, 2001, ENVIRON SCI TECHNOL, V35, P192, DOI 10.1021/es001223s; Sahling H, 2002, MAR ECOL PROG SER, V231, P121, DOI 10.3354/meps231121; SCHINDLER JE, 1971, LIMNOL OCEANOGR, V16, P837, DOI 10.4319/lo.1971.16.5.0837; Wilcock WSD, 1997, J POWER SOURCES, V66, P71, DOI 10.1016/S0378-7753(96)02483-4; ZHANG JJ, 1995, J ELECTROANAL CHEM, V385, P191, DOI 10.1016/0022-0728(94)03784-Z; [No title captured]	27	537	577	7	244	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2002	20	8					821	825		10.1038/nbt716	http://dx.doi.org/10.1038/nbt716			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	579MU	12091916				2022-12-25	WOS:000177182500034
J	Hammer, SM; Turmen, T; Vareldzis, B; Perriens, J				Hammer, SM; Turmen, T; Vareldzis, B; Perriens, J			Antiretroviral guidelines for resource-limited settings: The WHO's public health approach	NATURE MEDICINE			English	Editorial Material									Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; WHO, CH-1211 Geneva, Switzerland	Columbia University; World Health Organization	Hammer, SM (corresponding author), Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.								0	9	10	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2002	8	7					649	650		10.1038/nm0702-649	http://dx.doi.org/10.1038/nm0702-649			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	567QG	12091891				2022-12-25	WOS:000176495200011
J	Lomazzi, M; Moroni, MC; Jensen, MR; Frittoli, E; Helin, K				Lomazzi, M; Moroni, MC; Jensen, MR; Frittoli, E; Helin, K			Suppression of the p53-or pRB-mediated G1 checkpoint is required for E2F-induced S-phase entry	NATURE GENETICS			English	Article							CELL-CYCLE ARREST; TRANSCRIPTION FACTORS E2F-1; RETINOBLASTOMA PROTEIN; DEREGULATED EXPRESSION; ADENOVIRUS E1A; INK4A LOCUS; PROLIFERATION; APOPTOSIS; BINDING; FAMILY	Deregulation of the retinoblastoma protein (pRB) pathway is a hallmark of cancer(1). In the absence of other genetic alterations, this deregulation results in lack of differentiation, hyperproliferation and apoptosis(2). The pRB protein acts as a transcriptional repressor by targeting the E2F transcription factors, whose functions are required for entry into S phase(3,4). Increased E2F activity can induce S phase in quiescent cells this is a central element of most models for the development of cancer 1,3,4. We show that although E2F1 alone is not sufficient to induce S phase in diploid mouse and human fibroblasts, increased E2F1 activity can result in S-phase entry in diploid fibroblasts in which the p53-mediated G1 checkpoint is suppressed. In addition, we show that E2F1 can induce S phase in primary mouse fibroblasts lacking pRB. These results indicate that, in addition to acting as an E2F-dependent transcriptional repressor, pRB is also required for the cells to retain the G1 checkpoint in response to unprogrammed proliferative signals.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; FIRC Inst Mol Oncol, Milan, Italy	IRCCS European Institute of Oncology (IEO); IFOM - FIRC Institute of Molecular Oncology	Helin, K (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.		Helin, Kristian/K-2526-2019; Jensen, Michael/E-9677-2011; Helin, Kristian/HDM-8306-2022; Moroni, Maria Cristina/H-7044-2018	Helin, Kristian/0000-0003-1975-6097; Moroni, Maria Cristina/0000-0003-2409-5764				BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; DIMRI GP, 1994, J BIOL CHEM, V269, P16180; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FATTAEY AR, 1993, MOL CELL BIOL, V13, P7267, DOI 10.1128/MCB.13.12.7267; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1994, J VIROL, V68, P5027, DOI 10.1128/JVI.68.8.5027-5035.1994; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; JOHNSON AF, 1993, ECOSYSTEMS WORLD, V2, P365; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; Mann DJ, 1996, CURR BIOL, V6, P474, DOI 10.1016/S0960-9822(02)00515-8; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; QUINLAN MP, 1987, P NATL ACAD SCI USA, V84, P3283, DOI 10.1073/pnas.84.10.3283; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821	30	70	72	1	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2002	31	2					190	194		10.1038/ng891	http://dx.doi.org/10.1038/ng891			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	557HR	11992123				2022-12-25	WOS:000175903500017
J	Paul, CP; Good, PD; Winer, I; Engelke, DR				Paul, CP; Good, PD; Winer, I; Engelke, DR			Effective expression of small interfering RNA in human cells	NATURE BIOTECHNOLOGY			English	Article							SMALL NUCLEAR-RNA; MAMMALIAN-CELLS; POLYMERASE; ELEMENTS; SILENCE	In many eukaryotes, expression of nuclear-encoded mRNA can be strongly inhibited by the presence of a double-stranded RNA (dsRNA) corresponding to exon sequences in the mRNA (refs 1,2). The use of this "RNA interference" (RNAi) in mammalian studies had lagged well behind its utility in lower animals because uninterrupted RNA duplexes longer than 30 base pairs trigger generalized cellular responses through activation of dsRNA-dependent protein kinases(3). Recently it was demonstrated 4 that RNAi can be made to work in cultured human cells by introducing shorter, synthetic duplex RNAs (20 base pairs) through liposome transfection. We have explored several strategies for expressing similar short interfering RNA (siRNA) duplexes within cells from recombinant DNA constructs, because this might allow long-term target-gene suppression in cells, and potentially in whole organisms. Effective suppression of target gene product levels is achieved by using a human U6 small nuclear RNA (snRNA) promoter to drive nuclear expression of a single RNA transcript. The siRNA-like parts of the transcript consists of a 19-base pair siRNA stem with the two strands joined by a tightly structured loop and a U1-4 3 overhang at the end of the antisense strand. The simplicity of the U6 expression cassette and its widespread transcription in human cell types suggest that this mode of siRNA delivery could be useful for suppressing expression of a wide range of genes.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Med Scientist Training Program, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Engelke, DR (corresponding author), Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA.		Winer, Ira/M-4973-2019	Winer, Ira/0000-0001-6056-8296	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040936] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40936] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bernstein E, 2001, RNA, V7, P1509; Bertrand E, 1997, RNA, V3, P75; CHATTERJEE S, 1992, SCIENCE, V258, P1485, DOI 10.1126/science.1359646; CHEONG CJ, 1990, NATURE, V346, P680, DOI 10.1038/346680a0; DANZEISER DA, 1993, MOL CELL BIOL, V13, P4670, DOI 10.1128/MCB.13.8.4670; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Gil J, 2000, APOPTOSIS, V5, P107, DOI 10.1023/A:1009664109241; Good PD, 1997, GENE THER, V4, P45, DOI 10.1038/sj.gt.3300354; KUNKEL GR, 1986, P NATL ACAD SCI USA, V83, P8575, DOI 10.1073/pnas.83.22.8575; KUNKEL GR, 1988, GENE DEV, V2, P196, DOI 10.1101/gad.2.2.196; Lipardi C, 2001, CELL, V107, P297, DOI 10.1016/S0092-8674(01)00537-2; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; Zamore PD, 2001, NAT STRUCT BIOL, V8, P746, DOI 10.1038/nsb0901-746	14	654	1066	0	86	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2002	20	5					505	508		10.1038/nbt0502-505	http://dx.doi.org/10.1038/nbt0502-505			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	548AE	11981566				2022-12-25	WOS:000175364800035
J	Shih, SC; Katzmann, DJ; Schnell, JD; Sutanto, M; Emr, SD; Hicke, L				Shih, SC; Katzmann, DJ; Schnell, JD; Sutanto, M; Emr, SD; Hicke, L			Epsins and Vps27p/Hrs contain ubiquitin-binding domains that function in receptor endocytosis	NATURE CELL BIOLOGY			English	Article							MULTIUBIQUITIN CHAIN; UBA DOMAIN; PROTEIN; CLATHRIN; SURFACE; INTERNALIZATION; DEGRADATION; COMPONENTS; SIGNAL; HRS	Ubiquitin functions as a signal for sorting cargo at multiple steps of the endocytic pathway and controls the activity of trans-acting components of the endocytic machinery (reviewed in refs 1 and 2). By contrast to proteasome degradation, which generally requires a polyubiquitin chain that is at least four subunits long(3,4), internalization and sorting of endocytic cargo at the late endosome are mediated by mono-ubiquitination(5-8). Here, we demonstrate that ubiquitin-interacting motifs (UIMs) found in epsins and Vps27p ( ref. 9) from Saccharomyces cerevisiae are required for ubiquitin binding and protein transport. Epsin UIMs are important for the internalization of receptors into vesicles at the plasma membrane. Vps27p UIMs are necessary to sort biosynthetic and endocytic cargo into vesicles that bud into the lumen of a late endosomal compartment, the multivesicular body. We propose that monoubiquitin regulates internalization and endosomal sorting by interacting with modular ubiquitin-binding domains in core components of the protein transport machinery. UIM domains are found in a broad spectrum of proteins, consistent with the idea that mono-ubiquitin can function as a regulatory signal to control diverse biological activities.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Univ Calif San Diego, Sch Med, Div Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA	Northwestern University; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Shih, SC (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2153 Sheridan Rd, Evanston, IL 60208 USA.	semr@ucsd.edu; l-hicke@northwestern.edu	Schnell, Joshua/J-3142-2019; Schnell, Joshua/J-4000-2012	Schnell, Joshua/0000-0001-9241-7441; Schnell, Joshua/0000-0001-9241-7441	NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053257] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008061] Funding Source: NIH RePORTER; NCI NIH HHS [CA58689] Funding Source: Medline; NIDDK NIH HHS [DK53257] Funding Source: Medline; NIGMS NIH HHS [T32GM08061] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Chen L, 2001, EMBO REP, V2, P933, DOI 10.1093/embo-reports/kve203; Chin LS, 2001, J BIOL CHEM, V276, P7069, DOI 10.1074/jbc.M004129200; DULIC V, 1991, METHOD ENZYMOL, V194, P697; Dupre S, 2001, CURR BIOL, V11, pR932, DOI 10.1016/S0960-9822(01)00558-9; Gagny B, 2000, J CELL SCI, V113, P3309; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 2001, CELL, V106, P527, DOI 10.1016/S0092-8674(01)00485-8; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Komada M, 1997, J BIOL CHEM, V272, P20538, DOI 10.1074/jbc.272.33.20538; Nakatsu F, 2000, J BIOL CHEM, V275, P26213, DOI 10.1074/jbc.M907720199; Odorizzi G, 1998, CELL, V95, P847, DOI 10.1016/S0092-8674(00)81707-9; PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603; Reggiori F, 2001, EMBO J, V20, P5176, DOI 10.1093/emboj/20.18.5176; Rosenthal JA, 1999, J BIOL CHEM, V274, P33959, DOI 10.1074/jbc.274.48.33959; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; Sloper-Mould KE, 2001, J BIOL CHEM, V276, P30483, DOI 10.1074/jbc.M103248200; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Urbanowski JL, 2001, TRAFFIC, V2, P622, DOI 10.1034/j.1600-0854.2001.20905.x; Wendland B, 1999, EMBO J, V18, P4383, DOI 10.1093/emboj/18.16.4383; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; Young P, 1998, J BIOL CHEM, V273, P5461, DOI 10.1074/jbc.273.10.5461	30	340	347	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2002	4	5					389	393		10.1038/ncb790	http://dx.doi.org/10.1038/ncb790			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	547GR	11988742				2022-12-25	WOS:000175325100022
J	Kopf, M; Abel, B; Gallimore, A; Carroll, M; Bachmann, MF				Kopf, M; Abel, B; Gallimore, A; Carroll, M; Bachmann, MF			Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection	NATURE MEDICINE			English	Article							B-CELL; ACQUIRED-IMMUNITY; DEFICIENT MICE; ANTIBODY-RESPONSES; DEPENDENT ANTIGEN; HUMORAL RESPONSE; LYMPHOCYTES-B; IN-VITRO; RECEPTOR; INNATE	The complement cascade defines an important link between the innate and the specific immune system. Here we show that mice deficient for the third component of complement (C3(-/-) mice) are highly susceptible to primary infection with influenza virus. C3(-/-) mice showed delayed viral clearance and increased viral titers in lung, whereas mice deficient for complement receptors CR1 and CR2 (Cr2(-/-) mice) cleared the infection normally. Priming of T-helper cells and cytotoxic T cells ( CTLs) in lung-draining lymph nodes was reduced, and the recruitment into the lung of virus-specific CD4(+) and CD8(+) effector T cells producing interferon-gamma was severely impaired in C3(-/-) but not in Cr2(-/-) mice. Consequently, T-helper cell dependent IgG responses were reduced in C3(-/-) mice but remained intact in Cr2(-/-) mice. These results demonstrate that complement induces specific immunity by promoting T-cell responses.	Swiss Fed Inst Technol, Dept Environm Sci, Zurich, Switzerland; Basel Inst Immunol, Basel, Switzerland; John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DU, England; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Cytos Biotechnol AG, Schlieren, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Oxford; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Kopf, M (corresponding author), Swiss Fed Inst Technol, Dept Environm Sci, Zurich, Switzerland.		Kopf, Manfred/B-6907-2009	Kopf, Manfred/0000-0002-0628-7140; Gallimore, Awen/0000-0001-6675-7004				Ahearn JM, 1996, IMMUNITY, V4, P251, DOI 10.1016/S1074-7613(00)80433-1; BACHMANN MF, 1994, EUR J IMMUNOL, V24, P2567, DOI 10.1002/eji.1830241046; Bachmann MF, 1999, J IMMUNOL METHODS, V225, P105, DOI 10.1016/S0022-1759(99)00034-4; BACHMANN MF, 1994, CURR OPIN IMMUNOL, V6, P320, DOI 10.1016/0952-7915(94)90108-2; BROWN EJ, 1992, INFECT AGENT DIS, V1, P63; Carroll MC, 1998, CURR OPIN IMMUNOL, V10, P36; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; CARTER RH, 1988, J IMMUNOL, V141, P457; Croix DA, 1996, J EXP MED, V183, P1857, DOI 10.1084/jem.183.4.1857; Czermak BJ, 1999, NAT MED, V5, P788, DOI 10.1038/10512; Da Costa XJ, 1999, P NATL ACAD SCI USA, V96, P12708, DOI 10.1073/pnas.96.22.12708; DANIELS CA, 1969, SCIENCE, V165, P508, DOI 10.1126/science.165.3892.508; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; Doherty PC, 1997, IMMUNOL REV, V159, P105, DOI 10.1111/j.1600-065X.1997.tb01010.x; ENGEL P, 1995, IMMUNITY, V3, P39, DOI 10.1016/1074-7613(95)90157-4; FEARON DT, 1995, ANNU REV IMMUNOL, V13, P127, DOI 10.1146/annurev.immunol.13.1.127; Fischer MB, 1996, J IMMUNOL, V157, P549; Gerhard W, 1997, IMMUNOL REV, V159, P95, DOI 10.1111/j.1600-065X.1997.tb01009.x; Graham MB, 1997, J EXP MED, V186, P2063, DOI 10.1084/jem.186.12.2063; Guinamard R, 2000, NAT IMMUNOL, V1, P31, DOI 10.1038/76882; Hopken UE, 1996, NATURE, V383, P86, DOI 10.1038/383086a0; Huber VC, 2001, J IMMUNOL, V166, P7381, DOI 10.4049/jimmunol.166.12.7381; Humbles AA, 2000, NATURE, V406, P998, DOI 10.1038/35023175; Karp CL, 2000, NAT IMMUNOL, V1, P221, DOI 10.1038/79759; Klein MA, 2001, NAT MED, V7, P488, DOI 10.1038/86567; Kopf M, 1999, IMMUNITY, V11, P699, DOI 10.1016/S1074-7613(00)80144-2; LINSCOTT WD, 1969, P NATL ACAD SCI USA, V64, P520, DOI 10.1073/pnas.64.2.520; Mabbott NA, 2001, NAT MED, V7, P485, DOI 10.1038/86562; MORGAN BP, 1991, IMMUNOL TODAY, V12, P301, DOI 10.1016/0167-5699(91)90003-C; MULLEREBERHARD HJ, 1986, ANNU REV IMMUNOL, V4, P503, DOI 10.1146/annurev.iy.04.040186.002443; Nataf S, 2000, J IMMUNOL, V165, P5867, DOI 10.4049/jimmunol.165.10.5867; Nataf S, 1999, J IMMUNOL, V162, P4018; Ochsenbein AF, 1999, J EXP MED, V190, P1165, DOI 10.1084/jem.190.8.1165; PAPAMICHAIL M, 1975, SCAND J IMMUNOL, V4, P343, DOI 10.1111/j.1365-3083.1975.tb02635.x; PEPYS MB, 1974, J EXP MED, V140, P126, DOI 10.1084/jem.140.1.126; Reid RR, 1997, J IMMUNOL, V159, P970; Ruedl C, 2000, EUR J IMMUNOL, V30, P2056, DOI 10.1002/1521-4141(200007)30:7<2056::AID-IMMU2056>3.0.CO;2-S; TEW JG, 1990, IMMUNOL REV, V117, P185, DOI 10.1111/j.1600-065X.1990.tb00573.x; THIEBLEMONT N, 1995, J IMMUNOL, V155, P4861; VANNOESEL CJM, 1993, IMMUNOL TODAY, V14, P8, DOI 10.1016/0167-5699(93)90316-D; WANG Y, 1995, P NATL ACAD SCI USA, V92, P8955, DOI 10.1073/pnas.92.19.8955; WELSH RM, 1976, VIROLOGY, V73, P59, DOI 10.1016/0042-6822(76)90060-X; WESSELS MR, 1995, P NATL ACAD SCI USA, V92, P11490, DOI 10.1073/pnas.92.25.11490	43	245	254	3	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2002	8	4					373	378		10.1038/nm0402-373	http://dx.doi.org/10.1038/nm0402-373			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	536ML	11927943				2022-12-25	WOS:000174704800029
J	Mizumoto, N; Kumamoto, T; Robson, SC; Sevigny, J; Matsue, H; Enjyoji, K; Takashima, A				Mizumoto, N; Kumamoto, T; Robson, SC; Sevigny, J; Matsue, H; Enjyoji, K; Takashima, A			CD39 is the dominant Langerhans cell associated ecto-NTPDase: Modulatory roles in inflammation and immune responsiveness	NATURE MEDICINE			English	Article							MURINE DENDRITIC CELLS; EPIDERMAL T-CELLS; EXTRACELLULAR ATP; CONTACT SENSITIVITY; CYTOKINE PRODUCTION; PLATELET-FUNCTION; P2Y RECEPTORS; ANTIGEN; ACTIVATION; DIPHOSPHOHYDROLASE	CD39, the endothelial ecto-nucleoside triphosphate diphosphohydrolase ( NTPDase), regulates vascular inflammation and thrombosis by hydrolyzing ATP and ADP. Although ecto-NTPDase activities have been used as a marker of epidermal dendritic cells ( DCs) known as Langerhans cells, the identity and function of these activities remain unknown. Here we report that Langerhans cells in CD39(-/-) mice express no detectable ecto-NTPDase activity. Irritant chemicals triggered rapid ATP and ADP release from keratinocytes and caused exacerbated skin inflammation in CD39(-/-) mice. Paradoxically, T cell mediated allergic contact hypersensitivity was severely attenuated in CD39(-/-) mice. As to mechanisms, T cells increased pericellular ATP concentrations upon activation, and CD39(-/-) DCs showed ATP unresponsiveness ( secondary to P2-receptor desensitization) and impaired antigen-presenting capacity. Our results show opposing outcomes of CD39 deficiency in irritant versus allergic contact dermatitis, reflecting its diverse roles in regulating extracellular nucleotide-mediated signaling in inflammatory responses to environmental insults and DC T cell communication in antigen presentation.	Univ Texas, SW Med Ctr, Dept Dermatol, Dallas, TX 75235 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med, Boston, MA 02215 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Takashima, A (corresponding author), Univ Texas, SW Med Ctr, Dept Dermatol, Dallas, TX 75235 USA.	akira.takashima@utsouthwestern.edu	Sevigny, Jean/E-8039-2012; Sévigny, Jean/AGH-9323-2022; Robson, Simon C./AAA-8537-2021	Sevigny, Jean/0000-0003-2922-1600; Sévigny, Jean/0000-0003-2922-1600; 				Abeyama K, 2000, J CLIN INVEST, V105, P1751, DOI 10.1172/JCI9745; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Berchtold S, 1999, FEBS LETT, V458, P424, DOI 10.1016/S0014-5793(99)01197-7; Burnett CA, 1998, AM J IND MED, V34, P568, DOI 10.1002/(SICI)1097-0274(199812)34:6&lt;568::AID-AJIM4&gt;3.0.CO;2-Z; CHAKER MB, 1984, J INVEST DERMATOL, V82, P496, DOI 10.1111/1523-1747.ep12261031; Coutinho-Silva R, 1999, AM J PHYSIOL-CELL PH, V276, pC1139, DOI 10.1152/ajpcell.1999.276.5.C1139; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; DIVIRGILIO F, 1995, IMMUNOL TODAY, V16, P524, DOI 10.1016/0167-5699(95)80045-X; Enjyoji K, 1999, NAT MED, V5, P1010, DOI 10.1038/12447; Ferrari D, 2000, FASEB J, V14, P2466, DOI 10.1096/fj.00-0031com; FILIPPINI A, 1990, P NATL ACAD SCI USA, V87, P8267, DOI 10.1073/pnas.87.21.8267; Gayle RB, 1998, J CLIN INVEST, V101, P1851, DOI 10.1172/JCI1753; GIROLOMONI G, 1993, J INVEST DERMATOL, V100, P282, DOI 10.1111/1523-1747.ep12469769; GOCINSKI BL, 1990, J IMMUNOL, V144, P4121; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Kaczmarek E, 1996, J BIOL CHEM, V271, P33116, DOI 10.1074/jbc.271.51.33116; KANSAS GS, 1991, J IMMUNOL, V146, P2235; Khakh BS, 2001, NAT REV NEUROSCI, V2, P165, DOI 10.1038/35058521; Kumamoto T, 2002, NAT BIOTECHNOL, V20, P64, DOI 10.1038/nbt0102-64; Liu QH, 1999, FEBS LETT, V445, P402, DOI 10.1016/S0014-5793(99)00161-1; LOVESCHIMENTI CD, 1994, J IMMUNOL, V153, P3450; MALISZEWSKI CR, 1994, J IMMUNOL, V153, P3574; Marcus AJ, 1997, J CLIN INVEST, V99, P1351, DOI 10.1172/JCI119294; Marriott I, 1999, CELL IMMUNOL, V195, P147, DOI 10.1006/cimm.1999.1531; Matsue H, 1999, NAT MED, V5, P930, DOI 10.1038/11375; MATSUE H, 1993, J IMMUNOL, V151, P6012; Mummert ME, 2000, J EXP MED, V192, P769, DOI 10.1084/jem.192.6.769; Mutini C, 1999, J IMMUNOL, V163, P1958; Nihei OK, 2000, BLOOD, V96, P996, DOI 10.1182/blood.V96.3.996.015k02_996_1005; PILLAI S, 1992, J CLIN INVEST, V90, P42, DOI 10.1172/JCI115854; PLESNER L, 1995, INT REV CYTOL, V158, P141; Ralevic V, 1998, PHARMACOL REV, V50, P413; Sellers LK, 2001, J BIOL CHEM, V276, P16379, DOI 10.1074/jbc.M006617200; SREEKUMAR P, 1995, J CLIN INVEST, V96, P602, DOI 10.1172/JCI118075; SUTER MM, 1991, J INVEST DERMATOL, V97, P223, DOI 10.1111/1523-1747.ep12480162; Wang TF, 1996, J BIOL CHEM, V271, P9898, DOI 10.1074/jbc.271.17.9898; WOLFF K, 1967, J INVEST DERMATOL, V48, P50, DOI 10.1038/jid.1967.8; Xu H, 1996, J EXP MED, V183, P1001, DOI 10.1084/jem.183.3.1001; XU S, 1995, J IMMUNOL, V154, P2697; Zimmermann H, 2000, N-S ARCH PHARMACOL, V362, P299, DOI 10.1007/s002100000309; ZIMMERMANN H, 1992, BIOCHEM J, V285, P345, DOI 10.1042/bj2850345	41	256	272	1	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2002	8	4					358	365		10.1038/nm0402-358	http://dx.doi.org/10.1038/nm0402-358			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	536ML	11927941				2022-12-25	WOS:000174704800027
J	Andre, P; Prasad, KSS; Denis, CV; He, M; Papalia, JM; Hynes, RO; Phillips, DR; Wagner, DD				Andre, P; Prasad, KSS; Denis, CV; He, M; Papalia, JM; Hynes, RO; Phillips, DR; Wagner, DD			CD40L stabilizes arterial thrombi by a beta(3) integrin-dependent mechanism	NATURE MEDICINE			English	Article							VON-WILLEBRAND-FACTOR; TISSUE FACTOR; P-SELECTIN; MONOCLONAL-ANTIBODY; ENDOTHELIAL-CELLS; LIGAND; PLATELETS; EXPRESSION; ADHESION; DEFECTS	CD40L, a member of the tumor necrosis factor family of ligands, plays a major role in immune responses via its receptor, CD40. Recently, CD40L has been detected on the surfaces of activated platelets and shown to activate endothelium. Here we further addressed the function of platelet CD40L. We show that absence of CD40L affects the stability of arterial thrombi and delays arterial occlusion in vivo. Infusion of recombinant soluble (rs) CD40L restored normal thrombosis, whereas rsCD40L lacking the KGD integrin-recognition sequence did not. CD40-deficient mice exhibited normal thrombogenesis. rsCD40L specifically bound to purified integrin alpha(IIb)beta(3) and to activated platelets in a beta(3)-dependent manner and induced platelet spreading. In addition, rsCD40L promoted the aggregation of either human or mouse platelets under high shear rates. Thus, CD40L appears to be an alpha(IIb)beta(3) ligand, a platelet agonist, and necessary for stability of arterial thrombi.	Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; COR Therapeut, San Francisco, CA USA; MIT, Ctr Canc Res, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Wagner, DD (corresponding author), Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA.	wagner@cbr.med.harvard.edu	Denis, Cecile/A-7649-2011	Denis, Cecile/0000-0001-5152-9156	NHLBI NIH HHS [R37 HL41002, P01 HL056949, R01 HL041002, P01 HL56949] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL056949, R01HL041002, R37HL041002] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andre P, 2000, BLOOD, V96, P3322, DOI 10.1182/blood.V96.10.3322.h8003322_3322_3328; Andre P, 1996, ARTERIOSCL THROM VAS, V16, P56, DOI 10.1161/01.ATV.16.1.56; Andre P, 2000, P NATL ACAD SCI USA, V97, P13835, DOI 10.1073/pnas.250475997; Aukrust P, 1999, CIRCULATION, V100, P614, DOI 10.1161/01.CIR.100.6.614; CELI A, 1994, P NATL ACAD SCI USA, V91, P8767, DOI 10.1073/pnas.91.19.8767; CHARO IF, 1991, J BIOL CHEM, V266, P1415; Denis C, 1998, P NATL ACAD SCI USA, V95, P9524, DOI 10.1073/pnas.95.16.9524; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; Giesen PLA, 1999, P NATL ACAD SCI USA, V96, P2311, DOI 10.1073/pnas.96.5.2311; GRAF D, 1995, EUR J IMMUNOL, V25, P1749, DOI 10.1002/eji.1830250639; Henn V, 2001, BLOOD, V98, P1047, DOI 10.1182/blood.V98.4.1047; Henn V, 1998, NATURE, V391, P591, DOI 10.1038/35393; Hodivala-Dilke KM, 1999, J CLIN INVEST, V103, P229, DOI 10.1172/JCI5487; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; Kawai T, 2000, NAT MED, V6, P114, DOI 10.1038/72162; Kirk AD, 1999, NAT MED, V5, P686, DOI 10.1038/9536; Kotowicz K, 2000, IMMUNOLOGY, V100, P441, DOI 10.1046/j.1365-2567.2000.00061.x; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; LAWLER J, 1989, BLOOD, V74, P2022; Lindmark E, 2000, ARTERIOSCL THROM VAS, V20, P2322, DOI 10.1161/01.ATV.20.10.2322; Lutgens E, 2000, P NATL ACAD SCI USA, V97, P7464, DOI 10.1073/pnas.97.13.7464; Lutgens E, 1999, NAT MED, V5, P1313, DOI 10.1038/15271; Mach F, 1997, CIRCULATION, V96, P396; Melter M, 2000, BLOOD, V96, P3801, DOI 10.1182/blood.V96.12.3801.h8003801_3801_3808; Miller DL, 1998, J LEUKOCYTE BIOL, V63, P373, DOI 10.1002/jlb.63.3.373; Ni HY, 2000, J CLIN INVEST, V106, P385, DOI 10.1172/JCI9896; PHILLIPS DR, 1977, J CLIN INVEST, V60, P535, DOI 10.1172/JCI108805; Pullen SS, 1999, BIOCHEMISTRY-US, V38, P10168, DOI 10.1021/bi9909905; Ramesh N, 1999, PRIMARY IMMUNODEFICIENCY DISEASES, P233; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAKARIASSEN KS, 1988, THROMB HAEMOSTASIS, V60, P392; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1066; SCARBOROUGH RM, 1991, J BIOL CHEM, V266, P9359; Schonbeck U, 2000, P NATL ACAD SCI USA, V97, P7458, DOI 10.1073/pnas.97.13.7458; Schonbeck U, 2001, CELL MOL LIFE SCI, V58, P4, DOI 10.1007/PL00000776; van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2, DOI 10.1002/jlb.67.1.2	36	595	631	1	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2002	8	3					247	252		10.1038/nm0302-247	http://dx.doi.org/10.1038/nm0302-247			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	526PU	11875495				2022-12-25	WOS:000174139500029
J	Kalachikov, S; Evgrafov, O; Ross, B; Winawer, M; Barker-Cummings, C; Boneschi, FM; Choi, C; Morozov, P; Das, K; Teplitskaya, E; Yu, A; Cayanis, E; Penchaszadeh, G; Kottmann, AH; Pedley, TA; Hauser, WA; Ottman, R; Gilliam, TC				Kalachikov, S; Evgrafov, O; Ross, B; Winawer, M; Barker-Cummings, C; Boneschi, FM; Choi, C; Morozov, P; Das, K; Teplitskaya, E; Yu, A; Cayanis, E; Penchaszadeh, G; Kottmann, AH; Pedley, TA; Hauser, WA; Ottman, R; Gilliam, TC			Mutations in LGI1 cause autosomal-dominant partial epilepsy with auditory features	NATURE GENETICS			English	Article							LINKAGE ANALYSIS; MEMBRANE-PROTEINS; CHROMOSOME 10Q; GENE; MAP; IDENTIFICATION; DROSOPHILA; SEQUENCES; HELICES; SLIT	The epilepsies are a common, clinically heterogeneous group of disorders defined by recurrent unprovoked seizures(1). Here we describe identification of the causative gene in autosomal-dominant partial epilepsy with auditory features (ADPEAF, MIM 600512), a rare form of idiopathic lateral temporal lobe epilepsy characterized by partial seizures with auditory disturbances(2,3). We constructed a complete, 4.2-Mb physical map across the genetically implicated disease-gene region, identified 28 putative genes (Fig. 1) and resequenced all or part of 21 genes before identifying presumptive mutations in one copy of the leucine-rich, glioma-inactivated 1 gene (LGI1) in each of five families with ADPEAF. Previous studies have indicated that loss of both copies of LGI1 promotes glial tumor progression. We show that the expression pattern of mouse Lgi1 is predominantly neuronal and is consistent with the anatomic regions involved in temporal lobe epilepsy. Discovery of LGI1 as a cause of ADPEAF suggests new avenues for research on pathogenic mechanisms of idiopathic epilepsies.	Columbia Univ, Gertrude H Sergievsky Ctr, New York, NY 10032 USA; Columbia Univ, Columbia Genome Ctr, New York, NY 10032 USA; Columbia Univ, Dept Epidemiol, New York, NY 10032 USA; Columbia Univ, Dept Psychiat, New York, NY 10032 USA; Columbia Univ, Dept Neurol, New York, NY 10032 USA; Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA; New York State Psychiat Inst & Hosp, Dept Epidemiol Brain Disorders, New York, NY 10032 USA; New York State Psychiat Inst & Hosp, Dept Med Genet, New York, NY 10032 USA; PsychoGenics Inc, New York, NY USA	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; New York State Psychiatry Institute; New York State Psychiatry Institute	Ottman, R (corresponding author), Columbia Univ, Gertrude H Sergievsky Ctr, 630 W 168 St,P&S Box 16, New York, NY 10032 USA.		Ottman, Ruth/O-2371-2013; Hauser, W Allen/AAB-5277-2020; Kottmann, Andreas/Y-1180-2019; Boneschi, Filippo Martinelli/H-8592-2012	Ottman, Ruth/0000-0001-7074-242X; Kottmann, Andreas/0000-0002-5435-7502; martinelli boneschi, filippo/0000-0002-9955-1368	NINDS NIH HHS [R01 NS036319-08, R01 NS020656-13, R01 NS036319, R01 NS020656] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036319, R01NS020656] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aita VM, 1999, AM J HUM GENET, V64, P210, DOI 10.1086/302185; Battye R, 2001, J NEUROSCI, V21, P4290, DOI 10.1523/JNEUROSCI.21-12-04290.2001; CHANG Z, 1993, DEV BIOL, V160, P315, DOI 10.1006/dbio.1993.1310; Chernova OB, 1998, ONCOGENE, V17, P2873, DOI 10.1038/sj.onc.1202481; Commission on Classification and Terminology of the International League Against Epilepsy, 1989, EPILEPSIA, V30, P389; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; Goring HHH, 2000, AM J HUM GENET, V66, P1298, DOI 10.1086/302846; GRAY IC, 1995, GENOMICS, V28, P328, DOI 10.1006/geno.1995.1149; Gray IC, 1997, GENOMICS, V43, P85, DOI 10.1006/geno.1997.4809; HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x; Juretic D, 1998, COMPUT CHEM, V22, P279, DOI 10.1016/S0097-8485(97)00070-3; Kidd T, 1999, CELL, V96, P785, DOI 10.1016/S0092-8674(00)80589-9; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; Mautner VF, 2000, NEUROGENETICS, V3, P31, DOI 10.1007/s100480000091; Meisler MH, 2001, ANNU REV GENET, V35, P567, DOI 10.1146/annurev.genet.35.102401.091142; Michelucci R, 2000, EPILEPSIA, V41, P967, DOI 10.1111/j.1528-1157.2000.tb00280.x; MILPETZ F, 1995, TRENDS BIOCHEM SCI, V20, P204, DOI 10.1016/S0968-0004(00)89009-X; Nobile C, 1998, MAMM GENOME, V9, P835, DOI 10.1007/s003359900877; OTTMAN R, 1995, NAT GENET, V10, P56, DOI 10.1038/ng0595-56; Poza JJ, 1999, ANN NEUROL, V45, P182, DOI 10.1002/1531-8249(199902)45:2<182::AID-ANA8>3.0.CO;2-G; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Shah AB, 1997, AM J HUM GENET, V61, P317, DOI 10.1086/514864; Skradski SL, 2001, NEURON, V31, P537, DOI 10.1016/S0896-6273(01)00397-X; Somerville RPT, 2000, MAMM GENOME, V11, P622, DOI 10.1007/s0033500101280; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1016/S0378-1097(99)00149-4; Winawer MR, 2000, NEUROLOGY, V54, P2173, DOI 10.1212/WNL.54.11.2173; WINAWER MR, 2002, EPILEPSIA, V43, P55; Wu W, 1999, NATURE, V400, P331, DOI 10.1038/22477	30	457	476	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2002	30	3					335	341		10.1038/ng832	http://dx.doi.org/10.1038/ng832			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	526YP	11810107	Green Accepted			2022-12-25	WOS:000174157600022
J	Karsunky, H; Zeng, H; Schmidt, T; Zevnik, B; Kluge, R; Schmid, KW; Duhrsen, U; Moroy, T				Karsunky, H; Zeng, H; Schmidt, T; Zevnik, B; Kluge, R; Schmid, KW; Duhrsen, U; Moroy, T			Inflammatory reactions and severe neutropenia in mice lacking the transcriptional repressor Gfi1	NATURE GENETICS			English	Article							ZINC-FINGER PROTEIN; T-CELL LYMPHOMAGENESIS; PIM-1; MYC; NEUTROPHILS; STAT3	The transcriptional repressor Gfi1 is a nuclear zinc-finger protein expressed in T-cell precursors in the thymus and in activated mature T lymphocytes(1-4). Previous experiments have shown that Gfi1 is involved in T-cell lymphomagenesis and in the development of T-cell progenitors(5-7). Here we show that Gfi1 is also expressed outside the lymphoid system in granulocytes and activated macrophages, cells that mediate innate immunity (that is, non-specific immunity). We have generated Gfi1-deficient mice (Gfi1(-/-)) and show that these animals are severely neutropenic and accumulate immature monocytic cells in blood and bone marrow. Their myeloid precursor cells are unable to differentiate into granulocytes upon stimulation with granulocyte colony-stimulating factor (G-CSF) but can develop into mature macrophages. We found that Gfi1(-/-) macrophages produce enhanced levels of inflammatory cytokines, such as tumor necrosis factor (TNF), interleukin-10 (IL-10) and IL-1beta, when stimulated with bacterial lipopolysaccharide (LPS) and that Gfi1(-/-) mice succumb to low doses of this endotoxin that are tolerated by wildtype mice. We conclude that Gfi1 influences the differentiation of myeloid precursors into granulocytes or monocytes and acts in limiting the inflammatory immune response.	Univ Essen Gesamthsch Klinikum, IFZ, Inst Zellbiol Tumorforsch, D-45122 Essen, Germany; Rhein Westfal TH Aachen, Inst Versuchstierkunde, D-52074 Aachen, Germany; Univ Essen Gesamthsch Klinikum, Inst Pathol, D-45122 Essen, Germany; Univ Essen Gesamthsch Klinikum, Hamatol Abt, D-45122 Essen, Germany	University of Duisburg Essen; RWTH Aachen University; University of Duisburg Essen; University of Duisburg Essen	Moroy, T (corresponding author), Univ Essen Gesamthsch Klinikum, IFZ, Inst Zellbiol Tumorforsch, D-45122 Essen, Germany.		Moroy, Tarik/D-9923-2011; Zevnik, Branko/AAB-7853-2020	Zevnik, Branko/0000-0001-7845-9522				Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; Lagasse E, 1996, J IMMUNOL METHODS, V197, P139, DOI 10.1016/0022-1759(96)00138-X; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Napirei M, 2000, NAT GENET, V25, P177, DOI 10.1038/76032; Rodel B, 2000, EMBO J, V19, P5845, DOI 10.1093/emboj/19.21.5845; Scheijen B, 1997, J VIROL, V71, P9, DOI 10.1128/JVI.71.1.9-16.1997; Schmidt T, 1998, EMBO J, V17, P5349, DOI 10.1093/emboj/17.18.5349; Schmidt T, 1998, ONCOGENE, V17, P2661, DOI 10.1038/sj.onc.1202191; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Zornig M, 1996, ONCOGENE, V12, P1789; ZweidlerMcKay PA, 1996, MOL CELL BIOL, V16, P4024	12	246	251	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2002	30	3					295	300		10.1038/ng831	http://dx.doi.org/10.1038/ng831			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	526YP	11810106				2022-12-25	WOS:000174157600014
J	Carvalho, LH; Sano, GI; Hafalla, JCR; Morrot, A; de Lafaille, MAC; Zavala, F				Carvalho, LH; Sano, GI; Hafalla, JCR; Morrot, A; de Lafaille, MAC; Zavala, F			IL-4-secreting CD4(+) T cells are crucial to the development of CD8(+) T-cell responses against malaria liver stages	NATURE MEDICINE			English	Article							MONOCLONAL-ANTIBODY; CIRCUMSPOROZOITE PROTEIN; HELPER; MICE; LYMPHOCYTES; INDUCTION; IMMUNITY; INFLUENZA; MEMORY; REQUIREMENT	CD4(+) T cells are crucial to the development of CD8(+) T cell responses against hepatocytes infected with malaria parasites. In the absence of CD4(+) T cells, CD8(+) T cells initiate a seemingly normal differentiation and proliferation during the first few days after immunization. However, this response fails to develop further and is reduced by more than 90%, compared to that observed in the presence of CD4(+) T cells. We report here that interleukin-4 (IL-4) secreted by CD4(+) T cells is essential to the full development of this CD8(+) T cell response. This is the first demonstration that IL-4 is a mediator of CD4/CD8 cross-talk leading to the development of immunity against an infectious pathogen.	NYU, Sch Med, Dept Med & Mol Parasitol, New York, NY 10003 USA; NYU, Sch Med, Skirball Inst Biomol Med, Mol Pathogenesis Program, New York, NY USA	New York University; New York University	Zavala, F (corresponding author), NYU, Sch Med, Dept Med & Mol Parasitol, New York, NY 10003 USA.		carvalho, luzia H/C-4087-2013; Carvalho, Luzia H/AAW-3461-2021; Morrot, Alexandre/J-8727-2012	Curotto de Lafaille, Maria Alicia/0000-0002-3510-3777; Morrot, Alexandre/0000-0001-9432-9701				ALLAN W, 1990, J IMMUNOL, V144, P3980; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Andreasen SO, 2000, J IMMUNOL, V164, P3689, DOI 10.4049/jimmunol.164.7.3689; ARMITAGE RJ, 1990, INT IMMUNOL, V2, P1039, DOI 10.1093/intimm/2.11.1039; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; BODMER H, 1993, EUR J IMMUNOL, V23, P1649, DOI 10.1002/eji.1830230738; Borrow P, 1996, J EXP MED, V183, P2129, DOI 10.1084/jem.183.5.2129; Bucy RP, 2001, AIDS, V15, pS36, DOI 10.1097/00002030-200102002-00007; BULLER RML, 1987, NATURE, V328, P77, DOI 10.1038/328077a0; Cardin RD, 1996, J EXP MED, V184, P863, DOI 10.1084/jem.184.3.863; Carvalho LH, 2001, J IMMUNOL METHODS, V252, P207, DOI 10.1016/S0022-1759(01)00331-3; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; Franco A, 2000, NAT IMMUNOL, V1, P145, DOI 10.1038/77827; Huang LR, 2000, P NATL ACAD SCI USA, V97, P3406, DOI 10.1073/pnas.060026497; Kaplan MH, 1998, J LEUKOCYTE BIOL, V64, P2, DOI 10.1002/jlb.64.1.2; KEENE JA, 1982, J EXP MED, V155, P768, DOI 10.1084/jem.155.3.768; Kurts C, 1997, J EXP MED, V186, P2057, DOI 10.1084/jem.186.12.2057; Lu ZB, 2000, J EXP MED, V191, P541, DOI 10.1084/jem.191.3.541; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; McCune JM, 2001, NATURE, V410, P974, DOI 10.1038/35073648; MIYAHIRA Y, 1995, J IMMUNOL METHODS, V181, P45, DOI 10.1016/0022-1759(94)00327-S; OHARA J, 1985, NATURE, V315, P333, DOI 10.1038/315333a0; OHTEKI T, 1994, J EXP MED, V180, P699, DOI 10.1084/jem.180.2.699; Ossendorp F, 1998, J EXP MED, V187, P693, DOI 10.1084/jem.187.5.693; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PedrasVasconcelos JA, 1996, J IMMUNOL, V157, P3046; Peng LM, 2000, J IMMUNOL, V165, P5738, DOI 10.4049/jimmunol.165.10.5738; Riberdy JM, 2000, J VIROL, V74, P9762, DOI 10.1128/JVI.74.20.9762-9765.2000; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; RODRIGUES MM, 1991, INT IMMUNOL, V3, P579, DOI 10.1093/intimm/3.6.579; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; Sano G, 2001, J EXP MED, V194, P173, DOI 10.1084/jem.194.2.173; Schluns KS, 2000, NAT IMMUNOL, V1, P426, DOI 10.1038/80868; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; Schuler T, 1999, J EXP MED, V189, P803, DOI 10.1084/jem.189.5.803; SEAMAN WE, 1987, J IMMUNOL, V138, P4539; TRIPP RA, 1995, J IMMUNOL, V155, P2955; WEISS WR, 1993, J IMMUNOL, V151, P2690; Zavala F, 2001, VIROLOGY, V280, P155, DOI 10.1006/viro.2000.0792	39	174	179	1	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2002	8	2					166	170		10.1038/nm0202-166	http://dx.doi.org/10.1038/nm0202-166			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	517FN	11821901				2022-12-25	WOS:000173600600026
J	Launay, JM; Herve, P; Peoc'h, K; Tournois, C; Callebert, J; Nebigil, CG; Etienne, N; Drouet, L; Humbert, M; Simonneau, G; Maroteaux, L				Launay, JM; Herve, P; Peoc'h, K; Tournois, C; Callebert, J; Nebigil, CG; Etienne, N; Drouet, L; Humbert, M; Simonneau, G; Maroteaux, L			Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension	NATURE MEDICINE			English	Article							VASCULAR SMOOTH-MUSCLE; 5-HT2B RECEPTORS; DEXFENFLURAMINE TREATMENT; PLASMA SEROTONIN; CHRONIC HYPOXIA; ARTERY SMOOTH; FENFLURAMINE; MICE; CELLS; RATS	Primary pulmonary hypertension is a progressive and often fatal disorder in humans that results from an increase in pulmonary blood pressure associated with abnormal vascular proliferation. Dexfenfluramine increases the risk of pulmonary hypertension in humans, and its active metabolite is a selective serotonin 5-hydroxytryptamine 2B (5-HT2B) receptor agonist. Thus, we investigated the contribution of the 5-HT2B receptor to the pathogenesis of pulmonary hypertension. Using the chronic-hypoxic-mouse model of pulmonary hypertension, we found that the hypoxia-dependent increase in pulmonary blood pressure and lung remodeling are associated with an increase in vascular proliferation, elastase activity and transforming growth factor-beta levels, and that these parameters are potentiated by dexfenfluramine treatment. In contrast, hypoxic mice with genetically or pharmacologically inactive 5-HT2B receptors manifested no change in any of these parameters. In both humans and mice, pulmonary hypertension is associated with a substantial increase in 5-HT2B receptor expression in pulmonary arteries. These data show that activation of 5-HT2B receptors is a limiting step in the development of pulmonary hypertension.	Univ Strasbourg 1, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, Illkirch Graffenstaden, France; Hop Lariboisiere AP HP, Serv Biochim, CRC Bernard Pathol Expt & Commun Cellulaires, Paris, France; Hop Lariboisiere AP HP, Serv Angiohematol, CRC Bernard Pathol Expt & Commun Cellulaires, Paris, France; Ctr Chirurg Marie Lannelongue, Le Plessis Robinson, France; Hop Antoine Beclere AP HP, UPRES Malad Vasc & Pulm, Clamart, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Hopital Marie Lannelongue; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP	Maroteaux, L (corresponding author), Univ Strasbourg 1, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, Illkirch Graffenstaden, France.	lucm@igbmc.u-strasbg.fr	Simonneau, Gerald/ABE-6614-2020; Nebigil, Canan/AAK-7162-2021; Maroteaux, Luc/H-4585-2019; Peoc'h, Katell/V-1604-2017; callebert, jacques/L-4569-2017	Nebigil, Canan/0000-0002-2035-5795; Maroteaux, Luc/0000-0002-9499-8603; Peoc'h, Katell/0000-0002-8203-1243; Humbert, Marc/0000-0003-0703-2892				Abenhaim L, 1996, NEW ENGL J MED, V335, P609, DOI 10.1056/NEJM199608293350901; Belknap JK, 1997, AM J RESP CELL MOL, V16, P366, DOI 10.1165/ajrcmb.16.4.9115746; Bonhaus DW, 1999, BRIT J PHARMACOL, V127, P1075, DOI 10.1038/sj.bjp.0702632; BUCZKO W, 1975, BRIT J PHARMACOL, V53, P563, DOI 10.1111/j.1476-5381.1975.tb07395.x; Cowan KN, 2000, NAT MED, V6, P698, DOI 10.1038/76282; Cowan KN, 1999, CIRC RES, V84, P1223, DOI 10.1161/01.RES.84.10.1223; Eddahibi S, 1998, AM J RESP CRIT CARE, V157, P1111, DOI 10.1164/ajrccm.157.4.9704095; Eddahibi S, 2000, J CLIN INVEST, V105, P1555, DOI 10.1172/JCI8678; Eddahibi S, 2001, J CLIN INVEST, V108, P1141, DOI 10.1172/JCI12805; Eddahibi S, 2001, J PHARMACOL EXP THER, V297, P148; Egermayer P, 1999, THORAX, V54, P161, DOI 10.1136/thx.54.2.161; Fanburg BL, 1997, AM J PHYSIOL-LUNG C, V272, pL795, DOI 10.1152/ajplung.1997.272.5.L795; Fitzgerald LW, 2000, MOL PHARMACOL, V57, P75; Glusa E, 2000, BRIT J PHARMACOL, V130, P692, DOI 10.1038/sj.bjp.0703341; HERVE P, 1995, AM J MED, V99, P249, DOI 10.1016/S0002-9343(99)80156-9; Hoshikawa Y, 2001, AM J RESP CRIT CARE, V164, P314, DOI 10.1164/ajrccm.164.2.2010150; HUMBERT M, 1932, EUR RESPIR J, V20, P59; Keegan A, 2001, CIRC RES, V89, P1231, DOI 10.1161/hh2401.100426; Kereveur A, 2000, ARTERIOSCL THROM VAS, V20, P2233, DOI 10.1161/01.ATV.20.10.2233; Launay JM, 1996, J BIOL CHEM, V271, P3141, DOI 10.1074/jbc.271.6.3141; Lee SL, 1999, AM J PHYSIOL-LUNG C, V277, pL282, DOI 10.1152/ajplung.1999.277.2.L282; Loscalzo J, 2001, NEW ENGL J MED, V345, P367, DOI 10.1056/NEJM200108023450511; MacLean MR, 2000, BRIT J PHARMACOL, V131, P161, DOI 10.1038/sj.bjp.0703570; MacLean MR, 1999, TRENDS PHARMACOL SCI, V20, P490, DOI 10.1016/S0165-6147(99)01389-9; Mchelakis ED, 2001, AM J MED SCI, V321, P292, DOI 10.1097/00000441-200104000-00009; MIDHA KK, 1983, XENOBIOTICA, V13, P31, DOI 10.3109/00498258309052212; Morrell NW, 2001, CIRCULATION, V104, P790, DOI 10.1161/hc3201.094152; Naeije R, 1996, AM J RESP CRIT CARE, V154, P1347, DOI 10.1164/ajrccm.154.5.8912746; Nebigil CG, 2000, P NATL ACAD SCI USA, V97, P9508, DOI 10.1073/pnas.97.17.9508; Nebigil CG, 2000, P NATL ACAD SCI USA, V97, P2591, DOI 10.1073/pnas.050282397; Nebigil CG, 2001, CIRCULATION, V103, P2973, DOI 10.1161/01.CIR.103.24.2973; PITT BR, 1994, AM J PHYSIOL, V266, pL178, DOI 10.1152/ajplung.1994.266.2.L178; Rabinovitch M, 1999, AM J PHYSIOL-LUNG C, V277, pL5, DOI 10.1152/ajplung.1999.277.1.L5; Rabinovitch M, 1997, CARDIOVASC RES, V34, P268; Rabinovitch M, 2001, J CLIN INVEST, V108, P1109; RABINOVITCH M, 1988, Chest, V93, p119S; Rich S, 2000, CHEST, V117, P870, DOI 10.1378/chest.117.3.870; Rothman RB, 2000, CIRCULATION, V102, P2836; Rubin LJ, 1999, PEDIATR PULM, P194; Sanchez C, 1999, CELL MOL NEUROBIOL, V19, P467, DOI 10.1023/A:1006986824213; Steudel W, 1998, J CLIN INVEST, V101, P2468, DOI 10.1172/JCI2356; Tucker A, 2001, HIGH ALT MED BIOL, V2, P173, DOI 10.1089/152702901750265288; Ullmer C, 1996, BRIT J PHARMACOL, V117, P1081, DOI 10.1111/j.1476-5381.1996.tb16700.x; ULLMER C, 1995, FEBS LETT, V370, P215, DOI 10.1016/0014-5793(95)00828-W; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Zhao L, 1999, CIRCULATION, V99, P605, DOI 10.1161/01.CIR.99.5.605	46	301	322	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2002	8	10					1129	1135		10.1038/nm764	http://dx.doi.org/10.1038/nm764			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	599AN	12244304	Green Submitted			2022-12-25	WOS:000178311000040
J	Takashima, H; Boerkoel, CF; John, J; Saifi, GM; Salih, MAM; Armstrong, D; Mao, YX; Quiocho, FA; Roa, BB; Nakagawa, M; Stockton, DW; Lupski, JR				Takashima, H; Boerkoel, CF; John, J; Saifi, GM; Salih, MAM; Armstrong, D; Mao, YX; Quiocho, FA; Roa, BB; Nakagawa, M; Stockton, DW; Lupski, JR			Mutation of TDP1, encoding a topoisomerase I-dependent DNA damage repair enzyme, in spinocerebellar ataxia with axonal neuropathy	NATURE GENETICS			English	Article							PHOSPHOLIPASE-D SUPERFAMILY; COVALENT COMPLEXES; LINKAGE ANALYSIS; GENE; MEMBER; FAMILY; PHOSPHODIESTERASE; APOPTOSIS; MOTOR	Tyrosyl-DNA phosphodiesterase 1 (TDP1) repairs covalently bound topoisomerase I-DNA complexes(1-3) and is essential for preventing the formation of double-strand breaks that result when stalled topoisomerase I complexes interfere with DNA replication in yeast(4). Here we show that a deficiency of this DNA repair pathway in humans does not predispose to neoplasia or dysfunctions in rapidly replicating tissues, but instead causes spinocerebellar ataxia with axonal neuropathy (SCAN1) by affecting large, terminally differentiated, nondividing neuronal cells. Using genome-wide linkage mapping and a positional candidate approach in a Saudi Arabian family affected with autosomal recessive SCAN1, we identified a homozygous mutation in TDP1 (A1478G) that results in the substitution of histidine 493 with an arginine residue. The His493 residue is conserved in TDP1 across species and is located in the active site of the enzyme(3,5). Protein modeling predicts that mutation of this amino acid to arginine will disrupt the symmetric structure of the active site. We propose that loss-of-function mutations in TDP1 may cause SCAN1 either by interfering with DNA transcription or by inducing apoptosis in postmitotic neurons.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Kleberg Genotyping Ctr, Houston, TX 77030 USA; King Saud Univ, Coll Med, Dept Pediat, Div Pediat Neurol, Riyadh 11461, Saudi Arabia; Texas Childrens Hosp, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Baylor DNA Diagnost Lab, Houston, TX 77030 USA; Kagoshima Univ, Sch Med, Dept Internal Med 3, Kagoshima 890, Japan; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Ophthalmol, Houston, TX 77030 USA; Texas Childrens Hosp, Dept Pediat, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; King Saud University; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine; Kagoshima University; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Lupski, JR (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza, Houston, TX 77030 USA.		Boerkoel, Cornelius Franciscus/AFW-4948-2022; Salih, Mustafa/C-1222-2014	Boerkoel, Cornelius Franciscus/0000-0003-3097-241X; Mao, Yuxin/0000-0002-5064-1397; Salih, Mustafa/0000-0002-4379-2111				BENDIXEN C, 1990, BIOCHEMISTRY-US, V29, P5613, DOI 10.1021/bi00475a028; Date H, 2001, NAT GENET, V29, P184, DOI 10.1038/ng1001-184; Davies DR, 2002, STRUCTURE, V10, P237, DOI 10.1016/S0969-2126(02)00707-4; de Boer J, 2000, CARCINOGENESIS, V21, P453, DOI 10.1093/carcin/21.3.453; Debethune L, 2002, NUCLEIC ACIDS RES, V30, P1198, DOI 10.1093/nar/30.5.1198; den Dunnen JT, 2001, HUM GENET, V109, P121, DOI 10.1007/s004390100505; Di Donato S, 2001, NEUROL SCI, V22, P219, DOI 10.1007/s100720100017; Gobbel GT, 1998, J NEUROSCI, V18, P147; Gottlin EB, 1998, P NATL ACAD SCI USA, V95, P9202, DOI 10.1073/pnas.95.16.9202; Gudbjartsson DF, 2000, NAT GENET, V25, P12, DOI 10.1038/75514; HARDING A, 1993, BRAINS DIS NERVOUS S, P432; Inamura N, 2000, J NEUROSCI RES, V60, P450, DOI 10.1002/(SICI)1097-4547(20000515)60:4<450::AID-JNR3>3.3.CO;2-G; Interthal H, 2001, P NATL ACAD SCI USA, V98, P12009, DOI 10.1073/pnas.211429198; Jilani A, 1999, J BIOL CHEM, V274, P24176, DOI 10.1074/jbc.274.34.24176; KROEGER PE, 1989, NUCLEIC ACIDS RES, V17, P8495, DOI 10.1093/nar/17.21.8495; LATHROP GM, 1984, AM J HUM GENET, V36, P460; Mao YX, 2001, CELL, V104, P433, DOI 10.1016/S0092-8674(01)00230-6; Moreira MC, 2001, NAT GENET, V29, P189, DOI 10.1038/ng1001-189; Norbury CJ, 2001, ANNU REV PHARMACOL, V41, P367, DOI 10.1146/annurev.pharmtox.41.1.367; Ponting CP, 1996, PROTEIN SCI, V5, P914; Pouliot JJ, 1999, SCIENCE, V286, P552, DOI 10.1126/science.286.5439.552; Pouliot JJ, 2001, GENES CELLS, V6, P677, DOI 10.1046/j.1365-2443.2001.00452.x; Rudolph AE, 1999, J BIOL CHEM, V274, P11824, DOI 10.1074/jbc.274.17.11824; SCHAFFER AA, 1994, HUM HERED, V44, P225, DOI 10.1159/000154222; Sekijima Y, 1998, J NEUROL SCI, V158, P30, DOI 10.1016/S0022-510X(98)00103-8; Stuckey JA, 1999, NAT STRUCT BIOL, V6, P278; Thompson LH, 2000, MUTAT RES-DNA REPAIR, V459, P1, DOI 10.1016/S0921-8777(99)00058-0; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Whitehouse CJ, 2001, CELL, V104, P107, DOI 10.1016/S0092-8674(01)00195-7; Yang SW, 1996, P NATL ACAD SCI USA, V93, P11534, DOI 10.1073/pnas.93.21.11534	30	379	384	1	28	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2002	32	2					267	272		10.1038/ng987	http://dx.doi.org/10.1038/ng987			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	599AP	12244316				2022-12-25	WOS:000178311100015
J	Cho, JJ; Malhi, H; Wang, R; Joseph, B; Ludlow, JW; Susick, R; Gupta, S				Cho, JJ; Malhi, H; Wang, R; Joseph, B; Ludlow, JW; Susick, R; Gupta, S			Enzymatically labeled chromosomal probes for in situ identification of human cells in xenogeneic transplant models	NATURE MEDICINE			English	Article							IN-VIVO INFECTION; HEPATITIS-B VIRUS; HUMAN HEPATOCYTES; BONE-MARROW; LIVER; MICE; POLYPLOIDY; EXPRESSION; RATS	Analysis of the viability, differentiation, clonogenicity and function of human stem/progenitor cells requires suitable xenograft models. However, the identification of transplanted cells has been generally difficult. Fluorescence in situ hybridization is a tedious method for analyzing tissues, and localization of transplanted cells with X or Y chromosome probes is limited by the sparse signals produced. Therefore, we examined the possibility of generating either pan-nuclear signals with a total human DNA probe or multiple nuclear signals with a pan-centromeric human DNA probe. The probes were labeled with digoxigenin to make reaction products visible by light microscopy and to allow the use of immunohistochemistry methods incorporating various color schemes to demonstrate specific properties of transplanted cells. The ability to localize all types of nucleated human cells with such probes will facilitate studies of stem cell biology and cell and gene therapy, as well as the development of new animal models.	Yeshiva Univ Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Dept Pathol, Bronx, NY 10461 USA; Incara Cell Technol, Res Triangle Pk, NC 27709 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Gupta, S (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Dept Med, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NIDDK NIH HHS [P30-DK-41296, R01 DK46952] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046952, P30DK041296] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brown JJ, 2000, HEPATOLOGY, V31, P173, DOI 10.1002/hep.510310126; Dandri M, 2001, HEPATOLOGY, V33, P981, DOI 10.1053/jhep.2001.23314; Gorla GR, 2001, J CELL SCI, V114, P2943; Gupta S, 1999, AM J PHYSIOL-GASTR L, V276, pG629, DOI 10.1152/ajpgi.1999.276.3.G629; GUPTA S, 1995, P NATL ACAD SCI USA, V92, P5860, DOI 10.1073/pnas.92.13.5860; Gupta S, 2000, SEMIN CANCER BIOL, V10, P161; Korbling M, 2002, NEW ENGL J MED, V346, P738, DOI 10.1056/NEJMoa3461002; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Malhi H, 2002, J CELL SCI, V115, P2679; Malhi H, 2001, J Hepatobiliary Pancreat Surg, V8, P40, DOI 10.1007/s005340170049; Mercer DF, 2001, NAT MED, V7, P927, DOI 10.1038/90968; Ohashi K, 2000, NAT MED, V6, P327; Ott M, 1999, GENE EXPRESSION, V8, P175; Ott M, 1999, J PATHOL, V187, P365, DOI 10.1002/(SICI)1096-9896(199902)187:3<365::AID-PATH237>3.0.CO;2-Z; Ouyang EC, 2001, WORLD J GASTROENTERO, V7, P324; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; PONDER KP, 1991, P NATL ACAD SCI USA, V88, P1217, DOI 10.1073/pnas.88.4.1217; Rajvanshi P, 1998, CELL TRANSPLANT, V7, P275, DOI 10.1016/S0963-6897(98)00002-5; Theise ND, 2000, HEPATOLOGY, V31, P235, DOI 10.1002/hep.510310135; Zahler MH, 2000, J GENE MED, V2, P186	20	11	11	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2002	8	9					1033	1036		10.1038/nm756	http://dx.doi.org/10.1038/nm756			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	589KQ	12185363				2022-12-25	WOS:000177757900040
J	Pellois, JP; Zhou, XC; Srivannavit, O; Zhou, TC; Gulari, E; Gao, XL				Pellois, JP; Zhou, XC; Srivannavit, O; Zhou, TC; Gulari, E; Gao, XL			Individually addressable parallel peptide synthesis on microchips	NATURE BIOTECHNOLOGY			English	Article							SOLUTION PHOTOGENERATED ACIDS; LIGHT-DIRECTED SYNTHESIS; SOLID-PHASE SYNTHESIS; CHEMICAL SYNTHESIS; MEMBRANE SUPPORTS; EPITOPE LIBRARY; SPOT-SYNTHESIS; LIGANDS; PHAGE; MICROARRAYS	Miniaturized, spatially addressable microchips of peptides and peptidomimetics are powerful tools for high-throughput biomedical and pharmaceutical research and the advancement of proteomics. Here we report an efficient and flexible method for the parallel synthesis of peptides on individually addressable microchips, using digital photolithography and photogenerated acid in the deprotection step. We demonstrate that we are able to synthesize thousands of peptides in a 1 cm 2 area on a microchip using 20 natural amino acids as well as synthetic amino acid analogs, with high stepwise yields and short reaction-cycle times. Epitope screening experiments using a p53 antibody (PAb240) produced clearly defined binding patterns. The peptidomimetic sequences on the microchip show specific antibody binding and provide insights into the molecular details responsible for specificity of epitope binding. Our approach requires just a conventional synthesizer and a computer-controllable optical module, thereby allowing potential development of peptide microchips for various pharmaceutical and proteomic applications in routine research laboratories.	Univ Houston, Dept Chem, Houston, TX 77004 USA; Xeotron Co, Houston, TX 77054 USA; Univ Michigan, Dept Chem Engn, Ann Arbor, MI 48109 USA	University of Houston System; University of Houston; University of Michigan System; University of Michigan	Gao, XL (corresponding author), Univ Houston, Dept Chem, Univ Pk, Houston, TX 77004 USA.	xgao@uh.edu		Pellois, Jean-Philippe/0000-0001-8528-4652				[Anonymous], 1999, NAT GENET S, V21; BECKSICKINGER AG, 1996, COMBINATORIAL PEPTID, P79; Beier M, 2000, Nucleic Acids Res, V28, pE11, DOI 10.1093/nar/28.4.e11; Bochet CG, 2000, TETRAHEDRON LETT, V41, P6341, DOI 10.1016/S0040-4039(00)01050-9; CHO CY, 1993, SCIENCE, V261, P1303, DOI 10.1126/science.7689747; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; Emili AQ, 2000, NAT BIOTECHNOL, V18, P393, DOI 10.1038/74442; FELICI F, 1991, J MOL BIOL, V222, P301, DOI 10.1016/0022-2836(91)90213-P; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; FURKA A, 1996, COMBINATORIAL PEPTID, P111; Gao XL, 1998, J AM CHEM SOC, V120, P12698, DOI 10.1021/ja9827191; Gao XL, 2001, NUCLEIC ACIDS RES, V29, P4744, DOI 10.1093/nar/29.22.4744; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; Kramer A, 1998, METH MOL B, V87, P25; Kramer A, 1999, J PEPT RES, V54, P319, DOI 10.1034/j.1399-3011.1999.00108.x; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; Lam KS, 2002, CURR OPIN CHEM BIOL, V6, P353, DOI 10.1016/S1367-5931(02)00326-5; Lebl M, 1998, BIOPOLYMERS, V47, P397, DOI 10.1002/(SICI)1097-0282(1998)47:5<397::AID-BIP6>3.0.CO;2-U; LeProust E, 2000, J COMB CHEM, V2, P349, DOI 10.1021/cc000009x; LeProust E, 2001, NUCLEIC ACIDS RES, V29, P2171, DOI 10.1093/nar/29.10.2171; Li M, 2000, NAT BIOTECHNOL, V18, P1251, DOI 10.1038/82355; MACDONALD SA, 1994, ACCOUNTS CHEM RES, V27, P151, DOI 10.1021/ar00042a001; McGall GH, 1997, J AM CHEM SOC, V119, P5081, DOI 10.1021/ja964427a; MERRIFIELD B, 1986, SCIENCE, V232, P341, DOI 10.1126/science.3961484; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; Pellois JP, 2000, J COMB CHEM, V2, P355, DOI 10.1021/cc0000139; PELLOIS JP, 2002, THESIS U HOUSTON HOU; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; Singh-Gasson S, 1999, NAT BIOTECHNOL, V17, P974, DOI 10.1038/13664; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; Stewart JM, 1984, SOLID PHASE PEPTIDE; Wenschuh H, 2000, BIOPOLYMERS, V55, P188, DOI 10.1002/1097-0282(2000)55:3<188::AID-BIP20>3.0.CO;2-T; WILLSON CG, 1994, INTRO MICROLITHOGRAP, P138; Winssinger N, 2001, ANGEW CHEM INT EDIT, V40, P3152, DOI 10.1002/1521-3773(20010903)40:17<3152::AID-ANIE3152>3.0.CO;2-P	37	155	202	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2002	20	9					922	926		10.1038/nbt723	http://dx.doi.org/10.1038/nbt723			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	589KN	12134169				2022-12-25	WOS:000177757700025
J	Potter, CJ; Pedraza, LG; Xu, T				Potter, CJ; Pedraza, LG; Xu, T			Akt regulates growth by directly phosphorylating Tsc2	NATURE CELL BIOLOGY			English	Article							PROTEIN-KINASE-B; TUMOR-SUPPRESSOR PTEN; TUBEROUS SCLEROSIS; CELL-PROLIFERATION; DROSOPHILA HOMOLOG; SIGNALING PATHWAY; EYE DEVELOPMENT; GENETIC-CONTROL; ORGAN GROWTH; SMALL FLIES	The direct mechanism by which the serine/threonine kinase Akt (also known as protein kinase B (PKB)) regulates cell growth is unknown. Here, we report that Drosophila melanogaster Akt/PKB stimulates growth by phosphorylating the tuberous sclerosis complex 2 (Tsc2) tumour suppressor and inhibiting formation of a Tsc1-Tsc2 complex. We show that Akt/PKB directly phosphorylates Drosophila Tsc2 in vitro at the conserved residues, Ser 924 and Thr 1518. Mutation of these sites renders Tsc2 insensitive to Akt/PKB signalling, increasing the stability of the Tsc1-Tsc2 complex within the cell. Stimulating Akt/PKB signalling in vivo markedly increases cell growth/size, disrupts the Tsc1-Tsc2 complex and disturbs the distinct subcellular localization of Tsc1 and Tsc2. Furthermore, all Akt/PKB growth signals are blocked by expression of a Tsc2 mutant lacking Akt phosphorylation sites. Thus, Tsc2 seems to be the critical target of Akt in mediating growth signals for the insulin signalling pathway.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Genet,Howard Hughes Med Inst, New Haven, CT 06536 USA	Howard Hughes Medical Institute; Yale University	Xu, T (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Genet,Howard Hughes Med Inst, 295 Congress Ave, New Haven, CT 06536 USA.		Potter, Christopher John/H-5884-2019	Potter, Christopher John/0000-0002-5223-8112	NATIONAL CANCER INSTITUTE [R01CA069408] Funding Source: NIH RePORTER; NCI NIH HHS [CA69408] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cheadle JP, 2000, HUM GENET, V107, P97, DOI 10.1007/s004390000348; CONSORTIUM TEC, 1993, CELL, V75, P1305; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Edgar BA, 1999, NAT CELL BIOL, V1, pE191, DOI 10.1038/70217; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; Gao XS, 2000, DEV BIOL, V221, P404, DOI 10.1006/dbio.2000.9680; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Goberdhan DCI, 1999, GENE DEV, V13, P3244, DOI 10.1101/gad.13.24.3244; Gomez MR, 1988, TUBEROUS SCLEROSIS; GOMEZ MR, 1999, TUBEROUS SCLEROSIS; Halder G, 1998, DEVELOPMENT, V125, P2181; Hay BA, 1997, P NATL ACAD SCI USA, V94, P5195, DOI 10.1073/pnas.94.10.5195; Huang H, 1999, DEVELOPMENT, V126, P5365; Ito K, 1997, DEVELOPMENT, V124, P761; Ito N, 1999, CELL, V96, P529, DOI 10.1016/S0092-8674(00)80657-1; Lehner CF, 1999, NAT CELL BIOL, V1, pE129, DOI 10.1038/12961; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maheshwar MM, 1997, HUM MOL GENET, V6, P1991, DOI 10.1093/hmg/6.11.1991; Miloloza A, 2000, HUM MOL GENET, V9, P1721, DOI 10.1093/hmg/9.12.1721; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Nellist M, 1999, J BIOL CHEM, V274, P35647, DOI 10.1074/jbc.274.50.35647; Oldham S, 2000, GENE DEV, V14, P2689, DOI 10.1101/gad.845700; Plank TL, 1998, CANCER RES, V58, P4766; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Scanga SE, 2000, ONCOGENE, V19, P3971, DOI 10.1038/sj.onc.1203739; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stocker H, 2000, CURR OPIN GENET DEV, V10, P529, DOI 10.1016/S0959-437X(00)00123-4; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Theodosiou NA, 1998, DEVELOPMENT, V125, P3411; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; Weinkove D, 2000, CURR OPIN GENET DEV, V10, P75, DOI 10.1016/S0959-437X(99)00042-8; XU TA, 1995, DEVELOPMENT, V121, P1053; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000	47	727	756	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	2002	4	9					658	665		10.1038/ncb840	http://dx.doi.org/10.1038/ncb840			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	589WE	12172554				2022-12-25	WOS:000177783900009
J	Brader, ML; Sukumar, M; Pekar, AH; McClellan, DS; Chance, RE; Flora, DB; Cox, AL; Irwin, L; Myers, SR				Brader, ML; Sukumar, M; Pekar, AH; McClellan, DS; Chance, RE; Flora, DB; Cox, AL; Irwin, L; Myers, SR			Hybrid insulin cocrystals for controlled release delivery	NATURE BIOTECHNOLOGY			English	Article							ALBUMIN-BINDING; ACTING INSULIN; TIME-ACTION; CRYSTALS; THERAPY; ANALOG; PHENOL; HELIX; NN304; DOGS	The ability to tailor the release profile of a drug by manipulating its formulation matrix offers important therapeutic advantages. We show here that human insulin can be cocrystallized at preselected ratios with the fully active lipophilically modified insulin derivative octanoyl-N-LysB29-human insulin (C8-HI). The cocrystal is analogous to the NPH (neutral protamine Hagedorn) crystalline complex formed with human insulin, which is commonly used as the long-acting insulin component of diabetes therapy. The in vitro and in vivo release rates of the cocrystal can be controlled by adjusting the relative proportions of the two insulin components. We identified a cocrystal composition comprising 75% C8-HI and 25% human insulin that exhibits near-ideal basal pharmacodynamics in somatostatin-treated beagle dogs. The dependence of release rate on cocrystal ratio provides a robust mechanism for modulating insulin pharmacodynamics. These findings show that a crystalline protein matrix may accommodate a chemical modification that alters the dissolution rate of the crystal in a therapeutically useful way, yet that is structurally innocuous enough to preserve the pharmaceutical integrity of the original microcrystalline entity and the pharmacological activity of the parent molecule.	Eli Lilly & Co, Lilly Res Labs, Bioprod Pharmaceut Dev, Indianapolis, IN 46285 USA; Eli Lilly & Co, Lilly Res Labs, Phys & Struct Characterizat, Indianapolis, IN 46285 USA; Eli Lilly & Co, Lilly Res Labs, Bio Res Technol & Prot, Indianapolis, IN 46285 USA; Eli Lilly & Co, Lilly Res Labs, Endocrine Res, Indianapolis, IN 46285 USA	Eli Lilly; Eli Lilly; Eli Lilly; Eli Lilly	Brader, ML (corresponding author), Eli Lilly & Co, Lilly Res Labs, Bioprod Pharmaceut Dev, Indianapolis, IN 46285 USA.							Abel JJ, 1926, P NATL ACAD SCI USA, V12, P132, DOI 10.1073/pnas.12.2.132; BAKER E N, 1970, Journal of Molecular Biology, V54, P605, DOI 10.1016/0022-2836(70)90131-2; BAKER EN, 1988, PHILOS T ROY SOC B, V319, P369, DOI 10.1098/rstb.1988.0058; BALSCHMIDT P, 1991, ACTA CRYSTALLOGR B, V47, P975, DOI 10.1107/S010876819100842X; BANERJEE PS, 1991, PEPTIDE PROTEIN DELI, V4, P487; Brader ML, 1997, TECH PROT CHEM, V8, P289, DOI 10.1016/S1080-8914(97)80030-0; Brange J., 1987, GALENICS INSULIN; BREMS DN, 1992, PROTEIN ENG, V5, P527, DOI 10.1093/protein/5.6.527; DeFelippis MR, 1998, J PHARM SCI, V87, P170, DOI 10.1021/js970285m; Defelippis MR, 2000, PHARM FORMULATION DE, P113; DEREWENDA U, 1989, NATURE, V338, P594, DOI 10.1038/338594a0; FELIG P, 1984, JAMA-J AM MED ASSOC, V251, P393, DOI 10.1001/jama.251.3.393; GALLOWAY JA, 1994, HORM METAB RES, V26, P591, DOI 10.1055/s-2007-1001766; HAGEDORS H. C., 1936, Journal of the American Medical Association, V106, P177; Hamilton-Wessler M, 1999, DIABETOLOGIA, V42, P1254, DOI 10.1007/s001250051301; Hassiepen U, 1999, BIOPHYS J, V77, P1638, DOI 10.1016/S0006-3495(99)77012-8; Heinemann L, 1999, DIABETIC MED, V16, P332, DOI 10.1046/j.1464-5491.1999.00081.x; Jen A, 2001, PHARM RES-DORDR, V18, P1483, DOI 10.1023/A:1013057825942; KATSOYANNIS PG, 1981, STRUCTURAL STUDIES M, P454; Krayenbuhl C., 1946, REP STENO MEM HOSP N, V1, P60; Kurtzhals P, 1995, BIOCHEM J, V312, P725, DOI 10.1042/bj3120725; LANGER R, 1990, SCIENCE, V249, P1527, DOI 10.1126/science.2218494; MACPHERSON A, 1999, CRYSTALLIZATION BIOL; Markussen J, 1996, DIABETOLOGIA, V39, P281; Myers SR, 1997, DIABETES, V46, P637, DOI 10.2337/diabetes.46.4.637; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; Owens DR, 2001, LANCET, V358, P739, DOI 10.1016/S0140-6736(01)05842-1; Putney SD, 1998, NAT BIOTECHNOL, V16, P153, DOI 10.1038/nbt0298-153; Radziuk J, 1998, DIABETOLOGIA, V41, P116, DOI 10.1007/s001250050876; Radziuk J, 1998, DIABETOLOGIA, V41, P489; Ribel U, 1985, DIABETES 1985, P891; SHAH VP, 1992, PHARM TECHNOL, V5, P35; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; STEINER DF, 1973, NATURE, V243, P528, DOI 10.1038/243528a0; Stevens RC, 2000, CURR OPIN STRUC BIOL, V10, P558, DOI 10.1016/S0959-440X(00)00131-7; Whittingham JL, 1997, BIOCHEMISTRY-US, V36, P2826, DOI 10.1021/bi9625105; WHITTINGHAM JL, 1995, BIOCHEMISTRY-US, V34, P15553, DOI 10.1021/bi00047a022; Yip CM, 1998, BIOPHYS J, V75, P1172, DOI 10.1016/S0006-3495(98)74036-6	38	66	78	6	48	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2002	20	8					800	804		10.1038/nbt722	http://dx.doi.org/10.1038/nbt722			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	579MU	12134168				2022-12-25	WOS:000177182500030
J	Bessho, Y; Hodgson, DRW; Suga, H				Bessho, Y; Hodgson, DRW; Suga, H			A tRNA aminoacylation system for non-natural amino acids based on a programmable ribozyme	NATURE BIOTECHNOLOGY			English	Article							TRANSFER-RNA; ESCHERICHIA-COLI; GENETIC-CODE; PROTEINS	The ability to recognize tRNA identities is essential to the function of the genetic coding system. In translation aminoacyl-tRNA synthetases (ARSs) recognize the identities of tRNAs and charge them with their cognate amino acids. We show that an in vitro-evolved ribozyme can also discriminate between specific tRNAs, and can transfer amino acids to the 3' ends of cognate tRNAs. The ribozyme interacts with both the CCA-3 terminus and the anticodon loop of tRNA(fMet), and its tRNA specificity is controlled by these interactions. This feature allows us to program the selectivity of the ribozyme toward specific tRNAs, and therefore to tailor effective aminoacyl-transfer catalysts. This method potentially provides a means of generating aminoacyl tRNAs that are charged with non-natural amino acids, which could be incorporated into proteins through cell-free translation.	SUNY Buffalo, Dept Chem, Buffalo, NY 14260 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Suga, H (corresponding author), SUNY Buffalo, Dept Chem, Buffalo, NY 14260 USA.		Bessho, Yoshitaka/K-7702-2012; Hodgson, David/F-7174-2011	Bessho, Yoshitaka/0000-0001-9297-7473; Hodgson, David/0000-0003-4517-9166				Arslan T, 1997, J AM CHEM SOC, V119, P10877, DOI 10.1021/ja971927a; Doring V, 2001, SCIENCE, V292, P501, DOI 10.1126/science.1057718; Flynn-Charlebois A, 2001, BIOCHEMISTRY-US, V40, P13623, DOI 10.1021/bi011102k; HECKLER TG, 1984, BIOCHEMISTRY-US, V23, P1468, DOI 10.1021/bi00302a020; Hohsaka T, 1996, J AM CHEM SOC, V118, P9778, DOI 10.1021/ja9614225; Kigawa T, 1999, FEBS LETT, V442, P15, DOI 10.1016/S0014-5793(98)01620-2; Lee N, 2000, NAT STRUCT BIOL, V7, P28; Liu DR, 1999, P NATL ACAD SCI USA, V96, P4780, DOI 10.1073/pnas.96.9.4780; Liu DR, 1997, P NATL ACAD SCI USA, V94, P10092, DOI 10.1073/pnas.94.19.10092; Lohse PA, 1996, NATURE, V381, P442, DOI 10.1038/381442a0; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Putz J, 1997, NUCLEIC ACIDS RES, V25, P1862, DOI 10.1093/nar/25.9.1862; ROBERTSON SA, 1991, J AM CHEM SOC, V113, P2711; Schimmel P, 1997, P NATL ACAD SCI USA, V94, P10007, DOI 10.1073/pnas.94.19.10007; SPIRIN AS, 1988, SCIENCE, V242, P1162, DOI 10.1126/science.3055301; Wang L, 2001, SCIENCE, V292, P498, DOI 10.1126/science.1060077	16	44	49	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2002	20	7					723	728		10.1038/nbt0702-723	http://dx.doi.org/10.1038/nbt0702-723			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	567QC	12089559				2022-12-25	WOS:000176494800028
J	Colombo, E; Marine, JC; Danovi, D; Falini, B; Pelicci, PG				Colombo, E; Marine, JC; Danovi, D; Falini, B; Pelicci, PG			Nucleophosmin regulates the stability and transcriptional activity of p53	NATURE CELL BIOLOGY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; NON-HODGKINS-LYMPHOMA; ONCOGENIC RAS; PROTEIN B23; NUCLEOLAR LOCALIZATION; FUSION PROTEIN; NUCLEAR MATRIX; HUMAN-CELLS; IN-VIVO; P21(WAF1/CIP1)	Nucleophosmin (NPM) is a ubiquitously expressed nucleolar phosphoprotein that continuously shuttles between the nucleus and cytoplasm(1). It has been proposed to function in ribosomal protein assembly and transport(2), and also as a molecular chaperone that prevents proteins from aggregating in the crowded environment of the nucleolus(3). The NPM gene is involved in several tumour-associated chromosome translocations, which have resulted in the formation of fusion proteins that retain the amino terminus of NPM, including NPM-ALK(4), NPM-RAR(5) and NPM-MLF1 (ref. 6). It is generally thought that the NPM component is not involved in the transforming potential of these fusion proteins(7), but instead provides a dimerization interface for the oligomerization and the oncogenic conversion of the various NPM partners (ALK, RAR, MLF1). Here we show that NPM interacts directly with the tumour suppressor p53, regulates the increase in stability and transcriptional activation of p53 after different types of stress, and induces p53-dependent premature senescence on overexpression in diploid fibroblasts. These findings indicate that NPM is a crucial regulator of p53 and suggest that alterations of the NPM function by NPM fusion proteins might lead to deregulation of p53 in tumours.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Univ Perugia, Inst Haematol, I-06100 Perugia, Italy; Univ Perugia, Inst Internal Med, I-06100 Perugia, Italy; FIRC Inst Mol Oncol, I-20141 Milan, Italy	IRCCS European Institute of Oncology (IEO); University of Perugia; University of Perugia; IFOM - FIRC Institute of Molecular Oncology	Pelicci, PG (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Pipamonti 435, I-20141 Milan, Italy.		Pelicci, Pier Giuseppe/AAL-6572-2020; Danovi, Davide/P-2874-2019; Marine, Jean Christophe/J-2237-2015; Colombo, Emanuela/AAO-8113-2020; Marine, Jean-Christophe/K-3292-2016	Danovi, Davide/0000-0003-4119-5337; Colombo, Emanuela/0000-0003-2079-7398; Marine, Jean-Christophe/0000-0003-2433-9837; FALINI, Brunangelo/0000-0002-7198-5965				Allan LA, 1999, ONCOGENE, V18, P5403, DOI 10.1038/sj.onc.1202931; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Cordell JL, 1999, BLOOD, V93, P632, DOI 10.1182/blood.V93.2.632; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; HARVEY M, 1993, ONCOGENE, V8, P2457; He LZ, 1999, ONCOGENE, V18, P5278, DOI 10.1038/sj.onc.1203088; Jiang M, 2001, ONCOGENE, V20, P5449, DOI 10.1038/sj.onc.1204705; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Li YP, 1997, J VIROL, V71, P4098, DOI 10.1128/JVI.71.5.4098-4102.1997; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Mattern KA, 1996, J CELL BIOCHEM, V62, P275, DOI 10.1002/(SICI)1097-4644(199608)62:2<275::AID-JCB15>3.0.CO;2-K; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; OLSON MOJ, 1986, BIOCHEMISTRY-US, V25, P484, DOI 10.1021/bi00350a031; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Szebeni A, 1999, PROTEIN SCI, V8, P905; Thullberg M, 2000, HYBRIDOMA, V19, P63, DOI 10.1089/027245700315806; VALDEZ BC, 1994, J BIOL CHEM, V269, P23776; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YonedaKato N, 1996, ONCOGENE, V12, P265	28	421	441	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	2002	4	7					529	533		10.1038/ncb814	http://dx.doi.org/10.1038/ncb814			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	568UL	12080348				2022-12-25	WOS:000176562900019
J	Laakkonen, P; Porkka, K; Hoffman, JA; Ruoslahti, E				Laakkonen, P; Porkka, K; Hoffman, JA; Ruoslahti, E			A tumor-homing peptide with a targeting specificity related to lymphatic vessels	NATURE MEDICINE			English	Article							BLOOD-VESSELS; BREAST-CANCER; VEGF-C; LYMPHANGIOGENESIS; PROMOTES; GROWTH; CELLS; ENDOTHELIUM; LYVE-1; ANGIOGENESIS	Blood vessels of tumors carry specific markers that are usually angiogenesis-related(1,2). We previously used phage-displayed peptide libraries in vivo to identify peptides that home to tumors through the circulation and that specifically bind to the endothelia of tumor blood vessels(3,4). Here we devised a phage screening procedure that would favor tumor-homing to targets that are accessible to circulating phage, but are not blood vessels. Screening on MDA-MB-435 breast carcinoma xenografts yielded multiple copies of a phage that displays a cyclic 9-amino-acid peptide, LyP-1. Homing and binding to tumor-derived cell suspensions indicated that LyP-1 also recognizes an osteosarcoma xenograft, and spontaneous prostate and breast cancers in transgenic mice, but not two other tumor xenografts. Fluorescein-labeled LyP-1 peptide was detected in tumor structures that were positive for three lymphatic endothelial markers and negative for three blood vessel markers. LyP-1 accumulated in the nuclei of the putative lymphatic cells, and in the nuclei of tumor cells. These results suggest that tumor lymphatics carry specific markers and that it may be possible to specifically target therapies into tumor lymphatics.	Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA; Univ Calif San Diego, Sch Med, Burnham Inst, Program Mol Pathol, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	Ruoslahti, E (corresponding author), Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA.		; Porkka, Kimmo/O-2323-2016	Laakkonen, Pirjo/0000-0002-9620-095X; Porkka, Kimmo/0000-0003-4112-5902	NATIONAL CANCER INSTITUTE [K23CA082715, P30CA030199, R01CA074238] Funding Source: NIH RePORTER; NCI NIH HHS [CA30199, CA82715, CA74238] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Beasley NJP, 2002, CANCER RES, V62, P1315; Breiteneder-Geleff S, 1999, AM J PATHOL, V154, P385, DOI 10.1016/S0002-9440(10)65285-6; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Carreira CM, 2001, CANCER RES, V61, P8079; Chang YS, 2000, P NATL ACAD SCI USA, V97, P14608, DOI 10.1073/pnas.97.26.14608; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HOFFMAN JA, IN PRESS PHAGE DISPL; Jackson DG, 2001, TRENDS IMMUNOL, V22, P317, DOI 10.1016/S1471-4906(01)01936-6; Karpanen T, 2001, CANCER RES, V61, P1786; Kubo H, 2000, BLOOD, V96, P546; Leu AJ, 2000, CANCER RES, V60, P4324; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Oliver G, 2002, GENE DEV, V16, P773, DOI 10.1101/gad.975002; PORKKA K, IN PRESS P NATL ACAD; Prevo R, 2001, J BIOL CHEM, V276, P19420, DOI 10.1074/jbc.M011004200; Ruoslahti E, 2002, NAT REV CANCER, V2, P83, DOI 10.1038/nrc724; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; St Croix B, 2000, SCIENCE, V289, P1197; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Valtola R, 1999, AM J PATHOL, V154, P1381, DOI 10.1016/S0002-9440(10)65392-8; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003	25	377	428	6	128	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUL	2002	8	7					751	755		10.1038/nm720	http://dx.doi.org/10.1038/nm720			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	567QG	12053175				2022-12-25	WOS:000176495200038
J	Perez-Iratxeta, C; Bork, P; Andrade, MA				Perez-Iratxeta, C; Bork, P; Andrade, MA			Association of genes to genetically inherited diseases using data mining	NATURE GENETICS			English	Article								Although approximately one-quarter of the roughly 4,000 genetically inherited diseases currently recorded in respective databases (LocusLink(1), OMIM2) are already linked to a region of the human genome, about 450 have no known associated gene. Finding disease-related genes requires laborious examination of hundreds of possible candidate genes (sometimes, these are not even annotated; see, for example, refs 3,4). The public availability of the human genome(5) draft sequence has fostered new strategies to map molecular functional features of gene products to complex phenotypic descriptions, such as those of genetically inherited diseases. Owing to recent progress in the systematic annotation of genes using controlled vocabularies 6, we have developed a scoring system for the possible functional relationships of human genes to 455 genetically inherited diseases that have been mapped to chromosomal regions without assignment of a particular gene. In a benchmark of the system with 100 known disease-associated genes, the disease-associated gene was among the 8 best-scoring genes with a 25% chance, and among the best 30 genes with a 50% chance, showing that there is a relationship between the score of a gene and its likelihood of being associated with a particular disease. The scoring also indicates that for some diseases, the chance of identifying the underlying gene is higher.	European Mol Biol Lab, D-69012 Heidelberg, Germany; Max Delbruck Ctr Mol Med, Dept Bioinformat, D-13092 Berlin, Germany	European Molecular Biology Laboratory (EMBL); Helmholtz Association; Max Delbruck Center for Molecular Medicine	Bork, P (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69012 Heidelberg, Germany.	bork@embl-heidelberg.de	Andrade, Miguel A/B-6565-2008; Bork, Peer/F-1813-2013	Andrade, Miguel A/0000-0001-6650-1711; Bork, Peer/0000-0002-2627-833X				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; Garcia CK, 2001, SCIENCE, V292, P1394, DOI 10.1126/science.1060458; Hamosh A, 2000, HUM MUTAT, V15, P57, DOI 10.1002/(SICI)1098-1004(200001)15:1<57::AID-HUMU12>3.0.CO;2-G; Hogenesch JB, 2001, CELL, V106, P413, DOI 10.1016/S0092-8674(01)00467-6; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; PLAITAKIS A, 1993, CAN J NEUROL SCI, V20, P5109; Pruitt KD, 2001, NUCLEIC ACIDS RES, V29, P137, DOI 10.1093/nar/29.1.137; Zhou B, 2001, NAT GENET, V28, P345, DOI 10.1038/ng572; Zimmermann HJ, 1996, FUZZY SET THEORY ITS	11	253	262	0	13	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2002	31	3					316	319		10.1038/ng895	http://dx.doi.org/10.1038/ng895			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	567PW	12006977				2022-12-25	WOS:000176494100023
J	Borza, CM; Hutt-Fletcher, LM				Borza, CM; Hutt-Fletcher, LM			Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus	NATURE MEDICINE			English	Article							GENE-PRODUCT; CLASS-II; HLA-DQ; RECEPTOR; INFECTION; LYMPHOCYTES; ATTACHMENT; EXPRESSION; GH; IDENTIFICATION	Epstein-Barr virus is ubiquitous and is causally implicated in lymphoid and epithelial malignancies. Virus invades oropharyngeal mucosa and establishes latency in B lymphocytes. Reactivating lymphocytes shed virus into saliva for spread to new hosts. A complex of three virus glycoproteins, gH, gL and gp42, is essential for entry. B-cell entry requires binding of gp42 to human leukocyte antigen (HLA) class II whereas entry into epithelial cells lacking HLA class II requires complexes without gp42. To accommodate infection of each, the virus carries both three-part and two-part complexes. We show here that HLA class II in the virus-producing cell alters the ratio of three-part to two-part complexes. As a consequence, virus originating in epithelial cells efficiently infects B cells whereas B-cell-derived virus better infects epithelial cells. This molecular switch is a novel strategy that could alter tropism of virus from epithelium to B cells and then back to epithelium in a new host.	Univ Missouri, Sch Biol Sci, Kansas City, MO 64110 USA	University of Missouri System; University of Missouri Kansas City	Borza, CM (corresponding author), Univ Missouri, Sch Biol Sci, Kansas City, MO 64110 USA.	borzac@umkc.edu; huttfletcher@umkc.edu	Borza, Corina/A-1603-2013; Borza, Corina/AAF-5292-2020	Borza, Corina/0000-0001-9113-110X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020662] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI20662] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AB RICKINSON, 2001, FIELDS VIROLOGY, P2575; Borza CM, 1998, J VIROL, V72, P7577, DOI 10.1128/JVI.72.9.7577-7582.1998; Callan MFC, 1998, J EXP MED, V187, P1395, DOI 10.1084/jem.187.9.1395; CHANG CH, 1994, J EXP MED, V180, P1367, DOI 10.1084/jem.180.4.1367; FINGEROTH JD, 1984, P NATL ACAD SCI-BIOL, V81, P4510, DOI 10.1073/pnas.81.14.4510; Geraghty RJ, 2000, VIROLOGY, V268, P147, DOI 10.1006/viro.1999.0157; Goff S, 2001, FIELDS VIROLOGY, P1871; Haan KM, 2000, P NATL ACAD SCI USA, V97, P9252, DOI 10.1073/pnas.160171697; Haan KM, 2000, J VIROL, V74, P2451, DOI 10.1128/JVI.74.5.2451-2454.2000; HADDAD RS, 1989, J VIROL, V63, P4998, DOI 10.1128/JVI.63.12.4998-5005.1989; LI QX, 1995, J VIROL, V69, P3987, DOI 10.1128/JVI.69.7.3987-3994.1995; Li QX, 1997, J VIROL, V71, P4657, DOI 10.1128/JVI.71.6.4657-4662.1997; LI QX, 1992, NATURE, V356, P347, DOI 10.1038/356347a0; MELLMAN I, 1995, CURR OPIN CELL BIOL, V7, P564, DOI 10.1016/0955-0674(95)80014-X; MILLER N, 1988, J VIROL, V62, P2366, DOI 10.1128/JVI.62.7.2366-2372.1988; Moghaddam A, 1997, SCIENCE, V276, P2030, DOI 10.1126/science.276.5321.2030; Molesworth SJ, 2000, J VIROL, V74, P6324, DOI 10.1128/JVI.74.14.6324-6332.2000; NEMEROW GR, 1987, J VIROL, V61, P1416, DOI 10.1128/JVI.61.5.1416-1420.1987; NEMEROW GR, 1985, J VIROL, V55, P347, DOI 10.1128/JVI.55.2.347-351.1985; Spear PG, 2000, VIROLOGY, V275, P1, DOI 10.1006/viro.2000.0529; SVEDMYR E, 1984, CLIN IMMUNOL IMMUNOP, V30, P437, DOI 10.1016/0090-1229(84)90029-1; TAKADA K, 1984, INT J CANCER, V33, P27, DOI 10.1002/ijc.2910330106; TANNER J, 1987, CELL, V50, P203, DOI 10.1016/0092-8674(87)90216-9; VANVOORHIS WC, 1983, J EXP MED, V158, P126, DOI 10.1084/jem.158.1.126; Wang X, 1998, J VIROL, V72, P5552, DOI 10.1128/JVI.72.7.5552-5558.1998; Wang X, 1998, J VIROL, V72, P158, DOI 10.1128/JVI.72.1.158-163.1998; YASWEN LR, 1993, VIROLOGY, V195, P387, DOI 10.1006/viro.1993.1388	27	327	349	1	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2002	8	6					594	599		10.1038/nm0602-594	http://dx.doi.org/10.1038/nm0602-594			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	557KG	12042810				2022-12-25	WOS:000175907300030
J	Pratt, JR; Basheer, SA; Sacks, SH				Pratt, JR; Basheer, SA; Sacks, SH			Local synthesis of complement component C3 regulates acute renal transplant rejection	NATURE MEDICINE			English	Article							ALLOGRAFT-REJECTION; ANTIGEN RECEPTOR; EXPRESSION; ACTIVATION; LOCALIZATION; PATHWAY; INNATE; GAMMA; B7-1; MHC	Accumulating evidence suggests that innate immunity interacts with the adaptive immune system to identify potentially harmful antigens and eliminate them from the host. A central facet of innate immunity is complement, which for some time has been recognized as a contributor to inflammation in transplant rejection but without detailed analysis of its role in what is principally a T cell-mediated process. Moreover, epithelial and vascular tissues at local sites of inflammation secrete complement components; however, the role of such local synthesis remains unclear. Here we show that the absence of locally synthesized complement component C3 is capable of modulating the rejection of renal allografts in vivo and regulating T-cell responses in vivo and in vitro. The results indicate that improved success in kidney transplantation could come from therapeutic manipulation of innate immunity in concert with T cell-directed immunosuppression.	Kings Coll London, Guys Hosp, Dept Nephrol & Transplantat, London WC2R 2LS, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Sacks, SH (corresponding author), Kings Coll London, Guys Hosp, Dept Nephrol & Transplantat, London WC2R 2LS, England.	steven.sacks@kcl.ac.uk		Sacks, Steven/0000-0001-6361-9095				Abe K, 1998, KIDNEY INT, V54, P120, DOI 10.1046/j.1523-1755.1998.00961.x; ANDREWS PA, 1995, EUR J IMMUNOL, V25, P1087, DOI 10.1002/eji.1830250434; ANDREWS PA, 1994, TRANSPLANTATION, V58, P637, DOI 10.1097/00007890-199409150-00023; ARVIEUX J, 1988, IMMUNOLOGY, V65, P229; Banu N, 1999, KIDNEY INT, V55, P2250, DOI 10.1046/j.1523-1755.1999.00495.x; BIANCONE L, 1994, KIDNEY INT, V45, P451, DOI 10.1038/ki.1994.59; BREITNER S, 1995, ARTHRITIS RHEUM, V38, P492, DOI 10.1002/art.1780380406; BROOIMANS RA, 1991, J CLIN INVEST, V88, P379, DOI 10.1172/JCI115314; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; GASQUE P, 1995, J IMMUNOL, V154, P4726; HAGERTY DT, 1992, J IMMUNOL, V148, P2324; JACQUIERSARLIN MR, 1995, IMMUNOLOGY, V84, P164; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; KALINA SL, 1993, AUST NZ J SURG, V63, P213, DOI 10.1111/j.1445-2197.1993.tb00521.x; KELLEY VR, 1993, EXP NEPHROL, V1, P102; KINOSHITA T, 1991, IMMUNOL TODAY, V12, P291, DOI 10.1016/0167-5699(91)90001-A; Kozono Y, 1998, J IMMUNOL, V160, P1565; Matzinger P, 1998, SEMIN IMMUNOL, V10, P399, DOI 10.1006/smim.1998.0143; Meri S, 1998, VOX SANG, V74, P291, DOI 10.1111/j.1423-0410.1998.tb05434.x; Mongini PKA, 1997, J IMMUNOL, V159, P3782; Morgan BP, 1997, CLIN EXP IMMUNOL, V107, P1, DOI 10.1046/j.1365-2249.1997.d01-890.x; PASSWELL J, 1988, J CLIN INVEST, V82, P1676, DOI 10.1172/JCI113780; PASSWELL JH, 1990, IMMUNOLOGY, V71, P290; Pratt JR, 1996, AM J PATHOL, V149, P2055; Pratt JR, 2000, AM J PATHOL, V157, P825, DOI 10.1016/S0002-9440(10)64596-8; Prechl J, 2000, IMMUNOPHARMACOLOGY, V49, P117, DOI 10.1016/S0162-3109(00)80297-0; Sasaki O, 1997, AM J PATHOL, V151, P1249; Sheerin NS, 2001, EUR J IMMUNOL, V31, P1255, DOI 10.1002/1521-4141(200104)31:4<1255::AID-IMMU1255>3.0.CO;2-W; Takei Y, 2000, J AM SOC NEPHROL, V11, P250, DOI 10.1681/ASN.V112250; Tang S, 1999, J IMMUNOL, V162, P4336; TANG S, 1976, J COMPOS MATER, V10, P69, DOI 10.1177/002199837601000106; Tosello AC, 1998, J INFLAMM, V48, P13; Zhou WD, 2000, J CLIN INVEST, V105, P1363, DOI 10.1172/JCI8621	34	385	408	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2002	8	6					582	587		10.1038/nm0602-582	http://dx.doi.org/10.1038/nm0602-582			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	557KG	12042808				2022-12-25	WOS:000175907300028
J	Wilson, R; Goyal, L; Ditzel, M; Zachariou, A; Baker, DA; Agapite, J; Steller, H; Meier, P				Wilson, R; Goyal, L; Ditzel, M; Zachariou, A; Baker, DA; Agapite, J; Steller, H; Meier, P			The DIAP1 RING finger mediates ubiquitination of Dronc and is indispensable for regulating apoptosis	NATURE CELL BIOLOGY			English	Article							DROSOPHILA CASPASE DRONC; PROTEIN LIGASE ACTIVITY; PROGRAMMED CELL-DEATH; BACULOVIRUS INHIBITOR; HID; REAPER; GENE; GRIM; DEGRADATION; ASPARTATE	Members of the Inhibitor of Apoptosis Protein (IAP) family block activation of the intrinsic cell death machinery by binding to and neutralizing the activity of pro-apoptotic caspases. In Drosophila melanogaster, the pro-apoptotic proteins Reaper (Rpr), Grim and Hid (head involution defective) all induce cell death by antagonizing the antiapoptotic activity of Drosophila IAP1 (DIAP1), thereby liberating caspases. Here, we show that in vivo, the RING finger of DIAP1 is essential for the regulation of apoptosis induced by Rpr, Hid and Dronc. Furthermore, we show that the RING finger of DIAP1 promotes the ubiquitination of both itself and of Dronc. Disruption of the DIAP1 RING finger does not inhibit its binding to Rpr, Hid or Dronc, but completely abrogates ubiquitination of Dronc. Our data suggest that IAPs suppress apoptosis by binding to and targeting caspases for ubiquitination.	Inst Canc Res, Chester Beatty Labs, Breakthrough Toby Robins Breast Canc Res Ctr, London SW3 6JB, England; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Univ London Imperial Coll Sci & Technol, Fac Med, Inst Reprod & Dev Biol, London W12 0NN, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Howard Hughes Medical Institute; Rockefeller University; Imperial College London	Meier, P (corresponding author), Inst Canc Res, Chester Beatty Labs, Breakthrough Toby Robins Breast Canc Res Ctr, 237 Fulham Rd, London SW3 6JB, England.			Meier, Pascal/0000-0003-2760-6523	NIGMS NIH HHS [R01GM60124] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060124] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; Goyal L, 2001, CELL, V104, P805, DOI 10.1016/S0092-8674(01)00276-8; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Hawkins CJ, 2000, J BIOL CHEM, V275, P27084; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HAYS, NATURE CELL BIOL; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; HOLLEY, NATURE CELL BIOL; Huang HK, 2000, J BIOL CHEM, V275, P26661; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Lisi S, 2000, GENETICS, V154, P669; Meier P, 2000, EMBO J, V19, P598, DOI 10.1093/emboj/19.4.598; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Quinn LM, 2000, J BIOL CHEM, V275, P40416, DOI 10.1074/jbc.M002935200; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; RYOO, NATURE CELL BIOL; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Uren AG, 1998, TRENDS BIOCHEM SCI, V23, P159, DOI 10.1016/S0968-0004(98)01198-0; Vucic D, 1998, MOL CELL BIOL, V18, P3300, DOI 10.1128/MCB.18.6.3300; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; WING, NATURE CELL BIOL; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; YOO, NATURE CELL BIOL	30	199	206	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUN	2002	4	6					445	450		10.1038/ncb799	http://dx.doi.org/10.1038/ncb799			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	558NN	12021771				2022-12-25	WOS:000175973600015
J	Xue, F; Tian, XC; Du, FL; Kubota, C; Taneja, M; Dinnyes, A; Dai, YP; Levine, H; Pereira, LV; Yang, XZ				Xue, F; Tian, XC; Du, FL; Kubota, C; Taneja, M; Dinnyes, A; Dai, YP; Levine, H; Pereira, LV; Yang, XZ			Aberrant patterns of X chromosome inactivation in bovine clones	NATURE GENETICS			English	Article							MAMMALIAN DEVELOPMENT; MOUSE EMBRYOS; GENE; METHYLATION; EXPRESSION; BEHAVIOR; GENOMES; MICE; MAOA	In mammals, epigenetic marks on the X chromosomes are involved in dosage compensation. Specifically, they are required for X chromosome inactivation (XCI), the random transcriptional silencing of one of the two X chromosomes in female cells during late blastocyst development(1-8). During natural reproduction, both X chromosomes are active in the female zygote(2). In somatic-cell cloning, however, the cloned embryos receive one active (Xa) and one inactive (Xi) X chromosome from the donor cells. Patterns of XCI have been reported normal in cloned mice(9), but have yet to be investigated in other species. We examined allele-specific expression of the X-linked monoamine oxidase type A (MAOA) gene and the expression of nine additional X-linked genes in nine cloned XX calves. We found aberrant expression patterns in nine of ten X-linked genes and hypomethylation of Xist in organs of deceased clones. Analysis of MAOA expression in bovine placentae from natural reproduction revealed imprinted XCI with preferential inactivation of the paternal X chromosome. In contrast, we found random XCI in placentae of the deceased clones but completely skewed XCI in that of live clones. Thus, incomplete nuclear reprogramming may generate abnormal epigenetic marks on the X chromosomes of cloned cattle, affecting both random and imprinted XCI.	Univ Connecticut, Dept Anim Sci, Storrs, CT 06269 USA; Univ Connecticut, Ctr Regenerat Biol, Storrs, CT 06269 USA; Kagoshima Prefectural Cattle Breeding & Dev Inst, Kagoshima, Japan; Tufts Univ, Sch Vet Med, Dept Environm & Populat Hlth, S Woodstock, CT USA; Univ Sao Paulo, Inst Biociencias, Dept Biol, Ctr Estudos Genoma Humano, Sao Paulo, Brazil	University of Connecticut; University of Connecticut; Tufts University; Universidade de Sao Paulo	Yang, XZ (corresponding author), Univ Connecticut, Dept Anim Sci, Storrs, CT 06269 USA.		Pillay, Nischalan/F-9536-2012; Pereira, Lygia V/C-1049-2012; Dinnyes, Andras/D-5131-2013	Pereira, Lygia V/0000-0002-0002-725X; Dinnyes, Andras/0000-0003-3791-2583				Band MR, 2000, GENOME RES, V10, P1359, DOI 10.1101/gr.145900; Bassi MT, 1999, AM J HUM GENET, V64, P1604, DOI 10.1086/302408; BEIDLER JL, 1982, ANAL BIOCHEM, V126, P374, DOI 10.1016/0003-2697(82)90530-9; Brockdorff N, 1998, CURR OPIN GENET DEV, V8, P328, DOI 10.1016/S0959-437X(98)80090-7; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; BRUNNER HG, 1993, SCIENCE, V262, P578, DOI 10.1126/science.8211186; Carrel L, 1999, P NATL ACAD SCI USA, V96, P14440, DOI 10.1073/pnas.96.25.14440; CASES O, 1995, SCIENCE, V268, P1763, DOI 10.1126/science.7792602; De La Fuente R, 1999, BIOL REPROD, V60, P769, DOI 10.1095/biolreprod60.3.769; Dean W, 2001, P NATL ACAD SCI USA, V98, P13734, DOI 10.1073/pnas.241522698; Eggan K, 2000, SCIENCE, V290, P1578, DOI 10.1126/science.290.5496.1578; Ferguson-Smith AC, 2001, SCIENCE, V293, P1086, DOI 10.1126/science.1064020; Goto T, 1998, MICROBIOL MOL BIOL R, V62, P362, DOI 10.1128/MMBR.62.2.362-378.1998; HARPER MI, 1982, J EMBRYOL EXP MORPH, V67, P127; Heard E, 1997, ANNU REV GENET, V31, P571, DOI 10.1146/annurev.genet.31.1.571; Kang YK, 2001, NAT GENET, V28, P173, DOI 10.1038/88903; KAY GF, 1993, CELL, V72, P171, DOI 10.1016/0092-8674(93)90658-D; Kubota C, 2000, P NATL ACAD SCI USA, V97, P990, DOI 10.1073/pnas.97.3.990; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; Panning B, 1997, CELL, V90, P907, DOI 10.1016/S0092-8674(00)80355-4; Park Y, 2001, SCIENCE, V293, P1083, DOI 10.1126/science.1063073; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Rideout WM, 2001, SCIENCE, V293, P1093, DOI 10.1126/science.1063206; TAKAGI N, 1975, NATURE, V256, P640, DOI 10.1038/256640a0; Tivol EA, 1996, AM J MED GENET, V67, P92, DOI 10.1002/(SICI)1096-8628(19960216)67:1<92::AID-AJMG16>3.0.CO;2-K; Wrenzycki C, 2002, BIOL REPROD, V66, P127, DOI 10.1095/biolreprod66.1.127; Yool DA, 2000, HUM MOL GENET, V9, P987, DOI 10.1093/hmg/9.6.987	28	233	255	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2002	31	2					216	220		10.1038/ng900	http://dx.doi.org/10.1038/ng900			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	557HR	12032569				2022-12-25	WOS:000175903500022
J	Sotiriou, S; Gispert, S; Cheng, J; Wang, YH; Chen, A; Hoogstraten-Miller, S; Miller, GF; Kwon, O; Levine, M; Guttentag, SH; Nussbaum, RL				Sotiriou, S; Gispert, S; Cheng, J; Wang, YH; Chen, A; Hoogstraten-Miller, S; Miller, GF; Kwon, O; Levine, M; Guttentag, SH; Nussbaum, RL			Ascorbic-acid transporter Slc23a1 is essential for vitamin C transport into the brain and for perinatal survival	NATURE MEDICINE			English	Article							DEHYDROASCORBIC ACID; PREMATURE-INFANT; CLONING; PLASMA; CELLS	The only proven requirement for ascorbic acid (vitamin C) is in preventing scurvy(1,2), presumably because it is a cofactor for hydroxylases required for post-translational modifications that stabilize collagen(3). We have created mice deficient in the mouse ortholog (solute carrier family 23 member 1 or Slc23a1) of a rat ascorbic-acid transporter, Svct2 (ref. 4). Cultured embryonic fibroblasts from homozygous Slc23a1(-/-) mice had less than 5% of normal ascorbic-acid uptake. Ascorbic-acid levels were undetectable or markedly reduced in the blood and tissues of Slc23a1(-/-) mice. Prenatal supplementation of pregnant females did not elevate blood ascorbic acid in Slc23a1(-/-) fetuses, suggesting Slc23a1 is important in placental ascorbic-acid transport. Slc23a1(-/-) mice died within a few minutes of birth with respiratory failure and intraparenchymal brain hemorrhage. Lungs showed no postnatal expansion but had normal surfactant protein B levels. Brain hemorrhage was unlikely to be simply a form of scurvy since Slc23a1(-/-) mice showed no hemorrhage in any other tissues and their skin had normal skin 4-hydroxyproline levels despite low ascorbic-acid content. We conclude that Slc23a1 is required for transport of ascorbic acid into many tissues and across the placenta. Deficiency of the transporter is lethal in newborn mice, thereby revealing a previously unrecognized requirement for ascorbic acid in the perinatal period.	NHGRI, Genet Dis Res Branch, Bethesda, MD 20892 USA; NIDDKD, Mol & Clin Nutr Sect, Digest Dis Branch, Bethesda, MD 20892 USA; NIH, Vet Resources Program, Off Director, Bethesda, MD 20892 USA; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Div Neonatol, Philadelphia, PA 19104 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Nussbaum, RL (corresponding author), NHGRI, Genet Dis Res Branch, Bethesda, MD 20892 USA.		Guttentag, Susan H/D-8705-2013; Guttentag, Susan/ABE-7405-2020	Guttentag, Susan H/0000-0003-4420-5879; Guttentag, Susan/0000-0003-4420-5879	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000169] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK054506, Z01DK054506] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agus DB, 1997, J CLIN INVEST, V100, P2842, DOI 10.1172/JCI119832; Bass WT, 1998, AM J PERINAT, V15, P133, DOI 10.1055/s-2007-993913; BYERS PH, 2001, METABOLIC MOL BASES, V4, P5241; CHOI JL, 1989, AM J PHYSIOL, V257, pC110, DOI 10.1152/ajpcell.1989.257.1.C110; Daruwala R, 1999, FEBS LETT, V460, P480, DOI 10.1016/S0014-5793(99)01393-9; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; DHARIWAL KR, 1991, AM J CLIN NUTR, V54, P712, DOI 10.1093/ajcn/54.4.712; Gispert S, 2000, DNA RES, V7, P339, DOI 10.1093/dnares/7.6.339; GOLDENBERG H, 1994, J BIOENERG BIOMEMBR, V26, P359, DOI 10.1007/BF00762776; HODGES RE, 1971, AM J CLIN NUTR, V24, P432; Hogan B, 1994, MANIPULATING MOUSE E; JENNESS R, 1984, COMP BIOCHEM PHYS B, V78, P167, DOI 10.1016/0305-0491(84)90162-7; KRATZING CC, 1986, INT J VITAM NUTR RES, V56, P101; Levine M, 1999, JAMA-J AM MED ASSOC, V281, P1415, DOI 10.1001/jama.281.15.1415; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NORKUS EP, 1979, J NUTR, V109, P2205, DOI 10.1093/jn/109.12.2205; Rajan DP, 1999, BIOCHEM BIOPH RES CO, V262, P762, DOI 10.1006/bbrc.1999.1272; ROSSO P, 1976, J NUTR, V106, P767, DOI 10.1093/jn/106.6.767; Rumsey SC, 1997, J BIOL CHEM, V272, P18982, DOI 10.1074/jbc.272.30.18982; Rumsey SC, 1998, J NUTR BIOCHEM, V9, P116, DOI 10.1016/S0955-2863(98)00002-3; SILVERS KM, 1994, ARCH DIS CHILD-FETAL, V71, pF40, DOI 10.1136/fn.71.1.F40; Tsukaguchi H, 1999, NATURE, V399, P70, DOI 10.1038/19986; VOLPE JJ, 1989, CLIN PERINATOL, V16, P361, DOI 10.1016/S0095-5108(18)30637-7; WASHKO PW, 1993, J BIOL CHEM, V268, P15531; WELCH RW, 1993, BIOCHEM J, V294, P505, DOI 10.1042/bj2940505	25	266	276	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2002	8	5					514	517		10.1038/nm0502-514	http://dx.doi.org/10.1038/nm0502-514			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	547ZW	11984597	Green Published			2022-12-25	WOS:000175336800038
J	Fujita, Y; Krause, G; Scheffner, M; Zechner, D; Leddy, HEM; Behrens, J; Sommer, T; Birchmeier, W				Fujita, Y; Krause, G; Scheffner, M; Zechner, D; Leddy, HEM; Behrens, J; Sommer, T; Birchmeier, W			Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex	NATURE CELL BIOLOGY			English	Article							CELL-CELL-ADHESION; TYROSINE PHOSPHORYLATION; EPITHELIAL-CELLS; BETA-CATENIN; ENDOTHELIAL-CELLS; FACTOR RECEPTOR; KINASE; SYSTEM; MET; INTERNALIZATION	In epithelial cells, tyrosine kinases induce the tyrosine phosphorylation and ubiquitination of the E-cadherin complex, which induces endocytosis of E-cadherin. With a modified yeast 2-hybrid system, we isolated Hakai, an E-cadherin binding protein, which we have identified as an E3 ubiquitin-ligase. Hakai contains SH2, RING, zinc-finger and proline-rich domains, and interacts with E-cadherin in a tyrosine phosphorylation-dependent manner, inducing ubiquitination of the E-cadherin complex. Expression of Hakai in epithelial cells disrupts cell-cell contacts and enhances endocytosis of E-cadherin and cell motility. Through dynamic recycling of E-cadherin, Hakai can thus modulate cell adhesion, and could participate in the regulation of epithelial-mesenchymal transitions in development or metastasis.	Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; FMP, D-13125 Berlin, Germany; Univ Cologne, Inst Biochem, D-50931 Cologne, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Cologne	Fujita, Y (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13125 Berlin, Germany.		Scheffner, Martin/K-2940-2012; Fujita, Yasuyuki/A-4324-2012	Scheffner, Martin/0000-0003-2229-0128; 				Bauer A, 1998, J BIOL CHEM, V273, P28314, DOI 10.1074/jbc.273.43.28314; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1998, J CELL BIOL, V141, P349, DOI 10.1083/jcb.141.2.349; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Horak J, 1997, J BACTERIOL, V179, P1541, DOI 10.1128/jb.179.5.1541-1549.1997; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kamei T, 1999, ONCOGENE, V18, P6776, DOI 10.1038/sj.onc.1203114; Kemler R, 1992, Semin Cell Biol, V3, P149; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; MAHER PA, 1989, J CELL BIOL, V108, P2029, DOI 10.1083/jcb.108.6.2029; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; Nuber U, 1996, J BIOL CHEM, V271, P2795, DOI 10.1074/jbc.271.5.2795; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; RIETHMACHER D, 1995, P NATL ACAD SCI USA, V92, P855, DOI 10.1073/pnas.92.3.855; Roth AF, 1996, J CELL BIOL, V134, P661, DOI 10.1083/jcb.134.3.661; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; STOKER M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P81, DOI 10.1016/0304-419X(91)90008-9; Strous GJ, 1999, J CELL SCI, V112, P1417; TAGAWA M, 1990, J BIOL CHEM, V265, P20021; TAKATA K, 1988, J CELL BIOL, V106, P1757, DOI 10.1083/jcb.106.5.1757; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Taya S, 1999, GENES CELLS, V4, P757, DOI 10.1046/j.1365-2443.1999.00297.x; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Tsukamoto T, 1999, J BIOL CHEM, V274, P24579, DOI 10.1074/jbc.274.35.24579; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; Ukropec JA, 2000, J BIOL CHEM, V275, P5983, DOI 10.1074/jbc.275.8.5983; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Xu YR, 1997, J BIOL CHEM, V272, P13463, DOI 10.1074/jbc.272.21.13463	46	649	668	3	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAR	2002	4	3					222	231		10.1038/ncb758	http://dx.doi.org/10.1038/ncb758			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	527VR	11836526				2022-12-25	WOS:000174209100015
J	Tanaka, S; Diffley, JFX				Tanaka, S; Diffley, JFX			Interdependent nuclear accumulation of budding yeast Cdt1 and Mcm2-7 during G1 phase	NATURE CELL BIOLOGY			English	Article							DNA-REPLICATION; CELL-CYCLE; S-PHASE; SACCHAROMYCES-CEREVISIAE; FISSION YEAST; MITOSIS; INITIATION; PROTEINS; COMPLEX; GENE	Cdt1 is essential for loading Mcm2-7 proteins into prereplicative complexes (pre-RCs) during replication licensing and has been found in organisms as diverse as fission yeast and humans. We have identified a homologue of Cdt1 in Saccharomyces cerevisiae, which is required for pre-RC assembly. We show that, like Mcm2-7p, Cdt1p accumulates in the nucleus during G1 phase and is excluded from the nucleus later in the cell cycle by cyclin dependent kinases (cdks). Cdt1p interacts with the Mcm2-7p complex, and the nuclear accumulation of these proteins during G1 is interdependent. This coregulation of Cdt1p and Mcm2-7p represents a novel level of pre-RC control.	Canc Res UK, Clare Hall Labs, S Mimms EN6 3LD, Herts, England	Cancer Research UK	Tanaka, S (corresponding author), Canc Res UK, Clare Hall Labs, Blanche Lane, S Mimms EN6 3LD, Herts, England.		Tanaka, Seiji/Q-8601-2019	Tanaka, Seiji/0000-0003-3882-3494; Diffley, John/0000-0001-5184-7680				Belli G, 1998, YEAST, V14, P1127, DOI 10.1002/(SICI)1097-0061(19980915)14:12<1127::AID-YEA300>3.0.CO;2-#; Belli G, 1998, NUCLEIC ACIDS RES, V26, P942, DOI 10.1093/nar/26.4.942; Blow JJ, 2001, EMBO J, V20, P3293, DOI 10.1093/emboj/20.13.3293; Bousset K, 1998, GENE DEV, V12, P480, DOI 10.1101/gad.12.4.480; DALTON S, 1995, P NATL ACAD SCI USA, V92, P2514, DOI 10.1073/pnas.92.7.2514; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Diffley JFX, 2001, CURR BIOL, V11, pR367, DOI 10.1016/S0960-9822(01)00196-8; DOHMEN RJ, 1994, SCIENCE, V263, P1273, DOI 10.1126/science.8122109; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Drury LS, 2000, CURR BIOL, V10, P231, DOI 10.1016/S0960-9822(00)00355-9; Drury LS, 1997, EMBO J, V16, P5966, DOI 10.1093/emboj/16.19.5966; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Ferreira MG, 2000, MOL CELL BIOL, V20, P242; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; HOFMANN JFX, 1994, EMBO J, V13, P425, DOI 10.1002/j.1460-2075.1994.tb06277.x; Huang ME, 1997, YEAST, V13, P1181, DOI 10.1002/(SICI)1097-0061(19970930)13:12<1181::AID-YEA169>3.3.CO;2-F; Kearsey SE, 1998, BBA-GENE STRUCT EXPR, V1398, P113, DOI 10.1016/S0167-4781(98)00033-5; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; Kimura H, 1996, GENES CELLS, V1, P977, DOI 10.1046/j.1365-2443.1996.840284.x; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Labib K, 1999, NAT CELL BIOL, V1, P415, DOI 10.1038/15649; Labib K, 2001, MOL BIOL CELL, V12, P3658, DOI 10.1091/mbc.12.11.3658; Labib K, 2001, CURR OPIN GENET DEV, V11, P64, DOI 10.1016/S0959-437X(00)00158-1; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; McInerny CJ, 1997, GENE DEV, V11, P1277, DOI 10.1101/gad.11.10.1277; Nguyen VQ, 2000, CURR BIOL, V10, P195, DOI 10.1016/S0960-9822(00)00337-7; Nguyen VQ, 2001, NATURE, V411, P1068, DOI 10.1038/35082600; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Noton E, 2000, MOL CELL, V5, P85, DOI 10.1016/S1097-2765(00)80405-0; Pasion SG, 1999, MOL BIOL CELL, V10, P4043, DOI 10.1091/mbc.10.12.4043; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; Reid RJD, 1999, P NATL ACAD SCI USA, V96, P11440, DOI 10.1073/pnas.96.20.11440; ROWLEY A, 1995, EMBO J, V14, P2631, DOI 10.1002/j.1460-2075.1995.tb07261.x; Schepers A, 2001, J MOL BIOL, V308, P597, DOI 10.1006/jmbi.2001.4637; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Tercero JA, 2000, EMBO J, V19, P2082, DOI 10.1093/emboj/19.9.2082; Tye BK, 2000, J BIOL CHEM, V275, P34833, DOI 10.1074/jbc.R000018200; Whittaker AJ, 2000, GENE DEV, V14, P1765; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149; ZHOU C, 1990, J BIOL CHEM, V265, P19904; ZWERSCHKE W, 1994, J BIOL CHEM, V269, P23351	46	210	216	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAR	2002	4	3					198	207		10.1038/ncb757	http://dx.doi.org/10.1038/ncb757			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	527VR	11836525				2022-12-25	WOS:000174209100012
J	Karpuj, MV; Becher, MW; Springer, JE; Chabas, D; Youssef, S; Pedotti, R; Mitchell, D; Steinman, L				Karpuj, MV; Becher, MW; Springer, JE; Chabas, D; Youssef, S; Pedotti, R; Mitchell, D; Steinman, L			Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine	NATURE MEDICINE			English	Article							NEURONAL INTRANUCLEAR INCLUSIONS; MOUSE MODEL; NEURODEGENERATIVE DISEASES; TISSUE TRANSGLUTAMINASE; EXPANDED POLYGLUTAMINE; NEUROLOGICAL PHENOTYPE; AGGREGATE FORMATION; APOPTOSIS; SUPPRESSION; PROTEIN	An expanded polyglutamine domain in huntingtin underlies the pathogenic events in Huntington disease (HD), characterized by chorea, dementia and severe weight loss, culminating in death. Transglutaminase (TGase) may be critical in the pathogenesis, via cross-linking huntingtin. Administration of the TGase competitive inhibitor, cystamine, to transgenic mice expressing exon 1 of huntingtin containing an expanded polyglutamine repeat, altered the course of their HD-like disease. Cystamine given intraperitoneally entered brain where it inhibited TGase activity. When treatment began after the appearance of abnormal movements, cystamine extended survival, reduced associated tremor and abnormal movements and ameliorated weight loss. Treatment did not influence the appearance or frequency of neuronal nuclear inclusions. Unexpectedly, cystamine treatment increased transcription of one of the two genes shown to be neuroprotective for polyglutamine toxicity in Drosophila, dnaj (also known as HDJI and Hsp40 in humans and mice, respectively). Inhibition of TGase provides a new treatment strategy for HD and other polyglutamine diseases.	Stanford Univ, Dept Neurol Sci, Stanford, CA 94305 USA; Univ New Mexico, Hlth Sci Ctr, Dept Pathol, Albuquerque, NM 87131 USA; Univ Kentucky, Med Ctr, Dept Anat & Neurobiol, Lexington, KY 40536 USA	Stanford University; University of New Mexico; University of New Mexico's Health Sciences Center; University of Kentucky	Steinman, L (corresponding author), Stanford Univ, Dept Neurol Sci, Stanford, CA 94305 USA.	steinman@stanford.edu		Steinman, Lawrence/0000-0002-2437-2250	PHS HHS [R0118235] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bates GP, 1998, BRAIN PATHOL, V8, P699, DOI 10.1111/j.1750-3639.1998.tb00196.x; Becher MW, 1998, NEUROBIOL DIS, V4, P387, DOI 10.1006/nbdi.1998.0168; Chabas D, 2001, SCIENCE, V294, P1731, DOI 10.1126/science.1062960; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Clarke G, 2000, NATURE, V406, P195, DOI 10.1038/35018098; Cooper AJL, 1997, J NEUROCHEM, V69, P431; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; Curtis C G, 1976, Methods Enzymol, V45, P177; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Ferrante RJ, 2000, J NEUROSCI, V20, P4389, DOI 10.1523/JNEUROSCI.20-12-04389.2000; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; FOLK JE, 1966, BIOCHIM BIOPHYS ACTA, V122, P244, DOI 10.1016/0926-6593(66)90066-X; GREEN H, 1993, CELL, V74, P955, DOI 10.1016/0092-8674(93)90718-6; Huang CC, 1998, SOMAT CELL MOLEC GEN, V24, P217, DOI 10.1023/B:SCAM.0000007124.19463.e5; Igarashi S, 1998, NAT GENET, V18, P111, DOI 10.1038/ng0298-111; Isupov MN, 1996, STRUCTURE, V4, P801, DOI 10.1016/S0969-2126(96)00087-1; Jeitner TM, 2001, J NEUROCHEM, V79, P1109, DOI 10.1046/j.1471-4159.2001.00673.x; Kahlem P, 1998, MOL CELL, V1, P595, DOI 10.1016/S1097-2765(00)80059-3; Karpuj MV, 1999, P NATL ACAD SCI USA, V96, P7388, DOI 10.1073/pnas.96.13.7388; Kazemi-Esfarjani P, 2000, SCIENCE, V287, P1837, DOI 10.1126/science.287.5459.1837; Kobayashi Y, 2000, J BIOL CHEM, V275, P8772, DOI 10.1074/jbc.275.12.8772; Lesort M, 1999, J NEUROCHEM, V73, P2018; Lorand L, 1996, P NATL ACAD SCI USA, V93, P14310, DOI 10.1073/pnas.93.25.14310; LORAND L, 1979, BIOCHEMISTRY-US, V18, P1756, DOI 10.1021/bi00576a019; Lorand L, 1998, NAT GENET, V20, P231, DOI 10.1038/3033; LORAND L, 1984, MOL CELL BIOCHEM, V58, P25; Luthi-Carter R, 2000, HUM MOL GENET, V9, P1259, DOI 10.1093/hmg/9.9.1259; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Molberg O, 1998, NAT MED, V4, P713, DOI 10.1038/nm0698-713; Newcomb R, 1997, J BIOL CHEM, V272, P11276; Ona VO, 1999, NATURE, V399, P263, DOI 10.1038/20446; Ordway JM, 1997, CELL, V91, P753, DOI 10.1016/S0092-8674(00)80464-X; Orr HT, 2000, CELL, V101, P1, DOI 10.1016/S0092-8674(00)80617-0; Perutz MF, 1999, TRENDS BIOCHEM SCI, V24, P58, DOI 10.1016/S0968-0004(98)01350-4; Rittling SR, 1998, BIOCHEM BIOPH RES CO, V250, P287, DOI 10.1006/bbrc.1998.9306; Sathasivam K, 1999, HUM MOL GENET, V8, P813, DOI 10.1093/hmg/8.5.813; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Sisodia SS, 1998, CELL, V95, P1, DOI 10.1016/S0092-8674(00)81743-2; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Voehringer DW, 2000, P NATL ACAD SCI USA, V97, P2680, DOI 10.1073/pnas.97.6.2680; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6; Yu SP, 1999, SCIENCE, V284, P336, DOI 10.1126/science.284.5412.336; ZAINELLI G, 2000, SOC NEUR ABSTR, V26, P1297	46	316	343	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2002	8	2					143	149		10.1038/nm0202-143	http://dx.doi.org/10.1038/nm0202-143			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	517FN	11821898				2022-12-25	WOS:000173600600023
J	Xu, XL; Meiler, SE; Zhong, TP; Mohideen, M; Crossley, DA; Burggren, WW; Fishman, MC				Xu, XL; Meiler, SE; Zhong, TP; Mohideen, M; Crossley, DA; Burggren, WW; Fishman, MC			Cardiomyopathy in zebrafish due to mutation in an alternatively spliced exon of titin	NATURE GENETICS			English	Article							DILATED CARDIOMYOPATHY; CARDIAC-MUSCLE; DANIO-RERIO; GENE; DISRUPTION; EXPRESSION; EMBRYOS; SYSTEM	The zebrafish embryo is transparent and can tolerate absence of blood flow because its oxygen is delivered by diffusion rather than by the cardiovascular system(1). It is therefore possible to attribute cardiac failure directly to particular genes by ruling out the possibility that it is due to a secondary effect of hypoxia. We focus here on pickwick(m171) (pik(m171)), a recessive lethal mutation discovered in a large-scale genetic screen(2). There are three other alleles in the pik complementation group with this phenotype (pik(m242), pik(m740), pik(m186); ref. 3) and one allele (pik(mVO62H)) with additional skeletal paralysis(4). The pik heart develops normally but is poorly contractile from the first beat. Aside from the edema that inevitably accompanies cardiac dysfunction, development is normal during the first three days. We show by positional cloning that the 'causative' mutation is in an alternatively-spliced exon of the gene (ttn) encoding Titin. Titin is the biggest known protein and spans the half-sarcomere from Z-disc to M-line in heart and skeletal muscles. It has been proposed to provide a scaffold for the assembly of thick and thin filaments(6) and to provide elastic recoil engendered by stretch during diastole(7). We found that nascent myofibrils form in pik mutants, but normal sarcomeres are absent. Mutant cells transplanted to wildtype hearts remain thin and bulge outwards as individual cell aneurysms without affecting nearby wildtype cardiomyocytes, indicating that the contractile deficiency is cell-autonomous. Absence of Titin function thus results in blockage of sarcomere assembly and causes a functional disorder resembling human dilated cardiomyopathies, one form of which is described in another paper in this issue(8).	Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02129 USA; Univ Calif Irvine, Dept Biol Sci, Irvine, CA 92697 USA; Univ N Texas, Dept Biol Sci, Denton, TX 76203 USA	Harvard University; Massachusetts General Hospital; University of California System; University of California Irvine; University of North Texas System; University of North Texas Denton	Fishman, MC (corresponding author), Massachusetts Gen Hosp, Cardiovasc Res Ctr, 149 13th St, Charlestown, MA 02129 USA.		Burggren, Warren W/A-1561-2016	Burggren, Warren W/0000-0001-8023-420X				Badorff C, 1999, NAT MED, V5, P320, DOI 10.1038/6543; BURGGREN WW, 1991, ANNU REV PHYSIOL, V53, P107, DOI 10.1146/annurev.physiol.53.1.107; Cazorla O, 2000, CIRC RES, V86, P59, DOI 10.1161/01.RES.86.1.59; Draper BW, 2001, GENESIS, V30, P154, DOI 10.1002/gene.1053; Driever W, 1996, DEVELOPMENT, V123, P37; Fatkin D, 1999, NEW ENGL J MED, V341, P1715, DOI 10.1056/NEJM199912023412302; Freiburg A, 2000, CIRC RES, V86, P1114; Gerull B, 2002, NAT GENET, V30, P201, DOI 10.1038/ng815; GRANZIER HL, 1995, BIOPHYS J, V68, P1027, DOI 10.1016/S0006-3495(95)80278-X; Gregorio CC, 1999, CURR OPIN CELL BIOL, V11, P18, DOI 10.1016/S0955-0674(99)80003-9; Grunig E, 1998, J AM COLL CARDIOL, V31, P186, DOI 10.1016/S0735-1097(97)00434-8; Helmes M, 1999, CIRC RES, V84, P1339, DOI 10.1161/01.RES.84.11.1339; Hertig CM, 1999, J BIOL CHEM, V274, P37362, DOI 10.1074/jbc.274.52.37362; HO RK, 1990, NATURE, V348, P720; Kamisago M, 2000, NEW ENGL J MED, V343, P1688, DOI 10.1056/NEJM200012073432304; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; Linke WA, 1999, J CELL BIOL, V146, P631, DOI 10.1083/jcb.146.3.631; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; Pelster B, 1996, CIRC RES, V79, P358, DOI 10.1161/01.RES.79.2.358; Person V, 2000, J CELL SCI, V113, P3851; Shimoda N, 1999, GENOMICS, V58, P219, DOI 10.1006/geno.1999.5824; Stainier DYR, 1996, DEVELOPMENT, V123, P285; THISSE C, 1993, DEVELOPMENT, V119, P1203; Trinick J, 1996, CURR BIOL, V6, P258, DOI 10.1016/S0960-9822(02)00472-4; van der Ven PFM, 2000, J CELL SCI, V113, P1405; Warren KS, 2000, PHILOS T R SOC B, V355, P939, DOI 10.1098/rstb.2000.0629; WEINSTEIN BM, 1995, NAT MED, V1, P1143, DOI 10.1038/nm1195-1143; Zhang Y, 2000, J CELL SCI, V113, P3103	29	206	213	1	23	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2002	30	2					205	209		10.1038/ng816	http://dx.doi.org/10.1038/ng816			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	519CY	11788825				2022-12-25	WOS:000173708700023
J	Asakura, M; Kitakaze, M; Takashima, S; Liao, Y; Ishikura, F; Yoshinaka, T; Ohmoto, H; Node, K; Yoshino, K; Ishiguro, H; Asanuma, H; Sanada, S; Matsumura, Y; Takeda, H; Beppu, S; Tada, M; Hori, M; Higashiyama, S				Asakura, M; Kitakaze, M; Takashima, S; Liao, Y; Ishikura, F; Yoshinaka, T; Ohmoto, H; Node, K; Yoshino, K; Ishiguro, H; Asanuma, H; Sanada, S; Matsumura, Y; Takeda, H; Beppu, S; Tada, M; Hori, M; Higashiyama, S			Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy	NATURE MEDICINE			English	Article							FACTOR RECEPTOR TRANSACTIVATION; PROTEIN-COUPLED RECEPTORS; CONGESTIVE-HEART-FAILURE; GROWTH-FACTOR; EXPRESSION; GENES; DISINTEGRIN; REGRESSION; MYOCYTES	G-protein-coupled receptor (GPCR) agonists,are well-known inducers of cardiac hypertrophy. We found that the shedding of heparin-binding epidermal growth factor (HB-EGF) resulting from metalloproteinase activation and subsequent transactivation of the epidermal growth factor receptor occurred when cardiomyocytes were stimulated by GPCR agonists, leading to cardiac hypertrophy. A new inhibitor of HB-EGF shedding, KB-R7785, blocked this signaling. We cloned a disintegrin and metalloprotease 12 (ADAM12) as a specific enzyme to shed HB-EGF in the heart and found that dominant-negative expression of ADAM12 abrogated this signaling. KB-R7785 bound directly to ADAM12, suggesting that inhibition of ADAM 12 blocked the shedding of HB-EGF. In mice with cardiac hypertrophy; KB-R7785 inhibited the shedding of HB-EGF and attenuated hypertrophic changes. These data suggest that shedding of HB-EGF by ADAM12 plays an important role in cardiac hypertrophy, and that inhibition of HB-EGF shedding could be a potent therapeutic strategy for cardiac hypertrophy.	Osaka Univ, Fac Med, Dept Biochem, Sch Allied Hlth Sci, Osaka 530, Japan; Osaka Univ, Fac Med, Dept Echocardiog, Sch Allied Hlth Sci, Osaka 530, Japan; Osaka Univ, Dept Internal Med & Therapeut, Grad Sch Med, Osaka, Japan; Osaka Univ, Dept Pathol & Pathophysiol, Grad Sch Med, Osaka, Japan; Osaka Univ, Dept Med Informat, Grad Sch Med, Osaka, Japan; Fujita Hlth Univ, Sch Med, Inst Comprehens Med Sci, Toyoake, Aichi 47011, Japan; Nippon Organon KK, Osaka, Japan	Osaka University; Osaka University; Osaka University; Osaka University; Osaka University; Fujita Health University	Higashiyama, S (corresponding author), Osaka Univ, Fac Med, Dept Biochem, Sch Allied Hlth Sci, Osaka 530, Japan.		Liao, Yulin/AAP-6315-2021					CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Friddle CJ, 2000, P NATL ACAD SCI USA, V97, P6745, DOI 10.1073/pnas.100127897; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; ITO H, 1991, CIRC RES, V69, P209, DOI 10.1161/01.RES.69.1.209; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; KATZ AM, 1990, NEW ENGL J MED, V322, P100; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Saadane N, 1999, BRIT J PHARMACOL, V127, P1165, DOI 10.1038/sj.bjp.0702676; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; Schmieder RE, 1996, JAMA-J AM MED ASSOC, V275, P1507, DOI 10.1001/jama.275.19.1507; SIMPSON P, 1982, CIRC RES, V51, P787, DOI 10.1161/01.RES.51.6.787; Spinale FG, 1999, CIRC RES, V85, P364, DOI 10.1161/01.RES.85.4.364; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; Tokumaru S, 2000, J CELL BIOL, V151, P209, DOI 10.1083/jcb.151.2.209; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767	22	609	635	2	29	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2002	8	1					35	40		10.1038/nm0102-35	http://dx.doi.org/10.1038/nm0102-35			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	507XQ	11786904				2022-12-25	WOS:000173056900028
J	Liu, XM; Jiang, QS; Mansfield, SG; Puttaraju, M; Zhang, YL; Zhou, WH; Cohn, JA; Garcia-Blanco, MA; Mitchell, LG; Engelhardt, JF				Liu, XM; Jiang, QS; Mansfield, SG; Puttaraju, M; Zhang, YL; Zhou, WH; Cohn, JA; Garcia-Blanco, MA; Mitchell, LG; Engelhardt, JF			Partial correction of endogenous Delta F508 CFTR in human cystic fibrosis airway epithelia by spliceosome-mediated RNA trans-splicing	NATURE BIOTECHNOLOGY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; MESSENGER-RNA; GENE-THERAPY; EXPRESSION; CELLS; MANIFESTATIONS; MEMBRANE; VECTOR; LUNG	Spliceosome-mediated RNA trans-splicing (SMaRT) was investigated as a means for functionally correcting endogenous Delta F508 cystic fibrosis transmembrane conductance regulator (CFTR) transcripts using in vitro human cystic fibrosis (CF) polarized airway epithelia and in vivo human CF bronchial xenografts. Recombinant adenovirus (Ad.CFTR-PTM) encoding a pre-therapeutic molecule (PTM) targeted to CFTR intron 9 corrected transepithelial cyclic AMP (cAMP)-sensitive short-circuit current (Isc) in Delta F508 homozygous epithelia to a level 16% of that observed in normal human bronchial epithelia. Molecular analyses using RTPCR and western blotting confirmed SMaRT-mediated partial correction of endogenous Delta F508 messenger RNA (mRNA) transcripts and protein. In an in vivo model of Delta F508 CIF airway epithelia, human CIF bronchial xenografts infected with Ad. CFTR-PTM also demonstrated partial correction of CFTR-mediated Cl- permeability at a level 22% of that seen in non-CF xenografts. These results provide functional evidence for SMaRT-mediated repair of mutant endogenous CFTR mRNA in intact polarized CIF airway epithelial models.	Univ Iowa, Dept Anat & Cell Biol, Coll Med, Iowa City, IA 52242 USA; Univ Iowa, Dept Internal Med, Coll Med, Iowa City, IA 52242 USA; Univ Iowa, Ctr Gene Therapy Cyst Fibrosis & Other Genet Dis, Coll Med, Iowa City, IA 52242 USA; Intronn Inc, Raleigh, NC 27606 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	University of Iowa; University of Iowa; University of Iowa; Duke University	Engelhardt, JF (corresponding author), Univ Iowa, Dept Anat & Cell Biol, Coll Med, Iowa City, IA 52242 USA.			LIU, XIAOMING/0000-0002-3902-9105; Engelhardt, John/0000-0003-2389-9277	NIDDK NIH HHS [R44 DK56526, P 30 DK54759] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R44DK056526, P30DK054759] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson RD, 2000, GENE THER, V7, P1034, DOI 10.1038/sj.gt.3301197; Caudevilla C, 1998, P NATL ACAD SCI USA, V95, P12185, DOI 10.1073/pnas.95.21.12185; CHU CS, 1992, J CLIN INVEST, V90, P785, DOI 10.1172/JCI115952; COTTON CU, 1987, J CLIN INVEST, V79, P80, DOI 10.1172/JCI112812; Dallinger G, 2000, J INVEST DERMATOL, V115, P332, DOI 10.1046/j.1523-1747.2000.115002332.x; DUAN D, 1998, CURRENT PROTOCOLS HU; ENGELHARDT JF, 1994, J CLIN INVEST, V93, P737, DOI 10.1172/JCI117028; ENGELHARDT JF, 1992, NAT GENET, V2, P240, DOI 10.1038/ng1192-240; ENGELHARDT JF, 1993, NAT GENET, V4, P27, DOI 10.1038/ng0593-27; EUL J, 1995, EMBO J, V14, P3226, DOI 10.1002/j.1460-2075.1995.tb07325.x; Imler JL, 1996, GENE THER, V3, P49; Jiang QS, 1998, EUR J HUM GENET, V6, P12, DOI 10.1038/sj.ejhg.5200158; JOHNSON LG, 1992, NAT GENET, V2, P21, DOI 10.1038/ng0992-21; KORST RJ, 1995, AM J RESP CRIT CARE, V151, pS75, DOI 10.1164/ajrccm/151.3_Pt_2.S75; KUNZELMANN K, 1995, PFLUG ARCH EUR J PHY, V431, P1, DOI 10.1007/BF00374371; Mansfield SG, 2000, GENE THER, V7, P1885, DOI 10.1038/sj.gt.3301307; Mohammad-Panah R, 1998, AM J PHYSIOL-CELL PH, V274, pC310, DOI 10.1152/ajpcell.1998.274.2.C310; Puttaraju M, 1999, NAT BIOTECHNOL, V17, P246, DOI 10.1038/6986; Puttaraju M, 2001, MOL THER, V4, P105, DOI 10.1006/mthe.2001.0426; Reed R, 2000, CURR OPIN CELL BIOL, V12, P340, DOI 10.1016/S0955-0674(00)00097-1; Schiavi SC, 1996, AM J PHYSIOL-CELL PH, V270, pC341, DOI 10.1152/ajpcell.1996.270.1.C341; TRAPNELL BC, 1991, P NATL ACAD SCI USA, V88, P6565, DOI 10.1073/pnas.88.15.6565; WAGNER JA, 1995, ANNU REV PHARMACOL, V35, P257; WEI LY, 1995, BIOPHYS J, V69, P883, DOI 10.1016/S0006-3495(95)79962-3; WILSON JM, 1998, CURRENT PROTOCOLS HU; YHAN, 1996, AM J PHYSL, V270, pC1326; Zabner J, 1998, MOL CELL, V2, P397, DOI 10.1016/S1097-2765(00)80284-1; Zhang YL, 1998, HUM GENE THER, V9, P635, DOI 10.1089/hum.1998.9.5-635	28	126	149	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2002	20	1					47	52		10.1038/nbt0102-47	http://dx.doi.org/10.1038/nbt0102-47			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	507ME	11753361				2022-12-25	WOS:000173031600035
J	Ullrich, O; Diestel, A; Eyupoglu, IY; Nitsch, R				Ullrich, O; Diestel, A; Eyupoglu, IY; Nitsch, R			Regulation of microglial expression of integrins by poly(ADP-ribose) polymerase-1	NATURE CELL BIOLOGY			English	Article							HIPPOCAMPAL SLICE CULTURES; NF-KAPPA-B; ADP-RIBOSE POLYMERASE; DNA STRAND BREAKS; GENE-EXPRESSION; CEREBRAL-ISCHEMIA; NERVOUS-SYSTEM; CELLS MIGRATE; ACTIVATION; SYNTHETASE	Excitotoxic brain lesions initially result in the primary destruction of brain parenchyma, after which microglial cells migrate towards the sites of injury. At these sites, the cells produce large quantities of oxygen radicals and cause secondary damage that accounts for most of the loss of brain function, Here we show that this microglial migration is strongly controlled in living brain tissue by expression of the integrin CD11a, regulated by the nuclear enzyme poly(ADP-ribose) polymerase-1 (PARP-1) through the formation of a nuclear PARP-NF-kappaB-protein complex. Downregulation of PARP or CD11a by transfection with antisense DNA abrogated microglial migration almost completely and prevented neurons from secondary damage.	Humboldt Univ, Fac Med Charite, Inst Anat, Dept Cell & Neurobiol, D-10098 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Ullrich, O (corresponding author), Humboldt Univ, Fac Med Charite, Inst Anat, Dept Cell & Neurobiol, Schumannstr 20-21, D-10098 Berlin, Germany.	oliver.ullrich@charite.de	Nitsch, Robert/AAI-9129-2021					Adamchik Y, 2000, BRAIN RES PROTOC, V5, P153, DOI 10.1016/S1385-299X(00)00007-6; BANATI RB, 1994, DEV NEUROSCI-BASEL, V16, P114, DOI 10.1159/000112098; Bielinska A, 1996, NUCLEIC ACIDS RES, V24, P2176, DOI 10.1093/nar/24.11.2176; Bielinska AU, 1997, BBA-GENE STRUCT EXPR, V1353, P180, DOI 10.1016/S0167-4781(97)00069-9; BOULIKAS T, 1993, TOXICOL LETT, V67, P129, DOI 10.1016/0378-4274(93)90051-X; COLTON CA, 1993, ADV NEUROL, V59, P321; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Dantzer F, 1999, BIOCHIMIE, V81, P69, DOI 10.1016/S0300-9084(99)80040-6; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; EMIG S, 1995, J BIOL CHEM, V270, P13787, DOI 10.1074/jbc.270.23.13787; Flanders KC, 1998, PROG NEUROBIOL, V54, P71, DOI 10.1016/S0301-0082(97)00066-X; Gabriel C, 1999, MOL BRAIN RES, V65, P61, DOI 10.1016/S0169-328X(98)00330-1; Gahmberg CG, 1998, CELL MOL LIFE SCI, V54, P549, DOI 10.1007/s000180050183; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Ha HC, 2000, NEUROBIOL DIS, V7, P225, DOI 10.1006/nbdi.2000.0324; Hailer NP, 1997, EUR J NEUROSCI, V9, P863, DOI 10.1111/j.1460-9568.1997.tb01436.x; Hailer NP, 1998, BRAIN PATHOL, V8, P459; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; Heppner FL, 1998, EUR J NEUROSCI, V10, P3284, DOI 10.1046/j.1460-9568.1998.00379.x; Heyen JRR, 2000, MOL BRAIN RES, V77, P138, DOI 10.1016/S0169-328X(00)00042-5; Kameoka M, 2000, BIOCHEM J, V346, P641, DOI 10.1042/0264-6021:3460641; KIM JS, 1995, J NEUROL SCI, V128, P45, DOI 10.1016/0022-510X(94)00203-Z; KRUPITZA G, 1989, BIOCHEMISTRY-US, V28, P4054, DOI 10.1021/bi00435a063; KRUPITZA G, 1989, BIOCHEMISTRY-US, V28, P2034, DOI 10.1021/bi00431a011; Laake JH, 1999, BRAIN RES PROTOC, V4, P173, DOI 10.1016/S1385-299X(99)00021-5; LAUTIER D, 1993, MOL CELL BIOCHEM, V122, P171, DOI 10.1007/BF01076101; Lehrmann E, 1998, GLIA, V24, P437, DOI 10.1002/(SICI)1098-1136(199812)24:4<437::AID-GLIA9>3.0.CO;2-X; Mabuchi T, 2000, STROKE, V31, P1735, DOI 10.1161/01.STR.31.7.1735; Nagayama T, 2000, J NEUROCHEM, V74, P1636, DOI 10.1046/j.1471-4159.2000.0741636.x; OHASHI Y, 1986, BIOCHEM BIOPH RES CO, V140, P666, DOI 10.1016/0006-291X(86)90783-7; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Perrella MA, 1999, J BIOL CHEM, V274, P9045, DOI 10.1074/jbc.274.13.9045; Pieper AA, 2000, MOL MED, V6, P271, DOI 10.1007/BF03401936; Pieper AA, 2000, P NATL ACAD SCI USA, V97, P1845, DOI 10.1073/pnas.97.4.1845; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Roebuck KA, 1999, J LEUKOCYTE BIOL, V66, P876, DOI 10.1002/jlb.66.6.876; Sambrook J, 1989, MOL CLONING; Schlapbach R, 2000, EUR J IMMUNOL, V30, P3680, DOI 10.1002/1521-4141(200012)30:12<3680::AID-IMMU3680>3.0.CO;2-L; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Szabo C, 1997, J EXP MED, V186, P1041, DOI 10.1084/jem.186.7.1041; TSAI YJ, 1992, J BIOL CHEM, V267, P14436; Ullrich O, 1999, P NATL ACAD SCI USA, V96, P6223, DOI 10.1073/pnas.96.11.6223; Ullrich O, 2001, FASEB J, V15, P1460, DOI 10.1096/fj.00-0540fje; WesierskaGadek J, 1996, J CELL BIOCHEM, V62, P90, DOI 10.1002/(SICI)1097-4644(199607)62:1<90::AID-JCB10>3.0.CO;2-J; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; Zingarelli B, 1997, CARDIOVASC RES, V36, P205, DOI 10.1016/S0008-6363(97)00137-5; ZWILLING S, 1995, EMBO J, V14, P1198, DOI 10.1002/j.1460-2075.1995.tb07103.x	47	157	158	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2001	3	12					1035	1042		10.1038/ncb1201-1035	http://dx.doi.org/10.1038/ncb1201-1035			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	500AM	11781564				2022-12-25	WOS:000172603700008
J	Guillon, H; de Massy, B				Guillon, H; de Massy, B			An initiation site for meiotic crossing-over and gene conversion in the mouse	NATURE GENETICS			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; SACCHAROMYCES-CEREVISIAE; RECOMBINATION HOTSPOT; CHROMOSOMES; SEQUENCE; MEIOSIS; REPAIR; LOCUS; MLH1	During meiosis, the reductional segregation of homologous chromosomes at the first meiotic division requires reciprocal exchange (crossing over) between homologs(1). The number of crossovers is tightly regulated (one to two per homolog in mice 2), and their distribution in the genome is not random-recombination 'hot' and 'cold' regions can be identified(3,4). We developed a molecular assay to study these events directly in mouse germ cells. This analysis was developed with reference to the proteosome subunit beta type 9 (Psmb9, previously called Lmp2) hot-spot region identified through genetic analysis(5,6). Here we show that this hot spot is an initiation site of meiotic recombination on the basis of two observations: (i) crossover density is maximal in an interval of 210 bp and decreases on both sides of this region; (ii) a high frequency of gene conversion is found in the region of highest crossover density. We then used this strategy to carry out the first temporal analysis of meiotic recombination in mouse spermatogenesis and demonstrate that crossover events occur during the pachytene stage of meiotic prophase.	Inst Genet Humaine, CNRS, UPR 1142, F-34396 Montpellier 05, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	de Massy, B (corresponding author), Inst Genet Humaine, CNRS, UPR 1142, 141 Rue Cardonille, F-34396 Montpellier 05, France.							Anderson LK, 1999, GENETICS, V151, P1569; Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; BORTS RH, 1989, GENETICS, V123, P69; Cobb J, 1999, DEV BIOL, V205, P49, DOI 10.1006/dbio.1998.9101; DETLOFF P, 1992, GENETICS, V132, P113; GOETZ P, 1984, J CELL SCI, V65, P249; Jeffreys AJ, 2000, HUM MOL GENET, V9, P725, DOI 10.1093/hmg/9.5.725; Jeffreys AJ, 2001, NAT GENET, V29, P217, DOI 10.1038/ng1001-217; JEFFREYS AJ, 1990, CELL, V60, P473, DOI 10.1016/0092-8674(90)90598-9; LAWRIE NM, 1995, CHROMOSOMA, V104, P308, DOI 10.1007/BF00352262; Lichten M, 1995, ANNU REV GENET, V29, P423, DOI 10.1146/annurev.ge.29.120195.002231; Mizuno K, 1996, MAMM GENOME, V7, P490, DOI 10.1007/s003359900149; Peters AHFM, 1997, CHROMOSOME RES, V5, P66, DOI 10.1023/A:1018445520117; Petes TD, 2001, NAT REV GENET, V2, P360, DOI 10.1038/35072078; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; SCHULTES NP, 1990, GENETICS, V126, P813; SHIROISHI T, 1990, IMMUNOGENETICS, V31, P79, DOI 10.1007/BF00661217; SHIROISHI T, 1991, EMBO J, V10, P681, DOI 10.1002/j.1460-2075.1991.tb07997.x; SHIROISHI T, 1995, ADV BIOPHYS, V31, P119, DOI 10.1016/0065-227X(95)99387-5; SYMINGTON LS, 1991, GENETICS, V128, P717; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8	21	75	76	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2002	32	2					296	299		10.1038/ng990	http://dx.doi.org/10.1038/ng990			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	599AP	12244318				2022-12-25	WOS:000178311100020
J	Lee, JT				Lee, JT			Homozygous Tsix mutant mice reveal a sex-ratio distortion and revert to random X-inactivation	NATURE GENETICS			English	Article							ENHANCER-BLOCKING ACTIVITY; XIST GENE; CHROMOSOME INACTIVATION; MOUSE; CTCF; METHYLATION; EXPRESSION; TRANSCRIPTION; ANTISENSE; MUTATION	Tsix(1) controls X-chromosome inactivation (XCI) by blocking the accumulation of Xist(2-4) RNA on the future active X chromosome(5-7). Deleting Tsix on one X chromosome ((XX)-X-Delta) skews XCI toward the mutated X chromosome in the female soma. Here 1 have generated homozygous Tsix-null mice ((XXDelta)-X-Delta) to test how deleting the second allele affects the choice of XCI. Homozygosity leads to extremely low fertility and reveals two previously unknown non-mendelian patterns of inheritance. First, the sex ratio is skewed against female births so that one daughter is born for every two to three sons: Second, the pattern of XCI unexpectedly returns to random in surviving (XXDelta)-X-Delta mice. Thus, with respect to choice, mutation of Tsix yields a phenotypic abnormality in heterozygotes but not homozygotes. To reconcile the paradox of female loss with apparent reversion to random choice, I propose that deleting both Tsix alleles results In chaotic choice and that randomness in (XXDelta)-X-Delta survivors reflects a fortuitous selection of distinct X chromosomes as active and inactive.	Massachusetts Gen Hosp, Dept Mol Biol, Howard Hughes Med Inst, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Lee, JT (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Howard Hughes Med Inst, Boston, MA 02114 USA.	lee@frodo.mgh.harvard.edu						Avner P, 2001, NAT REV GENET, V2, P59, DOI 10.1038/35047580; Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Boumil RM, 2001, HUM MOL GENET, V10, P2225; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; Carrel L, 1996, HUM MOL GENET, V5, P391, DOI 10.1093/hmg/5.3.391; CATTANACH BM, 1981, GENET RES, V38, P57, DOI 10.1017/S0016672300020401; Chao W, 2002, SCIENCE, V295, P345, DOI 10.1126/science.1065982; Charlier C, 2001, NAT GENET, V27, P367, DOI 10.1038/86856; deVillena FPM, 1997, MAMM GENOME, V8, P642, DOI 10.1007/s003359900529; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Huynh KD, 2001, CURR OPIN CELL BIOL, V13, P690, DOI 10.1016/S0955-0674(00)00272-6; Kanduri C, 2000, CURR BIOL, V10, P853, DOI 10.1016/S0960-9822(00)00597-2; KAY GF, 1993, CELL, V72, P171, DOI 10.1016/0092-8674(93)90658-D; Lee JT, 2000, CELL, V103, P17, DOI 10.1016/S0092-8674(00)00101-X; Lee JT, 1999, CELL, V99, P47, DOI 10.1016/S0092-8674(00)80061-6; Lee JT, 1999, NAT GENET, V21, P400, DOI 10.1038/7734; Luikenhuis S, 2001, MOL CELL BIOL, V21, P8512, DOI 10.1128/MCB.21.24.8512-8520.2001; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; Marahrens Y, 1999, GENE DEV, V13, P2624, DOI 10.1101/gad.13.20.2624; Marahrens Y, 1998, CELL, V92, P657, DOI 10.1016/S0092-8674(00)81133-2; Okamoto I, 2000, DEVELOPMENT, V127, P4137; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; Percec I, 2002, SCIENCE, V296, P1136, DOI 10.1126/science.1070087; Plenge RM, 1997, NAT GENET, V17, P353, DOI 10.1038/ng1197-353; Sado T, 2001, DEVELOPMENT, V128, P1275; Stavropoulos N, 2001, P NATL ACAD SCI USA, V98, P10232, DOI 10.1073/pnas.171243598; TAKAGI N, 1975, NATURE, V256, P640, DOI 10.1038/256640a0	30	65	75	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2002	32	1					195	200		10.1038/ng939	http://dx.doi.org/10.1038/ng939			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	588RR	12145659				2022-12-25	WOS:000177714900022
J	Nagy, ZA; Hubner, B; Lohning, C; Rauchenberger, R; Reiffert, S; Thomassen-Wolf, E; Zahn, S; Leyer, S; Schier, EM; Zahradnik, A; Brunner, C; Lobenwein, K; Rattel, B; Stanglmaier, M; Hallek, M; Wing, M; Anderson, S; Dunn, M; Kretzschmar, T; Tesar, M				Nagy, ZA; Hubner, B; Lohning, C; Rauchenberger, R; Reiffert, S; Thomassen-Wolf, E; Zahn, S; Leyer, S; Schier, EM; Zahradnik, A; Brunner, C; Lobenwein, K; Rattel, B; Stanglmaier, M; Hallek, M; Wing, M; Anderson, S; Dunn, M; Kretzschmar, T; Tesar, M			Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells	NATURE MEDICINE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-II MOLECULES; HUMAN B-LYMPHOCYTES; SINGLE-CHAIN FV; C-KIT LIGAND; DOWN-REGULATION; ANTIGEN; APOPTOSIS; INHIBITION; HEMATOPOIESIS	The Human Combinatorial Antibody Library (HuCAL) was screened for antibodies specific to human leukocyte antigen-DR (HLA-DR) that induce programmed death of lymphoma/leukemia cells expressing the target antigen. The active Fab fragments were affinity-matured, and engineered to IgG(4) antibodies of sub-nanomolar affinity. The antibodies exhibited potent in vitro tumoricidal activity on several lymphoma and leukemia cell lines and on chronic lymphocytic leukemia patient samples. They were also active in vivo in xenograft models of non-Hodgkin lymphoma. Cell death occurred rapidly, without the need for exogenous immunological effector mechanisms, and was selective to activated/tumor-transformed cells. Although the expression of HLA-DR on normal hematopoietic cells is a potential safety concern, the antibodies caused no long-lasting hematological toxicity in primates, in vivo. Such monoclonal antibodies offer the potential for a novel therapeutic approach to lymphoid malignancies.	GPC Biotech AG, Martinsried, Germany; MorphoSys AG, Martinsried, Germany; Clin Grosshadern, Med Clin 3, Munich, Germany; Huntingdon Life Sci, Huntingdon, England; GPC Biotech Inc, Waltham, MA USA	GPC Biotech; MorphoSys; University of Munich	Nagy, ZA (corresponding author), GPC Biotech AG, Martinsried, Germany.		Hallek, Michael/Y-3191-2019	Hallek, Michael/0000-0002-7425-4455				ALTOMONTE M, 1993, J IMMUNOL, V151, P5115; BILLING R, 1983, TRANSPLANT P, V15, P649; BRIDGES SH, 1987, J IMMUNOL, V139, P4242; Buhmann R, 1999, BLOOD, V93, P1992, DOI 10.1182/blood.V93.6.1992.406k23_1992_2002; Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192; DeNardo S J, 1988, Int J Cancer Suppl, V3, P96; Drenou B, 1999, J IMMUNOL, V163, P4115; DYER MJS, 1989, BLOOD, V73, P1431; EPSTEIN AL, 1987, CANCER RES, V47, P830; FERREIRA MU, 1995, J IMMUNOL METHODS, V187, P297, DOI 10.1016/0022-1759(95)00186-4; GINGRICH RD, 1990, BLOOD, V75, P2375; GORGA JC, 1984, METHOD ENZYMOL, V108, P607; HONG DS, 1995, BLOOD, V86, P3341, DOI 10.1182/blood.V86.9.3341.bloodjournal8693341; Ito K, 1996, J EXP MED, V183, P2635, DOI 10.1084/jem.183.6.2635; JONKER M, 1988, TRANSPLANTATION, V45, P677, DOI 10.1097/00007890-198804000-00002; KABELITZ D, 1989, CELL IMMUNOL, V120, P21, DOI 10.1016/0008-8749(89)90171-8; KAUFMAN JF, 1984, CELL, V36, P1, DOI 10.1016/0092-8674(84)90068-0; Knappik A, 2000, J MOL BIOL, V296, P57, DOI 10.1006/jmbi.1999.3444; Krebs B, 2001, J IMMUNOL METHODS, V254, P67, DOI 10.1016/S0022-1759(01)00398-2; Lee JW, 1997, J IMMUNOL, V159, P3211; Link BK, 1998, INT J CANCER, V77, P251, DOI 10.1002/(SICI)1097-0215(19980717)77:2<251::AID-IJC14>3.3.CO;2-O; Low NM, 1996, J MOL BIOL, V260, P359, DOI 10.1006/jmbi.1996.0406; Marget M, 2000, TISSUE ANTIGENS, V56, P1, DOI 10.1034/j.1399-0039.2000.560101.x; NEWELL MK, 1993, P NATL ACAD SCI USA, V90, P10459, DOI 10.1073/pnas.90.22.10459; PEIPER SC, 1988, BLOOD, V72, P314; Schier R, 1996, J MOL BIOL, V263, P551, DOI 10.1006/jmbi.1996.0598; Schier R, 1996, J MOL BIOL, V255, P28, DOI 10.1006/jmbi.1996.0004; TEDDER TF, 1988, P NATL ACAD SCI USA, V85, P208, DOI 10.1073/pnas.85.1.208; TRUMAN JP, 1994, INT IMMUNOL, V6, P887, DOI 10.1093/intimm/6.6.887; VAICKUS L, 1989, CELL IMMUNOL, V119, P445, DOI 10.1016/0008-8749(89)90257-8; Vidovic D, 1995, EUR J IMMUNOL, V25, P3349, DOI 10.1002/eji.1830251222; Vidovic D, 1998, CANCER LETT, V128, P127, DOI 10.1016/S0304-3835(98)00034-2; VIRNEKAS B, 1994, NUCLEIC ACIDS RES, V22, P5600, DOI 10.1093/nar/22.25.5600; Vose JM, 2001, J CLIN ONCOL, V19, P389, DOI 10.1200/JCO.2001.19.2.389; YOSHINO T, 1995, EUR J IMMUNOL, V25, P2190, DOI 10.1002/eji.1830250811	35	121	163	0	4	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	AUG	2002	8	8					801	807		10.1038/nm736	http://dx.doi.org/10.1038/nm736			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	579WJ	12101408				2022-12-25	WOS:000177200900025
J	Yokoi, N; Komeda, K; Wang, HY; Yano, H; Kitada, K; Saitoh, Y; Seino, Y; Yasuda, K; Serikawa, T; Seino, S				Yokoi, N; Komeda, K; Wang, HY; Yano, H; Kitada, K; Saitoh, Y; Seino, Y; Yasuda, K; Serikawa, T; Seino, S			Cblb is a major susceptibility gene for rat type 1 diabetes mellitus	NATURE GENETICS			English	Article							AUTOIMMUNE THYROID-DISEASE; NEGATIVE REGULATOR; C-CBL; PROTEIN; KINASE; IDDM; ACTIVATION; CLONING; PRONE; MOUSE	The autoimmune disease type 1 diabetes mellitus (insulin-dependent diabetes mellitus, IDDM) has a multifactorial etiology. So far, the major histocompatibility complex (MHC) is the only major susceptibility locus that has been identified for this disease 1 and its animal models(2,3). The Komeda diabetes-prone (KDP) rat is a spontaneous animal model of human type 1 diabetes 4 in which the major susceptibility locus Iddm/kdp1 accounts, in combination with MHC, for most of the genetic predisposition to diabetes(5). Here we report the positional cloning of Iddm/kdp1 and identify a nonsense mutation in Cblb, a member of the Cbl/Sli family of ubiquitin-protein ligases(6,7). Lymphocytes of the KDP rat infiltrate into pancreatic islets and several tissues including thyroid gland and kidney, indicating autoimmunity. Similar findings in Cblb-deficient mice are caused by enhanced T-cell activation(8,9). Transgenic complementation with wildtype Cblb significantly suppresses development of the KDP phenotype. Thus, Cblb functions as a negative regulator of autoimmunity and Cblb is a major susceptibility gene for type 1 diabetes in the rat. Impairment of the Cblb signaling pathway may contribute to human autoimmune diseases, including type 1 diabetes.	Chiba Univ, Dept Cellular & Mol Med, Grad Sch Med, Chuo Ku, Chiba 2608670, Japan; Chiba Univ, Sch Med, Dept Med Genet, Novo Nordisk Pharma,Chuo Ku, Chiba 2608670, Japan; Tokyo Med Unig, Div Lab Anim Sci, Ctr Anim Res, Shinjuku Ku, Tokyo, Japan; Kyoto Univ, Grad Sch Med, Inst Lab Anim, Sakyo Ku, Kyoto 606, Japan; Tokyo Med Univ, Dept Internal Med 3, Shinjuku Ku, Tokyo, Japan; Kyoto Univ, Grad Sch Med, Dept Metab & Clin Nutr, Sakyo Ku, Kyoto, Japan; Int Med Ctr Japan, Dept Metab Disorder, Inst Res, Shinjuku Ku, Tokyo, Japan	Chiba University; Chiba University; Novo Nordisk; Kyoto University; Tokyo Medical University; Kyoto University; National Center for Global Health & Medicine - Japan	Seino, S (corresponding author), Chiba Univ, Dept Cellular & Mol Med, Grad Sch Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.							Bachmaier K, 2000, NATURE, V403, P211, DOI 10.1038/35003228; BOWEN MA, 1995, J EXP MED, V181, P2213, DOI 10.1084/jem.181.6.2213; Bustelo XR, 1997, ONCOGENE, V15, P2511, DOI 10.1038/sj.onc.1201430; Chiang YPJ, 2000, NATURE, V403, P216, DOI 10.1038/35003235; CHIKUBA N, 1992, INTERNAL MED, V31, P1076, DOI 10.2169/internalmedicine.31.1076; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; Ellerman KE, 2000, DIABETOLOGIA, V43, P890, DOI 10.1007/s001250051466; JACOB HJ, 1992, NAT GENET, V2, P56, DOI 10.1038/ng0992-56; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; KAWANO K, 1991, DIABETES, V40, P1375, DOI 10.2337/diabetes.40.11.1375; KEANE MM, 1995, ONCOGENE, V10, P2367; Komeda K, 1998, ENDOCR J, V45, P737, DOI 10.1507/endocrj.45.737; Krawczyk C, 2000, IMMUNITY, V13, P463, DOI 10.1016/S1074-7613(00)00046-7; Lorini R, 1996, J PEDIATR ENDOCR MET, V9, P89; Nepom GT, 1998, DIABETES, V47, P1177, DOI 10.2337/diabetes.47.8.1177; NISHI M, 1988, NATURE, V331, P267, DOI 10.1038/331267a0; Schwartz RH, 1996, J EXP MED, V184, P1, DOI 10.1084/jem.184.1.1; Shinkura R, 1999, NAT GENET, V22, P74, DOI 10.1038/8780; WICKER LS, 1995, ANNU REV IMMUNOL, V13, P179, DOI 10.1146/annurev.iy.13.040195.001143; Yokoi N, 1997, J CLIN INVEST, V100, P2015, DOI 10.1172/JCI119733	21	149	158	0	10	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2002	31	4					391	394		10.1038/ng927	http://dx.doi.org/10.1038/ng927			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	578XV	12118252				2022-12-25	WOS:000177147100014
J	Grimm, C; Wenzel, A; Groszer, M; Mayser, H; Seeliger, M; Samardzija, M; Bauer, C; Gassmann, M; Reme, CE				Grimm, C; Wenzel, A; Groszer, M; Mayser, H; Seeliger, M; Samardzija, M; Bauer, C; Gassmann, M; Reme, CE			HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration	NATURE MEDICINE			English	Article							INDUCED APOPTOSIS; GROWTH-FACTOR; CELL-DEATH; PHOTORECEPTORS; RHODOPSIN; DAMAGE; EXPRESSION; MICE; ACTIVATION; MEDIATOR	Erythropoietin (Epo) is upregulated by hypoxia and provides protection against apoptosis of erythroid progenitors in bone marrow and brain neurons. Here we show in the adult mouse retina that acute hypoxia dose-dependently stimulates expression of Epo, fibroblast growth factor 2 and vascular endothelial growth factor via hypoxia-inducible factor-1alpha (HIF-1alpha) stabilization. Hypoxic preconditioning protects retinal morphology and function against light-induced apoptosis by interfering with caspase-1 activation, a downstream event in the intracellular death cascade. In contrast, induction of activator protein-1, an early event in the light-stressed retina, is not affected by hypoxia. The Epo receptor required for Epo signaling localizes to photoreceptor cells. The protective effect of hypoxic preconditioning is mimicked by systemically applied Epo that crosses the blood-retina barrier and prevents apoptosis even when given therapeutically after light insult. Application of Epo may, through the inhibition of apoptosis, be beneficial for the treatment of different forms of retinal disease.	Univ Hosp, Dept Ophthalmol, Retinal Cell Biol, Zurich, Switzerland; Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90024 USA; Univ Tubingen, Dept Ophthalmol, Retinal Electrodiagnost Res Grp, Tubingen, Germany; Univ Zurich, Inst Physiol, Zurich, Switzerland; Univ Zurich, Inst Vet Physiol, Zurich, Switzerland	University of Zurich; University Zurich Hospital; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Zurich; University of Zurich	Grimm, C (corresponding author), Univ Hosp, Dept Ophthalmol, Retinal Cell Biol, Zurich, Switzerland.	cgrimm@opht.unizh.ch	Samardzija, Marijana/B-9245-2008	Samardzija, Marijana/0000-0003-0991-4653; Groszer, Matthias/0000-0002-6209-305X; Grimm, Christian/0000-0001-9318-4352; Gassmann, Max/0000-0003-2750-8878				Adler R, 1999, MOL VIS, V5; BARBE MF, 1988, SCIENCE, V241, P1817, DOI 10.1126/science.3175623; Bowers F, 2001, INVEST OPHTH VIS SCI, V42, P804; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Camenisch G, 1999, FASEB J, V13, P81, DOI 10.1096/fasebj.13.1.81; Chattopadhyay A, 2000, BIOCHEM PHARMACOL, V59, P419, DOI 10.1016/S0006-2952(99)00277-4; Chilov D, 2001, FASEB J, V15, P2613, DOI 10.1096/fj.01-0092com; Coffer PJ, 1998, BIOCHEM J, V335, P1; Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246; FAKTOROVICH EG, 1992, J NEUROSCI, V12, P3554; FAKTOROVICH EG, 1990, NATURE, V347, P83, DOI 10.1038/347083a0; FANDREY J, 1993, BLOOD, V81, P617; Fry J.C., 1993, BIOL DATA ANAL PRACT; Grimm C, 2000, NAT GENET, V25, P63, DOI 10.1038/75614; Grimm C, 2000, MOL VIS, V6, P252; HOFER T, 2002, PFLUGERS ARCH, V443, P5403; Honig LS, 2000, AM J MED, V108, P317, DOI 10.1016/S0002-9343(00)00291-6; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; Keller C, 2001, INVEST OPHTH VIS SCI, V42, P476; Kueng-Hitz N, 2000, INVEST OPHTH VIS SCI, V41, P909; LaVail MM, 1998, INVEST OPHTH VIS SCI, V39, P592; Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1; MIURA Y, 1994, J BIOL CHEM, V269, P29962; Nickells RW, 1999, SURV OPHTHALMOL, V43, pS151, DOI 10.1016/S0039-6257(99)00029-6; OSTROY SE, 1993, INVEST OPHTH VIS SCI, V34, P447; Ozaki H, 1999, INVEST OPHTH VIS SCI, V40, P182; Pierce EA, 1999, NAT GENET, V22, P248, DOI 10.1038/10305; Reme CE, 1998, PROG RETIN EYE RES, V17, P443, DOI 10.1016/S1350-9462(98)00009-3; Robinson GS, 2001, FASEB J, V15, P1215, DOI 10.1096/fj.00-0598fje; Saari JC, 2001, NEURON, V29, P739, DOI 10.1016/S0896-6273(01)00248-3; Seeliger MW, 2001, NAT GENET, V29, P70, DOI 10.1038/ng712; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Siren AL, 2001, EUR ARCH PSY CLIN N, V251, P179, DOI 10.1007/s004060170038; Spencer B, 2001, MOL THER, V3, P746, DOI 10.1006/mthe.2001.0307; STEINBERG RH, 1987, INVEST OPHTH VIS SCI, V28, P1888; Stroka DM, 2001, FASEB J, V15, P2445, DOI 10.1096/fj.01-0125com; TOUTENBERG H, 1995, EXPT DESIGN MODEL CH; Van Soest S, 1999, SURV OPHTHALMOL, V43, P321, DOI 10.1016/S0039-6257(98)00046-0; Wenzel A, 2000, J NEUROSCI, V20, P81, DOI 10.1523/JNEUROSCI.20-01-00081.2000; Wenzel A, 2001, INVEST OPHTH VIS SCI, V42, P1653; Wenzel A, 2001, J NEUROSCI, V21, P53, DOI 10.1523/JNEUROSCI.21-01-00053.2001; Yamada H, 2001, AM J PATHOL, V159, P1113, DOI 10.1016/S0002-9440(10)61787-7; Zaman K, 1999, J NEUROSCI, V19, P9821	44	421	464	0	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2002	8	7					718	724		10.1038/nm723	http://dx.doi.org/10.1038/nm723			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	567QG	12068288				2022-12-25	WOS:000176495200033
J	Li, J; Yang, Y; Peng, Y; Austin, RJ; van Eyndhoven, G; Nguyen, KCQ; Gabriele, T; McCurrach, ME; Marks, JR; Hoey, T; Lowe, SW; Powers, S				Li, J; Yang, Y; Peng, Y; Austin, RJ; van Eyndhoven, G; Nguyen, KCQ; Gabriele, T; McCurrach, ME; Marks, JR; Hoey, T; Lowe, SW; Powers, S			Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23	NATURE GENETICS			English	Article							COPY-NUMBER; AMPLICON; PROTEIN; KINASE; ZNF217; TUMORS; DNA	We found that PPM1D, encoding a serine/threonine protein phosphatase, lies within an epicenter of the region at 17q23 that is amplified in breast cancer. We show that overexpression of this gene confers two oncogenic phenotypes on cells in culture: attenuation of apoptosis induced by serum starvation and transformation of primary cells in cooperation with RAS.	Tularik Inc, Genom Div, Greenlawn, NY USA; Tularik Inc, San Francisco, CA USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Duke Univ, Ctr Med, Dept Surg, Durham, NC USA	Cold Spring Harbor Laboratory; Duke University	Powers, S (corresponding author), Tularik Inc, Genom Div, 266 Pulaski Rd, Greenlawn, NY USA.			Powers, Scott/0000-0003-2769-1932	NCI NIH HHS [P30 CA008748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748, P01CA129243] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Barlund M, 2000, J NATL CANCER I, V92, P1252, DOI 10.1093/jnci/92.15.1252; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Collins C, 1998, P NATL ACAD SCI USA, V95, P8703, DOI 10.1073/pnas.95.15.8703; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Lanni JS, 1997, P NATL ACAD SCI USA, V94, P9679, DOI 10.1073/pnas.94.18.9679; Latham C, 2001, CANCER GENET CYTOGEN, V127, P16, DOI 10.1016/S0165-4608(00)00427-1; Monni O, 2001, P NATL ACAD SCI USA, V98, P5711, DOI 10.1073/pnas.091582298; Nonet GH, 2001, CANCER RES, V61, P1250; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Schwab M, 1999, SEMIN CANCER BIOL, V9, P319, DOI 10.1006/scbi.1999.0126; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Wu GJ, 2001, CANCER RES, V61, P4951; Zheng PZ, 1998, P NATL ACAD SCI USA, V95, P14745, DOI 10.1073/pnas.95.25.14745	15	208	222	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2002	31	2					133	134		10.1038/ng888	http://dx.doi.org/10.1038/ng888			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	557HR	12021784				2022-12-25	WOS:000175903500007
J	Xu, J; Kao, SY; Lee, FJS; Song, WH; Jin, LW; Yankner, BA				Xu, J; Kao, SY; Lee, FJS; Song, WH; Jin, LW; Yankner, BA			Dopamine-dependent neurotoxicity of alpha-synuclein: A mechanism for selective neurodegeneration in Parkinson disease	NATURE MEDICINE			English	Article							LEWY BODIES; PATHOGENESIS; DEATH; AGGREGATION; APOPTOSIS; DEMENTIA; MUTATION; SYSTEM; CELLS	The mechanism by which dopaminergic neurons are selectively lost in Parkinson disease (PD) is unknown. Here we show that accumulation of alpha-synuclein in cultured human dopaminergic neurons results in apoptosis that requires endogenous dopamine production and is mediated by reactive oxygen species. In contrast, alpha-synuclein is not toxic in non-dopaminergic human cortical neurons, but rather exhibits neuroprotective activity. Dopamine-dependent neurotoxicity is mediated by 54-83-kD soluble protein complexes that contain alpha-synuclein and 14-3-3 protein, which are elevated selectively in the substantia nigra in PD. Thus, accumulation of soluble alpha-synuclein protein complexes can render endogenous dopamine toxic, suggesting a potential mechanism for the selectivity of neuronal loss in PD.	Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Childrens Hosp, Div Neurosci, Boston, MA 02115 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; University of Washington; University of Washington Seattle	Yankner, BA (corresponding author), Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA.		Song, Weihong/O-7623-2017; Lee, Frank J.S./D-5899-2017	Song, Weihong/0000-0001-9928-889X; Lee, Frank J.S./0000-0002-5768-3776; Xu, Jin/0000-0001-6617-5311	NATIONAL INSTITUTE ON AGING [R01AG017573] Funding Source: NIH RePORTER; NIA NIH HHS [AG17573] Funding Source: Medline; NINDS NIH HHS [NS03352] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baba M, 1998, AM J PATHOL, V152, P879; BREAKEFIELD XO, P NATL ACAD SCI US, V71, P2530; BUSCIGLIO J, 1995, NATURE, V378, P776, DOI 10.1038/378776a0; Campbell BCV, 2001, J NEUROCHEM, V76, P87, DOI 10.1046/j.1471-4159.2001.00021.x; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; da Costa CA, 2000, J BIOL CHEM, V275, P24065, DOI 10.1074/jbc.M002413200; Drukarch B, 1996, J NEUROSCI, V16, P6038; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Hashimoto M, 2001, NEURON, V32, P213, DOI 10.1016/S0896-6273(01)00462-7; Hastings TG, 1996, P NATL ACAD SCI USA, V93, P1956, DOI 10.1073/pnas.93.5.1956; Hsu LJ, 2000, AM J PATHOL, V157, P401, DOI 10.1016/S0002-9440(10)64553-1; Iwata A, 2001, J BIOL CHEM, V276, P45320, DOI 10.1074/jbc.M103736200; Junn E, 2002, NEUROSCI LETT, V320, P146, DOI 10.1016/S0304-3940(02)00016-2; Kawamoto Y, 2002, J NEUROPATH EXP NEUR, V61, P245, DOI 10.1093/jnen/61.3.245; Kirik D, 2002, J NEUROSCI, V22, P2780, DOI 10.1523/JNEUROSCI.22-07-02780.2002; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Tabrizi SJ, 2000, HUM MOL GENET, V9, P2683, DOI 10.1093/hmg/9.18.2683; Tompkins MM, 1997, BRAIN RES, V775, P24, DOI 10.1016/S0006-8993(97)00874-3; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhou WB, 2000, BRAIN RES, V866, P33, DOI 10.1016/S0006-8993(00)02215-0; Zhou WB, 2002, BRAIN RES, V926, P42, DOI 10.1016/S0006-8993(01)03292-9	30	605	631	1	63	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2002	8	6					600	606		10.1038/nm0602-600	http://dx.doi.org/10.1038/nm0602-600			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	557KG	12042811				2022-12-25	WOS:000175907300031
J	Fredriksson, S; Gullberg, M; Jarvius, J; Olsson, C; Pietras, K; Gustafsdottir, SM; Ostman, A; Landegren, U				Fredriksson, S; Gullberg, M; Jarvius, J; Olsson, C; Pietras, K; Gustafsdottir, SM; Ostman, A; Landegren, U			Protein detection using proximity-dependent DNA ligation assays	NATURE BIOTECHNOLOGY			English	Article							GROWTH-FACTOR; EXPONENTIAL ENRICHMENT; SYSTEMATIC EVOLUTION; LIGANDS; DIAGNOSTICS; MOLECULES; APTAMERS; RECEPTOR; CELLS; PDGF	The advent of in vitro DNA amplification has enabled rapid acquisition of genomic information. We present here an analogous technique for protein detection, in which the coordinated and proximal binding of a target protein by two DNA aptamers promotes ligation of oligonucleotides linked to each aptamer affinity probe. The ligation of two such proximity probes gives rise to an amplifiable DNA sequence that reflects the identity and amount of the target protein. This proximity ligation assay detects zeptomole (40 x 10(-21) mol) amounts of the cytokine platelet-derived growth factor (PDGF) without washes or separations, and the mechanism can be generalized to other forms of protein analysis.	Rudbeck Lab, Dept Genet & Pathol, Beijer Lab, SE-75185 Uppsala, Sweden; Uppsala Biomed Ctr, Ludwig Inst Canc Res, SE-75123 Uppsala, Sweden	Ludwig Institute for Cancer Research	Landegren, U (corresponding author), Rudbeck Lab, Dept Genet & Pathol, Beijer Lab, SE-75185 Uppsala, Sweden.		Landegren, Ulf D/A-8197-2019; Pietras, Kristian/ABE-8727-2020; Pietras, Kristian/ABG-2097-2021	Pietras, Kristian/0000-0001-6738-4705; Gullberg, Mats/0000-0002-9955-5668				Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; BONNER JC, 1995, J BIOL CHEM, V270, P16236, DOI 10.1074/jbc.270.27.16236; Brody EN, 1999, MOL DIAGN, V4, P381, DOI 10.1016/S1084-8592(99)80014-9; Dahlman T, 2000, J PATHOL, V191, P376, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH643>3.0.CO;2-W; Drolet DW, 1999, COMB CHEM HIGH T SCR, V2, P271; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; Green LS, 1996, BIOCHEMISTRY-US, V35, P14413, DOI 10.1021/bi961544+; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Jayasena SD, 1999, CLIN CHEM, V45, P1628; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; Leppanen O, 2000, BIOCHEMISTRY-US, V39, P2370, DOI 10.1021/bi9919192; Li M, 2000, NAT BIOTECHNOL, V18, P1251, DOI 10.1038/82355; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; MACAYA RF, 1995, BIOCHEMISTRY-US, V34, P4478, DOI 10.1021/bi00013a041; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; Robertson MP, 1999, NAT BIOTECHNOL, V17, P62, DOI 10.1038/5236; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANO T, 1992, SCIENCE, V258, P120, DOI 10.1126/science.1439758; Tasset DM, 1997, J MOL BIOL, V272, P688, DOI 10.1006/jmbi.1997.1275; THYBERG J, 1990, J CELL SCI, V97, P219; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121	23	987	1117	34	422	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2002	20	5					473	477		10.1038/nbt0502-473	http://dx.doi.org/10.1038/nbt0502-473			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	548AE	11981560				2022-12-25	WOS:000175364800029
J	Manfredi, G; Fu, J; Ojaimi, J; Sadlock, JE; Kwong, JQ; Guy, J; Schon, EA				Manfredi, G; Fu, J; Ojaimi, J; Sadlock, JE; Kwong, JQ; Guy, J; Schon, EA			Rescue of a deficiency in ATP synthesis by transfer of MTATP6, a mitochondrial DNA-encoded gene, to the nucleus	NATURE GENETICS			English	Article							INTERMEDIATE PEPTIDASE; ESCHERICHIA-COLI; ATPASE-6 GENE; CELL-LINES; SUBUNIT-C; SYNTHASE; MUTATION; SEQUENCE; PROTEIN; IMPORT	AT-->G transversion at nt 8993 in mitochondrial DNA of MTATP6 (encoding ATPase 6 of complex V of the respiratory chain) causes impaired mitochondrial ATP synthesis in two related mitochondrial disorders: neuropathy, ataxia and retinitis pigmentosa(1) and maternally inherited Leigh syndrome(2). To overcome the biochemical defect, we expressed wildtype ATPase 6 protein allotopically(3) from nucleus-transfected constructs encoding an amino-terminal mitochondrial targeting signal appended to a recoded ATPase 6 gene (made compatible with the universal genetic code) that also contained a carboxy-terminal FLAG epitope tag. After transfection of human cells, the precursor polypeptide was expressed, imported into and processed within mitochondria, and incorporated into complex V. Allotopic expression of stably transfected constructs in cytoplasmic hybrids (cybrids) homoplasmic with respect to the 8993T-->G mutation showed a significantly improved recovery after growth in selective medium as well as a significant increase in ATP synthesis. This is the first successful demonstration of allotopic expression of an mtDNA-encoded polypeptide in mammalian cells and could form the basis of a genetic approach to treat a number of human mitochondrial disorders.	Columbia Univ, Dept Neurol, New York, NY 10032 USA; Cornell Univ, Dept Neurol & Neurosci, New York, NY USA; Univ Florida, Coll Med, Dept Ophthalmol, Gainesville, FL 32610 USA; Columbia Univ, Dept Genet & Dev, New York, NY USA	Columbia University; Cornell University; State University System of Florida; University of Florida; Columbia University	Schon, EA (corresponding author), Columbia Univ, Dept Neurol, Room 4-431,630 W 168th St, New York, NY 10032 USA.		Fu, Jin/A-3510-2012; Kwong, Jennifer/L-4348-2019					Altendorf K, 2000, J EXP BIOL, V203, P19; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BRANDA SS, 1995, J BIOL CHEM, V270, P27366, DOI 10.1074/jbc.270.45.27366; BREEN GAM, 1986, J BIOL CHEM, V261, P1680; Chinnery PF, 1999, GENE THER, V6, P1919, DOI 10.1038/sj.gt.3301061; DEVRIES DD, 1993, ANN NEUROL, V34, P410, DOI 10.1002/ana.410340319; DiMauro S, 2000, BRAIN PATHOL, V10, P431; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; GALANIS M, 1991, FEBS LETT, V282, P425, DOI 10.1016/0014-5793(91)80529-C; Garcia JJ, 2000, J BIOL CHEM, V275, P11075, DOI 10.1074/jbc.275.15.11075; Geromel V, 2001, ANTISENSE NUCLEIC A, V11, P175, DOI 10.1089/108729001300338708; Gray R E, 1996, Methods Enzymol, V264, P369, DOI 10.1016/S0076-6879(96)64035-X; Hauswirth WW, 2000, METHOD ENZYMOL, V316, P743; HERLITZE S, 1990, GENE, V91, P143, DOI 10.1016/0378-1119(90)90177-S; HIGUTI T, 1993, BIOCHIM BIOPHYS ACTA, V1173, P87, DOI 10.1016/0167-4781(93)90249-D; HOLT IJ, 1990, AM J HUM GENET, V46, P428; Hutcheon ML, 2001, P NATL ACAD SCI USA, V98, P8519, DOI 10.1073/pnas.151236798; ISAYA G, 1992, P NATL ACAD SCI USA, V89, P8317, DOI 10.1073/pnas.89.17.8317; Jager H, 1998, EUR J BIOCHEM, V251, P122, DOI 10.1046/j.1432-1327.1998.2510122.x; JOHN UP, 1986, FEBS LETT, V207, P79, DOI 10.1016/0014-5793(86)80016-3; KLEMENT P, 1995, ANAL BIOCHEM, V231, P218, DOI 10.1006/abio.1995.1523; LAW RHP, 1988, FEBS LETT, V236, P501, DOI 10.1016/0014-5793(88)80086-3; Manfred G, 1999, J BIOL CHEM, V274, P9386, DOI 10.1074/jbc.274.14.9386; Manfredi G, 2001, METHOD CELL BIOL, V65, P133, DOI 10.1016/S0091-679X(01)65008-8; MARIOTTINI P, 1986, P NATL ACAD SCI USA, V83, P1563, DOI 10.1073/pnas.83.6.1563; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nakada K, 2001, NAT MED, V7, P934, DOI 10.1038/90976; Noji H, 2001, J BIOL CHEM, V276, P1665, DOI 10.1074/jbc.R000021200; Pallotti F, 2001, METHOD CELL BIOL, V65, P1, DOI 10.1016/S0091-679X(01)65002-7; Rastogi VK, 1999, NATURE, V402, P263, DOI 10.1038/46224; Rees S, 1996, BIOTECHNIQUES, V20, P102; RIZZUTO R, 1989, J BIOL CHEM, V264, P10595; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Ryan MT, 2001, METHOD CELL BIOL, V65, P189, DOI 10.1016/S0091-679X(01)65012-X; Schon EA, 2001, SEMIN CELL DEV BIOL, V12, P441, DOI 10.1006/scdb.2001.0281; Sciacco M, 1996, Methods Enzymol, V264, P509, DOI 10.1016/S0076-6879(96)64045-2; Seibel M, 1999, BIOL CHEM, V380, P961, DOI 10.1515/BC.1999.119; Strub A, 2000, BIOL CHEM, V381, P943, DOI 10.1515/BC.2000.115; SUTHERLAND L, 1995, BIOTECHNIQUES, V18, P458; TATUCH Y, 1993, BIOCHEM BIOPH RES CO, V192, P124, DOI 10.1006/bbrc.1993.1390; TATUCH Y, 1992, AM J HUM GENET, V50, P852; VazquezMemije ME, 1996, J INHERIT METAB DIS, V19, P43, DOI 10.1007/BF01799347; White SL, 1999, AM J HUM GENET, V65, P474, DOI 10.1086/302488; Zolotukhin S, 1996, J VIROL, V70, P4646, DOI 10.1128/JVI.70.7.4646-4654.1996	44	196	210	1	23	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2002	30	4					394	399		10.1038/ng851	http://dx.doi.org/10.1038/ng851			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	536BZ	11925565				2022-12-25	WOS:000174682000016
J	LeBlanc, H; Lawrence, D; Varfolomeev, E; Totpal, K; Morlan, J; Schow, P; Fong, S; Schwall, R; Sinicropi, D; Ashkenazi, A				LeBlanc, H; Lawrence, D; Varfolomeev, E; Totpal, K; Morlan, J; Schow, P; Fong, S; Schwall, R; Sinicropi, D; Ashkenazi, A			Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax	NATURE MEDICINE			English	Article							MICROSATELLITE MUTATOR PHENOTYPE; FLICE-INHIBITORY PROTEIN; CYTOCHROME-C RELEASE; SIGNALING COMPLEX; TRAIL RECEPTOR-2; IN-VIVO; LIGAND; CASPASE-8; CANCER; FADD	The importance of Bax for induction of tumor apoptosis through death receptors remains unclear. Here we show that Bax can be essential for death receptor-mediated apoptosis in cancer cells. Bax-deficient human colon carcinoma cells were resistant to death-receptor ligands, whereas Bax-expressing sister clones were sensitive. Bax was dispensable for apical death-receptor signaling events including caspase-8 activation, but crucial for mitochondrial changes and downstream caspase activation. Treatment of colon tumor cells deficient in DNA mismatch repair with the death-receptor ligand apo2 ligand (Apo2L)/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selected in vitro or in vivo for refractory subclones with Bax frameshift mutations including deletions at a novel site. Chemotherapeutic agents upregulated expression of the Apo2L/TRAIL receptor DR5 and the Bax homolog Bak in Bax(-/-) cells, and restored Apo2L/TRAIL sensitivity in vitro and in vivo. Thus, Bax mutation in mismatch repair-deficient tumors can cause resistance to death receptor-targeted therapy, but pre-exposure to chemotherapy rescues tumor sensitivity.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Analyt Assay Technol, San Francisco, CA 94080 USA; Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Ashkenazi, A (corresponding author), Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA.		Ashkenazi, Avi/ABG-2712-2020	Ashkenazi, Avi/0000-0002-6890-4589				Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Chuntharapai A, 2001, J IMMUNOL, V166, P4891, DOI 10.4049/jimmunol.166.8.4891; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Ionov Y, 2000, P NATL ACAD SCI USA, V97, P10872, DOI 10.1073/pnas.190210897; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Perucho M, 1996, BIOL CHEM, V377, P675; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; Pollack IF, 2001, CLIN CANCER RES, V7, P1362; Qin JZ, 2001, NAT MED, V7, P385, DOI 10.1038/86401; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Roth W, 1999, BIOCHEM BIOPH RES CO, V265, P479, DOI 10.1006/bbrc.1999.1693; Roy S, 2000, J EXP MED, V192, pF21, DOI 10.1084/jem.192.8.F21; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	41	460	470	1	23	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2002	8	3					274	281		10.1038/nm0302-274	http://dx.doi.org/10.1038/nm0302-274			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	526PU	11875499				2022-12-25	WOS:000174139500033
J	Thazhath, R; Liu, CB; Gaertig, J				Thazhath, R; Liu, CB; Gaertig, J			Polyglycylation domain of beta-tubulin maintains axonemal architecture and affects cytokinesis in Tetrahymena	NATURE CELL BIOLOGY			English	Article							ALPHA-TUBULIN; POSTTRANSLATIONAL MODIFICATION; GENE REPLACEMENT; THERMOPHILA; MICROTUBULES; MOTILITY; ANTIBODIES; TRANSFORMATION; EVOLUTION	Polyglycylation occurs through the post-translational addition of a polyglycine peptide to the gamma-carboxyl group of glutamic acids near the C terminus of alpha- and beta-tubulin(1), and has been found only in cells with axonemes, from protists to humans(2,3). In Tetrahymena thermophila, multiple sites of polyglycylation on alpha-tubulin are dispensable. By contrast, mutating similar sites on beta-tubulin has site-specific effects, affecting cell motility and cytokinesis, or resulting in cell death(4). Here, we address the lethality of a polyglycylation deficiency in T. thermophila using heterokaryons(5). Cells with a lethal mutation in the polyglycylation domain of beta-tubulin assembled axonemes that lack the central pair, B-subfibres and the transitional zone of outer microtubules (MTs). Furthermore, an arrest in cytokinesis occurred, and was associated with incomplete severing of cortical MTs positioned near the cleavage furrow. Thus, tubulin polyglycylation is required for the maintenance of some stable microtubular organelles that are all known to be polyglycylated in vivo, but its effects on MTs appear to be organelle-specific.	Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA	University System of Georgia; University of Georgia	Thazhath, R (corresponding author), Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA.	jgaertig@cb.uga.edu	Gaertig, Jacek/F-1553-2010		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054017] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 54017] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADOUTTE A, 1985, J MOL EVOL, V22, P220, DOI 10.1007/BF02099751; BEHNKE O, 1967, J CELL SCI, V2, P169; Bre MH, 1996, J CELL SCI, V109, P727; BRESSAC C, 1995, EUR J CELL BIOL, V67, P346; Brown JM, 1999, MOL BIOL CELL, V10, P3081, DOI 10.1091/mbc.10.10.3081; Brown JM, 1999, CELL BIOL INT, V23, P841, DOI 10.1006/cbir.1999.0480; Calzone FJ, 1982, EXP CELL RES, V140, P474; CassidyHanley D, 1997, GENETICS, V146, P135; ERRABOLU R, 1994, J CELL SCI, V107, P9; FRANKEL J, 2001, CELL POLARITY; GAERTIG J, 1995, J CELL BIOL, V129, P1301, DOI 10.1083/jcb.129.5.1301; GAERTIG J, 1994, NUCLEIC ACIDS RES, V22, P5391, DOI 10.1093/nar/22.24.5391; GAERTIG J, 1993, CELL MOTIL CYTOSKEL, V25, P243, DOI 10.1002/cm.970250305; GIBBONS I. R., 1965, ARCH BIOL, V76, P317; Hai B, 1997, P NATL ACAD SCI USA, V94, P1310, DOI 10.1073/pnas.94.4.1310; Hai B, 2000, METHOD CELL BIOL, V62, P513; JERKADZIADOSZ M, 1995, DEV BIOL, V169, P644, DOI 10.1006/dbio.1995.1176; LEDIZET M, 1991, METHOD ENZYMOL, V196, P264; LEVILLIERS N, 1995, J CELL SCI, V108, P3013; Quarmby L, 2000, J CELL SCI, V113, P2821; Raff EC, 2000, CURR BIOL, V10, P1391, DOI 10.1016/S0960-9822(00)00784-3; RASMUSSEN L, 1975, SCIENCE, V190, P464, DOI 10.1126/science.1166313; REDEKER V, 1994, SCIENCE, V266, P1688, DOI 10.1126/science.7992051; Smith EF, 1997, CELL MOTIL CYTOSKEL, V38, P1; STARGELL LA, 1992, MOL CELL BIOL, V12, P1443, DOI 10.1128/MCB.12.4.1443; STURGESS JM, 1980, NEW ENGL J MED, V303, P318, DOI 10.1056/NEJM198008073030606; TILNEY LG, 1968, PROTOPLASMA, V65, P167, DOI 10.1007/BF01666377; WHEATLEY DN, 1982, CENTRIOLE CENTRAL EN; WILLIAMS NE, 1990, DEVELOPMENT, V109, P935; Xia L, 2000, J CELL BIOL, V149, P1097, DOI 10.1083/jcb.149.5.1097	30	94	97	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2002	4	3					256	259		10.1038/ncb764	http://dx.doi.org/10.1038/ncb764			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	527VR	11862218				2022-12-25	WOS:000174209100020
J	Air, EL; Strowski, MZ; Benoit, SC; Conarello, SL; Salituro, GM; Guan, XM; Liu, K; Woods, SC; Zhang, BB				Air, EL; Strowski, MZ; Benoit, SC; Conarello, SL; Salituro, GM; Guan, XM; Liu, K; Woods, SC; Zhang, BB			Small molecule insulin mimetics reduce food intake and body weight and prevent development of obesity	NATURE MEDICINE			English	Article							ANTIDIABETIC ACTIVITY; SODIUM APPETITE; SENSITIVITY; DISCOVERY; INFUSION; RECEPTOR; BRAIN; PICA; MICE	Obesity and insulin resistance are major risk factors for a number of metabolic disorders, such as type 2 diabetes mellitus(1,2). Insulin has been suggested to function as one of the adiposity signals to the brain for modulation of energy balance. Administration of insulin into the brain reduces food intake and body weight(3-5), and mice with a genetic deletion of neuronal insulin receptors are hyperphagic and obese(6). However, insulin is also an anabolic factor; when administered systemically, pharmacological levels of insulin are associated with body weight gain in patients(7). In this study, we investigated the efficacy and feasibility of small molecule insulin mimetic compounds(8,9) to regulate key parameters of energy homeostasis. Central intracerebroventricular (i.c.v.) administration of an insulin mimetic resulted in a dose-dependent reduction of food intake and body weight in rats, and altered the expression of hypothalamic genes known to regulate food intake and body weight. Oral administration of a mimetic in a mouse model of high-fat diet-induced obesity reduced body weight gain, adiposity and insulin resistance. Thus, insulin mimetics have a unique advantage over insulin in the control of body weight and hold potential as a novel anti-obesity treatment.	Merck Res Labs, Dept Mol Endocrinol & Metab Disorders, Rahway, NJ 07065 USA; Univ Cincinnati, Coll Med, Dept Biomed Sci & Cell Biol, Cincinnati, OH USA; Univ Cincinnati, Coll Med, Dept Neurobiol & Anat, Cincinnati, OH USA; Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH USA; Merck Res Labs, Dept Med Chem, Rahway, NJ USA	Merck & Company; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Merck & Company	Zhang, BB (corresponding author), Merck Res Labs, Dept Mol Endocrinol & Metab Disorders, Rahway, NJ 07065 USA.	bei_zhang@merck.com						BAURA GD, 1993, J CLIN INVEST, V92, P1824, DOI 10.1172/JCI116773; BERNSTEIN IL, 1983, BEHAV NEURAL BIOL, V37, P134, DOI 10.1016/S0163-1047(83)91145-7; Bruning JC, 2000, SCIENCE, V289, P2122, DOI 10.1126/science.289.5487.2122; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; DeFronzo RA, 1999, ANN INTERN MED, V131, P281, DOI 10.7326/0003-4819-131-4-199908170-00008; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Liu K, 2000, J MED CHEM, V43, P3487, DOI 10.1021/jm000285q; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; Madden LJ, 1999, BEHAV NEUROSCI, V113, P826, DOI 10.1037/0735-7044.113.4.826; MITCHELL D, 1976, PHYSIOL BEHAV, V17, P691, DOI 10.1016/0031-9384(76)90171-2; Qureshi SA, 2000, J BIOL CHEM, V275, P36590, DOI 10.1074/jbc.M006287200; SCHWARTZ MW, 1992, ENDOCR REV, V13, P387, DOI 10.1210/er.13.3.387; SIPOLS AJ, 1995, DIABETES, V44, P147, DOI 10.2337/diabetes.44.2.147; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; STRICKER EM, 1987, BEHAV NEUROSCI, V101, P560, DOI 10.1037/0735-7044.101.4.560; Taylor SI, 1999, CELL, V97, P9, DOI 10.1016/S0092-8674(00)80709-6; WOODS SC, 1979, NATURE, V282, P503, DOI 10.1038/282503a0; Woods SC, 2000, ANNU REV PSYCHOL, V51, P255, DOI 10.1146/annurev.psych.51.1.255; Zhang B, 1999, SCIENCE, V284, P974, DOI 10.1126/science.284.5416.974	22	127	135	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2002	8	2					179	183		10.1038/nm0202-179	http://dx.doi.org/10.1038/nm0202-179			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	517FN	11821903				2022-12-25	WOS:000173600600028
J	Lloyd, AC				Lloyd, AC			Limits to lifespan	NATURE CELL BIOLOGY			English	Editorial Material							NORMAL HUMAN FIBROBLASTS; MOUSE EMBRYO CELLS; REPLICATIVE SENESCENCE; PREMATURE SENESCENCE; CELLULAR SENESCENCE; LACKING TELOMERASE; CULTURE; P53; P16(INK4A); INDUCTION	It has long-been accepted that normal somatic cells have intrinsic mechanisms that limit their! proliferative lifespan. Recent work has now challenged this view by demonstrating that extrinsic factors might The determining proliferative potential.										Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; LOO DT, 1987, SCIENCE, V236, P200, DOI 10.1126/science.3494308; LOO DT, 1995, J NEUROSCI RES, V42, P184, DOI 10.1002/jnr.490420205; Mathon NF, 2001, SCIENCE, V291, P872, DOI 10.1126/science.1056782; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Tang DG, 2001, SCIENCE, V291, P868, DOI 10.1126/science.1056780; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; Wright WE, 2000, NAT MED, V6, P849, DOI 10.1038/78592; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	27	53	57	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	FEB	2002	4	2					E25	E27		10.1038/ncb0202-e25	http://dx.doi.org/10.1038/ncb0202-e25			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	520RJ	11835050				2022-12-25	WOS:000173794600005
J	Daigle, I; Yousefi, S; Colonna, M; Green, DR; Simon, HU				Daigle, I; Yousefi, S; Colonna, M; Green, DR; Simon, HU			Death receptors bind SHP-1 and block cytokine-induced anti-apoptotic signaling in neutrophils	NATURE MEDICINE			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; FAS-MEDIATED APOPTOSIS; COLONY-STIMULATING FACTOR; KINASE C-DELTA; CELL-DEATH; INHIBITORY RECEPTORS; HUMAN EOSINOPHILS; T-LYMPHOCYTES; ACTIVATION; EXPRESSION	Death domain-containing receptors of the tumor necrosis factor (TNF)/nerve growth factor (NGF) family can induce apoptosis upon activation in many cellular systems. We show here that a conserved phosphotyrosine-containing motif within the death domain of these receptors can mediate inhibitory functions. The Src homology domain 2 (SH2)-containing tyrosine phosphatase-1 (SHP-1), SHP-2 and SH2-containing inositol phosphatase (SHIP) bound to this motif in a caspase-independent but cell-dependent manner. We also found that stimulation of death receptors disrupted anti-apoptosis pathways initiated (apt least under certain conditions) by survival factors in neutrophils. In these cells, activation of the tyrosine kinase Lyn, an important anti-apoptotic event, was prevented as a consequence of deaths-receptor stimulation, most likely through association of the receptor with activated SHP-1. Thus, we provide molecular and functional evidence for negative signaling by death receptors.	Univ Bern, Dept Pharmacol, Bern, Switzerland; Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; Basel Inst Immunol, Basel, Switzerland; La Jolla Inst Allergy & Immunol, San Diego, CA USA	University of Bern; Swiss Institute of Allergy & Asthma Research; La Jolla Institute for Immunology	Simon, HU (corresponding author), Univ Bern, Dept Pharmacol, Bern, Switzerland.		Yousefi, Shida/L-9689-2016; Simon, Hans-Uwe/AAU-7410-2020; Green, Douglas R/N-8083-2018; Yousefi, Shida/AAU-7986-2020; Simon, Hans-Uwe/AAU-5079-2020	Yousefi, Shida/0000-0002-9855-4305; Simon, Hans-Uwe/0000-0002-9404-7736; Green, Douglas R/0000-0002-7332-1417; Yousefi, Shida/0000-0002-9855-4305; Colonna, Marco/0000-0001-5222-4987				Allison J, 1997, P NATL ACAD SCI USA, V94, P3943, DOI 10.1073/pnas.94.8.3943; Cambier JC, 1997, P NATL ACAD SCI USA, V94, P5993, DOI 10.1073/pnas.94.12.5993; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Chartier C, 1996, J VIROL, V70, P4805, DOI 10.1128/JVI.70.7.4805-4810.1996; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Colonna M, 1997, J EXP MED, V186, P1809, DOI 10.1084/jem.186.11.1809; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; Dibbert B, 1999, P NATL ACAD SCI USA, V96, P13330, DOI 10.1073/pnas.96.23.13330; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Fleming TJ, 1997, J EXP MED, V186, P1307, DOI 10.1084/jem.186.8.1307; Gradl G., 1996, APOPTOSIS, V1, P131, DOI DOI 10.1007/BF01321019; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Guo DQ, 2000, J BIOL CHEM, V275, P11216, DOI 10.1074/jbc.275.15.11216; GUTHMANN MD, 1995, P NATL ACAD SCI USA, V92, P9397, DOI 10.1073/pnas.92.20.9397; HOLLER P, 1989, MAR GEOTECHNOL, V8, P1, DOI 10.1080/10641198909379855; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; Khwaja A, 1999, BLOOD, V94, P291, DOI 10.1182/blood.V94.1.291.413k10_291_301; Landowski TH, 1997, BLOOD, V89, P1854, DOI 10.1182/blood.V89.6.1854; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; Marino MW, 1997, P NATL ACAD SCI USA, V94, P8093, DOI 10.1073/pnas.94.15.8093; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pazdrak K, 1997, J EXP MED, V186, P561, DOI 10.1084/jem.186.4.561; Pazdrak K, 1998, J EXP MED, V188, P421, DOI 10.1084/jem.188.3.421; Peter ME, 1997, EUR J IMMUNOL, V27, P1207, DOI 10.1002/eji.1830270523; Pongracz J, 1999, J BIOL CHEM, V274, P37329, DOI 10.1074/jbc.274.52.37329; Rebel VI, 1999, J EXP MED, V190, P1493, DOI 10.1084/jem.190.10.1493; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; Simon HU, 1997, EUR J IMMUNOL, V27, P3536, DOI 10.1002/eji.1830271256; Smith KGC, 1996, EMBO J, V15, P5167, DOI 10.1002/j.1460-2075.1996.tb00901.x; Song KM, 2000, J EXP MED, V191, P1095, DOI 10.1084/jem.191.7.1095; SU X, 1995, IMMUNITY, V2, P353, DOI 10.1016/1074-7613(95)90143-4; Thangaraju M, 1999, J BIOL CHEM, V274, P29549, DOI 10.1074/jbc.274.41.29549; THOMBERRY NA, 1992, NATURE, V356, P768; Unkeless JC, 1997, CURR OPIN IMMUNOL, V9, P338, DOI 10.1016/S0952-7915(97)80079-9; Walsh CM, 1998, IMMUNITY, V8, P439, DOI 10.1016/S1074-7613(00)80549-X; Wei S, 1996, J IMMUNOL, V157, P5155; Yousefi S, 1996, J EXP MED, V183, P1407, DOI 10.1084/jem.183.4.1407; YOUSEFI S, 1994, P NATL ACAD SCI USA, V91, P10868, DOI 10.1073/pnas.91.23.10868	43	151	160	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JAN	2002	8	1					61	67		10.1038/nm0102-61	http://dx.doi.org/10.1038/nm0102-61			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	507XQ	11786908				2022-12-25	WOS:000173056900032
J	Oleksiak, MF; Churchill, GA; Crawford, DL				Oleksiak, MF; Churchill, GA; Crawford, DL			Variation in gene expression within and among natural populations	NATURE GENETICS			English	Article							FUNDULUS-HETEROCLITUS; CDNA MICROARRAY; PROMOTER; PATTERNS; VARIANCE; CANCER; SITE	Evolution may depend more strongly on variation in gene expression than on differences between variant forms of proteins(1). Regions of DNA that affect gene expression are highly variable, containing 0.6% polymorphic sites(2). These naturally occurring polymorphic nucleotides can alter in vivo transcription rates(3-7). Thus, one might expect substantial variation in gene expression between individuals. But the natural variation in mRNA expression for a large number of genes has not been measured. Here we report microarray studies addressing the variation in gene expression within and between natural populations of teleost fish of the genus Fundulus. We observed statistically significant differences in expression between individuals within the same population for approximately 18% of 907 genes. Expression typically differed by a factor of 1.5, and often more than 2.0. Differences between populations increased the variation. Much of the variation between populations was a positive function of the variation within populations and thus is most parsimoniously described as random. Some genes showed unexpected patterns of expression-changes unrelated to evolutionary distance. These data suggest that substantial natural variation exists in gene expression and that this quantitative variation is important in evolution.	Univ Missouri, Sch Biol Sci, Kansas City, MO 64110 USA; Jackson Lab, Bar Harbor, ME 04609 USA	University of Missouri System; University of Missouri Kansas City; Jackson Laboratory	Crawford, DL (corresponding author), Univ Missouri, Sch Biol Sci, 5007 Rockhill Rd, Kansas City, MO 64110 USA.		Churchill, Gary/AAY-7496-2020	Churchill, Gary/0000-0001-9190-9284; Crawford, Douglas/0000-0002-6239-4012				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; ANTONARAKIS SE, 1984, P NATL ACAD SCI-BIOL, V81, P1154, DOI 10.1073/pnas.81.4.1154; BEATY JS, 1995, MOL CELL BIOL, V15, P4771; BERNARDI G, 1995, COPEIA, P469; Brem RB, 2002, SCIENCE, V296, P752, DOI 10.1126/science.1069516; BROWN BL, 1991, EVOLUTION, V45, P1147, DOI 10.1111/j.1558-5646.1991.tb04381.x; Cashner R.C., 1993, P421; Crawford DL, 1999, MOL BIOL EVOL, V16, P194, DOI 10.1093/oxfordjournals.molbev.a026102; CRAWFORD DL, 1989, P NATL ACAD SCI USA, V86, P9365, DOI 10.1073/pnas.86.23.9365; DeRisi J, 1996, NAT GENET, V14, P457; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Enard W, 2002, SCIENCE, V296, P340, DOI 10.1126/science.1068996; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Jin W, 2001, NAT GENET, V29, P389, DOI 10.1038/ng766; Kerr MK, 2001, GENET RES, V77, P123; Kerr MK, 2000, J COMPUT BIOL, V7, P819, DOI 10.1089/10665270050514954; KING MC, 1975, SCIENCE, V188, P107, DOI 10.1126/science.1090005; KOIVISTO UM, 1994, P NATL ACAD SCI USA, V91, P10526, DOI 10.1073/pnas.91.22.10526; Lau WY, 2000, ONCOL RES, V12, P59; Lewohl JM, 2001, J BIOMED SCI, V8, P28, DOI 10.1007/BF02255968; LOTRICH VA, 1975, ECOLOGY, V56, P191, DOI 10.2307/1935311; Nei M., 1987, MOL EVOLUTIONARY GEN; Oleksiak MF, 2001, MAR BIOTECHNOL, V3, pS203, DOI 10.1007/s10126-001-0043-0; Pierce VA, 1997, SCIENCE, V276, P256, DOI 10.1126/science.276.5310.256; Podrabsky JE, 2000, AM J PHYSIOL-REG I, V279, pR2344, DOI 10.1152/ajpregu.2000.279.6.R2344; Segal JA, 1999, J MOL EVOL, V49, P736, DOI 10.1007/PL00006596; Sokal R. R, 1981, BIOMETRY; Stephens JC, 2001, SCIENCE, V293, P489, DOI 10.1126/science.1059431; Westfall P.H., 1993, RESAMPLING BASED MUL, V279; WILEY EO, 1986, AM ZOOL, V26, P121	30	561	576	0	91	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2002	32	2					261	266		10.1038/ng983	http://dx.doi.org/10.1038/ng983			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	599AP	12219088				2022-12-25	WOS:000178311100014
J	Akbari, O; Freeman, GJ; Meyer, EH; Greenfield, EA; Chang, TT; Sharpe, AH; Berry, G; DeKruyff, RH; Umetsu, DT				Akbari, O; Freeman, GJ; Meyer, EH; Greenfield, EA; Chang, TT; Sharpe, AH; Berry, G; DeKruyff, RH; Umetsu, DT			Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity	NATURE MEDICINE			English	Article							COLONY-STIMULATING FACTOR; HEAT-KILLED LISTERIA; MOUSE BONE-MARROW; DENDRITIC CELLS; IN-VIVO; IMMUNE-RESPONSES; CO-STIMULATION; MOLECULE ICOS; INFLAMMATION; EXPRESSION	Asthma is caused by T-helper cell 2 (Th2)-driven immune responses, but the immunological mechanisms that protect against asthma development are poorly understood. T-cell tolerance, induced by respiratory exposure to allergen, can inhibit the development of airway hyperreactivity (AHR), a cardinal feature of asthma, and we show here that regulatory T (T-R) cells can mediate this protective effect. Mature pulmonary dendritic cells in the bronchial lymph nodes of mice exposed to respiratory allergen induced the development of TR cells, in a process that required T-cell costimulation via the inducible costimulator (ICOS)-ICOS-ligand pathway. The TR cells produced IL-10, and had potent inhibitory activity; when adoptively transferred into sensitized mice, TR cells blocked the development of AHR. Both the development and the inhibitory function of regulatory cells were dependent on the presence of IL-10 and on ICOS-ICOS-ligand interactions. These studies demonstrate that TR cells and the ICOS-ICOS-ligand signaling pathway are critically involved in respiratory tolerance and in downregulating pulmonary inflammation in asthma.	Stanford Univ, Dept Pediat, Sch Med, Div Immunol & Allergy, Stanford, CA 94305 USA; Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Div Immunol Res, Boston, MA USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA	Stanford University; Stanford University; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Umetsu, DT (corresponding author), Stanford Univ, Dept Pediat, Sch Med, Div Immunol & Allergy, Stanford, CA 94305 USA.	umetsu@stanford.edu	Freeman, Gordon/AAC-5380-2019	Freeman, Gordon/0000-0002-7210-5616; Berry, Gerald/0000-0002-6176-2629	NATIONAL CANCER INSTITUTE [R01CA084500] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038310, R21AI024571, P01AI039671, T32AI007290, R01AI026322, R01AI024571, R37AI038310] Funding Source: NIH RePORTER; NCI NIH HHS [CA84500] Funding Source: Medline; NHLBI NIH HHS [R01HL62348] Funding Source: Medline; NIAID NIH HHS [AI39671, AI24571, T32 AI007290, AI26322, AI38310] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; ASSENMACHER M, 1994, EUR J IMMUNOL, V24, P1097, DOI 10.1002/eji.1830240513; Barrat FJ, 2002, J EXP MED, V195, P603, DOI 10.1084/jem.20011629; Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P1022; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; COFFMAN RL, 1991, RES IMMUNOL, V142, P7, DOI 10.1016/0923-2494(91)90002-Z; CORRIGAN CJ, 1990, AM REV RESPIR DIS, V141, P970, DOI 10.1164/ajrccm/141.4_Pt_1.; Coyle AJ, 2000, IMMUNITY, V13, P95, DOI 10.1016/S1074-7613(00)00011-X; DING L, 1993, J IMMUNOL, V151, P1224; Dong C, 2001, NATURE, V409, P97, DOI 10.1038/35051100; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Gonzalo JA, 2001, NAT IMMUNOL, V2, P597, DOI 10.1038/89739; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Hansen G, 2000, J CLIN INVEST, V105, P61, DOI 10.1172/JCI7589; Hansen G, 2000, J IMMUNOL, V164, P223, DOI 10.4049/jimmunol.164.1.223; Holgate ST, 1999, NATURE, V402, pB2, DOI 10.1038/35037000; Hsu CH, 1996, NAT MED, V2, P540, DOI 10.1038/nm0596-540; Huang FP, 2000, J EXP MED, V191, P435, DOI 10.1084/jem.191.3.435; Hutloff A, 1999, NATURE, V397, P263, DOI 10.1038/16717; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Jonuleit H, 2001, J EXP MED, V193, P1285, DOI 10.1084/jem.193.11.1285; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; Kim TS, 1997, J IMMUNOL, V158, P4137; Levings MK, 2000, J ALLERGY CLIN IMMUN, V106, pS109, DOI 10.1067/mai.2000.106635; Ling V, 2000, J IMMUNOL, V164, P1653, DOI 10.4049/jimmunol.164.4.1653; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; Mages HW, 2000, EUR J IMMUNOL, V30, P1040, DOI 10.1002/(SICI)1521-4141(200004)30:4<1040::AID-IMMU1040>3.0.CO;2-6; Makela MJ, 2000, P NATL ACAD SCI USA, V97, P6007, DOI 10.1073/pnas.100118997; MALONEY DG, 1985, HYBRIDOMA, V4, P191, DOI 10.1089/hyb.1985.4.191; MARRACK P, 1983, J EXP MED, V158, P1635, DOI 10.1084/jem.158.5.1635; McAdam AJ, 2000, J IMMUNOL, V165, P5035, DOI 10.4049/jimmunol.165.9.5035; McAdam AJ, 2001, NATURE, V409, P102, DOI 10.1038/35051107; McGuirk P, 2002, J EXP MED, V195, P221, DOI 10.1084/jem.20011288; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Nakajima A, 1997, INT IMMUNOL, V9, P637, DOI 10.1093/intimm/9.5.637; Oro AS, 1996, J ALLERGY CLIN IMMUN, V97, P1402, DOI 10.1016/S0091-6749(96)70210-5; Randolph DA, 1999, J IMMUNOL, V162, P2375; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; Roncarolo MG, 2001, J EXP MED, V193, pF5, DOI 10.1084/jem.193.2.F5; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; SANDER B, 1991, IMMUNOL REV, V119, P65, DOI 10.1111/j.1600-065X.1991.tb00578.x; Sauter B, 2000, J EXP MED, V191, P423, DOI 10.1084/jem.191.3.423; SCHEICHER C, 1992, J IMMUNOL METHODS, V154, P253, DOI 10.1016/0022-1759(92)90199-4; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; STOCKINGER B, 1994, INT IMMUNOL, V6, P247, DOI 10.1093/intimm/6.2.247; Swallow MM, 1999, IMMUNITY, V11, P423, DOI 10.1016/S1074-7613(00)80117-X; Thornton AM, 1998, J EXP MED, V188, P287, DOI 10.1084/jem.188.2.287; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; Tsitoura DC, 1999, J IMMUNOL, V163, P2592; Umetsu DT, 1997, J ALLERGY CLIN IMMUN, V100, P1, DOI 10.1016/S0091-6749(97)70186-6; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; Walter DM, 2001, J IMMUNOL, V167, P4668, DOI 10.4049/jimmunol.167.8.4668; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Yeung VP, 1998, J IMMUNOL, V161, P4146; Yoshinaga SK, 1999, NATURE, V402, P827, DOI 10.1038/45582	59	613	657	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2002	8	9					1024	1032		10.1038/nm745	http://dx.doi.org/10.1038/nm745			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	589KQ	12145647				2022-12-25	WOS:000177757900039
J	Levy, BD; DeSanctis, GT; Devchand, PR; Kim, E; Ackerman, K; Schmidt, BA; Szczeklik, W; Drazen, JM; Serhan, CN				Levy, BD; DeSanctis, GT; Devchand, PR; Kim, E; Ackerman, K; Schmidt, BA; Szczeklik, W; Drazen, JM; Serhan, CN			Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4)	NATURE MEDICINE			English	Article							ASPIRIN-TRIGGERED 15-EPI-LXA(4); BRONCHIAL HYPERRESPONSIVENESS; LEUKOTRIENE B-4; CUTTING EDGE; EOSINOPHILS; RESPONSES; RECEPTOR; ASTHMA; GENERATE; PROTEIN	The prevalence of asthma continues to increase and its optimal treatment remains a challenge. Here, we investigated the actions of lipoxin A(4) (LXA(4)) and its leukocyte receptor in pulmonary inflammation using a murine model of asthma. Allergen challenge initiated airway biosynthesis of LXA(4) and increased expression of its receptor. Administration of a stable analog of LXA(4) blocked both airway hyper-responsiveness and pulmonary inflammation, as shown by decreased leukocytes and mediators, including interleukin-5, interleukin-13, eotaxin, prostanoids and cysteinyl leukotrienes. Moreover, transgenic expression of human LXA(4) receptors in murine leukocytes led to significant inhibition of pulmonary inflammation and eicosanoid-initiated eosinophil tissue infiltration. Inhibition of airway hyper-responsiveness and allergic airway inflammation with a stable LXA(4) analog highlights a unique counter-regulatory profile for the LXA(4) system and its leukocyte receptor in airway responses. Moreover, our findings suggest that lipoxin and related pathways offer novel multi-pronged therapeutic approaches for human asthma.	Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pulm & Crit Care Med, Dept Internal Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Serhan, CN (corresponding author), Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Dept Anesthesiol Perioperat & Pain Med, 75 Francis St, Boston, MA 02115 USA.	cnserhan@zeus.bwh.harvard.edu	Drazen, Jeffrey M/E-5841-2012; Szczeklik, Wojciech/N-8096-2014	Szczeklik, Wojciech/0000-0002-1349-1123; Drazen, Jeffrey/0000-0003-2715-9890	NHLBI NIH HHS [P50-HL56383, HL-36110, K08-HL03788] Funding Source: Medline; NIDCR NIH HHS [P01-DE13499] Funding Source: Medline; NIDDK NIH HHS [DK-50305] Funding Source: Medline; NIGMS NIH HHS [GM-38765] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056383, K08HL003788, P01HL036110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE013499] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038765, R37GM038765, R01GM038765] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aliberti J, 2002, NAT IMMUNOL, V3, P76, DOI 10.1038/ni745; BADR KF, 1989, P NATL ACAD SCI USA, V86, P3438, DOI 10.1073/pnas.86.9.3438; Bandeira-Melo C, 2000, J IMMUNOL, V164, P1029, DOI 10.4049/jimmunol.164.2.1029; Bandeira-Melo C, 2000, J IMMUNOL, V164, P2267, DOI 10.4049/jimmunol.164.5.2267; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; Bryan SA, 2000, LANCET, V356, P2149, DOI 10.1016/S0140-6736(00)03497-8; Chiang N, 1999, J CLIN INVEST, V104, P309, DOI 10.1172/JCI7016; CHRISTIE PE, 1992, AM REV RESPIR DIS, V145, P1281, DOI 10.1164/ajrccm/145.6.1281; Clish CB, 1999, P NATL ACAD SCI USA, V96, P8247, DOI 10.1073/pnas.96.14.8247; Cowburn AS, 1999, J IMMUNOL, V163, P456; Dahlen S E, 1988, Adv Exp Med Biol, V229, P107; de Sanctis GT, 1999, J CLIN INVEST, V103, P507, DOI 10.1172/JCI4017; De Sanctis GT, 1999, J EXP MED, V189, P1621, DOI 10.1084/jem.189.10.1621; Drazen JM, 1998, AM J RESP CRIT CARE, V158, pS193, DOI 10.1164/ajrccm.158.supplement_2.13tac180; Drazen JM, 2000, BRIT MED BULL, V56, P1054, DOI 10.1258/0007142001903535; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; Godson C, 2000, J IMMUNOL, V164, P1663, DOI 10.4049/jimmunol.164.4.1663; Gronert K, 2001, AM J PATHOL, V158, P3, DOI 10.1016/S0002-9440(10)63937-5; Hisada T, 1999, AM J RESP CRIT CARE, V160, P571, DOI 10.1164/ajrccm.160.2.9810101; Holgate ST, 1999, NATURE, V402, pB2, DOI 10.1038/35037000; Laporte JC, 2001, AM J RESP CRIT CARE, V164, P141, DOI 10.1164/ajrccm.164.1.2008060; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; LEE TH, 1990, AM REV RESPIR DIS, V141, P1453, DOI 10.1164/ajrccm/141.6.1453; Leff AR, 2000, AM J RESP CRIT CARE, V161, pS125, DOI 10.1164/ajrccm.161.supplement_1.ltta-25; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; McMahon B, 2001, TRENDS PHARMACOL SCI, V22, P391, DOI 10.1016/S0165-6147(00)01771-5; Resnati M, 2002, P NATL ACAD SCI USA, V99, P1359, DOI 10.1073/pnas.022652999; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Samuelsson B, 1982, PRIX NOBEL NOBEL PRI, P153; Sanak M, 2000, EUR RESPIR J, V16, P44, DOI 10.1034/j.1399-3003.2000.16a08.x; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; SOYOMBO O, 1994, ALLERGY, V49, P230, DOI 10.1111/j.1398-9995.1994.tb02654.x; Takano T, 1997, J EXP MED, V185, P1693, DOI 10.1084/jem.185.9.1693; Venkayya R, 2002, AM J RESP CELL MOL, V26, P202, DOI 10.1165/ajrcmb.26.2.4600; Wu WJ, 2000, J CLIN INVEST, V105, P1455, DOI 10.1172/JCI9702	36	293	320	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2002	8	9					1018	1023		10.1038/nm748	http://dx.doi.org/10.1038/nm748			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	589KQ	12172542				2022-12-25	WOS:000177757900038
J	Seo, SH; Hoffmann, E; Webster, RG				Seo, SH; Hoffmann, E; Webster, RG			Lethal H5N1 influenza viruses escape host anti-viral cytokine responses	NATURE MEDICINE			English	Article							NECROSIS-FACTOR-ALPHA; A-VIRUS; NS1 PROTEIN; HONG-KONG; INTERFERON-PRODUCTION; WILD-TYPE; INFECTION; HUMANS; GENES; PATHOGENESIS	The H5N1 influenza viruses transmitted to humans in 1997 were highly virulent, but the mechanism of their virulence in humans is largely unknown. Here we show that lethal H5N1 influenza viruses, unlike other human, avian and swine influenza viruses, are resistant to the antiviral effects of interferons and tumor necrosis factor. The nonstructural (NS) gene of H5N1 viruses is associated with this resistance. Pigs infected with recombinant human H1N1 influenza virus that carried the H5N1 NS gene experienced significantly greater and more prolonged viremia, fever and weight loss than did pigs infected with wild-type human H1N1 influenza virus. These effects required the presence of glutamic acid at position 92 of the NS1 molecule. These findings may explain the mechanism of the high virulence of H5N1 influenza viruses in humans.	St Jude Childrens Res Hosp, Dept Infect Dis, Div Virol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Webster, RG (corresponding author), St Jude Childrens Res Hosp, Dept Infect Dis, Div Virol, 332 N Lauderdale St, Memphis, TN 38105 USA.	robert.webster@stjude.org			NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI095357] Funding Source: NIH RePORTER; NCI NIH HHS [CA-21765] Funding Source: Medline; NIAID NIH HHS [AI-29860, AI-95357] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Basler CF, 2001, P NATL ACAD SCI USA, V98, P2746, DOI 10.1073/pnas.031575198; BOSCH FX, 1979, VIROLOGY, V95, P197, DOI 10.1016/0042-6822(79)90414-8; Claas ECJ, 1998, LANCET, V351, P472, DOI 10.1016/S0140-6736(97)11212-0; deJong JC, 1997, NATURE, V389, P554, DOI 10.1038/39218; ENNIS FA, 1981, LANCET, V2, P891; Fritz RS, 1999, J INFECT DIS, V180, P586, DOI 10.1086/314938; Gao P, 1999, J VIROL, V73, P3184, DOI 10.1128/JVI.73.4.3184-3189.1999; Garcia-Sastre A, 1998, VIROLOGY, V252, P324, DOI 10.1006/viro.1998.9508; GREEN JA, 1982, J INFECT DIS, V145, P837, DOI 10.1093/infdis/145.6.837; Guan Y, 1999, P NATL ACAD SCI USA, V96, P9363, DOI 10.1073/pnas.96.16.9363; Hatta M, 2001, SCIENCE, V293, P1840, DOI 10.1126/science.1062882; HILL DA, 1972, J AMER MED ASSOC, V219, P1179, DOI 10.1001/jama.219.9.1179; Hoffmann E, 2000, J VIROL, V74, P6309, DOI 10.1128/JVI.74.14.6309-6315.2000; Hoffmann E, 2000, P NATL ACAD SCI USA, V97, P6108, DOI 10.1073/pnas.100133697; Isaacs A., 1957, P R SOC LOND B, V147, P258; Jameson J, 1999, J IMMUNOL, V162, P7578; Lin YP, 2000, P NATL ACAD SCI USA, V97, P9654, DOI 10.1073/pnas.160270697; Lu XH, 1999, J VIROL, V73, P5903, DOI 10.1128/JVI.73.7.5903-5911.1999; LU Y, 1995, VIROLOGY, V214, P222, DOI 10.1006/viro.1995.9937; MURPHY BR, 1973, J INFECT DIS, V128, P488, DOI 10.1093/infdis/128.4.488; Naniche D, 2000, J VIROL, V74, P7478, DOI 10.1128/JVI.74.16.7478-7484.2000; OGAWA T, 1981, VIROLOGY, V113, P304, DOI 10.1016/0042-6822(81)90157-4; Qian XY, 1995, RNA, V1, P948; RICHMAN DD, 1976, J CLIN MICROBIOL, V3, P223; Rimmelzwaan GF, 2001, J VIROL, V75, P6687, DOI 10.1128/JVI.75.14.6687-6691.2001; Seo SH, 2002, J VIROL, V76, P1071, DOI 10.1128/JVI.76.3.1071-1076.2002; Seo SH, 2001, J VIROL, V75, P9517, DOI 10.1128/JVI.75.19.9517-9525.2001; Shortridge KF, 1998, VIROLOGY, V252, P331, DOI 10.1006/viro.1998.9488; STAEHELI P, 1988, MOL CELL BIOL, V8, P4518, DOI 10.1128/MCB.8.10.4518; Subbarao K, 1998, SCIENCE, V279, P393, DOI 10.1126/science.279.5349.393; Talon J, 2000, J VIROL, V74, P7989, DOI 10.1128/JVI.74.17.7989-7996.2000; Taubenberger JK, 1997, SCIENCE, V275, P1793, DOI 10.1126/science.275.5307.1793; To KF, 2001, J MED VIROL, V63, P242, DOI 10.1002/1096-9071(200103)63:3&lt;242::AID-JMV1007&gt;3.0.CO;2-N; Van Reeth K, 1998, J INFECT DIS, V177, P1076, DOI 10.1086/517398; Yuan WM, 2001, EMBO J, V20, P362, DOI 10.1093/emboj/20.3.362; Zitzow LA, 2002, J VIROL, V76, P4420, DOI 10.1128/JVI.76.9.4420-4429.2002	36	546	626	3	49	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	SEP	2002	8	9					950	954		10.1038/nm757	http://dx.doi.org/10.1038/nm757			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	589KQ	12195436				2022-12-25	WOS:000177757900029
J	Bailey, J; Manoil, C				Bailey, J; Manoil, C			Genome-wide internal tagging of bacterial exported proteins	NATURE BIOTECHNOLOGY			English	Article							ESCHERICHIA-COLI; LOCALIZATION; INSERTION	As a result of the explosive growth of bacterial genomic and postgenomic information, there is a pressing need for efficient, inexpensive strategies for characterizing the in vivo behavior and function of newly identified gene products. We describe here an internal tagging procedure, based on transposon technology(1,2), to facilitate the analysis of membrane-bound and secreted proteins in Gram-negative bacteria. The technique is based on a broad-host range transposon (ISphoA/hah), which may be used to generate both alkaline phosphatase (AP) gene fusions and 63-codon in-frame insertions in the genome. The 63-codon insertion encodes an influenza hemagglutinin epitope and a hexahistidine sequence, permitting sensitive detection and metal affinity purification of tagged proteins. For each gene targeted, it is thus possible to monitor the disruption of phenotype (using the transposon insertion), the gene's transcription and translation (using the AP reporter activity), and the behavior of the unfused protein (using the internal tag). Studies on a sequence-defined collection of Escherichia coli strains generated using the transposon showed that the synthesis and subcellular localization of tagged proteins could be readily monitored. The use of ISphoA/hah should provide a cost-effective approach for genome-wide in vivo studies of the behavior of exported proteins in a number of bacterial species.	Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Manoil, C (corresponding author), Univ Washington, Dept Genome Sci, 357730, Seattle, WA 98195 USA.	manoil@u.washington.edu						BERG CM, 1995, MOBILE GENETIC ELEME, P38; Bornhorst JA, 2000, METHOD ENZYMOL, V326, P245; BRITTON L, 1977, J BACTERIOL, V131, P815, DOI 10.1128/JB.131.3.815-820.1977; DEAN DA, 1989, J BACTERIOL, V171, P503, DOI 10.1128/jb.171.1.503-510.1989; Ehrmann M, 1997, P NATL ACAD SCI USA, V94, P13111, DOI 10.1073/pnas.94.24.13111; Fritze CE, 2000, METHOD ENZYMOL, V327, P3, DOI 10.1016/S0076-6879(00)27263-7; Goryshin IY, 2000, NAT BIOTECHNOL, V18, P97, DOI 10.1038/72017; HERRERO M, 1990, J BACTERIOL, V172, P6557, DOI 10.1128/jb.172.11.6557-6567.1990; HOEKSTRA MF, 1991, P NATL ACAD SCI USA, V88, P5457, DOI 10.1073/pnas.88.12.5457; Judson N, 2000, TRENDS MICROBIOL, V8, P521, DOI 10.1016/S0966-842X(00)01865-5; KAUFMAN MR, 1994, METHOD ENZYMOL, V235, P426; Link AJ, 1997, ELECTROPHORESIS, V18, P1259, DOI 10.1002/elps.1150180807; Manoil C, 2000, METHOD ENZYMOL, V326, P35; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MANOIL C, 1990, J BACTERIOL, V172, P515, DOI 10.1128/jb.172.2.515-518.1990; Manoil C, 1997, J MOL BIOL, V267, P250, DOI 10.1006/jmbi.1996.0881; Manoil C, 2000, METHODS, V20, P55, DOI 10.1006/meth.1999.0905; NOSSAL NG, 1966, J BIOL CHEM, V241, P3055; Ross-Macdonald P, 1999, NATURE, V402, P413, DOI 10.1038/46558; RossMacdonald P, 1997, P NATL ACAD SCI USA, V94, P190, DOI 10.1073/pnas.94.1.190	20	30	32	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2002	20	8					839	842		10.1038/nbt715	http://dx.doi.org/10.1038/nbt715			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	579MU	12091915				2022-12-25	WOS:000177182500038
J	Ihmels, J; Friedlander, G; Bergmann, S; Sarig, O; Ziv, Y; Barkai, N				Ihmels, J; Friedlander, G; Bergmann, S; Sarig, O; Ziv, Y; Barkai, N			Revealing modular organization in the yeast transcriptional network	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; CLUSTERING ANALYSIS; GENE-EXPRESSION; PROTEIN; PATTERNS; DATABASE	Standard clustering methods can classify genes successfully when applied to relatively small data sets, but have limited use in the analysis of large-scale expression data, mainly owing to their assignment of a gene to a single cluster. Here we propose an alternative method for the global analysis of genome-wide expression data. Our approach assigns genes to context-dependent and potentially overlapping 'transcription modules', thus overcoming the main limitations of traditional clustering methods. We use our method to elucidate regulatory properties of cellular pathways and to characterize cis-regulatory elements. By applying our algorithm systematically to all of the available expression data on Saccharomyces cerevisiae, we identify a comprehensive set of overlapping transcriptional modules. Our results provide functional predictions for numerous genes, identify relations between modules and present a global view on the transcriptional network.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Phys Complex Syst, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Barkai, N (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.	naama.barkai@weizmann.ac.il		Bergmann, Sven/0000-0002-6785-9034; Friedlander, Gerard/0000-0002-6854-4261				Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; Bittner M, 1999, NAT GENET, V22, P213, DOI 10.1038/10265; Bojunga N, 1999, MOL GEN GENET, V262, P869, DOI 10.1007/s004380051152; Buscemi G, 2000, J CELL SCI, V113, P1199; Cheng Y., 2000, P 8 INT C INT SYST M, P93; Costanzo MC, 2001, NUCLEIC ACIDS RES, V29, P75, DOI 10.1093/nar/29.1.75; Costanzo MC, 2000, NUCLEIC ACIDS RES, V28, P73, DOI 10.1093/nar/28.1.73; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fikus MU, 2000, GENETICS, V154, P73; Getz G, 2000, P NATL ACAD SCI USA, V97, P12079, DOI 10.1073/pnas.210134797; Harnpicharnchai P, 2001, MOL CELL, V8, P505, DOI 10.1016/S1097-2765(01)00344-6; Liu ZC, 1999, MOL CELL BIOL, V19, P6720; Mewes HW, 2002, NUCLEIC ACIDS RES, V30, P31, DOI 10.1093/nar/30.1.31; Milkereit P, 2001, CELL, V105, P499, DOI 10.1016/S0092-8674(01)00358-0; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Zimmerman ZA, 2001, MOL BIOL CELL, V12, P201, DOI 10.1091/mbc.12.1.201	16	539	555	0	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2002	31	4					370	377		10.1038/ng941	http://dx.doi.org/10.1038/ng941			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	578XV	12134151				2022-12-25	WOS:000177147100011
J	McMahon, TJ; Moon, RE; Luschinger, BP; Carraway, MS; Stone, AE; Stolp, BW; Gow, AJ; Pawloski, JR; Watke, P; Singel, DJ; Piantadosi, CA; Stamler, JS				McMahon, TJ; Moon, RE; Luschinger, BP; Carraway, MS; Stone, AE; Stolp, BW; Gow, AJ; Pawloski, JR; Watke, P; Singel, DJ; Piantadosi, CA; Stamler, JS			Nitric oxide in the human respiratory cycle	NATURE MEDICINE			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; S-NITROSOHEMOGLOBIN; BLOOD-FLOW; HEMOGLOBIN; OXYGEN; NITROSYLATION; HYPERTENSION; ERYTHROCYTES; CIRCULATION; HEMATOCRIT	Interactions of nitric oxide (NO) with hemoglobin (Hb) could regulate the uptake and delivery of oxygen (O-2) by subserving the classical physiological responses of hypoxic vasodilation and hyperoxic vasconstriction in the human respiratory cycle. Here we show that in in vitro and ex vivo systems as well as healthy adults alternately exposed to hypoxia or hyperoxia (to dilate or constrict pulmonary and systemic arteries in vivo), binding of NO to hemes (FeNO) and thiols (SNO) of Hb varies as a function of HbO(2) saturation (FeO2). Moreover, we show that red blood cell (RBC)/SNO-mediated vasodilator activity is inversely proportional to FeO2 over a wide range, whereas RBC-induced vasoconstriction correlates directly with FeO2. Thus, native RBCs respond to changes in oxygen tension (pO(2)) with graded vasodilator and vasoconstrictor activity, which emulates the human physiological response subserving O-2 uptake and delivery. The ability to monitor and manipulate blood levels of NO, in conjunction with O-2 and carbon dioxide, may therefore prove useful in the diagnosis and treatment of many human conditions and in the development of new therapies. Our results also help elucidate the link between RBC dyscrasias and cardiovascular morbidity.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Montana State Univ, Dept Chem, Bozeman, MT 59717 USA	Duke University; Duke University; Duke University; Howard Hughes Medical Institute; Montana State University System; Montana State University Bozeman	Stamler, JS (corresponding author), Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.	staml001@mc.duke.edu	Gow, Andrew/AAR-2309-2020; McMahon, Tim/K-3986-2012; Gow, Andrew/N-8566-2013; Moon, Richard/AAF-2170-2019	Gow, Andrew/0000-0003-0876-5158; McMahon, Tim/0000-0002-3404-3223; Gow, Andrew/0000-0003-0876-5158; Moon, Richard/0000-0003-4432-0332; Stamler, Jonathan/0000-0002-6866-1572	NHLBI NIH HHS [HL04424-09, K08 HL04014] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL004014, K08HL004424] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andrews D A, 1999, Curr Opin Hematol, V6, P76, DOI 10.1097/00062752-199903000-00004; ANTONINI E, 1971, FRONTIERS BIOL, V13; Balagopalakrishna C, 1998, BIOCHEMISTRY-US, V37, P13194, DOI 10.1021/bi980941c; BAUR TS, 1990, CARDIOVASC RES, V24, P733, DOI 10.1093/cvr/24.9.733; Besarab A, 1998, NEW ENGL J MED, V339, P584, DOI 10.1056/NEJM199808273390903; Blitzer ML, 1996, J AM COLL CARDIOL, V28, P591, DOI 10.1016/0735-1097(96)00218-5; CIRILLO M, 1992, HYPERTENSION, V20, P319, DOI 10.1161/01.HYP.20.3.319; COBURN RF, 1973, AM J PHYSIOL, V224, P870, DOI 10.1152/ajplegacy.1973.224.4.870; DAUT J, 1990, SCIENCE, V247, P1341, DOI 10.1126/science.2107575; DEBELDER AJ, 1994, CARDIOVASC RES, V28, P691; Deem S, 1998, AM J RESP CRIT CARE, V157, P1181, DOI 10.1164/ajrccm.157.4.9707165; Embury SH, 1999, J CLIN INVEST, V103, P915, DOI 10.1172/JCI5977; FREEMAN G, 1978, ARCH ENVIRON HEALTH, V33, P19, DOI 10.1080/00039896.1978.10667303; French JA, 1997, BLOOD, V89, P4591, DOI 10.1182/blood.V89.12.4591; Funai EF, 1997, BIOCHEM BIOPH RES CO, V239, P875, DOI 10.1006/bbrc.1997.7565; Gladwin MT, 2000, P NATL ACAD SCI USA, V97, P9943, DOI 10.1073/pnas.180155397; GORCZYNSKI RJ, 1978, AM J PHYSIOL, V235, pH505, DOI 10.1152/ajpheart.1978.235.5.H505; Gow AJ, 1999, P NATL ACAD SCI USA, V96, P9027, DOI 10.1073/pnas.96.16.9027; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; HART RG, 1990, STROKE, V21, P1111, DOI 10.1161/01.STR.21.8.1111; Hebert PC, 1999, NEW ENGL J MED, V340, P1056; Heyman SN, 1999, MICROCIRCULATION, V6, P199; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Ketcham EM, 1999, ANN EMERG MED, V33, P326, DOI 10.1016/S0196-0644(99)70370-7; KOHNO M, 1995, FREE RADICAL BIO MED, V18, P451, DOI 10.1016/0891-5849(94)00165-G; KOSAKA H, 1994, BIOCHEM BIOPH RES CO, V204, P1055, DOI 10.1006/bbrc.1994.2569; Lipton AJ, 2001, NATURE, V413, P171, DOI 10.1038/35093117; McMahon TJ, 2000, J BIOL CHEM, V275, P16738, DOI 10.1074/jbc.M000532200; McMahon TJ, 1999, METHOD ENZYMOL, V301, P99; Padron J, 2000, BIOCHEM BIOPH RES CO, V271, P217, DOI 10.1006/bbrc.2000.2617; PARK KH, 1992, CIRC RES, V71, P992, DOI 10.1161/01.RES.71.4.992; Pawloski JR, 2001, NATURE, V409, P622, DOI 10.1038/35054560; Perutz MF, 1998, ANNU REV BIOPH BIOM, V27, P1, DOI 10.1146/annurev.biophys.27.1.1; Pezacki JP, 2001, J AM CHEM SOC, V123, P4615, DOI 10.1021/ja015716o; PINARD E, 1989, BRAIN RES, V481, P124, DOI 10.1016/0006-8993(89)90492-7; Reddy PL, 1997, CLIN CHEM, V43, P1442; Roccatello D, 1997, NEPHROL DIAL TRANSPL, V12, P292, DOI 10.1093/ndt/12.2.292; Ruschitzka FT, 2000, P NATL ACAD SCI USA, V97, P11609, DOI 10.1073/pnas.97.21.11609; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; Stephansson O, 2000, JAMA-J AM MED ASSOC, V284, P2611, DOI 10.1001/jama.284.20.2611; Takahashi Y, 1998, AM J PHYSIOL-HEART C, V274, pH349, DOI 10.1152/ajpheart.1998.274.1.H349; Tsuda K, 2000, BIOCHEM BIOPH RES CO, V275, P946, DOI 10.1006/bbrc.2000.3408; Weinberg JB, 1998, FREE RADICAL BIO MED, V24, P191, DOI 10.1016/S0891-5849(97)00217-7; Wu WC, 2001, NEW ENGL J MED, V345, P1230, DOI 10.1056/NEJMoa010615	45	382	400	0	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2002	8	7					711	717		10.1038/nm718	http://dx.doi.org/10.1038/nm718			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	567QG	12042776				2022-12-25	WOS:000176495200032
J	Yussman, MG; Toyokawa, T; Odley, A; Lynch, RA; Wu, GY; Colbert, MC; Aronow, BJ; Lorenz, JN; Dorn, GW				Yussman, MG; Toyokawa, T; Odley, A; Lynch, RA; Wu, GY; Colbert, MC; Aronow, BJ; Lorenz, JN; Dorn, GW			Mitochondrial death protein Nix is induced in cardiac hypertrophy and triggers apoptotic cardiomyopathy	NATURE MEDICINE			English	Article							HEAVY-CHAIN GENE; HEART-FAILURE; PRESSURE-OVERLOAD; MYOCARDIAL HYPERTROPHY; CARDIOVASCULAR BIOLOGY; TRANSGENIC MICE; CELL-DEATH; IN-VIVO; EXPRESSION; MYOCYTES	Loss of cardiomyocytes through programmed cell death is a key event in the development of heart failure, but the inciting molecular mechanisms are largely unknown. We used microarray analysis to identify a genetic program for myocardial apoptosis in Gq-mediated and pressure-overload cardiac hypertrophy. A critical component of this apoptotic program was Nix/Bnip3L. Nix localized to mitochondria and caused release of cytochrome c, activation of caspase-3 and apoptotic cell death, when expressed in HEK293 fibroblasts. A previously undescribed truncated Nix isoform, termed sNix, was not targeted to mitochondria but heterodimerized with Nix and protected against Nix-mediated apoptosis. Forced in vivo myocardial expression of Nix resulted in apoptotic cardiomyopathy and rapid death. Conversely, sNix protected against apoptotic peripartum cardiomyopathy in Galphaq-overexpressors. Thus, Nix/Bnip3L is upregulated in myocardial hypertrophy, and is both necessary and sufficient for Gq-mediated apoptosis of cardiomyocytes and resulting hypertrophy decompensation.	Univ Cincinnati, Med Ctr, Dept Internal Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Med Ctr, Dept Cellular & Mol Physiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Med Ctr, Dept Pediat, Cincinnati, OH 45267 USA; Univ Cincinnati, Med Ctr, Ctr Cardiovasc, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Dorn, GW (corresponding author), Univ Cincinnati, Med Ctr, Dept Internal Med, Cincinnati, OH 45267 USA.	dorngw@ucmail.uc.edu	Aronow, Bruce J/F-8438-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059888, R01HL058010] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58010, HL59888] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams JW, 2000, CIRC RES, V87, P1180, DOI 10.1161/01.RES.87.12.1180; Adams JW, 1998, P NATL ACAD SCI USA, V95, P10140, DOI 10.1073/pnas.95.17.10140; Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Aronow BJ, 2001, PHYSIOL GENOMICS, V6, P19, DOI 10.1152/physiolgenomics.2001.6.1.19; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CHIEN KR, 1993, SCIENCE, V260, P916, DOI 10.1126/science.8493528; Cook SA, 1999, CIRC RES, V85, P940; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; De Windt LJ, 2000, CIRC RES, V86, P255, DOI 10.1161/01.RES.86.3.255; Fatkin D, 1999, J CLIN INVEST, V103, P147, DOI 10.1172/JCI4631; GeisterferLowrance AAT, 1996, SCIENCE, V272, P731, DOI 10.1126/science.272.5262.731; Hirota H, 1999, CELL, V97, P189, DOI 10.1016/S0092-8674(00)80729-1; KATZ AM, 1990, NEW ENGL J MED, V322, P100; Leri A, 1998, J CLIN INVEST, V101, P1326, DOI 10.1172/JCI316; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; MacLellan WR, 1997, CIRC RES, V81, P137, DOI 10.1161/01.RES.81.2.137; MacLellan WR, 2000, ANNU REV PHYSIOL, V62, P289, DOI 10.1146/annurev.physiol.62.1.289; Mallat Z, 1996, NEW ENGL J MED, V335, P1190, DOI 10.1056/NEJM199610173351604; MIRSKY I, 1969, BIOPHYS J, V9, P189, DOI 10.1016/S0006-3495(69)86379-4; Misao J, 1996, CIRCULATION, V94, P1506, DOI 10.1161/01.CIR.94.7.1506; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304; Olivetti G, 1997, NEW ENGL J MED, V336, P1131, DOI 10.1056/NEJM199704173361603; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; Sakata Y, 1998, CIRCULATION, V97, P1488; Schneider MD, 2000, CIRCULATION, V102, P3026; Shi YG, 2001, NAT STRUCT BIOL, V8, P394, DOI 10.1038/87548; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Wettschureck N, 2001, NAT MED, V7, P1236, DOI 10.1038/nm1101-1236; Williams RS, 1999, NEW ENGL J MED, V341, P759, DOI 10.1056/NEJM199909023411012; Yasuda M, 1999, CANCER RES, V59, P533; Zhang D, 2000, NAT MED, V6, P556, DOI 10.1038/75037	36	246	257	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2002	8	7					725	730		10.1038/nm719	http://dx.doi.org/10.1038/nm719			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	567QG	12053174				2022-12-25	WOS:000176495200034
J	Yin, YL; Luciani, MG; Fahraeus, R				Yin, YL; Luciani, MG; Fahraeus, R			P53 stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products	NATURE CELL BIOLOGY			English	Article							MDM2; PROTEIN; DEGRADATION; ACTIVATION; MUTANT; DOMAIN	Activation of the p53 tumour suppressor protein can lead to cell-cycle arrest or apoptosis(1). p53 function is controlled by the mdm2 oncogene product, which targets p53 for proteasomal degradation(2,3). In this report we demonstrate that Mdm2 induces translation of the p53 mRNA from two alternative initiation sites, giving full-length p53 and another protein with a relative molecular mass (M-r) of approximately 47K; we designate this protein as p53/47. This translation induction requires Mdm2 to interact directly with the nascent p53 polypeptide. The alternatively translated p53/47 does not contain the Mdm2-binding site and it lacks the most amino-terminal transcriptional-activation domain of p53. Increased expression of p53/47 stabilizes p53 in the presence of Mdm2, and alters the expression levels of p53-induced gene products. These results show how the interaction of Mdm2 with p53 leads to a change in the ratio of full-length p53 to p53/47 by inducing translation of both p53 proteins and the subsequent selective degradation of full-length p53. Thus, Mdm2 controls the expression levels of p53 through a dual mechanism that involves induction of synthesis and targeting for degradation.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland	University of Dundee	Fahraeus, R (corresponding author), Univ Dundee, Sch Life Sci, Div Mol Physiol, Dundee DD1 5EH, Scotland.	r.fahraeus@dundee.ac.uk	fahraeus, robin/K-8726-2014	, robin/0000-0003-0402-8492				Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; Fontoura BMA, 1997, MOL CELL BIOL, V17, P3146, DOI 10.1128/MCB.17.6.3146; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; GANNON JV, 1991, NATURE, V349, P802; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LIU XL, 1994, CARCINOGENESIS, V15, P1969, DOI 10.1093/carcin/15.9.1969; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Venot C, 1999, ONCOGENE, V18, P2405, DOI 10.1038/sj.onc.1202539; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030	24	220	235	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2002	4	6					462	467		10.1038/ncb801	http://dx.doi.org/10.1038/ncb801			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	558NN	12032546				2022-12-25	WOS:000175973600018
J	Yoo, SJ; Huh, JR; Muro, I; Yu, H; Wang, LJ; Wang, SL; Feldman, RMR; Clem, RJ; Muller, HAJ; Hay, BA				Yoo, SJ; Huh, JR; Muro, I; Yu, H; Wang, LJ; Wang, SL; Feldman, RMR; Clem, RJ; Muller, HAJ; Hay, BA			Hid, Rpr and Grim negatively regulate DIAP1 levels through distinct mechanisms	NATURE CELL BIOLOGY			English	Article							UBIQUITIN-PROTEIN LIGASE; PROGRAMMED CELL-DEATH; DROSOPHILA CASPASE DRONC; IAP FUNCTION; IN-VITRO; APOPTOSIS; INHIBITOR; REAPER; IDENTIFICATION; DEGRADATION	Inhibitor of apoptosis (IAP) proteins suppress apoptosis and inhibit caspases. Several IAPs also function as ubiquitin-protein ligases. Regulators of IAP auto-ubiquitination, and thus IAP levels, have yet to be identified. Here we show that Head involution defective (Hid), Reaper (Rpr) and Grim downregulate Drosophila melanogaster IAP1 (DIAP) protein levels. Hid stimulates DIAP1 polyubiquitination and degradation. In contrast to Hid, Rpr and Grim can downregulate DIAP1 through mechanisms that do not require DIAP1 function as a ubiquitin-protein ligase. Observations with Grim suggest that one mechanism by which these proteins produce a relative decrease in DIAP1 levels is to promote a general suppression of protein translation. These observations define two mechanisms through which DIAP1 ubiquitination controls cell death: first, increased ubiquitination promotes degradation directly; second, a decrease in global protein synthesis results in a differential loss of short-lived proteins such as DIAP1. Because loss of DIAP1 is sufficient to promote caspase activation, these mechanisms should promote apoptosis.	Univ Dusseldorf, Inst Genet, D-40225 Dusseldorf, Germany; CALTECH, Div Biol, Pasadena, CA 91125 USA; Kansas State Univ, Div Biol, Mol Cellular & Dev Biol Program, Manhattan, KS 66506 USA	Heinrich Heine University Dusseldorf; California Institute of Technology; Kansas State University	Muller, HAJ (corresponding author), Univ Dusseldorf, Inst Genet, Univ Str 1, D-40225 Dusseldorf, Germany.		Muller, Hans-Arno/Q-2864-2019; Müller, Hans-Arno/G-5753-2012	Muller, Hans-Arno/0000-0002-7525-6874; Müller, Hans-Arno/0000-0002-7525-6874; Clem, Rollie/0000-0002-2368-720X	NIGMS NIH HHS [GM057422-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057422] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; Chen P, 1996, J BIOL CHEM, V271, P25735, DOI 10.1074/jbc.271.42.25735; Clemens MJ, 2000, CELL DEATH DIFFER, V7, P603, DOI 10.1038/sj.cdd.4400695; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; Fraser AG, 1997, EMBO J, V16, P2805, DOI 10.1093/emboj/16.10.2805; Fulda S, 2000, CANCER RES, V60, P3947; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; Hawkins CJ, 2000, J BIOL CHEM, V275, P27084; Hawkins CJ, 1999, P NATL ACAD SCI USA, V96, P2885, DOI 10.1073/pnas.96.6.2885; Hay BA, 2000, CELL DEATH DIFFER, V7, P1045, DOI 10.1038/sj.cdd.4400765; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HAY BA, 1994, DEVELOPMENT, V120, P2121; HAYS R, NATURE CELL BIOL; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HOLLEY CL, NATURE CELL BIOL; Huang HK, 2000, J BIOL CHEM, V275, P26661; Lisi S, 2000, GENETICS, V154, P669; Meier P, 2000, EMBO J, V19, P598, DOI 10.1093/emboj/19.4.598; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; Moore LA, 1998, DEVELOPMENT, V125, P667; Muller HAJ, 1996, J CELL BIOL, V134, P149, DOI 10.1083/jcb.134.1.149; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Quinn LM, 2000, J BIOL CHEM, V275, P40416, DOI 10.1074/jbc.M002935200; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RYOO HD, NATURE CELL BIOL; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tuschl T, 1999, GENE DEV, V13, P3191, DOI 10.1101/gad.13.24.3191; Vernooy SY, 2000, J CELL BIOL, V150, pF69, DOI 10.1083/jcb.150.2.F69; Vucic D, 1998, MOL CELL BIOL, V18, P3300, DOI 10.1128/MCB.18.6.3300; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; Weil M, 1996, J CELL BIOL, V133, P1053, DOI 10.1083/jcb.133.5.1053; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; Wing JP, 2001, MECH DEVELOP, V102, P193, DOI 10.1016/S0925-4773(01)00316-1; Wing JP, 1998, CELL DEATH DIFFER, V5, P930, DOI 10.1038/sj.cdd.4400423; WING JP, NATURE CELL BIOL; Wright CW, 2002, J BIOL CHEM, V277, P2454, DOI 10.1074/jbc.M110500200; Wu JW, 2001, MOL CELL, V8, P95, DOI 10.1016/S1097-2765(01)00282-9; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yokoyama H, 2000, J BIOL CHEM, V275, P12978, DOI 10.1074/jbc.275.17.12978	44	311	317	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUN	2002	4	6					416	424		10.1038/ncb793	http://dx.doi.org/10.1038/ncb793			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	558NN	12021767				2022-12-25	WOS:000175973600011
J	Miki, T; Suzuki, M; Shibasaki, T; Uemura, H; Sato, T; Yamaguchi, K; Koseki, H; Iwanaga, T; Nakaya, H; Seino, S				Miki, T; Suzuki, M; Shibasaki, T; Uemura, H; Sato, T; Yamaguchi, K; Koseki, H; Iwanaga, T; Nakaya, H; Seino, S			Mouse model of Prinzmetal angina by disruption of the inward rectifier Kir6.1	NATURE MEDICINE			English	Article							SENSITIVE K+ CHANNELS; CORONARY-ARTERY; POTASSIUM CHANNELS; ATP; SUBUNIT; MUSCLE; DEATH; JAPANESE; SPASM; MICE	The inwardly rectifying K+ channel Kir6.1 forms K+ channels by coupling with a sulfonylurea receptor in reconstituted systems, but the physiological roles of Kir6.1-containing K+ channels have not been determined. We report here that mice lacking the gene encoding Kir6.1 (known as Kcnj8) have a high rate of sudden death associated with spontaneous ST elevation followed by atrioventricular block as seen on an electrocardiogram. The K+ channel opener pinacidil did not induce K+ currents in vascular smooth-muscle cells of Kir6.1-null mice, and there was no vasodilation response to pinacidil. The administration of methylergometrine, a vasoconstrictive agent, elicited ST elevation followed by cardiac death in Kir6.1-null mice but not in wild-type mice, indicating a phenotype characterized by hypercontractility of coronary arteries and resembling Prinzmetal (or variant) angina in humans. The Kir6.1-containing K+ channel is critical in the regulation of vascular tonus, especially in the coronary arteries, and its disruption may cause Prinzmetal angina.	Chiba Univ, Grad Sch Med, Dept Cellular & Mol Med, Chiba, Japan; Chiba Univ, Grad Sch Med, Dept Pharmacol & Mol Embryol, Chiba, Japan; Chiba Univ, Ctr Gene Res, Chiba, Japan; Hokkaido Univ, Grad Sch Vet Med, Lab Anat, Sapporo, Hokkaido, Japan	Chiba University; Chiba University; Chiba University; Hokkaido University	Seino, S (corresponding author), Chiba Univ, Grad Sch Med, Dept Cellular & Mol Med, Chiba, Japan.	seino@med.m.chiba-u.ac.jp	MIKI, Takashi/ABD-3995-2020; Koseki, Haruhiko/I-3825-2014	MIKI, Takashi/0000-0001-5741-1626; Koseki, Haruhiko/0000-0001-8424-5854				Abraham MR, 1999, FASEB J, V13, P1901; Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; Ammala C, 1996, J PHYSIOL-LONDON, V494, P709, DOI 10.1113/jphysiol.1996.sp021526; Ashcroft FM, 1998, TRENDS NEUROSCI, V21, P288, DOI 10.1016/S0166-2236(98)01225-9; Barry DM, 1998, CIRC RES, V83, P560, DOI 10.1161/01.RES.83.5.560; BEECH DJ, 1993, BRIT J PHARMACOL, V110, P573, DOI 10.1111/j.1476-5381.1993.tb13849.x; Beltrame JF, 1999, J AM COLL CARDIOL, V33, P1442, DOI 10.1016/S0735-1097(99)00073-X; Drici MD, 1998, CIRC RES, V83, P95, DOI 10.1161/01.RES.83.1.95; EGASHIRA K, 1992, CIRC RES, V71, P435, DOI 10.1161/01.RES.71.2.435; Gutstein DE, 2001, CIRC RES, V88, P333, DOI 10.1161/01.RES.88.3.333; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; INAGAKI N, 1995, J BIOL CHEM, V270, P5691, DOI 10.1074/jbc.270.11.5691; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Isomoto S, 1996, J BIOL CHEM, V271, P24321, DOI 10.1074/jbc.271.40.24321; Jan LY, 1997, J PHYSIOL-LONDON, V505, P267, DOI 10.1111/j.1469-7793.1997.267bb.x; KAJIOKA S, 1991, J PHYSIOL-LONDON, V444, P397, DOI 10.1113/jphysiol.1991.sp018885; Keating MT, 2001, CELL, V104, P569, DOI 10.1016/S0092-8674(01)00243-4; Kono Y, 2000, PFLUG ARCH EUR J PHY, V440, P692, DOI 10.1007/s004240000315; Kupershmidt S, 1999, CIRC RES, V84, P146, DOI 10.1161/01.RES.84.2.146; Li RA, 2000, CIRC RES, V87, P837, DOI 10.1161/01.RES.87.10.837; Liu YG, 1998, CIRCULATION, V97, P2463, DOI 10.1161/01.CIR.97.24.2463; MACALPIN RN, 1993, AM HEART J, V125, P1011, DOI 10.1016/0002-8703(93)90108-L; MASERI A, 1987, J AM COLL CARDIOL, V9, P249, DOI 10.1016/S0735-1097(87)80372-8; Miki T, 2001, NAT NEUROSCI, V4, P507, DOI 10.1038/87455; Miki T, 1998, P NATL ACAD SCI USA, V95, P10402, DOI 10.1073/pnas.95.18.10402; Myerburg RJ, 1997, AM J CARDIOL, V80, pF10, DOI 10.1016/S0002-9149(97)00477-3; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Okumura K, 1996, J AM COLL CARDIOL, V27, P45, DOI 10.1016/0735-1097(95)00432-7; PRINZMETAL M, 1959, AM J MED, V27, P375, DOI 10.1016/0002-9343(59)90003-8; Pristipino C, 2000, CIRCULATION, V101, P1102, DOI 10.1161/01.CIR.101.10.1102; Robbins J, 2000, NAT MED, V6, P968, DOI 10.1038/79652; Seharaseyon J, 2000, J BIOL CHEM, V275, P17561, DOI 10.1074/jbc.275.23.17561; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; STANDEN NB, 1989, SCIENCE, V245, P177, DOI 10.1126/science.2501869; Suzuki M, 2002, J CLIN INVEST, V109, P509, DOI 10.1172/JC1200214270; Suzuki M, 2001, CIRC RES, V88, P570, DOI 10.1161/01.RES.88.6.570; Suzuki M, 1997, BIOCHEM BIOPH RES CO, V241, P693, DOI 10.1006/bbrc.1997.7891; Tanaka J, 1996, ARCH HISTOL CYTOL, V59, P485, DOI 10.1679/aohc.59.485; Thomzig A, 2001, MOL CELL NEUROSCI, V18, P671, DOI 10.1006/mcne.2001.1048; Yamada M, 1997, J PHYSIOL-LONDON, V499, P715, DOI 10.1113/jphysiol.1997.sp021963	40	269	276	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2002	8	5					466	472		10.1038/nm0502-466	http://dx.doi.org/10.1038/nm0502-466			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	547ZW	11984590				2022-12-25	WOS:000175336800031
J	Pharoah, PDP; Antoniou, A; Bobrow, M; Zimmern, RL; Easton, DF; Ponder, BAJ				Pharoah, PDP; Antoniou, A; Bobrow, M; Zimmern, RL; Easton, DF; Ponder, BAJ			Polygenic susceptibility to breast cancer and implications for prevention	NATURE GENETICS			English	Article							RISK; FAMILY; BRCA1; WOMEN; TWINS	The knowledge of human genetic variation that will come from the human genome sequence makes feasible a polygenic approach to disease prevention, in which it will be possible to identify individuals as susceptible by their genotype profile and to prevent disease by targeting interventions to those at risk. There is doubt, however, regarding the magnitude of these genetic effects and thus the potential to apply them to either individuals or populations. We have therefore examined the potential for prediction of risk based on common genetic variation using data from a population-based series of individuals with breast cancer. The data are compatible with a log-normal distribution of genetic risk in the population that is sufficiently wide to provide useful discrimination of high- and low-risk groups. Assuming all of the susceptibility genes could be identified, the half of the population at highest risk would account for 88% of all affected individuals. By contrast, if currently identified risk factors for breast cancer were used to stratify the population, the half of the population at highest risk would account for only 62% of all cases. These results suggest that the construction and use of genetic-risk profiles may provide significant improvements in the efficacy of population-based programs of intervention for cancers and other diseases.	Strangeways Res Labs, Dept Oncol, Canc Res UK Human Canc Genet Grp, Cambridge CB1 8RN, England; Strangeways Res Labs, Publ Hlth Genet Unit, Cambridge CB1 8RN, England; Strangeways Res Labs, Canc Res UK Genet Epidemiol Unit, Cambridge CB1 8RN, England; Addenbrookes Hosp, Dept Clin Genet, Cambridge CB1 2QQ, England	Cancer Research UK; Cancer Research UK; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Pharoah, PDP (corresponding author), Strangeways Res Labs, Dept Oncol, Canc Res UK Human Canc Genet Grp, Cambridge CB1 8RN, England.	paul.pharoah@srl.cam.ac.uk	Pharoah, Paul/V-6658-2019	Pharoah, Paul/0000-0001-8494-732X				Antoniou AC, 2001, GENET EPIDEMIOL, V21, P1, DOI 10.1002/gepi.1014; ANTONIOU AC, 2001, IN PRESS BR J CANC; Beaudet AL, 1999, AM J HUM GENET, V64, P1, DOI 10.1086/302217; Bell J, 1998, BMJ-BRIT MED J, V316, P618, DOI 10.1136/bmj.316.7131.618; Cui JS, 2001, AM J HUM GENET, V68, P420, DOI 10.1086/318187; Dunning AM, 1999, CANCER EPIDEM BIOMAR, V8, P843; Easton D F, 1999, Breast Cancer Res, V1, P14, DOI 10.1186/bcr6; Friend SH, 1999, BRIT MED J, V319, P1306, DOI 10.1136/bmj.319.7220.1306; Holtzman NA, 2000, NEW ENGL J MED, V343, P141, DOI 10.1056/NEJM200007133430213; KELSEY JL, 1993, EPIDEMIOL REV, V15, P36, DOI 10.1093/oxfordjournals.epirev.a036115; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Peto J, 2000, NAT GENET, V26, P411, DOI 10.1038/82533; Pharoah PDP, 1998, BREAST, V7, P255, DOI 10.1016/S0960-9776(98)90091-1; Pharoah PDP, 1997, INT J CANCER, V71, P800, DOI 10.1002/(SICI)1097-0215(19970529)71:5<800::AID-IJC18>3.3.CO;2-R; Ponder BAJ, 2000, BRIT J CANCER, V83, P1301; Risch N, 2001, CANCER EPIDEM BIOMAR, V10, P733; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; Vaittinen P, 2000, INT J CANCER, V88, P998, DOI 10.1002/1097-0215(20001215)88:6<998::AID-IJC25>3.0.CO;2-0; Vineis P, 2001, LANCET, V357, P709, DOI 10.1016/S0140-6736(00)04136-2	20	596	614	0	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2002	31	1					33	36		10.1038/ng853	http://dx.doi.org/10.1038/ng853			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	547ZF	11984562	Bronze			2022-12-25	WOS:000175362500011
J	Dickinson, AM; Wang, XN; Sviland, L; Vyth-Dreese, FA; Jackson, GH; Schumacher, TNM; Haanen, JBAG; Mutis, T; Goulmy, E				Dickinson, AM; Wang, XN; Sviland, L; Vyth-Dreese, FA; Jackson, GH; Schumacher, TNM; Haanen, JBAG; Mutis, T; Goulmy, E			In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens	NATURE MEDICINE			English	Article							CHRONIC MYELOID-LEUKEMIA; RELAPSED LEUKEMIA; DISEASE; MARROW; LYMPHOCYTES; HA-1; IMMUNOTHERAPY; RECIPIENTS; REMISSION; MODEL	Minor histocompatibility antigens (mHags) are immunogenic peptides from polymorphic cellular proteins that induce strong T-cell responses after human leukocyte antigen (HLA)-matched, mHag-mismatched stem-cell transplantation(1,2). mHags with broad or limited tissue expression are target antigens for graft-versus-host (GvH) and graft-versus-leukemia (GvL) reactivities(1). Separation of these activities is crucial for adoptive immunotherapy of leukemia without GvH disease. Therefore, using a skin-explant assay we investigated the in situ activities of cytotoxic T lymphocytes (CTLs) specific for the ubiquitously expressed mHag H-Y and for the hematopoietic-restricted mHags HA-1 and HA-2. H-Y-specific CTLs, visualized by tetrameric HLA mHag peptide complexes(3), infiltrated male skin sections within 24 hours, induced severe GvH reactions of grade III-IV and produced high levels of IFN-gamma. In contrast, CTLs specific for the hematopoietic system specific mHags HA-1 and HA-2 induced no or low GvH reactions above background and produced little or no interferon-gamma, unless the skin sections were preincubated with HA-1/HA-2 synthetic peptides. These results provide the first in situ dissection of GvH effects by mHag-specific CTLs and show that ubiquitously expressed mHags are the prime targets of GvH disease.	Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, Leiden, Netherlands; Newcastle Univ, Royal Victoria Infirm, Dept Haematol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Haukeland Hosp, Dept Pathol, Bergen, Norway; Netherlands Canc Inst, Dept Immunol, Amsterdam, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Newcastle University - UK; University of Bergen; Haukeland University Hospital; Netherlands Cancer Institute	Goulmy, E (corresponding author), Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, Leiden, Netherlands.	e.a.j.m.goulmy@lumc.nl	Schumacher, Ton/Y-2432-2019; Haanen, John/AAD-8578-2022; Jackson, Graham/GMW-7638-2022; Haanen, John/AAD-8534-2022	Schumacher, Ton/0000-0003-0517-8804; Jackson, Graham/0000-0003-0756-969X; Haanen, John/0000-0001-5884-7704				den Haan JMM, 1998, SCIENCE, V279, P1054, DOI 10.1126/science.279.5353.1054; DICKINSON AM, 1994, BONE MARROW TRANSPL, V13, P65; DICKINSON AM, 1988, BONE MARROW TRANSPL, V3, P323; Dickinson AM, 1998, TRANSPLANTATION, V66, P857, DOI 10.1097/00007890-199810150-00008; Falkenburg JHF, 1999, BLOOD, V94, P1201, DOI 10.1182/blood.V94.4.1201.416k08_1201_1208; Fontaine P, 2001, NAT MED, V7, P789, DOI 10.1038/89907; Goulmy E, 1996, NEW ENGL J MED, V334, P281, DOI 10.1056/NEJM199602013340501; Goulmy E, 1997, IMMUNOL REV, V157, P125, DOI 10.1111/j.1600-065X.1997.tb00978.x; Haanen JBAG, 1999, J EXP MED, V190, P1319, DOI 10.1084/jem.190.9.1319; Haanen JBAG, 2000, NAT MED, V6, P1056, DOI 10.1038/79573; Koh MBC, 1999, BONE MARROW TRANSPL, V23, P1071, DOI 10.1038/sj.bmt.1701749; Krenger W, 1997, TRANSPLANTATION, V64, P553, DOI 10.1097/00007890-199708270-00001; LERNER KG, 1974, TRANSPLANT P, V6, P367; Marijt WAF, 2000, BLOOD, V96, p478A; Molldrem JJ, 1997, BLOOD, V90, P2529, DOI 10.1182/blood.V90.7.2529.2529_2529_2534; Mutis T, 1999, BLOOD, V93, P2336, DOI 10.1182/blood.V93.7.2336.407k26_2336_2341; Mutis T, 1999, NAT MED, V5, P839, DOI 10.1038/10563; Mutis T, 2001, BONE MARROW TRANSPL, V27, pS1; Ruggeri L, 1999, BLOOD, V94, P333, DOI 10.1182/blood.V94.1.333.413a31_333_339; Shlomchik WD, 1999, SCIENCE, V285, P412, DOI 10.1126/science.285.5426.412; Stauss HJ, 1999, IMMUNOL TODAY, V20, P180, DOI 10.1016/S0167-5699(99)01443-7; Sviland L, 1999, J CLIN PATHOL, V52, P910, DOI 10.1136/jcp.52.12.910; Tseng LH, 1999, BLOOD, V94, P2911, DOI 10.1182/blood.V94.8.2911.420k21_2911_2914; VANELS CACM, 1992, IMMUNOGENETICS, V35, P161, DOI 10.1007/BF00185109; VOGELSANG GB, 1985, NEW ENGL J MED, V313, P645, DOI 10.1056/NEJM198509123131101	25	202	208	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2002	8	4					410	414		10.1038/nm0402-410	http://dx.doi.org/10.1038/nm0402-410			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	536ML	11927949				2022-12-25	WOS:000174704800035
J	Schoeberl, B; Eichler-Jonsson, C; Gilles, ED; Muller, G				Schoeberl, B; Eichler-Jonsson, C; Gilles, ED; Muller, G			Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors	NATURE BIOTECHNOLOGY			English	Article							EPIDERMAL-GROWTH-FACTOR; PROTEIN; CELLS; INSULIN; BINDING; RAS; TRAFFICKING; REQUIREMENT; ENDOCYTOSIS; TRANSIENT	We present a computational model that offers an integrated quantitative, dynamic, and topological representation of intracellular signal networks, based on known components of epidermal growth factor (EGF) receptor signal pathways. The model provides insight into signal-response relationships between the binding of EGF to its receptor at the cell surface and the activation of downstream proteins in the signaling cascade. It shows that EGF-induced responses are remarkably stable over a 100-fold range of ligand concentration and that the critical parameter in determining signal efficacy is the initial velocity of receptor activation. The predictions of the model agree well with experimental analysis of the effect of EGF on two downstream responses, phosphorylation of ERK-1/2 and expression of the target gene, c-fos.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany; Max Planck Inst Dynam Complex Tech Syst, D-39120 Magdeburg, Germany; Univ Stuttgart, Inst Syst Dynam & Control, D-70569 Stuttgart, Germany	University of Stuttgart; Max Planck Society; University of Stuttgart	Muller, G (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany.	Gertraud.Mueller@po.uni-stuttgart.de						BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BERKERS JAM, 1991, J BIOL CHEM, V266, P922; BRAY D, 1990, J THEOR BIOL, V143, P215, DOI 10.1016/S0022-5193(05)80268-1; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; CADENA DL, 1994, J BIOL CHEM, V269, P260; Carter RE, 1998, J BIOL CHEM, V273, P35000, DOI 10.1074/jbc.273.52.35000; Chung JC, 1997, BIOPHYS J, V73, P1089, DOI 10.1016/S0006-3495(97)78141-4; Corbalan-Garcia S, 1998, MOL CELL BIOL, V18, P880, DOI 10.1128/MCB.18.2.880; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; Eigen M., 1974, QUANTUM STAT MECH NA, pp 37; El-Masri HA, 1999, B MATH BIOL, V61, P379, DOI 10.1006/bulm.1998.0077; FRENCH AR, 1995, J BIOL CHEM, V270, P4334, DOI 10.1074/jbc.270.9.4334; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; HANSEN SH, 1991, J CELL BIOL, V113, P731, DOI 10.1083/jcb.113.4.731; Haugh JM, 1998, J THEOR BIOL, V195, P187, DOI 10.1006/jtbi.1998.0791; Haugh JM, 1999, J BIOL CHEM, V274, P8958, DOI 10.1074/jbc.274.13.8958; Huang CYF, 1996, P NATL ACAD SCI USA, V93, P10078, DOI 10.1073/pnas.93.19.10078; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; Kalb A, 1996, J BIOL CHEM, V271, P28097, DOI 10.1074/jbc.271.45.28097; Keilhack H, 1998, J BIOL CHEM, V273, P24839, DOI 10.1074/jbc.273.38.24839; Kholodenko BN, 1999, J BIOL CHEM, V274, P30169, DOI 10.1074/jbc.274.42.30169; Kim H, 1999, EXP CELL RES, V253, P78, DOI 10.1006/excr.1999.4706; LUND KA, 1990, J BIOL CHEM, V265, P15713; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Martin-Fernandez ML, 2000, CELL MOL BIOL, V46, P1103; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muller G, 1998, EMBO J, V17, P732, DOI 10.1093/emboj/17.3.732; Ni TC, 1996, J BIOL CHEM, V271, P7927, DOI 10.1074/jbc.271.14.7927; Rechenberg I., 1994, EVOLUTIONSSTRATEGIE; Sako Y, 2000, NAT CELL BIOL, V2, P168, DOI 10.1038/35004044; Saso K, 1997, GASTROENTEROLOGY, V112, P2073, DOI 10.1053/gast.1997.v112.pm9178701; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Sermon BA, 1998, J BIOL CHEM, V273, P9480, DOI 10.1074/jbc.273.16.9480; Sibilia M, 1998, EMBO J, V17, P719, DOI 10.1093/emboj/17.3.719; STARBUCK C, 1992, BIOTECHNOL PROGR, V8, P132, DOI 10.1021/bp00014a007; Sydor JR, 1998, BIOCHEMISTRY-US, V37, P14292, DOI 10.1021/bi980764f; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; Tyson JJ, 1996, TRENDS BIOCHEM SCI, V21, P89; UEKI K, 1994, J BIOL CHEM, V269, P15756; Wang ZX, 1996, CELL GROWTH DIFFER, V7, P123; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Waters SB, 1996, J BIOL CHEM, V271, P18224, DOI 10.1074/jbc.271.30.18224; WILEY HS, 1988, J CELL BIOL, V107, P801, DOI 10.1083/jcb.107.2.801	47	708	726	0	65	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2002	20	4					370	375		10.1038/nbt0402-370	http://dx.doi.org/10.1038/nbt0402-370			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	536BY	11923843				2022-12-25	WOS:000174681900024
J	Schwartz, MA; Ginsberg, MH				Schwartz, MA; Ginsberg, MH			Networks and crosstalk: integrin signalling spreads	NATURE CELL BIOLOGY			English	Editorial Material							RECEPTOR TYROSINE KINASES; MEDIATED ADHESION; SHEAR-STRESS; MICE LACKING; ALPHA(V)BETA(3); ACTIVATION; PHOSPHORYLATION; ANGIOGENESIS; CYTOSKELETON; REQUIREMENT	Multicellular organisms must coordinate signals from adhesion receptors with those from other signalling receptors (for example, growth factor receptors). Here, we briefly review paradigms of integrin-adhesion-receptor signalling. We discuss how adhesive signalling is coordinately regulated through intersecting networks. We also examine some examples of how some forms of integrin crosstalk may lead to unforeseen and potentially deleterious responses.	Scripps Res Inst, Dept Cell Biol, Div Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Schwartz, MA (corresponding author), Scripps Res Inst, Dept Cell Biol, Div Vasc Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	schwartz@scripps.edu; ginsberg@scripps.edu		schwartz, martin/0000-0002-2071-1243				ADAMS JC, 1993, DEVELOPMENT, V117, P1183; Aplin AE, 2001, J CELL BIOL, V153, P273, DOI 10.1083/jcb.153.2.273; Assoian RK, 2001, CURR OPIN GENET DEV, V11, P48, DOI 10.1016/S0959-437X(00)00155-6; Bader BL, 1998, CELL, V95, P507, DOI 10.1016/S0092-8674(00)81618-9; Belkin AM, 1998, J BIOL CHEM, V273, P15234, DOI 10.1074/jbc.273.24.15234; BLYSTONE SD, 1994, J CELL BIOL, V127, P1129, DOI 10.1083/jcb.127.4.1129; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Chan JR, 2000, J IMMUNOL, V164, P746, DOI 10.4049/jimmunol.164.2.746; Chen KD, 1999, J BIOL CHEM, V274, P18393, DOI 10.1074/jbc.274.26.18393; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; DeMali KA, 1999, J BIOL CHEM, V274, P19551, DOI 10.1074/jbc.274.28.19551; DiazGonzalez F, 1996, MOL BIOL CELL, V7, P1939, DOI 10.1091/mbc.7.12.1939; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Eliceiri BP, 2001, CURR OPIN CELL BIOL, V13, P563, DOI 10.1016/S0955-0674(00)00252-0; Fringer J, 2001, J BIOL CHEM, V276, P31047, DOI 10.1074/jbc.M101898200; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Juliano RL, 2001, METHOD ENZYMOL, V333, P151; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Maeshima Y, 2002, SCIENCE, V295, P140, DOI 10.1126/science.1065298; Maeshima Y, 2001, J BIOL CHEM, V276, P31959, DOI 10.1074/jbc.M103024200; May AE, 2000, BLOOD, V96, P506; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; Rehn M, 2001, P NATL ACAD SCI USA, V98, P1024, DOI 10.1073/pnas.031564998; Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27; Rose DM, 2000, BLOOD, V95, P602, DOI 10.1182/blood.V95.2.602; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Schwartz MA, 2001, J CELL SCI, V114, P2553; Shimizu Y, 1999, ADV IMMUNOL, V72, P325, DOI 10.1016/S0065-2776(08)60024-3; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Sundberg C, 1996, J CELL BIOL, V132, P741, DOI 10.1083/jcb.132.4.741; Tarui T, 2001, J BIOL CHEM, V276, P39562, DOI 10.1074/jbc.M101815200; Tzima E, 2001, EMBO J, V20, P4639, DOI 10.1093/emboj/20.17.4639; Wang HB, 2001, P NATL ACAD SCI USA, V98, P11295, DOI 10.1073/pnas.201201198; Wang R, 2001, J CELL BIOL, V153, P1023, DOI 10.1083/jcb.153.5.1023; Weber C, 1998, J IMMUNOL, V161, P6825; YANG JT, 1993, DEVELOPMENT, V119, P1093	39	636	657	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2002	4	4					E65	E68		10.1038/ncb0402-e65	http://dx.doi.org/10.1038/ncb0402-e65			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	541PY	11944032				2022-12-25	WOS:000174994000002
J	Dahlman, I; Eaves, IA; Kosoy, R; Morrison, VA; Heward, J; Gough, SCL; Allahabadia, A; Franklyn, JA; Tuomilehto, J; Tuomilehto-Wolf, E; Cucca, F; Guja, C; Ionescu-Tirgoviste, C; Stevens, H; Carr, P; Nutland, S; McKinney, P; Shield, JP; Wang, W; Cordell, HJ; Walker, N; Todd, JA; Concannon, P				Dahlman, I; Eaves, IA; Kosoy, R; Morrison, VA; Heward, J; Gough, SCL; Allahabadia, A; Franklyn, JA; Tuomilehto, J; Tuomilehto-Wolf, E; Cucca, F; Guja, C; Ionescu-Tirgoviste, C; Stevens, H; Carr, P; Nutland, S; McKinney, P; Shield, JP; Wang, W; Cordell, HJ; Walker, N; Todd, JA; Concannon, P			Parameters for reliable results in genetic association studies in common disease	NATURE GENETICS			English	Article							LINKAGE DISEQUILIBRIUM; SUSCEPTIBILITY; REGION	It is increasingly apparent that the identification of true genetic associations in common multifactorial disease will require studies comprising thousands rather than the hundreds of individuals employed to date. Using 2,873 families, we were unable to confirm a recently published association of the interleukin 12B gene in 422 type I diabetic families. These results emphasize the need for large datasets, small P values and independent replication if results are to be reliable.	Univ Cambridge, Cambridge Inst Med Res, JDRF WF Diabet & Inflammat Lab, Cambridge CB2 2XY, England; Univ Washington, Sch Med, Virginia Mason Res Ctr, Mol Genet Program, Seattle, WA USA; Univ Washington, Sch Med, Dept Immunol, Seattle, WA USA; Univ Birmingham, Birmingham Heartlands Hosp, Div Med Sci, Birmingham B9 5SS, W Midlands, England; Univ Birmingham, Queen Elizabeth Hosp, Div Med Sci, Birmingham B9 5SS, W Midlands, England; Natl Publ Hlth Inst, Diabet & Genet Epidemiol Unit, Helsinki, Finland; Univ Helsinki, Dept Publ Hlth, Helsinki 00300, Finland; Univ Cagliari, Dipartimento Sci Biobediche & Biotecnol, Cagliari, Italy; Inst Diabet Nutr & Metab Dis N Paulescu, Diabet Clin, Bucharest, Romania; Paediat Epidemiol Grp, Unit Epidemiol & HSR, Leeds, W Yorkshire, England; Univ Bristol, Royal Hosp Sick Children, Inst Child Hlth, Bristol, Avon, England	University of Cambridge; University of Washington; University of Washington Seattle; Virginia Mason Medical Center; University of Washington; University of Washington Seattle; Heart of England NHS Foundation Trust; University of Birmingham; University of Birmingham; Finland National Institute for Health & Welfare; University of Helsinki; University of Cagliari; University of Leeds; Bristol Royal Hospital For Children; University of Bristol	Todd, JA (corresponding author), Univ Cambridge, Cambridge Inst Med Res, JDRF WF Diabet & Inflammat Lab, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	john.todd@cimr.cam.ac.uk	Wang, William/E-7862-2013; Todd, John A/A-3542-2010; Guja, Cristian/K-2334-2019; Shield, Julian PH/D-6297-2014	Wang, William/0000-0002-5369-5446; Todd, John A/0000-0003-2740-8148; Shield, Julian PH/0000-0003-2601-7575; Concannon, Patrick/0000-0002-5801-1859; Cordell, Heather/0000-0002-1879-5572; CUCCA, Francesco/0000-0002-7414-1995; Dahlman, Ingrid/0000-0003-3819-5977; Walker, Neil/0000-0001-9796-7688				Adorini L, 2001, NAT GENET, V27, P131, DOI 10.1038/84732; Allahabadia A, 2001, LANCET, V358, P984, DOI 10.1016/S0140-6736(01)06125-6; BAIN SC, 1990, AUTOIMMUNITY, V7, P83, DOI 10.3109/08916939008993380; BENNETT ST, 1995, NAT GENET, V9, P284, DOI 10.1038/ng0395-284; Cox NJ, 2001, AM J HUM GENET, V69, P820, DOI 10.1086/323501; Goring HHH, 2001, AM J HUM GENET, V69, P1357, DOI 10.1086/324471; Huang D, 2000, GENES IMMUN, V1, P515, DOI 10.1038/sj.gene.6363720; LERNMARK A, 1990, AM J HUM GENET, V47, P1028; Mein CA, 2000, GENOME RES, V10, P330, DOI 10.1101/gr.10.3.330; Morahan G, 2001, NAT GENET, V27, P218, DOI 10.1038/84872; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; 1999, NATURE GENET, V22, P1	13	181	185	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2002	30	2					149	150		10.1038/ng825	http://dx.doi.org/10.1038/ng825			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	519CY	11799396				2022-12-25	WOS:000173708700013
J	Modrek, B; Lee, C				Modrek, B; Lee, C			A genomic view of alternative splicing	NATURE GENETICS			English	Editorial Material							PRE-MESSENGER-RNA; HUMAN GENES; SEQUENCE; DATABASE; INTRONS; CONSEQUENCES; INFORMATION; ELEGANS; VARIANT	Recent genome-wide analyses of alternative splicing indicate that 40-60% of human genes have alternative splice forms, suggesting that alternative splicing is one of the most significant components of the functional complexity of the human genome. Here we review these recent results from bioinformatics studies, assess their reliability and consider the impact of alternative splicing on biological functions. Although the 'big picture' of alternative splicing that is emerging from genomics is exciting, there are many challenges. High-throughput experimental verification of alternative splice forms, functional characterization, and regulation of alternative splicing are key directions for research. We recommend a community-based effort to discover and characterize alternative splice forms comprehensively throughout the human genome.	Univ Calif Los Angeles, Dept Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biochem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Lee, C (corresponding author), Univ Calif Los Angeles, Dept Chem, Los Angeles, CA 90095 USA.	leec@mbi.ucla.edu						Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Beaudoing E, 2000, GENOME RES, V10, P1001, DOI 10.1101/gr.10.7.1001; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Brett D, 2000, FEBS LETT, V474, P83, DOI 10.1016/S0014-5793(00)01581-7; Brudno M, 2001, NUCLEIC ACIDS RES, V29, P2338, DOI 10.1093/nar/29.11.2338; Burke J, 1998, GENOME RES, V8, P276, DOI 10.1101/gr.8.3.276; Burset M, 2000, NUCLEIC ACIDS RES, V28, P4364, DOI 10.1093/nar/28.21.4364; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Croft L, 2000, NAT GENET, V24, P340, DOI 10.1038/74153; Dralyuk I, 2000, NUCLEIC ACIDS RES, V28, P296, DOI 10.1093/nar/28.1.296; EARLY P, 1980, CELL, V20, P313, DOI 10.1016/0092-8674(80)90617-0; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; Hedjran F, 1997, P NATL ACAD SCI USA, V94, P12343, DOI 10.1073/pnas.94.23.12343; Hu GK, 2001, GENOME RES, V11, P1237, DOI 10.1101/gr.165501; HUH GS, 1994, GENE DEV, V8, P1561, DOI 10.1101/gad.8.13.1561; Ji HK, 2001, NUCLEIC ACIDS RES, V29, P260, DOI 10.1093/nar/29.1.260; Kan ZY, 2001, GENOME RES, V11, P889, DOI 10.1101/gr.155001; Kawamoto S, 1996, J BIOL CHEM, V271, P17613; Kent WJ, 2000, NUCLEIC ACIDS RES, V28, P91, DOI 10.1093/nar/28.1.91; Kent WJ, 2000, GENOME RES, V10, P1115, DOI 10.1101/gr.10.8.1115; KRAWCZAK M, 1992, HUM GENET, V90, P41; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Liu HX, 2001, NAT GENET, V27, P55, DOI 10.1038/83762; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Mironov AA, 1999, GENOME RES, V9, P1288, DOI 10.1101/gr.9.12.1288; MODAFFERI EF, 1997, MOL CELL BIOL, V17, P537; Modrek B, 2001, NUCLEIC ACIDS RES, V29, P2850, DOI 10.1093/nar/29.13.2850; Pennisi E, 2000, SCIENCE, V288, P1146, DOI 10.1126/science.288.5469.1146; ROSENFELD MG, 1982, P NATL ACAD SCI-BIOL, V79, P1717, DOI 10.1073/pnas.79.6.1717; SAMBROOK J, 1977, NATURE, V268, P101, DOI 10.1038/268101a0; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; Shoemaker DD, 2001, NATURE, V409, P922, DOI 10.1038/35057141; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Spingola M, 1999, RNA, V5, P221, DOI 10.1017/S1355838299981682; Stamm S, 2000, DNA CELL BIOL, V19, P739, DOI 10.1089/104454900750058107; STAMM S, 1994, NUCLEIC ACIDS RES, V22, P1515, DOI 10.1093/nar/22.9.1515; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wheeler DL, 2000, NUCLEIC ACIDS RES, V28, P10, DOI 10.1093/nar/28.1.10	39	998	1074	7	106	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2002	30	1					13	19		10.1038/ng0102-13	http://dx.doi.org/10.1038/ng0102-13			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	508TL	11753382				2022-12-25	WOS:000173105600005
J	Park, M; Moon, RT				Park, M; Moon, RT			The planar cell-polarity gene stbm regulates cell behaviour and cell fate in vertebrate embryos	NATURE CELL BIOLOGY			English	Article							N-TERMINAL KINASE; TISSUE POLARITY; SIGNALING PATHWAYS; GASTRULATION MOVEMENTS; TRANSMEMBRANE DOMAINS; CONVERGENT EXTENSION; FRIZZLED HOMOLOGS; XENOPUS-EMBRYOS; BETA-CATENIN; VAN-GOGH	The gene strabismus (stbm)/Van Gogh (Vang) functions in the planar cell-polarity pathway in Drosophila. As the existence of such a pathway in vertebrates has not been firmly established, we investigated the functions and signalling activities encoded by stbm in vertebrate embryos. In regard to cell fate, inhibition of Stbm function in zebrafish embryos leads to reduction of anterior neural markers, whereas gain of function leads to a rise in the levels of these markers. In regard to cell behaviour, both gain-of-function and loss-of-function assays reveal a role for Stbm in mediating cell movements during gastrulation. Mechanistically, Stbm inhibits Wnt-mediated activation of betacatenin-dependent transcription while promoting phosphorylation of c-Jun- and AP-1-dependent transcription. This complex effect on intracellular signalling pathways probably involves dishevelled (dsh), as Stbm was found to interact with the Dsh protein, and as Dsh is known to function in both planar cell-polarity and beta-catenin pathways in Drosophila.	Univ Washington, Sch Med, Dept Pharmacol, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Sch Med, Ctr Dev Biol, Seattle, WA 98195 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Park, M (corresponding author), Univ Washington, Sch Med, Dept Pharmacol, Howard Hughes Med Inst, Box 357370, Seattle, WA 98195 USA.		Moon, Randall/M-5605-2019; Moon, Randall T/B-1743-2014	Moon, Randall/0000-0002-9352-1408; Moon, Randall T/0000-0002-9352-1408				Adler PN, 2000, MECH DEVELOP, V96, P197, DOI 10.1016/S0925-4773(00)00392-0; Axelrod JD, 2001, GENE DEV, V15, P1182; Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Boutros M, 1999, MECH DEVELOP, V83, P27, DOI 10.1016/S0925-4773(99)00046-5; Fanto M, 1998, MECH DEVELOP, V74, P51, DOI 10.1016/S0925-4773(98)00063-X; GUBB D, 1982, J EMBRYOL EXP MORPH, V68, P37; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; Heisenberg CP, 2000, NATURE, V405, P76, DOI 10.1038/35011068; Henry CA, 2000, CURR BIOL, V10, P1063, DOI 10.1016/S0960-9822(00)00677-1; Itoh K, 1997, MECH DEVELOP, V61, P113, DOI 10.1016/S0925-4773(96)00627-2; KELLER RE, 1985, J EMBRYOL EXP MORPH, V89, P185; Kibar Z, 2001, NAT GENET, V28, P251, DOI 10.1038/90081; Kieser A, 1997, EMBO J, V16, P6478, DOI 10.1093/emboj/16.21.6478; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Krasnow RE, 1995, DEVELOPMENT, V121, P4095; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; Kuhl M, 2000, J BIOL CHEM, V275, P12701, DOI 10.1074/jbc.275.17.12701; Lekven AC, 2001, DEV CELL, V1, P103, DOI 10.1016/S1534-5807(01)00007-7; Li L, 1999, J BIOL CHEM, V274, P129, DOI 10.1074/jbc.274.1.129; MCGREW LL, 1995, DEV BIOL, V172, P337, DOI 10.1006/dbio.1995.0027; McGrew LL, 1997, MECH DEVELOP, V69, P105, DOI 10.1016/S0925-4773(97)00160-3; McKay RM, 2001, DEV BIOL, V235, P388, DOI 10.1006/dbio.2001.0308; Miller JR, 1999, J CELL BIOL, V146, P427, DOI 10.1083/jcb.146.2.427; MOON RT, 1993, DEVELOPMENT, V119, P97; Moriguchi T, 1999, J BIOL CHEM, V274, P30957, DOI 10.1074/jbc.274.43.30957; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; Noselli S, 1999, CURR OPIN GENET DEV, V9, P466, DOI 10.1016/S0959-437X(99)80071-9; PARK WJ, 1994, MECH DEVELOP, V45, P127, DOI 10.1016/0925-4773(94)90026-4; Rousset R, 2001, GENE DEV, V15, P658, DOI 10.1101/gad.869201; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; Sepich DS, 2000, GENESIS, V27, P159, DOI 10.1002/1526-968X(200008)27:4<159::AID-GENE50>3.0.CO;2-T; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; Slusarski DC, 1997, DEV BIOL, V182, P114, DOI 10.1006/dbio.1996.8463; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; Tada M, 2000, DEVELOPMENT, V127, P2227; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Taylor J, 1998, GENETICS, V150, P199; Tomlinson A, 1997, DEVELOPMENT, V124, P4515; VINSON CR, 1989, NATURE, V338, P263, DOI 10.1038/338263a0; Wallingford JB, 2000, NATURE, V405, P81, DOI 10.1038/35011077; Weber U, 2000, DEVELOPMENT, V127, P3619; Wharton KA, 2001, DEV BIOL, V234, P93, DOI 10.1006/dbio.2001.0238; Wolff T, 1998, DEVELOPMENT, V125, P1149; WONG LL, 1993, J CELL BIOL, V123, P209, DOI 10.1083/jcb.123.1.209; Yan D, 2001, P NATL ACAD SCI USA, V98, P3802, DOI 10.1073/pnas.071041898; Zeng WL, 2000, NATURE, V403, P789, DOI 10.1038/35001615	48	298	309	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JAN	2002	4	1					20	25		10.1038/ncb716	http://dx.doi.org/10.1038/ncb716			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	513MC	11780127				2022-12-25	WOS:000173381500011
J	Patnaik, R; Louie, S; Gavrilovic, V; Perry, K; Stemmer, WPC; Ryan, CM; del Cardayre, S				Patnaik, R; Louie, S; Gavrilovic, V; Perry, K; Stemmer, WPC; Ryan, CM; del Cardayre, S			Genome shuffling of Lactobacillus for improved acid tolerance	NATURE BIOTECHNOLOGY			English	Article							DIRECTED EVOLUTION; ESCHERICHIA-COLI; CORYNEBACTERIUM-GLUTAMICUM; LACTIC-ACID; ACETIC-ACID; FERMENTATION; PATHWAY; STRESS; HYPERPRODUCTION; TRYPTOPHAN	Fermentation-based bioprocesses rely extensively on strain improvement for commercialization. Whole-cell biocatalysts are commonly limited by low tolerance of extreme process conditions such as temperature, pH, and solute concentration. Rational approaches to improving such complex phenotypes lack good models and are especially difficult to implement without genetic tools. Here we describe the use of genome shuffling to improve the acid tolerance of a poorly characterized industrial strain of Lactobacillus. We used classical strain-improvement methods to generate populations with subtle improvements in pH tolerance, and then shuffled these populations by recursive pool-wise protoplast fusion. We identified new shuffled lactobacilli that grow at substantially lower pH than does the wild-type strain on both liquid and solid media. In addition, we identified shuffled strains that produced threefold more lactic acid than the wild type at pH 4.0. Genome shuffling seems broadly useful for the rapid evolution of tolerance and other complex phenotypes in industrial microorganisms.	Codexis, Redwood City, CA 94063 USA; Cargill Dow LLC, Minnetonka, MN 55345 USA	Cargill	del Cardayre, S (corresponding author), Codexis, 515 Galveston Dr, Redwood City, CA 94063 USA.	stephen.delcardayre@maxygen.com						Aristidou A, 2000, CURR OPIN BIOTECH, V11, P187, DOI 10.1016/S0958-1669(00)00085-9; Arnold CN, 2001, J BACTERIOL, V183, P2178, DOI 10.1128/JB.183.7.2178-2186.2001; Arnold FH, 1999, CURR OPIN CHEM BIOL, V3, P54, DOI 10.1016/S1367-5931(99)80010-6; Audia JP, 2001, INT J MED MICROBIOL, V291, P97, DOI 10.1078/1438-4221-00106; Benninga H, 1990, HIST LACTIC ACID MAK; Braunegg G, 1998, J BIOTECHNOL, V65, P127, DOI 10.1016/S0168-1656(98)00126-6; Choi J, 2000, APPL MICROBIOL BIOT, V53, P646, DOI 10.1007/s002530000326; CHONTANI G, 2000, BIOCHIM BIOPHYS ACTA, V1543, P434; COCCONCELLI PS, 1986, FEMS MICROBIOL LETT, V35, P211, DOI 10.1111/j.1574-6968.1986.tb01529.x; Crameri A, 1998, NATURE, V391, P288, DOI 10.1038/34663; De Angelis M, 2001, MICROBIOL-SGM, V147, P1863, DOI 10.1099/00221287-147-7-1863; DELCARDAYRE SB, 2002, Patent No. 0204629; Donnelly MI, 1998, APPL BIOCHEM BIOTECH, V70-2, P187, DOI 10.1007/BF02920135; Gong C S, 1999, Adv Biochem Eng Biotechnol, V65, P207; Gonzalez-Vara A, 2000, BIOTECHNOL BIOENG, V67, P147, DOI [10.1002/(SICI)1097-0290(20000120)67:2&lt;147::AID-BIT4&gt;3.0.CO;2-F, 10.1002/(SICI)1097-0290(20000120)67:2<147::AID-BIT4>3.3.CO;2-6]; Hashimoto S, 1999, CURR OPIN BIOTECH, V10, P604, DOI 10.1016/S0958-1669(99)00041-5; Ho N W, 1999, Adv Biochem Eng Biotechnol, V65, P163; Ho NWY, 1998, APPL ENVIRON MICROB, V64, P1852; HONGO M, 1986, APPL ENVIRON MICROB, V32, P227; Ikeda M, 1999, APPL ENVIRON MICROB, V65, P2497; Jaeger KE, 2001, APPL MICROBIOL BIOT, V55, P519, DOI 10.1007/s002530100643; KATSUMATA R, 1993, BIO-TECHNOL, V11, P921, DOI 10.1038/nbt0893-921; KAUTOLA H, 1990, J BIOTECHNOL, V13, P315, DOI 10.1016/0168-1656(90)90079-Q; Larsson S, 2000, APPL BIOCHEM BIOTECH, V84-6, P617, DOI 10.1385/ABAB:84-86:1-9:617; Lawford HG, 1998, APPL BIOCHEM BIOTECH, V70-2, P161, DOI 10.1007/BF02920133; Lee SY, 2001, ADV BIOCHEM ENG BIOT, V71, P183; Martinez A, 2000, BIOTECHNOL BIOENG, V69, P526, DOI [10.1002/1097-0290(20000905)69:5<526::AID-BIT7>3.0.CO;2-E, 10.1002/1097-0290(20000905)69:5&lt;526::AID-BIT7&gt;3.0.CO;2-E]; MCLAUREN J, 1999, DOEGO10099706, P1; MILLER JH, 1972, EXPT MOL GENETICS, P125; MORELLI L, 1987, PLASMID, V17, P73, DOI 10.1016/0147-619X(87)90013-8; Ness JE, 2001, ADV PROTEIN CHEM, V55, P261, DOI 10.1016/S0065-3233(01)55006-8; OSullivan E, 1997, APPL ENVIRON MICROB, V63, P4210, DOI 10.1128/AEM.63.11.4210-4215.1997; Park JH, 2000, BIOTECHNOL PROGR, V16, P564, DOI 10.1021/bp0000611; Perkins JB, 1999, J IND MICROBIOL BIOT, V22, P8, DOI 10.1038/sj.jim.2900587; Porro D, 1999, APPL ENVIRON MICROB, V65, P4211; Rallu F, 2000, MOL MICROBIOL, V35, P517, DOI 10.1046/j.1365-2958.2000.01711.x; Schmidt-Dannert C, 2000, NAT BIOTECHNOL, V18, P750, DOI 10.1038/77319; Schulze B, 1999, CURR OPIN BIOTECH, V10, P609, DOI 10.1016/S0958-1669(99)00042-7; Soong NW, 2000, NAT GENET, V25, P436, DOI 10.1038/78132; Varadarajan S, 1999, BIOTECHNOL PROGR, V15, P845, DOI 10.1021/bp9900965; Wackett LP, 1998, ANN NY ACAD SCI, V864, P142, DOI 10.1111/j.1749-6632.1998.tb10297.x; Zaldivar J, 2000, BIOTECHNOL BIOENG, V68, P524, DOI 10.1002/(SICI)1097-0290(20000605)68:5<524::AID-BIT6>3.0.CO;2-T; Zhang YX, 2002, NATURE, V415, P644, DOI 10.1038/415644a	43	281	371	4	92	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2002	20	7					707	712		10.1038/nbt0702-707	http://dx.doi.org/10.1038/nbt0702-707			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	567QC	12089556				2022-12-25	WOS:000176494800025
J	Platani, M; Goldberg, I; Lamond, AI; Swedlow, JR				Platani, M; Goldberg, I; Lamond, AI; Swedlow, JR			Cajal Body dynamics and association with chromatin are ATP-dependent	NATURE CELL BIOLOGY			English	Article							SMALL NUCLEAR-RNA; SINGLE-PARTICLE TRACKING; COILED BODIES; ANOMALOUS DIFFUSION; HUMAN-CELLS; CHROMOSOME DYNAMICS; GENE-EXPRESSION; LIVING CELLS; SNRNA GENES; MONTE-CARLO	Cajal bodies (CBs) are nuclear organelles that contain factors required for splicing, ribosome biogenesis and transcription. Our previous analysis in living cells showed that CBs are dynamic structures. Here, we show that CB mobility is described by anomalous diffusion and that bodies alternate between association with chromatin and diffusion within the interchromatin space. CB mobility increases after ATP depletion and inhibition of transcription, suggesting that the association of CB and chromatin requires ATP and active transcription. This behaviour is fundamentally different from the ATP-dependent mobility observed for chromatin and suggests that a novel mechanism governs CB, and possibly other, nuclear body dynamics.	Univ Dundee, Inst Med Sci, Sch Life Sci, Div Gene Regulat & Express,Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland; MIT, Dept Biol, Cambridge, MA 02139 USA	University of Dundee; Massachusetts Institute of Technology (MIT)	Swedlow, JR (corresponding author), Univ Dundee, Inst Med Sci, Sch Life Sci, Div Gene Regulat & Express,Wellcome Trust Bioctr, Dow St, Dundee DD1 5EH, Scotland.		Goldberg, Ilya/H-5307-2011	Goldberg, Ilya/0000-0001-8514-6110; Platani, Melpomeni/0000-0001-6408-4774; Swedlow, Jason/0000-0002-2198-1958; Lamond, Angus/0000-0001-6204-6045	NCI NIH HHS [CA47135] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047135] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [ZICAG000671, Z01AG000671] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; ANDRADE LEC, 1993, P NATL ACAD SCI USA, V90, P1947, DOI 10.1073/pnas.90.5.1947; Bauer DW, 1997, MOL BIOL CELL, V8, P73, DOI 10.1091/mbc.8.1.73; Bornfleth H, 1999, BIOPHYS J, V77, P2871, DOI 10.1016/S0006-3495(99)77119-5; Boudonck K, 1999, MOL BIOL CELL, V10, P2297, DOI 10.1091/mbc.10.7.2297; BRASCH K, 1992, EXP CELL RES, V202, P211, DOI 10.1016/0014-4827(92)90068-J; Brown KE, 1999, MOL CELL, V3, P207, DOI 10.1016/S1097-2765(00)80311-1; CALLAN HG, 1991, CHROMOSOMA, V101, P245, DOI 10.1007/BF00365156; Carvalho T, 1999, J CELL BIOL, V147, P715, DOI 10.1083/jcb.147.4.715; Croft JA, 1999, J CELL BIOL, V145, P1119, DOI 10.1083/jcb.145.6.1119; Cullen BR, 2000, MOL CELL BIOL, V20, P4181, DOI 10.1128/MCB.20.12.4181-4187.2000; Eissenberg JC, 2000, CURR OPIN GENET DEV, V10, P204, DOI 10.1016/S0959-437X(00)00058-7; Feder TJ, 1996, BIOPHYS J, V70, P2767, DOI 10.1016/S0006-3495(96)79846-6; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Francastel C, 1999, CELL, V99, P259, DOI 10.1016/S0092-8674(00)81657-8; FREY MR, 1995, P NATL ACAD SCI USA, V92, P5915, DOI 10.1073/pnas.92.13.5915; Frey MR, 1999, CURR BIOL, V9, P126, DOI 10.1016/S0960-9822(99)80066-9; Frey MR, 2001, J CELL BIOL, V154, P499, DOI 10.1083/jcb.200105084; Gall JG, 2000, ANNU REV CELL DEV BI, V16, P273, DOI 10.1146/annurev.cellbio.16.1.273; GALL JG, 1995, DEV GENET, V16, P25, DOI 10.1002/dvg.1020160107; Gao LI, 1997, NUCLEIC ACIDS RES, V25, P4740, DOI 10.1093/nar/25.23.4740; Heun P, 2001, SCIENCE, V294, P2181, DOI 10.1126/science.1065366; Jacobs EY, 1999, MOL BIOL CELL, V10, P1653, DOI 10.1091/mbc.10.5.1653; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; Lundgren M, 2000, CELL, V103, P733, DOI 10.1016/S0092-8674(00)00177-X; Marshall WF, 1996, MOL BIOL CELL, V7, P825, DOI 10.1091/mbc.7.5.825; Marshall WF, 1997, CURR BIOL, V7, P930, DOI 10.1016/S0960-9822(06)00412-X; Matera AG, 1999, TRENDS CELL BIOL, V9, P302, DOI 10.1016/S0962-8924(99)01606-2; Misteli T, 2001, SCIENCE, V291, P843, DOI 10.1126/science.291.5505.843; Morton WM, 2000, NAT CELL BIOL, V2, P376, DOI 10.1038/35014075; Muratani M, 2002, NAT CELL BIOL, V4, P106, DOI 10.1038/ncb740; Pederson T, 2001, CELL, V104, P635, DOI 10.1016/S0092-8674(02)01455-1; Platani M, 2000, J CELL BIOL, V151, P1561, DOI 10.1083/jcb.151.7.1561; Qian H, 1991, BIOPHYS J, V60, P910, DOI 10.1016/S0006-3495(91)82125-7; Ramon y Cajal S., 1903, TRAD LAB INVEST BIOL, V2, P129; Saxton MJ, 1996, BIOPHYS J, V70, P1250, DOI 10.1016/S0006-3495(96)79682-0; Saxton MJ, 1997, BIOPHYS J, V72, P1744, DOI 10.1016/S0006-3495(97)78820-9; SAXTON MJ, 1994, BIOPHYS J, V66, P394, DOI 10.1016/S0006-3495(94)80789-1; SCHARDIN M, 1985, HUM GENET, V71, P281, DOI 10.1007/BF00388452; SHEETZ MP, 1989, NATURE, V340, P284, DOI 10.1038/340284a0; Shopland LS, 2001, MOL BIOL CELL, V12, P565, DOI 10.1091/mbc.12.3.565; Simson R, 1998, BIOPHYS J, V74, P297, DOI 10.1016/S0006-3495(98)77787-2; Sleeman JE, 1999, CURR BIOL, V9, P1065, DOI 10.1016/S0960-9822(99)80475-8; Smith KP, 1995, J CELL BIOCHEM, V59, P473, DOI 10.1002/jcb.240590408; Smith PR, 1999, BIOPHYS J, V76, P3331, DOI 10.1016/S0006-3495(99)77486-2; Snaar S, 2000, J CELL BIOL, V151, P653, DOI 10.1083/jcb.151.3.653; Spector DL, 2001, J CELL SCI, V114, P2891; SWEDLOW JR, 2001, GENOME BIOL     0309; Tucker KE, 2001, J CELL BIOL, V154, P293, DOI 10.1083/jcb.200104083; Tumbar T, 2001, NAT CELL BIOL, V3, P134, DOI 10.1038/35055033; Vazquez J, 2001, CURR BIOL, V11, P1227, DOI 10.1016/S0960-9822(01)00390-6; WU CHH, 1993, P NATL ACAD SCI USA, V90, P6257, DOI 10.1073/pnas.90.13.6257	52	223	229	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	2002	4	7					502	508		10.1038/ncb809	http://dx.doi.org/10.1038/ncb809			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	568UL	12068306				2022-12-25	WOS:000176562900014
J	Wu, LF; Hughes, TR; Davierwala, AP; Robinson, MD; Stoughton, R; Altschuler, SJ				Wu, LF; Hughes, TR; Davierwala, AP; Robinson, MD; Stoughton, R; Altschuler, SJ			Large-scale prediction of Saccharomyces cerevisiae gene function using overlapping transcriptional clusters	NATURE GENETICS			English	Article							CELL NUCLEAR ANTIGEN; EXPRESSION PROFILES; RIBOSOME BIOGENESIS; PROTEIN FUNCTION; GENOME; YEAST; SEQUENCE; DATABASE; IDENTIFICATION; REPLICATION	Genome sequencing has led to the discovery of tens of thousands of potential new genes. Six years after the sequencing of the well-studied yeast Saccharomyces cerevisiae and the discovery that its genome encodes 6,000 predicted proteins, more than 2,000 have not yet been characterized experimentally, and determining their functions seems far from a trivial task. One crucial constraint is the generation of useful hypotheses about protein function. Using a new approach to interpret microarray data, we assign likely cellular functions with confidence values to these new yeast proteins. We perform extensive genome-wide validations of our predictions and offer visualization methods for exploration of the large numbers of functional predictions. We identify potential new members of many existing functional categories including 285 candidate proteins involved in transcription, processing and transport of non-coding RNA molecules. We present experimental validation confirming the involvement of several of these proteins in ribosomal RNA processing. Our methodology can be applied to a variety of genomics data types and organisms.	Rosetta Inpharmat, Kirkland, WA USA; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON, Canada	Merck & Company; University of Toronto	Altschuler, SJ (corresponding author), Harvard Univ, Bauer Ctr Genom Res, Cambridge, MA 02138 USA.	saltschuler@cgr.harvard.edu	Robinson, Mark D/A-6432-2015; Robinson, Mark D./O-2254-2019	Robinson, Mark D/0000-0002-3048-5518; Robinson, Mark D./0000-0002-3048-5518				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Ball CA, 2000, NUCLEIC ACIDS RES, V28, P77, DOI 10.1093/nar/28.1.77; Bassler J, 2001, MOL CELL, V8, P517, DOI 10.1016/S1097-2765(01)00342-2; Bork P, 1998, J MOL BIOL, V283, P707, DOI 10.1006/jmbi.1998.2144; Brown MPS, 2000, P NATL ACAD SCI USA, V97, P262, DOI 10.1073/pnas.97.1.262; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Chen C, 1999, MOL CELL BIOL, V19, P7801; CHENG Y, 1995, SCIENCE, V267, P1807, DOI 10.1126/science.7534442; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; Gelperin D, 2001, RNA, V7, P1268, DOI 10.1017/S1355838201013073; GOFFEAU A, 1996, SCIENCE, V274, P563, DOI DOI 10.1126/SCIENCE.274.5287.546; Goldstein DR, 2002, STAT SINICA, V12, P219; Hartigan J., 1975, CLUSTERING ALGORITHM; Hishigaki H, 2001, YEAST, V18, P523, DOI 10.1002/yea.706; Hodges PE, 1999, NUCLEIC ACIDS RES, V27, P69, DOI 10.1093/nar/27.1.69; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Jeffery CJ, 1999, TRENDS BIOCHEM SCI, V24, P8, DOI 10.1016/S0968-0004(98)01335-8; Jenssen TK, 2001, NAT GENET, V28, P21, DOI 10.1038/88213; Kim SK, 2001, SCIENCE, V293, P2087, DOI 10.1126/science.1061603; King RD, 2000, YEAST, V17, P283, DOI 10.1002/1097-0061(200012)17:4<283::AID-YEA52>3.0.CO;2-F; Kressler D, 1999, MOL CELL BIOL, V19, P7897; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Marcotte EM, 1999, NATURE, V402, P83, DOI 10.1038/47048; Mewes HW, 1997, NUCLEIC ACIDS RES, V25, P28, DOI 10.1093/nar/25.1.28; Miki R, 2001, P NATL ACAD SCI USA, V98, P2199, DOI 10.1073/pnas.041605498; Niehrs C, 1999, NATURE, V402, P483, DOI 10.1038/990025; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; Prosperi E, 1997, Prog Cell Cycle Res, V3, P193; Roberts CJ, 2000, SCIENCE, V287, P873, DOI 10.1126/science.287.5454.873; Shatkay H, 2000, Proc Int Conf Intell Syst Mol Biol, V8, P317; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Spingola M, 1999, RNA, V5, P221, DOI 10.1017/S1355838299981682; Tavazoie S, 1999, NAT GENET, V22, P281, DOI 10.1038/10343; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wen XL, 1998, P NATL ACAD SCI USA, V95, P334, DOI 10.1073/pnas.95.1.334; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; 1909, SCIENCE, V282, P2012	41	255	267	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2002	31	3					255	265		10.1038/ng906	http://dx.doi.org/10.1038/ng906			11	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	567PW	12089522				2022-12-25	WOS:000176494100012
J	Golling, G; Amsterdam, A; Sun, ZX; Antonelli, M; Maldonado, E; Chen, WB; Burgess, S; Haldi, M; Artzt, K; Farrington, S; Lin, SY; Nissen, RM; Hopkins, N				Golling, G; Amsterdam, A; Sun, ZX; Antonelli, M; Maldonado, E; Chen, WB; Burgess, S; Haldi, M; Artzt, K; Farrington, S; Lin, SY; Nissen, RM; Hopkins, N			Insertional mutagenesis in zebrafish rapidly identifies genes essential for early vertebrate development	NATURE GENETICS			English	Article							MUTATIONS; SPECIFICATION; MELANOSOMES; PESCADILLO; HINDBRAIN; ORGANIZER; MUTANTS; SEARCH; SCREEN; EMBRYO	To rapidly identify genes required for early vertebrate development, we are carrying out a large-scale, insertional mutagenesis screen in zebrafish, using mouse retroviral vectors as the mutagen. We will obtain mutations in 450 to 500 different genes-roughly 20% of the genes that can be mutated to produce a visible embryonic phenotype in this species-and will clone the majority of the mutated alleles. So far, we have isolated more than 500 insertional mutants. Here we describe the first 75 insertional mutants for which the disrupted genes have been identified. In agreement with chemical mutagenesis screens, approximately one-third of the mutants have developmental defects that affect primarily one or a small number of organs, body shape or swimming behavior; the rest of the mutants show more widespread or pleiotropic abnormalities. Many of the genes we identified have not been previously assigned a biological role in vivo. Roughly 20% of the mutants result from lesions in genes for which the biochemical and cellular function of the proteins they encode cannot be deduced with confidence, if at all, from their predicted amino-acid sequences. All of the genes have either orthologs or clearly related genes in human. These results provide an unbiased view of the genetic construction kit for a vertebrate embryo, reveal the diversity of genes required for vertebrate development and suggest that hundreds of genes of unknown biochemical function essential for vertebrate development have yet to be identified.	MIT, Ctr Canc Res, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Univ Texas, Inst Cellular & Mol Biol, Dept Microbiol, Austin, TX USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); University of Texas System; University of Texas Austin	Hopkins, N (corresponding author), MIT, Ctr Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.		Maldonado, Ernesto/I-1032-2016; Maldonado, Ernesto/ABG-9116-2020; Chen, Wenbiao/ABG-1276-2020	Maldonado, Ernesto/0000-0002-9627-967X; Chen, Wenbiao/0000-0002-0750-8275; Burgess, Shawn/0000-0003-1147-0596; Nissen, Robert/0000-0002-0591-1167	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000183, ZIAHG000183] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Allende ML, 1996, GENE DEV, V10, P3141, DOI 10.1101/gad.10.24.3141; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Amsterdam A, 1999, GENE DEV, V13, P2713, DOI 10.1101/gad.13.20.2713; Becker TS, 1998, DEVELOPMENT, V125, P4369; Belting HG, 2001, DEVELOPMENT, V128, P4165; Bhatnagar V, 1998, MOL CELL BIOCHEM, V189, P99, DOI 10.1023/A:1006876411202; Burgess S, 2002, DEVELOPMENT, V129, P905; Charpentier AH, 2000, CANCER RES, V60, P5977; Chen WB, 2001, DEVELOPMENT, V128, P2385; DIMENT S, 1995, J BIOL CHEM, V270, P4213, DOI 10.1074/jbc.270.9.4213; Driever W, 1996, DEVELOPMENT, V123, P37; Feldman B, 1998, NATURE, V395, P181, DOI 10.1038/26013; Gaiano N, 1996, NATURE, V383, P829, DOI 10.1038/383829a0; Haffter P, 1996, DEVELOPMENT, V123, P1; Horikawa Y, 1997, NAT GENET, V17, P384, DOI 10.1038/ng1297-384; Iwasaki N, 1998, DIABETES CARE, V21, P2144, DOI 10.2337/diacare.21.12.2144; Jordan S, 2000, PIGM CELL RES, V13, P70, DOI 10.1034/j.1600-0749.2000.130204.x; Kane DA, 1996, DEVELOPMENT, V123, P57; Kinoshita Y, 2001, J BIOL CHEM, V276, P6656, DOI 10.1074/jbc.M008536200; Lloyd V, 1998, TRENDS CELL BIOL, V8, P257, DOI 10.1016/S0962-8924(98)01270-7; MULLINS MC, 1994, CURR BIOL, V4, P189, DOI 10.1016/S0960-9822(00)00048-8; Neuhauss SCF, 1996, DEVELOPMENT, V123, P357; Pearson H, 2001, NATURE, V413, P244, DOI 10.1038/35095116; Rauch GJ, 1997, COLD SPRING HARB SYM, V62, P227, DOI 10.1101/SQB.1997.062.01.028; Schilling TF, 1996, DEVELOPMENT, V123, P329; Stainier DYR, 1996, DEVELOPMENT, V123, P285; Sun ZX, 2001, GENE DEV, V15, P3217, DOI 10.1101/gad946701; Topczewski J, 2001, DEV CELL, V1, P251, DOI 10.1016/S1534-5807(01)00005-3; Varga ZM, 2001, DEVELOPMENT, V128, P3497; Walsh EC, 2001, SCIENCE, V293, P1670, DOI 10.1126/science.293.5535.1670	30	426	466	0	23	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2002	31	2					135	140		10.1038/ng896	http://dx.doi.org/10.1038/ng896			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	557HR	12006978				2022-12-25	WOS:000175903500008
J	Riechmann, V; Gutierrez, GJ; Filardo, P; Nebreda, AR; Ephrussi, A				Riechmann, V; Gutierrez, GJ; Filardo, P; Nebreda, AR; Ephrussi, A			Par-1 regulates stability of the posterior determinant Oskar by phosphorylation	NATURE CELL BIOLOGY			English	Article							C-ELEGANS EMBRYOS; MESSENGER-RNA; CELL-FORMATION; DROSOPHILA; PROTEIN; LOCALIZATION; POLE; OOCYTE; VASA; TRANSLATION	Par-1 kinase is critical for polarization of the Drosophila melanogaster oocyte and the one-cell Caenorhabditis elegans embryo. Although Par-1 localizes specifically to the posterior pole in both cells, neither its targets nor its function at the posterior pole have been elucidated. Here we show that Drosophila Par-1 phosphorylates the posterior determinant Oskar (Osk) and demonstrate genetically that Par-1 is required for accumulation of Osk protein. We show in cell-free extracts that Osk protein is intrinsically unstable and that it is stabilized after phosphorylation by Par-1. Our data indicate that posteriorly localized Par-1 regulates posterior patterning by stabilizing Osk.	European Mol Biol Lab, D-69012 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Riechmann, V (corresponding author), European Mol Biol Lab, Meyerhofstr 1,Postfach 10-2209, D-69012 Heidelberg, Germany.	ephrussi@embl-heidelberg.de	Gutierrez, Gustavo/B-6771-2013; Ephrussi, Anne/ABD-4393-2021; Gutierrez, Gustavo/AAO-9957-2021; Ephrussi, Anne/AAG-4075-2020; Nebreda, Angel Rodriguez/R-9594-2019	Gutierrez, Gustavo/0000-0003-4133-5002; Ephrussi, Anne/0000-0002-5061-4620; Gutierrez, Gustavo/0000-0001-8652-972X; 				Bowerman B, 1997, DEVELOPMENT, V124, P3815; Boyd L, 1996, DEVELOPMENT, V122, P3075; Breitwieser W, 1996, GENE DEV, V10, P2179, DOI 10.1101/gad.10.17.2179; Cox DN, 2001, CURR BIOL, V11, P75, DOI 10.1016/S0960-9822(01)00027-6; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Gunkel N, 1998, GENE DEV, V12, P1652, DOI 10.1101/gad.12.11.1652; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; HAY B, 1990, DEVELOPMENT, V109, P425; Huynh JR, 2001, DEVELOPMENT, V128, P1201; Kemphues K, 2000, CELL, V101, P345, DOI 10.1016/S0092-8674(00)80844-2; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KIMHA J, 1995, CELL, V81, P403, DOI 10.1016/0092-8674(95)90393-3; Lasko P, 1999, FASEB J, V13, P421, DOI 10.1096/fasebj.13.3.421; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; MARKUSSEN FH, 1995, DEVELOPMENT, V121, P3723; Markussen FH, 1997, COLD SPRING HARB SYM, V62, P13; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; RONGO C, 1995, DEVELOPMENT, V121, P2737; Rorth P, 1998, MECH DEVELOP, V78, P113, DOI 10.1016/S0925-4773(98)00157-9; Shulman JM, 2000, CELL, V101, P377, DOI 10.1016/S0092-8674(00)80848-X; SMITH JL, 1992, CELL, V70, P849, DOI 10.1016/0092-8674(92)90318-7; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; Tomancak P, 2000, NAT CELL BIOL, V2, P458, DOI 10.1038/35017101; Webster PJ, 1997, GENE DEV, V11, P2510, DOI 10.1101/gad.11.19.2510	28	58	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2002	4	5					337	342		10.1038/ncb782	http://dx.doi.org/10.1038/ncb782			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	547GR	11951092				2022-12-25	WOS:000175325100014
J	Saha, S; Sparks, AB; Rago, C; Akmaev, V; Wang, CJ; Vogelstein, B; Kinzler, KW; Velculescu, VE				Saha, S; Sparks, AB; Rago, C; Akmaev, V; Wang, CJ; Vogelstein, B; Kinzler, KW; Velculescu, VE			Using the transcriptome to annotate the genome	NATURE BIOTECHNOLOGY			English	Article							HUMAN-CHROMOSOME 22; RESTRICTION-ENDONUCLEASE; GENE-EXPRESSION; SEQUENCE; DNA; PREDICTION; MMEI	A remaining challenge for the human genome project involves the identification and annotation of expressed genes. The public and private sequencing efforts have identified 15,000 sequences that meet stringent criteria for genes, such as correspondence with known genes from humans or other species, and have made another similar to10,000-20,000 gene predictions of lower confidence, supported by various types of in silico evidence, including homology studies, domain searches, and ab initio gene predictions(1,2). These computational methods have limitations, both because they are unable to identify a significant fraction of genes and exons and because they are unable to provide definitive evidence about whether a hypothetical gene is actually expressed(3,4). As the in silico approaches identified a smaller number of genes than anticipated(5-9), we wondered whether high-throughput experimental analyses could be used to provide evidence for the expression of hypothetical genes and to reveal previously undiscovered genes. We describe here the development of such a method-called long serial analysis of gene expression (LongSAGE), an adaption of the original SAGE approach(10)-that can be used to rapidly identify novel genes and exons.	Johns Hopkins Med Inst, Howard Hughes Med Inst, Baltimore, MD 21231 USA; Johns Hopkins Med Inst, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA; Johns Hopkins Med Inst, Program Cellular & Mol Med, Baltimore, MD 21231 USA; Genzyme Corp, Mol Oncol, Framingham, MA 01701 USA	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Sanofi-Aventis; Genzyme Corporation	Kinzler, KW (corresponding author), Johns Hopkins Med Inst, Howard Hughes Med Inst, Baltimore, MD 21231 USA.	kinzlke@jhmi.edu; velculescu@jhmi.edu	Velculescu, Victor/ABF-4846-2020	Velculescu, Victor/0000-0003-1195-438X	NCI NIH HHS [CA57345] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA057345, R01CA057345] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS MD, 1995, NATURE, V377, P3; BOYD AC, 1986, NUCLEIC ACIDS RES, V14, P5255, DOI 10.1093/nar/14.13.5255; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Caron H, 2001, SCIENCE, V291, P1289, DOI 10.1126/science.1056794; de Souza SJ, 2000, P NATL ACAD SCI USA, V97, P12690, DOI 10.1073/pnas.97.23.12690; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; FIELDS C, 1994, NAT GENET, V7, P345, DOI 10.1038/ng0794-345; Guigo R, 2000, GENOME RES, V10, P1631, DOI 10.1101/gr.122800; Lal A, 1999, CANCER RES, V59, P5403; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Liang F, 2000, NAT GENET, V25, P239, DOI 10.1038/76126; Okubo K, 1994, DNA Res, V1, P37, DOI 10.1093/dnares/1.1.37; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Shoemaker DD, 2001, NATURE, V409, P922, DOI 10.1038/35057141; TUCHOLSKI J, 1995, GENE, V157, P87, DOI 10.1016/0378-1119(94)00787-S; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Velculescu VE, 1999, NAT GENET, V23, P387, DOI 10.1038/70487; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wheelan SJ, 1998, GENOME RES, V8, P168, DOI 10.1101/gr.8.3.168	19	445	506	0	32	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2002	20	5					508	512		10.1038/nbt0502-508	http://dx.doi.org/10.1038/nbt0502-508			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	548AE	11981567				2022-12-25	WOS:000175364800036
J	Kleymann, G; Fischer, R; Betz, UAK; Hendrix, M; Bender, W; Schneider, U; Handke, G; Eckenberg, P; Hewlett, G; Pevzner, V; Baumeister, J; Weber, O; Henninger, K; Keldenich, J; Jensen, A; Kolb, J; Bach, U; Popp, A; Maben, J; Frappa, I; Haebich, D; Lockhoff, O; Rubsamen-Waigmann, H				Kleymann, G; Fischer, R; Betz, UAK; Hendrix, M; Bender, W; Schneider, U; Handke, G; Eckenberg, P; Hewlett, G; Pevzner, V; Baumeister, J; Weber, O; Henninger, K; Keldenich, J; Jensen, A; Kolb, J; Bach, U; Popp, A; Maben, J; Frappa, I; Haebich, D; Lockhoff, O; Rubsamen-Waigmann, H			New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease	NATURE MEDICINE			English	Article							VIRUS; INFECTIONS; EFFICACY; MODEL; MICE	The vast majority of the world population is infected with at least one member of the human herpesvirus family. Herpes simplex virus (HSV) infections are the cause of cold sores and genital herpes as well as life-threatening or sight-impairing disease mainly in immunocompromized patients, pregnant women and newborns. Since the milestone development in the late 1970s of acyclovir ( Zovirax), a nucleosidic inhibitor of the herpes DNA polymerase, no new non-nucleosidic anti-herpes drugs have been introduced. Here we report new inhibitors of the HSV helicase-primase with potent in vitro anti-herpes activity, a novel mechanism of action, a low resistance rate and superior efficacy against HSV in animal models. BAY 57-1293 (N- [5- (aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide), a well-tolerated member of this class of compounds, significantly reduces time to healing, prevents rebound of disease after cessation of treatment and, most importantly, reduces frequency and severity of recurrent disease. Thus, this class of drugs has significant potential for the treatment of HSV disease in humans, including those resistant to current medications.	Bayer AG, Pharma Res, Wuppertal, Germany	Bayer AG	Kleymann, G (corresponding author), Bayer AG, Pharma Res, Wuppertal, Germany.	gerald.kleymann@freenet.de						Boehmer PE, 1997, ANNU REV BIOCHEM, V66, P347, DOI 10.1146/annurev.biochem.66.1.347; BROWN SM, 1998, HERPES SIMPLEX VIRUS; Collins P., 1991, REV MED VIROL, V1, P19; CRUMPACKER CS, 1979, ANTIMICROB AGENTS CH, V15, P642, DOI 10.1128/AAC.15.5.642; DECLERCQ E, 1976, J INFECT DIS, V133, pA226, DOI 10.1093/infdis/133.Supplement_2.A226; FIELD HJ, 1984, J GEN VIROL, V65, P707, DOI 10.1099/0022-1317-65-4-707; FISCHER R, 2000, Patent No. 1161423; FISCHER R, 2000, Patent No. 01498; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; Keating MR, 1999, MAYO CLIN PROC, V74, P1266, DOI 10.4065/74.12.1266; KERN ER, 1984, HERPESVIRUS, P617; OBRIEN JJ, 1989, DRUGS, V37, P233, DOI 10.2165/00003495-198937030-00002; Roizman B, 2001, FIELDS VIROLOGY, P2399; SCHAEFFER HJ, 1978, NATURE, V272, P583, DOI 10.1038/272583a0; SIMMONS A, 1984, J VIROL, V52, P816, DOI 10.1128/JVI.52.3.816-821.1984; Spector FC, 1998, J VIROL, V72, P6979, DOI 10.1128/JVI.72.9.6979-6987.1998; 2000, Patent No. 0053591	17	240	263	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2002	8	4					392	398		10.1038/nm0402-392	http://dx.doi.org/10.1038/nm0402-392			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	536ML	11927946				2022-12-25	WOS:000174704800032
J	Rajfur, Z; Roy, P; Otey, C; Romer, L; Jacobson, K				Rajfur, Z; Roy, P; Otey, C; Romer, L; Jacobson, K			Dissecting the link between stress fibres and focal adhesions by CALI with EGFP fusion proteins	NATURE CELL BIOLOGY			English	Article							ASSISTED LASER INACTIVATION; TYROSINE KINASE; ALPHA-ACTININ; CELL-ADHESION; BINDING; PHOSPHORYLATION; LOCALIZATION; ORGANIZATION; PP125(FAK); ACTIVATION	Chromophore-assisted laser inactivation (CALI) is a light-mediated technique used to selectively inactivate proteins within cells. Here, we demonstrate that GFP can be used as a CALI reagent to locally inactivate proteins in living cells. We show that focused laser irradiation of EGFP-alpha-actinin expressed in Swiss 3T3 fibroblasts results in the detachment of stress fibres from focal adhesions (FAs), whereas the integrity of FAs, as determined by interference reflection microscopy (IRM), is preserved. Moreover, consistent with a function for focal adhesion kinase (FAK) in FA signalling and not FA structure, laser irradiation of EGFP-FAK did not cause either visible FA damage or stress fibre detachment, although in vitro CALI of isolated EGFP-FAK decreased its kinase activity, but not its binding to paxillin. These data indicate that CALI of specific FA components may be used to precisely dissect the functional significance of individual proteins required for the maintenance of this cytoskeletal structure. In vitro CALI experiments also demonstrated a reduction of EGFP-alpha-actinin binding to the cytoplasmic domain of the beta(1) integrin subunit, but not to actin. Thus, alpha-actinin is essential for the binding of microfilaments to integrins in the FA. CALI-induced changes in alpha-actinin result in the breakage of that link and the subsequent retraction of the stress fibre.	Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27515 USA; Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC USA; Johns Hopkins Univ, Dept Anesthesiol, Baltimore, MD USA; Johns Hopkins Univ, Dept Cell Biol, Baltimore, MD USA; Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21218 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of North Carolina; University of North Carolina Chapel Hill	Jacobson, K (corresponding author), Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27515 USA.	frap@med.unc.edu	Jacobson, Kenneth Alan/A-1530-2009; Rajfur, Zenon/H-2506-2013	Jacobson, Kenneth Alan/0000-0001-8104-1493; Rajfur, Zenon/0000-0003-1265-6480; Roy, Partha/0000-0002-4946-8531	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P60DE013079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM064346, R01GM035325] Funding Source: NIH RePORTER; NIDCR NIH HHS [P60-DE13079] Funding Source: Medline; NIGMS NIH HHS [IK54GM64346, GM 35325] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CHANG HY, 1995, NATURE, V376, P686, DOI 10.1038/376686a0; Cooley MA, 2000, MOL BIOL CELL, V11, P3247, DOI 10.1091/mbc.11.9.3247; Edlund M, 2001, CELL MOTIL CYTOSKEL, V48, P190, DOI 10.1002/1097-0169(200103)48:3<190::AID-CM1008>3.0.CO;2-C; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Greenwood JA, 2000, J CELL BIOL, V150, P627, DOI 10.1083/jcb.150.3.627; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; ILLC D, 1995, NATURE, V377, P539; JAY DG, 1988, P NATL ACAD SCI USA, V85, P5454, DOI 10.1073/pnas.85.15.5454; KOPPEL DE, 1979, BIOPHYS J, V28, P281, DOI 10.1016/S0006-3495(79)85176-0; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; Lamb RF, 1997, CURR BIOL, V7, P682, DOI 10.1016/S0960-9822(06)00295-8; LAZARIDES E, 1975, CELL, V6, P289, DOI 10.1016/0092-8674(75)90180-4; LIAO JC, 1994, P NATL ACAD SCI USA, V91, P2659, DOI 10.1073/pnas.91.7.2659; OTEY CA, 1993, J BIOL CHEM, V268, P21193; Otey CA, 1996, INT REV CYTOL, V167, P161, DOI 10.1016/S0074-7696(08)61347-9; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; PAVALKO FM, 1991, BIOCHEM SOC T, V19, P1065, DOI 10.1042/bst0191065; PAVALKO FM, 1993, J IMMUNOL, V151, P3795; PAVALKO FM, 1991, J CELL BIOL, V114, P481, DOI 10.1083/jcb.114.3.481; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; ROMER LH, 1994, MOL BIOL CELL, V5, P349, DOI 10.1091/mbc.5.3.349; Sampath R, 1998, J BIOL CHEM, V273, P33588, DOI 10.1074/jbc.273.50.33588; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHMUCKER D, 1994, P NATL ACAD SCI USA, V91, P2664, DOI 10.1073/pnas.91.7.2664; Surrey T, 1998, P NATL ACAD SCI USA, V95, P4293, DOI 10.1073/pnas.95.8.4293; Wang FS, 1996, TRENDS CELL BIOL, V6, P442, DOI 10.1016/S0962-8924(96)40005-8	30	153	155	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	APR	2002	4	4					286	293		10.1038/ncb772	http://dx.doi.org/10.1038/ncb772			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	541PY	11912490				2022-12-25	WOS:000174994000016
J	Bai, RY; Koester, C; Ouyang, T; Hahn, SA; Hammerschmidt, M; Peschel, C; Duyster, J				Bai, RY; Koester, C; Ouyang, T; Hahn, SA; Hammerschmidt, M; Peschel, C; Duyster, J			SMIF, a Smad4-interacting protein that functions as a co-activator in TGF beta signalling	NATURE CELL BIOLOGY			English	Article							GROWTH-FACTOR-BETA; TUMOR-SUPPRESSOR; SMAD PROTEINS; DNA-BINDING; TRANSCRIPTIONAL COACTIVATOR; SIGNALING PATHWAYS; COLORECTAL-CANCER; GENE-EXPRESSION; SMAD4/DPC4; ZEBRAFISH	Proteins of the transforming growth factor beta (TGFbeta) superfamily regulate diverse cellular responses, including cell growth and differentiation. After TGFbeta stimulation, receptor-associated Smads are phosphorylated and form a complex with the common mediator Smad4. Here, we report the cloning of SMIF, a ubiquitously expressed, Smad4-interacting transcriptional co-activator. SMIF forms a TGFbeta/bone morphogenetic protein 4 (BMP4)-inducible complex with Smad4, but not with others Smads, and translocates to the nucleus in a TGFbeta/BMP4-inducible and Smad4-dependent manner. SMIF possesses strong intrinsic TGFbeta-inducible transcriptional activity, which is dependent on Smad4 in mammalian cells and requires p300/CBP. A point mutation in Smad4 abolished binding to SMIF and impaired its activity in transcriptional assays. Overexpression of wild-type SMIF enhanced expression of TGFbeta/BMP regulated genes, whereas a dominant-negative SMIF mutant suppressed expression. Furthermore, dominant-negative SMIF is able to block TGFbeta-induced growth inhibition. In a knockdown approach with morpholinoantisense oligonucleotides targeting zebrafish SMIF, severe but distinct phenotypic defects were observed in zebrafish embryos. Thus, we propose that SMIF is a crucial activator of TGFbeta signalling.	Tech Univ Munich, Dept Internal Med 3, Lab Leukemogenesis, D-81675 Munich, Germany; Max Planck Inst Immunbiol, Hans Spemann Lab, D-79108 Freiburg, Germany; Ruhr Univ Bochum, Dept Internal Med, D-44892 Bochum, Germany	Technical University of Munich; University of Munich; Max Planck Society; Ruhr University Bochum	Bai, RY (corresponding author), Tech Univ Munich, Dept Internal Med 3, Lab Leukemogenesis, Ismaningerstr 22, D-81675 Munich, Germany.		Hahn, Stephan A./AAV-6062-2021; Hahn, Stephan/E-3880-2010	Hahn, Stephan A./0000-0003-0855-9741; Hahn, Stephan/0000-0003-0855-9741				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bai RY, 1998, ONCOGENE, V17, P941, DOI 10.1038/sj.onc.1202024; BOYD FT, 1989, J BIOL CHEM, V264, P2272; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Davidson AJ, 2000, CURR TOP DEV BIOL, V50, P45, DOI 10.1016/S0070-2153(00)50003-9; de Caestecker MP, 2000, J BIOL CHEM, V275, P2115, DOI 10.1074/jbc.275.3.2115; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; Dunwoodie SL, 1998, MECH DEVELOP, V72, P27, DOI 10.1016/S0925-4773(98)00011-2; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; Hammerschmidt M, 1996, DEVELOPMENT, V123, P95; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Itoh S, 2000, NUCLEIC ACIDS RES, V28, P4291, DOI 10.1093/nar/28.21.4291; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; LAIHO M, 1990, J BIOL CHEM, V265, P18518; Lange D, 1999, INT J ONCOL, V14, P1049; Lele Z, 2001, GENESIS, V30, P190, DOI 10.1002/gene.1063; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Marazzi G, 1997, DEV BIOL, V186, P127, DOI 10.1006/dbio.1997.8576; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, GENE DEV, V14, P627; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; Phippard DJ, 1996, DEVELOPMENT, V122, P2729; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Schier AF, 2000, NATURE, V403, P385, DOI 10.1038/35000126; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Shimizu K, 2001, MOL CELL BIOL, V21, P3901, DOI 10.1128/MCB.21.12.3901-3912.2001; Shioda T, 1998, P NATL ACAD SCI USA, V95, P9785, DOI 10.1073/pnas.95.17.9785; Shioda T, 1996, P NATL ACAD SCI USA, V93, P12298, DOI 10.1073/pnas.93.22.12298; Solnica-Krezel L, 1999, CURR TOP DEV BIOL, V41, P1; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; Yahata T, 2000, J BIOL CHEM, V275, P8825, DOI 10.1074/jbc.275.12.8825; Zhou SB, 1998, P NATL ACAD SCI USA, V95, P2412, DOI 10.1073/pnas.95.5.2412	50	71	81	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	MAR	2002	4	3					181	190		10.1038/ncb753	http://dx.doi.org/10.1038/ncb753			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	527VR	11836524				2022-12-25	WOS:000174209100010
J	Del Pozo, MA; Kiosses, WB; Alderson, NB; Meller, N; Hahn, KM; Schwartz, MA				Del Pozo, MA; Kiosses, WB; Alderson, NB; Meller, N; Hahn, KM; Schwartz, MA			Integrins regulate GTP-Rac localized effector interactions through dissociation of Rho-GDI	NATURE CELL BIOLOGY			English	Article							CELL-MIGRATION; LIVING CELLS; IN-VIVO; PROTEINS; ACTIVATION; ADHESION; GTPASES; MEMBRANE; KINASE; CDC42	The proper function of Rho GTPases requires precise spatial and temporal regulation of effector interactions. Integrin-mediated cell adhesion modulates the interaction of GTP-Rac with its effectors by controlling GTP-Rac membrane targeting. Here, we show that the translocation of GTP-Rac to membranes is independent of effector interactions, but instead requires the polybasic sequence near the carboxyl terminus. Cdc42 also requires integrin-mediated adhesion for translocation to membranes. A recently developed fluorescence resonance energy transfer (FRET)-based assay yields the surprising result that, despite its uniform distribution, the interaction of activated V12-Rac with a soluble, cytoplasmic effector domain is enhanced at specific regions near cell edges and is induced locally by integrin stimulation. This enhancement requires Rac membrane targeting. We show that Rho-GDI, which associates with cytoplasmic GTP-Rac, blocks effector binding. Release of Rho-GDI after membrane translocation allows Rac to bind to effectors. Thus, Rho-GDI confers spatially restricted regulation of Rac-effector interactions.	Scripps Res Inst, Res Inst, Div Vasc Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Del Pozo, MA (corresponding author), Scripps Res Inst, Res Inst, Div Vasc Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	mdelpozo@scripps.edu; schwartz@scripps.edu	del Pozo, Miguel Angel/L-2861-2014	del Pozo, Miguel Angel/0000-0001-9077-391X; schwartz, martin/0000-0002-2071-1243; Hahn, Klaus/0000-0002-1970-7562	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047214, R01GM039434] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM47214, GM39434] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bourguignon LYW, 2000, J BIOL CHEM, V275, P1829, DOI 10.1074/jbc.275.3.1829; Chamberlain C, 2000, TRAFFIC, V1, P755, DOI 10.1034/j.1600-0854.2000.011002.x; Chamberlain CE, 2000, METHOD ENZYMOL, V325, P389; Chant T, 1999, ANNU REV CELL DEV BI, V15, P365, DOI 10.1146/annurev.cellbio.15.1.365; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; de Curtis I, 2001, EMBO REP, V2, P277, DOI 10.1093/embo-reports/kve072; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; del Pozo MA, 1999, EUR J IMMUNOL, V29, P3609; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; DiracSvejstrup AB, 1997, EMBO J, V16, P465, DOI 10.1093/emboj/16.3.465; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; Glaven JA, 1999, J BIOL CHEM, V274, P2279, DOI 10.1074/jbc.274.4.2279; Gong MC, 2001, AM J PHYSIOL-CELL PH, V281, pC257, DOI 10.1152/ajpcell.2001.281.1.C257; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; Jordan JD, 2000, CELL, V103, P193, DOI 10.1016/S0092-8674(00)00112-4; Keep NH, 1997, STRUCTURE, V5, P623, DOI 10.1016/S0969-2126(97)00218-9; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; Kiosses WB, 2001, NAT CELL BIOL, V3, P316, DOI 10.1038/35060120; Knaus UG, 1998, J BIOL CHEM, V273, P21512, DOI 10.1074/jbc.273.34.21512; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Leng J, 1999, J BIOL CHEM, V274, P37855, DOI 10.1074/jbc.274.53.37855; LEWIS JM, 1995, MOL BIOL CELL, V6, P151, DOI 10.1091/mbc.6.2.151; Lian LY, 2000, STRUCT FOLD DES, V8, P47, DOI 10.1016/S0969-2126(00)00080-0; Longenecker K, 1999, ACTA CRYSTALLOGR D, V55, P1503, DOI 10.1107/S090744499900801X; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Moriyoshi K, 1996, NEURON, V16, P255, DOI 10.1016/S0896-6273(00)80044-6; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Read PW, 2000, PROTEIN SCI, V9, P376; Read PW, 2000, METHOD ENZYMOL, V325, P15; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Scheffzek K, 2000, NAT STRUCT BIOL, V7, P122, DOI 10.1038/72392; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; Seabra MC, 1998, CELL SIGNAL, V10, P167, DOI 10.1016/S0898-6568(97)00120-4; Symons M, 2000, CURR BIOL, V10, pR535, DOI 10.1016/S0960-9822(00)00588-1; Teruel MN, 2000, CELL, V103, P181, DOI 10.1016/S0092-8674(00)00109-4; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183	47	279	282	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAR	2002	4	3					232	239		10.1038/ncb759	http://dx.doi.org/10.1038/ncb759			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	527VR	11862216				2022-12-25	WOS:000174209100016
J	Hopyan, S; Gokgoz, N; Poon, R; Gensure, RC; Yu, CY; Cole, WG; Bell, RS; Juppner, H; Andrulis, IL; Wunder, JS; Alman, BA				Hopyan, S; Gokgoz, N; Poon, R; Gensure, RC; Yu, CY; Cole, WG; Bell, RS; Juppner, H; Andrulis, IL; Wunder, JS; Alman, BA			A mutant PTH/PTHrP type I receptor in enchondromatosis	NATURE GENETICS			English	Article							HORMONE-RELATED PEPTIDE; PARATHYROID-HORMONE; INDIAN HEDGEHOG; METAPHYSEAL CHONDRODYSPLASIA; BLOMSTRAND-CHONDRODYSPLASIA; TRANSGENIC MICE; BONE-GROWTH; GENE; DIFFERENTIATION; CHONDROCYTES	Enchondromas are common benign cartilage tumors of bone. They can occur as solitary lesions or as multiple lesions in enchondromatosis (Ollier and Maffucci diseases). Clinical problems caused by enchondromas include skeletal deformity and the potential for malignant change to chondrosarcoma(1-3). The extent of skeletal involvement is variable in enchondromatosis and may include dysplasia that is not directly attributable to enchondromas(4). Enchondromatosis is rare, obvious inheritance of the condition is unusual and no candidate loci have been identified. Enchondromas are usually in close proximity to, or in continuity with, growth-plate cartilage. Consequently, they may result from abnormal regulation of proliferation and terminal differentiation of chondrocytes in the adjoining growth plate. In normal growth plates, differentiation of proliferative chondrocytes to post-mitotic hypertrophic chondrocytes is regulated in part by a tightly coupled signaling relay involving parathyroid hormone related protein (PTHrP) and Indian hedgehog (IHH)(5-9). PTHrP delays the hypertrophic differentiation of proliferating chondrocytes, whereas IHH promotes chondrocyte proliferation. We identified a mutant PTH/PTHrP type I receptor (PTHR1) in human enchondromatosis that signals abnormally in vitro and causes enchondroma-like lesions in transgenic mice. The mutant receptor constitutively activates Hedgehog signaling, and excessive Hedgehog signaling is sufficient to cause formation of enchondroma-like lesions.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Mol Biol & Canc, Toronto, ON M5G 1X5, Canada; Hosp Sick Children, Res Inst, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Surg, Div Orthopaed, Toronto, ON, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada; Massachusetts Gen Hosp, Dept Med, Endocrine Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Med, Pediat Endocrine Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; Hosp Sick Children, Div Orthopaed, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada; Mt Sinai Hosp, Univ Musculoskeletal Oncol Unit, Toronto, ON M5G 1X5, Canada; Mt Sinai Hosp, Div Orthopaed, Toronto, ON M5G 1X5, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto	Wunder, JS (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Mol Biol & Canc, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.		Andrulis, Irene L./E-7267-2013					BRUGGEMAN LA, 1991, TERATOLOGY, V44, P203, DOI 10.1002/tera.1420440208; Carter PH, 1999, ENDOCRINOLOGY, V140, P4972, DOI 10.1210/en.140.11.4972; Chung UI, 1998, P NATL ACAD SCI USA, V95, P13030, DOI 10.1073/pnas.95.22.13030; Grachtchouk M, 2000, NAT GENET, V24, P216, DOI 10.1038/73417; GUO J, 2000, J BONE MINER RES, V15, P5152; HALAL F, 1991, AM J MED GENET, V38, P588, DOI 10.1002/ajmg.1320380418; Hopyan S, 1999, J ORTHOPAED RES, V17, P633, DOI 10.1002/jor.1100170503; HUVOS AG, 1991, BONE TUMORS DIAGNOSI, P264; Jaffe HL, 1972, METABOLIC DEGENERATI, P222; Jobert AS, 1998, J CLIN INVEST, V102, P34, DOI 10.1172/JCI2918; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; Karaplis AC, 1998, ENDOCRINOLOGY, V139, P5255, DOI 10.1210/en.139.12.5255; Karp SJ, 2000, DEVELOPMENT, V127, P543; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; Levesque J., 1998, CLIN GUIDE PRIMARY B, P98; Li C, 1998, AM J PATHOL, V153, P709, DOI 10.1016/S0002-9440(10)65614-3; Mo R, 1997, DEVELOPMENT, V124, P113; OKEEFE RJ, 1994, J BONE MINER RES, V9, P1713; Sasaki H, 1999, DEVELOPMENT, V126, P3915; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; SCHIPANI E, 1995, J CLIN ENDOCR METAB, V80, P1611, DOI 10.1210/jc.80.5.1611; Schipani E, 1996, NEW ENGL J MED, V335, P708, DOI 10.1056/NEJM199609053351004; SCHWARTZ HS, 1987, J BONE JOINT SURG AM, V69A, P269, DOI 10.2106/00004623-198769020-00016; St-Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Xie LY, 1998, ENDOCRINOLOGY, V139, P4563, DOI 10.1210/en.139.11.4563; YAMADA Y, 1990, ANN NY ACAD SCI, V580, P81, DOI 10.1111/j.1749-6632.1990.tb17920.x; ZACK P, 1995, AM J MED GENET, V55, P478, DOI 10.1002/ajmg.1320550417	29	176	194	0	11	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2002	30	3					306	310		10.1038/ng844	http://dx.doi.org/10.1038/ng844			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	526YP	11850620				2022-12-25	WOS:000174157600016
J	Sato, M; Ozawa, T; Inukai, K; Asano, T; Umezawa, Y				Sato, M; Ozawa, T; Inukai, K; Asano, T; Umezawa, Y			Fluorescent indicators for imaging protein phosphorylation in single living cells	NATURE BIOTECHNOLOGY			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; PLECKSTRIN HOMOLOGY DOMAIN; KINASE-C; TYROSINE PHOSPHORYLATION; ENERGY-TRANSFER; IRS-1; DISCOVERY; BINDING; SIGNALS	To visualize signal transduction based on protein phosphorylation in living cells, we have developed genetically encoded fluorescent indicators, named phocuses. Two different color mutants of green fluorescent protein (GFP) were joined by a tandem fusion domain composed of a substrate domain for the protein kinase of interest, a flexible linker sequence, and a phosphorylation recognition domain that binds with the phosphorylated substrate domain. Intramolecular interaction of the substrate domain and the adjacent phosphorylation recognition domain within a phocus was dependent upon phosphorylation of the substrate domain by protein kinase, which influenced the efficiency of fluorescence resonance energy transfer (FRET) between the GFPs within a phocus. In the present study, we employed phocuses composed of insulin signaling proteins to visualize protein phosphorylation by the insulin receptor. This method may provide a general approach for studying the dynamics of protein phosphorylation-based signal transduction in living cells.	Univ Tokyo, Sch Sci, Dept Chem, Bunkyo Ku, Tokyo 1130033, Japan; Japan Sci & Technol Corp, Tokyo 1130033, Japan; Univ Tokyo, Sch Med, Dept Internal Med 3, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; Japan Science & Technology Agency (JST); University of Tokyo	Umezawa, Y (corresponding author), Univ Tokyo, Sch Sci, Dept Chem, Bunkyo Ku, Tokyo 1130033, Japan.	umezawa@chem.s.u-tokyo.ac.jp	Sato, Moritoshi/O-2735-2018	Sato, Moritoshi/0000-0002-3095-5831				ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; Casey JL, 2000, PROTEIN ENG, V13, P445, DOI 10.1093/protein/13.6.445; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Higashi H, 1996, NEUROREPORT, V7, P2695, DOI 10.1097/00001756-199611040-00058; Higashi H, 1997, FEBS LETT, V414, P55, DOI 10.1016/S0014-5793(97)00970-8; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; Honda A, 2001, P NATL ACAD SCI USA, V98, P2437, DOI 10.1073/pnas.051631298; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; MCILROY BK, 1991, ANAL BIOCHEM, V195, P148, DOI 10.1016/0003-2697(91)90310-P; Mere L, 1999, DRUG DISCOV TODAY, V4, P363, DOI 10.1016/S1359-6446(99)01377-X; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; Nagai Y, 2000, NAT BIOTECHNOL, V18, P313, DOI 10.1038/73767; Ng T, 1999, SCIENCE, V283, P2085, DOI 10.1126/science.283.5410.2085; NIKOLICRORDORF T, 1995, J BIOL CHEM, V270, P3662; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; PAGANON SD, 1999, P NATL ACAD SCI USA, V96, P8378; Sato M, 1999, ANAL CHEM, V71, P3948, DOI 10.1021/ac990318d; Sato M, 2000, ANAL CHEM, V72, P5918, DOI 10.1021/ac0006167; Sawyer TK, 1998, BIOPOLYMERS, V47, P243, DOI 10.1002/(SICI)1097-0282(1998)47:3<243::AID-BIP4>3.0.CO;2-P; Selvin PR, 2000, NAT STRUCT BIOL, V7, P730, DOI 10.1038/78948; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; Ting AY, 2001, P NATL ACAD SCI USA, V98, P15003, DOI 10.1073/pnas.211564598; Truong K, 2001, NAT STRUCT BIOL, V8, P1069, DOI 10.1038/nsb728; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; Verveer PJ, 2000, SCIENCE, V290, P1567, DOI 10.1126/science.290.5496.1567; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; White MF, 1997, DIABETOLOGIA, V40, pS2, DOI 10.1007/s001250051387; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; Wood HB, 2000, BIOORG MED CHEM LETT, V10, P1189, DOI 10.1016/S0960-894X(00)00206-7; Wouters FS, 1999, CURR BIOL, V9, P1127, DOI 10.1016/S0960-9822(99)80484-9; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958; Zaccolo M, 2000, NAT CELL BIOL, V2, P25, DOI 10.1038/71345; Zacharias DA, 2000, CURR OPIN NEUROBIOL, V10, P416, DOI 10.1016/S0959-4388(00)00101-X; Zhang B, 1999, SCIENCE, V284, P974, DOI 10.1126/science.284.5416.974; Zhang J, 2001, P NATL ACAD SCI USA, V98, P14997, DOI 10.1073/pnas.211566798; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zlokarnik G, 1998, SCIENCE, V279, P84, DOI 10.1126/science.279.5347.84	46	227	241	0	51	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2002	20	3					287	294		10.1038/nbt0302-287	http://dx.doi.org/10.1038/nbt0302-287			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	526RE	11875431				2022-12-25	WOS:000174142800048
J	Tamashiro, KLK; Wakayama, T; Akutsu, H; Yamazaki, Y; Lachey, JL; Wortman, MD; Seeley, RJ; D'Alessio, DA; Woods, SC; Yanagimachi, R; Sakai, RR				Tamashiro, KLK; Wakayama, T; Akutsu, H; Yamazaki, Y; Lachey, JL; Wortman, MD; Seeley, RJ; D'Alessio, DA; Woods, SC; Yanagimachi, R; Sakai, RR			Cloned mice have an obese phenotype not transmitted to their offspring	NATURE MEDICINE			English	Article							NUCLEAR TRANSFER; FETAL OVERGROWTH; TELOMERE LENGTHS; CLONING; EMBRYO; CELLS; CATTLE	Mammalian cloning using somatic cells has been accomplished successfully in several species, and its potential basic, clinical and therapeutic applications are being pursued on many fronts. Determining the long-term effects of cloning on offspring is crucial for consideration of future application of the technique. Although full-term development of animals cloned from adult somatic cells has been reported, problems in the resulting progeny indicate that the cloning procedure may not produce animals that are phenotypically identical to their cell donor. We used a mouse model to take advantage of its short generation time and lifespan. Here we report that the increased body weight of cloned B6C3F1 female mice reflects an increase of body fat in addition to a larger body size, and that these mice share many characteristics consistent with obesity. We also show that the obese phenotype is not transmitted to offspring generated by mating male and female cloned mice.	Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH 45221 USA; Univ Cincinnati, Coll Med, Div Endocrinol, Cincinnati, OH USA; Univ Hawaii, John A Burns Sch Med, Inst Biogenesis Res, Dept Anat & Reprod Biol, Honolulu, HI 96822 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University of Hawaii System	Sakai, RR (corresponding author), Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH 45221 USA.	randall.sakai@uc.edu	Wortman, Matt/A-6536-2010	Wortman, Matt/0000-0002-5081-9554; Wortman, Matthew/0000-0002-1263-4145; Seeley, Randy/0000-0002-3721-5625; Tamashiro, Kellie/0000-0002-9398-8796	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK048061, R37DK017844, R01DK017844, R01DK048061] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-48061, DK-17844] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baguisi A, 1999, NAT BIOTECHNOL, V17, P456, DOI 10.1038/8632; COLEMAN A, 1999, CLONING, V1, P185; DULIOUST E, 1995, P NATL ACAD SCI USA, V92, P589, DOI 10.1073/pnas.92.2.589; Eggan K, 2000, SCIENCE, V290, P1578, DOI 10.1126/science.290.5496.1578; Eggan K, 2001, P NATL ACAD SCI USA, V98, P6209, DOI 10.1073/pnas.101118898; ENSINCK JW, 1991, DIABETES, V40, P1163, DOI 10.2337/diabetes.40.9.1163; Evans MJ, 1999, NAT GENET, V23, P90, DOI 10.1038/12696; Galli C, 1999, Cloning, V1, P161, DOI 10.1089/15204559950019924; Humpherys D, 2001, SCIENCE, V293, P95, DOI 10.1126/science.1061402; Inoue K, 2002, SCIENCE, V295, P297, DOI 10.1126/science.295.5553.297; *JACKS LAB, 1997, 468 JAX JACKS LAB MA, P442; Kato Y, 1998, SCIENCE, V282, P2095, DOI 10.1126/science.282.5396.2095; Kikyo N, 2000, J CELL SCI, V113, P11; Kubota C, 2000, P NATL ACAD SCI USA, V97, P990, DOI 10.1073/pnas.97.3.990; Lanza RP, 2000, SCIENCE, V288, P665, DOI 10.1126/science.288.5466.665; LANZA RP, 2001, NATURE, V294, P1893; Ogura A, 2000, BIOL REPROD, V62, P1579, DOI 10.1095/biolreprod62.6.1579; Ohgane J, 2001, GENESIS, V30, P45, DOI 10.1002/gene.1031; Polejaeva IA, 2000, NATURE, V407, P86, DOI 10.1038/35024082; Prather R S, 2000, Cloning, V2, P117, DOI 10.1089/152045500750039815; Renard JP, 1999, LANCET, V353, P1489, DOI 10.1016/S0140-6736(98)12173-6; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Seeley RJ, 1997, NATURE, V390, P349, DOI 10.1038/37016; Shiels PG, 1999, NATURE, V399, P316, DOI 10.1038/20580; Solter D, 2000, NAT REV GENET, V1, P199, DOI 10.1038/35042066; Steinborn R, 2000, NAT GENET, V25, P255, DOI 10.1038/77000; Tamashiro KLK, 2000, BIOL REPROD, V63, P328, DOI 10.1095/biolreprod63.1.328; Tian XC, 2000, NAT GENET, V26, P272, DOI 10.1038/81559; Tsunoda Y, 2000, ZOOL SCI, V17, P1177, DOI 10.2108/zsj.17.1177; Turturro A, 1999, J GERONTOL A-BIOL, V54, pB492, DOI 10.1093/gerona/54.11.B492; Wakayama T, 2000, NATURE, V407, P318, DOI 10.1038/35030301; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wakayama T, 2001, MOL REPROD DEV, V58, P376, DOI 10.1002/1098-2795(20010401)58:4<376::AID-MRD4>3.0.CO;2-L; Wakayama T, 1999, NAT GENET, V22, P127, DOI 10.1038/9632; Walker SK, 1996, THERIOGENOLOGY, V45, P111, DOI 10.1016/0093-691X(95)00360-K; Wells DN, 1999, BIOL REPROD, V60, P996, DOI 10.1095/biolreprod60.4.996; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Woods SC, 1998, SCIENCE, V280, P1378, DOI 10.1126/science.280.5368.1378; Yamazaki Y, 2001, P NATL ACAD SCI USA, V98, P14022, DOI 10.1073/pnas.231489398; YANAGIMACHI R, IN PRESS MOL CELL EN; Young LE, 2000, THERIOGENOLOGY, V53, P627, DOI 10.1016/S0093-691X(99)00263-0; Young LE, 1998, REV REPROD, V3, P155, DOI 10.1530/revreprod/3.3.155; Young LE, 2001, NAT GENET, V27, P153, DOI 10.1038/84769	43	266	286	0	14	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2002	8	3					262	267		10.1038/nm0302-262	http://dx.doi.org/10.1038/nm0302-262			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	526PU	11875497				2022-12-25	WOS:000174139500031
J	Varley, H; Pickett, HA; Foxon, JL; Reddel, RR; Royle, NJ				Varley, H; Pickett, HA; Foxon, JL; Reddel, RR; Royle, NJ			Molecular characterization of inter-telomere and intra-telomere mutations in human ALT cells	NATURE GENETICS			English	Article							IMMORTALIZED HUMAN-CELLS; HUMAN XP/YP TELOMERE; HUMAN FIBROBLASTS; LENGTH; MAINTENANCE; RECOMBINATION; MECHANISM; DYNAMICS; CONTAIN; PATHWAY	Telomeres in most immortal cells(1-3) are maintained by the enzyme telomerase(4), allowing cells to divide indefinitely. Some telomerase-negative tumors and immortal cell lines maintain long heterogeneous telomeres by the ALT (alternative lengthening of telomeres) mechanism(5,6); such tumors are expected to be resistant to anti-telomerase drug therapies. Occasionally telomerase-negative Saccharomyces cerevisiae mutants survive, and 10% of them (type II survivors) have unstable telomeres(7,8). As in human ALT+ cells(9), short telomeres in yeast type II survivors lengthen abruptly; in yeast, this is dependent on the recombination proteins Rad52p and Rad50p(10). In human cells, ALT involves copying of sequence from a donor to a recipient telomere(11). We have characterized for the first time a class of complex telomere mutations seen only in ALT+ cells. The mutant telomeres are defined by the replacement of the progenitor telomere at a discrete point (fusion point) with a different telomere repeat array. Among 19 characterized fusion points, one occurred within the first six repeats of the telomere, indicating that these recombination-like events can occur anywhere within the telomere. One mutant telomere may have been involved in a secondary recombination-like mutation event, suggesting that these mutations are sporadic but ongoing in ALT+ cells. We also identified simple intra-allelic mutations at high frequency, which evidently contribute to telomere instability in ALT+ cells.	Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England; Childrens Med Res Inst, Canc Res Unit, Sydney, NSW, Australia	University of Leicester; Children's Medical Research Institute - Australia; University of Sydney	Royle, NJ (corresponding author), Univ Leicester, Dept Genet, Univ Rd, Leicester LE1 7RH, Leics, England.		Reddel, Roger R/A-6635-2014	Reddel, Roger R/0000-0002-6302-6107; Royle, Nicola/0000-0003-1174-6329				ALLSHIRE RC, 1989, NUCLEIC ACIDS RES, V17, P4611, DOI 10.1093/nar/17.12.4611; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; ALLSOPP RC, 1995, EXP CELL RES, V219, P130, DOI 10.1006/excr.1995.1213; BAIRD DM, 1995, EMBO J, V14, P5433, DOI 10.1002/j.1460-2075.1995.tb00227.x; Baird DM, 1997, HUM MOL GENET, V6, P2291, DOI 10.1093/hmg/6.13.2291; Baird DM, 2000, AM J HUM GENET, V66, P235, DOI 10.1086/302721; Bryan TM, 1997, HUM MOL GENET, V6, P921, DOI 10.1093/hmg/6.6.921; Bryan TM, 1997, EUR J CANCER, V33, P767, DOI 10.1016/S0959-8049(97)00065-8; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Coleman J, 1999, HUM MOL GENET, V8, P1637, DOI 10.1093/hmg/8.9.1637; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Ford LP, 2001, J BIOL CHEM, V276, P32198, DOI 10.1074/jbc.M104469200; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; JEFFREYS AJ, 1991, NATURE, V354, P204, DOI 10.1038/354204a0; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; Rizki A, 2001, NATURE, V411, P713, DOI 10.1038/35079641; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Teng SC, 2000, MOL CELL, V6, P947, DOI 10.1016/S1097-2765(05)00094-8; Teng SC, 1999, MOL CELL BIOL, V19, P8083; WARNEFORD SG, 1992, CELL GROWTH DIFFER, V3, P839; Wright WE, 1996, DEV GENET, V18, P173; Yeager TR, 1999, CANCER RES, V59, P4175	28	94	97	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2002	30	3					301	305		10.1038/ng834	http://dx.doi.org/10.1038/ng834			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	526YP	11919561				2022-12-25	WOS:000174157600015
J	Fujiwara, H; Hasegawa, M; Dohmae, N; Kawashima, A; Masliah, E; Goldberg, MS; Shen, J; Takio, K; Iwatsubo, T				Fujiwara, H; Hasegawa, M; Dohmae, N; Kawashima, A; Masliah, E; Goldberg, MS; Shen, J; Takio, K; Iwatsubo, T			alpha-Synuclein is phosphorylated in synucleinopathy lesions	NATURE CELL BIOLOGY			English	Article							PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; LEWY BODIES; TAU; FIBRILLIZATION; INCLUSIONS; FILAMENTS	The deposition of the abundant presynaptic brain protein alpha-synuclein as fibrillary aggregates in neurons or glial cells is a hallmark lesion in a subset of neurodegenerative disorders. These disorders include Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy, collectively referred to as synucleinopathies(1,2). Importantly, the identification of missense mutations in the alpha-synuclein gene in some pedigrees of familial PD has strongly implicated alpha-synuclein in the pathogenesis of PD and other synucleinopathies(3). However, specific post-translational modifications that underlie the aggregation of alpha-synuclein in affected brains have not, as yet, been identified. Here, we show by mass spectrometry analysis and studies with an antibody that specifically recognizes phospho-Ser 129 of alpha-synuclein, that this residue is selectively and extensively phosphorylated in synucleinopathy lesions. Furthermore, phosphorylation of alpha-synuclein at Ser 129 promoted fibril formation in vitro. These results highlight the importance of phosphorylation of filamentous proteins in the pathogenesis of neurodegenerative disorders.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, Tokyo 1130033, Japan; RIKEN, Characterizat Ctr, Biomol Characterizat Div, Wako, Saitama 3510198, Japan; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Harvard Univ, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA	University of Tokyo; RIKEN; University of California System; University of California San Diego; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Iwatsubo, T (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.		Goldberg, Matthew/T-7827-2019; Dohmae, Naoshi/C-2040-2011	Dohmae, Naoshi/0000-0002-5242-9410; Goldberg, Matthew/0000-0002-5172-9841				Baba M, 1998, AM J PATHOL, V152, P879; Biere AL, 2000, J BIOL CHEM, V275, P34574, DOI 10.1074/jbc.M005514200; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Crowther RA, 1998, FEBS LETT, V436, P309, DOI 10.1016/S0014-5793(98)01146-6; Culvenor JG, 1999, AM J PATHOL, V155, P1173, DOI 10.1016/S0002-9440(10)65220-0; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Goedert M, 1999, NATURE, V399, P739, DOI 10.1038/21550; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; IWATSUBO T, 1994, ACTA NEUROPATHOL, V88, P129; Jakes R, 1999, NEUROSCI LETT, V269, P13, DOI 10.1016/S0304-3940(99)00411-5; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Pandey A, 2000, NATURE, V405, P837, DOI 10.1038/35015709; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Pronin AN, 2000, J BIOL CHEM, V275, P26515, DOI 10.1074/jbc.M003542200; Rochet JC, 2000, BIOCHEMISTRY-US, V39, P10619, DOI 10.1021/bi001315u; Sharon R, 2001, P NATL ACAD SCI USA, V98, P9110, DOI 10.1073/pnas.171300598; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398	25	1386	1433	2	86	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	FEB	2002	4	2					160	164		10.1038/ncb748	http://dx.doi.org/10.1038/ncb748			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	520RJ	11813001				2022-12-25	WOS:000173794600021
J	Perez, OD; Nolan, GP				Perez, OD; Nolan, GP			Simultaneous measurement of multiple active kinase states using polychromatic flow cytometry	NATURE BIOTECHNOLOGY			English	Article							GROWTH-FACTOR RECEPTOR; JURKAT T-CELLS; PROTEIN; EXPRESSION; INHIBITOR; ACTIVATION; CD69	Intracellular assays of signaling systems have been limited by an inability to correlate functional subsets of cells in complex populations on the basis of active kinase states. Such correlations could be important in distinguishing changes in signaling status that arise in rare cell subsets during functional activation or in disease manifestation. Here we demonstrate the ability to simultaneously detect activated kinase members of the mitogen-activated protein kinases family (p38 MAPK, p44/42 MAPK, JNK/SAPK), members of cell survival pathways (AKT/PKB), and members of T-cell activation pathways (TYK2), among others, in subpopulations of complex cell populations by multiparameter flow-cytometric analysis. We demonstrate the utility of these probes in identifying distinct signaling cascades for (1) both artificial and physiological stimulatory conditions of peripheral blood mononuclear cells (PBMCs), (2) cytokine stimulation in human memory and naive lymphocyte subsets as identified by five differentiation markers, and (3) ordering of kinase activation in potential signaling hierarchies. Polychromatic flow-cytometric active kinase measurements demonstrate that multidimensional analysis of signaling pathways can provide functional signaling pathway assessment on a single-cell level and allow for potential correlation with biological and clinical parameters.	Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Baxter Lab Genet Pharmacol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University	Nolan, GP (corresponding author), Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA.		Nolan, Garry/AAE-7903-2019	Nolan, Garry/0000-0002-8862-9043	NIAID NIH HHS [AI35504, P01-AI39646] Funding Source: Medline; NIAMS NIH HHS [N01-AR-6-2227, AR44565] Funding Source: Medline; NIH HHS [A1/GF41520-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI039646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [N01AR062227, R01AR044565] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bennecib M, 2000, FEBS LETT, V485, P87, DOI 10.1016/S0014-5793(00)02203-1; Breittmayer JP, 1996, J LIPID MEDIAT CELL, V13, P151, DOI 10.1016/0929-7855(95)00059-3; Bucciantini M, 1999, FEBS LETT, V456, P73, DOI 10.1016/S0014-5793(99)00828-5; De Rosa SC, 2001, NAT MED, V7, P245, DOI 10.1038/84701; DeSilva DR, 1998, J IMMUNOL, V160, P4175; Duncia JV, 1998, BIOORG MED CHEM LETT, V8, P2839, DOI 10.1016/S0960-894X(98)00522-8; Eyers PA, 1998, CHEM BIOL, V5, P321, DOI 10.1016/S1074-5521(98)90170-3; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FIERING SN, 1991, CYTOMETRY, V12, P291, DOI 10.1002/cyto.990120402; Franklin RA, 2000, MOL IMMUNOL, V37, P675, DOI 10.1016/S0161-5890(00)00087-0; Fukuchi K, 2000, BBA-MOL CELL RES, V1496, P207, DOI 10.1016/S0167-4889(00)00018-5; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; KISS Z, 1995, BBA-MOL CELL RES, V1265, P93, DOI 10.1016/0167-4889(94)00242-7; Marhaba R, 1996, J IMMUNOL, V157, P1468; Montgomery RB, 1995, J BIOL CHEM, V270, P30562, DOI 10.1074/jbc.270.51.30562; Morrison P, 1996, J BIOL CHEM, V271, P12891, DOI 10.1074/jbc.271.22.12891; Nielsen SD, 1998, CLIN EXP IMMUNOL, V114, P66; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; RISSO A, 1991, J IMMUNOL, V146, P4105; Rolli-Derkinderen M, 2000, BIOL CHEM, V381, P193, DOI 10.1515/BC.2000.026; SPINOZZI F, 1994, LEUKEMIA RES, V18, P431, DOI 10.1016/0145-2126(94)90079-5; UDDIN S, 1995, J BIOL CHEM, V270, P24627, DOI 10.1074/jbc.270.42.24627; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624	23	217	246	0	17	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2002	20	2					155	162		10.1038/nbt0202-155	http://dx.doi.org/10.1038/nbt0202-155			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	517FT	11821861				2022-12-25	WOS:000173601000024
J	Perrotti, D; Cesi, V; Trotta, R; Guerzoni, C; Santilli, G; Campbell, K; Iervolino, A; Condorelli, F; Gambacorti-Passerini, C; Caligiuri, MA; Calabretta, B				Perrotti, D; Cesi, V; Trotta, R; Guerzoni, C; Santilli, G; Campbell, K; Iervolino, A; Condorelli, F; Gambacorti-Passerini, C; Caligiuri, MA; Calabretta, B			BCR-ABL suppresses C/EBP alpha expression through inhibitory action of hnRNP E2	NATURE GENETICS			English	Article							BINDING PROTEIN-ALPHA; CHRONIC MYELOGENOUS LEUKEMIA; RECEPTOR MESSENGER-RNA; KH-DOMAIN PROTEINS; GRANULOCYTIC DIFFERENTIATION; ERYTHROID-DIFFERENTIATION; RIBONUCLEOPROTEIN-K; PU.1 SPI-1; TRANSCRIPTION; TRANSLATION	The arrest of differentiation is a feature of both chronic myelogenous leukemia cells in myeloid blast crisis and myeloid precursors that ectopically express the p210(BCR-ABL) oncoprotein; however, its underlying mechanisms remain poorly understood. Here we show that expression of BCR-ABL in myeloid precursor cells leads to transcriptional suppression of the granulocyte colony-stimulating factor receptor G-CSF-R (encoded by CSF3R), possibly through down-modulation of C/EBPalpha-the principal regulator of granulocytic differentiation. Expression of C/EBPalpha protein is barely detectable in primary marrow cells taken from individuals affected with chronic myeloid leukemia in blast crisis. In contrast, CEBPA RNA is clearly present. Ectopic expression of C/EBPalpha induces granulocytic differentiation of myeloid precursor cells expressing BCR-ABL. Expression of C/EBPalpha is suppressed at the translational level by interaction of the poly(rC)-binding protein hnRNP E2 with CEBPA mRNA, and ectopic expression of hnRNP E2 in myeloid precursor cells down-regulates both C/EBPalpha. and G-CSF-R and leads to rapid cell death on treatment with G-CSF (encoded by CSF3). Our results indicate that BCR-ABL regulates the expression of C/EBPalpha by inducing hnRNP E2-which inhibits the translation of CEBPA mRNA.	Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Univ Modena, Sect Gen Pathol, Dept Biomed Sci, I-41100 Modena, Italy; NCI, I-20133 Milan, Italy; S Gerardo Hosp, Hematol Sect, I-20052 Monza, Italy; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Canc & Leukemia Grp B, Chicago, IL USA	Jefferson University; Universita di Modena e Reggio Emilia; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Perrotti, D (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA.	Danilo.Perrotti@mail.tju.edu	Perrotti, Danilo/E-3852-2011; Condorelli, Fabrizio/J-4726-2016	Condorelli, Fabrizio/0000-0002-9943-0857; Trotta, Rossana/0000-0003-4546-2615; GAMBACORTI PASSERINI, CARLO/0000-0001-6058-515X				Bellon T, 1997, BLOOD, V90, P1828, DOI 10.1182/blood.V90.5.1828; Blyn LB, 1997, J VIROL, V71, P6243, DOI 10.1128/JVI.71.8.6243-6246.1997; Calkhoven CF, 2000, GENE DEV, V14, P1920; Cambier N, 1998, ONCOGENE, V16, P335, DOI 10.1038/sj.onc.1201490; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Cazzola M, 2000, BLOOD, V95, P3280, DOI 10.1182/blood.V95.11.3280.011k41_3280_3288; Cheng T, 1996, P NATL ACAD SCI USA, V93, P13158, DOI 10.1073/pnas.93.23.13158; Collier B, 1998, J BIOL CHEM, V273, P22648, DOI 10.1074/jbc.273.35.22648; Dai ZH, 1998, GENE DEV, V12, P1415, DOI 10.1101/gad.12.10.1415; Elmaagacli AH, 2000, ANN HEMATOL, V79, P424, DOI 10.1007/s002770000169; GAIGER A, 1995, BLOOD, V86, P2371, DOI 10.1182/blood.V86.6.2371.bloodjournal8662371; Gamarnik AV, 1997, RNA, V3, P882; Gordon MY, 1999, J CLIN PATHOL, V52, P719, DOI 10.1136/jcp.52.10.719; Graff J, 1998, J VIROL, V72, P9668, DOI 10.1128/JVI.72.12.9668-9675.1998; Ilaria RL, 1999, BLOOD, V93, P4154, DOI 10.1182/blood.V93.12.4154.412k15_4154_4166; Issaad C, 2000, LEUKEMIA, V14, P662, DOI 10.1038/sj.leu.2401730; KANTARJIAN HM, 1993, BLOOD, V82, P691; KANTARJIAN HM, 1987, AM J MED, V83, P445, DOI 10.1016/0002-9343(87)90754-6; KOZAK M, 1995, P NATL ACAD SCI USA, V92, P2662, DOI 10.1073/pnas.92.7.2662; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; LANEUVILLE P, 1991, ONCOGENE, V6, P275; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; Lincoln AJ, 1998, J BIOL CHEM, V273, P9552, DOI 10.1074/jbc.273.16.9552; Orkin SH, 2000, NAT REV GENET, V1, P57, DOI 10.1038/35049577; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; Ostareck DH, 2001, CELL, V104, P281, DOI 10.1016/S0092-8674(01)00212-4; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Ostareck-Lederer A, 1998, TRENDS BIOCHEM SCI, V23, P409, DOI 10.1016/S0968-0004(98)01301-2; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Perrotti D, 2000, MOL CELL BIOL, V20, P6159, DOI 10.1128/MCB.20.16.6159-6169.2000; Perrotti D, 1998, EMBO J, V17, P4442, DOI 10.1093/emboj/17.15.4442; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; SCOTT LM, 1992, BLOOD, V80, P1725; Silvera D, 1999, J BIOL CHEM, V274, P38163, DOI 10.1074/jbc.274.53.38163; Smith LT, 1996, BLOOD, V88, P1234, DOI 10.1182/blood.V88.4.1234.bloodjournal8841234; STEINMAN RA, 1994, BLOOD, V83, P119; Thisted T, 2001, J BIOL CHEM, V276, P17484, DOI 10.1074/jbc.M010594200; Thomson AM, 1999, BIOTECHNIQUES, V27, P1032, DOI 10.2144/99275rr03; TKATCH LS, 1995, J LEUKOCYTE BIOL, V57, P964, DOI 10.1002/jlb.57.6.964; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; Wang XP, 1999, BLOOD, V94, P560, DOI 10.1182/blood.V94.2.560.414k41_560_571; Ward AC, 2000, LEUKEMIA, V14, P973, DOI 10.1038/sj.leu.2401808; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; WONG KK, 1995, MOL CELL BIOL, V15, P6535; Zhang DE, 1996, CURR TOP MICROBIOL, V211, P137; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zou XM, 1999, J BIOL CHEM, V274, P18141, DOI 10.1074/jbc.274.26.18141	50	252	268	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2002	30	1					48	58		10.1038/ng791	http://dx.doi.org/10.1038/ng791			11	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	508TL	11753385				2022-12-25	WOS:000173105600013
J	Antoine, AF; Faure, JE; Dumas, C; Feijo, JA				Antoine, AF; Faure, JE; Dumas, C; Feijo, JA			Differential contribution of cytoplasmic Ca2+ and Ca2+ influx to gamete fusion and egg activation in maize	NATURE CELL BIOLOGY			English	Article							SEA-URCHIN EGGS; IN-VITRO FERTILIZATION; FLOWERING PLANTS; VOLTAGE CLAMP; SPERM ENTRY; CALCIUM; WAVE; ZYGOTE; EVENTS; CELLS	In multicellular organisms, gamete fusion triggers a set of events, collectively known as egg activation, that leads to the development of a new individual. Every species that has been studied shows at least one rise in cytoplasmic Ca2+ concentration ([Ca2+]cyt) after gamete fusion(1) which is believed to be involved in activation. Yet the source and regulation of this Ca2+ signal and the way it is transduced inside the zygote are controversial(1). In higher plants, in vitro fertilization (IVF)(2,3) has enabled the description of a rise in [Ca2+] (ref. 4) that is sufficient for activation(5), and of a Ca2+ influx that spreads as a wavefront from the fusion site(5) The relationship between these two responses is unknown. Using a new combination of methods that simultaneously monitor the extracellular flux with a Ca2+-vibrating probe, and [Ca2+](Cyt) by widefield imaging, we directly determined that the Ca2+ influx precedes the [Ca2+](Cyt) elevation by 40-120 s. In addition, results from experiments using the Ca2+-channel inhibitor gadolinium (Gd3+) suggest that the Ca2+ influx may be necessary for sperm incorporation. We also present evidence for a putative sperm-dependent Gd3+-insensitive localized Ca2+ influx confined to the fusion point.	Univ Sci & Technol Lille, Dev Biol Lab, F-59655 Villeneuve Dascq, France; Univ Lisbon, Fac Ciencias, Ctr Biotecnol Vegetal, PT-1749016 Lisbon, Portugal; Gulbenkian Inst Sci, PT-2780156 Oeiras, Portugal; Univ Lyon 1, Ecole Normale Super Lyon, CNRS, INRA,UMR 5667,Lab Reprod & Dev Plantes, F-69364 Lyon 07, France	Universite de Lille - ISITE; Universite de Lille; Universidade de Lisboa; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); INRAE; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Ecole Normale Superieure de Lyon (ENS de LYON)	Antoine, AF (corresponding author), Univ Sci & Technol Lille, Dev Biol Lab, SN3, F-59655 Villeneuve Dascq, France.		Feijo, Jose A./ADM-0262-2022	Feijo, Jose A./0000-0002-1100-5478				Antoine AF, 2000, P NATL ACAD SCI USA, V97, P10643, DOI 10.1073/pnas.180243697; Antoine AF, 2001, SEX PLANT REPROD, V14, P21, DOI 10.1007/s004970100088; ANTOINE AF, 2000, THESIS ENS LYON LYON; DAVID C, 1988, J PHYSIOL-LONDON, V402, P139, DOI 10.1113/jphysiol.1988.sp017197; Digonnet C, 1997, DEVELOPMENT, V124, P2867; EDDY EM, 1976, J CELL BIOL, V71, P35, DOI 10.1083/jcb.71.1.35; EISEN A, 1984, J CELL BIOL, V99, P1647, DOI 10.1083/jcb.99.5.1647; FAURE JE, 1992, PROTOPLASMA, V171, P97, DOI 10.1007/BF01403723; FAURE JE, 1994, SCIENCE, V263, P1598, DOI 10.1126/science.263.5153.1598; FREY T, 1995, CYTOMETRY, V21, P265, DOI 10.1002/cyto.990210307; Jaffe L.F., 1980, Annals of the New York Academy of Sciences, V339, P86, DOI 10.1111/j.1749-6632.1980.tb15971.x; Jones KT, 1998, DEVELOPMENT, V125, P4627; KRANZ E, 1995, PLANT J, V8, P9, DOI 10.1046/j.1365-313X.1995.08010009.x; Kranz E, 1999, METH MOL B, V111, P259; Lee KW, 1999, DEV BIOL, V214, P168, DOI 10.1006/dbio.1999.9396; LINDSAY LL, 1992, DEV BIOL, V152, P94, DOI 10.1016/0012-1606(92)90159-E; LYNN JW, 1984, DEV BIOL, V102, P98, DOI 10.1016/0012-1606(84)90178-7; LYNN JW, 1988, DEV BIOL, V128, P305, DOI 10.1016/0012-1606(88)90294-1; MCDOUGALL A, 1995, ZYGOTE, V3, P251, DOI 10.1017/S0967199400002641; Mohri T, 1998, DEVELOPMENT, V125, P293; MORRIS SJ, 1993, METHOD ENZYMOL, V221, P42, DOI 10.1016/0076-6879(93)21006-T; SHEN SS, 1993, DEV BIOL, V157, P157, DOI 10.1006/dbio.1993.1120; SHEN SS, 1985, J CELL BIOL, V101, P420, DOI 10.1083/jcb.101.2.420; Shipley AM, 1999, FERTILIZATION HIGHER, P235; SMITH PJS, 1994, METHOD CELL BIOL, V40, P115; Stricker SA, 1999, DEV BIOL, V211, P157, DOI 10.1006/dbio.1999.9340	26	62	69	1	10	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2001	3	12					1120	1123		10.1038/ncb1201-1120	http://dx.doi.org/10.1038/ncb1201-1120			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	500AM	11781574				2022-12-25	WOS:000172603700018
J	Fujiwara, I; Takahashi, S; Tadakuma, H; Funatsu, T; Ishiwata, S				Fujiwara, I; Takahashi, S; Tadakuma, H; Funatsu, T; Ishiwata, S			Microscopic analysis of polymerization dynamics with individual actin filaments	NATURE CELL BIOLOGY			English	Article							F-ACTIN; HEAVY-MEROMYOSIN; BINDING; MYOSIN; MICROTUBULES; INSTABILITY; HYDROLYSIS; INVITRO; GROWTH	The polymerization-depolymerization dynamics of actin is a key process in a variety of cellular functions. Many spectroscopic studies have been performed in solution, but studies on single actin filaments have just begun. Here, we show that the time course of polymerization of individual filaments consists of a polymerization phase and a subsequent steady-state phase. During the steady-state phase, a treadmilling process of elongation at the barbed end and shortening at the pointed end occurs, in which both components of the process proceed at approximately the same rate. The time correlation of length fluctuation of the filaments in the steady-state phase showed that the polymerization-depolymerization dynamics follow a diffusion (stochastic) process, which cannot be explained by simple association and dissociation of monomers at both ends of the filaments.	Waseda Univ, Sch Sci & Engn, Dept Phys, Shinjuku Ku, Tokyo 1698555, Japan; Waseda Univ, Adv Res Inst Sci & Engn, Shinjuku Ku, Tokyo 1698555, Japan	Waseda University; Waseda University	Ishiwata, S (corresponding author), Waseda Univ, Sch Sci & Engn, Dept Phys, Shinjuku Ku, 3-4-1 Okubo, Tokyo 1698555, Japan.	ishiwata@waseda.jp	Fujiwara, Ikuko/H-5717-2016; Funatsu, Takashi/Q-1404-2015	Fujiwara, Ikuko/0000-0002-9361-636X; Funatsu, Takashi/0000-0002-9656-8308				Amann KJ, 2001, P NATL ACAD SCI USA, V98, P15009, DOI 10.1073/pnas.211556398; BRENNER SL, 1983, J BIOL CHEM, V258, P5013; CARLIER MF, 1989, INT REV CYTOL, V115, P139; DELACRUZ EM, 1994, BIOCHEMISTRY-US, V35, P14054; ESTES JE, 1992, J MUSCLE RES CELL M, V13, P272, DOI 10.1007/BF01766455; Fujiwara I, 2002, BIOCHEM BIOPH RES CO, V293, P1550, DOI 10.1016/S0006-291X(02)00421-7; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HAYASHI T, 1976, Journal of Mechanochemistry and Cell Motility, V3, P163; HONDA H, 1986, J MOL BIOL, V191, P131, DOI 10.1016/0022-2836(86)90428-6; HORIO T, 1986, NATURE, V321, P605, DOI 10.1038/321605a0; Howard J., 2001, MECH MOTOR PROTEINS; HUANG ZJ, 1992, ANAL BIOCHEM, V200, P199, DOI 10.1016/0003-2697(92)90299-M; ISHIWATA S, 2001, MOL INTERACTIONS ACT, P79; KONDO H, 1976, J BIOCHEM-TOKYO, V79, P159, DOI 10.1093/oxfordjournals.jbchem.a131043; KORN ED, 1987, SCIENCE, V238, P638, DOI 10.1126/science.3672117; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MURPHY DB, 1988, J CELL BIOL, V106, P1947, DOI 10.1083/jcb.106.6.1947; OOSAWA F, 1962, J MOL BIOL, V4, P10, DOI 10.1016/S0022-2836(62)80112-0; Oosawa F., 1975, THERMODYNAMICS POLYM; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; WEGNER A, 1976, J MOL BIOL, V108, P139, DOI 10.1016/S0022-2836(76)80100-3; WOODRUM DT, 1975, J CELL BIOL, V67, P231, DOI 10.1083/jcb.67.1.231; YANAGIDA T, 1984, NATURE, V307, P58, DOI 10.1038/307058a0; Yasuda R, 1996, J MOL BIOL, V263, P227, DOI 10.1006/jmbi.1996.0571	27	147	152	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2002	4	9					666	673		10.1038/ncb841	http://dx.doi.org/10.1038/ncb841			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	589WE	12198494				2022-12-25	WOS:000177783900010
J	Ishiuchi, S; Tsuzuki, K; Yoshida, Y; Yamada, N; Hagimura, N; Okado, H; Miwa, A; Kurihara, H; Nakazato, Y; Tamura, M; Sasaki, T; Ozawa, S				Ishiuchi, S; Tsuzuki, K; Yoshida, Y; Yamada, N; Hagimura, N; Okado, H; Miwa, A; Kurihara, H; Nakazato, Y; Tamura, M; Sasaki, T; Ozawa, S			Blockage of Ca2+-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells	NATURE MEDICINE			English	Article							GLUTAMATE RECEPTORS; CENTRAL NEUROCYTOMA; EXPRESSION; ACTIVATION; CHANNELS; PROTEIN; GROWTH; RELEASE; DIFFERENTIATION; DEPOLARIZATION	Glioblastoma multiforme is the most undifferentiated type of brain tumor, and its prognosis is extremely poor. Glioblastoma cells exhibit highly migratory and invasive behavior, which makes surgical intervention unsuccessful. Here, we showed that glioblastoma cells express Ca2+ permeable alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA)-type glutamate receptors assembled from the GluR1 and/or GluR4 subunits, and that their conversion to Ca2+-impermeable receptors by adenovirus-mediated transfer of the GluR2 cDNA inhibited cell locomotion and induced apoptosis. In contrast, overexpression of Ca2+-permeable AMPA receptors facilitated migration and proliferation of the tumor cells. These findings indicate that Ca2+-permeable AMPA receptors have crucial roles in growth of glioblastoma. Blockage of these Ca2+-permeable receptors may be a useful therapeutic strategy for the prevention of glioblastoma invasion.	Gunma Univ, Sch Med, Dept Neurosurg, Gunma, Japan; Gunma Univ, Sch Med, Dept Physiol, Gunma, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama, Japan; Tokyo Metropolitan Inst Neurosci, Dept Neurobiol, Fuchu, Tokyo 183, Japan; Gunma Univ, Sch Med, Dept Pathol, Gunma, Japan; Kyushu Univ, Sch Med, Dept Neurosurg, Fukuoka 812, Japan	Gunma University; Gunma University; Japan Science & Technology Agency (JST); Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science; Gunma University; Kyushu University	Ishiuchi, S (corresponding author), Gunma Univ, Sch Med, Dept Neurosurg, Gunma, Japan.	ishogo@showa.gunma-u.ac.jp		Ozawa, Seiji/0000-0003-4893-3443				Bezzi P, 1998, NATURE, V391, P281, DOI 10.1038/34651; BLAKEMORE WF, 1996, GLIAL CELL DEV BASIC, P209; Chew LJ, 1997, J NEUROSCI, V17, P227, DOI 10.1523/JNEUROSCI.17-01-00227.1997; Cotrina ML, 1998, J NEUROSCI, V18, P8794; Gallo V, 2000, TRENDS PHARMACOL SCI, V21, P252, DOI 10.1016/S0165-6147(00)01494-2; GALLO V, 1987, J NEUROSCI, V7, P2203; GALLO V, 1994, GLIA, V10, P149, DOI 10.1002/glia.440100209; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Ishiuchi S, 1998, J NEUROSCI RES, V51, P526, DOI 10.1002/(SICI)1097-4547(19980215)51:4<526::AID-JNR12>3.0.CO;2-1; Ishiuchi S, 1997, ACTA NEUROPATHOL, V94, P425, DOI 10.1007/s004010050729; Ishiuchi S, 2001, NEUROREPORT, V12, P745, DOI 10.1097/00001756-200103260-00026; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KHINE MM, 1994, LAB INVEST, V70, P125; Kleihues P., 2000, PATHOLOGY GENETICS T, P29; Kohara A, 1998, J PHARM PHARMACOL, V50, P795, DOI 10.1111/j.2042-7158.1998.tb07142.x; KOIKE T, 1989, P NATL ACAD SCI USA, V86, P6421, DOI 10.1073/pnas.86.16.6421; Kondo M, 1997, J NEUROSCI, V17, P1570; Labrakakis C, 1998, EUR J NEUROSCI, V10, P2153, DOI 10.1046/j.1460-9568.1998.00226.x; Lino M, 2001, SCIENCE, V292, P926, DOI 10.1126/science.1058827; Meucci O, 1996, J NEUROSCI, V16, P519; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Mogami H, 1997, CELL, V88, P49, DOI 10.1016/S0092-8674(00)81857-7; NAKAZATO Y, 1985, VIRCHOWS ARCH A, V405, P299, DOI 10.1007/BF00710066; NOBLE M, 1995, GLIA, V15, P222, DOI 10.1002/glia.440150304; Ozawa S, 1998, PROG NEUROBIOL, V54, P581, DOI 10.1016/S0301-0082(97)00085-3; Rzeski W, 2001, P NATL ACAD SCI USA, V98, P6372, DOI 10.1073/pnas.091113598; SAKURAI T, 1992, BRAIN RES, V573, P197, DOI 10.1016/0006-8993(92)90763-Y; Sasaki A, 1998, J NEUROPATH EXP NEUR, V57, P653, DOI 10.1097/00005072-199807000-00002; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Sudo M, 1999, MOL BRAIN RES, V65, P176, DOI 10.1016/S0169-328X(98)00348-9; Takano T, 2001, NAT MED, V7, P1010, DOI 10.1038/nm0901-1010; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Yoshioka A, 1996, J NEUROSCI RES, V46, P164	34	231	245	1	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2002	8	9					971	978		10.1038/nm746	http://dx.doi.org/10.1038/nm746			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	589KQ	12172541				2022-12-25	WOS:000177757900032
J	Kuranaga, E; Kanuka, H; Igaki, T; Sawamoto, K; Ichijo, H; Okano, H; Miura, M				Kuranaga, E; Kanuka, H; Igaki, T; Sawamoto, K; Ichijo, H; Okano, H; Miura, M			Reaper-mediated inhibition of DIAP1-induced DTRAF1 degradation results in activation of JNK in Drosophila	NATURE CELL BIOLOGY			English	Article							PROGRAMMED CELL-DEATH; BACULOVIRUS INHIBITOR; CASPASE ACTIVATION; APOPTOSIS; PROTEIN; IAP; INDUCTION; GRIM; GENE; PATHWAY	Although Jun amino-terminal kinase (JNK) is known to mediate a physiological stress signal that leads to cell death, the exact role of the JNK pathway in the mechanisms underlying intrinsic cell death is largely unknown. Here we show through a genetic screen that a mutant of Drosophila melanogaster tumour-necrosis factor receptor-associated factor 1 (DTRAF1) is a dominant suppressor of Reaper-induced cell death. We show that Reaper modulates the JNK pathway through Drosophila inhibitor-of-apoptosis protein 1 (DIAP1), which negatively regulates DTRAF1 by proteasome-mediated degradation. Reduction of JNK signals rescues the Reaper-induced small eye phenotype, and overexpression of DTRAF1 activates the Drosophila ASK1 (apoptosis signal-regulating kinase 1; a mitogen-activated protein kinase kinase kinase) and JNK pathway, thereby inducing cell death. Overexpresson of DIAP1 facilitates degradation of DTRAF1 in a ubiquitin-dependent manner and simultaneously inhibits activation of JNK. Expression of Reaper leads to a loss of DIAP1 inhibition of DTRAF1-mediated JNK activation in Drosophila cells. Taken together, our results indicate that DIAP1 may modulate cell death by regulating JNK activation through a ubiquitin-proteasome pathway.	RIKEN, Brain Sci Inst, Lab Cell Recovery Mech, Wako, Saitama 3510198, Japan; Osaka Univ, Grad Sch Med, Dept Cell Biol & Neurosci, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Biomed Res Ctr, Div Neuroanat, Suita, Osaka 5650871, Japan; Tokyo Med & Dent Univ, Grad Sch, Lab Cell Signaling, Bunkyo Ku, Tokyo 1138549, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Med Pharmaceut, Bunkyo Ku, Tokyo 1130033, Japan; Keio Univ, Sch Med, Dept Physiol, Sinjuku Ku, Tokyo 1608582, Japan; CREST, Sinjuku Ku, Tokyo 1608582, Japan	RIKEN; Osaka University; Osaka University; Tokyo Medical & Dental University (TMDU); University of Tokyo; Keio University; Japan Science & Technology Agency (JST)	Miura, M (corresponding author), RIKEN, Brain Sci Inst, Lab Cell Recovery Mech, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.		Okano, Hideyuki/I-7584-2019; Kuranaga, Erina/AAE-4309-2019	Kuranaga, Erina/0000-0001-6300-2087; Ichijo, Hidenori/0000-0002-5005-6438; Igaki, Tatsushi/0000-0001-5839-9526; Sawamoto, Kazunobu/0000-0003-1984-5129				Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Geleziunas R, 2001, NATURE, V410, P834, DOI 10.1038/35071111; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Hays R, 2002, NAT CELL BIOL, V4, P425, DOI 10.1038/ncb794; Holley CL, 2002, NAT CELL BIOL, V4, P439, DOI 10.1038/ncb798; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Igaki T, 2000, P NATL ACAD SCI USA, V97, P662, DOI 10.1073/pnas.97.2.662; Kanuka H, 1999, MOL CELL, V4, P757, DOI 10.1016/S1097-2765(00)80386-X; Kanuka H, 1999, P NATL ACAD SCI USA, V96, P145, DOI 10.1073/pnas.96.1.145; Liu HZ, 1999, CURR BIOL, V9, P101, DOI 10.1016/S0960-9822(99)80023-2; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; Ryoo HD, 2002, NAT CELL BIOL, V4, P432, DOI 10.1038/ncb795; Sawamoto K, 1999, J CELL BIOL, V146, P361, DOI 10.1083/jcb.146.2.361; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vucic D, 1998, J BIOL CHEM, V273, P33915, DOI 10.1074/jbc.273.51.33915; Vucic D, 1997, P NATL ACAD SCI USA, V94, P10183, DOI 10.1073/pnas.94.19.10183; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; Wassarman DA, 1996, GENE, V169, P283, DOI 10.1016/0378-1119(95)00790-3; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; Wing JP, 2002, NAT CELL BIOL, V4, P451, DOI 10.1038/ncb800; Wing JP, 2001, MECH DEVELOP, V102, P193, DOI 10.1016/S0925-4773(01)00316-1; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793	29	112	116	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	2002	4	9					705	710		10.1038/ncb842	http://dx.doi.org/10.1038/ncb842			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	589WE	12198495				2022-12-25	WOS:000177783900015
J	Meller, N; Irani-Tehrani, M; Kiosses, WB; Del Pozo, MA; Schwartz, MA				Meller, N; Irani-Tehrani, M; Kiosses, WB; Del Pozo, MA; Schwartz, MA			Zizimin1, a novel Cdc42 activator, reveals a new GEF domain for Rho proteins	NATURE CELL BIOLOGY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; CELL-MIGRATION; SALMONELLA-TYPHIMURIUM; GTPASES; FAMILY; PHAGOCYTOSIS; DOCK180; DBL; TRANSFORMATION; MOLECULES	The Rho family GTPases Rac, Rho and Cdc42 are critical in regulating the actin-based cytoskeleton, cell migration, growth, survival and gene expression. These GTPases are activated by guanine nucleotide-exchange factors (GEFs). A biochemical search for Cdc42 activators led to the cloning of zizimin1, a new protein whose overexpression induces Cdc42 activation. Sequence comparison combined with mutational analysis identified a new domain, which we named CZH2, that mediates direct interaction with Cdc42. CZH2-containing proteins constitute a new superfamily that includes the so-called 'CDM' proteins that bind to and activate Rac. Together, the results suggest that CZH2 is a new GEF domain for the Rho family of proteins.	Scripps Res Inst, Dept Cell Biol, Div Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Schwartz, MA (corresponding author), Scripps Res Inst, Dept Cell Biol, Div Vasc Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	schwartz@scripps.edu	del Pozo, Miguel Angel/L-2861-2014	del Pozo, Miguel Angel/0000-0001-9077-391X; schwartz, martin/0000-0002-2071-1243	NIGMS NIH HHS [R01 GM41721] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; del Pozo MA, 1999, EUR J IMMUNOL, V29, P3609; Fukui Y, 2001, NATURE, V412, P826, DOI 10.1038/35090591; Gumienny TL, 2001, CELL, V107, P27, DOI 10.1016/S0092-8674(01)00520-7; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; HART MJ, 1994, J BIOL CHEM, V269, P62; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Keep NH, 1997, STRUCTURE, V5, P623, DOI 10.1016/S0969-2126(97)00218-9; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; Kikuno R, 1999, DNA Res, V6, P197, DOI 10.1093/dnares/6.3.197; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Lupas A, 1996, METHOD ENZYMOL, V266, P513; NHIEU GTV, 1999, EMBO J, V18, P3249; Nishihara H, 1999, BBA-MOL CELL RES, V1452, P179, DOI 10.1016/S0167-4889(99)00133-0; Nolan KM, 1998, GENE DEV, V12, P3337, DOI 10.1101/gad.12.21.3337; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; Rudolph MG, 1999, J BIOL CHEM, V274, P30501, DOI 10.1074/jbc.274.43.30501; Valster AH, 2000, TRENDS CELL BIOL, V10, P141, DOI 10.1016/S0962-8924(00)01728-1; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163	29	140	144	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	2002	4	9					639	647		10.1038/ncb835	http://dx.doi.org/10.1038/ncb835			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	589WE	12172552				2022-12-25	WOS:000177783900007
J	Wheeler, JC; VanderZwan, C; Xu, XT; Swantek, D; Tracey, WD; Gergen, JP				Wheeler, JC; VanderZwan, C; Xu, XT; Swantek, D; Tracey, WD; Gergen, JP			Distinct in vivo requirements for establishment versus maintenance of transcriptional repression	NATURE GENETICS			English	Article							ZINC-FINGER PROTEINS; DROSOPHILA SEGMENTATION; HISTONE DEACETYLASE; GENE RUNT; TRAMTRACK; GROUCHO; DOMAIN; EMBRYO; EXPRESSION; ACTIVATION	Low-level ectopic expression of the Runt transcription factor blocks activation of the Drosophila melanogaster segmentation gene engrailed (en) in odd-numbered parasegments and is associated with a lethal phenotype. Here we show, by using a genetic screen for maternal factors that contribute in a dose-dependent fashion to Runt-mediated repression, that there are two distinct steps in the repression of en by Runt. The initial establishment of repression is sensitive to the dosage of the zinc-finger transcription factor Tramtrack. By contrast, the corepressor proteins Groucho and dCtBP, and the histone deacetylase Rpd3, do not affect establishment but instead maintain repression after the blastoderm stage. The distinction between establishment and maintenance is confirmed by experiments with Runt derivatives that are impaired specifically for either co-repressor interaction or DNA binding. Other transcription factors can also establish repression in Rpd3-deficient embryos, which indicates that the distinction between establishment and maintenance may be a general feature of eukaryotic transcriptional repression.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Ctr Dev Genet, Stony Brook, NY 11794 USA; SUNY Stony Brook, Grad Program Genet, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Gergen, JP (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.			Tracey, W. Daniel/0000-0003-4666-8199				Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; BRAND AH, 1993, DEVELOPMENT, V118, P401; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; Chou TB, 1996, GENETICS, V144, P1673; DeRubertis F, 1996, NATURE, V384, P589; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; Giesen K, 1997, DEVELOPMENT, V124, P2307; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KLINGLER M, 1993, MECH DEVELOP, V43, P3, DOI 10.1016/0925-4773(93)90019-T; Kramer SG, 1999, DEVELOPMENT, V126, P191; Mannervik M, 1999, P NATL ACAD SCI USA, V96, P6797, DOI 10.1073/pnas.96.12.6797; MANOUKIAN AS, 1992, GENE DEV, V6, P1740, DOI 10.1101/gad.6.9.1740; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; Phippen TM, 2000, J BIOL CHEM, V275, P37628, DOI 10.1074/jbc.M004234200; READ D, 1992, MECH DEVELOP, V38, P183, DOI 10.1016/0925-4773(92)90052-L; READ D, 1992, EMBO J, V11, P1035, DOI 10.1002/j.1460-2075.1992.tb05142.x; Reichmann Veit, 1997, Development (Cambridge), V124, P2915; Tracey WD, 2000, GENETICS, V154, P273; TSAI CC, 1994, DEVELOPMENT, V120, P1671; XIONG WC, 1993, GENE DEV, V7, P1085, DOI 10.1101/gad.7.6.1085; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	23	45	45	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2002	32	1					206	210		10.1038/ng942	http://dx.doi.org/10.1038/ng942			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	588RR	12145660				2022-12-25	WOS:000177714900024
J	Shindo, T; Manabe, I; Fukushima, Y; Tobe, K; Aizawa, K; Miyamoto, S; Kowase, KK; Moriyama, N; Imai, Y; Kawakami, H; Nishimatsu, H; Ishikawa, T; Suzuki, T; Morita, H; Maemura, K; Sata, M; Hirata, Y; Komukai, M; Kagechika, H; Kadowaki, T; Kurabayashi, M; Nagai, R				Shindo, T; Manabe, I; Fukushima, Y; Tobe, K; Aizawa, K; Miyamoto, S; Kowase, KK; Moriyama, N; Imai, Y; Kawakami, H; Nishimatsu, H; Ishikawa, T; Suzuki, T; Morita, H; Maemura, K; Sata, M; Hirata, Y; Komukai, M; Kagechika, H; Kadowaki, T; Kurabayashi, M; Nagai, R			Kruppel-like zinc-finger transcription factor KLF5/BTEB2 is a target for angiotensin II signaling and an essential regulator of cardiovascular remodeling	NATURE MEDICINE			English	Article							SMOOTH-MUSCLE-CELLS; RETINOBENZOIC ACIDS; GENE-TRANSCRIPTION; EXPRESSION; GROWTH; BTEB2; DEFICIENT; PATHWAYS; MYOCYTES; FAMILY	We recently isolated a Kruppel-like zinc-finger transcription factor 5 (KLF5; also known as BTEB2 and IKLF), which is markedly induced in activated vascular smooth-muscle cells and fibroblasts. Here we describe our analysis of the in vivo function of KLF5 using heterozygous KLF5-knockout mice ( Klf5(+/-)). In response to external stress, Klf5(+/-) mice showed diminished levels of arterial- wall thickening, angiogenesis, cardiac hypertrophy and interstitial fibrosis. Also, angiotensin II induced expression of KLF5, which in turn activated platelet-derived growth factor-A (PDGF-A) and transforming growth factor-beta (TGF-beta) expression. In addition, we determined that KLF5 interacted with the retinoic-acid receptor (RAR), that synthetic RAR ligands modulated KLF5 transcriptional activity, and that in vivo administration of RAR ligands affected stress responses in the cardiovascular system in a KLF5-dependent manner. KLF5 thus seems to be a key element linking external stress and cardiovascular remodeling.	Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Tokyo, Japan; Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Tokyo, Japan; Univ Tokyo, Grad Sch Med, Dept Metab Dis, Tokyo, Japan; Univ Tokyo, Grad Sch Med, Dept Urol, Tokyo, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Tokyo, Japan; Gunma Univ, Sch Med, Dept Internal Med 2, Gunma, Japan; Kyorin Univ, Dept Anat, Tokyo, Japan; Inst Med Mol Design Inc, Tokyo, Japan	University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo; Gunma University; Kyorin University	Nagai, R (corresponding author), Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Tokyo, Japan.	nagai-tky@umin.ac.jp	Manabe, Ichiro/E-1529-2014; Manabe, Ichiro/AAE-5105-2021	Kagechika, Hiroyuki/0000-0002-6747-1013; Suzuki, Toru/0000-0002-8371-664X				AIKAWA M, 1995, ANN NY ACAD SCI, V748, P578; Akishita M, 1997, ATHEROSCLEROSIS, V130, P1, DOI 10.1016/S0021-9150(96)06023-6; Berk BC, 2001, PHYSIOL REV, V81, P999, DOI 10.1152/physrev.2001.81.3.999; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Carmeliet P, 2000, J PATHOL, V190, P387; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; EYROLLES L, 1994, J MED CHEM, V37, P1508, DOI 10.1021/jm00036a017; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; Glass CK, 2000, GENE DEV, V14, P121; Hoshino Y, 2000, CIRCULATION, V102, P2528, DOI 10.1161/01.CIR.102.20.2528; Karlsson L, 2000, DEVELOPMENT, V127, P3457; Kawai-Kowase K, 1999, CIRC RES, V85, P787, DOI 10.1161/01.RES.85.9.787; Kihm AJ, 1998, P NATL ACAD SCI USA, V95, P14816, DOI 10.1073/pnas.95.25.14816; KOMURO I, 1990, J BIOL CHEM, V265, P3595; KUROO M, 1989, J BIOL CHEM, V264, P18272; Libby P, 2000, J INTERN MED, V247, P349, DOI 10.1046/j.1365-2796.2000.00654.x; Manabe I, 1997, BIOCHEM BIOPH RES CO, V239, P598, DOI 10.1006/bbrc.1997.7512; Manabe I, 2001, CIRC RES, V88, P1127, DOI 10.1161/hh1101.091339; Matsusaka T, 1999, J CLIN INVEST, V103, P1451, DOI 10.1172/JCI5056; Moroi M, 1998, J CLIN INVEST, V101, P1225, DOI 10.1172/JCI1293; Oh-hashi Y, 2001, CIRC RES, V89, P983, DOI 10.1161/hh2301.100812; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC1, DOI 10.1152/ajpcell.1999.277.1.C1; Shindo T, 2000, J CLIN INVEST, V105, P1345, DOI 10.1172/JCI8635; Shindo T, 2001, CIRCULATION, V104, P1964, DOI 10.1161/hc4101.097111; Silverman ES, 1999, AM J PATHOL, V154, P665, DOI 10.1016/S0002-9440(10)65312-6; Umemiya H, 1997, J MED CHEM, V40, P4222, DOI 10.1021/jm9704309; Valen G, 2001, J AM COLL CARDIOL, V38, P307, DOI 10.1016/S0735-1097(01)01377-8; Wang HD, 2001, CIRC RES, V88, P947, DOI 10.1161/hh0901.089987; Watanabe N, 1999, CIRC RES, V85, P182, DOI 10.1161/01.RES.85.2.182; Weir MR, 1999, AM J HYPERTENS, V12, p205S; Yamauchi-Takihara K, 2000, TRENDS CARDIOVAS MED, V10, P298, DOI 10.1016/S1050-1738(01)00066-4; Zdunek M, 2001, KIDNEY INT, V60, P2097, DOI 10.1046/j.1523-1755.2001.00041.x	33	317	343	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2002	8	8					856	863		10.1038/nm738	http://dx.doi.org/10.1038/nm738			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	579WJ	12101409				2022-12-25	WOS:000177200900032
J	Kikuchi, S; Hata, M; Fukumoto, K; Yamane, Y; Matsui, T; Tamura, A; Yonemura, S; Yamagishi, H; Keppler, D; Tsukita, S; Tsukita, S				Kikuchi, S; Hata, M; Fukumoto, K; Yamane, Y; Matsui, T; Tamura, A; Yonemura, S; Yamagishi, H; Keppler, D; Tsukita, S; Tsukita, S			Radixin deficiency causes conjugated hyperbilirubinemia with loss of Mrp2 from bile canalicular membranes	NATURE GENETICS			English	Article							MULTIDRUG-RESISTANCE PROTEIN; DUBIN-JOHNSON-SYNDROME; EZRIN/RADIXIN/MOESIN ERM PROTEINS; EXPORT PUMP; CELL-ADHESION; DRUG-RESISTANCE; CDNA CLONING; GENE; MOESIN; FAMILY	The ezrin-radixin-moesin (ERM) family of proteins crosslink actin filaments and integral membrane proteins(1-3). Radixin (encoded by Rdx) is the dominant ERM protein in the liver of wildtype mice(4,5) and is concentrated at bile canalicular membranes (BCMs)(5). Here we show that Rdx(-/-) mice are normal at birth, but their serum concentrations of conjugated bilirubin begin to increase gradually around 4 weeks, and they show mild liver injury after 8 weeks. This phenotype is similar to human conjugated hyperbilirubinemia in Dubin-Johnson syndrome(6,7), which is caused by mutations in the multidrug resistance protein 2 (MRP2, gene symbol ABCC2)(8-11), although this syndrome is not associated with overt liver injury. In wildtype mice, Mrp2 concentrates at BCMs to secrete conjugated bilirubin into bile(8,11,12). In the BCMs of Rdx(-/-) mice, Mrp2 is decreased compared with other BCM proteins such as dipeptidyl peptidase IV (CD26) and P-glycoproteins. In vitro binding studies show that radixin associates directly with the carboxy-terminal cytoplasmic domain of human MRP2. These findings indicate that radixin is required for secretion of conjugated bilirubin through its support of Mrp2 localization at BCMs.	Kyoto Univ, Fac Med, Dept Cell Biol, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Prefectural Univ Med, Dept Surg, Kamigyo Ku, Kyoto 6028566, Japan; KAN Res Inst, Shimogyo Ku, Kyoto 6008815, Japan; RIKEN, Ctr Dev Biol, Lab Cellular Morphogenesis, Chuo Ku, Kobe, Hyogo 6500047, Japan; Deutsch Krebsforschungszentrum, Div Tumor Biochem, D-69120 Heidelberg, Germany; Kyoto Univ, Coll Med Technol, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University; Kyoto Prefectural University of Medicine; KAN Research Institute; RIKEN; Helmholtz Association; German Cancer Research Center (DKFZ); Kyoto University	Tsukita, S (corresponding author), Kyoto Univ, Fac Med, Dept Cell Biol, Sakyo Ku, Kyoto 6068501, Japan.	atsukita@mfour.med.kyoto-u.ac.jp	Keppler, Dietrich/A-5528-2013	Keppler, Dietrich/0000-0003-2964-2333; Kikuchi, Shojiro/0000-0002-6217-8352				Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; Buchler M, 1996, J BIOL CHEM, V271, P15091; CHILDS S, 1995, CANCER RES, V55, P2029; Cui YH, 1999, MOL PHARMACOL, V55, P929; Denker SP, 2000, MOL CELL, V6, P1425, DOI 10.1016/S1097-2765(00)00139-8; Doi Y, 1999, J BIOL CHEM, V274, P2315, DOI 10.1074/jbc.274.4.2315; DUBIN IN, 1954, MEDICINE, V33, P155, DOI 10.1097/00005792-195409000-00001; Fouassier L, 2001, HEPATOLOGY, V33, P166, DOI 10.1053/jhep.2001.21143; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; Kartenbeck J, 1996, HEPATOLOGY, V23, P1061; Keitel V, 2000, HEPATOLOGY, V32, P1317, DOI 10.1053/jhep.2000.19791; Kocher O, 1999, LAB INVEST, V79, P1161; Kondo T, 1997, J CELL BIOL, V139, P749, DOI 10.1083/jcb.139.3.749; Konig J, 1999, BBA-BIOMEMBRANES, V1461, P377, DOI 10.1016/S0005-2736(99)00169-8; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; Mangeat P, 1999, TRENDS CELL BIOL, V9, P187, DOI 10.1016/S0962-8924(99)01544-5; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Nies AT, 2002, EUR J BIOCHEM, V269, P1866, DOI 10.1046/j.1432-1033.2002.02832.x; Nies AT, 1998, HEPATOLOGY, V28, P1332, DOI 10.1002/hep.510280523; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Paulusma CC, 1997, HEPATOLOGY, V25, P1539, DOI 10.1002/hep.510250635; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; SATO N, 1992, J CELL SCI, V103, P131; SPRINZ H, 1954, ANN INTERN MED, V41, P952, DOI 10.7326/0003-4819-41-5-952; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita S, 1999, J BIOL CHEM, V274, P34507, DOI 10.1074/jbc.274.49.34507; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885	30	260	269	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2002	31	3					320	325		10.1038/ng905	http://dx.doi.org/10.1038/ng905			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	567PW	12068294				2022-12-25	WOS:000176494100024
J	Pollock, R; Giel, M; Linher, K; Clackson, T				Pollock, R; Giel, M; Linher, K; Clackson, T			Regulation of endogenous gene expression with a small-molecule dimerizer	NATURE BIOTECHNOLOGY			English	Article							ZINC-FINGER PROTEINS; HYBRID TRANSCRIPTION FACTOR; ACTIVATION DOMAINS; MAMMALIAN-CELLS; TRANSGENIC MICE; DNA; DESIGN; SYSTEM; ANGIOGENESIS; SEQUENCES	Artificial transcription factors containing designer zinc-finger DNA-binding domains (DBDs) have been used to activate or repress expression of a growing number of endogenous genes. We have combined targeted zinc-finger DBD technology with a dimerizer-regulated gene expression system to permit the small-molecule control of endogenous gene transcription. We constructed a dimerizer-responsive transcription factor that incorporates an artificial zinc-finger DBD targeted to the promoter of the human VEGF gene. Introduction of this activator into human cells allowed expression of the chromosomal VEGF gene to be induced by a small-molecule dimerizer compound consisting of a nonimmunosuppressive rapamycin analog. We found that by directly regulating zinc-finger protein (ZFP) activity, we could circumvent difficulties encountered in the generation of cell lines stably expressing conventional unregulated activators. Dimerizer-dependent VEGF induction was rapid, tight, and dose dependent, and resulted in VEGF protein expression levels several-fold greater than those produced by the natural hypoxic response.	ARIAD Gene Therapeut Inc, Cambridge, MA 02139 USA		Pollock, R (corresponding author), ARIAD Gene Therapeut Inc, 26 Landsdowne St, Cambridge, MA 02139 USA.							Baron U, 1997, NUCLEIC ACIDS RES, V25, P2723, DOI 10.1093/nar/25.14.2723; Bartsevich VV, 2000, MOL PHARMACOL, V58, P1; Beerli RR, 2000, J BIOL CHEM, V275, P32617, DOI 10.1074/jbc.M005108200; Beerli RR, 2000, P NATL ACAD SCI USA, V97, P1495, DOI 10.1073/pnas.040552697; Beerli RR, 2002, NAT BIOTECHNOL, V20, P135, DOI 10.1038/nbt0202-135; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BRAND AH, 1993, DEVELOPMENT, V118, P401; Carmeliet P, 2000, NAT MED, V6, P1102, DOI 10.1038/80430; Dreier B, 2001, J BIOL CHEM, V276, P29466, DOI 10.1074/jbc.M102604200; GILBERT DM, 1993, MOL CELL BIOL, V13, P462, DOI 10.1128/MCB.13.1.462; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Greisman HA, 1997, SCIENCE, V275, P657, DOI 10.1126/science.275.5300.657; Guyer D, 1998, GENETICS, V149, P633; Ho SN, 1996, NATURE, V382, P822, DOI 10.1038/382822a0; Kim JS, 1998, P NATL ACAD SCI USA, V95, P2812, DOI 10.1073/pnas.95.6.2812; Liu PQ, 2001, J BIOL CHEM, V276, P11323, DOI 10.1074/jbc.M011172200; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Moore M, 2001, P NATL ACAD SCI USA, V98, P1437, DOI 10.1073/pnas.98.4.1437; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Pabo CO, 2001, ANNU REV BIOCHEM, V70, P313, DOI 10.1146/annurev.biochem.70.1.313; Pollock R, 2000, P NATL ACAD SCI USA, V97, P13221, DOI 10.1073/pnas.230446297; POMERANTZ JL, 1995, SCIENCE, V267, P93, DOI 10.1126/science.7809612; Rivera VM, 1996, NAT MED, V2, P1028, DOI 10.1038/nm0996-1028; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; Vincent KA, 2000, CIRCULATION, V102, P2255; WANG YL, 1994, P NATL ACAD SCI USA, V91, P8180, DOI 10.1073/pnas.91.17.8180; Wolfe SA, 2000, ANNU REV BIOPH BIOM, V29, P183, DOI 10.1146/annurev.biophys.29.1.183; Xu L, 2001, MOL THER, V3, P262, DOI 10.1006/mthe.2000.0254; Zhang L, 2000, J BIOL CHEM, V275, P33850, DOI 10.1074/jbc.M005341200	30	66	67	0	7	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2002	20	7					729	733		10.1038/nbt0702-729	http://dx.doi.org/10.1038/nbt0702-729			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	567QC	12089560				2022-12-25	WOS:000176494800029
J	Ferguson, NM; Anderson, RM				Ferguson, NM; Anderson, RM			Predicting evolutionary change in the influenza A virus	NATURE MEDICINE			English	Editorial Material									Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Infect Dis Epidemiol, London, England	Imperial College London	Ferguson, NM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Infect Dis Epidemiol, London, England.		Ferguson, Neil/B-8578-2008	Ferguson, Neil/0000-0002-1154-8093; Anderson, Roy/0000-0002-9528-3175				Bush RM, 2000, P NATL ACAD SCI USA, V97, P6974, DOI 10.1073/pnas.97.13.6974; Bush RM, 1999, SCIENCE, V286, P1921, DOI 10.1126/science.286.5446.1921; Everitt B. S., 2001, CLUSTER ANAL; FITCH WM, 1991, P NATL ACAD SCI USA, V88, P4270, DOI 10.1073/pnas.88.10.4270; Glezen WP, 1996, EPIDEMIOL REV, V18, P64, DOI 10.1093/oxfordjournals.epirev.a017917; Gordon AD, 1999, CLASSIFICATION; Plotkin JB, 2002, P NATL ACAD SCI USA, V99, P6263, DOI 10.1073/pnas.082110799	7	19	19	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2002	8	6					562	563		10.1038/nm0602-562	http://dx.doi.org/10.1038/nm0602-562			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	557KG	12042802				2022-12-25	WOS:000175907300023
J	Snow, AA				Snow, AA			Transgenic crops - why gene flow matters	NATURE BIOTECHNOLOGY			English	Editorial Material							BIOTECHNOLOGY; PLANTS		Ohio State Univ, Dept Ecol Evolut & Organismal Biol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Snow, AA (corresponding author), Ohio State Univ, Dept Ecol Evolut & Organismal Biol, Columbus, OH 43210 USA.							Crawley MJ, 2001, NATURE, V409, P682, DOI 10.1038/35055621; Ellstrand NC, 1999, ANNU REV ECOL SYST, V30, P539, DOI 10.1146/annurev.ecolsys.30.1.539; Holm L., 1997, NATURAL HIST DISTRIB; Snow AA, 1997, BIOSCIENCE, V47, P86, DOI 10.2307/1313019; TIEDJE JM, 1989, ECOLOGY, V70, P298, DOI 10.2307/1937535; United States National Research Council, 2002, ENV EFF TRANSG PLANT; Wolfenbarger LL, 2000, SCIENCE, V290, P2088, DOI 10.1126/science.290.5499.2088	7	104	112	1	26	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2002	20	6					542	542		10.1038/nbt0602-542	http://dx.doi.org/10.1038/nbt0602-542			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	558NM	12042845	Bronze			2022-12-25	WOS:000175973500009
J	Jobling, SA; Westcott, RJ; Tayal, A; Jeffcoat, R; Schwall, GP				Jobling, SA; Westcott, RJ; Tayal, A; Jeffcoat, R; Schwall, GP			Production of a freeze-thaw-stable potato starch by antisense inhibition of three starch synthase genes	NATURE BIOTECHNOLOGY			English	Article							SOLANUM-TUBEROSUM L; FUNCTIONAL-ANALYSIS; BRANCHING ENZYME; CHAIN-LENGTH; SBE-A; CLONING; GRANULE; FORMS	The use of unmodified starches in frozen foods is severely limited by the undesirable textural changes that occur after freezing and thawing. Retrogradation of glucan chains leads to syneresis, a separation of the starch gel and water phases. Stabilization of the starch structure is normally achieved by chemical modification to prevent these changes from occurring. We have now created a freeze-thaw-stable potato starch by alteration of starch composition and structure by genetic modification. An amylose-free starch with short-chain amylopectin was produced by simultaneous antisense downregulation of three starch synthase genes. This starch is extremely freeze-thaw stable and shows no syneresis even after five freeze-thaw cycles. The use of this starch has potential for environmental and consumer benefits because its production requires no chemical modification.	Unilever Res Labs Colworth, Colworth House, Sharnbrook MK44 1LQ, Beds, England; Natl Starch & Chem Corp, Bridgewater, NJ 08807 USA; ProteoSys AG, D-55139 Mainz, Germany	Unilever; ProteoSys AG	Jobling, SA (corresponding author), Unilever Res Labs Colworth, Colworth House, Sharnbrook MK44 1LQ, Beds, England.		Jobling, Stephen A/B-6056-2009	Jobling, Stephen A/0000-0001-6649-7329; Schwall, Gerhard/0000-0001-5046-1225				Abel GJW, 1996, PLANT J, V10, P981, DOI 10.1046/j.1365-313X.1996.10060981.x; EDWARDS A, 1995, PLANT J, V8, P283, DOI 10.1046/j.1365-313X.1995.08020283.x; Edwards A, 1999, PLANT J, V17, P251, DOI 10.1046/j.1365-313X.1999.00371.x; GIDLEY MJ, 1987, CARBOHYD RES, V161, P291, DOI 10.1016/S0008-6215(00)90086-7; Jobling SA, 1999, PLANT J, V18, P163, DOI 10.1046/j.1365-313X.1999.00441.x; Kossmann J, 1999, PLANTA, V208, P503, DOI 10.1007/s004250050587; Kossmann J, 2000, CRIT REV PLANT SCI, V19, P171, DOI 10.1016/S0735-2689(00)80002-7; KUIPERS AGJ, 1994, PLANT MOL BIOL, V26, P1759, DOI 10.1007/BF00019490; Lloyd JR, 1999, BIOCHEM J, V338, P515, DOI 10.1042/0264-6021:3380515; Marshall J, 1996, PLANT CELL, V8, P1121, DOI 10.1105/tpc.8.7.1121; PFANNEMULLER B, 1987, INT J BIOL MACROMOL, V9, P105, DOI 10.1016/0141-8130(87)90034-1; Safford R, 1998, CARBOHYD POLYM, V35, P155, DOI 10.1016/S0144-8617(97)00249-X; Schwall GP, 2000, NAT BIOTECHNOL, V18, P551, DOI 10.1038/75427; Tatge H, 1999, PLANT CELL ENVIRON, V22, P543, DOI 10.1046/j.1365-3040.1999.00437.x; VISSER RGF, 1991, MOL GEN GENET, V225, P289, DOI 10.1007/BF00269861; Westcott, 2001, Patent No. [01/19975, 0119975]; WURTZBURG O, 1984, Patent No. 4428972; Zheng GH, 1998, J FOOD SCI, V63, P134, DOI 10.1111/j.1365-2621.1998.tb15693.x	18	91	111	0	29	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2002	20	3					295	299		10.1038/nbt0302-295	http://dx.doi.org/10.1038/nbt0302-295			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	526RE	11875432				2022-12-25	WOS:000174142800049
J	Mitchell, P				Mitchell, P			A perspective on protein microarrays	NATURE BIOTECHNOLOGY			English	Article								Proteins, not genes, are the true targets of medicines, but their analysis by array technology still poses significant challenges for drug developers.										Karlstrom A, 2001, ANAL BIOCHEM, V295, P22, DOI 10.1006/abio.2001.5186; MacBeath G, 2000, SCIENCE, V289, P1760; Zhu H, 2001, SCIENCE, V293, P2101, DOI 10.1126/science.1062191; Ziauddin J, 2001, NATURE, V411, P107, DOI 10.1038/35075114	4	280	293	2	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2002	20	3					225	229		10.1038/nbt0302-225	http://dx.doi.org/10.1038/nbt0302-225			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	526RE	11875416				2022-12-25	WOS:000174142800029
J	Cagney, G; Emili, A				Cagney, G; Emili, A			De novo peptide sequencing and quantitative profiling of complex protein mixtures using mass-coded abundance tagging	NATURE BIOTECHNOLOGY			English	Article							SPECTROMETRY; LYSINE; EXPRESSION; TAGS	Proteomic studies require efficient, robust, and practical methods of characterizing proteins present in biological samples. Here we describe an integrated strategy for systematic proteome analysis based on differential guanidination of C-terminal lysine residues on tryptic peptides followed by capillary liquid chromatography-electrospray tandem mass spectrometry. The approach, termed mass-coded abundance tagging (MCAT), facilitates the automated, large-scale, and comprehensive de novo determination of peptide sequence and relative quantitation of proteins in biological samples in a single analysis. MCAT offers marked advantages as compared with previously described methods and is simple, economic, and effective when applied to complex proteomic mixtures. MCAT is used to identify proteins, including polymorphic variants, from complex mixtures and measure variation in protein levels from diverse cell types.	Univ Toronto, Banting & Best Dept Med Res, Program Proteom & Bioinformat, Toronto, ON, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON, Canada	University of Toronto; University of Toronto	Emili, A (corresponding author), Univ Toronto, Banting & Best Dept Med Res, Program Proteom & Bioinformat, Toronto, ON, Canada.		Cagney, Gerard/A-4648-2009	Cagney, Gerard/0000-0001-7189-9496				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Andersen JS, 1996, NAT BIOTECHNOL, V14, P449, DOI 10.1038/nbt0496-449; Beardsley RL, 2000, RAPID COMMUN MASS SP, V14, P2147, DOI 10.1002/1097-0231(20001215)14:23<2147::AID-RCM145>3.0.CO;2-M; Brancia FL, 2000, RAPID COMMUN MASS SP, V14, P2070, DOI 10.1002/1097-0231(20001115)14:21<2070::AID-RCM133>3.0.CO;2-G; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Hale JE, 2000, ANAL BIOCHEM, V287, P110, DOI 10.1006/abio.2000.4834; Han DK, 2001, NAT BIOTECHNOL, V19, P946, DOI 10.1038/nbt1001-946; Keough T, 2000, RAPID COMMUN MASS SP, V14, P2348, DOI 10.1002/1097-0231(20001230)14:24<2348::AID-RCM175>3.0.CO;2-8; Kimmel J., 1967, METH ENZYMOLOGY, V11, P584; Kinter M., 2000, PROTEIN SEQUENCING I, DOI 10.1002/0471721980; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Munchbach M, 2000, ANAL CHEM, V72, P4047, DOI 10.1021/ac000265w; Oda Y, 1999, P NATL ACAD SCI USA, V96, P6591, DOI 10.1073/pnas.96.12.6591; Pandey A, 2000, NATURE, V405, P837, DOI 10.1038/35015709; Shevchenko A, 1997, RAPID COMMUN MASS SP, V11, P1015, DOI 10.1002/(SICI)1097-0231(19970615)11:9<1015::AID-RCM958>3.0.CO;2-H; Washburn MP, 2000, CURR OPIN MICROBIOL, V3, P292, DOI 10.1016/S1369-5274(00)00092-8	19	193	219	2	19	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2002	20	2					163	170		10.1038/nbt0202-163	http://dx.doi.org/10.1038/nbt0202-163			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	517FT	11821862				2022-12-25	WOS:000173601000025
J	Abreu, JG; Ketpura, NI; Reversade, B; De Robertis, EM				Abreu, JG; Ketpura, NI; Reversade, B; De Robertis, EM			Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta	NATURE CELL BIOLOGY			English	Article							DIRECT BINDING; CHORDIN; XENOPUS; FAMILY; EXPRESSION; PROTEINS; RECEPTOR; THROMBOSPONDIN; SUPERFAMILY; STIMULATION	Connective-tissue growth factor (CTGF) is a secreted protein implicated in multiple cellular events including angiogenesis, skeletogenesis and wound healing(1). It is a member of the CCN family of secreted proteins, named after CTGF, cysteine-rich 61 (CYR61), and nephroblastoma overexpressed (NOV) proteins. The molecular mechanism by which CTGF or other CCN proteins regulate cell signalling is not known. CTGF contains a cysteine-rich domain (CR) similar to those found in chordin and other secreted proteins(2), which in some cases have been reported to function as bone morphogenetic protein (BMP) and TGF-beta binding domains(3-6). Here we show that CTGF directly binds BMP4 and TGF-beta1 through its CR domain. CTGF can antagonize BMP4 activity by preventing its binding to BMP receptors and has the opposite effect, enhancement of receptor binding, on TGF-beta1. These results show that CTGF inhibits BMP and activates TGF-beta signals by direct binding in the extracellular space.	Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	De Robertis, EM (corresponding author), Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA.	derobert@hhmi.ucla.edu	Abreu, Jose G/ABB-1199-2021; Abreu, Jose G/G-6159-2010	Abreu, Jose G/0000-0002-1363-1755; Abreu, Jose G/0000-0002-9875-7786; REVERSADE, Bruno/0000-0002-4070-7997	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD021502] Funding Source: NIH RePORTER; NICHD NIH HHS [R37 HD021502, R37 HD21502-16, R37 HD021502-16] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abreu JG, 2002, GENE, V287, P39, DOI 10.1016/S0378-1119(01)00827-7; Adams JC, 2000, DEV DYNAM, V218, P280; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; Holmes A, 2001, J BIOL CHEM, V276, P10594, DOI 10.1074/jbc.M010149200; HUNT LT, 1987, BIOCHEM BIOPH RES CO, V144, P876, DOI 10.1016/S0006-291X(87)80046-3; Iemura S, 1998, P NATL ACAD SCI USA, V95, P9337, DOI 10.1073/pnas.95.16.9337; Inoki I, 2001, FASEB J, V15, P219, DOI 10.1096/fj.01-0332fje; KATAGIRI T, 1990, BIOCHEM BIOPH RES CO, V172, P295, DOI 10.1016/S0006-291X(05)80208-6; Kim HS, 1997, P NATL ACAD SCI USA, V94, P12981, DOI 10.1073/pnas.94.24.12981; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; Kothapalli D, 1997, CELL GROWTH DIFFER, V8, P61; Larrain J, 2001, DEVELOPMENT, V128, P4439; Larrain J, 2000, DEVELOPMENT, V127, P821; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; MASUHARA K, 1995, BONE, V16, P91, DOI 10.1016/S8756-3282(94)00014-X; Moussad EEDA, 2000, MOL GENET METAB, V71, P276, DOI 10.1006/mgme.2000.3059; Nakayama N, 2001, DEV BIOL, V232, P372, DOI 10.1006/dbio.2001.0200; Pearce JJH, 1999, DEV BIOL, V209, P98, DOI 10.1006/dbio.1999.9240; Persson U, 1998, FEBS LETT, V434, P83, DOI 10.1016/S0014-5793(98)00954-5; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; Robson P, 2001, DEV BIOL, V234, P317, DOI 10.1006/dbio.2001.0274; Sakuta H, 2001, SCIENCE, V293, P111, DOI 10.1126/science.1058379; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; Segarini PR, 2001, J BIOL CHEM, V276, P40659, DOI 10.1074/jbc.M105180200; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Zhu Y, 1999, J CELL BIOL, V144, P1069, DOI 10.1083/jcb.144.5.1069	30	714	751	2	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2002	4	8					599	604		10.1038/ncb826	http://dx.doi.org/10.1038/ncb826			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	579WK	12134160	Green Accepted			2022-12-25	WOS:000177201100015
J	Carter, N; Nakamoto, T; Hirai, H; Hunter, T				Carter, N; Nakamoto, T; Hirai, H; Hunter, T			EphrinA1-induced cytoskeletal re-organization requires FAK and p130(cas)	NATURE CELL BIOLOGY			English	Article							FOCAL-ADHESION-KINASE; RECEPTOR TYROSINE KINASE; COUPLES EPH RECEPTORS; PROSTATE-CANCER; CELL-MIGRATION; TRANSMEMBRANE LIGANDS; INTEGRIN ACTIVATION; NEURAL DEVELOPMENT; PROTEIN; RAS	Ephrins and Eph receptors are involved in axon guidance and cellular morphogenesis. An interaction between ephrin and Eph receptors elicits neuronal growth-cone collapse through cytoskeletal disassembly. When NIH3T3 cells were plated onto an ephrinA1-coated surface, the cells both adhered and spread. Adhesion and spreading proceeded concomitantly with changes in both the actin and microtubule cytoskeleton. EphA2, focal adhesion kinase (FAK) and p130(cas) were identified as the major ephrin-dependent phosphotyrosyl proteins during the ephrin-induced morphological changes. Mouse embryonic fibroblasts (MEFs) derived from FAK(-/-) and p130(cas-/-) mice had severe defects in ephrinA1-induced cell spreading, which were reversed after re-expression of FAK or p130 cas, respectively. Expression of a constitutively active EphA2 induced NIH3T3 cells to undergo identical, but ligand-independent, morphological changes. These data show that ephrinA1 can induce cell adhesion and actin cytoskeletal changes in fibroblasts in a FAK- and p130(cas)-dependent manner, through activation of the EphA2 receptor. The finding that ephrin-Eph signalling can result in actin cytoskeletal assembly, rather than disassembly, has many implications for ephrin-Eph responses in other cell types.	Salk Inst Biol Studies, Mol & Cell Biol Lab, La Jolla, CA 92037 USA; Univ Tokyo, Grad Sch Med, Dept Haematol & Oncol, Tokyo 1138655, Japan	Salk Institute; University of Tokyo	Carter, N (corresponding author), Salk Inst Biol Studies, Mol & Cell Biol Lab, La Jolla, CA 92037 USA.							Becker E, 2000, MOL CELL BIOL, V20, P1537, DOI 10.1128/MCB.20.5.1537-1545.2000; Berrier AL, 2000, J CELL BIOL, V151, P1549, DOI 10.1083/jcb.151.7.1549; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Davy A, 2000, EMBO J, V19, P5396, DOI 10.1093/emboj/19.20.5396; Davy A, 1999, GENE DEV, V13, P3125, DOI 10.1101/gad.13.23.3125; Dodelet VC, 1999, J BIOL CHEM, V274, P31941, DOI 10.1074/jbc.274.45.31941; Elowe S, 2001, MOL CELL BIOL, V21, P7429, DOI 10.1128/MCB.21.21.7429-7441.2001; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Gao PP, 2000, J NEUROSCI RES, V60, P427, DOI 10.1002/(SICI)1097-4547(20000515)60:4<427::AID-JNR1>3.3.CO;2-4; Gerlai R, 2001, NAT REV NEUROSCI, V2, P205, DOI 10.1038/35058582; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; Gu C, 2001, MOL CELL BIOL, V21, P4579, DOI 10.1128/MCB.21.14.4579-4597.2001; Harte MT, 2000, BBA-MOL CELL RES, V1499, P34, DOI 10.1016/S0167-4889(00)00104-X; Hauck CR, 2000, IMMUNOL RES, V21, P293, DOI 10.1385/IR:21:2-3:293; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; Holmberg J, 2000, NATURE, V408, P203, DOI 10.1038/35041577; Honda H, 1999, BIOCHEM BIOPH RES CO, V262, P25, DOI 10.1006/bbrc.1999.1162; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Huai JS, 2001, J BIOL CHEM, V276, P6689, DOI 10.1074/jbc.M008127200; Huynh-Do U, 1999, EMBO J, V18, P2165, DOI 10.1093/emboj/18.8.2165; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Jiang W, 1998, MOL CELL, V2, P877, DOI 10.1016/S1097-2765(00)80302-0; Klein R, 2001, CURR OPIN CELL BIOL, V13, P196, DOI 10.1016/S0955-0674(00)00197-6; Klingbeil CK, 2001, J CELL BIOL, V152, P97, DOI 10.1083/jcb.152.1.97; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; Liu AY, 2000, CANCER RES, V60, P3429; Lu Q, 2001, CELL, V105, P69, DOI 10.1016/S0092-8674(01)00297-5; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Monschau B, 1997, EMBO J, V16, P1258, DOI 10.1093/emboj/16.6.1258; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Pasquale EB, 1997, CURR OPIN CELL BIOL, V9, P608, DOI 10.1016/S0955-0674(97)80113-5; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; Ruest PJ, 2000, CELL GROWTH DIFFER, V11, P41; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schmucker D, 2001, CELL, V105, P701, DOI 10.1016/S0092-8674(01)00391-9; Shamah SM, 2001, CELL, V105, P233, DOI 10.1016/S0092-8674(01)00314-2; Sieg DJ, 1999, J CELL SCI, V112, P2677; Stanzione R, 2001, LAB INVEST, V81, P51, DOI 10.1038/labinvest.3780211; Torring N, 2000, ANTICANCER RES, V20, P91; Wahl S, 2000, J CELL BIOL, V149, P263, DOI 10.1083/jcb.149.2.263; Walker-Daniels J, 1999, PROSTATE, V41, P275, DOI 10.1002/(SICI)1097-0045(19991201)41:4<275::AID-PROS8>3.0.CO;2-T; Wilkinson DG, 2001, NAT REV NEUROSCI, V2, P155, DOI 10.1038/35058515; Yu HH, 2001, ONCOGENE, V20, P3995, DOI 10.1038/sj.onc.1204524; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zhou FQ, 2001, J CELL BIOL, V153, P1071, DOI 10.1083/jcb.153.5.1071; Zisch AH, 1998, ONCOGENE, V16, P2657, DOI 10.1038/sj.onc.1201823; Zou JX, 1999, P NATL ACAD SCI USA, V96, P13813, DOI 10.1073/pnas.96.24.13813	53	155	163	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2002	4	8					565	573		10.1038/ncb823	http://dx.doi.org/10.1038/ncb823			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	579WK	12134157				2022-12-25	WOS:000177201100011
J	Feng, BJ; Huang, W; Shugart, YY; Lee, MK; Zhang, F; Xia, JC; Wang, HY; Huang, TB; Jian, SW; Huang, P; Feng, QS; Huang, LX; Yu, XJ; Li, D; Chen, LZ; Jia, WH; Fang, Y; Huang, HM; Zhu, JL; Liu, XM; Zhao, Y; Liu, WQ; Deng, MQ; Hu, WH; Wu, SX; Mo, HY; Hong, MF; King, MC; Chen, Z; Zeng, YX				Feng, BJ; Huang, W; Shugart, YY; Lee, MK; Zhang, F; Xia, JC; Wang, HY; Huang, TB; Jian, SW; Huang, P; Feng, QS; Huang, LX; Yu, XJ; Li, D; Chen, LZ; Jia, WH; Fang, Y; Huang, HM; Zhu, JL; Liu, XM; Zhao, Y; Liu, WQ; Deng, MQ; Hu, WH; Wu, SX; Mo, HY; Hong, MF; King, MC; Chen, Z; Zeng, YX			Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4	NATURE GENETICS			English	Article							RISK-FACTORS; MICROSATELLITES; SCORES; MODEL; MAPS	Nasopharyngeal carcinoma (NPC) occurs with high frequency in Asian populations, especially among people of Cantonese ancestry. In areas with high incidence, NPC clusters in families, which suggests that both geography and genetics may influence disease risk(1-6). Although the HLA-Bw46 locus is associated with increased risk of NPC7,8, no predisposing genes have been identified so far. Here we report the results of a genome-wide search carried out in families at high risk of NPC from Guangdong Province, China. Parametric analyses provide evidence of linkage to the D4S405 marker on chromosome 4 with a logarithm of odds for linkage (lod) score of 3.06 and a heterogeneity-adjusted lod (hlod) score of 3.21. Fine mapping with additional markers flanking D4S405 resulted in a lod score of 3.54 and hlod score of 3.67 for the region 4p15.1-q12. Multipoint nonparametric linkage analysis gives lod scores of 3.54 at D4S405 (P = 5.4 x 10(-5)) and 4.2 at D4S3002 (P = 1.1 x 10(-5)), which is positioned 4.5 cM away from D4S405. When Epstein-Barr virus antibody titer was included as a covariate, the lod scores reached 4.70 (P = 2.0 x 10(-5)) and 5.36 (P = 4.36 x 10(-6)) for D4S405 and D4S3002, respectively. Our findings provide evidence of a major susceptibility locus for NPC on chromosome 4 in a subset of families.	Sun Yat Sen Univ, Inst Canc, Guangzhou, Peoples R China; Sun Yat Sen Univ, Dept Nasopharyngeal Carcinoma, Guangzhou, Peoples R China; Sun Yat Sen Univ, Dept Radiotherapy, Ctr Canc, Guangzhou, Peoples R China; Chinese Natl Human Genome Ctr, Shanghai, Peoples R China; Shanghai Med Univ 2, Rui Jin Hosp, Shanghai, Peoples R China; Shanghai Med Univ 2, Hlth Sci Ctr, Shanghai, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sc, Shanghai, Peoples R China; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; Univ Washington, Dept Med & Genet, Seattle, WA 98195 USA	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Chinese Academy of Sciences; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Washington; University of Washington Seattle	Zeng, YX (corresponding author), Sun Yat Sen Univ, Inst Canc, Guangzhou, Peoples R China.	yxzeng@gzsums.edu.cn	Liu, Xiaoming/C-2743-2008; Feng, Bing-Jian/C-6974-2009	Liu, Xiaoming/0000-0001-8285-5528; YAO, YIN/0000-0003-3053-8429; King, Mary-Claire/0000-0001-9426-1743				Broman KW, 1998, AM J HUM GENET, V63, P861, DOI 10.1086/302011; CHAN S H, 1990, Annals Academy of Medicine Singapore, V19, P201; Chen DL, 1997, CANCER LETT, V117, P17, DOI 10.1016/S0304-3835(97)00182-1; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; FISCHER A, 1984, PATHOLOGY, V16, P23, DOI 10.3109/00313028409067906; Goddard KAB, 2001, AM J HUM GENET, V68, P1197, DOI 10.1086/320103; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HENDERSON BE, 1976, NEW ENGL J MED, V295, P1101, DOI 10.1056/NEJM197611112952003; Huang TB, 1998, NASOPHARYNGEAL CARCI, P6; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LATHROP GM, 1986, GENET EPIDEMIOL, V3, P39, DOI 10.1002/gepi.1370030105; LU SJ, 1990, NATURE, V346, P470, DOI 10.1038/346470a0; NEVO S, 1971, CANCER, V28, P807, DOI 10.1002/1097-0142(197109)28:3<807::AID-CNCR2820280342>3.0.CO;2-C; Olson JM, 1999, AM J HUM GENET, V65, P1760, DOI 10.1086/302662; Ooi EE, 1997, INT J CANCER, V74, P229; OTT J, 1986, GENET EPIDEMIOL, P251; SCHAFFER AA, 1994, HUM HERED, V44, P225, DOI 10.1159/000154222; SELF SG, 1987, J AM STAT ASSOC, V82, P605, DOI 10.2307/2289471; Smith JR, 1996, SCIENCE, V274, P1371, DOI 10.1126/science.274.5291.1371; Sobel E, 1996, AM J HUM GENET, V58, P1323; Vokes EE, 1997, LANCET, V350, P1087, DOI 10.1016/S0140-6736(97)07269-3	24	194	222	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2002	31	4					395	399		10.1038/ng932	http://dx.doi.org/10.1038/ng932			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	578XV	12118254				2022-12-25	WOS:000177147100015
J	Meijers-Heijboer, H; van den Ouweland, A; Klijn, J; Wasielewski, M; de Snoo, A; Oldenburg, R; Hollestelle, A; Houben, M; Crepin, E; van Veghel-Plandsoen, M; Elstrodt, F; van Duijn, C; Bartels, C; Meijers, C; Schutte, M; McGuffog, L; Thompson, D; Easton, DF; Sodha, N; Seal, S; Barfoot, R; Mangion, J; Chang-Claude, J; Eccles, D; Eeles, R; Evans, DG; Houlston, R; Murday, V; Narod, S; Peretz, T; Peto, J; Phelan, C; Zhang, HX; Szabo, C; Devilee, P; Goldgar, D; Futreal, PA; Nathanson, KL; Weber, BL; Rahman, N; Stratton, MR				Meijers-Heijboer, H; van den Ouweland, A; Klijn, J; Wasielewski, M; de Snoo, A; Oldenburg, R; Hollestelle, A; Houben, M; Crepin, E; van Veghel-Plandsoen, M; Elstrodt, F; van Duijn, C; Bartels, C; Meijers, C; Schutte, M; McGuffog, L; Thompson, D; Easton, DF; Sodha, N; Seal, S; Barfoot, R; Mangion, J; Chang-Claude, J; Eccles, D; Eeles, R; Evans, DG; Houlston, R; Murday, V; Narod, S; Peretz, T; Peto, J; Phelan, C; Zhang, HX; Szabo, C; Devilee, P; Goldgar, D; Futreal, PA; Nathanson, KL; Weber, BL; Rahman, N; Stratton, MR		CHEK2-Breast Canc Consortium	Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations	NATURE GENETICS			English	Article							LI-FRAUMENI-SYNDROME; DNA-DAMAGE CHECKPOINT; CHK2; GENES; P53; PHOSPHORYLATION; FAMILIES; ATM	Mutations in BRCA1 and BRCA2 confer a high risk of breast and ovarian cancer(1), but account for only a small fraction of breast cancer susceptibility(1,2). To find additional genes conferring susceptibility to breast cancer, we analyzed CHEK2 (also known as CHK2), which encodes a cell-cycle checkpoint kinase that is implicated in DNA repair processes involving BRCA1 and p53 (refs 3-5). We show that CHEK2*1100delC, a truncating variant that abrogates the kinase activity(6), has a frequency of 1.1% in healthy individuals. However, this variant is present in 5.1% of individuals with breast cancer from 718 families that do not carry mutations in BRCA1 or BRCA2 (P=0.00000003), including 13.5% of individuals from families with male breast cancer (P=0.00015). We estimate that the CHEK2*1100delC variant results in an approximately twofold increase of breast cancer risk in women and a tenfold increase of risk in men. By contrast, the variant confers no increased cancer risk in carriers of BRCA1 or BRCA2 mutations. This suggests that the biological mechanisms underlying the elevated risk of breast cancer in CHEK2 mutation carriers are already subverted in carriers of BRCA1 or BRCA2 mutations, which is consistent with participation of the encoded proteins in the same pathway.	Inst Canc Res, Haddow Labs, Canc Genet Sect, Sutton SM2 5NG, Surrey, England; Erasmus Med Ctr, Dept Clin Genet, Rotterdam, Netherlands; Erasmus Med Ctr, Dept Med Oncol, Rotterdam, Netherlands; Erasmus Med Ctr, Dept Epidemiol & Biostat, Rotterdam, Netherlands; Erasmus Med Ctr, Dept Surg Oncol, Rotterdam, Netherlands; Erasmus Med Ctr, Dept Pathol, Rotterdam, Netherlands; Univ Cambridge, Strangeways Res Labs, Canc Res UK Genet Epidemiol Unit, Cambridge CB2 1TN, England; German Canc Res Ctr, Div Epidemiol, D-6900 Heidelberg, Germany; Princess Anne Hosp, Wessex Clin Genet Serv, Southampton, Hants, England; St Marys Hosp, Dept Med Genet, Manchester M13 0JH, Lancs, England; St Georges Med Sch, Med Genet Unit, London, England; Womens Coll Hosp, Ctr Res Womens Hlth, Toronto, ON M5S 1B2, Canada; Hadassah Univ Hosp, Sharett Inst Oncol, IL-91120 Jerusalem, Israel; Inst Canc Res, Haddow Labs, Epidemiol Sect, Surrey, England; London Sch Hyg & Trop Med, London WC1, England; Univ Penn, Med Ctr, Dept Hematol Oncol, Philadelphia, PA 19104 USA; Int Agcy Res Canc, F-69372 Lyon, France; Leiden Univ, Dept Pathol Human Genet, Leiden, Netherlands; Wellcome Trust Sanger Inst, Canc Genome Project, Hinxton, Cambs, England	University of London; Institute of Cancer Research - UK; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Cancer Research UK; University of Cambridge; Helmholtz Association; German Cancer Research Center (DKFZ); University of Manchester; St Georges University London; University of Toronto; University Toronto Affiliates; Womens College Hospital; Hebrew University of Jerusalem; University of London; Institute of Cancer Research - UK; University of London; London School of Hygiene & Tropical Medicine; University of Pennsylvania; World Health Organization; International Agency for Research on Cancer (IARC); Leiden University; Leiden University - Excl LUMC; Wellcome Trust Sanger Institute	Rahman, N (corresponding author), Inst Canc Res, Haddow Labs, Canc Genet Sect, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.		DEVILEE, PETER/ABR-2140-2022; Evans, D Gareth/AAB-4308-2022; Rahman, Nazneen/B-8890-2012; Eccles, Diana/K-6327-2019; Narod, Steven A/AAA-6112-2022; Rahman, Nazneen/D-2802-2013	Evans, D Gareth/0000-0002-8482-5784; Eccles, Diana/0000-0002-9935-3169; Van Duijn, Cornelia/0000-0002-2374-9204; Hollestelle, Antoinette/0000-0003-1166-1966; Nathanson, Katherine/0000-0002-6740-0901; Houlston, Richard/0000-0002-5268-0242; Eeles, Rosalind/0000-0002-3698-6241; Rahman, Nazneen/0000-0003-4376-0440				Ahn JY, 2000, CANCER RES, V60, P5934; Antoniou AC, 2001, GENET EPIDEMIOL, V21, P1, DOI 10.1002/gepi.1014; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chehab NH, 2000, GENE DEV, V14, P278; Dunning AM, 1999, CANCER EPIDEM BIOMAR, V8, P843; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; LANGE K, 1988, GENET EPIDEMIOL, V5, P471, DOI 10.1002/gepi.1370050611; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Lee SB, 2001, CANCER RES, V61, P8062; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Peto J, 1999, J NATL CANCER I, V91, P943, DOI 10.1093/jnci/91.11.943; PetrijBosch A, 1997, NAT GENET, V17, P341, DOI 10.1038/ng1197-341; Shieh SY, 2000, GENE DEV, V14, P289; Sodha N, 2002, HUM MUTAT, V19, P173, DOI 10.1002/humu.10031; Sodha N, 2000, Science, V289, P359; Vahteristo P, 2001, CANCER RES, V61, P5718; Wu XL, 2001, J BIOL CHEM, V276, P2971, DOI 10.1074/jbc.M009727200	19	814	838	0	25	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2002	31	1					55	59		10.1038/ng879	http://dx.doi.org/10.1038/ng879			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	547ZF	11967536	Bronze			2022-12-25	WOS:000175362500014
J	Zhu, DC; Kepley, CL; Zhang, M; Zhang, K; Saxon, A				Zhu, DC; Kepley, CL; Zhang, M; Zhang, K; Saxon, A			A novel human immunoglobulin Fc gamma-Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation	NATURE MEDICINE			English	Article							MAST-CELL ACTIVATION; AFFINITY IGE RECEPTOR; NEGATIVE REGULATION; PHOSPHATASE SHIP; BINDING-SITE; BASOPHILS; MICE	Human mast cells and basophils that express the high-affinity immunoglobulin E (IgE) receptor, Fcepsilon receptor 1 (FcepsilonRI), have key roles in allergic diseases. FcepsilonRI cross-linking stimulates the release of allergic mediators(1). Mast cells and basophils co-express FcgammaRIIb, a low affinity receptor containing an immunoreceptor tyrosine-based inhibitory motif and whose co-aggregation with FcepsilonRI can block FcepsilonRI-mediated reactivity(2-4). Here we designed, expressed and tested the human basophil and mast-cell inhibitory function of a novel chimeric fusion protein, whose structure is gammaHinge-CHgamma2-CHgamma3-15aa linker-CHepsilon2-CHepsilon3-CHepsilon4. This Fcgamma-Fcepsilon fusion protein was expressed as the predicted 140-kD dimer that reacted with anti-human epsilon- and gamma-chain specific antibodies. Fcgamma-Fcepsilon bound to both human FcepsilonRI and FcgammaRII. It also showed dose- and time-dependent inhibition of antigen-driven IgE-mediated histamine release from fresh human basophils sensitized with IgE directed against NIP (4-hydroxy-3-iodo-5-nitrophenylacetyl). This was associated with altered Syk signaling. The fusion protein also showed increased inhibition of human anti-NP (4-hydroxy-3-nitrophenylacetyl) and anti-dansyl IgE-mediated passive cutaneous anaphylaxis in transgenic mice expressing human FcepsilonRIalpha. Our results show that this chimeric protein is able to form complexes with both FcepsilonRI and FcgammaRII, and inhibit mast-cell and basophil function. This approach, using a Fcgamma-Fcepsilon fusion protein to co-aggregate FcepsilonRI with a receptor containing an immunoreceptor tyrosine-based inhibition motif, has therapeutic potential in IgE- and FcepsilonRI-mediated diseases.	Univ Calif Los Angeles, Sch Med, Dept Med, Div Clin Immunol,Hart & Louise Lyon Lab, Los Angeles, CA 90024 USA; Univ New Mexico, Hlth Sci Ctr, Dept Pathol, Albuquerque, NM 87131 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of New Mexico; University of New Mexico's Health Sciences Center	Saxon, A (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Div Clin Immunol,Hart & Louise Lyon Lab, Los Angeles, CA 90024 USA.				NIAID NIH HHS [R01 AI015251, R21 AI015251, AI-15251] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI015251, R01AI015251] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Daeron M, 1997, INT ARCH ALLERGY IMM, V113, P138, DOI 10.1159/000237528; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; Daeron M, 1996, IMMUNOL LETT, V54, P73, DOI 10.1016/S0165-2478(96)02652-1; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; Dombrowicz D, 1996, J IMMUNOL, V157, P1645; Fong DC, 1996, IMMUNOL LETT, V54, P83, DOI 10.1016/S0165-2478(96)02654-5; FungLeung WP, 1996, J EXP MED, V183, P49, DOI 10.1084/jem.183.1.49; HELM B, 1988, NATURE, V331, P180, DOI 10.1038/331180a0; HENDERSHOT LM, 1988, MOL IMMUNOL, V25, P585, DOI 10.1016/0161-5890(88)90081-8; HULETT MD, 1994, J BIOL CHEM, V269, P15287; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; Kepley CL, 2000, J ALLERGY CLIN IMMUN, V106, P337, DOI 10.1067/mai.2000.107931; Malbec O, 1998, J IMMUNOL, V160, P1647; Oliver JM, 2000, IMMUNOPHARMACOLOGY, V48, P269, DOI 10.1016/S0162-3109(00)00224-1; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Ott VL, 2000, J ALLERGY CLIN IMMUN, V106, P429, DOI 10.1067/mai.2000.109428; Ravetch JV, 1997, CURR OPIN IMMUNOL, V9, P121, DOI 10.1016/S0952-7915(97)80168-9; Ravetch JV, 2000, SCIENCE, V290, P84, DOI 10.1126/science.290.5489.84; Takai T, 1996, NATURE, V379, P346, DOI 10.1038/379346a0; Wedi B, 1996, ARCH DERMATOL RES, V289, P21, DOI 10.1007/s004030050147	21	171	220	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAY	2002	8	5					518	521		10.1038/nm0502-518	http://dx.doi.org/10.1038/nm0502-518			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	547ZW	11984598	Green Accepted			2022-12-25	WOS:000175336800039
J	Ha, SJ; Chang, J; Song, MK; Suh, YS; Jin, HT; Lee, CH; Nam, GH; Choi, G; Choi, KY; Lee, SH; Kim, WB; Sung, YC				Ha, SJ; Chang, J; Song, MK; Suh, YS; Jin, HT; Lee, CH; Nam, GH; Choi, G; Choi, KY; Lee, SH; Kim, WB; Sung, YC			Engineering N-glycosylation mutations in IL-12 enhances sustained cytotoxic T lymphocyte responses for DNA immunization	NATURE BIOTECHNOLOGY			English	Article							BLOOD MONONUCLEAR-CELLS; IN-VIVO; GENE-THERAPY; INTERLEUKIN-12; IMMUNITY; MURINE; VIRUS; CONSTRUCTION; RECEPTOR	Interleukin-12 (IL-12), consisting of p40 and p35 subunits, produces both p70 heterodimer and free p40. p70 is essential for the induction of T-helper 1 (Th1) and cytotoxic T-cell (CTL) immunity, whereas p40 inhibits p70-mediated function. Here, we found that mutations introduced into N-glycosylation sites (N220 of murine p40 and N222 of human p40) reduced secretion of p40 but not p70. Co-immunization of N220 mutant mIL-12 gene with hepatitis C virus (HCV) E2 DNA significantly enhanced long-term E2-specific CD8(+) T-cell response and protection against tumor challenge compared with that of wild type. Our results indicate that the ratio of p70 to p40 is important for generating sustained long-term cell-mediated immunity. Thus, the mutant IL-12 could be utilized for the development of DNA vaccines as an adjuvant for the generation of long-term memory T-cell responses.	Pohang Univ Sci & Technol, Dept Life Sci, Natl Res Lab DNA Med, Pohang 790784, Kyungbuk, South Korea; ProGen Co Ltd, Yongin 449905, Kyunggi, South Korea	Pohang University of Science & Technology (POSTECH)	Sung, YC (corresponding author), Pohang Univ Sci & Technol, Dept Life Sci, Natl Res Lab DNA Med, San 31, Pohang 790784, Kyungbuk, South Korea.			CHANG, JUN/0000-0002-8423-5987; Ha, Sang-Jun/0000-0002-1192-6031				Anderson R, 1997, HUM GENE THER, V8, P1125, DOI 10.1089/hum.1997.8.9-1125; Carra G, 2000, J IMMUNOL, V164, P4752, DOI 10.4049/jimmunol.164.9.4752; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; Gately MK, 1996, ANN NY ACAD SCI, V795, P1, DOI 10.1111/j.1749-6632.1996.tb52650.x; Ha SJ, 1998, IMMUNOLOGY, V95, P156; HARAGUCHI M, 1995, BIOCHEM J, V312, P273, DOI 10.1042/bj3120273; Kieper WC, 2001, J IMMUNOL, V166, P5515, DOI 10.4049/jimmunol.166.9.5515; Ku CC, 2000, SCIENCE, V288, P675, DOI 10.1126/science.288.5466.675; Kuzushima K, 1999, BLOOD, V94, P3094, DOI 10.1182/blood.V94.9.3094.421k14_3094_3100; Lee SW, 1998, J VIROL, V72, P8430, DOI 10.1128/JVI.72.10.8430-8436.1998; Lee YL, 1998, HUM GENE THER, V9, P457, DOI 10.1089/hum.1998.9.4-457; Lieschke GJ, 1997, NAT BIOTECHNOL, V15, P35, DOI 10.1038/nbt0197-35; LING P, 1995, J IMMUNOL, V154, P116; Lode HN, 1998, P NATL ACAD SCI USA, V95, P2475, DOI 10.1073/pnas.95.5.2475; Marth T, 1999, J IMMUNOL, V162, P7233; PODLASKI FJ, 1992, ARCH BIOCHEM BIOPHYS, V294, P230, DOI 10.1016/0003-9861(92)90162-P; STERN AS, 1990, P NATL ACAD SCI USA, V87, P6808, DOI 10.1073/pnas.87.17.6808; Tough DF, 2001, J IMMUNOL, V166, P6007, DOI 10.4049/jimmunol.166.10.6007; Trinchieri G, 1998, ADV IMMUNOL, V70, P83, DOI 10.1016/S0065-2776(08)60387-9; Wu CY, 1997, EUR J IMMUNOL, V27, P147, DOI 10.1002/eji.1830270122; Zhang XH, 1998, IMMUNITY, V8, P591, DOI 10.1016/S1074-7613(00)80564-6	21	47	51	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	2002	20	4					381	386		10.1038/nbt0402-381	http://dx.doi.org/10.1038/nbt0402-381			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	536BY	11923845				2022-12-25	WOS:000174681900026
J	Kazantsev, A; Walker, HA; Slepko, N; Bear, JE; Preisinger, E; Steffan, JS; Zhu, YZ; Gertler, FB; Housman, DE; Marsh, JL; Thompson, LM				Kazantsev, A; Walker, HA; Slepko, N; Bear, JE; Preisinger, E; Steffan, JS; Zhu, YZ; Gertler, FB; Housman, DE; Marsh, JL; Thompson, LM			A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in Drosophila	NATURE GENETICS			English	Article							NEURONAL INTRANUCLEAR INCLUSIONS; TRANSGENIC MOUSE MODEL; NUCLEAR-LOCALIZATION; PROTEIN AGGREGATION; GLUTAMINE REPEATS; MUTANT HUNTINGTIN; CELL-DEATH; DISEASE; RECRUITMENT; CHAPERONES	Huntington disease is caused by the expansion of a polyglutamine repeat in the Huntingtin protein (Htt) that leads to degeneration of neurons in the central nervous system and the appearance of visible aggregates within neurons. We have developed and tested suppressor polypeptides that bind mutant Htt and interfere with the process of aggregation in cell culture. In a Drosophila model, the most potent suppressor inhibits both adult lethality and photoreceptor neuron degeneration. The appearance of aggregates in photoreceptor neurons correlates strongly with the occurrence of pathology, and expression of suppressor polypeptides delays and limits the appearance of aggregates and protects photoreceptor neurons. These results suggest that targeting the protein interactions leading to aggregate formation may be beneficial for the design and development of therapeutic agents for Huntington disease.	Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA; MIT, Ctr Canc Res, Dept Biol, Cambridge, MA 02139 USA; Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Psychiat & Human Behav, Irvine, CA 92697 USA	University of California System; University of California Irvine; Massachusetts Institute of Technology (MIT); University of California System; University of California Irvine; University of California System; University of California Irvine	Thompson, LM (corresponding author), Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA.	lmthomps@uci.edu						Aebischer P, 2001, TRENDS NEUROSCI, V24, P533, DOI 10.1016/S0166-2236(00)01899-3; Bates GP, 1998, BRAIN PATHOL, V8, P699, DOI 10.1111/j.1750-3639.1998.tb00196.x; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; Boutell JM, 1999, HUM MOL GENET, V8, P1647, DOI 10.1093/hmg/8.9.1647; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; CAGAN RL, 1989, DEV BIOL, V136, P346, DOI 10.1016/0012-1606(89)90261-3; Carmichael J, 2000, P NATL ACAD SCI USA, V97, P9701, DOI 10.1073/pnas.170280697; Chai YH, 1999, HUM MOL GENET, V8, P673, DOI 10.1093/hmg/8.4.673; Chai YH, 1999, J NEUROSCI, V19, P10338; Chan HYE, 2000, HUM MOL GENET, V9, P2811, DOI 10.1093/hmg/9.19.2811; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Chen S, 2001, J MOL BIOL, V311, P173, DOI 10.1006/jmbi.2001.4850; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Fernandez-Funez P, 2000, NATURE, V408, P101, DOI 10.1038/35040584; Ferrante RJ, 2000, J NEUROSCI, V20, P4389, DOI 10.1523/JNEUROSCI.20-12-04389.2000; GUSELLA JF, 1995, SEMIN CELL BIOL, V6, P21, DOI 10.1016/1043-4682(95)90011-X; Huang CC, 1998, SOMAT CELL MOLEC GEN, V24, P217, DOI 10.1023/B:SCAM.0000007124.19463.e5; Kafri T, 2001, CURR OPIN MOL THER, V3, P316; Kazantsev A, 1999, P NATL ACAD SCI USA, V96, P11404, DOI 10.1073/pnas.96.20.11404; Kazemi-Esfarjani P, 2000, SCIENCE, V287, P1837, DOI 10.1126/science.287.5459.1837; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Li H, 2001, J NEUROSCI, V21, P8473, DOI 10.1523/JNEUROSCI.21-21-08473.2001; Li H, 1999, HUM MOL GENET, V8, P1227, DOI 10.1093/hmg/8.7.1227; Liu L, 1999, NATURE, V400, P753, DOI 10.1038/23456; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Marsh JL, 2000, HUM MOL GENET, V9, P13, DOI 10.1093/hmg/9.1.13; McBride SMJ, 1999, NEURON, V24, P967, DOI 10.1016/S0896-6273(00)81043-0; McCampbell A, 2000, HUM MOL GENET, V9, P2197, DOI 10.1093/hmg/9.14.2197; McGowan DP, 2000, NEUROSCIENCE, V100, P677, DOI 10.1016/S0306-4522(00)00391-2; Mollereau B, 2001, NATURE, V412, P911, DOI 10.1038/35091076; Muchowski PJ, 2000, P NATL ACAD SCI USA, V97, P7841, DOI 10.1073/pnas.140202897; Nagai Y, 2000, J BIOL CHEM, V275, P10437, DOI 10.1074/jbc.275.14.10437; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; NUDFORA FC, 2001, SCIENCE, V291, P2423; Parkansky N, 1995, SURF COAT TECH, V76, P197, DOI 10.1016/0257-8972(95)02588-X; Paulson HL, 1999, AM J HUM GENET, V64, P339, DOI 10.1086/302269; Penney JB, 1997, ANN NEUROL, V41, P689, DOI 10.1002/ana.410410521; Perez MK, 1998, J CELL BIOL, V143, P1457, DOI 10.1083/jcb.143.6.1457; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Scherzinger E, 1999, P NATL ACAD SCI USA, V96, P4604, DOI 10.1073/pnas.96.8.4604; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Sigurdsson EM, 2000, J NEUROPATH EXP NEUR, V59, P11, DOI 10.1093/jnen/59.1.11; SKINNER PJ, IN PRESS NEURO MOL M; Soto C, 1998, NAT MED, V4, P822, DOI 10.1038/nm0798-822; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Suhr ST, 2001, J CELL BIOL, V153, P283, DOI 10.1083/jcb.153.2.283; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TROJANOWSKI JQ, 2000, NY ACAD SCI, V924, P62; TRUMAN JW, 1993, DEV DROSOPHILA MELAN; Waelter S, 2001, MOL BIOL CELL, V12, P1393, DOI 10.1091/mbc.12.5.1393; Wanker EE, 2000, BIOL CHEM, V381, P937, DOI 10.1515/BC.2000.114; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	60	137	142	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	APR	2002	30	4					367	376		10.1038/ng864	http://dx.doi.org/10.1038/ng864			10	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	536BZ	11925563	Green Published			2022-12-25	WOS:000174682000013
J	Poy, MN; Yang, Y; Rezaei, K; Fernstrom, MA; Lee, AD; Kido, Y; Erickson, SK; Najjar, SM				Poy, MN; Yang, Y; Rezaei, K; Fernstrom, MA; Lee, AD; Kido, Y; Erickson, SK; Najjar, SM			CEACAM1 regulates insulin clearance in liver	NATURE GENETICS			English	Article							RECEPTOR TYROSINE KINASE; FREE FATTY-ACIDS; CELL-ADHESION MOLECULE; APOLIPOPROTEIN-A-I; ENDOGENOUS SUBSTRATE; ADIPOSE-TISSUE; BILIARY GLYCOPROTEIN; PORTAL-VEIN; RESISTANCE; PP120	We hypothesized that insulin stimulates phosphorylation of CEACAM1 which in turn leads to upregulation of receptor-mediated insulin endocytosis and degradation in the hepatocyte. We have generated transgenic mice over-expressing in liver a dominant-negative, phosphorylation-defective S503A-CEACAM1 mutant. Supporting our hypothesis, we found that S503A-CEACAM1 transgenic mice developed hyperinsulinemia resulting from impaired insulin clearance. The hyperinsulinemia caused secondary insulin resistance with impaired glucose tolerance and random, but not fasting, hyperglycemia. Transgenic mice developed visceral adiposity with increased amounts of plasma free fatty acids and plasma and hepatic triglycerides. These findings suggest a mechanism through which insulin signaling regulates insulin sensitivity by modulating hepatic insulin clearance.	Med Coll Ohio, Dept Pharmacol & Therapeut, Toledo, OH 43614 USA; Med Coll Ohio, Dept Phys Therapy, Toledo, OH 43614 USA; Kobe Univ, Sch Med, Dept Internal Med 2, Chuo Ku, Kobe, Hyogo 650, Japan; Dept Med, San Francisco, CA USA; Univ Calif San Francisco, Vet Affairs Med Ctr, San Francisco, CA 94143 USA	Kobe University; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Najjar, SM (corresponding author), Med Coll Ohio, Dept Pharmacol & Therapeut, 3035 Arlington Ave,HSci Bldg Room 270, Toledo, OH 43614 USA.		Poy, Matthew/F-6914-2017; Najjar, Sonia M/GXW-2217-2022	Poy, Matthew/0000-0002-4904-2426; 				BACKER JM, 1992, J BIOL CHEM, V267, P1367; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Bergman RN, 2000, TRENDS ENDOCRIN MET, V11, P351, DOI 10.1016/S1043-2760(00)00323-4; Bergman RN, 2000, DIABETOLOGIA, V43, P946, DOI 10.1007/s001250051474; BISAHA JG, 1995, J BIOL CHEM, V270, P19979, DOI 10.1074/jbc.270.34.19979; BOSELLO O, 1990, ANN NUTR METAB, V34, P359, DOI 10.1159/000177610; CALZI SL, 1997, AM J PHYSIOL, V273, pE801; Chen XH, 1999, J CLIN INVEST, V103, P365, DOI 10.1172/JCI5479; CHEUNG PH, 1993, J BIOL CHEM, V268, P6139; Choice CV, 1998, J BIOL CHEM, V273, P22194, DOI 10.1074/jbc.273.35.22194; Cinti S, 1998, DIABETOLOGIA, V41, P171, DOI 10.1007/s001250050886; DIEM P, 1990, DIABETES, V39, P534, DOI 10.2337/diabetes.39.5.534; Duckworth WC, 1998, ENDOCR REV, V19, P608, DOI 10.1210/er.19.5.608; Escobar O, 1999, AM J MED SCI, V317, P282, DOI 10.1097/00000441-199905000-00003; FERRANNINI E, 1983, J CLIN INVEST, V72, P1737, DOI 10.1172/JCI111133; FOLCH J, 1957, J BIOL CHEM, V226, P497; FORMISANO P, 1995, J BIOL CHEM, V270, P24073, DOI 10.1074/jbc.270.41.24073; Han E, 2001, BIOCHEM J, V355, P417, DOI 10.1042/0264-6021:3550417; HENNES MMI, 1990, INT J OBESITY, V14, P831; HSIEH JT, 1995, CANCER RES, V55, P190; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; Kim JK, 2000, J CLIN INVEST, V105, P1791, DOI 10.1172/JCI8305; KISSEBAH AH, 1976, DIABETOLOGIA, V12, P563, DOI 10.1007/BF01220632; Koopmans SJ, 1999, METABOLISM, V48, P330, DOI 10.1016/S0026-0495(99)90081-1; LEE AD, 1995, AM J PHYSIOL-REG I, V268, pR997, DOI 10.1152/ajpregu.1995.268.4.R997; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; Luo WP, 1997, ONCOGENE, V14, P1697, DOI 10.1038/sj.onc.1200999; Maddux BA, 2000, DIABETES, V49, P13, DOI 10.2337/diabetes.49.1.13; Mathews ST, 2000, MOL CELL ENDOCRINOL, V164, P87, DOI 10.1016/S0303-7207(00)00237-9; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; MONDON CE, 1975, METABOLISM, V24, P153, DOI 10.1016/0026-0495(75)90016-5; NAJJAR SM, 1995, BIOCHEMISTRY-US, V34, P9341, DOI 10.1021/bi00029a009; Najjar SM, 1998, J BIOL CHEM, V273, P12923, DOI 10.1074/jbc.273.21.12923; NAJJAR SM, 1993, J BIOL CHEM, V268, P1201; Najjar SM, 1996, J BIOL CHEM, V271, P8809, DOI 10.1074/jbc.271.15.8809; NESTEL PJ, 1978, METABOLISM, V27, P589, DOI 10.1016/0026-0495(78)90025-2; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; PEIRIS AN, 1986, J CLIN INVEST, V78, P1648, DOI 10.1172/JCI112758; RANDLE PJ, 1965, ANN NY ACAD SCI, V131, P324, DOI 10.1111/j.1749-6632.1965.tb34800.x; RANDLE PJ, 1994, DIABETOLOGIA, V37, P155; REAVEN GM, 1988, DIABETES METAB REV, V4, P639, DOI 10.1002/dmr.5610040703; Rooney DP, 1996, DIABETES, V45, P134, DOI 10.2337/diabetes.45.2.134; ROSENBERG M, 1993, CANCER RES, V53, P4938; RUCH RJ, 1988, CANCER RES, V48, P2519; Soni P, 2000, MOL CELL BIOL, V20, P3896, DOI 10.1128/MCB.20.11.3896-3905.2000; SVEDBERG J, 1990, DIABETES, V39, P570, DOI 10.2337/diabetes.39.5.570; SVEDBERG J, 1991, J CLIN INVEST, V88, P2054, DOI 10.1172/JCI115534; WALSH A, 1989, J BIOL CHEM, V264, P6488	48	190	193	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2002	30	3					270	276		10.1038/ng840	http://dx.doi.org/10.1038/ng840			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	526YP	11850617				2022-12-25	WOS:000174157600010
J	Yarden, RI; Pardo-Reoyo, S; Sgagias, M; Cowan, KH; Brody, LC				Yarden, RI; Pardo-Reoyo, S; Sgagias, M; Cowan, KH; Brody, LC			BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage	NATURE GENETICS			English	Article							CELL-CYCLE; PHOSPHORYLATION; PROTEIN; CDC25; SERINE-216; LINKAGE; COMPLEX; LINE; ATM	The breast cancer tumor-suppressor gene, BRCA1, encodes a protein with a BRCT domain-a motif that is found in many proteins that are implicated in DNA damage response and in genome stability(1). Phosphorylation of BRCA1 by the DNA damage-response proteins ATM, ATR and hCds1/Chk2 changes in response to DNA damage and at replication-block checkpoints(2-5). Although cells that lack BRCA1 have an abnormal response to DNA damage, the exact role of BRCA1 in this process has remained unclear. Here we show that BRCA1 is essential for activating the Chk1 kinase that regulates DNA damage-induced G2/M arrest. Thus, BRCA1 controls the expression, phosphorylation and cellular localization of Cdc25C and Cdc2/cyclin B kinase-proteins that are crucial for the G2/M transition. We show that BRCA1 regulates the expression of both Wee1 kinase, an inhibitor of Cdc2/cyclin B kinase, and the 14-3-3 family of proteins that sequesters phosphorylated Cdc25C and Cdc2/cyclin B kinase in the cytoplasm(6). We conclude that BRCA1 regulates key effectors that control the G2/M checkpoint and is therefore involved in regulating the onset of mitosis.	NHGRI, Genome Technol Branch, NIH, Bethesda, MD 20892 USA; Univ Nebraska, Med Ctr, Eppley Inst Res Canc, Omaha, NE 68198 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Nebraska System; University of Nebraska Medical Center	Brody, LC (corresponding author), NHGRI, Genome Technol Branch, NIH, Bethesda, MD 20892 USA.							Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Chen JJ, 2000, CANCER RES, V60, P5037; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Foray N, 1999, ONCOGENE, V18, P7334, DOI 10.1038/sj.onc.1203165; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; OCONNOR PM, 1993, J BIOL CHEM, V268, P8298; OGG S, 1994, J BIOL CHEM, V269, P30461; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Tomlinson GE, 1998, CANCER RES, V58, P3237; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	25	388	416	0	23	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2002	30	3					285	289		10.1038/ng837	http://dx.doi.org/10.1038/ng837			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	526YP	11836499				2022-12-25	WOS:000174157600012
J	Wang, RF; Wang, HY				Wang, RF; Wang, HY			Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells	NATURE BIOTECHNOLOGY			English	Article							CYTOTOXIC T-LYMPHOCYTES; TYROSINASE-RELATED PROTEIN-2; TUMOR REJECTION ANTIGEN; IN-VIVO; HUMAN CANCER; PEPTIDE; MELANOMA; VACCINATION; DELIVERY; IDENTIFICATION	Vaccination with dendritic cells (DCs) pulsed with antigenic peptides derived from various tumor antigens has great, but as yet significantly unrealized, potential in cancer treatment. Here, we describe a strategy for prolonged presentation of an MHC class I-restricted self-peptide on DCs through linkage of it to a cell penetrating peptide (CPP). DCs loaded with a peptide derived from tyrosinase-related protein 2 (TRP2) covalently linked to a CPP1 sequence retained full capacity to stimulate T cells for at least 24 h, completely protected immunized mice from subsequent tumor challenge, and significantly inhibited lung metastases in a 3-day tumor model. DCs pulsed with TRP2 alone failed to provide any of these protections. In addition, we demonstrate that both CD4+ and CD8+ T cells were required for potent antitumor immunity. This CPP-based approach may be generally applicable to enhance the efficacy of DC-based peptide vaccines against cancer and other diseases.	Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Wang, RF (corresponding author), Baylor Coll Med, Ctr Cell & Gene Therapy, 1 Baylor Plaza, Houston, TX 77030 USA.	rongfuw@bcm.tmc.edu						Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bellone M, 2000, J IMMUNOL, V165, P2651, DOI 10.4049/jimmunol.165.5.2651; Bloom MB, 1997, J EXP MED, V185, P453, DOI 10.1084/jem.185.3.453; Boon T, 1996, J EXP MED, V183, P725, DOI 10.1084/jem.183.3.725; Bowne WB, 1999, J EXP MED, V190, P1717, DOI 10.1084/jem.190.11.1717; Caron NJ, 2001, MOL THER, V3, P310, DOI 10.1006/mthe.2001.0279; Casares N, 2001, EUR J IMMUNOL, V31, P1780, DOI 10.1002/1521-4141(200106)31:6<1780::AID-IMMU1780>3.0.CO;2-I; Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030; Celluzzi CM, 1996, J EXP MED, V183, P283, DOI 10.1084/jem.183.1.283; Dallal RM, 2000, CURR OPIN IMMUNOL, V12, P583, DOI 10.1016/S0952-7915(00)00146-1; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Gilboa E, 1999, IMMUNITY, V11, P263, DOI 10.1016/S1074-7613(00)80101-6; GREENBERG PD, 1991, ADV IMMUNOL, V49, P281; Houghton AN, 2001, CURR OPIN IMMUNOL, V13, P134, DOI 10.1016/S0952-7915(00)00195-3; Hung K, 1998, J EXP MED, V188, P2357, DOI 10.1084/jem.188.12.2357; Kim DT, 1997, J IMMUNOL, V159, P1666; Labeur MS, 1999, J IMMUNOL, V162, P168; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Ludewig B, 1999, IMMUNOL REV, V169, P45, DOI 10.1111/j.1600-065X.1999.tb01305.x; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; Overwijk WW, 1999, P NATL ACAD SCI USA, V96, P2982, DOI 10.1073/pnas.96.6.2982; Paglia P, 1996, J EXP MED, V183, P317, DOI 10.1084/jem.183.1.317; Pardoll DM, 1998, CURR OPIN IMMUNOL, V10, P588, DOI 10.1016/S0952-7915(98)80228-8; Parkhurst MR, 1996, J IMMUNOL, V157, P2539; Parkhurst MR, 1998, CANCER RES, V58, P4895; Phelan A, 1998, NAT BIOTECHNOL, V16, P440, DOI 10.1038/nbt0598-440; Rojas M, 1998, NAT BIOTECHNOL, V16, P370, DOI 10.1038/nbt0498-370; Rosenberg SA, 1998, NAT MED, V4, P321, DOI 10.1038/nm0398-321; Schreurs MWJ, 2000, CANCER RES, V60, P6995; Schuler G, 1997, J EXP MED, V186, P1183, DOI 10.1084/jem.186.8.1183; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Slansky JE, 2000, IMMUNITY, V13, P529, DOI 10.1016/S1074-7613(00)00052-2; Specht JM, 1997, J EXP MED, V186, P1213, DOI 10.1084/jem.186.8.1213; Srivastava PK, 2000, NAT IMMUNOL, V1, P363, DOI 10.1038/80795; SUHRBIER A, 1993, J IMMUNOL, V150, P2169; Thurner B, 1999, J EXP MED, V190, P1669, DOI 10.1084/jem.190.11.1669; Toes REM, 1999, J EXP MED, V189, P753, DOI 10.1084/jem.189.5.753; Wang RF, 1999, IMMUNOL REV, V170, P85, DOI 10.1111/j.1600-065X.1999.tb01331.x; Wang RF, 1996, J EXP MED, V184, P2207, DOI 10.1084/jem.184.6.2207; Wang RF, 2001, TRENDS IMMUNOL, V22, P269, DOI 10.1016/S1471-4906(01)01896-8; Winzler C, 1997, J EXP MED, V185, P317, DOI 10.1084/jem.185.2.317; Young JW, 1996, J EXP MED, V183, P7, DOI 10.1084/jem.183.1.7; Zeh HJ, 1999, J IMMUNOL, V162, P989	46	89	111	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2002	20	2					149	154		10.1038/nbt0202-149	http://dx.doi.org/10.1038/nbt0202-149			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	517FT	11821860				2022-12-25	WOS:000173601000023
J	D'Orazi, G; Cecchinelli, B; Bruno, T; Manni, I; Higashimoto, Y; Saito, S; Gostissa, M; Coen, S; Marchetti, A; Del Sal, G; Piaggio, G; Fanciulli, M; Appella, E; Soddu, S				D'Orazi, G; Cecchinelli, B; Bruno, T; Manni, I; Higashimoto, Y; Saito, S; Gostissa, M; Coen, S; Marchetti, A; Del Sal, G; Piaggio, G; Fanciulli, M; Appella, E; Soddu, S			Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis	NATURE CELL BIOLOGY			English	Article							P53-DEPENDENT APOPTOSIS; NUCLEAR-BODIES; IN-VITRO; PML; MDM2; INHIBITION; EXPRESSION; SUMO-1	Phosphorylation of p53 at Ser 46 was shown to regulate p53 apoptotic activity. Here we demonstrate that homeodomain-interacting protein kinase-2 (HIPK2), a member of a novel family of nuclear serine/threonine kinases, binds to and activates p53 by directly phosphorylating it at Ser 46. HIPK2 localizes with p53 and PML-3 into the nuclear bodies and is activated after irradiation with ultraviolet. Antisense inhibition of HIPK2 expression reduces the ultraviolet-induced apoptosis. Furthermore, HIPK2 and p53 cooperate in the activation of p53-dependent transcription and apoptotic pathways. These data define a new functional interaction between p53 and HIPK2 that results in the targeted subcellular localization of p53 and initiation of apoptosis.	Regina Elena Inst Canc Res, Mol Oncogenesis Lab, I-00158 Rome, Italy; Regina Elena Inst Canc Res, Cell Metab & Pharmacokinet Lab, I-00158 Rome, Italy; Univ G DAnnunzio, Dept Oncol & Neurosci, I-66013 Chieti, Italy; NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; Interuniv Consortium Biotechnol, Natl Lab, I-34012 Trieste, Italy; Dept Biochem Biophys & Chem Macromol, I-34100 Trieste, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; G d'Annunzio University of Chieti-Pescara; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	D'Orazi, G (corresponding author), Regina Elena Inst Canc Res, Mol Oncogenesis Lab, Via Messi Oro 156, I-00158 Rome, Italy.	soddu@ifo.it	Soddu, Silvia/ABH-6774-2020; Soddu, Silvia/K-2467-2018; Manni, Isabella/ABH-6460-2020; Piaggio, Giulia/AAD-7336-2022; fanciulli, maurizio/ABH-6745-2020; Marchetti, Alessandra/AAD-5498-2019; D'Orazi, Gabriella/T-2792-2019; Piaggio, Giulia/J-7214-2018; bruno, tiziana/AAC-4913-2022	Soddu, Silvia/0000-0001-8526-0044; Soddu, Silvia/0000-0001-8526-0044; Manni, Isabella/0000-0003-4823-0596; D'Orazi, Gabriella/0000-0001-6876-9105; Piaggio, Giulia/0000-0003-2114-1892; bruno, tiziana/0000-0003-0352-4523; MARCHETTI, ALESSANDRA/0000-0001-9706-848X; DEL SAL, GIANNINO/0000-0003-2185-6003; Higashimoto, Yuichiro/0000-0003-1382-8598				BACCHETTI S, 1993, INT J ONCOL, V3, P781; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Fanciulli M, 2000, FASEB J, V14, P904, DOI 10.1096/fasebj.14.7.904; Fanciulli M, 1996, FEBS LETT, V384, P48, DOI 10.1016/0014-5793(96)00277-3; FEREYRE G, 2000, GENE DEV, V14, P2015; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Higashimoto Y, 2000, J BIOL CHEM, V275, P23199, DOI 10.1074/jbc.M002674200; Hofmann TG, 2000, BIOCHIMIE, V82, P1123, DOI 10.1016/S0300-9084(00)01196-2; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Ito K, 2000, IMMUNOL LETT, V74, P245, DOI 10.1016/S0165-2478(00)00266-2; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Leonetti C, 1996, JNCI-J NATL CANCER I, V88, P419, DOI 10.1093/jnci/88.7.419; Lombard DB, 2000, CANCER RES, V60, P2331; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; MIYASHITA T, 1995, CELL, V80, P293; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; SCHMID P, 1991, DEVELOPMENT, V113, P857; Schneider S, 1996, BIOTECHNIQUES, V20, P960; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	35	553	567	3	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2002	4	1					11	19		10.1038/ncb714	http://dx.doi.org/10.1038/ncb714			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	513MC	11780126				2022-12-25	WOS:000173381500010
J	van Drogen, F; Stucke, VM; Jorritsma, G; Peter, M				van Drogen, F; Stucke, VM; Jorritsma, G; Peter, M			MAP kinase dynamics in response to pheromones in budding yeast	NATURE CELL BIOLOGY			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; MUTATIONAL ANALYSIS; FUNCTIONAL-ANALYSIS; SCAFFOLD PROTEIN; INVASIVE GROWTH; G-BETA; STE5; PHOSPHORYLATION	Although scaffolding is a major regulator of mitogen-activated protein kinase (MAPK) pathways, scaffolding proteins are poorly understood. During yeast mating, MAPK Fus3p is phosphorylated by MAPKK Ste7p, which is activated by MAPKKK Ste11p. This MAPK module interacts with the scaffold molecule Ste5p. Here we show that Ste11p and Ste7p were predominantly cytoplasmic proteins, while Ste5p and Fus3p were found in the nucleus and the cytoplasm. Ste5p, Ste7p and Fus3p also localized to tips of mating projections in pheromone-treated cells. Using fluorescence recovery after photobleaching (FRAP), we demonstrate that Fus3p rapidly shuttles between the nucleus and the cytoplasm independently of pheromones, Fus3p phosphorylation and Ste5p. Membrane-bound Ste5p can specifically recruit Fus3p and Ste7p to the cell cortex. Ste5p remains stably bound at the plasma membrane, unlike activated Fus3p, which dissociates from Ste5p and translocates to the nucleus.	Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland	Swiss Institute Experimental Cancer Research	van Drogen, F (corresponding author), Swiss Inst Expt Canc Res, Chemin des Boveresses 155, CH-1066 Epalinges, Switzerland.			Peter, Matthias/0000-0002-2160-6824				Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; Ausubel FM., 2006, ENZYMATIC MANIPULATI; Blondel M, 1999, GENE DEV, V13, P2284, DOI 10.1101/gad.13.17.2284; Brown JL, 1997, GENE DEV, V11, P2972, DOI 10.1101/gad.11.22.2972; Choi KY, 1999, MOL BIOL CELL, V10, P1553, DOI 10.1091/mbc.10.5.1553; CHOI KY, 1994, CELL, V78, P499; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Cook JG, 1996, GENE DEV, V10, P2831, DOI 10.1101/gad.10.22.2831; Dohlman HG, 2001, ANNU REV BIOCHEM, V70, P703, DOI 10.1146/annurev.biochem.70.1.703; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; Elion EA, 2000, CURR OPIN MICROBIOL, V3, P573, DOI 10.1016/S1369-5274(00)00143-0; ELLENBERG J, 1998, CELLS LAB MANUAL; Feng YY, 1998, CURR BIOL, V8, P267, DOI 10.1016/S0960-9822(98)70108-3; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Gaits F, 1998, GENE DEV, V12, P1464, DOI 10.1101/gad.12.10.1464; Garrison TR, 1999, J BIOL CHEM, V274, P36387, DOI 10.1074/jbc.274.51.36387; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gulli MP, 2000, MOL CELL, V6, P1155, DOI 10.1016/S1097-2765(00)00113-1; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Guthrie C, 1991, GUIDE YEAST GENETICS; Inouye C, 1997, GENETICS, V147, P479; Jaquenoud M, 1998, EMBO J, V17, P5360, DOI 10.1093/emboj/17.18.5360; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; KRANZ JE, 1994, GENE DEV, V8, P313, DOI 10.1101/gad.8.3.313; Leberer E, 1997, EMBO J, V16, P83, DOI 10.1093/emboj/16.1.83; Leeuw T, 1998, NATURE, V391, P191, DOI 10.1038/34448; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; Madhani HD, 1998, TRENDS GENET, V14, P151, DOI 10.1016/S0168-9525(98)01425-5; Mahanty SK, 1999, CELL, V98, P501, DOI 10.1016/S0092-8674(00)81978-9; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; Mattison CP, 2000, GENE DEV, V14, P1229; Moskow JJ, 2000, MOL CELL BIOL, V20, P7559, DOI 10.1128/MCB.20.20.7559-7571.2000; OEHLEN B, 1994, CURR OPIN CELL BIOL, V6, P836, DOI 10.1016/0955-0674(94)90053-1; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; Pryciak PM, 1998, GENE DEV, V12, P2684, DOI 10.1101/gad.12.17.2684; Raitt DC, 2000, EMBO J, V19, P4623, DOI 10.1093/emboj/19.17.4623; Reiser V, 2000, NAT CELL BIOL, V2, P620, DOI 10.1038/35023568; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Sette C, 2000, MOL BIOL CELL, V11, P4033, DOI 10.1091/mbc.11.11.4033; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Tedford K, 1997, CURR BIOL, V7, P228, DOI 10.1016/S0960-9822(06)00118-7; Valtz N, 1997, METHOD ENZYMOL, V283, P350; van Drogen F, 2000, CURR BIOL, V10, P630, DOI 10.1016/S0960-9822(00)00511-X; White J, 1999, TRENDS CELL BIOL, V9, P61, DOI 10.1016/S0962-8924(98)01433-0; WHITE P, 1998, LIFE SCI NEWS, V0001, P00023; WHITEWAY MS, 1995, SCIENCE, V269, P1572, DOI 10.1126/science.7667635	49	101	104	0	12	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2001	3	12					1051	1059		10.1038/ncb1201-1051	http://dx.doi.org/10.1038/ncb1201-1051			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	500AM	11781566				2022-12-25	WOS:000172603700010
J	Kondo, S; Schutte, BC; Richardson, RJ; Bjork, BC; Knight, AS; Watanabe, Y; Howard, E; de Lima, RLLF; Daack-Hirsch, S; Sander, A; McDonald-McGinn, DM; Zackai, EH; Lammer, EJ; Aylsworth, AS; Ardinger, HH; Lidral, AC; Pober, BR; Moreno, L; Arcos-Burgos, M; Valencia, C; Houdayer, C; Bahuau, M; Moretti-Ferreira, D; Richieri-Costa, A; Dixon, MJ; Murray, JC				Kondo, S; Schutte, BC; Richardson, RJ; Bjork, BC; Knight, AS; Watanabe, Y; Howard, E; de Lima, RLLF; Daack-Hirsch, S; Sander, A; McDonald-McGinn, DM; Zackai, EH; Lammer, EJ; Aylsworth, AS; Ardinger, HH; Lidral, AC; Pober, BR; Moreno, L; Arcos-Burgos, M; Valencia, C; Houdayer, C; Bahuau, M; Moretti-Ferreira, D; Richieri-Costa, A; Dixon, MJ; Murray, JC			Mutations in IRF6 cause Van der Woude and popliteal pterygium syndromes	NATURE GENETICS			English	Article							INTERFERON REGULATORY FACTORS; SEQUENCE; GENE; EXPRESSION; 1Q32-Q41; HOMOLOG; DEFECTS; LINKAGE; DOMAIN; PALATE	Interferon regulatory factor 6 (IRF6) belongs to a family of nine transcription factors that share a highly conserved helix-turn-helix DNA-binding domain and a less conserved protein-binding domain. Most IRFs regulate the expression of interferon-alpha and -beta after viral infection(1), but the function of IRF6 is unknown. The gene encoding IRF6 is located in the critical region for the Van der Woude syndrome (VWS; OMIM 119300) locus at chromosome 1q32-q41 (refs 2,3). The disorder is an autosomal dominant form of cleft lip and palate with lip pits(4), and is the most common syndromic form of cleft lip or palate. Popliteal pterygium syndrome (PPS; OMIM 119500) is a disorder with a similar orofacial phenotype that also includes skin and genital anomalies(5). Phenotypic overlap(6) and linkage data(7) suggest that these two disorders are allelic. We found a nonsense mutation in IRF6 in the affected twin of a pair of monozygotic twins who were discordant for VWS. Subsequently, we identified mutations in IRF6 in 45 additional unrelated families affected with VWS and distinct mutations in 13 families affected with PPS. Expression analyses showed high levels of Irf6 mRNA along the medial edge of the fusing palate, tooth buds, hair follicles, genitalia and skin. Our observations demonstrate that haploinsufficiency of IRF6 disrupts orofacial development and are consistent with dominant-negative mutations disturbing development of the skin and genitalia.	Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; Univ Iowa, Interdisciplinary PhD Program Genet, Iowa City, IA 52242 USA; Univ Manchester, Sch Biol Sci, Manchester, Lancs, England; Univ Manchester, Dept Dent Med & Surg, Manchester, Lancs, England; Harvard Univ, Brigham & Womens Hosp, Boston, MA 02115 USA; Univ Estadual Paulista, Serv Aconselhamento Genet, Botucatu, SP, Brazil; Univ Hamburg, Clin Oral Maxillofacial Surg, Hamburg, Germany; Childrens Hosp Philadelphia, Div Human Genet & Mol Biol, Philadelphia, PA 19104 USA; Childrens Hosp, Oakland, CA 94609 USA; Univ N Carolina, Dept Pediat & Genet, Chapel Hill, NC USA; Univ Kansas, Childrens Med Ctr, Dept Pediat, Kansas City, KS USA; Univ Iowa, Dept Orthodont, Iowa City, IA USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; Univ Iowa, PhD Program Oral Sci, Iowa City, IA USA; Univ Antioquia, Medellin, Colombia; Hop Enfants Armand Trousseau, Serv Biochim & Biol Mol, Paris, France; Hop Enfants Armand Trousseau, Serv Chirurg Maxillofaciale & Plast Stomatol, Paris, France; Univ Sao Paulo, Serv Chirurg Maxillofaciale & Lesoes Labio Palati, Dept Clin Genet, Bauru, Brazil; Univ Iowa, Dept Biol, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Manchester; University of Manchester; Harvard University; Brigham & Women's Hospital; Universidade Estadual Paulista; University of Hamburg; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute; University of North Carolina; University of North Carolina Chapel Hill; University of Kansas; University of Iowa; Yale University; University of Iowa; Universidad de Antioquia; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; Universidade de Sao Paulo; University of Iowa	Murray, JC (corresponding author), Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA.		Moretti-Ferreira, Danilo/P-3456-2019; Richieri-Costa, Antonio/B-2514-2013; Moretti-Ferreira, Danilo/F-9565-2012; McDonald-McGinn, Donna/L-8643-2019; Arcos-Burgos, Mauricio/H-1326-2017	Moretti-Ferreira, Danilo/0000-0002-9256-7623; Daack-Hirsch, Sandra/0000-0003-1192-7154; Richardson, Beck/0000-0002-4701-8713; Watanabe, Yoriko/0000-0003-4685-8021; Houdayer, Claude/0000-0002-5190-0389; McDonald-McGinn, Donna/0000-0003-4077-250X; Arcos-Burgos, Mauricio/0000-0002-8529-0574	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P60DE013076, R01DE014667] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01 DE014667-03, R01 DE014667, P60 DE013076-030005, P60 DE013076-020005, P60 DE013076-040005, P60 DE013076-010005, P60 DE013076, R01 DE014667-01, P60 DE013076-050005, P60 DE013076-01S10005, R01 DE014667-02, P60 DE013076-03S10005, R01 DE014667-04] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Au WC, 2001, VIROLOGY, V280, P273, DOI 10.1006/viro.2000.0782; BIXLER D, 1973, CLIN GENET, V4, P220; BOCIAN M, 1987, AM J MED GENET, V26, P437, DOI 10.1002/ajmg.1320260223; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; Dixon J, 1997, HUM MOL GENET, V6, P727, DOI 10.1093/hmg/6.5.727; Eroshkin A, 1999, J MOL MED, V77, P403, DOI 10.1007/s001090050369; Escalante CR, 1998, NATURE, V391, P103, DOI 10.1038/34224; FITZPATRICK DR, 1990, DEVELOPMENT, V109, P585; FRASER F C, 1955, Acta Genet Stat Med, V5, P358; GORLIN RJ, 1968, PEDIATRICS, V41, P503; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; Lees MM, 1999, J MED GENET, V36, P888; Lin RT, 1999, MOL CELL BIOL, V19, P959; Machin GA, 1996, AM J MED GENET, V61, P216, DOI 10.1002/(SICI)1096-8628(19960122)61:3<216::AID-AJMG5>3.0.CO;2-S; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; MATZUK MM, 1995, NATURE, V374, P354, DOI 10.1038/374354a0; McGrath JA, 2001, HUM MOL GENET, V10, P221, DOI 10.1093/hmg/10.3.221; MURRAY JC, 1990, AM J HUM GENET, V46, P486; Nieto MA, 1996, METHOD CELL BIOL, V51, P219, DOI 10.1016/S0091-679X(08)60630-5; PROETZEL G, 1995, NAT GENET, V11, P409, DOI 10.1038/ng1295-409; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; SANDER A, 1994, HUM MOL GENET, V3, P575, DOI 10.1093/hmg/3.4.575; Sanford LP, 1997, DEVELOPMENT, V124, P2659; Schutte BC, 1999, AM J MED GENET, V84, P145, DOI 10.1002/(SICI)1096-8628(19990521)84:2<145::AID-AJMG11>3.0.CO;2-L; Schutte BC, 2000, GENOME RES, V10, P81; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; van den Boogaard MJH, 2000, NAT GENET, V24, P342, DOI 10.1038/74155; VANDERWOUDE A, 1954, AM J HUM GENET, V6, P244	29	590	618	2	77	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2002	32	2					285	289		10.1038/ng985	http://dx.doi.org/10.1038/ng985			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	599AP	12219090	Green Accepted, Green Published			2022-12-25	WOS:000178311100018
J	Castillo-Davis, CI; Mekhedov, SL; Hartl, DL; Koonin, EV; Kondrashov, FA				Castillo-Davis, CI; Mekhedov, SL; Hartl, DL; Koonin, EV; Kondrashov, FA			Selection for short introns in highly expressed genes	NATURE GENETICS			English	Article							GENOME EVOLUTION; CODON BIAS; C-ELEGANS; DROSOPHILA; LENGTH; TRANSCRIPTION; RATES; SIZE; DNA; CAENORHABDITIS	Transcription is a slow and expensive process: in eukaryotes, approximately 20 nucleotides can be transcribed per second(1,2) at the expense of at least two ATP molecules per nucleotide(3). Thus, at least for highly expressed genes, transcription of long introns, which are particularly common in mammals, is costly. Using data on the expression of genes that encode proteins in Caenorhabditis elegans and Homo sapiens, we show that introns in highly expressed genes are substantially shorter than those in genes that are expressed at low levels. This difference is greater in humans, such that introns are, on average, 14 times shorter in highly expressed genes than in genes with low expression, whereas in C. elegans the difference in intron length is only twofold. In contrast, the density of introns in a gene does not strongly depend on the level of gene expression. Thus, natural selection appears to favor short introns in highly expressed genes to minimize the cost of transcription and other molecular processes, such as splicing.	Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA; Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA	National Institutes of Health (NIH) - USA; Harvard University	Kondrashov, FA (corresponding author), Natl Ctr Biotechnol Informat, NIH, 8600 Rockville Pike, Bethesda, MD 20894 USA.	fkondras@ncbi.nlm.nih.gov	Kondrashov, Fyodor Alexeevich/H-6331-2015	Kondrashov, Fyodor Alexeevich/0000-0001-8243-4694	NATIONAL LIBRARY OF MEDICINE [Z01LM000073, ZIALM000073] Funding Source: NIH RePORTER	NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Akashi H, 2001, CURR OPIN GENET DEV, V11, P660, DOI 10.1016/S0959-437X(00)00250-1; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bortoluzzi S, 1999, TRENDS GENET, V15, P118, DOI 10.1016/S0168-9525(98)01682-5; BOULIKAS T, 1992, J MOL EVOL, V35, P156, DOI 10.1007/BF00183227; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Carels N, 2000, GENETICS, V154, P1819; Carvalho AB, 1999, NATURE, V401, P344, DOI 10.1038/43827; Coghlan A, 2000, YEAST, V16, P1131, DOI 10.1002/1097-0061(20000915)16:12<1131::AID-YEA609>3.0.CO;2-F; Comeron JM, 2000, GENETICS, V156, P1175; Deutsch M, 1999, NUCLEIC ACIDS RES, V27, P3219, DOI 10.1093/nar/27.15.3219; Duret L, 1999, P NATL ACAD SCI USA, V96, P4482, DOI 10.1073/pnas.96.8.4482; EyreWalker A, 1996, MOL BIOL EVOL, V13, P864, DOI 10.1093/oxfordjournals.molbev.a025646; Hill AA, 2000, SCIENCE, V290, P809, DOI 10.1126/science.290.5492.809; Hurst LD, 1999, TRENDS GENET, V15, P437, DOI 10.1016/S0168-9525(99)01832-6; Hurst LD, 1996, NAT GENET, V12, P234, DOI 10.1038/ng0396-234; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LEE NH, 1995, P NATL ACAD SCI USA, V92, P8303, DOI 10.1073/pnas.92.18.8303; LEHNINGER AL, 1982, PRINCIPLES BIOCH, P615; Moriyama EN, 1998, MOL BIOL EVOL, V15, P770, DOI 10.1093/oxfordjournals.molbev.a025980; Nixon JEJ, 2002, P NATL ACAD SCI USA, V99, P3701, DOI 10.1073/pnas.042700299; Ogata H, 1996, FEBS LETT, V390, P99, DOI 10.1016/0014-5793(96)00636-9; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; Ophir R, 1997, GENE, V205, P191, DOI 10.1016/S0378-1119(97)00398-3; Petrov DA, 1996, NATURE, V384, P346, DOI 10.1038/384346a0; Reinke V, 2000, MOL CELL, V6, P605, DOI 10.1016/S1097-2765(00)00059-9; Robertson HM, 2000, GENOME RES, V10, P192, DOI 10.1101/gr.10.2.192; SULLIVAN DT, 1995, CURR OPIN GENET DEV, V5, P786, DOI 10.1016/0959-437X(95)80012-T; UCKER DS, 1984, J BIOL CHEM, V259, P7416; Zhou ZL, 2000, NATURE, V407, P401, DOI 10.1038/35030160	30	386	404	3	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2002	31	4					415	418		10.1038/ng940	http://dx.doi.org/10.1038/ng940			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	578XV	12134150	Green Published			2022-12-25	WOS:000177147100019
J	Patel, H; Cross, H; Proukakis, C; Hershberger, R; Bork, P; Ciccarelli, FD; Patton, MA; McKusick, VA; Crosby, AH				Patel, H; Cross, H; Proukakis, C; Hershberger, R; Bork, P; Ciccarelli, FD; Patton, MA; McKusick, VA; Crosby, AH			SPG20 is mutated in Troyer syndrome, an hereditary spastic paraplegia	NATURE GENETICS			English	Article							PROTEIN TRAFFICKING; MAMMALIAN-CELLS; MORPHOLOGY; VPS4P	Troyer syndrome (TRS) is an autosomal recessive complicated hereditary spastic paraplegia (HSP) that occurs with high frequency in the Old Order Amish. We report mapping of the TRS locus to chromosome 13q12.3 and identify a frameshift mutation in SPG20, encoding spartin. Comparative sequence analysis indicates that spartin shares similarity with molecules involved in endosomal trafficking and with spastin, a molecule implicated in microtubule interaction that is commonly mutated in HSP.	Univ London St Georges Hosp, Sch Med, Dept Med Genet, London SW17 0RE, England	St Georges University London	Crosby, AH (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Med Genet, Cranmer Terrace, London SW17 0RE, England.	acrosby@sghms.ac.uk	Crosby, Andrew H/E-2218-2015; Cross, J. Helen/ACK-3032-2022; proukakis, christos/ABE-3447-2020; Proukakis, Christos/G-4548-2013; Bork, Peer/F-1813-2013; Ciccarelli, Francesca/D-5380-2014	Crosby, Andrew H/0000-0003-3667-9054; Cross, J. Helen/0000-0001-7345-4829; proukakis, christos/0000-0001-6423-6539; Bork, Peer/0000-0002-2627-833X; Ciccarelli, Francesca/0000-0002-9325-0900				Babst M, 1997, EMBO J, V16, P1820, DOI 10.1093/emboj/16.8.1820; Barr VA, 2000, TRAFFIC, V1, P904, DOI 10.1034/j.1600-0854.2000.011109.x; Bloom GS, 1998, J CELL BIOL, V140, P1277, DOI 10.1083/jcb.140.6.1277; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; CROSS HE, 1967, ARCH NEUROL-CHICAGO, V16, P473, DOI 10.1001/archneur.1967.00470230025003; de Rouvroit CL, 2001, MECH DEVELOP, V105, P47, DOI 10.1016/S0925-4773(01)00396-3; Errico A, 2002, HUM MOL GENET, V11, P153, DOI 10.1093/hmg/11.2.153; MATTEONI R, 1987, J CELL BIOL, V105, P1253, DOI 10.1083/jcb.105.3.1253; Patel H, 2001, AM J HUM GENET, V69, P209, DOI 10.1086/321267; Rampoldi L, 2001, NAT GENET, V28, P119, DOI 10.1038/88821; Scheuring S, 2001, J MOL BIOL, V312, P469, DOI 10.1006/jmbi.2001.4917; Terada S, 2000, CURR OPIN NEUROBIOL, V10, P566, DOI 10.1016/S0959-4388(00)00129-X; Yang Y, 2001, NAT GENET, V29, P160, DOI 10.1038/ng1001-160; Yoshimori T, 2000, MOL BIOL CELL, V11, P747, DOI 10.1091/mbc.11.2.747	14	184	192	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2002	31	4					347	348		10.1038/ng937	http://dx.doi.org/10.1038/ng937			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	578XV	12134148				2022-12-25	WOS:000177147100007
J	Steinmetz, LM; Scharfe, C; Deutschbauer, AM; Mokranjac, D; Herman, ZS; Jones, T; Chu, AM; Giaever, G; Prokisch, H; Oefner, PJ; Davis, RW				Steinmetz, LM; Scharfe, C; Deutschbauer, AM; Mokranjac, D; Herman, ZS; Jones, T; Chu, AM; Giaever, G; Prokisch, H; Oefner, PJ; Davis, RW			Systematic screen for human disease genes in yeast	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE GENOME; LOCUS HETEROGENEITY; OPTIC ATROPHY; MITOCHONDRIAL; CHROMOSOME; EXPRESSION; SEQUENCES; DATABASE; DELETION; LINKAGE	High similarity between yeast and human mitochondria allows functional genomic study of Saccharomyces cerevisiae to be used to identify human genes involved in disease(1). So far, 102 heritable disorders have been attributed to defects in a quarter of the known nuclear-encoded mitochondrial proteins in humans(2). Many mitochondrial diseases remain unexplained, however, in part because only 40-60% of the presumed 700-1,000 proteins involved in mitochondrial function and biogenesis have been identified(3). Here we apply a systematic functional screen using the pre-existing whole-genome pool of yeast deletion mutants(4-6) to identify mitochondrial proteins. Three million measurements of strain fitness identified 466 genes whose deletions impaired mitochondrial respiration, of which 265 were new. Our approach gave higher selection than other systematic approaches, including fivefold greater selection than gene expression analysis. To apply these advantages to human disorders involving mitochondria, human orthologs were identified and linked to heritable diseases using genomic map positions.	Stanford Univ, Dept Biochem, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA; Stanford Genome Technol Ctr, Palo Alto, CA 94304 USA; Univ Munich, Inst Physiol Chem, D-8000 Munich, Germany	Stanford University; Stanford University; Stanford University; University of Munich	Steinmetz, LM (corresponding author), Stanford Univ, Dept Biochem, Sch Med, Stanford, CA 94305 USA.	larsms@stanford.edu; curts@stanford.edu	Prokisch, Holger/N-8964-2013	Prokisch, Holger/0000-0003-2379-6286; Steinmetz, Lars/0000-0002-3962-2865; Mokranjac, Dejana/0000-0002-4005-6979				Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094; Ashe MP, 2000, MOL BIOL CELL, V11, P833, DOI 10.1091/mbc.11.3.833; Assink JJM, 1997, AM J HUM GENET, V61, P934, DOI 10.1086/514884; Birrell GW, 2001, P NATL ACAD SCI USA, V98, P12608, DOI 10.1073/pnas.231366398; BOGUSKI MS, 1995, NAT GENET, V10, P369, DOI 10.1038/ng0895-369; Christodoulou K, 2001, NEUROGENETICS, V3, P127, DOI 10.1007/s100480100112; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DiMauro S, 1998, NAT GENET, V19, P214, DOI 10.1038/883; Foury F, 1997, GENE, V195, P1, DOI 10.1016/S0378-1119(97)00140-6; Grivell LA, 1999, FEBS LETT, V452, P57, DOI 10.1016/S0014-5793(99)00532-3; HENTATI A, 1994, HUM MOL GENET, V3, P1263, DOI 10.1093/hmg/3.8.1263; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Kerrison JB, 1999, ARCH OPHTHALMOL-CHIC, V117, P805; Kumar A, 2002, GENE DEV, V16, P707, DOI 10.1101/gad.970902; MALMGREN H, 1993, AM J HUM GENET, V52, P1046; McMullan TFW, 2000, AM J HUM GENET, V66, P1455, DOI 10.1086/302860; Mewes HW, 2000, NUCLEIC ACIDS RES, V28, P37, DOI 10.1093/nar/28.1.37; Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689; Ooi SL, 2001, SCIENCE, V294, P2552, DOI 10.1126/science.1065672; PRIEST JM, 1995, GENOMICS, V29, P409, DOI 10.1006/geno.1995.9987; Scharfe C, 2000, NUCLEIC ACIDS RES, V28, P155, DOI 10.1093/nar/28.1.155; Schwikowski B, 2000, NAT BIOTECHNOL, V18, P1257, DOI 10.1038/82360; Shoemaker DD, 1996, NAT GENET, V14, P450, DOI 10.1038/ng1296-450; TZAGOLOFF A, 1986, ANNU REV BIOCHEM, V55, P249, DOI 10.1146/annurev.bi.55.070186.001341; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Wood V, 2001, COMP FUNCT GENOM, V2, P143, DOI 10.1002/cfg.86; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627	29	425	434	0	36	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2002	31	4					400	404		10.1038/ng929	http://dx.doi.org/10.1038/ng929			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	578XV	12134146				2022-12-25	WOS:000177147100016
J	Jauliac, S; Lopez-Rodriguez, C; Shaw, LM; Brown, LF; Rao, A; Toker, A				Jauliac, S; Lopez-Rodriguez, C; Shaw, LM; Brown, LF; Rao, A; Toker, A			The role of NFAT transcription factors in integrin-mediated carcinoma invasion	NATURE CELL BIOLOGY			English	Article							T-CELL ACTIVATION; ALPHA-6-BETA-4 INTEGRIN; CYCLOSPORINE-A; NUCLEAR FACTOR; CALCINEURIN; EXPRESSION; PROTEIN; LOCALIZATION; RECEPTORS; BREAST	Integrins, receptors for extracellular matrix ligands, are critical regulators of the invasive phenotype(1). Specifically, the alpha(6)beta(4) integrin has been linked with epithelial cell motility, cellular survival and carcinoma invasion, hallmarks of metastatic tumours(2-4). Previous studies have also shown that antagonists of the NFAT (nuclear factor of activated T-cells) family of transcription factors(5,6) exhibit strong anti-tumour-promoting activity(7). This suggests that NFAT may function in tumour metastasis. Here, we investigate the involvement of NFAT in promoting carcinoma invasion downstream of the alpha(6)beta(4) integrin. We provide evidence that both NFAT1, and the recently identified NFAT5 isoform, are expressed in invasive human ductal breast carcinomas and participate in promoting carcinoma invasion using cell lines derived from human breast and colon carcinomas. NFAT1 and NFAT5 activity correlates with the expression of the alpha(6)beta(4) integrin. In addition, the transcriptional activity of NFAT5 is induced by alpha(6)beta(4) clustering in the presence of chemo-attractants, resulting in enhanced cell migration. These observations show that NFATs are targets of alpha(6)beta(4) integrin signalling and are involved in promoting carcinoma invasion, highlighting a novel function for this family of transcription factors in human cancer.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Dept Pathol, Div Canc Biol & Angiogenesis, Boston, MA 02215 USA; Ctr Blood Res, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM)	Toker, A (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.		Lopez-Rodriguez, C/G-4482-2014; Jauliac, Sebastien/B-7847-2010	Lopez-Rodriguez, C/0000-0002-2311-2406; Jauliac, Sebastien/0000-0002-1712-3416	NATIONAL CANCER INSTITUTE [R21CA081325, R37CA042471, R21CA082695, R01CA042471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK064854] Funding Source: NIH RePORTER; NCI NIH HHS [CA42471, CA82695, CA81325] Funding Source: Medline; NIDDK NIH HHS [DK64854] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; Boss V, 1998, J BIOL CHEM, V273, P19664, DOI 10.1074/jbc.273.31.19664; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Crabtree GR, 2001, J BIOL CHEM, V276, P2313, DOI 10.1074/jbc.R000024200; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; Feske S, 2000, J IMMUNOL, V165, P297, DOI 10.4049/jimmunol.165.1.297; Graef IA, 2001, CURR OPIN GENET DEV, V11, P505, DOI 10.1016/S0959-437X(00)00225-2; JIANG H, 1993, CARCINOGENESIS, V14, P67, DOI 10.1093/carcin/14.1.67; John Anitha, 2001, Pathology and Oncology Research, V7, P14; KOUKOULIS GK, 1991, AM J PATHOL, V139, P787; Lopez-Rodriguez C, 1999, P NATL ACAD SCI USA, V96, P7214, DOI 10.1073/pnas.96.13.7214; Lopez-Rodriguez C, 2001, IMMUNITY, V15, P47, DOI 10.1016/S1074-7613(01)00165-0; Macian F, 2000, EMBO J, V19, P4783, DOI 10.1093/emboj/19.17.4783; Mercurio AM, 2001, SEMIN CANCER BIOL, V11, P129, DOI 10.1006/scbi.2000.0364; MILAN D, 1994, CELL, V79, P437, DOI 10.1016/0092-8674(94)90253-4; Miyakawa H, 1999, P NATL ACAD SCI USA, V96, P2538, DOI 10.1073/pnas.96.5.2538; Miyakawa H, 1998, AM J PHYSIOL-RENAL, V274, pF753, DOI 10.1152/ajprenal.1998.274.4.F753; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Plyte S, 2001, J BIOL CHEM, V276, P14350, DOI 10.1074/jbc.M007854200; Rabinovitz I, 1997, J CELL BIOL, V139, P1873, DOI 10.1083/jcb.139.7.1873; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Tagliabue E, 1998, CLIN CANCER RES, V4, P407; Trama J, 2000, J IMMUNOL, V165, P4884, DOI 10.4049/jimmunol.165.9.4884; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0	27	339	350	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	2002	4	7					540	544		10.1038/ncb816	http://dx.doi.org/10.1038/ncb816			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	568UL	12080349				2022-12-25	WOS:000176562900021
J	Kurdistani, SK; Robyr, D; Tavazoie, S; Grunstein, M				Kurdistani, SK; Robyr, D; Tavazoie, S; Grunstein, M			Genome-wide binding map of the histone deacetylase Rpd3 in yeast	NATURE GENETICS			English	Article							CHROMATIN REMODELING COMPLEX; SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; TRANSCRIPTIONAL REPRESSION; TARGETED RECRUITMENT; COREPRESSOR; ACETYLATION; COMPONENT; PROTEINS; UME6	We describe the genome-wide distribution of the histone deacetylase and repressor Rpd3 and its associated proteins Ume1 and Ume6 in Saccharomyces cerevisiae. Using a new cross-linking protocol, we found that Rpd3 binds upstream of many individual genes and upstream of members of gene classes with similar functions in anabolic processes. In addition, Rpd3 is preferentially associated with promoters that direct high transcriptional activity. We also found that Rpd3 was absent from large sub-telomeric domains. We show by co-immunoprecipitation and by the high similarity of their binding maps that Ume1 interacts with Rpd3. In contrast, despite the known role of Ume6 in Rpd3 recruitment, only a limited number of the genes targeted by Rpd3 are also enriched for (or targeted by) Ume6. This suggests that Rpd3 is brought to many promoters by alternative recruiters, some of which may bind the putative cis-regulatory DNA elements that we have identified in sets of Rpd3 target genes. Finally, we show that comparing the genome-wide pattern of Rpd3 binding with gene expression and histone acetylation in the rpd3Delta mutant strain reveals new sites of Rpd3 function.	Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Princeton Univ, Lewis Thomas Labs, Dept Mol Biol, Princeton, NJ USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Princeton University	Grunstein, M (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA.			Kurdistani, Siavash/0000-0003-3295-3511				Bernstein BE, 2000, P NATL ACAD SCI USA, V97, P13708, DOI 10.1073/pnas.250477697; Gelbart ME, 2001, MOL CELL BIOL, V21, P2098, DOI 10.1128/MCB.21.6.2098-2106.2001; Goldmark JP, 2000, CELL, V103, P423, DOI 10.1016/S0092-8674(00)00134-3; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Hughes JD, 2000, J MOL BIOL, V296, P1205, DOI 10.1006/jmbi.2000.3519; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; Kadosh D, 1998, MOL CELL BIOL, V18, P5121, DOI 10.1128/MCB.18.9.5121; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kasten MM, 1997, MOL CELL BIOL, V17, P4852, DOI 10.1128/MCB.17.8.4852; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Laherty CD, 1998, MOL CELL, V2, P33, DOI 10.1016/S1097-2765(00)80111-2; Lechner T, 2000, J BIOL CHEM, V275, P40961, DOI 10.1074/jbc.M005730200; Lieb JD, 2001, NAT GENET, V28, P327, DOI 10.1038/ng569; Loewith R, 2001, J BIOL CHEM, V276, P24068, DOI 10.1074/jbc.M102176200; Orphanides G, 2000, NATURE, V407, P471, DOI 10.1038/35035000; Pemberton LF, 1997, MOL CELL BIOL, V17, P4830, DOI 10.1128/MCB.17.8.4830; Pile LA, 2000, EMBO J, V19, P6131, DOI 10.1093/emboj/19.22.6131; Reid JL, 2000, MOL CELL, V6, P1297, DOI 10.1016/S1097-2765(00)00128-3; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; Robyr D, 2002, CELL, V109, P437, DOI 10.1016/S0092-8674(02)00746-8; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Tavazoie S, 1999, NAT GENET, V22, P281, DOI 10.1038/10343; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Waterborg JH, 2001, BIOCHEMISTRY-US, V40, P2599, DOI 10.1021/bi002480c; Wittschieben BO, 1999, MOL CELL, V4, P123, DOI 10.1016/S1097-2765(00)80194-X; Wu JS, 2001, MOL CELL, V7, P117, DOI 10.1016/S1097-2765(01)00160-5; Wyrick JJ, 1999, NATURE, V402, P418, DOI 10.1038/46567	30	226	230	1	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2002	31	3					248	254		10.1038/ng907	http://dx.doi.org/10.1038/ng907			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	567PW	12089521				2022-12-25	WOS:000176494100011
J	Morrish, TA; Gilbert, N; Myers, JS; Vincent, BJ; Stamato, TD; Taccioli, GE; Batzer, MA; Moran, JV				Morrish, TA; Gilbert, N; Myers, JS; Vincent, BJ; Stamato, TD; Taccioli, GE; Batzer, MA; Moran, JV			DNA repair mediated by endonuclease-independent LINE-1 retrotransposition	NATURE GENETICS			English	Article							STRAND BREAK-REPAIR; HAMSTER OVARY CELL; REVERSE-TRANSCRIPTASE; V(D)J RECOMBINATION; MUSCULAR-DYSTROPHY; GENE; INSERTION; ELEMENT; ENCODES; RNA	Long interspersed elements (LINE-1s) are abundant retrotransposons in mammalian genomes that probably retrotranspose by target site-primed reverse transcription (TPRT)(1,2). During TPRT, the LINE-1 endonuclease cleaves genomic DNA 3, freeing a 3 hydroxyl that serves as a primer for reverse transcription of LINE-1 RNA by LINE-1 reverse transcriptase. The nascent LINE-1 cDNA joins to genomic DNA, generating LINE-1 structural hallmarks such as frequent 5' truncations, a 3' poly( A)(+) tail and variable-length target site duplications (TSDs)(2). Here we describe a pathway for LINE-1 retrotransposition in Chinese hamster ovary (CHO) cells that acts independently of endonuclease but is dependent upon reverse transcriptase. We show that endonuclease-independent LINE-1 retrotransposition occurs at near-wildtype levels in two mutant cell lines that are deficient in nonhomologous end-joining (NHEJ). Analysis of the pre- and post-integration sites revealed that endonuclease-independent retrotransposition results in unusual structures because the LINE-1s integrate at atypical target sequences, are truncated predominantly at their 3 ends and lack TSDs. Moreover, two of nine endonuclease-independent retrotranspositions contained cDNA fragments at their 3 ends that are probably derived from the reverse transcription of endogenous mRNA. Thus, our results suggest that LINE-1s can integrate into DNA lesions, resulting in retrotransposon-mediated DNA repair in mammalian cells.	Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48105 USA; Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48105 USA; Louisiana State Univ, Biol Computat & Visualizat Ctr, Dept Biol Sci, Baton Rouge, LA USA; Lankenau Inst Med Res, Wynnewood, PA USA; Boston Univ, Sch Med, Dept Microbiol, Boston, MA USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Louisiana State University System; Louisiana State University; Lankenau Medical Center; Lankenau Institute for Medical Research; Boston University	Moran, JV (corresponding author), Univ Michigan, Sch Med, Dept Human Genet, 1241 E Catherine St, Ann Arbor, MI 48105 USA.		Gilbert, Nicolas/M-9568-2018	Gilbert, Nicolas/0000-0003-3311-7494; Morrish, Tammy/0000-0002-6725-0253				BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Carroll ML, 2001, J MOL BIOL, V311, P17, DOI 10.1006/jmbi.2001.4847; CHAMBEYRON S, 2002, J BIOL CHEM     0306; Cost GJ, 1998, BIOCHEMISTRY-US, V37, P18081, DOI 10.1021/bi981858s; DOMBROSKI BA, 1991, SCIENCE, V254, P1805, DOI 10.1126/science.1662412; Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2; FULLER LF, 1988, MUTAT RES, V193, P109, DOI 10.1016/0167-8817(88)90041-7; GIACCIA AJ, 1990, AM J HUM GENET, V47, P459; Higashiyama T, 1997, EMBO J, V16, P3715, DOI 10.1093/emboj/16.12.3715; Kojima T, 2000, MOL BRAIN RES, V75, P121, DOI 10.1016/S0169-328X(99)00313-7; Kondo-Iida E, 1999, HUM MOL GENET, V8, P2303, DOI 10.1093/hmg/8.12.2303; Levin HL, 1997, CELL, V88, P5, DOI 10.1016/S0092-8674(00)81851-6; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Li ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; LUAN DD, 1995, MOL CELL BIOL, V15, P3882; MAGER DL, 1985, NUCLEIC ACIDS RES, V13, P6559, DOI 10.1093/nar/13.18.6559; Moran J.V., 2002, MOBILE DNA, P836; Moran JV, 1996, CELL, V87, P917, DOI 10.1016/S0092-8674(00)81998-4; NARITA N, 1993, J CLIN INVEST, V91, P1862, DOI 10.1172/JCI116402; Ovchinnikov I, 2001, GENOME RES, V11, P2050, DOI 10.1101/gr.194701; Pardue ML, 1997, GENETICA, V100, P73, DOI 10.1023/A:1018352706024; Priestley A, 1998, NUCLEIC ACIDS RES, V26, P1965, DOI 10.1093/nar/26.8.1965; Sassaman DM, 1997, NAT GENET, V16, P37, DOI 10.1038/ng0597-37; STAMATO TD, 1983, SOMAT CELL GENET, V9, P165, DOI 10.1007/BF01543175; Stoneking M, 1997, GENOME RES, V7, P1061, DOI 10.1101/gr.7.11.1061; Teng SC, 1996, NATURE, V383, P641, DOI 10.1038/383641a0; VOLIVA CF, 1984, J MOL BIOL, V178, P795, DOI 10.1016/0022-2836(84)90312-7; Wei W, 2000, ANAL BIOCHEM, V284, P435, DOI 10.1006/abio.2000.4675; Wei W, 2001, MOL CELL BIOL, V21, P1429, DOI 10.1128/MCB.21.4.1429-1439.2001	30	331	342	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2002	31	2					159	165		10.1038/ng898	http://dx.doi.org/10.1038/ng898			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	557HR	12006980				2022-12-25	WOS:000175903500011
J	Smyth, S; Khachatourians, GG; Phillips, PWB				Smyth, S; Khachatourians, GG; Phillips, PWB			Liabilities and economics of transgenic crops	NATURE BIOTECHNOLOGY			English	Editorial Material							CORN POLLEN; BRASSICA-NAPUS; MONARCH LARVAE; POLLINATION; SPREAD; IMPACT		Univ Saskatchewan, Dept Appl Microbiol & Food Sci, Saskatoon, SK S7N 0W0, Canada	University of Saskatchewan	Smyth, S (corresponding author), Univ Saskatchewan, Dept Appl Microbiol & Food Sci, Saskatoon, SK S7N 0W0, Canada.	sjs064@mail.usask.ca						Bing DJ, 1996, PLANT BREEDING, V115, P470, DOI 10.1111/j.1439-0523.1996.tb00959.x; Canola Council of Canada, 2001, AGR EC ASS TRANSG CA; CHEVRE A, 2000, 6 INT S BIOS GEN MOD, P45; EASTHAM K, 2002, GENETICALLY MODIFIED; Furst I, 1999, NAT BIOTECHNOL, V17, P629, DOI 10.1038/10837; Giddings G, 2000, THEOR APPL GENET, V100, P971, DOI 10.1007/s001220051378; HARRINGTON, 1932, J SCI AGR, V12, P470; Hellmich RL, 2001, P NATL ACAD SCI USA, V98, P11925, DOI 10.1073/pnas.211297698; Hucl P, 1996, CAN J PLANT SCI, V76, P423, DOI 10.4141/cjps96-075; Hucl P, 2001, CROP SCI, V41, P1348, DOI 10.2135/cropsci2001.4141348x; KHAN MN, 1973, CROP SCI, V13, P223, DOI 10.2135/cropsci1973.0011183X001200020022x; Lefol E, 1996, FIELD CROP RES, V45, P153, DOI 10.1016/0378-4290(95)00067-4; Lefol E, 1996, SEX PLANT REPROD, V9, P189, DOI 10.1007/BF02173097; Losey JE, 1999, NATURE, V399, P214, DOI 10.1038/20338; Mayer H, 1999, FOOD POLICY, V24, P431, DOI 10.1016/S0306-9192(99)00043-3; METZ PLJ, 1997, THEOR APPL GENET, V95, P275; Nip, 2002, TRANSGENIC PLANTS CR; Oberhauser KS, 2001, P NATL ACAD SCI USA, V98, P11913, DOI 10.1073/pnas.211234298; Phillips P. W. B., 2001, BIOTECHNOLOGY REVOLU; Pleasants JM, 2001, P NATL ACAD SCI USA, V98, P11919, DOI 10.1073/pnas.211287498; Pohl-Orf M, 1999, EUPHYTICA, V108, P181, DOI 10.1023/A:1003680931766; SEARS M, 2000, 6 INT S BIOS GEN MOD, P120; Sears MK, 2001, P NATL ACAD SCI USA, V98, P11937, DOI 10.1073/pnas.211329998; Staniland BK, 2000, CAN J PLANT SCI, V80, P521, DOI 10.4141/P99-117; Stanley-Horn DE, 2001, P NATL ACAD SCI USA, V98, P11931, DOI 10.1073/pnas.211277798; TIMMONS AM, 1995, EUPHYTICA, V85, P417, DOI 10.1007/BF00023975; Tomiuk J., 1996, TRANSGENIC ORGANISMS; VISSER B, 2001, POTENTIAL IMPACTS GE; Zangerl AR, 2001, P NATL ACAD SCI USA, V98, P11908, DOI 10.1073/pnas.171315698	29	59	64	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2002	20	6					537	541		10.1038/nbt0602-537	http://dx.doi.org/10.1038/nbt0602-537			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	558NM	12042844				2022-12-25	WOS:000175973500008
J	Harvey, AJ; Speksnijder, G; Baugh, LR; Morris, JA; Ivarie, R				Harvey, AJ; Speksnijder, G; Baugh, LR; Morris, JA; Ivarie, R			Expression of exogenous protein in the egg white of transgenic chickens	NATURE BIOTECHNOLOGY			English	Article							VIRUS-BASED VECTORS; CELL-LINE; LEUKOSIS; MILK; REPLICATION; GENES	Using a replication-deficient retroviral vector based on the avian leukosis virus (ALV), we inserted into the chicken genome a transgene encoding a secreted protein, beta-lactamase, under the control of the ubiquitous cytomegalovirus (CMV) promoter. Biologically active beta-lactamase was secreted into the serum and egg white of four generations of transgenic chickens. The expression levels were similar in successive generations, and expression levels in the magnum of the oviduct were constant over at least 16 months in transgenic hens, indicating that the transgene was stable and not subject to silencing. These results support the potential of the hen as a bioreactor for the production of commercially valuable, biologically active proteins in egg white.	AviGenet Inc, Georgia BioBusiness Ctr, Athens, GA 30605 USA; Univ Georgia, Dept Genet, Athens, GA 30602 USA	University System of Georgia; University of Georgia	Harvey, AJ (corresponding author), AviGenet Inc, Georgia BioBusiness Ctr, 111 Riverbend Rd, Athens, GA 30605 USA.		Baugh, L. Ryan/GRS-0507-2022	Baugh, L. Ryan/0000-0003-2148-5492				AHRVEY AJ, 2002, POULTRY SCI, V81, P202; BOSSELMAN RA, 1989, J VIROL, V63, P2680, DOI 10.1128/JVI.63.6.2680-2689.1989; CARSIENCE RS, 1993, DEVELOPMENT, V117, P669; CLARK AJ, 1989, GENOME, V31, P950, DOI 10.1139/g89-166; COSSET FL, 1990, J VIROL, V64, P1070, DOI 10.1128/JVI.64.3.1070-1078.1990; COSSET FL, 1992, J VIROL, V66, P5671, DOI 10.1128/JVI.66.9.5671-5676.1992; COSSET FL, 1991, J VIROL, V65, P3388, DOI 10.1128/JVI.65.6.3388-3394.1991; DEVINOY E, 1994, TRANSGENIC RES, V3, P79, DOI 10.1007/BF01974085; EBERT KM, 1991, BIO-TECHNOL, V9, P835, DOI 10.1038/nbt0991-835; Fadly AM, 1999, AVIAN DIS, V43, P391, DOI 10.2307/1592636; LOVE J, 1994, BIO-TECHNOL, V12, P60, DOI 10.1038/nbt0194-60; Moore JT, 1997, ANAL BIOCHEM, V247, P203, DOI 10.1006/abio.1997.2092; PETROPOULOS CJ, 1992, J VIROL, V66, P3391, DOI 10.1128/JVI.66.6.3391-3397.1992; Raju TS, 2000, GLYCOBIOLOGY, V10, P477, DOI 10.1093/glycob/10.5.477; SALTER DW, 1986, POULTRY SCI, V65, P1445, DOI 10.3382/ps.0651445; Schaefer-Klein J, 1998, VIROLOGY, V248, P305, DOI 10.1006/viro.1998.9291; THORAVAL P, 1995, TRANSGENIC RES, V4, P369, DOI 10.1007/BF01973755; VELANDER WH, 1992, P NATL ACAD SCI USA, V89, P12003, DOI 10.1073/pnas.89.24.12003	18	101	144	2	19	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	2002	20	4					396	399		10.1038/nbt0402-396	http://dx.doi.org/10.1038/nbt0402-396			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	536BY	11923848				2022-12-25	WOS:000174681900029
J	Klose, J; Nock, C; Herrmann, M; Stuhler, K; Marcus, K; Bluggel, M; Krause, E; Schalkwyk, LC; Rastan, S; Brown, SDM; Bussow, K; Himmelbauer, H; Lehrach, H				Klose, J; Nock, C; Herrmann, M; Stuhler, K; Marcus, K; Bluggel, M; Krause, E; Schalkwyk, LC; Rastan, S; Brown, SDM; Bussow, K; Himmelbauer, H; Lehrach, H			Genetic analysis of the mouse brain proteome	NATURE GENETICS			English	Article							SINGLE-NUCLEOTIDE POLYMORPHISMS; POLYACRYLAMIDE-GEL-ELECTROPHORESIS; 2-DIMENSIONAL ELECTROPHORESIS; MASS-SPECTROMETRY; PROTEINS; GENOME; MAP; IDENTIFICATION; RESOLUTION; SEPARATION	Proteome analysis is a fundamental step in systematic functional genomics. Here we have resolved 8,767 proteins from the mouse brain proteome by large-gel two-dimensional electrophoresis. We detected 1,324 polymorphic proteins from the European collaborative interspecific backcross. Of these, we mapped 665 proteins genetically and identified 466 proteins by mass spectrometry. Qualitatively polymorphic proteins, to 96%, reflect changes in conformation and/or mass. Quantitatively polymorphic proteins show a high frequency (73%) of allele-specific transmission in codominant heterozygotes. Variations in protein isoforms and protein quantity often mapped to chromosomal positions different from that of the structural gene, indicating that single proteins may act as polygenic traits. Genetic analysis of proteomes may detect the types of polymorphism that are most relevant in disease-association studies.	Humboldt Univ, Charite, Inst Humangenet, D-13353 Berlin, Germany; Free Univ Berlin, Fachbereich Biol, D-14195 Berlin, Germany; Max Planck Inst Mol Genet, D-14195 Berlin, Germany; Ruhr Univ Bochum, Inst Physiol Chem, D-44780 Bochum, Germany; Protagen AG, D-44801 Bochum, Germany; Inst Mol Pharmakol, D-13125 Berlin, Germany; Inst Psychiat, SGDP Res Ctr, London SE5 8AF, England; MWB Business Exchange, Cambridge CB1 1BH, England; MRC, Mammalian Genet Unit, Oxford OX11 0RD, England; UK Mouse Genome Ctr, Oxford OX11 0RD, England	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Max Planck Society; Ruhr University Bochum; Protagen Protein Services (PPS); University of London; King's College London	Klose, J (corresponding author), Humboldt Univ, Charite, Inst Humangenet, Campus Virchow Klinikum,Augustenburger Pl 1, D-13353 Berlin, Germany.		Schalkwyk, Leonard C/A-2150-2010	Schalkwyk, Leonard C/0000-0001-7030-5756; Himmelbauer, Heinz/0000-0001-8897-2928				ANDERSON NG, 2002, PROTEOMICS, V2, pP; AVNER P, 1988, TRENDS GENET, V4, P18, DOI 10.1016/0168-9525(88)90123-0; BREEN M, 1994, HUM MOL GENET, V3, P621, DOI 10.1093/hmg/3.4.621; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; Church G M, 1985, Prog Clin Biol Res, V177, P17; DAMERVAL C, 1994, GENETICS, V137, P289; DIETRICH W, 1992, GENETICS, V131, P423; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERRIS SD, 1983, GENETICS, V105, P681; Gauss C, 1999, ELECTROPHORESIS, V20, P575, DOI 10.1002/(SICI)1522-2683(19990301)20:3<575::AID-ELPS575>3.0.CO;2-3; Gerstner A, 2000, ELECTROPHORESIS, V21, P834, DOI 10.1002/(SICI)1522-2683(20000301)21:5<834::AID-ELPS834>3.0.CO;2-X; GOOLEY AA, 2001, PROTEOME RES NEW FRO, P65; Halushka MK, 1999, NAT GENET, V22, P239, DOI 10.1038/10297; HERMEL E, 1993, IMMUNOGENETICS, V38, P106; Janke C, 1996, FEBS LETT, V379, P222, DOI 10.1016/0014-5793(95)01522-1; Kato GJ, 1999, HUM MUTAT, V13, P87, DOI 10.1002/(SICI)1098-1004(1999)13:2<87::AID-HUMU1>3.0.CO;2-K; Klose J, 1999, METH MOL B, V112, P147; KLOSE J, 1975, HUMANGENETIK, V26, P231; Klose J, 1999, METH MOL B, V112, P67; KLOSE J, 1995, ELECTROPHORESIS, V16, P1034, DOI 10.1002/elps.11501601175; Klose J, 1999, ELECTROPHORESIS, V20, P643; LACOMBE C, 1985, PROTIDES BIOL FLUIDS, V32, P1001; Lai K, 1998, HUM MUTAT, V11, P28; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; Le Stunff C, 2000, NAT GENET, V26, P444, DOI 10.1038/82579; LEHMANN WD, 1996, MASSENSPEKTROMETRIE, P410; LITERSKY JM, 1993, BRAIN RES, V604, P32, DOI 10.1016/0006-8993(93)90349-R; Marcus K, 2000, ELECTROPHORESIS, V21, P2622, DOI 10.1002/1522-2683(20000701)21:13<2622::AID-ELPS2622>3.0.CO;2-3; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; NOEL D, 1979, BIOCHEMISTRY-US, V18, P4159, DOI 10.1021/bi00586a017; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Pesole G, 2000, NUCLEIC ACIDS RES, V28, P193, DOI 10.1093/nar/28.1.193; Phillips PC, 1999, TRENDS GENET, V15, P6, DOI 10.1016/S0168-9525(98)01622-9; Rhodes M, 1998, GENOME RES, V8, P531, DOI 10.1101/gr.8.5.531; Schalkwyk LC, 2001, GENOME RES, V11, P2142, DOI 10.1101/gr.176201; Schalkwyk LC, 1999, GENOME RES, V9, P878, DOI 10.1101/gr.9.9.878; Scriver CR, 1999, TRENDS GENET, V15, P267, DOI 10.1016/S0168-9525(99)01761-8; SILVA AJ, 1988, CELL, V54, P145, DOI 10.1016/0092-8674(88)90546-6; STRUPAT K, 1994, ANAL CHEM, V66, P464, DOI 10.1021/ac00076a008; Sunyaev S, 2000, TRENDS GENET, V16, P198, DOI 10.1016/S0168-9525(00)01988-0; Thiellement H, 1999, ELECTROPHORESIS, V20, P2013, DOI 10.1002/(SICI)1522-2683(19990701)20:10&lt;2013::AID-ELPS2013&gt;3.0.CO;2-#; Weiss KM, 2000, NAT GENET, V26, P151, DOI 10.1038/79866; WHITNEY JB, 1985, P NATL ACAD SCI USA, V82, P7646, DOI 10.1073/pnas.82.22.7646; Wiltfang J, 1997, ELECTROPHORESIS, V18, P527, DOI 10.1002/elps.1150180332; Zhang WZ, 2000, ANAL CHEM, V72, P2482, DOI 10.1021/ac991363o	47	197	205	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2002	30	4					385	393		10.1038/ng861	http://dx.doi.org/10.1038/ng861			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	536BZ	11912495				2022-12-25	WOS:000174682000015
J	Stock, M; Lamatsch, DK; Steinlein, C; Epplen, JT; Grosse, WR; Hock, R; Klapperstuck, T; Lampert, KP; Scheer, U; Schmid, M; Schartl, M				Stock, M; Lamatsch, DK; Steinlein, C; Epplen, JT; Grosse, WR; Hock, R; Klapperstuck, T; Lampert, KP; Scheer, U; Schmid, M; Schartl, M			A bisexually reproducing all-triploid vertebrate	NATURE GENETICS			English	Article							POLYMORPHIC MICROSATELLITE LOCI; LAMPBRUSH CHROMOSOMES; ALBURNOIDES COMPLEX; FLOW-CYTOMETRY; BUFO; DIVERSITY; DNA; ELIMINATION; SEQUENCES; AMPHIBIA	Green toads are common in the Palaearctic region, where they have differentiated into several taxa(1,2). The toads exist with variable amounts of ploidy, similar to other anuran species(3) or reptiles(4). In vertebrate biology, the very rare occurrence of triploidy is coupled with infertility or unisexuality, or requires the coexistence of individuals of different ploidy in a reproductive community. The reproduction of naturally occurring triploids has been reported to occur only through parthenogenesis, gynogenesis or hybridogenesis. The bisexual reproduction of pure triploids has been considered to be impossible because of the problem of equally distributing three chromosome sets in meiosis. Here we report geographically isolated populations of green toads (Bufo viridis complex) that are all-triploid and reproduce bisexually.	Theodor Boveri Inst, Lehrstuhl Phyziol Chem 1, D-97074 Wurzburg, Germany; Univ Halle Wittenberg, Inst Zool, D-06099 Halle Saale, Saale, Germany; Biozentrum, Theodor Boveri Inst, Inst Humangenet, D-97074 Wurzburg, Germany; Biozentrum, Theodor Boveri Inst, Lehrstuhl Zool 1, D-97074 Wurzburg, Germany; Ruhr Univ Bochum, Abt Mol Humangenet, D-44780 Bochum, Germany; Univ Halle Wittenberg, Klin Dermatol & Venerol, D-06097 Halle Saale, Saale, Germany	University of Wurzburg; Martin Luther University Halle Wittenberg; University of Wurzburg; University of Wurzburg; Ruhr University Bochum; Martin Luther University Halle Wittenberg	Schartl, M (corresponding author), Theodor Boveri Inst, Lehrstuhl Phyziol Chem 1, D-97074 Wurzburg, Germany.		Stöck, Matthias/E-7245-2014	Stöck, Matthias/0000-0003-4888-8371; Schartl, Manfred/0000-0001-9882-5948; Epplen, Joerg T./0000-0002-6087-3327				Alves MJ, 1998, MOL BIOL EVOL, V15, P1233, DOI 10.1093/oxfordjournals.molbev.a025852; Beukeboom LW, 1998, J EVOLUTION BIOL, V11, P755, DOI 10.1007/s000360050117; BICKHAM JW, 1993, COPEIA, P723; Borkin Leo J., 2001, Russian Journal of Herpetology, V8, P45; Borkin LJ, 1999, PATTERNS OF DISTRIBUTION OF AMPHIBIANS: A GLOBAL PERSPECTIVE, P329; CALLAN HG, 1987, CHROMOSOMA, V95, P236, DOI 10.1007/BF00294780; Carmona JA, 1997, GENETICS, V146, P983; Castellano S, 1998, BIOL J LINN SOC, V63, P257, DOI 10.1006/bijl.1997.0189; CHEN H, 1995, BIOCHEM GENET, V33, P297, DOI 10.1007/BF02399929; GALL JG, 1991, METHOD CELL BIOL, V36, P149; Green D.M., 1991, AMPHIBIAN CYTOGENETI; Gunther R., 1979, Mitteilungen aus dem Zoologischen Museum in Berlin, V55, P35; Klapperstuck T, 1996, CYTOMETRY, V25, P82, DOI 10.1002/(SICI)1097-0320(19960901)25:1<82::AID-CYTO9>3.0.CO;2-G; MEZHZHERIN SV, 1995, GENETIKA+, V31, P43; MORGAN GT, 1980, CHROMOSOMA, V80, P309, DOI 10.1007/BF00292687; OHTANI H, 1993, CHROMOSOMA, V102, P158, DOI 10.1007/BF00387730; PISANETS EM, 1978, DOKLADY AKAD NAUK B, V3, P280; Roth P., 1987, P335; Rowe G, 1997, MOL ECOL, V6, P401, DOI 10.1046/j.1365-294X.1997.00197.x; SCHARTL M, 1991, P NATL ACAD SCI USA, V88, P8759, DOI 10.1073/pnas.88.19.8759; SCHMID M, 1978, CHROMOSOMA, V66, P361, DOI 10.1007/BF00328536; SCRIBNER KT, 1994, MOL BIOL EVOL, V11, P737; Stock M, 1999, ITAL J ZOOL, V66, P215; Stock M., 2001, ZOOLOGICAL ABHANDLUN, V51, P253; STOCK M, 2001, THESIS M LUTHER U HA; Stock Matthias, 1997, Alytes (Paris), V15, P72; Sumida Masayuki, 1993, Scientific Report of the Laboratory for Amphibian Biology Hiroshima University, V12, P133; Tikel D, 2000, MOL ECOL, V9, P1927, DOI 10.1046/j.1365-294x.2000.01074-6.x; UZZELL T, 1970, AM NAT, V104, P433, DOI 10.1086/282678; VINOGRADOV AE, 1990, GENOME, V33, P619, DOI 10.1139/g90-092	30	93	100	0	23	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2002	30	3					325	328		10.1038/ng839	http://dx.doi.org/10.1038/ng839			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	526YP	11836500				2022-12-25	WOS:000174157600020
J	Suzuki, T; Li, W; Zhang, Q; Karim, A; Novak, EK; Sviderskaya, EV; Hill, SP; Bennett, DC; Levin, AV; Nieuwenhuis, HK; Fong, CT; Castellan, C; Miterski, B; Swank, RT; Spritz, A				Suzuki, T; Li, W; Zhang, Q; Karim, A; Novak, EK; Sviderskaya, EV; Hill, SP; Bennett, DC; Levin, AV; Nieuwenhuis, HK; Fong, CT; Castellan, C; Miterski, B; Swank, RT; Spritz, A			Hermansky-Pudlak syndrome is caused by mutations in HPS4, the human homolog of the mouse light-ear gene	NATURE GENETICS			English	Article							MULTI-ORGANELLAR DISORDERS; PALE EAR; PIGMENTATION; PROTEIN; EP	Hermansky-Pudlak syndrome (HPS) is a disorder of organelle biogenesis in which oculocutaneous albinism, bleeding and pulmonary fibrosis result from defects of melanosomes, platelet dense granules and lysosomes(1-4). HPS is common in Puerto Rico 5,6, where it is caused by mutations in the genes HPS1(7) and, less often, HPS3 (ref. 8). In contrast, only half of non-Puerto Rican individuals with HPS have mutations in HPS1 (ref. 9), and very few in HPS3 (ref. 10). In the mouse, more than 15 loci manifest mutant phenotypes similar to human HPS 11,12, including pale ear (ep), the mouse homolog of HPS1 (refs 13,14). Mouse ep has a phenotype identical to another mutant, light ear (le)(15-18), which suggests that the human homolog of le is a possible human HPS locus. We have identified and found mutations of the human le homolog, HPS4, in a number of non-Puerto Rican individuals with HPS, establishing HPS4 as an important HPS locus in humans. In addition to their identical phenotypes, le and ep mutant mice have identical abnormalities of melanosomes, and in transfected melanoma cells the HPS4 and HPS1 proteins partially co-localize in vesicles of the cell body. In addition, the HPS1 protein is absent in tissues of le mutant mice. These results suggest that the HPS4 and HPS1 proteins may function in the same pathway of organelle biogenesis.	Univ Colorado, Hlth Sci Ctr, Human Med Genet Program, Denver, CO 80262 USA; Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA; Univ London St Georges Hosp, Sch Med, Dept Anat & Cell Biol, London SW17 0RE, England; Hosp Sick Children, Dept Ophthalmol, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dept Pediat, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dept Genet, Toronto, ON M5G 1X8, Canada; Univ Utrecht Hosp, Dept Hematol, Utrecht, Netherlands; Univ Rochester, Med Ctr, Dept Pediat, Rochester, NY 14642 USA; Genet Beratungsstelle, Bolzano, Italy; Ruhr Univ Bochum, Abt Mol Humangenet, D-4630 Bochum, Germany	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Roswell Park Cancer Institute; St Georges University London; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Utrecht University; Utrecht University Medical Center; University of Rochester; Ruhr University Bochum	Spritz, A (corresponding author), Univ Colorado, Hlth Sci Ctr, Human Med Genet Program, 4200 E 9th Ave, Denver, CO 80262 USA.		Sviderskaya, Elena V/D-2419-2009; Bennett, Dorothy C/C-2418-2008	Bennett, Dorothy C/0000-0002-3639-7527				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anikster Y, 2001, NAT GENET, V28, P376, DOI 10.1038/ng576; BENNETT DC, 1993, INT REV CYTOL, V146, P191, DOI 10.1016/S0074-7696(08)60383-6; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CHAPMAN VM, 1975, MOUSE NEWS LETT, V53, P61; CUOMO M, 1991, J INVEST DERMATOL, V96, P446, DOI 10.1111/1523-1747.ep12470092; DELLANGELICA EC, 1999, MOL CELL, V3, P1; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; Feng GH, 1997, HUM MOL GENET, V6, P793, DOI 10.1093/hmg/6.5.793; Feng LJ, 1999, HUM MOL GENET, V8, P323, DOI 10.1093/hmg/8.2.323; Gardner JM, 1997, P NATL ACAD SCI USA, V94, P9238, DOI 10.1073/pnas.94.17.9238; HERMANSKY F, 1959, BLOOD, V14, P162, DOI 10.1182/blood.V14.2.162.162; LANE PW, 1967, J HERED, V58, P17, DOI 10.1093/oxfordjournals.jhered.a107529; LANE PW, 1967, J HERED, V58, P21, DOI 10.1093/oxfordjournals.jhered.a107531; Lee ST, 1995, MOL CELLS, V5, P668; MEISLER M, 1980, AM J PATHOL, V101, P581; MEISLER MH, 1984, J HERED, V75, P103, DOI 10.1093/oxfordjournals.jhered.a109881; NOVAK EK, 1984, BLOOD, V63, P536; Oh J, 2000, HUM MOL GENET, V9, P375, DOI 10.1093/hmg/9.3.375; Oh J, 1996, NAT GENET, V14, P300, DOI 10.1038/ng1196-300; Oh J, 1998, AM J HUM GENET, V62, P593, DOI 10.1086/301757; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; Spritz RA, 2000, PIGM CELL RES, V13, P15, DOI 10.1034/j.1600-0749.2000.130104.x; Spritz RA, 1999, TRENDS GENET, V15, P337, DOI 10.1016/S0168-9525(99)01785-0; Spritz RA, 1999, CLIN GENET, V55, P309, DOI 10.1034/j.1399-0004.1999.550503.x; Spritz RA, 1999, PRIMARY IMMUNODEFICIENCY DISEASES, P389; SUZUKI T, 2001, GENOMICS, V78, P1; Swank RT, 1998, PIGM CELL RES, V11, P60, DOI 10.1111/j.1600-0749.1998.tb00713.x; Witkop C J, 1990, Bol Asoc Med P R, V82, P333; WITKOP CJ, 1990, OPHTHALMIC PAED GEN, V11, P245, DOI 10.3109/13816819009020986	30	142	146	0	3	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2002	30	3					321	324		10.1038/ng835	http://dx.doi.org/10.1038/ng835			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	526YP	11836498				2022-12-25	WOS:000174157600019
J	Du, QS; Stukenberg, PT; Macara, IG				Du, QS; Stukenberg, PT; Macara, IG			A mammalian Partner of inscuteable binds NuMA and regulates mitotic spindle organization	NATURE CELL BIOLOGY			English	Article							ASYMMETRIC CELL DIVISIONS; DROSOPHILA NEUROBLASTS; PROTEIN; IDENTIFICATION; LOCALIZATION; EXTRACTS; POLARITY; MITOSIS; COMPLEX; MOTIF	Asymmetric cell division requires the orientation of mitotic spindles along the cell-polarity axis. In Drosophila neuroblasts, this involves the interaction of the proteins Inscuteable (Insc) and Partner of inscuteable (Pins). We report here that a human Pins-related protein, called LGN, is instead essential for the assembly and organization of the mitotic spindle. LGN is cytoplasmic in interphase cells, but associates with the spindle poles during mitosis. Ectopic expression of LGN disrupts spindle-pole organization and chromosome segregation. Silencing of LGN expression by RNA interference also disrupts spindle-pole organization and prevents normal chromosome segregation. We found that LGN binds the nuclear mitotic apparatus protein NuMA, which tethers spindles at the poles, and that this interaction is required for the LGN phenotype. Anti-LGN antibodies and the LGN-binding domain of NuMA both trigger microtubule aster formation in mitotic Xenopus egg extracts, and the NuMA-binding domain of LGN blocks aster assembly in egg extracts treated with taxol. Thus, we have identified a mammalian Pins homologue as a key regulator of spindle organization during mitosis.	Univ Virginia, Sch Med, Ctr Cell Signalling, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Pharmacol, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Biochem, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Du, QS (corresponding author), Univ Virginia, Sch Med, Ctr Cell Signalling, Charlottesville, VA 22908 USA.			Du, Quansheng/0000-0003-4079-8662; Stukenberg, Todd/0000-0002-6788-2111	NCI NIH HHS [CA40042] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; Bernard ML, 2001, J BIOL CHEM, V276, P1585, DOI 10.1074/jbc.M005291200; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; COMPTON DA, 1993, J CELL BIOL, V120, P947, DOI 10.1083/jcb.120.4.947; COMPTON DA, 1992, J CELL BIOL, V116, P1395, DOI 10.1083/jcb.116.6.1395; De Vries L, 2000, P NATL ACAD SCI USA, V97, P14364, DOI 10.1073/pnas.97.26.14364; Desai A, 1999, METHOD CELL BIOL, V61, P385; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; GAGLIO T, 1995, J CELL BIOL, V131, P693, DOI 10.1083/jcb.131.3.693; Gaglio T, 1996, J CELL BIOL, V135, P399, DOI 10.1083/jcb.135.2.399; Gordon MB, 2001, J CELL BIOL, V152, P425, DOI 10.1083/jcb.152.3.425; Gotta M, 2001, NAT CELL BIOL, V3, P297, DOI 10.1038/35060092; GuethHallonet C, 1996, EXP CELL RES, V225, P207, DOI 10.1006/excr.1996.0171; Harborth J, 1999, EMBO J, V18, P1689, DOI 10.1093/emboj/18.6.1689; Joberty G, 1999, MOL CELL BIOL, V19, P6585; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Merdes A, 1996, CELL, V87, P447, DOI 10.1016/S0092-8674(00)81365-3; Merdes A, 2000, J CELL BIOL, V149, P851, DOI 10.1083/jcb.149.4.851; Miller KG, 2000, GENETICS, V156, P1649; Mochizuki N, 1996, GENE, V181, P39, DOI 10.1016/S0378-1119(96)00456-8; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nachury MV, 2001, CELL, V104, P95, DOI 10.1016/S0092-8674(01)00194-5; Natochin M, 2000, J BIOL CHEM, V275, P40981, DOI 10.1074/jbc.M006478200; Parmentier ML, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-14-j0003.2000; Schaefer M, 2000, CURR BIOL, V10, P353, DOI 10.1016/S0960-9822(00)00401-2; Schober M, 1999, NATURE, V402, P548, DOI 10.1038/990135; Scholey JM, 2001, J CELL BIOL, V154, P261, DOI 10.1083/jcb.200101097; Schuyler SC, 2001, J CELL SCI, V114, P247; Siderovski DP, 1999, TRENDS BIOCHEM SCI, V24, P340, DOI 10.1016/S0968-0004(99)01441-3; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; Wiese C, 2001, SCIENCE, V291, P653, DOI 10.1126/science.1057661; Wodarz A, 1999, NATURE, V402, P544, DOI 10.1038/990128; YANG CH, 1992, J CELL BIOL, V116, P1303, DOI 10.1083/jcb.116.6.1303; YANG CH, 1992, MOL BIOL CELL, V3, P1259, DOI 10.1091/mbc.3.11.1259; Yu FW, 2000, CELL, V100, P399, DOI 10.1016/S0092-8674(00)80676-5	38	214	218	0	8	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2001	3	12					1069	1075		10.1038/ncb1201-1069	http://dx.doi.org/10.1038/ncb1201-1069			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	500AM	11781568				2022-12-25	WOS:000172603700012
J	Marra, P; Maffucci, T; Daniele, T; Di Tullio, G; Ikehara, Y; Chan, EKL; Luini, A; Beznoussenko, G; Mironov, A; De Matteis, MA				Marra, P; Maffucci, T; Daniele, T; Di Tullio, G; Ikehara, Y; Chan, EKL; Luini, A; Beznoussenko, G; Mironov, A; De Matteis, MA			The GM130 and GRASP65 Golgi proteins cycle through and define a subdomain of the intermediate compartment	NATURE CELL BIOLOGY			English	Article							ENDOPLASMIC-RETICULUM; IN-VIVO; ELECTRON-MICROSCOPY; TRANSPORT COMPLEXES; ADP-RIBOSYLATION; MATRIX PROTEIN; LIVING CELLS; ER; P115; DYNAMICS	Integrating the pleomorphic membranes of the intermediate compartment (IC) into the array of Golgi cisternae is a crucial step in membrane transport, but it is poorly understood. To gain insight into this step, we investigated the dynamics by which cis-Golgi matrix proteins such as GM130 and GRASP65 associate with, and incorporate, incoming IC elements. We found that GM130 and GRASP65 cycle via membranous tubules between the Golgi complex and a constellation of mobile structures that we call late IC stations. These stations are intermediate between the IC and the cis-Golgi in terms of composition, and they receive cargo from earlier IC elements and deliver it to the Golgi complex. Late IC elements are transient in nature and sensitive to fixatives; they are seen in only a fraction of fixed cells, whereas they are always visible in living cells. Finally, late IC stations undergo homotypic fusion and establish tubular connections between themselves and the Golgi. Overall, these features indicate that late IC stations mediate the transition between IC elements and the cis-Golgi face.	Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, I-66030 Santa Maria Imbaro, Chieti, Italy; Fukuoka Univ, Sch Med, Dept Biochem, Fukuoka 8140180, Japan; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Fukuoka University; Scripps Research Institute	Marra, P (corresponding author), Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, I-66030 Santa Maria Imbaro, Chieti, Italy.	demattei@cmns.mnegri.it	Luini, Alberto/L-1372-2013; De Matteis, Maria Antonietta/AHE-5161-2022; Daniele, Tiziana/AAN-1916-2020; Chan, Edward K. L./B-5671-2009	Luini, Alberto/0000-0002-8729-2549; De Matteis, Maria Antonietta/0000-0003-0053-3061; Chan, Edward K. L./0000-0003-3938-9503; Daniele, Tiziana/0000-0002-6465-1078	Telethon [E.0732] Funding Source: Medline	Telethon(Fondazione Telethon)		Allan BB, 2000, SCIENCE, V289, P444, DOI 10.1126/science.289.5478.444; Alvarez C, 2001, J BIOL CHEM, V276, P2693, DOI 10.1074/jbc.M007957200; Alvarez C, 1999, J CELL BIOL, V147, P1205, DOI 10.1083/jcb.147.6.1205; Bannykh SI, 1997, J CELL BIOL, V138, P1, DOI 10.1083/jcb.138.1.1; Barr FA, 1998, EMBO J, V17, P3258, DOI 10.1093/emboj/17.12.3258; Barros L.C., 1997, P 7 IFSA WORLD C, V2, P3; BARROSO M, 1995, P NATL ACAD SCI USA, V92, P527, DOI 10.1073/pnas.92.2.527; Blum R, 2000, J CELL SCI, V113, P3151; Chao DS, 1999, J CELL BIOL, V144, P869, DOI 10.1083/jcb.144.5.869; De Matteis MA, 2000, J CELL SCI, V113, P2331; FRITZLER MJ, 1993, J EXP MED, V178, P49, DOI 10.1084/jem.178.1.49; GALLIONE CJ, 1985, J VIROL, V54, P374, DOI 10.1128/JVI.54.2.374-382.1985; Garcia-Mata R, 2000, EUR J CELL BIOL, V79, P229, DOI 10.1078/S0171-9335(04)70026-6; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; Godi A, 1998, P NATL ACAD SCI USA, V95, P8607, DOI 10.1073/pnas.95.15.8607; Hammond AT, 2000, MOL BIOL CELL, V11, P3013, DOI 10.1091/mbc.11.9.3013; Hauri HP, 2000, J CELL SCI, V113, P587; Hay JC, 1998, J CELL BIOL, V141, P1489, DOI 10.1083/jcb.141.7.1489; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; Klumperman J, 2000, CURR OPIN CELL BIOL, V12, P445, DOI 10.1016/S0955-0674(00)00115-0; Klumperman J, 1998, J CELL SCI, V111, P3411; KRIJNSELOCKER J, 1994, J CELL BIOL, V124, P55, DOI 10.1083/jcb.124.1.55; KUISMANEN E, 1989, METHOD CELL BIOL, V32, P257; LOTTI LV, 1992, J CELL BIOL, V118, P43, DOI 10.1083/jcb.118.1.43; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; Mironov A, 1997, J CELL BIOL, V139, P1109, DOI 10.1083/jcb.139.5.1109; Mironov AA, 2000, TRENDS CELL BIOL, V10, P349, DOI 10.1016/S0962-8924(00)01787-6; Moyer BD, 2001, TRAFFIC, V2, P268, DOI 10.1034/j.1600-0854.2001.1o007.x; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PEREZVILAR J, 1991, J BIOL CHEM, V266, P23967; Peters PJ, 2001, METHOD ENZYMOL, V329, P210; Powell RD, 1998, MICROSC RES TECHNIQ, V42, P2, DOI 10.1002/(SICI)1097-0029(19980701)42:1<2::AID-JEMT2>3.0.CO;2-Y; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; SARASTE J, 1991, J CELL SCI, V100, P415; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; Seemann J, 2000, NATURE, V407, P1022, DOI 10.1038/35039538; Seemann J, 2000, MOL BIOL CELL, V11, P635, DOI 10.1091/mbc.11.2.635; Shima DT, 1999, CURR BIOL, V9, P821, DOI 10.1016/S0960-9822(99)80365-0; Shorter J, 1999, J CELL BIOL, V146, P57, DOI 10.1083/jcb.146.1.57; SITIA R, 1992, MOL BIOL CELL, V3, P1067, DOI 10.1091/mbc.3.10.1067; SLUSAREWICZ P, 1994, J CELL BIOL, V124, P405, DOI 10.1083/jcb.124.4.405; Sonnichsen B, 1998, J CELL BIOL, V140, P1013, DOI 10.1083/jcb.140.5.1013; Stephens DJ, 2000, J CELL SCI, V113, P2177; Tang BL, 1995, EUR J CELL BIOL, V68, P398; WATERS MG, 1992, J CELL BIOL, V118, P1015, DOI 10.1083/jcb.118.5.1015; Weide T, 2001, EMBO REP, V2, P336, DOI 10.1093/embo-reports/kve065; Ying M, 2000, J CELL SCI, V113, P3623	49	119	125	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2001	3	12					1101	1113		10.1038/ncb1201-1101	http://dx.doi.org/10.1038/ncb1201-1101			13	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	500AM	11781572				2022-12-25	WOS:000172603700016
J	Bota, DA; Davies, KJA				Bota, DA; Davies, KJA			Lon protease preferentially degrades oxidized mitochondrial aconitase by an ATP-stimulated mechanism	NATURE CELL BIOLOGY			English	Article							OXIDATIVELY-DENATURED PROTEINS; TRANSPORT CHAIN COMPONENTS; FREE-RADICAL GENERATION; DEPENDENT PROTEASE; MAMMALIAN-CELLS; HYDROGEN-PEROXIDE; CARDIAC MITOCHONDRIA; GLUTAMINE-SYNTHETASE; CALORIC RESTRICTION; LIVER-MITOCHONDRIA	Mitochondrial aconitase is sensitive to oxidative inactivation and can aggregate and accumulate in many age-related disorders. Here we report that Lon protease, an ATP-stimulated mitochondrial matrix protein, selectively recognizes and degrades the oxidized, hydrophobic form of aconitase after mild oxidative modification, but that severe oxidation results in aconitase aggregation, which makes it a poor substrate for Lon. Similarly, a morpholino oligodeoxynucleotide directed against the lon gene markedly decreases the amount of Lon protein, Lon activity and aconitase degradation in WI-38 VA-13 human lung fibroblasts and causes accumulation of oxidatively modified aconitase. The ATP-stimulated Lon protease may be an essential defence against the stress of life in an oxygen environment. By recognizing minor oxidative changes to protein structure and rapidly degrading the mildly modified protein, Lon protease may prevent extensive oxidation, aggregation and accumulation of aconitase, which could otherwise compromise mitochondrial function and cellular viability. Aconitase is probably only one of many mitochondrial matrix proteins that are preferentially degraded by Lon protease after oxidative modification.	Univ So Calif, Ethel Percy Andrus Gerontol Ctr, Los Angeles, CA 90089 USA; Univ So Calif, Div Mol & Computat Biol, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Davies, KJA (corresponding author), Univ So Calif, Ethel Percy Andrus Gerontol Ctr, Los Angeles, CA 90089 USA.			Davies, Kelvin/0000-0001-7790-3003; Bota, Daniela/0000-0002-9680-9060	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R23ES003598, R01ES003598] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016256] Funding Source: NIH RePORTER; NIA NIH HHS [AG16256] Funding Source: Medline; NIEHS NIH HHS [ES03598] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMERIK AY, 1994, FEBS LETT, V340, P25, DOI 10.1016/0014-5793(94)80166-5; Azzone G F, 1979, Methods Enzymol, V55, P46; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Bota DA, 2001, MITOCHONDRION, V1, P33, DOI 10.1016/S1567-7249(01)00005-8; Bradley JL, 2000, HUM MOL GENET, V9, P275, DOI 10.1093/hmg/9.2.275; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Das N, 2001, BIOCHEM J, V360, P209, DOI 10.1042/0264-6021:3600209; DAVIES K J A, 1986, Journal of Free Radicals in Biology and Medicine, V2, P155, DOI 10.1016/S0748-5514(86)80066-6; DAVIES KJA, 1986, J BIOL CHEM, V261, P3060; DAVIES KJA, 1988, FREE RADICAL BIO MED, V5, P225, DOI 10.1016/0891-5849(88)90016-0; DAVIES KJA, 1987, J BIOL CHEM, V262, P9914; DEAN RT, 1985, BIOCHEM BIOPH RES CO, V126, P1082, DOI 10.1016/0006-291X(85)90296-7; DESAUTELS M, 1982, P NATL ACAD SCI-BIOL, V79, P1869, DOI 10.1073/pnas.79.6.1869; DESAUTELS M, 1982, J BIOL CHEM, V257, P1673; DOROSHOW JH, 1986, J BIOL CHEM, V261, P3068; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; GARDNER PR, 1994, P NATL ACAD SCI USA, V91, P12248, DOI 10.1073/pnas.91.25.12248; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GIULIVI C, 1994, ARCH BIOCHEM BIOPHYS, V311, P329, DOI 10.1006/abbi.1994.1245; Grune T, 1998, J BIOL CHEM, V273, P10857, DOI 10.1074/jbc.273.18.10857; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; Grune T, 2001, J GERONTOL A-BIOL, V56, pB459, DOI 10.1093/gerona/56.11.B459; Hausladen A, 1996, METHOD ENZYMOL, V269, P37; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; Kennedy MC, 1997, J BIOL CHEM, V272, P20340, DOI 10.1074/jbc.272.33.20340; KUZELA S, 1994, METHOD ENZYMOL, V244, P376; Lass A, 1998, FREE RADICAL BIO MED, V25, P1089, DOI 10.1016/S0891-5849(98)00144-0; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; LEVINE RL, 1981, P NATL ACAD SCI-BIOL, V78, P2120, DOI 10.1073/pnas.78.4.2120; MARCILLAT O, 1988, BIOCHEM J, V254, P677, DOI 10.1042/bj2540677; MARCILLAT O, 1989, BIOCHEM J, V259, P181, DOI 10.1042/bj2590181; Ostrowska H, 1997, BIOCHEM BIOPH RES CO, V234, P729, DOI 10.1006/bbrc.1997.6434; Park LCH, 2001, J NEUROSCI RES, V66, P1028, DOI 10.1002/jnr.10062; RAPOPORT S, 1982, FEBS LETT, V147, P93, DOI 10.1016/0014-5793(82)81018-1; RIVETT AJ, 1985, J BIOL CHEM, V260, P2600; Sitte N, 2000, FASEB J, V14, P2503, DOI 10.1096/fj.00-0210com; SOHAL RS, 1994, FREE RADICAL BIO MED, V16, P621, DOI 10.1016/0891-5849(94)90062-0; Summerton J, 1997, ANTISENSE NUCLEIC A, V7, P187, DOI 10.1089/oli.1.1997.7.187; SUZUKI CK, 1994, SCIENCE, V264, P891, DOI 10.1126/science.8178144; SUZUKI CK, 1994, SCIENCE, V264, P273, DOI 10.1126/science.8146662; Tabrizi SJ, 1999, ANN NEUROL, V45, P25, DOI 10.1002/1531-8249(199901)45:1<25::AID-ART6>3.0.CO;2-E; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; Ullrich O, 1999, P NATL ACAD SCI USA, V96, P6223, DOI 10.1073/pnas.96.11.6223; van Dyck L, 1998, GENE DEV, V12, P1515, DOI 10.1101/gad.12.10.1515; VANDYCK L, 1994, J BIOL CHEM, V269, P238; WANG N, 1993, P NATL ACAD SCI USA, V90, P11247, DOI 10.1073/pnas.90.23.11247; WATABE S, 1985, J BIOL CHEM, V260, P5511; WATABE S, 1985, J BIOL CHEM, V260, P4498; Williams MD, 1998, J BIOL CHEM, V273, P28510, DOI 10.1074/jbc.273.43.28510; Yan LJ, 1998, P NATL ACAD SCI USA, V95, P1968; Yan LJ, 1997, P NATL ACAD SCI USA, V94, P11168, DOI 10.1073/pnas.94.21.11168; Yan LJ, 1998, P NATL ACAD SCI USA, V95, P12896, DOI 10.1073/pnas.95.22.12896; ZHANG Y, 1990, J BIOL CHEM, V265, P16330	54	426	439	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	2002	4	9					674	680		10.1038/ncb836	http://dx.doi.org/10.1038/ncb836			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	589WE	12198491	Green Published			2022-12-25	WOS:000177783900011
J	Giordano, S; Corso, S; Conrotto, P; Artigiani, S; Gilestro, G; Barberis, D; Tamagnone, L; Comoglio, PM				Giordano, S; Corso, S; Conrotto, P; Artigiani, S; Gilestro, G; Barberis, D; Tamagnone, L; Comoglio, PM			The Semaphorin 4D receptor controls invasive growth by coupling with Met	NATURE CELL BIOLOGY			English	Article							FACTOR SCATTER FACTOR; TYROSINE KINASE; C-MET; TRANSMEMBRANE; MORPHOGENESIS; FAMILY; TRANSFORMATION; CD100	Semaphorins are cell surface and soluble signals that control axonal guidance(1,2). Recently, semaphorin receptors (plexins) have been discovered and shown to be widely expressed(3-5). Their biological activities outside the nervous system and the signal transduction mechanism(s) they utilize are largely unknown. Here, we show that in epithelial cells, Semaphorin 4D (Sema 4D) triggers invasive growth, a complex programme that includes cell-cell dissociation, anchorage-independent growth and branching morphogenesis(6). Interestingly, the same response is also controlled by scatter factors through their tyrosine kinase receptors, which share striking structural homology with plexins in their extracellular domain(3). We found that in cells expressing the endogenous proteins, Plexin B1 (the Sema 4D Receptor) and Met (the Scatter Factor 1/Hepatocyte Growth Factor Receptor) associate in a complex. In addition, binding of Sema 4D to Plexin B1 stimulates the tyrosine kinase activity of Met, resulting in tyrosine phosphorylation of both receptors. Finally, cells lacking Met expression do not respond to Sema 4D unless exogenous Met is expressed. This work identifies a novel biological function of semaphorins and suggests the involvement of an unexpected signalling mechanism, namely, the coupling of a plexin to a tyrosine kinase receptor.	Univ Turin, Sch Med, Inst Canc Res & Treatment, I-10060 Turin, Italy	University of Turin	Giordano, S (corresponding author), Univ Turin, Sch Med, Inst Canc Res & Treatment, I-10060 Turin, Italy.	sgiordarno@ircc.unito.it	Gilestro, Giorgio/A-8721-2010; Giordano, Silvia/J-9858-2018; Tamagnone, Luca/J-8948-2018	Gilestro, Giorgio/0000-0001-7512-8541; Giordano, Silvia/0000-0003-1854-1086; Tamagnone, Luca/0000-0002-2884-7946; Comoglio, Paolo/0000-0002-7056-5328; CORSO, Simona/0000-0002-5069-1503	Telethon [E.1129] Funding Source: Medline	Telethon(Fondazione Telethon)		Bardelli A, 1999, J BIOL CHEM, V274, P29274, DOI 10.1074/jbc.274.41.29274; Birchmeier W, 1997, CIBA F SYMP, V212, P230; Christensen CRL, 1998, CANCER RES, V58, P1238; Di Renzo MF, 2000, ONCOGENE, V19, P1547, DOI 10.1038/sj.onc.1203455; Ebens A, 1996, NEURON, V17, P1157, DOI 10.1016/S0896-6273(00)80247-0; Elhabazi A, 2001, J IMMUNOL, V166, P4341, DOI 10.4049/jimmunol.166.7.4341; Giordano S, 2000, FASEB J, V14, P399, DOI 10.1096/fasebj.14.2.399; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; Goodman CS, 1999, CELL, V97, P551, DOI 10.1016/S0092-8674(00)80766-7; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Kumanogoh A, 2000, IMMUNITY, V13, P621, DOI 10.1016/S1074-7613(00)00062-5; Maestrini E, 1996, P NATL ACAD SCI USA, V93, P674, DOI 10.1073/pnas.93.2.674; Maina F, 1997, GENE DEV, V11, P3341, DOI 10.1101/gad.11.24.3341; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; Morotti A, 2002, ONCOGENE, V21, P4885, DOI 10.1038/sj.onc.1205622; Nakamura F, 2000, J NEUROBIOL, V44, P219, DOI 10.1002/1097-4695(200008)44:2<219::AID-NEU11>3.0.CO;2-W; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Prat M, 1998, J CELL SCI, V111, P237; Raper JA, 2000, CURR OPIN NEUROBIOL, V10, P88, DOI 10.1016/S0959-4388(99)00057-4; Sachs M, 1996, J CELL BIOL, V133, P1095, DOI 10.1083/jcb.133.5.1095; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; Tamagnone L, 2000, TRENDS CELL BIOL, V10, P377, DOI 10.1016/S0962-8924(00)01816-X; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8	30	343	392	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2002	4	9					720	724		10.1038/ncb843	http://dx.doi.org/10.1038/ncb843			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	589WE	12198496				2022-12-25	WOS:000177783900018
J	Kawaguchi, Y; Cooper, B; Gannon, M; Ray, M; MacDonald, RJ; Wright, CVE				Kawaguchi, Y; Cooper, B; Gannon, M; Ray, M; MacDonald, RJ; Wright, CVE			The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors	NATURE GENETICS			English	Article							CRE-MEDIATED RECOMBINATION; DIFFERENTIATION; GENE; CELLS; EXOCRINE; PROTEIN; PDX-1; P48; EXPRESSION; PHENOTYPE	Pancreas development begins with the formation of buds at specific sites in the embryonic foregut endoderm. We used recombination-based lineage tracing in vivo to show that Ptf1a (also known as PTF1-p48) is expressed at these early stages in the progenitors of pancreatic ducts, exocrine and endocrine cells, rather than being an exocrine-specific gene as previously described. Moreover, inactivation of Ptf1a switches the character of pancreatic progenitors such that their progeny proliferate in and adopt the normal fates of duodenal epithelium, including its stem-cell compartment. Consistent with the proposal that Ptf1a supports the specification of precursors of all three pancreatic cell types, transgene-based expression of Pdx1, a gene essential to pancreas formation, from Ptf1a cis-regulatory sequences restores pancreas tissue to Pdx1-null mice that otherwise lack mature exocrine and endocrine cells because of an early arrest in organogenesis. These experiments provide evidence that Ptf1a expression is specifically connected to the acquisition of pancreatic fate by undifferentiated foregut endoderm.	Vanderbilt Univ, Sch Med, Vanderbilt Dev Biol Program, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med & Mol Physiol & Biophys, Nashville, TN 37232 USA; Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Wright, CVE (corresponding author), Vanderbilt Univ, Sch Med, Vanderbilt Dev Biol Program, 1161 21st Ave S, Nashville, TN 37232 USA.		MacDonald, Ray/AAA-1290-2022; Gannon, Maureen A/F-9060-2012					Adell T, 2000, CELL GROWTH DIFFER, V11, P137; Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; Edlund H, 2001, DIABETES, V50, pS5, DOI 10.2337/diabetes.50.2007.S5; Gannon M, 2000, GENESIS, V26, P143, DOI 10.1002/(SICI)1526-968X(200002)26:2<143::AID-GENE13>3.0.CO;2-L; Gannon M, 2000, GENESIS, V26, P139, DOI 10.1002/(SICI)1526-968X(200002)26:2<139::AID-GENE12>3.0.CO;2-7; GU G, 2000, DEVELOPMENT, V129, P2447; Herrera PL, 2000, DEVELOPMENT, V127, P2317; HOGAN B, 1994, MANIPUALTING MOUSE E; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Kim SK, 2001, GENE DEV, V15, P111, DOI 10.1101/gad.859401; Krapp A, 1996, EMBO J, V15, P4317, DOI 10.1002/j.1460-2075.1996.tb00806.x; Krapp A, 1998, GENE DEV, V12, P3752, DOI 10.1101/gad.12.23.3752; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; Lammert E, 2001, SCIENCE, V294, P564, DOI 10.1126/science.1064344; Li H, 2001, DEV BIOL, V240, P247, DOI 10.1006/dbio.2001.0440; Lumelsky N, 2001, SCIENCE, V292, P1389, DOI 10.1126/science.1058866; MACDONALD RJ, 1977, J BIOL CHEM, V252, P5522; Matsumoto K, 2001, SCIENCE, V294, P559, DOI 10.1126/science.1063889; Obata J, 2001, GENES CELLS, V6, P345, DOI 10.1046/j.1365-2443.2001.00422.x; Offield MF, 1996, DEVELOPMENT, V122, P983; PESHAVARIA M, 1994, MOL ENDOCRINOL, V8, P806, DOI 10.1210/me.8.6.806; Rose SD, 2001, J BIOL CHEM, V276, P44018, DOI 10.1074/jbc.M106264200; Sasaki H, 1996, GENES CELLS, V1, P59, DOI 10.1046/j.1365-2443.1996.04004.x; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Wu KL, 1997, MOL CELL BIOL, V17, P6002, DOI 10.1128/MCB.17.10.6002; Zaret KS, 2001, CURR OPIN GENET DEV, V11, P568, DOI 10.1016/S0959-437X(00)00234-3	26	736	758	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2002	32	1					128	134		10.1038/ng959	http://dx.doi.org/10.1038/ng959			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	588RR	12185368				2022-12-25	WOS:000177714900011
J	Reiss, M				Reiss, M			Labeling GM foods - the ethical way forward	NATURE BIOTECHNOLOGY			English	Editorial Material							EU		Univ London, Inst Educ, London WC1N 1AZ, England	University of London; University College London; UCL Institute of Education	Reiss, M (corresponding author), Univ London, Inst Educ, London WC1N 1AZ, England.		Reiss, Michael Jonathan/P-8205-2017	Reiss, Michael Jonathan/0000-0003-1207-4229				Dorey E, 2001, NAT BIOTECHNOL, V19, P795, DOI 10.1038/nbt0901-795a; Fox JL, 2001, NAT BIOTECHNOL, V19, P897, DOI 10.1038/nbt1001-897a; Reiss MJ, 2001, J AGR ENVIRON ETHIC, V14, P179, DOI 10.1023/A:1011384323885; REISS MJ, 1996, IMPROVING NATURE SCI	4	5	5	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2002	20	9					868	868		10.1038/nbt0902-868	http://dx.doi.org/10.1038/nbt0902-868			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	589KN	12205497	Bronze			2022-12-25	WOS:000177757700010
J	Mykytyn, K; Nishimura, DY; Searby, CC; Shastri, M; Yen, HJ; Beck, JS; Braun, T; Streb, LM; Cornier, AS; Cox, GF; Fulton, AB; Carmi, R; Luleci, G; Chandrasekharappa, SC; Collins, FS; Jacobson, SG; Heckenlively, JR; Weleber, RG; Stone, EM; Sheffield, VC				Mykytyn, K; Nishimura, DY; Searby, CC; Shastri, M; Yen, HJ; Beck, JS; Braun, T; Streb, LM; Cornier, AS; Cox, GF; Fulton, AB; Carmi, R; Luleci, G; Chandrasekharappa, SC; Collins, FS; Jacobson, SG; Heckenlively, JR; Weleber, RG; Stone, EM; Sheffield, VC			Identification of the gene (BBS1) most commonly involved in Bardet-Biedl syndrome, a complex human obesity syndrome	NATURE GENETICS			English	Article							CHROMOSOME 16Q; SYNDROME LOCUS; DNA; MUTATIONS; INTERVAL; LINKAGE	Bardet-Biedl syndrome (BBS, OMIM 209900) is a genetic disorder with the primary features of obesity, pigmentary retinopathy, polydactyly, renal malformations, mental retardation and hypogenitalism(1-4). Individuals with BBS are also at increased risk for diabetes mellitus, hypertension and congenital heart disease(4-6). What was once thought to be a homogeneous autosomal recessive disorder is now known to map to at least six loci: 11q13 (BBS1), 16q21 (BBS2), 3p13-p12 (BBS3), 15q22.3-q23 (BBS4), 2q31 (BBS5) and 20p12 (BBS6)(7-13). There has been considerable interest in identifying the genes that underlie BBS, because some components of the phenotype are common. Cases of BBS mapping ro BBS6 are caused by mutations in MKKS12,13; mutations in this gene also cause McKusick-Kaufman syndrome (hydrometrocolpos, post-axial polydactyly and congenital heart defects)(14,15). In addition, we recently used positional cloning to identify the genes underlying BBS2 (ref. 16) and BBS4 (ref. 17). The BBS6 protein has similarity to a Thermoplasma acidophilum chaperonin(15), whereas BBS2 and BBS4 have no significant similarity to chaperonins. It has recently been suggested that three mutated alleles (two at one locus, and a third at a second locus) may be required for manifestation of BBS (triallelic inheritance)(18). Here we report the identification of the gene BBS1 and show that a missense mutation of this gene is a frequent cause of BBS. In addition, we provide data showing that this common mutation is not involved in triallelic inheritance.	Univ Iowa, Dept Pediat, Div Med Genet, Iowa City, IA 52242 USA; Univ Iowa, Howard Hughes Med Inst, Iowa City, IA 52242 USA; Univ Iowa, Dept Elect Engn, Iowa City, IA 52242 USA; Univ Iowa, Dept Ophthalmol, Iowa City, IA 52242 USA; Ponce Sch Med, Dept Biochem, Ponce, PR USA; Childrens Hosp, Div Genet, Boston, MA 02115 USA; Childrens Hosp, Dept Ophthalmol, Boston, MA 02115 USA; Ben Gurion Univ Negev, Inst Genet, Soroka Med Ctr, IL-84105 Beer Sheva, Israel; Arkdeniz Univ, Dept Med Biol Genet, Antalya, Turkey; NHGRI, NIH, Bethesda, MD 20892 USA; Univ Penn, Scheie Eye Inst, Philadelphia, PA 19104 USA; Harbor UCLA Med Ctr, Jules Stein Eye Inst, Torrance, CA 90509 USA; Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97201 USA	University of Iowa; Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Iowa; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Ben Gurion University; Soroka Medical Center; Akdeniz University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Pennsylvania; Pennsylvania Medicine; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Oregon Health & Science University	Sheffield, VC (corresponding author), Univ Iowa, Dept Pediat, Div Med Genet, Iowa City, IA 52242 USA.	val-sheffield@uiowa.edu	Mykytyn, Kirk/E-3723-2011	Mykytyn, Kirk/0000-0002-0158-4592; Searby, Charles/0000-0002-8108-8782; Sheffield, Val/0000-0002-6282-0835; Stone, Edwin M./0000-0003-3343-4414; Jacobson, Samuel/0000-0003-2122-169X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bardet G., 1920, THESIS U PARIS; BASSAM BJ, 1991, ANAL BIOCHEM, V196, P80, DOI 10.1016/0003-2697(91)90120-I; Biedl A., 1922, DEUT MED WOCHENSCHR, V48, P1630; CARMI R, 1995, HUM MOL GENET, V4, P9, DOI 10.1093/hmg/4.1.9; ELBEDOUR K, 1994, AM J MED GENET, V52, P164, DOI 10.1002/ajmg.1320520208; GREEN JS, 1989, NEW ENGL J MED, V321, P1002, DOI 10.1056/NEJM198910123211503; HARNETT JD, 1988, NEW ENGL J MED, V319, P615, DOI 10.1056/NEJM198809083191005; Katsanis N, 2001, SCIENCE, V293, P2256, DOI 10.1126/science.1063525; Katsanis N, 1999, AM J HUM GENET, V65, P1672, DOI 10.1086/302684; Katsanis N, 2000, NAT GENET, V26, P67, DOI 10.1038/79201; KWITEKBLACK AE, 1993, NAT GENET, V5, P392, DOI 10.1038/ng1293-392; LEPPERT M, 1994, NAT GENET, V7, P108, DOI 10.1038/ng0594-108; Mykytyn K, 2001, NAT GENET, V28, P188, DOI 10.1038/88925; Nishimura DY, 2001, HUM MOL GENET, V10, P865, DOI 10.1093/hmg/10.8.865; ROBINOW M, 1979, J PEDIATR-US, V94, P776, DOI 10.1016/S0022-3476(79)80155-9; SHEFFIELD VC, 1994, HUM MOL GENET, V3, P1331, DOI 10.1093/hmg/3.8.1331; Slavotinek AM, 2000, NAT GENET, V26, P15, DOI 10.1038/79116; SOLISCOHEN S, 1924, T ASSOC AM PHYSICIAN, V39, P356; Stone DL, 2000, NAT GENET, V25, P79, DOI 10.1038/75637; Young TL, 1999, AM J HUM GENET, V64, P900, DOI 10.1086/302301; Young TL, 1999, AM J HUM GENET, V65, P1680, DOI 10.1086/302686	22	248	258	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2002	31	4					435	438		10.1038/ng935	http://dx.doi.org/10.1038/ng935			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	578XV	12118255				2022-12-25	WOS:000177147100023
J	Vetter, DE; Li, CE; Zhao, LY; Contarino, A; Liberman, MC; Smith, GW; Marchuk, Y; Koob, GF; Heinemann, SF; Vale, W; Lee, KF				Vetter, DE; Li, CE; Zhao, LY; Contarino, A; Liberman, MC; Smith, GW; Marchuk, Y; Koob, GF; Heinemann, SF; Vale, W; Lee, KF			Urocortin-deficient mice show hearing impairment and increased anxiety-like behavior	NATURE GENETICS			English	Article							CORTICOTROPIN-RELEASING FACTOR; RAT OLIVOCOCHLEAR NEURONS; TYPE-2 CRF RECEPTORS; GENE-RELATED PEPTIDE; LATERAL-LINE ORGAN; GUINEA-PIG; HORMONE RECEPTOR-2; UROTENSIN-I; MAMMALIAN COCHLEA; BASILAR-MEMBRANE	Urocortin is a member of the corticotropin-releasing hormone peptide family and is found in many discrete brain regions. The distinct expression pattern of urocortin suggests that it influences such behaviors as feeding, anxiety and auditory processing. To better define the physiological roles of urocortin, we have generated mice carrying a null mutation of the urocortin gene. Urocortin-deficient mice have normal basal feeding behavior and stress responses, but show heightened anxiety-like behaviors in the elevated plus maze and open-field tests. In addition, hearing is impaired in the mutant mice at the level of the inner ear, suggesting that urocortin is involved in the normal development of cochlear sensory-cell function. These results provide the first example of a function for any peptidergic system in hearing.	Salk Inst Biol Studies, La Jolla, CA 92037 USA; Scripps Res Inst, Res Inst, Dept Neuropharmacol, La Jolla, CA 92037 USA; Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA; Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA	Salk Institute; Scripps Research Institute; Harvard University; Harvard Medical School; Harvard University; Massachusetts Eye & Ear Infirmary	Lee, KF (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Contarino, Angelo/C-9429-2014; Vetter, Douglas E./O-8150-2019	Contarino, Angelo/0000-0002-7286-6941	NIDCD NIH HHS [P30 DC005209] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [P30DC005209] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ABOUMADI L, 1987, HEARING RES, V30, P135, DOI 10.1016/0378-5955(87)90131-6; ADAMS JC, 1987, BRAIN RES, V419, P347, DOI 10.1016/0006-8993(87)90606-8; ALTSCHULER RA, 1984, J HISTOCHEM CYTOCHEM, V32, P839, DOI 10.1177/32.8.6379037; ALTSCHULER RA, 1985, HEARING RES, V17, P249, DOI 10.1016/0378-5955(85)90069-3; Bailey GP, 2000, J NEUROSCI, V20, P5163; Bale TL, 2000, NAT GENET, V24, P410, DOI 10.1038/74263; Bittencourt JC, 1999, J COMP NEUROL, V415, P285; CHADWICK D, 1993, CORTICOTROPIN RELEAS; Coste SC, 2000, NAT GENET, V24, P403, DOI 10.1038/74255; ELGOYHEN AB, 1994, CELL, V79, P705, DOI 10.1016/0092-8674(94)90555-X; EYBALIN M, 1993, PHYSIOL REV, V73, P309, DOI 10.1152/physrev.1993.73.2.309; HASHIMOTO S, 1990, ACTA OTO-LARYNGOL, V109, P228, DOI 10.3109/00016489009107438; HOFFMAN DW, 1985, HEARING RES, V17, P47, DOI 10.1016/0378-5955(85)90129-7; HOFFMAN DW, 1983, HEARING RES, V9, P71, DOI 10.1016/0378-5955(83)90135-1; Hsu SY, 2001, NAT MED, V7, P605, DOI 10.1038/87936; Kihara N, 2001, AM J PHYSIOL-GASTR L, V280, pG406, DOI 10.1152/ajpgi.2001.280.3.G406; Kishimoto T, 2000, NAT GENET, V24, P415, DOI 10.1038/74271; Kozicz T, 1998, J COMP NEUROL, V391, P1, DOI 10.1002/(SICI)1096-9861(19980202)391:1<1::AID-CNE1>3.0.CO;2-6; LEDERIS K, 1982, SCIENCE, V218, P162, DOI 10.1126/science.6981844; LEDERIS K, 1982, P W PHARMACOL SOC, V25, P223; Lewis K, 2001, P NATL ACAD SCI USA, V98, P7570, DOI 10.1073/pnas.121165198; LIBERMAN MC, 1980, HEARING RES, V3, P189, DOI 10.1016/0378-5955(80)90046-5; MONTECUCCHI PC, 1981, INT J PEPT PROT RES, V18, P113; Moreau JL, 1997, NEUROREPORT, V8, P1697, DOI 10.1097/00001756-199705060-00027; PROBST R, 1991, J ACOUST SOC AM, V89, P2027, DOI 10.1121/1.400897; Reyes TM, 2001, P NATL ACAD SCI USA, V98, P2843, DOI 10.1073/pnas.051626398; Ruggero M A, 1992, Curr Opin Neurobiol, V2, P449, DOI 10.1016/0959-4388(92)90179-O; RUGGERO MA, 1992, PHILOS T ROY SOC B, V336, P307, DOI 10.1098/rstb.1992.0063; SEWELL WF, 1991, J NEUROPHYSIOL, V65, P1158, DOI 10.1152/jn.1991.65.5.1158; Skelton KH, 2000, J NEUROSCI, V20, P1240, DOI 10.1523/JNEUROSCI.20-03-01240.2000; Slawecki CJ, 1999, PEPTIDES, V20, P211, DOI 10.1016/S0196-9781(98)00160-0; Smagin GN, 1998, NEUROREPORT, V9, P1601, DOI 10.1097/00001756-199805110-00063; Smith GW, 1998, NEURON, V20, P1093, DOI 10.1016/S0896-6273(00)80491-2; Spina M, 1996, SCIENCE, V273, P1561, DOI 10.1126/science.273.5281.1561; Spina MG, 2002, PSYCHOPHARMACOLOGY, V160, P113, DOI 10.1007/s00213-001-0940-y; Timpl P, 1998, NAT GENET, V19, P162, DOI 10.1038/520; Turnbull AV, 1999, ENDOCRINOLOGY, V140, P71, DOI 10.1210/en.140.1.71; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VAUGHAN J, 1995, NATURE, V378, P287, DOI 10.1038/378287a0; VETTER DE, 1992, ANAT EMBRYOL, V185, P1, DOI 10.1007/BF00213596; VETTER DE, 1991, SYNAPSE, V7, P21, DOI 10.1002/syn.890070104; Vetter DE, 1999, NEURON, V23, P93, DOI 10.1016/S0896-6273(00)80756-4; Walsh EJ, 1998, J NEUROSCI, V18, P3859; Warr W.B., 1992, Springer Handbook of Auditory Research, V1, P410	44	131	134	0	12	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2002	31	4					363	369		10.1038/ng914	http://dx.doi.org/10.1038/ng914			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	578XV	12091910				2022-12-25	WOS:000177147100010
J	Jovine, L; Qi, HY; Williams, Z; Litscher, E; Wassarman, PM				Jovine, L; Qi, HY; Williams, Z; Litscher, E; Wassarman, PM			The ZP domain is a conserved module for polymerization of extracellular proteins	NATURE CELL BIOLOGY			English	Article							TAMM-HORSFALL GLYCOPROTEIN; ZONA-PELLUCIDA GLYCOPROTEINS; AUTOSOMAL-DOMINANT; TECTORIAL MEMBRANE; BETA-TECTORIN; HEARING-LOSS; INNER-EAR; EXPRESSION; SEQUENCES; GLYCOSYLATION	Many eukaryotic extracellular proteins share a sequence of unknown function, called the zona pellucida (ZP) domain(1). Among these proteins are the mammalian sperm receptors ZP2 and ZP3, non-mammalian egg coat proteins, Tamm-Horsfall protein (THP), glycoprotein-2 (GP-2), alpha- and beta-tectorins, transforming growth factor (TGF)-beta receptor III and endoglin, DMBT-1 (deletd in malignant brain tumour-1), NompA (no-mechanoreceptor-potential-A), Dumpy and cuticlin-1 (refs 1,2). Here, we report that the ZP domain of ZP2, ZP3 and THP is responsible for polymerization of these proteins into filaments of similar supramolecular structure. Most ZP domain proteins are synthesized as precursors with carboxy-terminal transmembrane domains or glycosyl phosphatidylinositol (GPI) anchors(1,2). Our results demonstrate that the C-terminal transmembrane domain and short cytoplasmic tail of ZP2 and ZP3 are not required for secretion, but are essential for assembly. Finally, we suggest a molecular basis for dominant human hearing disorders caused by point mutations within the ZP domain of alpha-tectorin(3-5).	CUNY Mt Sinai Sch Med, Dept Mol Cell & Dev Biol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Wassarman, PM (corresponding author), CUNY Mt Sinai Sch Med, Dept Mol Cell & Dev Biol, 1 Gustave L Levy Pl, New York, NY 10029 USA.		Jovine, Luca/E-8170-2010; Jovine, Luca/J-3563-2019	Jovine, Luca/0000-0002-2679-6946; Jovine, Luca/0000-0002-2679-6946	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD035105] Funding Source: NIH RePORTER; NICHD NIH HHS [HD35105] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAYER ME, 1964, J CELL BIOL, V21, P265, DOI 10.1083/jcb.21.2.265; BORK P, 1992, FEBS LETT, V300, P237, DOI 10.1016/0014-5793(92)80853-9; Cavallone D, 2001, BIOCHEM BIOPH RES CO, V280, P110, DOI 10.1006/bbrc.2000.4090; Easton RL, 2000, J BIOL CHEM, V275, P21928, DOI 10.1074/jbc.M001534200; Harris JD, 1999, PROTEIN EXPRES PURIF, V16, P298, DOI 10.1006/prep.1999.1060; Harrison PT, 1996, MOL MEMBR BIOL, V13, P67, DOI 10.3109/09687689609160579; HEUSER J, 1989, J ELECTRON MICR TECH, V13, P244, DOI 10.1002/jemt.1060130310; Hyllner SJ, 2001, BIOL REPROD, V64, P805, DOI 10.1095/biolreprod64.3.805; KARP DR, 1982, J BIOL CHEM, V257, P7330; KILLICK R, 1995, J CELL BIOL, V129, P535, DOI 10.1083/jcb.129.2.535; Kirschhofer K, 1998, CYTOGENET CELL GENET, V82, P126, DOI 10.1159/000015086; Knipper M, 2001, J BIOL CHEM, V276, P39046, DOI 10.1074/jbc.M103385200; Kokot F, 2000, NEPHRON, V85, P97, DOI 10.1159/000045640; Legan PK, 2000, NEURON, V28, P273, DOI 10.1016/S0896-6273(00)00102-1; Legan PK, 1997, J BIOL CHEM, V272, P8791, DOI 10.1074/jbc.272.13.8791; Litscher ES, 1999, BIOCHEMISTRY-US, V38, P12280, DOI 10.1021/bi991154y; MAXFIELD M, 1963, ANN NY ACAD SCI, V106, P288; Moreno-Pelayo M A, 2001, J Med Genet, V38, pE13, DOI 10.1136/jmg.38.5.e13; Ponting CP, 1999, NUCLEIC ACIDS RES, V27, P229, DOI 10.1093/nar/27.1.229; Qi HY, 2002, MOL BIOL CELL, V13, P530, DOI 10.1091/mbc.01-09-0440; Sawada H, 2002, P NATL ACAD SCI USA, V99, P1223, DOI 10.1073/pnas.032389499; SERAFINICESSI F, 1989, J IMMUNOL METHODS, V120, P185, DOI 10.1016/0022-1759(89)90241-X; Steel KP, 2001, NAT GENET, V27, P143, DOI 10.1038/84758; Sugiyama H, 1999, J BIOCHEM-TOKYO, V125, P469, DOI 10.1093/oxfordjournals.jbchem.a022310; TAMM I, 1950, P SOC EXP BIOL MED, V74, P108, DOI 10.3181/00379727-74-17825; Tsubamoto H, 1999, BIOL REPROD, V61, P1649, DOI 10.1095/biolreprod61.6.1649; Verhoeven K, 1998, NAT GENET, V19, P60, DOI 10.1038/ng0598-60; WASSARMAN PM, 1988, ANNU REV BIOCHEM, V57, P415, DOI 10.1146/annurev.bi.57.070188.002215; WASSARMAN PM, 1991, INT REV CYTOL, V130, P85, DOI 10.1016/S0074-7696(08)61502-8; Wassarman PM, 2001, NAT CELL BIOL, V3, pE59, DOI 10.1038/35055178	30	255	270	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUN	2002	4	6					457	461		10.1038/ncb802	http://dx.doi.org/10.1038/ncb802			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	558NN	12021773				2022-12-25	WOS:000175973600017
J	Linker, RA; Maurer, M; Gaupp, S; Martini, R; Holtmann, B; Giess, R; Rieckmann, P; Lassmann, H; Toyka, KV; Sendtner, M; Gold, R				Linker, RA; Maurer, M; Gaupp, S; Martini, R; Holtmann, B; Giess, R; Rieckmann, P; Lassmann, H; Toyka, KV; Sendtner, M; Gold, R			CNTF is a major protective factor in demyelinating CNS disease: A neurotrophic cytokine as modulator in neuroinflammation	NATURE MEDICINE			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; MULTIPLE-SCLEROSIS; PROGENITOR CELLS; LESIONS; PATHOGENESIS; APOPTOSIS; NECROSIS; THERAPY; RAT	Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS)(1). So far, immunological mechanisms responsible for demyelination have been the focus of interest(2). However, mechanisms regulating axon maintenance as well as glial precursor-cell proliferation and oligodendrocyte survival might also influence disease outcome(3). The cytokine ciliary neurotrophic factor (CNTF), which was originally identified as a survival factor for isolated neurons, promotes differentiation, maturation and survival of oligodendrocytes(4-6). To investigate the role of endogenous CNTF in inflammatory demyelinating disease, we studied myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE) in CNTF-deficient and wild-type C57BL/6 mice. Disease was more severe in CNTF-deficient mice and recovery was poor, with a 60% decrease in the number of proliferating oligodendrocyte precursor cells (OPCs) and a more than 50% increase in the rate of oligodendrocyte apoptosis. In addition, vacuolar dystrophy of myelin and axonal damage were more severe in CNTF-deficient mice. These specific pathological features could be prevented by treatment with an antiserum against tumor necrosis factor-alpha, suggesting that endogenous CNTF may counterbalance this effect of TNF-alpha (ref. 7). Here we identify a factor that modulates, in an inflammatory environment, glial cell survival and is an outcome determinant of EAE.	Univ Wurzburg, Dept Neurol, Clin Res Grp Multiple Sclerosis, D-8700 Wurzburg, Germany; Univ Wurzburg, Dept Neurol, Sect Dev Neurobiol, D-8700 Wurzburg, Germany; Univ Wurzburg, Dept Clin Neurobiol, Wurzburg, Germany; Brain Res Inst, Vienna, Austria	University of Wurzburg; University of Wurzburg; University of Wurzburg	Gold, R (corresponding author), Univ Wurzburg, Dept Neurol, Clin Res Grp Multiple Sclerosis, Josef Schneider Str 11, D-8700 Wurzburg, Germany.		Messier, Claude/A-2322-2008; Sendtner, Michael/M-8137-2014; Linker, Ralf/AAD-8884-2020; Sendtner, Michael/J-1542-2012; Lassmann, Hans/Z-2269-2019	Messier, Claude/0000-0002-4791-1763; Sendtner, Michael/0000-0002-4737-2974; Sendtner, Michael/0000-0002-4737-2974; Lassmann, Hans/0000-0001-8617-5052; Martini, Rudolf/0000-0002-5463-5592				Arnason BGW, 1999, NEUROLOGY, V53, P457, DOI 10.1212/wnl.53.3.457; Bachmann R, 1999, AM J PATHOL, V154, P1417, DOI 10.1016/S0002-9440(10)65395-3; Barres BA, 1996, MOL CELL NEUROSCI, V8, P146, DOI 10.1006/mcne.1996.0053; BARRES BA, 1993, DEVELOPMENT, V118, P283; BROSNAN CF, 1989, J NEUROIMMUNOL, V25, P227, DOI 10.1016/0165-5728(89)90141-0; Chang A, 2000, J NEUROSCI, V20, P6404, DOI 10.1523/JNEUROSCI.20-17-06404.2000; DITTRICH F, 1994, ANN NEUROL, V35, P151, DOI 10.1002/ana.410350206; Dupree JL, 1998, J NEUROSCI, V18, P1642; Ebers GC, 1996, NAT GENET, V13, P472, DOI 10.1038/ng0896-472; Giess R, 2002, ARCH NEUROL-CHICAGO, V59, P407, DOI 10.1001/archneur.59.3.407; GOLD R, 1994, LAB INVEST, V71, P219; GROVES AK, 1993, NATURE, V362, P453, DOI 10.1038/362453a0; HARTUNG HP, 1988, BRAIN, V111, P1039, DOI 10.1093/brain/111.5.1039; Kornek B, 2000, AM J PATHOL, V157, P267, DOI 10.1016/S0002-9440(10)64537-3; Lassmann H, 2001, TRENDS MOL MED, V7, P115, DOI 10.1016/S1471-4914(00)01909-2; Lassmann H, 1997, GLIA, V19, P104, DOI 10.1002/(SICI)1098-1136(199702)19:2<104::AID-GLIA2>3.3.CO;2-R; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; Probert L, 2000, BRAIN, V123, P2005, DOI 10.1093/brain/123.10.2005; Raine CS, 1997, J NEUROIMMUNOL, V77, P135, DOI 10.1016/S0165-5728(97)00073-8; SENDTNER M, 1992, J CELL BIOL, V118, P139, DOI 10.1083/jcb.118.1.139; SENDTNER M, 1995, BAILLIERE CLIN NEUR, V4, P575; Storch MK, 1998, BRAIN PATHOL, V8, P681, DOI 10.1111/j.1750-3639.1998.tb00194.x; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Weishaupt A, 2000, J IMMUNOL, V165, P7157, DOI 10.4049/jimmunol.165.12.7157; YAO DL, 1995, P NATL ACAD SCI USA, V92, P6190, DOI 10.1073/pnas.92.13.6190	25	334	344	0	14	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2002	8	6					620	624		10.1038/nm0602-620	http://dx.doi.org/10.1038/nm0602-620			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	557KG	12042814				2022-12-25	WOS:000175907300034
J	Wei, XY; Malicki, J				Wei, XY; Malicki, J			nagie oko, encoding a MAGUK-family protein, is essential for cellular patterning of the retina	NATURE GENETICS			English	Article							ELECTRON-MICROSCOPIC ANALYSIS; ZEBRAFISH DANIO-RERIO; TUMOR-SUPPRESSOR GENE; NEURAL RETINA; DROSOPHILA STARDUST; MOUSE RETINA; POLARITY; KINASE; CELLS; DIFFERENTIATION	A layered organization of cells is a common architectural feature of many neuronal formations. Mutations of the zebrafish gene nagie oko (nok) produce a severe disruption of retinal architecture, indicating a key role for this locus in neuronal patterning. We show that nok encodes a membrane-associated guanylate kinase-family scaffolding protein. Nok localizes to the vicinity of junctional complexes in retinal neuroepithelium and in the photoreceptor cell layer. Mosaic analysis indicates that the nok retinal patterning phenotype is not cell-autonomous. We propose that nok function in patterning of postmitotic neurons is mediated through neuroepithelial cells and is necessary for guiding neurons to their proper destinations in retinal laminae.	Harvard Univ, Sch Med, MEEI, Dept Ophthalmol, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary	Malicki, J (corresponding author), Harvard Univ, Sch Med, MEEI, Dept Ophthalmol, 243 Chrales St, Boston, MA 02114 USA.		malicki, jarema/G-8611-2014	malicki, jarema/0000-0002-5947-8805				Bachmann A, 2001, NATURE, V414, P638, DOI 10.1038/414638a; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Chenn A, 1998, MOL CELL NEUROSCI, V11, P183, DOI 10.1006/mcne.1998.0680; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; Dowling J. E., 1987, RETINA; Dyer MA, 2001, J NEUROSCI, V21, P4259, DOI 10.1523/JNEUROSCI.21-12-04259.2001; Feng YY, 2000, NEURON, V28, P665, DOI 10.1016/S0896-6273(00)00145-8; FUJISAWA H, 1971, DEV GROWTH DIFFER, V13, P25; Georges-Labouesse E, 1998, CURR BIOL, V8, P983, DOI 10.1016/S0960-9822(98)70402-6; HINDS JW, 1979, J COMP NEUROL, V187, P495, DOI 10.1002/cne.901870303; HINDS JW, 1974, DEV BIOL, V37, P381, DOI 10.1016/0012-1606(74)90156-0; HO RK, 1990, NATURE, V348, P728, DOI 10.1038/348728a0; Hong Y, 2001, NATURE, V414, P634, DOI 10.1038/414634a; Hsueh YP, 2000, NATURE, V404, P298, DOI 10.1038/35005118; Hu M, 1999, DEV BIOL, V207, P309, DOI 10.1006/dbio.1998.9031; Jensen AM, 2001, DEVELOPMENT, V128, P95; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Kamberov E, 2000, J BIOL CHEM, V275, P11425, DOI 10.1074/jbc.275.15.11425; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Knapik EW, 1998, NAT GENET, V18, P338, DOI 10.1038/ng0498-338; Knapik EW, 1996, DEVELOPMENT, V123, P451; LAHEY T, 1994, NEURON, V13, P823, DOI 10.1016/0896-6273(94)90249-6; Malicki J, 1999, DEVELOPMENT, V126, P1235; Malicki J, 1999, METHODS CELL BIOL, V59, P273; Malicki J, 1996, DEVELOPMENT, V123, P263; Marfatia SM, 1997, J BIOL CHEM, V272, P24191, DOI 10.1074/jbc.272.39.24191; MATSUNAGA M, 1988, NEURON, V1, P289, DOI 10.1016/0896-6273(88)90077-3; Muller HAJ, 2000, DEV DYNAM, V218, P52; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; Nix SL, 2000, J BIOL CHEM, V275, P41192, DOI 10.1074/jbc.M002078200; Ohshiro T, 2000, NATURE, V408, P593, DOI 10.1038/35046087; Peng CY, 2000, NATURE, V408, P596, DOI 10.1038/35046094; Pujic Z, 2001, DEV BIOL, V234, P454, DOI 10.1006/dbio.2001.0251; SHEFFIELD JB, 1970, DEV BIOL, V23, P36, DOI 10.1016/S0012-1606(70)80006-9; STREISINGER G, 1986, GENETICS, V112, P311; STUMPO DJ, 1995, P NATL ACAD SCI USA, V92, P944, DOI 10.1073/pnas.92.4.944; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TOMASIEWICZ H, 1993, NEURON, V11, P1163, DOI 10.1016/0896-6273(93)90228-J; Tomita K, 1996, NEURON, V16, P723, DOI 10.1016/S0896-6273(00)80093-8; Westerfield M., 2000, ZEBRAFISH BOOK GUIDE, V4th Edn; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X	42	155	157	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2002	31	2					150	157		10.1038/ng883	http://dx.doi.org/10.1038/ng883			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	557HR	11992120				2022-12-25	WOS:000175903500010
J	Kulkarni, RN; Holzenberger, M; Shih, DQ; Ozcan, U; Stoffel, M; Magnuson, MA; Kahn, CR				Kulkarni, RN; Holzenberger, M; Shih, DQ; Ozcan, U; Stoffel, M; Magnuson, MA; Kahn, CR			beta-cell-specific deletion of the Igf1 receptor leads to hyperinsulinemia and glucose intolerance but does not alter beta-cell mass	NATURE GENETICS			English	Article							GROWTH-FACTOR-I; INSULIN-RECEPTOR; GENE-EXPRESSION; MICE CAUSES; DIFFERENTIATION; TRANSCRIPTION; EXOCYTOSIS; SECRETION; KNOCKOUT; HORMONE	Regulation of glucose homeostasis by insulin depends on the maintenance of normal beta-cell mass and function. Insulin-like growth factor 1 (Igf1) has been implicated in islet development and differentiated function(1,2), but the factors controlling this process are poorly understood. Pancreatic islets produce Igf1 and Igf2, which bind to specific receptors on beta-cells(3-6). Igf1 has been shown to influence beta-cell apoptosis(7), and both Igf1 and Igf2 increase islet growth(8,9); Igf2 does so in a manner additive with fibroblast growth factor 2 (ref. 10). When mice deficient for the Igf1 receptor (Igf1r(+/-)) are bred with mice lacking insulin receptor substrate 2 (Irs2(-/-)), the resulting compound knockout mice show a reduction in mass of beta-cells(11) similar to that observed in pancreas of Igf1r(-/-) mice (ref. 11), suggesting a role for Igf1r in growth of beta-cells. It is possible, however, that the effects in these mice occur secondary to changes in vascular endothelium(12) or in the pancreatic ductal cells, or because of a decrease in the effects of other hormones implicated in islet growth. To directly define the role of Igf1, we have created a mouse with a beta-cell-specific knockout of Igf1r (Igf1r(-/-)). These mice show normal growth and development of beta-cells, but have reduced expression of Slc2a2 (also known as Glut2) and Gck (encoding glucokinase) in beta-cells, which results in defective glucose-stimulated insulin secretion and impaired glucose tolerance. Thus, Igf1r is not crucial for islet beta-cell development, but participates in control of differentiated function.	Harvard Univ, Sch Med, Dept Med, Joslin Diabet Ctr,Res Div, Boston, MA 02215 USA; Hop St Antoine, INSERM, U515, F-75571 Paris, France; Rockefeller Univ, Lab Metab Dis, New York, NY 10021 USA; Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37212 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Rockefeller University; Vanderbilt University	Kulkarni, RN (corresponding author), Harvard Univ, Sch Med, Dept Med, Joslin Diabet Ctr,Res Div, 1 Joslin Pl, Boston, MA 02215 USA.	rohit.kulkarni@joslin.harvard.edu	Holzenberger, Martin/N-9732-2018; Kahn, Ronald/AAY-2435-2021; Magnuson, Mark A/B-1335-2009; Magnuson, Mark/AAY-7172-2021	Kahn, Ronald/0000-0002-7583-9228; Magnuson, Mark A/0000-0002-8824-6499; Magnuson, Mark/0000-0002-8824-6499; Stoffel, Markus/0000-0003-1304-5817; Holzenberger, Martin/0000-0003-4869-725X				Arany E, 2000, PEDIATR RES, V48, P389, DOI 10.1203/00006450-200009000-00023; Argetsinger LS, 1996, J BIOL CHEM, V271, P29415, DOI 10.1074/jbc.271.46.29415; Aspinwall CA, 2000, J BIOL CHEM, V275, P22331, DOI 10.1074/jbc.M909647199; Blakesley VA, 1999, CONT ENDOCRINOL, V17, P143; Bole-Feysot C, 1998, ENDOCR REV, V19, P225, DOI 10.1210/edrv.19.3.0334; BONNERWEIR S, 1994, TRENDS ENDOCRIN MET, V5, P60, DOI 10.1016/1043-2760(94)90003-5; DEMEYTS P, 1994, HORM RES, V42, P152, DOI 10.1159/000184188; Duncan SA, 1998, SCIENCE, V281, P692, DOI 10.1126/science.281.5377.692; Gannon M, 2000, GENESIS, V26, P139, DOI 10.1002/(SICI)1526-968X(200002)26:2<139::AID-GENE12>3.0.CO;2-7; Holzenberger M, 2000, ENDOCRINOLOGY, V141, P2557, DOI 10.1210/en.141.7.2557; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Kulkarni RN, 1999, J CLIN INVEST, V104, pR69, DOI 10.1172/JCI8339; KULKARNI RN, 2001, MOL BASIS PANCREAS D, P299; Lammert E, 2001, SCIENCE, V294, P564, DOI 10.1126/science.1064344; LEAHY JL, 1990, ENDOCRINOLOGY, V126, P1593, DOI 10.1210/endo-126-3-1593; Leibiger B, 2001, MOL CELL, V7, P559, DOI 10.1016/S1097-2765(01)00203-9; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; Nguyen HQ, 1996, ONCOGENE, V12, P2109; OTONKOSKI T, 1988, DIABETES, V37, P1678, DOI 10.2337/diabetes.37.12.1678; RABINOVITCH A, 1982, DIABETES, V31, P160, DOI 10.2337/diabetes.31.2.160; Rhodes CJ, 2000, J MOL ENDOCRINOL, V24, P303, DOI 10.1677/jme.0.0240303; SANFORD LP, 2001, GENE KNOCKOUT PROTOC, P217; SMITH FE, 1991, P NATL ACAD SCI USA, V88, P6152, DOI 10.1073/pnas.88.14.6152; SWENNE I, 1992, DIABETOLOGIA, V35, P193, DOI 10.1007/BF00400917; VANSCHRAVENDIJK CFH, 1987, ENDOCRINOLOGY, V121, P1784, DOI 10.1210/endo-121-5-1784; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4; Withers DJ, 1999, NAT GENET, V23, P32, DOI 10.1038/12631; Xavier GD, 2000, J BIOL CHEM, V275, P36269, DOI 10.1074/jbc.M006597200; Zhang QM, 1997, P NATL ACAD SCI USA, V94, P6232, DOI 10.1073/pnas.94.12.6232	29	286	297	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2002	31	1					111	115		10.1038/ng872	http://dx.doi.org/10.1038/ng872			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	547ZF	11923875	Bronze			2022-12-25	WOS:000175362500025
J	Lee, NS; Dohjima, T; Bauer, G; Li, HT; Li, MJ; Ehsani, A; Salvaterra, P; Rossi, J				Lee, NS; Dohjima, T; Bauer, G; Li, HT; Li, MJ; Ehsani, A; Salvaterra, P; Rossi, J			Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells	NATURE BIOTECHNOLOGY			English	Article							MESSENGER-RNAS; MAMMALIAN-CELLS; GENE; RIBOZYMES; ANTISENSE; OOCYTES	RNA interference (RNAi) is the process of sequence-specific, posttranscriptional gene silencing in animals and plants initiated by double-stranded (ds) RNA that is homologous to the silenced gene(1-7). This technology has usually involved injection or transfection of dsRNA in model nonvertebrate organisms. The longer dsRNAs are processed into short (19-25 nucleotides) small interfering RNAs (siRNAs) by a ribonucleotide-protein complex that includes an RNAse III-related nuclease (Dicer)(7), a helicase family member(8), and possibly a kinase(9) and an RNA-dependent RNA polymerase (RdRP)(10,11). In mammalian cells it is known that dsRNA 30 base pairs or longer can trigger interferon responses that are intrinsically sequence-nonspecific(12), thus limiting the application of RNAi as an experimental and therapeutic agent. Duplexes of 21-nucleotide siRNAs with short 3 overhangs, however, can mediate RNAi in a sequence-specific manner in cultured mammalian cells(12,13). One limitation in the use of siRNA as a therapeutic reagent in vertebrate cells is that short, highly defined RNAs need to be delivered to target cells-a feat thus far only accomplished by the use of synthetic, duplex RNAs delivered exogenously to cells(12,13). In this report, we describe a mammalian Pol III promoter system capable of expressing functional double-stranded siRNAs following transfection into human cells. In the case of the 293 cells cotransfected with the HIV-1 pNL4-3 proviral DNA and the siRNA-producing constructs, we were able to achieve up to 4 logs of inhibition of expression from the HIV-1 DNA.	City Hope Natl Med Ctr, Grad Sch Biol Sci, Div Mol Biol, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Grad Sch Biol Sci, Div Neurosci, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Grad Sch Biol Sci, Beckman Res Inst, Duarte, CA 91010 USA	City of Hope; City of Hope; City of Hope; Beckman Research Institute of City of Hope	Rossi, J (corresponding author), City Hope Natl Med Ctr, Grad Sch Biol Sci, Div Mol Biol, 1500 E Duarte Rd, Duarte, CA 91010 USA.				NIAID NIH HHS [AI42552, AI 29329, AI 46030] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI046030, R37AI029329, R01AI029329] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Bertrand E, 1997, RNA, V3, P75; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Dalmay T, 2001, EMBO J, V20, P2069, DOI 10.1093/emboj/20.8.2069; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fire A, 1999, TRENDS GENET, V15, P358, DOI 10.1016/S0168-9525(99)01818-1; Good PD, 1997, GENE THER, V4, P45, DOI 10.1038/sj.gt.3300354; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Lee NS, 2001, FASEB J, V15, P2390, DOI 10.1096/fj.01-0116com; Lipardi C, 2001, CELL, V107, P297, DOI 10.1016/S0092-8674(01)00537-2; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; Scherr M, 1998, NUCLEIC ACIDS RES, V26, P5079, DOI 10.1093/nar/26.22.5079; Scherr M, 2001, MOL THER, V4, P454, DOI 10.1006/mthe.2001.0481; Sharp PA, 2001, GENE DEV, V15, P485, DOI 10.1101/gad.880001; Sijen T, 2001, CELL, V107, P465, DOI 10.1016/S0092-8674(01)00576-1; Smardon A, 2000, CURR BIOL, V10, P169, DOI 10.1016/S0960-9822(00)00323-7; Svoboda P, 2000, DEVELOPMENT, V127, P4147	19	782	1160	2	67	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2002	20	5					500	505		10.1038/nbt0502-500	http://dx.doi.org/10.1038/nbt0502-500			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	548AE	11981565				2022-12-25	WOS:000175364800034
J	Mantamadiotis, T; Lemberger, T; Bleckmann, SC; Kern, H; Kretz, O; Villalba, AM; Tronche, F; Kellendonk, C; Gau, D; Kapfhammer, J; Otto, C; Schmid, W; Schutz, G				Mantamadiotis, T; Lemberger, T; Bleckmann, SC; Kern, H; Kretz, O; Villalba, AM; Tronche, F; Kellendonk, C; Gau, D; Kapfhammer, J; Otto, C; Schmid, W; Schutz, G			Disruption of CREB function in brain leads to neurodegeneration	NATURE GENETICS			English	Article							ELEMENT-BINDING PROTEIN; HUNTINGTONS-DISEASE; MICE LACKING; EXPANDED POLYGLUTAMINE; MEDIATED TRANSCRIPTION; BCL-2 EXPRESSION; MUTANT MICE; CELL-DEATH; SURVIVAL; GENE	Control of cellular survival and proliferation is dependent on extracellular signals and is a prerequisite for ordered tissue development and maintenance. Activation of the cAMP responsive element binding protein (CREB) by phosphorylation has been implicated in the survival of mammalian cells. To define its roles in the mouse central nervous system, we disrupted Creb1 in brain of developing and adult mice using the Cre/loxP system. Mice with a Crem(-/-) background and lacking Creb in the central nervous system during development show extensive apoptosis of postmitotic neurons. By contrast, mice in which both Creb1 and Crem are disrupted in the postnatal fore-brain show progressive neurodegeneration in the hippocampus and in the dorsolateral striatum. The striatal phenotype is reminiscent of Huntington disease and is consistent with the postulated role of CREB-mediated signaling in polyglutamine-triggered diseases.	Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany; Univ Basel, Inst Anat, CH-4003 Basel, Switzerland	Helmholtz Association; German Cancer Research Center (DKFZ); University of Basel	Schutz, G (corresponding author), Deutsch Krebsforschungszentrum, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Mantamadiotis, Theo/W-9010-2019; Kellendonk, Christoph/O-7229-2018; TRONCHE, François/F-3895-2011; Mantamadiotis, Theo/AAM-1346-2020; Lemberger, Thomas/A-7301-2008	Mantamadiotis, Theo/0000-0003-3971-5380; Kellendonk, Christoph/0000-0003-3302-2188; Lemberger, Thomas/0000-0002-2499-4025; Martin-Villalba, Ana/0000-0002-9405-8910; Kretz, Oliver/0000-0003-1152-5956				BIRREN B, 1997, ANAL DNA; BLECKMANN SC, 1908, MOL CELL BIOL, V22, P1919; Blendy JA, 1996, EMBO J, V15, P1098, DOI 10.1002/j.1460-2075.1996.tb00447.x; Blendy JA, 1996, NATURE, V380, P162, DOI 10.1038/380162a0; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Clarke G, 2000, NATURE, V406, P195, DOI 10.1038/35018098; Dragatsis I, 2000, NAT GENET, V26, P300, DOI 10.1038/81593; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Finkbeiner S, 2000, NEURON, V25, P11, DOI 10.1016/S0896-6273(00)80866-1; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; Jean D, 1998, J BIOL CHEM, V273, P24884, DOI 10.1074/jbc.273.38.24884; Kellendonk C, 1999, J MOL BIOL, V285, P175, DOI 10.1006/jmbi.1998.2307; LALONDE R, 1987, EXP BRAIN RES, V65, P479; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Mantamadiotis T, 1998, BIOTECHNIQUES, V25, P968, DOI 10.2144/98256bm07; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; McCampbell A, 2000, HUM MOL GENET, V9, P2197, DOI 10.1093/hmg/9.14.2197; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; ROSSI JM, 1992, P NATL ACAD SCI USA, V89, P2456, DOI 10.1073/pnas.89.6.2456; Rudolph D, 1998, P NATL ACAD SCI USA, V95, P4481, DOI 10.1073/pnas.95.8.4481; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Shimohata T, 2000, NAT GENET, V26, P29, DOI 10.1038/79139; SIKORSKI RS, 1989, GENETICS, V122, P19; Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127; Somers JP, 1999, MOL ENDOCRINOL, V13, P1364, DOI 10.1210/me.13.8.1364; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703; van den Akker E, 1999, MECH DEVELOP, V89, P103, DOI 10.1016/S0925-4773(99)00212-9; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Wyttenbach A, 2001, HUM MOL GENET, V10, P1829, DOI 10.1093/hmg/10.17.1829; Yamada M, 2001, MOL CELL BIOL, V21, P3807, DOI 10.1128/MCB.21.11.3807-3819.2001	37	544	554	2	29	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2002	31	1					47	54		10.1038/ng882	http://dx.doi.org/10.1038/ng882			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	547ZF	11967539				2022-12-25	WOS:000175362500013
J	van Berkel, PHC; Welling, MM; Geerts, M; van Veen, HA; Ravensbergen, B; Salaheddine, M; Pauwels, EKJ; Pieper, F; Nuijens, JH; Nibbering, PH				van Berkel, PHC; Welling, MM; Geerts, M; van Veen, HA; Ravensbergen, B; Salaheddine, M; Pauwels, EKJ; Pieper, F; Nuijens, JH; Nibbering, PH			Large scale production of recombinant human lactoferrin in the milk of transgenic cows	NATURE BIOTECHNOLOGY			English	Article							IN-VITRO; GENERATION; INFECTIONS; CATTLE	The limited capacity of current bioreactors has led the biopharmaceutical industry to investigate alternative protein expression systems. The milk of transgenic cattle may provide an attractive vehicle for large-scale production of biopharmaceuticals, but there have been no reports on the characteristics of such recombinant proteins. Here we describe the production of recombinant human lactoferrin (rhLF), an iron-binding glycoprotein involved in innate host defense, at gram per liter concentrations in bovine milk. Natural hLF from human milk and rhLF had identical iron-binding and -release properties. Although natural hLF and rhLF underwent differential N-linked glycosylation, they were equally effective in three different in vivo infection models employing immunocompetent and leukocytopenic mice, and showed similar localization at sites of infection. Taken together, the results illustrate the potential of transgenic cattle in the large-scale production of biopharmaceuticals.	Pharming, Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Radiol, Div Nucl Med, Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Infect Dis, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	van Berkel, PHC (corresponding author), Pharming, Leiden, Netherlands.		Welling, Mick/A-4582-2012	Welling, Mick/0000-0002-2249-5601				ANDERSON BF, 1989, J MOL BIOL, V209, P711, DOI 10.1016/0022-2836(89)90602-5; Brink MF, 2000, THERIOGENOLOGY, V53, P139, DOI 10.1016/S0093-691X(99)00247-2; Edmunds T, 1998, BLOOD, V91, P4561, DOI 10.1182/blood.V91.12.4561; Garber K, 2001, NAT BIOTECHNOL, V19, P184, DOI 10.1038/85559; HASEGAWA K, 1994, JPN J MED SCI BIOL, V47, P73, DOI 10.7883/yoken1952.47.73; Kamerling J. P., 1989, MASS SPECTROMETRY, P176; KRIMPENFORT P, 1991, BIO-TECHNOL, V9, P844, DOI 10.1038/nbt0991-844; Nibbering PH, 2001, INFECT IMMUN, V69, P1469, DOI 10.1128/IAI.69.3.1469-1476.2001; Nuijens JH, 1996, J MAMMARY GLAND BIOL, V1, P285, DOI 10.1007/BF02018081; Nuijens JH, 1997, J BIOL CHEM, V272, P8802, DOI 10.1074/jbc.272.13.8802; SOUKKA T, 1992, FEMS MICROBIOL LETT, V69, P223; vanBerkel PHC, 1996, BIOCHEM J, V319, P117, DOI 10.1042/bj3190117; VANBERKEL PHC, 1995, BIOCHEM J, V312, P107, DOI 10.1042/bj3120107; VELANDER WH, 1992, P NATL ACAD SCI USA, V89, P12003, DOI 10.1073/pnas.89.24.12003; Welling MM, 2000, EUR J NUCL MED, V27, P292, DOI 10.1007/s002590050036; Zhang GH, 1999, INFECT IMMUN, V67, P1353, DOI 10.1128/IAI.67.3.1353-1358.1999	16	198	228	4	45	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2002	20	5					484	487		10.1038/nbt0502-484	http://dx.doi.org/10.1038/nbt0502-484			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	548AE	11981562				2022-12-25	WOS:000175364800031
J	Ye, ZM; Hellstrom, I; Hayden-Ledbetter, M; Dahlin, A; Ledbetter, JA; Hellstrom, KE				Ye, ZM; Hellstrom, I; Hayden-Ledbetter, M; Dahlin, A; Ledbetter, JA; Hellstrom, KE			Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB	NATURE MEDICINE			English	Article							ANTITUMOR IMMUNITY; CYTOPLASMIC TAIL; T-LYMPHOCYTES; CELL SURFACE; COSTIMULATION; CD28; VACCINATION; ANTIGEN; B7; AMPLIFICATION	Monoclonal antibodies against the T-cell activation molecule 4-1BB have been effective in the treatment of established mouse tumors. To create a vaccine that stimulates the immune system similarly to the efficacious monoclonal anti-4-1BB antibody, 1D8, we constructed a vector encoding cell-bound single-chain Fv fragments from 1D8. We transfected the vector into cells from the K1735 melanoma, selected because of its low immunogenicity and very low expression of major histocompatibility complex class I. The transfected cells induced a strong type 1 T-helper cell response, for which CD4(+) but not CD8(+) T lymphocytes were necessary and that involved natural killer cells. Vaccinated mice rejected established wild-type K1735 tumors growing as subcutaneous nodules or in the lung. An analogous approach may be effective against micrometastases in human patients, including tumors whose expression of major histocompatibility complex class I is very low.	Pacific NW Res Inst, Seattle, WA USA; Second Mil Med Univ, Int Canc Inst, Shanghai, Peoples R China	Naval Medical University	Hellstrom, KE (corresponding author), Pacific NW Res Inst, Seattle, WA USA.	khellstrom@pnri.org			NATIONAL CANCER INSTITUTE [R01CA085780, R01CA090143, R01CA079490, P50CA083636] Funding Source: NIH RePORTER; NCI NIH HHS [CA90143, CA79490, 1P50 CA83636, CA85780] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boon T, 1997, IMMUNOL TODAY, V18, P267, DOI 10.1016/S0167-5699(97)80020-5; CHEEVER MA, 1995, IMMUNOL REV, V145, P33, DOI 10.1111/j.1600-065X.1995.tb00076.x; CHEN LP, 1994, J EXP MED, V179, P523, DOI 10.1084/jem.179.2.523; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; Chen WJ, 1998, J EXP MED, V188, P1849, DOI 10.1084/jem.188.10.1849; den Haan JMM, 2000, J EXP MED, V192, P1685, DOI 10.1084/jem.192.12.1685; Doty RT, 1996, J IMMUNOL, V157, P3270; Doty RT, 1998, J IMMUNOL, V161, P2700; ESTIN CD, 1988, P NATL ACAD SCI USA, V85, P1052, DOI 10.1073/pnas.85.4.1052; FERRONE S, 1995, IMMUNOL TODAY, V16, P487, DOI 10.1016/0167-5699(95)80033-6; FIDLER IJ, 1981, CANCER RES, V41, P3266; Gilliland LK, 1996, TISSUE ANTIGENS, V47, P1, DOI 10.1111/j.1399-0039.1996.tb02509.x; Gorelik L, 2001, NAT MED, V7, P1118, DOI 10.1038/nm1001-1118; GREENBERG PD, 1991, ADV IMMUNOL, V49, P281; Hayden MS, 1996, TISSUE ANTIGENS, V48, P242, DOI 10.1111/j.1399-0039.1996.tb02642.x; Hellstrom KE, 1999, HANDB EXP PHARMACOL, V133, P463; KAHN M, 1991, J IMMUNOL, V146, P3235; KARRE K, 1995, SCIENCE, V267, P978, DOI 10.1126/science.7863341; Kiessling R, 1999, CANCER IMMUNOL IMMUN, V48, P353, DOI 10.1007/s002620050586; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Li YW, 1996, J EXP MED, V183, P639, DOI 10.1084/jem.183.2.639; LI YW, 1994, J IMMUNOL, V153, P421; Melero I, 1997, NAT MED, V3, P682, DOI 10.1038/nm0697-682; Melero I, 1998, EUR J IMMUNOL, V28, P1116, DOI 10.1002/(SICI)1521-4141(199803)28:03<1116::AID-IMMU1116>3.0.CO;2-A; MELIEF CJM, 1995, IMMUNOL REV, V145, P167, DOI 10.1111/j.1600-065X.1995.tb00081.x; Nakamura K, 2001, J EXP MED, V194, P629, DOI 10.1084/jem.194.5.629; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; Pardoll DM, 2000, CLIN IMMUNOL, V95, pS44, DOI 10.1006/clim.1999.4819; Pardoll DM, 1996, CURR OPIN IMMUNOL, V8, P619, DOI 10.1016/S0952-7915(96)80076-8; Rosenberg SA, 1998, NAT MED, V4, P321, DOI 10.1038/nm0398-321; Shuford WW, 1997, J EXP MED, V186, P47, DOI 10.1084/jem.186.1.47; WARD PL, 1989, J EXP MED, V170, P217, DOI 10.1084/jem.170.1.217; Winberg G, 1996, IMMUNOL REV, V153, P209, DOI 10.1111/j.1600-065X.1996.tb00926.x; YANG G, 1997, EXPERT OPIN INV DRUG, V6, P1	34	130	158	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2002	8	4					343	348		10.1038/nm0402-343	http://dx.doi.org/10.1038/nm0402-343			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	536ML	11927939				2022-12-25	WOS:000174704800025
J	Kurima, K; Peters, LM; Yang, YD; Riazuddin, S; Ahmed, ZM; Naz, S; Arnaud, D; Drury, S; Mo, JH; Makishima, T; Ghosh, M; Menon, PSN; Deshmukh, D; Oddoux, C; Ostrer, H; Khan, S; Riazuddin, S; Deininger, PL; Hampton, LL; Sullivan, SL; Battey, JF; Keats, BJB; Wilcox, ER; Friedman, TB; Griffith, AJ				Kurima, K; Peters, LM; Yang, YD; Riazuddin, S; Ahmed, ZM; Naz, S; Arnaud, D; Drury, S; Mo, JH; Makishima, T; Ghosh, M; Menon, PSN; Deshmukh, D; Oddoux, C; Ostrer, H; Khan, S; Riazuddin, S; Deininger, PL; Hampton, LL; Sullivan, SL; Battey, JF; Keats, BJB; Wilcox, ER; Friedman, TB; Griffith, AJ			Dominant and recessive deafness caused by mutations of a novel gene, TMC1, required for cochlear hair-cell function	NATURE GENETICS			English	Article							INNER-EAR; LOCUS DN; MOUSE; CHROMOSOME-19; SENSITIVITY; DFNB3; MICE	Positional cloning of hereditary deafness genes is a direct approach to identify molecules and mechanisms underlying auditory function. Here we report a locus for dominant deafness, DFNA36, which maps to human chromosome 9q13-21 in a region overlapping the DFNB7/B11 locus for recessive deafness. We identified eight mutations in a new gene, transmembrane cochlear-expressed gene 1 (TMC1), in a DFNA36 family and eleven DFNB7/B11 families. We detected a 1.6-kb genomic deletion encompassing exon 14 of Tmc1 in the recessive deafness (dn) mouse mutant, which lacks auditory responses and has hair-cell degeneration(1,2). TMC1 and TMC2 on chromosome 20p13 are members of a gene family predicted to encode transmembrane proteins. Tmc1 mRNA is expressed in hair cells of the postnatal mouse cochlea and vestibular end organs and is required for normal function of cochlear hair cells.	Natl Inst Deafness & Other Commun Disorders, Sect Gene Struct & Funct, Mol Genet Lab, NIH, Rockville, MD 20850 USA; Natl Inst Deafness & Other Commun Disorders, Sect Human Genet, Mol Genet Lab, NIH, Rockville, MD 20850 USA; Univ Punjab, Ctr Excellence Mol Biol, Lahore, Pakistan; Louisiana State Univ, Hlth Sci Ctr, Dept Genet, New Orleans, LA USA; All India Inst Med Sci, Dept Pediat, Genet Unit, New Delhi, India; Rotary Deaf Sch, Ichalkaranji Tilawani, Maharashtra, India; NYU, Sch Med, Dept Pediat, Human Genet Program, New York, NY USA; Tulane Univ, Med Ctr, Dept Environm Hlth Sci, New Orleans, LA USA; NINCDS, G Prot Coupled Receptors Sect, NIH, Bethesda, MD 20892 USA; Natl Inst Deafness & Other Commun Disorders, Mol Neurosci Sect, NIH, Rockville, MD 20850 USA; Natl Inst Deafness & Other Commun Disorders, Hearing Sect, NIH, Rockville, MD 20850 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); University of Punjab; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; All India Institute of Medical Sciences (AIIMS) New Delhi; New York University; Tulane University; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Griffith, AJ (corresponding author), Natl Inst Deafness & Other Commun Disorders, Sect Gene Struct & Funct, Mol Genet Lab, NIH, 5 Res Court, Rockville, MD 20850 USA.		Makishima, Tomoko/L-2439-2019; Drury, Stacy/O-9181-2017; Naz, Sadaf/C-3911-2019; naz, sadaf/F-4406-2015; Peters, Linda/P-5370-2018	Makishima, Tomoko/0000-0003-3397-6395; Drury, Stacy/0000-0001-5950-0091; Naz, Sadaf/0000-0002-1912-0235; Peters, Linda/0000-0002-9961-4293; Deininger, Prescott/0000-0002-1067-3028	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [ZIADC000048, ZIADC000039, Z01DC000039, ZIADC000060, Z01DC000048, Z01DC000035, Z01DC000060] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Ahmed ZM, 2001, AM J HUM GENET, V69, P25, DOI 10.1086/321277; Alagramam KN, 2001, NAT GENET, V27, P99, DOI 10.1038/83837; Ashmore JF, 2001, CURR OPIN NEUROBIOL, V11, P449, DOI 10.1016/S0959-4388(00)00233-6; Belyantseva IA, 2000, J NEUROSCI, V20, part. no.; BOCK GR, 1983, ACTA OTO-LARYNGOL, V96, P39, DOI 10.3109/00016488309132873; Bolz H, 2001, NAT GENET, V27, P108, DOI 10.1038/83667; Bork JM, 2001, AM J HUM GENET, V68, P26, DOI 10.1086/316954; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; DEOL M. S., 1958, HEREDITY, V12, P463, DOI 10.1038/hdy.1958.46; Gillespie PG, 2001, NATURE, V413, P194, DOI 10.1038/35093011; Griffith AJ, 1999, NAT GENET, V21, P347, DOI 10.1038/7668; Huang JM, 1998, HEARING RES, V117, P24, DOI 10.1016/S0378-5955(98)00005-7; HUDSPETH AJ, 1977, P NATL ACAD SCI USA, V74, P2407, DOI 10.1073/pnas.74.6.2407; JAIN PK, 1995, HUM MOL GENET, V4, P2391, DOI 10.1093/hmg/4.12.2391; KEATS BJB, 1995, MAMM GENOME, V6, P8, DOI 10.1007/BF00350886; Kiernan AE, 1999, J NEUROCYTOL, V28, P969, DOI 10.1023/A:1007090626294; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Liang Y, 1999, GENOMICS, V61, P243, DOI 10.1006/geno.1999.5976; Moller S, 2001, BIOINFORMATICS, V17, P646, DOI 10.1093/bioinformatics/17.7.646; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; PUJOL R, 1983, HEARING RES, V12, P57, DOI 10.1016/0378-5955(83)90118-1; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; Rivolta MN, 1998, P ROY SOC B-BIOL SCI, V265, P1595, DOI 10.1098/rspb.1998.0477; Romero P, 2001, PROTEINS, V42, P38, DOI 10.1002/1097-0134(20010101)42:1<38::AID-PROT50>3.0.CO;2-3; SASSOON DA, 1988, DEVELOPMENT, V104, P155; Scott DA, 2000, GENE, V246, P265, DOI 10.1016/S0378-1119(00)00090-1; Scott DA, 1996, AM J HUM GENET, V59, P385; STEEL KP, 1980, NATURE, V288, P159, DOI 10.1038/288159a0; Suzuki Y, 2000, GENOMICS, V64, P286, DOI 10.1006/geno.2000.6076; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Verpy E, 2001, NAT GENET, V29, P345, DOI 10.1038/ng726; Vinas AM, 1998, BBA-MOL BASIS DIS, V1407, P257, DOI 10.1016/S0925-4439(98)00050-7; Vreugde S, 2002, NAT GENET, V30, P257, DOI 10.1038/ng848; Wang AH, 1998, SCIENCE, V280, P1447, DOI 10.1126/science.280.5368.1447; Wilcox ER, 2001, CELL, V104, P165, DOI 10.1016/S0092-8674(01)00200-8	36	299	320	2	32	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAR	2002	30	3					277	284		10.1038/ng842	http://dx.doi.org/10.1038/ng842			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	526YP	11850618	Green Published			2022-12-25	WOS:000174157600011
J	Storek, MJ; Ernst, A; Verdine, GL				Storek, MJ; Ernst, A; Verdine, GL			High-resolution footprinting of sequence-specific protein-DNA contacts	NATURE BIOTECHNOLOGY			English	Article							ESCHERICHIA-COLI-ADA; RNA-POLYMERASE; INTERFERENCE; PROMOTER; SITES; RECOGNITION; BINDING; COMPLEX; AIDB	Gene transcription is regulated by proteins that bind specific DNA sequences and control the initiation of RNA synthesis. A major challenge is to map all of the regulatory sites in the genome and to identify the proteins that bind them. Because members of transcription factor families often exhibit similar sequence preferences, methods for determining intermolecular contacts in protein-DNA interfaces must be sensitive to even subtle structural differences. The most detailed structural views of protein-DNA interfaces have been obtained through X-ray crystallography and NMR spectroscopy, and these methods have revolutionized the understanding of the structural determinants of sequence-specific recognition(1). Neither crystallography nor NMR, however, is particularly well-suited to high-throughput applications such as pan-genomic elucidation of regulatory sequences; in addition, these methods yield no information on the energetic contribution of particular contacts. Here we report a straightforward, high-resolution biochemical method for mapping, at single-nucleotide resolution, DNA bases that are subject to sequence-specific contacts by regulatory proteins.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA	Harvard University	Verdine, GL (corresponding author), Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA.	verdine@chemistry.harvard.edu		Ernst, Alexander/0000-0003-1100-8158				BRUNELLE A, 1987, P NATL ACAD SCI USA, V84, P6673, DOI 10.1073/pnas.84.19.6673; HAYASHIBARA KC, 1991, J AM CHEM SOC, V113, P5104, DOI 10.1021/ja00013a080; HAYASHIBARA KC, 1992, BIOCHEMISTRY-US, V31, P11265, DOI 10.1021/bi00161a002; HAYES JJ, 1989, BIOCHEMISTRY-US, V28, P9521, DOI 10.1021/bi00450a041; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KALNIK MW, 1989, BIOCHEMISTRY-US, V28, P3373, DOI 10.1021/bi00434a037; KOVACS T, 1988, TETRAHEDRON LETT, V29, P4525, DOI 10.1016/S0040-4039(00)80537-7; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Landini P, 1998, J BIOL CHEM, V273, P13307, DOI 10.1074/jbc.273.21.13307; LANDINI P, 1995, J BIOL CHEM, V270, P8285, DOI 10.1074/jbc.270.14.8285; Lockhart DJ, 2000, NATURE, V405, P827, DOI 10.1038/35015701; MASCARENAS JL, 1993, J AM CHEM SOC, V115, P373, DOI 10.1021/ja00054a068; Maxam A M, 1980, Methods Enzymol, V65, P499; Min CH, 1996, J AM CHEM SOC, V118, P6116, DOI 10.1021/ja953658z; Pabo CO, 2000, J MOL BIOL, V301, P597, DOI 10.1006/jmbi.2000.3918; Ross W, 2001, GENE DEV, V15, P491, DOI 10.1101/gad.870001; SEDGWICK B, 1988, J BIOL CHEM, V263, P4430; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; TEO I, 1986, CELL, V45, P315, DOI 10.1016/0092-8674(86)90396-X; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040	20	15	22	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2002	20	2					183	186		10.1038/nbt0202-183	http://dx.doi.org/10.1038/nbt0202-183			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	517FT	11821865				2022-12-25	WOS:000173601000028
J	Weber, G; Shendure, J; Tanenbaum, DM; Church, GM; Meyerson, M				Weber, G; Shendure, J; Tanenbaum, DM; Church, GM; Meyerson, M			Identification of foreign gene sequences by transcript filtering against the human genome	NATURE GENETICS			English	Article							DNA-SEQUENCES; PATHOGENS; SEARCH; TAGS	We have developed a computational subtraction approach to detect microbial causes for putative infectious diseases by filtering a set of human tissue-derived sequences against the human genome. We demonstrate the potential of this method by identifying sequences from known pathogens in established expressed-sequence tag libraries.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Brigham & Womens Hosp, Decis Syst Grp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Meyerson, M (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.	matthew_meyerson@dfci.harvard.edu	Meyerson, Matthew L/E-7123-2012	church, george/0000-0001-6232-9969; Weber, Griffin/0000-0002-2597-881X; Shendure, Jay/0000-0002-1516-1865				ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Befeler AS, 2000, INFECT DIS CLIN N AM, V14, P617, DOI 10.1016/S0891-5520(05)70124-0; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; BURGER RA, 1996, J NATL CANCER I, V88, P1360; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; RELMAN DA, 1992, NEW ENGL J MED, V327, P293, DOI 10.1056/NEJM199207303270501; Relman DA, 1999, SCIENCE, V284, P1308, DOI 10.1126/science.284.5418.1308; RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Zhang Z, 2000, J COMPUT BIOL, V7, P203, DOI 10.1089/10665270050081478	14	55	58	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2002	30	2					141	142		10.1038/ng818	http://dx.doi.org/10.1038/ng818			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	519CY	11788827				2022-12-25	WOS:000173708700009
J	Elsasser, S; Gali, RR; Schwickart, M; Larsen, CN; Leggett, DS; Muller, B; Feng, MT; Tubing, F; Dittmar, GAG; Finley, D				Elsasser, S; Gali, RR; Schwickart, M; Larsen, CN; Leggett, DS; Muller, B; Feng, MT; Tubing, F; Dittmar, GAG; Finley, D			Proteasome subunit Rpn1 binds ubiquitin-like protein domains	NATURE CELL BIOLOGY			English	Article							SACCHAROMYCES-CEREVISIAE; REGULATORY PARTICLE; 26S PROTEASOME; UBA DOMAIN; DNA-REPAIR; DEGRADATION; YEAST; RECOGNITION; MOTIF; RAD23	The yeast protein Rad23 belongs to a diverse family of proteins that contain an amino-terminal ubiquitin-like (UBL) domain. This domain mediates the binding of Rad23 to proteasomes, which in turn promotes DNA repair and modulates protein degradation, possibly by delivering ubiquitinylated cargo to proteasomes. Here we show that Rad23 binds proteasomes by directly interacting with the base subcomplex of the regulatory particle of the proteasome. A component of the base, Rpn1, specifically recognizes the UBL domain of Rad23 through its leucine-rich-repeat-like (LRR-like) domain. A second UBL protein, Dsk2, competes with Rad23 for proteasome binding, which suggests that the LRR-like domain of Rpn1 may participate in the recognition of several ligands of the proteasome. We propose that the LRR domain of Rpn1 may be positioned in the base to allow the cargo proteins carried by Rad23 to be presented to the proteasomal ATPases for unfolding. We also report that, contrary to expectation, the base subunit Rpn10 does not mediate the binding of UBL proteins to the proteasome in yeast, although it can apparently contribute to the binding of ubiquitin chains by intact proteasomes.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Finley, D (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.		Dittmar, Gunnar/C-6333-2019; Dittmar, Gunnar/B-6383-2016	Dittmar, Gunnar/0000-0003-3647-8623; Dittmar, Gunnar/0000-0003-3647-8623; Feng, Matthew/0000-0003-0862-9877	NIGMS NIH HHS [F32 GM019359] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019359] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANERJEE A, 1993, J BIOL CHEM, V268, P5668; Beal RE, 1998, BIOCHEMISTRY-US, V37, P2925, DOI 10.1021/bi972514p; Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; Biggins S, 1996, J CELL BIOL, V133, P1331, DOI 10.1083/jcb.133.6.1331; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; Cagney G, 2001, PHYSIOL GENOMICS, V7, P27, DOI 10.1152/physiolgenomics.2001.7.1.27; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; Finley D, 2002, NAT CELL BIOL, V4, pE121, DOI 10.1038/ncb0502-e121; Fu HY, 1998, J BIOL CHEM, V273, P1970, DOI 10.1074/jbc.273.4.1970; Funakoshi M, 2002, P NATL ACAD SCI USA, V99, P745, DOI 10.1073/pnas.012585199; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hiyama H, 1999, J BIOL CHEM, V274, P28019, DOI 10.1074/jbc.274.39.28019; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kleijnen MF, 2000, MOL CELL, V6, P409, DOI 10.1016/S1097-2765(00)00040-X; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Lambertson D, 1999, GENETICS, V153, P69; LEGGETT DL, IN PRESS MOL CELL; Lupas A, 1997, TRENDS BIOCHEM SCI, V22, P195, DOI 10.1016/S0968-0004(97)01058-X; Ortolan TG, 2000, NAT CELL BIOL, V2, P601, DOI 10.1038/35023547; Rao H, 2002, J BIOL CHEM, V277, P11691, DOI 10.1074/jbc.M200245200; Russell SJ, 1999, MOL CELL, V3, P687, DOI 10.1016/S1097-2765(01)80001-0; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Strickland E, 2000, J BIOL CHEM, V275, P5565, DOI 10.1074/jbc.275.8.5565; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; Verma R, 2001, MOL CELL, V8, P439, DOI 10.1016/S1097-2765(01)00308-2; Walters KJ, 2002, BIOCHEMISTRY-US, V41, P1767, DOI 10.1021/bi011892y; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; Zachariae W, 1996, MOL BIOL CELL, V7, P791, DOI 10.1091/mbc.7.5.791	37	357	367	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	2002	4	9					725	730		10.1038/ncb845	http://dx.doi.org/10.1038/ncb845			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	589WE	12198498				2022-12-25	WOS:000177783900019
J	Fulga, TA; Rorth, P				Fulga, TA; Rorth, P			Invasive cell migration is initiated by guided growth of long cellular extensions	NATURE CELL BIOLOGY			English	Article							ACTIN FUSION PROTEIN; DROSOPHILA-OOGENESIS; NEURONAL MIGRATION; BORDER CELLS; MORPHOGENESIS; CHEMOTAXIS; GUIDANCE; RECEPTOR; GENETICS; CADHERIN	The migration of border cells during Drosophila melanogaster oogenesis is a simple and powerful system for studying invasive cell migration in vivo. Border cells are somatic cells that delaminate from the follicular epithelium of an egg chamber and invade the germ line cluster. They migrate between the nurse cells to reach the oocyte(1,2), using DE-cadherin for adhesion to the substratum(3). Border cells take approximately 6 h to migrate a distance of 100 mum(4). The migration is guided by EGFR (epidermal growth factor receptor) and PVR (platelet-derived growth factor (PDGF)/vascular endothelial growth factor (VEGF) receptor)(5,6). Here, we show that a single long cellular extension (LCE), several cell diameters in length, is formed at the initiation of migration. The LCE may function as a 'pathfinder' in response to guidance cues. LCE growth requires directional guidance signals and specific adhesion to the substratum. Interference with actin-myosin interactions allows continued LCE growth while preventing translocation of the cell bodies. We discuss similarities between LCEs and axons and the use of LCE-like structures as a general mechanism for initiating invasive migration in vivo.	European Mol Biol Lab, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Rorth, P (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Rørth, Pernille/H-3020-2011	Fulga, Tudor/0000-0002-1056-0082				Aizawa H, 1997, CELL STRUCT FUNCT, V22, P335, DOI 10.1247/csf.22.335; Britton JS, 2002, DEV CELL, V2, P239, DOI 10.1016/S1534-5807(02)00117-X; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; Clark IE, 1997, DEVELOPMENT, V124, P461; Duchek P, 2001, CELL, V107, P17, DOI 10.1016/S0092-8674(01)00502-5; Duchek P, 2001, SCIENCE, V291, P131, DOI 10.1126/science.291.5501.131; Edwards KA, 1996, DEVELOPMENT, V122, P1499; Firtel RA, 2000, BIOESSAYS, V22, P603, DOI 10.1002/1521-1878(200007)22:7<603::AID-BIES3>3.0.CO;2-#; Funamoto S, 2002, CELL, V109, P611, DOI 10.1016/S0092-8674(02)00755-9; Iijima M, 2002, CELL, V109, P599, DOI 10.1016/S0092-8674(02)00745-6; King R. C., 1970, OVARIAN DEV DROSOPHI; Knight B, 2000, CURR BIOL, V10, P576, DOI 10.1016/S0960-9822(00)00486-3; Koster RW, 2001, CURR BIOL, V11, P1858, DOI 10.1016/S0960-9822(01)00585-1; Kulesa P, 2000, DEVELOPMENT, V127, P2843; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Loureiro JJ, 2001, DEV BIOL, V235, P33, DOI 10.1006/dbio.2001.0292; MONTELL DJ, 1992, CELL, V71, P51, DOI 10.1016/0092-8674(92)90265-E; Niewiadomska P, 1999, J CELL BIOL, V144, P533, DOI 10.1083/jcb.144.3.533; O'Keefe L, 1997, DEVELOPMENT, V124, P4837; ODA H, 1994, DEV BIOL, V165, P716, DOI 10.1006/dbio.1994.1287; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; Rorth P, 2000, MOL CELL, V6, P23; Rorth P, 1998, DEVELOPMENT, V125, P1049; Spradling Allan C., 1993, P1; Verkhusha VV, 1999, FEBS LETT, V445, P395, DOI 10.1016/S0014-5793(99)00124-6; Westphal M, 1997, CURR BIOL, V7, P176, DOI 10.1016/S0960-9822(97)70088-5; Wimmer EA, 1997, DEVELOPMENT, V124, P1509; Yee KT, 1999, NEURON, V24, P607, DOI 10.1016/S0896-6273(00)81116-2	29	113	115	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	2002	4	9					715	719		10.1038/ncb848	http://dx.doi.org/10.1038/ncb848			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	589WE	12198500				2022-12-25	WOS:000177783900017
J	Lewis, DL; Hagstrom, JE; Loomis, AG; Wolff, JA; Herweijer, H				Lewis, DL; Hagstrom, JE; Loomis, AG; Wolff, JA; Herweijer, H			Efficient delivery of siRNA for inhibition of gene expression in postnatal mice	NATURE GENETICS			English	Article							DOUBLE-STRANDED-RNA; DROSOPHILA CELLS; PLASMID DNA; INTERFERENCE	It has recently been shown that RNA interference can be induced in cultured mammalian cells by delivery of short interfering RNAs (siRNAs). Here we describe a method for efficient in vivo delivery of siRNAs to organs of postnatal mice and demonstrate effective and specific inhibition of transgene expression in a variety of organs.	Mirus Corp, Madison, WI 53719 USA; Univ Wisconsin, Waisman Ctr, Dept Pediat & Med Genet, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison	Lewis, DL (corresponding author), Mirus Corp, 505 S Rosa Rd, Madison, WI 53719 USA.							Billy E, 2001, P NATL ACAD SCI USA, V98, P14428, DOI 10.1073/pnas.261562698; Caplen NJ, 2000, GENE, V252, P95, DOI 10.1016/S0378-1119(00)00224-9; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Parrish S, 2000, MOL CELL, V6, P1077, DOI 10.1016/S1097-2765(00)00106-4; Svoboda P, 2000, DEVELOPMENT, V127, P4147; Tuschl T, 2001, CHEMBIOCHEM, V2, P239, DOI 10.1002/1439-7633(20010401)2:4<239::AID-CBIC239>3.0.CO;2-R; Wianny F, 2000, NAT CELL BIOL, V2, P70, DOI 10.1038/35000016; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zhang GF, 1999, HUM GENE THER, V10, P1735, DOI 10.1089/10430349950017734	15	461	594	1	55	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2002	32	1					107	108		10.1038/ng944	http://dx.doi.org/10.1038/ng944			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	588RR	12145662				2022-12-25	WOS:000177714900008
J	Borowsky, B; Durkin, MM; Ogozalek, K; Marzabadi, MR; DeLeon, J; Heurich, R; Lichtblau, H; Shaposhnik, Z; Daniewska, I; Blackburn, TP; Branchek, TA; Gerald, C; Vaysse, PJ; Forray, C				Borowsky, B; Durkin, MM; Ogozalek, K; Marzabadi, MR; DeLeon, J; Heurich, R; Lichtblau, H; Shaposhnik, Z; Daniewska, I; Blackburn, TP; Branchek, TA; Gerald, C; Vaysse, PJ; Forray, C			Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist	NATURE MEDICINE			English	Article							MCH; MICE; IDENTIFICATION; DISTRESS; CLONING; SYSTEM	Melanin concentrating hormone (MCH) is an orexigenic hypothalamic neuropeptide, which plays an important role in the complex regulation of energy balance and body weight. Here we show that SNAP-7941, a selective, high-affinity MCH1 receptor ( MCH1-R) antagonist, inhibited food intake stimulated by central administration of MCH, reduced consumption of palatable food, and, after chronic administration to rats with diet-induced obesity, resulted in a marked, sustained decrease in body weight. In addition, after mapping the binding sites for [H-3] SNAP-7941 in rat brain, we evaluated its effects in a series of behavioral models. SNAP-7941 produced effects similar to clinically used antidepressants and anxiolytics in three animal models of depression/ anxiety: the rat forced-swim test, rat social interaction and guinea pig maternal-separation vocalization tests. Given these observations, an MCH1-R antagonist may be useful not only in the management of obesity but also as a treatment for depression and/or anxiety.	Synapt Pharmaceut Corp, Paramus, NJ USA		Forray, C (corresponding author), Synapt Pharmaceut Corp, Paramus, NJ USA.	cforray@synapticcorp.com						BITTENCOURT JC, 1992, J COMP NEUROL, V319, P218, DOI 10.1002/cne.903190204; Bonini JA, 2000, J BIOL CHEM, V275, P39324, DOI 10.1074/jbc.M004385200; Bradley RL, 2000, DIABETES, V49, P1073, DOI 10.2337/diabetes.49.7.1073; Chambers J, 1999, NATURE, V400, P261, DOI 10.1038/22313; FILE SE, 1978, BRIT J PHARMACOL, V62, P19, DOI 10.1111/j.1476-5381.1978.tb07001.x; GERALD C, 1995, J BIOL CHEM, V270, P26758, DOI 10.1074/jbc.270.45.26758; Gonzalez MI, 1996, PEPTIDES, V17, P171, DOI 10.1016/0196-9781(95)02092-6; Hervieu GJ, 2000, EUR J NEUROSCI, V12, P1194, DOI 10.1046/j.1460-9568.2000.00008.x; Hill J, 2001, J BIOL CHEM, V276, P20125, DOI 10.1074/jbc.M102068200; Kokkotou EG, 2001, ENDOCRINOLOGY, V142, P680, DOI 10.1210/en.142.2.680; Kramer MS, 1998, SCIENCE, V281, P1640, DOI 10.1126/science.281.5383.1640; LIGHTOWLER S, 1994, PHARMACOL BIOCHEM BE, V49, P281, DOI 10.1016/0091-3057(94)90422-7; Lucki I, 2001, PSYCHOPHARMACOLOGY, V155, P315, DOI 10.1007/s002130100694; Ludwig DS, 2001, J CLIN INVEST, V107, P379, DOI 10.1172/JCI10660; Monzon ME, 1999, PHYSIOL BEHAV, V67, P813, DOI 10.1016/S0031-9384(99)00117-1; NAHON JL, 1989, ENDOCRINOLOGY, V125, P2056, DOI 10.1210/endo-125-4-2056; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; PETTIJOHN TF, 1979, PSYCHOL REP, V44, P918, DOI 10.2466/pr0.1979.44.3.918; PETTIJOHN TF, 1979, DEV PSYCHOBIOL, V12, P73, DOI 10.1002/dev.420120109; PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; Sailer AW, 2001, P NATL ACAD SCI USA, V98, P7564, DOI 10.1073/pnas.121170598; Saito Y, 1999, NATURE, V400, P265, DOI 10.1038/22321; Shimada M, 1998, NATURE, V396, P670, DOI 10.1038/25341	25	411	451	3	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2002	8	8					825	830		10.1038/nm741	http://dx.doi.org/10.1038/nm741			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	579WJ	12118247	Bronze			2022-12-25	WOS:000177200900028
J	Jessen, JR; Topczewski, J; Bingham, S; Sepich, DS; Marlow, F; Chandrasekhar, A; Solnica-Krezel, L				Jessen, JR; Topczewski, J; Bingham, S; Sepich, DS; Marlow, F; Chandrasekhar, A; Solnica-Krezel, L			Zebrafish trilobite identifies new roles for Strabismus in gastrulation and neuronal movements	NATURE CELL BIOLOGY			English	Article							CONVERGENT EXTENSION; TISSUE POLARITY; DANIO-RERIO; LOOP-TAIL; GENE; DROSOPHILA; MORPHOGENESIS; GOGH	Embryonic morphogenesis is driven by a suite of cell behaviours, including coordinated shape changes, cellular rearrangements and individual cell migrations, whose molecular determinants are largely unknown. In the zebrafish, Dani rerio, trilobite mutant embryos have defects in gastrulation movements(1-4) and posterior migration of hindbrain neurons(5). Here, we have used positional cloning to demonstrate that trilobite mutations disrupt the transmembrane protein Strabismus (Stbm)/Van Gogh (Vang), previously associated with planar cell polarity (PCP) in Drosophila melanogaster(6,7), and PCP and canonical Wnt/beta-catenin signalling in vertebrates(8,9). Our genetic and molecular analyses argue that during gastrulation, trilobite interacts with the PCP pathway without affecting canonical Wnt signalling. Furthermore, trilobite may regulate neuronal migration independently of PCP molecules. We show that trilobite mediates polarization of distinct movement behaviours. During gastrulation convergence and extension movements, trilobite regulates mediolateral cell polarity underlying effective intercalation and directed dorsal migration at increasing velocities. In the hindbrain, trilobite controls effective migration of branchiomotor neurons towards posterior rhombomeres. Mosaic analyses show trilobite functions cell-autonomously and non-autonomously in gastrulae and the hindbrain. We propose Trilobite/Stbm mediates cellular interactions that confer directionality on distinct movements during vertebrate embryogenesis.	Vanderbilt Univ, Dept Sci Biol, VU Stn, Nashville, TN 37235 USA; Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA	Vanderbilt University; University of Missouri System; University of Missouri Columbia	Solnica-Krezel, L (corresponding author), Vanderbilt Univ, Dept Sci Biol, VU Stn, B 351634, Nashville, TN 37235 USA.		Topczewski, Jacek/D-5895-2016	Topczewski, Jacek/0000-0001-6023-9556	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR015682] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007751] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS040449, R01NS040449] Funding Source: NIH RePORTER; NCRR NIH HHS [1S10RR015682] Funding Source: Medline; NHLBI NIH HHS [T32 HL007751, T32HL07751] Funding Source: Medline; NIGMS NIH HHS [R01 GM055101, GM55101] Funding Source: Medline; NINDS NIH HHS [R01 NS040449-02, R01 NS040449, NS40449, R56 NS040449, R01 NS040449-01A1] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adler PN, 2001, CURR OPIN CELL BIOL, V13, P635, DOI 10.1016/S0955-0674(00)00263-5; Bingham S, 2002, DEV BIOL, V242, P149, DOI 10.1006/dbio.2001.0532; Chandrasekhar A, 1997, DEVELOPMENT, V124, P2633; Concha ML, 1998, DEVELOPMENT, V125, P983; Darken RS, 2002, EMBO J, V21, P976, DOI 10.1093/emboj/21.5.976; Driever W, 1996, DEVELOPMENT, V123, P37; Erter CE, 2001, DEVELOPMENT, V128, P3571; Haffter P, 1996, DEVELOPMENT, V123, P1; Hammerschmidt M, 1996, DEVELOPMENT, V123, P143; Heisenberg CP, 2000, NATURE, V405, P76, DOI 10.1038/35011068; Heisenberg CP, 2002, CURR BIOL, V12, pR126, DOI 10.1016/S0960-9822(02)00704-2; Heisenberg CP, 1997, DEV BIOL, V184, P85, DOI 10.1006/dbio.1997.8511; Higashijima S, 2000, J NEUROSCI, V20, P206, DOI 10.1523/JNEUROSCI.20-01-00206.2000; Kibar Z, 2001, NAT GENET, V28, P251, DOI 10.1038/90081; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Lekven AC, 2001, DEV CELL, V1, P103, DOI 10.1016/S1534-5807(01)00007-7; Marlow F, 1998, DEV BIOL, V203, P382, DOI 10.1006/dbio.1998.9032; Marlow F, 2002, CURR BIOL, V12, P876, DOI 10.1016/S0960-9822(02)00864-3; Moens CB, 1999, METHODS CELL BIOL, V59, P253; Murdoch JN, 2001, HUM MOL GENET, V10, P2593, DOI 10.1093/hmg/10.22.2593; Myers DC, 2002, DEV BIOL, V243, P81, DOI 10.1006/dbio.2001.0523; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; Park M, 2002, NAT CELL BIOL, V4, P467, DOI 10.1038/ncb803; Park M, 2002, NAT CELL BIOL, V4, P20, DOI 10.1038/ncb716; Peifer M, 2002, CELL, V109, P271, DOI 10.1016/S0092-8674(02)00739-0; Sepich DS, 2000, GENESIS, V27, P159, DOI 10.1002/1526-968X(200008)27:4<159::AID-GENE50>3.0.CO;2-T; Sokol SY, 1996, CURR BIOL, V6, P1456, DOI 10.1016/S0960-9822(96)00750-6; SolnicaKrezel L, 1996, DEVELOPMENT, V123, P67; Taylor J, 1998, GENETICS, V150, P199; Topczewski J, 2001, DEV CELL, V1, P251, DOI 10.1016/S1534-5807(01)00005-3; Tree DRP, 2002, CELL, V109, P371, DOI 10.1016/S0092-8674(02)00715-8; Trinkaus JP, 1998, J EXP ZOOL, V281, P328, DOI 10.1002/(SICI)1097-010X(19980701)281:4<328::AID-JEZ7>3.0.CO;2-Q; Wallingford JB, 2000, NATURE, V405, P81, DOI 10.1038/35011077; Westerfield M, 1995, ZEBRAFISH BOOK; Wilson SW, 2000, NEURON, V28, P641, DOI 10.1016/S0896-6273(00)00171-9; Wolff T, 1998, DEVELOPMENT, V125, P1149	36	381	386	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2002	4	8					610	615		10.1038/ncb828	http://dx.doi.org/10.1038/ncb828			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	579WK	12105418	Green Accepted			2022-12-25	WOS:000177201100017
J	Hartig, JS; Najafi-Shoushtari, SH; Grune, I; Yan, A; Ellington, AD; Famulok, M				Hartig, JS; Najafi-Shoushtari, SH; Grune, I; Yan, A; Ellington, AD; Famulok, M			Protein-dependent ribozymes report molecular interactions in real time	NATURE BIOTECHNOLOGY			English	Article							REV-BINDING-ELEMENT; RECOMBINANT HIRUDIN; HAIRPIN RIBOZYME; RNA; HIV-1; SELECTION; IDENTIFICATION; OPTIMIZATION; RECOGNITION; DESIGN	Most approaches to monitoring interactions between biological macromolecules require large amounts of material, rely upon the covalent modification of an interaction partner, or are not amenable to real-time detection. We have developed a generalizable assay system based on interactions between proteins and reporter ribozymes. The assay can be configured in a modular fashion to monitor the presence and concentration of a protein or of molecules that modulate protein function. We report two applications of the assay: screening for a small molecule that disrupts protein binding to its nucleic acid target and screening for protein-protein interactions. We screened a structurally diverse library of antibiotics for small molecules that modulate the activity of HIV-1 Rev-responsive ribozymes by binding to Rev. We identified an inhibitor that subsequently inhibited HIV-1 replication in cells. A simple format switch allowed reliable monitoring of domain-specific interactions between the blood-clotting factor thrombin and its protein partners. The rapid identification of interactions between proteins or of compounds that disrupt such interactions should have substantial utility for the drug-discovery process.	Univ Bonn, Kekule Inst Organ Chem & Biochem, D-53121 Bonn, Germany; Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA	University of Bonn; University of Texas System; University of Texas Austin	Famulok, M (corresponding author), Univ Bonn, Kekule Inst Organ Chem & Biochem, Gerhard Domagk Str 1, D-53121 Bonn, Germany.	m.famulok@uni-bonn.de		Najafi-Shoushtari, Hani/0000-0002-7562-4083	NIAID NIH HHS [AI-36083] Funding Source: Medline; NIGMS NIH HHS [GM-61789] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061789] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atsumi S, 2001, EMBO J, V20, P5453, DOI 10.1093/emboj/20.19.5453; Battiste JL, 1996, SCIENCE, V273, P1547, DOI 10.1126/science.273.5281.1547; BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; Bohan Cindy A., 1992, Gene Expression, V2, P391; Bramlage B, 1998, TRENDS BIOTECHNOL, V16, P434, DOI 10.1016/S0167-7799(98)01236-0; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CECH TR, 1993, RNA WORLD, P239; Cox JC, 2001, BIOORGAN MED CHEM, V9, P2525, DOI 10.1016/S0968-0896(01)00028-1; Doherty EA, 2000, ANNU REV BIOCHEM, V69, P597, DOI 10.1146/annurev.biochem.69.1.597; Esteban JA, 1997, J BIOL CHEM, V272, P13629, DOI 10.1074/jbc.272.21.13629; Famulok M, 2001, CHEM BIOL, V8, P931, DOI 10.1016/S1074-5521(01)00070-9; Geiger C, 2000, EMBO J, V19, P2525, DOI 10.1093/emboj/19.11.2525; GIVER L, 1993, NUCLEIC ACIDS RES, V21, P5509, DOI 10.1093/nar/21.23.5509; Gosser Y, 2001, NAT STRUCT BIOL, V8, P146, DOI 10.1038/84138; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; HERSCHLAG D, 1994, EMBO J, V13, P2913, DOI 10.1002/j.1460-2075.1994.tb06586.x; Hung LW, 2000, P NATL ACAD SCI USA, V97, P5107, DOI 10.1073/pnas.090588197; Ippolito JA, 2000, J MOL BIOL, V295, P711, DOI 10.1006/jmbi.1999.3405; Jayawickreme CK, 1997, CURR OPIN BIOTECH, V8, P629, DOI 10.1016/S0958-1669(97)80040-7; Jenne A, 1999, ANGEW CHEM INT EDIT, V38, P1300, DOI 10.1002/(SICI)1521-3773(19990503)38:9<1300::AID-ANIE1300>3.0.CO;2-Q; Jenne A, 2001, NAT BIOTECHNOL, V19, P56, DOI 10.1038/83513; Jose AM, 2001, NUCLEIC ACIDS RES, V29, P1631, DOI 10.1093/nar/29.7.1631; LONG DM, 1993, FASEB J, V7, P25, DOI 10.1096/fasebj.7.1.8422971; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; Mayer G, 2001, P NATL ACAD SCI USA, V98, P4961, DOI 10.1073/pnas.091100698; Mendelsohn AR, 1999, SCIENCE, V284, P1948, DOI 10.1126/science.284.5422.1948; NIEHRS C, 1990, J BIOL CHEM, V265, P9314; Nissen P, 2000, SCIENCE, V289, P920, DOI 10.1126/science.289.5481.920; Pandey A, 2000, NATURE, V405, P837, DOI 10.1038/35015709; Peterson RD, 1996, J MOL BIOL, V264, P863, DOI 10.1006/jmbi.1996.0683; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; Rademann J, 2000, SCIENCE, V287, P1947, DOI 10.1126/science.287.5460.1947; Rezaie AR, 2000, TRENDS CARDIOVAS MED, V10, P333, DOI 10.1016/S1050-1738(01)00070-6; Robertson MP, 2000, NUCLEIC ACIDS RES, V28, P1751, DOI 10.1093/nar/28.8.1751; Robertson MP, 2001, NAT BIOTECHNOL, V19, P650, DOI 10.1038/90256; Rossi JJ, 1999, CHEM BIOL, V6, pR33, DOI 10.1016/S1074-5521(99)80001-5; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; Soukup GA, 1999, P NATL ACAD SCI USA, V96, P3584, DOI 10.1073/pnas.96.7.3584; SULLENGER BA, 1995, CHEM BIOL, V2, P249, DOI 10.1016/1074-5521(95)90043-8; SULLENGER BA, 1994, NATURE, V371, P619, DOI 10.1038/371619a0; Thompson LA, 1996, CHEM REV, V96, P555, DOI 10.1021/cr9402081; Valadkhan S, 2001, NATURE, V413, P701, DOI 10.1038/35099500; Verma S, 1997, CURR OPIN CHEM BIOL, V1, P532, DOI 10.1016/S1367-5931(97)80049-X; Vitiello D, 2000, RNA, V6, P628, DOI 10.1017/S1355838200990964; Walter NG, 1998, CURR OPIN CHEM BIOL, V2, P24, DOI 10.1016/S1367-5931(98)80032-X; Warashina M, 2000, CURR OPIN BIOTECH, V11, P354, DOI 10.1016/S0958-1669(00)00110-5; Westhof E, 1999, CURR OPIN STRUC BIOL, V9, P293, DOI 10.1016/S0959-440X(99)80039-6	47	120	138	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2002	20	7					717	722		10.1038/nbt0702-717	http://dx.doi.org/10.1038/nbt0702-717			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	567QC	12089558				2022-12-25	WOS:000176494800027
J	Nagano, T; Yoneda, T; Hatanaka, Y; Kubota, C; Murakami, F; Sato, M				Nagano, T; Yoneda, T; Hatanaka, Y; Kubota, C; Murakami, F; Sato, M			Filamin A-interacting protein (FILIP) regulates cortical cell migration out of the ventricular zone	NATURE CELL BIOLOGY			English	Article							ACTIN-BINDING PROTEIN; PERIVENTRICULAR HETEROTOPIA; NEURONAL MIGRATION; VLDL RECEPTOR; NEOCORTEX; REELIN; DEPENDENCE; DISABLED-1; INTEGRIN; CLONING	Precisely regulated radial migration out of the ventricular zone is essential for corticogenesis. Here, we identify a mechanism that can tether ventricular zone cells in situ. FILIP interacts with Filamin A, an indispensable actin-binding protein that is required for cell motility, and induces its degradation in COS-7 cells. Degradation of Filamin A is identified in the cortical ventricular zone, where filip mRNA is localized. Furthermore, most ventricular zone cells that overexpress FILIP fail to migrate in explants. These results demonstrate that FILIP functions through a Filamin A-F-actin axis to control the start of neocortical cell migration from the ventricular zone.	Fukui Med Univ, Dept Anat 2, Fukui 9101193, Japan; Osaka City Univ, Sch Med, Dept Anat 1, Abeno Ku, Osaka 5458585, Japan; Natl Inst Basic Biol, Div Behav Neurobiol, Aichi 4448585, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan; Osaka Univ, Grad Sch Frontier Biosci, Neurosci Lab, Osaka 5608531, Japan	University of Fukui; Osaka Metropolitan University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Japan Science & Technology Agency (JST); Osaka University	Sato, M (corresponding author), Fukui Med Univ, Dept Anat 2, 23 Shimoaizuki, Fukui 9101193, Japan.			Murakami, Fujio/0000-0002-1519-5096				Anderson SA, 1997, SCIENCE, V278, P474, DOI 10.1126/science.278.5337.474; Bayer S.A., 1991, NEOCORTICAL DEV; BROTSCHI EA, 1978, J BIOL CHEM, V253, P8988; CUNNINGHAM CC, 1995, J CELL BIOL, V129, P1589, DOI 10.1083/jcb.129.6.1589; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; Dulabon L, 2000, NEURON, V27, P33, DOI 10.1016/S0896-6273(00)00007-6; Eksioglu YZ, 1996, NEURON, V16, P77, DOI 10.1016/S0896-6273(00)80025-2; Fox JW, 1998, NEURON, V21, P1315, DOI 10.1016/S0896-6273(00)80651-0; Glogauer M, 1998, J BIOL CHEM, V273, P1689, DOI 10.1074/jbc.273.3.1689; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; HATANAKA Y, IN PRESS J COMP NEUR; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; LUSKIN MB, 1985, J COMP NEUROL, V242, P611, DOI 10.1002/cne.902420409; MCCONNELL SK, 1991, SCIENCE, V254, P282, DOI 10.1126/science.1925583; Miyata T, 2001, NEURON, V31, P727, DOI 10.1016/S0896-6273(01)00420-2; Nadarajah B, 2001, NAT NEUROSCI, V4, P143, DOI 10.1038/83967; Nagano T, 2000, J NEUROCHEM, V75, P1, DOI 10.1046/j.1471-4159.2000.0750001.x; Noctor SC, 2001, NATURE, V409, P714, DOI 10.1038/35055553; Parent A., 1996, CARPENTERS HUMAN NEU, V9th. Edn; RAKIC P, 1972, J COMP NEUROL, V145, P61, DOI 10.1002/cne.901450105; Senzaki K, 1999, CELL, V99, P635, DOI 10.1016/S0092-8674(00)81552-4; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; Tomioka N, 2000, J NEUROSCI, V20, P5802, DOI 10.1523/JNEUROSCI.20-15-05802.2000; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Xie ZW, 1998, BIOCHEM BIOPH RES CO, V251, P914, DOI 10.1006/bbrc.1998.9506; Yoneda T, 1998, MOL BRAIN RES, V62, P187, DOI 10.1016/S0169-328X(98)00249-6	31	98	108	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	2002	4	7					495	501		10.1038/ncb808	http://dx.doi.org/10.1038/ncb808			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	568UL	12055638				2022-12-25	WOS:000176562900013
J	Nieuwenhuis, EES; Matsumoto, T; Exley, M; Schleipman, RA; Glickman, J; Bailey, DT; Corazza, N; Colgan, SP; Onderdonk, AB; Blumberg, RS				Nieuwenhuis, EES; Matsumoto, T; Exley, M; Schleipman, RA; Glickman, J; Bailey, DT; Corazza, N; Colgan, SP; Onderdonk, AB; Blumberg, RS			CD1d-dependent macrophage-mediated clearance of Pseudomonas aeruginosa from lung	NATURE MEDICINE			English	Article							KILLER T-CELLS; TUMOR-NECROSIS-FACTOR; ALPHA-GALACTOSYLCERAMIDE; HOST-DEFENSE; NKT CELLS; ALVEOLAR MACROPHAGES; TH1 RESPONSE; ACTIVATION; CD1D; EXPRESSION	CD1d-restricted T cells are implicated as key players in host defense against various microbial infections. However, the mechanisms involved and the role they play, if any, at the mucosal surfaces where pathogenic infections are initiated is unknown. In a murine pneumonia model established by intranasal application of Pseudomonas aeruginosa, CD1d(-/-) mice showed markedly reduced pulmonary eradication of P. aeruginosa compared with wild-type mice; this was associated with significantly lower amounts of macrophage inflammatory protein-2 and reduced numbers of neutrophils within the bronchoalveolar lavage fluid. Corollarily, treatment of mice with alpha-galactosylceramide-a lipid that activates CD1d-restricted T cells-increased the amount of interferon-gamma; this was associated with rapid pulmonary clearance through enhanced phagocytosis of P. aeruginosa by alveolar macrophages. These results reveal a crucial role played by CD1d-restricted T cells in regulating the antimicrobial immune functions of macrophages at the lung mucosal surface.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Gastroenterol, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Lab Mucosal Immunol, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol,Channing Lab, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Expt Therapeut & Reperfus Injury, Boston, MA 02115 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Canc Biol Program, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Blumberg, RS (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Gastroenterol, Boston, MA 02115 USA.		Colgan, Sean P./B-4573-2009	Exley, Mark/0000-0002-5088-1032	NIDCR NIH HHS [P01 DE 13499] Funding Source: Medline; NIDDK NIH HHS [DK51362, DK53056, DK44319] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE013499] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053056, R01DK051362, R37DK044319, R01DK044319] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chen GH, 2000, J IMMUNOL, V165, P6496, DOI 10.4049/jimmunol.165.11.6496; Cheung DOY, 2000, INFECT IMMUN, V68, P4585, DOI 10.1128/IAI.68.8.4585-4592.2000; Contursi C, 2000, P NATL ACAD SCI USA, V97, P91, DOI 10.1073/pnas.97.1.91; Exley MA, 2001, J LEUKOCYTE BIOL, V69, P713; Faunce DE, 2001, J IMMUNOL, V166, P313, DOI 10.4049/jimmunol.166.1.313; Gonzalez-Aseguinolaza G, 2000, P NATL ACAD SCI USA, V97, P8461, DOI 10.1073/pnas.97.15.8461; Hashimoto S, 1996, AM J PHYSIOL-LUNG C, V270, pL819, DOI 10.1152/ajplung.1996.270.5.L819; Kawakami K, 2001, J IMMUNOL, V167, P6525, DOI 10.4049/jimmunol.167.11.6525; Kawakami K, 2001, INFECT IMMUN, V69, P213, DOI 10.1128/IAI.69.1.213-220.2001; KINDLER V, 1989, CELL, V56, P731, DOI 10.1016/0092-8674(89)90676-4; Kooguchi K, 1998, INFECT IMMUN, V66, P3164, DOI 10.1128/IAI.66.7.3164-3169.1998; Kumar H, 2000, J IMMUNOL, V165, P4797, DOI 10.4049/jimmunol.165.9.4797; MUNOZFERNANDEZ MA, 1992, EUR J IMMUNOL, V22, P301, DOI 10.1002/eji.1830220203; Naidenko OV, 1999, J EXP MED, V190, P1069, DOI 10.1084/jem.190.8.1069; PAULNOCK DM, 1992, CURR OPIN IMMUNOL, V4, P344, DOI 10.1016/0952-7915(92)90087-U; Porcelli SA, 1999, ANNU REV IMMUNOL, V17, P297, DOI 10.1146/annurev.immunol.17.1.297; Roark JH, 1998, J IMMUNOL, V160, P3121; Saubermann LJ, 2000, GASTROENTEROLOGY, V119, P119, DOI 10.1053/gast.2000.9114; Schroeder TH, 2001, J IMMUNOL, V166, P7410, DOI 10.4049/jimmunol.166.12.7410; Smiley ST, 1997, SCIENCE, V275, P977, DOI 10.1126/science.275.5302.977; Sonoda KH, 1999, J EXP MED, V190, P1215, DOI 10.1084/jem.190.9.1215; Spada FM, 2000, EUR J IMMUNOL, V30, P3468, DOI 10.1002/1521-4141(2000012)30:12<3468::AID-IMMU3468>3.0.CO;2-C; SPEERT DP, 1992, J CLIN INVEST, V90, P1085, DOI 10.1172/JCI115924; STOUT RD, 1989, J IMMUNOL, V142, P760; Tsai WC, 2000, INFECT IMMUN, V68, P4289, DOI 10.1128/IAI.68.7.4289-4296.2000; Vernacchio L, 2000, J INFECT DIS, V181, P1162, DOI 10.1086/315307; Wilson SB, 2001, CURR OPIN IMMUNOL, V13, P555, DOI 10.1016/S0952-7915(00)00258-2	27	249	278	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	JUN	2002	8	6					588	593		10.1038/nm0602-588	http://dx.doi.org/10.1038/nm0602-588			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	557KG	12042809				2022-12-25	WOS:000175907300029
J	Guelzim, N; Bottani, S; Bourgine, P; Kepes, F				Guelzim, N; Bottani, S; Bourgine, P; Kepes, F			Topological and causal structure of the yeast transcriptional regulatory network	NATURE GENETICS			English	Article							SMALL-WORLD; BINDING	Interpretation of high-throughput biological data requires a knowledge of the design principles underlying the networks that sustain cellular functions. Of particular importance is the genetic network, a set of genes that interact through directed transcriptional regulation. Genes that exert a regulatory role encode dedicated transcription factors (hereafter referred to as regulating proteins) that can bind to specific DNA control regions of regulated genes to activate or inhibit their transcription. Regulated genes may themselves act in a regulatory manner, in which case they participate in a causal pathway. Looping pathways form feedback circuits. Because a gene can have several connections, circuits and pathways may crosslink and thus represent connected components. We have created a graph of 909 genetically or biochemically established interactions among 491 yeast genes. The number of regulating proteins per regulated gene has a narrow distribution with an exponential decay. The number of regulated genes per regulating protein has a broader distribution with a decay resembling a power law. Assuming in computer-generated graphs that gene connections fulfill these distributions but are otherwise random, the local clustering of connections and the number of short feedback circuits are largely underestimated. This deviation from randomness probably reflects functional constraints that include biosynthetic cost, response delay and differentiative and homeostatic regulation.	ATelier Genom Cognit, CNRS, ESA 8071, Genopole, F-91000 Evry, France; Ecole Polytech, Ctr Rech Epistemol Appl, F-75230 Paris, France; Univ Paris 07, UFR Phys, Grp Modelisat Phys Interfaces Biol, Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Kepes, F (corresponding author), ATelier Genom Cognit, CNRS, ESA 8071, Genopole, 523 Terrasses Agora, F-91000 Evry, France.	Francois.Kepes@genopole.cnrs.fr						Albert R, 2000, NATURE, V406, P378, DOI 10.1038/35019019; Becskei A, 2000, NATURE, V405, P590, DOI 10.1038/35014651; Carlson M, 1999, CURR OPIN MICROBIOL, V2, P202, DOI 10.1016/S1369-5274(99)80035-6; dAri R., 1990, BIOL FEEDBACK; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Erdos P, 1959, PUBL MATH-DEBRECEN, V6, P290, DOI DOI 10.2307/1999405; Fell DA, 2000, NAT BIOTECHNOL, V18, P1121, DOI 10.1038/81025; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Huang MX, 1998, CELL, V94, P595, DOI 10.1016/S0092-8674(00)81601-3; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; Jeong H, 2000, NATURE, V407, P651, DOI 10.1038/35036627; Karp PD, 2001, SCIENCE, V293, P2040, DOI 10.1126/science.1064621; Lieb JD, 2001, NAT GENET, V28, P327, DOI 10.1038/ng569; Lorenz MC, 1998, EMBO J, V17, P1236, DOI 10.1093/emboj/17.5.1236; RAINE DJ, 2000, INTERJOURNAL COMPLEX; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Rogers B, 2001, J MOL MICROB BIOTECH, V3, P207; Simon I, 2001, CELL, V106, P697, DOI 10.1016/S0092-8674(01)00494-9; Svetlov VV, 1995, YEAST, V11, P1439, DOI 10.1002/yea.320111502; Thieffry D, 1998, BIOESSAYS, V20, P433, DOI 10.1002/(SICI)1521-1878(199805)20:5<433::AID-BIES10>3.0.CO;2-2; Vershon AK, 2000, CURR OPIN CELL BIOL, V12, P334, DOI 10.1016/S0955-0674(00)00104-6; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; Zhang L, 1999, CELL MOL LIFE SCI, V56, P415, DOI 10.1007/s000180050442	23	428	441	2	34	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2002	31	1					60	63		10.1038/ng873	http://dx.doi.org/10.1038/ng873			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	547ZF	11967534	Bronze			2022-12-25	WOS:000175362500015
J	Lock, C; Hermans, G; Pedotti, R; Brendolan, A; Schadt, E; Garren, H; Langer-Gould, A; Strober, S; Cannella, B; Allard, J; Klonowski, P; Austin, A; Lad, N; Kaminski, N; Galli, SJ; Oksenberg, JR; Raine, CS; Heller, R; Steinman, L				Lock, C; Hermans, G; Pedotti, R; Brendolan, A; Schadt, E; Garren, H; Langer-Gould, A; Strober, S; Cannella, B; Allard, J; Klonowski, P; Austin, A; Lad, N; Kaminski, N; Galli, SJ; Oksenberg, JR; Raine, CS; Heller, R; Steinman, L			Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis	NATURE MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; TUMOR-NECROSIS-FACTOR; MYELIN BASIC-PROTEIN; B-CELL; MOLECULAR-CLONING; EXPRESSION; FAMILY; CSF; AUTOANTIBODIES; IDENTIFICATION	Microarray analysis of multiple sclerosis (MS) lesions obtained at autopsy revealed increased transcripts of genes encoding inflammatory cytokines, particularly interleukin-6 and -17, interferon-gamma and associated downstream pathways. Comparison of two poles of MS pathologyacute lesions with inflammation versus 'silent' lesions without inflammation-revealed differentially transcribed genes. Some products of these genes were chosen as targets for therapy of experimental autoimmune encephalomyelitis (EAE) in mice. Granulocyte colony-stimulating factor is upregulated in acute, but not in chronic, MS lesions, and the effect on ameliorating EAE is more pronounced in the acute phase, in contrast to knocking out the immunoglobulin Fc receptor common gamma chain where the effect is greatest on chronic disease. These results in EAE corroborate the microarray studies on MS lesions. Large-scale analysis of transcripts in MS lesions elucidates new aspects of pathology and opens possibilities for therapy.	Roche Biosci, Palo Alto, CA 94304 USA; Albert Einstein Coll Med, Dept Pathol Neuropathol & Neurol, Bronx, NY 10467 USA; Univ Calif San Francisco, Sch Med, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Lung Biol Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Inst Cardiovasc Res, San Francisco, CA 94143 USA; Stanford Univ, Dept Neurol & Neurosci, Beckman Ctr, Stanford, CA 94305 USA; Stanford Univ, Dept Med, Stanford, CA 94305 USA; Stanford Univ, Dept Pathol, Stanford, CA 94305 USA; Rosetta Inpharmat, Informat, Kirkland, WA USA	Roche Holding; Yeshiva University; Albert Einstein College of Medicine; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Stanford University; Stanford University; Stanford University; Merck & Company	Heller, R (corresponding author), Roche Biosci, Palo Alto, CA 94304 USA.	rheller@stanford.edu; steinman@stanford.edu		Steinman, Lawrence/0000-0002-2437-2250; Brendolan, Andrea/0000-0003-0109-6879; Kaminski, Naftali/0000-0001-5917-4601; Lock, Christopher/0000-0002-4087-5894; Hermans, Guy/0000-0001-7767-6912	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R15AI035761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS011920, P01NS011920] Funding Source: NIH RePORTER; NIAID NIH HHS [AI35761] Funding Source: Medline; NINDS NIH HHS [NS11920, NS08953] Funding Source: Medline; PHS HHS [18235, 41402, 28579, 30201] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ACHIRON A, 1994, J CLIN INVEST, V93, P600, DOI 10.1172/JCI117012; Akassoglou K, 1997, J IMMUNOL, V158, P438; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; DABIRI GA, 1992, J BIOL CHEM, V267, P16545; Davoust N, 1999, J IMMUNOL, V163, P6551; Ebers GC, 1996, NAT GENET, V13, P472, DOI 10.1038/ng0896-472; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Genain CP, 1999, NAT MED, V5, P170, DOI 10.1038/5532; GIJBELS K, 1995, MOL MED, V1, P795, DOI 10.1007/BF03401894; Haines JL, 1996, NAT GENET, V13, P469, DOI 10.1038/ng0896-469; HAUSER SL, 1990, NEUROLOGY, V40, P1735, DOI 10.1212/WNL.40.11.1735; HONG JX, 1993, J IMMUNOL, V150, P3895; JACOBS CA, 1991, J IMMUNOL, V146, P2983; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Lucchinetti C, 2000, ANN NEUROL, V47, P707, DOI 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; Matarese G, 2001, J IMMUNOL, V166, P5909, DOI 10.4049/jimmunol.166.10.5909; Matusevicius D, 1999, MULT SCLER J, V5, P101, DOI 10.1177/135245859900500206; Miyajima I, 1997, J CLIN INVEST, V99, P901, DOI 10.1172/JCI119255; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; Pedotti R, 2001, NAT IMMUNOL, V2, P216, DOI 10.1038/85266; Penkowa M, 2001, J NEUROIMMUNOL, V119, P248, DOI 10.1016/S0165-5728(01)00357-5; Pitt D, 2000, NAT MED, V6, P67, DOI 10.1038/71555; Poliak S, 1997, J IMMUNOL, V158, P5751; Raine CS, 1998, REV NEUROL-FRANCE, V154, P577; Raine CS, 1997, MULTIPLE SCLEROSIS C, P151; Rehli M, 1997, GENOMICS, V43, P221, DOI 10.1006/geno.1997.4778; Samuelsson A, 2001, SCIENCE, V291, P484, DOI 10.1126/science.291.5503.484; Sawcer S, 1996, NAT GENET, V13, P464, DOI 10.1038/ng0896-464; Schadt EE, 2001, J CELL BIOCHEM, V84, P120, DOI 10.1002/jcb.10073; Schadt EE, 2000, J CELL BIOCHEM, V80, P192; Steinman L, 1999, NEURON, V24, P511, DOI 10.1016/S0896-6273(00)81107-1; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; WALSH LA, 1992, TISSUE ANTIGENS, V40, P213, DOI 10.1111/j.1399-0039.1992.tb02048.x; Waring JF, 2001, TOXICOL APPL PHARM, V175, P28, DOI 10.1006/taap.2001.9243; WARREN KG, 1995, P NATL ACAD SCI USA, V92, P11061, DOI 10.1073/pnas.92.24.11061; Whitney LW, 1999, ANN NEUROL, V46, P425; WRAITH DC, 1989, CELL, V59, P247, DOI 10.1016/0092-8674(89)90287-0; Wucherpfennig KW, 1997, J CLIN INVEST, V100, P1114, DOI 10.1172/JCI119622; YAN YM, 1993, NEURON, V11, P423, DOI 10.1016/0896-6273(93)90147-J; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0; Zavala F, 2002, J IMMUNOL, V168, P2011, DOI 10.4049/jimmunol.168.4.2011	43	1302	1381	1	53	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2002	8	5					500	508		10.1038/nm0502-500	http://dx.doi.org/10.1038/nm0502-500			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	547ZW	11984595				2022-12-25	WOS:000175336800036
J	Sehnert, AJ; Huq, A; Weinstein, BM; Walker, C; Fishman, M; Stainier, DYR				Sehnert, AJ; Huq, A; Weinstein, BM; Walker, C; Fishman, M; Stainier, DYR			Cardiac troponin T is essential in sarcomere assembly and cardiac contractility	NATURE GENETICS			English	Article							FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; SUDDEN-DEATH; CARDIOVASCULAR-SYSTEM; MUTATIONS; ZEBRAFISH; TROPOMYOSIN; DISEASE; CHAIN; GENES	Mutations of the gene (TNNT2) encoding the thin-filament contractile protein cardiac troponin T are responsible for 15% of all cases of familial hypertrophic cardiomyopathy, the leading cause of sudden death in young athletes(1,2). Mutant proteins are thought to act through a dominant-negative mode that impairs function of heart muscle(3). TNNT2 mutations can also lead to dilated cardiomyopathy, a leading cause of heart failure(4). Despite the importance of cardiac troponin T in human disease, its loss-of-function phenotype has not been described. We show that the zebrafish silent heart (sih) mutation affects the gene tnnt2. We characterize two mutated alleles of sih that severely reduce tnnt2 expression: one affects mRNA splicing, and the other affects gene transcription. Tnnt2, together with alpha-tropomyosin (Tpma) and cardiac troponins C and I (Tnni3), forms a calcium-sensitive regulatory complex within sarcomeres(5). Unexpectedly, in addition to loss of Tnnt2 expression in sih mutant hearts, we observed a significant reduction in Tpma and Tnni3, and consequently, severe sarcomere defects. This interdependence of thin-filament protein expression led us to postulate that some mutations in tnnt2 may trigger misregulation of thin-filament protein expression, resulting in sarcomere loss and myocyte disarray, the life-threatening hallmarks of TNNT2 mutations in mice and humans(6,7).	Univ Calif San Francisco, Dept Biochem & Biophys, Program Dev Biol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, Genet Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, Program Human Genet, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; NICHHD, Mol Genet Lab, NIH, Bethesda, MD 20892 USA; Univ Oregon, Inst Neurosci, Eugene, OR 97403 USA; Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Oregon; Harvard University; Massachusetts General Hospital	Stainier, DYR (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, Program Dev Biol, 513 Parnassus Ave,Box 0448, San Francisco, CA 94143 USA.			Stainier, Didier/0000-0002-0382-0026				Alexander J, 1998, DEV GENET, V22, P288, DOI 10.1002/(SICI)1520-6408(1998)22:3<288::AID-DVG10>3.3.CO;2-T; Amemiya CT, 1999, METHOD CELL BIOL, V60, P235; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BURGGREN WW, 1991, ANNU REV PHYSIOL, V53, P107, DOI 10.1146/annurev.physiol.53.1.107; Chen JN, 1996, DEVELOPMENT, V123, P293; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; FYRBERG E, 1990, J MOL BIOL, V216, P657, DOI 10.1016/0022-2836(90)90390-8; Kamisago M, 2000, NEW ENGL J MED, V343, P1688, DOI 10.1056/NEJM200012073432304; LIN JJC, 1985, HYBRIDOMA, V4, P223, DOI 10.1089/hyb.1985.4.223; MALOUF NN, 1992, J BIOL CHEM, V267, P9269; Maquat LE, 2001, CELL, V104, P173, DOI 10.1016/S0092-8674(01)00202-1; Maron BJ, 1996, JAMA-J AM MED ASSOC, V276, P199, DOI 10.1001/jama.276.3.199; Moolman JC, 1997, J AM COLL CARDIOL, V29, P549, DOI 10.1016/S0735-1097(96)00530-X; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; O'Neil JP, 1998, MUTAT RES-REV MUTAT, V411, P179, DOI 10.1016/S1383-5742(98)00013-1; OHARA O, 1989, P NATL ACAD SCI USA, V86, P5673, DOI 10.1073/pnas.86.15.5673; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; Stainier DYR, 1996, DEVELOPMENT, V123, P285; Tardiff JC, 1999, J CLIN INVEST, V104, P469, DOI 10.1172/JCI6067; Tardiff JC, 1998, J CLIN INVEST, V101, P2800, DOI 10.1172/JCI2389; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; Varnava AM, 2001, CIRCULATION, V104, P1380, DOI 10.1161/hc3701.095952; Westerfield M, 1995, ZEBRAFISH BOOK; Yelon D, 1999, DEV BIOL, V214, P23, DOI 10.1006/dbio.1999.9406	25	450	460	1	41	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2002	31	1					106	110		10.1038/ng875	http://dx.doi.org/10.1038/ng875			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	547ZF	11967535				2022-12-25	WOS:000175362500024
J	Crute, JJ; Grygon, CA; Hargrave, KD; Simoneau, B; Faucher, AM; Bolger, G; Kibler, P; Liuzzi, M; Cordingley, MG				Crute, JJ; Grygon, CA; Hargrave, KD; Simoneau, B; Faucher, AM; Bolger, G; Kibler, P; Liuzzi, M; Cordingley, MG			Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease	NATURE MEDICINE			English	Article							RIBONUCLEOTIDE REDUCTASE INHIBITOR; ANTIVIRAL ACTIVITY; ORAL ACYCLOVIR; IN-VIVO; TYPE-1; INFECTIONS; REPLICATION; DNA; VALACICLOVIR; RESISTANCE	Herpes simplex virus infections are the cause of significant morbidity, and currently used therapeutics are largely based on modified nucleoside analogs that inhibit viral DNA polymerase function. To target this disease in a new way, we have identified and optimized selective thiazolylphenyl-containing inhibitors of the herpes simplex virus (HSV) helicase-primase enzyme. The most potent compounds inhibited the helicase, the primase and the DNA-dependent ATPase activities of the enzyme with IC50 (50% inhibitory concentration) values less than 100 nM. Inhibition of the enzymatic activities was through stabilization of the interaction between the helicase-primase and DNA substrates, preventing the progression through helicase or primase catalytic cycles. Helicase-primase inhibitors also prevented viral replication as demonstrated in viral growth assays. One compound, BILS 179 BS, displayed an EC50 (effective concentration inhibiting viral growth by 50%) of 27 nM against viral growth with a selectivity index greater than 2,000. Antiviral activity was also demonstrated for multiple strains of HSV, including strains resistant to nucleoside-based therapies. Most importantly, BILS 179 BS was orally active against HSV infections in murine models of HSV-1 and HSV-2 disease and more effective than acyclovir when the treatment frequency per day was reduced or when initiation of treatment was delayed up to 65 hours after infection. These studies validate the use of helicase-primase inhibitors for the treatment of acute herpesvirus infections and provide new lead compounds for optimization and design of superior anti-HSV agents.	Boehringer Ingelheim Pharmaceut Inc, Ctr Res & Dev, Ridgefield, CT 06877 USA; Boehringer Ingelheim Canada Ltd, Res & Dev, Laval, PQ, Canada	Boehringer Ingelheim; Boehringer Ingelheim	Crute, JJ (corresponding author), Boehringer Ingelheim Pharmaceut Inc, Ctr Res & Dev, 90 E Ridge POB 368, Ridgefield, CT 06877 USA.							Bolger GT, 1997, ANTIVIR RES, V35, P157, DOI 10.1016/S0166-3542(97)00024-7; Challberg M., 1996, DNA REPLICATION EUKA, P721; CHATIS PA, 1992, ANTIMICROB AGENTS CH, V36, P1589, DOI 10.1128/AAC.36.8.1589; CRUTE JJ, 1991, J BIOL CHEM, V266, P4484; CRUTE JJ, 1988, NUCLEIC ACIDS RES, V16, P6585, DOI 10.1093/nar/16.14.6585; DODSON MS, 1989, J BIOL CHEM, V264, P20835; DRACHEVA S, 1995, J BIOL CHEM, V270, P14148, DOI 10.1074/jbc.270.23.14148; Duan JM, 1998, ANTIMICROB AGENTS CH, V42, P1629, DOI 10.1128/AAC.42.7.1629; ERLICH KS, 1989, NEW ENGL J MED, V320, P293, DOI 10.1056/NEJM198902023200506; KERN ER, 1982, AM J MED, V73, P100, DOI 10.1016/0002-9343(82)90073-0; KIMBERLIN DW, 1995, ANTIVIR RES, V26, P423, DOI 10.1016/0166-3542(95)00031-G; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE, P145; LANGELIER Y, 1978, J VIROL, V26, P547, DOI 10.1128/JVI.26.3.547-553.1978; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Lawetz C, 1998, ANTIVIR RES, V39, P35, DOI 10.1016/S0166-3542(98)00028-X; Lehman IR, 1999, J BIOL CHEM, V274, P28059, DOI 10.1074/jbc.274.40.28059; LIUZZI M, 1994, NATURE, V372, P695, DOI 10.1038/372695a0; MATTHEWS JT, 1993, ANTIVIR RES, V20, P89, DOI 10.1016/0166-3542(93)90001-Y; MORAHAN PS, 1977, J IMMUNOL, V119, P2030; Perry CM, 1996, DRUGS, V52, P754, DOI 10.2165/00003495-199652050-00009; REARDON J E, 1991, P1; REICHMAN RC, 1984, JAMA-J AM MED ASSOC, V251, P2103, DOI 10.1001/jama.251.16.2103; Selway CN, 1996, BIOORGAN MED CHEM, V4, P645, DOI 10.1016/0968-0896(96)00058-2; Shin YK, 2001, J CLIN MICROBIOL, V39, P913, DOI 10.1128/JCM.39.3.913-917.2001; Spector FC, 1998, J VIROL, V72, P6979, DOI 10.1128/JVI.72.9.6979-6987.1998; SPRUANCE SL, 1990, J INFECT DIS, V161, P185, DOI 10.1093/infdis/161.2.185; TENNEY DJ, 1995, J BIOL CHEM, V270, P9129, DOI 10.1074/jbc.270.16.9129; Thackray AM, 1996, J INFECT DIS, V173, P291, DOI 10.1093/infdis/173.2.291; Vere Hodge R. A., 1993, Antiviral Chemistry and Chemotherapy, V4, P67; WHITLEY RJ, 1995, FIELDS VIROLOGY, P2297; ZHU LA, 1992, J VIROL, V66, P1458	31	180	200	2	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	APR	2002	8	4					386	391		10.1038/nm0402-386	http://dx.doi.org/10.1038/nm0402-386			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	536ML	11927945				2022-12-25	WOS:000174704800031
J	Klein, CA; Seidl, S; Petat-Dutter, K; Offner, S; Geigl, JB; Schmidt-Kittler, O; Wendler, N; Passlick, B; Huber, RM; Schlimok, G; Baeuerle, PA; Riethmuller, G				Klein, CA; Seidl, S; Petat-Dutter, K; Offner, S; Geigl, JB; Schmidt-Kittler, O; Wendler, N; Passlick, B; Huber, RM; Schlimok, G; Baeuerle, PA; Riethmuller, G			Combined transcriptome and genome analysis of single micrometastatic cells	NATURE BIOTECHNOLOGY			English	Article							CDNA LIBRARIES; BONE-MARROW; TUMOR-CELLS; PROGNOSTIC-SIGNIFICANCE; MONOCLONAL-ANTIBODIES; ACTIN CYTOSKELETON; GENE-EXPRESSION; MAMMALIAN-CELLS; KAPPA-B; CANCER	In human cancer, early systemic spread of tumor cells is recognized as a leading cause of death. Adjuvant therapies are administered to patients after complete resectioning of their primary tumors to eradicate the few residual and latent metastatic cells. These therapeutic regimens, however, are currently designed without direct information about the presence or nature of the latent cells. To address this problem, we developed a PCR-based technique to analyze the transcriptome of individual tumor cells isolated from the bone marrow of cancer patients. From the same cells, genomic aberrations were identified by comparative genomic hybridization. The utility of this approach for understanding the biology of occult disseminated cells and for the identification of new therapeutic targets is demonstrated here by the detection of frequent extracellular matrix metalloproteinase inducer (EMMPRIN; CD147) expression which was verified by immunostaining.	Univ Munich, Klinikum Innenstadt, Inst Immunol, D-80336 Munich, Germany; Univ Munich, Klinikum Innenstadt, Chirurg Klin, D-80336 Munich, Germany; Univ Munich, Klinikum Innenstadt, Med Klin, D-80336 Munich, Germany; Zent Klinikum, Med Klin 2, D-86156 Augsburg, Germany; Micromet AG, D-82152 Martinsried, Germany	University of Munich; University of Munich; University of Munich; University of Hamburg; University Medical Center Hamburg-Eppendorf; Amgen; Amgen Research Munich GmbH; Micromet AG	Klein, CA (corresponding author), Univ Munich, Klinikum Innenstadt, Inst Immunol, D-80336 Munich, Germany.	christoph.klein@ifi.med.uni-muenchen.de	Huber, Rudolf M./L-2464-2019	Huber, Rudolf M./0000-0001-7041-6368; Klein, Christoph A./0000-0001-7128-1725				*AFF, 2000, GEN EUK SMALL SAMPL; Alberts B., 1994, MOL BIOL CELL; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BARNES DE, 1992, CELL, V69, P495, DOI 10.1016/0092-8674(92)90450-Q; BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; BISWAS C, 1995, CANCER RES, V55, P434; BRADY G, 1993, METHOD ENZYMOL, V225, P611; Brail LH, 1999, MUTAT RES-GENOMICS, V406, P45, DOI 10.1016/S1383-5726(98)00009-0; Braun S, 2000, NEW ENGL J MED, V342, P525, DOI 10.1056/NEJM200002243420801; Braun S, 2001, CANCER RES, V61, P1890; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; Gomez-Marquez J, 1998, BIOCHEM J, V333, P1; GOTTLINGER HG, 1986, INT J CANCER, V38, P47; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; KARRER EE, 1995, P NATL ACAD SCI USA, V92, P3814, DOI 10.1073/pnas.92.9.3814; Klein CA, 2000, TRENDS CELL BIOL, V10, P489, DOI 10.1016/S0962-8924(00)01846-8; Klein CA, 1999, P NATL ACAD SCI USA, V96, P4494, DOI 10.1073/pnas.96.8.4494; Koch C, 1999, INT IMMUNOL, V11, P777, DOI 10.1093/intimm/11.5.777; Kufer P, 2002, CANCER RES, V62, P251; Lee SE, 1997, MOL CELL BIOL, V17, P1425, DOI 10.1128/MCB.17.3.1425; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LINDEMANN F, 1992, LANCET, V340, P685, DOI 10.1016/0140-6736(92)92230-D; Lu KP, 1996, NATURE, V380, P544; Luo L, 1999, NAT MED, V5, P117, DOI 10.1038/4806; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Mahadevappa M, 1999, NAT BIOTECHNOL, V17, P1134, DOI 10.1038/15124; Muhua L, 1998, NATURE, V393, P487, DOI 10.1038/31014; Nelson T, 1979, Methods Enzymol, V68, P41; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Pantel K, 1999, JNCI-J NATL CANCER I, V91, P1113, DOI 10.1093/jnci/91.13.1113; Pantel K, 1996, LANCET, V347, P649, DOI 10.1016/S0140-6736(96)91203-9; Polette M, 1997, J HISTOCHEM CYTOCHEM, V45, P703, DOI 10.1177/002215549704500508; SCHLIMOK G, 1987, P NATL ACAD SCI USA, V84, P8672, DOI 10.1073/pnas.84.23.8672; Serrano A, 1999, INT J CANCER, V83, P664; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324; ZIEGLERHEITBROCK HWL, 1994, J BIOL CHEM, V269, P17001	40	235	251	3	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2002	20	4					387	392		10.1038/nbt0402-387	http://dx.doi.org/10.1038/nbt0402-387			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	536BY	11923846				2022-12-25	WOS:000174681900027
J	Kurotaki, N; Imaizumi, K; Harada, N; Masuno, M; Kondoh, T; Nagai, T; Ohashi, H; Naritomi, K; Tsukahara, M; Makita, Y; Sugimoto, T; Sonoda, T; Hasegawa, T; Chinen, Y; Tomita, H; Kinoshita, A; Mizuguchi, T; Yoshiura, K; Ohta, T; Kishino, T; Fukushima, Y; Niikawa, N; Matsumoto, N				Kurotaki, N; Imaizumi, K; Harada, N; Masuno, M; Kondoh, T; Nagai, T; Ohashi, H; Naritomi, K; Tsukahara, M; Makita, Y; Sugimoto, T; Sonoda, T; Hasegawa, T; Chinen, Y; Tomita, H; Kinoshita, A; Mizuguchi, T; Yoshiura, K; Ohta, T; Kishino, T; Fukushima, Y; Niikawa, N; Matsumoto, N			Haploinsufficiency of NSD1 causes Sotos syndrome	NATURE GENETICS			English	Article							CEREBRAL GIGANTISM; CHROMATIN; DOMAINS; PROTEIN	We isolated NSD1 from the 5q35 breakpoint in an individual with Sotos syndrome harboring a chromosomal translocation. We identified 1 nonsense, 3 frameshift and 20 submicroscopic deletion mutations of NSD1 among 42 individuals with sporadic cases of Sotos syndrome. The results indicate that haploinsufficiency of NSD1 is the major cause of Sotos syndrome.	Nagasaki Univ, Sch Med, Dept Human Genet, Nagasaki 852, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Japan; Kanagawa Childrens Med Ctr, Div Med Genet, Yokohama, Kanagawa, Japan; Kyushu Med Sci Nagasaki Lab, Nagasaki, Japan; Nagasaki Univ, Sch Med, Dept Pediat, Nagasaki 852, Japan; Dokkyo Univ, Sch Med, Koshigaya Hosp, Dept Pediat, Koshigaya, Japan; Saitama Childrens Med Ctr, Div Med Genet, Kawagoe, Saitama, Japan; Univ Ryukyus, Sch Med, Dept Med Genet, Okinawa, Japan; Yamaguchi Univ, Sch Med, Fac Hlth Sci, Ube, Yamaguchi 755, Japan; Asahikawa Med Coll, Dept Publ Hlth, Asahikawa, Hokkaido 078, Japan; Kansai Med Univ, Otokoyama Hosp, Dept Pediat, Yawata, Japan; Miyazaki Med Coll, Dept Pediat, Miyazaki 88916, Japan; Shizuoka Childrens Med Ctr, Div Clin Genet & Cytogenet, Shizuoka, Japan; Univ Ryukyus, Sch Med, Dept Pediat, Okinawa, Japan; Nagasaki Univ, Ctr Gene Res, Nagasaki 852, Japan; Shinshu Univ, Sch Med, Dept Hyg & Med Genet, Matsumoto, Nagano 390, Japan	Nagasaki University; Japan Science & Technology Agency (JST); Nagasaki University; Dokkyo Medical University; Saitama Children's Medical Center; University of the Ryukyus; Yamaguchi University; Asahikawa Medical College; Kansai Medical University; University of Miyazaki; University of the Ryukyus; Nagasaki University; Shinshu University	Matsumoto, N (corresponding author), Nagasaki Univ, Sch Med, Dept Human Genet, Nagasaki 852, Japan.			Tomita, Hiroaki/0000-0003-2628-880X				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; BALE AE, 1985, AM J MED GENET, V20, P613, DOI 10.1002/ajmg.1320200407; BOMAN H, 1980, CLIN GENET, V18, P421; Huang NW, 1998, EMBO J, V17, P3398, DOI 10.1093/emboj/17.12.3398; Imaizumi K, 2002, AM J MED GENET, V107, P58, DOI 10.1002/ajmg.10080; Jenuwein T, 1998, CELL MOL LIFE SCI, V54, P80, DOI 10.1007/s000180050127; Kurotaki N, 2001, GENE, V279, P197, DOI 10.1016/S0378-1119(01)00750-8; Opitz JM, 1998, AM J MED GENET, V79, P294, DOI 10.1002/(SICI)1096-8628(19981002)79:4<294::AID-AJMG12>3.0.CO;2-M; Stec I, 2000, FEBS LETT, V473, P1, DOI 10.1016/S0014-5793(00)01449-6; TOWNES PL, 1976, J MED GENET, V13, P80, DOI 10.1136/jmg.13.1.80	10	410	425	1	19	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	APR	2002	30	4					365	366		10.1038/ng863	http://dx.doi.org/10.1038/ng863			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	536BZ	11896389				2022-12-25	WOS:000174682000012
J	Houseman, BT; Huh, JH; Kron, SJ; Mrksich, M				Houseman, BT; Huh, JH; Kron, SJ; Mrksich, M			Peptide chips for the quantitative evaluation of protein kinase activity	NATURE BIOTECHNOLOGY			English	Article							SURFACE-PLASMON RESONANCE; SELF-ASSEMBLED MONOLAYERS; TYROSINE KINASE; SOLID-PHASE; OLIGO(ETHYLENE GLYCOL); SUBSTRATE-SPECIFICITY; GENE-EXPRESSION; MICROARRAYS; INHIBITORS; CELL	Peptide chips are an emerging technology that could replace many of the bioanalytical methods currently used in drug discovery, diagnostics, and cell biology. Despite the promise of these chips, their development for quantitative assays has been limited by several factors, including a lack of well-defined surface chemistries to immobilize peptides, the heterogeneous presentation of immobilized ligands, and nonspecific adsorption of protein to the substrate. This paper describes a peptide chip that overcomes these limitations, and demonstrates its utility in activity assays of the nonreceptor tyrosine kinase c-Src. The chip was prepared by the Diels-Alder-mediated immobilization of the kinase substrate AcIYGEFKKKC-NH2 on a self-assembled monolayer of alkanethiolates on gold. Phosphorylation of the immobilized peptides was characterized by surface plasmon resonance, fluorescence, and phosphorimaging. Three inhibitors of the enzyme were quantitatively evaluated in an array format on a single, homogeneous substrate.	Univ Chicago, Dept Chem, Chicago, IL 60637 USA; Univ Chicago, Inst Biophys Dynam, Chicago, IL 60637 USA; Univ Chicago, Ctr Mol Oncol, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago	Mrksich, M (corresponding author), Univ Chicago, Dept Chem, 5735 S Ellis Ave, Chicago, IL 60637 USA.		Mrksich, Milan/G-2469-2011	Mrksich, Milan/0000-0002-4964-796X; Kron, Stephen/0000-0003-1518-2436	NICHD NIH HHS [HD 09007] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aebersold R, 2001, CHEM REV, V101, P269, DOI 10.1021/cr990076h; Arenkov P, 2000, ANAL BIOCHEM, V278, P123, DOI 10.1006/abio.1999.4363; Braunwalder AF, 1996, ANAL BIOCHEM, V234, P23, DOI 10.1006/abio.1996.0044; Cox S, 1995, BIOCHEMISTRY-US, V34, P16203, DOI 10.1021/bi00049a036; DUAN YJ, 1994, ANAL BIOCHEM, V216, P431, DOI 10.1006/abio.1994.1064; Eisen MB, 1999, METHOD ENZYMOL, V303, P179; Falsey JR, 2001, BIOCONJUGATE CHEM, V12, P346, DOI 10.1021/bc000141q; Gan ZB, 1999, ANAL BIOCHEM, V268, P151, DOI 10.1006/abio.1998.3053; Golomb G, 1997, ADV DRUG DELIVER REV, V24, P53, DOI 10.1016/S0169-409X(96)00482-6; Green RJ, 2000, BIOMATERIALS, V21, P1823, DOI 10.1016/S0142-9612(00)00077-6; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hergenrother PJ, 2000, J AM CHEM SOC, V122, P7849, DOI 10.1021/ja0014032; Himpel S, 2000, J BIOL CHEM, V275, P2431, DOI 10.1074/jbc.275.4.2431; Houseman BT, 1998, J ORG CHEM, V63, P7552, DOI 10.1021/jo981113s; Houseman BT, 2001, BIOMATERIALS, V22, P943, DOI 10.1016/S0142-9612(00)00259-3; KEMP BE, 1977, J BIOL CHEM, V252, P4888; Lahiri J, 1999, ANAL CHEM, V71, P777, DOI 10.1021/ac980959t; Lee PS, 2000, CURR OPIN BIOTECH, V11, P171, DOI 10.1016/S0958-1669(00)00077-X; Liu Y, 1999, CHEM BIOL, V6, P671, DOI 10.1016/S1074-5521(99)80118-5; Lueking A, 1999, ANAL BIOCHEM, V270, P103, DOI 10.1006/abio.1999.4063; MacBeath G, 2000, SCIENCE, V289, P1760; Maly DJ, 2000, P NATL ACAD SCI USA, V97, P2419, DOI 10.1073/pnas.97.6.2419; Mrksich M, 1997, ACS SYM SER, V680, P361; Mrksich M, 2000, CHEM SOC REV, V29, P267, DOI 10.1039/a705397e; PALEGROSDEMANGE C, 1991, J AM CHEM SOC, V113, P12, DOI 10.1021/ja00001a002; Reineke U, 2001, CURR OPIN BIOTECH, V12, P59, DOI 10.1016/S0958-1669(00)00178-6; Rich RL, 2000, CURR OPIN BIOTECH, V11, P54, DOI 10.1016/S0958-1669(99)00054-3; ROBINSON SP, 1993, INT J ONCOL, V2, P253; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TEGGE W, 1995, BIOCHEMISTRY-US, V87, P99; Vijayendran RA, 2001, ANAL CHEM, V73, P471, DOI 10.1021/ac000523p; Wenschuh H, 2000, BIOPOLYMERS, V55, P188, DOI 10.1002/1097-0282(2000)55:3<188::AID-BIP20>3.0.CO;2-T; Yousaf MN, 2001, ANGEW CHEM INT EDIT, V40, P1093, DOI 10.1002/1521-3773(20010316)40:6<1093::AID-ANIE10930>3.3.CO;2-H; Yousaf MN, 1999, J AM CHEM SOC, V121, P4286, DOI 10.1021/ja983529t; Zhu H, 2001, CURR OPIN CHEM BIOL, V5, P40, DOI 10.1016/S1367-5931(00)00170-8	35	643	690	1	116	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2002	20	3					270	274		10.1038/nbt0302-270	http://dx.doi.org/10.1038/nbt0302-270			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	526RE	11875428				2022-12-25	WOS:000174142800045
J	Pai, R; Soreghan, B; Szabo, IL; Pavelka, M; Baatar, D; Tarnawski, AS				Pai, R; Soreghan, B; Szabo, IL; Pavelka, M; Baatar, D; Tarnawski, AS			Prostaglandin E-2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy	NATURE MEDICINE			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; PROTEIN-COUPLED RECEPTORS; RECTAL MUCOSA; FACTOR-ALPHA; EXPRESSION; CHEMOPREVENTION; CARCINOMA; NEOPLASIA; RAT	Prostaglandins (PGs), bioactive lipid molecules produced by cyclooxygenase enzymes (COX-1 and COX-2), have diverse biological activities, including growth-promoting actions on gastrointestinal mucosa(1-5). They are also implicated in the growth of colonic polyps and cancers(6). However, the precise mechanisms of these trophic actions of PGs remain unclear. As activation of the epidermal growth factor receptor (EGFR) triggers mitogenic signaling in gastrointestinal mucosa, and its expression is also upregulated in colonic cancers and most neoplasms(7-9), we investigated whether PGs transactivate EGFR. Here we provide evidence that prostaglandin E-2 (PGE(2)) rapidly phosphorylates EGFR and triggers the extracellular signal-regulated kinase 2 (ERK2)-mitogenic signaling pathway in normal gastric epithelial (RGM1) and colon cancer (Caco-2, LoVo and HT-29) cell lines. Inactivation of EGFR kinase with selective inhibitors significantly reduces PGE(2)-induced ERK2 activation, c-fos mRNA expression and cell proliferation. Inhibition of matrix metalloproteinases (MMPs), transforming growth factor-alpha (TGF-alpha) or c-Src blocked PGE(2)-mediated EGFR transactivation and downstream signaling indicating that PGE(2)-induced EGFR transactivation involves signaling transduced via TGF-alpha, an EGFR ligand, likely released by c-Src-activated MMP(s). Our findings that PGE(2) transactivates EGFR reveal a previously unknown mechanism by which PGE(2) mediates trophic actions resulting in gastric and intestinal hypertrophy as well as growth of colonic polyps and cancers.	Dept Vet Affairs Med Ctr, Med Serv, Long Beach, CA USA; Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine	Tarnawski, AS (corresponding author), Dept Vet Affairs Med Ctr, Med Serv, Long Beach, CA USA.							Barnes CJ, 1999, CANCER EPIDEM BIOMAR, V8, P311; Baselga J, 2000, ANN ONCOL, V11, P187, DOI 10.1023/A:1011144502974; Callejas NA, 2001, HEPATOLOGY, V33, P860, DOI 10.1053/jhep.2001.23002; DEMBINSKI A, 1985, AM J PHYSIOL, V248, pG170, DOI 10.1152/ajpgi.1985.248.2.G170; DuBois RN, 1996, J GASTROENTEROL, V31, P898, DOI 10.1007/BF02358623; Eguchi S, 2001, J BIOL CHEM, V276, P7957, DOI 10.1074/jbc.M008570200; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; JOHANSSON C, 1983, ADV PROSTAG THROMB L, V12, P403; JOHANSSON C, 1982, SCAND J GASTROENTERO, V17, P21; Kinoshita T, 1999, BBA-MOL CELL BIOL L, V1438, P120, DOI 10.1016/S1388-1981(99)00034-7; Kobayashi I, 1996, IN VITRO CELL DEV-AN, V32, P259; Levy GN, 1997, FASEB J, V11, P234, DOI 10.1096/fasebj.11.4.9068612; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; MaleckaPanas E, 1997, HEPATO-GASTROENTEROL, V44, P435; MOSKAL TL, 1995, CANCER EPIDEM BIOMAR, V4, P127; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; REINHART WH, 1983, GASTROENTEROLOGY, V85, P1003; RESNICK MB, 1995, CANCER-AM CANCER SOC, V76, P187, DOI 10.1002/1097-0142(19950715)76:2<187::AID-CNCR2820760205>3.0.CO;2-C; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Shimada N, 1998, J GASTROEN HEPATOL, V13, P794, DOI 10.1111/j.1440-1746.1998.tb00735.x; Torrance CJ, 2000, NAT MED, V6, P1024, DOI 10.1038/79534; Yang VW, 2000, PROSTAG OTH LIPID M, V60, P83, DOI 10.1016/S0090-6980(99)00054-4; Younes M, 1996, ANTICANCER RES, V16, P1999	26	717	753	2	36	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	MAR	2002	8	3					289	293		10.1038/nm0302-289	http://dx.doi.org/10.1038/nm0302-289			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	526PU	11875501				2022-12-25	WOS:000174139500035
J	Sgadari, C; Barillari, G; Toschi, E; Carlei, D; Bacigalupo, I; Baccarini, S; Palladino, C; Leone, P; Bugarini, R; Malavasi, L; Cafaro, A; Falchi, M; Valdembri, D; Rezza, G; Bussolino, F; Monini, P; Ensoli, B				Sgadari, C; Barillari, G; Toschi, E; Carlei, D; Bacigalupo, I; Baccarini, S; Palladino, C; Leone, P; Bugarini, R; Malavasi, L; Cafaro, A; Falchi, M; Valdembri, D; Rezza, G; Bussolino, F; Monini, P; Ensoli, B			HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma	NATURE MEDICINE			English	Article							FIBROBLAST-GROWTH-FACTOR; ACTIVE ANTIRETROVIRAL THERAPY; VIRUS-1 TAT PROTEIN; INFLAMMATORY CYTOKINES; VASCULAR-PERMEABILITY; CELL-GROWTH; IN-VIVO; ENDOTHELIAL-CELLS; T-CELLS; HUMAN-HERPESVIRUS-8	Treatment with HIV-1 protease inhibitors (PI) is associated with a reduced incidence or regression of Kaposi sarcoma (KS). Here we show that systemic administration of the PIs indinavir or saquinavir to nude mice blocks the development and induces regression of angioproliferative KS-like lesions promoted by primary human KS cells, basic fibroblast growth factor (bFGF), or bFGF and vascular endothelial growth factor (VEGF) combined. These PIs also block bFGF or VEGF-induced angiogenesis in the chorioallantoic membrane assay with a potency similar to paclitaxel (Taxol). These effects are mediated by the inhibition of endothelial- and KS-cell invasion and of matrix metalloproteinase-2 proteolytic activation by PIs at concentrations present in plasma of treated individuals. As PIs also inhibit the in vivo growth and invasion of an angiogenic tumor-cell line, these data indicate that PIs are potent anti-angiogenic and anti-tumor molecules that might be used in treating non-HIV KS and in other HIV-associated tumors.	Ist Super Sanita, Virol Lab, I-00161 Rome, Italy; Ist Super Sanita, Epidemiol & Biostat Lab, I-00161 Rome, Italy; Ist Super Sanita, Lab Ultrastruct, I-00161 Rome, Italy; Univ Roma Tor Vergata, Dept Expt Med, Rome, Italy; Univ Turin, Dept Oncol Sci, Inst Canc Res & Treatment, Turin, Italy	Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); University of Rome Tor Vergata; University of Turin	Ensoli, B (corresponding author), Ist Super Sanita, Virol Lab, Viale Regina Elena 299, I-00161 Rome, Italy.	ensoli@iss.it	Sgadari, Cecilia/H-4302-2016; Palladino, Clelia/K-7555-2016; Ensoli, Barbara/J-9169-2016; Bussolino, Federico/AES-3951-2022; iMed.ULisboa, EEPHIV/B-4222-2014; Monini, Paolo/K-1429-2016; Cafaro, Aurelio/K-5314-2016; Toschi, Elena/M-7051-2017; rezza, giovanni/D-4393-2016; Bussolino, Federico/K-2500-2016	Sgadari, Cecilia/0000-0003-0364-4912; Palladino, Clelia/0000-0003-0740-5863; Ensoli, Barbara/0000-0002-0545-8737; Monini, Paolo/0000-0002-4941-6854; rezza, giovanni/0000-0003-0268-6790; Valdembri, Donatella/0000-0003-4590-417X; Toschi, Elena/0000-0002-9720-5971; Bacigalupo, ilaria/0000-0002-4249-1982; Carlei, Davide/0000-0002-7151-6077; Cafaro, Aurelio/0000-0001-9675-6344; Baccarini, Sara/0000-0001-8070-1656; Falchi, Mario/0000-0002-8290-5406; Bussolino, Federico/0000-0002-5348-1341; Leone, Patrizia/0000-0002-5281-4917				Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296-1371; Andre P, 1998, P NATL ACAD SCI USA, V95, P13120, DOI 10.1073/pnas.95.22.13120; Appleby P, 2000, JNCI-J NATL CANCER I, V92, P1823, DOI 10.1093/jnci/92.22.1823; Ascherl G, 1999, BLOOD, V93, P4232; Ascherl G, 2001, AIDS RES HUM RETROV, V17, P1035, DOI 10.1089/088922201300343717; Barillari G, 1999, BLOOD, V94, P663; Barillari G, 1999, J IMMUNOL, V163, P1929; Belotti D, 1996, CLIN CANCER RES, V2, P1843; Bower M, 1999, AIDS, V13, P2105, DOI 10.1097/00002030-199910220-00014; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Carr A, 1998, LANCET, V351, P1881, DOI 10.1016/S0140-6736(98)03391-1; Cassone A, 1999, J INFECT DIS, V180, P448, DOI 10.1086/314871; Cattelan AM, 1999, EUR J CANCER, V35, P1809, DOI 10.1016/S0959-8049(99)00161-6; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chavan S, 2001, BLOOD, V98, P383, DOI 10.1182/blood.V98.2.383; COOPER DA, 1993, NEW ENGL J MED, V329, P297, DOI 10.1056/NEJM199307293290501; Cornali E, 1996, AM J PATHOL, V149, P1851; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1994, J CLIN INVEST, V94, P1736, DOI 10.1172/JCI117521; Ensoli B, 1998, CYTOKINE GROWTH F R, V9, P63, DOI 10.1016/S1359-6101(97)00037-3; Ensoli B, 2001, ADV CANCER RES, V81, P161, DOI 10.1016/S0065-230X(01)81005-8; Fiorelli V, 1998, BLOOD, V91, P956; Gruber A, 2001, J BIOL CHEM, V276, P47840, DOI 10.1074/jbc.M105582200; Hidalgo M, 2001, JNCI-J NATL CANCER I, V93, P178, DOI 10.1093/jnci/93.3.178; Kedes DH, 1997, J CLIN INVEST, V99, P2082, DOI 10.1172/JCI119380; Koivunen E, 1999, NAT BIOTECHNOL, V17, P768, DOI 10.1038/11703; Lebbe C, 1998, AIDS, V12, pF45, DOI 10.1097/00002030-199807000-00002; Ledru E, 2000, BLOOD, V95, P3191, DOI 10.1182/blood.V95.10.3191.010k10_3191_3198; Liang JS, 2001, NAT MED, V7, P1327, DOI 10.1038/nm1201-1327; Masood R, 1997, P NATL ACAD SCI USA, V94, P979, DOI 10.1073/pnas.94.3.979; Monini P, 1999, BLOOD, V93, P4044; Nakamura S, 1997, J IMMUNOL, V158, P4992; Osman M, 1999, J VIROL, V73, P6136, DOI 10.1128/JVI.73.7.6136-6140.1999; Rabkin CS, 1997, NEW ENGL J MED, V336, P988, DOI 10.1056/NEJM199704033361403; REAL FX, 1985, NEW ENGL J MED, V313, P1659; Ribatti D, 1996, INT J DEV BIOL, V40, P1189; Samaniego F, 1997, J IMMUNOL, V158, P1887; Samaniego F, 1998, AM J PATHOL, V152, P1433; Sgadari C, 2000, J IMMUNOL, V165, P509, DOI 10.4049/jimmunol.165.1.509; Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870; Sturzl M, 2001, ADV CANCER RES, V81, P125, DOI 10.1016/S0065-230X(01)81004-6; Torre-Cisneros J, 2000, AIDS, V14, P2215, DOI 10.1097/00002030-200009290-00026; Toschi E, 2001, MOL BIOL CELL, V12, P2934, DOI 10.1091/mbc.12.10.2934; Tovo PA, 2000, AIDS, V14, P743, DOI 10.1097/00002030-200004140-00014; Vaccher E, 1999, J ACQ IMMUN DEF SYND, V22, P407; Wang QJ, 2000, J INFECT DIS, V182, P928, DOI 10.1086/315777; Weichold FF, 1999, J HUMAN VIROL, V2, P261	50	253	268	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2002	8	3					225	232		10.1038/nm0302-225	http://dx.doi.org/10.1038/nm0302-225			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	526PU	11875492				2022-12-25	WOS:000174139500026
J	Passegue, E; Jochum, W; Behrens, A; Ricci, R; Wagner, EF				Passegue, E; Jochum, W; Behrens, A; Ricci, R; Wagner, EF			JunB can substitute for Jun in mouse development and cell proliferation	NATURE GENETICS			English	Article							D1 MESSENGER-RNA; C-JUN; TRANSCRIPTIONAL ACTIVATION; CYCLE PROGRESSION; EXPRESSION; FOS; APOPTOSIS; GROWTH; AP-1; PHOSPHORYLATION	The Jun and JunB components of the AP-1 transcription factor are known to have antagonistic functions. Here we show, by a knock-in strategy and a transgenic complementation approach, that Junb can substitute for absence of Jun during mouse development. Junb can rescue both liver and cardiac defects in Jun-null mice in a manner dependent on gene dosage. JunB restores the expression of genes regulated by Jun/Fos, but not those regulated by Jun/ATF, thereby rescuing Jun-dependent defects in vivo as well as in primary fibroblasts and fetal hepatoblasts in vitro. Thus, the transcriptionally less active JunB has the potential to substitute for Jun, indicating that the spatial and temporal regulation of expression of the transcription factor AP-1 may be more important than the coding sequence of its components.	Res Inst Mol Pathol, A-1030 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Wagner, EF (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.	wagner@nt.imp.univie.ac.at	Ricci, Romeo/K-3009-2013	Ricci, Romeo/0000-0002-9766-4369; Wagner, Erwin F/0000-0001-7872-0196; Behrens, Axel/0000-0002-1557-1143; Passegue, Emmanuelle/0000-0002-3516-297X				Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; BENBROOK DM, 1990, ONCOGENE, V5, P295; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; Brewer JW, 1999, P NATL ACAD SCI USA, V96, P8505, DOI 10.1073/pnas.96.15.8505; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; Cirillo G, 1999, MOL CELL BIOL, V19, P6240; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Eferl R, 1999, J CELL BIOL, V145, P1049, DOI 10.1083/jcb.145.5.1049; Fleischmann A, 2000, GENE DEV, V14, P2695, DOI 10.1101/gad.187900; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HSU JC, 1993, CANCER RES, V53, P3789; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Joyce D, 2001, CYTOKINE GROWTH F R, V12, P73, DOI 10.1016/S1359-6101(00)00018-6; KITABAYASHI I, 1993, J BIOL CHEM, V268, P14482; Kockel L, 2001, ONCOGENE, V20, P2347, DOI 10.1038/sj.onc.1204300; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; Lin SK, 2000, MOL CELL BIOL, V20, P7903, DOI 10.1128/MCB.20.21.7903-7913.2000; Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Schorpp M, 1996, NUCLEIC ACIDS RES, V24, P1787, DOI 10.1093/nar/24.9.1787; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Srivastava D, 2000, NATURE, V407, P221, DOI 10.1038/35025190; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Wagner EF, 2001, ONCOGENE, V20, P2334, DOI 10.1038/sj.onc.1204416; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188	41	121	122	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2002	30	2					158	166		10.1038/ng790	http://dx.doi.org/10.1038/ng790			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	519CY	11818961				2022-12-25	WOS:000173708700015
J	Wutz, A; Rasmussen, TP; Jaenisch, R				Wutz, A; Rasmussen, TP; Jaenisch, R			Chromosomal silencing and localization are mediated by different domains of Xist RNA	NATURE GENETICS			English	Article							X-INACTIVATION CENTER; DOSAGE COMPENSATION; HISTONE MACROH2A1; MAMMALIAN-CELLS; GENE; EXPRESSION; TETRACYCLINE; INTEGRATION; NUCLEUS; STRAIN	The gene Xist initiates the chromosomal silencing process of X inactivation in mammals. Its product, a noncoding RNA, is expressed from and specifically associates with the inactive X chromosome in female cells. Here we use an inducible Xist expression system in mouse embryonic stem cells that recapitulates long-range chromosomal silencing to elucidate which Xist RNA sequences are necessary for chromosomal association and silencing. We show that chromosomal association and spreading of Xist RNA can be functionally separated from silencing by specific mutations. Silencing requires a conserved repeat sequence located at the 5' end of Xist. Deletion of this element results in Xist RNA that still associates with chromatin and spreads over the chromosome but does not effect transcriptional repression. Association of Xist RNA with chromatin is mediated by functionally redundant sequences that act cooperatively and are dispersed throughout the remainder of Xist but show little or no homology.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute	Jaenisch, R (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.			Rasmussen, Theodore/0000-0001-9450-3394				Allaman-Pillet N, 2000, GENE EXPRESSION, V9, P93; Avner P, 2001, NAT REV GENET, V2, P59, DOI 10.1038/35047580; Baron U, 1997, NUCLEIC ACIDS RES, V25, P2723, DOI 10.1093/nar/25.14.2723; BARON U, 1995, NUCLEIC ACIDS RES, V23, P3605, DOI 10.1093/nar/23.17.3605; BARR ML, 1949, NATURE, V163, P676, DOI 10.1038/163676a0; Beletskii A, 2001, P NATL ACAD SCI USA, V98, P9215, DOI 10.1073/pnas.161173098; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; Bronson SK, 1996, P NATL ACAD SCI USA, V93, P9067, DOI 10.1073/pnas.93.17.9067; BROWN CJ, 1989, CYTOGENET CELL GENET, V51, P971; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; Costanzi C, 1998, NATURE, V393, P599, DOI 10.1038/31275; Csankovszki G, 1999, NAT GENET, V22, P323, DOI 10.1038/11887; FUKUSHIGE S, 1992, P NATL ACAD SCI USA, V89, P7905, DOI 10.1073/pnas.89.17.7905; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Herzing LBK, 1997, NATURE, V386, P272, DOI 10.1038/386272a0; KARN J, 1994, RNA PROTEIN INTERACT, P192; Kelley RL, 2000, CELL, V103, P9, DOI 10.1016/S0092-8674(00)00099-4; Lee JT, 1999, NAT GENET, V21, P400, DOI 10.1038/7734; Lee JT, 1996, CELL, V86, P83, DOI 10.1016/S0092-8674(00)80079-3; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; Marahrens Y, 1998, CELL, V92, P657, DOI 10.1016/S0092-8674(00)81133-2; Marahrens Y, 1997, GENE DEV, V11, P156, DOI 10.1101/gad.11.2.156; Nesterova TB, 2001, GENOME RES, V11, P833, DOI 10.1101/gr.174901; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; Rasmussen TP, 2000, J CELL BIOL, V150, P1189, DOI 10.1083/jcb.150.5.1189; Rasmussen TP, 2001, CHROMOSOMA, V110, P411, DOI 10.1007/s004120100158; RUSSELL LB, 1961, SCIENCE, V133, P1795, DOI 10.1126/science.133.3467.1795; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Tinker AV, 1998, NUCLEIC ACIDS RES, V26, P2935, DOI 10.1093/nar/26.12.2935; Wutz A, 2000, MOL CELL, V5, P695, DOI 10.1016/S1097-2765(00)80248-8; Wutz A, 2001, DEVELOPMENT, V128, P1881; Zambrowicz BP, 1997, P NATL ACAD SCI USA, V94, P3789, DOI 10.1073/pnas.94.8.3789	34	550	585	1	48	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	FEB	2002	30	2					167	174		10.1038/ng820	http://dx.doi.org/10.1038/ng820			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	519CY	11780141				2022-12-25	WOS:000173708700016
J	Yamauchi, T; Oike, Y; Kamon, J; Waki, H; Komeda, K; Tsuchida, A; Date, Y; Li, MX; Miki, H; Akanuma, Y; Nagai, R; Kimura, S; Saheki, T; Nakazato, M; Naitoh, T; Yamamura, K; Kadowaki, T				Yamauchi, T; Oike, Y; Kamon, J; Waki, H; Komeda, K; Tsuchida, A; Date, Y; Li, MX; Miki, H; Akanuma, Y; Nagai, R; Kimura, S; Saheki, T; Nakazato, M; Naitoh, T; Yamamura, K; Kadowaki, T			Increased insulin sensitivity despite lipodystrophy in Crebbp heterozygous mice	NATURE GENETICS			English	Article							PPAR-GAMMA; ADIPOSE-TISSUE; PROTEIN; ACTIVATION; MECHANISMS; RECEPTORS; OBESITY; LACKING; ALPHA	The CBP protein (cAMP response element binding protein (CREB) binding protein)(1) is a co-activator(2) for several transcription factors with a wide range of important biological functions, such as sterol regulatory element binding proteins (SREBPs)(3), CCAAT/enhancer-binding proteins (C/EBPs)(4), nuclear receptors(5,6) (including peroxisome proliferator-activated receptors, PPARS)(7), and signal transducers and activators of transcription (STATs)(8). In contrast to these individual transcription factors, the biological roles of CBP are poorly understood. CBP enhances transcriptional activities via histone acetylation and the recruitment of additional co-activators such as SRC (steroid coactivator)-1 (ref. 9). To identify its physiological functions using a loss-of-function mutant, we analyzed CBP-deficient mice(10-12). As Crebbp null mice (Crebbp(-/-)) died during embryogenesis(10-12), we used Crebbp(+/-) mice(12). Unexpectedly, Crebbp(+/-) mice showed markedly reduced weight of white adipose tissue (WAT) but not of other tissues. Despite this lipodystrophy, Crebbp(+/-) mice showed increased insulin sensitivity and glucose tolerance and were completely protected from body weight gain induced by a high-fat (HF) diet. We observed increased leptin sensitivity and increased serum adiponectin levels in Crebbp(+/-) mice. These increased effects of insulin-sensitizing hormones secreted from WAT may explain, at least in part, the phenotypes of Crebbp(+/-) mice. This study demonstrates that CBP may function as a 'master-switch' between energy storage and expenditure.	Univ Tokyo, Dept Internal Med, Grad Sch Med, Tokyo 1138655, Japan; Kumamoto Univ, Dept Cell Differentiat, Inst Mol Embryol & Genet, Kumamoto 8600811, Japan; Nissan Chem Ind Co Ltd, Biol Res Labs, Saito 3490294, Japan; Tokyo Med & Dent Univ, Div Lab Anim Sci, Anim Res Ctr, Tokyo 1608402, Japan; Miyazaki Med Coll, Dept Internal Med 3, Miyazaki 8891692, Japan; Kagoshima Univ, Fac Med, Dept Biochem, Kagoshima 8908520, Japan; Asahi Life Fdn, Inst Diabet Care & Res, Tokyo 1000005, Japan; Kumamoto Univ, Dept Dev Genet, Inst Mol Embryol & Genet, Kumamoto 8620976, Japan	University of Tokyo; Kumamoto University; Nissan Chemical Corporation; Tokyo Medical & Dental University (TMDU); University of Miyazaki; Kagoshima University; Asahi Life Foundation; Kumamoto University	Kadowaki, T (corresponding author), Univ Tokyo, Dept Internal Med, Grad Sch Med, Tokyo 1138655, Japan.	kadowaki-3im@h.u-tokyo.ac.jp	Waki, Hironori/AAE-3942-2020	Waki, Hironori/0000-0002-5302-9793				AILAUD G, 1998, HDB OBESITY, P359; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; Friedman JM, 2000, NATURE, V404, P632, DOI 10.1038/35007504; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Gavrilova O, 2000, J CLIN INVEST, V105, P271, DOI 10.1172/JCI7901; Goodman RH, 2000, GENE DEV, V14, P1553; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; Hotamisligil GS, 1999, J INTERN MED, V245, P621, DOI 10.1046/j.1365-2796.1999.00490.x; HOUSTEK J, 1988, BIOCHIM BIOPHYS ACTA, V935, P19, DOI 10.1016/0005-2728(88)90103-X; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; KIM JB, 1995, MOL CELL BIOL, V15, P2582; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; Mark M, 1999, P NUTR SOC, V58, P609, DOI 10.1017/S0029665199000798; MCKENNA NJ, 2000, J STEROID BIOCHEM, V74, P255; Miles PDG, 2000, J CLIN INVEST, V105, P287, DOI 10.1172/JCI8538; Murakami K, 1998, DIABETES, V47, P1841, DOI 10.2337/diabetes.47.12.1841; Nakazato M, 2001, NATURE, V409, P194, DOI 10.1038/35051587; Oike Y, 1999, HUM MOL GENET, V8, P387, DOI 10.1093/hmg/8.3.387; Perlmann T, 1997, CELL, V90, P391, DOI 10.1016/S0092-8674(00)80498-5; Rosen ED, 2000, GENE DEV, V14, P1293; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Tanaka Y, 1997, P NATL ACAD SCI USA, V94, P10215, DOI 10.1073/pnas.94.19.10215; Westin S, 2000, ADV PHARMACOL, V47, P89; Yamauchi T, 2001, J BIOL CHEM, V276, P41245, DOI 10.1074/jbc.M103241200; YAMAUCHI T, 2001, NAT MED, V7, P641; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4	30	130	138	1	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	FEB	2002	30	2					221	226		10.1038/ng829	http://dx.doi.org/10.1038/ng829			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	519CY	11818964				2022-12-25	WOS:000173708700026
J	Gouya, L; Puy, H; Robreau, AM; Bourgeois, M; Lamoril, J; Da Silva, V; Grandchamp, B; Deybach, JC				Gouya, L; Puy, H; Robreau, AM; Bourgeois, M; Lamoril, J; Da Silva, V; Grandchamp, B; Deybach, JC			The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype FECH	NATURE GENETICS			English	Article							HIRSCHSPRUNG-DISEASE	Erythropoietic protoporphyria (EPP) is an inherited disorder of heme biosynthesis caused by a partial deficiency of ferrochelatase (FECH, EC 4.99.1.1)(1,2). EPP is transmitted as an autosomal dominant disorder(3) with an incomplete penetrance(1). Using haplotype segregation analysis, we have identified an intronic single nucleotide polymorphism (SNP), IVS3-48T/C, that modulates the use of a constitutive aberrant acceptor splice site. The aberrantly spliced mRNA is degraded by a nonsense-mediated decay mechanism (NMD), producing a decreased steady-state level of mRNA and the additional FECH enzyme deficiency necessary for EPP phenotypic expression.	Hop Louis Mourier, Fac Xavier Bichat, INSERM, U 409, F-92701 Colombes, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Louis-Mourier - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Deybach, JC (corresponding author), Hop Louis Mourier, Fac Xavier Bichat, INSERM, U 409, F-92701 Colombes, France.		PUY, HERVE/O-1785-2017	PUY, HERVE/0000-0003-3362-2634; Gouya, Laurent/0000-0002-1326-7025				ANDERSON KE, 2001, METABOLIC MOL BASES, P2991; Borrego S, 1999, J MED GENET, V36, P771, DOI 10.1136/jmg.36.10.771; Borrego S, 2000, J MED GENET, V37, P572, DOI 10.1136/jmg.37.8.572; Gouya L, 1996, AM J HUM GENET, V58, P292; Gouya L, 1999, BLOOD, V93, P2105, DOI 10.1182/blood.V93.6.2105.406k28_2105_2110; LAMORIL J, 1991, BIOCHEM BIOPH RES CO, V181, P594, DOI 10.1016/0006-291X(91)91231-Z; Li F M, 1987, Biomed Chromatogr, V2, P164, DOI 10.1002/bmc.1130020408; SARKANY RP, 1994, LANCET, V8910, P1394; TODD DJ, 1994, BRIT J DERMATOL, V131, P751, DOI 10.1111/j.1365-2133.1994.tb08577.x; WENT LN, 1984, ANN HUM GENET, V48, P105, DOI 10.1111/j.1469-1809.1984.tb01006.x	10	185	193	0	6	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2002	30	1					27	28		10.1038/ng809	http://dx.doi.org/10.1038/ng809			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	508TL	11753383				2022-12-25	WOS:000173105600009
